PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hashimoto, M; Takeda, A; Hsu, LJ; Takenouchi, T; Masliah, E				Hashimoto, M; Takeda, A; Hsu, LJ; Takenouchi, T; Masliah, E			Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; PARKINSONS-DISEASE; NEURODEGENERATIVE DISORDERS; NACP/ALPHA-SYNUCLEIN; PRECURSOR PROTEIN; CROSS-LINKING; IN-VITRO; BODIES; NACP; IMMUNOREACTIVITY	alpha-Synuclein is a major component of aggregates forming amyloid-like fibrils in diseases with Lewy bodies and other neurodegenerative disorders, yet the mechanism by which alpha-synuclein is intracellularly aggregated during neurodegeneration is poorly understood. Recent studies suggest that oxidative stress reactions might contribute to abnormal aggregation of this molecule. In this context, the main objective of the present study was to determine the potential role of the heme protein cytochrome c in alpha-synuclein aggregation. When recombinant alpha-synuclein was coincubated with cytochrome c/hydrogen peroxide, alpha-synuclein was concomitantly induced to be aggregated. This process was blocked by antioxidant agents such as N-acetyl-L-cysteine. Hemin/hydrogen peroxide similarly induced aggregation of alpha-synuclein, and both cytochrome c/hydrogen peroxide- and hemin/hydrogen peroxide-induced aggregation of alpha-synuclein was partially inhibited by treatment with iron chelator deferoxisamine. This indicates that iron-catalyzed oxidative reaction mediated by cytochrome c/hydrogen peroxide might be critically involved in promoting alpha-synuclein aggregation. Furthermore, double labeling studies for cytochrome c/alpha-synuclein showed that they were colocalized in Lewy bodies of patients with Parkinson's disease. Taken together, these results suggest that cytochrome c, a well known electron transfer, and mediator of apoptotic cell death may be involved in the oxidative stress-induced aggregation of alpha-synuclein in Parkinson's disease and related disorders.	Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Yokohama City Univ, Sch Med, Dept Psychiat, Kanazawa Ku, Yokohama, Kanagawa 236, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Yokohama City University	Masliah, E (corresponding author), Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA.	emasliah@ucsd.edu			NIA NIH HHS [AG10689, AG05131] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010689] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS JD, 1991, FREE RADICAL BIO MED, V10, P161, DOI 10.1016/0891-5849(91)90009-R; Baba M, 1998, AM J PATHOL, V152, P879; BODANESS RS, 1984, ARCH BIOCHEM BIOPHYS, V231, P461, DOI 10.1016/0003-9861(84)90409-0; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; DYRKS T, 1992, J BIOL CHEM, V267, P18210; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; HANAN T, 1995, FREE RADICAL RES, V22, P215, DOI 10.3109/10715769509147541; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; Miller YI, 1996, ARCH BIOCHEM BIOPHYS, V326, P252, DOI 10.1006/abbi.1996.0073; Paik SR, 1997, ARCH BIOCHEM BIOPHYS, V344, P325, DOI 10.1006/abbi.1997.0207; Paik SR, 1998, FEBS LETT, V421, P73, DOI 10.1016/S0014-5793(97)01537-8; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SOLAR I, 1990, ARCH BIOCHEM BIOPHYS, V283, P81, DOI 10.1016/0003-9861(90)90615-6; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takeda A, 1998, LAB INVEST, V78, P1169; Takeda A, 1998, AM J PATHOL, V152, P367; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141; YOUDIM MBH, 1989, ACTA NEUROL SCAND, V80, P47, DOI 10.1111/j.1600-0404.1989.tb01782.x	34	213	217	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28849	28852		10.1074/jbc.274.41.28849	http://dx.doi.org/10.1074/jbc.274.41.28849			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506125	hybrid			2022-12-25	WOS:000083017800004
J	Haney, PJ; Stees, M; Konisky, J				Haney, PJ; Stees, M; Konisky, J			Analysis of thermal stabilizing interactions in mesophilic and thermophilic adenylate kinases from the genus Methanococcus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED PROTEIN THERMOSTABILITY; CONFORMATIONAL STABILITY; HYDROPHOBIC INTERACTION; SEQUENCE STATISTICS; PYROCOCCUS-FURIOSUS; GLOBULAR-PROTEINS; CRYSTAL-STRUCTURE; ALPHA-HELICES; AMINO-ACIDS; DEHYDROGENASE	Adenylate kinases (ADKs) from four closely related methanogenic members of the Archaea (the mesophile Methanococcus voltae (MVO), the thermopile Methanococcus thermolithotrophicus (MTH), and the extreme thermopiles Methanococcus igneus (MIG) and Methano coccus jannaschii (MJA)) were characterized for their resistance to thermal denaturation, Despite possessing between 68 and 81% sequence identity, the methanococcal ADKs significantly differed in their stability against thermal denaturation, with melting points ranging from 69 to 103 degrees C, The high sequence identity between these organisms allowed regions of the MVO and MJA ADKs to be exchanged, producing chimeric ADKs with significantly altered thermal stability. Up to a 20 degrees C increase or decrease in stability was achieved for chimeric ADKs, whereas 88% of the original protein sequence was maintained. Based on our previous structural modeling studies, we conclude that cooperative interactions within the hydrophobic protein core play an integral role in determining the differences in structural stability observed between the methanococcal ADKs, From comparisons of the effects of temperature on protein unfolding and optimal enzymatic activity, we also conclude that thermostability and enzymatic temperature optima are influenced differently by molecular modifications and thus that the protein flexibility required for activity and stability, respectively, is not unconditionally linked within the methanococcal ADKs.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Konisky, J (corresponding author), Rice Univ, Dept Biochem & Cell Biol, POB 1892, Houston, TX USA.	konisky@rice.edu						Adams MWW, 1995, CHEM ENG NEWS, V73, P32, DOI 10.1021/cen-v073n051.p032; AHERN TJ, 1985, SCIENCE, V228, P1280, DOI 10.1126/science.4001942; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BOHM G, 1994, INT J PEPT PROT RES, V43, P97; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BRITTON KL, 1995, EUR J BIOCHEM, V229, P688, DOI 10.1111/j.1432-1033.1995.tb20515.x; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Ferber DM, 1997, GENE, V185, P239, DOI 10.1016/S0378-1119(96)00651-8; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; Haney P, 1997, PROTEINS, V28, P117, DOI 10.1002/(SICI)1097-0134(199705)28:1<117::AID-PROT12>3.0.CO;2-M; Haney PJ, 1999, P NATL ACAD SCI USA, V96, P3578, DOI 10.1073/pnas.96.7.3578; HEINZ DW, 1992, P NATL ACAD SCI USA, V89, P3751, DOI 10.1073/pnas.89.9.3751; IKAI A, 1980, J BIOCHEM-TOKYO, V88, P1895; KELLY CA, 1993, BIOCHEMISTRY-US, V32, P3913, DOI 10.1021/bi00066a010; KIRINO H, 1994, EUR J BIOCHEM, V220, P275, DOI 10.1111/j.1432-1033.1994.tb18623.x; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MENENDEZARIAS L, 1989, J MOL BIOL, V206, P397, DOI 10.1016/0022-2836(89)90488-9; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; OLSEN O, 1991, MOL GEN GENET, V225, P177, DOI 10.1007/BF00269845; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; Pace CN, 1996, FASEB J, V10, P75, DOI 10.1096/fasebj.10.1.8566551; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PACE CN, 1992, J MOL BIOL, V226, P29, DOI 10.1016/0022-2836(92)90121-Y; PAUPTIT RA, 1988, J MOL BIOL, V199, P525, DOI 10.1016/0022-2836(88)90623-7; PERUTZ MF, 1975, NATURE, V255, P256, DOI 10.1038/255256a0; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; Querol E, 1996, PROTEIN ENG, V9, P265, DOI 10.1093/protein/9.3.265; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RUSNAK P, 1995, J BACTERIOL, V177, P2977, DOI 10.1128/jb.177.11.2977-2981.1995; RUSSELL RB, 1994, J MOL BIOL, V244, P332, DOI 10.1006/jmbi.1994.1733; SERRANO L, 1992, J MOL BIOL, V227, P544, DOI 10.1016/0022-2836(92)90906-Z; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SUZUKI Y, 1989, P JPN ACAD B-PHYS, V65, P146, DOI 10.2183/pjab.65.146; SUZUKI Y, 1987, APPL MICROBIOL BIOT, V26, P546, DOI 10.1007/BF00253030; SZILAGYI A, 1995, PROTEIN ENG, V8, P779, DOI 10.1093/protein/8.8.779; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3092; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3086; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; VOGT G, 1997, PROTEIN FOLDING, V2, pS40; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895; ZHANG YL, 1993, BIOCHIM BIOPHYS ACTA, V1164, P61, DOI 10.1016/0167-4838(93)90112-5	44	40	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28453	28458		10.1074/jbc.274.40.28453	http://dx.doi.org/10.1074/jbc.274.40.28453			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497207	hybrid			2022-12-25	WOS:000082912700056
J	Salemink, I; Franssen, J; Willems, GM; Hemker, HC; Lindhout, T				Salemink, I; Franssen, J; Willems, GM; Hemker, HC; Lindhout, T			Inhibition of tissue factor-factor VIIa-catalyzed factor X activation by factor Xa-tissue factor pathway inhibitor - A rotating disc study on the effect of phospholipid membrane composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-X; CONTINUOUS-FLOW; ANTICOAGULANT ACTIVITY; BLOOD-COAGULATION; FACTOR COMPLEXES; CELL-SURFACES; FULL-LENGTH; C-TERMINUS; BINDING; PROTHROMBIN	The physiological inhibitor of tissue factor (TF) factor Wa (FVIIa), full-length tissue factor pathway inhibitor (TFPIFL) in complex with factor Xa (FXa), has a high affinity for anionic phospholipid membranes, The role of anionic phospholipids in the inhibition of TF.FVIIa-catalyzed FX activation was investigated. FXa generation at a rotating disc coated with TF embedded in a membrane composed of pure phosphatidylcholine (TF PC) or 25% phosphatidylserine and 75% phosphatidylcholine (TF.PSPC) was measured in the presence of preformed complexes of FXa.TFPIFL or FXa.TFPI1-161 (TFPI lacking the third Kunitz domain and C terminus). At TF.PC, FXa.TFPIFL and FXa.TFPI1-161 showed similar rate constants of inhibition (0.07 x 10(8) M-1 s(-1) and 0.1 x 10s RI-1 S-1, respectively). With phosphatidylserine present, the rate constant of inhibition for FXa.TFPIFL increased 3-fold compared with a 9-fold increase in the rate constant for FXa.TFPI1-161. Incubation of TF.PSPC with FXa TFPI,, in the absence of FVIIa followed by depletion of solution FXa.TFPI1-161 showed that FXa.TFPIFL remained bound at the membrane and pursued its inhibitory activity. This was not observed with FXa.TFPI1-161 or at TF.PC membranes. These data suggest that the membrane-bound pool of FXa. TFPIa may be of physiological importance in an on-site regulation of TF.FVIIa activity.	Maastricht Univ, Dept Biochem, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Cardiovasc Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands	Maastricht University; Maastricht University	Lindhout, T (corresponding author), Maastricht Univ, Dept Biochem, NL-6200 MD Maastricht, Netherlands.			Hemker, Coen/0000-0003-1669-2358				ANDREE HAM, 1994, BIOCHEMISTRY-US, V33, P4368, DOI 10.1021/bi00180a034; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; BOM VJJ, 1990, THROMB HAEMOSTASIS, V63, P224; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; CALLANDER NS, 1992, J BIOL CHEM, V267, P876; CASTNER JF, 1984, BIOCHEMISTRY-US, V23, P2203, DOI 10.1021/bi00305a016; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DIAZCOLLIER JA, 1994, THROMB HAEMOSTASIS, V71, P339; DRAKE TA, 1989, AM J PATHOL, V134, P1087; ENJYOJI K, 1995, BIOCHEMISTRY-US, V34, P5725, DOI 10.1021/bi00017a004; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; GEMMELL CH, 1990, BLOOD, V76, P2266; GIESEN PLA, 1991, J BIOL CHEM, V266, P18720; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; HAMAMOTO T, 1993, J BIOL CHEM, V268, P8704; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; JESTY J, 1994, BIOCHEMISTRY-US, V33, P12686, DOI 10.1021/bi00208a020; Kazama Y, 1997, THROMB HAEMOSTASIS, V77, P492; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; Levich V.G., 1962, PHYSICOCHEMICAL HYDR; LINDHOUT MJ, 1978, BIOCHIM BIOPHYS ACTA, V533, P327, DOI 10.1016/0005-2795(78)90379-3; LINDHOUT T, 1994, BIOCHEM J, V297, P131, DOI 10.1042/bj2970131; LINDHOUT T, 1995, THROMB HAEMOSTASIS, V74, P910; Lindhout T, 1996, HAEMOSTASIS, V26, P89; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; NEMERSON Y, 1988, BLOOD, V71, P1; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; NORDFANG O, 1991, BIOCHEMISTRY-US, V30, P10371, DOI 10.1021/bi00107a002; PETERSEN JGL, 1993, J BIOL CHEM, V268, P13344; Petersen LC, 1996, EUR J BIOCHEM, V235, P310, DOI 10.1111/j.1432-1033.1996.0310f.x; RAO LVM, 1995, BIOCHEMISTRY-US, V34, P10867, DOI 10.1021/bi00034a020; RAO LVM, 1992, THROMB HAEMOSTASIS, V67, P654; RAPAPORT SI, 1991, THROMB HAEMOSTASIS, V66, P6; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; Salemink I, 1998, THROMB HAEMOSTASIS, V80, P273, DOI 10.1055/s-0037-1615187; SCHOEN P, 1990, THROMB HAEMOSTASIS, V64, P542; SHU FR, 1976, ANAL CHEM, V48, P1679, DOI 10.1021/ac50006a014; SMITH RL, 1973, J BIOL CHEM, V248, P2418; VALENTIN S, 1993, BLOOD COAGUL FIBRIN, V4, P713, DOI 10.1097/00001721-199304050-00007; Valentin S, 1996, THROMB HAEMOSTASIS, V75, P796; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WILLEMS GM, 1993, BLOOD, V82, P497, DOI 10.1182/blood.V82.2.497.bloodjournal822497; Willems GM, 1998, BIOCHEMISTRY-US, V37, P3321, DOI 10.1021/bi972194+; WUN TC, 1988, J BIOL CHEM, V263, P6001	49	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28225	28232		10.1074/jbc.274.40.28225	http://dx.doi.org/10.1074/jbc.274.40.28225			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497177	hybrid			2022-12-25	WOS:000082912700026
J	Marchio, S; Primo, L; Pagano, M; Palestro, G; Albini, A; Veikkola, T; Cascone, I; Alitalo, K; Bussolino, F				Marchio, S; Primo, L; Pagano, M; Palestro, G; Albini, A; Veikkola, T; Cascone, I; Alitalo, K; Bussolino, F			Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VEGF-C; LYMPHATIC ENDOTHELIUM; SPINDLE CELLS; IN-VITRO; RECEPTOR; ANGIOGENESIS; EXPRESSION; AIDS; PERMEABILITY; CYTOKINES	Recent evidence suggesting vascular endothelial growth factor-C (VEGF-C), which is a regulator of lymphatic and vascular endothelial development, raised the question whether this molecule could be involved in Kaposi's sarcoma (KS), a strongly angiogenic and inflammatory tumor often associated with infection by human immunodeficiency virus-1. This disease is characterized by the presence of a core constituted of three main populations of "spindle" cells, having the features of lymphatic/vascular endothelial cells, macrophagic/ dendritic cells, and of a mixed macrophage endothelial phenotype. In this study we evaluated the biological response of KS cells to VEGF-C, using an immortal cell line derived from a KS lesion (KS IMM), which retains most features of the parental tumor and can induce KS-like sarcomas when injected subcutaneously in nude mice. We show that VEGFR-3, the specific receptor for VEGF-C, is expressed by KS IMM cells grown in vitro and in vivo. In vitro, VEGF-C induces the tyrosine phosphorylation of VEGFR-2, a receptor also for VEGF-A, as well as that of VEGFR-3. The activation of these two receptors in KS IMM cells is followed by a dose-responsive mitogenic and motogenic response. The stimulation of KS IMM cells with a mutant VEGF-C unable to bind and activate VEFGR-2 resulted in no proliferative response and in a weak motogenic stimulation, suggesting that VEGFR-2 is essential in transducing a proliferative signal and cooperates with VEGFR-3 in inducing cell migration. Our data add new insights on the pathogenesis of KS, suggesting that the involvement of endothelial growth factors may not only determine KS-associated angiogenesis, but also play a critical role in controlling KS cell growth and/or migration and invasion.	Univ Turin, Sch Med, Dept Genet Biol & Biochem, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Univ Turin, Sch Med, Dept Biomed Sci & Oncol, I-10100 Turin, Italy; Natl Inst Canc Res, I-16100 Genoa, Italy; Ctr Adv Biotechnol, I-16100 Genoa, Italy; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, SF-00014 Helsinki, Finland	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; University of Genoa; IRCCS AOU San Martino IST; University of Helsinki	Bussolino, F (corresponding author), Univ Turin, Sch Med, Dept Genet Biol & Biochem, Inst Canc Res & Treatment, SP 142, I-10060 Candiolo, Italy.	fbussoli@mail.ircc.unito.it	Bussolino, Federico/AES-3951-2022; Marchiò, Serena/G-9054-2017; Alitalo, Kari K/J-5013-2014; Cascone, Ilaria/Q-7844-2018; Bussolino, Federico/K-2500-2016	Marchiò, Serena/0000-0001-8214-0776; Alitalo, Kari K/0000-0002-7331-0902; Cascone, Ilaria/0000-0003-4903-8926; Bussolino, Federico/0000-0002-5348-1341; PRIMO, Luca/0000-0002-1294-0441; Albini, Adriana/0000-0002-9624-5103				Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; ALLES VV, 1994, BLOOD, V84, P3483; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BECKSTEAD JH, 1985, AM J PATHOL, V119, P294; BROOKS JJ, 1986, LANCET, V2, P1309; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Cornali E, 1996, AM J PATHOL, V149, P1851; DICTOR M, 1988, AM J PATHOL, V130, P411; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; ENSOLI B, 1989, CANCER CELL-MON REV, V1, P93; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FIORELLI V, 1995, J CLIN INVEST, V95, P1723, DOI 10.1172/JCI117849; GOTTLIEB GJ, 1982, HUM PATHOL, V13, P882, DOI 10.1016/S0046-8177(82)80047-6; Hewett PW, 1996, BIOCHEM BIOPH RES CO, V221, P697, DOI 10.1006/bbrc.1996.0659; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Joukov V, 1996, EMBO J, V15, P290; Jussila L, 1998, CANCER RES, V58, P1599; KAAYA EE, 1995, J ACQ IMMUN DEF SYND, V10, P295; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kukk E, 1996, DEVELOPMENT, V122, P3829; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; MAGLIONE D, 1993, ONCOGENE, V8, P925; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PENN I, 1979, TRANSPLANTATION, V27, P8, DOI 10.1097/00007890-197901000-00003; Pepper MS, 1998, J CELL PHYSIOL, V177, P439, DOI 10.1002/(SICI)1097-4652(199812)177:3<439::AID-JCP7>3.0.CO;2-2; REGEZI JA, 1993, AM J PATHOL, V143, P240; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; RUSZCZAK Z, 1987, AM J DERMATOPATH, V9, P388, DOI 10.1097/00000372-198710000-00004; Samaniego F, 1998, AM J PATHOL, V152, P1433; SLAVIN G, 1969, BRIT J CANCER, V23, P349, DOI 10.1038/bjc.1969.45; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; TAYLOR JF, 1972, BRIT J CANCER, V26, P483, DOI 10.1038/bjc.1972.66; UCCINI S, 1994, J PATHOL, V173, P23, DOI 10.1002/path.1711730105; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774; ZHANG YM, 1994, AM J PATHOL, V144, P51; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	50	78	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27617	27622		10.1074/jbc.274.39.27617	http://dx.doi.org/10.1074/jbc.274.39.27617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488101	hybrid			2022-12-25	WOS:000082739100040
J	Morikawa, Y; Goto, T; Sano, K				Morikawa, Y; Goto, T; Sano, K			In vitro assembly of human immunodeficiency virus type 1 Gag protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; NUCLEOCAPSID PROTEIN; CAPSID PROTEIN; MATRIX PROTEIN; PARTICLE MATURATION; INFECTED-CELLS; RNA-BINDING; RELEASE; HIV-1; MYRISTOYLATION	Retroviral Gag protein is sufficient to produce Gag virus-like particles when expressed in higher eukaryotic cells. Here we describe the in vitro assembly reaction of human immunodeficiency virus Gag protein, which consists of two sequential steps showing the optimal conditions for each reaction. Following expression and purification, Gag protein lacking only the C-terminal p6 domain was present as a monomer (50 kDa) by velocity sedimentation analysis. Initial assembly of the Gag protein to 60 S intermediates occurred by dialysis at 4 degrees C in low salt at neutral to alkaline pH. However, higher order of assembly required incubation at 37 degrees C and was facilitated by the addition of Mg2+. Prolonged incubation under these conditions produced complete assembly (600 S), equivalent to Gag virus-like particles obtained from Gag-expressing cells. Neither form disassembled by treatment with nonionic detergent, suggesting that correct assembly might occur in vitro. Electron microscopic observation confirmed that the 600 S assembly products were spherical particles similar to authentic immature human immunodeficiency virus particles. The latter assembly stage but not the former was accelerated by the addition of RNA although not inhibited by RNaseA treatment. These results suggest that Gag protein alone assembles in vitro, but that additional RNA facilitates the assembly reaction.	Kitasato Inst, Minato Ku, Tokyo 1088642, Japan; Osaka Med Coll, Dept Microbiol, Osaka 5698686, Japan	Osaka Medical College	Morikawa, Y (corresponding author), Kitasato Inst, Minato Ku, Shirokane 5-9-1, Tokyo 1088642, Japan.							BERKOWITZ RD, 1993, J VIROL, V67, P7190, DOI 10.1128/JVI.67.12.7190-7200.1993; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; Campbell S, 1999, J VIROL, V73, P2270, DOI 10.1128/JVI.73.3.2270-2279.1999; CAMPBELL S, 1995, J VIROL, V69, P6487, DOI 10.1128/JVI.69.10.6487-6497.1995; DANNULL J, 1994, EMBO J, V13, P1525, DOI 10.1002/j.1460-2075.1994.tb06414.x; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FACKE M, 1993, J VIROL, V67, P4972; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; GOTO T, 1990, ARCH VIROL, V111, P87, DOI 10.1007/BF01310507; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; Gross I, 1998, J VIROL, V72, P4798, DOI 10.1128/JVI.72.6.4798-4810.1998; Gross I, 1997, EUR J BIOCHEM, V249, P592, DOI 10.1111/j.1432-1033.1997.t01-1-00592.x; Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099; HOSHIKAWA N, 1991, J GEN VIROL, V72, P2509, DOI 10.1099/0022-1317-72-10-2509; JOWETT JBM, 1992, J GEN VIROL, V73, P3079, DOI 10.1099/0022-1317-73-12-3079; KAPLAN AH, 1994, J VIROL, V68, P6782, DOI 10.1128/JVI.68.10.6782-6786.1994; KLIKOVA M, 1995, J VIROL, V69, P1093, DOI 10.1128/JVI.69.2.1093-1098.1995; Krausslich HG, 1996, CURR TOP MICROBIOL, V214, P25; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; Morikawa Y, 1996, J BIOL CHEM, V271, P2868, DOI 10.1074/jbc.271.5.2868; Morikawa Y, 1998, J VIROL, V72, P7659, DOI 10.1128/JVI.72.9.7659-7663.1998; PARK J, 1992, J VIROL, V66, P6304, DOI 10.1128/JVI.66.11.6304-6313.1992; REICIN AS, 1995, J VIROL, V69, P642, DOI 10.1128/JVI.69.2.642-650.1995; ROSE JR, 1995, J VIROL, V69, P2751; ROYER M, 1992, J VIROL, V66, P3230, DOI 10.1128/JVI.66.5.3230-3235.1992; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; Schmalzbauer E, 1996, J VIROL, V70, P771, DOI 10.1128/JVI.70.2.771-777.1996; SMITH AJ, 1993, J VIROL, V67, P2266, DOI 10.1128/JVI.67.4.2266-2275.1993; STEWART L, 1990, J VIROL, V64, P5076, DOI 10.1128/JVI.64.10.5076-5092.1990; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vogt VM, 1996, CURR TOP MICROBIOL, V214, P95; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; Wang CT, 1998, J VIROL, V72, P7950, DOI 10.1128/JVI.72.10.7950-7959.1998; YU XF, 1992, J VIROL, V66, P4966, DOI 10.1128/JVI.66.8.4966-4971.1992; Zhang WH, 1996, J GEN VIROL, V77, P743, DOI 10.1099/0022-1317-77-4-743	38	34	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27997	28002		10.1074/jbc.274.39.27997	http://dx.doi.org/10.1074/jbc.274.39.27997			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488150	hybrid			2022-12-25	WOS:000082739100089
J	Rees, D; Sloane, T; Jessup, W; Dean, RT; Kritharides, L				Rees, D; Sloane, T; Jessup, W; Dean, RT; Kritharides, L			Apolipoprotein A-I stimulates secretion of apolipoprotein E by foam cell macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; E-DEFICIENT MICE; REVERSE CHOLESTEROL TRANSPORT; BONE-MARROW TRANSPLANTATION; HUMAN THP-1 MACROPHAGES; TRANSGENIC MICE; APOPROTEIN-E; SEVERE HYPERCHOLESTEROLEMIA; MOUSE MACROPHAGES	Apolipoprotein A-I (apoA-I) overexpression inhibits atherogenesis in mice, and apolipoprotein E (apoE) secreted by foam cell macrophages may exert antiatherogenic effects within the arterial wall. We hypothesized that interaction between apoA-I and apoE contributed to the antiatherogenic properties of apoA-I, and therefore investigated whether apoA-I stimulated secretion of apoE by foam cell macrophages, Cholesterol enrichment of primary murine and human macrophages increased spontaneous apoE secretion 2-fold, as quantified by Western blot and chemiluminescence detection. Human apoA-I caused a further marked increase of apoE secretion from both murine (3.8-fold, p < 0.01) and human (3.2-fold, p = 0.01) foam cells in a time- and concentration- dependent manner, and this increase was confirmed by immunoprecipitation of [S-35]methionine-labeled macrophage apoE, The protein synthesis inhibitor cycloheximide, but not the transcription inhibitor actinomycin D, markedly inhibited apoE secretion to apoA-I (73.1 +/- 9.8% inhibition at 4 h) and completely suppressed apoE secretion beyond 4 h, Pretreatment of macrophages with Pronase inhibited initial apoA-I-mediated apoE secretion by 70.5 +/- 6.5% at 2 h, but by 8 h apoA-I-induced apoE secretion was the same in Pronase-pretreated and non-pretreated cells. Non-apolipoprotein-mediated cholesterol efflux induced by trimethyl-beta cyclodextrin did not enhance apoE secretion, whereas phospholipid vesicles inducing the same degree of cholesterol efflux substantially enhanced apoE secretion, and apoA-I and phospholipid vesicles in combination demonstrated additive induction of apoE secretion. We conclude that apoA-I concurrently stimulates apoE secretion and cholesterol efflux from foam cell macrophages and that lipoprotein-derived apoA-I may enhance local secretion and accumulation of apoE in atherosclerotic lesions.	Heart Res Inst, Clin Res Grp, Sydney, NSW 2050, Australia; Heart Res Inst, Cell Biol Grp, Sydney, NSW 2050, Australia; Univ Sydney, Concord Hosp, Dept Cardiol, Sydney, NSW 2139, Australia	University of Sydney; Heart Research Institute; University of Sydney; Heart Research Institute; Concord Repatriation General Hospital; University of Sydney	Kritharides, L (corresponding author), Heart Res Inst, Clin Res Grp, 145 Missenden Rd, Sydney, NSW 2050, Australia.		Kritharides, Leonard/AAQ-2720-2020	Dean, Roger Thornton/0000-0002-8859-8902				Asztalos B, 1997, ARTERIOSCL THROM VAS, V17, P1630, DOI 10.1161/01.ATV.17.9.1630; ASZTALOS BF, 1995, ARTERIOSCL THROM VAS, V15, P1419, DOI 10.1161/01.ATV.15.9.1419; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BASU SK, 1982, J BIOL CHEM, V257, P9788; BEDOSSA P, 1989, ARCH PATHOL LAB MED, V113, P777; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; Bielicki JK, 1999, J LIPID RES, V40, P85; Boisvert WA, 1997, ATHEROSCLEROSIS, V134, P365, DOI 10.1016/S0021-9150(97)89855-3; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; BOISVERT WA, J LIPID RES, V40, P80699; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BRAND K, 1993, J CLIN INVEST, V91, P2031, DOI 10.1172/JCI116425; Brown AJ, 1996, J LIPID RES, V37, P320; CLAY MA, 1995, BIOCHEMISTRY-US, V34, P11142, DOI 10.1021/bi00035a020; CONTRERAS JA, 1994, ARTERIOSCLER THROMB, V14, P443, DOI 10.1161/01.ATV.14.3.443; DENG J, 1995, J LIPID RES, V38, P217; DENG JT, 1995, J LIPID RES, V36, P2129; DORY L, 1991, J LIPID RES, V32, P783; Duan HW, 1997, J BIOL CHEM, V272, P31156, DOI 10.1074/jbc.272.49.31156; Fan JL, 1998, J CLIN INVEST, V101, P2151, DOI 10.1172/JCI1599; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FIELDING CJ, 1995, J LIPID RES, V36, P211; Garner B, 1997, ATHEROSCLEROSIS, V128, P47, DOI 10.1016/S0021-9150(96)05979-5; GARNER B, 1994, BIOCHEM J, V301, P421, DOI 10.1042/bj3010421; GELISSEN I, 1999, IN PRESS J LIPID RES, V40; Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852; GORDON V, 1983, J BIOL CHEM, V258, P6202; GOTTO AM, 1986, METHOD ENZYMOL, V128, P3; Graham A, 1996, ATHEROSCLEROSIS, V120, P135, DOI 10.1016/0021-9150(95)05695-5; HARA H, 1991, J BIOL CHEM, V266, P3080; Hasty AH, 1999, CIRCULATION, V99, P2571, DOI 10.1161/01.CIR.99.19.2571; HERSCOVITZ H, 1992, J LIPID RES, V33, P791; HO YK, 1980, J LIPID RES, V21, P391; Huang YD, 1998, J BIOL CHEM, V273, P17483, DOI 10.1074/jbc.273.28.17483; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Jessup W, 1997, ARTERIOSCL THROM VAS, V17, P18, DOI 10.1161/01.ATV.17.1.18; JESSUP W, 1990, BIOCHEM J, V265, P399, DOI 10.1042/bj2650399; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P167, DOI 10.1016/0005-2760(92)90287-6; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; KELLY ME, 1994, CELL IMMUNOL, V159, P124, DOI 10.1006/cimm.1994.1302; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KOO C, 1985, J BIOL CHEM, V260, P1934; Kritharides L, 1996, J BIOL CHEM, V271, P27450, DOI 10.1074/jbc.271.44.27450; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLYSTAUDERMAN M, 1993, J LIPID RES, V34, P190; Linker A., 1972, METHODS ENZYMOL, P902; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1989, J LIPID RES, V30, P1055; MAZZONE T, 1994, J LIPID RES, V35, P1345; MCLEAN JW, 1983, J BIOL CHEM, V258, P8993; OBRIEN KD, 1994, AM J PATHOL, V144, P538; Oram JF, 1996, J LIPID RES, V37, P2473; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RAJAVASHISTH TB, 1985, P NATL ACAD SCI USA, V82, P8085, DOI 10.1073/pnas.82.23.8085; RALL SC, 1982, J BIOL CHEM, V257, P4171; REICHL D, 1994, ATHEROSCLEROSIS, V105, P117, DOI 10.1016/0021-9150(94)90042-6; ROHEIM PS, 1990, EUR HEART J, V11, P225, DOI 10.1093/eurheartj/11.suppl_E.225; Rothblat G H, 1986, Methods Enzymol, V129, P628; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; SMITH EB, 1990, EUR HEART J, V11, P72, DOI 10.1093/eurheartj/11.suppl_E.72; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; Spangenberg J, 1997, BBA-LIPID LIPID MET, V1349, P109, DOI 10.1016/S0005-2760(97)00123-9; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; WANGIVERSON P, 1985, BIOCHIM BIOPHYS ACTA, V834, P256, DOI 10.1016/0005-2760(85)90163-8; WERB Z, 1989, AM J PATHOL, V134, P661; WESTMAN J, 1995, SCAND J CLIN LAB INV, V55, P23, DOI 10.3109/00365519509075375; Westman JA, 1995, NUTR METAB CARDIOVAS, V5, P297; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; ZANNIS VI, 1986, METHOD ENZYMOL, V128, P690; Zhang WY, 1996, J BIOL CHEM, V271, P28641, DOI 10.1074/jbc.271.45.28641	82	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27925	27933		10.1074/jbc.274.39.27925	http://dx.doi.org/10.1074/jbc.274.39.27925			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488140	hybrid			2022-12-25	WOS:000082739100079
J	Shibutani, S; Fernandes, A; Suzuki, N; Zhou, L; Johnson, F; Grollman, AP				Shibutani, S; Fernandes, A; Suzuki, N; Zhou, L; Johnson, F; Grollman, AP			Mutagenesis of the N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine DNA adduct in mammalian cells - Sequence context effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER-MICROSOMES; FOOD-DERIVED MUTAGEN; HETEROCYCLIC AMINES; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE PHIP; METABOLIC-ACTIVATION; COOKED FOODS; PYRIDINE PHIP; OPPOSITE DC; IDENTIFICATION; CARCINOGEN	Site-specifically modified oligodeoxynucleotides were used to investigate the mutagenic properties of a major cooked food mutagen-derived DNA adduct, N-(deoxyguano sin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (dG-C8-PhIP). dG-C8-PhIP-modified oligodeoxynucleotides were prepared by reacting an oligodeoxynucleotide containing a single dG (5'-TCCTC-CTX (G) under bar CCTCTC, where X = C, A, G, or T) with N-acetoxy-PhIP. The unmodified and dG-C8-PhIP-modified oligomers were inserted into single stranded phagemid vectors. These single-stranded vectors were transfected into simian kidney (COS-7) cells. The progeny plasmid obtained was used to transform Escherichia coli DH10B, When dC was at the 5'-flanking position to dG-C8-PhIP, preferential incorporation of dCMP, the correct base, was observed opposite the dG-C8-PhIP. Targeted G --> T transversions were detected, along with lesser amounts of G --> A transitions and G --> C transversions. No mutations were detected for the unmodified vector. The influence of sequence context on the dG-C8-PhIP mutation frequency and spectrum was also explored. When the dC 5'-flanking base was replaced by dT, dG or dG, the mutational spectra were similar to that observed with dC-flanking base. Higher mutational frequencies (28-30%) were observed when dC or dG was 5' to dG-C8-PhIP, A lower mutational frequency (13%) was observed when dA was at the 5' to the lesion. Single-base deletions were detected only when dG or dT flanked the adduct, We conclude that dG-C8-PhIP is mutagenic, generating primarily G --> T transversions in mammalian cells. The mutational frequency and specificity of dG-C8-PhIP vary depending on the neighboring sequence context.	SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Shibutani, S (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.	shinya@pharm.som.sunysb.edu		Shibutani, Shinya/0000-0003-4190-9512	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04068] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABUZEID M, 1992, CARCINOGENESIS, V13, P1307, DOI 10.1093/carcin/13.8.1307; BUONARATI MH, 1990, MUTAT RES, V245, P185, DOI 10.1016/0165-7992(90)90048-O; CAROTHRS AM, 1994, CHEM RES TOXICOL, V7, P209, DOI 10.1021/tx00038a015; CHOU HC, 1995, CANCER RES, V55, P525; Crofts FG, 1997, CARCINOGENESIS, V18, P1793, DOI 10.1093/carcin/18.9.1793; Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969; DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408; ESUMI H, 1989, JPN J CANCER RES, V80, P1176, DOI 10.1111/j.1349-7006.1989.tb01651.x; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Felton J. S, 1990, HDB EXPT PHARM, V94, P471; FELTON JS, 1986, ENVIRON HEALTH PERSP, V67, P17, DOI 10.2307/3430312; FELTON JS, 1991, MUTAT RES, V259, P205, DOI 10.1016/0165-1218(91)90118-6; FRANDSEN H, 1991, MUTAGENESIS, V6, P93, DOI 10.1093/mutage/6.1.93; FRANDSEN H, 1992, CARCINOGENESIS, V13, P629, DOI 10.1093/carcin/13.4.629; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; GROSS GA, 1993, CARCINOGENESIS, V14, P2313, DOI 10.1093/carcin/14.11.2313; GROSS GA, 1992, J CHROMATOGR, V592, P271, DOI 10.1016/0021-9673(92)85095-B; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLME JA, 1989, CARCINOGENESIS, V10, P1389, DOI 10.1093/carcin/10.8.1389; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503; JOHNSON F, 1992, J AM CHEM SOC, V114, P4923, DOI 10.1021/ja00038a079; KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910; LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39; LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016; LYNCH AM, 1992, CANCER RES, V52, P6216; MALFATTI MA, 1994, CHEM RES TOXICOL, V7, P139, DOI 10.1021/tx00038a005; MANABE S, 1991, CARCINOGENESIS, V12, P1945, DOI 10.1093/carcin/12.10.1945; Mao B, 1998, BIOCHEMISTRY-US, V37, P81, DOI 10.1021/bi972257o; Mao B, 1998, BIOCHEMISTRY-US, V37, P95, DOI 10.1021/bi972258g; MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357; MORGENTHALER PML, 1995, CARCINOGENESIS, V16, P713, DOI 10.1093/carcin/16.4.713; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1988, P NATL ACAD SCI USA, V85, P1586, DOI 10.1073/pnas.85.5.1586; NORMAN D, 1989, BIOCHEMISTRY-US, V28, P7462, DOI 10.1021/bi00444a046; Okonogi H, 1997, CARCINOGENESIS, V18, P745, DOI 10.1093/carcin/18.4.745; PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713; Sadrieh N, 1996, CANCER RES, V56, P2683; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIFFMAN MH, 1990, PROG CLIN BIOL RES, V340, P205; SHIBUTANI S, 1991, CARCINOGENESIS, V12, P813, DOI 10.1093/carcin/12.5.813; Shibutani S, 1998, BIOCHEMISTRY-US, V37, P12034, DOI 10.1021/bi981059+; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P4615, DOI 10.1021/bi00068a019; Shirai T, 1997, CANCER RES, V57, P195; SUGIMURA T, 1994, J NATL CANCER I, V86, P2, DOI 10.1093/jnci/86.1.2; SUGIMURA T, 1982, CANCER, V49, P1970, DOI 10.1002/1097-0142(19820515)49:10<1970::AID-CNCR2820491005>3.0.CO;2-F; SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3; TAKAYAMA K, 1989, JPN J CANCER RES, V80, P1145, DOI 10.1111/j.1349-7006.1989.tb01644.x; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TURTELTAUB KW, 1990, CARCINOGENESIS, V11, P941, DOI 10.1093/carcin/11.6.941; USHIYAMA H, 1991, CARCINOGENESIS, V12, P1417, DOI 10.1093/carcin/12.8.1417; WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468; WALLIN H, 1990, CARCINOGENESIS, V11, P489, DOI 10.1093/carcin/11.3.489; WU RW, 1995, CARCINOGENESIS, V16, P1207, DOI 10.1093/carcin/16.5.1207; YadollahiFarsani M, 1996, CARCINOGENESIS, V17, P617, DOI 10.1093/carcin/17.4.617; ZHAO K, 1994, CARCINOGENESIS, V15, P1285, DOI 10.1093/carcin/15.6.1285	57	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27433	27438		10.1074/jbc.274.39.27433	http://dx.doi.org/10.1074/jbc.274.39.27433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488075	hybrid			2022-12-25	WOS:000082739100014
J	Flagella, M; Clarke, LL; Miller, ML; Erway, LC; Giannella, RA; Andringa, A; Gawenis, LR; Kramer, J; Duffy, JJ; Doetschman, T; Lorenz, JN; Yamoah, EN; Cardell, EL; Shull, GE				Flagella, M; Clarke, LL; Miller, ML; Erway, LC; Giannella, RA; Andringa, A; Gawenis, LR; Kramer, J; Duffy, JJ; Doetschman, T; Lorenz, JN; Yamoah, EN; Cardell, EL; Shull, GE			Mice lacking the basolateral Na-K-2Cl cotransporter have impaired epithelial chloride secretion and are profoundly deaf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; MEDULLARY COLLECTING DUCT; GASTRIC PARIETAL-CELLS; MOLECULAR-CLONING; CYSTIC-FIBROSIS; ACID-SECRETION; FUNCTIONAL EXPRESSION; NA+/H+ EXCHANGER; HCO3 SECRETION; GERBIL COCHLEA	In chloride-secretory epithelia, the basolateral Na-K-2Cl cotransporter (NKCC1) is thought to play a major role in transepithelial Cl- and fluid transport. Similarly, in marginal cells of the inner ear, NKCC1 has been proposed as a component of the entry pathway for K+ that is secreted into the endolymph, thus playing a critical role in hearing. To test these hypotheses, we generated and analyzed an NKCC1-deficient mouse, Homozygous mutant (Nkcc1(-/-)) mice exhibited growth retardation, a 28% incidence of death around the time of weaning, and mild difficulties in maintaining their balance. Mean arterial blood pressure was significantly reduced in both heterozygous and homozygous mutants, indicating an important function for NKCC1 in the maintenance of blood pressure. cAMP-induced short circuit currents, which are dependent on the CFTR Cl- channel, were reduced in jejunum, cecum, and trachea of Nkcc1(-/-) mice, indicating that NRCC1 contributes do cAMP-induced Cl- secretion. In contrast, secretion of gastric acid in adult Nkcc1(-/-) stomachs and enterotoxin-stimulated fluid secretion in the intestine of suckling Nkcc1(-/-) mice were normal, Finally, homozygous mutants were deaf, and histological analysis of the inner ear revealed a collapse of the membranous labyrinth, consistent with a critical role for NKCC1 in transepithelial K+ movements involved in generation of the K+-rich endolymph and the endocochlear potential.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Sci Biol, Cincinnati, OH 45221 USA; Univ Missouri, Dalton Cardiovasc Res Ctr, Dept Vet Biomed Sci, Columbia, MO 65211 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Missouri System; University of Missouri Columbia	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050594, R01DK050594, R29DK048816, R01DK048816, R56DK048816] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41496] Funding Source: Medline; NIDDK NIH HHS [DK48816, DK50594, R29 DK048816] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYALON A, 1980, AM J PHYSIOL, V239, pG532, DOI 10.1152/ajpgi.1980.239.6.G532; BOSHER SK, 1978, NATURE, V273, P377, DOI 10.1038/273377a0; BROWN RD, 1976, TOXICOL APPL PHARM, V38, P137, DOI 10.1016/0041-008X(76)90167-8; BROWN RD, 1978, ANNU REV PHARMACOL, V18, P233, DOI 10.1146/annurev.pa.18.040178.001313; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; CLARKE LL, 1992, AM J PHYSIOL, V263, pL519, DOI 10.1152/ajplung.1992.263.5.L519; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; Clarke LL, 1996, AM J PHYSIOL-GASTR L, V270, pG259, DOI 10.1152/ajpgi.1996.270.2.G259; Crouch JJ, 1997, J HISTOCHEM CYTOCHEM, V45, P773, DOI 10.1177/002215549704500601; CUTHBERT AW, 1994, BRIT J PHARMACOL, V112, P31, DOI 10.1111/j.1476-5381.1994.tb13024.x; DAndrea L, 1996, J BIOL CHEM, V271, P28969, DOI 10.1074/jbc.271.46.28969; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; ERWAY LC, 1993, HEARING RES, V65, P125, DOI 10.1016/0378-5955(93)90207-H; GAMBA G, 1994, J BIOL CHEM, V269, P17713; GIANNELLA RA, 1976, INFECT IMMUN, V14, P95, DOI 10.1128/IAI.14.1.95-99.1976; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Guba M, 1996, GASTROENTEROLOGY, V111, P1558, DOI 10.1016/S0016-5085(96)70018-5; HAAS M, 1994, AM J PHYSIOL, V267, P869; HE X, 1997, EUR J PHYSL, V433, P260; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; IWANO T, 1989, J HISTOCHEM CYTOCHEM, V37, P353, DOI 10.1177/37.3.2537354; Joo NS, 1998, AM J PHYSIOL-GASTR L, V274, pG633, DOI 10.1152/ajpgi.1998.274.4.G633; Kaplan MR, 1996, J CLIN INVEST, V98, P723, DOI 10.1172/JCI118844; Kaplan MR, 1996, ANNU REV PHYSIOL, V58, P649, DOI 10.1146/annurev.ph.58.030196.003245; Klingensmith ME, 1996, SURGERY, V120, P242, DOI 10.1016/S0039-6060(96)80294-7; KUIJPERS W, 1970, PFLUG ARCH EUR J PHY, V320, P348, DOI 10.1007/BF00588213; KUSAKARI J, 1978, LARYNGOSCOPE, V88, P12; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; MUALLEM S, 1988, J BIOL CHEM, V263, P14703; MUALLEM S, 1985, J BIOL CHEM, V260, P6641; ONEILL WC, 1995, AM J PHYSIOL-CELL PH, V269, pC267, DOI 10.1152/ajpcell.1995.269.1.C267; OWEN NE, 1989, AM J PHYSIOL, V257, pC629, DOI 10.1152/ajpcell.1989.257.4.C629; PARADISO AM, 1986, AM J PHYSIOL, V250, pG524, DOI 10.1152/ajpgi.1986.250.4.G524; PARADISO AM, 1989, AM J PHYSIOL, V257, pC554, DOI 10.1152/ajpcell.1989.257.3.C554; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; QUICK CA, 1975, ANN OTO RHINOL LARYN, V84, P94, DOI 10.1177/000348947508400114; ROUSE RC, 1984, ACTA OTO-LARYNGOL, V98, P61, DOI 10.3109/00016488409107535; RYBAK LP, 1986, ACTA OTO-LARYNGOL, V101, P59, DOI 10.3109/00016488609108608; Sakaguchi N, 1998, HEARING RES, V118, P114, DOI 10.1016/S0378-5955(98)00022-7; SCHULTE BA, 1989, J HISTOCHEM CYTOCHEM, V37, P127, DOI 10.1177/37.2.2536055; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; SEWELL WF, 1984, HEARING RES, V14, P305, DOI 10.1016/0378-5955(84)90057-1; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; SOYBEL DI, 1995, AM J PHYSIOL-CELL PH, V269, pC242, DOI 10.1152/ajpcell.1995.269.1.C242; STUARTTILLEY A, 1994, AM J PHYSIOL, V266, pC559, DOI 10.1152/ajpcell.1994.266.2.C559; THOMAS HA, 1991, CELL REGUL, V2, P727, DOI 10.1091/mbc.2.9.727; Wang Z, 1996, J BIOL CHEM, V271, P7835, DOI 10.1074/jbc.271.13.7835	53	298	304	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26946	26955		10.1074/jbc.274.38.26946	http://dx.doi.org/10.1074/jbc.274.38.26946			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480906	hybrid			2022-12-25	WOS:000082570700045
J	Rich, RL; Kreikemeyer, B; Owens, RT; LaBrenz, S; Narayana, SVL; Weinstock, GM; Murray, BE; Hook, M				Rich, RL; Kreikemeyer, B; Owens, RT; LaBrenz, S; Narayana, SVL; Weinstock, GM; Murray, BE; Hook, M			Ace is a collagen-binding MSCRAMM from Enterococcus faecalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; VIRULENCE DETERMINANT; SEPTIC ARTHRITIS; PROTEIN; ADHESIN; IDENTIFICATION; EXPRESSION; GENE; GENERATION; ADHERENCE	A putative collagen-binding MSCRAMM, Ace, of Enterococcus faecalis was identified by searching bacterial genome data bases for proteins containing domains homologous to the ligand-binding region of Cna, the collagen-binding MSCRAMM from Staphylococcus aureus. Ace was predicted to have a molecular mass of 71 kDa and contains features characteristic of cell surface proteins on Gram-positive bacteria, including a LPXTG motif for cross-linking to the cell wall. The N-terminal region of Ace contained a region (residues 174-319) in which 56% of the residues are identical or similar when compared with the minimal ligand-binding region of Cna (Cna 151-318); the remainder of the Ace A domain has 46% similarity with the corresponding region of the Cna A domain. Antibodies raised against recombinant Ace A domain were used to verify the cell surface expression of Ace on E. faecalis. These antibodies also effectively inhibited the adhesion of enterococcal cells to a collagen substrate, suggesting that Ace is a functional collagen-binding MSCRAMM. Structural modeling of the conserved region in Ace (residues 174-319) suggested a structure very similar to that reported for residues 151-318 of the Cna collagen-binding domain in which the ligand-binding site was identified as a trench transversing a beta-sheet face (Symersky, J., Patti, J. M., Carson, M., House-Pompeo, K., Teale, M., Moore, D., Jin, L., DeLucas, L. J., Hook, M., and Narayana, S. V. L. (1997) Nat. Struct. Biol. 10, 833-838). Biochemical analyses of recombinant Ace and Cna A domains supported the modeling data in that the secondary structures were similar as determined by CD spectroscopy and both proteins bound at multiple sites in type I collagen with micromolar affinities, but with different apparent kinetics. We conclude that Ace is a collagen-binding MSCRAMM on enterococci and is structurally and functionally related to the staphylococcal Cna protein.	Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Univ Alabama, Ctr Macromol Crystallog, Birmingham, AL 35294 USA; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA; Univ Texas, Sch Med, Ctr Study Emerging & Reemerging Pathogens, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Internal Med, Div Infect Dis, Houston, TX 77030 USA	Texas A&M University System; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas System; University of Texas System	Hook, M (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA.		Weinstock, George M/C-6314-2013	Weinstock, George M/0000-0002-2997-4592; Kreikemeyer, Bernd/0000-0001-9527-5098	NIAMS NIH HHS [AR44415] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044415] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; CAPARON MG, 1987, P NATL ACAD SCI USA, V84, P8677, DOI 10.1073/pnas.84.23.8677; deChateau M, 1996, P NATL ACAD SCI USA, V93, P8490, DOI 10.1073/pnas.93.16.8490; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Gillaspy AF, 1997, GENE, V196, P239, DOI 10.1016/S0378-1119(97)00256-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; House-Pompeo Karen, 1994, Methods (Orlando), V6, P134, DOI 10.1006/meth.1994.1016; JETT BD, 1994, CLIN MICROBIOL REV, V7, P462, DOI 10.1128/CMR.7.4.462-478.1994; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; Nilsson IM, 1998, J CLIN INVEST, V101, P2640, DOI 10.1172/JCI1823; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; PATTI JM, 1992, J BIOL CHEM, V267, P4766; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; SAHM DF, 1989, ANTIMICROB AGENTS CH, V33, P1588, DOI 10.1128/AAC.33.9.1588; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Singh KV, 1998, J INFECT DIS, V178, P1416, DOI 10.1086/314453; SWITALSKI LM, 1993, MOL MICROBIOL, V7, P99, DOI 10.1111/j.1365-2958.1993.tb01101.x; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; TALAY SR, 1991, MOL MICROBIOL, V5, P1727, DOI 10.1111/j.1365-2958.1991.tb01921.x; VALENTINWEIGAND P, 1988, AM J VET RES, V49, P485; Xiao JG, 1998, FEMS IMMUNOL MED MIC, V21, P287, DOI 10.1111/j.1574-695X.1998.tb01176.x; ZAREBA TW, 1996, CURR MICROBIOL, V34, P6	28	166	181	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26939	26945		10.1074/jbc.274.38.26939	http://dx.doi.org/10.1074/jbc.274.38.26939			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480905	hybrid			2022-12-25	WOS:000082570700044
J	Yang, JP; Hori, M; Takahashi, N; Kawabe, T; Kato, H; Okamoto, T				Yang, JP; Hori, M; Takahashi, N; Kawabe, T; Kato, H; Okamoto, T			NF-kappa B subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2	ONCOGENE			English	Article						53BP2; NF-kappa B; cell death; interaction	TUMOR-SUPPRESSOR P53; ANKYRIN REPEATS; SH3 DOMAINS; APOPTOSIS; PROTEIN; ACTIVATION; BCL-2; BAX; DNA; LOCALIZATION	Nuclear factor kappa B (NF-kappa B) is a transcription factor that controls the expression of many cellular and viral genes. The p65 (RelA) subunit plays a critical role as a transcriptional activator and recent observations have highlighted its role in the control of apoptosis, Here we report that 53BP2, a protein previously identified by interaction with wild type p53 and Bcl-2, also binds to p65 in a yeast two-hybrid system. This specific interaction was confirmed by pull-down assay in vitro and by a mammalian two-hybrid assay irt vivo. We observed that full-length 53BP2 fused to GFP had a punctate distribution in cytoplasm, predominantly in perinuclear region whereas the N-terminal 53BP2 localized in cytoplasm and C-terminal 53BP2 localized in the nucleus. Furthermore, we found that overexpression of GFP-53BP2 induced apoptosis in transiently transfected cells. Neither the N-terminal nor the C-terminal of 53BP2 fused to GFP induced cell death. Interestingly, co-transfection with a p65 expression plasmid significantly inhibited 53BP2-induced cell death. The previous findings that 53BP2 bound to p53 and Bcl-2 together with our present observations suggest that 53BP2 may play a central role in the regulation of apoptosis and cell growth.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Hokkaido Univ, Fac Pharmaceut Sci, Dept Mol Biol, Sapporo, Hokkaido 0608636, Japan	Nagoya City University; Hokkaido University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Mizuho Cho, Nagoya, Aichi 4678601, Japan.							Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HARDIN JA, 1992, TOXICOL APPL PHARM, V117, P155, DOI 10.1016/0041-008X(92)90232-H; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Lippincott-Schwartz J, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P243; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; PINES J, 1995, TRENDS GENET, V11, P326, DOI 10.1016/S0168-9525(00)89092-7; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Sakurada S, 1996, INT IMMUNOL, V8, P1483, DOI 10.1093/intimm/8.10.1483; Sambrook J., 2002, MOL CLONING LAB MANU; Sato T, 1998, AIDS RES HUM RETROV, V14, P293, DOI 10.1089/aid.1998.14.293; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SIEBENLIST U, 1995, INDUCIBLE GENE EXPRE, V1, P93; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yamabhai M, 1997, ANAL BIOCHEM, V247, P143, DOI 10.1006/abio.1997.2040; Yang JP, 1997, CYTOGENET CELL GENET, V78, P61, DOI 10.1159/000134630	41	97	103	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5177	5186		10.1038/sj.onc.1202904	http://dx.doi.org/10.1038/sj.onc.1202904			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498867				2022-12-25	WOS:000082555700006
J	Jiang, H; Takeda, K; Lazarovici, P; Katagiri, Y; Yu, ZX; Dickens, G; Chabuk, A; Liu, XW; Ferrans, V; Guroff, G				Jiang, H; Takeda, K; Lazarovici, P; Katagiri, Y; Yu, ZX; Dickens, G; Chabuk, A; Liu, XW; Ferrans, V; Guroff, G			Nerve growth factor (NGF)-induced calcium influx and intracellular calcium mobilization in 3T3 cells expressing NGF receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY NEUROTROPHIN RECEPTOR; FACTOR-INDUCED INCREASE; PC12 CELLS; SIGNAL-TRANSDUCTION; NEURONAL DIFFERENTIATION; RAT PHEOCHROMOCYTOMA; CHROMAFFIN CELLS; FIBER OUTGROWTH; TRK RECEPTORS; RELEASE	The neurotrophins have been implicated in the acute regulation of synaptic plasticity. Neurotrophin-stimulated presynaptic calcium uptake appears to play a key role in this process. To understand the mechanism of neurotrophin-stimulated calcium uptake, the regulation of calcium uptake and intracellular mobilization by nerve growth factor (NGF) was investigated using NCH 3T3 cells stably transfected with either the high affinity NGF receptor p140(trk) (3T3-Trk) or the low affinity NGF receptor p75(NGFR) (3T3-p75). In 3T3-Trk cells, NGF increased both calcium uptake and intracellular calcium mobilization. In 3T3-p75 cells, NGF increased calcium uptake but not intracellular calcium mobilization. K-252a alone increased intracellular calcium in 3T3-Trk cells but not in 3T3-p75 cells. Nifedipine, an inhibitor of calcium uptake through L-type calcium channels, inhibited the action of NGF on both 3T3-Trk cells and 3T3-p75 cells, indicating that both p140(trk) and p75NGFR receptors are linked to nifedipine-sensitive L-type calcium channels. These studies show that either NGF receptor will support increases in intracellular calcium but that p140(trK) does so by increasing both uptake and mobilization, whereas p75NGFR does so by increasing uptake only.	NICHHD, Growth Factors Sect, NIH, Bethesda, MD 20892 USA; NHLBI, Pathol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Jiang, H (corresponding author), Henry Ford Hlth Sci Ctr, William T Gossett Neurol Labs, 1 Ford Pl,4D Res, Detroit, MI 48202 USA.							ALOE L, 1979, P NATL ACAD SCI USA, V76, P1246, DOI 10.1073/pnas.76.3.1246; ALONSO AP, 1986, FEBS LETT, V208, P48; ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Blochl A, 1996, J BIOL CHEM, V271, P21100; Canossa M, 1997, P NATL ACAD SCI USA, V94, P13279, DOI 10.1073/pnas.94.24.13279; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; COLLINS F, 1991, J NEUROSCI, V11, P2582; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; DeBernardi MA, 1996, J BIOL CHEM, V271, P6092, DOI 10.1074/jbc.271.11.6092; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; Dickens G, 1997, J NEUROSCI RES, V47, P271, DOI 10.1002/(SICI)1097-4547(19970201)47:3<271::AID-JNR5>3.0.CO;2-F; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HASHIMOTO S, 1986, J NEUROCHEM, V46, P1599, DOI 10.1111/j.1471-4159.1986.tb01782.x; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; Jiang H, 1997, J CELL BIOCHEM, V66, P229, DOI 10.1002/(SICI)1097-4644(19970801)66:2<229::AID-JCB10>3.0.CO;2-C; Jiang H, 1997, J BIOL CHEM, V272, P6835, DOI 10.1074/jbc.272.11.6835; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KOZAK A, 1992, J NEUROSCI RES, V33, P30, DOI 10.1002/jnr.490330105; Kruttgen A, 1998, P NATL ACAD SCI USA, V95, P9614, DOI 10.1073/pnas.95.16.9614; LANDRETH G, 1980, NATURE, V283, P202, DOI 10.1038/283202a0; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; Liu HY, 1996, J NEUROSCI, V16, P7557; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MARTINEZ HJ, 1985, P NATL ACAD SCI USA, V82, P7777, DOI 10.1073/pnas.82.22.7777; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MINTA A, 1989, J BIOL CHEM, V264, P8171; MOBLEY WC, 1985, SCIENCE, V229, P282; Muragaki Y, 1997, J NEUROSCI, V17, P530; NIKODIJEVIC B, 1992, J NEUROSCI RES, V31, P591, DOI 10.1002/jnr.490310402; NIKODIJEVIC B, 1990, J NEUROSCI RES, V26, P288, DOI 10.1002/jnr.490260304; NIKODIJEVIC B, 1991, J NEUROSCI RES, V28, P192, DOI 10.1002/jnr.490280206; NIKODIJEVIC B, 1995, J NEUROSCI RES, V40, P495; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Sala R, 1998, EUR J NEUROSCI, V10, P2185, DOI 10.1046/j.1460-9568.1998.00227.x; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Stoop R, 1996, J NEUROSCI, V16, P3256; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; vonBartheld CS, 1996, J NEUROSCI, V16, P2995	57	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26209	26216		10.1074/jbc.274.37.26209	http://dx.doi.org/10.1074/jbc.274.37.26209			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473574	hybrid			2022-12-25	WOS:000082469700040
J	Yang, EY; Schulman, H				Yang, EY; Schulman, H			Structural examination of autoregulation of multifunctional calcium/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASES; CALMODULIN-BINDING; MUTATIONAL ANALYSIS; CA-2+ CALMODULIN; AUTOINHIBITORY DOMAIN; CATALYTIC SUBUNIT; AUTOPHOSPHORYLATION DOMAINS; AUTONOMOUS ENZYME; BASIC RESIDUES; SMOOTH-MUSCLE	Regulation of Ca2+/calmodulin-dependent protein kinase II is likely based on an auto-inhibitory mechanism in which a segment of the kinase occupies the catalytic site in the absence of calmodulin, We analyze potential auto-inhibitory associations by employing charge reversal and hydrophobic-to-charged residue mutagenesis, We identify interacting amino acid pairs by using double mutants to test which modification in the catalytic domain complements a given change in the auto-inhibitory domain. Our studies identify the core pseudosubstrate sequence (residues 297-300) but reveal that distinct sequences centered about the autophosphorylation site at Thr-286 are involved in the critical auto-inhibitory interactions. Individual changes in any of the residues Arg-274, His-282, Arg-283, Lys-291, Arg-297, Phe-293, and Asn-294 in the auto-inhibitory domain or their interacting partners in the catalytic domain produces an enhanced affinity for calmodulin or generates a constitutively active enzyme. A structural model of Ca2+/calmodulin-dependent protein kinase II that incorporates these interactions shows that Thr-286 is oriented inwardly into a hydrophobic channel. The model explains why calmodulin must bind to the auto-inhibitory domain in order for Thr-286 in that domain to be phosphorylated and why introduction of phospho-Thr-286 produces the important Ca2+-independent state of the enzyme.	Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA	Stanford University	Schulman, H (corresponding author), Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA.	schulman@cmgm.stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030179, R01GM030179] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30179] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; FONG YL, 1989, J BIOL CHEM, V264, P16759; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; ISHIDA A, 1995, J BIOL CHEM, V270, P2163, DOI 10.1074/jbc.270.5.2163; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KING MM, 1988, J BIOL CHEM, V263, P4754; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MUKHERJI S, 1994, J BIOL CHEM, V269, P20733; MUKHERJI S, 1995, J BIOL CHEM, V270, P14062, DOI 10.1074/jbc.270.23.14062; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; POTTER JD, 1975, J BIOL CHEM, V250, P4628; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; Rich RC, 1998, J BIOL CHEM, V273, P28424, DOI 10.1074/jbc.273.43.28424; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; SHIELDS SM, 1984, J NEUROCHEM, V43, P1599, DOI 10.1111/j.1471-4159.1984.tb06084.x; SMITH MK, 1992, J BIOL CHEM, V267, P1761; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; STULL JT, 1990, J BIOL CHEM, V265, P16683; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851	49	101	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26199	26208		10.1074/jbc.274.37.26199	http://dx.doi.org/10.1074/jbc.274.37.26199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473573	hybrid			2022-12-25	WOS:000082469700039
J	Yang, JW; Chang, E; Cherry, AM; Bangs, CD; Oei, Y; Bodnar, A; Bronstein, A; Chiu, CP; Herron, GS				Yang, JW; Chang, E; Cherry, AM; Bangs, CD; Oei, Y; Bodnar, A; Bronstein, A; Chiu, CP; Herron, GS			Human endothelial cell life extension by telomerase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLASTS; PHENOTYPIC CHANGES; ALPHA-THALASSEMIA; HUMAN-CHROMOSOMES; IN-VIVO; APOPTOSIS; SENESCENCE; LINE; ANGIOGENESIS; INDUCTION	Normal human endothelial cells, like other somatic cells in culture, divide a limited number of times before entering a nondividing state called replicative senescence. Expression of the catalytic component of human telomerase, human telomerase reverse transcriptase (hTERT), extends the life span of human fibroblasts and retinal pigment epithelial cells beyond senescence without causing neoplastic transformation (Bodnar, A. G;., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., and Wright, W. E. (1998) Science 279, 349-352; Jiang, X, Jimenez, G., Chang, E., Frolkis, M., Kusler, B., Sage, M., Beeche, M., Bodnar, A, Wahl, G., Tlsty, T., and Chiu, C.-P. (1999) Not. Genet. 21, 111-114). Here, we show that both human large vessel and microvascular endothelial cells also bypass replicative senescence after introduction of hTERT. For the first time, we report that hTERT expression in these life-extended vascular cells does not affect their differentiated and functional phenotype and that these cells maintain their angiogenic potential in vitro. Furthermore, hTERT(+) microvascular endothelial cells have normal karyotype, and hTERT(+) endothelial cell strains do not exhibit a transformed phenotype. Relative to parental cells at senescence, hTERT-expressing endothelial cells exhibit resistance to induction of apoptosis by a variety of different conditions. Such characteristics are highly desirable for designing vascular transplantation and gene therapy delivery systems in vivo.	Stanford Univ, Dept Dermatol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Cytogenet, Sch Med, Stanford, CA 94305 USA; Geron Corp, Menlo Pk, CA 94025 USA	Stanford University; Stanford University; Geron Corporation	Herron, GS (corresponding author), Stanford Univ, Dept Dermatol, Sch Med, MSLS Bldg P205, Stanford, CA 94305 USA.	gbh@leland.stanford.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044012] Funding Source: NIH RePORTER; NIAMS NIH HHS [P0-1 AR44012] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BARCH MJ, 1997, AGT CYTOGENETICS LAB, V13, P666; BICKNELL R, 1996, ENDOTHELIAL CELL CUL, pR12; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Burger AM, 1997, EUR J CANCER, V33, P638, DOI 10.1016/S0959-8049(96)00521-7; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Candal FJ, 1996, MICROVASC RES, V52, P221, DOI 10.1006/mvre.1996.0060; CARROLL JD, 1991, J CLIN INVEST, V87, P1002, DOI 10.1172/JCI115058; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Chang EH, 1997, ARCH OTOLARYNGOL, V123, P507; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Cines DB, 1998, BLOOD, V91, P3527; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; COCKERILL GW, 1994, LAB INVEST, V71, P497; COMI P, 1995, EXP CELL RES, V219, P304, DOI 10.1006/excr.1995.1232; COOPER LT, 1994, J GERONTOL, V49, pB191, DOI 10.1093/geronj/49.5.B191; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; FLINT J, 1994, AM J HUM GENET, V55, P505; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONTIJN R, 1995, EXP CELL RES, V216, P199, DOI 10.1006/excr.1995.1025; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Gobe G, 1997, J STRUCT BIOL, V118, P63, DOI 10.1006/jsbi.1996.3835; GORDON D, 1986, CIRC RES, V59, P633, DOI 10.1161/01.RES.59.6.633; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Hande MP, 1998, MUTAT RES-FUND MOL M, V404, P205, DOI 10.1016/S0027-5107(98)00115-8; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; Hsiao RS, 1997, ANTICANCER RES, V17, P827; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; JOHNSON TE, 1992, J CELL PHYSIOL, V150, P17, DOI 10.1002/jcp.1041500104; KAJI K, 1981, EXP CELL RES, V131, P410, DOI 10.1016/0014-4827(81)90245-7; KANNEL W, 1980, CARDIOVASCULAR RISK, P65; Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509; KARASEK MA, 1989, J INVEST DERMATOL, V93, pS33, DOI 10.1111/1523-1747.ep12580906; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karsan A, 1998, TRENDS CARDIOVAS MED, V8, P19, DOI 10.1016/S1050-1738(97)00126-6; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Koester SK, 1997, CYTOMETRY, V29, P306; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; LANG R, 1994, DEVELOPMENT, V120, P3395; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; MAIER JAM, 1993, EXP CELL RES, V208, P270, DOI 10.1006/excr.1993.1246; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Matsumura T, 1980, Adv Exp Med Biol, V129, P31; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; NICHOLS WW, 1987, J CELL PHYSIOL, V132, P453, DOI 10.1002/jcp.1041320307; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; PETZELBAUER P, 1999, ENDOTHELIUM DERMATOL, V1, P305; PILI R, 1994, JNCI-J NATL CANCER I, V86, P1303, DOI 10.1093/jnci/86.17.1303; Pollman MJ, 1999, J CELL PHYSIOL, V178, P359, DOI 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.3.CO;2-F; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Romero LI, 1997, J CELL PHYSIOL, V173, P84, DOI 10.1002/(SICI)1097-4652(199710)173:1<84::AID-JCP10>3.0.CO;2-N; SATO I, 1993, BIOCHEM BIOPH RES CO, V195, P1070, DOI 10.1006/bbrc.1993.2153; SEABRIGH.M, 1971, LANCET, V2, P971; Sgonc R, 1996, J CLIN INVEST, V98, P785, DOI 10.1172/JCI118851; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHOLLEY MM, 1976, AM J ANAT, V147, P243, DOI 10.1002/aja.1001470208; TOKUNAGA O, 1991, AM J PATHOL, V138, P941; VAZIRI H, 1993, AM J HUM GENET, V52, P661; WANG E, 1995, CANCER RES, V55, P2284; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Watanabe Y, 1997, EXP CELL RES, V233, P340, DOI 10.1006/excr.1997.3583; WEST MD, 1994, ARCH DERMATOL, V130, P87, DOI 10.1001/archderm.130.1.87; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	78	399	437	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26141	26148		10.1074/jbc.274.37.26141	http://dx.doi.org/10.1074/jbc.274.37.26141			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473565	hybrid			2022-12-25	WOS:000082469700031
J	Zwickl, P; Ng, D; Woo, KM; Klenk, HP; Goldberg, AL				Zwickl, P; Ng, D; Woo, KM; Klenk, HP; Goldberg, AL			An archaebacterial ATPase, homologous to ATPases in the eukaryotic 26 S proteasome, activates protein breakdown by 20 S proteasomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; THERMOPLASMA-ACIDOPHILUM; REGULATORY PARTICLE; METHANOSARCINA-THERMOPHILA; METHANOCOCCUS-JANNASCHII; METHANOGENIC ARCHAEON; DEPENDENT PROTEASES; CRYSTAL-STRUCTURE; COILED COILS	In eukaryotes, the 20 S proteasome is the proteolytic core of the 26 S proteasome, which degrades ubiquitinated proteins in an ATP-dependent process. Archaebacteria lack ubiquitin and 26 S proteasomes but do contain 20 S proteasomes. Many archaebacteria, such as Methanococcus jannaschii, also contain a gene (S4) that is highly homologous to the six ATPases in the 19 S (PA700) component of the eukaryotic 26 S proteasome, To test if this putative ATPase may regulate proteasome function, we expressed it in Escherichia colt and purified the 50-kDa product as a 650-kDa complex with ATPase activity. When mixed with the well characterized 20 S proteasomes from Thermoplasma acidophilum and ATP, this complex stimulated degradation of several unfolded proteins 8-25-fold, It also stimulated proteolysis by 20 S proteasomes from another archaebacterium and mammals, This effect required ATP hydrolysis since ADP and the nonhydrolyzable analog, 5'-adenylyl beta,gamma-imidophosphate, were ineffective. CTP and to a lesser extent GTP and UTP were also hydrolyzed and also stimulated proteolysis. We therefore named this complex PAN for proteasome-activating nucleotidase. However, PAN did not promote the degradation of small peptides, which, unlike proteins, should readily diffuse into the proteasome. This ATPase complex appears to have been the evolutionary precursor of the eukaryotic 19 S complex, before the coupling of proteasome function to ubiquitination.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Inst Gen Res, Rockville, MD 20850 USA	Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.							Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Bauer MW, 1997, APPL ENVIRON MICROB, V63, P1160, DOI 10.1128/AEM.63.3.1160-1164.1997; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Beyer A, 1997, PROTEIN SCI, V6, P2043; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHUNG CH, 1993, SCIENCE, V262, P372, DOI 10.1126/science.8211156; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; DURNER J, 1995, J BIOL CHEM, V270, P3720, DOI 10.1074/jbc.270.8.3720; Ehlers C, 1997, BIOL CHEM, V378, P249; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hoffman L, 1996, J BIOL CHEM, V271, P32538, DOI 10.1074/jbc.271.51.32538; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Knipfer N, 1997, MOL MICROBIOL, V25, P375, DOI 10.1046/j.1365-2958.1997.4721837.x; Langer T, 1996, EXPERIENTIA, V52, P1069, DOI 10.1007/BF01952104; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; Lupas A, 1995, COLD SPRING HARB SYM, V60, P515, DOI 10.1101/SQB.1995.060.01.055; Maupin-Furlow JA, 1998, J BACTERIOL, V180, P1480, DOI 10.1128/JB.180.6.1480-1487.1998; MAUPINFURLOW JA, 1995, J BIOL CHEM, V270, P28617, DOI 10.1074/jbc.270.48.28617; Nagy I, 1998, J BACTERIOL, V180, P5448, DOI 10.1128/JB.180.20.5448-5453.1998; PARK SK, 1993, J BIOL CHEM, V268, P20170; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; RICE RH, 1971, J BIOL CHEM, V246, P831; Richmond C, 1997, J BIOL CHEM, V272, P13403, DOI 10.1074/jbc.272.20.13403; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Russell SJ, 1996, J BIOL CHEM, V271, P32810, DOI 10.1074/jbc.271.51.32810; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SEOL JH, 1994, J BIOL CHEM, V269, P29468; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Swaffield JC, 1997, J MOL EVOL, V45, P549, DOI 10.1007/PL00006259; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WOLF S, 1993, FEBS LETT, V326, P42, DOI 10.1016/0014-5793(93)81757-Q; Wolf S, 1998, J MOL BIOL, V277, P13, DOI 10.1006/jmbi.1997.1589; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7; ZWICKL P, 1999, IN PRESS PROTEASOMES	64	123	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26008	26014		10.1074/jbc.274.37.26008	http://dx.doi.org/10.1074/jbc.274.37.26008			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473546	hybrid			2022-12-25	WOS:000082469700012
J	Sourvinos, G; Tsatsanis, C; Spandidos, DA				Sourvinos, G; Tsatsanis, C; Spandidos, DA			Overexpression of the Tpl-2/Cot oncogene in human breast cancer	ONCOGENE			English	Article						Tpl-2/Cot; gene amplification; breast cancer	NF-KAPPA-B; COMPARATIVE GENOMIC HYBRIDIZATION; POLYMERASE CHAIN-REACTION; ACTIVATED PROTEIN-KINASE; CARCINOMA IN-SITU; T-CELL LINES; MAP KINASE; GENETIC ALTERATIONS; COPY NUMBER; EXPRESSION	Tpl-2/Cot proto-oncogene encodes a serine threonine kinase and was initially cloned as a provirus insertion site in MoMuLV-induced T cell lymphomas in rats. Tpl-2 locus was also shown to be affected by provirus insertion in MMTV-induced mammary carcinomas in mice, The involvement of Tpl-2 in 35 human breast paired tumour specimens versus their corresponding adjacent normal tissue was evaluated. Tpl-2 was found overexpressed in 14 of the 35 breast tumours tested using a semi-quantitative RT-PCR method. Gene amplification was detected in eight out of the 14 specimens overexpressing Tpl-2, suggesting the increased number of copies of Tpl-2 gene as a possible mechanism for Tpl-2 overexpression. Significant association was found between the overexpression of Tpl-2 and stage I of the tumours, indicating that this molecular alteration may be an early event in the development of the disease. Furthermore, overexpression of Tpl-2 was associated with positive progesterone receptor status of the samples. This is the first report on the Tpl-2 oncogene linked to human breast tumours suggesting that it may be a key molecule for the study of human breast cancer.	Univ Crete, Sch Med, Virol Lab, Iraklion 71409, Crete, Greece; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Crete; Jefferson University	Spandidos, DA (corresponding author), Univ Crete, Sch Med, Virol Lab, POB 1393, Iraklion 71409, Crete, Greece.		Tsatsanis, Christos/AAM-9362-2020	Tsatsanis, Christos/0000-0003-1214-4151; Spandidos, Demetrios/0000-0002-1146-931X				Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BLACK DM, 1994, EUR J CANCER, V30A, P1957, DOI 10.1016/0959-8049(94)00386-J; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Christeli E, 1996, ONCOL REP, V3, P1115; Coutts AS, 1998, CANCER RES, V58, P4071; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davis CD, 1995, CARCINOGENESIS, V16, P3087, DOI 10.1093/carcin/16.12.3087; De Jong JS, 1998, J PATHOL, V184, P53, DOI 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7; Erny KM, 1996, ONCOGENE, V13, P2015; FRYE RA, 1989, ONCOGENE, V4, P1153; ITO I, 1995, BRIT J CANCER, V71, P438, DOI 10.1038/bjc.1995.89; James LA, 1997, ONCOGENE, V14, P1059, DOI 10.1038/sj.onc.1200923; Janssen JAMJL, 1998, LANCET, V352, P490, DOI 10.1016/S0140-6736(05)79230-8; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KIARIS H, 1994, INT J ONCOL, V5, P1243; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; MURPHY DS, 1995, J NATL CANCER I, V87, P1694, DOI 10.1093/jnci/87.22.1694; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NEUBAUER A, 1992, ONCOGENE, V7, P1019; OHARA R, 1995, J CELL SCI, V108, P97; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1994, J VIROL, V68, P7927, DOI 10.1128/JVI.68.12.7927-7932.1994; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RIED T, 1995, CANCER RES, V55, P5415; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sourvinos G, 1997, TUMOR BIOL, V18, P157, DOI 10.1159/000218026; SZOLLOSI J, 1995, CANCER RES, V55, P5400; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; Visscher DW, 1997, GENE CHROMOSOME CANC, V18, P1	37	73	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4968	4973		10.1038/sj.onc.1202891	http://dx.doi.org/10.1038/sj.onc.1202891			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490831				2022-12-25	WOS:000082321700009
J	Cai, ZQ; Maeda, Y; Cedzich, A; Torres, VE; Wu, GQ; Hayashi, T; Mochizuki, T; Park, JH; Witzgall, R; Somlo, S				Cai, ZQ; Maeda, Y; Cedzich, A; Torres, VE; Wu, GQ; Hayashi, T; Mochizuki, T; Park, JH; Witzgall, R; Somlo, S			Identification and characterization of polycystin-2, the PKD2 gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM LOCALIZATION; KIDNEY-DISEASE; TRANSMEMBRANE DOMAIN; PROTEIN; SIGNAL; GOLGI; CELLS; RETENTION; ENCODES; FAMILY	PKD2, the second gene for the autosomal dominant polycystic kidney disease (ADPKD), encodes a protein, polycystin-2, with predicted structural similarity to cation channel subunits, However, the function of polycystin-2 remains unknown. We used polyclonal antisera specific for the intracellular NH, and COOH termini to identify polycystin-2 as an similar to 110-kDa integral membrane glycoprotein, Polycystin-2 from both native tissues and cells in culture is sensitive to Endo H suggesting the continued presence of high-mannose oligosaccharides typical of pre-middle Golgis proteins. Immunofluorescent cell staining of polycystin-2 shows a pattern consistent with localization in the endoplasmic reticulum. This finding is confirmed by co-localization with protein-disulfide isomerase as determined by double indirect immunofluorescence and co-distribution with calnexin in subcellular fractionation studies. Polycystin-2 translation products truncated at or after Gly(821) retain their exclusive endoplasmic reticulum localization while products truncated at or before Glu(787) additionally traffic to the plasma membrane. Truncation mutants that traffic to the plasma membrane acquire Endo H resistance and can be biotinylated on the cell surface in intact cells. The 34-amino acid region Glu(787)-Ser(820), containing two putative phosphorylation sites, is responsible for the exclusive endoplasmic reticulum localization of polycystin-2 and is the site of specific interaction with an as yet unidentified protein binding partner for polycystin-2. The localization of full-length polycystin-2 to intracellular membranes raises the possibility that the PKD2 gene product is a subunit of intracellular channel complexes.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Renal, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Div Renal, Bronx, NY 10461 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Nephrol Res Unit, Rochester, MN 55905 USA; Heidelberg Univ, Inst Anat & Cell Biol, D-69120 Heidelberg, Germany	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Mayo Clinic; Ruprecht Karls University Heidelberg	Somlo, S (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Nephrol Sect, Rm 136C,295 Congress Ave, New Haven, CT 06536 USA.	stefan.somlo@yale.edu		Witzgall, Ralph/0000-0002-5283-4846	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048383] Funding Source: NIH RePORTER; NIDDK NIH HHS [1RO1DK48383] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Benoff S, 1998, MOL HUM REPROD, V4, P453, DOI 10.1093/molehr/4.5.453; Brasier JL, 1997, J CLIN INVEST, V99, P194, DOI 10.1172/JCI119147; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Daniells C, 1998, HUM GENET, V102, P216, DOI 10.1007/s004390050681; Folco E, 1997, J BIOL CHEM, V272, P26505, DOI 10.1074/jbc.272.42.26505; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Geng L, 1996, J CLIN INVEST, V98, P2674, DOI 10.1172/JCI119090; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Griffin MD, 1997, KIDNEY INT, V52, P1196, DOI 10.1038/ki.1997.444; Hughes J, 1999, HUM MOL GENET, V8, P543, DOI 10.1093/hmg/8.3.543; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Koptides M, 1999, HUM MOL GENET, V8, P509, DOI 10.1093/hmg/8.3.509; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	34	277	285	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28557	28565		10.1074/jbc.274.40.28557	http://dx.doi.org/10.1074/jbc.274.40.28557			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497221	hybrid			2022-12-25	WOS:000082912700070
J	Hornsten, L; Su, C; Osbourn, AE; Garosi, P; Hellman, U; Wernstedt, C; Oliw, EH				Hornsten, L; Su, C; Osbourn, AE; Garosi, P; Hellman, U; Wernstedt, C; Oliw, EH			Cloning of linoleate diol synthase reveals homology with prostaglandin H synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS GAEUMANNOMYCES-GRAMINIS; HYDROPEROXIDE ISOMERASE; 5,8,11-EICOSATRIENOIC ACID; ASPERGILLUS-NIDULANS; PEROXIDASE GENE; LIPOXYGENASE; METABOLITES; OXYGENATION; SITE; IDENTIFICATION	Linoleate diol synthase is a homotetrameric ferric hemeprotein, which catalyzes dioxygenation of linoleic acid to (8R)-hydroperoxylinoleate and isomerization of the hydroperoxide to (7S,8S) dihydroxylinoleate. Ferryl intermediates and a tyrosyl radical are formed in the reaction. Linoleate diol synthase was digested with endoproteinase Lys-C, and internal peptides were sequenced. The sequence information was used for reverse transcription-polymerase chain reaction analysis, and a cDNA probe was obtained. Northern blot analysis of linoleate diol synthase suggested a 3.7-kilobase pair (kb) mRNA. A full-length clone of the linoleate diol synthase gene was obtained by screening of a genomic A-ZAP II library of the fungus Gaeumannomyces graminis. The 5'-untranslated region contained CAAT- and TATA-like boxes, The gene contained three short introns and spanned over 3.2-kb. The deduced open reading frame consisted of 2.9-kb, which corresponded to 978 amino acids and a molecular subunit mass of 108,000, Data base analysis with the gapped BLAST algorithm showed that 391 residues of linoleate diol synthase was 23-24% identical and 36-37% positive with the catalytic domain of mammalian prostaglandin H (PGH) synthase-a. Based on homology with PGH synthases, the proximal heme ligand of linoleate diol synthase was tentatively identified as His-379 and the important tyrosine for catalysis as residue 376 (apparent consensus EFNXXXYXWTH). The distal heme ligand was tentatively identified as His-203 (apparent consensus THXPFXT). We conclude from catalytic and structural similarities that linoleate diol synthase and PGH synthases likely share common ancestry and may belong to a gene family of fatty acid heme dioxygenases.	Swedish Univ Agr Sci, Uppsala Biomed Ctr, Dept Pharmaceut Biosci, SE-75124 Uppsala, Sweden; John Innes Ctr, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Uppsala Biomed Ctr, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden	Swedish University of Agricultural Sciences; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Ludwig Institute for Cancer Research	Oliw, EH (corresponding author), Swedish Univ Agr Sci, Uppsala Biomed Ctr, Dept Pharmaceut Biosci, SE-75124 Uppsala, Sweden.	Ernst.Oliw@bmc.uu.se		Oliw, Ernst/0000-0002-7986-8130				ABELSON PH, 1995, SCIENCE, V269, P1027, DOI 10.1126/science.269.5227.1027; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; BOWERS WS, 1986, SCIENCE, V232, P105, DOI 10.1126/science.232.4746.105; BOWYER P, 1995, SCIENCE, V267, P371, DOI 10.1126/science.7824933; BRODOWSKY ID, 1992, BIOCHIM BIOPHYS ACTA, V1124, P59, DOI 10.1016/0005-2760(92)90126-G; BRODOWSKY ID, 1992, J BIOL CHEM, V267, P14738; BRODOWSKY ID, 1993, BIOCHIM BIOPHYS ACTA, V1168, P68, DOI 10.1016/0005-2760(93)90267-D; CHAMPE SP, 1989, J BACTERIOL, V171, P3982, DOI 10.1128/jb.171.7.3982-3988.1989; DAVIS LG, 1994, BASIC METHODS MOL BI, P113; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; EUN HM, 1996, ENZYMOLOGY PRIMER RE, P647; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; HAMBERG M, 1994, ARCH BIOCHEM BIOPHYS, V309, P77, DOI 10.1006/abbi.1994.1087; Hellman U, 1997, SPRING LAB MAN, P97; Herman R.P., 1999, EICOSANOIDS RELATED, DOI [10.1515/9781400873111-008, DOI 10.1515/9781400873111-008]; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KIMURA S, 1989, BIOCHEMISTRY-US, V28, P4481, DOI 10.1021/bi00436a054; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Marnett Lawrence J., 1995, P49; MAZUR P, 1990, TETRAHEDRON LETT, V31, P3837, DOI 10.1016/S0040-4039(00)97482-3; NG SW, 1992, BIOCHIM BIOPHYS ACTA, V1171, P224, DOI 10.1016/0167-4781(92)90127-L; Oliw EH, 1998, LIPIDS, V33, P843, DOI 10.1007/s11745-998-0280-0; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V305, P288, DOI 10.1006/abbi.1993.1425; Oliw EH, 1997, J CHROMATOGR B, V690, P332, DOI 10.1016/S0378-4347(96)00372-6; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Sanz A, 1998, PLANT CELL, V10, P1523, DOI 10.1105/tpc.10.9.1523; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Su C, 1998, J BIOL CHEM, V273, P20744, DOI 10.1074/jbc.273.33.20744; Su C, 1996, J BIOL CHEM, V271, P14112, DOI 10.1074/jbc.271.24.14112; SU C, 1995, LIPIDS, V30, P43, DOI 10.1007/BF02537040; Su C, 1998, J BIOL CHEM, V273, P13072, DOI 10.1074/jbc.273.21.13072; TSAI AL, 1994, J BIOL CHEM, V269, P5085; TURNER G, 1993, EUKARYOTIC GENOME OR, P107; vanderBiezen EA, 1996, MOL GEN GENET, V251, P267, DOI 10.1007/BF02172517	39	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28219	28224		10.1074/jbc.274.40.28219	http://dx.doi.org/10.1074/jbc.274.40.28219			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497176	hybrid			2022-12-25	WOS:000082912700025
J	Leblanc, N; David, K; Grosclaude, J; Pradier, JM; Barbier-Brygoo, H; Labiau, S; Perrot-Rechenmann, C				Leblanc, N; David, K; Grosclaude, J; Pradier, JM; Barbier-Brygoo, H; Labiau, S; Perrot-Rechenmann, C			A novel immunological approach establishes that the auxin-binding protein, Nt-abp1, is an element involved in auxin signaling at the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZEA-MAYS-L; MONOCLONAL-ANTIBODIES; PROTOPLASTS; PURIFICATION; COLEOPTILES; RESOLUTION; PEPTIDE; GENES; CELLS; SITES	Interactions of a collection of monoclonal antibodies (mAbs) to the recombinant. Nicotiana tabacum auxin-binding protein 1 (Nt-abp1) were extensively characterized using surface plasmon resonance. Dynamic interaction studies using combinations of Nt-abp1, synthetic peptides corresponding to conserved sequences within auxin-binding proteins, and the mAbs have shown that a number of the mAbs recognized discontinuous epitopes revealing the junction of distinct domains in the folded protein. In particular, the two putative auxin binding domains and the C terminus of the protein were shown to interact with each other in the folded protein. Using the auxin-induced electrical response of tobacco protoplasts as a functional assay, all the mAbs exhibited either auxin antagonist or hormonomimetic properties. These effects, measured for the first time in homologous conditions, confirm that Nt-abp1 is present at the plasma membrane and is involved in the activation of the auxin-dependent electrical response of tobacco protoplasts, Based on our surface plasmon resonance data, we propose that the key event leading to the activation of this auxin electrical response consists of a conformational change in Nt-abp1.	CNRS, Inst Sci Vegetales, Grp Auxin Percept & Transport, F-91198 Gif Sur Yvette, France; INRA, Lab Virol & Immunol Mol, F-78352 Jouy En Josas, France; CNRS, Inst Sci Vegetales, Grp Transmembrane Transporters, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Perrot-Rechenmann, C (corresponding author), CNRS, Inst Sci Vegetales, Grp Auxin Percept & Transport, Ave Terrasse,Bat 23, F-91198 Gif Sur Yvette, France.	rechenmann@isv.cnrs-gif.fr	BARBIER-BRYGOO, HELENE/A-8435-2013	David, Karine/0000-0002-3924-5078				Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; BarbierBrygoo H, 1996, PLANT GROWTH REGUL, V18, P23, DOI 10.1007/BF00028484; BARBIERBRYGOO H, 1991, PLANT J, V1, P83, DOI 10.1111/j.1365-313X.1991.00083.x; BARRIERBRYGOO H, 1989, P NATL ACAD SCI USA, V86, P891, DOI 10.1073/pnas.86.3.891; BROWN JC, 1994, J BIOL CHEM, V269, P21136; CABOCHE M, 1980, PLANTA, V149, P7, DOI 10.1007/BF00386221; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Davies Peter J., 1995, P1; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; DUBS MC, 1992, J CHROMATOGR, V597, P391, DOI 10.1016/0021-9673(92)80136-I; EPHRITIKHINE G, 1987, PLANT PHYSIOL, V83, P801, DOI 10.1104/pp.83.4.801; Guilfoyle T, 1998, PLANT PHYSIOL, V118, P341, DOI 10.1104/pp.118.2.341; HERTEL R, 1995, J EXP BOT, V46, P461, DOI 10.1093/jxb/46.5.461-a; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Jones AM, 1998, SCIENCE, V282, P1114, DOI 10.1126/science.282.5391.1114; JONES AM, 1994, ANNU REV PLANT PHYS, V45, P393, DOI 10.1146/annurev.pp.45.060194.002141; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; LACEY E, 1987, ANAL BIOCHEM, V163, P151, DOI 10.1016/0003-2697(87)90105-9; Leblanc N, 1999, FEBS LETT, V449, P57, DOI 10.1016/S0014-5793(99)00398-1; Leblanc N, 1997, PLANT MOL BIOL, V33, P679, DOI 10.1023/A:1005757815212; LOBLER M, 1985, J BIOL CHEM, V260, P9848; NAPIER RM, 1988, PLANTA, V176, P519, DOI 10.1007/BF00397659; NAPIER RM, 1990, PLANTA, V182, P313, DOI 10.1007/BF00197128; NAPIER RM, 1992, BIOCHEM J, V284, P841, DOI 10.1042/bj2840841; NAVE JF, 1984, PLANT PHYSIOL, V74, P1035, DOI 10.1104/pp.74.4.1035; NOWINSKI RC, 1979, VIROLOGY, V93, P111, DOI 10.1016/0042-6822(79)90280-0; PANAYOTOU G, 1993, CURR BIOL, V3, P913, DOI 10.1016/0960-9822(93)90236-H; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; RAY PM, 1977, PLANT PHYSIOL, V59, P357, DOI 10.1104/pp.59.3.357; RUCK A, 1993, PLANT J, V4, P41, DOI 10.1046/j.1365-313X.1993.04010041.x; SHIMOMURA S, 1986, J BIOCHEM-TOKYO, V99, P1513, DOI 10.1093/oxfordjournals.jbchem.a135621; THIEL G, 1993, P NATL ACAD SCI USA, V90, P11493, DOI 10.1073/pnas.90.24.11493; TILLMANN U, 1989, EMBO J, V8, P2463, DOI 10.1002/j.1460-2075.1989.tb08381.x; VENIS MA, 1992, P NATL ACAD SCI USA, V89, P7208, DOI 10.1073/pnas.89.15.7208; VENIS MA, 1995, CRIT REV PLANT SCI, V14, P27, DOI 10.1080/713608065; VENIS MA, 1990, PLANTA, V182, P232, DOI 10.1007/BF00197116; VENIS MA, 1977, PLANTA, V134, P145, DOI 10.1007/BF00384963; Walker L, 1998, CURR OPIN PLANT BIOL, V1, P434, DOI 10.1016/S1369-5266(98)80269-0; ZIMMERMANN S, 1994, PLANT J, V6, P707, DOI 10.1046/j.1365-313X.1994.6050707.x	39	73	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28314	28320		10.1074/jbc.274.40.28314	http://dx.doi.org/10.1074/jbc.274.40.28314			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497189	Green Published, hybrid			2022-12-25	WOS:000082912700038
J	Merkel, O; Fido, M; Mayr, JA; Pruger, H; Raab, F; Zandonella, G; Kohlwein, SD; Paltauf, F				Merkel, O; Fido, M; Mayr, JA; Pruger, H; Raab, F; Zandonella, G; Kohlwein, SD; Paltauf, F			Characterization and function in vivo of two novel phospholipases B/lysophospholipases from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANES; YEAST; PURIFICATION; PROTEIN; GENE; PHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPASE; GENERATION; ENZYMES; CELLS	The yeast genome contains two genes, designated as PLB2 and PLB3, that are 67% and 62% identical, respectively, to PLB1, which codes for a phospholipase B/lysophospholipase in yeast (Lee, S. K., Patton, J. L., Fido, M., Dines, L. K., Kohlwein, S. D., Paltauf, F,, Henry, S. A., and Levin, D. E. (1994) J. Biol, Chem. 269, 19725-19730). Deletion and overexpression studies and in vivo and in vitro activity measurements suggest that both genes indeed code for phospholipases B/lysophospholipases. In cell free extracts of a plb1 plb2 plb3 triple mutant, no phospholipase B activity was detectable. Upon overexpression of PLB2 in a plb1 plb3 mutant background, phospholipase B activity was detectable in the plasma membrane, periplasmic space extracts and the culture supernatant. Similar to Plb1p, Plb2p appears to accept all major phospholipid classes, with a preference for acidic phospholipids including phosphatidylinositol 3',4'-bisphosphate and phosphatidic acid. Consistent with a function as an extracellular lysophospholipase, PLB2 overexpression conferred resistance to lyso-phosphatidylcholine. Deletion of Plb2p function had no effect on glycerophosphoinositol or glycerophosphocholine re. lease in vivo, in contrast to a deletion of Plb3p function, which resulted in a 50% reduction of phosphatidylinositol breakdown and glycerophosphoinositol release from the cells, lit vitro, Plb3p hydrolyzes only phosphatidylinositol and phosphatidylserine and, to a lesser extent, their lyso-analogs. Plb3p activity in a plb1 plb2 mutant background was observed in periplasmic space extracts. Both Plb3p and Plb2p display transacylase activity in vitro, in the presence or absence, respectively, of detergent.	Graz Univ Technol, Inst Biochem & Lebensmittelchem, A-8010 Graz, Austria; Graz Univ Technol, Speczialforsch Biomembrane Res Ctr, A-8010 Graz, Austria	Graz University of Technology; Graz University of Technology	Paltauf, F (corresponding author), Graz Univ Technol, Inst Biochem & Lebensmittelchem, Petersgasse 12, A-8010 Graz, Austria.	f548palt@mbox.tu-graz.ac.at		Kohlwein, Sepp Dieter/0000-0002-1030-0598; Merkel, Olaf/0000-0001-5089-344X; Mayr, Johannes/0000-0001-6970-336X				Ausubel FA, 1990, CURRENT PROTOCOLS MO; BROEKHUYSE RM, 1968, BIOCHIM BIOPHYS ACTA, V152, P307, DOI 10.1016/0005-2760(68)90038-6; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ghannoum M A, 1998, Nihon Ishinkin Gakkai Zasshi, V39, P55; GHERIANIGRUSZKA N, 1988, J BIOL CHEM, V263, P11808; Hamada K, 1998, MOL GEN GENET, V258, P53, DOI 10.1007/s004380050706; HAWKINS PT, 1986, BIOCHEM J, V238, P507, DOI 10.1042/bj2380507; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Horton P., 1996, P INT SYST MOL BIOL, V4, P109; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LEE KS, 1994, J BIOL CHEM, V269, P19725; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASUDA N, 1991, EUR J BIOCHEM, V202, P783, DOI 10.1111/j.1432-1033.1991.tb16433.x; Oishi H, 1996, BIOSCI BIOTECH BIOCH, V60, P1087; PATTON JL, 1995, J BACTERIOL, V177, P3379, DOI 10.1128/jb.177.12.3379-3385.1995; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Ruetz S, 1997, BIOCHEMISTRY-US, V36, P8180, DOI 10.1021/bi970564o; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Sherman F., 1982, METHODS YEAST GENETI; Tevzadze GG, 1996, GENE, V177, P253, DOI 10.1016/0378-1119(96)00261-2; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; UDENFRIEND S, 1995, METHOD ENZYMOL, V250, P571; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WAGNER S, 1994, YEAST, V10, P1429, DOI 10.1002/yea.320101106; WATANABE Y, 1994, FEMS MICROBIOL LETT, V124, P29, DOI 10.1111/j.1574-6968.1994.tb07257.x; WITT W, 1982, BIOCHIM BIOPHYS ACTA, V711, P403, DOI 10.1016/0005-2760(82)90054-6; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P117, DOI 10.1016/0005-2760(84)90111-5; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P108, DOI 10.1016/0005-2760(84)90110-3; YOKOO T, 1995, MOL GEN GENET, V247, P148, DOI 10.1007/BF00705644; ZON LI, 1989, BIOTECHNIQUES, V7, P696	37	88	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28121	28127		10.1074/jbc.274.40.28121	http://dx.doi.org/10.1074/jbc.274.40.28121			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497163	hybrid			2022-12-25	WOS:000082912700012
J	Paul, BZS; Daniel, JL; Kunapuli, SP				Paul, BZS; Daniel, JL; Kunapuli, SP			Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways - Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT-CHAIN; HUMAN-BLOOD-PLATELETS; GTP-BINDING PROTEIN; SMOOTH-MUSCLE; INTACT PLATELETS; MOLECULAR-BASIS; PHOSPHORYLATION; ACTIVATION; ADP; PHOSPHATASE	Platelets undergo shape change upon activation with agonists, During shape change, disc-shaped platelets turn into spiculated spheres with protruding filopodia, When agonist-induced cytosolic Ca2+ increases were prevented using the cytosolic Ca2+ chelator, 5,5'-dimethyl-bis-(o-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid (5,5'-dimethyl-BAPTA), platelets still underwent shape change, although the onset was delayed and the initial rate was dramatically decreased. In the absence of cytosolic Ca2+, agonist-stimulated myosin light chain phosphorylation was significantly inhibited. The myosin light chain was maximally phosphorylated at 2 s in control platelets compared with 30 s in 5,5'-dimethyl-BAPTA-treated platelets. ADP, thrombin, or U46619-induced Ca2+-independent platelet shape change was significantly reduced by staurosporine, a nonselective kinase inhibitor, by the selective p160 Rho-associated coiled-coil containing protein kinase inhibitor Y-27632, or by HA 1077. Both Y-27632 and HA 1077 reduced peak levels of ADP-induced platelet shape change and myosin light chain phosphorylation in control platelets. In 5,5'-dimethyl-BAPTA-treated platelets, Y-27632 and HA 1077 completely abolished both ADP-induced platelet shape change and myosin light chain phosphorylation. Our results indicate that Ca2+/calmodulin-stimulated myosin light chain kinase and p160 Rho-associated coiled-coil-containing protein kinase independently contribute to myosin light chain phosphorylation and platelet shape change, through Ca2+-sensitive and Ca2+-insensitive pathways, respectively.	Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Kunapuli, SP (corresponding author), Temple Univ, Sch Med, Dept Physiol, 3420 N Broad St, Philadelphia, PA 19140 USA.				NHLBI NIH HHS [HL60683] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060683] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BEARER EL, 1995, CELL MOTIL CYTOSKEL, V30, P50, DOI 10.1002/cm.970300107; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; COX AC, 1984, J CELL BIOL, V98, P8, DOI 10.1083/jcb.98.1.8; DANIEL JL, 1984, J BIOL CHEM, V259, P9826; DANIEL JL, 1976, BIOCHEMISTRY-US, V15, P2370, DOI 10.1021/bi00656a019; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; DANIEL JL, 1981, J BIOL CHEM, V256, P7510; DERANLEAU DA, 1982, P NATL ACAD SCI-BIOL, V79, P7297, DOI 10.1073/pnas.79.23.7297; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; FUJITA A, 1995, J PHARMACOL EXP THER, V274, P555; HALLAM TJ, 1985, BIOCHEM J, V232, P373, DOI 10.1042/bj2320373; HANTGAN RR, 1984, BLOOD, V64, P896; HATHAWAY DR, 1981, NATURE, V291, P252, DOI 10.1038/291252a0; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Holmgren P., 1990, INDEX HERBARIORUM 1; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Jen CJ, 1996, BLOOD, V87, P3775, DOI 10.1182/blood.V87.9.3775.bloodjournal8793775; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Johnson GJ, 1996, BIOCHEM J, V318, P1023, DOI 10.1042/bj3181023; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kunapuli SP, 1998, TRENDS PHARMACOL SCI, V19, P391, DOI 10.1016/S0165-6147(98)01248-6; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LEBOWITZ EA, 1978, J BIOL CHEM, V253, P5443; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MacKenzie AB, 1996, J BIOL CHEM, V271, P2879, DOI 10.1074/jbc.271.6.2879; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Murphy RA, 1993, PHYSIOLOGY, P309; Nakai K, 1997, BLOOD, V90, P3936, DOI 10.1182/blood.V90.10.3936; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; RINK TJ, 1982, FEBS LETT, V148, P21, DOI 10.1016/0014-5793(82)81234-9; Savi P, 1998, FEBS LETT, V422, P291, DOI 10.1016/S0014-5793(98)00025-8; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; Shattil SJ, 1997, J CLIN INVEST, V100, P1, DOI 10.1172/JCI119500; SIEMANKOWSKI RF, 1978, J BIOL CHEM, V253, P8648; SMITH JB, 1990, ANAL BIOCHEM, V187, P173, DOI 10.1016/0003-2697(90)90437-E; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAYASU M, 1986, J NEUROSURG, V65, P80, DOI 10.3171/jns.1986.65.1.0080; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; ZABLOCKI JA, 1993, J MED CHEM, V36, P1811, DOI 10.1021/jm00065a003	60	151	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28293	28300		10.1074/jbc.274.40.28293	http://dx.doi.org/10.1074/jbc.274.40.28293			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497186	hybrid			2022-12-25	WOS:000082912700035
J	Reynaud, D; Ali, M; Demin, P; Pace-Asciak, CR				Reynaud, D; Ali, M; Demin, P; Pace-Asciak, CR			Formation of 14,15-hepoxilins of the A(3) and B-3 series through a 15-lipoxygenase and hydroperoxide isomerase present in garlic roots	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPOXILIN A(3)-SPECIFIC BINDING; RAT HIPPOCAMPAL SLICES; HUMAN-NEUTROPHILS; ARACHIDONIC-ACID; PANCREATIC-ISLETS; HUMAN-PLATELETS; CALCIUM; RELEASE; INHIBITION; EXPRESSION	We report herein for the first time the formation by freshly grown garlic roots and the structural characterization of 14,15-epoxide positional analogs of the hepoxilins formed via the 15-lipoxygenase-induced oxygenation of arachidonic acid. These compounds are formed through the combined actions of a 15(S)-lipoxygenase and a hydroperoxyeicosatetraenoic acid (HPETE) isomerase. The compounds were formed when either arachidonic acid or 15-HPETE were used as substrates. Both the "A"-type and the "B"-type products are formed although the B-type compounds are formed in greater relative quantities. Chiral phase high performance liquid chromatography analysis confirmed the formation of hepoxilins from 15(S)- but not 15(R)-HPETE, indicating high stereoselectivity of the isomerase, Additionally, the lipoxygenase was of the 15(S)-type as only 15(S)hydroxyeicosatetraenoic acid was formed when arachidonic acid was used as substrate. The structures of the products were confirmed by gas chromatography-mass spectrometry of the methyl ester trimethylsilyl ether derivatives as well as after characteristic epoxide ring opening catalytically with hydrogen leading to dihydroxy products. That 15(S)-lipoxygenase activity is of functional importance in garlic was shown by the inhibition of root growth by BW 755C, a dual cyclooxygenase/lipoxygenase inhibitor and nordihydroguaiaretic acid, a lipoxygenase inhibitor. Additional biological studies were carried out with the purified intact 14(S),15(S)-hepoxilins, which were investigated for hepoxilin-like actions in causing the release of intracellular calcium in human neutrophils. The 14,15-hepoxilins dose-dependently caused a rise in cytosolic calcium, but their actions were 5-10-fold less active than 11(S),1B(S)-hepoxilins derived from 1B(S)-HPETE. These studies provide evidence that 15(S)-lipoxygenase is functionally important to normal root growth and that HPETE isomerization into the hepoxilin-like structure may be ubiquitous; the hepoxilin-evoked release of calcium in human neutrophils, which is receptor-mediated, is sensitive to the location within the molecule of the hydroxyepoxide functionality.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Kuwait Univ, Fac Sci, Dept Biochem, Safat 13060, Kuwait; Univ Toronto, Fac Med, Dept Pharmacol, Toronto, ON M5A 1S8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Kuwait University; University of Toronto	Pace-Asciak, CR (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	pace@sickkids.on.ca						ALI M, 1990, PROSTAG LEUKOTR ESS, V41, P95, DOI 10.1016/0952-3278(90)90060-X; Ali M, 1998, FOURTH INTERNATIONAL CONGRESS ON ESSENTIAL FATTY ACIDS AND EICOSANOIDS, P400; APITZCASTRO R, 1986, THROMB RES, V42, P303, DOI 10.1016/0049-3848(86)90259-8; BELARDETTI F, 1989, NEURON, V3, P497, DOI 10.1016/0896-6273(89)90208-0; CARLEN PL, 1994, NEUROSCIENCE, V58, P493, DOI 10.1016/0306-4522(94)90075-2; CARLEN PL, 1989, BRAIN RES, V497, P171, DOI 10.1016/0006-8993(89)90984-0; DEMIN P, 1995, ANAL BIOCHEM, V226, P252, DOI 10.1006/abio.1995.1222; DEMIN P, 1995, J CHROMATOGR B, V672, P282, DOI 10.1016/0378-4347(95)00214-4; DHO S, 1990, BIOCHEM J, V266, P63, DOI 10.1042/bj2660063; EVBUOMWAN M I, 1992, Medical Science Research, V20, P591; Grechkin AN, 1997, EUR J BIOCHEM, V245, P137, DOI 10.1111/j.1432-1033.1997.00137.x; GRINSTEIN S, 1986, AM J PHYSIOL, V251, pC55, DOI 10.1152/ajpcell.1986.251.1.C55; KAKHEJA AN, 1990, AGENTS ACTIONS, V29, P360; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; KUHN H, 1994, J LIPID RES, V35, P1749; Kuhn H, 1997, CURR OPIN LIPIDOL, V8, P111; LANEUVILLE O, 1991, EICOSANOIDS, V4, P95; LANEUVILLE O, 1993, BIOCHEM J, V295, P393, DOI 10.1042/bj2950393; LANEUVILLE O, 1992, BRIT J PHARMACOL, V107, P808, DOI 10.1111/j.1476-5381.1992.tb14528.x; LANEUVILLE O, 1992, BRIT J PHARMACOL, V105, P297, DOI 10.1111/j.1476-5381.1992.tb14249.x; MARGALIT A, 1993, P NATL ACAD SCI USA, V90, P2589, DOI 10.1073/pnas.90.7.2589; MAYEUX PR, 1988, AGENTS ACTIONS, V25, P182, DOI 10.1007/BF01969110; Mills L, 1997, EXP CELL RES, V230, P337, DOI 10.1006/excr.1996.3425; PACEASCIAK CR, 1990, BIOCHEM BIOPH RES CO, V173, P949, DOI 10.1016/S0006-291X(05)80877-0; PACEASCIAK CR, 1986, PROG LIPID RES, V25, P625, DOI 10.1016/0163-7827(86)90127-X; PACEASCIAK CR, 1988, BIOCHEM BIOPH RES CO, V151, P493, DOI 10.1016/0006-291X(88)90620-1; PACEASCIAK CR, 1990, P NATL ACAD SCI USA, V87, P3037, DOI 10.1073/pnas.87.8.3037; PACEASCIAK CR, 1983, J BIOL CHEM, V258, P6835; PACEASCIAK CR, 1984, PROSTA LEUKOTR MED, V16, P173, DOI 10.1016/0262-1746(84)90069-6; PACEASCIAK CR, 1985, BIOCHEM BIOPH RES CO, V128, P942, DOI 10.1016/0006-291X(85)90137-8; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P1721, DOI 10.1073/pnas.86.5.1721; REYNAUD D, 1994, J BIOL CHEM, V269, P23976; Reynaud D, 1996, BIOCHEM J, V313, P537, DOI 10.1042/bj3130537; REYNAUD D, 1995, AGENT ACTION SUPPL, V45, P291; Schaffer EM, 1997, NUTR CANCER, V27, P162, DOI 10.1080/01635589709514519; Shen JH, 1996, J CLIN INVEST, V98, P2201, DOI 10.1172/JCI119029; Shen JH, 1995, FASEB J, V9, P1623, DOI 10.1096/fasebj.9.15.8529842; Singh SV, 1996, BIOCHEM BIOPH RES CO, V225, P660, DOI 10.1006/bbrc.1996.1226; WELCH C, 1992, CANCER LETT, V63, P211, DOI 10.1016/0304-3835(92)90263-U	39	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28213	28218		10.1074/jbc.274.40.28213	http://dx.doi.org/10.1074/jbc.274.40.28213			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497175	hybrid			2022-12-25	WOS:000082912700024
J	Rosenkranz, S; DeMali, KA; Gelderloos, JA; Bazenet, C; Kazlauskas, A				Rosenkranz, S; DeMali, KA; Gelderloos, JA; Bazenet, C; Kazlauskas, A			Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA; FACTOR-ALPHA-RECEPTOR; PDGF RECEPTOR; PHOSPHATIDYLINOSITOL-3 KINASE; BINDING; TRANSDUCTION; SRC; PHOSPHORYLATION; ACTIVATION; PATHWAYS	Activation of the platelet-derived growth factor (PDGF) alpha receptor (alpha PDGFR) leads to cell migration and DNA synthesis. These events are preceded by the ligand-induced tyrosine phosphorylation of the receptor and its association with SH2-containing signaling enzymes including Src family members (Src), the phosphotyrosine phosphatase SHP-2, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-gamma 1 (PLC gamma), In this study, we sought to systematically evaluate the relative roles of the signaling enzymes that are recruited to the alpha PDGFR for DNA synthesis and cell migration. Our approach was to generate and characterize tyrosine to phenylalanine alpha PDGFR mutants that failed to associate with one or more of the above listed signaling enzymes. In a 3T3-like cell line (Ph cells), PDGF-dependent DNA synthesis was strictly dependent on only one of the receptor-associated proteins, PI3K, In contrast, multiple signaling enzymes were required for maximal chemotaxis, as receptors unable to associate with either Src, PI3K, or PLC gamma initiated chemotaxis to 4, 47, or 56% of the wild-type level, respectively. Furthermore, coexpression of mutant receptors revealed that these signaling enzymes do not need to be on the same receptor for a cell to respond chemotactically to PDGF, We conclude that for the alpha PDGFR, PI3K plays a major role in initiating DNA synthesis, whereas PI3K, PLC gamma, and especially Src are required for chemotaxis.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute	Kazlauskas, A (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.			DeMali, Kris/0000-0003-0906-1371	NATIONAL EYE INSTITUTE [R01EY011693] Funding Source: NIH RePORTER; NEI NIH HHS [EY11693] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAZENET CE, 1994, ONCOGENE, V9, P517; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; Godwin SL, 1997, J BIOL CHEM, V272, P11307; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Hooshmand-Rad R, 1998, J CELL SCI, V111, P607; HOSANG M, 1989, J CELL PHYSIOL, V140, P558, DOI 10.1002/jcp.1041400322; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; OsornioVargas AR, 1996, AM J PHYSIOL-LUNG C, V271, pL93, DOI 10.1152/ajplung.1996.271.1.L93; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Yokote K, 1996, J BIOL CHEM, V271, P5101; YU JC, 1995, J BIOL CHEM, V270, P7033, DOI 10.1074/jbc.270.13.7033; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	26	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28335	28343		10.1074/jbc.274.40.28335	http://dx.doi.org/10.1074/jbc.274.40.28335			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497192	hybrid			2022-12-25	WOS:000082912700041
J	Somasekaram, A; Jarmuz, A; How, A; Scott, J; Navaratnam, N				Somasekaram, A; Jarmuz, A; How, A; Scott, J; Navaratnam, N			Intracellular localization of human cytidine deaminase - Identification of a functional nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DEOXYCYTIDINE KINASE; NUCLEOCYTOPLASMIC TRANSPORT; CHROMOSOMAL LOCATION; NUCLEOTIDE-SEQUENCE; PROTEIN IMPORT; ACTIVE-SITE; CELLS; CLONING; ENZYME; GENE	The cytidine deaminases belong to the family of multisubunit enzymes that catalyze the hydrolytic deamination of their substrate to a corresponding uracil product. They play a major role in pyrimidine nucleoside and nucleotide salvage. The intracellular distribution of cytidine deaminase and related enzymes has previously been considered to be cytosolic. Here we show that human cytidine deaminase (HCDA) is present in the nucleus. A highly specific, affinity purified polyclonal antibody against HCDA was used to analyze the intracellular localization of native HCDA in a variety of mammalian cells by in situ immunochemistry. Native HCDA was found to be present in the nucleus as well as the cytoplasm in several cell types. Indirect immunofluorescence microscopy indicated a predominantly nuclear localization of FLAG-tagged HCDA overexpressed in these cells. We have identified an amino-terminal bipartite nuclear localization signal that is both necessary and sufficient to direct HCDA and a non-nuclear reporter protein to the nucleus. We also show HCDA binding to the nuclear import receptor, importin alpha. Similar putative bipartite nuclear localization sequences are found in other cytidine/deoxycytidylate deaminases. The results presented here suggest that the pyrimidine nucleotide salvage pathway may operate in the nucleus. This localization may have implications in the regulation of nucleoside and nucleotide metabolism and nucleic acid biosynthesis.	Hammersmith Hosp, MRC, Mol Med Grp, Ctr Clin Sci,Imperial Coll,Sch Med, London W12 0NN, England; Hammersmith Hosp, Div Nat Heart & Lung Inst, Imperial Coll, Sch Med, London W12 0NN, England	Imperial College London; Imperial College London	Scott, J (corresponding author), Hammersmith Hosp, MRC, Mol Med Grp, Ctr Clin Sci,Imperial Coll,Sch Med, DuCane Rd, London W12 0NN, England.	j.scott@ic.ac.uk; nnaveene@hgmp.mrc.ac.uk						BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BOUFFARD DY, 1993, BIOCHEM PHARMACOL, V45, P1857, DOI 10.1016/0006-2952(93)90444-2; BOYUM A, 1994, EXP HEMATOL, V22, P208; Brightwell G, 1997, GENE, V194, P115, DOI 10.1016/S0378-1119(97)00178-9; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHIBA P, 1989, BRIT J HAEMATOL, V71, P451, DOI 10.1111/j.1365-2141.1989.tb06301.x; CHIU CS, 1977, J BIOL CHEM, V252, P8603; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; Fujino T, 1998, GENOMICS, V47, P266, DOI 10.1006/geno.1997.5110; GELBARD AS, 1969, BIOCHIM BIOPHYS ACTA, V182, P564, DOI 10.1016/0005-2787(69)90209-3; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gran C, 1998, BLOOD, V91, P4127, DOI 10.1182/blood.V91.11.4127.411k42_4127_4135; Hatzis P, 1998, J BIOL CHEM, V273, P30239, DOI 10.1074/jbc.273.46.30239; JACKSON RC, 1978, J BIOL CHEM, V253, P7440; Johansson M, 1997, P NATL ACAD SCI USA, V94, P11941, DOI 10.1073/pnas.94.22.11941; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KUHN K, 1993, BIOCHEM BIOPH RES CO, V190, P1, DOI 10.1006/bbrc.1993.1001; LALIBERTE J, 1994, CANCER RES, V54, P5401; Lim A, 1996, EMBO J, V15, P4050, DOI 10.1002/j.1460-2075.1996.tb00778.x; MALEY F, 1960, J BIOL CHEM, V235, P2968; MALEY F, 1961, CANCER RES, V21, P1421; MALEY GF, 1959, J BIOL CHEM, V234, P2975; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MEJER J, 1988, LEUKEMIA RES, V12, P405, DOI 10.1016/0145-2126(88)90059-8; MOMPARLER RL, 1990, LEUKEMIA RES, V14, P751, DOI 10.1016/0145-2126(90)90067-J; MULLER WEG, 1979, CANCER RES, V39, P1102; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nygaard P, 1986, Adv Exp Med Biol, V195 Pt B, P415; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUSSELL L, 1996, DNA CLONING, V2, P169; SMITH AA, 1994, BIOCHEMISTRY-US, V33, P6468, DOI 10.1021/bi00187a012; SONG BH, 1989, MOL GEN GENET, V216, P462, DOI 10.1007/BF00334391; STEUART CD, 1971, NATURE-NEW BIOL, V233, P109, DOI 10.1038/newbio233109a0; Vincenzetti S, 1997, BIOCHEM MOL BIOL INT, V42, P477; Vincenzetti S, 1996, PROTEIN EXPRES PURIF, V8, P247, DOI 10.1006/prep.1996.0097; VITA A, 1989, ADV EXP MED BIOL, V253, P71; WEINER KXB, 1995, J BIOL CHEM, V270, P18727, DOI 10.1074/jbc.270.32.18727; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Xiang SB, 1996, BIOCHEMISTRY-US, V35, P1335, DOI 10.1021/bi9525583; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; YANG C, 1992, BIOCHEMISTRY-US, V31, P4168, DOI 10.1021/bi00132a003	48	18	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28405	28412		10.1074/jbc.274.40.28405	http://dx.doi.org/10.1074/jbc.274.40.28405			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497201	hybrid			2022-12-25	WOS:000082912700050
J	Becker, JAJ; Wallace, A; Garzon, A; Ingallinella, P; Bianchi, E; Cortese, R; Simonin, F; Kieffer, BL; Pessi, A				Becker, JAJ; Wallace, A; Garzon, A; Ingallinella, P; Bianchi, E; Cortese, R; Simonin, F; Kieffer, BL; Pessi, A			Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-S BINDING; NOCICEPTIN/ORPHANIN FQ; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; POTENT INHIBITORS; HIGH-AFFINITY; ORPHANIN-FQ; G-PROTEIN; AGONIST; RECOGNITION	We have screened a synthetic peptide combinatorial library composed of 2 x 10(7) P-turn constrained peptides in binding assays on four structurally related receptors, the human opioid receptors mu, delta, and kappa and the opioid receptor-like ORL1. Sixty-six individual peptides were synthesized from the primary screening and tested in the four receptor binding assays. Three peptides composed essentially of unnatural amino acids were found to show high affinity for human kappa-opioid receptor. Investigation of their activity in agonist-promoted stimulation of [S-35]guanosine 5'-3-O-(thio)triphosphate binding assay revealed that we have identified the first inverse agonist as well as peptidic antagonists for kappa-receptors. To fine-tune the potency and selectivity of these kappa-peptides we replaced their turn-forming template by other turn mimetic molecules. This "turn-scan" process allowed the discovery of compounds with modified selectivity and activity profiles. One peptide displayed comparable affinity and partial agonist activity toward all four receptors. Interestingly, another peptide showed selectivity for the ORL1 receptor and displayed antagonist activity at ORL1 and agonist activity at opioid receptors. In conclusion, we have identified peptides that represent an entirely new class of ligands for opioid and ORL1 receptors and exhibit novel pharmacological activity. This study demonstrates that conformationally constrained peptide combinatorial libraries are a rich source of ligands that are more suitable for the design of nonpeptidal drugs.	Ecole Super Biotechnol Strasbourg, F-67400 Illkirch Graffenstaden, France; IRBM, I-00040 Rome, Italy	Merck & Company	Simonin, F (corresponding author), Ecole Super Biotechnol Strasbourg, Parc Innovat,Bld Sebastien Brand, F-67400 Illkirch Graffenstaden, France.	simonin@esbs.u-strasbg.fr; pessi@irbm.it	Becker, Jerome/I-7879-2016	Becker, Jerome/0000-0002-0039-0067; Bianchi, Elisabetta/0000-0002-5302-6912				Adapa ID, 1997, NEUROPEPTIDES, V31, P403, DOI 10.1016/S0143-4179(97)90032-9; Barbato G, 1996, J BIOMOL NMR, V8, P36; BARNARD EA, 1993, CURR BIOL, V3, P211, DOI 10.1016/0960-9822(93)90335-L; Befort K, 1996, NEUROCHEM RES, V21, P1301, DOI 10.1007/BF02532371; Befort K, 1996, J BIOL CHEM, V271, P10161, DOI 10.1074/jbc.271.17.10161; BIANCHI E, 1995, J MOL BIOL, V247, P154, DOI 10.1006/jmbi.1994.0129; BIANCHI E, 1996, INNOVATION PERSPECTI, P159; BROWNSTEIN MJ, 1993, P NATL ACAD SCI USA, V90, P5391, DOI 10.1073/pnas.90.12.5391; CHANG KJ, 1993, J PHARMACOL EXP THER, V267, P852; Chiu TT, 1996, MOL PHARMACOL, V50, P1651; CORBETT AD, 1986, BRIT J PHARMACOL, V89, P245, DOI 10.1111/j.1476-5381.1986.tb11141.x; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COTTON R, 1984, EUR J PHARMACOL, V97, P331, DOI 10.1016/0014-2999(84)90470-9; Darland T, 1998, TRENDS NEUROSCI, V21, P215, DOI 10.1016/S0166-2236(97)01204-6; DELOMBAERT S, 1994, TETRAHEDRON LETT, V35, P7513, DOI 10.1016/S0040-4039(00)78331-6; Dooley CT, 1998, J BIOL CHEM, V273, P18848, DOI 10.1074/jbc.273.30.18848; DOOLEY CT, 1995, PEPTIDE RES, V8, P124; DOOLEY CT, 1993, P NATL ACAD SCI USA, V90, P10811, DOI 10.1073/pnas.90.22.10811; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; Dooley CT, 1997, J PHARMACOL EXP THER, V283, P735; ERNEST I, 1990, TETRAHEDRON LETT, V31, P4011, DOI 10.1016/S0040-4039(00)94485-X; ERNEST I, 1990, TETRAHEDRON LETT, V31, P4015, DOI 10.1016/S0040-4039(00)94486-1; Farmer P. S., 1980, DRUG DESIGN, VX, P119; FLOEGEL R, 1992, BIOPOLYMERS, V32, P1283, DOI 10.1002/bip.360321004; Gillespie P, 1997, BIOPOLYMERS, V43, P191, DOI 10.1002/(SICI)1097-0282(1997)43:3<191::AID-BIP2>3.3.CO;2-2; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; Griffin J F, 1988, NIDA Res Monogr, V87, P41; Hosohata K, 1998, EUR J PHARMACOL, V346, P111, DOI 10.1016/S0014-2999(98)00117-4; HRUBY VJ, 1990, BIOCHEM J, V268, P249, DOI 10.1042/bj2680249; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; KIEFFER BL, 1997, PAIN HDB EXPT PHARM, V130, P281; Lapalu S, 1998, FEBS LETT, V427, P296, DOI 10.1016/S0014-5793(98)00452-9; Lee J, 1995, LETT PEPT SCI, V2, P253, DOI 10.1007/BF00119165; MAIGRET B, 1986, MOL PHARMACOL, V29, P314; Marshall G.R, 1992, CURR OPINION STRUCT, V2, P904; Meng F, 1998, MOL PHARMACOL, V53, P772, DOI 10.1124/mol.53.4.772; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MOORE GJ, 1994, TRENDS PHARMACOL SCI, V2, P253; Mullaney L, 1996, BIOCHEM J, V315, P227, DOI 10.1042/bj3150227; NAGAI U, 1985, TETRAHEDRON LETT, V26, P647, DOI 10.1016/S0040-4039(00)89169-8; NIKOLAIEV V, 1993, PEPTIDE RES, V6, P161; Noda Y, 1998, J BIOL CHEM, V273, P18047, DOI 10.1074/jbc.273.29.18047; OLSON GL, 1993, J MED CHEM, V36, P3039, DOI 10.1021/jm00073a001; PARSONS WH, 1983, BIOCHEM BIOPH RES CO, V117, P108, DOI 10.1016/0006-291X(83)91547-4; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; PICONE D, 1990, EUR J BIOCHEM, V192, P433, DOI 10.1111/j.1432-1033.1990.tb19245.x; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; ROBL JA, 1994, J AM CHEM SOC, V116, P2348, DOI 10.1021/ja00085a014; SCHILELR PW, 1993, HDB EXPT PHARM OPIOI, V1, P104; SCHUG SA, 1992, DRUG SAFETY, V7, P200, DOI 10.2165/00002018-199207030-00005; Selley DE, 1997, MOL PHARMACOL, V51, P87, DOI 10.1124/mol.51.1.87; Shimohigashi Y, 1996, J BIOL CHEM, V271, P23642, DOI 10.1074/jbc.271.39.23642; Sim LJ, 1996, NEUROREPORT, V7, P729, DOI 10.1097/00001756-199602290-00012; SIMONIN F, 1995, P NATL ACAD SCI USA, V92, P7006, DOI 10.1073/pnas.92.15.7006; SIMONIN F, 1994, MOL PHARMACOL, V46, P1015; SOLLAZZO M, 1995, COMBINATORIAL LIB, P127; WALLACE A, 1994, PEPTIDE RES, V7, P27; Wallace A, 1996, J BIOL CHEM, V271, P31306, DOI 10.1074/jbc.271.49.31306; WANG JB, 1994, J BIOL CHEM, V269, P25966; Zhu JM, 1997, J PHARMACOL EXP THER, V282, P676	66	97	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27513	27522		10.1074/jbc.274.39.27513	http://dx.doi.org/10.1074/jbc.274.39.27513			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488086	hybrid			2022-12-25	WOS:000082739100025
J	Harrington, MA; Gunderson, KL; Kopito, RR				Harrington, MA; Gunderson, KL; Kopito, RR			Redox reagents and divalent cations alter the kinetics of cystic fibrosis transmembrane conductance regulator channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER P-GLYCOPROTEIN; NITRIC-OXIDE; ATP-BINDING; SACCHAROMYCES-CEREVISIAE; CHLORIDE CHANNEL; CL CONDUCTANCE; H+-ATPASE; CFTR; HYDROLYSIS; ACTIVATION	Gating of the cystic fibrosis Cl- channel requires hydrolysis of ATP by its nucleotide binding folds, but how this process controls the kinetics of channel gating is poorly understood. In the present work we show that the kinetics of channel gating and presumably the rate of ATP hydrolysis depends on the species of divalent cation present and the oxidation state of the protein. With Ca2+ as the dominant divalent cation instead of Mg2+, the open burst duration of the channel is increased approximately 20-fold, and this change is reversible upon washout of Ca2+. In contrast, "soft" divalent cations such as Cd2+ interact covalently with cystic fibrosis transmembrane conductance regulator (CFTR). These metals decrease both opening and closing rates of the channel, and the effects are not reversed by washout. Oxidation of CFTR channels with a variety of oxidants resulted in a similar slowing of channel gating, In contrast, reducing agents had the opposite effect, increasing both opening and closing rates of the channel. In cell-attached patches, CFTR channels exhibit both oxidized and reduced types of gating, raising the possibility that regulation of the redox state of the channel may be a physiological mode of control of CFTR channel activity.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Harrington, MA (corresponding author), Morehouse Coll, Dept Biol, 830 Westview Dr SW, Atlanta, GA 30314 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009717] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK009717, DK09717] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARAI K, 1993, J BIOL CHEM, V268, P5649; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; COHN M, 1990, ANN NY ACAD SCI, V603, P151; Cotten JF, 1997, J BIOL CHEM, V272, P25617, DOI 10.1074/jbc.272.41.25617; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; FENG Y, 1994, J BIOL CHEM, V269, P13224; FISCHER H, 1994, J GEN PHYSIOL, V104, P541, DOI 10.1085/jgp.104.3.541; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; Harvey WR, 1997, J EXP BIOL, V200, P203; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; HSIEH S, 1992, NUCLEIC ACIDS RES, V20, P5647, DOI 10.1093/nar/20.21.5647; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; Hwang TC, 1997, AM J PHYSIOL-CELL PH, V273, pC988, DOI 10.1152/ajpcell.1997.273.3.C988; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Ishihara H, 1997, AM J PHYSIOL-CELL PH, V273, pC1278, DOI 10.1152/ajpcell.1997.273.4.C1278; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; KEIRE DA, 1992, J ORG CHEM, V57, P123, DOI 10.1021/jo00027a023; KOETTGEN M, 1996, PFLUEGERS ARCH EUR J, V431, P548; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; MORBACH S, 1993, J BIOL CHEM, V268, P18617; OROURKE B, 1993, BIOCHEM PHARMACOL, V46, P1103, DOI 10.1016/0006-2952(93)90456-7; RENGASAMY A, 1994, AM J PHYSIOL-LUNG C, V267, pL704, DOI 10.1152/ajplung.1994.267.6.L704; RINGE D, 1990, NATURE, V346, P312, DOI 10.1038/346312a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; SCHULTZ BD, 1996, J MEMBR BIOL, V151; SHINOHARA Y, 1990, BIOPHYS CHEM, V36, P201, DOI 10.1016/0301-4622(90)80025-3; SIGURDSON WJ, 1987, J EXP BIOL, V127, P191; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STUTTS MJ, 1994, J BIOL CHEM, V269, P8667; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; Xue C, 1996, J HISTOCHEM CYTOCHEM, V44, P463, DOI 10.1177/44.5.8627003	52	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27536	27544		10.1074/jbc.274.39.27536	http://dx.doi.org/10.1074/jbc.274.39.27536			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488089	hybrid			2022-12-25	WOS:000082739100028
J	Sharer, JD; Kahn, RA				Sharer, JD; Kahn, RA			The ARF-like 2 (ARL2)-binding protein, BART - Purification, cloning, and initial characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTPASE-ACTIVATING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE-D; STRUCTURAL BASIS; BINDING PROTEIN; GOLGI-COMPLEX; CHOLERA-TOXIN; MEMBRANE	ARF-like proteins (ARLs) comprise a functionally distinct group of incompletely characterized members in the ARF family of RAS-related GTPases. We took advantage of the GTP binding characteristics of human ARL2 to develop a specific, high affinity binding assay that allowed the purification of a novel ARL2-binding protein. A 19-kDa protein (BART, Binder of Arl Two) was identified and purified from bovine brain homogenate. BART binding is specific to ARL2.GTP with high affinity but does not interact with ARL2.GDP or activated ARF or RHO proteins. Based on peptide sequences of purified bovine BART, the human cDNA sequence was determined. The 489-base pair BART open reading frame encodes a novel 163-amino acid protein with a predicted molecular mass of 18,822 Da. Recombinant BART was found to bind ARL2.GTP in a manner indistinguishable from native BART. Northern and Western analyses indicated BART is expressed in all tissues sampled. The lack of detectable membrane association of ARL2 or BART upon activation of ARL2 is suggestive of actions quite distinct from those of the ARFs. The lack of ARL2 GT-Pase-activating protein activity in BART led us to conclude that the specific interaction with ARL2 GTP is most consistent with BART being the first identified ARL2-specific effector.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NCI NIH HHS [1F32CA73202] Funding Source: Medline; NIGMS NIH HHS [R01GM55823, R01GM55148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA073202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055823, R01GM055148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hong JX, 1998, J BIOL CHEM, V273, P15872, DOI 10.1074/jbc.273.25.15872; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Poon PP, 1999, EMBO J, V18, P555, DOI 10.1093/emboj/18.3.555; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1995, METHOD ENZYMOL, V257, P128; Rudge SA, 1998, MOL BIOL CELL, V9, P2025, DOI 10.1091/mbc.9.8.2025; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; Zhang CJ, 1998, J BIOL CHEM, V273, P19792, DOI 10.1074/jbc.273.31.19792	38	49	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27553	27561		10.1074/jbc.274.39.27553	http://dx.doi.org/10.1074/jbc.274.39.27553			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488091	hybrid			2022-12-25	WOS:000082739100030
J	Choi, S; Park, S				Choi, S; Park, S			Phosphorylation at Tyr-838 in the kinase domain of EphA8 modulates Fyn binding to the Tyr-615 site by enhancing tyrosine kinase activity	ONCOGENE			English	Article						Eph; receptor tyrosine kinase; Fyn	NEURAL CREST MIGRATION; RETINAL AXON GUIDANCE; COMMISSURAL AXONS; LIGAND ACTIVATION; PROTEIN-KINASES; IN-VITRO; RECEPTOR; FAMILY; ELF-1; CELLS	Eph-related receptors and their ephrin ligands are highly conserved protein families which play important roles in targeting axons and migrating cells. In this study we have examined the functional roles of two major autophosphorylation sites, Tyr-615 and Tyr-838, in the EphA8 receptor. Two-dimensional phosphopeptide mapping analysis demonstrated that Tyr-615 and Tyr-838 constitute major autophosphorylation sites in EphA8. Tyr-615 was phosphorylated to the highest stoichiometry, suggesting that phosphorylation at this site may have a physiologically important role. Upon conservative mutation of Tyr-838 located in the tyrosine kinase domain, the catalytic activity of EphA8 was strikingly reduced both in vitro and in vivo, whereas a mutation at Tyr-615 in the juxtamembrane domain did not impair the tyrosine kinase activity. In vitro binding experiments revealed that phosphorylation at Tyr-615 in EphA8 mediates the preferential binding to Fyn-SH2 domain rather than Src and Ras GTPase-activating protein (Ras GAP)-SH2 domains. Additionally, a high level of EphA8 was detected in Fyn immunoprecipitates in intact cells, indicating that EphA8 and Fyn can physically associate in vivo. In contrast, the association of full-length Fyn to EphA8 containing mutation at either Tyr-615 or Tyr-838 was greatly reduced. These data indicate that phosphorylation of Tyr-615 is critical for determining the association with Fyn whereas the integrity of Tyr-838 phosphorylation is required for efficient phosphorylation at Tyr-615 as well as other major sites. Finally, it was observed that cell attachment responses are attenuated by overexpression of wild type EphA8 receptor but to much less extent by EphA8 mutants lacking phosphorylation at either Tyr-615 or Tyr-838. Furthermore, transient expression of kinase-inactive Fyn in EphA8-overexpressing cells blocked cell attachment responses attenuated by the EphA8 signaling. We therefore propose that Fyn kinase is one of the major downstream targets for the EphA8 signaling pathway leading to a modification of cell adhesion, and that autophosphorylation at Tyr-838 is critical for positively regulating the EphA8 signaling event.	Hallym Univ, Inst Environm & Life Sci, Chunchon 200702, Kangwon Do, South Korea	Hallym University	Park, S (corresponding author), Hallym Univ, Inst Environm & Life Sci, 1 Okcheon Dong, Chunchon 200702, Kangwon Do, South Korea.							[Anonymous], 1997, Cell, V90, P403; BARE DJ, 1993, ONCOGENE, V8, P1429; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; Gao PP, 1998, P NATL ACAD SCI USA, V95, P5329, DOI 10.1073/pnas.95.9.5329; Gao PP, 1996, P NATL ACAD SCI USA, V93, P11161, DOI 10.1073/pnas.93.20.11161; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; INGRAHAM CA, 1992, ONCOGENE, V7, P95; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Lackmann M, 1998, J BIOL CHEM, V273, P20228, DOI 10.1074/jbc.273.32.20228; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Park S, 1997, ONCOGENE, V14, P533, DOI 10.1038/sj.onc.1200857; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAGI T, 1993, ONCOGENE, V8, P3343; YAGI T, 1994, ONCOGENE, V9, P2433; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	45	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5413	5422		10.1038/sj.onc.1202917	http://dx.doi.org/10.1038/sj.onc.1202917			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498895				2022-12-25	WOS:000082718600006
J	Dominguez, D; Altmann, M; Benz, J; Baumann, U; Trachsel, H				Dominguez, D; Altmann, M; Benz, J; Baumann, U; Trachsel, H			Interaction of translation initiation factor eIF4G with eIF4A in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROTEIN-SYNTHESIS; RNA RECOGNITION MOTIF; FACTOR 4G EIF4G; BINDING-PROTEIN; MESSENGER-RNA; DEPENDENT TRANSLATION; FUNCTIONAL DOMAINS; FACTOR EIF-4A; SEQUENCE; COMPLEX	Eukaryotic initiation factor (eIF) 4A is an essential protein that, in conjunction with eIF4B, catalyzes the ATP-dependent melting of RNA secondary structure in the 5'-untranslated region of mRNA during translation initiation, In higher eukaryotes, eIF4A is assumed to be recruited to the mRNA through its interaction with eIF4G, However, the failure to detect this interaction in yeast brought into question the generality of this model, The work presented here demonstrates that yeast eIF4G; interacts with eIF4A both in vivo and in vitro, The eIF4A-binding site was mapped to amino acids 542-883 of yeast eIF4G1. Expression in yeast cells of the eIF4G1 domain that binds eIF4A results in cell growth inhibition, and addition of this domain to an eIF4A-dependent in vitro system inhibits translation in a dose-dependent manner, Both in vitro translation and cell growth can be specifically restored by increasing the eIF4G. concentration, These data demonstrate that yeast eIF4A and eIF4G interact and suggest that this interaction is required for translation and cell growth.	Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland; Univ Bern, Inst Chem & Biochem, CH-3012 Bern, Switzerland	University of Bern; University of Bern	Dominguez, D (corresponding author), Univ Bern, Inst Biochem & Mol Biol, Buhlstr 28, CH-3012 Bern, Switzerland.		Baumann, Ulrich/B-1220-2013					ALTMANN M, 1990, GENE, V91, P127, DOI 10.1016/0378-1119(90)90173-O; Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; ALTMANN M, 1990, BIOCHIM BIOPHYS ACTA, V1050, P155, DOI 10.1016/0167-4781(90)90158-X; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; BLUM S, 1992, P NATL ACAD SCI USA, V89, P7664, DOI 10.1073/pnas.89.16.7664; BLUM S, 1989, P NATL ACAD SCI USA, V86, P6043, DOI 10.1073/pnas.86.16.6043; Browning KS, 1996, PLANT MOL BIOL, V32, P107, DOI 10.1007/BF00039380; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; De Gregorio E, 1998, RNA, V4, P828, DOI 10.1017/S1355838298980372; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LANKER S, 1992, J BIOL CHEM, V267, P21167; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; MADER S, 1995, MOL CELL BIOL, V15, P4990; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Merrick WC., 1996, TRANSLATION CONTROL, P31; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; Methot N, 1996, MOL CELL BIOL, V16, P5328; Metz AM, 1996, J BIOL CHEM, V271, P31033, DOI 10.1074/jbc.271.49.31033; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Niederberger N, 1998, RNA, V4, P1259, DOI 10.1017/S1355838298980487; Ohlmann T, 1997, EMBO J, V16, P844, DOI 10.1093/emboj/16.4.844; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SCHMID SR, 1991, MOL CELL BIOL, V11, P3463, DOI 10.1128/MCB.11.7.3463; Sherman F., 1986, METHODS YEAST GENETI; Tarun SZ, 1997, MOL CELL BIOL, V17, P6876, DOI 10.1128/MCB.17.12.6876; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997	44	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26720	26726		10.1074/jbc.274.38.26720	http://dx.doi.org/10.1074/jbc.274.38.26720			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480875	hybrid			2022-12-25	WOS:000082570700014
J	Vinals, F; Chambard, JC; Pouyssegur, J				Vinals, F; Chambard, JC; Pouyssegur, J			p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; PHOSPHATIDYLINOSITOL 3-KINASE; DNA-SYNTHESIS; MAP KINASES; ACTIVATION; RAPAMYCIN; PHOSPHORYLATION; P27(KIP1); P70(S6K); SIGNAL	In this work, we analyzed the role of the PI3K-p70 S6 kinase (S6K) signaling cascade in the stimulation of endothelial cell proliferation. We found that inhibitors of the p42/p44 MAPK pathway (PD98059) and the PI3K-p70 S6K pathway (wortmannin, Ly294002, and rapamycin) all block thymidine incorporation stimulated by fetal calf serum in the resting mouse endothelial cell line 1G11. The action of rapamycin can be generalized, since it completely inhibits the mitogenic effect of fetal calf serum in primary endothelial cell cultures(human umbilical vein endothelial cells) and another established capillary endothelial cell line (LIBE cells). The inhibitory effect of rapamycin is only observed when the inhibitor is added at the early stages of G(0)-G(1) progression, suggesting an inhibitory action early in G(1). Rapamycin completely inhibits growth factor stimulation of protein synthesis, which perfectly correlates with the inhibition of cell proliferation. In accordance with its inhibitory action on protein synthesis, activation of cyclin D1 and p21 proteins by growth factors is also blocked by preincubation with rapamycin. Expression of a p70 S6K, mutant partially resistant to rapamycin reverses the inhibitory effect of the drug on DNA synthesis, indicating that rapamycin action is via p70 S6K, Thus, in vascular endothelial cells, activation of protein synthesis via p70 S6K is an essential step for cell cycle progression in response to growth factors.	Univ Nice, Ctr Biochim, CNRS, F-06108 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Vinals, F (corresponding author), Univ Nice, Ctr Biochim, CNRS, Parc Valrose, F-06108 Nice 2, France.		Vinals, Francesc/P-6278-2019; Viñals, Francesc/F-5928-2016	Viñals, Francesc/0000-0002-9918-6751; CHAMBARD, Jean Claude/0000-0003-4722-2308				BARBIERI B, 1981, P SOC EXP BIOL MED, V168, P204; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Luo Y, 1996, MOL CELL BIOL, V16, P6744; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pedersen S, 1997, EUR J BIOCHEM, V247, P449, DOI 10.1111/j.1432-1033.1997.00449.x; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Vinals F, 1999, MOL CELL BIOL, V19, P2763; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Withers DJ, 1997, J BIOL CHEM, V272, P2509	46	138	143	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26776	26782		10.1074/jbc.274.38.26776	http://dx.doi.org/10.1074/jbc.274.38.26776			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480882	Green Published, hybrid			2022-12-25	WOS:000082570700021
J	Ye, JP; Young, HA; Zhang, XY; Castranova, V; Vallyathan, V; Shi, XL				Ye, JP; Young, HA; Zhang, XY; Castranova, V; Vallyathan, V; Shi, XL			Regulation of a cell type-specific silencer in the human interleukin-3 gene promoter by the transcription factor YY1 and an AP2 sequence-recognizing factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA GENE; NF-KAPPA-B; INTERFERON-GAMMA; T-CELL; EXPRESSION; ELEMENTS; ACTIVATION; BINDING; SITE; IDENTIFICATION	Negative regulation of cytokine gene transcription is an important mechanism in maintaining homeostasis of immune function. In this study, we characterized a silencer element in the human interleukin-3 gene promoter that is responsible for the cell-specific expression of interleukin-3. This silencer activity was proposed to be mediated by an unidentified nuclear inhibitory protein (NIP). In this study, we have identified two nuclear factors that are responsible for the silencer activity in T cells. The NIP element forms four specific DNA-protein complexes (designated as complexes A-D) with the Jurkat nuclear proteins. Complex A contains a nuclear protein that shares DNA-binding specificity with the transcription factor AP2 (designated as an AP2 sequence-recognizing factor (ASRF)). Formation of this ASRF complex is required for the NIP silencer function, as mutation of the ASRF-binding site abrogated the silencer activity. Complex B contains the nuclear factor YY1 ((Y) under bar in-(Y) under bar ang (1) under bar), whose function is to down-regulate ASRF activity in the silencer. YY1 activity is supported by data from mutation and cotransfection analyses. Complexes C and D are formed by nonspecific binding proteins and do not express any regulatory activity in the NIP element. These data indicate that a cell type-specific silencer activity might be determined by a unique profile of ubiquitous transcription factors.	NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, NIH, Morgantown, WV 26505 USA; NCI, Expt Immunol Lab, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Ye, JP (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, NIH, 1095 Willowdale Rd, Morgantown, WV 26505 USA.	jby4@cdc.gov	Young, Howard/A-6350-2008; Shi, Xianglin/B-8588-2012; Ye, Jianping/N-1998-2017	Young, Howard/0000-0002-3118-5111; Ye, Jianping/0000-0003-3875-365X				CHRIVIA JC, 1990, J EXP MED, V172, P661, DOI 10.1084/jem.172.2.661; CLARK AR, 1989, NUCLEIC ACIDS RES, V17, P10130, DOI 10.1093/nar/17.23.10130; ENGELAND K, 1995, J BIOL CHEM, V270, P24572, DOI 10.1074/jbc.270.41.24572; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FONG CLW, 1994, NUCLEIC ACIDS RES, V22, P1108, DOI 10.1093/nar/22.6.1108; FONG CLW, 1995, J INTERF CYTOK RES, V15, P887, DOI 10.1089/jir.1995.15.887; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; METCALF D, 1992, TRENDS BIOCHEM SCI, V17, P286, DOI 10.1016/0968-0004(92)90436-D; MIN LW, 1992, J IMMUNOL, V148, P1913; NABEL GJ, 1988, P NATL ACAD SCI USA, V85, P2934, DOI 10.1073/pnas.85.9.2934; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SPIVAK JL, 1985, J CLIN INVEST, V76, P1613, DOI 10.1172/JCI112145; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; WIMPERIS JZ, 1989, BLOOD, V74, P1525; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; Ye JP, 1996, MOL CELL BIOL, V16, P157; Ye JP, 1997, FASEB J, V11, P825, DOI 10.1096/fasebj.11.11.9285480; Ye JP, 1996, MOL CELL BIOL, V16, P4744; YE JP, 1994, J BIOL CHEM, V269, P25728; YE JP, 1994, NUCLEIC ACIDS RES, V22, P5672, DOI 10.1093/nar/22.25.5672; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q	31	17	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26661	26667		10.1074/jbc.274.38.26661	http://dx.doi.org/10.1074/jbc.274.38.26661			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480868	hybrid			2022-12-25	WOS:000082570700007
J	Bieche, I; Nogues, C; Lidereau, R				Bieche, I; Nogues, C; Lidereau, R			Overexpression of BRCA2 gene in sporadic breast tumours	ONCOGENE			English	Article						breast carcinoma; BRCA2; quantitative RT-PCR	CANCER SUSCEPTIBILITY GENE; CHROMOSOME 13Q12-Q13; MUTATION ANALYSIS; OVARIAN CANCERS; RT-PCR; HETEROZYGOSITY; EXPRESSION; CELLS; DIFFERENTIATION; PROLIFERATION	The breast cancer susceptibility gene BRCA2 is expressed in a wide range of tissues as an Il-lib mRNA transcript that encodes a 3418-amino acid protein involved in the response to DNA damage. To obtain better a molecular characterization of BRCA2 expression in sporadic breast cancer, we quantified BRCA2 mRNA by means of RT- PCR in a large series of human primary breast tumours, BRCA2 expression showed wide variations in tumour tissues, being underexpressed in 14/127 (11%) and overexpressed in 25/127 (20%), BRCA2 overexpression (but not underexpression) correlated significantly with Scarff, Bloom and Richardson (SBR) histopathological grade III (P=0.007) and was mainly attributed to nuclear polymorphism (P=0.005) and mitotic index (P=0.048), suggesting that the BRCA2 gene contributes to the proliferation rate in breast tumours, BRCA2 status (under and/or overexpression versus normal expression) was not associated with subsequent relapse and with significantly shorter disease-free survival. The observed disruption of BRCA2 expression is not due to allelic loss, because the latter did not correlate with altered BRCA2 mRNA expression in our tumour series. Taken together, these data suggest the involvement, especially by overexpression, of the BRCA2 gene in sporadic breast tumours, and the existence of another important tumour-suppressor gene in breast cancer, in the 13q12-q13 region.	Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France; Ctr Rene Huguenin, Dept Stat Med, F-92211 St Cloud, France; Fac Sci Pharmaceut & Biol Paris, Genet Mol Lab, F-75006 Paris, France	Rene Huguenin Hospital; Rene Huguenin Hospital; UDICE-French Research Universities; Universite Paris Cite	Lidereau, R (corresponding author), Ctr Rene Huguenin, Lab Oncogenet, 35 Rue Dailly, F-92211 St Cloud, France.		Bièche, Ivan/O-7399-2017	Bièche, Ivan/0000-0002-2430-5429				Beckmann MW, 1996, BRIT J CANCER, V73, P1220, DOI 10.1038/bjc.1996.234; Bieche I, 1997, BRIT J CANCER, V76, P1416, DOI 10.1038/bjc.1997.572; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526; COLLINS N, 1995, ONCOGENE, V10, P1673; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; DIRNHOFER S, 1995, TRENDS GENET, V11, P380, DOI 10.1016/S0168-9525(00)89115-5; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Hamann U, 1996, CANCER RES, V56, P1988; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kelsell DP, 1996, LANCET, V347, P1554, DOI 10.1016/S0140-6736(96)90707-2; KERANGUEVEN F, 1995, GENE CHROMOSOME CANC, V13, P291, DOI 10.1002/gcc.2870130410; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; LAZAR V, 1995, CANCER RES, V55, P3735; MANIATIS T, 1982, MOL CLONING LABORATO, P458; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mullen CA, 1998, AM J REPROD IMMUNOL, V39, P41; PANNETIER C, 1993, NUCLEIC ACIDS RES, V21, P577, DOI 10.1093/nar/21.3.577; PERSYN JP, 1980, EUR J CANCER, V16, P1513; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; SARKAR G, 1994, BIOTECHNIQUES, V17, P864; Sellner LN, 1996, MOL CELL PROBE, V10, P481, DOI 10.1006/mcpr.1996.0068; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; Spillman MA, 1996, ONCOGENE, V13, P1639; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; vandenBerg J, 1996, BRIT J CANCER, V74, P1615, DOI 10.1038/bjc.1996.597; Vaughn JP, 1996, CANCER RES, V56, P4590; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8	37	65	69	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5232	5238		10.1038/sj.onc.1202903	http://dx.doi.org/10.1038/sj.onc.1202903			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498873				2022-12-25	WOS:000082555700012
J	Michieli, P; Basilico, C; Pennacchietti, S; Maffe, A; Tamagnone, L; Giordano, S; Bardelli, A; Comoglio, PM				Michieli, P; Basilico, C; Pennacchietti, S; Maffe, A; Tamagnone, L; Giordano, S; Bardelli, A; Comoglio, PM			Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists	ONCOGENE			English	Article						growth factors; invasive growth; oncogenes; transformation; tyrosine kinases	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; RECEPTOR TYROSINE KINASE; CONSTITUTIVELY ACTIVATING MUTATIONS; GASTROINTESTINAL STROMAL TUMORS; PAPILLARY RENAL CARCINOMAS; C-MET; CELL-LINE; PROTOONCOGENE PRODUCT; FACTOR/SCATTER FACTOR	Mutations in the genes encoding for Met, Ret and Kit receptor tyrosine kinases invariably result in increased kinase activity and in the acquisition of transforming potential. However, the requirement of receptor ligands for the transformation process is still unclear. We have investigated the role of hepatocyte growth factor (HGF), the high-affinity ligand for Met, in mutant Met-mediated cell transformation. We provide evidence that the transforming potential displayed by mutant forms of Met found in human cancer is not only sensitive but entirely dependent on the presence of HGF, by showing that mutant Met transforms NIH3T3 fibroblasts, which produce endogenous HGF, but is not able to transform epithelial cells, unless exogenous HGF is supplied. Accordingly, mutant Met-induced transformation of NIH3T3 cells can be inhibited by HGF antagonists and increased by HGF stimulation, We also show that an engineered Met receptor which contains an oncogenic mutation but is impaired in its ability to bind HGF completely loses its transforming activity, which can be rescued by causing receptor dimerization using a monoclonal antibody. These results indicate that point mutations resulting in Met kinase activation are necessary but not sufficient to cause cell transformation, the latter being dependent on ligand-induced receptor dimerization, They also suggest that mutant Met-driven tumour growth depends on the availability and tissue distribution of active HGF, and provide proof-of-concept for the treatment of mutant-Met related pathologies by HGF-antagonizing drugs.	Univ Turin, Sch Med, IRCC, Inst Canc Res & Treatment,Dept Mol Oncol, I-10060 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Michieli, P (corresponding author), Univ Turin, Sch Med, IRCC, Inst Canc Res & Treatment,Dept Mol Oncol, Str Provinciale 142,Km 3-95, I-10060 Turin, Italy.		Basilico, Cristina/A-3253-2011; Pennacchietti, Selma/A-3252-2011; Michieli, Paolo/A-2588-2011; Giordano, Silvia/J-9858-2018; Tamagnone, Luca/J-8948-2018; BARDELLI, Alberto/J-9721-2018	Michieli, Paolo/0000-0002-3093-8871; Giordano, Silvia/0000-0003-1854-1086; Tamagnone, Luca/0000-0002-2884-7946; Comoglio, Paolo/0000-0002-7056-5328; BARDELLI, Alberto/0000-0003-1647-5070				Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; BARDELLI A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P41; Birchmeier W, 1997, CIBA F SYMP, V212, P230; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; Borrello MG, 1995, ONCOGENE, V11, P2419; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; CHAN AML, 1988, ONCOGENE, V2, P593; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Chirgadze DY, 1998, FEBS LETT, V430, P126, DOI 10.1016/S0014-5793(98)00558-4; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; Date K, 1998, ONCOGENE, V17, P3045, DOI 10.1038/sj.onc.1202231; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Giordano S, 1992, Eur J Cancer Prev, V1 Suppl 3, P45, DOI 10.1097/00008469-199210003-00007; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kitayama H, 1996, BLOOD, V88, P995; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MARK MR, 1992, J BIOL CHEM, V267, P26166; MASUMOTO K, 1993, HEPATOCYTE GROWTH FA, P225; MICHIELI P, 1996, ONCOGENE, V12, P755; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moriyama Y, 1996, J BIOL CHEM, V271, P3347; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prat M, 1998, J CELL SCI, V111, P237; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; VANDEWOUDE J, 1997, CIBA FDN S, V212, P119; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZHEN Z, 1994, ONCOGENE, V9, P1691; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	71	115	121	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5221	5231		10.1038/sj.onc.1202899	http://dx.doi.org/10.1038/sj.onc.1202899			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498872				2022-12-25	WOS:000082555700011
J	Almeida, R; Levery, SB; Mandel, U; Kresse, H; Schwientek, T; Bennett, EP; Clausen, H				Almeida, R; Levery, SB; Mandel, U; Kresse, H; Schwientek, T; Bennett, EP; Clausen, H			Cloning and expression of a proteoglycan UDP-galactose :beta-xylose beta 1,4-galactosyltransferase I - A seventh member of the human beta 4-galactosyltransferase gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; MAGNETIC-RESONANCE SPECTROSCOPY; PROTEIN LINKAGE REGION; ALPHA-D-GALACTOSAMINE; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; GALACTOSYLTRANSFERASE-I; MOLECULAR-CLONING; GENOMIC STRUCTURE; CDNA CLONING; BIOSYNTHESIS	A seventh member of the human beta 4-galactosyltransferase family, beta 4Gal-T7, was identified by BLAST analysis of expressed sequence tags. The coding region of beta 4Gal-T7 depicts a type II transmembrane protein with sequence similarity to beta 4-galactosyltransferases, but the sequence was distinct in known motifs and did not contain the cysteine residues conserved in the other six members of the beta 4Gal-T family. The genomic organization of beta 4Gal-T7 was different from previous beta 4Gal-Ts, Expression of beta 4Gal-T7 in insect cells showed that the gene product had beta 1,4-galactosyltransferase activity with beta-xylosides, and the linkage formed was Gal beta 1-4Xyl, Thus, beta 4Gal-T7 represents galactosyltransferase I enzyme (xylosylprotein pl,4-galactosyltransferase; EC 2,4,1,133), which attaches the first galactose in the proteoglycan linkage region GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-Ser, Sequence analysis of beta 4Gal-T7 from a fibroblast cell line of a patient with a progeroid syndrome and signs of the Ehlers-Danlos syndrome, previously shown to exhibit reduced galactosyltransferase I activity (Quentin, E,, Gladen, A., Roden, L., and Kresse, H, (1990) Proc. Natl, Acad. Sci, U, S. A. 87, 1342-1346), revealed two inherited allelic variants, beta 4Gal-T7(186D) and beta 4Gal-T7(206P), each with a single missense substitution in the putative catalytic domain of the enzyme. beta 4Gal-T7(186D) exhibited a 4-fold elevated K-m for the donor substrate, whereas essentially no activity was demonstrated with beta 4Gal-T7(206P). Molecular cloning of beta 4Gal-T7 should facilitate general studies of its pathogenic role in progeroid syndromes and connective tissue disorders with affected proteoglycan biosynthesis.	Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark; Univ Porto, Inst Mol Pathol & Immunol, P-4200 Oporto, Portugal; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Munster, Inst Physiol Chem & Pathobiochem, D-48129 Munster, Germany	University of Copenhagen; Universidade do Porto; University System of Georgia; University of Georgia; University of Munster	Clausen, H (corresponding author), Univ Copenhagen, Sch Dent, Norre Alle 20, DK-2200 Copenhagen N, Denmark.		Almeida, Raquel/B-9647-2012; clausen, henrik/AAD-8016-2021; Bennett, Eric/AAG-6120-2020	Almeida, Raquel/0000-0002-5622-1633; Bennett, Eric/0000-0002-4976-0647	NCRR NIH HHS [5 P41 RR05351] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; AMADO M, 1999, IN PRESS BIOCH BIOPH; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bush CA, 1988, B MAGN RESON, V10, P73; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; ESKO JD, 1987, J BIOL CHEM, V262, P12189; Gorin P. A. J., 1981, ADV CARBOHYD CHEM BI, VV38, P13, DOI DOI 10.1016/S0065-2318(08)60309-1; HELTING T, 1968, BIOCHEM BIOPH RES CO, V31, P786, DOI 10.1016/0006-291X(68)90631-1; HELTING T, 1969, J BIOL CHEM, V244, P2790; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; KHATRA BS, 1974, EUR J BIOCHEM, V44, P537, DOI 10.1111/j.1432-1033.1974.tb03513.x; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRESSE H, 1987, AM J HUM GENET, V41, P436; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Mandel U, 1999, GLYCOBIOLOGY, V9, P43, DOI 10.1093/glycob/9.1.43; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; QUENTIN E, 1990, P NATL ACAD SCI USA, V87, P1342, DOI 10.1073/pnas.87.4.1342; Quentin-Hoffmann Edlegard, 1993, Paediatrie und Paedologie, V28, P37; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SCHWARTZ NB, 1975, FEBS LETT, V49, P342, DOI 10.1016/0014-5793(75)80781-2; SCHWARTZ NB, 1974, BIOCHEM BIOPH RES CO, V56, P717, DOI 10.1016/0006-291X(74)90664-0; SCHWARTZ NB, 1975, J BIOL CHEM, V250, P5200; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; VANHALBEEK H, 1982, EUR J BIOCHEM, V127, P1; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	38	187	192	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26165	26171		10.1074/jbc.274.37.26165	http://dx.doi.org/10.1074/jbc.274.37.26165			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473568	hybrid			2022-12-25	WOS:000082469700034
J	Balsinde, J; Shinohara, H; Lefkowitz, LJ; Johnson, CA; Balboa, MA; Dennis, EA				Balsinde, J; Shinohara, H; Lefkowitz, LJ; Johnson, CA; Balboa, MA; Dennis, EA			Group V phospholipase A(2)-dependent induction of cyclooxygenase-2 in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2; MOUSE OSTEOBLASTIC CELLS; MAST-CELLS; P388D(1) MACROPHAGES; MOLECULAR-CLONING; D-2 GENERATION; E-2 GENERATION; DELAYED PHASE; A(2); EXPRESSION	When exposed for prolonged periods of time (up to 20 h) to bacterial lipopolysaccharide (]LPS) murine P388D(1) macrophages exhibit a delayed prostaglandin biosynthetic response that is entirely mediated by cyclooxygenase-a (COX-2). Both the constitutive Group IV cytosolic phospholipase A(2) (cPLA(2)) and the inducible Group V secretory phospholipase A(2) (sPLA(2)) are involved in the cyclooxygenase-2-dependent generation of prostaglandins in response to LPS. Using the selective sPLA(2) inhibitor 3- (3-acetamide-1-benzyl-2-ethylindolyl-5-oxy)propane sulfonic acid (LY311727) and an antisense oligonucleotide specific for Group V sPLA(2) we found that induction of COX-2 expression is strikingly dependent on Group V sPLA(2) which was further confirmed by experiments in which exogenous Group V sPLA(2) was added to the cells. Exogenous Group V sPLA(2) was able to induce significant arachidonate mobilization on its own and to induce expression of the COX-2. None of these effects was observed if inactive Group V sPLA(2) was utilized, implying that enzyme activity is crucial for these effects to take place. Therefore, not only delayed prostaglandin production but also COX-2 gene induction are dependent on a catalytically active Group V sPLA(2). COX-2 expression was also found to be blunted by the Group TV cPLA(2) inhibitor methyl arachidonyl fluorophosphonate, which we have previously found to block Group V sPLA(2) induction as well. Collectively, the results support a model whereby Group IV cPLA(2) activation regulates the expression of Group V sPLA(2) which in turn is responsible for delayed prostaglandin production by regulating COX-2 expression.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Dennis, EA (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 4080 Basic Sci Bldg,9500 Gilman Dr, La Jolla, CA 92093 USA.	edennis@ucsd.edu	Balsinde, Jesús/C-7833-2018; Balboa, María A./V-9493-2018; Dennis, Edward A./M-5554-2019	Balsinde, Jesús/0000-0002-4157-6714; Balboa, María A./0000-0002-2130-5298; Dennis, Edward A./0000-0003-3738-3140	NICHD NIH HHS [HD26171] Funding Source: Medline; NIDDK NIH HHS [5T32 DK07202] Funding Source: Medline; NIGMS NIH HHS [GM2051] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; CHEN J, 1994, J BIOL CHEM, V269, P2365; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; DENNIS EA, 1987, BIO-TECHNOL, V5, P1294, DOI 10.1038/nbt1287-1294; Hackeng TM, 1997, P NATL ACAD SCI USA, V94, P7845, DOI 10.1073/pnas.94.15.7845; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KISHINO J, 1994, J BIOL CHEM, V269, P5092; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Naraba H, 1998, J IMMUNOL, V160, P2974; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Tada K, 1998, J IMMUNOL, V161, P5008; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; White CE, 1995, PROTEIN ENG, V8, P1177, DOI 10.1093/protein/8.11.1177	30	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					25967	25970		10.1074/jbc.274.37.25967	http://dx.doi.org/10.1074/jbc.274.37.25967			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473537	hybrid			2022-12-25	WOS:000082469700003
J	Durbeej, M; Campbell, KP				Durbeej, M; Campbell, KP			Biochemical characterization of the epithelial dystroglycan complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; GIRDLE MUSCULAR-DYSTROPHY; ACETYLCHOLINE-RECEPTOR AGGREGATION; ALPHA-DYSTROGLYCAN; SARCOGLYCAN COMPLEX; DELTA-SARCOGLYCAN; SKELETAL-MUSCLE; NEUROMUSCULAR-JUNCTION; EPSILON-SARCOGLYCAN; MOUSE EMBRYOGENESIS	Dystroglycan is a widely expressed extracellular matrix receptor that plays a critical role in basement membrane formation, epithelial development, and synaptogenesis. Dystroglycan was originally characterized in skeletal muscle as an integral component of the dystrophin glycoprotein complex, which is critical for muscle cell viability. Although the dystroglycan complex has been well characterized in skeletal muscle, there is little information on the structural composition of the dystroglycan complex outside skeletal muscle. Here we have biochemically characterized the dystroglycan complex in lung and kidney. We demonstrate that the presence of sarcoglycans and sarcospan in lung reflects association with dystroglycan in the smooth muscle. The smooth muscle dystroglycan complex in lung, composed of dystroglycan, dystrophin/utrophin, beta-, delta-, is an element of-sarcoglycan, and sarcospan, can be biochemically separated from epithelial dystroglycan, which is not associated with any of the known sarcoglycans or sarcospan. Similarly, dystroglycan in kidney epithelial cells is not associated with any of the sarcoglycans or sarcospan. Thus, our data demonstrate that there are distinct dystroglycan complexes in non-skeletal muscle organs as follows: one from smooth muscle, which is associated with sarcoglycans forming a similar complex as in skeletal muscle, and one from epithelial cells.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Neurol, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol Biophys, 400 EMRB, Iowa City, IA 52242 USA.			Durbeej Hjalt, Madeleine/0000-0002-5491-2457; Campbell, Kevin/0000-0003-2066-5889				Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blank M, 1997, J COMP NEUROL, V389, P668; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; BYERS TJ, 1993, NAT GENET, V4, P87; Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079; Chiba A, 1997, J BIOL CHEM, V272, P2156; CLERK A, 1993, HISTOCHEM J, V25, P554; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; Durbeej M, 1998, J HISTOCHEM CYTOCHEM, V46, P449, DOI 10.1177/002215549804600404; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; Durbeej M, 1997, DEV BIOL, V181, P156, DOI 10.1006/dbio.1996.8430; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ettinger AJ, 1997, J BIOL CHEM, V272, P32534, DOI 10.1074/jbc.272.51.32534; Froehner SC, 1997, SOC GEN PHY, V52, P197; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; GORECKI DC, 1994, HUM MOL GENET, V3, P1589; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Holt KH, 1998, MOL CELL, V1, P841, DOI 10.1016/S1097-2765(00)80083-0; HOUZELSTEIN D, 1992, J CELL BIOL, V119, P811, DOI 10.1083/jcb.119.4.811; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Iwata Y, 1996, J MOL CELL CARDIOL, V28, P2501, DOI 10.1006/jmcc.1996.9999; Jacobson C, 1998, J NEUROSCI, V18, P6340; James M, 1996, CELL MOTIL CYTOSKEL, V33, P163, DOI 10.1002/(SICI)1097-0169(1996)33:3<163::AID-CM1>3.0.CO;2-C; Jung D, 1996, J BIOL CHEM, V271, P32321, DOI 10.1074/jbc.271.50.32321; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Kachinsky AM, 1999, J CELL BIOL, V145, P391, DOI 10.1083/jcb.145.2.391; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; Lidov HGW, 1998, LAB INVEST, V78, P1543; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; McNally EM, 1998, FEBS LETT, V422, P27, DOI 10.1016/S0014-5793(97)01593-7; Montanaro F, 1998, J NEUROSCI, V18, P1250; Nigro V, 1996, HUM MOL GENET, V5, P1179, DOI 10.1093/hmg/5.8.1179; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; Peng HB, 1998, CELL ADHES COMMUN, V5, P475, DOI 10.3109/15419069809005605; Peters MF, 1997, J BIOL CHEM, V272, P31561, DOI 10.1074/jbc.272.50.31561; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Puca AA, 1998, FEBS LETT, V425, P7, DOI 10.1016/S0014-5793(98)00097-0; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; Saito F, 1999, J BIOL CHEM, V274, P8240, DOI 10.1074/jbc.274.12.8240; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; Sasaki T, 1998, BBA-GEN SUBJECTS, V1425, P599, DOI 10.1016/S0304-4165(98)00114-7; SCHOFIELD J, 1993, DEV DYNAM, V198, P254, DOI 10.1002/aja.1001980403; SCHOFIELD JN, 1994, HUM MOL GENET, V3, P1309; Straub V, 1998, AM J PATHOL, V153, P1623, DOI 10.1016/S0002-9440(10)65751-3; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	64	94	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26609	26616		10.1074/jbc.274.37.26609	http://dx.doi.org/10.1074/jbc.274.37.26609			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473626	hybrid			2022-12-25	WOS:000082469700092
J	Hildesheim, J; Foster, RA; Chamberlin, ME; Vogel, JC				Hildesheim, J; Foster, RA; Chamberlin, ME; Vogel, JC			Characterization of the regulatory domains of the human Skn-1a/Epoc-1/Oct-11 POU transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REMOTE ENHANCER POSITION; DNA-BINDING; OCT2 TRANSACTIVATION; INSITU HYBRIDIZATION; CYTOKERATIN GENES; MAMMALIAN-CELLS; CROSS-LINKING; EXPRESSION; DIFFERENTIATION; ACTIVATION	The Skn-1a POU transcription factor is primarily expressed in keratinocytes of murine embryonic and adult epidermis. Although some POU factors expressed in a tissue-specific manner are important for normal differentiation, the biological function of Skn-1a remains unknown. Previous in vitro studies indicate that Skn-1a has the ability to transactivate markers of keratinocyte differentiation. In this study, we have characterized Skn-1a's transactivation domain(s) and engineered a dominant negative protein that lacked this transactivation domain. Deletional analysis of the human homologue of Skn-1a with three target promoters revealed the presence of two functional domains: a primary C-terminal transactivation domain and a combined N-terminal inhibitory domain and transactivation domain. Skn-1a lacking the C-terminal region completely lost transactivation ability, irrespective of the promoter tested, and was able to block transactivation by normal Skn-1a in competition assays. Compared with full-length, Skn-1a lacking the N-terminal region demonstrated either increased transactivation (bovine cytokeratin 6 promoter), comparable transactivation (human papillomavirus type 1a long control region), or loss of transactivation (human papillomavirus type 18 long control region). The identification of a primary C-terminal transactivation domain enabled us to generate a dominant negative Skn-1a factor, which will be useful in the quest for a better understanding of this keratinocyte-specific gene regulator.	NCI, Dermatol Branch, NIH, Bethesda, MD 20892 USA; NICHD, Cellular Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Vogel, JC (corresponding author), NCI, Dermatol Branch, NIH, Bldg 10,Rm 12N238,10 Ctr Dr,MSC 1908, Bethesda, MD 20892 USA.	jonvogel@box-j.nih.gov						ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Andersen B, 1997, J BIOL CHEM, V272, P15905, DOI 10.1074/jbc.272.25.15905; Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; Brehm A, 1997, MOL CELL BIOL, V17, P154, DOI 10.1128/MCB.17.1.154; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DALE BA, 1998, MOL BIOL SKIN, P79; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; FUCHS E, 1993, J CELL SCI, P197; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GOLDSBOROUGH AS, 1993, NUCLEIC ACIDS RES, V21, P127, DOI 10.1093/nar/21.1.127; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOHL D, 1993, DIFFERENTIATION, V54, P25, DOI 10.1111/j.1432-0436.1993.tb00656.x; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4503, DOI 10.1093/nar/19.16.4503; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2204, DOI 10.1128/MCB.8.5.2204; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Latchman DS, 1996, PHILOS T R SOC B, V351, P511, DOI 10.1098/rstb.1996.0049; LILLYCROP KA, 1995, MOL BIOL REP, V21, P87, DOI 10.1007/BF00986498; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STEINERT PM, 1991, PHYSL BIOCH MOL BIOL, P113; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Vigano MA, 1996, NUCLEIC ACIDS RES, V24, P2112, DOI 10.1093/nar/24.11.2112; WALKER S, 1994, CELL, V79, P841, DOI 10.1016/0092-8674(94)90073-6; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; YUKAWA K, 1993, GENE, V133, P163; Yukawa K, 1996, J VIROL, V70, P10, DOI 10.1128/JVI.70.1.10-16.1996	51	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26399	26406		10.1074/jbc.274.37.26399	http://dx.doi.org/10.1074/jbc.274.37.26399			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473598	hybrid			2022-12-25	WOS:000082469700064
J	Werner, S; Wohrl, BM				Werner, S; Wohrl, BM			Soluble Rous sarcoma virus reverse transcriptases alpha, alpha beta, and beta purified from insect cells are processive DNA polymerases that lack an RNase H 3 '-> 5 ' directed processing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AVIAN-MYELOBLASTOSIS VIRUS; TEMPLATE-PRIMER UTILIZATION; RIBONUCLEASE-H; ENDONUCLEASE ACTIVITY; ESCHERICHIA-COLI; STRAND TRANSFER; RETROVIRUS; P66; MECHANISM	Reverse transcriptase (RT) isolated from Rous sarcoma virus (RSV) consists of heterodimeric RT alpha beta, RT alpha, and RT beta. The alpha subunit (63 kDa) contains an N-terminal polymerase and a C-terminal RNase H domain. The N terminus of beta (95 kDa) corresponds to alpha with the integrase domain attached to the C terminus (32 kDa). We have constructed baculoviruses expressing the genes for alpha or beta or the entire pol (99 kDa). Infection of insect cells with recombinant virus yielded highly active and soluble RSV RT enzymes that could be purified to >90% homogeneity. HPLC gel filtration showed that a is a dimeric enzyme that can be partially monomerized upon the addition of 45% Me2SO, DNA synthesis on DNA-DNA and DNA-RNA primer-templates in the presence of competitor substrates revealed that alpha beta and beta as well as a are processive polymerases. However, the affinity of beta and alpha beta for primer-template substrates appears to be higher than that of alpha. All RSV enzymes investigated have the potential to displace RNA-RNA duplexes more efficiently than human immunodeficiency virus type 1 RT. Unlike human immunodeficiency virus type 1 RT, RSV RTs can catalyze an initial RNase H endonucleolytic cleavage of the RNA template but not a 3' --> 5' directed processing activity.	Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany	Max Planck Society	Wohrl, BM (corresponding author), Max Planck Inst Mol Physiol, Phys Biochem Abt, Otto Hahn Str 11, D-44227 Dortmund, Germany.	birgit.woehrl@mpi-dortmund.mpg.de						ALEXANDER F, 1987, J VIROL, V61, P534, DOI 10.1128/JVI.61.2.534-542.1987; BAMBARA RA, 1978, J BIOL CHEM, V253, P413; COLLETT MS, 1978, J VIROL, V26, P498, DOI 10.1128/JVI.26.2.498-509.1978; DEVICO A, 1991, VIROLOGY, V185, P387, DOI 10.1016/0042-6822(91)90786-B; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; GOLOMB M, 1979, J BIOL CHEM, V254, P1606; GRANDGENETT DP, 1976, J VIROL, V17, P950, DOI 10.1128/JVI.17.3.950-961.1976; GRANDGENETT DP, 1973, P NATL ACAD SCI USA, V70, P230, DOI 10.1073/pnas.70.1.230; GRANDGENETT DP, 1978, VIROLOGY, V89, P119, DOI 10.1016/0042-6822(78)90046-6; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HIZI A, 1977, J BIOL CHEM, V252, P2281; HIZI A, 1977, J BIOL CHEM, V252, P2290; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1991, P NATL ACAD SCI USA, V88, P10895, DOI 10.1073/pnas.88.23.10895; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P26472; KACIAN DL, 1971, BIOCHIM BIOPHYS ACTA, V246, P365, DOI 10.1016/0005-2787(71)90773-8; KATZ RA, 1988, J VIROL, V62, P528, DOI 10.1128/JVI.62.2.528-533.1988; KRAUS G, 1990, EUR J BIOCHEM, V192, P207, DOI 10.1111/j.1432-1033.1990.tb19216.x; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LIN TH, 1991, J BIOL CHEM, V266, P1635; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RESTLE T, 1992, FEBS LETT, V300, P97, DOI 10.1016/0014-5793(92)80172-D; RHO HM, 1975, J BIOL CHEM, V250, P5278; Sambrook J, 1994, MOL CLONING LAB MANU; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHIFF RD, 1978, J VIROL, V28, P279, DOI 10.1128/JVI.28.1.279-291.1978; SOLTIS DA, 1988, P NATL ACAD SCI USA, V85, P3372, DOI 10.1073/pnas.85.10.3372; Souquet M, 1998, BIOCHEMISTRY-US, V37, P12144, DOI 10.1021/bi9731596; STEWART L, 1993, J VIROL, V67, P7582, DOI 10.1128/JVI.67.12.7582-7596.1993; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; Trentin B, 1998, J VIROL, V72, P6504, DOI 10.1128/JVI.72.8.6504-6510.1998; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; Wohrl BM, 1997, J BIOL CHEM, V272, P17581, DOI 10.1074/jbc.272.28.17581; WOHRL BM, 1994, J BIOL CHEM, V269, P8541	42	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26329	26336		10.1074/jbc.274.37.26329	http://dx.doi.org/10.1074/jbc.274.37.26329			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473589	hybrid			2022-12-25	WOS:000082469700055
J	Zhao, MC; Li, P; Li, XL; Zhang, L; Winkfein, RJ; Chen, SRW				Zhao, MC; Li, P; Li, XL; Zhang, L; Winkfein, RJ; Chen, SRW			Molecular identification of the ryanodine receptor pore-forming segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; INOSITOL TRISPHOSPHATE; FUNCTIONAL EXPRESSION; CONDUCTION; CDNA; CLONING; CELLS	A sequence motif, GXRXGGGXGD, located in the putative channel-forming domain, is conserved in all known ryanodine receptors and inositol 1, 4,5-trisphosphate receptors, The functional significance of this conserved region was investigated by using site-directed mutagenesis together with functional assays consisting :of Ca2+ release measurements, [H-3]ryanodine binding, and single channel recordings in planar lipid bilayers, We report here that single point mutations introduced into this region of the mouse cardiac ryanodine receptor reduce or abolish high affinity [H-3]ryanodine binding. Single channel analysis revealed that a single substitution of alanine for glycine 4824 within this region reduced the single channel conductance by 97%, from 798 picosiemens (pS) for the wild type channel to 22 pS, The G4824A mutant channel was modulated by Ca2+, Mg2+, ATP, caffeine, ruthenium red, and ryanodine, Co-expression of the wild type and G4824A. mutant proteins produced single channels that have intermediate unitary conductances of 516, 256, 176, and 60 pS, These data suggest that this conserved region constitutes an essential part of the ryanodine binding site and the channel conduction pathway of the ryanodine receptor.	Univ Calgary, Dept Physiol & Biophys, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, MRC, Grp Ion Channels & Transporters, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Chen, SRW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada.							AIREY JA, 1990, J BIOL CHEM, V265, P14187; Balshaw D, 1999, P NATL ACAD SCI USA, V96, P3345, DOI 10.1073/pnas.96.7.3345; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Du GG, 1998, J BIOL CHEM, V273, P33259, DOI 10.1074/jbc.273.50.33259; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; Gao L, 1999, BIOPHYS J, V76, pA303; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Lynch PJ, 1999, P NATL ACAD SCI USA, V96, P4164, DOI 10.1073/pnas.96.7.4164; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; Mak DOD, 1997, J GEN PHYSIOL, V109, P571, DOI 10.1085/jgp.109.5.571; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OTSU K, 1990, J BIOL CHEM, V265, P13472; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; TINKER A, 1992, J GEN PHYSIOL, V100, P495, DOI 10.1085/jgp.100.3.495; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	30	170	180	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					25971	25974		10.1074/jbc.274.37.25971	http://dx.doi.org/10.1074/jbc.274.37.25971			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473538	hybrid			2022-12-25	WOS:000082469700004
J	Tintut, Y; Parhami, F; Le, V; Karsenty, G; Demer, LL				Tintut, Y; Parhami, F; Le, V; Karsenty, G; Demer, LL			Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells - Ubiquitin/proteasome-dependent regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE; CLEIDOCRANIAL DYSPLASIA; GENE-EXPRESSION; FACTOR OSF2/CBFA1; BONE-CELLS; DIFFERENTIATION; BINDING; BETA; HETEROGENEITY; CALCIFICATION	The cAMP pathway, a major intracellular pathway mediating parathyroid hormone signal, regulates osteoblastic function. Parathyroid hormone (through activation of protein kinase A) has also been shown to stimulate ubiquitin/proteasome activity in osteoblasts. Since the osteoblast-specific transcription factor Osf2/Cbfa1 is important for differentiation of osteoblastic cells, we examined the roles of the cAMP and ubiquitin/proteasome pathways in regulation of Cbfa1. In the osteoblastic cell line, MC3T3-E1, continuous treatment with cAMP elevating agents inhibited both osteoblastic differentiation based on alkaline phosphatase assay and DNA binding ability of Cbfa1 based on a gel retardation assay. Cbfa1 inhibition was paralleled by an inhibitory effect of forskolin on Cbfa1-regulated genes. Northern and Western blot analyses suggested that the inhibition of Cbfa1 by forskolin was mainly at the protein level. Pretreatment with proteasome inhibitors prior to forskolin treatment reversed the effect of forskolin. Furthermore, addition of proteasome inhibitors to forskolin-pretreated samples resulted in recovery of Cbfa1 protein levels and accumulation of polyubiquitinated forms of Cbfa1, indicating a role for the proteasome pathway in the degradation of Cbfa1. These results suggest that suppression of osteoblastic function by the cAMP pathway is through proteolytic degradation of Cbfa1 involving a ubiquitin/proteasome-dependent mechanism.	Univ Calif Los Angeles, Med Ctr,Sch Med,Div Cardiol, Dept Med Cardiol, Ctr Hlth Sci, Los Angeles, CA 90095 USA; Baylor Coll Med, Dept Human & Mol Genet, Houston, TX 77030 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Baylor College of Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tintut, Y (corresponding author), Univ Calif Los Angeles, Med Ctr,Sch Med,Div Cardiol, Dept Med Cardiol, Ctr Hlth Sci, Rm 47-123, Los Angeles, CA 90095 USA.		Demer, Linda L/I-5770-2013	Demer, Linda L/0000-0002-9618-6895	NHLBI NIH HHS [HL-30568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; Isogai Y, 1996, J BONE MINER RES, V11, P1384; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KREAM BE, 1980, P NATL ACAD SCI-BIOL, V77, P5654, DOI 10.1073/pnas.77.10.5654; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Leis HJ, 1997, J BONE MINER RES, V12, P541, DOI 10.1359/jbmr.1997.12.4.541; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Murray EJB, 1998, EXP CELL RES, V242, P460, DOI 10.1006/excr.1998.4090; Murray EJB, 1997, METABOLISM, V46, P1090, DOI 10.1016/S0026-0495(97)90284-5; NODA M, 1989, J CELL BIOL, V108, P713, DOI 10.1083/jcb.108.2.713; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680; PARTRIDGE N, 1989, MOL ENDOCRINOL, V89, P232; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Tintut Y, 1998, J BIOL CHEM, V273, P7547, DOI 10.1074/jbc.273.13.7547; TOWLER DA, 1995, ENDOCRINOLOGY, V136, P1089, DOI 10.1210/en.136.3.1089; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; Walowitz JL, 1998, J BIOL CHEM, V273, P6656, DOI 10.1074/jbc.273.12.6656; Yang RJ, 1996, J BIOL CHEM, V271, P29839, DOI 10.1074/jbc.271.47.29839; YOHAY DA, 1994, J CELL PHYSIOL, V158, P467, DOI 10.1002/jcp.1041580311; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V	34	118	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28875	28879		10.1074/jbc.274.41.28875	http://dx.doi.org/10.1074/jbc.274.41.28875			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506130	hybrid			2022-12-25	WOS:000083017800009
J	Patil, S; Jedsadayanmata, A; Wencel-Drake, JD; Wang, W; Knezevic, I; Lam, SCT				Patil, S; Jedsadayanmata, A; Wencel-Drake, JD; Wang, W; Knezevic, I; Lam, SCT			Identification of a talin-binding site in the integrin beta(3) subunit distinct from the NPLY regulatory motif of post-ligand binding functions - The talin N-terminal head domain interacts with the membrane-proximal region of the beta(3) cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PLATELET GPIIB-IIIA; POLYMERASE CHAIN-REACTION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; FOCAL ADHESIONS; RECEPTOR OCCUPANCY; STRUCTURAL MODEL; ALPHA-ACTININ; NPXY MOTIF	Following platelet aggregation, integrin alpha(IIb)beta(3) becomes associated with the platelet cytoskeleton, The conserved NPLY sequence represents a potential beta-turn motif in the beta(3) cytoplasmic tail and has been suggested to mediate the interaction of beta(3) integrins with talin, In the present study, we performed a double mutation (N744Q/P745A) in the integrin beta(3) subunit to test the functional significance of this beta-turn motif. Chinese hamster ovary cells were co-transfected with cDNA constructs encoding mutant beta(3) and mild type alpha(IIb). Cells expressing either wild type (A5) or mutant (D4) alpha(IIb)beta(3) adhered to fibrinogen; however, as opposed to control A5 cells, adherent D4 cells failed to spread, form focal adhesions, or initiate protein tyrosine phosphorylation, To investigate the role of the NPLY motif in talin binding, we examined the ability of the mutant alpha(IIb)beta(3) to interact with talin in a solid phase binding assay. Both mild type and mutant alpha(IIb)beta(3), purified by RGD affinity chromatography, bound to a similar extent to immobilized talin, Additionally, purified talin failed to interact with peptides containing the AKWDTANNPLYK sequence indicating that the talin binding domain in the integrin beta(3) subunit does not reside in the NPLY motif. In contrast, specific binding of talin to peptides containing the membrane-proximal HDRKEFAKFEEERARAK sequence of the beta(3) cytoplasmic tail was observed, and this interaction was blocked by a recombinant protein fragment corresponding to the 47-kDa N-terminal head domain of talin (rTalin-N), In addition, RGD affinity purified platelet alpha(IIb)beta(3) bound dose-dependently to immobilized rTalin-N, indicating that an integrin-binding site is present in the talin N-terminal head domain. Collectively, these studies demonstrate that the NPLY beta-turn motif regulates post-ligand binding functions of alpha(IIb)beta(3) in a manner independent of talin interaction. Moreover, talin was shown to bind through its N-terminal head domain to the membrane-proximal sequence of the beta(3) cytoplasmic tail.	Univ Illinois, Dept Pharmacol MC 868, Chicago, IL 60612 USA; Univ Illinois, Sch Biomed & Hlth Informat Sci, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lam, SCT (corresponding author), Univ Illinois, Dept Pharmacol MC 868, 835 S Wolcott Ave, Chicago, IL 60612 USA.		Jedsadayanmata, Arom/AAR-9251-2021	Jedsadayanmata, Arom/0000-0002-5776-1439	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041793, R29HL041793, R01HL052755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41793, HL-52755] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRAVES WS, 1987, J CELL BIOL, V105, P1183; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COHEN I, 1982, J CELL BIOL, V93, P775, DOI 10.1083/jcb.93.3.775; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; Haas TA, 1997, PROTEIN ENG, V10, P1395, DOI 10.1093/protein/10.12.1395; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; IUPAC-IUB commission on biochemical nomenclature, 1968, J BIOL CHEM, V243, P3557; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEE SW, 1992, J BIOL CHEM, V267, P16355; Leisner TM, 1999, J BIOL CHEM, V274, P12945, DOI 10.1074/jbc.274.18.12945; LEONG L, 1995, J CELL SCI, V108, P3817; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; OTEY C, 1990, HYBRIDOMA, V9, P57, DOI 10.1089/hyb.1990.9.57; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PIDARD D, 1983, J BIOL CHEM, V258, P2582; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; TAPLEY P, 1989, ONCOGENE, V4, P325; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; TURNER CE, 1989, EUR J CELL BIOL, V49, P202; TUSZYNSKI GP, 1984, J BIOL CHEM, V259, P5247; Vignoud L, 1997, J CELL SCI, V110, P1421; WENCELDRAKE JD, 1993, BLOOD, V81, P62; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885	59	76	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28575	28583		10.1074/jbc.274.40.28575	http://dx.doi.org/10.1074/jbc.274.40.28575			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497223	hybrid			2022-12-25	WOS:000082912700072
J	Rouillon, A; Surdin-Kerjan, Y; Thomas, D				Rouillon, A; Surdin-Kerjan, Y; Thomas, D			Transport of sulfonium compounds - Characterization of the S-adenosylmethionine and S-methylmethionine permeases from the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYLSULPHONIOPROPIONATE; METABOLISM; SEQUENCES; PRECURSOR; DNA	We report here the characterization and the molecular analysis of the two high affinity permeases that mediate the transport of S-adenosylmethionine (AdoMet) and S-methylmethionine (SMM) across the plasma membrane of yeast cells. Mutant cells unable to use AdoMet as a sulfur source were first isolated and demonstrated to lack high affinity AdoMet transport capacities. Functional complementation cloning allowed us to identify the corresponding gene (SAM3), which encodes an integral membrane protein comprising 12 putative membrane spanning regions and belonging to the amino acid permease family. Among amino acid permease members, the closest relative of Sam3p is encoded by the YLL061w, open reading frame. Disruption of YLL061w was shown to specifically lead to cells unable to use SMM as a sulfur source. Accordingly, transport assays demonstrated that YLL061w disruption mutation impaired the high affinity SMM permease, and YLL061w was therefore renamed MMP1. Further study of sam3 Delta and mmp1 Delta mutant cells showed that in addition to high affinity permeases, both sulfonium compounds are transported into yeast cells by low affinity transport systems that appear to be carrier-facilitated diffusion.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Thomas, D (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.		rouillon, astrid/L-2102-2015	rouillon, astrid/0000-0001-9280-2577				Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BALASUNDARAM D, 1994, J BACTERIOL, V176, P6407, DOI 10.1128/jb.176.20.6407-6409.1994; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; BISSON LF, 1993, CRIT REV BIOCHEM MOL, V28, P259, DOI 10.3109/10409239309078437; Cherest H, 1997, GENETICS, V145, P627; CHEREST H, 1992, GENETICS, V130, P51; CONE MC, 1982, J BACTERIOL, V151, P510, DOI 10.1128/JB.151.1.510-515.1982; COOPER TG, 1982, T SACCHAROMYCAS CERE, P399; DICKSON DM, 1980, PLANTA, V150, P158, DOI 10.1007/BF00582360; DICKSON DMJ, 1986, PLANTA, V167, P536, DOI 10.1007/BF00391230; Fink GR., 1970, METHODS ENZYMOL VOL, V17, P59, DOI DOI 10.1016/0076-6879(71)17167-4; Gage DA, 1997, NATURE, V387, P891, DOI 10.1038/43160; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; GREENE RC, 1960, BIOCHIM BIOPHYS ACTA, V43, P360, DOI 10.1016/0006-3002(60)90457-1; Higgins D G, 1994, Methods Mol Biol, V25, P307; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; JEBBAR M, 1994, MICROBIOLOGY, V140, P2415; LAGUNAS R, 1993, FEMS MICROBIOL LETT, V104, P229, DOI 10.1016/0378-1097(93)90598-V; LANG JM, 1987, J BACTERIOL, V169, P2932, DOI 10.1128/jb.169.7.2932-2937.1987; LEVER M, 1996, BIOCHIM BIOPHYS ACTA, V1291, P189; MCRORIE RA, 1954, J AM CHEM SOC, V76, P115, DOI 10.1021/ja01630a032; MUDD SH, 1990, PLANT PHYSIOL, V93, P623, DOI 10.1104/pp.93.2.623; MURPHY JT, 1972, J BACTERIOL, V109, P499, DOI 10.1128/JB.109.2.499-504.1972; PETROTTASIMPSON TF, 1975, J BACTERIOL, V123, P516, DOI 10.1128/JB.123.2.516-522.1975; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHAPIRO SK, 1964, J BIOL CHEM, V239, P1551; SHERMAN F, 1979, METHODS YEAST GENETI, P9; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028; SPENCE KD, 1971, J BACTERIOL, V106, P325, DOI 10.1128/JB.106.2.325-330.1971; SPENCE KD, 1977, BIOCH ADENOSYLMETHIO, P77; STONER GL, 1975, J BIOL CHEM, V250, P4029; SUMRADA R, 1976, J BACTERIOL, V125, P1048, DOI 10.1128/JB.125.3.1048-1056.1976; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; Trossat C, 1998, PLANT PHYSIOL, V116, P165, DOI 10.1104/pp.116.1.165	34	61	66	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28096	28105		10.1074/jbc.274.40.28096	http://dx.doi.org/10.1074/jbc.274.40.28096			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497160	hybrid			2022-12-25	WOS:000082912700009
J	Hirota, K; Murata, M; Sachi, Y; Nakamura, H; Takeuchi, J; Mori, K; Yodoi, J				Hirota, K; Murata, M; Sachi, Y; Nakamura, H; Takeuchi, J; Mori, K; Yodoi, J			Distinct roles of thioredoxin in the cytoplasm and in the nucleus - A two-step mechanism of redox regulation of transcription factor NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-DERIVED FACTOR; DNA-BINDING ACTIVITY; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; GENE-EXPRESSION; T-LYMPHOCYTES; S-THIOLATION; ACTIVATION; KINASE; PROTEIN	Oxidative stresses such as UV irradiation to mammalian cells triggers a variety of oxistress responses including activation of transcription factors. Recently, activation of nuclear factor-kappa B (NF-kappa B) has been shown to be under oxidoreduction (redox) regulation controlled by thioredoxin (TRX), which is one of major endogenous redox-regulating molecules with thiol reducing activity. In order to elucidate where in the cellular compartment TRX participates in NF-kappa B regulation, we investigated the intracellular localization of TRX. UVB irradiation induced translocation of TRX from the cytoplasm into the nucleus. In our in vitro diamide-induced cross-linking study, we showed that TRX can associate directly with NF-kappa B p50. Overexpression of wild-type TRX suppressed induction of luciferase activity under NF-kappa B-binding sites in response to UV irradiation compared with the mock transfectant. In contrast, overexpression of nuclear-targeted TRX enhanced the luciferase activity. Thus, TRX seems to play dual and opposing roles in the regulation of NF-kappa B. In the cytoplasm, it interferes with the signals to I kappa B kinases and blocks the degradation of I kappa B. In the nucleus, however, TRX enhances NF-kappa KB transcriptional activities by enhancing its ability to bind DNA. This two-step TRX-dependent regulation of the NF-kappa B complex may be a novel activation mechanism of redox-sensitive transcription factors.	Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 60601, Japan; Kyoto Univ Hosp, Dept Anesthesia, Kyoto, Japan; Grad Sch Med, Dept Integrat Brain Sci, Kyoto, Japan	Kyoto University; Kyoto University	Hirota, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, 53 Shogoin Kawahara-Cho, Kyoto 60601, Japan.		Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; CATHERINE HR, 1997, CELL, V90, P373; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; delArco PG, 1996, J BIOL CHEM, V271, P26335; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIDIONATE JA, 1997, NATURE, V388, P548; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROGE W, 1994, FASEB J, V8, P1131; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hiramoto M, 1998, J IMMUNOL, V160, P810; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HORI K, 1994, BRAIN RES, V652, P304, DOI 10.1016/0006-8993(94)90241-0; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KONDO S, 1981, BRIT J DERMATOL, V105, P125, DOI 10.1111/j.1365-2133.1981.tb01196.x; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MITOMO K, 1994, GENE, V145, P197; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; NAKAMURA H, 1992, CANCER-AM CANCER SOC, V69, P2091, DOI 10.1002/1097-0142(19920415)69:8<2091::AID-CNCR2820690814>3.0.CO;2-X; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nishiyama A, 1999, IMMUNOL LETT, V68, P155, DOI 10.1016/S0165-2478(99)00045-0; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; SACHI Y, 1995, IMMUNOL LETT, V44, P189, DOI 10.1016/0165-2478(95)00213-O; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sasada T, 1996, J CLIN INVEST, V97, P2268, DOI 10.1172/JCI118668; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STEVENSON MA, 1994, CANCER RES, V54, P12; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Tanaka T, 1997, LAB INVEST, V77, P145; Taniguchi Y, 1996, NUCLEIC ACIDS RES, V24, P2746, DOI 10.1093/nar/24.14.2746; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	67	490	508	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27891	27897		10.1074/jbc.274.39.27891	http://dx.doi.org/10.1074/jbc.274.39.27891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488136	hybrid			2022-12-25	WOS:000082739100075
J	Chan, PC; Lai, JF; Cheng, CH; Tang, MJ; Chiu, CC; Chen, HC				Chan, PC; Lai, JF; Cheng, CH; Tang, MJ; Chiu, CC; Chen, HC			Suppression of ultraviolet irradiation-induced apoptosis by overexpression of focal adhesion kinase in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE KINASES; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; STABLE ASSOCIATION; V-SRC; BINDING; ACTIVATION; PP125(FAK)	Focal adhesion kinase (FAK) has been implicated tea play a role in suppression of apoptosis. In this study, we have demonstrated that UV irradiation induced cleavage of FAK and two of its interacting proteins Src and p130(Cas) in Madin-Darby canine kidney cells, concomitant with an increase in cell death. The cleavage of these proteins upon UV irradiation was completely inhibited by ZVAD-FMK, a broad range inhibitor of caspases, and apparently delayed by Bcl2 overexpression. To examine if FAK plays a role in suppressing UV-induced apoptosis, stable Madin-Darby canine kidney cell lines overexpressing FAK were established. Our results showed that a marked (30-40%) increase in cell survival upon UV irradiation was achieved by this strategy. In our efforts to determine the mechanism by which FAK transduces survival signals to the downstream, we found that a PAK mutant deficient in binding to phosphatidylinositol 3-kinase failed to promote cell survival. Moreover, the expression of the Src homology 3 domain of p130(Cas), which competed with endogenous p130(Cas) for FAK binding, abrogated the FAK-promoted cell survival. Together, these results suggest that the integrity of FAK and its binding to phosphatidylinositol 3-kinase and p130(Cas) are required for FAK to exert its antiapoptotic function.	Natl Chung Hsing Univ, Inst Biochem, Taichung, Taiwan; Natl Chung Hsing Univ, Dept Zool, Taichung, Taiwan; Taichung Vet Gen Hosp, Nephrol Sect, Taichung, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan, Taiwan	National Chung Hsing University; National Chung Hsing University; Taichung Veterans General Hospital; National Cheng Kung University	Chen, HC (corresponding author), Natl Chung Hsing Univ, Inst Biochem, Taichung, Taiwan.			Tang, Ming-Jer/0000-0002-0883-4363				Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Crouch DH, 1996, ONCOGENE, V12, P2689; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Guan JL, 1996, INT REV CYTOL, V168, P81, DOI 10.1016/S0074-7696(08)60883-9; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RECH MD, 1994, CELL, V76, P411; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shimizu S, 1996, ONCOGENE, V12, P2251; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Tang MJ, 1998, AM J PHYSIOL-CELL PH, V275, pC921, DOI 10.1152/ajpcell.1998.275.4.C921; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	51	98	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26901	26906		10.1074/jbc.274.38.26901	http://dx.doi.org/10.1074/jbc.274.38.26901			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480899	hybrid			2022-12-25	WOS:000082570700038
J	Denecke, B; Meyerdierks, A; Bottger, EC				Denecke, B; Meyerdierks, A; Bottger, EC			RGS1 is expressed in monocytes and acts as a GTPase-activating protein for G-protein-coupled chemoattractant receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNITS; FAMILY MEMBERS; CELL-LINE; RESPONSES; REGULATOR; MEMBRANE; GAIP; GENE; DESENSITIZATION	The leukocyte response to chemoattractants is transduced by the interaction of transmembrane receptors with GTP-binding regulatory proteins (G-proteins). RGS1 is a member of a protein family constituting a newly appreciated and large group of proteins that act as deactivators of G-protein signaling pathways by accelerating the GTPase activity of G-protein alpha subunits. We demonstrate here that RGS1 is expressed in human monocytes; by immunofluorescence and subcellular fractionation RGS1 was localized to the plasma membrane. By using a mixture of RGS1 and plasma membranes, we were able to demonstrate GAP activity of RGS1 on receptor-activated G-proteins; RGS1 did not affect ligand-stimulated GDP-GTP exchange;We found that RGS1 desensitizes a variety of chemotactic receptors including receptors for N-formyl-methionyl-leucylphenylalanine, leukotriene B4, and C5a. Interaction of RGS proteins and ligand-induced G-protein signaling can be demonstrated by determining GTPase activity using purified RGS proteins and plasma membranes.	Med Hsch Hannover, Inst Med Mikrobiol, D-30625 Hannover, Germany	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf	Denecke, B (corresponding author), Med Hsch Hannover, Inst Med Mikrobiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.		Böttger, Erik C./F-6175-2011					AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BIRNBOIM HC, 1988, NUCLEIC ACIDS RES, V16, P1487, DOI 10.1093/nar/16.4.1487; BLASZCZAK MAW, 1994, NEURON, V13, P1215; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Chen QJ, 1996, MOL CELL BIOL, V16, P247; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; HONG JX, 1993, J IMMUNOL, V150, P3895; HONORE B, 1993, EUR J BIOCHEM, V218, P421, DOI 10.1111/j.1432-1033.1993.tb18392.x; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JOHNSTON RB, 1988, NEW ENGL J MED, V318, P747, DOI 10.1056/NEJM198803243181205; KATONA IM, 1991, J IMMUNOL, V146, P708; KAY GE, 1983, INFECT IMMUN, V41, P1166, DOI 10.1128/IAI.41.3.1166-1174.1983; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NANOFF C, 1990, BRIT J PHARMACOL, V100, P63, DOI 10.1111/j.1476-5381.1990.tb12052.x; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; NEPTUNE ER, 1997, P NATL ACAD SCI USA, V94, P14484; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; Offermanns S, 1996, CANCER SURV, V27, P177; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; Sagoo MS, 1997, NATURE, V389, P392, DOI 10.1038/38750; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; SCHEPERS TM, 1993, BIOCHEM J, V289, P469, DOI 10.1042/bj2890469; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	51	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26860	26868		10.1074/jbc.274.38.26860	http://dx.doi.org/10.1074/jbc.274.38.26860			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480894	hybrid			2022-12-25	WOS:000082570700033
J	Bai, JX; Rodriguez, AM; Melendez, JA; Cederbaum, AI				Bai, JX; Rodriguez, AM; Melendez, JA; Cederbaum, AI			Overexpression of catalase in cytosolic or mitochondrial compartment protects HepG2 cells against oxidative injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOCHROME P4502E1; HYDROGEN-PEROXIDE; PERMEABILITY TRANSITION; RESPIRATORY-CHAIN; INDUCED APOPTOSIS; G2 CELLS; SUPEROXIDE; MECHANISM; OXYGEN; STRESS	HepG2 cells were transfected with vectors containing human catalase cDNA and catalase cDNA with a mitochondrial leader sequence to allow comparison of the effectiveness of catalase overexpressed in the cytosolic or mitochondrial compartments to protect against oxidant-induced injury. Overexpression of catalase in cytosol and in mitochondria was confirmed by Western blot, and activity measurement and stable cell lines were established. The intracellular level of H2O, induced by exogenously added H2O2 or antimycin A was lower in C33 cell lines overexpressing catalase in the cytosol and mC5 cell lines overexpressing catalase in the mitochondria as compared with Hp cell lines transfected with empty vector. Cell death caused by H2O2, antimycin A, and menadione was considerably suppressed in both the mC5 and C33 cell lines. C33 and mC5 cells were also more resistant to apoptosis induced by H2O2 and to the loss of mitochondrial membrane potential induced by H2O2 and antimycin A. In view of the comparable protection by catalase overexpressed in the cytosol versus the mitochondria, catalase produced in both cellular compartments might act as a sink to decompose H2O2 and move diffusable H2O2 down its concentration gradient. The present study suggests that catalase in cytosol and catalase in mitochondria are capable of protecting HepG2 cells against cytotoxicity or apoptosis induced by oxidative stress.	Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; Albany Med Coll, Dept Biochem & Mol Biol, Albany, NY 12208 USA	Icahn School of Medicine at Mount Sinai; Albany Medical College	Cederbaum, AI (corresponding author), Mt Sinai Sch Med, Dept Biochem & Mol Biol, Box 1020,1 Gustave Levy Pl, New York, NY 10029 USA.	acederb@smtplink.mssm.edu		Melendez, Juan/0000-0001-8021-3097	NCI NIH HHS [CA 77068] Funding Source: Medline; NIAAA NIH HHS [AA 03312] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA003312, R01AA003312] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Castilho RF, 1998, ARCH BIOCHEM BIOPHYS, V354, P151, DOI 10.1006/abbi.1998.0657; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; DAVIS S, 1985, J BIOL CHEM, V260, P3844; Dringen R, 1997, BRAIN RES, V759, P67, DOI 10.1016/S0006-8993(97)00233-3; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; Hagar H, 1996, AM J PHYSIOL-RENAL, V271, pF209, DOI 10.1152/ajprenal.1996.271.1.F209; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; Hirokawa M, 1998, ALCOHOL CLIN EXP RES, V22, p111S, DOI 10.1111/acer.1998.22.s3_part1.111s; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LEHNINGER AL, 1978, P NATL ACAD SCI USA, V75, P1690, DOI 10.1073/pnas.75.4.1690; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Melendez JA, 1996, J BIOL CHEM, V271, P18898, DOI 10.1074/jbc.271.31.18898; Piette J, 1997, BIOL CHEM, V378, P1237; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RADI R, 1991, J BIOL CHEM, V266, P22028; Shimizu S, 1996, ONCOGENE, V13, P21; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Singh K, 1997, Indian J Med Sci, V51, P226; SKOWRONEK P, 1990, CURR GENET, V18, P265, DOI 10.1007/BF00318391; Tada-Oikawa S, 1999, FEBS LETT, V442, P65, DOI 10.1016/S0014-5793(98)01618-4; Teramoto S, 1999, JPN J PHARMACOL, V79, P33, DOI 10.1254/jjp.79.33; TRITSCHLER HJ, 1994, BIOCHEM MOL BIOL INT, V34, P169; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VERCESI AE, 1984, BIOCHEM BIOPH RES CO, V119, P305, DOI 10.1016/0006-291X(84)91652-8; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	43	246	250	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26217	26224		10.1074/jbc.274.37.26217	http://dx.doi.org/10.1074/jbc.274.37.26217			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473575	hybrid			2022-12-25	WOS:000082469700041
J	Eynon, EE; Schlax, C; Pieters, J				Eynon, EE; Schlax, C; Pieters, J			A secreted form of the major histocompatibility complex class II-associated invariant chain inhibiting T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; RESTRICTED ANTIGEN PRESENTATION; INTRACELLULAR-TRANSPORT; ENDOCYTIC PATHWAY; PEPTIDE BINDING; HLA-DM; MOLECULES; SEQUENCE; COMPARTMENTS; CONTAINS	Major histocompatibility complex (MHC) class II molecules function at the cell surface to present antigenic peptides to T helper cells. Intracellularly, MHC class II molecules are associated with the invariant chain (Ii). Ii can modulate MHC class II-dependent T cell activation through (i) assistance in the export of MHC class II molecules from the endoplasmic reticulum, (ii) providing a targeting signal for endosomal/lysosomal compartments, and (iii) preventing peptides from associating prematurely with MHC class II molecules. Here we describe the generation and subsequent secretion of a lumenal form of Ii, IiP25. IiP25 lacked the targeting sequences for transport to MHC class II compartments but contained part of the CLIP region that is known to compete with antigenic peptides for binding to MHC class II molecules. When added to an antigenic peptide presentation model system, IiP25 inhibited T cell activation by competing for the CLIP binding site at the plasma membrane. Secretion of a lumenal Ii fragment may represent an additional mechanism to modulate T cell activation by MHC class LI molecules.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Netherlands Canc Inst, Amsterdam, Netherlands	Netherlands Cancer Institute	Pieters, J (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.			Pieters, Jean/0000-0002-5284-9757				ALEXANDER MA, 1989, J IMMUNOL, V142, P4070; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; ARNESON LS, 1995, J CELL BIOL, V129, P1217, DOI 10.1083/jcb.129.5.1217; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERTOLINO P, 1995, J IMMUNOL, V154, P5620; Bevec T, 1996, J EXP MED, V183, P1331, DOI 10.1084/jem.183.4.1331; BIJLMAKERS MJE, 1994, J EXP MED, V180, P623, DOI 10.1084/jem.180.2.623; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DEMOTZ S, 1993, MOL IMMUNOL, V30, P1623, DOI 10.1016/0161-5890(93)90435-E; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Engering A, 1997, ELECTROPHORESIS, V18, P2523, DOI 10.1002/elps.1150181406; Ferrari G, 1997, J CELL BIOL, V139, P1433, DOI 10.1083/jcb.139.6.1433; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; FREISEWINKEL IM, 1993, P NATL ACAD SCI USA, V90, P9703, DOI 10.1073/pnas.90.20.9703; GAUTAM AM, 1995, P NATL ACAD SCI USA, V92, P335, DOI 10.1073/pnas.92.1.335; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; JOHNSON JP, 1981, EUR J IMMUNOL, V11, P825, DOI 10.1002/eji.1830111015; JONES PP, 1979, MOL IMMUNOL, V16, P51, DOI 10.1016/0161-5890(79)90027-0; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; KRETZSCHMAR E, 1992, J GEN VIROL, V73, P839, DOI 10.1099/0022-1317-73-4-839; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MALCHEREK G, 1995, J EXP MED, V181, P527, DOI 10.1084/jem.181.2.527; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MEHRINGER JH, 1991, J IMMUNOL, V146, P920; PARK SJ, 1995, P NATL ACAD SCI USA, V92, P11289, DOI 10.1073/pnas.92.24.11289; Pieters J, 1997, CURR OPIN IMMUNOL, V9, P89, DOI 10.1016/S0952-7915(97)80164-1; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; PIETERS J, 1993, J CELL SCI, V106, P831; Pieters J, 1997, BIOL CHEM, V378, P751; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROMAGNOLI P, 1994, J EXP MED, V180, P1107, DOI 10.1084/jem.180.3.1107; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STRUBIN M, 1986, EMBO J, V5, P3483, DOI 10.1002/j.1460-2075.1986.tb04673.x; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; THOMAS LJ, 1988, J IMMUNOL, V140, P2670; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143; Valitutti S, 1997, IMMUNOL TODAY, V18, P299, DOI 10.1016/S0167-5699(97)01075-X; Warmerdam PAM, 1996, J CELL BIOL, V133, P281, DOI 10.1083/jcb.133.2.281; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	49	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26266	26271		10.1074/jbc.274.37.26266	http://dx.doi.org/10.1074/jbc.274.37.26266			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473581	hybrid			2022-12-25	WOS:000082469700047
J	Nayak, S; Bryant, FR				Nayak, S; Bryant, FR			Differential rates of NTP hydrolysis by the mutant [S69G]RecA protein - Evidence for a coupling of NTP turnover to DNA strand exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECA PROTEIN; ESCHERICHIA-COLI; ATP HYDROLYSIS; BINDING; PHASE	The x-ray crystal structure of the Escherichia coli RecA protein indicates that the phosphate groups of the nucleotide cofactor are bound by a loop whose amino acid sequence ((66)GPESSGKT(73)) corresponds to a consensus phosphate binding loop sequence (GXXXXGK[T/S]) found in many NTP-binding proteins. As part of an investigation of the role of the P-loop in ATP hydrolysis, we prepared a mutant RecA protein in which serine 69 was replaced by a glycine residue, We have found that the [S69G;]RecA mutation has a differential effect on the hydrolysis of various nucleoside triphosphates, The [S69G]RecA protein catalyzes the single-stranded DNA-dependent hydrolysis of rATP, ddATP, and dATP with turnover numbers of 10, 20, and 36 min(-l), respectively. The wild type RecA protein, in contrast, hydrolyzes each of these nucleoside triphosphates with similar turnover numbers of 20-24 min(-l). Significantly, the [SG9G]RecA protein promotes strand exchange with all three nucleoside triphosphates, and the rate of strand exchange is directly proportional to the rate of hydrolysis of each of the nucleotide cofactors, These findings with the [S69G]RecA protein provide support for the existence of a mechanistic coupling between NTP hydrolysis and DNA strand exchange.	Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Johns Hopkins University	Bryant, FR (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA.				NIGMS NIH HHS [R01 GM36516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126	12	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					25979	25982		10.1074/jbc.274.37.25979	http://dx.doi.org/10.1074/jbc.274.37.25979			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473540	hybrid			2022-12-25	WOS:000082469700006
J	Mitsuuchi, Y; Johnson, SW; Sonoda, G; Tanno, S; Golemis, EA; Testa, JR				Mitsuuchi, Y; Johnson, SW; Sonoda, G; Tanno, S; Golemis, EA; Testa, JR			Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2	ONCOGENE			English	Article						AKT2; serine-threonine kinase; APPL; protein interaction	PROTEIN-KINASE; CENP-E; INSULIN; ONCOGENE; CELLS; CLONING; DOMAINS; PHOSPHORYLATION; ACTIVATION; BINDING	AKT2 is a serine/threonine kinase implicated in human ovarian and pancreatic cancers, AKT2 is activated by a variety of growth factors and insulin via phosphatidylinositol 3-kinase (PI3K), However, its normal cellular role is not well understood, To gain insight into the function of AKT2, we performed yeast two-hybrid system to screen for interacting proteins. Using this technique, we identified a novel interactor, designated APPL, which contains a pleckstrin homology (PH) domain, a phosphotyrosine binding (PTB) domain and a leucine zipper, classes of motifs defined in signaling molecules as functional interaction domains with specific targets. The PH domain of APPL shows similarity to those found in GTPase-activating proteins such as oligophrenin-1 and Craf, whereas its PTB domain exhibits homology with CED-6, an adaptor protein that promotes engulfment of apoptotic cells, and IB1, a transactivator of the GLUT2 gene. APPL is highly expressed in skeletal muscle, heart, ovary and pancreas, tissues in which AKT2 mRNA is abundant. APPL interacts with the inactive form of AKT2; moreover, APPL binds to the PI3K catalytic subunit, p110 alpha. These data suggest that APPL is an adaptor that may tether inactive AKT2 to p110 alpha in the cytoplasm and thereby may expedite recruitment of AKT2 and p110 alpha to the cell membrane upon mitogenic stimulation. Furthermore, the APPL gene was mapped to human chromosome 3p14.3-p21.1, where deletions and other rearrangements have often been reported in a variety of tumor types, The identification of APPL may facilitate further analysis of the physiological and oncogenic activities of AKT2.	Fox Chase Canc Ctr, Mol Oncol Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Mol Oncol Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA77429, CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; ALTOMARE DA, 1995, ONCOGENE, V11, P1055; BELL DW, 1995, CYTOGENET CELL GENET, V70, P263, DOI 10.1159/000134048; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANKES WT, 1993, BIOCHIM BIOPHYS ACTA, V1216, P479, DOI 10.1016/0167-4781(93)90018-9; Liu AX, 1998, CANCER RES, V58, P2973; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Mitsuuchi Y, 1998, J CELL BIOCHEM, V70, P433, DOI 10.1002/(SICI)1097-4644(19980915)70:4<433::AID-JCB1>3.0.CO;2-K; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	37	165	179	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4891	4898		10.1038/sj.onc.1203080	http://dx.doi.org/10.1038/sj.onc.1203080			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490823				2022-12-25	WOS:000082321700001
J	Chang, BD; Xuan, YZ; Broude, EV; Zhu, HM; Schott, B; Fang, J; Roninson, IB				Chang, BD; Xuan, YZ; Broude, EV; Zhu, HM; Schott, B; Fang, J; Roninson, IB			Role of p53 and p21(waf1/cip1) in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs	ONCOGENE			English	Article						drug effects; p53; p21; senescence; cell death	RETROVIRAL VECTORS; HUMAN FIBROBLASTS; DNA-DAMAGE; ANTICANCER AGENTS; GROWTH ARREST; CYCLE ARREST; G(1) ARREST; P16(INK4A); DEATH; INDUCTION	Exposure of human tumor cell lines to moderate doses of anticancer agents induces terminal proliferation arrest accompanied by morphologic and enzymatic changes that resemble senescence of normal cells, We have investigated the role of p53 and p21(waf1/cip1) in the induction of this response in drug-treated tumor cells. Doxorubicin treatment induced the senescence-like phenotype (SLP) and its associated terminal growth arrest in wild-type HCT116 colon carcinoma cells; this response was strongly decreased but not abolished in HCT116 lines with homozygous knockout of p53 or p21, Transduction of HT1080 fibrosarcoma cells with a genetic inhibitor of p53 also decreased the induction of SLP and increased drug-induced mitotic cell death, To determine if drug-stimulated p21 expression was responsible for senescence-like growth arrest, we have expressed different levels of p21 from an inducible promoter, While high-level overexpression of p21 was sufficient to induce SLP in HT1080 cells, the levels of p21 expressed in doxorubicin-treated cells could account for only a fraction of doxorubicin-induced SLP, Our results indicate that p53 and p21 act as positive regulators of senescence-like terminal proliferation arrest, but their function is neither sufficient nor absolutely required for this treatment response in tumor cells.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roninson, IB (corresponding author), Univ Illinois, Dept Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.		Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NCI NIH HHS [R37CA40333, R01CA62099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040333, R01CA062099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1996, GENE, V183, P137, DOI 10.1016/S0378-1119(96)00532-X; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; HORAN PK, 1989, NATURE, V340, P167, DOI 10.1038/340167a0; Jordan MA, 1996, CANCER RES, V56, P816; Kandel ES, 1997, SOMAT CELL MOLEC GEN, V23, P325, DOI 10.1007/BF02674280; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lock RB, 1996, CANCER RES, V56, P4006; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Myohanen SK, 1998, CANCER RES, V58, P591; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PERRY ME, 1992, MUTAT RES, V276, P189, DOI 10.1016/0165-1110(92)90008-W; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; SCHOTT B, 1996, SOMAT CELL MOLEC GEN, V22, P292; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Torres K, 1998, CANCER RES, V58, P3620; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XH, 1998, CANCER RES, V58, P5019; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	43	313	332	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4808	4818		10.1038/sj.onc.1203078	http://dx.doi.org/10.1038/sj.onc.1203078			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490814				2022-12-25	WOS:000082184800005
J	Binkert, C; Demetriou, M; Sukhu, B; Szweras, M; Tenenbaum, HC; Dennis, JW				Binkert, C; Demetriou, M; Sukhu, B; Szweras, M; Tenenbaum, HC; Dennis, JW			Regulation of osteogenesis by fetuin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1 GENE; OSTEOPOROSIS-LIKE PHENOTYPE; ALPHA-2 HS-GLYCOPROTEIN; FORMATION IN-VITRO; OSTEOBLAST PHENOTYPE; ALKALINE-PHOSPHATASE; BONE-FORMATION; TGF-BETA; EXPRESSION	Osteoporosis is a common problem of aging and results from a failure of homeostatic mechanisms to regulate osteogenesis and mineralization, Bovine and human forms of fetuin glycoprotein bind to the transforming growth factor (TGF)-beta/BMP (bone morphogenic protein) cytokines and block their osteogenic activity in cell culture assays (Demetriou, M., Binkert, C,, Sukhu, B., Tenenbaum, H. C., and Dennis, J. W. (1996) J, Biol. Chem, 271, 12755-12761). Fetuin is a prominent serum glycoprotein and a major noncollagenous component of mineralized bone in mammals. In this study, we show that recombinant fetuin and native serum protein have similar potency as inhibitors of osteogenesis in dexamethasone-treated rat bone marrow cell cultures (dex-RBMC). Recombinant bovine fetuin also bound to TGF-beta 1 and BMP-2 in vitro with kinetics similar to native fetuin, Although TGF-beta 1 is required for osteogenesis in dex-RBMC, the cytokine also inhibited osteogenesis at concentrations greater than or equal to 10 pM. Titration of fetuin or anti-TGF-beta 1 antibodies into the bone marrow cultures in the presence of 10 pM TGF-beta 1 restored osteogenesis, whereas titrations of the same reagents into cultures with 0.3 pM added TGF-beta 1 were inhibitory, confirming the biphasic nature of the TGF-beta 1 response. Suppression of osteogenesis by both TGF-beta 1 and the antagonist proteins required their presence within the first 6 days of culture, well before mineralization at 10-12 days. Northern analysis showed that both fetuin and high dose TGF-beta 1 suppressed expression of the bone-associated transcripts alkaline phosphatase, osteopontin, collagen type I, and bone sialoprotein. The suppression of osteogenesis by fetuin and by high dose TGF-beta 1 was accompanied by the differentiation of an alternate cell lineage with adipocyte characteristics. In summary, the biphasic osteogenic response to TGF-beta 1 suggests that overlapping gradients of TGF-beta/EMP cytokines and fetuin regulate osteogenesis in remodeling bone.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Dept Dent, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University of Toronto	Dennis, JW (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Dennis, James/E-7268-2013					ASHTON BA, 1980, CLIN SCI, V58, P435, DOI 10.1042/cs0580435; Barkai N, 1998, NATURE, V396, P422, DOI 10.1038/24760; BASKIES AM, 1980, CANCER, V45, P3050, DOI 10.1002/1097-0142(19800615)45:12<3050::AID-CNCR2820451229>3.0.CO;2-8; Boden SD, 1997, ENDOCRINOLOGY, V138, P2820, DOI 10.1210/en.138.7.2820; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; CENTRELLA M, 1991, J BONE JOINT SURG AM, V73A, P1418, DOI 10.2106/00004623-199173090-00022; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Demetriou M, 1996, J BIOL CHEM, V271, P12755, DOI 10.1074/jbc.271.22.12755; DICKSON IR, 1975, NATURE, V256, P430, DOI 10.1038/256430a0; DICKSON IR, 1983, CALCIFIED TISSUE INT, V35, P16, DOI 10.1007/BF02405000; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; Faure S, 1999, J BIOL CHEM, V274, P3573, DOI 10.1074/jbc.274.6.3573; Gazit D, 1998, J CELL BIOCHEM, V70, P478, DOI 10.1002/(SICI)1097-4644(19980915)70:4<478::AID-JCB5>3.0.CO;2-G; Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756-3282(98)00078-7; HERBERTSON A, 1995, J BONE MINER RES, V10, P285; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Jones CM, 1998, DEV BIOL, V194, P12, DOI 10.1006/dbio.1997.8752; LEBRETON JP, 1979, J CLIN INVEST, V64, P118; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; NIE Z, 1992, AM J MED, V263, P551; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OURSLER MJ, 1993, ENDOCRINOLOGY, V133, P2187, DOI 10.1210/en.133.5.2187; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Pedersen KO, 1944, NATURE, V154, P575, DOI 10.1038/154575a0; Pfeilschifter J, 1998, J BONE MINER RES, V13, P716, DOI 10.1359/jbmr.1998.13.4.716; PINERO GJ, 1995, ARCH ORAL BIOL, V40, P145, DOI 10.1016/0003-9969(94)00144-Z; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; SEBETAN IM, 1988, Z RECHTSMED, V101, P205; Sukhu B, 1997, ENDOCRINOLOGY, V138, P3269, DOI 10.1210/en.138.8.3269; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; VANVLASSELAER P, 1994, J CELL BIOL, V124, P569, DOI 10.1083/jcb.124.4.569; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Yamada Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/jbmr.1998.13.10.1569; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YANG F, 1991, BONE, V12, P7, DOI 10.1016/8756-3282(91)90048-N; Zmuda JM, 1998, CALCIFIED TISSUE INT, V63, P5, DOI 10.1007/s002239900481	40	107	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28514	28520		10.1074/jbc.274.40.28514	http://dx.doi.org/10.1074/jbc.274.40.28514			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497215	hybrid, Green Published			2022-12-25	WOS:000082912700064
J	Veale, M; Raab, M; Li, ZW; da Silva, AJ; Kraeft, SK; Weremowicz, S; Morton, CC; Rudd, CE				Veale, M; Raab, M; Li, ZW; da Silva, AJ; Kraeft, SK; Weremowicz, S; Morton, CC; Rudd, CE			Novel isoform of lymphoid adaptor FYN-T-binding protein (FYB-130) interacts with SLP-76 and up-regulates interleukin 2 production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; CELL RECEPTOR; MOLECULAR-CLONING; CD4 ENDOCYTOSIS; ZAP-70 KINASE; ACTIVATION; TCR; PHOSPHORYLATION; DOMAIN; VAV	T-cell activation involves the participation of protein-tyrosine kinases p56(lck) and ZAP-70/SYK. as well as lymphoid proteins such as SLP-76 and FYB/SLAP. FYB/SLAP has the hallmarks of an adaptor protein that binds to the SH2 domains of the Src kinase FYN-T and SLP-76, Whereas two forms of FYB at 120 and 130 kDa have been identified biochemically, a cDNA encoding only the lower molecular weight isoform has been cloned (termed FYB-120 or SLAP-130), In this study, we report the isolation of an alternative isoform of FYB with a molecular mass of 130 kDa (FYB-130) that has the same structure as FYB-130 except for an insertion of 46 amino acids toward the carboxyl-terminal region of the protein. FYB-120 and FYB-130 share an ability to bind to the SH2 domains of FYN-T and SLP-76, to act as substrates for p59(FYN-T), and to be expressed in the cytoplasm and nucleus of T-cells, Differences were noted between the isoforms in the efficiency of binding to SLP-76 and in the preferential expression of FYB-130 in mature T-cells. When co-expressed together with FYN-T and SLP-76, FYB-130 caused a significant increase in anti-CD3-driven NF-AT transcription. Finally, fluorescence in situ hybridization analysis localized the FYB gene to human chromosome 5 at position p13.1. FYB-130 therefore represents a novel variant of FYB protein that can up-regulate T-cell receptor-driven interleukin 2 production in mature T-cells.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Obstet & Gynecol & Reprod Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Rudd, CE (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.	christopher_rudd@dfci.harvard.edu	Rudd, Christopher E/ABF-7259-2021; Rudd, Christopher E/GOH-2021-2022	Rudd, Christopher E/0000-0001-5295-9019				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Akashi K, 1998, P NATL ACAD SCI USA, V95, P2486, DOI 10.1073/pnas.95.5.2486; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BERG MA, 1993, AM J HUM GENET, V52, P998; BERMINGHAM N, 1995, HUM GENET, V96, P671, DOI 10.1007/BF00210297; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; daSilva AJ, 1997, J IMMUNOL, V158, P2007; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Fang N, 1996, J IMMUNOL, V157, P3769; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Lai LJ, 1998, J IMMUNOL, V160, P2280; Liu J, 1998, P NATL ACAD SCI USA, V95, P8779, DOI 10.1073/pnas.95.15.8779; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; Peterson EJ, 1998, CURR OPIN IMMUNOL, V10, P337, DOI 10.1016/S0952-7915(98)80173-8; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Raab M, 1999, J BIOL CHEM, V274, P21170, DOI 10.1074/jbc.274.30.21170; Raab M, 1997, IMMUNITY, V6, P155, DOI 10.1016/S1074-7613(00)80422-7; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Sunden SLF, 1996, GENOMICS, V35, P269, DOI 10.1006/geno.1996.0354; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Worley KC, 1998, BIOINFORMATICS, V14, P890, DOI 10.1093/bioinformatics/14.10.890; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	46	62	66	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28427	28435		10.1074/jbc.274.40.28427	http://dx.doi.org/10.1074/jbc.274.40.28427			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497204	hybrid			2022-12-25	WOS:000082912700053
J	Thomason, PA; Traynor, D; Stock, JB; Kay, RR				Thomason, PA; Traynor, D; Stock, JB; Kay, RR			The RdeA-RegA system, a eukaryotic phospho-relay controlling cAMP breakdown	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SIGNAL-TRANSDUCTION SYSTEMS; RAPIDLY DEVELOPING MUTANTS; DICTYOSTELIUM-DISCOIDEUM; MULTISTEP PHOSPHORELAY; CELL-DIFFERENTIATION; TERMINAL DIFFERENTIATION; RESPONSE REGULATOR; ACTIVATION; PRESPORE	The regA and rdeA gene products of Dictyostelium are involved in the regulation of cAMP signaling. The response regulator, RegA, is composed of an N-terminal receiver domain linked to a C-terminal cAMP-phosphodiesterase domain. RdeA may be a phospho-transfer protein that supplies phosphates to RegA. We show genetically that phospho-RegA is the activated form of the enzyme in vivo, in that the predicted site of aspartate phosphorylation is required for full activity. We show biochemically that RdeA and RegA communicate, as evidenced by phospho-transfer between the two proteins in vitro. Phospho-transfer is dependent on the presumed phospho-accepting amino acids, histidine 65 of RdeA and aspartate 212 of RegA, and occurs in both directions. Phosphorylation of RegA by a heterologous phospho-donor protein activates RegA phosphodiesterase activity at least 20-fold. Our results suggest that the histidine phosphotransfer protein, RdeA, and the response regulator, RegA, constitute two essential elements in a eukaryotic His-Asp phospho-relay network that regulates Dictyostelium development and fruiting body maturation.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	MRC Laboratory Molecular Biology; Princeton University	Thomason, PA (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Kay, Robert R/0000-0001-9836-7967; Thomason, Peter/0000-0003-3104-8392				ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; Anjard C, 1998, DEV BIOL, V193, P146, DOI 10.1006/dbio.1997.8804; Appleby JL, 1996, CELL, V86, P845, DOI 10.1016/S0092-8674(00)80158-0; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BROWN JL, 1994, EMBO J, V13, P5186, DOI 10.1002/j.1460-2075.1994.tb06849.x; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Chang WT, 1998, EMBO J, V17, P2809, DOI 10.1093/emboj/17.10.2809; Firtel RA, 1996, CURR OPIN GENET DEV, V6, P545, DOI 10.1016/S0959-437X(96)80082-7; Freeman JA, 1999, J BACTERIOL, V181, P899, DOI 10.1128/JB.181.3.899-906.1999; Georgellis D, 1998, J BIOL CHEM, V273, P32864, DOI 10.1074/jbc.273.49.32864; HARWOOD AJ, 1992, DEV BIOL, V149, P90, DOI 10.1016/0012-1606(92)90266-J; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; HOPPER NA, 1993, EMBO J, V12, P2459, DOI 10.1002/j.1460-2075.1993.tb05900.x; HOPPER NA, 1993, DEVELOPMENT, V119, P147; Janiak-Spens F, 1999, J BACTERIOL, V181, P411, DOI 10.1128/JB.181.2.411-417.1999; KESSIN RH, 1977, CELL, V10, P703, DOI 10.1016/0092-8674(77)90104-0; Kim HJ, 1998, J BIOL CHEM, V273, P30859, DOI 10.1074/jbc.273.47.30859; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; Levit M, 1996, J BIOL CHEM, V271, P32057, DOI 10.1074/jbc.271.50.32057; Li S, 1998, EMBO J, V17, P6952, DOI 10.1093/emboj/17.23.6952; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MANN SKO, 1993, DEVELOPMENT, V119, P135; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; Mann SKO, 1997, DEV BIOL, V183, P208, DOI 10.1006/dbio.1996.8499; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; Perego M, 1996, TRENDS GENET, V12, P97, DOI 10.1016/0168-9525(96)81420-X; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Schuster SC, 1996, EMBO J, V15, P3880, DOI 10.1002/j.1460-2075.1996.tb00762.x; Shaulsky G, 1998, DEVELOPMENT, V125, P691; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; Singleton CK, 1998, DEV BIOL, V203, P345, DOI 10.1006/dbio.1998.9049; Thomason P, 1999, TRENDS GENET, V15, P15, DOI 10.1016/S0168-9525(98)01635-7; Thomason PA, 1998, EMBO J, V17, P2838, DOI 10.1093/emboj/17.10.2838; Wang N, 1996, EMBO J, V15, P3890, DOI 10.1002/j.1460-2075.1996.tb00763.x; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; Zinda MJ, 1998, DEV BIOL, V196, P171, DOI 10.1006/dbio.1998.8854	37	64	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27379	27384		10.1074/jbc.274.39.27379	http://dx.doi.org/10.1074/jbc.274.39.27379			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488068	hybrid			2022-12-25	WOS:000082739100007
J	Dy, LC; Pei, Y; Travers, JB				Dy, LC; Pei, Y; Travers, JB			Augmentation of ultraviolet B radiation-induced tumor necrosis factor production by the epidermal platelet-activating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; STRUCTURAL IDENTIFICATION; HUMAN KERATINOCYTES; FACTOR-ALPHA; PAF-ACETHER; CELLS; EXPRESSION; RELEASE; MECHANISM; LIPIDS	Ultraviolet B radiation (UVB) has been shown to damage human keratinocytes in part by inducing oxidative stress and cytokine production. Indeed, UVB-induced production of the pro-inflammatory and cytotoxic cytokine tumor necrosis factor alpha (TNF-alpha) has been implicated in the epidermal damage seen in response to acute solar radiation, Though the lipid mediator platelet-activating factor (PAF) is synthesized in response to oxidative stress, and keratinocytes express PAF receptors linked to cytokine biosynthesis, it is not known whether PAF is involved in UVB-induced epidermal cell cytokine production. These studies examined the role of the PAF system in UVB-induced epidermal cell TNF-alpha biosynthesis using a novel model system created by retroviral-mediated transduction of the PAF receptor-negative human epidermal cell line KB with the human PAF receptor (PAF-R). Treatment of PAF-R-expressing RE cells with the metabolically stable PAF-R agonist carbamoyl-PAF resulted in increased TNF-alpha mRNA and protein, indicating that activation of the epidermal PAF-R was linked to TNF-alpha production. UVB irradiation of PAP-R-expressing KB cells resulted in significant increases in both TNF-alpha mRNA and protein in comparison to UVB-treated control KB cells. However, UVB treatment up-regulated cyclooxygenase-2 mRNA levels to the same extent in both PAF-R-expressing and control KB cells. Pretreatment with the antioxidant vitamin E or the PAF-R antagonists WEB 2086 and A-85783 inhibited UVB-induced TNF-alpha production in the PAF-R-positive but not control KB cells. These studies suggest that the epidermal PAF-R may be a pharmacological target for UVB in skin.	Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Travers, JB (corresponding author), Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, HB Wells Ctr Pediat Res, 702 Barnhill Dr,Rm 2659, Indianapolis, IN 46202 USA.			Travers, Jeffrey/0000-0001-7232-1039	NIAMS NIH HHS [KK08AR1993] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001993] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLOATTI G, 1994, J PHARMACOL EXP THER, V269, P766; AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; Barber LA, 1998, J BIOL CHEM, V273, P18891, DOI 10.1074/jbc.273.30.18891; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; GREWE M, 1993, J INVEST DERMATOL, V101, P528, DOI 10.1111/1523-1747.ep12365904; HANAHAN DJ, 1992, CURR TOP CELL REGUL, V33, P65; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HENOCQ E, 1986, LANCET, V1, P1378; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Lehr HA, 1997, J CLIN INVEST, V99, P2358, DOI 10.1172/JCI119417; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; LEVESQUE JP, 1986, P NATL ACAD SCI USA, V83, P6494, DOI 10.1073/pnas.83.17.6494; LEWIS MS, 1988, J CLIN INVEST, V82, P2045, DOI 10.1172/JCI113825; MALLET AI, 1985, BIOCHEM BIOPH RES CO, V126, P192, DOI 10.1016/0006-291X(85)90590-X; MICHEL L, 1990, J INVEST DERMATOL, V95, P576, DOI 10.1111/1523-1747.ep12505563; Murphy RC, 1996, ADV EXP MED BIOL, V416, P51; NAKAMURA M, 1992, FEBS LETT, V314, P125, DOI 10.1016/0014-5793(92)80957-I; NORINS AL, 1962, J INVEST DERMATOL, V39, P445, DOI 10.1038/jid.1962.137; OGURA R, 1991, J INVEST DERMATOL, V97, P1044, DOI 10.1111/1523-1747.ep12492553; Pei Y, 1998, J IMMUNOL, V161, P1954; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; RUIS NM, 1991, LIPIDS, V26, P1060, DOI 10.1007/BF02536502; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; SHENG YH, 1995, CURR EYE RES, V14, P341, DOI 10.3109/02713689508999931; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; Stewart MS, 1996, J INVEST DERMATOL, V106, P1086, DOI 10.1111/1523-1747.ep12339344; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; Travers JB, 1998, PROSTAG OTH LIPID M, V56, P305, DOI 10.1016/S0090-6980(98)00060-4; TRAVERS JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P193, DOI 10.1016/0005-2760(90)90007-K; TRAVERS JB, 1995, J INVEST DERMATOL, V105, P816, DOI 10.1111/1523-1747.ep12326581; Travers JB, 1996, J INVEST DERMATOL, V107, P88, DOI 10.1111/1523-1747.ep12298295; TRIGGIANI M, 1991, BIOCHIM BIOPHYS ACTA, V1084, P41, DOI 10.1016/0005-2760(91)90053-K; ULLRICH SE, 1995, PHOTOCHEM PHOTOBIOL, V62, P389, DOI 10.1111/j.1751-1097.1995.tb02359.x; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WILCOX RW, 1987, LIPIDS, V22, P800, DOI 10.1007/BF02535534; ZIMMERMAN GA, 1995, J NUTR, V125, P16615	47	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26917	26921		10.1074/jbc.274.38.26917	http://dx.doi.org/10.1074/jbc.274.38.26917			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480902	hybrid			2022-12-25	WOS:000082570700041
J	Pandya, MJ; Williams, PB; Dempsey, CE; Shewry, PR; Clarke, AR				Pandya, MJ; Williams, PB; Dempsey, CE; Shewry, PR; Clarke, AR			Direct kinetic evidence for folding via a highly compact, misfolded state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; HELIANTHUS-ANNUUS L; MASS-SPECTROMETRY; TRANSITION-STATES; 3-STATE MODEL; AMINO-ACIDS; PROTEIN; INTERMEDIATE; SPECTROSCOPY; STABILITY	The 2 S seed storage protein, sunflower albumin 8 (SFA-8), contains an unusually high proportion of hydrophobic: residues including 16 methionines (some of which may form a surface hydrophobic patch) in a disulfide cross-linked, alpha-helical structure. Circular dichroism and fluorescence spectroscopy show that SFA-8 is highly stable to denaturation by heating or chaotropic agents, the latter resulting in a reversible two-state unfolding transition. The small m(U) (-4.7 M-1 at 10 degrees C) and Delta C-P (-0.95 kcal mol(-1) K-1) values indicate that relatively little nonpolar surface of the protein is exposed during unfolding. Commensurate with the unusual distribution of hydrophobic residues, stopped-flow fluorescence data show that the folding pathway of SFA-8 is highly atypical, in that the initial product of the rapid collapse phase of folding is a compact nonnative state (or collection of nonnative states) that must unfold before acquiring the native conformation. The inhibited folding reaction of SFA-8, in which the misfolded state (m(M) = -0.95 M-1 at 10 degrees C) is more compact than the transition state for folding (m(T) = -2.5 M-1 at 10 degrees C), provides direct kinetic evidence for the transient misfolding of a protein.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Mol Recognit Ctr, Bristol BS8 1TD, Avon, England; Univ Bristol, Long Ashton Res Stn, Dept Agr Sci, Inst Arable Crops Res, Bristol BS18 9AF, Avon, England	University of Bristol; University of Bristol; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Rothamsted Research; University of Bristol	Pandya, MJ (corresponding author), Univ Sussex, Sch Biol Sci, Dept Biochem, Falmer BN1 9QG, E Sussex, England.			Dempsey, Christopher/0000-0002-1933-7805				Arai M, 1998, J MOL BIOL, V275, P149, DOI 10.1006/jmbi.1997.1456; ATKINS PW, 1995, PHYSICAL CHEM, P855; Balbach J, 1999, J MOL BIOL, V285, P829, DOI 10.1006/jmbi.1998.2364; Baldwin RL, 1996, BIOPHYS J, V71, P2056, DOI 10.1016/S0006-3495(96)79404-3; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; Ballew RM, 1996, P NATL ACAD SCI USA, V93, P5759, DOI 10.1073/pnas.93.12.5759; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; CHAN HS, 1993, PHYS TODAY, V46, P24, DOI 10.1063/1.881371; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DYSON HJ, 1993, CURR OPIN STRUC BIOL, V3, P60, DOI 10.1016/0959-440X(93)90203-W; Eaton WA, 1997, CURR OPIN STRUC BIOL, V7, P10, DOI 10.1016/S0959-440X(97)80003-6; FLIGNER KL, 1991, ACS SYM SER, V454, P1; Gueguen J, 1996, J AGR FOOD CHEM, V44, P1184, DOI 10.1021/jf950683f; Houry WA, 1996, BIOCHEMISTRY-US, V35, P11719, DOI 10.1021/bi960745a; HUANG GS, 1995, P NATL ACAD SCI USA, V92, P6878, DOI 10.1073/pnas.92.15.6878; Imoto T., 1989, PROTEIN FUNCTION PRA, P247; KARPLUS M, 1994, PROTEIN SCI, V3, P650; Kazmirski SL, 1998, J MOL BIOL, V284, P793, DOI 10.1006/jmbi.1998.2192; Khorasanizadeh S, 1996, NAT STRUCT BIOL, V3, P193, DOI 10.1038/nsb0296-193; KORTT AA, 1991, EUR J BIOCHEM, V195, P329, DOI 10.1111/j.1432-1033.1991.tb15710.x; LICHAN E, 1991, ACS SYM SER, V448, P193; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; Miranker A, 1996, FASEB J, V10, P93, DOI 10.1096/fasebj.10.1.8566553; Mok YK, 1996, NAT STRUCT BIOL, V3, P711, DOI 10.1038/nsb0896-711; MORRIS GA, 1978, J MAGN RESON, V29, P433, DOI 10.1016/0022-2364(78)90003-3; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; Parker MJ, 1997, BIOCHEMISTRY-US, V36, P13396, DOI 10.1021/bi971294c; PARKER MJ, 1995, J MOL BIOL, V253, P771, DOI 10.1006/jmbi.1995.0590; Parker MJ, 1998, BIOCHEMISTRY-US, V37, P2538, DOI 10.1021/bi972459k; Pascher T, 1996, SCIENCE, V271, P1558, DOI 10.1126/science.271.5255.1558; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; Rohl CA, 1996, PROTEIN SCI, V5, P2623, DOI 10.1002/pro.5560051225; Rothwarf DM, 1996, BIOCHEMISTRY-US, V35, P13797, DOI 10.1021/bi9608119; SCHINDLER T, 1995, NAT STRUCT BIOL, V2, P663, DOI 10.1038/nsb0895-663; Shao X, 1998, BIOCHEMISTRY-US, V37, P7850, DOI 10.1021/bi973171y; SHORTLE D, 1988, BIOCHEMISTRY-US, V27, P4761, DOI 10.1021/bi00413a027; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Sosnick TR, 1996, PROTEINS, V24, P413; STANIFORTH RA, 1993, BIOCHEMISTRY-US, V32, P3842, DOI 10.1021/bi00066a003; STROBL S, 1995, BIOCHEMISTRY-US, V34, P8281, DOI 10.1021/bi00026a009; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; THIRUMALAI D, 1995, BIOPOLYMERS, V35, P137, DOI 10.1002/bip.360350114; Vanhove M, 1998, BIOCHEMISTRY-US, V37, P1941, DOI 10.1021/bi972143c; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WELLER A, 1961, PROG REACT KINET MEC, V1, P187; Wildegger G, 1997, J MOL BIOL, V270, P294, DOI 10.1006/jmbi.1997.1030; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; ZHANG JX, 1993, BIOCHEMISTRY-US, V32, P14075, DOI 10.1021/bi00214a001	55	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26828	26837		10.1074/jbc.274.38.26828	http://dx.doi.org/10.1074/jbc.274.38.26828			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480890	hybrid			2022-12-25	WOS:000082570700029
J	Chen, YA; Duvvuri, V; Schulman, H; Scheller, RH				Chen, YA; Duvvuri, V; Schulman, H; Scheller, RH			Calmodulin and protein kinase C increase Ca2+-stimulated secretion by modulating membrane-attached exocytic machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; NEUROTRANSMITTER RELEASE; CA2+-ACTIVATED SECRETION; CAENORHABDITIS-ELEGANS; SYNAPTIC TRANSMISSION; REGULATED SECRETION; CYTOSOLIC PROTEIN; CA2+ CHANNELS; PHOSPHORYLATION; CA2+/CALMODULIN	The molecular mechanisms underlying the Ca2+ regulation of hormone and neurotransmitter release are largely unknown. Using a reconstituted [H-3]norepinephrine release assay in permeabilized PC12 cells, we found that essential proteins that support the triggering stage of Ca2+-stimulated exocytosis are enriched in an EGTA extract of brain membranes. Fractionation of this extract allowed purification of two factors that stimulate secretion in the absence of any other cytosolic proteins. These are calmodulin and protein kinase C alpha (PKC alpha). Their effects on secretion were confirmed using commercial and recombinant proteins. Calmodulin enhances secretion in the absence of ATP, whereas PKC requires ATP to increase secretion, suggesting that phosphorylation is involved in PKC- but not calmodulin-mediated stimulation. Both proteins modulate release events that occur in the triggering stage of exocytosis. The half-maximal increase was elicited by 3 nM PKC and 75 nM calmodulin. These results suggest that calmodulin and PKC increase Ca2+-activated exocytosis by directly modulating the membrane- or cytoskeleton-attached exocytic machinery downstream of Ca2+ elevation.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University	Scheller, RH (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.	scheller@cmgm.stanford.edu	Duvvuri, Vikas/M-1904-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 08327] Funding Source: Medline; NIMH NIH HHS [MH48108] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ann K, 1997, J BIOL CHEM, V272, P19637, DOI 10.1074/jbc.272.32.19637; Artalejo CR, 1996, NEURON, V16, P195, DOI 10.1016/S0896-6273(00)80036-7; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; BIRCH KA, 1992, J CELL BIOL, V118, P1501, DOI 10.1083/jcb.118.6.1501; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BITTNER MA, 1993, CELL MOL NEUROBIOL, V13, P649, DOI 10.1007/BF00711564; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BURGOYNE RD, 1982, PROC R SOC SER B-BIO, V216, P111, DOI 10.1098/rspb.1982.0064; Byrne JH, 1996, J NEUROSCI, V16, P425; Calakos N, 1996, PHYSIOL REV, V76, P1; Chakravarthy B, 1999, TRENDS NEUROSCI, V22, P12, DOI 10.1016/S0166-2236(98)01288-0; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CHAPMAN PF, 1995, NEURON, V14, P591, DOI 10.1016/0896-6273(95)90315-1; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chin D, 1997, J BIOL CHEM, V272, P5510, DOI 10.1074/jbc.272.9.5510; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; Corradi N, 1996, J BIOL CHEM, V271, P27116, DOI 10.1074/jbc.271.43.27116; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GANGULY A, 1992, BIOCHEM BIOPH RES CO, V182, P254, DOI 10.1016/S0006-291X(05)80138-X; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hilfiker S, 1999, J PHYSIOL-LONDON, V515, P1, DOI 10.1111/j.1469-7793.1999.001ad.x; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; KENIGSBERG RL, 1985, NEUROSCIENCE, V14, P335, DOI 10.1016/0306-4522(85)90183-6; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; MARSHAK DR, 1996, STATEGIES PROTEIN PU; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NISHIZAKI T, 1992, J BIOL CHEM, V267, P23972; Park JB, 1997, J BIOL CHEM, V272, P20857, DOI 10.1074/jbc.272.33.20857; Perin MS, 1996, BIOCHEMISTRY-US, V35, P13808, DOI 10.1021/bi960853x; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; STEINHARDT RA, 1982, NATURE, V295, P114; Stevens CF, 1998, NEURON, V21, P885, DOI 10.1016/S0896-6273(00)80603-0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; TRIFARO JM, 1989, NEUROSCIENCE, V29, P1, DOI 10.1016/0306-4522(89)90327-8; Verhage M, 1995, EUR J PHARM-MOLEC PH, V291, P387, DOI 10.1016/0922-4106(95)90081-0; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Waxham MN, 1998, J BIOL CHEM, V273, P17579, DOI 10.1074/jbc.273.28.17579; Xu XZS, 1998, J BIOL CHEM, V273, P31297, DOI 10.1074/jbc.273.47.31297; Yawo H, 1999, J PHYSIOL-LONDON, V515, P169, DOI 10.1111/j.1469-7793.1999.169ad.x; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	57	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26469	26476		10.1074/jbc.274.37.26469	http://dx.doi.org/10.1074/jbc.274.37.26469			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473607	hybrid			2022-12-25	WOS:000082469700073
J	Soroka, CJ; Pate, MK; Boyer, JL				Soroka, CJ; Pate, MK; Boyer, JL			Canalicular export pumps traffic with polymeric immunoglobulin A receptor on the same microtubule-associated vesicle in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE PROTEINS; EPIDERMAL GROWTH-FACTOR; CYTOPLASMIC DYNEIN; IGA RECEPTOR; HEPATOCYTE COUPLETS; ENDOCYTIC VESICLES; IMMUNOELECTRON MICROSCOPY; INTRACELLULAR FORMS; GOLGI-APPARATUS; APICAL DOMAIN	Basolateral to apical vesicular transcytosis in the hepatocyte is an essential pathway for the delivery of compounds from the sinusoidal blood to the bile and to traffic newly synthesized resident apical membrane proteins to their site of function at the canalicular membrane front, To characterize this pathway better, microtubules in a hepatocyte homogenate were polymerized by addition of taxol, and associated membrane-bound vesicles were isolated, This fraction was enriched in polymeric immunoglobulin A receptor and contained apical membrane proteins. Immunoelectron microscopy demonstrated that polymeric immunoglobulin A receptor was localized predominantly on vesicles ranging from 100 to 160 nm and that the multidrug resistance protein 2 and the bile salt export pump co-localized on these vesicles. The minus-ended microtubule motor, dynein, was highly enriched in the fraction, and its intermediate chain could be released effectively by incubation with 1 mM ATP or GTP, However, the association of the transcytotic vesicles with the microtubules was not sensitive to hydrolyzable or non-hydrolyzable nucleotides. This study characterizes a fraction of microtubule-associated vesicles from rat hepatocytes and demonstrates that several resident apical membrane transport proteins and the polymeric immunoglobulin A receptor traffic on the same vesicle.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Liver, New Haven, CT 06520 USA	Yale University; Yale University	Soroka, CJ (corresponding author), Yale Univ, Sch Med, Dept Internal Med Digest Dis, 333 Cedar St,POB 208019, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025636, P30DK034989, R37DK025636] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25636, DK 34989] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BARR VA, 1993, GASTROENTEROLOGY, V105, P554, DOI 10.1016/0016-5085(93)90734-T; BARR VA, 1995, J BIOL CHEM, V270, P27834, DOI 10.1074/jbc.270.46.27834; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BENEDETTI A, 1994, P NATL ACAD SCI USA, V91, P792, DOI 10.1073/pnas.91.2.792; BLEIL JD, 1982, EMBO J, V1, P351, DOI 10.1002/j.1460-2075.1982.tb01173.x; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; Boyer James L., 1993, P597; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; BOYER JL, 1990, METHOD ENZYMOL, V192, P501; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; BRUCK R, 1993, AM J PHYSIOL, V265, pG347, DOI 10.1152/ajpgi.1993.265.2.G347; Bu Guojun, 1994, P259; Buchler M, 1996, J BIOL CHEM, V271, P15091; CASCIOLAROSEN LA, 1992, J BIOL CHEM, V267, P8213; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; DABORA SL, 1988, CELL MOTIL CYTOSKEL, V10, P482, DOI 10.1002/cm.970100405; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; GRAF J, 1984, P NATL ACAD SCI-BIOL, V81, P6516, DOI 10.1073/pnas.81.20.6516; HANDLER JS, 1988, AM J PHYSIOL, V255, pF375, DOI 10.1152/ajprenal.1988.255.3.F375; HAYAKAWA T, 1990, AM J PHYSIOL, V259, pG727, DOI 10.1152/ajpgi.1990.259.5.G727; HAYAKAWA T, 1990, GASTROENTEROLOGY, V99, P216, DOI 10.1016/0016-5085(90)91251-Z; Hubbard Ann L., 1994, P189; Kubitz R, 1997, GASTROENTEROLOGY, V113, P1438, DOI 10.1053/gast.1997.v113.pm9352844; Kubitz R, 1999, GASTROENTEROLOGY, V116, P401, DOI 10.1016/S0016-5085(99)70138-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1991, J CELL SCI, V98, P205; LARKIN JM, 1986, P NATL ACAD SCI USA, V83, P4759, DOI 10.1073/pnas.83.13.4759; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MARKS DL, 1994, J CELL SCI, V107, P2417; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MCINTOSH JR, 1989, J BIOL CHEM, V264, P6001; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Meier PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG801, DOI 10.1152/ajpgi.1995.269.6.G801; MITHIEUX G, 1989, J BIOL CHEM, V264, P4664; MUELLER M, 1997, AM J PHYSIOL, V272, pG1285; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; Nathanson Michael H., 1994, P655; ODA H, 1995, J BIOL CHEM, V270, P15242, DOI 10.1074/jbc.270.25.15242; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; RENSTON RH, 1980, SCIENCE, V208, P1276, DOI 10.1126/science.7375938; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; Roelofsen H, 1998, J CELL SCI, V111, P1137; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; SCOTT LJ, 1992, J BIOL CHEM, V267, P6099; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STEER CJ, 1980, J BIOL CHEM, V255, P3008; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; SZTUL ES, 1985, J CELL BIOL, V100, P1248, DOI 10.1083/jcb.100.4.1248; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; Trauner M, 1998, NEW ENGL J MED, V339, P1217, DOI 10.1056/NEJM199810223391707; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; WOLOSIN JM, 1981, J BIOL CHEM, V256, P3149	68	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26416	26424		10.1074/jbc.274.37.26416	http://dx.doi.org/10.1074/jbc.274.37.26416			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473600	hybrid			2022-12-25	WOS:000082469700066
J	Wassmann, C; Hellberg, A; Tannich, E; Bruchhaus, I				Wassmann, C; Hellberg, A; Tannich, E; Bruchhaus, I			Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICHOMONAS-VAGINALIS; DRUG-RESISTANCE; TRITRICHOMONAS-FOETUS; ANAEROBIC RESISTANCE; SUSCEPTIBLE STRAINS; OXYGEN AFFINITIES; GIARDIA; PROTEIN; INVITRO; GENE	To obtain insight into the mechanism of metronidazole resistance in the protozoan parasite Entamoeba histolytica, amoeba trophozoites were selected in vitro by stepwise exposures to increasing amounts of metronidazole, starting with sublethal doses of 4 mu M. Subsequently, amoebae made resistant were able to continuously multiply in the presence of a 40 mu M concentration of the drug. In contrast to mechanisms of metronidazole resistance in other protozoan parasites, resistant amoebae did not substantially down-regulate pyruvate:ferredoxin oxidoreductase or up-regulate P-glycoproteins, but exhibited increased expression of iron-containing superoxide dismutase (Fe-SOD) and peroxiredoxin and decreased expression of flavin reductase and ferredoxin 1. Episomal transfection and overexpression of the various antioxidant enzymes revealed significant reduction in susceptibility to metronidazole only in those cells overexpressing Fe-SOD, Reduction was highest in transfected cells simultaneously overexpressing Fe-SOD and peroxiredoxin, Although induced overexpression of Fe-SOD did not confer metronidazole resistance to the extent found in drug-selected cells, transfected cells quickly adapted to constant exposures of otherwise lethal metronidazole concentrations, Moreover, metronidazole selection of transfected amoebae favored retention of the Fe-SOD-containing plasmid, These results strongly suggest that peroxiredoxin and, in particular, Fe-SOD together with ferredoxin 1 are important components involved in the mechanism of metronidazole resistance in E. histolytica.	Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin	Bruchhaus, I (corresponding author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	bruchhaus@bnu.uni-hamburg.de						BIAGLOW JE, 1986, BIOCHEM PHARMACOL, V35, P77, DOI 10.1016/0006-2952(86)90561-7; Bruchhaus I, 1998, BIOCHEM J, V330, P1217, DOI 10.1042/bj3301217; BRUCHHAUS I, 1993, TROP MED PARASITOL, V44, P116; Bruchhaus I, 1997, BIOCHEM J, V326, P785, DOI 10.1042/bj3260785; BRUCHHAUS I, 1992, ARCHIVES OF MEDICAL RESEARCH, VOL 23, NO 2, P27; BRUCHHAUS I, 1995, MOL BIOCHEM PARASIT, V70, P187, DOI 10.1016/0166-6851(94)00214-8; CERKASOVOVA AP, 1984, MOL BIOCHEM PARASIT, V11, P105, DOI 10.1016/0166-6851(84)90058-6; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; DIERICKX PJ, 1990, BIOCHEM INT, V22, P593; DOCAMPO R, 1986, FED PROC, V45, P2471; ELLIS JE, 1993, INT J PARASITOL, V23, P35, DOI 10.1016/0020-7519(93)90095-G; FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/science.6322306; Freeman CD, 1997, DRUGS, V54, P679, DOI 10.2165/00003495-199754050-00003; GAULT MJ, 1985, T ROY SOC TROP MED H, V79, P60, DOI 10.1016/0035-9203(85)90236-6; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; HAMANN L, 1995, P NATL ACAD SCI USA, V92, P8975, DOI 10.1073/pnas.92.19.8975; Hamann L, 1997, MOL BIOCHEM PARASIT, V84, P83, DOI 10.1016/S0166-6851(96)02771-5; INOUYE S, 1994, FEBS LETT, V347, P163, DOI 10.1016/0014-5793(94)00528-1; JOHNSON PJ, 1993, PARASITOL TODAY, V9, P183, DOI 10.1016/0169-4758(93)90143-4; KNIGHT R, 1980, J ANTIMICROB CHEMOTH, V6, P577, DOI 10.1093/jac/6.5.577; KULDA J, 1993, J EUKARYOT MICROBIOL, V40, P262, DOI 10.1111/j.1550-7408.1993.tb04915.x; KULDA J, 1984, EXP PARASITOL, V57, P93, DOI 10.1016/0014-4894(84)90068-7; Land KM, 1997, EXP PARASITOL, V87, P305, DOI 10.1006/expr.1997.4223; LEIPPE M, 1991, P NATL ACAD SCI USA, V88, P7659, DOI 10.1073/pnas.88.17.7659; LO HS, 1980, MOL BIOCHEM PARASIT, V2, P23, DOI 10.1016/0166-6851(80)90045-6; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MULLER M, 1986, BIOCHEM PHARMACOL, V35, P37, DOI 10.1016/0006-2952(86)90552-6; MULLER M, 1988, SEX TRANSM DIS, V15, P17, DOI 10.1097/00007435-198801000-00004; Poole LB, 1997, FREE RADICAL BIO MED, V23, P955, DOI 10.1016/S0891-5849(97)00066-X; QUON DVK, 1992, P NATL ACAD SCI USA, V89, P4402, DOI 10.1073/pnas.89.10.4402; RAVDIN JI, 1995, CLIN INFECT DIS, V20, P1453, DOI 10.1093/clinids/20.6.1453; REEVES RE, 1984, ADV PARASIT, V23, P105, DOI 10.1016/S0065-308X(08)60286-9; Samarawickrema NA, 1997, J ANTIMICROB CHEMOTH, V40, P833, DOI 10.1093/jac/40.6.833; SCULLY BE, 1988, MED CLIN N AM, V72, P613, DOI 10.1016/S0025-7125(16)30761-1; SINDAR P, 1982, J MED MICROBIOL, V15, P503, DOI 10.1099/00222615-15-4-503; SMITH NC, 1988, INT J PARASITOL, V18, P991, DOI 10.1016/0020-7519(88)90183-X; TACHEZY J, 1993, PARASITOLOGY, V106, P31, DOI 10.1017/S0031182000074783; TANNICH E, 1991, MOL BIOCHEM PARASIT, V49, P61, DOI 10.1016/0166-6851(91)90130-X; TOWNSON SM, 1994, ACTA TROP, V56, P173, DOI 10.1016/0001-706X(94)90062-0; TOWNSON SM, 1992, T ROY SOC TROP MED H, V86, P521, DOI 10.1016/0035-9203(92)90095-T; UPCROFT JA, 1993, PARASITOL TODAY, V9, P187, DOI 10.1016/0169-4758(93)90144-5; UPCROFT JA, 1992, PARASITOLOGY, V104, P397, DOI 10.1017/S0031182000063642; Watanabe M, 1998, J BIOL CHEM, V273, P23922, DOI 10.1074/jbc.273.37.23922; WHITMORE GF, 1986, BIOCHEM PHARMACOL, V35, P97, DOI 10.1016/0006-2952(86)90565-4; YARLETT N, 1986, MOL BIOCHEM PARASIT, V19, P111, DOI 10.1016/0166-6851(86)90115-5; YARLETT N, 1986, BIOCHEM PHARMACOL, V35, P1703, DOI 10.1016/0006-2952(86)90327-8	46	184	186	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26051	26056		10.1074/jbc.274.37.26051	http://dx.doi.org/10.1074/jbc.274.37.26051			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473552	hybrid			2022-12-25	WOS:000082469700018
J	Xu, HY; Sethi, JK; Hotamisligil, GS				Xu, HY; Sethi, JK; Hotamisligil, GS			Transmembrane tumor necrosis factor (TNF)-alpha inhibits adipocyte differentiation by selectively activating TNF receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; FACTOR-ALPHA; GENE-EXPRESSION; 3T3-L1 CELLS; IN-VIVO; ADIPOSE-TISSUE; HUMAN OBESITY; CLONING; MICE; PROTEIN	Tumor necrosis factor alpha (TNF alpha) is a potent cytokine with multiple biological activities and exists in two forms as follows: a 17-kDa soluble form that is a cleaved product of the 26-kDa transmembrane form (mTNF alpha), It has been suggested that the transmembrane form of TNF alpha is mainly responsible for localized responses via cell-cell contact. Here, we have examined the activities of transmembrane TNF alpha in cultured adipocytes, A non-cleavable transmembrane form of TNF alpha (mTNF alpha 1-9K11E) was expressed in several preadipocyte cell lines using retroviral gene transfer, In wild type preadipocytes carrying both TNF receptors, expression of mTNF Delta 1-9K11E resulted in inhibition of the differentiation program. The extent of this varied depending on the nature and strength of the adipogenic stimuli. The TNF receptor responsible for this function was determined by expressing mTNF Delta 1-9K11E in preadipocyte cell lines lacking either TNF receptor 1 (TNFR1), 2 (TNFR2), or both. In order to confirm the results in the same cellular background, TNF receptors were also reconstituted in the cell lines lacking corresponding receptors, These experiments demonstrated that TNFR1 was necessary and sufficient for mediating mTNF Delta 1-9K11E-induced inhibition of adipogenesis and that this action was similar to that of soluble TNF alpha. In conclusion, our results indicate that mTNF Delta 1-9K11E is biologically active in cultured adipocytes and can alter the adipogenic program of these cells by selectively activating TNFR1. This may have physiological implications where local TNF alpha actions are thought to be generated at sites such as adipose tissue.	Harvard Univ, Sch Publ Hlth, Div Biol Sci, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Hotamisligil, GS (corresponding author), Harvard Univ, Sch Publ Hlth, Div Biol Sci, 665 Huntington Ave, Boston, MA 02115 USA.	ghotamis@hsph.harvard.edu	Sethi, Jaswinder K./B-1413-2008	Sethi, Jaswinder K./0000-0003-4157-0475	NIDDK NIH HHS [DK52539] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052539] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akassoglou K, 1997, J IMMUNOL, V158, P438; Alexopoulou L, 1997, EUR J IMMUNOL, V27, P2588, DOI 10.1002/eji.1830271018; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Cheung AT, 1998, ENDOCRINOLOGY, V139, P4928, DOI 10.1210/en.139.12.4928; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Grell M, 1996, J INFLAMM, V47, P8; GRUNFELD C, 1991, BIOTHERAPY, V3, P143, DOI 10.1007/BF02172087; Gutierrez JA, 1997, J CELL BIOL, V139, P895, DOI 10.1083/jcb.139.4.895; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Hotamisligil GS, 1997, DIABETES, V46, P451, DOI 10.2337/diabetes.46.3.451; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kirchgessner TG, 1997, J CLIN INVEST, V100, P2777, DOI 10.1172/JCI119824; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; Kusters S, 1997, EUR J IMMUNOL, V27, P2870, DOI 10.1002/eji.1830271119; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; Lazdins JK, 1997, J EXP MED, V185, P81, DOI 10.1084/jem.185.1.81; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Liu LS, 1998, DIABETES, V47, P515, DOI 10.2337/diabetes.47.4.515; Lucas R, 1997, EUR J IMMUNOL, V27, P1719, DOI 10.1002/eji.1830270719; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MAHADIK SP, 1992, J NEUROSCI RES, V32, P209, DOI 10.1002/jnr.490320210; Miles PDG, 1997, DIABETES, V46, P1678, DOI 10.2337/diabetes.46.11.1678; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; OHSUMI J, 1994, ENDOCRINOLOGY, V135, P2279, DOI 10.1210/en.135.5.2279; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Schreyer SA, 1998, J CLIN INVEST, V102, P402, DOI 10.1172/JCI2849; SETHI JK, 1998, INT J OBES S3, V22, P80; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; Uysal KT, 1998, ENDOCRINOLOGY, V139, P4832, DOI 10.1210/en.139.12.4832; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Ventre J, 1997, DIABETES, V46, P1526, DOI 10.2337/diabetes.46.9.1526; Xing H, 1997, ENDOCRINOLOGY, V138, P2776, DOI 10.1210/en.138.7.2776; Yamaguchi M, 1998, BIOCHEM BIOPH RES CO, V244, P30, DOI 10.1006/bbrc.1998.8199	52	114	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26287	26295		10.1074/jbc.274.37.26287	http://dx.doi.org/10.1074/jbc.274.37.26287			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473584	hybrid			2022-12-25	WOS:000082469700050
J	Simonsen, A; Gaullier, JM; D'Arrigo, A; Stenmark, H				Simonsen, A; Gaullier, JM; D'Arrigo, A; Stenmark, H			The Rab5 effector EEA1 interacts directly with syntaxin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOSOME FUSION; MEMBRANE-FUSION; VESICLE TRAFFICKING; T-SNARE; GOLGI; TRANSPORT; PROTEIN; ENDOCYTOSIS; RABAPTIN-5; FINGERS	The fusion of transport vesicles with their cognate target membranes, an essential event in intracellular membrane trafficking, is regulated by SNARE proteins and Rab GTPases. Rab GTPases are thought to act prior to SNAREs in vesicle docking, but the exact biochemical relationship between the two classes of molecules is not known. We recently identified the early endosomal autoantigen EEA1 as an effector of Rab5 in endocytic membrane fusion. Here we demonstrate that EEA1 interacts directly and specifically with syntaxin-6, a SNARE implicated in trans-Golgi network to early endosome trafficking. The binding site for syntaxin-6 overlaps with that of Rab5-GTP at the C terminus of EEA1. Syntaxin-6 and EEA1 were found to colocalize extensively on early endosomes, although syntaxin-6 is present in the trans-Golgi network as well. Our results indicate that SNAREs can interact directly with Rab effecters, and suggest that EEA1 may participate in trans-Golgi network to endosome as well as in endocytic membrane traffic.	Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway	University of Oslo	Stenmark, H (corresponding author), Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway.		Stenmark, Harald/B-8868-2008	Simonsen, Anne/0000-0003-4711-7057				Barbieri MA, 1998, J BIOL CHEM, V273, P25850, DOI 10.1074/jbc.273.40.25850; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Olkkonen VM, 1997, INT REV CYTOL, V176, P1, DOI 10.1016/S0074-7696(08)61608-3; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Tall GG, 1999, MOL BIOL CELL, V10, P1873, DOI 10.1091/mbc.10.6.1873; Tellam JT, 1997, J BIOL CHEM, V272, P6187, DOI 10.1074/jbc.272.10.6187; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Valdez AC, 1999, J CELL SCI, V112, P845; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang H, 1997, GENE, V199, P39, DOI 10.1016/S0378-1119(97)00343-0; Webb GC, 1997, MOL BIOL CELL, V8, P871, DOI 10.1091/mbc.8.5.871; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	35	182	188	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28857	28860		10.1074/jbc.274.41.28857	http://dx.doi.org/10.1074/jbc.274.41.28857			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506127	hybrid			2022-12-25	WOS:000083017800006
J	Davarinos, NA; Pollenz, RS				Davarinos, NA; Pollenz, RS			Aryl hydrocarbon receptor imported into the nucleus following ligand binding is rapidly degraded via the cytosplasmic proteasome following nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DNA INTERACTIONS; INDUCIBLE FACTOR 1-ALPHA; MOUSE HEPATOMA-CELLS; HEAT-SHOCK PROTEIN; AH-RECEPTOR; TRANSLOCATOR PROTEIN; DOWN-REGULATION; TRANSCRIPTION FACTOR; ONCORHYNCHUS-MYKISS; GENE-TRANSCRIPTION	The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that dimerizes with the AHR nuclear translocator protein to mediate gene regulation. However, the AHR protein is rapidly depleted in vitro and in vivo following exposure to Ligands. The purpose of the studies in this report was to characterize the mechanism of AHR degradation and determine the consequence of blocking the degradation process. Western blot and immunological analysis of rat smooth muscle (A?), murine Hepa-l, and human HepG2 cells show that ligand-induced degradation of AKR is blocked when the proteasome is inhibited by MG-132. AHR degradation is also blocked in Hepa-1 and HepG2 cells when nuclear export is inhibited with leptomycin B. Mutation of a putative nuclear export signal present in the AHR results in the accumulation of AHR in the nucleus and reduced levels of degradation following ligand exposure. In addition, inhibition of AHR degradation results in an increase in the concentration of AHR AHR nuclear translocator complexes associated with DNA and extends the duration that the complex resides in the nucleus. These findings show that nuclear export and degradation of the AHR protein are two additional steps in the AHR-mediated signal transduction pathway and suggest novel areas for regulatory control.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA	Medical University of South Carolina	Pollenz, RS (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29403 USA.				NIEHS NIH HHS [ES-08980] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008980] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbott BD, 1999, TOXICOL APPL PHARM, V155, P62, DOI 10.1006/taap.1998.8601; ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Bush KT, 1997, J BIOL CHEM, V272, P9086; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; Chen HS, 1997, ARCH BIOCHEM BIOPHYS, V348, P190, DOI 10.1006/abbi.1997.0398; Chen YH, 1996, J BIOL CHEM, V271, P26261, DOI 10.1074/jbc.271.42.26261; Corey MJ, 1997, J IMMUNOL METHODS, V207, P43, DOI 10.1016/S0022-1759(97)00098-7; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Ema M, 1996, MOL CELL BIOL, V16, P5865; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Garrison PM, 1996, FUND APPL TOXICOL, V30, P194, DOI 10.1006/faat.1996.0056; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GIANNONE JV, 1995, CAN J PHYSIOL PHARM, V73, P7, DOI 10.1139/y95-002; Giannone JV, 1998, BIOCHEM PHARMACOL, V55, P489, DOI 10.1016/S0006-2952(97)00493-0; Goldberg AL, 1997, BIOL CHEM, V378, P131; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HENRY EC, 1993, BIOCHEM J, V294, P95, DOI 10.1042/bj2940095; HOECK W, 1989, J BIOL CHEM, V264, P14396; Holmes JL, 1997, MOL PHARMACOL, V52, P202, DOI 10.1124/mol.52.2.202; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hushka LJ, 1998, TOXICOL APPL PHARM, V152, P200, DOI 10.1006/taap.1998.8508; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; Kozak KR, 1997, DEV BIOL, V191, P297, DOI 10.1006/dbio.1997.8758; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; Li SY, 1997, ARCH BIOCHEM BIOPHYS, V340, P73, DOI 10.1006/abbi.1997.9905; Long WP, 1999, J BIOL CHEM, V274, P12391, DOI 10.1074/jbc.274.18.12391; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MILLER AG, 1983, J BIOL CHEM, V258, P3523; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, ARCH BIOCHEM BIOPHYS, V291, P284, DOI 10.1016/0003-9861(91)90136-7; Peters JM, 1999, TOXICOL SCI, V47, P86, DOI 10.1093/toxsci/47.1.86; Pollenz RS, 1998, AQUAT TOXICOL, V41, P31, DOI 10.1016/S0166-445X(97)00073-8; Pollenz RS, 1998, TOXICOL SCI, V42, P117; Pollenz RS, 1996, J BIOL CHEM, V271, P30886, DOI 10.1074/jbc.271.48.30886; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; Pollenz RS, 1996, MOL PHARMACOL, V49, P391; Pugh CW, 1997, J BIOL CHEM, V272, P11205; REICK M, 1994, MOL CELL BIOL, V14, P5653, DOI 10.1128/MCB.14.9.5653; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Roman BL, 1998, TOXICOL APPL PHARM, V150, P228, DOI 10.1006/taap.1998.8388; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sambrook J., 2002, MOL CLONING LAB MANU; Semenza GL, 1998, J LAB CLIN MED, V131, P207, DOI 10.1016/S0022-2143(98)90091-9; SHEN ES, 1992, J BIOL CHEM, V267, P6815; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Sommer RJ, 1999, TOXICOL APPL PHARM, V155, P177, DOI 10.1006/taap.1998.8597; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Tanaka K, 1998, J BIOCHEM-TOKYO, V123, P195; Thompson JF, 1997, J BIOL CHEM, V272, P18766, DOI 10.1074/jbc.272.30.18766; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; WU L, 1993, NUCLEIC ACIDS RES, V21, P119, DOI 10.1093/nar/21.1.119; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017	66	215	221	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28708	28715		10.1074/jbc.274.40.28708	http://dx.doi.org/10.1074/jbc.274.40.28708			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497241	hybrid			2022-12-25	WOS:000082912700090
J	Krem, MM; Rose, T; Di Cera, E				Krem, MM; Rose, T; Di Cera, E			The C-terminal sequence encodes function in serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; ACTIVE-SITE GEOMETRY; BLOOD-COAGULATION; MOLECULAR EVOLUTION; SUBSTRATE-SPECIFICITY; CHYMOTRYPSIN; TRYPSIN; CONSERVATION; DROSOPHILA; THROMBIN	Serine proteases of the chymotrypsin family have maintained a common fold over an evolutionary span of more than one billion years. Notwithstanding modest changes in sequence, this class of enzymes has developed a wide variety of substrate specificities and important biological functions. Remarkably, the C-terminal portion of the sequence in the protease domain accounts fully for this functional diversity. This portion is often encoded by a single exon and contains most of the residues forming the contact surface in the active site for the P1-P3 residues of the substrate, as well as domains responsible for the modulation of catalytic activity. The evolution of serine proteases was therefore driven by optimization of contacts made with the unprimed subsites of the substrate and targeted a relatively short portion of the sequence toward the C-terminal end. The dominant role of the C-terminal sequence should facilitate the identification of function in newly discovered genes belonging to this class of enzymes.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.			ROSE, Thierry/0000-0001-8863-0207	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL058141, R01HL049413] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58141, HL49413] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; BARTUNIK HD, 1989, J MOL BIOL, V210, P813, DOI 10.1016/0022-2836(89)90110-1; BELL GI, 1984, J BIOL CHEM, V259, P4265; BLAKE CCF, 1987, COLD SPRING HARB SYM, V52, P925, DOI 10.1101/SQB.1987.052.01.101; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BODE W, 1992, PROTEIN SCI, V1, P426; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; DOOLITTLE RF, 1987, COLD SPRING HARB SYM, V52, P869, DOI 10.1101/SQB.1987.052.01.095; FARRIES TC, 1991, IMMUNOL TODAY, V12, P295, DOI 10.1016/0167-5699(91)90002-B; FELSENSTEIN J, 1995, PHYLIP PHYLOGENY INF; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Hong CC, 1996, GENETICS, V143, P1653; HUANG RY, 1994, IMMUNOGENETICS, V40, P397, DOI 10.1007/BF00177823; IRWIN DM, 1988, J MOL BIOL, V200, P31, DOI 10.1016/0022-2836(88)90331-2; Krem MM, 1998, PROTEINS, V30, P34, DOI 10.1002/(SICI)1097-0134(19980101)30:1<34::AID-PROT3>3.0.CO;2-K; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; Lesk AM, 1996, J MOL BIOL, V258, P501, DOI 10.1006/jmbi.1996.0264; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; Murray S R, 1992, Agents Actions Suppl, V38 ( Pt 1), P26; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PATTHY L, 1990, SEMIN THROMB HEMOST, V16, P245, DOI 10.1055/s-2007-1002677; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; Renatus M, 1998, J MED CHEM, V41, P5445, DOI 10.1021/jm981068g; Roach JC, 1997, J MOL EVOL, V45, P640, DOI 10.1007/PL00006268; RYPNIEWSKI WR, 1994, PROTEIN ENG, V7, P57, DOI 10.1093/protein/7.1.57; SALVESEN G, 1991, BIOMED BIOCHIM ACTA, V50, P665; Sanschagrin PC, 1998, PROTEIN SCI, V7, P2054, DOI 10.1002/pro.5560071002; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SMITH C, 1994, GENETICS, V136, P1355; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUKADA H, 1985, J MOL BIOL, V184, P703, DOI 10.1016/0022-2836(85)90314-6; VELOSO D, 1986, THROMB RES, V43, P153, DOI 10.1016/0049-3848(86)90056-3; Vindigni A, 1997, NAT BIOTECHNOL, V15, P891, DOI 10.1038/nbt0997-891; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; [No title captured]	41	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28063	28066		10.1074/jbc.274.40.28063	http://dx.doi.org/10.1074/jbc.274.40.28063			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497153	hybrid			2022-12-25	WOS:000082912700002
J	Mitidieri, F; de Meis, L				Mitidieri, F; de Meis, L			Ca2+ release and heat production by the endoplasmic reticulum Ca2+-ATPase of blood platelets - Effect of the platelet activating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; TRANSPORT ATPASES; ATP HYDROLYSIS; CALCIUM-PUMP; MUSCLE; THERMOGENESIS; ENERGY; INHIBITION; THAPSIGARGIN; MODULATION	Different sarco/endoplasmic reticulum Ca2+-ATPases isoforms are found in blood platelets and in skeletal muscle. The amount of heat produced during ATP hydrolysis by vesicles derived from the endoplasmic reticulum of blood platelets was the same in the absence and presence of a transmembrane Ca2+ gradient. Addition of platelets activating factor (PAF) to the medium promoted both a Ca2+ efflux that was arrested by thapsigargin and an increase of the yield of heat produced during ATP hydrolysis. The calorimetric enthalpy of ATP hydrolysis (Delta H-cal) measured during Ca2+ transport varied between -10 and -12 kcal/mol without PAF and between -20 and -24 kcal/mol with 4 mu M PAF. Different from platelets, in skeletal muscle vesicles a thapsigargin-sensitive Ca2+ efflux and a high heat production during ATP hydrolysis were measured without PAF and the Delta H-cal varied between -10 and -12 kcal/mol in the absence of Ca2+ and between -22 up to -32 kcal/mol after formation of a transmembrane Ca2+ gradient. PAF did not enhance the rate of thapsigargin-sensitive Ca2+ efflux nor increase the yield of heat produced during ATP hydrolysis. These findings indicate that the platelets of Ca2+-ATPase isoforms are only able to convert osmotic energy into heat in the presence of PAF.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	de Meis, L (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.	demeis@server.bioqmed.ufrj.br						BARLOGIE B, 1971, FEBS LETT, V12, P267, DOI 10.1016/0014-5793(71)80194-1; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; BOBE R, 1994, J BIOL CHEM, V269, P1417; CARDOSO CM, 1993, BIOCHEM J, V296, P49, DOI 10.1042/bj2960049; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHIESI M, 1979, J BIOL CHEM, V254, P370; CHINET A, 1992, J PHYSIOL-LONDON, V455, P663, DOI 10.1113/jphysiol.1992.sp019321; CLAUSEN T, 1991, PHYSIOL REV, V71, P733, DOI 10.1152/physrev.1991.71.3.733; De Meis L, 1998, AM J PHYSIOL-CELL PH, V274, pC1738, DOI 10.1152/ajpcell.1998.274.6.C1738; de Meis L, 1998, BIOCHEM BIOPH RES CO, V243, P598, DOI 10.1006/bbrc.1997.8028; deMeis L, 1996, BBA-BIOENERGETICS, V1275, P105, DOI 10.1016/0005-2728(96)00058-8; DEMEIS L, 1992, FEBS LETT, V299, P33, DOI 10.1016/0014-5793(92)80093-V; DEMEIS L, 1974, J CELL BIOL, V62, P505, DOI 10.1083/jcb.62.2.505; DEMEIS L, 1994, J BIOL CHEM, V269, P14525; DEMEIS L, 1993, ARCH BIOCHEM BIOPHYS, V306, P287, DOI 10.1006/abbi.1993.1514; deMeis L, 1997, FEBS LETT, V406, P201, DOI 10.1016/S0014-5793(97)00244-5; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; DEMEIS L, 1981, SARCOPLASMIC RETICUL, V2; DUMONTEIL E, 1993, AM J PHYSIOL, V265, pC507, DOI 10.1152/ajpcell.1993.265.2.C507; DUMONTEIL E, 1995, AM J PHYSIOL-CELL PH, V269, pC955, DOI 10.1152/ajpcell.1995.269.4.C955; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; ENOUF J, 1992, BIOCHEM J, V286, P135, DOI 10.1042/bj2860135; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GAJEWSKI E, 1986, J BIOL CHEM, V261, P2733; GALINA A, 1991, J BIOL CHEM, V266, P17978; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; JANSKY L, 1995, PHYSIOL REV, V75, P237, DOI 10.1152/physrev.1995.75.2.237; LEPEUCH CJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P456, DOI 10.1016/0005-2736(83)90041-X; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; SORENSON MM, 1986, J MEMBRANE BIOL, V90, P219, DOI 10.1007/BF01870128; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; WOLOSKER H, 1994, AM J PHYSIOL, V266, pC1376, DOI 10.1152/ajpcell.1994.266.5.C1376; WUYTACK F, 1994, J BIOL CHEM, V269, P1410	39	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28344	28350		10.1074/jbc.274.40.28344	http://dx.doi.org/10.1074/jbc.274.40.28344			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497193	hybrid			2022-12-25	WOS:000082912700042
J	Paz, K; Liu, YF; Shorer, H; Hemi, R; LeRoith, D; Quan, M; Kanety, H; Seger, R; Zick, Y				Paz, K; Liu, YF; Shorer, H; Hemi, R; LeRoith, D; Quan, M; Kanety, H; Seger, R; Zick, Y			Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; TYROSINE PHOSPHORYLATION; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE PROTEIN; JUXTAMEMBRANE REGION; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; POTENTIAL ROLE; ADIPOSE-CELLS	Incubation of cells with insulin leads to a transient rise in Tyr phosphorylation of insulin receptor substrate (IRS) proteins, accompanied by elevation in their Ser(P)/Thr(P) content and their dissociation from the insulin receptor (IR), Wortmannin, a phosphatidylinositol 3-kinase inhibitor, selectively prevented the increase in Ser(P)/Thr(P) content of IRS-1, its dissociation from IR, and the decrease in its Tyr(P) content following 60 min of insulin treatment. Four conserved phosphorylation sites within the phosphotyrosine binding/SAIN domains of IRS-1 and IRS-S served as in vitro substrates for protein kinase B (PKB), a Ser/Thr kinase downstream of phosphatidylinositol 3-kinase, Furthermore, PKB and IRS-1 formed stable complexes in vivo, and overexpression of PKB enhanced Ser phosphorylation of IRS-l. Overexpression of PKB did not affect the acute Tyr phosphorylation of IRS-l; however, it significantly attenuated its rate of Tyr dephosphorylation following 60 min of treatment with insulin. Accordingly, overexpression of IRS-1(4A), lacking the four potential PKB phosphorylation sites, markedly enhanced the rate of Tyr dephosphorylation of IRS-I, while inclusion of vanadate reversed this effect. These results implicate a wortmannin-sensitive Ser/Thr kinase, different from PKB, as the kinase that phosphorylates IRS-I and acts as the feedback control regulator that turns off insulin signals by inducting the dissociation of IRS proteins from IR, In contrast, insulin-stimulated PKB-mediated phosphorylation of Ser residues within the phosphotyrosine binding/SAIN domain of IRS-1 protects IRS-1 from the rapid action of protein-tyrosine phosphatases and enables it to maintain its Tyr-phosphorylated active conformation. These findings implicate PHB as a positive regulator of IRS-l functions.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Chaim Sheba Med Ctr, Inst Endocrinol, IL-52621 Tel Hashomer, Israel; NHLBI, Hypertens Endocrine Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Mol & Cellular Endocrinol Branch, Bethesda, MD 20892 USA	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Zick, Y (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	Lizick@weizmann.weizmann.ac.il	Zick, Yehiel/K-1479-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL003608] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Delahaye L, 1998, ENDOCRINOLOGY, V139, P4911, DOI 10.1210/en.139.12.4911; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Frevert EU, 1996, BIOCHEM J, V316, P865, DOI 10.1042/bj3160865; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Paz K, 1996, J BIOL CHEM, V271, P6998, DOI 10.1074/jbc.271.12.6998; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; ZICK Y, 1983, J BIOL CHEM, V258, P75	56	157	170	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28816	28822		10.1074/jbc.274.40.28816	http://dx.doi.org/10.1074/jbc.274.40.28816			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497255	hybrid			2022-12-25	WOS:000082912700104
J	Petrova, TV; Akama, KT; Van Eldik, LJ				Petrova, TV; Akama, KT; Van Eldik, LJ			Selective modulation of BV-2 microglial activation by prostaglandin E-2 - Differential effects on endotoxin-stimulated cytokine induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; CENTRAL-NERVOUS-SYSTEM; FACTOR-ALPHA; IL-6-DEFICIENT MICE; ALZHEIMERS-DISEASE; GENE-EXPRESSION; PROTEIN-KINASE	The influence of prostaglandins on glial functions and, more specifically, on glial activation is not well understood. We report here that prostaglandin E-2 (PGE(2)), one of the major prostaglandins produced in the brain, acts as a potent and selective inhibitor of tumor necrosis factor alpha (TNF-alpha) production in lipopolysaccharide-stimulated primary microglia and the microglial cell line BV-2. The IC50 for this effect is I nM, and 100 nM PGE(2) suppresses TNF-alpha production by >95%. More detailed studies of BV-2 cells show that PGE(2) also prevents the secretion of interleukin (IL)-6 but does not significantly modify lipopolysaccharide-stimulated expression of cyclooxygenase-2, pro-IL-1 beta, or inducible nitric oxide synthase. PGE, appears to act primarily at the level of translation or protein stability, because TNF-alpha and IL-6 mRNA levels were only modestly decreased at high PGE(2) concentrations; concomitantly with this inhibition, PGE(2) up-regulated the levels of IL-1 beta mRNA The effects of PGE(2) could be largely mimicked by 8-bromo-cAMP, suggesting that, as in other cell types, PGE(2) action is mediated at least in part by a rise in intracellular cyclic AMP. However, the protein kinase A inhibitor H89 only partially reversed the inhibition of TNF-alpha production by PGE(2), implying that the PGE(2) effect in BV-2 cells is mediated through both protein kinase A-dependent and A-dependent pathways.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, NW Drug Discovery Program, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Van Eldik, LJ (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave,Ward 4-202, Chicago, IL 60611 USA.	vaneldik@nwu.edu			NATIONAL INSTITUTE ON AGING [P01AG015501, R37AG013939, R01AG013939] Funding Source: NIH RePORTER; NIA NIH HHS [AG13939, AG15501] Funding Source: Medline; NIGMS NIH HHS [GM08061] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Bhat NR, 1998, J NEUROSCI, V18, P1633; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Caggiano AO, 1999, J NEUROCHEM, V72, P565, DOI 10.1046/j.1471-4159.1999.0720565.x; Caggiano AO, 1998, J NEUROCHEM, V70, P2357; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DICKSON DW, 1988, AM J PATHOL, V132, P86; ESTLER HC, 1992, BIOL CHEM H-S, V373, P271, DOI 10.1515/bchm3.1992.373.1.271; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; LEE SC, 1993, J IMMUNOL, V150, P2659; MAY LT, 1989, BIOCHEM BIOPH RES CO, V159, P991, DOI 10.1016/0006-291X(89)92206-7; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-#; Minghetti L, 1997, ADV EXP MED BIOL, V433, P181; MINGHETTI L, 1995, J NEUROCHEM, V65, P2690; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Murphy GM, 1998, J BIOL CHEM, V273, P20967, DOI 10.1074/jbc.273.33.20967; NEGISHI M, 1995, J LIPID MEDIAT CELL, V12, P379, DOI 10.1016/0929-7855(95)00024-K; NORTHEMANN W, 1989, J BIOL CHEM, V264, P16072; OBanion MK, 1996, J NEUROCHEM, V66, P2532; Okuda Y, 1998, INT IMMUNOL, V10, P703, DOI 10.1093/intimm/10.5.703; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Samoilova EB, 1998, J IMMUNOL, V161, P6480; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296	42	76	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28823	28827		10.1074/jbc.274.40.28823	http://dx.doi.org/10.1074/jbc.274.40.28823			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497256	hybrid			2022-12-25	WOS:000082912700105
J	Zen, K; Karsan, A; Stempien-Otero, A; Yee, E; Tupper, J; Li, XW; Eunson, T; Kay, MA; Wilson, CB; Winn, RK; Harlan, JM				Zen, K; Karsan, A; Stempien-Otero, A; Yee, E; Tupper, J; Li, XW; Eunson, T; Kay, MA; Wilson, CB; Winn, RK; Harlan, JM			NF-kappa B activation is required for human endothelial survival during exposure to tumor necrosis factor-alpha but not to interleukin-1 beta or lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; INDUCED CELL-DEATH; TNF-ALPHA; PROTEIN-SYNTHESIS; INDUCED APOPTOSIS; TERMINAL KINASE; FAMILY MEMBER; GENE-TRANSFER; SIGNAL; PHOSPHORYLATION	In the presence of a protein synthesis inhibitor, cyclohexeimide, tumor necrosis factor-alpha (TNF-alpha), interleukin 1-beta (IL-1 beta), or lipopolysaccharide (LPS) induces human umbilical vein endothelial cells (HUVECs) to undergo apoptosis, suggesting that constitutive or inducible cytoprotective pathways are required for cell survival. We studied the correlation between nuclear factor-kappa B (NF-kappa B) activation and cell death induced by TNF-alpha, IL-1 beta, or LPS. Adenovirus-mediated overexpression of a dominant-negative I kappa B alpha (inhibitor of kappa B) mutant blocked NF-kappa B activation by gel shift assay and blocked induction of vascular cell adhesion molecule-1 protein by TNF-alpha, IL-1 beta, and LPS, a NF-kappa B-dependent response. In cells overexpressing the I kappa B alpha mutant, TNF-alpha induced cell death, whereas IL-1 beta or LPS did not. We conclude that cell survival following TNF-alpha stimulation is NF-kappa B-dependent but that a constitutive or inducible NF-kappa B-independent pathway(s) protects IL-1 beta- or LPS-treated HUVECs from cell death.	Univ Washington, Div Hematol, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Univ British Columbia, Dept Pathol, McDonald Res Labs, Vancouver, BC V6Z 1Y6, Canada	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Stanford University; University of British Columbia	Harlan, JM (corresponding author), Univ Washington, Div Hematol, Dept Med, Box 357710, Seattle, WA 98195 USA.		Karsan, Aly/K-2067-2015	Kay, Mark/0000-0002-2799-2615	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047754] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645, HL03174] Funding Source: Medline; NIDDK NIH HHS [DK47754] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bach FH, 1997, NAT MED, V3, P944, DOI 10.1038/nm0997-944; BALDWIN ASJ, 1996, ANNU REV IMMUNOL, V83, P649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DATA M, 1998, J CLIN INVEST, V102, P1682; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; FRATELLI M, 1995, BLOOD, V85, P3532, DOI 10.1182/blood.V85.12.3532.bloodjournal85123532; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; HONG Z, 1995, CHINESE MED J, V108, P493; Hoshino K, 1999, J IMMUNOL, V162, P3749; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; LIEBER A, 1995, P NATL ACAD SCI USA, V92, P6210, DOI 10.1073/pnas.92.13.6210; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Loweth AC, 1998, DIABETES, V47, P727, DOI 10.2337/diabetes.47.5.727; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MCCARTY JM, 1995, FEBS LETT, V372, P194, DOI 10.1016/0014-5793(95)00976-G; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zen K, 1998, EXP CELL RES, V243, P425, DOI 10.1006/excr.1998.4162; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	62	71	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28808	28815		10.1074/jbc.274.40.28808	http://dx.doi.org/10.1074/jbc.274.40.28808			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497254	hybrid			2022-12-25	WOS:000082912700103
J	El Bawab, S; Bielawska, A; Hannun, YA				El Bawab, S; Bielawska, A; Hannun, YA			Purification and characterization of a membrane-bound nonlysosomal ceramidase from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ACID CERAMIDASE; MIXED MICELLES; FARBER-DISEASE; SPHINGOMYELIN; BIOSYNTHESIS; SPHINGOSINE; CLONING	We have purified a membrane bound ceramidase 22,300-fold to apparent homogeneity. The purification scheme included Triton X-100 extraction of membranes followed by Q-Sepharose, blue Sepharose, phenyl-Sepharose, and MonoS column chromatography. The purified enzyme showed an apparent molecular mass of 90 kDa as estimated by SDS-polyacrylamide gel electrophoresis under reducing conditions and 95 kDa by chromatography on Superose 12. Using C-16-ceramide as substrate, the enzyme showed a broad pH optimum in the neutral to alkaline range. A mixed micelle assay was developed, and using Triton X-100/ceramide mixed micelles, the enzyme exhibited classical Michaelis-Menten kinetics, with a K-m of 1.29 mol % and a V-max of 4.4 mu mol/min/mg. When dihydroceramide was used as substrate, these values were 3.84 mol % and 1.2 mu mol/min/mg, respectively, indicating that the enzyme hydrolyzes ceramides preferentially. The activity of the purified ceramidase did not require cations, and it was inhibited by reducing agents. Phosphatidylcholine and sphingomyelin were without effect on the enzyme activity, whereas phosphatidic acid and phosphatidylserine stimulated the activity 3-fold. Sphingosine acted as a competitive inhibitor with an IC50 of 5-10 mu M. These results indicate that the purified enzyme is a novel ceramidase.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.				NIGMS NIH HHS [GM 43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; GATT S, 1963, J BIOL CHEM, V238, P3131; HANNUN YA, 1985, J BIOL CHEM, V260, P39; ITO M, 1995, J BIOL CHEM, V270, P24370, DOI 10.1074/jbc.270.41.24370; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; MOMOI T, 1982, BIOCHEM J, V205, P419, DOI 10.1042/bj2050419; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; PERRY DK, 1998, BIOCHIM BIOPHYS ACTA, V1436, P223; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; SPENCE MW, 1986, BIOCHEM CELL BIOL, V64, P400, DOI 10.1139/o86-056; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; SUGITA M, 1972, SCIENCE, V178, P1100, DOI 10.1126/science.178.4065.1100; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; YADA Y, 1995, J BIOL CHEM, V270, P12677, DOI 10.1074/jbc.270.21.12677; YAVIN E, 1969, BIOCHEMISTRY-US, V8, P1692, DOI 10.1021/bi00832a052	25	68	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27948	27955		10.1074/jbc.274.39.27948	http://dx.doi.org/10.1074/jbc.274.39.27948			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488143	hybrid			2022-12-25	WOS:000082739100082
J	Johnson, CA; Balboa, MA; Balsinde, J; Dennis, EA				Johnson, CA; Balboa, MA; Balsinde, J; Dennis, EA			Regulation of cyclooxygenase-2 expression by phosphatidate phosphohydrolase in human amnionic WISH cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; PRETERM LABOR; PROSTAGLANDIN; PHOSPHOLIPASE-A2; BIOSYNTHESIS; PARTURITION; INHIBITION; SYNTHASE-2	Prostaglandins are known to play a key role in the initiation of labor in humans, but the mechanisms governing their synthesis in amnion are largely unknown. In this study, we have examined the regulatory pathways for prostaglandin E-2 (PGE(2)) production during protein kinase C-dependent activation of human WISH cells. In these cells, PGE(2) synthesis appears to be limited not by free arachidonic acid availability but by the expression levels of cyclooxygenase-2 (COX-2), Concomitant with the cells being able to synthesize and secrete PGE(2), we detected significant elevations of both COX-2 protein and mRNA levels. Specific inhibition of COX-2 by NS-398 totally ablated PGE(2) synthesis. All of these responses were found to be strikingly dependent on an active phosphatidate phosphohydrolase 1 (PAP-1), Inhibition of PAP-1 activity by three different strategies (i,e, use of bromoenol lactone, propranolol, and ethanol) resulted in inhibition of COX-2 expression and hence of PGE(2) production. These data unveil a novel signaling mechanism for the regulation of PGE(2) production via regulation of COX-2 expression and implicate phosphatidate phosphohydrolase 1 as a key regulatory component of eicosanoid metabolic pathways in the amnion.	Univ Calif San Diego, Revelle Coll & Sch Med, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Dennis, EA (corresponding author), Univ Calif San Diego, Revelle Coll & Sch Med, Dept Chem & Biochem, La Jolla, CA 92093 USA.		Dennis, Edward A./M-5554-2019; Balboa, María A./V-9493-2018; Balsinde, Jesús/C-7833-2018	Dennis, Edward A./0000-0003-3738-3140; Balboa, María A./0000-0002-2130-5298; Balsinde, Jesús/0000-0002-4157-6714	NICHD NIH HHS [HD-26171] Funding Source: Medline; NIGMS NIH HHS [GM-20501] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; Fuentes A, 1996, PROSTAGLANDINS, V52, P261, DOI 10.1016/S0090-6980(96)00088-3; HAYFLICK L, 1961, EXP CELL RES, V23, P14, DOI 10.1016/0014-4827(61)90059-3; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Hulkower KI, 1997, J PHARMACOL EXP THER, V280, P1065; Jiang YW, 1996, J BIOL CHEM, V271, P29529, DOI 10.1074/jbc.271.47.29529; Kniss DA, 1996, PROSTAGLANDINS, V51, P87, DOI 10.1016/0090-6980(95)00181-6; KNISS DA, 1990, AM J OBSTET GYNECOL, V163, P1883, DOI 10.1016/0002-9378(90)90768-3; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Lundgren DW, 1997, J BIOL CHEM, V272, P20118, DOI 10.1074/jbc.272.32.20118; MAGGI M, 1994, J ENDOCRINOL INVEST, V17, P757, DOI 10.1007/BF03347772; Majerus PW, 1998, CURR BIOL, V8, pR87, DOI 10.1016/S0960-9822(98)70053-3; Mijovic JE, 1997, AM J PHYSIOL-ENDOC M, V272, pE832, DOI 10.1152/ajpendo.1997.272.5.E832; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Perkins DJ, 1997, BIOCHEM J, V321, P677, DOI 10.1042/bj3210677; Perkins DJ, 1997, PROSTAG OTH LIPID M, V54, P727, DOI 10.1016/S0090-6980(97)00144-5; ROMERO R, 1994, ANN NY ACAD SCI, V734, P414, DOI 10.1111/j.1749-6632.1994.tb21771.x; ROMERO R, 1987, AM J OBSTET GYNECOL, V157, P1461, DOI 10.1016/S0002-9378(87)80245-4; SCHULTZ FM, 1975, AM J OBSTET GYNECOL, V123, P650, DOI 10.1016/0002-9378(75)90891-1; SLATER DM, 1995, AM J OBSTET GYNECOL, V172, P77, DOI 10.1016/0002-9378(95)90087-X; SUCHARD SJ, 1994, J BIOL CHEM, V269, P8063; TEIXEIRA FJ, 1994, J CLIN ENDOCR METAB, V78, P1396, DOI 10.1210/jc.78.6.1396; Zakar T, 1998, BBA-LIPID LIPID MET, V1391, P37, DOI 10.1016/S0005-2760(97)00195-1	25	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27689	27693		10.1074/jbc.274.39.27689	http://dx.doi.org/10.1074/jbc.274.39.27689			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488110	Green Published			2022-12-25	WOS:000082739100049
J	Kitaura, M; Suzuki, N; Imai, T; Takagi, S; Suzuki, R; Nakajima, T; Hirai, K; Nomiyama, H; Yoshie, O				Kitaura, M; Suzuki, N; Imai, T; Takagi, S; Suzuki, R; Nakajima, T; Hirai, K; Nomiyama, H; Yoshie, O			Molecular cloning of a novel human CC chemokine (eotaxin-3) that is a functional ligand of CC chemokine receptor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EOSINOPHIL; EXPRESSION; IDENTIFICATION; SEQUENCES; BASOPHILS	Previously, we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 (MPIF-2)/eotaxin-2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J,, Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340). Since chemokine genes tend to be clustered, unknown chemokines may be present in the vicinity of those mapped to new chromosomal loci. Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3. The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of similar to 40 kilobases, By Northern blot analysis, eotaxin-3 mRNA was constitutively expressed in the heart and ovary. We have generated recombinant eotaxin-3 in a baculovirus expression system. Eotaxin-3 induced transient calcium mobilization specifically in CC chemokine receptor 3 (CCR3)-expressing L1.2 cells with an EC50 of 3 nM. Eotaxin-3 competed the binding of I-125-eotaxin to CCR3-expressing L1.2 cells with an IC50 of 13 nM. Eotaxin-3 was chemotactic for normal peripheral blood eosinophils and basophils at high concentrations. Collectively, eotaxin-3 is yet another functional ligand for CCR3. The potency of eotaxin-3 as a CCR3 ligand seems, however, to be similar to 10-fold less than that of eotaxin, Identification of eotaxin-3 will further promote our understanding of the control of eosinophil trafficking and other CCR3-mediated biological phenomena. The strategy used in this study may also be applicable to identification of other unknown chemokine genes.	Kumamoto Univ, Sch Med, Dept Biochem, Kumamoto 8600811, Japan; Shionogi Inst Med Sci, Osaka 5660022, Japan; Kinki Univ, Sch Med, Dept Bacteriol, Osaka 5898511, Japan; Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Tokyo 1138655, Japan	Kumamoto University; Shionogi & Company Limited; Kindai University (Kinki University); University of Tokyo	Nomiyama, H (corresponding author), Kumamoto Univ, Sch Med, Dept Biochem, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Nomiyama, Hisayuki/F-2840-2013	Nomiyama, Hisayuki/0000-0002-2716-4043; Yoshie, Osamu/0000-0003-4353-5809				Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GOTOH O, 1995, COMPUT APPL BIOSCI, V11, P543; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Nomiyama H, 1998, GENOMICS, V49, P339, DOI 10.1006/geno.1998.5250; Patel VP, 1997, J EXP MED, V185, P1163, DOI 10.1084/jem.185.7.1163; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Yamada H, 1997, BIOCHEM BIOPH RES CO, V231, P365, DOI 10.1006/bbrc.1997.6100; Yoshida R, 1998, J BIOL CHEM, V273, P7118, DOI 10.1074/jbc.273.12.7118; Yoshie O, 1997, J LEUKOCYTE BIOL, V62, P634, DOI 10.1002/jlb.62.5.634; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	23	185	198	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27975	27980		10.1074/jbc.274.39.27975	http://dx.doi.org/10.1074/jbc.274.39.27975			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488147	hybrid			2022-12-25	WOS:000082739100086
J	Lindholm, CK; Gylfe, E; Zhang, WG; Samelson, LE; Welsh, M				Lindholm, CK; Gylfe, E; Zhang, WG; Samelson, LE; Welsh, M			Requirement of the Src homology 2 domain protein Shb for T cell receptor-dependent activation of the interleukin-2 gene nuclear factor for activation of T cells element in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ANTIGEN-RECEPTOR; KINASE-C; P21(RAS); CALCINEURIN; STIMULATION; APOPTOSIS; EFFECTOR; GRB2	Stimulation of the T cell antigen receptor (TCR) induces tyrosine phosphorylation of numerous intracellular proteins. We have recently investigated the role of the adaptor protein Shb in the early events of T cell signaling and observed that Shb associates with Grb2, linker for activation of T cells (LAT) and the TCR zeta-chain in Jurkat cells. We now report that Shb also associates with phospholipase C-gamma 1 (PLC-gamma 1) in these cells. Overexpression of Src homology 2 domain defective Shb caused diminished phosphorylation of LAT and consequently the activation of mitogen-activated protein kinases was decreased upon TCR stimulation. In addition, the Shb mutant also blocked phosphorylation of PLC-gamma 1 and the increase in cytoplasmic Ca2+ following TCR stimulation. Nuclear factor for activation of T cells is a major target for Ras and calcium signaling pathways in T cells following TCR stimulation, and the overexpression of the mutant Shb prevented TCR-dependent activation of the nuclear factor for activation of T cells. Consequently, endogenous interleukin-2 production was decreased under these conditions. The results indicate a role for Shb as a link between the TCR and downstream signaling events involving LAT and PLC-gamma 1 and resulting in the activation of transcription of the interleukin-2 gene.	Univ Uppsala, Biomedicum, Dept Med Cell Biol, S-75123 Uppsala, Sweden; NCI, Cellular & Mol Biol Lab, DBS, NIH, Bethesda, MD 20892 USA	Uppsala University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Welsh, M (corresponding author), Univ Uppsala, Biomedicum, Dept Med Cell Biol, Box 571, S-75123 Uppsala, Sweden.		Welsh, Michael/AAF-8564-2020	Welsh, Michael/0000-0002-5467-9755; Gylfe, Erik/0000-0002-8414-2107	NATIONAL CANCER INSTITUTE [Z01BC010304, ZIABC010304] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUDAY L, 1994, J BIOL CHEM, V269, P9019; CHANCE B, 1975, ANAL BIOCHEM, V66, P498, DOI 10.1016/0003-2697(75)90617-X; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GYLFE E, 1988, J BIOL CHEM, V263, P5044; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARLSSON T, 1995, ONCOGENE, V10, P1475; Karlsson T, 1996, ONCOGENE, V13, P955; Karlsson T, 1998, CELL GROWTH DIFFER, V9, P757; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Peterson EJ, 1998, CURR OPIN IMMUNOL, V10, P337, DOI 10.1016/S0952-7915(98)80173-8; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WELSH M, 1994, ONCOGENE, V9, P19; Welsh M, 1998, ONCOGENE, V16, P891, DOI 10.1038/sj.onc.1201607; WILLIAMS DH, 1995, EUR J IMMUNOL, V25, P42, DOI 10.1002/eji.1830250109; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WOODROW MA, 1993, J IMMUNOL, V150, P3853; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	29	33	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					28050	28057		10.1074/jbc.274.39.28050	http://dx.doi.org/10.1074/jbc.274.39.28050			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488157	hybrid			2022-12-25	WOS:000082739100096
J	Ray, K; Hauschild, BC; Steinbach, PJ; Goldsmith, PK; Hauache, O; Spiegel, AM				Ray, K; Hauschild, BC; Steinbach, PJ; Goldsmith, PK; Hauache, O; Spiegel, AM			Identification of the cysteine residues in the amino-terminal extracellular domain of the human Ca2+ receptor critical for dimerization - Implications for function of monomeric Ca2+ receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; CALCIUM-SENSING RECEPTOR; CELL-SURFACE EXPRESSION; N-LINKED GLYCOSYLATION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; MULTIGENE FAMILY; PROTEIN; MAMMALS; DIMER	We analyzed the effect of substituting serine for each of the 19 cysteine residues within the amino-terminal extracellular domain of the human Ca2+ receptor on cell surface expression and receptor dimerization. C129S, C131S, C437S, C449S, and C482S were similar to wild type receptor; the other 14 cysteine to serine mutants were retained intracellularly. Four of these, C60S, C101S, C358S and C395S, were unable to dimerize. A C129S/C131S double mutant failed to dimerize but was unique in that the monomeric form expressed at the cell surface. Substitution of a cysteine for serine 132 within the C129S/C131S mutant restored receptor dimerization. Mutation of residues Cys-129, Cys-131, and Ser-132, singly and in various combinations caused a left shift in Ca2+ response compared with wild type receptor. These results identify cysteines 129 and 131 as critical in formation of intermolecular disulfide bond(s) responsible for receptor dimerization. In a "venus flytrap" model of the receptor extracellular domain, Cys-129 and Cys-131 are located within a region protruding from one lobe of the flytrap. We suggest that this region represents a dimer interface for the receptor and that mutation of residues within the interface causes important changes in Ca2+ response of the receptor.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NIH, Ctr Informat Technol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT)	Spiegel, AM (corresponding author), NIDDK, Metab Dis Branch, NIH, 10-9N-222, Bethesda, MD 20892 USA.	allens@amb.niddk.nih.gov			CENTER FOR INFORMATION TECHNOLOGY [ZIACT000265, Z01CT000265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043011] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1999, AM J MED, V106, P238, DOI 10.1016/S0002-9343(98)00418-5; Butters RR, 1997, J BONE MINER RES, V12, P568, DOI 10.1359/jbmr.1997.12.4.568; Diaz R, 1997, AM J PHYSIOL-REG I, V273, pR1008, DOI 10.1152/ajpregu.1997.273.3.R1008; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Goldsmith PK, 1997, J BONE MINER RES, V12, P1780, DOI 10.1359/jbmr.1997.12.11.1780; Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; Zhao XM, 1999, FEBS LETT, V448, P180, DOI 10.1016/S0014-5793(99)00368-3	37	160	166	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27642	27650		10.1074/jbc.274.39.27642	http://dx.doi.org/10.1074/jbc.274.39.27642			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488104	hybrid			2022-12-25	WOS:000082739100043
J	Wartenberg, M; Diedershagen, H; Hescheler, J; Sauer, H				Wartenberg, M; Diedershagen, H; Hescheler, J; Sauer, H			Growth stimulation versus induction of cell quiescence by hydrogen peroxide in prostate tumor spheroids is encoded by the duration of the Ca2+ response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVATION; SIGNAL-REGULATED KINASE; SMOOTH-MUSCLE CELLS; S-PHASE FRACTION; C-FOS EXPRESSION; OXIDATIVE STRESS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; EPITHELIAL-CELLS; FREE-RADICALS	With increasing size, multicellular prostate tumor spheroids develop regions of quiescent, multidrug-resistant cells expressing the cyclin-dependent kinase inhibitor p27(kip1). Treatment of small (diameter 60 +/- 20 mu m) spheroids with 200 mu M hydrogen peroxide (H2O2) resulted in cell cycle arrest owing to up-regulation of p27(kip1) and down-regulation of the transcription factor c-Fos, Incubation with 100 nM mu M H2O2 led to up-regulation of c-Fos and enhanced tumor growth. Growth stimulation was inhibited by bisindolylmaleimide I, indicating a role for protein kinase C in the signaling cascade that involved the mitogen-activated protein kinase members MEK1,2, ERK1, -2, and c-Jun N-terminal kinase. Changes in Ca2+ influx underlined the differential effects of H2O2. Incubation with 200 mu M H2O2 released [Ca2+](i) from intracellular stores followed by prolonged Ca2+ influx. Inhibition of influx by Ca2+-free media or Ni2+, La3+, Mn2+ and SKF-96365 prevented the induction of quiescence and stimulated spheroid growth. Consequently, treatment with 200 mu M H2O2 in Ca2+-free media down-regulated p27(kip1) and increased Fos protein. ATP exerted effects comparably to those observed with H2O2. Encoding growth stimulation by [Ca2+](i) release and induction of cell quiescence by prolonged Ca2+ influx may provide a general mechanism for the control of tumor growth.	Univ Cologne, Dept Neurophysiol, D-50931 Cologne, Germany	University of Cologne	Sauer, H (corresponding author), Univ Cologne, Dept Neurophysiol, Robert-Koch-Str 39, D-50931 Cologne, Germany.							Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Abe MK, 1998, AM J RESP CELL MOL, V18, P562, DOI 10.1165/ajrcmb.18.4.2958; Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Bauer V, 1997, BRIT J PHARMACOL, V121, P867, DOI 10.1038/sj.bjp.0701202; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; Bielefeldt K, 1997, AM J PHYSIOL-GASTR L, V272, pG1439, DOI 10.1152/ajpgi.1997.272.6.G1439; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Brandstetter T, 1998, INT J CANCER, V75, P847, DOI 10.1002/(SICI)1097-0215(19980316)75:6<847::AID-IJC6>3.0.CO;2-V; BURDON RH, 1990, FREE RADICAL RES COM, V11, P65, DOI 10.3109/10715769009109669; CABELLO OA, 1993, BIOCHEM J, V295, P357, DOI 10.1042/bj2950357; Dolmetsch RE, 1997, NATURE, V388, P308, DOI 10.1038/40912; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Goke M, 1998, GASTROENTEROLOGY, V114, P697, DOI 10.1016/S0016-5085(98)70583-9; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Goldstone SD, 1996, BBA-MOL CELL RES, V1314, P175, DOI 10.1016/S0167-4889(96)00082-1; Griffith CE, 1998, J BIOL CHEM, V273, P10771, DOI 10.1074/jbc.273.17.10771; HEBERT JM, 1996, FEBS LETT, V395, P43; Heist EK, 1998, CELL CALCIUM, V23, P103; HIETANEN P, 1995, BRIT J CANCER, V71, P1029, DOI 10.1038/bjc.1995.198; Husain M, 1997, CIRC RES, V80, P617, DOI 10.1161/01.RES.80.5.617; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kanterewicz BI, 1998, J NEUROCHEM, V70, P1009; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; Kwon TK, 1996, CELL GROWTH DIFFER, V7, P1305; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; Liu BQ, 1996, J INTERF CYTOK RES, V16, P77; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Lo YYC, 1998, J CELL BIOCHEM, V69, P19, DOI 10.1002/(SICI)1097-4644(19980401)69:1<19::AID-JCB3>3.0.CO;2-Y; Meyer TN, 1996, KIDNEY INT, V49, P388, DOI 10.1038/ki.1996.57; Morita Y, 1995, AM J PHYSIOL-HEART C, V269, pH1833, DOI 10.1152/ajpheart.1995.269.6.H1833; MUEHLEMATTER D, 1988, CARCINOGENESIS, V9, P239, DOI 10.1093/carcin/9.2.239; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; OLIVE PL, 1994, CANCER METAST REV, V13, P121, DOI 10.1007/BF00689632; Pahl HL, 1996, FEBS LETT, V392, P129, DOI 10.1016/0014-5793(96)00800-9; PURI PL, 1995, ANN NY ACAD SCI, V752, P394, DOI 10.1111/j.1749-6632.1995.tb17447.x; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Qin SF, 1997, J BIOL CHEM, V272, P2098; Rao GN, 1997, CELL SIGNAL, V9, P181, DOI 10.1016/S0898-6568(96)00139-8; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; REMVIKOS Y, 1993, ANN NY ACAD SCI, V698, P193, DOI 10.1111/j.1749-6632.1993.tb17209.x; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; Sauer H, 1998, J CELL PHYSIOL, V175, P129, DOI 10.1002/(SICI)1097-4652(199805)175:2<129::AID-JCP2>3.0.CO;2-Q; Sauer H, 1997, FEBS LETT, V419, P201, DOI 10.1016/S0014-5793(97)01456-7; Sauer H, 1997, BRIT J CANCER, V75, P1481, DOI 10.1038/bjc.1997.253; SHIBUYA I, 1992, ENDOCRINOLOGY, V131, P1936, DOI 10.1210/en.131.4.1936; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; StCroix B, 1996, NAT MED, V2, P1204; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Swanson CA, 1997, P NATL ACAD SCI USA, V94, P1194, DOI 10.1073/pnas.94.4.1194; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; Volk T, 1997, MOL CELL BIOCHEM, V171, P11, DOI 10.1023/A:1006886215193; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wartenberg M, 1998, INT J CANCER, V75, P855, DOI 10.1002/(SICI)1097-0215(19980316)75:6<855::AID-IJC7>3.3.CO;2-2; Wasilenko WJ, 1997, PROSTATE, V30, P167; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3	60	43	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27759	27767		10.1074/jbc.274.39.27759	http://dx.doi.org/10.1074/jbc.274.39.27759			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488120	hybrid			2022-12-25	WOS:000082739100059
J	Nguyen, H; Teskey, L; Lin, RT; Hiscott, J				Nguyen, H; Teskey, L; Lin, RT; Hiscott, J			Identification of the secretory leukocyte protease inhibitor (SLPI) as a target of IRF-1 regulation	ONCOGENE			English	Article						interferon regulatory factor (IRF)-1; secretory leukocyte protease inhibitor (SLPI); transcription	IFN-INDUCIBLE GENES; TRANSCRIPTION FACTOR; LEUKOPROTEASE INHIBITOR; NITRIC-OXIDE; FACTOR-I; INTERFERON SYSTEM; EPITHELIAL-CELLS; EXPRESSION; INDUCTION; BETA	Interferon Regulatory Factor (IRF)-1 is a multifunctional transcription factor, involved in cell growth regulation, pathogen response and immune activation. To identify novel gene targets that may contribute to IRF-1 mediated activities, RNA fingerprinting was performed using NIH3T3 cells that inducibly express a hybrid form of IRF-1 under tetracycline regulated control. Secretory leukocyte protease inhibitor (SLPI)-a regulator of inflammation and an inhibitor of the LPS response-was identified as a gene repressed after doxycycline induced IRF-1 expression, Preliminary analysis of the human SLPI promoter identified an ISRE-like site located within the -221 to -200 region to which IRF-1 binds and a second, putative IRF-1 binding site upstream of the TATA box. Furthermore, co-transfection studies demonstrated that SLPI expression was inhibited by IRF-1 co-expression. The identification of SLPI as a target of IRF-1 regulation reveals a unique involvement of IRF-1 in repression of gene transcription and assigns a novel role for IRF-1 in inflammation.	McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Hiscott, J (corresponding author), Lady Davis Inst Med Res, 3755 Cote St Catherine,Room 526, Montreal, PQ H3T 1E2, Canada.		Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				CHA Y, 1994, J BIOL CHEM, V269, P5279; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; COHEN L, 1991, CELL GROWTH DIFFER, V2, P323; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P445; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; LEE CH, 1993, AM REV RESPIR DIS, V147, P710, DOI 10.1164/ajrccm/147.3.710; LIN R, 1992, J BACTERIOL, V174, P2779, DOI 10.1128/JB.174.9.2779-2784.1992; LIN RT, 1994, J BIOL CHEM, V269, P17542; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MARUYAMA M, 1994, J CLIN INVEST, V94, P368, DOI 10.1172/JCI117331; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nonkwelo C, 1997, J VIROL, V71, P6887, DOI 10.1128/JVI.71.9.6887-6897.1997; PENNINGER JM, 1994, IMMUNOL REV, V142, P231, DOI 10.1111/j.1600-065X.1994.tb00892.x; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733, DOI 10.1165/ajrcmb.11.6.7946401; TAKI S, 1997, IMMUNITY, V6, P1; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vogelmeier C, 1996, CHEST, V110, pS261, DOI 10.1378/chest.110.6_Supplement.261S; Wang IM, 1996, MOL CELL BIOL, V16, P6313; [No title captured]	37	19	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5455	5463		10.1038/sj.onc.1202924	http://dx.doi.org/10.1038/sj.onc.1202924			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498899				2022-12-25	WOS:000082718600010
J	Brown, S; McGrath, MJ; Ooms, LM; Gurung, R; Maimone, MM; Mitchell, CA				Brown, S; McGrath, MJ; Ooms, LM; Gurung, R; Maimone, MM; Mitchell, CA			Characterization of two isoforms of the skeletal muscle LIM protein 1, SLIM1 - Localization of SLIM1 at focal adhesions and the isoform slimmer in the nucleus of myoblasts and cytoplasm of myotubes suggests distinct roles in the cytoskeleton and in nuclear-cytoplasmic communication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; MYOGENIC DIFFERENTIATION; CELL-ADHESION; ALPHA-ACTININ; EXPORT SIGNAL; HIV-1 REV; DOMAIN; IDENTIFICATION; MOTIF; GENE	We have cloned and characterized a novel isoform of the skeletal muscle LIM protein 1 (SLIM1), designated SLIMMER. SLIM1 contains an N-terminal single zinc finger followed by four LIM domains. SLIMMER is identical to SLIM1 over the first three LIM domains but contains a novel C-terminal 96 amino acids with three potential bipartite nuclear localization signals, a putative nuclear export sequence, and 27 amino acids identical to the RBP-J binding region of KyoT2, a murine isoform of SLIM1. SLIM1 localized to the cytosol of So8 myoblasts and myotubes. SLIMMER was detected in the nucleus of myoblasts and, following differentiation into myotubes, was exclusively cytosolic. Recombinant green fluorescent protein-SLIM1 localized to, the cytoplasm and associated with focal adhesions and actin filaments in COS-7 cells, while green fluorescent protein-SLIMMER was predominantly nuclear. SLIMMER truncation mutants revealed that the first nuclear localization signal mediates nuclear localization. The addition of the proposed nuclear export sequence decreased the level of exclusively nuclear expression and increased cytosolic SLIMMER expression in COS-7 cells. The leucine-rich nuclear export signal was required for the export of SLIMMER from the nucleus of myoblasts to the cytoplasm of myotubes. Collectively, these results suggest distinct roles for SLIM1 and SLIMMER in focal adhesions and nuclear-cytoplasmic communication.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; SUNY Hlth Sci Ctr, Dept Anat & Cell Biol, Syracuse, NY 13210 USA	Monash University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia.		Ooms, Lisa/AGZ-7420-2022	Mitchell, Christina A/0000-0001-9372-3192; McGrath, Meagan/0000-0002-9414-6558; Ooms, Lisa Michelle/0000-0002-8918-9932; Brown, Sue/0000-0001-8112-933X				AMAKAWA R, 1993, GENOMICS, V17, P306, DOI 10.1006/geno.1993.1326; Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; CAMPOSORTEGA JA, 1993, J NEUROBIOL, V24, P1305, DOI 10.1002/neu.480241005; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Curtiss J, 1998, BIOESSAYS, V20, P58, DOI 10.1002/(SICI)1521-1878(199801)20:1&lt;58::AID-BIES9&gt;3.0.CO;2-O; DAUBAS P, 1988, NUCLEIC ACIDS RES, V16, P1251, DOI 10.1093/nar/16.4.1251; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; DESMEDT F, 1994, FEBS LETT, V347, P69, DOI 10.1016/0014-5793(94)00509-5; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Jurata LW, 1998, CURR TOP MICROBIOL, V228, P75; KLEINSCHMIDT JA, 1988, EMBO J, V7, P1605, DOI 10.1002/j.1460-2075.1988.tb02986.x; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; Lee SMY, 1998, GENE, V216, P163, DOI 10.1016/S0378-1119(98)00302-3; MADISON EL, 1992, GENE, V121, P179, DOI 10.1016/0378-1119(92)90179-S; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MORGAN MJ, 1995, BIOCHEM BIOPH RES CO, V212, P840, DOI 10.1006/bbrc.1995.2045; Morgan MJ, 1996, BIOCHEM BIOPH RES CO, V225, P632, DOI 10.1006/bbrc.1996.1222; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; Yoshida N, 1998, J CELL SCI, V111, P769; Zhang MJ, 1998, BIOCHEM BIOPH RES CO, V243, P113, DOI 10.1006/bbrc.1997.8070	51	81	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27083	27091		10.1074/jbc.274.38.27083	http://dx.doi.org/10.1074/jbc.274.38.27083			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480922	hybrid			2022-12-25	WOS:000082570700061
J	Fitzgerald, DJ; Anderson, JN				Fitzgerald, DJ; Anderson, JN			Selective nucleosome disruption by drugs that bind in the minor groove of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PARTICLE; CONFORMATIONAL CHANGE; RNA GENE; TRANSCRIPTION FACTOR; CHROMATIN STRUCTURE; CURVED DNA; SEQUENCE; MECHANISM; LIGANDS; DISTAMYCIN	Previous studies have shown that drugs which bind in the DNA minor groove reduce the curvature of bent DNA. In this article, we examined the effects of these drugs on the nucleosome assembly of DNA molecules that display different degrees of intrinsic curvature, DAPI (4,6-diamidino-2-phenylindole) inhibited the assembly of a histone octamer onto a 192-base pair circular DNA fragment from Caenorhabditis elegans and destabilized a nucleosome that was previously assembled on this segment. The inhibitory effect was highly selective since it was not seen with nonbent molecules, bent molecules with noncircular shapes, or total genomic DNA. This marked template specificity was attributed to the binding of the ligand to multiple oligo A-tracts distributed over the length of the fragment, A likely mechanism for the effect is that the bound ligand prevents the further compression of the DNA into the minor groove which is required for assembly of DNA into nucleosomes. To further characterize the effects of the drug on chromatin formation, a nucleosome was assembled onto a 322-base pair DNA fragment that contained the circular element and a flanking nonbent segment of DNA. The position of the nucleosome along the fragment was then determined using a variety of nuclease probes including exonuclease III, micrococcal nuclease, DNase I, and restriction enzymes. The results of these studies revealed that the nucleosome was preferentially positioned along the circular element in the absence of DAPI but assembled onto the nonbent flanking sequence in the presence of the drug. DAPI also induced the directional movement of the nucleosome from the circular element onto the nonbent flanking sequence when a nucleosome preassembled onto this template was exposed to the drug under physiologically relevant conditions.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Anderson, JN (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.							ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ALBERT FG, 1995, J BIOL CHEM, V270, P23570, DOI 10.1074/jbc.270.40.23570; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; Beato M, 1997, NUCLEIC ACIDS RES, V25, P3559, DOI 10.1093/nar/25.18.3559; BIRD DM, 1989, MOL CELL BIOL, V9, P4119, DOI 10.1128/MCB.9.10.4119; BROWN JW, 1986, J BIOL CHEM, V261, P1349; Brown PM, 1996, J MOL BIOL, V262, P671, DOI 10.1006/jmbi.1996.0544; BUTTINELLI M, 1993, P NATL ACAD SCI USA, V90, P9315, DOI 10.1073/pnas.90.20.9315; Cairns MJ, 1996, BIOCHEMISTRY-US, V35, P8753, DOI 10.1021/bi9600207; Caneva R, 1996, BBA-GENE STRUCT EXPR, V1306, P117, DOI 10.1016/0167-4781(96)00015-2; CHAIRES JB, 1983, BIOCHEMISTRY-US, V22, P284, DOI 10.1021/bi00271a009; CHAO MV, 1979, BIOCHEMISTRY-US, V18, P1068, DOI 10.1021/bi00573a021; COSTANZO G, 1990, J MOL BIOL, V216, P363, DOI 10.1016/S0022-2836(05)80327-4; COTTON RW, 1981, NUCLEIC ACIDS RES, V9, P445, DOI 10.1093/nar/9.2.445; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P247, DOI 10.1093/nar/15.1.247; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Enright H, 1996, CARCINOGENESIS, V17, P1175, DOI 10.1093/carcin/17.5.1175; ERIKSSON S, 1993, BIOCHEMISTRY-US, V32, P2987, DOI 10.1021/bi00063a009; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FITZGERALD DJ, 1994, J BIOL CHEM, V269, P21303; Fitzgerald DJ, 1998, NUCLEIC ACIDS RES, V26, P2526, DOI 10.1093/nar/26.11.2526; FITZGERALD PC, 1985, J BIOL CHEM, V260, P5318; Flaus A, 1998, J MOL BIOL, V275, P427, DOI 10.1006/jmbi.1997.1464; FOX KR, 1987, NUCLEIC ACIDS RES, V15, P491, DOI 10.1093/nar/15.2.491; Gavin IM, 1998, J BIOL CHEM, V273, P2429, DOI 10.1074/jbc.273.4.2429; GEIERSTANGER BH, 1995, ANNU REV BIOPH BIOM, V24, P463, DOI 10.1146/annurev.bb.24.060195.002335; GRUSS C, 1993, EMBO J, V12, P4533, DOI 10.1002/j.1460-2075.1993.tb06142.x; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; KAS E, 1993, EMBO J, V12, P115, DOI 10.1002/j.1460-2075.1993.tb05637.x; LOW CML, 1986, NUCLEIC ACIDS RES, V14, P6785, DOI 10.1093/nar/14.17.6785; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Maniatis T., 1989, MOL CLONING LAB MANU; MARKY NL, 1991, BIOPOLYMERS, V31, P1543, DOI 10.1002/bip.360311310; MARKY NL, 1995, J MOL BIOL, V254, P50, DOI 10.1006/jmbi.1995.0598; MCMURRAY CT, 1991, BIOCHEMISTRY-US, V30, P5644, DOI 10.1021/bi00237a002; MISRA VK, 1994, J MOL BIOL, V238, P245, DOI 10.1006/jmbi.1994.1285; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PENNINGS S, 1992, NUCLEIC ACIDS RES, V20, P6667, DOI 10.1093/nar/20.24.6667; PENNINGS S, 1989, J MOL BIOL, V207, P183, DOI 10.1016/0022-2836(89)90449-X; PEREZ JJ, 1990, NUCLEIC ACIDS RES, V18, P3731, DOI 10.1093/nar/18.13.3731; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Protacio RU, 1997, J MOL BIOL, V274, P708, DOI 10.1006/jmbi.1997.1440; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RADIC MZ, 1987, CELL, V50, P1101, DOI 10.1016/0092-8674(87)90176-0; Ramakrishnan V, 1997, ANNU REV BIOPH BIOM, V26, P83, DOI 10.1146/annurev.biophys.26.1.83; Samuelson Per, 1994, Journal of Molecular Recognition, V7, P233, DOI 10.1002/jmr.300070313; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SEN D, 1986, BIOCHEMISTRY-US, V25, P1503, DOI 10.1021/bi00355a005; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; SIMPSON RT, 1979, J BIOL CHEM, V254, P123; SUQUET C, 1993, J BIOL CHEM, V268, P23755; Svaren J, 1996, CURR OPIN GENET DEV, V6, P164, DOI 10.1016/S0959-437X(96)80046-3; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; TRIFONOV EN, 1980, P NATL ACAD SCI-BIOL, V77, P3816, DOI 10.1073/pnas.77.7.3816; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Turner PR, 1996, MUTAT RES-FUND MOL M, V355, P141, DOI 10.1016/0027-5107(96)00027-9; van Holde KE., 1989, SPRINGER SERIES MOL; VANWYE JD, 1991, NUCLEIC ACIDS RES, V19, P5253, DOI 10.1093/nar/19.19.5253; VOTAVOVA H, 1981, BIOCHIM BIOPHYS ACTA, V654, P175, DOI 10.1016/0005-2787(81)90169-6; Wang YH, 1996, J MOL BIOL, V263, P511, DOI 10.1006/jmbi.1996.0593; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; Widom J, 1997, SCIENCE, V278, P1899, DOI 10.1126/science.278.5345.1899; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; YAGER TD, 1989, BIOCHEMISTRY-US, V28, P2271, DOI 10.1021/bi00431a045; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2	74	57	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27128	27138		10.1074/jbc.274.38.27128	http://dx.doi.org/10.1074/jbc.274.38.27128			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480928	hybrid			2022-12-25	WOS:000082570700067
J	Forsberg, EC; Johnson, K; Zaboikina, TN; Mosser, EA; Bresnick, EH				Forsberg, EC; Johnson, K; Zaboikina, TN; Mosser, EA; Bresnick, EH			Requirement of an E1A-sensitive coactivator for long-range transactivation by the beta-globin locus control region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; DOMINANT CONTROL REGION; LEUCINE ZIPPER PROTEIN; RNA-POLYMERASE-II; BINDING PROTEIN; GENE-EXPRESSION; HISTONE ACETYLTRANSFERASES; DNA-BINDING; REGULATED TRANSCRIPTION; HYPERSENSITIVE SITE-2	Four erythroid-specific DNase I-hypersensitive sites at the 5'-end of the beta-globin locus confer high-level transcription to the beta-globin genes, To identify coactivators that mediate long-range transactivation by this locus control region (LCR), we assessed the influence of E1A, an inhibitor of the CBP/p300 histone acetylase, on LCR function. E1A strongly inhibited transactivation of A gamma- and beta-globin promoters by the HS2, HS2-HS3, and HS1-HS4 subregions of the LCR in human K562 and mouse erythroleukemia cells. Short- and long-range transactivation mediated by the LCR were equally sensitive to E1A. The E1A sensitivity was apparent in transient and stable transfection assays, and E1A inhibited expression of the endogenous gamma-globin genes, Only sites for NF-E2 within HS2 were required for E1A sensitivity in K562 cells, and EIA abolished transactivation mediated by the activation domain of NF-E2. E1A mutants defective in CBP/p300 binding only weakly inhibited HS2-mediated transactivation, whereas a mutant defective in retinoblastoma protein binding strongly inhibited transactivation. Expression of CBP/p300 potentiated HS2-mediated transactivation. Moreover, expression of GAL4-CBP strongly increased transactivation of a reporter containing HS2 with a GAL4 site substituted for the NF-E2 sites. Thus, we propose that a CBP/p300-containing coactivator complex is the E1A-sensitive factor important for LCR function.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050107, R01DK050107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50107] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amrolia PJ, 1997, P NATL ACAD SCI USA, V94, P10051, DOI 10.1073/pnas.94.19.10051; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Bean TL, 1997, NUCLEIC ACIDS RES, V25, P2509, DOI 10.1093/nar/25.12.2509; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bresnick EH, 1997, P NATL ACAD SCI USA, V94, P4566, DOI 10.1073/pnas.94.9.4566; BRESNICK EH, 1997, CHEMTRACTS BIOCH MOL, V10, P1001; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHANG JC, 1992, P NATL ACAD SCI USA, V89, P3107, DOI 10.1073/pnas.89.7.3107; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEAN A, 1981, SCIENCE, V212, P459, DOI 10.1126/science.6163216; Elnitski L, 1997, J BIOL CHEM, V272, P369; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; Forsberg EC, 1997, BIOCHEMISTRY-US, V36, P15918, DOI 10.1021/bi971664x; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lam LT, 1996, J BIOL CHEM, V271, P32421, DOI 10.1074/jbc.271.50.32421; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Marks P A, 1985, Prog Clin Biol Res, V191, P185; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MOON AM, 1991, BLOOD, V77, P2272; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Versaw WK, 1998, P NATL ACAD SCI USA, V95, P8756, DOI 10.1073/pnas.95.15.8756; Webster JC, 1997, J BIOL CHEM, V272, P9287; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	57	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26850	26859		10.1074/jbc.274.38.26850	http://dx.doi.org/10.1074/jbc.274.38.26850			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480893	hybrid			2022-12-25	WOS:000082570700032
J	Friederich, E; Vancompernolle, K; Louvard, D; Vandekerckhove, J				Friederich, E; Vancompernolle, K; Louvard, D; Vandekerckhove, J			Villin function in the organization of the actin cytoskeleton - Correlation of in vivo effects to its biochemical activities in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; MICROVILLUS CYTOSKELETON; BUNDLING PROTEIN; BINDING-PROTEINS; PHYSARUM ACTIN; GELSOLIN; DOMAINS; CALCIUM; SEQUENCE; CELLS	Villin is an actin-binding protein of the intestinal brush border that bundles, nucleates, caps, and severs actin in a Ca2+-dependent manner in vitro, Villin induces the growth of microvilli in transfected cells, an activity that requires a carboxyl-terminally located KKEK motif. By combining cell transfection and biochemical assays, we show that the capacity of villin to induce growth of microvilli in cells correlates with its ability to bundle F-actin in vitro but not with its nucleating activity. In agreement with its importance for microfilament bundling in cells, the KKEK motif of the carboxyl-terminal F-actin-binding site is crucial for bundling in vitro, In addition, substitutions of basic residues in a second site, located in the amino-terminal portion of villin, impaired its activity in cells and reduced its binding to F-actin in the absence of Ca2+ as well as its bundling and severing activities in vitro. Altogether, these findings suggest that villin participates in the organization and stabilization of the brush border core bundle but does not initiate its assembly by nucleation of actin filaments.	Inst Curie, CNRS, UMR 144, Lab Morphogenese & Signalisat Cellulaire, F-75248 Paris 05, France; State Univ Ghent VIB, Dept Biochem, B-9000 Ghent, Belgium	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Flanders Institute for Biotechnology (VIB); Ghent University	Friederich, E (corresponding author), Inst Curie, CNRS, UMR 144, Lab Morphogenese & Signalisat Cellulaire, 26 Rue Ulm, F-75248 Paris 05, France.	Evelyne.Friederich@curie.fr						AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; ANDRE E, 1988, J BIOL CHEM, V263, P722; ARPIN M, 1994, J CELL BIOL, V127, P1995, DOI 10.1083/jcb.127.6.1995; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; Arpin Monique, 1992, P245; Bartles JR, 1998, J CELL BIOL, V143, P107, DOI 10.1083/jcb.143.1.107; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER SL, 1983, J BIOL CHEM, V258, P5013; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; COLUCCIO LM, 1989, J CELL BIOL, V108, P495, DOI 10.1083/jcb.108.2.495; CRAIG SW, 1980, CELL, V22, P739, DOI 10.1016/0092-8674(80)90550-4; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; DEBEAUREGARD MAC, 1995, EMBO J, V14, P409, DOI 10.1002/j.1460-2075.1995.tb07017.x; Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699; DUDOUET B, 1987, J CELL BIOL, V105, P359, DOI 10.1083/jcb.105.1.359; EICHINGER L, 1991, J CELL BIOL, V112, P665, DOI 10.1083/jcb.112.4.665; FERARY E, 1999, IN PRESS J CELL BIOL; FINIDORI J, 1992, J CELL BIOL, V116, P1145, DOI 10.1083/jcb.116.5.1145; FRANCK Z, 1990, J CELL BIOL, V111, P2475, DOI 10.1083/jcb.111.6.2475; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; GETTEMANS J, 1995, J BIOL CHEM, V270, P2644, DOI 10.1074/jbc.270.6.2644; GLENNEY JR, 1981, CELL, V24, P471, DOI 10.1016/0092-8674(81)90338-X; GLENNEY JR, 1981, P NATL ACAD SCI-BIOL, V78, P2810, DOI 10.1073/pnas.78.5.2810; HEINTZELMAN MB, 1992, CURR TOP DEV BIOL, V26, P93, DOI 10.1016/S0070-2153(08)60442-1; HESTERBERG LK, 1983, J BIOL CHEM, V258, P359; HOFMANN A, 1993, FEBS LETT, V328, P71, DOI 10.1016/0014-5793(93)80968-Z; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JENSEN FC, 1964, P NATL ACAD SCI USA, V52, P53, DOI 10.1073/pnas.52.1.53; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHAJANMIKLOS S, 1994, CELL, V78, P291, DOI 10.1016/0092-8674(94)90298-4; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; MATSUDAIRA PT, 1982, J CELL BIOL, V92, P648, DOI 10.1083/jcb.92.3.648; MATTHIAS PD, 1982, EMBO J, V2, P1487; McKnight CJ, 1997, NAT STRUCT BIOL, V4, P180, DOI 10.1038/nsb0397-180; MOOSEKER MS, 1980, J CELL BIOL, V87, P809, DOI 10.1083/jcb.87.3.809; Pinson KI, 1998, DEV DYNAM, V211, P109, DOI 10.1002/(SICI)1097-0177(199801)211:1<109::AID-AJA10>3.0.CO;2-7; POPE B, 1994, FEBS LETT, V338, P58, DOI 10.1016/0014-5793(94)80116-9; REGGIO H, 1983, METHOD ENZYMOL, V98, P379; Sambrook J., 2002, MOL CLONING LAB MANU; SIMENEL C, 1995, INT J PEPT PROT RES, V45, P574; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUN HQ, 1994, J BIOL CHEM, V269, P9473; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; ZIGMOND SH, 1992, J CELL BIOL, V119, P559, DOI 10.1083/jcb.119.3.559	53	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26751	26760		10.1074/jbc.274.38.26751	http://dx.doi.org/10.1074/jbc.274.38.26751			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480879	hybrid			2022-12-25	WOS:000082570700018
J	Majumdar, M; Seasholtz, TM; Buckmaster, C; Toksoz, D; Brown, JH				Majumdar, M; Seasholtz, TM; Buckmaster, C; Toksoz, D; Brown, JH			A Rho exchange factor mediates thrombin and G alpha(12)-induced cytoskeletal responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; PLECKSTRIN HOMOLOGY DOMAINS; INDUCED NEURITE RETRACTION; 1321N1 ASTROCYTOMA-CELLS; GENE-EXPRESSION; DNA-SYNTHESIS; P115 RHOGEF; KINASE; G-ALPHA(13); RECEPTOR	Thrombin induces astrocytoma cell rounding through a Rho-dependent pathway (Majumdar, M., Seasholtz, T. M., Goldstein, D., de Lanerolle, P,, and Brown, J. H. (1998) J. Biol. Chem. 273, 10099-10106), The involvement of the G(12) family of G proteins and the role of specific Rho exchange factors in transducing signals from the thrombin receptor to Rho-dependent cytoskeletal responses was examined. Microinjection of cDNAs for activated G alpha(12) or G alpha(13) induced cell rounding, and antibodies to G alpha(12) or G alpha(13) blocked the response to thrombin, in contrast, activation or inhibition of G alpha(q) function had relatively little effect. The cytoskeletal response to G alpha(12) was inhibited by microinjection of C3 exoenzyme, indicating Rho dependence. Two Rho-specific guanine nucleotide exchange factors (GEFs), oncogenic lbc and p115, increased the percentage of rounded cells 4-5-fold, and this was inhibited by C3. Mutant GEFs lacking the Dbl homology (DH) domain required for exchange factor activity failed to induce cell rounding. However, the DH mutants of Ibc and p115 were efficacious inhibitors off rounding induced by thrombin or G alpha(12). The effects of lbc were dependent on an intact pleckstrin homology domain, which may be required for appropriate targeting of the Rho-GEF, These findings identify the G alpha(12) protein family as transducers of thrombin signaling to the cytoskeleton and provide the first evidence that a Rho-GEF transduces signals between G protein-coupled receptors and Rho-mediated cytoskeletal responses.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Tufts Univ, Dept Physiol, Boston, MA 02111 USA	University of California System; University of California San Diego; Tufts University	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927, R56GM036927] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36927] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Katoh H, 1996, J BIOL CHEM, V271, P29780, DOI 10.1074/jbc.271.47.29780; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Koyama Y, 1996, GLIA, V16, P342, DOI 10.1002/(SICI)1098-1136(199604)16:4<342::AID-GLIA6>3.0.CO;2-1; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOBES CD, 1995, J CELL SCI, V108, P225; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Tigyi G, 1996, J NEUROCHEM, V66, P537; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VANAELST L, 1997, GENE DEV, V11, P2296; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388	44	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26815	26821		10.1074/jbc.274.38.26815	http://dx.doi.org/10.1074/jbc.274.38.26815			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480888	hybrid			2022-12-25	WOS:000082570700027
J	Pastore, D; Stoppelli, MC; Di Fonzo, N; Passarella, S				Pastore, D; Stoppelli, MC; Di Fonzo, N; Passarella, S			The existence of the K+ channel in plant mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY MITOCHONDRIA; ATP CHANNEL; ALTERNATIVE OXIDASE; SUPEROXIDE PRODUCTION; POTATO MITOCHONDRIA; LIVER MITOCHONDRIA; YEAST MITOCHONDRIA; HYDROGEN-PEROXIDE; INNER MEMBRANE; TRANSPORT	In this study, evidence is given that a number of isolated coupled plant mitochondria (from durum wheat, bread wheat, spelt, rye, barley, potato, and spinach) can take up externally added K+ ions. This was observed by following mitochondrial swelling in isotonic KCl solutions and was confirmed by a novel method in which the membrane potential decrease due to externally added K+ is measured fluorimetrically by using safranine. A detailed investigation of K+ uptake by durum wheat mitochondria shows hyperbolic dependence on the ion concentration and specificity. K+ uptake electrogenicity and the non-competitive inhibition due to either ATP or NADH are also shown. In the whole, the experimental findings reported in this paper demonstrate the existence of the mitochondrial K-ATP(+) channel in plants (PmitoK(ATP)) Interestingly, Mg2+ and glyburide, which can inhibit mammalian K+ channel, have no effect on Pmito(KAT)P,. In the presence of the superoxide anion producing system (xanthine plus xanthine oxidase), PmnitoK(ATP) activation was found. Moreover, an inverse relationship was found between channel activity and mitochondrial superoxide anion formation, as measured via epinephrine photometric assay. These findings strongly suggest that mitochondrial K+ uptake could be involved in plant defense mechanism against oxidative stress due to reactive oxygen species generation.	Univ Molise, Dipartimento Sci Anim Vegetali & Ambiente, I-86100 Campobasso, Italy; Ist Sperimentale Cerealicoltura, I-71100 Foggia, Italy	University of Molise; Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA)	Passarella, S (corresponding author), Univ Molise, Dipartimento Sci Anim Vegetali & Ambiente, Via De Sanctis, I-86100 Campobasso, Italy.		Pastore, Donato/B-5673-2013	PASTORE, DONATO/0000-0001-9124-4374				AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; ATLANTE A, 1994, ARCH BIOCHEM BIOPHYS, V309, P139, DOI 10.1006/abbi.1994.1096; ATLANTE A, 1994, ARCH BIOCHEM BIOPHYS, V315, P369, DOI 10.1006/abbi.1994.1513; Barile M, 1997, EUR J BIOCHEM, V249, P777, DOI 10.1111/j.1432-1033.1997.00777.x; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; Bensasson R.V., 1993, EXCITED STATES FREE; BERNARDI P, 1989, J BIOL CHEM, V264, P18902; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; DIOLEZ P, 1985, BIOCHIM BIOPHYS ACTA, V806, P56, DOI 10.1016/0005-2728(85)90081-7; Diolez P., 1987, PLANT MITOCHONDRIA S, P17; DIWAN JJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P155, DOI 10.1016/S0304-4173(87)80001-0; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; GARLID KD, 1986, J BIOL CHEM, V261, P1529; Harris D.A., 1987, SPECTROPHOTOMETRY SP, P59; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Jaburek M, 1998, J BIOL CHEM, V273, P13578; Jezek P, 1996, J BIOL CHEM, V271, P32743, DOI 10.1074/jbc.271.51.32743; KLINGENBERG M, 1959, BIOCHEM Z, V331, P486; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; MANON S, 1995, BBA-BIOENERGETICS, V1231, P282, DOI 10.1016/0005-2728(95)00088-Z; MANON S, 1993, J BIOENERG BIOMEMBR, V25, P671; MATLIB MA, 1976, ARCH BIOCHEM BIOPHYS, V173, P27, DOI 10.1016/0003-9861(76)90230-7; MATTHUIS FJM, 1997, PLANT PHYSIOL, V114, P1141; McKersie B.D., 1994, STRESS STRESS COPING; MOORE AL, 1982, PLANT PHYSIOL, V70, P1271, DOI 10.1104/pp.70.5.1271; MOORE AL, 1987, METHOD ENZYMOL, V148, P415; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NICOLLI A, 1991, J BIOL CHEM, V266, P9465; Pallotta ML, 1998, FEBS LETT, V428, P245, DOI 10.1016/S0014-5793(98)00544-4; Paucek P, 1996, J BIOL CHEM, V271, P32084, DOI 10.1074/jbc.271.50.32084; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; Popov VN, 1997, FEBS LETT, V415, P87, DOI 10.1016/S0014-5793(97)01099-5; Purvis AC, 1997, PHYSIOL PLANTARUM, V100, P165, DOI 10.1034/j.1399-3054.1997.1000119.x; PURVIS AC, 1995, PHYSIOL PLANTARUM, V94, P743, DOI [10.1111/j.1399-3054.1995.tb00993.x, 10.1034/j.1399-3054.1995.940429.x]; RASCIO A, 1994, PHYSIOL PLANTARUM, V90, P715, DOI 10.1111/j.1399-3054.1994.tb02528.x; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; Skulachev VP, 1997, BIOSCIENCE REP, V17, P347, DOI 10.1023/A:1027344914565; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Szewczyk A, 1996, BIOCHEM MOL BIOL INT, V38, P477; Szewczyk A, 1997, BIOCHEM BIOPH RES CO, V230, P611, DOI 10.1006/bbrc.1996.6023; Szewczyk A, 1996, ACTA BIOCHIM POL, V43, P713; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; Wagner AM, 1997, BIOSCIENCE REP, V17, P319, DOI 10.1023/A:1027388729586; WAGNER AM, 1995, PHYSIOL PLANTARUM, V95, P318, DOI 10.1111/j.1399-3054.1995.tb00844.x; WHITE PJ, 1995, J EXP BOT, V46, P361, DOI 10.1093/jxb/46.4.361; WU WH, 1991, PLANT PHYSIOL, V97, P1551, DOI 10.1104/pp.97.4.1551; YarovYarovoy V, 1997, BBA-BIOENERGETICS, V1321, P128, DOI 10.1016/S0005-2728(97)00051-0; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZOTTINI M, 1993, PLANT PHYSIOL, V102, P579, DOI 10.1104/pp.102.2.579	53	98	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26683	26690		10.1074/jbc.274.38.26683	http://dx.doi.org/10.1074/jbc.274.38.26683			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480870	hybrid			2022-12-25	WOS:000082570700009
J	Sanghani, SP; Sanghani, PC; Moran, RG				Sanghani, SP; Sanghani, PC; Moran, RG			Identification of three key active site residues in the C-terminal domain of human recombinant folylpoly-gamma-glutamate synthetase by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER CELLS; ESCHERICHIA-COLI; BINDING-SITE; ATP-BINDING; FOLC GENE; CLONING; FOLATE; EXPRESSION; MUTANTS; ENZYMES	Three cysteines in human recombinant folylpoly-gamma-glutamate synthetase (FPGS) that were reactive with iodoacetamide were located in peptides that were highly conserved across species; the functions of two of these peptides, located in the C-terminal domain, were studied by site-directed mutagenesis. When cDNAs containing mutations in each conserved ionic residue on these peptides were transfected into AUXB1 cells, which lack endogenous FPGS activity, one mutant (D335A) did not complement the auxotrophy, and another (R377A) allowed only minimal, growth FPGS activity could not be detected in insect cells expressing abundant levels of these two mutant proteins from recombinant baculoviruses nor from a virus encoding an H338A mutant FPGS. Kinetic analysis of the purified proteins demonstrated that each of these three mutants was quite different from the others. The major kinetic change detected for the H338A mutation was a 600-fold increase in the K-m for glutamic acid. For the D335A mutation, the binding of all three substrates (aminopterin, ATP, and glutamic acid) was affected, For R377A, the K-m for glutamic acid was increased by 1500-fold, and there was an approximate to 20-fold decrease in the k(cat) of the reaction. The binding of the K+ ion, a known activator of FPGS, was affected by the D335A and H338A mutations. We conclude that these three amino acids participate in the alignment of glutamic acid in the active site and that Arg-377 is also involved in the mechanism of the reaction.	Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Moran, RG (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, 1101 E Marshall St, Richmond, VA 23298 USA.	rmoran@hsc.vcu.edu			NATIONAL CANCER INSTITUTE [R01CA039687] Funding Source: NIH RePORTER; NCI NIH HHS [CA39687] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIBHAI M, 1994, BIOCHEMISTRY-US, V33, P682, DOI 10.1021/bi00169a008; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOGNAR AL, 1985, J BIOL CHEM, V260, P5625; DHALLA AM, 1994, PROTEIN SCI, V3, P476; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; Fussenegger M, 1996, MOL GEN GENET, V250, P277; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Kaneko T, 1996, DNA Res, V3, P109; LIAW SH, 1994, BIOCHEMISTRY-US, V33, P675, DOI 10.1021/bi00169a007; LIAW SH, 1995, PROTEIN SCI, V4, P2358, DOI 10.1002/pro.5560041114; LIN BF, 1993, J BIOL CHEM, V268, P21674; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; MORAN RG, 1984, ANAL BIOCHEM, V140, P326, DOI 10.1016/0003-2697(84)90174-X; Sanghani Paresh, 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P379; Spinella MJ, 1996, BBA-GENE STRUCT EXPR, V1305, P11, DOI 10.1016/0167-4781(95)00193-X; Sun XL, 1998, P NATL ACAD SCI USA, V95, P6647, DOI 10.1073/pnas.95.12.6647; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; TOY J, 1994, ARCH BIOCHEM BIOPHYS, V314, P344, DOI 10.1006/abbi.1994.1452; TOY J, 1990, J BIOL CHEM, V265, P2492; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	26	22	22	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27018	27027		10.1074/jbc.274.38.27018	http://dx.doi.org/10.1074/jbc.274.38.27018			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480915	hybrid			2022-12-25	WOS:000082570700054
J	Yamamoto, Y; Yin, MJ; Lin, KM; Gaynor, RB				Yamamoto, Y; Yin, MJ; Lin, KM; Gaynor, RB			Sulindac inhibits activation of the NF-kappa B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TUMOR-NECROSIS-FACTOR; SITE-SPECIFIC PHOSPHORYLATION; UBIQUITIN-PROTEASOME PATHWAY; COLON ADENOCARCINOMA CELLS; COLORECTAL-CANCER; ASPIRIN USE; ALPHA PROTEOLYSIS; SODIUM-SALICYLATE	Sulindac is a non-steroidal anti-inflammatory agent that is related both structurally and pharmacologically to indomethacin. In addition to its anti-inflammatory properties, sulindac has been demonstrated to have a role in the prevention of colon cancer. Both its growth inhibitory and anti-inflammatory properties are due at least in part to its ability to decrease prostaglandin synthesis by inhibiting the activity of cyclooxygenases. Recently, we demonstrated that both aspirin and sodium salicylate, but not indomethacin, inhibited the activity of an I kappa B kinase beta (IKK beta) that is required to activate the nuclear factor-kappa B (NF-kappa B) pathway. In this study, we show that sulindac: and its metabolites sulindac sulfide and sulindac sulfone can also inhibit the NF-kappa B pathway in both colon cancer and other cell lines. Similar to our previous results with aspirin, this inhibition is due to sulindac-mediated decreases in IKK beta kinase activity. Concentrations of sulindac that inhibit IKK beta activity also reduce the proliferation of colon cancer cells. These results suggest that the growth inhibitory and anti-inflammatory properties of sulindac may be regulated in part by inhibition of kinases that regulate the NF-kappa B pathway.	Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DUGGAN DE, 1977, J PHARMACOL EXP THER, V201, P8; DUGGAN DE, 1980, DRUG METAB DISPOS, V8, P241; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; Goldberg Y, 1996, ONCOGENE, V12, P893; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Insel PA, 1996, PHARMACOL BASIS THER, P617; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; Qiao L, 1998, INT J CANCER, V76, P99, DOI 10.1002/(SICI)1097-0215(19980330)76:1<99::AID-IJC16>3.0.CO;2-B; RAO CV, 1995, CANCER RES, V55, P1464; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RIGAU J, 1991, ANN INTERN MED, V115, P952, DOI 10.7326/0003-4819-115-12-952; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Ruschoff J, 1998, P NATL ACAD SCI USA, V95, P11301, DOI 10.1073/pnas.95.19.11301; Shen T Y, 1977, Adv Drug Res, V12, P90; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; Thompson HJ, 1997, CANCER RES, V57, P267; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; WINDE G, 1995, DIS COLON RECTUM, V38, P813, DOI 10.1007/BF02049838; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	60	445	463	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27307	27314		10.1074/jbc.274.38.27307	http://dx.doi.org/10.1074/jbc.274.38.27307			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480951	hybrid			2022-12-25	WOS:000082570700090
J	Boonyaratanakornkit, V; Strong, DD; Mohan, S; Baylink, DJ; Beck, CA; Linkhart, TA				Boonyaratanakornkit, V; Strong, DD; Mohan, S; Baylink, DJ; Beck, CA; Linkhart, TA			Progesterone stimulation of human insulin-like growth factor-binding protein-5 gene transcription in human osteoblasts is mediated by a CACCC sequence in the proximal promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-B EXPRESSION; HUMAN BREAST-CANCER; CELL-PROLIFERATION; A-ISOFORM; FACTOR-I; REGULATORY ELEMENTS; RESPONSE ELEMENTS; MESSENGER-RNA; IGF ACTIONS; HUMAN BONE	Insulin-like growth factor-binding protein-5 (IGFBP-5) is produced by osteoblasts and potentiates insulin-like growth factor mitogenic stimulation in osteoblast cell. cultures. Progesterone (PG) increased IGFBP-5 expression in normal human osteoblasts and increased IGEBP-5 transcription in U2 human osteosarcoma cells. We developed a chloramphenicol acetyltransferase reporter construct containing the human IGFBP-5 proximal promoter sequence, which includes TATA and CAAT boxes, and five putative PG response element half-sites. 10(-8) M PG increased promoter activity of this construct in U2 cells co-transfected with a PG receptor isoform A (PRA) expression vector. Analysis of 5' deletion constructs indicates that PG transactivation of IGFBP-5 promoter activity does not require the PG response element half-sites but does require the region -162 to -124 containing two tandem CACCC box sequences. Mutation of the proximal CACCC box at -139 eliminated PG transactivation. Gel shift assays using a -162 to -124 DNA fragment, U2 cell nuclear extracts, and purified PRA protein indicate that nuclear factors bind to a CACCC sequence at -139 and that PRA alters the pattern of transcription factor interaction with the CACCC sequence. Using a luciferase reporter construct containing base pairs -252 to +24 of the IGFBP-5 promoter, we found that both PRA and PRB isoforms mediated PG stimulation of promoter activity. These results suggest that PG may stimulate IGFBP-5 gene transcription via a novel mechanism involving PR and CACCC-binding factors.	Loma Linda Univ, JL Pettis VAMC, Musculoskeletal Dis Ctr, Res Serv 151, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Biochem, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Microbiol & Mol Genet, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Pediat, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Physiol, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Med, Loma Linda, CA 92357 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA	Loma Linda University; Loma Linda University; Loma Linda University; Loma Linda University; Loma Linda University; Loma Linda University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Linkhart, TA (corresponding author), Loma Linda Univ, JL Pettis VAMC, Musculoskeletal Dis Ctr, Res Serv 151, 11201 Benton St, Loma Linda, CA 92357 USA.	linkhart@llvamc.va.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031062] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 31062] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLANDER SV, 1994, J BIOL CHEM, V269, P10891; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; BAILLY A, 1986, EMBO J, V5, P3235, DOI 10.1002/j.1460-2075.1986.tb04634.x; Barengolts EI, 1996, J BONE MINER RES, V11, P1406; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; Bowman BM, 1996, J BONE MINER RES, V11, P15; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Campbell PG, 1997, AM J PHYSIOL-ENDOC M, V273, pE1005, DOI 10.1152/ajpendo.1997.273.5.E1005; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chevalley T, 1996, EUR J ENDOCRINOL, V134, P591, DOI 10.1530/eje.0.1340591; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN C, 1985, LANCET, V2, P800; Clemmons DR, 1998, MOL CELL ENDOCRINOL, V140, P19, DOI 10.1016/S0303-7207(98)00024-0; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG Y, 1995, ENDOCRINOLOGY, V136, P2000, DOI 10.1210/en.136.5.2000; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Franchimont N, 1997, ENDOCRINOLOGY, V138, P3380, DOI 10.1210/en.138.8.3380; FRIDOCICHKIEL JL, 1989, BIOTECHNIQUES, V5, P572; Gabbitas B, 1996, J BIOL CHEM, V271, P9033, DOI 10.1074/jbc.271.15.9033; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; Graham JD, 1995, J BIOL CHEM, V270, P30693, DOI 10.1074/jbc.270.51.30693; GRAHAM JD, 1995, CANCER RES, V55, P5063; Grey A, 1996, CLIN ENDOCRINOL, V44, P293, DOI 10.1046/j.1365-2265.1996.667488.x; HAYDEN JM, 1995, BONE, V17, pS93, DOI 10.1016/8756-3282(95)00186-H; Ishida Y, 1996, J BONE MINER RES, V11, P921; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KOU K, 1995, DNA CELL BIOL, V14, P241, DOI 10.1089/dna.1995.14.241; LAU KHW, 1994, J BONE MINER RES, V9, P695; LEMPERT UG, 1992, INT CONGR SER, V1003, P239; Leslie KK, 1997, ANN NY ACAD SCI, V828, P17, DOI 10.1111/j.1749-6632.1997.tb48520.x; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; MacNamara P, 1998, CALCIFIED TISSUE INT, V63, P39; Mallick S, 1997, DNA CELL BIOL, V16, P807, DOI 10.1089/dna.1997.16.807; McCarthy TL, 1996, J BIOL CHEM, V271, P6666, DOI 10.1074/jbc.271.12.6666; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Nasu M, 1998, ENDOCR J, V45, P229, DOI 10.1507/endocrj.45.229; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; Parker A, 1998, MOL BIOL CELL, V9, P2383, DOI 10.1091/mbc.9.9.2383; PRIOR JC, 1994, AM J MED, V96, P521, DOI 10.1016/0002-9343(94)90092-2; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEVEN BAA, 1992, BIOCHEM BIOPH RES CO, V186, P54, DOI 10.1016/S0006-291X(05)80774-0; Schmid C, 1996, AM J PHYSIOL-ENDOC M, V271, pE1029, DOI 10.1152/ajpendo.1996.271.6.E1029; Schrader W T, 1981, Recent Prog Horm Res, V37, P583; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHWEERS LA, 1990, J BIOL CHEM, V265, P7590; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SNOW GR, 1985, CALCIFIED TISSUE INT, V37, P282, DOI 10.1007/BF02554875; STRONG DD, 1991, J BONE MINER RES, V6, P15; SUKOVICH DA, 1994, MOL CELL BIOL, V14, P7134, DOI 10.1128/MCB.14.11.7134; Sunic D, 1998, ENDOCRINOLOGY, V139, P2356, DOI 10.1210/en.139.5.2356; Syvala H, 1997, BIOCHEM BIOPH RES CO, V231, P573, DOI 10.1006/bbrc.1997.6149; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TREMOLLIERES FA, 1992, ACTA ENDOCRINOL-COP, V126, P329, DOI 10.1530/acta.0.1260329; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; VERHAAR HJJ, 1994, BONE, V15, P307, DOI 10.1016/8756-3282(94)90293-3; Wang X, 1998, ENDOCRINOLOGY, V139, P1054, DOI 10.1210/en.139.3.1054; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; WEI L, 1993, BIOCHEM BIOPH RES CO, V195, P5215; WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yeh LCC, 1998, J CELL PHYSIOL, V175, P78, DOI 10.1002/(SICI)1097-4652(199804)175:1<78::AID-JCP9>3.0.CO;2-9; Zhou YH, 1996, ENDOCRINOLOGY, V137, P975, DOI 10.1210/en.137.3.975	84	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26431	26438		10.1074/jbc.274.37.26431	http://dx.doi.org/10.1074/jbc.274.37.26431			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473602	hybrid			2022-12-25	WOS:000082469700068
J	Dukan, S; Nystrom, T				Dukan, S; Nystrom, T			Oxidative stress defense and deterioration of growth-arrested Escherichia coli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SUPEROXIDE-DISMUTASE; PROTEIN OXIDATION; LIFE-SPAN; SURVIVAL; HEAT; RESISTANCE; REGULATOR; ELECTROPHORESIS; IDENTIFICATION	Analysis of protein carbonylation demonstrates that the stasis-induced catalases and cytoplasmic superoxide dismutases (SOD) have a role in preventing accelerated protein oxidation during growth arrest of Escherichia coli cells. A larger number of proteins are carbonylated in cells lacking cytoplasmic SOD compared with cells lacking catalases, OxyR, or RpoS which, in turn, exhibit a larger number of oxidized proteins than the wild-type parent. Proteins exclusively oxidized during stasis in mutants lacking cytoplasmic SOD include GroEL, EF-G, and the acidic isoform of H-NS indicating that these mutants experience problems in peptide elongation and maintaining protein and DNA architecture. These mutants also survive stasis poorly. Likewise, but to a much lesser extent, mutations in oxyR, an oxidative stress regulator, shorten the life-span of stationary phase cells. The low plating efficiency of cells lacking OxyR is the result of their inability to grow on standard culture plates unless plating is performed anaerobically or with high concentration of catalase, In contrast, cells lacking cytoplasmic SOD appear to die prior to plating. Our data points to the importance of oxidative stress defense in stasis survival, and we also demonstrate that the lifespan of growth-arrested wild-type E. coli cells can be significantly extended by omitting oxygen.	Univ Gothenburg, Dept Cell & Mol Biol Microbiol, S-40530 Gothenburg, Sweden; Univ Lund, Dept Microbiol, S-22362 Lund, Sweden	University of Gothenburg; Lund University	Nystrom, T (corresponding author), CNRS, Lab Microbiol Marine, UPR 223, Campus Luminy Case 907-163,Ave Luminy, F-13288 Marseille 9, France.							BENOV L, 1995, ARCH BIOCHEM BIOPHYS, V322, P291, DOI 10.1006/abbi.1995.1465; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; Dukan S, 1998, GENE DEV, V12, P3431, DOI 10.1101/gad.12.21.3431; EISENSTARK A, 1992, BIOCHEM BIOPH RES CO, V188, P1054, DOI 10.1016/0006-291X(92)91338-Q; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GonzalezFlecha B, 1997, J BACTERIOL, V179, P382, DOI 10.1128/jb.179.2.382-388.1997; HUISMAN GW, 1996, ESCHERICHIA COLI SAL, P1672; JENKINS DE, 1988, J BACTERIOL, V170, P3910, DOI 10.1128/jb.170.9.3910-3914.1988; JENKINS DE, 1991, J BACTERIOL, V173, P1992, DOI 10.1128/jb.173.6.1992-1996.1991; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; LOEWEN PC, 1985, ARCH BIOCHEM BIOPHYS, V243, P144, DOI 10.1016/0003-9861(85)90782-9; LOEWEN PC, 1984, J BACTERIOL, V160, P668, DOI 10.1128/JB.160.2.668-675.1984; MATIN A, 1991, MOL MICROBIOL, V5, P3, DOI 10.1111/j.1365-2958.1991.tb01819.x; Miller J.H., 1972, EXPT MOL GENETICS; Murakami S, 1998, CURR BIOL, V8, P1091, DOI 10.1016/S0960-9822(98)70448-8; Nakamura A, 1996, J BIOCHEM, V119, P768; Nystrom T, 1996, EMBO J, V15, P3219, DOI 10.1002/j.1460-2075.1996.tb00686.x; NYSTROM T, 1994, MOL MICROBIOL, V11, P537, DOI 10.1111/j.1365-2958.1994.tb00334.x; Nystrom T, 1998, FEMS MICROBIOL REV, V21, P283, DOI 10.1111/j.1574-6976.1998.tb00354.x; NYSTROM T, 1994, MOL MICROBIOL, V12, P833, DOI 10.1111/j.1365-2958.1994.tb01069.x; Nystrom Thomas, 1995, Trends in Microbiology, V3, P131, DOI 10.1016/S0966-842X(00)88901-5; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; VANBOGELEN RA, 1990, ELECTROPHORESIS, V11, P1131, DOI 10.1002/elps.1150111205; VANBOGELEN RA, 1996, ESCHERICHIA COLI SAL, P2067; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	34	184	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26027	26032		10.1074/jbc.274.37.26027	http://dx.doi.org/10.1074/jbc.274.37.26027			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473549	hybrid			2022-12-25	WOS:000082469700015
J	Gross, S; Knebel, A; Tenev, T; Neininger, A; Gaestel, M; Herrlich, P; Bohmer, FD				Gross, S; Knebel, A; Tenev, T; Neininger, A; Gaestel, M; Herrlich, P; Bohmer, FD			Inactivation of protein-tyrosine phosphatases as mechanism of UV-induced signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PDGF-BETA-RECEPTOR; KINASE-ACTIVITY; PHOSPHOTYROSINE PHOSPHATASE; PHOSPHORYLATION SITE; INSULIN-RECEPTOR; EGF RECEPTOR; INTACT-CELLS; SH2 DOMAIN; ACTIVATION	UV irradiation of cells causes ligand-independent activation of receptor tyrosine kinases. On the basis of dephosphorylation kinetics, UV-induced inactivation of receptor-directed tyrosine phosphatases (PTP) has been proposed as the mechanism of receptor activation (Knebel, A., Rahmsdorf, H. J., Ullrich, A., and Herrlich, P. (1996) EMBO J, 15, 5314-5325), Here we show that four defined protein-tyrosine phosphatases (PTPs), SHP-1, RPTP alpha, RPTP sigma and DEP-1, are partially inactivated upon UV irradiation of PTP-overexpressing cells. The dephosphorylation of coexpressed platelet-derived growth factor beta (PDGF beta) receptor by RPTP alpha is inhibited upon UV irradiation. UV converts RPTP alpha into a substrate-trapping enzyme which can coprecipitate PDGF beta receptor, similarly to the PTP mutant at the active-center cysteine: C433S. In agreement with the proposed mechanism that inactivation of PTPs accounts for receptor tyrosine kinase activation, no evidence for a UV-induced receptor cross-linking could be obtained in PDGF beta receptor-enriched membrane micelle preparations and in PDGF beta receptor overexpressing 293 cells. The intrinsic activity of PDGF beta receptor kinase was required for the UV-induced enhancement of receptor phosphorylation, but was not changed upon UV irradiation. The data support a mechanism of UV-induced signal transduction involving inactivation of PTPs through an unknown reactive intermediate that oxidizes the conserved cysteine in the active sites of PTPs.	Univ Jena, Klinikum, Res Unit Mol Cell Biol, D-76344 Jena, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76344 Eggenstein Leopoldshafen, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Univ Halle Wittenberg, Innovat Skolleg Zellspezialiseirung, D-06120 Halle, Germany	Friedrich Schiller University of Jena; Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Martin Luther University Halle Wittenberg	Bohmer, FD (corresponding author), Univ Jena, Fac Med, Res Unit Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.	i5frbo@rz.uni-jena.de	Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652; Knebel, Axel/0000-0002-9197-6054; Tenev, Tencho/0000-0001-8762-1069				Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; COFFER PJ, 1995, ONCOGENE, V11, P561; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HEIDIN CH, 1995, CELL, V80, P213; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Herrlich P, 1999, CR ACAD SCI III-VIE, V322, P121, DOI 10.1016/S0764-4469(99)80033-X; Herrlich P, 1997, BIOL CHEM, V378, P1217; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kovalenko M, 1997, BIOCHEMISTRY-US, V36, P6260, DOI 10.1021/bi962553l; KOVALENKO M, 1994, CANCER RES, V54, P6106; Kulas DT, 1996, J BIOL CHEM, V271, P755, DOI 10.1074/jbc.271.2.755; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Lammers R, 1997, FEBS LETT, V404, P37, DOI 10.1016/S0014-5793(97)00080-X; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; OGATA M, 1994, J IMMUNOL, V153, P4478; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; TOMASKA L, 1993, J BIOL CHEM, V268, P5317; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Waltenberger J, 1999, CIRC RES, V85, P12; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; Zipser Y, 1997, FEBS LETT, V406, P126, DOI 10.1016/S0014-5793(97)00263-9	56	141	142	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26378	26386		10.1074/jbc.274.37.26378	http://dx.doi.org/10.1074/jbc.274.37.26378			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473595	hybrid			2022-12-25	WOS:000082469700061
J	Kim, YH; Park, TJ; Lee, YH; Baek, KJ; Suh, PG; Ryu, SH; Kim, KT				Kim, YH; Park, TJ; Lee, YH; Baek, KJ; Suh, PG; Ryu, SH; Kim, KT			Phospholipase C-delta 1 is activated by capacitative calcium entry that follows phospholipase C-beta activation upon bradykinin stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; PC12 CELLS; BINDING PROTEINS; RECEPTORS; GAMMA; ISOZYMES; G(H); HETEROGENEITY; PURIFICATION; HYDROLYSIS	To characterize the regulatory mechanism of phospholipase C-delta 1 (PLC-delta 1) in the bradykinin (BK) receptor-mediated signaling pathway, we used a clone of PC12 cells, which stably overexpress PLC-delta 1 (PC12-D1). Stimulation with BK induced a significantly higher Ca2+ elevation and inositol 1,4,5-trisphosphate (IP3) production with a much lower half-maximal effective concentration (EC50) of BK in PC12-D1 cells than in wild type (PC12-W) or vector-transfected (PC12-V) cells. However, BK-induced intracellular Ca2+ release and IF, generation was similar between PC12-V and PC12-D1 cells in the absence of extracellular Ca2+, suggesting that the availability of extracellular Ca2+ is essential to the activation of PLC-delta 1. When PC12-D1 cells were treated with agents that induce Ca2+ influx, more IP3 was produced, suggesting that the Ca2+ entry induces IP3 production in PC12-D1 cells. Furthermore, the additional IP3 production after BK-induced capacitative calcium entry was detected in PC12-D1 cells, suggesting that PLC-delta 1 is mainly activated by capacitative calcium entry. When cells were stimulated with BK in the presence of extracellular Ca2+, [H-3]norepinephrine secretion was much greater from PC12-D1 cells than from PC12-V cells. Our results suggest that PLC-delta 1 is activated by capacitative calcium entry following the activation of PLC-P, additively inducing IF, production and Ca2+ rise in BK-stimulated PC12 cells.	POSTECH, Dept Life Sci, Pohang 790784, South Korea; Chung Ang Univ, Coll Med, Dept Biochem, Seoul 156756, South Korea	Pohang University of Science & Technology (POSTECH); Chung Ang University; Chung Ang University Hospital	Kim, KT (corresponding author), POSTECH, Dept Life Sci, San 31,Hyoja Dong, Pohang 790784, South Korea.		Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048; KIM, KYONG-TAI/0000-0001-7292-2627				Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BANNO Y, 1993, BIOCHEM J, V292, P401, DOI 10.1042/bj2920401; BANNO Y, 1994, J BIOL CHEM, V269, P15846; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOEGE F, 1991, EUR J BIOCHEM, V199, P1, DOI 10.1111/j.1432-1033.1991.tb16085.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; COCKCROFT S, 1992, BIOCHEM J, V288, P1; EBERHARD DA, 1988, TRENDS NEUROSCI, V11, P517, DOI 10.1016/0166-2236(88)90174-9; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIM UH, 1991, J BIOL CHEM, V266, P1359; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee H, 1997, J BIOL CHEM, V272, P21831, DOI 10.1074/jbc.272.35.21831; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LINSE K, 1988, J BIOL CHEM, V263, P15205; MARTIN TFJ, 1991, BIOCHEM J, V280, P753, DOI 10.1042/bj2800753; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIRAGLIA CC, 1985, ANAL BIOCHEM, V144, P165, DOI 10.1016/0003-2697(85)90099-5; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Ogino Y, 1996, EUR J PHARMACOL, V316, P105, DOI 10.1016/S0014-2999(96)00653-X; Park ES, 1998, BIOCHEM J, V331, P283, DOI 10.1042/bj3310283; Park TJ, 1997, J NEUROCHEM, V68, P2177; Park TJ, 1996, J NEUROCHEM, V66, P83; Park TJ, 1998, SYNAPSE, V29, P248, DOI 10.1002/(SICI)1098-2396(199807)29:3<248::AID-SYN7>3.0.CO;2-6; RENARD DC, 1992, BIOCHEM J, V281, P775, DOI 10.1042/bj2810775; RHEE SG, 1991, BIOCHEM SOC T, V19, P337, DOI 10.1042/bst0190337; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUH BC, 1995, J NEUROCHEM, V64, P1071; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WATSON S, 1994, G PROTEIN LINKED REC, P372	42	106	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26127	26134		10.1074/jbc.274.37.26127	http://dx.doi.org/10.1074/jbc.274.37.26127			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473563	hybrid, Green Published			2022-12-25	WOS:000082469700029
J	Champagne, N; Bertos, NR; Pelletier, N; Wang, AH; Vezmar, M; Yang, Y; Heng, HH; Yang, XJ				Champagne, N; Bertos, NR; Pelletier, N; Wang, AH; Vezmar, M; Yang, Y; Heng, HH; Yang, XJ			Identification of a human histone acetyltransferase related to monocytic leukemia zinc finger protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; TRANSCRIPTIONAL REGULATION; DOSAGE COMPENSATION; YEAST GCN5P; HUMAN GENES; CHROMATIN; ACETYLATION; CBP; COMPLEX; ACTIVATION	We describe here the identification and functional characterization of a novel human histone acetyltransferase, termed MORF (monocytic leukemia zinc finger protein-related factor). MORF is a 1781-residue protein displaying significant sequence similarity to MOZ (monocytic leukemia zinc finger protein). MORF is ubiquitously expressed in adult human tissues, and its gene is located at human chromosome band 10q22. MORF has intrinsic histone acetyltransferase activity. in addition to its histone acetyltransferase domain, MORF possesses a strong transcriptional repression domain at its N terminus and a highly potent activation domain at its C terminus. Therefore, MORF is a novel histone acetyltransferase that contains multiple functional domains and may be involved in both positive and negative regulation of transcription.	McGill Univ, Dept Med, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; York Univ, Dept Biol, N York, ON M3J 1P3, Canada	McGill University; York University - Canada	Yang, XJ (corresponding author), Royal Victoria Hosp, Mol Oncol Grp, Rm H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	yangxj@lan1.molonc.mcgill.ca						AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ariyasu T, 1998, Hum Cell, V11, P43; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu WG, 1998, DEV GENET, V22, P56, DOI 10.1002/(SICI)1520-6408(1998)22:1<56::AID-DVG6>3.0.CO;2-6; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; HORIUCHI K, 1975, ANAL BIOCHEM, V69, P491, DOI 10.1016/0003-2697(75)90151-7; Hovey RM, 1998, CANCER RES, V58, P3555; Howe L, 1998, J BIOL CHEM, V273, P20693, DOI 10.1074/jbc.273.33.20693; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; Lucchesi JC, 1998, CURR OPIN GENET DEV, V8, P179, DOI 10.1016/S0959-437X(98)80139-1; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Rowley JD, 1997, BLOOD, V90, P535; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tse C, 1998, J BIOL CHEM, V273, P32388, DOI 10.1074/jbc.273.49.32388; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; van Holde KE., 1989, SPRINGER SERIES MOL; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Wolffe A., 1995, CHROMATIN STRUCTURE; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	60	120	130	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28528	28536		10.1074/jbc.274.40.28528	http://dx.doi.org/10.1074/jbc.274.40.28528			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497217	hybrid			2022-12-25	WOS:000082912700066
J	Huggins, GS; Chin, MT; Sibinga, NES; Lee, SL; Haber, E; Lee, ME				Huggins, GS; Chin, MT; Sibinga, NES; Lee, SL; Haber, E; Lee, ME			Characterization of the mUBC9-binding sites required for E2A protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; LOOP-HELIX PROTEINS; KAPPA-B-ALPHA; CELL DEVELOPMENT; C-JUN; SACCHAROMYCES-CEREVISIAE; PROTEASOME PATHWAY; MAMMALIAN-CELLS; DNA-BINDING; GENE	Mammalian Ubc9 (mUbc9) is required for rapid degradation of the E2A proteins E12 and E47 by the ubiquitin-proteasome system. We have shown elsewhere that mUbc9 interacts with amino acids 477-530 of E12/E47. Here we test the hypothesis that this region, rich in proline, glutamic acid, serine, and threonine (PEST) residues, serves as the E2A protein degradation domain (DD), An E2A protein lacking this region, E47 Delta(478-531), was significantly more stable than wild-type E47(half-life of more than 6 h versus 55 min). Deletion of the E2A DD had no effect on the E-box-binding and transcriptional activity of E47, We mapped two discreet mUbc9-interacting regions within the E2A DD: amino acids 476-494 and 505-513. E2A(505-513) interacted with mUbc9 but not with human Ubc5, MyoD, ids, or the polymyositis-scleroderma autoantigen, Substitution of the E2A(505-513) central hydrophobic residues with basic residues abolished interaction with mUbc9, Also, full-length E47 lacking the second mUbc9-interacting region was significantly more stable than wild-type E47, Reintroduction of the E2A DD into the long-lived, naturally occurring chimeric oncoprotein E2A-HLF (hepatic leukemic factor) destabilized it, suggesting that this domain can transfer a degradation signal to a heterologous protein. E2A-HLF-DD chimeric protein was stabilized by the proteasome inhibitor LLNL, indicating the role of the ubiquitin-proteasome system mediating degradation through the E2A degradation domain. Our experiments indicate that the E2A DD mediates E2A protein interactions with the ubiquitin-proteasome system and that the E2A DD is required for metabolism of these widely expressed proteins.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiac Unit, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Lee, ME (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.		Sibinga, Nicholas/GOJ-8544-2022	Sibinga, Nicholas/0000-0003-4838-910X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003667] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL03667-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; Gilon T, 1998, EMBO J, V17, P2759, DOI 10.1093/emboj/17.10.2759; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Haas AL, 1997, FASEB J, V11, P1257; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Honda H, 1999, BLOOD, V93, P2780; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; Kho CJ, 1997, J BIOL CHEM, V272, P13426, DOI 10.1074/jbc.272.20.13426; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Loveys DA, 1997, GENE, V201, P169, DOI 10.1016/S0378-1119(97)00444-7; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; Massari ME, 1996, MOL CELL BIOL, V16, P121; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; SADIS S, 1995, MOL CELL BIOL, V15, P4086; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; Zhuang YA, 1998, MOL CELL BIOL, V18, P3340, DOI 10.1128/MCB.18.6.3340	51	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28690	28696		10.1074/jbc.274.40.28690	http://dx.doi.org/10.1074/jbc.274.40.28690			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497239	hybrid			2022-12-25	WOS:000082912700088
J	Jaworski, J; Biedermann, IW; Lapinska, J; Szklarczyk, A; Figiel, I; Konopka, D; Nowicka, D; Filipkowski, RK; Hetman, M; Kowalczyk, A; Kaczmarek, L				Jaworski, J; Biedermann, IW; Lapinska, J; Szklarczyk, A; Figiel, I; Konopka, D; Nowicka, D; Filipkowski, RK; Hetman, M; Kowalczyk, A; Kaczmarek, L			Neuronal excitation-driven and AP-1-dependent activation of tissue inhibitor of metalloproteinases-1 gene expression in rodent hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; CHONDROITIN SULFATE PROTEOGLYCAN; VISUAL-CORTEX; RAT-BRAIN; MATRIX METALLOPROTEINASES; TRANSCRIPTION FACTORS; INDUCED SEIZURES; NERVOUS-SYSTEM; CELL-DEATH; AP-1	Understanding of biological function of AP-1 transcription factor in central nervous system may greatly benefit from identifying its target genes. In this study, we present several lines of evidence implying A9-1 in regulating expression of tissue inhibitor of metalloproteinases-l (timp-1) gene in rodent hippocampus in response to increased neuronal excitation. Such a notion is supported by the findings that timp-1 mRNA accumulation occurs in the rat hippocampus after either kainate- or pentylenetetrazole-evoked seizures with a delayed, in comparison with AP-1 components, time course, as well as with spatial overlap with c-Fos protein (major inducible AP-1 component) expression. Furthermore, AP-1 sequence derived from timp-1 promoter is specifically bound by hippocampal AP-1 proteins after treating the rats with either pro-convulsive agent. Finally, timp-1 promoter responds to excitatory activation both in vivo, in transgenic mice harboring the timp-LacZ gene construct, and in vitro in neurons of the hippocampal dentate gyrus cultures, These findings suggest that the AP-1 transcription factor may exert its role in the brain through affecting extracellular matrix remodeling.	M Nencki Inst Expt Biol, Mol Neurobiol Lab, PL-02093 Warsaw, Poland; Med Res Ctr, PL-02106 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Kaczmarek, L (corresponding author), M Nencki Inst Expt Biol, Mol Neurobiol Lab, Pasteura 3, PL-02093 Warsaw, Poland.		Kaczmarek, Leszek/AHA-0076-2022; Konopka-Postupolska, Dorota M/H-1916-2012; Konopka-Postupolska, Dorota/AAE-9134-2020; Kaczmarek, Leszek/B-6171-2008	Kaczmarek, Leszek/0000-0002-7207-3490; Kaczmarek, Leszek/0000-0002-7207-3490; Figiel, Izabela/0000-0001-5028-0168; Jaworski, Jacek/0000-0001-8760-7865; Nowicka, Dorota/0000-0001-9999-0793; Konopka-Postupolska, Dorota/0000-0002-3181-5478; Dzwonek, Joanna/0000-0002-3834-2175				Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Doyle GAR, 1997, BIOCHEMISTRY-US, V36, P2492, DOI 10.1021/bi962161e; Figiel I, 1997, NEUROCHEM INT, V31, P229, DOI 10.1016/S0197-0186(96)00152-0; FILIPKOWSKI RK, 1994, NEUROREPORT, V51, P538; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; Gorecki DC, 1998, NEUROSCIENCE, V84, P467, DOI 10.1016/S0306-4522(97)00562-9; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HETMAN M, 1995, EXP NEUROL, V136, P53, DOI 10.1006/exnr.1995.1083; HUGHES P, 1995, PHARMACOL REV, V47, P133; Inoue A, 1997, SCIENCE, V276, P1428, DOI 10.1126/science.276.5317.1428; Kaczmarek L, 1997, BRAIN RES REV, V23, P237, DOI 10.1016/S0165-0173(97)00005-2; KAMINSKA B, 1994, EUR J NEUROSCI, V6, P1558, DOI 10.1111/j.1460-9568.1994.tb00546.x; Kaminska B, 1997, ACTA BIOCHIM POL, V44, P781, DOI 10.18388/abp.1997_4382; Kaminska B, 1996, J NEUROSCI, V16, P3968; Konopka D, 1998, NEUROSCIENCE, V86, P499, DOI 10.1016/S0306-4522(98)00046-3; KONOPKA D, 1995, NEUROSCI LETT, V185, P167, DOI 10.1016/0304-3940(95)11252-R; Lander C, 1997, J NEUROSCI, V17, P1928; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; LUKASIUK K, 1994, BRAIN RES, V643, P227, DOI 10.1016/0006-8993(94)90029-9; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Muller CM, 1998, NAT NEUROSCI, V1, P47, DOI 10.1038/248; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; Patton BL, 1998, NATURE, V393, P698, DOI 10.1038/31502; PRZEWLOCKI R, 1995, NEUROSCIENCE, V68, P73, DOI 10.1016/0306-4522(95)00144-8; Rivera S, 1997, J NEUROSCI, V17, P4223; RIVERA S, 1999, IN PRESS ADV SYNOPTI; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yamada H, 1997, J NEUROSCI, V17, P7784; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Zuo J, 1998, J NEUROSCI, V18, P5203, DOI 10.1523/JNEUROSCI.18-14-05203.1998	37	62	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28106	28112		10.1074/jbc.274.40.28106	http://dx.doi.org/10.1074/jbc.274.40.28106			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497161	hybrid			2022-12-25	WOS:000082912700010
J	Matthias, A; Jacobsson, A; Cannon, B; Nedergaard, J				Matthias, A; Jacobsson, A; Cannon, B; Nedergaard, J			The bioenergetics of brown fat mitochondria from UCP1-ablated mice - UCP1 is not involved in fatty acid-induced de-energization ("uncoupling")	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE MITOCHONDRIA; PROTON CONDUCTANCE; PHYSIOLOGICAL REGULATION; MOLECULAR-CLONING; PROTEIN HOMOLOG; RAT-LIVER; EXPRESSION; HAMSTER; RESPIRATION; TRANSPORT	The bioenergetics of brown fat mitochondria isolated from UCP1-ablated mice were investigated. The mitochondria had lost the high GDP-binding capacity normally found in brown fat mitochondria, and they were innately in an energized state, in contrast to wild-type mitochondria, GDP, which led to energization of wildtype mitochondria, was without effect on the brown fat mitochondria from UCP1-ablated mice. The absence of thermogenic function did not result in reintroduction of high ATP synthase activity. Remarkably and unexpectedly, the mitochondria from UCP1-ablated mice were as sensitive to the de-energizing ("uncoupling") effect of free fatty acids as were UCP1-containing mitochondria. Therefore, the de-energizing effect of free fatty acids does not appear to be mediated via UCP1, and free fatty acids would not seem to be the intracellular physiological activator involved in mediation of the thermogenic signal from the adrenergic receptor to UCP1. In the UCP1-ablated mice, Ucp2 mRNA levels in brown adipose tissue were 14-fold higher and Ucp3 mRNA levels were marginally lower than in wild-type. The Ucp2 and Ucp3 mRNA levels were therefore among the highest found in any tissue. These high mRNA levels did not confer on the isolated mitochondria any properties associated with de-energization. Thus, the mere observation of a high level of Ucp2 or Ucp3 mRNA in a tissue cannot be taken as an indication that mitochondria isolated from that tissue will display innate de-energization or thermogenesis.	Stockholm Univ, Arrhenius Lab, Wenner Gren Inst, SE-10691 Stockholm, Sweden	Stockholm University	Nedergaard, J (corresponding author), Stockholm Univ, Arrhenius Lab, Wenner Gren Inst, F3, SE-10691 Stockholm, Sweden.	jan@metabol.su.se	Nedergaard, Jan/A-1706-2010; Nedergaard, Jan/Q-8286-2019; Cannon, Barbara/B-3089-2016	Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587				Andersson U, 1997, BIOCHEM J, V323, P379, DOI 10.1042/bj3230379; ARECHAGA I, 1993, BIOCHEM J, V296, P693, DOI 10.1042/bj2960693; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; CANNON B, 1984, BIOCHIM BIOPHYS ACTA, V766, P483, DOI 10.1016/0005-2728(84)90264-0; Cannon B, 1999, PROG OBES R, P13; CANNON B, 1977, FEBS LETT, V74, P43, DOI 10.1016/0014-5793(77)80748-5; Cannon B, 1979, Methods Enzymol, V55, P65; CANNON B, 1982, FEBS LETT, V150, P129, DOI 10.1016/0014-5793(82)81319-7; Cannon B., 1973, MECHANISMS BIOENERGE, P357; Carretero MV, 1998, FEBS LETT, V439, P55, DOI 10.1016/S0014-5793(98)01335-0; Chinet A, 1978, Experientia Suppl, V32, P25; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; FLEURY C, 1997, NEW PERSPECTIVES MIT; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gonzalez-Barroso MM, 1998, J BIOL CHEM, V273, P15528, DOI 10.1074/jbc.273.25.15528; Hidaka S, 1998, BBA-LIPID LIPID MET, V1389, P178, DOI 10.1016/S0005-2760(97)00188-4; HIMMSHAGEN J, 1992, OBESITY, P15; HOUSTEK J, 1990, BIOCHIM BIOPHYS ACTA, V1015, P441, DOI 10.1016/0005-2728(90)90077-H; HOUSTEK J, 1995, J BIOL CHEM, V270, P7689, DOI 10.1074/jbc.270.13.7689; JACOBSSON A, 1994, AM J PHYSIOL-REG I, V267, pR999, DOI 10.1152/ajpregu.1994.267.4.R999; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; JENNINGS G, 1986, COMP BIOCHEM PHYS A, V85, P583, DOI 10.1016/0300-9629(86)90451-2; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; JOEL CD, 1967, BIOCHEM BIOPH RES CO, V29, P490, DOI 10.1016/0006-291X(67)90510-4; KATIYAR SS, 1991, BIOCHEM BIOPH RES CO, V175, P1104, DOI 10.1016/0006-291X(91)91679-7; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; KOZAK LP, 1991, GENE DEV, V5, P2256, DOI 10.1101/gad.5.12a.2256; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; LANOUE KF, 1982, J BIOL CHEM, V257, P13740; Larrouy D, 1997, BIOCHEM BIOPH RES CO, V235, P760, DOI 10.1006/bbrc.1997.6852; LOCKE RM, 1982, EUR J BIOCHEM, V129, P373, DOI 10.1111/j.1432-1033.1982.tb07060.x; LOCKE RM, 1981, FEBS LETT, V135, P249, DOI 10.1016/0014-5793(81)80793-4; Maia IG, 1998, FEBS LETT, V429, P403, DOI 10.1016/S0014-5793(98)00634-6; Matthias P, 1998, SEMIN IMMUNOL, V10, P155, DOI 10.1006/smim.1998.0117; Monemdjou S, 1999, AM J PHYSIOL-ENDOC M, V276, pE1073, DOI 10.1152/ajpendo.1999.276.6.E1073; MONEMDJOU S, 1997, OBES RES S, V5, pS26; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; NEDERGAARD J, 1983, EUR J BIOCHEM, V133, P185, DOI 10.1111/j.1432-1033.1983.tb07446.x; NEDERGAARD J, 1987, EUR J BIOCHEM, V164, P681, DOI 10.1111/j.1432-1033.1987.tb11180.x; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NICHOLLS DG, 1977, EUR J BIOCHEM, V75, P601, DOI 10.1111/j.1432-1033.1977.tb11560.x; NICHOLLS DG, 1972, EUR J BIOCHEM, V31, P526, DOI 10.1111/j.1432-1033.1972.tb02561.x; PRUSINER SB, 1968, EUR J BIOCHEM, V7, P51, DOI 10.1111/j.1432-1033.1968.tb19572.x; RAFAEL J, 1969, H-S Z PHYSIOL CHEM, V350, P1121, DOI 10.1515/bchm2.1969.350.2.1121; Reed T. B., 1968, Journal of Crystal Growth, V2, P243, DOI 10.1016/0022-0248(68)90008-0; RIAL E, 1983, EUR J BIOCHEM, V137, P197, DOI 10.1111/j.1432-1033.1983.tb07815.x; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; Ricquier D, 1997, PROG NUCLEIC ACID RE, V56, P83, DOI 10.1016/S0079-6603(08)61003-X; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Sanchis D, 1998, J BIOL CHEM, V273, P34611, DOI 10.1074/jbc.273.51.34611; STRIELEMAN PJ, 1985, J BIOL CHEM, V260, P3402; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WINKLER E, 1994, J BIOL CHEM, V269, P2508; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; YACOE ME, 1981, BIOCHEM J, V194, P653, DOI 10.1042/bj1940653	67	96	100	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28150	28160		10.1074/jbc.274.40.28150	http://dx.doi.org/10.1074/jbc.274.40.28150			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497167	hybrid			2022-12-25	WOS:000082912700016
J	Saxon, ML; Lee, DC				Saxon, ML; Lee, DC			Mutagenesis reveals a role for epidermal growth factor receptor extracellular subdomain TV in ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-RECEPTOR; SIGNAL-TRANSDUCTION; ERBB RECEPTORS; BIOLOGICAL-ACTIVITIES; CELLULAR-RESPONSE; DISULFIDE BOND; ALPHA-BINDING; DOMAIN; ACTIVATION; HETERODIMERIZATION	The extracellular domain of the epidermal growth factor (EGF) receptor (EGFR) comprises four subdomains (I-IV) and mediates binding of several different poly-peptide ligands, including EGE, transforming growth factor-alpha, and heparin-binding EGF. Previous studies have predominantly implicated subdomain III in ligand binding. To investigate a possible role for sequences in subdomain IV, we constructed several mutant EGFRs in which clusters of charged or aromatic amino acids mere replaced with alanine. Analysis of stably transfected Chinese hamster ovary cells expressing mutant EGFRs confirmed that they were present on the cell surface at levels approaching that of the wild-type receptor. Although tyrosine phosphorylation of most mutants was markedly induced by EGF, a cluster mutation (mt25) containing four alanine substitutions in the span of residues 521-527 failed to respond. EGF-induced tyrosine phosphorylation of an alternative mutant (Delta EN) with amino acids 518-589 deleted was also greatly diminished. Larger doses of EGF or heparin-binding EGF induced only weak tyrosine phosphorylation of mt25, whereas the response to transforming growth factor-a was undetectable. These results suggest that mt25 might be defective with respect to either ligand binding or receptor dimerization, Quantitative analyses showed that binding of I-125-EGF to mt25 and Delta EN was reduced to near background levels, whereas binding of EGF to other cluster mutants was reduced 60-70% compared with wild-type levels. Among the mutants, only mt25 and Delta EN failed to form homodimers or to transphosphorylate HER2/Neu in response to EGF treatment. Collectively, our results are the first to provide direct evidence that discrete subdomain IV residues are required for normal binding of EGF family ligands, Significantly, they were obtained with the full-length receptor in vivo, rather than a soluble truncated receptor, which has been frequently used for structure/function studies of the EG;FR extracellular region.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Lee, DC (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Campus Box 7260, Chapel Hill, NC 27599 USA.	dclee@med.unc.edu			NCI NIH HHS [CA43793, CA69779-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA069779, R01CA043793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HARTE MT, 1995, ARCH BIOCHEM BIOPHYS, V322, P378, DOI 10.1006/abbi.1995.1478; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOHDA D, 1993, J BIOL CHEM, V268, P1976; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LAX I, 1991, J BIOL CHEM, V266, P13828; LAX I, 1990, CELL REGUL, V1, P173, DOI 10.1091/mbc.1.2.173; LEE DC, 1995, PHARMACOL REV, V47, P51; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; MORIAI T, 1994, P NATL ACAD SCI USA, V91, P10217, DOI 10.1073/pnas.91.21.10217; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; PARTIS MD, 1983, J PROTEIN CHEM, V2, P263, DOI 10.1007/BF01025358; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; QIAN XL, 1994, ONCOGENE, V9, P1507; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; SOROKIN A, 1995, ONCOGENE, V11, P1531; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WU DG, 1989, J BIOL CHEM, V264, P17469; WU DG, 1990, P NATL ACAD SCI USA, V87, P3151, DOI 10.1073/pnas.87.8.3151; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	52	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28356	28362		10.1074/jbc.274.40.28356	http://dx.doi.org/10.1074/jbc.274.40.28356			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497195	Green Published, hybrid			2022-12-25	WOS:000082912700044
J	Tjalsma, H; Zanen, G; Venema, G; Bron, S; van Dijl, JM				Tjalsma, H; Zanen, G; Venema, G; Bron, S; van Dijl, JM			The potential active site of the lipoprotein-specific (type II) signal peptidase of Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; TEMPORALLY CONTROLLED EXPRESSION; BACTERIUM MYCOPLASMA-PNEUMONIAE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; LSP GENE; CATALYTIC MECHANISM; RETROVIRAL PROTEASES; ASPARTIC PROTEASES; PROTEIN SECRETION	Type II signal peptidases (SPase II) remove signal peptides from lipid-modified preproteins of eubacteria. As the catalytic mechanism employed by type II SPases was not known, the present studies were aimed at the identification of their potential active site residues. Comparison of the deduced amino acid sequences of 19 known type II SPases revealed the presence of five conserved domains. The importance of the 15 best conserved residues in these domains was investigated using the type II SPase of Bacillus subtilis, which, unlike SPase II of Escherichia coli, is not essential for viability. The results showed that only six residues are important for SPase II activity. These are Asp-14, Asn-99, Asp-102, Asn-126, Ala-128, and Asp-129, Only Asp-14 was required for stability of SPase II, indicating that the other five residues are required for catalysis, the active site geometry, or the specific recognition of lipid-modified preproteins. As Asp-102 and Asp-129 are the only residues invoked in the known catalytic mechanisms of proteases, me hypothesize that these two residues are directly involved in SPase II-mediated catalysis, This implies that type II SPases belong to a novel family of aspartic proteases.	Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9750 AA Haren, Netherlands	University of Groningen	van Dijl, JM (corresponding author), Univ Groningen, Dept Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	j.m.van.dijl@farm.rug.nl	Tjalsma, Harold/I-7146-2012; van Dijl, Jan Maarten/G-1205-2013					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Bengtsson J, 1999, J BACTERIOL, V181, P685, DOI 10.1128/JB.181.2.685-688.1999; Bolhuis A, 1996, MOL MICROBIOL, V22, P605, DOI 10.1046/j.1365-2958.1996.d01-4676.x; BRON S, 1972, MUTAT RES, V15, P1, DOI 10.1016/0027-5107(72)90086-3; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DEV IK, 1984, J BIOL CHEM, V259, P1114; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GIAM CZ, 1984, EUR J BIOCHEM, V141, P331, DOI 10.1111/j.1432-1033.1984.tb08196.x; GOLDBLUM A, 1990, FEBS LETT, V261, P241, DOI 10.1016/0014-5793(90)80562-W; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; IDO E, 1991, J BIOL CHEM, V266, P24359; INNIS MA, 1984, P NATL ACAD SCI-BIOL, V81, P3708, DOI 10.1073/pnas.81.12.3708; INUKAI M, 1978, J ANTIBIOT, V31, P1203, DOI 10.7164/antibiotics.31.1203; ISAKI L, 1990, J BACTERIOL, V172, P469, DOI 10.1128/JB.172.1.469-472.1990; ISAKI L, 1990, J BACTERIOL, V172, P6512, DOI 10.1128/jb.172.11.6512-6517.1990; Kaneko T, 1996, DNA Res, V3, P109; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Liu HY, 1996, J MOL BIOL, V261, P454, DOI 10.1006/jmbi.1996.0476; Lory S, 1994, SIGNAL PEPTIDASES, P31; MEIJER WJJ, 1995, MOL MICROBIOL, V17, P621, DOI 10.1111/j.1365-2958.1995.mmi_17040621.x; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PEARL LH, 1987, NATURE, V328, P482, DOI 10.1038/328482b0; Pragai Z, 1997, MICROBIOL-UK, V143, P1327, DOI 10.1099/00221287-143-4-1327; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Pyrowolakis G, 1998, J BIOL CHEM, V273, P24792, DOI 10.1074/jbc.273.38.24792; RAO JKM, 1991, BIOCHEMISTRY-US, V30, P4663, DOI 10.1021/bi00233a005; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P105; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; SANKARAN K, 1994, SIGNAL PEPTIDASES, P17; Silva AM, 1996, J MOL BIOL, V255, P321, DOI 10.1006/jmbi.1996.0026; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; TOKUNAGA M, 1985, J BIOL CHEM, V260, P5610; TOKUNAGA M, 1998, P NATL ACAD SCI USA, V79, P2253; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; VONHEIJNE G, 1989, PROTEIN ENG, V2, P531, DOI 10.1093/protein/2.7.531; WEBER IT, 1989, SCIENCE, V243, P928, DOI 10.1126/science.2537531; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; WITKE C, 1995, FEMS MICROBIOL LETT, V126, P233, DOI 10.1016/0378-1097(95)00015-W; YAMAGATA H, 1982, J BACTERIOL, V152, P1163; ZHAO XJ, 1992, FEBS LETT, V299, P80, DOI 10.1016/0014-5793(92)80105-P	65	53	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28191	28197		10.1074/jbc.274.40.28191	http://dx.doi.org/10.1074/jbc.274.40.28191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497172	hybrid			2022-12-25	WOS:000082912700021
J	Uhde, I; Toman, A; Gross, I; Schwanstecher, C; Schwanstecher, M				Uhde, I; Toman, A; Gross, I; Schwanstecher, C; Schwanstecher, M			Identification of the potassium channel opener site on sulfonylurea receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; RAT ISOLATED AORTA; CELL LINE; BINDING; STOICHIOMETRY; SUBUNIT; GLIBENCLAMIDE; NUCLEOTIDES; MEMBRANE; CLONING	Diversity of sulfonylurea receptor (SUR) subunits underlies tissue specific pharmacology of K-ATP channels, which represent critical regulators of electrical activity in numerous cells. Notably, the neuronal/pancreatic P-cell receptor, SUR1, imparts high sensitivity to hypoglycemic sulfonylureas (SUs; e.g. glibenclamide) and low to potassium channel openers (KCOs; e.g. P1075), whereas the opposite drug sensitivities are conferred by cardiovascular receptors, SUR2A and SUR2B. By exchanging domains between SUR1 and SUR2B, we identify two regions (KCO I: Thr(1059)-Leu(1087) and KCO II: Arg(1218)-Asn(1320); rat SUR2 numbering) within the second set of transmembrane domains (TMDII) as critical for KCO binding. Swapping both regions reconstitutes KCO affinities and sensitivities of the donor SUR isoform. High glibenclamide affinity of SUR1 is not reduced by transfer of KCO I plus II from SUR2B, demonstrating that high SU and KCO affinity can coexist in the same SUR molecule. Consistently, high SU affinity was imparted on SUR2B by substituting the region separating KCO I and II (Ile(1088)-Val(1217)) with the corresponding domain of SUR1, We infer the receptor sites for KCOs and SUs to be closely associated within a regulatory domain (Thr(1059)-Asn(1320)) in TMDII of SURs.	Tech Univ Braunschweig, Inst Pharmakol & Toxikol, D-38106 Braunschweig, Germany	Braunschweig University of Technology	Schwanstecher, M (corresponding author), Tech Univ Braunschweig, Inst Pharmakol & Toxikol, Mendelssohnstr 1, D-38106 Braunschweig, Germany.							Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashfield R, 1999, DIABETES, V48, P1341, DOI 10.2337/diabetes.48.6.1341; Babenko AP, 1998, CIRC RES, V83, P1132, DOI 10.1161/01.RES.83.11.1132; Chutkow WA, 1996, DIABETES, V45, P1439, DOI 10.2337/diabetes.45.10.1439; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Dorschner H, 1999, MOL PHARMACOL, V55, P1060; EDWARDS G, 1993, ANNU REV PHARMACOL, V33, P597, DOI 10.1146/annurev.pa.33.040193.003121; Gribble FM, 1998, DIABETES, V47, P1412, DOI 10.2337/diabetes.47.9.1412; Hambrock A, 1998, BRIT J PHARMACOL, V125, P577, DOI 10.1038/sj.bjp.0702109; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Lawson K, 1996, PHARMACOL THERAPEUT, V70, P39, DOI 10.1016/0163-7258(96)00003-4; Loffler C, 1997, BRIT J PHARMACOL, V120, P476, DOI 10.1038/sj.bjp.0700919; Loffler-Walz C, 1998, N-S ARCH PHARMACOL, V357, P183, DOI 10.1007/PL00005153; Okuyama Y, 1998, PFLUG ARCH EUR J PHY, V435, P595, DOI 10.1007/s004240050559; QUAST U, 1993, MOL PHARMACOL, V43, P474; SCHWANSTECHER M, 1994, BRIT J PHARMACOL, V113, P903, DOI 10.1111/j.1476-5381.1994.tb17078.x; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; SCHWANSTECHER M, 1992, BRIT J PHARMACOL, V106, P295, DOI 10.1111/j.1476-5381.1992.tb14331.x; SCHWANSTECHER M, 1991, N-S ARCH PHARMACOL, V343, P83; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963	27	102	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28079	28082		10.1074/jbc.274.40.28079	http://dx.doi.org/10.1074/jbc.274.40.28079			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497157	hybrid			2022-12-25	WOS:000082912700006
J	Corson, LB; Folmer, J; Strain, JJ; Culotta, VC; Cleveland, DW				Corson, LB; Folmer, J; Strain, JJ; Culotta, VC; Cleveland, DW			Oxidative stress and iron are implicated in fragmenting vacuoles of Saccharomyces cerevisiae lacking Cu,Zn-superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; FE-S CLUSTER; OXYGEN RADICALS; 21-AMINOSTEROID U74006F; DNA-DAMAGE; IN-VIVO; YEAST; GENE; MUTANTS; CELL	The absence of the antioxidant enzyme Cu,Zn-superoxide dismutase (SOD1) is shown here to cause vacuolar fragmentation in Saccharomyces cerevisiae. Wild-type yeast have 1-3 large vacuoles whereas the sod1 Delta yeast have as many as 50 smaller vacuoles. Evidence that this fragmentation is oxygen-mediated includes the findings that aerobically (but not anaerobically) grown sod1 Delta yeast exhibit aberrant vacuoles and genetic suppressors of other oxygen-dependent sod1 null phenotypes rescue the vacuole defect. Surprisingly, iron also is implicated in the fragmentation process as iron addition exacerbates the sod1 Delta vacuole defect while iron starvation ameliorates it. Because the vacuole is reported to be a site of iron storage and iron reacts avidly with reactive oxygen species to generate toxic side products, we propose that vacuole damage in sod1 Delta cells arises from an elevation of iron-mediated oxidation within the vacuole or from elevated pools of "free" iron that may bind nonproductively to vacuolar ligands. Furthermore, additional pleiotropic phenotypes of sod1 Delta cells (including increased sensitivity to pH, nutrient deprivation, and metals) may be secondary to vacuolar compromise. Our findings support the hypothesis that oxidative stress alters cellular iron homeostasis which in turn increases oxidative damage. Thus, our findings may have medical relevance as both oxidative stress and alterations in iron homeostasis have been implicated in diverse human disease processes. Our findings suggest that strategies to decrease intracellular iron may significantly reduce oxidatively induced cellular damage.	Johns Hopkins Univ, Predoctoral Program Human Genet, Baltimore, MD 21205 USA; Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Johns Hopkins University; Ludwig Institute for Cancer Research; Johns Hopkins University; University of California System; University of California San Diego; University of California System; University of California San Diego	Cleveland, DW (corresponding author), Ludwig Inst Canc Res, 9500 Gilman Dr, La Jolla, CA 92032 USA.		Cleveland, Don/AAN-9783-2021	Corson, Laura/0000-0003-2772-3375; Cleveland, Don/0000-0002-1934-3682	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050016, R37GM050016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027036, R01NS027036] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50016] Funding Source: Medline; NINDS NIH HHS [NS 27036] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Achstetter T, 1985, Yeast, V1, P139, DOI 10.1002/yea.320010203; AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; ARCHIBALD FS, 1981, J BACTERIOL, V146, P928, DOI 10.1128/JB.146.3.928-936.1981; ARICHIBALD FS, 1982, ARCH BIOCHEM BIOPHYS, V214, P452; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BIEMOND P, 1984, J CLIN INVEST, V73, P1576, DOI 10.1172/JCI111364; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BILINSKI T, 1989, BIOCHIM BIOPHYS ACTA, V1001, P102, DOI 10.1016/0005-2760(89)90312-3; Bostek C C, 1989, AANA J, V57, P231; Brennan RJ, 1996, MUTAT RES-FUND MOL M, V356, P171, DOI 10.1016/0027-5107(96)00051-6; CHANG EC, 1989, J BIOL CHEM, V264, P12172; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; Fenton H., 1894, J CHEM SOC T, V65, P899, DOI [10.1039/CT8946500899, DOI 10.1039/CT8946500899]; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P644; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HALL ED, 1988, J NEUROSURG, V68, P462, DOI 10.3171/jns.1988.68.3.0462; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALLIWELL B, 1988, HUM TOXICOL, V7, P7, DOI 10.1177/096032718800700102; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HALLIWELL B, 1984, LANCET, V1, P1396; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; JONES EW, 1982, GENETICS, V102, P665; Kaiser C., 1994, METHODS YEAST GENETI; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LESAGE GD, 1986, J CLIN INVEST, V77, P90, DOI 10.1172/JCI112307; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIU XF, 1992, J BIOL CHEM, V267, P18298; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Murakami K, 1997, BIOCHEM MOL BIOL INT, V41, P481; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; Radisky DC, 1998, BIOCHEM J, V336, P201, DOI 10.1042/bj3360201; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wisnicka R, 1998, BIOCHEM MOL BIOL INT, V44, P635	60	53	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27590	27596		10.1074/jbc.274.39.27590	http://dx.doi.org/10.1074/jbc.274.39.27590			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488097	hybrid			2022-12-25	WOS:000082739100036
J	Ramilo, CA; Leveque, V; Guan, Y; Lepock, JR; Tainer, JA; Nick, HS; Silverman, DN				Ramilo, CA; Leveque, V; Guan, Y; Lepock, JR; Tainer, JA; Nick, HS; Silverman, DN			Interrupting the hydrogen bond network at the active site of human manganese superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TETRAMERIC INTERFACE; IRON; TYROSINE-34; PROTEIN; MUTANT	Histidine 30 in human manganese superoxide dismutase (MnSOD) is located at a site partially exposed to solvent with its side chain participating in a hydrogen-bonded network that includes the active-site residues Tyr(166) and Tyr(34) and extends to the manganese-bound solvent molecule. We have replaced His(30) with a series of amino acids and Tyr(166) With Phe in human MnSOD, The crystal structure of the mutant of MnSOD containing Asn(30) superimposed closely with the wild type, but the side chain of Asn(30) did not participate in the hydrogen-bonded network in the active site. The catalytic activity of a number of mutants with replacements at position 30 and for the mutant containing Phe(166) showed a 10-40-fold decrease in k(cat). This is the same magnitude of decrease in k(cat) obtained with the replacement of Tyr(34) by Phe, suggesting that interrupting the hydrogen-bonded active-site network at any of the sites of these three participants (His(30), Tyr(34) and Tyr(166)) leads to an equivalent decrease in k(cat) and probably less efficient proton transfer to product peroxide. The specific geometry of His(30) on the hydrogen bond network is essential for stability since the disparate mutations H30S, H30A, and H30Q reduce T-m by similar amounts (10-16 degrees C) compared with wild type.	Univ Florida, Ctr Hlth, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Waterloo, Dept Phys, Waterloo, ON N2L 3G1, Canada	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Scripps Research Institute; University of Waterloo	Silverman, DN (corresponding author), Univ Florida, Ctr Hlth, Dept Pharmacol & Therapeut, Box 100267, Gainesville, FL 32610 USA.		Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048495, R01GM054903] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39593] Funding Source: Medline; NIGMS NIH HHS [GM54903, GM48495] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BECK Y, 1988, BIO-TECHNOL, V6, P930, DOI 10.1038/nbt0888-930; Borders CL, 1998, BIOCHEMISTRY-US, V37, P11323, DOI 10.1021/bi980167t; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; Borgstahl GEO, 1996, BIOCHEMISTRY-US, V35, P4287, DOI 10.1021/bi951892w; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BULL C, 1991, J AM CHEM SOC, V113, P4069, DOI 10.1021/ja00011a003; BULL C, 1985, J AM CHEM SOC, V107, P3295, DOI 10.1021/ja00297a040; FEE JA, 1976, J BIOL CHEM, V251, P6157; Guan Y, 1998, BIOCHEMISTRY-US, V37, P4722, DOI 10.1021/bi972394l; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; Hsieh YS, 1998, BIOCHEMISTRY-US, V37, P4731, DOI 10.1021/bi972395d; Hsu JL, 1996, J BIOL CHEM, V271, P17687, DOI 10.1074/jbc.271.30.17687; Hunter T, 1997, BIOCHEMISTRY-US, V36, P4925, DOI 10.1021/bi9629541; Jackson SMJ, 1998, BIOMETALS, V11, P159, DOI 10.1023/A:1009238214394; LAH MS, 1995, BIOCHEMISTRY-US, V34, P1646, DOI 10.1021/bi00005a021; MCADAM ME, 1977, BIOCHEM J, V165, P71, DOI 10.1042/bj1650071; MCCLUNE GJ, 1978, BIOPHYS J, V24, P65, DOI 10.1016/S0006-3495(78)85340-5; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RABANI J, 1969, J PHYS CHEM-US, V73, P3736, DOI 10.1021/j100845a030; Sorkin DL, 1997, BIOCHEMISTRY-US, V36, P8202, DOI 10.1021/bi970533t; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; VALENTINE JS, 1975, J AM CHEM SOC, V97, P224, DOI 10.1021/ja00834a058; VANCE CK, 1999, THESIS J HOPKINS U B; Whittaker MM, 1997, BIOCHEMISTRY-US, V36, P8923, DOI 10.1021/bi9704212; [No title captured]	29	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27711	27716		10.1074/jbc.274.39.27711	http://dx.doi.org/10.1074/jbc.274.39.27711			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488113	hybrid			2022-12-25	WOS:000082739100052
J	Smith, JM; Katz, S; Mayer, BJ				Smith, JM; Katz, S; Mayer, BJ			Activation of the Abl tyrosine kinase in vivo by Src homology 3 domains from the Src homology 2/Src homology 3 adaptor Nck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; C-ABL; PROTEIN-BINDING; GENE-PRODUCT; SH3 DOMAIN; MONOCLONAL-ANTIBODIES; TRANSFORMING ABILITY; PHOSPHORYLATION; LOCALIZATION; STRESS	The nonreceptor tyrosine kinase c-Abl is tightly regulated in vivo, but the mechanisms that normally repress its activity are not well understood, We find that a construct encoding the first two Src homology 3 (SH3) domains of the Src homology 2/SH3 adaptor protein Nck can activate c-Abl in human 293T cells. A myristoylated Nck SH3 domain construct, which is expected to localize to membranes, potently activated Abl when expressed at low levels. An unmyristoylated Nck SH3 domain construct, which localizes to the cytosol and nucleus, also activated Abl but only at high levels of expression. Activation by both myristoylated and unmyristoylated Nck constructs required the C terminus of Abl; a C-terminally truncated form of Abl was not activated, although this construct could still be activated by deletion of its SH3 domain. Activation did not require the major binding sites in the Abl C terminus for Nck SH3 domains, however, suggesting that the mechanism of activation does not require direct binding to the C terminus. Activation of c-Abl by Nck SH3 domains provides a robust experimental system for analyzing the mechanisms that normally repress Abl activity and how that normal regulation can be perturbed.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Mayer, BJ (corresponding author), Childrens Hosp, Howard Hughes Med Inst, 320 Longwood Ave, Boston, MA 02115 USA.							Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PARK JW, 1992, J BIOL CHEM, V267, P17327; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; Raitano AB, 1997, BBA-REV CANCER, V1333, pF201, DOI 10.1016/S0304-419X(97)00023-1; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1995, ONCOGENE, V10, P1977; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	49	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27956	27962		10.1074/jbc.274.39.27956	http://dx.doi.org/10.1074/jbc.274.39.27956			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488144	hybrid			2022-12-25	WOS:000082739100083
J	Hocking, DC; Sottile, J; Reho, T; Fassler, R; McKeown-Longo, PJ				Hocking, DC; Sottile, J; Reho, T; Fassler, R; McKeown-Longo, PJ			Inhibition of fibronectin matrix assembly by the heparin-binding domain of vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; LYSOPHOSPHATIDIC ACID; ENDOTHELIAL-CELLS; PROTEIN-KINASE; ANTITHROMBIN-III; FOCAL ADHESIONS; CROSS-LINKING; S-PROTEIN; INTEGRIN; SITES	The deposition of fibronectin into the extracellular matrix is an integrin-dependent, multistep process that is tightly regulated in order to ensure controlled matrix deposition. Reduced fibronectin deposition has been associated with altered embryonic development, tumor cell invasion, and abnormal wound repair. In one of the initial steps of fibronectin matrix assembly, the aminoterminal region of fibronectin binds to cell surface receptors, termed matrix assembly sites. The present study was undertaken to investigate the role of extracellular signals in the regulation of fibronectin deposition. Our data indicate that the interaction of cells with the extracellular glycoprotein, vitronectin, specifically inhibits matrix assembly site expression and fibronectin deposition. The region of vitronectin responsible for the inhibition of fibronectin deposition was localized to the heparin-binding domain. Vitronectin's heparin-binding domain inhibited both beta(1) and non-beta(1) integrin-depend ent matrix assembly site expression and could be over come by treatment of cells with lysophosphatidic acid, an agent that promotes actin polymerization. The interaction of cells with the heparin-binding domain of vitronectin resulted in changes in actin microfilament organization and the subcellular distribution of the actin-associated proteins alpha-actinin and talin. These data suggest a mechanism whereby the heparin-binding domain of vitronectin regulates the deposition of fibronectin into the extracellular matrix through alterations in the organization of the actin cytoskeleton.	Albany Med Coll, Cell & Mol Biol Program, Albany, NY 12208 USA; Albany Med Coll, Dept Physiol & Cell Biol, Albany, NY 12208 USA; Univ Lund, Dept Expt Pathol, S-22185 Lund, Sweden	Albany Medical College; Albany Medical College; Lund University	McKeown-Longo, PJ (corresponding author), Albany Med Coll, Cell & Mol Biol Program, MC-165, Albany, NY 12208 USA.		Hocking, Denise/H-7903-2012	Hocking, Denise/0000-0003-2337-0357	NCI NIH HHS [CA-58626, CA-69612] Funding Source: Medline; NHLBI NIH HHS [HL-50549] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069612, R56CA058626, R01CA058626] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALLENHOFFMANN BL, 1987, J BIOL CHEM, V262, P14361; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; CHECOVICH WJ, 1993, ARTERIOSCLER THROMB, V13, P1662, DOI 10.1161/01.ATV.13.11.1662; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; Christopher RA, 1997, J CELL SCI, V110, P569; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; DANOWSKI BA, 1988, EXP CELL RES, V177, P47, DOI 10.1016/0014-4827(88)90024-9; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DELANNET M, 1994, DEVELOPMENT, V120, P2687; DZAMBA BJ, 1994, J BIOL CHEM, V269, P19646; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GLADSON CL, 1995, J CELL SCI, V108, P947; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HAYMAN EG, 1985, EXP CELL RES, V160, P245, DOI 10.1016/0014-4827(85)90173-9; Higuchi R., 1992, PCR TECHNOLOGY, P61; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; Hocking DC, 1998, J CELL BIOL, V141, P241, DOI 10.1083/jcb.141.1.241; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; Hynes RO, 1990, FIBRONECTINS, P335; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KOST C, 1992, J BIOL CHEM, V267, P12098; KOWALCZYK AP, 1990, BLOOD, V75, P2335; KOWALCZYK AP, 1992, J CELL PHYSIOL, V152, P126, DOI 10.1002/jcp.1041520117; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LERCH RA, 1993, NUCLEIC ACIDS RES, V21, P1753, DOI 10.1093/nar/21.8.1753; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher, 1989, FIBRONECTIN, P1; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MURPHYULLRICH JE, 1985, BLOOD, V66, P1098; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; Sambrook J., 2002, MOL CLONING LAB MANU; SEIFFERT D, 1995, DEV DYNAM, V203, P71, DOI 10.1002/aja.1002030108; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SOMERS CE, 1993, J BIOL CHEM, V268, P22277; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TOMASINIJOHANSSON BR, 1994, EXP CELL RES, V214, P303, DOI 10.1006/excr.1994.1262; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VOLKER W, 1993, J HISTOCHEM CYTOCHEM, V41, P1823, DOI 10.1177/41.12.7504009; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; WilkinsPort CE, 1996, BIOCHEM CELL BIOL, V74, P887, DOI 10.1139/o96-094; WOODS A, 1992, J CELL SCI, V101, P277; WU C, 1995, J CELL SCI, V108, P2155; Wu CY, 1996, CELL ADHES COMMUN, V4, P149, DOI 10.3109/15419069609014219; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yan SR, 1996, FEBS LETT, V380, P198; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhang QH, 1999, J BIOL CHEM, V274, P368, DOI 10.1074/jbc.274.1.368; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	72	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27257	27264		10.1074/jbc.274.38.27257	http://dx.doi.org/10.1074/jbc.274.38.27257			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480945	hybrid			2022-12-25	WOS:000082570700084
J	Ibrahimi, A; Bonen, A; Blinn, WD; Hajri, T; Li, X; Zhong, K; Cameron, R; Abumrad, NA				Ibrahimi, A; Bonen, A; Blinn, WD; Hajri, T; Li, X; Zhong, K; Cameron, R; Abumrad, NA			Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; CD36 DEFICIENCY; GENE-EXPRESSION; OXIDIZED LDL; PPAR-GAMMA; TRANSPORT; PROTEIN; BINDING; ADIPOCYTE; RAT	Increasing evidence has implicated the membrane protein CD36 (FAT) in binding and transport of long chain fatty acids (FA). To determine the physiological role of CD36, we examined effects of its overexpression in muscle, a tissue that depends on FA for its energy needs and is responsible for clearing a major fraction of circulating FA. Mice with CD36 overexpression in muscle were generated using the promoter of the muscle creatine kinase gene (MCK). Transgenic (MCK-CD36) mice had a slightly lower body weight than control litter mates. This reflected a leaner body mass with less overall adipose tissue, as evidenced by magnetic resonance spectroscopy. Soleus muscles from transgenic animals exhibited a greatly enhanced ability to oxidize fatty acids in response to stimulation/contraction; This increased oxidative ability was not associated with significant alterations in histological appearance of muscle fibers. Transgenic mice had lower blood levels of triglycerides and fatty acids and a reduced triglyceride content of very low density lipoproteins. Blood cholesterol levels were slightly lower, but no significant decrease in the cholesterol content of major lipoprotein fractions was measured. Blood glucose was significantly increased, while insulin levels were similar in the fed state and higher in the fasted state. However, glucose tolerance curves, determined at 20 weeks of age, were similar in control and transgenic mice. In summary, the study documented, in vivo, the role of CD36 to facilitate cellular FA uptake. It also illustrated importance of the uptake process in muscle to overall FA metabolism and glucose utilization.	SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Waterloo, Dept Kinesiol, Waterloo, ON N2L 3G1, Canada; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Waterloo; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; United States Department of Energy (DOE); Brookhaven National Laboratory	Abumrad, NA (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.		Hajri, Tahar/AAQ-6499-2020	Hajri, Tahar/0000-0003-3805-3717; Ibrahimi, Azeddine/0000-0003-3226-3836	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033301] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Baillie AGS, 1996, J MEMBRANE BIOL, V153, P75, DOI 10.1007/s002329900111; Bollheimer LC, 1998, J CLIN INVEST, V101, P1094, DOI 10.1172/JCI420; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Caveliers V, 1998, J NUCL MED, V39, P1672; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dohm GL, 1998, ADV EXP MED BIOL, V441, P27; Dyck DJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE888, DOI 10.1152/ajpendo.1998.275.5.E888; Dyck DJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE340, DOI 10.1152/ajpendo.1997.272.3.E340; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; GNUDI L, 1995, ENDOCRINOLOGY, V136, P995, DOI 10.1210/en.136.3.995; GOULINET S, 1993, J LIPID RES, V34, P943; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; GREENWALT DE, 1992, BLOOD, V80, P1105; HARLAN DM, 1995, DIABETES, V44, P816, DOI 10.2337/diabetes.44.7.816; HARMON CM, 1993, J MEMBRANE BIOL, V133, P43; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; Jucker BM, 1997, J BIOL CHEM, V272, P10464, DOI 10.1074/jbc.272.16.10464; KASHIWAGI H, 1995, J CLIN INVEST, V95, P1040, DOI 10.1172/JCI117749; Kashiwagi H, 1996, ARTERIOSCL THROM VAS, V16, P1026, DOI 10.1161/01.ATV.16.8.1026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; Luiken JJFP, 1999, J LIPID RES, V40, P1007; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; RONEN A, 1999, AM J PHYSIOL, V276, pE642; Sambrook J, 1988, MOL CLONING LAB MANU; Sfeir Z, 1997, PROSTAG LEUKOTR ESS, V57, P17, DOI 10.1016/S0952-3278(97)90487-7; Sfeir Z, 1999, MOL CELL BIOCHEM, V192, P3, DOI 10.1023/A:1006811300125; Tanaka T, 1997, JPN CIRC J, V61, P724, DOI 10.1253/jcj.61.724; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Turcotte LP, 1998, J APPL PHYSIOL, V84, P1788, DOI 10.1152/jappl.1998.84.5.1788; VANNIEUWENHOVEN FA, 1995, BIOCHEM BIOPH RES CO, V207, P747, DOI 10.1006/bbrc.1995.1250	39	275	283	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26761	26766		10.1074/jbc.274.38.26761	http://dx.doi.org/10.1074/jbc.274.38.26761			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480880	hybrid			2022-12-25	WOS:000082570700019
J	Jensen, CJ; Buch, MB; Krag, TO; Hemmings, BA; Gammeltoft, S; Frodin, M				Jensen, CJ; Buch, MB; Krag, TO; Hemmings, BA; Gammeltoft, S; Frodin, M			90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COFFIN-LOWRY-SYNDROME; KAPPA-B-ALPHA; CREB KINASE; PP90(RSK); IDENTIFICATION; P70(S6K); INSULIN; DOMAIN; RSK-2; PDK1	90-kDa ribosomal S6 kinase-2 (RSK2) belongs to a family of growth factor-activated serine/threonine kinases composed of two kinase domains connected by a regulatory linker region. The N-terminal kinase of RSK2 is involved in substrate phosphorylation. Its activation requires phosphorylation of the linker region at Ser(369), catalyzed by extracellular signal-regulated kinase (ERK), and at Ser(386), catalyzed by the C-terminal kinase, after its activation by ERK. In addition, the N-terminal kinase must be phosphorylated at Ser(227) in the activation loop by an as yet unidentified kinase. Here, we show that the isolated N-terminal kinase of RSK2 (amino acids 1-360) is phosphorylated at Ser(227) by PDK1, a constitutively active kinase, leading to 100-fold stimulation of kinase activity. In COS7 cells, ectopic PDK1 induced the phosphorylation of full-length RSK2 at Ser(227) and Ser(386), without involvement of ERK, leading to partial activation of RSK2. Similarly, two other members of the RSK family, RSK1 and RSK3, were partially activated by PDK1 in COS7 cells. Finally, our data indicate that full activation of RSK2 by growth factor requires the cooperation of ERK and PDK1 through phosphorylation of Ser(227), Ser(369), and Ser(386). Our study extend recent findings which implicate PDK1 in the activation of protein kinases B and C and p70(S6K), suggesting that PDK1 controls several major growth factor-activated signal transduction pathways.	Univ Copenhagen, Glostrup Hosp, Dept Clin Biochem, DK-2600 Glostrup, Denmark; Friedrich Miescher Inst, CH-4558 Basel, Switzerland	University of Copenhagen; Friedrich Miescher Institute for Biomedical Research	Frodin, M (corresponding author), Univ Copenhagen, Glostrup Hosp, Dept Clin Biochem, DK-2600 Glostrup, Denmark.		Krag, Thomas/AAD-3307-2021	Krag, Thomas/0000-0001-9330-668X; Frodin, Morten/0000-0003-3691-9820				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALESSI DR, 1997, CURR BIOL, V7, P69; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JOHNSON BH, 1994, BIO-TECHNOL, V12, P1357, DOI 10.1038/nbt1294-1357; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Merienne K, 1998, J MED GENET, V35, P890, DOI 10.1136/jmg.35.11.890; MOLLER DE, 1994, AM J PHYSIOL, V266, P351; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	43	212	225	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27168	27176		10.1074/jbc.274.38.27168	http://dx.doi.org/10.1074/jbc.274.38.27168			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480933	hybrid			2022-12-25	WOS:000082570700072
J	Wang, G; Miskimins, R; Miskimins, WK				Wang, G; Miskimins, R; Miskimins, WK			The cyclin-dependent kinase inhibitor p27(Kip1) is localized to the cytosol in Swiss/3T3 cells	ONCOGENE			English	Article						p27(Kip1); Cdk2; cyclin E; cell cycle	MESSENGER-RNA; GROWTH-FACTOR; BREAST-CANCER; EXPRESSION; P27; ACCUMULATION; FIBROBLASTS; ACTIVATION; PROTEIN; ARREST	p27(Kip1) plays an important role in cell cycle progression by negatively regulating the activity of cyclin-Cdk complexes. To understand how p27(Kip1) functions, the level and subcellular location of p27(Kip1) in Swiss/3T3 cells following serum stimulation of quiescent cells was examined. Surprisingly, p27(Kip1) was observed exclusively in the cytosol throughout G1 and into early S phase. However, as expected, p27(Kip1) in the cytosolic fraction was greatly reduced following serum stimulation and reached very low levels hy late G1, The decline in the level of p27(Kip1) corresponded in time to an increase in the nuclear level of both Cdk2 and cyclin E. In quiescent 3T3 cells Cdk2 was inactive and co-precipitated with p27(Kip1). After serum stimulation, both nuclear and cytosolic Cdk2 was activated and this corresponded to the decline in p27(Kip1). Overexpression of p27(Kip1) allowed accumulation of the inhibitor in the nucleus but inhibited entry of Cdk2 into the nucleus following serum stimulation. The subcellular localization of p27(Kip1) was also examined in a,variety of other mammalian cells. In all the cell lines examined the preponderance of p27(Kip1) was found in the cytosolic fraction. However, a substantial level of nuclear p27(Kip1) was observed for several cell lines. In a primary mixed glial cell culture p27(Kip1) localized to the nucleus. The results suggest that cytosolic p27(Kip1) has a functional role in regulating cell cycle progression, possibly through inhibiting transport of cyclin E-Cdk 2 complexes into the nucleus.	Univ S Dakota, Sch Med, Div Basic Biomed Sci, Biochem & Mol Biol Grp, Vermillion, SD 57069 USA	University of South Dakota	Miskimins, WK (corresponding author), Univ S Dakota, Sch Med, Div Basic Biomed Sci, Biochem & Mol Biol Grp, Vermillion, SD 57069 USA.				NINDS NIH HHS [R01-NS36164] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036164] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Friessen AJ, 1997, J NEUROSCI RES, V50, P373; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; Kamesaki H, 1998, J IMMUNOL, V160, P770; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; MISKIMINS WK, 1982, J CELL BIOCHEM, V20, P41, DOI 10.1002/jcb.240200105; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Moro A, 1998, BIOCHEM BIOPH RES CO, V245, P752, DOI 10.1006/bbrc.1998.8512; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; OUYANG Q, 1993, MOL CELL BIOL, V13, P1796, DOI 10.1128/MCB.13.3.1796; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, GENE DEV, V98, P9; RAVITZ MJ, 1995, CANCER RES, V55, P1413; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Shiyanov P, 1997, MOL BIOL CELL, V8, P1815, DOI 10.1091/mbc.8.9.1815; Singh SP, 1998, CANCER RES, V58, P1730; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253	26	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5204	5210		10.1038/sj.onc.1202912	http://dx.doi.org/10.1038/sj.onc.1202912			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498870				2022-12-25	WOS:000082555700009
J	Leblanc, V; Delumeau, I; Tocque, B				Leblanc, V; Delumeau, I; Tocque, B			Ras-GTPase activating protein inhibition specifically induces apoptosis of tumour cells	ONCOGENE			English	Article						Ras-GAP; apoptosis; RhoA; tumour cells	ACTIN STRESS FIBERS; BINDING PROTEIN; SIGNALING PATHWAY; ONCOGENIC RAS; RHO; EXPRESSION; TRANSFORMATION; GAP; ANTIBODIES; KINASES	Oncogenes and tumour suppressor genes control the balance between apoptotic death and anti-apoptotic survival signals determining whether a cell proliferates or dies. Through which effecters might oncoproteins generate sensitivity to apoptosis remains to be determined. Ras GTPase activating protein (Ras-GAP) is a key element in the Ras signalling pathway, being both a negative regulator and possibly an effector of Pas, Ras-GAP acts as a regulator of transcription, and possibly connects Ras to stress-activated protein kinases, A role for Ras-GAP in cell survival has been suspected from the study of knock-out mouse embryos. In search for selective killing of tumour cells, we asked whether Ras-GAP inhibition by other means would lead to apoptosis in established cell lines. We injected a monoclonal antibody directed against the SH3 domain of Ras-GAP (mAb200) that has been shown to block Res-GAP downstream signalling into various human normal and tumour cell lines. We show that inhibition of Res-GAP induces apoptosis specifically in tumour, but not in normal cells, therefore pointing at a specific role for Ras-GAP in tumour cell survival. MAb200-induced apoptosis is largely prevented by coinjection of activated RhoA or Cdc42 proteins, by injection of a constitutively activated mutant of phosphoinositide 3-OH kinase (PI3-K), but not by injection of v-Raf, These results show that targeting of Ras-GAP could represent a no, el anticancer approach.	ExonHit Therapeut, F-75013 Paris, France; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Cent Res, F-94403 Vitry, France	Sanofi-Aventis	Leblanc, V (corresponding author), ExonHit Therapeut, 65 Bld Massena, F-75013 Paris, France.							ALONSO T, 1990, MOL CELL BIOL, V10, P3117, DOI 10.1128/MCB.10.6.3117; Arceci R J, 1995, Curr Opin Hematol, V2, P268; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cochet O, 1998, CANCER RES, V58, P1170; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fenton RG, 1998, CANCER RES, V58, P3391; Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOLLAT P, 1992, BIO-TECHNOL, V10, P1151, DOI 10.1038/nbt1092-1151; Moorman JP, 1996, J IMMUNOL, V156, P4146; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	33	33	38	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4884	4889		10.1038/sj.onc.1202855	http://dx.doi.org/10.1038/sj.onc.1202855			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490822				2022-12-25	WOS:000082184800013
J	Pei, Y; Ho, CK; Schwer, B; Shuman, S				Pei, Y; Ho, CK; Schwer, B; Shuman, S			Mutational analyses of yeast RNA triphosphatases highlight a common mechanism of metal-dependent NTP hydrolysis and a means of targeting enzymes to pre-mRNAs in vivo by fusion to the guanylyltransferase component of the capping apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL DOMAIN; MESSENGER-RNA; POLYMERASE-II; NUCLEOSIDE TRIPHOSPHATASE; 5'-TRIPHOSPHATASE; SUBUNIT; GENE; PHOSPHORYLATION; PURIFICATION; ASSOCIATION	Saccharomyces cerevisiae Cet1p is the prototype of a family of metal-dependent RNA 5'-triphosphatases/ NTPases encoded by fungi and DNA viruses; the family is defined by conserved sequence motifs A, B, and C, We tested the effects of 12 alanine substitutions and 16 conservative modifications at 18 positions of the motifs, Eight residues were identified as important for triphosphatase activity. These were Glu-305, Glu-307, and Phe310 in motif A (IELEMKF); Arg-454 and Lys-456 in motif B (RTK); Glu-492, Glu-494, and Glu-496 in motif C (EVELE), Four acidic residues, Glu-305, Glu-307, Glu-494, and Glu-496, may comprise the metal-binding site(s), insofar as their replacement by glutamine inactivated Cet1p, E492Q retained triphosphatase activity. Basic residues Arg-454 and Lys-456 in motif B are implicated in binding to the 5'-triphosphate, Changing Arg-454 to alanine or glutamine resulted in a 30-fold increase in the K-m for ATP, whereas substitution with lysine increased K-m 6-fold. Changing Lys-456 to alanine or glutamine increased K-m an order of magnitude; ATP binding was restored when arginine was introduced. Alanine in lieu of Phe-310 inactivated Cet1p, whereas Tyr or Leu restored function, Alanine mutations at aliphatic residues Leu-306, Val-493, and Leu-495 resulted in thermal instability in vivo and in vitro. A second S. cerevisiae RNA triphosphatase/NTPase (named Cth1p) containing motifs A, B, and C was identified and characterized. Cth1p activity was abolished by E87A and E89A mutations in motif A. Cth1p is nonessential for yeast growth and, by itself, cannot fulfill the essential role played by Cet1p in vivo, Yet, fusion of Cth1p in cis to the guanylyltransferase domain of mammalian capping enzyme allowed Cth1p to complement growth of cet1 Delta yeast cells. This finding illustrates that mammalian guanylyltransferase can be used as a vehicle to deliver enzymes to nascent pre-mRNAs in vivo, most likely through its binding to the phosphorylated CTD of RNA polymerase II.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.		Pei, Yi/D-8998-2011; Ho, KIong/GPP-6051-2022	Pei, Yi/0000-0002-3466-760X; 				Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; ITOH N, 1987, J BIOL CHEM, V262, P1989; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Myette JR, 1996, J BIOL CHEM, V271, P11945, DOI 10.1074/jbc.271.20.11945; Rodriguez CR, 1999, NUCLEIC ACIDS RES, V27, P2181, DOI 10.1093/nar/27.10.2181; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996; Yu L, 1997, J VIROL, V71, P9837, DOI 10.1128/JVI.71.12.9837-9843.1997; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	24	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28865	28874		10.1074/jbc.274.41.28865	http://dx.doi.org/10.1074/jbc.274.41.28865			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506129	hybrid			2022-12-25	WOS:000083017800008
J	Jin, YJ; Yun, CL; Burakoff, SJ				Jin, YJ; Yun, CL; Burakoff, SJ			Human 70-kDa SHP-1L differs from 68-kDa SHP-1 in its C-terminal structure and catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; HEMATOPOIETIC-CELL PHOSPHATASE; MOTH-EATEN MICE; ANTIGEN RECEPTOR; SH2 DOMAINS; INHIBITORY RECEPTOR; SIGNAL-TRANSDUCTION; LYMPHOCYTE-ACTIVATION; CRYSTAL-STRUCTURE; T-CELLS	The tyrosine phosphatase SHP-1 functions as a negative regulator in hematopoietic cell development, proliferation, and receptor-mediated cellular activation. In Jurkat T cells, a major 68-kDa band and a minor 70-kDa band were immunoprecipitated by a monoclonal antibody against the SHP-1 protein-tyrosine phosphatase domain, while an antibody against the SHP-1 C-terminal 19 amino acids recognized only the 68-kDa SHP-1. The SDS-gel-purified 70-kDa protein was subjected to tryptic mapping and microsequencing, which was followed by molecular cloning. It revealed that the 70-kDa protein, termed SHP-1L, is a C-terminal alternatively spliced form of SHP-1. SHP-1L is 29 amino acids longer than SHP-1, and its 66 C-terminal amino acids are different from SHP-1. The C terminus of SHP-1L contains a proline-rich motif PVPGPPVLSP, a potential Src homology 3 domain-binding site. In contrast to SHP-1, tyrosine phosphorylation of SHP-1L is not detected upon stimulation in Jurkat T cells. This is apparently due to the lack of a single in vivo tyrosine phosphorylation site, which only exists in the C terminus of SHP-1 (Y564). COS cell expressed glutathione S-transferase-SHP-1L can dephosphorylate tyrosine-phosphorylated ZAP70. At pH 7.4, SHP-1L was shown to be more active than SHP-1 in the dephosphorylation of ZAP70, At pH 5.4, SHP-1L and SHP-1 exhibited similar catalytic activity. It is likely that these two isoforms play different roles in the regulation of hematopoietic cell signal transduction.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Jin, YJ (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, Rm M654,44 Binney St, Boston, MA 02115 USA.	yong-jiu_jin@dfci.harvard.edu	Yu, Chao-Lan/D-1834-2011	Yu, Chao-Lan/0000-0002-9381-6011	NATIONAL CANCER INSTITUTE [R01CA070758] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 70758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi T, 1998, J IMMUNOL, V160, P4662; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Jin YJ, 1998, J IMMUNOL, V161, P1743; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Migone TS, 1998, P NATL ACAD SCI USA, V95, P3845, DOI 10.1073/pnas.95.7.3845; Mizuno K, 1996, J EXP MED, V184, P457, DOI 10.1084/jem.184.2.457; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; Olcese L, 1996, J IMMUNOL, V156, P4531; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Raab M, 1996, BIOCHEM BIOPH RES CO, V222, P50, DOI 10.1006/bbrc.1996.0696; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; TSUI FWL, 1994, IMMUNOL REV, V138, P185, DOI 10.1111/j.1600-065X.1994.tb00852.x; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; Yang WT, 1998, BLOOD, V91, P3746; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	54	25	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28301	28307		10.1074/jbc.274.40.28301	http://dx.doi.org/10.1074/jbc.274.40.28301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497187	hybrid			2022-12-25	WOS:000082912700036
J	Choi, SJ; Reddy, SV; Devlin, RD; Menaa, C; Chung, HY; Boyce, BF; Roodman, GD				Choi, SJ; Reddy, SV; Devlin, RD; Menaa, C; Chung, HY; Boyce, BF; Roodman, GD			Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARROW CULTURES; NORMAL MICE; CLONING; CELLS; OSTEOPROTEGERIN; INTERLEUKIN-1; DEGRADATION; EXPRESSION; HEMOGLOBIN; PROTEIN	We screened a human osteoclast (OCL) cDNA expression library for OCL inhibitory factors and identified a clone that blocked both human and murine OCL formation and bone resorption by more than 60%. This clone was identical to human legumain, a cysteine endopeptidase. Legumain significantly inhibited OCL-like multinucleated cell formation induced by 1,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) and parathyroid hormone-related protein (PTHrP) in mouse and human bone marrow cultures, and bone resorption in the fetal rat long bone assay in a dose-dependent manner. Legumain was detected in freshly isolated marrow plasma from normal donors and conditioned media from human marrow cultures. Furthermore, treatment of human marrow cultures with an antibody to legumain induced OCL formation to levels that were as high as those induced by 1,25-(OH)(2)D-3. Implantation in nude mice of 293 cells transfected with the legumain cDNA and constitutively expressing high levels of the protein significantly reduced hypercalcemia induced by PTHrP by about 50%, and significantly inhibited the increase in OCL surface and in OCL number expressed per mm(2) bone area and per mm bone surface induced by PTHrP. These results suggest that legumain may be a physiologic local regulator of OCL activity that can negatively modulate OCL formation and activity.	Audie L Murphy Mem Vet Adm Med Ctr, Res Serv 151, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Med Hematol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Roodman, GD (corresponding author), Audie L Murphy Mem Vet Adm Med Ctr, Res Serv 151, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA.	roodman@uthscsa.edu	Chung, Hoyeon/AAI-3103-2020		NIAMS NIH HHS [AR44603, AR41336] Funding Source: Medline; NIA NIH HHS [AG13625] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044603, R01AR041336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013625] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BISKOBING DM, 1995, J BONE MINER RES, V10, P1025; BOYCE BF, 1989, ENDOCRINOLOGY, V125, P2780, DOI 10.1210/endo-125-5-2780; BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo-125-3-1142; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Brindley PJ, 1997, MOL BIOCHEM PARASIT, V89, P1, DOI 10.1016/S0166-6851(97)00098-4; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Chen JM, 1998, BIOCHEM J, V335, P111, DOI 10.1042/bj3350111; Choi SJ, 1998, J CLIN INVEST, V102, P1360, DOI 10.1172/JCI2667; FISHER JE, 1993, ENDOCRINOLOGY, V132, P1411, DOI 10.1210/en.132.3.1411; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Hofbauer LC, 1998, BIOCHEM BIOPH RES CO, V250, P776, DOI 10.1006/bbrc.1998.9394; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; JEE WSS, 1963, NATURE, V200, P225, DOI 10.1038/200226a0; KEMBHAVI AA, 1993, ARCH BIOCHEM BIOPHYS, V303, P208, DOI 10.1006/abbi.1993.1274; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; MACDONALD BR, 1987, ENDOCRINOLOGY, V120, P2326, DOI 10.1210/endo-120-6-2326; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; RAISZ JG, 1969, ENDOCRINOLOGY, V85, P446, DOI 10.1210/endo-85-3-446; Reddy S, 1998, J CELL PHYSIOL, V177, P636, DOI 10.1002/(SICI)1097-4652(199812)177:4<636::AID-JCP14>3.3.CO;2-8; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TAKAHASHI S, 1994, J BIOL CHEM, V269, P28696; TAKEDA O, 1994, J BIOCHEM-TOKYO, V116, P541, DOI 10.1093/oxfordjournals.jbchem.a124559	23	84	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27747	27753		10.1074/jbc.274.39.27747	http://dx.doi.org/10.1074/jbc.274.39.27747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488118	hybrid			2022-12-25	WOS:000082739100057
J	Fitzgerald, J; Lamande, SR; Bateman, JF				Fitzgerald, J; Lamande, SR; Bateman, JF			Proteasomal degradation of unassembled mutant type I collagen pro-alpha 1(I) chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL PROPEPTIDE; NEWLY SYNTHESIZED COLLAGEN; PERINATAL OSTEOGENESIS IMPERFECTA; GLUCOSE-REGULATED PROTEINS; ENDOPLASMIC-RETICULUM; LUNG FIBROBLASTS; INTRACELLULAR DEGRADATION; FRAMESHIFT MUTATION; DEFECTIVE COLLAGEN; SECRETORY PROTEINS	We have previously shown that type I procollagen pro-alpha 1(I) chains from an osteogenesis imperfecta patient (OI26) with a frameshift mutation resulting in a truncated C-propeptide, have impaired assembly, and are degraded by an endoplasmic reticulum-associated pathway (Lamande, S. R., Chessler, S. D., Golub, S. B., Byers, P. H., Chan, D., Cole, W. G., Sillence, D. O. and Bateman, J. F. (1995) J. Biol. Chem, 270, 8642-8649). To further explore the degradation of procollagen chains with mutant C-propeptides, mouse Mov13 cells, which produce no endogenous pro-alpha 1(I), were stably transfected with a pro-alpha 1(I) expression construct containing a frameshift mutation that predicts the synthesis of a protein 85 residues longer than normal. Despite high levels of mutant mRNA in transfected Mov13 cells, only minute amounts of mutant pro-alpha 1(I) could be detected indicating that the majority of the mutant pro-alpha 1(I) chains synthesized are targeted for rapid intracellular degradation. Degradation was not prevented by brefeldin A, monensin, or NH4Cl, agents that interfere with intracellular transport or lysosomal function. However, mutant pro-alpha 1(I) chains in both transfected Mov13 cells and OI26 cells were protected from proteolysis by specific proteasome inhibitors. Together these data demonstrate for the first time that procollagen chains containing C-propeptide mutations that impair assembly are degraded by the cytoplasmic proteasome complex, and that the previously identified endoplasmic reticulum-associated degradation of mutant pro-alpha 1(I) in OI26 is mediated by proteasomes.	Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne; University of Melbourne	Bateman, JF (corresponding author), Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia.			Bateman, John/0000-0001-8542-0730; Lamande, Shireen/0000-0003-2938-2711				BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BARILE FA, 1990, ARCH BIOCHEM BIOPHYS, V276, P125, DOI 10.1016/0003-9861(90)90018-T; BATEMAN JF, 1989, J BIOL CHEM, V264, P10960; BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BERG RA, 1984, BIOCHEMISTRY-US, V23, P2134, DOI 10.1021/bi00305a005; BERG RA, 1980, P NATL ACAD SCI-BIOL, V77, P4746, DOI 10.1073/pnas.77.8.4746; BIENKOWSKI RS, 1978, NATURE, V276, P413, DOI 10.1038/276413a0; BIENKOWSKI RS, 1983, BIOCHEM J, V214, P1; BIENKOWSKI RS, 1978, J BIOL CHEM, V253, P4356; BIENKOWSKI RS, 1990, BIOCHEM BIOPH RES CO, V168, P479, DOI 10.1016/0006-291X(90)92346-2; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Chapman JA, 1984, ULTRASTRUCTURE CONNE; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHESSLER SD, 1993, J BIOL CHEM, V268, P18218; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; COLE WG, 1981, BIOCHEM J, V197, P377, DOI 10.1042/bj1970377; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Dick LR, 1997, J BIOL CHEM, V272, P182; Fisher L. W., 1989, CONNECT TISSUE RES, V21, P43; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Kielty Cay M., 1993, P103; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; LAMANDE SR, 1995, J BIOL CHEM, V270, P17858, DOI 10.1074/jbc.270.30.17858; LAMANDE SR, 1993, BIOCHEM J, V293, P387, DOI 10.1042/bj2930387; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RIPLEY CR, 1993, J BIOL CHEM, V268, P3677; Ripley CR, 1997, EXP CELL RES, V236, P147, DOI 10.1006/excr.1997.3707; SCHNIEKE A, 1987, P NATL ACAD SCI USA, V84, P764, DOI 10.1073/pnas.84.3.764; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; WAKE SA, 1985, BIOCHEM J, V228, P425, DOI 10.1042/bj2280425; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	43	67	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27392	27398		10.1074/jbc.274.39.27392	http://dx.doi.org/10.1074/jbc.274.39.27392			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488070	hybrid			2022-12-25	WOS:000082739100009
J	Marshall, BA; Tordjman, K; Host, HH; Ensor, NJ; Kwon, G; Marshall, CA; Coleman, T; McDaniel, ML; Semenkovich, CF				Marshall, BA; Tordjman, K; Host, HH; Ensor, NJ; Kwon, G; Marshall, CA; Coleman, T; McDaniel, ML; Semenkovich, CF			Relative hypoglycemia and hyperinsulinemia in mice with heterozygous lipoprotein lipase (LPL) deficiency - Islet LPL regulates insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; RAT PANCREATIC-ISLETS; FATTY-ACIDS; CHOLESTEROL LEVELS; MISSENSE MUTATION; SKELETAL-MUSCLE; GLUCOSE; EXPRESSION; METABOLISM; PLASMA	Lipoprotein lipase (LPL) provides tissues with fatty acids, which have complex effects on glucose utilization and insulin secretion. To determine if LPL has direct effects on glucose metabolism, we studied mice with heterozygous LPL deficiency (LPL+/-), LPL+/- mice had mean fasting glucose values that were up to 39 mg/dl lower than LPL+/+ littermates. Despite having lower glucose levels, LPL+/- mice had fasting insulin levels that were twice those of +/+ mice. Hyperinsulinemic clamp experiments showed no effect of genotype on basal or insulin-stimulated glucose utilization. LPL message was detected in mouse islets, INS-1 cells (a rat insulinoma cell line), and human islets, LPL enzyme activity was detected in the media from both mouse and human islets incubated in vitro. In mice, +/- islets expressed half the enzyme activity of +/+ islets, Islets isolated from +/+ mice secreted less insulin in vitro than +/- and -/- islets, suggesting that LPL suppresses insulin secretion. To test this notion directly, LPL enzyme activity was manipulated in INS-1 cells. INS-1 cells treated with an adeno-associated virus expressing human LPL had more LPL enzyme activity and secreted less insulin than adeno-associated virus-P-galactosidase-treated cells. INS-1 cells transfected with an antisense LPL oligonucleotide had less LPL enzyme activity and secreted more insulin than cells transfected with a control oligonucleotide. These data suggest that islet LPL is a novel regulator of insulin secretion. They further suggest that genetically determined levels of LPL play a role in establishing glucose levels in mice.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Semenkovich, CF (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave,Box 8046, St Louis, MO 63110 USA.	semenkov@im.wustl.edu		Semenkovich, Clay/0000-0003-1163-1871	NHLBI NIH HHS [HL58427] Funding Source: Medline; NIDDK NIH HHS [DK02339, DK53198] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002339, R01DK053198] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; Benlian P., 1996, INSERM C, P79; Bollheimer LC, 1998, J CLIN INVEST, V101, P1094, DOI 10.1172/JCI420; CAMPILLO JE, 1979, DIABETOLOGIA, V16, P267, DOI 10.1007/BF01221954; COLEMAN T, 1995, J BIOL CHEM, V270, P12518, DOI 10.1074/jbc.270.21.12518; CRESPIN SR, 1969, J CLIN INVEST, V48, P1934, DOI 10.1172/JCI106160; EISENBERG S, 1979, J LIPID RES, V20, P614; ELBEIN SC, 1994, J CLIN ENDOCR METAB, V79, P1450, DOI 10.1210/jc.79.5.1450; ELKS ML, 1993, ENDOCRINOLOGY, V133, P208, DOI 10.1210/en.133.1.208; FISHER RM, 1995, J LIPID RES, V36, P2104; FRIED SK, 1987, INT J OBESITY, V11, P129; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; Goldberg IJ, 1996, J LIPID RES, V37, P693; GREENOUGH WB, 1967, LANCET, V2, P1334; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; LEBOEUF RC, 1994, J LIPID RES, V35, P121; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; LevakFrank S, 1997, J BIOL CHEM, V272, P17182, DOI 10.1074/jbc.272.27.17182; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; Liang Y, 1997, DIABETOLOGIA, V40, P1018, DOI 10.1007/s001250050783; MADISON LL, 1968, METABOLISM, V17, P301, DOI 10.1016/0026-0495(68)90097-8; Marshall BA, 1999, AM J PHYSIOL-ENDOC M, V276, pE390, DOI 10.1152/ajpendo.1999.276.2.E390; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MARSHALL BA, 1994, AM J PHYSIOL-ENDOC M, V267, pE738, DOI 10.1152/ajpendo.1994.267.5.E738; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; McLean L R, 1986, Methods Enzymol, V129, P738; Merkel M, 1998, J CLIN INVEST, V102, P893, DOI 10.1172/JCI2912; MIESENBOCK G, 1993, J CLIN INVEST, V91, P448, DOI 10.1172/JCI116222; MONTAGUE W, 1968, NATURE, V217, P853, DOI 10.1038/217853a0; Mulder H, 1999, DIABETES, V48, P228, DOI 10.2337/diabetes.48.1.228; Nordestgaard BG, 1997, CIRCULATION, V96, P1737, DOI 10.1161/01.CIR.96.6.1737; ONG JM, 1988, J BIOL CHEM, V263, P12933; Piston DW, 1999, J BIOL CHEM, V274, P1000, DOI 10.1074/jbc.274.2.1000; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; Ramanadham S, 1998, BBA-LIPID LIPID MET, V1390, P301, DOI 10.1016/S0005-2760(97)00189-6; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; Sekine N, 1997, DIABETES, V46, P1424, DOI 10.2337/diabetes.46.9.1424; Semenkovich CF, 1997, DIABETES, V46, P327, DOI 10.2337/diabetes.46.3.327; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; STOCKS J, 1980, LIPIDS, V15, P186, DOI 10.1007/BF02540967; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; WAITE M, 1973, J BIOL CHEM, V248, P7985; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Weinstock PH, 1997, P NATL ACAD SCI USA, V94, P10261, DOI 10.1073/pnas.94.19.10261; WILSON DE, 1990, J CLIN INVEST, V86, P735, DOI 10.1172/JCI114770; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042	55	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27426	27432		10.1074/jbc.274.39.27426	http://dx.doi.org/10.1074/jbc.274.39.27426			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488074	hybrid			2022-12-25	WOS:000082739100013
J	Cooper, ST; Harkness, PC; Baker, ER; Millar, NS				Cooper, ST; Harkness, PC; Baker, ER; Millar, NS			Up-regulation of cell-surface alpha 4 beta 2 neuronal nicotinic receptors by lower temperature and expression of chimeric subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; ION-CHANNEL; RAT-BRAIN; FUNCTIONAL EXPRESSION; SENSITIVE EXPRESSION; TRANSFECTED CELLS; MOUSE FIBROBLASTS; XENOPUS OOCYTES; BETA-SUBUNIT; MUSCLE-CELLS	The predominant nicotinic acetylcholine receptor (nAChR) expressed in vertebrate brain is a pentamer containing alpha 4 and beta 2 subunits, In this study we have examined how temperature and the expression of subunit chimeras can influence the efficiency of cell-surface expression of the rat alpha 4 beta 2 nAChR, Functional recombinant alpha 4 beta 2 nAChRs, showing high affinity binding of nicotinic radioligands (K(d) = 41 +/- 22 pM for [(3)H]epibatidine), are expressed in both stably and transiently transfected mammalian cell lines, Despite this, only very low levels of alpha 4 beta 2 nAChRs can be detected on the cell surface of transfected mammalian cells maintained at 37 degrees C. At 30 degrees C, however, cells expressing alpha 4 beta 2 nAChRs show a 12-fold increase in radioligand binding (with no change in affinity), and a 5-fold up-regulation in cell-surface receptors with no increase in total subunit protein. In contrast to "wild-type" alpha 4 and beta 2 subunits, chimeric nicotinic/serotonergic subunits ("alpha 4 chi" and "beta 2 chi") are expressed very efficiently on the cell surface (at 30 degrees C or 37 degrees C), either as hetero-oligomeric complexes (e.g. alpha 4 chi+beta 2 or alpha 4 chi+beta 2 chi) or when expressed alone. Compared with alpha 4 beta 2 nAChRs, expression of complexes containing: chimeric subunits typically results in up to 20-fold increase in nicotinic radioligand binding sites (with no change in affinity) and a similar increase in cell-surface receptor, despite a similar level of total chimeric and wild-type protein.	UCL, Dept Pharmacol, Wellcome Lab Mol Pharmacol, London WC1E 6BT, England	University of London; University College London	Millar, NS (corresponding author), UCL, Dept Pharmacol, Wellcome Lab Mol Pharmacol, Mortimer St, London WC1E 6BT, England.	n.millar@ucl.ac.uk						ANAND R, 1991, J BIOL CHEM, V266, P11192; BENCHERIF M, 1995, J PHARMACOL EXP THER, V275, P987; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; Blumenthal EM, 1997, J NEUROSCI, V17, P6094; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; Buisson B, 1996, J NEUROSCI, V16, P7880; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen DN, 1998, J NEUROCHEM, V70, P349; CLAUDIO T, 1989, J CELL BIOL, V108, P2277, DOI 10.1083/jcb.108.6.2277; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; Cooper ST, 1998, J NEUROCHEM, V70, P2585; Cooper ST, 1997, J NEUROCHEM, V68, P2140; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; Dineley Kelly T., 1998, Society for Neuroscience Abstracts, V24, P838; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; FLORES CM, 1992, MOL PHARMACOL, V41, P31; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; GREEN WN, 1991, P NATL ACAD SCI USA, V88, P854, DOI 10.1073/pnas.88.3.854; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; Kassner PD, 1997, J NEUROBIOL, V33, P968, DOI 10.1002/(SICI)1097-4695(199712)33:7<968::AID-NEU8>3.0.CO;2-6; Lansdell SJ, 1997, J NEUROCHEM, V68, P1812; Lewis TM, 1997, J PHYSIOL-LONDON, V505, P299, DOI 10.1111/j.1469-7793.1997.299bb.x; LUKAS RJ, 1991, J NEUROCHEM, V56, P1134, DOI 10.1111/j.1471-4159.1991.tb11403.x; MARGIOTTA JF, 1987, J NEUROSCI, V7, P3612; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MARKS MJ, 1993, J PHARMACOL EXP THER, V266, P1268; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; PAULSON HL, 1990, J CELL BIOL, V110, P1705, DOI 10.1083/jcb.110.5.1705; PENG X, 1994, MOL PHARMACOL, V46, P523; Quiram PA, 1998, J BIOL CHEM, V273, P11001, DOI 10.1074/jbc.273.18.11001; Ragozzino D, 1997, EUR J NEUROSCI, V9, P480, DOI 10.1111/j.1460-9568.1997.tb01625.x; Rangwala F, 1997, J NEUROSCI, V17, P8201; Rothhut B, 1996, J NEUROBIOL, V29, P115, DOI 10.1002/(SICI)1097-4695(199601)29:1<115::AID-NEU9>3.0.CO;2-E; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SINE SM, 1991, J BIOL CHEM, V266, P13679; Turton S., 1993, Molecular Neuropharmacology, V3, P167; WHITING P, 1987, FEBS LETT, V219, P459, DOI 10.1016/0014-5793(87)80272-7; WHITING P, 1991, MOL PHARMACOL, V40, P463; WHITING P, 1987, P NATL ACAD SCI USA, V84, P595, DOI 10.1073/pnas.84.2.595; WHITING PJ, 1988, J NEUROSCI, V8, P3395; ZHANG X, 1995, NEUROREPORT, V6, P313, DOI 10.1097/00001756-199501000-00022	47	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27145	27152		10.1074/jbc.274.38.27145	http://dx.doi.org/10.1074/jbc.274.38.27145			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480930	hybrid			2022-12-25	WOS:000082570700069
J	Kooter, IM; Moguilevsky, N; Bollen, A; van der Veen, LA; Otto, C; Dekker, HL; Wever, R				Kooter, IM; Moguilevsky, N; Bollen, A; van der Veen, LA; Otto, C; Dekker, HL; Wever, R			The sulfonium ion linkage in myeloperoxidase - Direct spectroscopic detection by isotopic labeling and effect of mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RECOMBINANT MYELOPEROXIDASE; HUMAN EOSINOPHIL PEROXIDASE; CIRCULAR-DICHROISM; PROSTHETIC GROUP; ACTIVE-SITE; CHLORINATING ACTIVITY; SPECTRAL PROPERTIES; THYROID PEROXIDASE; AUTOLYTIC CLEAVAGE; CATALYTIC ACTIVITY	The heme group of myeloperoxidase is covalently linked via two ester bonds to the protein and a unique sulfonium ion linkage involving Met(243). Mutation of Met(243) into Thr, Gin, and Val, which are the corresponding residues of eosinophil peroxidase, lactoperoxidase, and thyroid peroxidase, respectively, and into Cys was performed. The Soret band in the optical absorbance spectrum in the oxidized mutants is now found at approximately 411 nm, Both the pyridine hemochrome spectra and resonance Raman spectra of the mutants are affected by the mutation. In the Met(243) mutants the affinity for chloride has decreased 100-fold, All mutants have lost their chlorination activity, except for the M243T mutant, which still has 15% activity left. By Fourier transform infared difference spectroscopy it was possible to specifically detect the (CD3)-C-13-labeled methionyl sulfonium ion linkage. We conclude that the sulfonium ion linkage serves two roles. First, it serves as an electron-withdrawing substituent via its positive charge, and, second, together with its neighboring residue Glu(242), it appears to be responsible for the lower symmetry of the heme group and distortion from the planar conformation normally seen in heme-containing proteins.	Univ Amsterdam, EC Slater Inst, Biocentrum, NL-1018 TV Amsterdam, Netherlands; Univ Brussels, Dept Appl Genet, B-1400 Nivelles, Belgium; Univ Amsterdam, Inst Mol Chem Homogeneous Catalysis, NL-1018 WS Amsterdam, Netherlands; Univ Twente, Dept Appl Phys, NL-7500 AE Enschede, Netherlands	University of Amsterdam; Universite Libre de Bruxelles; University of Amsterdam; University of Twente	Wever, R (corresponding author), Univ Amsterdam, EC Slater Inst, Biocentrum, Plantage Muidergracht 12, NL-1018 TV Amsterdam, Netherlands.		Otto, Cees/H-8421-2019; Wever, Ron/AAM-4520-2020					Agner K., 1941, ACTA PHYSIOL SCAND, V2, P1; [Anonymous], 1985, HURRIYET 0627, P15; BABCOCK GT, 1985, BIOCHIM BIOPHYS ACTA, V828, P58, DOI 10.1016/0167-4838(85)90009-3; BAKKENIST ARJ, 1980, BIOCHIM BIOPHYS ACTA, V613, P337, DOI 10.1016/0005-2744(80)90088-1; Bellamy L.J., 1956, INFRARED SPECTRA COM; BOLSCHER BGJ, 1984, BIOCHIM BIOPHYS ACTA, V84, P189; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V788, P1, DOI 10.1016/0167-4838(84)90290-5; BUYS J, 1984, IMMUNOLOGY, V51, P601; CALS MM, 1991, EUR J BIOCHEM, V198, P733, DOI 10.1111/j.1432-1033.1991.tb16073.x; CARLSTROM A, 1969, ACTA CHEM SCAND, V23, P203, DOI 10.3891/acta.chem.scand.23-0203; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; DePillis GD, 1997, J BIOL CHEM, V272, P8857; DUGAD LB, 1990, J BIOL CHEM, V265, P7173; EGLINTON DG, 1982, BIOCHIM BIOPHYS ACTA, V703, P187, DOI 10.1016/0167-4838(82)90047-4; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; FLORIS R, 1995, J AM CHEM SOC, V117, P3907, DOI 10.1021/ja00119a003; FRITZ J, 1971, BIOCHIM BIOPHYS ACTA, V253, P110, DOI 10.1016/0005-2728(71)90239-8; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HARRISON JE, 1978, BIOCHIM BIOPHYS ACTA, V536, P341, DOI 10.1016/0005-2795(78)90492-0; HEWSON WD, 1979, J BIOL CHEM, V254, P3175; HORI H, 1990, BIOCHEMISTRY-US, V29, P7106, DOI 10.1021/bi00482a023; IKEDASAITO M, 1985, FEBS LETT, V184, P52, DOI 10.1016/0014-5793(85)80651-7; IKEDASAITO M, 1987, BIOCHEMISTRY-US, V26, P4344, DOI 10.1021/bi00388a024; JACQUET A, 1991, ARCH BIOCHEM BIOPHYS, V291, P132, DOI 10.1016/0003-9861(91)90115-Y; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V957, P185, DOI 10.1016/0167-4838(88)90271-3; KETTLE AJ, 1994, OXYGEN RADICALS BI C, V223, P502; KIMURA S, 1987, P NATL ACAD SCI USA, V84, P5555, DOI 10.1073/pnas.84.16.5555; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; Kooter IM, 1997, J BIOL INORG CHEM, V2, P191, DOI 10.1007/s007750050124; Kooter IM, 1997, J AM CHEM SOC, V119, P11542, DOI 10.1021/ja9725460; Lubben M, 1996, FEBS LETT, V397, P303, DOI 10.1016/S0014-5793(96)01174-X; MARQUEZ LA, 1994, J BIOL CHEM, V269, P7950; MELOAN CE, 1963, ELEMENTARY INFRARED, P121; MOGUILEVSKY N, 1991, EUR J BIOCHEM, V197, P605, DOI 10.1111/j.1432-1033.1991.tb15950.x; NAIDER F, 1972, BIOCHEMISTRY-US, V11, P3208, DOI 10.1021/bi00767a011; NEWTON N, 1965, BIOCHIM BIOPHYS ACTA, V96, P476, DOI 10.1016/0005-2787(65)90564-2; ODAJIMA T, 1980, J BIOCHEM-TOKYO, V87, P379, DOI 10.1093/oxfordjournals.jbchem.a132758; SAKAMAKI K, 1989, J BIOL CHEM, V264, P16828; SCHULTZ J, 1964, BIOCHEMISTRY-US, V3, P1234, DOI 10.1021/bi00897a009; SIBBETT SS, 1984, BIOCHEMISTRY-US, V23, P3007, DOI 10.1021/bi00308a025; SIEVERS G, 1980, BIOCHIM BIOPHYS ACTA, V624, P249, DOI 10.1016/0005-2795(80)90244-5; SONO M, 1991, P NATL ACAD SCI USA, V88, P11148, DOI 10.1073/pnas.88.24.11148; SONO M, 1986, BIOCHIM BIOPHYS ACTA, V873, P62, DOI 10.1016/0167-4838(86)90190-1; TAYLOR KL, 1992, J BIOL CHEM, V267, P25282; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; Thomas E L, 1986, Methods Enzymol, V132, P569; TOENNIES G, 1945, J AM CHEM SOC, V67, P849, DOI 10.1021/ja01221a046; TOLLIN G, 1995, J BIOENERG BIOMEMBR, V27, P303, DOI 10.1007/BF02110100; Ueda T, 1997, EUR J BIOCHEM, V243, P32, DOI 10.1111/j.1432-1033.1997.0032a.x; WEVER R, 1981, FEBS LETT, V123, P327, DOI 10.1016/0014-5793(81)80320-1	52	60	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26794	26802		10.1074/jbc.274.38.26794	http://dx.doi.org/10.1074/jbc.274.38.26794			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480885	hybrid			2022-12-25	WOS:000082570700024
J	Nikaido, K; Ames, GFL				Nikaido, K; Ames, GFL			One intact ATP-binding subunit is sufficient to support ATP hydrolysis and translocation in an ABC transporter, the histidine permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE ACTIVITY; P-GLYCOPROTEIN MUTANTS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; PERIPLASMIC PERMEASES; CYSTIC-FIBROSIS; TRAFFIC ATPASE; MULTIDRUG-RESISTANCE; STRUCTURAL MODEL; PROTEINS	The membrane-bound complex of the Salmonella typhimurium histidine permease, a member of the ABC transporters (or traffic ATPases) superfamily, is composed of two integral membrane proteins, HisQ and HisM, and two copies of an ATP-binding subunit, HisP, which hydrolyze ATP, thus supplying the energy for translocation. The three-dimensional structure of HisP has been resolved. Extensive evidence indicates that the HisP subunits form a dimer. We investigated the mechanism of action of such a dimer, both within the complex and in soluble form, by creating heterodimers between the wild type and mutant HisP proteins. The data strongly suggest that within the complex both subunits hydrolyze ATP and that one subunit is activated by the other. In a heterodimer containing one wild, type and one hydrolysis defective subunit both hydrolysis and ligand translocation occur at half the rate of the wild type. Soluble HisP also hydrolyzes ATP if one subunit is inactive; its specific activity is identical to that of the wild type, indicating that only one of the subunits in a soluble dimer is involved in hydrolysis. We show that the activating ability varies depending on the nature off the substitution of a well conserved residue, His-211.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Ames, GFL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, 401 Barker Hall, Berkeley, CA 94720 USA.	giovanna@uclink4.berkeley.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012121, R01DK012121] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK12121] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GF, 1985, BIOCHIMIE, V67, P149, DOI 10.1016/S0300-9084(85)80242-X; Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; AMES GFL, 1985, CURR TOP MEMBR TRANS, V23, P103; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; Bear CE, 1997, J BIOENERG BIOMEMBR, V29, P465, DOI 10.1023/A:1022435007193; Beaudet L, 1998, BIOCHEMISTRY-US, V37, P9073, DOI 10.1021/bi972656j; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOSHI AK, 1989, J BIOL CHEM, V264, P2126; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; LIU CE, 1996, THESIS U CALIFORNIA; Liu PQ, 1999, J BIOL CHEM, V274, P18310, DOI 10.1074/jbc.274.26.18310; Liu PQ, 1998, P NATL ACAD SCI USA, V95, P3495, DOI 10.1073/pnas.95.7.3495; LIU PQ, 1997, THESIS U CALIFORNIA; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NIKAIDO H, 1994, FEBS LETT, V346, P55, DOI 10.1016/0014-5793(94)00315-7; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	40	87	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26727	26735		10.1074/jbc.274.38.26727	http://dx.doi.org/10.1074/jbc.274.38.26727			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480876	hybrid			2022-12-25	WOS:000082570700015
J	Ron, D; Jiang, Z; Yao, LN; Vagts, A; Diamond, I; Gordon, A				Ron, D; Jiang, Z; Yao, LN; Vagts, A; Diamond, I; Gordon, A			Coordinated movement of RACK1 with activated beta IIPKC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADRENERGIC-RECEPTOR KINASE; SIGNAL-TRANSDUCTION; ANCHORING PROTEIN; GAMMA-SUBUNITS; LOCALIZATION; CELLS; BINDING; ISOZYMES; CLONING	Protein kinase C (PKC) isozymes move upon activation from one intracellular site to another. PKC-binding proteins, such as receptors for activated C kinase (RACKs), play an important role in regulating the localization and diverse functions of PKC isozymes. RACK1, the receptor for activated beta IIPKC, determines the localization and functional activity of beta IIPKC. However, the mechanism by which RACK1 localizes activated beta IIPKC is not known. Here, we provide evidence that the intracellular localization of RACK1 changes in response to PKC activation. In Chinese hamster ovary cells transfected with the dopamine D2L receptor and in NG108-15 cells, PKC activation by either phorbol ester or a dopamine D2 receptor agonist caused the movement of RACK1. Moreover, PKC activation resulted in the in situ association and movement of RACK1 and beta IIPKC to the same intracellular sites. Time course studies indicate that PKC activation induces the association of the two proteins prior to their co-movement. We further show that association of RACK1 and beta IIPKC is required for the movement of both proteins. Our results suggest that RACK1 is a PKC shuttling protein that moves beta IIPKC from one intracellular site to another.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Res Ctr, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94110 USA; Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ctr Neurobiol Addict, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ron, D (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94110 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010039] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA10039] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Battaini F, 1997, TRENDS NEUROSCI, V20, P410, DOI 10.1016/S0166-2236(97)01084-9; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Eide T, 1998, EXP CELL RES, V238, P305, DOI 10.1006/excr.1997.3855; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; FISHBURN CS, 1995, J BIOL CHEM, V270, P29819; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Gordon AS, 1997, MOL PHARMACOL, V52, P554, DOI 10.1124/mol.52.4.554; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; MOCHLYROSEN D, 1995, BIOCHEM SOC T, V23, P596, DOI 10.1042/bst0230596; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Padanilam BJ, 1997, AM J PHYSIOL-RENAL, V272, pF160, DOI 10.1152/ajprenal.1997.272.2.F160; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rotenberg SA, 1998, J BIOL CHEM, V273, P2390, DOI 10.1074/jbc.273.4.2390; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; WANG DS, 1994, BIOCHEM BIOPH RES CO, V203, P29, DOI 10.1006/bbrc.1994.2144; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Zhou LY, 1996, J INVEST DERMATOL, V107, P248, DOI 10.1111/1523-1747.ep12329733	32	149	155	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27039	27046		10.1074/jbc.274.38.27039	http://dx.doi.org/10.1074/jbc.274.38.27039			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480917	hybrid			2022-12-25	WOS:000082570700056
J	Zhang, P; Mo, JY; Perez, A; Leon, A; Liu, L; Mazloum, N; Xu, H; Lee, MYWT				Zhang, P; Mo, JY; Perez, A; Leon, A; Liu, L; Mazloum, N; Xu, H; Lee, MYWT			Direct interaction of proliferating cell nuclear antigen with the p125 catalytic subunit of mammalian DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PCNA BINDING; REPLICATION; EXPRESSION; CYCLE; PROCESSIVITY; PROTEINS; REGION	The formation of a complex between DNA polymerase delta (pol delta) and its sliding clamp, proliferating cell nuclear antigen (PCNA), is responsible for the maintenance of processive DNA synthesis at the leading strand of the replication fork. In this study, the ability of the p125 catalytic subunit of DNA polymerase delta to engage in protein-protein interactions with PCNA was established by biochemical and genetic methods. p125 and PCNA were shown to co-immunoprecipitate from either calf thymus or HeLa extracts, or when they were ectopically co-expressed in Cos 7 cells. Because pol delta is a multimeric protein, this interaction could be indirect. Thus, rigorous evidence was sought for a direct interaction of the p125 catalytic subunit and PCNA. To do this, the ability of recombinant p125 to interact with PCNA was established by biochemical means. p125 co-expressed with PCNA in Sf9 cells was shown to form a physical complex that can be detected on gel filtration and that can be cross-linked with the bifunctional cross-linking agent Sulfo-EGS (ethylene glycol bis (sulfosuccinimidylsuccinate)), An interaction between p125 and PCNA could also be demonstrated in the yeast two hybrid system. Overlay experiments using biotinylated PCNA showed that the free p125 subunit interacts with PCNA The PCNA overlay blotting method was also used to demonstrate the binding of synthetic peptides: corresponding to the N2 region of pol delta and provides evidence for a site on pol delta that is involved in the protein-protein interactions between PCNA and pol delta, This region contains a sequence that is a potential member of the PCNA binding motif found in other PCNA-binding proteins. These studies provide an unequivocal demonstration that the p125 subunit of pol delta interacts with PCNA.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Lee, MYWT (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31973] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Cox LS, 1997, TRENDS CELL BIOL, V7, P493, DOI 10.1016/S0962-8924(97)01170-7; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; MIYACHI K, 1978, J IMMUNOL, V121, P2228; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; Roos G, 1996, EXP CELL RES, V226, P208, DOI 10.1006/excr.1996.0220; Sun YB, 1997, J BIOL CHEM, V272, P13013, DOI 10.1074/jbc.272.20.13013; Tratner I, 1997, BIOCHEM BIOPH RES CO, V231, P321, DOI 10.1006/bbrc.1997.6082; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZENG XR, 1994, J BIOL CHEM, V269, P24027; ZHANG P, 1995, BIOCHEMISTRY-US, V34, P10703, DOI 10.1021/bi00034a002; ZHANG P, 1995, J BIOL CHEM, V270, P7993, DOI 10.1074/jbc.270.14.7993; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094	27	78	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26647	26653		10.1074/jbc.274.38.26647	http://dx.doi.org/10.1074/jbc.274.38.26647			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480866	hybrid			2022-12-25	WOS:000082570700005
J	Egan, LJ; Mays, DC; Huntoon, CJ; Bell, MP; Pike, MG; Sandborn, WJ; Lipsky, JJ; McKean, DJ				Egan, LJ; Mays, DC; Huntoon, CJ; Bell, MP; Pike, MG; Sandborn, WJ; Lipsky, JJ; McKean, DJ			Inhibition of interleukin-1-stimulated NF-kappa B RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; EPITHELIAL-CELLS; GENE-EXPRESSION; IL-1 RECEPTOR; ACTIVATION; ALPHA; KINASE; SALICYLATE; MECHANISM; ASPIRIN	Nuclear factor kappa B (NF-kappa B) is an inducible transcription factor that regulates genes important in immunity and inflammation, The activity of NF-kappa B is highly regulated: transcriptionally active NF-kappa B proteins are sequestered in the cytoplasm by inhibitory proteins, I kappa B, A variety of extracellular signals, including interleukin-1 (IL-1), activate NF-kappa B by inducing phosphorylation and degradation of I kappa B, allowing nuclear translocation and DNA binding of NF-kappa B. Many of the stimuli that activate NF-kappa B by inducing I kappa B degradation also cause phosphorylation of the NF-kappa B RelA (p65) polypeptide. The transactivating capacity of RelA is positively regulated by phosphorylation, suggesting that in addition to cytosolic sequestration by I kappa B, phosphorylation represents another mechanism for control of NF-kappa B activity. In this report, we demonstrate that mesalamine, an anti-inflammatory aminosalicylate, dose-dependently inhibits IL-1-stimulated NF-kappa B-dependent transcription without preventing I kappa B degradation or nuclear translocation and DNA binding of the transcriptionally active NF-kappa B proteins, RelA, c-Rel, or RelB. Mesalamine was found to inhibit IL-1-stimulated RelA phosphorylation. These data suggest that pharmacologic modulation of the phosphorylation status of RelA regulates the transcriptional activity of NF-kappa B, independent of nuclear translocation and DNA binding. These findings highlight the importance of inducible phosphorylation of RelA. in the control of NF-kappa B activity.	Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Clin Pharmacol Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Egan, LJ (corresponding author), Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.		Sandborn, William/ABE-8342-2020		NIDDK NIH HHS [DK 07198-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007198] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; AZADKHAN AK, 1977, LANCET, V2, P892; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Egan LJ, 1998, DRUGS TODAY, V34, P431, DOI 10.1358/dot.1998.34.5.485242; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Jobin C, 1997, J IMMUNOL, V158, P226; Kalli K, 1998, MOL CELL BIOL, V18, P3140, DOI 10.1128/MCB.18.6.3140; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Marok R, 1996, ARTHRITIS RHEUM, V39, P583, DOI 10.1002/art.1780390407; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MCKEAN DJ, 1995, INT IMMUNOL, V7, P9, DOI 10.1093/intimm/7.1.9; MCKEAN DJ, 1994, J EXP MED, V180, P1321, DOI 10.1084/jem.180.4.1321; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	32	173	176	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26448	26453		10.1074/jbc.274.37.26448	http://dx.doi.org/10.1074/jbc.274.37.26448			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473604	hybrid			2022-12-25	WOS:000082469700070
J	Zhang, J; Ma, BY; Marshak-Rothstein, A; Fine, A				Zhang, J; Ma, BY; Marshak-Rothstein, A; Fine, A			Characterization of a novel cis-element that regulates fas ligand expression in corneal endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE PRIVILEGE; CD95 LIGAND; INDUCED APOPTOSIS; DEATH FACTOR; T-CELLS; PROMOTER; GENE; PROTEIN; ANTIGEN; FAMILY	Constitutively expressed Fas ligand in the cornea, Sertoli cell of the testes, Paneth cell of the intestines, and Clara cell of the airway protect surrounding parenchymal tissue by inducing apoptosis of Fas(+) immune cells during inflammatory reactions. Indeed, the action of corneal Fas ligand has been suggested to facilitate successful allogeneic cornea transplantation. To study the transcriptional regulation of Fas ligand in the eye, we employed an immortalized mouse corneal endothelial cell line (C3H3) that constitutively expresses Fas ligand. By deletion analysis of the mouse Fas ligand promoter, gel mobility shift assays, and site-directed mutagenesis, we found that a TCCT motif located -299 base pairs upstream from the transcriptional start site served as a major positive regulatory cis-element in C3H3 cells. In contrast, this element was not required for Fas ligand transcriptional activity in Sertoli cells and airway epithelial cells. By UV cross-linking analysis, we found that an similar to 30-kDa corneal nuclear protein binds to the Fas ligand promoter TCCT box and, thus, likely plays an important role in Fas ligand expression in corneal endothelial cells.	Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Zhang, J (corresponding author), Boston Univ, Sch Med, Ctr Pulm, R-3,80 E Concord St, Boston, MA 02118 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI041994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035230] Funding Source: NIH RePORTER; NEI NIH HHS [EY12513] Funding Source: Medline; NIAID NIH HHS [5T32 AI-41994] Funding Source: Medline; NIAMS NIH HHS [AR35230] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; CRISPE IN, 1994, IMMUNITY, V1, P347; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Fine A, 1997, AM J PHYSIOL-LUNG C, V273, pL64, DOI 10.1152/ajplung.1997.273.1.L64; French L E, 1996, Behring Inst Mitt, P156; Gochuico BR, 1998, AM J PHYSIOL-LUNG C, V274, pL444, DOI 10.1152/ajplung.1998.274.3.L444; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LIU SH, 1995, DEV GENET, V16, P229, DOI 10.1002/dvg.1020160303; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; Matsui K, 1998, J IMMUNOL, V161, P3469; Matsui K, 1997, EUR J IMMUNOL, V27, P2269, DOI 10.1002/eji.1830270922; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Saoud CJ, 1996, BIOCHEM BIOPH RES CO, V229, P916, DOI 10.1006/bbrc.1996.1902; SAYAMA K, 1994, J INVEST DERMATOL, V103, P330, DOI 10.1111/1523-1747.ep12394858; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Stuart PM, 1997, J CLIN INVEST, V99, P396, DOI 10.1172/JCI119173; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274	29	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26537	26542		10.1074/jbc.274.37.26537	http://dx.doi.org/10.1074/jbc.274.37.26537			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473616	hybrid			2022-12-25	WOS:000082469700082
J	Waikel, RL; Wang, XJ; Roop, DR				Waikel, RL; Wang, XJ; Roop, DR			Targeted expression of c-Myc in the epidermis alters normal proliferation, differentiation and UV-B induced apoptosis	ONCOGENE			English	Article						c-Myc; epidermis; differentiation; keratinocyte; apoptosis and transgenic	TRANSCRIPTION FACTOR NETWORK; TRANSGENIC MICE; GENE-TRANSCRIPTION; INDUCTION; GROWTH; CELLS; MAD; TUMORIGENESIS; ONCOGENE; PROTEIN	c-Myc overexpression has been associated with several types of human cancers. To study the role of c-myc in epidermal differentiation and carcinogenesis, a transgenic mouse model was created to overexpress c-myc in the epidermis, Human c-myc 2 cDNA was subcloned into a 6.5 kb mouse loricrin expression vector, ML.myc2. This loricrin promoter primarily directs expression in the epidermis in both proliferating and differentiated keratinocytes. On day 4, ML.myc2 transgenic pups develop a hyperkeratotic phenotype, which progressively worsens until day 7. Upon histological analysis, both hyperplasia and hyperkeratosis were evident. Bromodeoxyuridine (BrdU) incorporation revealed that transgenic mice had a threefold increase in the number of proliferating cells as compared with a normal littermate, Proliferative cells in the ML.myc2 epidermis were also found to be suprabasal, suggesting an inhibition of terminal differentiation in keratinocytes, Inhibition of terminal differentiation by c-Myc overexpression was further suggested by aberrant expression of differentiation markers, keratin 1, keratin 6, loricrin, and filaggrin in ML.myc2 transgenic mice, Interestingly, ML.myc2 keratinocytes exhibit a reduced sensitivity to UV-B induced apoptosis, in vivo. In vitro studies reveal the reduced sensitivity of ML.myc2 keratinocytcs to UV-B irradiation is growth factor dependent. These findings provide evidence that overexpression of c-Myc in the epidermis induces proliferation, inhibits terminal differentiation and decreases the sensitivity of keratinocytes to UV-B induced apoptosis.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Roop, DR (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA52607, CA09197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BERTSCH S, 1982, CELL TISSUE KINET, V15, P81, DOI 10.1111/j.1365-2184.1982.tb01026.x; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; COTTER FE, 1993, CANCER SURV, V16, P157; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GARMYN M, 1992, J INVEST DERMATOL, V99, P743, DOI 10.1111/1523-1747.ep12614470; GAZDAR AF, 1994, ANTICANCER RES, V14, P261; GREENHALG DA, 1995, SKIN CANC MECHANISMS, P317; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; HOGAN B, 1986, MANIPULATING MOUSE E; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; JIN Y, 1992, RADIAT RES, V132, P193, DOI 10.2307/3578526; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KOPAN R, 1989, GENE DEV, V5, P1; KOPNIN B, 1993, TUMORI, V79, P235, DOI 10.1177/030089169307900401; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rothnagel J A, 1995, J Invest Dermatol, V104, p42S; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; Sato H, 1997, PHOTOCHEM PHOTOBIOL, V65, P908, DOI 10.1111/j.1751-1097.1997.tb01942.x; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Trudel M, 1998, AM J PATHOL, V152, P219; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wu M, 1996, MOL CELL BIOL, V16, P5015; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	52	66	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4870	4878		10.1038/sj.onc.1203040	http://dx.doi.org/10.1038/sj.onc.1203040			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490820				2022-12-25	WOS:000082184800011
J	Jockers, R; Angers, S; Da Silva, A; Benaroch, P; Strosberg, AD; Bouvier, M; Marullo, S				Jockers, R; Angers, S; Da Silva, A; Benaroch, P; Strosberg, AD; Bouvier, M; Marullo, S			beta(2)-adrenergic receptor down-regulation - Evidence for a pathway that does not require endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; EPIDERMAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTOR; AGONIST-PROMOTED DESENSITIZATION; UBIQUITIN-PROTEASOME PATHWAY; HUMAN ASTROCYTOMA-CELLS; MEDIATED ENDOCYTOSIS; BETA-2-ADRENERGIC RECEPTOR; TYROSINE KINASE; PLASMA-MEMBRANE	Sustained activation of most G protein-coupled receptors causes a time-dependent reduction of receptor density in intact cells. This phenomenon, known as downregulation, is believed to depend on a ligand-promoted change of receptor sorting from the default endosome-plasma membrane recycling pathway to the endosome-lysosome degradation pathway. This model is based on previous studies of epidermal growth factor (EGF) receptor degradation and implies that receptors need to be endocytosed to be down-regulated. In stable clones of L cells expressing beta(2)-adrenergic receptors (beta(2)ARs), sustained agonist treatment caused a time-dependant decrease in both beta(2)AR binding sites and immune-detectable receptor. Blocking beta(2)AR endocytosis with chemical. treatments or by expressing a dominant negative mutant of dynamin could not prevent this phenomenon. Specific blockers of the two main intracellular degradation pathways, lysosomal and proteasome-associated, were ineffective in preventing beta(2)AR down-regulation. Further evidence for an endocytosis-independent pathway of beta(2)AR down-regulation was provided by studies in A431 cells, a cell Line expressing both endogenous beta(2)AR and EGF receptors. In these cells, inhibition of endocytosis and inactivation of the lysosomal degradation pathway did not block beta(2)AR down-regulation, whereas EGF degradation was inhibited. These data indicate that, contrary to what is currently postulated, receptor endocytosis is not a necessary prerequisite for beta(2)AR down-regulation and that the inactivation of beta(2)ARs, leading to a reduction in binding sites, may occur at the plasma membrane.	Univ Paris 05, ICGM, F-75679 Paris 14, France; CNRS, UPR 415, F-75014 Paris, France; Univ Paris 07, ICGM, F-75014 Paris, France; CNRS, UPRES A 8068, F-75679 Paris 14, France; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montreal	Marullo, S (corresponding author), Univ Paris 05, ICGM, Pavillon Gustave Roussy,27 Rue Faubourg St Jacque, F-75679 Paris 14, France.		Bouvier, Michel/H-2758-2014; Angers, Stephane/E-1432-2014; Jockers, Ralf/P-2272-2017; Jockers, Ralf/Q-2100-2019; Marullo, Stefano/C-6142-2008	Bouvier, Michel/0000-0003-1128-0100; Angers, Stephane/0000-0001-7241-9044; Jockers, Ralf/0000-0002-4354-1750; Jockers, Ralf/0000-0002-4354-1750; Marullo, Stefano/0000-0001-9604-9973; Benaroch, Philippe/0000-0002-2655-0129				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CHEN J, 1994, J BIOL CHEM, V269, P16041; CRESSWELL P, 1997, CURR BIOL, V7, P552; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Danner S, 1998, J BIOL CHEM, V273, P3223, DOI 10.1074/jbc.273.6.3223; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DELAVIERKLUTCHKO C, 1984, FEBS LETT, V169, P151, DOI 10.1016/0014-5793(84)80308-7; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DOSS RC, 1981, J BIOL CHEM, V256, P2281; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HEIN L, 1994, J BIOL CHEM, V269, P27719; HERTEL C, 1985, J BIOL CHEM, V260, P2547; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Marullo S, 1999, RECEPTOR CHANNEL, V6, P255; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MORISHIMA I, 1980, MOL PHARMACOL, V18, P370; NANTEL F, 1995, BRIT J PHARMACOL, V114, P1045, DOI 10.1111/j.1476-5381.1995.tb13311.x; NANTEL F, 1994, J BIOL CHEM, V269, P13148; NANTEL F, 1993, MOL PHARMACOL, V43, P548; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SORKIN AD, 1988, EXP CELL RES, V175, P192, DOI 10.1016/0014-4827(88)90266-2; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WALDO GL, 1984, MOL PHARMACOL, V26, P424; WILLINGHAM MC, 1983, EXP CELL RES, V146, P163, DOI 10.1016/0014-4827(83)90334-8; YANG J, 1995, MOL PHARMACOL, V48, P477; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	62	84	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28900	28908		10.1074/jbc.274.41.28900	http://dx.doi.org/10.1074/jbc.274.41.28900			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506134	hybrid			2022-12-25	WOS:000083017800013
J	Gordon, DM; Roof, DM				Gordon, DM; Roof, DM			The kinesin-related protein Kip1p of Saccharomyces cerevisiae is bipolar	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; MITOTIC SPINDLE; CRYSTAL-STRUCTURE; COILED COILS; HEAVY-CHAIN; LIGHT-CHAIN; BIMC FAMILY; MOTOR; DROSOPHILA; GENE	Kip1p is a mitotic spindle-associated kinesin-related protein in Saccharomyces cerevisiae that participates in spindle pole separation. Here, we define the domain arrangement and polypeptide composition of the Kip1p holoenzyme. Electron microscopy of rotary shadowed Kip1p molecules revealed two globular domains 14 nm in diameter connected by a 73-nm long stalk. When the Kip1p domain homologous to the kinesin motor domain was decorated with an unrelated protein, the diameter of the globular domains at both ends of the stalk increased, indicating that Kip1p is bipolar. Soluble Kip1p isolated from S. cerevisiae cells was homomeric, based on the similarity of the sedimentation coefficients of native Kip1p from S. cerevisiae and Kip1p which was purified after expression in insect cells. The holoenzyme molecular weight was estimated using the sedimentation coefficient and Stokes radius, and was most consistent with a tetrameric composition. Kip1p exhibited an ionic strength-dependent transition in its sedimentation coefficient, revealing a potential regulatory mechanism. The position of kinesin motor-related domains at each end of the stalk may allow Kip1p to cross-link, either parallel or antiparallel microtubules during mitotic spindle assembly and pole separation.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Roof, DM (corresponding author), Univ Penn, Sch Med, Dept Physiol, 3700 Hamilton Walk, Philadelphia, PA 19104 USA.				NIGMS NIH HHS [GM50884] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; Cantor C.R., 1980, BIOPHYS CHEM; COLE DG, 1994, J BIOL CHEM, V269, P22913; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Drummond DR, 1998, J CELL SCI, V111, P853; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; Gheber L, 1999, J BIOL CHEM, V274, P9564, DOI 10.1074/jbc.274.14.9564; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LOESSER KE, 1990, J STRUCT BIOL, V103, P48, DOI 10.1016/1047-8477(90)90085-Q; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MURRAY M, 1997, MOL CELL BIOL, V17, P2991; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Rose MD., 1990, METHODS YEAST GENETI; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Stock MF, 1999, J BIOL CHEM, V274, P14617, DOI 10.1074/jbc.274.21.14617; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Tanford C., 1961, PHYS CHEM MACROMOLEC; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; Wedaman KP, 1996, J CELL BIOL, V132, P371, DOI 10.1083/jcb.132.3.371; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	47	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28779	28786		10.1074/jbc.274.40.28779	http://dx.doi.org/10.1074/jbc.274.40.28779			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497250	hybrid			2022-12-25	WOS:000082912700099
J	Lou, DQ; Tannour, M; Selig, L; Thomas, D; Kahn, A; Vasseur-Cognet, M				Lou, DQ; Tannour, M; Selig, L; Thomas, D; Kahn, A; Vasseur-Cognet, M			Chicken ovalbumin upstream promoter-transcription factor II, a new partner of the glucose response element of the L-type pyruvate kinase gene, acts as an inhibitor of the glucose response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-4; COUP-TF; STIMULATORY FACTOR; CARBOHYDRATE REGULATION; MEDIATED ACTIVATION; TISSUE-SPECIFICITY; THYROID-HORMONE; OXYTOCIN GENE; RAT-LIVER; EXPRESSION	Transcription of the L-type pyruvate kinase (L-PK) gene is induced by glucose in the presence of insulin and repressed by glucagon via cyclic AMP, The DNA regulatory sequence responsible for mediating glucose and cyclic AMP responses, called glucose response element (GlRE), consists of two degenerated E boxes spaced by 5 base pairs and is able to bind basic helix-loop-helix/leucine zipper proteins, in particular the upstream stimulatory factors (USFs), From ex vivo and in vivo experiments, it appears that USFs are required for correct response of the L-PK gene to glucose, but their expression and binding activity are not known to be regulated by glucose. A genetic screen in yeast has allowed us to identify a novel transcriptional factor binding to the GlRE, i.e. the chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII), Binding of COUP-TFII to the GlRE was confirmed by electrophoretic mobility shift assays, and COUP-TFII-containing complexes were detectable in liver nuclear extracts. Neither abundance nor binding activity of COUP-TFII appeared to be significantly regulated by diets. In footprinting experiments, two COUP-TFII-binding sites overlapping the E boxes were detected. Overexpression of COUP-TFII abrogated the USF-dependent transactivation of an artificial GlRE-dependent promoter in COS cells and the glucose responsiveness of the L-PK promoter in hepatocytes in primary culture. In addition, a mutated GlRE with increased affinity for USF and very low affinity for COUP-TFII conferred a dramatically decreased glucose responsiveness on the L-PK promoter in hepatocytes in primary culture by increasing activity of the reporter gene in low glucose condition. We propose that COUP-TFII could be a negative regulatory component of the glucose sensor complex assembled on the GlRE of the L-PK gene and most likely of other glucose-responsive genes as well.	Univ Paris 05, Inst Cochin Genet Mol, INSERM, U129, F-75014 Paris, France; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Vasseur-Cognet, M (corresponding author), Univ Paris 05, Inst Cochin Genet Mol, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		Vasseur, Mireille/L-6958-2017; TANNOUR LOUET, Mounia/G-5413-2017; Mounia, TANNOUR LOUET/T-2622-2019	Vasseur, Mireille/0000-0001-6963-4114; TANNOUR LOUET, Mounia/0000-0003-0614-063X; Mounia, TANNOUR LOUET/0000-0003-0614-063X				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BAKKE M, 1995, MOL ENDOCRINOL, V9, P327, DOI 10.1210/me.9.3.327; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Blaiseau PL, 1997, MOL CELL BIOL, V17, P3640, DOI 10.1128/MCB.17.7.3640; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; Chu K, 1998, MOL CELL ENDOCRINOL, V137, P145, DOI 10.1016/S0303-7207(97)00241-4; COGNET M, 1991, J BIOL CHEM, V266, P7368; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Hasegawa J, 1999, J BIOL CHEM, V274, P1100, DOI 10.1074/jbc.274.2.1100; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; Hillgartner FB, 1996, BIOCHEM J, V319, P263, DOI 10.1042/bj3190263; JUMP DB, 1990, J BIOL CHEM, V265, P3474; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; Lazennec G, 1997, MOL CELL BIOL, V17, P5053, DOI 10.1128/MCB.17.9.5053; Leclerc I, 1998, FEBS LETT, V431, P180, DOI 10.1016/S0014-5793(98)00745-5; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LIU ZR, 1995, BIOCHEM J, V308, P105, DOI 10.1042/bj3080105; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; Miquerol L, 1996, GENE EXPRESSION, V5, P315; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Portois L, 1999, J BIOL CHEM, V274, P8181, DOI 10.1074/jbc.274.12.8181; POWER RF, 1992, TRENDS PHARMACOL SCI, V13, P318, DOI 10.1016/0165-6147(92)90099-R; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; Raclot T, 1998, BIOCHEM BIOPH RES CO, V245, P510, DOI 10.1006/bbrc.1998.8469; Rodriguez JC, 1997, BIOCHEM J, V326, P587, DOI 10.1042/bj3260587; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEBER A, 1984, J BIOL CHEM, V259, P1798; Yamada K, 1999, BIOCHEM BIOPH RES CO, V257, P44, DOI 10.1006/bbrc.1999.0410; Yamada K, 1997, BIOCHEM J, V324, P917, DOI 10.1042/bj3240917	55	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28385	28394		10.1074/jbc.274.40.28385	http://dx.doi.org/10.1074/jbc.274.40.28385			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497199	hybrid			2022-12-25	WOS:000082912700048
J	Ma, AD; Abrams, CS				Ma, AD; Abrams, CS			Pleckstrin induces cytoskeletal reorganization via a Rac-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BRUTON TYROSINE KINASE; BETA-GAMMA-SUBUNITS; HOMOLOGY-DOMAIN; PHOSPHOINOSITIDE 3-KINASE; CRYSTAL-STRUCTURE; PH DOMAINS; PHOSPHATIDYLINOSITOL 4-KINASE; G(BETA-GAMMA) SUBUNITS; BINDING	Pleckstrin homology (PH) domains are present in over one hundred signaling molecules, where they are thought to mediate membrane targeting by binding to phosphoinositides, They were initially defined at the NH2 and COOH termini of the molecule, pleckstrin, a major substrate for protein kinase C in platelets. We have previously reported that pleckstrin associates with the plasma membrane, where it induces the formation of villous and ruffled structures from the surface of transfected cells (1). We now show that overexpression of pleckstrin results in reorganization of the actin cytoskeleton. This pleckstrin effect is regulated by its phosphorylation and requires the NH2-terminal, but not the COOH-terminal, PH domain. Overexpression of the NH2-terminal PH domain alone of pleckstrin is sufficient to induce the cytoskeletal effects. Pleckstrin-induced actin rearrangements are not inhibited by pharmacologic inhibition of phosphatidylinositol 3-kinase, nor are they blocked by co-expression of a dominant negative phosphatidylinositol 3-kinase. The cytoskeletal effects of pleckstrin can be blocked by co-expression of a dominant negative Rac1 variant, but not wild-type Rac and not a dominant negative Cdc42 variant. These data indicate that the NH2-terminal PH domain of pleckstrin induces reorganization of the actin cytoskeleton via a pathway dependent on Rac but independent of Cdc42 and phosphatidylinositol 3-kinase.	Univ Penn, Div Hematol Oncol, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Abrams, CS (corresponding author), Univ Penn, Div Hematol Oncol, Sch Med, Dept Med, Biomed Res Bldg 2-3,912,421 Curie Blvd, Philadelphia, PA 19104 USA.	abramsc@mail.med.upenn.edu			NHLBI NIH HHS [HL40387, HL54500, HL03505] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500, P01HL040387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1995, J BIOL CHEM, V270, P23317, DOI 10.1074/jbc.270.40.23317; Abrams CS, 1996, J BIOL CHEM, V271, P25192, DOI 10.1074/jbc.271.41.25192; Abrams CS, 1996, BBA-MOL CELL RES, V1314, P233, DOI 10.1016/S0167-4889(96)00109-7; ABRAMS CS, 1995, J BIOL CHEM, V270, P14485, DOI 10.1074/jbc.270.24.14485; Auethavekiat V, 1997, J BIOL CHEM, V272, P1786, DOI 10.1074/jbc.272.3.1786; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Leung T, 1996, MOL CELL BIOL, V16, P5313; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Ma AD, 1998, BLOOD, V92, p303A; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	44	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28730	28735		10.1074/jbc.274.40.28730	http://dx.doi.org/10.1074/jbc.274.40.28730			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497244	hybrid			2022-12-25	WOS:000082912700093
J	Majumder, S; Ghoshal, K; Li, ZL; Jacob, ST				Majumder, S; Ghoshal, K; Li, ZL; Jacob, ST			Hypermethylation of metallothionein-I promoter and suppression of its induction in cell lines overexpressing the large subunit of Ku protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; AUTOANTIGEN-KU; REPRESS TRANSCRIPTION; HSP70 EXPRESSION; METHYLATED DNA; FACTOR CPBF; MECP2; GENE; PURIFICATION; SENSITIVITY	We have shown previously that the heavy metal-induced metallothionein-I (MT-I) gene expression is specifically repressed in a rat fibroblast cell line (Ku-80) overexpressing the 80-kDa subunit of Ku autoantigen but not in cell Lines overexpressing the 70-kDa subunit or Ku heterodimer. Here, we explored the molecular mechanism of silencing of MT-I gene in Ku-80 cells. Genomic footprinting analysis revealed both basal and heavy metal-inducible binding at specific cis elements in the parental cell line (Rat-1), By contrast, MT-I promoter in Ku-80 cells was refractory to any transactivating factors, implying alteration of chromatin structure. Treatment of two clonal lines of Ku-80 cells with 5-azacytidine, a potent DNA demethylating agent, rendered MT-I gene inducible by heavy metals, suggesting that the gene is methylated in these cells. Bisulfite genomic sequencing revealed that all 21 CpG dinucleotides in MT-I immediate promoter were methylated in Ku-80 cells, whereas only four CpG dinucleotides were methylated in Rat-1 cells. Almost all methylated CpG dinucleotides were demethylated in Ku-80 cells after 5-azacytidine treatment. To our knowledge, this is the Gst report that describes hypermethylation of a specific gene promoter and its resultant silencing in response to overexpression of a cellular protein.	Ohio State Univ, Coll Med, Dept Med Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Jacob, ST (corresponding author), Ohio State Univ, Coll Med, Dept Med Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.				NCI NIH HHS [R01 CA061321-05, CA 61321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Baylin SB, 1998, ADV CANCER RES, V72, P141; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DATTA PK, 1995, J BIOL CHEM, V270, P8637, DOI 10.1074/jbc.270.15.8637; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Ghosh AK, 1997, ONCOGENE, V14, P589, DOI 10.1038/sj.onc.1200866; Ghoshal K, 1998, P NATL ACAD SCI USA, V95, P10390, DOI 10.1073/pnas.95.18.10390; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KIM D, 1995, J BIOL CHEM, V270, P15277, DOI 10.1074/jbc.270.25.15277; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; LI GC, 1995, P NATL ACAD SCI USA, V92, P4512, DOI 10.1073/pnas.92.10.4512; MAY G, 1991, J BIOL CHEM, V266, P3052; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NIU H, 1994, P NATL ACAD SCI USA, V91, P9101, DOI 10.1073/pnas.91.19.9101; Niu Huifeng, 1995, Gene Expression, V4, P111; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; Radtke F, 1996, BIOL CHEM H-S, V377, P47, DOI 10.1515/bchm3.1996.377.1.47; Romero F, 1996, MOL CELL BIOL, V16, P37; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; Yang SH, 1996, MOL CELL BIOL, V16, P3799, DOI 10.1128/mcb.16.7.3799	32	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28584	28589		10.1074/jbc.274.40.28584	http://dx.doi.org/10.1074/jbc.274.40.28584			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497224	Green Accepted, hybrid			2022-12-25	WOS:000082912700073
J	Wang, J; Takeuchi, T; Yokota, H; Izumi, T				Wang, J; Takeuchi, T; Yokota, H; Izumi, T			Novel rabphilin-3-like protein associates with insulin-containing granules in pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY VESICLES; SYNAPTIC VESICLES; SYNAPTOTAGMIN-III; CHROMAFFIN CELLS; ENDOCRINE-CELLS; FUNCTIONAL-ROLE; EXOCYTOSIS; EXPRESSION; BINDING; LOCALIZATION	A novel rabphilin-3-like gene, granuphilin, has been identified in pancreatic beta cells by comparing genes expressed in pancreatic alpha and beta cell lines using mRNA differential display. The domain structure of the protein products of the granuphilin gene contains an amino-terminal zinc-finger motif and carboxyl-terminal C-2-domains, similar to that of the rabphilin-3 gene. There are two isoforms: the larger isoform, granuphilin-a, has two C-2-domains, whereas the smaller one, granuphilin-b, contains only the first C-2-domain, Granuphilin is specifically expressed in pancreatic beta cells and the pituitary gland, but not in pancreatic alpha cells, the adrenal gland, or other major organs such as the brain. A portion of granuphilin associates with insulin-containing dense-core granules, but not with synaptic-like microvesicles in beta cells, Thus, its distribution pattern presents a striking contrast with that of rabphilin-3, which associates with small synaptic vesicles in neurons. The first C-2-domain of granuphilin binds phospholipids in a Ca2+-independent manner, whereas the second one does not. These distinctive characteristics of granuphilin suggest that it is not a simple counterpart of rabphilin-3 in endocrine cells and that it has a unique role in the regulated exocytosis of dense-core granules in endocrine tissues.	Gunma Univ, Inst Mol & Cellular Regulat, Dept Mol Med, Maebashi, Gumma 3718512, Japan	Gunma University	Izumi, T (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Dept Mol Med, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.							CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Hirayama I, 1999, DIABETES, V48, P1237, DOI 10.2337/diabetes.48.6.1237; INAGAKI N, 1994, J BIOCHEM-TOKYO, V116, P239, DOI 10.1093/oxfordjournals.jbchem.a124512; Kayo T, 1997, DIABETES, V46, P1296, DOI 10.2337/diabetes.46.8.1296; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Martin TFJ, 1998, VITAM HORM, V54, P207, DOI 10.1016/S0083-6729(08)60926-7; Martin TFJ, 1997, J BIOL CHEM, V272, P14447, DOI 10.1074/jbc.272.22.14447; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mizuta M, 1997, DIABETES, V46, P2002, DOI 10.2337/diabetes.46.12.2002; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; OBENDORF D, 1988, J NEUROCHEM, V51, P1573, DOI 10.1111/j.1471-4159.1988.tb01127.x; OHO C, 1995, NEUROSCI LETT, V186, P208, DOI 10.1016/0304-3940(95)11317-P; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; PASTERIS NG, 1994, CELL, V79, P669; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; Regazzi R, 1996, J CELL SCI, V109, P2265; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SCHIGGER H, 1987, ANAL BIOCHEM, V166, P368; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; THOMASREETZ AC, 1994, FASEB J, V8, P209, DOI 10.1096/fasebj.8.2.7907072; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164	35	93	98	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28542	28548		10.1074/jbc.274.40.28542	http://dx.doi.org/10.1074/jbc.274.40.28542			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497219	hybrid			2022-12-25	WOS:000082912700068
J	Bandoh, K; Aoki, J; Hosono, H; Kobayashi, S; Kobayashi, T; Murakami-Murofushi, K; Tsujimoto, M; Arai, H; Inoue, K				Bandoh, K; Aoki, J; Hosono, H; Kobayashi, S; Kobayashi, T; Murakami-Murofushi, K; Tsujimoto, M; Arai, H; Inoue, K			Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SIGNALING PATHWAYS; CA2+ MOBILIZATION; PHOSPHOLIPASE-C; IDENTIFICATION; PROLIFERATION; ACTIVATION; INHIBITION; MESSENGER; ENCODES	Lysophosphatidic acid (LPA), together with sphingosine l-phosphate, is a bioactive lipid mediator that acts on G-protein-coupled receptors to evoke multiple cellular responses, including Ca2+ mobilization, modulation of adenylyl cyclase, and mitogen-activated protein (MAP) kinase activation. In this study, we isolated a human cDNA encoding a novel G-protein-coupled receptor, designated EDG7, and characterized it as a cellular receptor for LPA. The amino acid sequence of the EDG7 protein is 53.7 and 48.8% identical to those of the human functional LPA receptors EDGE and EDG4, respectively, previously identified. LPA (oleoyl) but not other lysophospholipids induced an increase in the [Ca2+](i) of EDG7-overexpressing Sf9 cells. Other LPA receptors, EDG4 but not EDG2, transduced the Ca2+ response by LPA when expressed in Sf9 cells. LPAs with an unsaturated fatty acid but not with a saturated fatty acid induced an increase in the [Ca2+](i) of EDG7-expressing Sf9 cells, whereas LPAs with both saturated and unsaturated fatty acids elicited a Ca2+ response in Sf9 cells expressing EDG4. In EDG7- or EDG4-expressing Sf9 cells, LPA stimulated forskolin-induced increase in intracellular cAMP levels, which was not observed in EDG2-expressing cells. In PC12 cells, EDG4 but not EDG2 or EDG7 mediated the activation of MAP kinase by LPA. Neither the EDG7- nor EDG4-transduced Ca2+ response or cAMP accumulation was inhibited by pertussis toxin. In conclusion, the present study demonstrates that EDG7, a new member of the EDG family of G-protein-coupled receptors, is a specific LPA receptor that shows distinct properties from known cloned LPA receptors in ligand specificities, Ca2+ response, modulation of adenylyl cyclase, and MAP kinase activation.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Sci Univ Tokyo, Fac Pharmaceut Sci, Shinjuku Ku, Tokyo 1620826, Japan; Ochanomizu Univ, Fac Sci, Dept Biol, Bunkyo Ku, Tokyo 1128610, Japan; Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan	University of Tokyo; Tokyo University of Science; Ochanomizu University; RIKEN	Aoki, J (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.			Aoki, Junken/0000-0001-9435-1896				An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Dixon RJ, 1999, AM J PHYSIOL-RENAL, V276, pF191, DOI 10.1152/ajprenal.1999.276.2.F191; DURIEUX ME, 1992, AM J PHYSIOL, V263, pC869; Erickson JP, 1998, J BIOL CHEM, V273, P1506, DOI 10.1074/jbc.273.3.1506; Felder CC, 1998, J PHARMACOL EXP THER, V284, P291; Figler RA, 1996, MOL PHARMACOL, V50, P1587; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HLA T, 1990, J BIOL CHEM, V265, P9308; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Liliom K, 1996, MOL PHARMACOL, V50, P616; Liliom K, 1996, AM J PHYSIOL-CELL PH, V270, pC772, DOI 10.1152/ajpcell.1996.270.3.C772; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; Macrae AD, 1996, MOL BRAIN RES, V42, P245, DOI 10.1016/S0169-328X(96)00128-3; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; MURAKAMIMUROFUSHI K, 1992, J BIOL CHEM, V267, P21512; Ohata H, 1997, LIFE SCI, V60, P1287, DOI 10.1016/S0024-3205(97)00072-6; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	38	452	472	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27776	27785		10.1074/jbc.274.39.27776	http://dx.doi.org/10.1074/jbc.274.39.27776			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488122	hybrid			2022-12-25	WOS:000082739100061
J	Manganello, JM; Djellas, Y; Borg, C; Antonakis, K; Le Breton, GC				Manganello, JM; Djellas, Y; Borg, C; Antonakis, K; Le Breton, GC			Cyclic AMP-dependent phosphorylation of thromboxane A(2) receptor-associated G alpha(13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NUCLEOTIDE-BINDING-PROTEIN; BETA-ADRENERGIC-RECEPTOR; HUMAN-BLOOD PLATELETS; PORTAL-VEIN MYOCYTES; ALPHA-SUBUNITS; ADENYLATE-CYCLASE; PHOSPHOLIPASE-C; PERTUSSIS-TOXIN; MOLECULAR MECHANISMS	Although it is well established that cAMP inhibits platelet activation induced by all agonists, the thromboxane A(2) signal transduction pathway was found to be particularly sensitive to such inhibition. Therefore, we examined whether cAMP-dependent kinase mediates phosphorylation of the thromboxane A(2) receptor-G-protein complex. It was found that cAMP induces protein kinase A-dependent [gamma-P-32]ATP labeling of solubilized membrane proteins in the region of G alpha subunits, i.e. 38-45 kDa. Moreover, ligand affinity chromatography purification of thromboxane A(2) receptor-G-protein complexes from these membranes revealed that 38-45-kDa phosphoproteins co-purify with thromboxane A(2) receptors. Immunoprecipitation of the affinity column eluate with a G alpha(13) antibody demonstrated that 8-Br-cAMP increased phosphorylation of thromboxane A(2) receptor-associated G alpha(13) by 87 +/- 27%. In separate experiments, immunopurification of G alpha(13) On microtiter wells coated with a different G alpha(13) antibody revealed that 8-Br-cAMP increased G alpha(13) phosphorylation by 53 +/- 19%. Finally, treatment of P-32-labeled whole platelets with prostacyclin resulted in a 90 +/- 14% increase in phosphorylated Ga-13 that was abolished by pretreatment with the adenylate cyclase inhibitor MDL-12. These results provide the first evidence that protein kinase A mediates phosphorylation of G alpha(13) both in vitro and in vivo and provides a basis for the preferential inhibition of thromboxane A(2)-mediated signaling in platelets by cAMP.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Ecole Natl Super Chim Paris, CNRS, UMR 133, F-75231 Paris, France	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Chimie ParisTech	Le Breton, GC (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott St,M-C 868, Chicago, IL 60612 USA.				NHLBI NIH HHS [HL-24530, T32 HL07692] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024530, T32HL007692] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDASSARE JJ, 1993, BIOCHEM J, V291, P235, DOI 10.1042/bj2910235; Bohm SK, 1997, BIOCHEM J, V322, P1; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; BRACE LD, 1985, AM J PHYSIOL, V249, pH1, DOI 10.1152/ajpheart.1985.249.1.H1; BRASS LF, 1987, J CLIN INVEST, V79, P1269, DOI 10.1172/JCI112947; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHENG HC, 1986, J BIOL CHEM, V261, P989; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Djellas Y, 1999, J BIOL CHEM, V274, P14325, DOI 10.1074/jbc.274.20.14325; DORN GW, 1990, CIRCULATION, V81, P212, DOI 10.1161/01.CIR.81.1.212; FEINSTEIN MB, 1983, J BIOL CHEM, V258, P1250; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; FISCHER TH, 1987, BIOCHEM BIOPH RES CO, V149, P700, DOI 10.1016/0006-291X(87)90424-4; FITZGERALD GA, 1987, FASEB J, V46, P154; FOX JEB, 1979, BIOCHEM J, V184, P651, DOI 10.1042/bj1840651; Habib A, 1999, J BIOL CHEM, V274, P2645, DOI 10.1074/jbc.274.5.2645; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HALENDA SP, 1986, FEBS LETT, V204, P341, DOI 10.1016/0014-5793(86)80840-7; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HATHAWAY DR, 1981, NATURE, V291, P252, DOI 10.1038/291252a0; HETTASCH JM, 1987, BIOCHIM BIOPHYS ACTA, V931, P49, DOI 10.1016/0167-4889(87)90049-8; IMAIZUMI T, 1991, EUR J PHARM-MOLEC PH, V207, P189, DOI 10.1016/0922-4106(91)90030-L; KASERGLANZMANN R, 1979, BIOCHIM BIOPHYS ACTA, V558, P344, DOI 10.1016/0005-2736(79)90271-2; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KIM SO, 1992, BIOCHEM PHARMACOL, V43, P313; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; KITAMURA K, 1995, AM J PHYSIOL, V268, P101; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEVISTRE R, 1995, BIOCHEM J, V306, P765, DOI 10.1042/bj3060765; LEVY RI, 1980, CIRCULATION, V61, P1165; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MILLIGAN G, 1992, FEBS LETT, V297, P186, DOI 10.1016/0014-5793(92)80357-M; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAMBI P, 1985, J BIOL CHEM, V260, P2165; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1996, J BIOL CHEM, V271, P26044, DOI 10.1074/jbc.271.42.26044; OGLETREE ML, 1987, FED PROC, V46, P133; OWEN NE, 1981, AM J PHYSIOL, V241, pH613, DOI 10.1152/ajpheart.1981.241.4.H613; PERKINS JP, 1983, CURR TOP MEMBR TRANS, V18, P85; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PYNE NJ, 1992, BIOCHEM BIOPH RES CO, V186, P1081, DOI 10.1016/0006-291X(92)90857-H; SEISS W, 1990, BIOCHEM J, V271, P815; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SIESS W, 1985, BLOOD, V65, P1141; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; SVENSSON J, 1977, PROSTAGLANDINS, V14, P425, DOI 10.1016/0090-6980(77)90258-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; WHITTLE BJR, 1983, BRIT MED BULL, V39, P232, DOI 10.1093/oxfordjournals.bmb.a071825; WILLIAMS AG, 1990, BLOOD, V76, P721; YATOMI Y, 1992, EUR J BIOCHEM, V205, P1003, DOI 10.1111/j.1432-1033.1992.tb16867.x	66	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					28003	28010		10.1074/jbc.274.39.28003	http://dx.doi.org/10.1074/jbc.274.39.28003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488151	hybrid			2022-12-25	WOS:000082739100090
J	Tang, Y; Beuerlein, G; Pecht, G; Chilton, T; Huse, WD; Watkins, JD				Tang, Y; Beuerlein, G; Pecht, G; Chilton, T; Huse, WD; Watkins, JD			Use of a peptide mimotope to guide the humanization of MRK-16, an anti-P-glycoprotein monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE-EPITOPE LIBRARY; BACTERIAL TRANSPORT PROTEINS; RESHAPING HUMAN-ANTIBODIES; SITE-SPECIFIC MUTAGENESIS; RESISTANT TUMOR-CELLS; FILAMENTOUS PHAGE; MULTIDRUG-RESISTANCE; INVITRO IMMUNIZATION; PHENOTYPIC SELECTION; IMMUNE-RESPONSE	A mimotope-guided strategy for engineering antibodies directed against orphan targets or antigens that are difficult to purify was developed and used to humanize the murine MRK-16 monoclonal antibody (mAb), MRK-16 recognizes a conformational epitope of a 170-kDa membrane protein, termed P-glycoprotein (P-gp). Elevated expression of P-gp on tumor cells is associated with resistance to cytotoxic drugs, a major obstacle in chemotherapy. Murine MRK-16 was used to enrich and screen a phage-displayed peptide library to identify reactive mimotopes, One peptide, termed ALR1, was enriched to a greater extent than others and subsequently was expressed as a fusion protein with glutathione S-transferase. ALR1 fusion protein bound MRK-16 specifically and inhibited binding of MRK-16 to cells expressing elevated levels of P-gp. To humanize MRK-16, the murine complementarity determining regions were grafted onto homologous human heavy and light chain variable region frameworks. Framework residues that differed between the murine MRK-16 and the homologous human templates were analyzed and subsequently, five framework positions potentially important for maintaining the specificity and affinity of MRK-16 were identified. A combinatorial library consisting of 32 variants encoding all possible combinations of murine and human residues at the five differing framework positions was expressed in a phage system. In the absence of purified P-gp, ALR1 fusion protein was used as surrogate antigen to screen the antibody library to identify the framework combination that most preserved the binding activity of the mAb. On the basis of the initial screening against the mimotope four antibody variants were selected for further characterization. The binding affinity of these variants for the ALR1 fusion protein correlated with their binding to cells expressing elevated levels of P-gp. Thus, peptide mimotopes which can be identified for virtually any antibody including those that recognize conformational or carbohydrate epitopes, can serve as antigen templates for antibody engineering.	Ixsys Inc, San Diego, CA 92121 USA		Watkins, JD (corresponding author), Ixsys Inc, San Diego, CA 92121 USA.	jwatkins@ixsysinc.com						BALASS M, 1993, P NATL ACAD SCI USA, V90, P10638, DOI 10.1073/pnas.90.22.10638; BORREBAECK CAK, 1988, P NATL ACAD SCI USA, V85, P3995, DOI 10.1073/pnas.85.11.3995; BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Chargelegue D, 1998, J VIROL, V72, P2040, DOI 10.1128/JVI.72.3.2040-2046.1998; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; DMello F, 1997, VIROLOGY, V237, P319, DOI 10.1006/viro.1997.8774; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GLASER SM, 1992, J IMMUNOL, V149, P3903; GORMAN SD, 1991, P NATL ACAD SCI USA, V88, P4181, DOI 10.1073/pnas.88.10.4181; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; Haaparanta T, 1995, MOL DIVERS, V1, P39, DOI 10.1007/BF01715808; HALE G, 1988, LANCET, V2, P1394; Hale G, 1995, IMMUNOTECHNOLOGY, V1, P175, DOI 10.1016/1380-2933(95)00017-8; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HAMADA H, 1987, CANCER RES, V47, P2860; HO MK, 1985, J IMMUNOL, V135, P3831; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; HUSE WD, 1992, J IMMUNOL, V149, P3914; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KABAT EA, 1977, J BIOL CHEM, V252, P6609; Kabat EA, 1991, SEQUENCES PROTEINS I; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; KHAZAELI MB, 1994, J IMMUNOTHER, V15, P42, DOI 10.1097/00002371-199401000-00006; KRISTENSSON K, 1995, VACCINES, P39; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lefkovits J, 1996, AM J CARDIOL, V77, P1045, DOI 10.1016/S0002-9149(96)00128-2; Mendez MJ, 1997, NAT GENET, V15, P146, DOI 10.1038/ng0297-146; Miller JL, 1996, P NATL ACAD SCI USA, V93, P3565, DOI 10.1073/pnas.93.8.3565; MILLER RA, 1983, BLOOD, V62, P988; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; Murray A, 1997, J CHROMATOGR A, V782, P49, DOI 10.1016/S0021-9673(97)00674-2; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; PADLAN EA, 1991, MOL IMMUNOL, V28, P489, DOI 10.1016/0161-5890(91)90163-E; Presta LG, 1997, CANCER RES, V57, P4593; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; Rosok MJ, 1996, J BIOL CHEM, V271, P22611, DOI 10.1074/jbc.271.37.22611; Rudolf MP, 1998, J IMMUNOL, V160, P3315; RUSSEL M, 1991, MOL MICROBIOL, V5, P1607, DOI 10.1111/j.1365-2958.1991.tb01907.x; Scheinberg David A., 1995, P45; SCHROFF RW, 1985, CANCER RES, V45, P879; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; STEWARD MW, 1995, J VIROL, V69, P7668, DOI 10.1128/JVI.69.12.7668-7673.1995; STOUTE JA, 1995, INFECT IMMUN, V63, P934, DOI 10.1128/IAI.63.3.934-939.1995; STUDNICKA GM, 1994, PROTEIN ENG, V7, P805, DOI 10.1093/protein/7.6.805; TSURUO T, 1989, JPN J CANCER RES, V80, P627, DOI 10.1111/j.1349-7006.1989.tb01688.x; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287; Watkins JD, 1998, ANAL BIOCHEM, V256, P169, DOI 10.1006/abio.1997.2523; Watkins JD, 1997, ANAL BIOCHEM, V253, P37, DOI 10.1006/abio.1997.2335; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; WOODLE ES, 1992, J IMMUNOL, V148, P2756; Wu HR, 1998, P NATL ACAD SCI USA, V95, P6037, DOI 10.1073/pnas.95.11.6037	60	7	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27371	27378		10.1074/jbc.274.39.27371	http://dx.doi.org/10.1074/jbc.274.39.27371			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488067	hybrid			2022-12-25	WOS:000082739100006
J	Xirodimas, DP; Lane, DP				Xirodimas, DP; Lane, DP			Molecular evolution of the thermosensitive PAb1620 epitope of human p53 by DNA shuffling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE; MUTANT P53; TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR; MONOCLONAL-ANTIBODY; BINDING ACTIVITY; CANCER-THERAPY; IN-VITRO; PROTEIN; MUTATIONS	Conformational stability of the p53 protein is an absolute necessity for its physiological function as a tumor suppressor. Recent in vitro studies have shown that wild-type p53 is a highly temperature-sensitive protein at the structural and functional levels. Upon heat treatment at 37 degrees C, p53 loses its wild-type (PAb1620(+)) conformation and its ability to bind DNA, but can be stabilized by different classes of ligands. To further investigate the thermal instability of p53, we isolated p53 mutants resistant to heat denaturation. For this purpose, we applied a recently developed random mutagenesis technique called DNA shuffling and screened for p53 variants that could retain reactivity to the native conformation-specific anti-p53 antibody PAb1620 upon thermal treatment. After three rounds of mutagenesis and screening, mutants were isolated with the desired phenotype. The isolated mutants were translated in vitro in either Escherichia coli or rabbit reticulocyte lysate and characterized biochemically. Mutational analysis identified 20 amino acid residues in the core domain of p53 (amino acids 101-120) responsible for the thermostable phenotype. Furthermore, the thermostable mutants could partially protect the PAb1620(+) conformation of tumor-derived p53 mutants from thermal unfolding, providing a novel approach for restoration of wild-type structure and possibly function to a subset of p53 mutants in tumor cells.	Univ Dundee, Inst Med Sci, Dept Biochem, Canc Res Campaign,Cell Transformat Grp, Dundee DD1 4HN, Scotland	University of Dundee	Lane, DP (corresponding author), Univ Dundee, Inst Med Sci, Dept Biochem, Canc Res Campaign,Cell Transformat Grp, Dundee DD1 4HN, Scotland.	dplane@bad.dundee.ac.uk	Lane, David P/C-4920-2008	Xirodimas, Dimitris/0000-0001-9275-1140; Lane, David/0000-0003-0551-3545				Abarzua P, 1996, ONCOGENE, V13, P2477; Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CANNON JV, 1990, EMBO J, V9, P1595; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Crameri A, 1997, NAT BIOTECHNOL, V15, P436, DOI 10.1038/nbt0597-436; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall AR, 1997, ONCOGENE, V14, P1371, DOI 10.1038/sj.onc.1200962; Hall PA, 1996, J PATHOL, V180, P1; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN M, 1994, CARCINOGENESIS, V15, P1, DOI 10.1093/carcin/15.1.1; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; Matsumura I, 1996, NAT BIOTECHNOL, V14, P366, DOI 10.1038/nbt0396-366; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1987, ONCOGENE, V1, P453; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Ravera MW, 1998, ONCOGENE, V16, P1993, DOI 10.1038/sj.onc.1201717; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	58	21	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					28042	28049		10.1074/jbc.274.39.28042	http://dx.doi.org/10.1074/jbc.274.39.28042			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488156	hybrid			2022-12-25	WOS:000082739100095
J	Zhu, QS; von Dippe, P; Xing, WX; Levy, D				Zhu, QS; von Dippe, P; Xing, WX; Levy, D			Membrane topology and cell surface targeting of microsomal epoxide hydrolase - Evidence for multiple topological orientations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID TRANSPORT; SIGNAL-ANCHOR PROTEINS; ENDOPLASMIC-RETICULUM; CATALYTIC ACTIVITY; PLASMA-MEMBRANE; HYDROPHOBIC SEGMENT; N-GLYCOSYLATION; RAT HEPATOCYTES; SEQUENCE; DOMAIN	Microsomal epoxide hydrolase (mEH) is a bifunctional membrane protein that plays a central role in the metabolism of xenobiotics and in the hepatocyte uptake of bile acids. Numerous studies have established that this protein is expressed both in the endoplasmic reticulum and at the sinusoidal plasma membrane. Preliminary evidence has suggested that mEH is expressed in the endoplasmic reticulum (ER) membrane with two distinct topological orientations. To further characterize the membrane topology and targeting of this protein, an N-glycosylation site was engineered into mEH to serve as a topological probe for the elucidation of the cellular location of mEH domains. The cDNAs for mEH and this mEH derivative (mEHg) were then expressed in vitro and in COS-7 cells. Analysis of total expressed protein in these systems indicated that mEHg was largely unglycosylated, suggesting that expression in the ER was primarily of a type I orientation (Ccyt/Nexo), However, analysis, by biotin/avidin labeling procedures, of mEHg expressed at the surface of transfected COS-7 cells, showed it to be fully glycosylated, indicating that the topological form targeted to this site originally had a type II orientation (Cexo/Ncyt) in the ER, The surface expression of mEH was also confirmed by confocal fluorescence scanning microscopy, The sensitivity of mEH topology to the charge at the N-terminal domain was demonstrated by altering the net charge over a range of 0 to +3. The introduction of one positive charge led to a significant inversion in mEH topology based on glycosylation site analysis. A truncated form of mEH lacking the N-terminal hydrophobic transmembrane domain was also detected on the extracellular surface of transfected COS-7 cells, demonstrating the existence of at least one additional transmembrane segment. These results suggest that mEH may be integrated into the membrane with multiple transmembrane domains and is inserted into the ER membrane with two topological orientations, one of which is targeted to the plasma membrane where it mediates bile acid transport.	Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of Southern California	Levy, D (corresponding author), Univ So Calif, Sch Med, Dept Biochem & Mol Biol, 2011 Zonal Ave, Los Angeles, CA 90033 USA.				NIDDK NIH HHS [DK 25836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN KS, 1993, J BIOL CHEM, V268, P18726; ALVES C, 1993, J BIOL CHEM, V268, P20148; Amarneh BA, 1996, MOL CELL ENDOCRINOL, V119, P69, DOI 10.1016/0303-7207(96)03796-3; ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CHANG XB, 1994, J BIOL CHEM, V269, P18572; Chen MG, 1996, MOL MEMBR BIOL, V13, P33, DOI 10.3109/09687689609160572; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; CRAFT JA, 1990, BIOCHIM BIOPHYS ACTA, V1046, P32, DOI 10.1016/0005-2760(90)90091-B; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; Eliasson E, 1996, MOL PHARMACOL, V50, P573; Endicott J A, 1991, DNA Seq, V2, P89, DOI 10.3109/10425179109039677; ESSER V, 1988, J BIOL CHEM, V263, P13282; Eusebio A, 1998, EXP CELL RES, V241, P181, DOI 10.1006/excr.1998.4042; FRIEDBERG T, 1994, BIOCHEM J, V303, P967, DOI 10.1042/bj3030967; Friedberg T, 1996, BIOCHEM J, V319, P131, DOI 10.1042/bj3190131; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GEETHAHABIB M, 1990, J BIOL CHEM, V265, P13655; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; GUENGERICH FP, 1982, ARCH BIOCHEM BIOPHYS, V215, P462, DOI 10.1016/0003-9861(82)90105-9; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; HEINEMANN FS, 1984, J BIOL CHEM, V259, P797; Holler R, 1997, BIOCHEM BIOPH RES CO, V236, P754, DOI 10.1006/bbrc.1997.7044; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; JACKSON MR, 1987, NUCLEIC ACIDS RES, V15, P7188, DOI 10.1093/nar/15.17.7188; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KAWASAKI ES, 1990, PCR PROTOCOLS; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LOEPER J, 1993, GASTROENTEROLOGY, V104, P203, DOI 10.1016/0016-5085(93)90853-5; OHTA Y, 1994, J BIOL CHEM, V269, P15597; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; PORTER TD, 1986, ARCH BIOCHEM BIOPHYS, V248, P121, DOI 10.1016/0003-9861(86)90408-X; ROBIN MA, 1995, GASTROENTEROLOGY, V108, P1110, DOI 10.1016/0016-5085(95)90210-4; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SKACH WR, 1993, J BIOL CHEM, V268, P6903; STASIECKI P, 1980, EUR J CELL BIOL, V21, P79; STOLZ A, 1989, ANNU REV PHYSIOL, V51, P161, DOI 10.1146/annurev.ph.51.030189.001113; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; THOMAS H, 1990, FRONTIERS BIOTRANSFO, V2, P278; VONDIPPE P, 1993, AM J PHYSIOL, V264, pG528, DOI 10.1152/ajpgi.1993.264.3.G528; VONDIPPE P, 1990, J BIOL CHEM, V265, P14812; VONDIPPE P, 1983, J BIOL CHEM, V258, P8896; VONDIPPE P, 1983, J BIOL CHEM, V258, P8890; vonDippe P, 1996, J BIOL CHEM, V271, P18176, DOI 10.1074/jbc.271.30.18176; VONDIPPE P, 1990, J BIOL CHEM, V265, P5942; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; WU DF, 1992, HEPATOLOGY, V15, P515, DOI 10.1002/hep.1840150326	54	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27898	27904		10.1074/jbc.274.39.27898	http://dx.doi.org/10.1074/jbc.274.39.27898			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488137	hybrid			2022-12-25	WOS:000082739100076
J	Asthagiri, AR; Nelson, CM; Horwitz, AF; Lauffenburger, DA				Asthagiri, AR; Nelson, CM; Horwitz, AF; Lauffenburger, DA			Quantitative relationship among integrin-ligand binding, adhesion, and signaling via focal adhesion kinase and extracellular signal-regulated kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; CELL-ADHESION; TYROSINE KINASES; IN-VIVO; GROWTH; TRANSDUCTION; PATHWAYS; PHOSPHORYLATION; RAS	Because integrin-mediated signals are transferred through a physical architecture and synergistic biochemical network whose properties are not well defined, quantitative relationships between extracellular integrin-ligand binding events and key intracellular responses are poorly understood. We begin to address this by quantifying integrin-mediated FAK and ERK2 responses in CHO cells for varied alpha(5)beta(1) expression level and substratum fibronectin density. Plating cells on fibronectin-coated surfaces initiated a transient, biphasic ERK2 response, the magnitude and kinetics off which depended on integrin-ligand binding properties. Whereas ERK2 activity initially increased with a rate proportional to integrin-ligand bond number for low fibronectin density, the desensitization rate was independent of integrin and fibronectin amount but proportional to the ERK2 activity level with an exponential decay constant of 0.3 (+/- 0.08) min(-1). Unlike the ERK2 activation time course, FAK phosphorylation followed a superficially disparate time course. However, analysis of the early kinetics of the two signals revealed them to be correlated. The initial rates of FAK and ERK2 signal generation exhibited similar dependence on fibronectin surface density, with both rates monotonically increasing with fibronectin amount until saturating at high fibronectin density. Because of this similar initial rate dependence on integrin-ligand bond formation, the disparity in their time courses is attributed to differences in feedback regulation of these signals. Whereas FAK phosphorylation increased to a steady-state level as new integrin-ligand bond formation continued during cell spreading, ERK2 activity was decoupled from the integrin-ligand stimulus and decayed back to a basal level. Accordingly, we propose different functional metrics for representing these two disparate dynamic signals: the steady-state tyrosine phosphorylation level for FAK and the integral of the pulse response for ERK2, These measures of FAK and ERK2 activity were found to correlate with short term cell-substratum adhesivity, indicating that signaling via FAK and ERK2 is proportional to the number of integrin-fibronectin bonds.	MIT, Dept Chem Engn, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Virginia	Lauffenburger, DA (corresponding author), MIT, Dept Chem Engn, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA.		Nelson, Celeste/AAT-7612-2021	Nelson, Celeste/0000-0001-9973-8870	NIGMS NIH HHS [GM 23244, GM 53905] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053905, R37GM023244, R01GM023244] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; Asthagiri AR, 1999, ANAL BIOCHEM, V269, P342, DOI 10.1006/abio.1999.4055; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; Bray D, 1998, ANNU REV BIOPH BIOM, V27, P59, DOI 10.1146/annurev.biophys.27.1.59; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; BUDAY L, 1995, ONCOGENE, V11, P1327; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DIMILLA PA, 1992, J COLLOID INTERF SCI, V153, P212, DOI 10.1016/0021-9797(92)90313-B; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Horwitz AF, 1997, SCI AM, V276, P68, DOI 10.1038/scientificamerican0597-68; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Pozzi M, 1998, J CELL BIOL, V142, P587; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	36	85	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27119	27127		10.1074/jbc.274.38.27119	http://dx.doi.org/10.1074/jbc.274.38.27119			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480927	hybrid			2022-12-25	WOS:000082570700066
J	Li, Z; Rossi, EA; Hoheisel, JD; Kalderon, D; Rubin, CS				Li, Z; Rossi, EA; Hoheisel, JD; Kalderon, D; Rubin, CS			Generation. of a novel A kinase anchor protein and a myristoylated alanine-rich C kinase substrate-like analog from a single gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; AFFINITY BINDING-PROTEIN; A-KINASE; SIGNAL-TRANSDUCTION; II-BETA; MOLECULAR CHARACTERIZATION; DROSOPHILA-MELANOGASTER; CAENORHABDITIS-ELEGANS; ELECTROSTATIC SWITCH; MEMBRANE ASSOCIATION	A unique Drosophila gene encodes two novel signaling proteins. Drosophila A kinase anchor protein 200 (DAKAP200) (753 amino acids) binds regulatory subunits of protein kinase All (PKAII) isoforms in vitro and in intact cells. The acidic DAKAP200 polypeptide (pI similar to 3.8) contains an optimal N-terminal myristoylation site and a positively charged domain that resembles the mul tifunctional phosphorylation site domain of vertebrate myristoylated alanine-rich C kinase substrate proteins. The 15-kilobase pair DAHAP200 gene contains six exons and encodes a second protein, Delta DAKAP200. Delta DAKAP200 is derived from DAKAP200 transcripts by excision of exon 5 (381 codons), which encodes the PKAII binding region and a Pro-rich sequence. Delta DAKAP200 appears to be a myristoylated alanine-rich C kinase substrate analog. DAKAP200 and Delta DAKAP200 are evident in vivo at all stages of Drosophila development. Thus, both proteins may play important physiological roles throughout the life span of the organism. Nevertheless, DAKAP200 gene expression is regulated. Maximal levels of DAKAP200 are detected in the pupal phase of development; Delta DAKAP200 content is elevated 7-fold in adult head (brain) relative to other body parts. Enhancement or suppression of exon 5 excision during DAKAP200 pre-mRNA processing provides potential mechanisms for regulating anchoring of PKAII and targeting of cAMP signals to effector sites in cytoskeleton and/or organelles.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Bronx, NY 10461 USA; Deutsch Krebsforschungszentrum, Dept Mol Genet Genome Anal, D-69120 Heidelberg, Germany; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Yeshiva University; Albert Einstein College of Medicine; Helmholtz Association; German Cancer Research Center (DKFZ); Columbia University	Rubin, CS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol F229, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIDDK NIH HHS [DK07513] Funding Source: Medline; NIGMS NIH HHS [GM22792, GM07260] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792, T32GM007260] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arbuzova A, 1997, J BIOL CHEM, V272, P27167, DOI 10.1074/jbc.272.43.27167; Arbuzova A, 1998, BBA-REV BIOMEMBRANES, V1376, P369, DOI 10.1016/S0304-4157(98)00011-2; BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1991, J BIOL CHEM, V266, P14188; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Dong F, 1998, J BIOL CHEM, V273, P6533, DOI 10.1074/jbc.273.11.6533; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Feliciello A, 1998, J BIOL CHEM, V273, P23361, DOI 10.1074/jbc.273.36.23361; FOSTER JL, 1984, J BIOL CHEM, V259, P3049; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Gorman C M, 1990, Curr Opin Biotechnol, V1, P36, DOI 10.1016/0958-1669(90)90008-9; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Han JD, 1997, J BIOL CHEM, V272, P26611, DOI 10.1074/jbc.272.42.26611; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; HU ED, 1990, J BIOL CHEM, V265, P5072; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANE ME, 1995, MECH DEVELOP, V49, P191, DOI 10.1016/0925-4773(94)00317-G; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; LU XY, 1990, J BIOL CHEM, V265, P3293; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; Rossi EA, 1999, J BIOL CHEM, V274, P27201, DOI 10.1074/jbc.274.38.27201; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543	58	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27191	27200		10.1074/jbc.274.38.27191	http://dx.doi.org/10.1074/jbc.274.38.27191			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480936	hybrid, Green Submitted			2022-12-25	WOS:000082570700075
J	Moreno, J; Spreitzer, RJ				Moreno, J; Spreitzer, RJ			C172S substitution in the chloroplast-encoded large subunit affects stability and stress-induced turnover of ribulose-1,5-bisphosphate carboxylase/oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; LEMNA-MINOR FRONDS; COUPLING FACTOR-I; CHLAMYDOMONAS-REINHARDII; CRYSTAL-STRUCTURE; OXIDATIVE MODIFICATION; DIRECTED MUTAGENESIS; CYSTEINE RESIDUES; EUGLENA-GRACILIS; REDOX REGULATION	Previous work has indicated that the turnover of chloroplast ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco; EC 4.1.1.39) may be controlled by the redox state of certain cysteine residues, To test this hypothesis, directed mutagenesis and chloroplast transformation were employed to create a C172S substitution in the Rubisco large subunit of the green alga Chlamydomonas reinhardtii, The C172S mutant strain was not substantially different from the wild type with respect to growth rate, and the purified mutant enzyme had a normal circular dichroism spectrum. However, the mutant enzyme was inactivated faster than the wild-type enzyme at 40 and 50 degrees C, In contrast, C172S mutant Rubisco was more resistant to sodium arsenite, which reacts with vicinal dithiols. The effect of arsenite may be directed to the cysteine 172/192 pair that is present in the wild-type enzyme, but absent in the mutant enzyme. The mutant enzyme was also more resistant to proteinase K in vitro at low redox potential. Furthermore, oxidative (hydrogen peroxide) or osmotic (mannitol) stress-induced degradation of Rubisco in vivo was delayed in C172S mutant cells relative to wild-type cells. Thus, cysteine residues could play a role in regulating the degradation of Rubisco under in vivo stress conditions.	Univ Valencia, Fac Ciencias Biol, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Valencia; University of Nebraska System; University of Nebraska Lincoln	Moreno, J (corresponding author), Univ Valencia, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Av Dr Moliner 50, E-46100 Burjassot, Spain.							Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; BRUGGEMANN W, 1995, PLANT CELL PHYSIOL, V36, P733; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; Desimone M, 1996, PLANT PHYSIOL, V111, P789, DOI 10.1104/pp.111.3.789; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; ECKARDT NA, 1995, PLANT PHYSIOL BIOCH, V33, P273; FERREIRA RB, 1989, PLANTA, V179, P448, DOI 10.1007/BF00397584; FERREIRA RB, 1989, PLANTA, V179, P456, DOI 10.1007/BF00397585; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; GARCIAFERRIS C, 1993, PHOTOSYNTH RES, V35, P55, DOI 10.1007/BF02185411; GARCIAFERRIS C, 1994, PLANTA, V193, P208; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; Kanevski I, 1999, PLANT PHYSIOL, V119, P133, DOI 10.1104/pp.119.1.133; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; Larson EM, 1997, J BIOL CHEM, V272, P17033, DOI 10.1074/jbc.272.27.17033; LEEGOOD RC, 1995, J EXP BOT, V46, P1397, DOI 10.1093/jxb/46.special_issue.1397; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEHTA RA, 1992, J BIOL CHEM, V267, P2810; MORENO J, 1995, PLANT PHYSIOL BIOCH, V33, P121; NALIN CM, 1984, J BIOL CHEM, V259, P7275; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; PENARRUBIA L, 1990, ARCH BIOCHEM BIOPHYS, V281, P227; RANTY B, 1991, EUR J BIOCHEM, V200, P353, DOI 10.1111/j.1432-1033.1991.tb16192.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHLOSS JV, 1978, J BIOL CHEM, V253, P5707; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; SPREITZER RJ, 1988, PLANT PHYSIOL, V86, P987, DOI 10.1104/pp.86.4.987; SPREITZER RJ, 1982, FEBS LETT, V148, P117, DOI 10.1016/0014-5793(82)81255-6; SPREITZER RJ, 1983, P NATL ACAD SCI-BIOL, V80, P6293, DOI 10.1073/pnas.80.20.6293; SPREITZER RJ, 1985, P NATL ACAD SCI USA, V82, P5460, DOI 10.1073/pnas.82.16.5460; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; SPREITZER RJ, 1998, MOL BIOL CHLOROPLAST, P515; SUGIYAMA T, 1968, ARCH BIOCHEM BIOPHYS, V125, P98, DOI 10.1016/0003-9861(68)90643-7; TANAKA S, 1988, PHOTOSYNTH RES, V17, P255, DOI 10.1007/BF00035452; Torchinsky Y, 1981, SULFUR PROTEINS; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; Watson GMF, 1997, FEMS MICROBIOL LETT, V146, P13, DOI 10.1016/S0378-1097(96)00417-X; Zhu GH, 1996, J BIOL CHEM, V271, P18494, DOI 10.1074/jbc.271.31.18494; ZHU GH, 1994, J BIOL CHEM, V269, P3952	44	41	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26789	26793		10.1074/jbc.274.38.26789	http://dx.doi.org/10.1074/jbc.274.38.26789			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480884	hybrid			2022-12-25	WOS:000082570700023
J	Saretzki, G; Sitte, N; Merkel, U; Wurm, RE; von Zglinicki, T				Saretzki, G; Sitte, N; Merkel, U; Wurm, RE; von Zglinicki, T			Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments	ONCOGENE			English	Article						telomeres; p53; check point; cell cycle; DNA damage	HUMAN OVARIAN-CARCINOMA; HUMAN FIBROBLASTS; HUMAN CANCER; G(1) ARREST; LIFE-SPAN; P53; GROWTH; TUMOR; ACTIVATION; EXPRESSION	It has been repeatedly suspected that telomere shortening might be one possible trigger of the p53-dependent cell cycle arrest, although the mechanism of this arrest remained unclear. Telomeres in human cells under mild oxidative stress accumulate single-strand damage faster than interstitial repetitive sequences, In MRC-5 fibroblasts and U87 glioblastoma cells, which both express wild-type p53, oxidative stress-mediated production of single-strand damage in telomeres is concomitant to the accumulation of p53 and p21 and to cell cycle arrest. This response can be modeled by treatment of cells with short single stranded telomeric G-rich DNA fragments. The arrest is transient in U87 cells. Recovery from it is accompanied by up-regulation of telomerase activity and elongation of telomeres, Overexpression of mutated p53 is sufficient to reverse the phenotype of inhibition as well as the delayed activation of telomerase, These data suggest that the production of G-rich single stranded fragments during the course of telomere shortening is sufficient to trigger a p53 dependent cell cycle arrest.	Inst Pathol, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Clin Radiat Therapy, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	von Zglinicki, T (corresponding author), Inst Pathol, Schumannstr 20-21, D-10098 Berlin, Germany.		Saretzki, Gabriele Christine/I-7175-2019	Saretzki, Gabriele Christine/0000-0003-2100-8223; von Zglinicki, Thomas/0000-0002-5939-0248				ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Joo OH, 1998, MUTAT RES-FUND MOL M, V401, P121, DOI 10.1016/S0027-5107(97)00321-7; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KORNBLUTH S, 1992, MOL CELL BIOL, V12, P3216, DOI 10.1128/MCB.12.7.3216; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leteurtre F, 1997, LEUKEMIA, V11, P1681, DOI 10.1038/sj.leu.2400784; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Linke SP, 1997, CANCER RES, V57, P1171; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Mukhopadhyay T, 1998, ONCOGENE, V17, P901, DOI 10.1038/sj.onc.1202011; NAGASAWA H, 1995, CANCER RES, V55, P1842; NEGRINI M, 1994, CANCER RES, V54, P1818; Petersen S, 1998, EXP CELL RES, V239, P152, DOI 10.1006/excr.1997.3893; Poulos NE, 1996, CANCER RES, V56, P1719; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Saretzki G, 1998, J GERONTOL A-BIOL, V53, pB438, DOI 10.1093/gerona/53A.6.B438; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; WYNFORDTHOMAS D, 1995, MOL CARCINOGEN, V12, P119; YAGINUMA Y, 1992, CANCER RES, V52, P4196	38	134	138	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5148	5158		10.1038/sj.onc.1202898	http://dx.doi.org/10.1038/sj.onc.1202898			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498864				2022-12-25	WOS:000082555700003
J	Campbell, NA; Kim, HS; Blumberg, RS; Mayer, L				Campbell, NA; Kim, HS; Blumberg, RS; Mayer, L			The nonclassical class I molecule CD1d associates with the novel CD8 ligand gp180 on intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; RAT SMALL-INTESTINE; T-CELLS; ANTIGEN PRESENTATION; SUPPRESSOR CELLS; ORAL TOLERANCE; IMMUNE-RESPONSES; PEYERS-PATCHES; MOUSE CD1; EXPRESSION	Previous studies have shown that normal intestinal epithelial cells (IECs) are able to selectively activate CD8(+) T cells with suppressor activity, inducing proliferation associated with the activation of both the CD8-associated kinase p56(lck) and the T cell receptor (TCR)associated kinase p59(fyn). This process appears to relate in part to a 180-kDa IEC surface glycoprotein, gp180, which binds to CDS and activates CDS-associated p56(lck). However, purified gp180 alone is unable to induce T cell proliferation and does not activate p59(fyn). Because the class Ib molecule CD1d is expressed by IECs and monoclonal antibodies (mAbs) against CD1d inhibit IEC-induced proliferation of CD8(+) T cells, co-immunoprecipitation and enzyme-linked immunosorbent assay studies were performed, which demonstrated an association of gp180 and CD1d on the IEC surface. Interestingly, the activation of p59(fyn) in IEC-T cell co-cultures was blocked by the anti-CD1d mAb D5 but not by the anti-gp180 mAb B9. Conversely, treatment of IECs with mAb B9 inhibited IEC-induced activation of p56(lck) but not p59(fyn). More directly, a human CD1d cDNA (FO-1 D5) transfectant was able to activate p59(fyn) but not p56(lck). These data suggest that the CD1d-gp180 complex on the surface of IECs can be recognized by the TCR-CDS co-receptor, resulting in the activation of CD8(+) T cells.	Mt Sinai Med Ctr, Div Clin Immunol, New York, NY 10029 USA; Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA	Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital	Campbell, NA (corresponding author), Genentech Inc, Dept Immunol, 1 DNA Way, San Francisco, CA 94080 USA.	nicola@gene.com			NIAID NIH HHS [AI 24671, AI 23504, AI 41583] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023504, P01AI024671] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALK SP, 1994, SCIENCE, V265, P259, DOI 10.1126/science.7517575; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BLAND P, 1988, IMMUNOL TODAY, V9, P174, DOI 10.1016/0167-5699(88)91293-5; BLAND PW, 1986, IMMUNOLOGY, V58, P1; BLAND PW, 1986, IMMUNOLOGY, V58, P9; BLAND PW, 1989, IMMUNOLOGY, V68, P497; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BLUMBERG RS, 1991, J IMMUNOL, V147, P2518; Blumberg RS, 1997, CLIN EXP IMMUNOL, V109, P223, DOI 10.1046/j.1365-2249.1997.4381336.x; CANCHIS PW, 1993, IMMUNOLOGY, V80, P561; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; CHALLACOMBE SJ, 1980, J EXP MED, V152, P1459, DOI 10.1084/jem.152.6.1459; Colgan SP, 1996, AM J PHYSIOL-CELL PH, V271, pC276, DOI 10.1152/ajpcell.1996.271.1.C276; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; Jullien D, 1997, J CLIN INVEST, V99, P2071, DOI 10.1172/JCI119378; Kasai K, 1997, CLIN EXP IMMUNOL, V109, P317, DOI 10.1046/j.1365-2249.1997.3661267.x; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; Kim HS, 1999, J BIOL CHEM, V274, P9289, DOI 10.1074/jbc.274.14.9289; LI Y, 1995, J EXP MED, V182, P1079, DOI 10.1084/jem.182.4.1079; LUI Z, 1998, INT IMMUNOL, V10, P775; MATTINGLY JA, 1979, J IMMUNOL, V122, P787; MATTINGLY JA, 1978, J IMMUNOL, V121, P1878; MAYER L, 1991, GASTROENTEROLOGY, V100, P3, DOI 10.1016/0016-5085(91)90575-6; MAYER L, 1987, J EXP MED, V166, P1471, DOI 10.1084/jem.166.5.1471; MILLER A, 1993, J IMMUNOL, V151, P7307; MILLER SD, 1979, J IMMUNOL, V123, P2344; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; MOWAT AM, 1985, IMMUNOLOGY, V56, P253; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; NAGLERANDERSON C, 1986, P NATL ACAD SCI USA, V83, P7443, DOI 10.1073/pnas.83.19.7443; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; SANTOS LMB, 1994, CELL IMMUNOL, V157, P439, DOI 10.1006/cimm.1994.1240; Somnay-Wadgaonkar K, 1999, INT IMMUNOL, V11, P383, DOI 10.1093/intimm/11.3.383; THOMAS HC, 1974, IMMUNOLOGY, V27, P631; Wells HG, 1911, J INFECT DIS, V9, P147, DOI 10.1093/infdis/9.2.147; Yio XY, 1997, J BIOL CHEM, V272, P12786, DOI 10.1074/jbc.272.19.12786; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	39	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26259	26265		10.1074/jbc.274.37.26259	http://dx.doi.org/10.1074/jbc.274.37.26259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473580	hybrid			2022-12-25	WOS:000082469700046
J	Copic, A; Vucemilo, N; Gubensek, F; Krizaj, I				Copic, A; Vucemilo, N; Gubensek, F; Krizaj, I			Identification and purification of a novel receptor for secretory phospholipase A(2) in porcine cerebral cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; PANCREATIC-TYPE PHOSPHOLIPASE-A(2); NEURONAL PENTRAXIN; MOLECULAR-CLONING; AMMODYTOXIN-C; AMINO-ACID; EXPRESSION; CELLS; SITE; MUSCLE	A specific phospholipase A(2) receptor from porcine cerebral cortex has been characterized (K-d = 145 nM, B-max = 0.4 pmol/mg membrane protein) by using a radioiodinated derivative of ammodytoxin C (AtxC), a snake venom presynaptically neurotoxic group IIA phospholipase A(2). After the receptor was solubilized in a ligand-binding form, it was approximately 14,000-fold enriched by chromatography on wheat germ lectin-Sepharose and AtxC-Affi-Gel 10. The receptor is a single chain glycoprotein with an apparent molecular mass of 180 kDa and binds toxic and non-toxic phospholipases A(2) of either group I or II. It also recognizes conjugates of bovine serum albumin with mannose, N-acetylglucosamine, and galactose. In its molecular mass and pharmacological profile, the AtxC receptor resembles the M-type receptor for secretory phospholipases A(2) from rabbit skeletal muscle (a C-type multilectin, homologous to macrophage mannose receptor), yet in terms of relative abundance in brain and antigenicity, these two receptors are completely different. A further AtxC receptor of approximately 200 kDa discovered in porcine liver was, however, recognized by anti-rabbit M-type phospholipase A(2) receptor antibodies. There are, therefore, two immunologically distinct secretory phospholipase A(2) receptors of about 200 kDa in the same species. Although the liver receptor is related to the M-type secretory phospholipase A(2) receptors, the brain receptor is not and belongs to a novel group of secretory phospholipase A(2) receptors.	Univ Ljubljana, Jozef Stefan Inst, Dept Biochem & Mol Biol, Ljubljana 1000, Slovenia; Univ Ljubljana, Fac Chem & Chem Technol, Dept Chem & Biochem, Ljubljana 1000, Slovenia	Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; University of Ljubljana; University of Ljubljana	Krizaj, I (corresponding author), Univ Ljubljana, Jozef Stefan Inst, Dept Biochem & Mol Biol, Jamova 39, Ljubljana 1000, Slovenia.	igor.krizaj@ijs.si		Copic, Alenka/0000-0003-0166-7731				Abe T, 1997, INT J CANCER, V74, P245, DOI 10.1002/(SICI)1097-0215(19970620)74:3<245::AID-IJC2>3.0.CO;2-Z; ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; ARITA H, 1991, J BIOL CHEM, V266, P19139; BENNETT V, 1986, METHOD ENZYMOL, V134, P55; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Dodds DC, 1997, J BIOL CHEM, V272, P21488, DOI 10.1074/jbc.272.34.21488; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; GUBENSEK F, 1980, PERIOD BIOL, V82, P443; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; HANASAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P233, DOI 10.1016/0005-2760(92)90226-L; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KANEMASA T, 1992, FEBS LETT, V303, P217, DOI 10.1016/0014-5793(92)80523-J; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; Kini R. M., 1997, VENOM PHOSPHOLIPASE, P1; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KRIZAJ I, 1989, BIOCHIM BIOPHYS ACTA, V999, P198, DOI 10.1016/0167-4838(89)90218-5; KRIZAJ I, 1994, BIOCHEMISTRY-US, V33, P13938, DOI 10.1021/bi00250a049; KRIZAJ I, 1992, EUR J BIOCHEM, V204, P1057, DOI 10.1111/j.1432-1033.1992.tb16728.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Lambeau G, 1997, VENOM PHOSPHOLIPASE, P389; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; NEVALAINEN TJ, 1993, CLIN CHEM, V39, P2453; Rae D, 1996, SCAND J GASTROENTERO, V31, P24, DOI 10.3109/00365529609104995; Rosenberg P., 1990, HDB TOXINOLOGY, P67; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; Vucemilo N, 1998, BIOCHEM BIOPH RES CO, V251, P209, DOI 10.1006/bbrc.1998.9427; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121	45	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26315	26320		10.1074/jbc.274.37.26315	http://dx.doi.org/10.1074/jbc.274.37.26315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473587	hybrid			2022-12-25	WOS:000082469700053
J	Peralba, JM; Cederlund, E; Crosas, B; Moreno, A; Julia, P; Martinez, SE; Persson, B; Farres, J; Pares, X; Jornvall, H				Peralba, JM; Cederlund, E; Crosas, B; Moreno, A; Julia, P; Martinez, SE; Persson, B; Farres, J; Pares, X; Jornvall, H			Structural and enzymatic properties of a gastric NADP(H)-dependent and retinal-active alcohol dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-HYDROXYFATTY ACIDS; CLASS-IV; HUMAN STOMACH; ALDEHYDE DEHYDROGENASE; SUBSTRATE-SPECIFICITY; CDNA SEQUENCE; LIVER-ENZYME; CLASS-III; EXPRESSION; METABOLISM	A class IV-type, gastric alcohol dehydrogenase (ADH) has been purified from frog (Rana perezi) tissues, meaning detection of this enzyme type also in nonmammalian vertebrates. However, the protein is unique among vertebrate ADHs thus far characterized in having preference for NADP(+) rather than NAD(+). Similarly, it deviates structurally from other class IV ADHs and has a phylogenetic tree position outside that of the conventional class IV cluster. The NADP(+) preference is structurally correlated with a replacement of Asp-223 of all other vertebrate ADHs with Gly-223, largely directing the coenzyme specificity. This residue replacement Is expected metabolically to correlate with a change of the reaction direction catalyzed, from preferential alcohol oxidation to preferential aldehyde reduction. This is of importance in cellular growth regulation through retinoic acid formed from retinol/retinal precursors because the enzyme is highly efficient in retinal reduction (k(cat)/K-m = 3.4.10(4) mM(-1) min(-1)). Remaining enzymatic details are also particular but resemble those of the human class I/class TV enzymes. However, overall structural relationships are distant (58-60% residue identity), and residues at substrate binding and coenzyme binding positions are fairly deviant, reflecting the formation of the new activity. The results are concluded to represent early events in the duplicatory origin of the class IV line or of a separate, class IV-type line. In both cases, the novel enzyme illustrates enzymogenesis of classes in the ADH system. The early origin (with tetrapods), the activity (with retinoids), and the specific location of this enzyme (gastric, like the gastric and epithelial location of the human class IV enzyme) suggest important functions of the class IV ADH type in vertebrates.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Autonoma Barcelona, Fac Sci, Dept Biochem & Mol Biol, Bellaterra 08193, Barcelona, Spain	Karolinska Institutet; Autonomous University of Barcelona	Jornvall, H (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.		Pares, Xavier/K-8228-2017	Pares, Xavier/0000-0002-5071-9465				Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; BANNISTE.WH, 1967, EXPERIENTIA, V23, P715, DOI 10.1007/BF02154130; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOLEDA MD, 1989, ARCH BIOCHEM BIOPHYS, V274, P74, DOI 10.1016/0003-9861(89)90416-5; Burdette DS, 1996, BIOCHEM J, V316, P115, DOI 10.1042/bj3160115; CEDERLUND E, 1991, BIOCHEMISTRY-US, V30, P2811, DOI 10.1021/bi00225a011; Costaridis P, 1996, DEV DYNAM, V205, P41; DANIELSSON O, 1992, BIOCHEMISTRY-US, V31, P3751, DOI 10.1021/bi00130a004; DANIELSSON O, 1994, P NATL ACAD SCI USA, V91, P4980, DOI 10.1073/pnas.91.11.4980; DANIELSSON O, 1992, P NATL ACAD SCI USA, V89, P9247, DOI 10.1073/pnas.89.19.9247; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; EKLUND H, 1987, BIOCHEMISTRY-US, V23, P5982; FAN F, 1991, BIOCHEMISTRY-US, V30, P6397, DOI 10.1021/bi00240a008; FARRES J, 1994, EUR J BIOCHEM, V224, P549, DOI 10.1111/j.1432-1033.1994.00549.x; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Haber PS, 1996, GASTROENTEROLOGY, V111, P863, DOI 10.1016/S0016-5085(96)70054-9; HJELMQVIST L, 1995, P NATL ACAD SCI USA, V92, P10904, DOI 10.1073/pnas.92.24.10904; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; JORNVALL H, 1995, ALCOHOL ALCOHOLISM, V30, P153; JULIA P, 1987, EUR J BIOCHEM, V162, P179, DOI 10.1111/j.1432-1033.1987.tb10559.x; KEDISHVILI NY, 1995, J BIOL CHEM, V270, P3625, DOI 10.1074/jbc.270.8.3625; Kedishvili NY, 1997, J BIOL CHEM, V272, P7494, DOI 10.1074/jbc.272.11.7494; Korkhin Y, 1998, J MOL BIOL, V278, P967, DOI 10.1006/jmbi.1998.1750; KRAFT JC, 1994, BIOCHEM J, V301, P111, DOI 10.1042/bj3010111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moreno A, 1996, FEBS LETT, V395, P99, DOI 10.1016/0014-5793(96)01009-5; MORENO A, 1991, J BIOL CHEM, V266, P1128; PARES X, 1990, METHOD ENZYMOL, V189, P436; PARES X, 1994, P NATL ACAD SCI USA, V91, P1893, DOI 10.1073/pnas.91.5.1893; PERETZ M, 1989, BIOCHEMISTRY-US, V28, P6549, DOI 10.1021/bi00442a004; SARAU HM, 1975, J BIOL CHEM, V250, P8321; SCADDING SR, 1994, DEV BIOL, V162, P608, DOI 10.1006/dbio.1994.1114; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Williamson D. H., 1974, METHODS ENZYMATIC AN, P2266, DOI [10.1016/B978-0-12-091304-6.50093-8, DOI 10.1016/B978-0-12-091304-6.50093-8]; Xie PG, 1997, J BIOL CHEM, V272, P18558, DOI 10.1074/jbc.272.30.18558; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x	38	30	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26021	26026		10.1074/jbc.274.37.26021	http://dx.doi.org/10.1074/jbc.274.37.26021			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473548	hybrid			2022-12-25	WOS:000082469700014
J	Eymin, B; Sordet, O; Droin, N; Munsch, B; Haugg, M; Van de Craen, M; Vandenabeele, P; Solary, E				Eymin, B; Sordet, O; Droin, N; Munsch, B; Haugg, M; Van de Craen, M; Vandenabeele, P; Solary, E			Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27(Kip1) mediates its anti-apoptotic activity	ONCOGENE			English	Article						p27(Kip1); apoptosis; cell cycle; leukemia; caspase	TOPOISOMERASE-II INHIBITORS; CYTOCHROME-C; CELLS; ACTIVATION; CLEAVAGE; PROTEASE; P27; HYPERPLASIA; DEGRADATION; RESISTANCE	The caspase-mediated cleavage of a limited number of cellular proteins is a common feature of apoptotic cell death. This cleavage usually inhibits the function of the target protein or generates peptides that actively contribute to the death process. In the present study, we demonstrate that the cyclin-dependent kinase inhibitor p27(Kip1) is cleaved by caspases in human leukemic cells exposed to apoptotic stimuli. We have shown recently that p27(Kip1) overexpression delayed leukemic cell death in response to cytotoxic drugs, In transient transfection experiments, the p23 and the p15 N-terminal peptides generated by p27(Kip1) proteolysis demonstrate an anti-apoptotic effect similar to that induced by the wild-type protein, whereas cleavage-resistant mutants have lost their protective effect. Moreover, stable transfection of a cleavage-resistant mutant of p27(Kip1) sensitizes leukemic cells to drug-induced cell death. Altogether, these results indicate that proteolysis of p27(Kip1) triggered by caspases mediates the anti-apoptotic activity of the protein.	Fac Med & Pharm, INSERM, U517, F-21033 Dijon, France; State Univ Ghent VIB, Dept Mol Biol, B-9000 Ghent, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Flanders Institute for Biotechnology (VIB); Ghent University	Solary, E (corresponding author), Fac Med & Pharm, INSERM, U517, 7 Blvd Jeanne Darc, F-21033 Dijon, France.		Sordet, Olivier/M-3271-2014; Droin, Nathalie M/Y-5506-2018; Vandenabeele, Peter/C-8597-2009; eymin, beatrice/U-4670-2019; Vandenabeele, Peter/AAD-5793-2022; Eymin, Beatrice/M-1962-2013	Sordet, Olivier/0000-0001-6027-4925; Droin, Nathalie M/0000-0002-6099-5324; eymin, beatrice/0000-0002-7311-3810; Vandenabeele, Peter/0000-0002-6669-8822; Eymin, Beatrice/0000-0002-7311-3810; Solary, Eric/0000-0002-8629-1341				Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cock JGRBD, 1998, APOPTOSIS, V3, P17, DOI 10.1023/A:1009603001888; Dimanche-Boitrel MT, 1998, INT J CANCER, V77, P796, DOI 10.1002/(SICI)1097-0215(19980831)77:5<796::AID-IJC20>3.0.CO;2-Z; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; HENTGARTNER MO, 1998, NATURE, V391, P441; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAMATA N, 1995, CANCER RES, V55, P2266; KIYOKAWA H, 1996, CELL, V85, P71; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAI A, 1996, NATURE, V380, P262; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SOLARY E, 1993, BLOOD, V81, P1359; StCroix B, 1996, NAT MED, V2, P1204; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsihlias J, 1998, CANCER RES, V58, P542; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	46	78	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4839	4847		10.1038/sj.onc.1202860	http://dx.doi.org/10.1038/sj.onc.1202860			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490817				2022-12-25	WOS:000082184800008
J	Auger, R; Robin, P; Camier, B; Vial, G; Rossignol, B; Tenu, JP; Raymond, MN				Auger, R; Robin, P; Camier, B; Vial, G; Rossignol, B; Tenu, JP; Raymond, MN			Relationship between phosphatidic acid level and regulation of protein transit in colonic epithelial cell line HT29-cl19A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVATION; ADP-RIBOSYLATION FACTOR; KINASE-C; GOLGI-COMPLEX; ENDOPLASMIC-RETICULUM; CYCLIC-AMP; MDCK CELLS; EXOCYTIC TRANSPORT; MEMBRANE-RECEPTORS; SECRETORY VESICLES	Colonic epithelial HT29-cl19A cells are polarized and secrete proteins among which alpha(1)-antitrypsin represents about 95%. Secretion occurs via a constitutive pathway, so that the rates of secretion directly reflect the rates of protein transit. In this paper we have demonstrated that: 1) in resting cells phospholipase D (PLD) is implicated in the control of apical protein transit; 2) phorbol esters stimulate apical protein transit (stimulation factor 2.2), which is correlated with a PLD-catalyzed production of phosphatidic acid (PA) (2.45-fold increase); 3) the stimulation of cholinergic receptors by carbachol results in an increase (stimulation factor 1.45) of apical protein transit which is independent of protein kinase C and PLD activities, but related to PA formation (1.7-fold increase) via phospholipase(s) C and diacylglycerol kinase activation; 4) an elevation of the cAMP level enhances apical protein transit by a PA-independent mechanism; 5) a trans-Golgis network or post-trans-Golgi network step of the transit is the target for the regulatory events. In conclusion, we have shown that PA can be produced by two independent signaling pathways; whatever the pathway followed, a close relationship between the amount of PA and the level of secretion was observed.	Univ Paris 11, CNRS, UMR 8619, Lab Biochim Transports Cellulaires, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Raymond, MN (corresponding author), Univ Paris 11, CNRS, UMR 8619, Lab Biochim Transports Cellulaires, Batiment 432, F-91405 Orsay, France.							Amtmann E, 1996, DRUG EXP CLIN RES, V22, P287; AUGERON C, 1984, CANCER RES, V44, P3961; AUGERON C, 1986, INSERM S, V26, P363; BAJNATH RB, 1995, PFLUG ARCH EUR J PHY, V430, P705, DOI 10.1007/BF00386165; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BOUHANNA C, 1994, BIOCHEM J, V299, P579, DOI 10.1042/bj2990579; BREWER CB, 1995, J CELL SCI, V108, P789; Buccione R, 1996, J BIOL CHEM, V271, P3523; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DIAZMECO MT, 1989, BIOCHEM J, V263, P115, DOI 10.1042/bj2630115; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; FABBRI M, 1994, J BIOL CHEM, V269, P26848; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIFFITHS G, 1990, J CELL SCI, V96, P691; GUILLEMAIN I, 1995, FEBS LETT, V363, P13, DOI 10.1016/0014-5793(95)00264-A; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; Jilling T, 1996, J BIOL CHEM, V271, P4381; Kennedy CRJ, 1996, AM J PHYSIOL-CELL PH, V271, pC1064, DOI 10.1152/ajpcell.1996.271.4.C1064; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LUCOCQ J, 1991, J CELL SCI, V100, P753; MCKENZIE FR, 1992, J BIOL CHEM, V267, P22759; Muniz M, 1996, J BIOL CHEM, V271, P30935, DOI 10.1074/jbc.271.48.30935; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; Robin P, 1998, AM J PHYSIOL-CELL PH, V274, pC262, DOI 10.1152/ajpcell.1998.274.1.C262; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; Simon JP, 1996, J CELL BIOL, V135, P355, DOI 10.1083/jcb.135.2.355; Simon JP, 1996, J BIOL CHEM, V271, P16952, DOI 10.1074/jbc.271.28.16952; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANDENBERGHE N, 1992, BIOCHEM J, V285, P673, DOI 10.1042/bj2850673; WARHURST G, 1994, CELL CALCIUM, V15, P162, DOI 10.1016/0143-4160(94)90055-8; Westermann P, 1996, BIOCHEM J, V320, P651, DOI 10.1042/bj3200651; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Zhang W, 1997, CELL STRUCT FUNCT, V22, P379, DOI 10.1247/csf.22.379	46	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28652	28659		10.1074/jbc.274.40.28652	http://dx.doi.org/10.1074/jbc.274.40.28652			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497234	hybrid			2022-12-25	WOS:000082912700083
J	Camina, JP; Casabiell, X; Casanueva, FF				Camina, JP; Casabiell, X; Casanueva, FF			Inositol 1,4,5-trisphosphate-independent Ca2+ mobilization triggered by a lipid factor isolated from vitreous body	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CAPACITATIVE CALCIUM-ENTRY; PORTAL-VEIN MYOCYTES; HL-60 LEUKEMIA-CELLS; NIH 3T3 CELLS; PHOSPHOLIPASE-C; DIACYLGLYCEROL KINASE; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; INTRACELLULAR STORES	A complex phospholipid from bovine vitreous body with a strong Ca2+-mobilizing activity has been recently isolated to homogeneity by our group. In this work, a sequential analysis of its transmembrane signaling pathway has been undertaken to characterize the intracellular mechanisms responsible for the Ca2+ rise. The results show that this phospholipid induces, in a dose-dependent manner (ED50 of around 0.25 mu g/ml), a Ca2+ mobilization from inositol 1,4,5-trisphosphate-insensitive intracellular stores, with no participation of extracellular Ca2+. Upon repeated administration, it shows no signs of autologous desensitization, does not induce heterologous desensitization of the L-alpha-lysophosphatidic acid (LPA) receptor but is desensitized by the previous administration of LPA. The Ca2+-mobilizing activity requires a membrane protein, is blocked after pre-incubation of the cells with pertussis tcPxin and phorbol eaters, as well as by U73122 tan inhibitor of phospholipases C/D, R59022 (a diacylglycerol kinase inhibitor), and D609 (which inhibits phosphatidylcholine-specific phospholipase C). Upon administration of this phospholipid, the intracellular levels of phosphatidic acid (PA) rise with a time course that parallels that of the Ca2+ mobilization, suggesting that PA could be responsible for this Ca2+ signal. Exposure to AACOCF(3) (a specific inhibitor of phospholipase A(2)) does not modify the Ca2+ rise, ruling out the possibility that the PA generated could be further converted to LPA by the action of phospholipase A(2). Based on the experimental data obtained, a signaling pathway involving a phosphatidylcholine-specific phospholipase C coupled to diacylglycerol kinase is proposed. This compound may represent a new class of bioactive lipids with a putative role in the physiology of the vitreous body.	Univ Santiago Compostela, Sch Med, Dept Med, Cellular Endocrinol Lab, E-15780 Santiago De Compostela, Spain; Univ Santiago Compostela, Sch Med, Dept Physiol, Cellular Endocrinol Lab, E-15780 Santiago De Compostela, Spain; Univ Santiago, Complejo Hosp, E-15780 Santiago De Compostela, Spain	Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela	Casanueva, FF (corresponding author), Univ Santiago Compostela, Sch Med, Dept Med, Cellular Endocrinol Lab, POB 563, E-15780 Santiago De Compostela, Spain.			Casabiell, Jesus/0000-0002-0602-7453				BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BYRON KL, 1992, J BIOL CHEM, V267, P108; Camina JP, 1998, BIOCHEM BIOPH RES CO, V244, P696, DOI 10.1006/bbrc.1998.8320; CASABIELL X, 1991, BIOCHEM J, V278, P679, DOI 10.1042/bj2780679; Casanueva FF, 1996, P NATL ACAD SCI USA, V93, P1406, DOI 10.1073/pnas.93.4.1406; CHAO CP, 1994, J BIOL CHEM, V269, P5849; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREEMAN EJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P84, DOI 10.1006/abbi.1995.1269; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HA KS, 1993, J BIOL CHEM, V268, P10534; HOVIS JG, 1986, J BIOL CHEM, V261, P380; LEPRETRE N, 1994, J BIOL CHEM, V269, P29546; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MacrezLepretre N, 1996, BIOCHEM BIOPH RES CO, V218, P30, DOI 10.1006/bbrc.1996.0006; MATO JM, 1987, J BIOL CHEM, V262, P2131; MeivarLevy I, 1997, J BIOL CHEM, V272, P1558, DOI 10.1074/jbc.272.3.1558; Mogami H, 1997, BIOCHEM J, V324, P645, DOI 10.1042/bj3240645; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHTSUKA T, 1990, J BIOL CHEM, V265, P15418; Okajima F, 1996, FEBS LETT, V379, P260, DOI 10.1016/0014-5793(95)01526-4; OKAJIMA F, 1995, J BIOL CHEM, V270, P26332, DOI 10.1074/jbc.270.44.26332; Orlati S, 1998, BIOCHEM J, V334, P641, DOI 10.1042/bj3340641; Perez FR, 1997, ENDOCRINOLOGY, V138, P264, DOI 10.1210/en.138.1.264; Pombo C, 1996, GRAEF ARCH CLIN EXP, V234, P155, DOI 10.1007/BF00462027; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; Riordan J F, 1972, Methods Enzymol, V25, P449, DOI 10.1016/S0076-6879(72)25040-6; SAKANE F, 1991, J BIOL CHEM, V266, P7096; Sakano S, 1996, J BIOL CHEM, V271, P11148, DOI 10.1074/jbc.271.19.11148; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1994, J BIOL CHEM, V269, P4098; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; ZHANG BX, 1992, J BIOL CHEM, V267, P15419; ZUGAZA JL, 1995, EXP CELL RES, V219, P54, DOI 10.1006/excr.1995.1204	50	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28134	28141		10.1074/jbc.274.40.28134	http://dx.doi.org/10.1074/jbc.274.40.28134			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497165	hybrid			2022-12-25	WOS:000082912700014
J	Izawa, S; Maeda, K; Sugiyama, K; Mano, J; Inoue, Y; Kimura, A				Izawa, S; Maeda, K; Sugiyama, K; Mano, J; Inoue, Y; Kimura, A			Thioredoxin deficiency causes the constitutive activation of Yap1, an AP-1-like transcription factor in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS-RESPONSE; GLUTATHIONE-REDUCTASE; HYDROGEN-PEROXIDE; ADAPTIVE RESPONSE; PLEIOTROPIC DRUG; REDOX REGULATION; DISULFIDE BONDS; TARGET GENE; DNA-BINDING; JUN FAMILY	Yap1 is a transcription factor that responds to oxidative stress in Saccharomyces cerevisiae. The activity of Yap1 is regulated at the level of its intracellular localization, and a cysteine-rich domain at the C terminus of Yap1 is involved in this regulation. We investigated the effects of redox-regulatory proteins, thioredoxin and glutaredoxin, on the regulation of Yap1, using the deficient mutants of these thiol-disulfide oxidoreductases. In the thioredoxin-deficient mutant (trx1 Delta/trx2 Delta), Yap1 was constitutively concentrated in the nucleus and the level of expression of the Yap1 target genes was high under normal conditions, while this was not the case for the glutaredoxin-deficient mutant (grx1 Delta/grx2 Delta). No distinct difference was observed in the levels of Yap1 protein between the wild type and trx1 Delta/trx2 Delta. The constitutive activation of Yap1 in trx1 Delta/trx2 Delta was observed under aerobic conditions but not under anaerobic conditions. These findings suggest that thioredoxin has negative effects on this regulation via the redox states. We also show the synthetic lethality between yap1 Delta and trx1 Delta/trx2 Delta mutation, but the yap1 Delta/grx1 Delta/grx2 Delta triple mutant was viable, suggesting a difference of the functions between thioredoxin and glutaredoxin and a genetic interaction between Yap1 and thioredoxin in vivo.	Kyoto Univ, Food Sci Res Inst, Dept Mol Breeding Microorganisms, Uji, Kyoto 6110011, Japan	Kyoto University	Inoue, Y (corresponding author), Kyoto Univ, Food Sci Res Inst, Dept Mol Breeding Microorganisms, Uji, Kyoto 6110011, Japan.		kimura, akira/D-1215-2010; Mano, Jun'ichi/K-7437-2019	Mano, Jun'ichi/0000-0001-5030-8845; Izawa, Shingo/0000-0002-4920-2450				Alarco AM, 1997, J BIOL CHEM, V272, P19304, DOI 10.1074/jbc.272.31.19304; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; COLLINSON LP, 1995, GENE, V156, P123, DOI 10.1016/0378-1119(95)00026-3; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Demple B, 1998, SCIENCE, V279, P1655, DOI 10.1126/science.279.5357.1655; GAN ZR, 1992, BIOCHEM BIOPH RES CO, V187, P949, DOI 10.1016/0006-291X(92)91289-3; GAN ZR, 1991, J BIOL CHEM, V266, P1692; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HUSSAIN M, 1991, GENE, V101, P149, DOI 10.1016/0378-1119(91)90238-7; Izawa S, 1998, BIOCHEM J, V330, P811, DOI 10.1042/bj3300811; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; Izawa S, 1996, BIOCHEM J, V320, P61, DOI 10.1042/bj3200061; Jamieson D. J., 1997, OXIDATIVE STRESS MOL, P91; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Miller JH., 1972, EXPT MOL GENETICS; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; OHTAKE Y, 1991, YEAST, V7, P6953; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Rose MD., 1990, METHODS YEAST GENETI; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; Takeuchi T, 1997, FEBS LETT, V416, P339, DOI 10.1016/S0014-5793(97)01233-7; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; Wemmie JA, 1997, J BIOL CHEM, V272, P7908, DOI 10.1074/jbc.272.12.7908; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	52	114	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28459	28465		10.1074/jbc.274.40.28459	http://dx.doi.org/10.1074/jbc.274.40.28459			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497208	hybrid			2022-12-25	WOS:000082912700057
J	Kelman, Z; Pietrokovski, S; Hurwitz, J				Kelman, Z; Pietrokovski, S; Hurwitz, J			Isolation and characterization of a split B-type DNA polymerase from the archaeon Methanobacterium thermoautotrophicum Delta H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; METHANOCOCCUS-JANNASCHII; BINDING PROTEIN; GENE CLONING; REPLICATION; INTEINS; ALIGNMENT; EVOLUTION	We describe here the isolation and characterization of a B-type DNA polymerase (PolB) from the archaeon Methanobacterium thermoautotrophicum Delta H. Uniquely, the catalytic domains of M. thermoautotrophicum PolB are encoded from two different genes, a feature that has not been observed as yet in other polymerases. The two genes were cloned, and the proteins were overexpressed in Escherichia colt and purified individually and as a complex. We demonstrate that both polypeptides are needed to form the active polymerase. Similar to other polymerases constituting the B-type family, PolB possesses both polymerase and 3'-5' exonuclease activities. We found that a homolog of replication protein A from M. thermoautotrophicum inhibits the PolB activity. The inhibition of DNA synthesis by replication protein A from M. thermoautotrophicum can be relieved by the addition of M. thermoautotrophicum homologs of replication factor C and proliferating cell nuclear antigen. The possible roles of PolB in M. thermoautotrophicum replication are discussed.	Mem Sloan Kettering Canc Ctr, Dept Biol Mol, New York, NY 10021 USA; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Memorial Sloan Kettering Cancer Center; Weizmann Institute of Science	Kelman, Z (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Biol Mol, 1275 York Ave,Box 97, New York, NY 10021 USA.	z-kelman@ski.mskcc.org		Pietrokovski, Shmuel/0000-0001-8573-5863	NIGMS NIH HHS [GM 38559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; CHA TA, 1988, CANCER CELL, V6, P1; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Edgell DR, 1997, J BACTERIOL, V179, P2632, DOI 10.1128/jb.179.8.2632-2640.1997; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; Gorbalenya AE, 1998, NUCLEIC ACIDS RES, V26, P1741, DOI 10.1093/nar/26.7.1741; HENIKOFF S, 1995, GENE-COMBIS, V163, pGC17, DOI 10.1016/0378-1119(95)00486-P; HONG W, 1998, P NATL ACAD SCI USA, V95, P9226; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; Ishiai M, 1996, J BIOL CHEM, V271, P20868, DOI 10.1074/jbc.271.34.20868; Ishino Y, 1998, J BACTERIOL, V180, P2232, DOI 10.1128/JB.180.8.2232-2236.1998; Jager Joachim, 1999, Current Opinion in Structural Biology, V9, P21, DOI 10.1016/S0959-440X(99)80004-9; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Kelly TJ, 1998, P NATL ACAD SCI USA, V95, P14634, DOI 10.1073/pnas.95.25.14634; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KIM YT, 1992, J BIOL CHEM, V267, P15032; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Koonin EV, 1997, MOL MICROBIOL, V25, P619, DOI 10.1046/j.1365-2958.1997.4821861.x; Kornberg A., 1992, DNA REPLICATION; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Makiniemi M, 1999, TRENDS BIOCHEM SCI, V24, P14, DOI 10.1016/S0968-0004(98)01327-9; MOLINEUX IJ, 1974, P NATL ACAD SCI USA, V71, P3858, DOI 10.1073/pnas.71.10.3858; NIEHAUS F, 1997, GENE, P3; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; Perler FB, 1999, NUCLEIC ACIDS RES, V27, P346, DOI 10.1093/nar/27.1.346; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Pietrokovski S, 1998, CURR BIOL, V8, pR634, DOI 10.1016/S0960-9822(07)00409-5; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; Takagi M, 1997, APPL ENVIRON MICROB, V63, P4504, DOI 10.1128/AEM.63.11.4504-4510.1997; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; ZEIKUS JG, 1972, J BACTERIOL, V109, P707, DOI 10.1128/JB.109.2.707-713.1972	40	54	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28751	28761		10.1074/jbc.274.40.28751	http://dx.doi.org/10.1074/jbc.274.40.28751			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497247	hybrid			2022-12-25	WOS:000082912700096
J	Rota, C; Fann, YC; Mason, RP				Rota, C; Fann, YC; Mason, RP			Phenoxyl free radical formation during the oxidation of the fluorescent dye 2 ',7 '-dichlorofluorescein by horseradish peroxidase - Possible consequences for oxidative stress measurements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN RESONANCE; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; NITRIC-OXIDE; PROBE 2',7'-DICHLOROFLUORESCIN; RECEPTOR ACTIVATION; CELL-LINE; IN-VITRO; STIMULATION; SUPEROXIDE	The oxidation of the fluorescent dye 2',7' dichlorofluorescein (DCF) by horseradish peroxidase was investigated by optical absorption, electron spin resonance (ESR), and oxygen consumption measurements. Spectrophotometric measurements showed that DCF could be oxidized either by horseradish peroxidase-compound I or -compound II with the obligate generation of the DCF phenoxyl radical (DCF'), This one-electron oxidation was confirmed by ESR spin-trapping experiments. DCF' oxidizes GSH, generating the glutathione thiyl radical (GS'), which was detected by the ESR spin-trapping technique. In this case, oxygen was consumed by a sequence of reactions initiated by the GS' radical. Similarly, DCF' oxidized NADH, generating the NAD' radical that reduced oxygen to superoxide (O-2(radical anion)), which was also detected by the ESR spin-trapping technique. Superoxide dismutated to generate H2O2, which reacted with horseradish peroxidase, setting up an enzymatic chain reaction leading to H2O2 production and oxygen consumption. In contrast, when ascorbic acid reduced the DCF phenoxyl radical back to its parent molecule, it formed the unreactive ascorbate anion radical. Clearly, DCF catalytically stimulates the formation of reactive oxygen species in a manner that is dependent on and affected by various biochemical reducing agents, This study, together with our earlier studies, demonstrates that DCFH cannot be used conclusively to measure superoxide or hydrogen peroxide formation in cells undergoing oxidative stress.	NIEHS, Informat Technol Support Serv, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Pharmacol & Chem, Free Radical Metabolite Sect, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Mason, RP (corresponding author), NIEHS, Informat Technol Support Serv, NIH, MD F0-01,POB 12233, Res Triangle Pk, NC 27709 USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109; Rota, Cristina/0000-0002-4392-4700				Atlante A, 1997, J NEUROCHEM, V68, P2038, DOI 10.1046/j.1471-4159.1997.68052038.x; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BASS DA, 1983, J IMMUNOL, V130, P1910; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P127; BUROW S, 1987, EUR J CELL BIOL, V43, P128; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; CLAIBORNE A, 1979, BIOCHEMISTRY-US, V18, P2329, DOI 10.1021/bi00578a030; DAVIES MJ, 1987, CHEM-BIOL INTERACT, V61, P177, DOI 10.1016/0009-2797(87)90038-X; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; ENTMAN ML, 1992, J CLIN INVEST, V90, P1335, DOI 10.1172/JCI115999; FUJIMORI K, 1991, BIOCHEM BIOPH RES CO, V176, P846, DOI 10.1016/S0006-291X(05)80263-3; FUKUMURA D, 1995, J GASTROENTEROL, V30, P565, DOI 10.1007/BF02367780; GADELHA FR, 1992, CHEM-BIOL INTERACT, V85, P35, DOI 10.1016/0009-2797(92)90051-L; Gunasekar PG, 1996, J PHARMACOL EXP THER, V277, P150; GUNASEKAR PG, 1995, J NEUROCHEM, V65, P2016; Gunther MR, 1998, BIOCHEM J, V330, P1293; Hagar H, 1996, AM J PHYSIOL-RENAL, V271, pF209, DOI 10.1152/ajprenal.1996.271.1.F209; HILDEBRANDT AG, 1975, ARCH BIOCHEM BIOPHYS, V171, P385, DOI 10.1016/0003-9861(75)90047-8; HORIO F, 1994, DIABETOLOGIA, V37, P22; KUROSE I, 1993, CANCER RES, V53, P2676; KUROSE I, 1991, CANCER LETT, V59, P201, DOI 10.1016/0304-3835(91)90142-5; LAROFF GP, 1972, J AM CHEM SOC, V94, P9062, DOI 10.1021/ja00781a013; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; MAKINO K, 1981, RADIAT RES, V86, P294, DOI 10.2307/3575507; Marchesi E, 1999, FREE RADICAL BIO MED, V26, P148, DOI 10.1016/S0891-5849(98)00174-9; MARESCA M, 1992, CELL BIOCHEM FUNCT, V10, P79, DOI 10.1002/cbf.290100203; MASON RP, 1992, BIOL CONSEQUENCES OX, P23; MOTTLEY C, 1987, MOL PHARMACOL, V31, P417; OYAMA Y, 1994, BRAIN RES, V635, P113, DOI 10.1016/0006-8993(94)91429-X; PICHOT C, 1977, J MACROMOL SCI CHEM, VA 11, P251, DOI 10.1080/00222337708061266; Puntarulo S, 1996, BBA-GEN SUBJECTS, V1289, P238, DOI 10.1016/0304-4165(95)00157-3; RABESANDRATANA H, 1992, INT J IMMUNOPHARMACO, V14, P895, DOI 10.1016/0192-0561(92)90089-4; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; ROTA C, 1999, IN PRESS FREE RADICA, V27; SAITO H, 1992, INT J CANCER, V51, P124, DOI 10.1002/ijc.2910510122; SCOTT JA, 1988, FREE RADICAL BIO MED, V4, P79, DOI 10.1016/0891-5849(88)90067-6; Shen HM, 1996, FREE RADICAL BIO MED, V21, P139, DOI 10.1016/0891-5849(96)00019-6; Sturgeon BE, 1998, J BIOL CHEM, V273, P30116, DOI 10.1074/jbc.273.46.30116; SUDA N, 1993, BIOCHIM BIOPHYS ACTA, V1157, P318, DOI 10.1016/0304-4165(93)90116-P; Takeuchi T, 1996, CARCINOGENESIS, V17, P1543, DOI 10.1093/carcin/17.8.1543; TSUCHIYA M, 1994, METHOD ENZYMOL, V233, P128; Wang JF, 1996, FREE RADICAL BIO MED, V20, P533, DOI 10.1016/0891-5849(95)02085-3; Yang CF, 1997, ENVIRON HEALTH PERSP, V105, P712, DOI 10.1289/ehp.97105712; ZHU H, 1994, ARCH TOXICOL, V68, P582, DOI 10.1007/s002040050118	45	189	195	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28161	28168		10.1074/jbc.274.40.28161	http://dx.doi.org/10.1074/jbc.274.40.28161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497168	hybrid			2022-12-25	WOS:000082912700017
J	Cuevas, B; Lu, YL; Watt, S; Kumar, R; Zhang, JY; Siminovitch, KA; Mills, GB				Cuevas, B; Lu, YL; Watt, S; Kumar, R; Zhang, JY; Siminovitch, KA; Mills, GB			SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE PHOSPHATASES; JURKAT T-CELLS; SIGNAL-TRANSDUCTION; IN-VIVO; C-KIT; KINASE; ACTIVATION; ASSOCIATION; P56(LCK)	Ligation of the T cell antigen receptor (TCR) activates the Src family tyrosine kinase p56 Lck, which, in turn, phosphorylates a variety of intracellular substrates. The phosphatidylinositol 3-kinase (PI3K) and the tyrosine phosphatase SHP-1 are two Lck substrates that have been implicated in TGR signaling. In this study, we demonstrate that SHP-1 co-immunoprecipitates with the p85 regulatory subunit of PI3K in Jurkat T cells, and that this association is increased by ligation of the TCR complex. Go-expression of SHP-1 and PI3K with a constitutively activated form of Lck in COS7 cells demonstrated the carboxyl-terminal SH2 domain of PI3K to inducibly associate with the full-length SHP-1 protein. By contrast, a truncated SHP-1 mutant lacking the Lck phosphorylation site (Tyr(564)) failed to bind p85. Wild-type but not catalytically inactive SHP-1 induced dephosphorylation of p85, Furthermore, expression of SHP-1 decreased PI3K enzyme activity in anti-phosphotyrosine immunoprecipitates and phosphorylation of serine 473 in Akt, a process dependent on PI3K activity. These results indicate the presence of a functional interaction between PI3K and SHP-1 and suggest that PI3K signaling, which has been implicated in cell proliferation, apoptosis, cytoskeletal reorganization, and many other biological activities, can be regulated by SHP-1 in T lymphocytes.	Univ Texas, MD Anderson Canc Ctr, Div Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Cell Growth Regulat Lab, Houston, TX 77030 USA; Univ Toronto, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X5, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University of Toronto; University of Toronto	Mills, GB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Siminovitch, Katherine/K-1475-2013		NCI NIH HHS [CA71418] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071418] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CONE JC, 1993, EUR J IMMUNOL, V23, P2488; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; Jiao HY, 1997, EXP HEMATOL, V25, P592; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; MILLS GB, 1991, BIOCHEM SOC T, V19, P277, DOI 10.1042/bst0190277; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Plas DR, 1998, J MOL MED-JMM, V76, P589, DOI 10.1007/s001090050254; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Smith A, 1998, CURR BIOL, V8, pR241, DOI 10.1016/S0960-9822(98)70150-2; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; Weil R, 1996, CURR TOP MICROBIOL, V205, P63; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687	46	126	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27583	27589		10.1074/jbc.274.39.27583	http://dx.doi.org/10.1074/jbc.274.39.27583			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488096	hybrid			2022-12-25	WOS:000082739100035
J	Oyama, H; Abe, S; Ushiyama, S; Takahashi, S; Oda, K				Oyama, H; Abe, S; Ushiyama, S; Takahashi, S; Oda, K			Identification of catalytic residues of pepstatin-insensitive carboxyl proteinases from prokaryotes by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCYTALIDIUM-LIGNICOLUM M-133; ACID PROTEASES; ASPARTIC PROTEINASE; LENTINUS-EDODES; BACILLUS SP; PURIFICATION; PEPSIN; INHIBITOR; SUBSTRATE; GENE	Pepstatin-insensitive carboxyl proteinases from Pseudomonas sp. (PCP) and Xanthomonas sp. (XCP) have no conserved catalytic residue sequences, -Asp*-Thr-Gly- (Asp is the catalytic residue) for aspartic proteinases. To identify the catalytic residues of PCP and XCP, we selected presumed catalytic residues based on their high sequence similarity, assuming that such significant sites as catalytic residues will be generally conserved. Several Ala mutants of Asp or Glu residues were constructed and analyzed. The D170A, E222A, and D328A mutants for PCP and XD79A, XD169A, and XD348A mutants for XCP were not converted to mature protein after activation, and no catalytic activity could be detected in these mutants, The specificity constants toward chromogenic substrate of the other PCP and XCP mutants, except for the D84A mutant of PCP, were similar to that of wild-type PCP or XCP. Coupled with the result of chemical modification (Ito, M., Narutaki, S., Uchida, K., and Oda, K. (1999) J. Biochem. (Tokyo) 125, 210-216), a pair of Asp residues (170 and 328) for PCP and a pair of Asp residues (169 and 348) for XCP were elucidated to be their catalytic residues, respectively. The Glu(222) residue in PCP or Asp(79) residue in XCP was excluded from the candidates as catalytic residues, since the corresponding mutant retained its original activity.	Kyoto Inst Technol, Fac Text Sci, Dept Appl Biol, Sakyo Ku, Kyoto 6068588, Japan	Kyoto Institute of Technology	Oda, K (corresponding author), Kyoto Inst Technol, Fac Text Sci, Dept Appl Biol, Sakyo Ku, Kyoto 6068588, Japan.							CHANG WJ, 1976, J BIOCHEM-TOKYO, V80, P975, DOI 10.1093/oxfordjournals.jbchem.a131385; FRUTON JS, 1987, ASPARTIC PROTEINASES, V16, P1; Ito M, 1999, J BIOCHEM, V125, P210, DOI 10.1093/oxfordjournals.jbchem.a022261; Ito M, 1996, J BIOCHEM, V120, P845; KOBAYASHI H, 1985, AGR BIOL CHEM TOKYO, V49, P2393, DOI 10.1080/00021369.1985.10867083; KOELSCH G, 1994, FEBS LETT, V343, P6, DOI 10.1016/0014-5793(94)80596-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN XL, 1989, J BIOL CHEM, V264, P4482; MAITA T, 1984, J BIOCHEM-TOKYO, V95, P465, DOI 10.1093/oxfordjournals.jbchem.a134628; MAJIMA E, 1988, AGR BIOL CHEM TOKYO, V52, P787; MORIHARA K, 1979, J BIOCHEM, V85, P661; MORIHARA K, 1981, COMP SPECIFICITY MIC, P213; MURAO S, 1970, AGR BIOL CHEM TOKYO, V34, P1265, DOI 10.1080/00021369.1970.10859764; MURAO S, 1993, J BIOL CHEM, V268, P349; MURAO S, 1988, AGR BIOL CHEM TOKYO, V52, P1629; MURAO S, 1973, AGR BIOL CHEM TOKYO, V37, P1417, DOI 10.1080/00021369.1973.10860841; MURAO S, 1972, AGR BIOL CHEM TOKYO, V36, P1647, DOI 10.1080/00021369.1972.10860454; NAKATANI H, 1975, BIOCHIM BIOPHYS ACTA, V391, P415, DOI 10.1016/0005-2744(75)90266-1; Narutaki S, 1999, J BIOCHEM, V125, P75, DOI 10.1093/oxfordjournals.jbchem.a022271; ODA K, 1989, AGR BIOL CHEM TOKYO, V53, P405, DOI 10.1080/00021369.1989.10869302; Oda K, 1996, J BIOCHEM, V120, P564; ODA K, 1994, J BIOL CHEM, V269, P26518; ODA K, 1981, AGR BIOL CHEM TOKYO, V45, P2339, DOI 10.1080/00021369.1981.10864881; ODA K, 1976, AGR BIOL CHEM TOKYO, V40, P859, DOI 10.1080/00021369.1976.10862145; ODA K, 1975, AGR BIOL CHEM TOKYO, V39, P477, DOI 10.1080/00021369.1975.10861610; ODA K, 1986, AGR BIOL CHEM TOKYO, V50, P651, DOI 10.1080/00021369.1986.10867441; ODA K, 1992, BIOCHIM BIOPHYS ACTA, V1120, P208, DOI 10.1016/0167-4838(92)90272-F; ODA K, 1974, AGR BIOL CHEM TOKYO, V38, P2435, DOI 10.1080/00021369.1974.10861522; ODA K, 1987, AGR BIOL CHEM TOKYO, V51, P3073; ODA K, 1987, BIOCHIM BIOPHYS ACTA, V923, P463, DOI 10.1016/0304-4165(87)90055-9; PRESCOTT M, 1995, INT J BIOCHEM CELL B, V27, P729, DOI 10.1016/1357-2725(95)00032-K; RAJAGOPALAN TG, 1966, J BIOL CHEM, V241, P4295; Sambrook J., 2002, MOL CLONING LAB MANU; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; TANG J, 1978, NATURE, V271, P618, DOI 10.1038/271618a0; TANG J, 1971, J BIOL CHEM, V246, P4510; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TERASHITA T, 1981, AGR BIOL CHEM TOKYO, V45, P1937, DOI 10.1080/00021369.1981.10864821; TERASHITA T, 1984, AGR BIOL CHEM TOKYO, V48, P2639, DOI 10.1080/00021369.1984.10866568; TERASHITA T, 1984, AGR BIOL CHEM TOKYO, V48, P1029, DOI 10.1080/00021369.1984.10866245; TOOGOOD HS, 1995, BIOCHEM J, V307, P783, DOI 10.1042/bj3070783; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259	43	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27815	27822		10.1074/jbc.274.39.27815	http://dx.doi.org/10.1074/jbc.274.39.27815			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488127	hybrid			2022-12-25	WOS:000082739100066
J	Schurke, P; Freeman, JC; Dabrowski, MJ; Atkins, WM				Schurke, P; Freeman, JC; Dabrowski, MJ; Atkins, WM			Metal-dependent self-assembly of protein tubes from Escherichia coli glutamine synthetase - Cu2+ EPR studies of the ligation and stoichiometry of intermolecular metal binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DODECAMER STACKING	Escherichia coli glutamine synthetase (GS) is a dodecameric assembly of identical subunits arranged as two back-to-back hexagonal rings. In the presence of divalent metal ions, the dodecamers "stack" along their six-fold axis of symmetry to yield elongated tubes. This self-assembly process provides a useful model for probing metal-dependent protein-protein interactions. However, no direct spectroscopic or structural data have confirmed the identity of the ligands to the shared metal ions in "stacked" GS, Here, 9-GHz Cu2+ EPR studies have been used to probe the ligand structure and stoichiometry of the metal binding sites. The wild type protein, with N-terminal sequence (His-4)-X-3-(Met-8) -X-3-(His-12), exhibits a classic Cu2+-nitrogen spectrum, with g(perpendicular to) = 2.06 G, g(parallel to) = 2.24 G, and A(parallel to) = 19.3 x 10(-3) cm(-1). No superhyperfine structure is observed, The H4C mutant affords a spectrum that is the combination of two spectra at all stages of saturation. One of the overlapping spectra is nearly identical to the spectrum of wild type, and is due to His ligation, The second spectrum observed yields g(parallel to) = 2.28 and A(parallel to) = 17.1 x 10(-3) cm(-1). The linewidth and tensor values of the second component have been assigned to Cu2+-S ligation. In contrast, the H12C mutant exhibits an EPR spectrum at low Cu2+ occupancy that is very similar to the second set of spectral features observed for H4C, and which is assigned to Cu2+-S ligation, No Cu2+-His ligation is apparent until the Cu2+/N-terminal helices ratio is > 1.0, At saturation, the g = 2.00-2.06 region of the spectrum is essentially a mirror image of the spectrum obtained with H4C, and is due to overlapping Cu2+-N and Cu2+-S EPR spectra, The M8L and M8C mutants were also studied, in order to probe the role of position 8 in the N-terminal helix. Spectral parameters of these mutants are nearly identical to each other and to the wild type spectrum at saturating Cu2+, suggesting that Met-8 does not act as a direct metal ligand, Together, the results provide the first direct evidence for a binuclear metal ion site between each N-terminal helix pair at the GS GS interface, with both His-4 and His-12 providing metal ligands.	Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; SUNY Coll Fredonia, Dept Chem, Fredonia, NY 14063 USA; SUNY Coll Fredonia, Dept Biol, Fredonia, NY 14063 USA	University of Washington; University of Washington Seattle; State University of New York (SUNY) System; SUNY Fredonia; State University of New York (SUNY) System; SUNY Fredonia	Atkins, WM (corresponding author), Univ Washington, Dept Med Chem, Box 357610, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ESO7033] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; Antson AA, 1996, CURR OPIN STRUC BIOL, V6, P142, DOI 10.1016/S0959-440X(96)80067-4; ATKINS WM, 1994, BIOCHEMISTRY-US, V33, P14965, DOI 10.1021/bi00254a003; Boas J.F., 1978, BIOL MAGN RESON, P277; Bonander N, 1996, BIOCHEMISTRY-US, V35, P2429, DOI 10.1021/bi9522110; Chen JP, 1997, PROTEIN ENG, V10, P1289, DOI 10.1093/protein/10.11.1289; CHRISTIANSON DW, 1990, NATURE, V346, P225, DOI 10.1038/346225b0; DABROWSKI MJ, 1994, BIOCHEMISTRY-US, V33, P14957, DOI 10.1021/bi00254a002; Dabrowski MJ, 1998, CHEM BIOL, V5, P689, DOI 10.1016/S1074-5521(98)90662-7; Dabrowski MJ, 1995, ADV MATER, V7, P1015, DOI 10.1002/adma.19950071209; FREY TG, 1975, P NATL ACAD SCI USA, V72, P3402, DOI 10.1073/pnas.72.9.3402; Hartgerink JD, 1996, J AM CHEM SOC, V118, P43, DOI 10.1021/ja953070s; HUNT JB, 1980, J BIOL CHEM, V255, P590; Knowles P.F., 1976, MAGNETIC RESONANCE B; MAURIZI MR, 1986, BIOCHEMISTRY-US, V25, P141, DOI 10.1021/bi00349a021; MAURIZI MR, 1982, J BIOL CHEM, V257, P4271; MCGRATH ME, 1993, BIOCHEMISTRY-US, V32, P1914, DOI 10.1021/bi00059a005; MILLER RE, 1974, ARCH BIOCHEM BIOPHYS, V163, P155, DOI 10.1016/0003-9861(74)90465-2; NAKAGAWA S, 1981, CHEM PHARM BULL, V29, P1; SCHURKE P, 1996, P 34 HANF S HLTH ENV; VALENTINE RC, 1966, ARCH BIOCHEM BIOPHYS, V116, P171; Vanngard T., 1972, BIOL APPLICATIONS EL, P411; YANCHUNAS J, 1994, BIOCHEMISTRY-US, V33, P14949, DOI 10.1021/bi00254a001	24	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27963	27968		10.1074/jbc.274.39.27963	http://dx.doi.org/10.1074/jbc.274.39.27963			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488145	hybrid			2022-12-25	WOS:000082739100084
J	Straub, V; Ettinger, AJ; Durbeej, M; Venzke, DP; Cutshall, S; Sanes, JR; Campbell, KP				Straub, V; Ettinger, AJ; Durbeej, M; Venzke, DP; Cutshall, S; Sanes, JR; Campbell, KP			epsilon-sarcoglycan replaces alpha-sarcoglycan in smooth muscle to form a unique dystrophin-glycoprotein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIRDLE MUSCULAR-DYSTROPHY; DELTA-SARCOGLYCAN; BETA-SARCOGLYCAN; DEFICIENT MICE; CARDIOMYOPATHIC HAMSTER; EXTRACELLULAR-MATRIX; SKELETAL-MUSCLE; COMPONENT; GENE; UTROPHIN	The sarcoglycan complex has been well characterized in striated muscle, and defects in its components are associated with muscular dystrophy and cardiomyopathy. Here, we have characterized the smooth muscle sarcoglycan complex. By examination of embryonic muscle lineages and biochemical fractionation studies, we demonstrated that epsilon-sarcoglycan is an integral component of the smooth muscle sarcoglycan complex along with beta- and delta-sarcoglycan. Analysis of genetically defined animal models for muscular dystrophy supported this conclusion. The delta-sarcoglycan-deficient cardiomyopathic hamster and mice deficient in both dystrophin and utrophin showed loss of the smooth muscle sarcoglycan complex, whereas the complex was unaffected in alpha-sarcoglycan null mice in agreement with the finding that alpha-sarcoglycan is not expressed in smooth muscle cells. In the cardiomyopathic hamster, the smooth muscle sarcoglycan complex, containing epsilon-sarcoglycan, was fully restored following intramuscular injection of recombinant delta-sarcoglycan adenovirus. Together, these results demonstrate a tissue-dependent variation in the sarcoglycan complex and show that epsilon-sarcoglycan replaces alpha-sarcoglycan as an integral component of the smooth muscle dystrophin-glycoprotein complex. Our results also suggest a molecular basis for possible differential smooth muscle dysfunction in sarcoglycan deficient patients.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; Washington University (WUSTL)	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, 400 EMRB, Iowa City, IA 52242 USA.			Campbell, Kevin/0000-0003-2066-5889; Venzke, David/0000-0001-8180-9562; Straub, Volker/0000-0001-9046-3540; Durbeej Hjalt, Madeleine/0000-0002-5491-2457				BAROHN RJ, 1988, NEW ENGL J MED, V319, P15, DOI 10.1056/NEJM198807073190103; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Cox GF, 1997, CURR OPIN CARDIOL, V12, P329; Crespo M J, 1997, J Card Fail, V3, P311, DOI 10.1016/S1071-9164(97)90031-2; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Duclos F, 1998, NEUROMUSCULAR DISORD, V8, P30, DOI 10.1016/S0960-8966(97)00135-1; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Dumont EC, 1996, BRIT J PHARMACOL, V118, P1141, DOI 10.1111/j.1476-5381.1996.tb15516.x; Durbeej M, 1998, J HISTOCHEM CYTOCHEM, V46, P449, DOI 10.1177/002215549804600404; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; ENGEL WK, 1977, J NEUROL, V215, P161, DOI 10.1007/BF00312474; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ettinger AJ, 1997, J BIOL CHEM, V272, P32534, DOI 10.1074/jbc.272.51.32534; FACTOR SM, 1982, CIRCULATION, V66, P342, DOI 10.1161/01.CIR.66.2.342; Froehner SC, 1997, SOC GEN PHY, V52, P197; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; Greelish JP, 1999, NAT MED, V5, P439, DOI 10.1038/7439; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; HALLMANN R, 1995, DEV DYNAM, V202, P325, DOI 10.1002/aja.1002020402; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Holt KH, 1998, MOL CELL, V1, P841, DOI 10.1016/S1097-2765(00)80083-0; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JAFFE KM, 1990, ARCH PHYS MED REHAB, V71, P742; Jung D, 1996, J BIOL CHEM, V271, P32321, DOI 10.1074/jbc.271.50.32321; LEON SH, 1986, GASTROENTEROLOGY, V90, P455, DOI 10.1016/0016-5085(86)90948-0; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; McNally EM, 1998, FEBS LETT, V422, P27, DOI 10.1016/S0014-5793(97)01593-7; MIZUNO Y, 1995, AM J PATHOL, V146, P530; Nonaka I, 1998, LAB ANIM SCI, V48, P8; NOWAK TV, 1982, GASTROENTEROLOGY, V82, P800; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; PATAPOUTIAN A, 1995, SCIENCE, V270, P1818, DOI 10.1126/science.270.5243.1818; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Straub V, 1998, AM J PATHOL, V153, P1623, DOI 10.1016/S0002-9440(10)65751-3; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; YAMAMOTO H, 1994, J BIOCHEM-TOKYO, V115, P162, DOI 10.1093/oxfordjournals.jbchem.a124294; Yoshida M, 1997, FEBS LETT, V403, P143, DOI 10.1016/S0014-5793(97)00040-9	51	103	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27989	27996		10.1074/jbc.274.39.27989	http://dx.doi.org/10.1074/jbc.274.39.27989			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488149	hybrid			2022-12-25	WOS:000082739100088
J	Yang, XY; Chen, YZ; Gabuzda, D				Yang, XY; Chen, YZ; Gabuzda, D			ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TUMOR NECROSIS FACTOR; ACTIVE ANTIRETROVIRAL THERAPY; PROTEIN-KINASE; GENE-EXPRESSION; T-CELLS; TRANSCRIPTION FACTORS; MONOCYTIC CELLS; BINDING-SITES	Human immunodeficiency virus type 1 (HIV-1) can establish latent infection following provirus integration into the host genome. NF-kappa B plays a critical role in activation of HIV-1 gene expression by cytokines and other stimuli, but the signal transduction pathways that regulate the switch from latent to productive infection have not been defined. Here, we show that ERK1/ERK2 mitogen-activated protein kinase (MAPK) plays a central role in linking signals at the cell surface to activation of HIV-1 gene expression in latently infected cells. MAPK was activated by cytokines and phorbol 12-myristate 13-acetate in latently infected U1 cells. The induction of HIV-1 expression by these stimuli was inhibited by PD98059 and U0126, which are specific inhibitors of MAPK activation. Studies using constitutively active MEK or Raf kinase mutants demonstrated that MAPK activates the HIV-1 long terminal repeat (LTR) through the NF-kappa B sites. Most HIV-1 inducers activated NF-kappa B via a MAPK-independent pathway, indicating that activation of NF-kappa B is not sufficient to explain the activation of HIV-1 gene expression by MAPK. In contrast, all of the stimuli activated AP-1 via a MAPK-dependent pathway. NF-kappa B and AP-1 components c-Fos and c-Jun were shown to physically associate by yeast two-hybrid assays and electrophoretic mobility shift assays. Coexpression of NF-kappa B and c-Fos or c-Jun synergistically transactivated the HIV-1 LTR through the NF-kappa B sites. These studies suggest that MAPK acts by stimulating AP-1 and a subsequent physical and functional interaction of AP-1 with NF-kappa B, resulting in a complex that synergistically transactivates the HIV-1 LTR. These results define a mechanism for signal-dependent activation of HIV-1 replication in latently infected cells and suggest potential therapeutic strategies for unmasking latent reservoirs of HIV-1.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Gabuzda, D (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, JF 816,44 Binney St, Boston, MA 02115 USA.				NIAID NIH HHS [AI28691, AI36186] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036186, P30AI028691] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS M, 1994, P NATL ACAD SCI USA, V91, P3862, DOI 10.1073/pnas.91.9.3862; AHLERS A, 1994, MOL PHARMACOL, V46, P1077; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BISWAS DK, 1995, J VIROL, V69, P7437, DOI 10.1128/JVI.69.12.7437-7444.1995; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BUTERA ST, 1994, J VIROL, V68, P2726, DOI 10.1128/JVI.68.4.2726-2730.1994; CANNON P, 1994, J VIROL, V68, P1993, DOI 10.1128/JVI.68.3.1993-1997.1994; Cartier C, 1997, J VIROL, V71, P4832, DOI 10.1128/JVI.71.6.4832-4837.1997; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; Emiliani S, 1998, J VIROL, V72, P1666, DOI 10.1128/JVI.72.2.1666-1670.1998; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finzi D, 1998, CELL, V93, P665, DOI 10.1016/S0092-8674(00)81427-0; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOLKS TM, 1988, J IMMUNOL, V140, P1117; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARCIABLANCO MA, 1991, SCIENCE, V254, P815, DOI 10.1126/science.1658933; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; Gibellini D, 1997, BLOOD, V89, P1654, DOI 10.1182/blood.V89.5.1654.1654_1654_1664; GREENE WC, 1990, ANNU REV IMMUNOL, V8, P453, DOI 10.1146/annurev.iy.08.040190.002321; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kumar A, 1998, J IMMUNOL, V161, P776; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LIU JS, 1992, J VIROL, V66, P3883, DOI 10.1128/JVI.66.6.3883-3887.1992; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MCCUNE JM, 1995, CELL, V82, P183, DOI 10.1016/0092-8674(95)90305-4; MICHAEL NL, 1991, J VIROL, V65, P1291, DOI 10.1128/JVI.65.3.1291-1303.1991; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; POLI G, 1994, P NATL ACAD SCI USA, V91, P108, DOI 10.1073/pnas.91.1.108; POMERANTZ RJ, 1992, J VIROL, V66, P1809, DOI 10.1128/JVI.66.3.1809-1813.1992; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; Rabbi MF, 1997, VIROLOGY, V233, P235, DOI 10.1006/viro.1997.8602; ROEBUCK KA, 1993, J CLIN INVEST, V92, P1336, DOI 10.1172/JCI116707; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SESHAMMA T, 1992, P NATL ACAD SCI USA, V89, P10663, DOI 10.1073/pnas.89.22.10663; Shapiro L, 1998, P NATL ACAD SCI USA, V95, P7422, DOI 10.1073/pnas.95.13.7422; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; VANLINT C, 1991, J VIROL, V65, P7066, DOI 10.1128/JVI.65.12.7066-7072.1991; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VERDIN E, 1990, P NATL ACAD SCI USA, V87, P4874, DOI 10.1073/pnas.87.12.4874; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VIETOR I, 1993, J BIOL CHEM, V268, P18994; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yang XY, 1999, J VIROL, V73, P3460, DOI 10.1128/JVI.73.4.3460-3466.1999; Yang XY, 1998, J BIOL CHEM, V273, P29879, DOI 10.1074/jbc.273.45.29879	77	166	171	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27981	27988		10.1074/jbc.274.39.27981	http://dx.doi.org/10.1074/jbc.274.39.27981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488148	hybrid			2022-12-25	WOS:000082739100087
J	Lykidis, A; Baburina, I; Jackowski, S				Lykidis, A; Baburina, I; Jackowski, S			Distribution of CTP : phosphocholine cytidylyltransferase (CCT) isoforms - Identification of a new CCT beta splice variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; MEMBRANE-BINDING DOMAIN; CDP-CHOLINE PATHWAY; HAMSTER OVARY CELLS; PHOSPHATIDYLCHOLINE SYNTHESIS; INTRACELLULAR-LOCALIZATION; PHOSPHORYLATION SITES; NUCLEAR-LOCALIZATION; INCREASED EXPRESSION; TERMINAL DOMAIN	CTP:phosphocholine cytidylyltransferase is a major regulator of phosphatidylcholine biosynthesis. A single isoform, CCT alpha, has been studied extensively and a second isoform, CCT beta, was recently identified. We identify and characterize a third cDNA, CCT beta 2, that differs from CCT beta 1 at the carboxyl-terminal end and is predicted to arise as a splice variant of the CCT beta gene. Like CCT alpha, CCT beta 2 is heavily phosphorylated in vivo, in contrast to CCT beta 1. CCT beta 1 and CCT beta 2 mRNAs were differentially expressed by the human tissues examined, whereas CCT alpha was more uniformly represented. Using isoform-specific antibodies, both CCT beta 1 and CCT beta 2 localized to the endoplasmic reticulum of cells, in contrast to CCT alpha which resided in the nucleus in addition to associating with the endoplasmic reticulum. CCT beta 2 protein has enzymatic activity in vitro and was able to complement the temperature-sensitive cytidylyltransferase defect in CHO58 cells, just as CCT alpha and CCT beta 1 supporting proliferation at the nonpermissive conditions. Overexpression experiments did not reveal discrete physiological functions for the three isoforms that catalyze the same biochemical reaction; however, the differential cellular localization and tissue-specific distribution suggest that CCT beta 1 and CCT beta 2 may play a role that is distinct from ubiquitously expressed CCT alpha.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.		Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; BIEZENSKI JJ, 1971, BIOCHIM BIOPHYS ACTA, V239, P92, DOI 10.1016/0005-2760(71)90197-4; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cornell R.B., 1996, ADV LIPOBIOLOGY, P1; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1995, BIOCHEM J, V310, P699, DOI 10.1042/bj3100699; CRAIG L, 1994, J BIOL CHEM, V269, P3311; DECHAVES EP, 1995, J CELL BIOL, V128, P913, DOI 10.1083/jcb.128.5.913; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1981, J BIOL CHEM, V256, P7388; HOGAN M, 1994, AM J PHYSIOL, V267, pL25, DOI 10.1152/ajplung.1994.267.1.L25; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; HOUWELING M, 1995, J BIOL CHEM, V270, P16277, DOI 10.1074/jbc.270.27.16277; Houweling M, 1996, EUR J CELL BIOL, V69, P55; IHLE JN, 1995, P ANN M AM ASS CANC, V36, pA652; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Johnson JE, 1997, BBA-BIOMEMBRANES, V1324, P273, DOI 10.1016/S0005-2736(96)00233-7; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; JOHNSON JE, 1992, BIOCHEM J, V285, P815, DOI 10.1042/bj2850815; KALMAR GB, 1994, BBA-GENE STRUCT EXPR, V1219, P328, DOI 10.1016/0167-4781(94)90056-6; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KINGSTON RE, 1994, CURRENT PROTOCOLS MO; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; PELECH SL, 1982, J BIOL CHEM, V257, P4198; RUTHERFORD MS, 1993, GENOMICS, V18, P698, DOI 10.1016/S0888-7543(05)80377-5; Sharma P, 1998, BIOCHEMISTRY-US, V37, P4759, DOI 10.1021/bi972746o; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; YAMAGISHI M, 1993, EMBO J, V12, P625, DOI 10.1002/j.1460-2075.1993.tb05695.x; YANG W, 1995, J BIOL CHEM, V270, P23951, DOI 10.1074/jbc.270.41.23951; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503	50	125	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26992	27001		10.1074/jbc.274.38.26992	http://dx.doi.org/10.1074/jbc.274.38.26992			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480912	hybrid			2022-12-25	WOS:000082570700051
J	Tu, CJ; Schuenemann, D; Hoffman, NE				Tu, CJ; Schuenemann, D; Hoffman, NE			Chloroplast FtsY, chloroplast signal recognition particle, and GTP are required to reconstitute the soluble phase of light-harvesting chlorophyll protein transport into thylakoid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; PRECURSOR PROTEIN; BETA-SUBUNIT; RECEPTOR; TRANSLOCATION; HOMOLOG; INTEGRATION; INSERTION; PATHWAYS	The integration, of light-harvesting chlorophyll proteins (LHCPs) into the thylakoid membrane proceeds in two steps. First, LHCP interacts with a chloroplast signal recognition particle (cpSRP) to form a soluble targeting intermediate called the transit complex. Second, LHCP integrates into the thylakoid membrane in the presence of GTP, at least one other soluble factor, and undefined membrane components. We previously determined that cpSRP is composed of 43- and 54-kDa polypeptides. We :have examined the subunit stoichiometry of cpSRP and find that it is trimeric and composed of two subunits of cpSRP43/subunit of cpSRP54. A chloroplast homologue of FtsY, an Escherichia coli protein that is critical for the function off. coli SRP, was found largely in the stroma unassociated with cpSRP. When chloroplast FtsY was combined with cpSRP and GTP, the three factors promoted efficient LHCP integration into thylakoid membranes in the absence of stroma, demonstrating that they are all required for reconstituting the soluble phase of LHCP transport.	Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA	Carnegie Institution for Science	Hoffman, NE (corresponding author), Paradigm Genet, 104 Alexander Dr,Bldg 2,POB 14528, Res Triangle Pk, NC 27709 USA.	nhoffman@paragen.com		Schuenemann, Danja/0000-0001-8894-7685				ADAM Z, 1993, PLANT PHYSIOL, V102, P35, DOI 10.1104/pp.102.1.35; AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AMIN P, 1999, IN PRESS PLANT PHYSL; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1989, J BIOL CHEM, V264, P14225; CLINE K, 1986, J BIOL CHEM, V261, P4804; DMANUELSSON O, 1999, PROETEINS CI, V8, P978; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; GILL DR, 1987, MOL GEN GENET, V210, P504, DOI 10.1007/BF00327204; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; Harlow E., 1988, ANTIBODIES LAB MANUA; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; HULFORD A, 1994, J BIOL CHEM, V269, P3251; Klimyuk VI, 1999, PLANT CELL, V11, P87, DOI 10.1105/tpc.11.1.87; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; MEYER DI, 1980, J CELL BIOL, V87, P503, DOI 10.1083/jcb.87.2.503; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; NAKAI M, 1994, J BIOL CHEM, V269, P31338; Nilsson R, 1999, EMBO J, V18, P733, DOI 10.1093/emboj/18.3.733; Ogg SC, 1998, J CELL BIOL, V142, P341, DOI 10.1083/jcb.142.2.341; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; Pilgrim ML, 1998, PLANT J, V13, P177, DOI 10.1046/j.1365-313X.1998.00021.x; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; Schuenemann D, 1999, J BIOL CHEM, V274, P12177, DOI 10.1074/jbc.274.17.12177; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; SUCHUENEMANN D, 1999, BIOCHEM BIOPH RES CO, V254, P253; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633; YUAN JG, 1994, J BIOL CHEM, V269, P18463	42	97	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27219	27224		10.1074/jbc.274.38.27219	http://dx.doi.org/10.1074/jbc.274.38.27219			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480939	hybrid			2022-12-25	WOS:000082570700078
J	Levandoski, MM; Lin, YX; Moise, L; McLaughlin, JT; Cooper, E; Hawrot, E				Levandoski, MM; Lin, YX; Moise, L; McLaughlin, JT; Cooper, E; Hawrot, E			Chimeric analysis of a neuronal nicotinic acetylcholine receptor reveals amino acids conferring sensitivity to alpha-bungarotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTOXIN BINDING-SITES; MOLECULAR DISSECTION; SUBUNIT INTERFACES; IDENTIFICATION; DIVERSITY; RESIDUES; SELECTIVITY; ANTAGONIST; INHIBITION; KINETICS	We have investigated the molecular determinants responsible for cy-bungarotoxin (alpha Bgtx) binding to nicotinic acetylcholine receptors through chimeric analysis of two homologous alpha subunits, one highly sensitive to alpha Bgtx block (alpha 1) and the other, alpha Bgtx-insensitive (alpha 3). By replacing rat (alpha 3) residues 184-191 with the corresponding region from the Torpedo alpha 1 subunit, we introduced a cluster of five alpha 1 residues (Trp-184, Trp-187, Val-188, Tyr-189, and Thr-lgl) into the (alpha 3 subunit. Functional activity and alpha Bgtx sensitivity were assessed following co-expression in Xenopus oocytes of the chimeric alpha 3 subunit (alpha 3/alpha 1[5]) with either rat beta 2 or beta 4 subunits. Agonist-evoked responses of alpha 3/alpha 1[5]-containing receptors were blocked by alpha Bgtx with nanomolar affinity IC50 values: 41 nM for (alpha 3/alpha 1[5]beta 2 and 19 nM for alpha 3/alpha 1[5]beta 4). Furthermore, receptors containing the single point mutation alpha 3K189Y acquire significant sensitivity to alpha Bgtx block ICS, values: 186 nM for alpha 3K189Y beta 2 and 179 nM for (alpha 3K189Y beta 4), Another alpha 3 chimeric subunit, alpha 3/alpha 7[6], similar to alpha 3/alpha 1[5] but incorporating the corresponding residues from the alpha Bgtx-sensitive cur subunit, also conferred potent alpha Bgtx sensitivity to chimeric receptors when co-expressed with the beta 4 subunit (IC50 value = 31 nM). Our findings demonstrate that the residues between positions 184 and 191 of the alpha Bgtx-sensitive subunits al and alpha 7 play a critical functional role in the interaction of alpha Bgtx with nicotinic acetylcholine receptors sensitive to this toxin.	Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA; Brown Univ, Div Biol & Med, Dept Neurosci, Providence, RI 02912 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA; McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	Brown University; Brown University; Medical University of South Carolina; McGill University	Hawrot, E (corresponding author), Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.		Moise, Lenny/AAE-7448-2019	Moise, Lenny/0000-0002-4410-865X	NIGMS NIH HHS [GM32629] Funding Source: Medline; NINDS NIH HHS [NS34348] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034348] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Ackermann EJ, 1997, BIOCHEMISTRY-US, V36, P12836, DOI 10.1021/bi971513u; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; CACHELIN AB, 1994, MOL PHARMACOL, V46, P1168; CLAUDIO T, 1987, SCIENCE, V238, P1688, DOI 10.1126/science.3686008; COHEN BN, 1995, J GEN PHYSIOL, V105, P745, DOI 10.1085/jgp.105.6.745; Corringer PJ, 1998, J NEUROSCI, V18, P648; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Endo T., 1991, P165; ENDO T, 1986, BIOCHEMISTRY-US, V25, P395, DOI 10.1021/bi00350a019; Grant GA, 1998, BIOCHEMISTRY-US, V37, P12166, DOI 10.1021/bi981227y; Groot-Kormelink PJ, 1998, J BIOL CHEM, V273, P15317, DOI 10.1074/jbc.273.25.15317; Harvey SC, 1996, J NEUROSCI, V16, P3798; KARLIN A, 1995, NEURON, V15, P1237; LIMBIRD LE, 1996, CELL SURFACE RECEPTO, P133; LUETJE CW, 1993, MOL PHARMACOL, V44, P657; MARCHOT P, 1988, EUR J BIOCHEM, V174, P537, DOI 10.1111/j.1432-1033.1988.tb14132.x; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; Osaka H, 1999, J BIOL CHEM, V274, P9581, DOI 10.1074/jbc.274.14.9581; PAPKE RL, 1994, J PHARMACOL EXP THER, V268, P718; PAPKE RL, 1993, P ROY SOC B-BIOL SCI, V252, P141, DOI 10.1098/rspb.1993.0058; PAPKE RL, 1994, MOL PHARMACOL, V45, P142; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; Rosenthal JA, 1999, BIOCHEMISTRY-US, V38, P7847, DOI 10.1021/bi990045g; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SEGUELA P, 1993, J NEUROSCI, V13, P596; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; Spura A, 1999, BIOCHEMISTRY-US, V38, P4912, DOI 10.1021/bi982656z; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; WILSON PT, 1985, P NATL ACAD SCI USA, V82, P8790, DOI 10.1073/pnas.82.24.8790	33	49	49	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26113	26119		10.1074/jbc.274.37.26113	http://dx.doi.org/10.1074/jbc.274.37.26113			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473561	hybrid			2022-12-25	WOS:000082469700027
J	Matthews, SA; Rozengurt, E; Cantrell, D				Matthews, SA; Rozengurt, E; Cantrell, D			Characterization of serine 916 as an in vivo autophosphorylation site for protein kinase D/protein kinase C mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CELL ANTIGEN RECEPTOR; PHORBOL ESTERS; INTACT-CELLS; D ACTIVATION; FAMILY; DIACYLGLYCEROL; RESPONSES; DOMAIN; TARGET	Activation of the serine kinase protein kinase D (PKD)/PKC mu is controlled by the phosphorylation of two serine residues within its activation loop via a PKC-dependent signaling cascade. In this study we have identified the C-terminal serine 916 residue as an in vivo phosphorylation site within active PKD/PKC mu. An antibody that recognized PKD/PKC mu proteins specifically phosphorylated on the serine 916 residue was generated and used to show that phosphorylation of Ser-916 is induced by phorbol ester treatment of cells. Thus, the pS916 antibody is a useful tool to study the regulation of PKD/PKC mu activity in vivo. Antigen receptor ligation of T and B lymphocytes also induced phosphorylation of the serine 916 residue of PKD/PKC mu. Furthermore the regulatory Fc gamma RIIB receptor, which mediates vital negative feedback signals to the B cell antigen receptor complex, inhibited the antigen receptor-induced activation and serine 916 phosphorylation of PKD/PKC mu. The degree of serine 916 phosphorylation during lymphocyte activation and inhibition exactly correlated with the activation status of PKD/PKC mu. Moreover, using different mutants of PKD/PKC mu, we show that serine 916 is not trans-phosphorylated by an upstream kinase but is rather an autophosphorylation event that occurs following activation of PKD/PKC mu.	Imperial Canc Res Fund, Lymphocyte Activat Lab, London WC2A 3PX, England; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	Cancer Research UK; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Matthews, SA (corresponding author), Imperial Canc Res Fund, Lymphocyte Activat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	smatthew@icrf.icnet.uk; cantrell@icrf.icnet.uk		Matthews, Sharon/0000-0002-8634-9355				Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; HESCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; Rennecke J, 1996, EUR J BIOCHEM, V242, P428, DOI 10.1111/j.1432-1033.1996.0428r.x; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	31	187	194	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26543	26549		10.1074/jbc.274.37.26543	http://dx.doi.org/10.1074/jbc.274.37.26543			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473617	hybrid			2022-12-25	WOS:000082469700083
J	Pajalunga, D; Tognozzi, D; Tiainen, M; D'Angelo, M; Ferrantelli, F; Helin, K; Sacchi, A; Crescenzi, M				Pajalunga, D; Tognozzi, D; Tiainen, M; D'Angelo, M; Ferrantelli, F; Helin, K; Sacchi, A; Crescenzi, M			E2F activates late-G1 events but cannot replace E1A in inducing S phase in terminally differentiated skeletal muscle cells	ONCOGENE			English	Article						differentiation; recombinant adenovirus; cell cycle; transcription; p27	CARDIAC GENE-TRANSCRIPTION; CYCLIN-A; RETINOBLASTOMA PROTEIN; NUCLEAR-LOCALIZATION; ADENOVIRUS E1A; SUBCELLULAR-LOCALIZATION; DEREGULATED EXPRESSION; VENTRICULAR MYOCYTES; FAMILY MEMBERS; GROWTH	We have previously shown that the adenovirus E1A oncogene can reactivate the cell cycle in terminally differentiated cells. Current models imply that much or all of this E1A activity is mediated by the release of the E2F transcription factors from pocket-protein control. In contrast, me show here that overexpression of E2F-1, E2F-2 and E2F-4, or a chimeric E2F-4 tethered to a nuclear localization signal cannot reactivate postmitotic skeletal muscle cells (myotubes). This is not due to lack of transcriptional activity, as demonstrated on both a reporter construct and a number of endogenous target genes. Although cyclin E was strongly overexpressed in E2F-transduced myotubes, it lacked associated kinase activity, possibly explaining the inability of the myotubes to enter S phase and accumulate cyclin A. Although E2F is not sufficient to trigger DNA synthesis in myotubes, its activity is necessary even in the presence of E1A, as dominant-negative DP-1 mutants inhibit E1A-mediated cell cycle reentry. Our data show that, to reactivate myotubes, E1A must exert other functions, in addition to releasing E2F. They also establish mouse myotubes as an experimental system uniquely suited to study the most direct E2F functions in the absence of downstream cell cycle effects.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Rome, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS European Institute of Oncology (IEO)	Crescenzi, M (corresponding author), Ist Super Sanita, Lab Compared Toxicol & Ecotoxicol, Viale Regina Elena 299, I-00161 Rome, Italy.		Crescenzi, Marco/J-3603-2018; Ferrantelli, Flavia/J-7794-2016; pajalunga, deborah/K-2423-2018; Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Crescenzi, Marco/0000-0003-0156-1494; Ferrantelli, Flavia/0000-0002-0768-1078; pajalunga, deborah/0000-0003-4892-8396; Helin, Kristian/0000-0003-1975-6097	Telethon [761] Funding Source: Medline	Telethon(Fondazione Telethon)		Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; CRESCENZI M, 1995, ANN NY ACAD SCI, V752, P9, DOI 10.1111/j.1749-6632.1995.tb17402.x; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; delaLuna S, 1996, J CELL SCI, V109, P2443; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Endo T., 1989, CELLULAR MOL BIOL MU, P95; FOGEL M, 1967, P NATL ACAD SCI USA, V58, P967, DOI 10.1073/pnas.58.3.967; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Magae J, 1996, J CELL SCI, V109, P1717; Muller H, 1997, MOL CELL BIOL, V17, P5508; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OKAZAKI K, 1966, P NATL ACAD SCI USA, V56, P1484, DOI 10.1073/pnas.56.5.1484; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Puri PL, 1998, CANCER RES, V58, P1325; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; TRIVEDI RA, 1995, J NEUROCHEM, V64, P2230; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Wu CL, 1996, MOL CELL BIOL, V16, P3698; YAFFE D, 1967, NATURE, V215, P421, DOI 10.1038/215421a0; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407	40	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	1999	18	36					5054	5062		10.1038/sj.onc.1202897	http://dx.doi.org/10.1038/sj.onc.1202897			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490842				2022-12-25	WOS:000082497100005
J	Chuang, YJ; Gettins, PGW; Olson, ST				Chuang, YJ; Gettins, PGW; Olson, ST			Importance of the P2 glycine of antithrombin in target proteinase specificity, heparin activation, and the efficiency of proteinase trapping as revealed by a P2 Gly -> Pro mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY HEPARIN; REACTIVE CENTER LOOP; ACTIVE-SITE; FACTOR-XA; RECOMBINANT ANTITHROMBIN; KINETIC CHARACTERIZATION; CONFORMATIONAL CHANGE; ALPHA-THROMBIN; ANTI-THROMBIN; BINDING	A sequence-specific heparin pentasaccharide activates the serpin, antithrombin, to inhibit factor Ya through an allosteric mechanism, whereas full-length heparin chains containing this sequence further activate the serpin to inhibit thrombin by an alternative bridging mechanism. To test whether the factor Xa specificity of allosterically activated antithrombin is encoded in the serpin reactive center loop, we mutated the factor Xa-preferred P2 Gly to the thrombin-preferred P2 Pro. Kinetic studies revealed that the mutation maximally enhanced the reactivity of antithrombin with thrombin 15-fold and decreased its reactivity toward factor Xa a-fold when the serpin was activated by heparin pentasaccharide, thereby transforming antithrombin into an allosterically activated inhibitor of both factor Xa and thrombin, Surprisingly, the enhanced thrombin specificity of the mutant antithrombin was attenuated when a full-length bridging heparin was the activator, due both to a reduced rate of covalent reaction of the mutant serpin and thrombin and preferred reaction of the mutant serpin as a substrate. These results demonstrate that the reactive center loop sequence determines the specificity of allosterically activated antithrombin for factor Xa and that the conformational flexibility of the P2 Gly may be critical for optimal bridging of antithrombin and thrombin by physiologic heparin and for preventing antithrombin from reacting as a substrate in the bridging complex.	Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Olson, ST (corresponding author), Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Rm 530E Dent,M-C 860,801 S Paulina St, Chicago, IL 60612 USA.		Chuang, Yung-Jen/D-2362-2013	Chuang, Yung-Jen/0000-0002-6022-0107	NHLBI NIH HHS [HL 39888, HL 49234] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049234, R37HL039888, R29HL039888, R37HL049234, R01HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; Bjork I, 1997, ADV EXP MED BIOL, V425, P17; BJORK I, 1982, J BIOL CHEM, V257, P9487; BJORK I, 1992, BIOCHEM J, V286, P793; BJORK I, 1992, J BIOL CHEM, V267, P19047; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; FAN BQ, 1993, J BIOL CHEM, V268, P17588; Fersht A., 1985, ENZYME STRUCTURE MEC; FISH WW, 1979, EUR J BIOCHEM, V101, P31, DOI 10.1111/j.1432-1033.1979.tb04212.x; Futamura A, 1998, BIOCHEMISTRY-US, V37, P13110, DOI 10.1021/bi981234m; GAN ZR, 1994, J BIOL CHEM, V269, P1301; Garone L, 1996, BIOCHEMISTRY-US, V35, P8881, DOI 10.1021/bi960542m; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; JESTY J, 1979, J BIOL CHEM, V254, P44; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1995, J BIOL CHEM, V270, P9717, DOI 10.1074/jbc.270.17.9717; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Olson ST, 1997, ARCH BIOCHEM BIOPHYS, V341, P212, DOI 10.1006/abbi.1997.9973; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P1026, DOI 10.1021/bi9620823; Rezaie AR, 1998, PROTEIN SCI, V7, P349; SHEFFIELD WP, 1994, THROMB RES, V75, P293, DOI 10.1016/0049-3848(94)90240-2; SHEFFIELD WP, 1994, FEBS LETT, V339, P147, DOI 10.1016/0014-5793(94)80403-6; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TURKO IV, 1993, FEBS LETT, V335, P9, DOI 10.1016/0014-5793(93)80429-X; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; Vindigni A, 1997, NAT BIOTECHNOL, V15, P891, DOI 10.1038/nbt0997-891; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Zettlmeissl G, 1988, Behring Inst Mitt, P26	53	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28142	28149		10.1074/jbc.274.40.28142	http://dx.doi.org/10.1074/jbc.274.40.28142			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497166	hybrid			2022-12-25	WOS:000082912700015
J	Green, BN; Bordoli, RS; Hanin, LG; Lallier, FH; Toulmond, A; Vinogradov, SN				Green, BN; Bordoli, RS; Hanin, LG; Lallier, FH; Toulmond, A; Vinogradov, SN			Electrospray ionization mass spectrometric determination of the molecular mass of the similar to 200-kDa globin dodecamer subassemblies in hexagonal bilayer hemoglobins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMBRICUS-TERRESTRIS HEMOGLOBIN; POLYPEPTIDE-CHAIN COMPOSITION; WORM RIFTIA-PACHYPTILA; EXTRACELLULAR HEMOGLOBIN; 3-DIMENSIONAL RECONSTRUCTION; QUATERNARY STRUCTURE; CRYOELECTRON MICROSCOPY; ALVINELLA-POMPEJANA; MAXIMUM-ENTROPY; SUBUNIT	Hexagonal bilayer hemoglobins (Hbs) are similar to 3.6-MDa complexes of similar to 17-kDa globin chains and 24-32-kDa, nonglobin linker chains in a similar to 2:1 mass ratio found in annelids and related species, Studies of the dissociation and reassembly of Lumbricus terrestris Hb have provided ample evidence for the presence of a similar to 200-kDa linker-free subassembly consisting of monomer (RI) and disulfide-bonded trimer (T) subunits, Electrospray ionization mass spectrometry (ESI-MS) of the subassemblies obtained by gel filtration of partially dissociated L, terrestris and Arenicola marina Hbs showed the presence of noncovalent complexes of IM and T subunits with masses in the 213.3-215.4 and 204.6-205.6 kDa ranges, respectively. The observed mass of the L. terrestris subassembly decreased linearly with an increase in de-clustering voltage from similar to 215,400 Ha at 60 V to similar to 213,300 Ha at 200 V, In contrast, the mass of the A. marina complex decreased linearly from 60 to 120 V and reached an asymptote at similar to 204,600 Ha (180-200 V). The decrease in mass was probably due to the progressive removal of complexed water and alkali metal cations, ESI-MS at an acidic pH showed both subassemblies to consist of only M and T subunits, and the experimental masses demonstrated them to have the composition M,T,. Because there are three isoforms of M and four isoforms of T in Lumbricus and two isoforms of M and 5 isoforms of T in Arenicola, the masses of the M,T, subassemblies are not unique. A random assembly model was used to calculate the mass distributions of the subassemblies, using the known ESI-MS masses and relative intensities of the M and T subunit isforms, The expected mass of randomly assembled subassemblies was 213,436 Ha for Lumbricus Hb and 204,342 Ha for Arenicola Hb, in good agreement with the experimental values.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Observ Oceanol Roscoff, Equipe Ecophysiol, F-29682 Roscoff, France; Idaho State Univ, Dept Math, Pocatello, ID 83209 USA; Micromass UK Ltd, Altrincham WA14 5RZ, Cheshire, England	Wayne State University; UDICE-French Research Universities; Sorbonne Universite; Idaho; Idaho State University	Vinogradov, SN (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.							ADAMS S, 1997, MAPLE TALK; Chung E, 1998, STRUCTURE, V6, P1141, DOI 10.1016/S0969-2126(98)00115-4; COTTRELL JC, 1991, P 39 C MASS SPECTR A, P234; deHaas F, 1996, J MOL BIOL, V255, P140, DOI 10.1006/jmbi.1996.0012; deHaas F, 1996, J MOL BIOL, V264, P111, DOI 10.1006/jmbi.1996.0627; deHaas F, 1996, BIOPHYS J, V70, P1973, DOI 10.1016/S0006-3495(96)79762-X; deHaas F, 1996, PROTEINS, V26, P241; deHaas F, 1997, BIOCHEMISTRY-US, V36, P7330, DOI 10.1021/bi970131l; Fabris D, 1999, ANAL CHEM, V71, P384, DOI 10.1021/ac980753s; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; GREEN BN, 1995, J BIOL CHEM, V270, P18209, DOI 10.1074/jbc.270.31.18209; Green BN, 1998, BIOCHEMISTRY-US, V37, P6598, DOI 10.1021/bi972644y; Green BN, 1999, INT J MASS SPECTROM, V188, P105, DOI 10.1016/S1387-3806(98)14285-9; Ladbury JE, 1996, CHEM BIOL, V3, P973, DOI 10.1016/S1074-5521(96)90164-7; Lamy JN, 1996, CHEM REV, V96, P3113, DOI 10.1021/cr9600058; Martin PD, 1996, J MOL BIOL, V255, P154, DOI 10.1006/jmbi.1996.0013; OWNBY DW, 1993, J BIOL CHEM, V268, P13539; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; Sharma PK, 1996, J BIOL CHEM, V271, P8754, DOI 10.1074/jbc.271.15.8754; TAYLOR H., 1998, INTRO STOCHASTIC MOD; Vinogradov S.N., 1985, P9; Vinogradov S. N., 1982, ELECTRON MICROS, P135; VINOGRADOV SN, 1994, METHOD ENZYMOL, V231, P112; VINOGRADOV SN, 1977, BIOCHIM BIOPHYS ACTA, V492, P136, DOI 10.1016/0005-2795(77)90221-5; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; VINOGRADOV SN, 1991, COMP BIOCHEM PHYS B, V98, P187, DOI 10.1016/0305-0491(91)90165-A; WEBER RE, 1995, J MOL BIOL, V251, P703, DOI 10.1006/jmbi.1995.0466; Zal F, 1996, J BIOL CHEM, V271, P8875, DOI 10.1074/jbc.271.15.8875; Zal F, 1997, BIOCHEMISTRY-US, V36, P11777, DOI 10.1021/bi9712899; Zal F, 1997, EUR J BIOCHEM, V243, P85, DOI 10.1111/j.1432-1033.1997.85_1a.x; Zhu H, 1996, J BIOL CHEM, V271, P30007, DOI 10.1074/jbc.271.47.30007; Zhu H, 1996, J BIOL CHEM, V271, P29999, DOI 10.1074/jbc.271.47.29999	34	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28206	28212		10.1074/jbc.274.40.28206	http://dx.doi.org/10.1074/jbc.274.40.28206			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497174	hybrid			2022-12-25	WOS:000082912700023
J	Larin, D; Mekios, C; Das, K; Ross, B; Yang, AS; Gilliam, TC				Larin, D; Mekios, C; Das, K; Ross, B; Yang, AS; Gilliam, TC			Characterization of the interaction between the Wilson and Menkes disease proteins and the cytoplasmic copper chaperone, HAH1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORTING ATPASE; CANDIDATE GENE; ATX1 GENE; IN-VITRO; ENCODES; HOMEOSTASIS; YEAST; CELLS; LOCALIZATION	Wilson disease (WD) and Menkes disease (MNK) are inherited disorders of copper metabolism. The genes that mutate to give rise to these disorders encode highly homologous copper transporting ATPases, We use yeast and mammalian two-hybrid systems, along with an in vitro assay to demonstrate a specific, copper-dependent interaction between the six metal-binding domains of the WD and MNK ATPases and the cytoplasmic copper chaperone HAH1, We demonstrate that several metal-binding domains interact independently or in combination with HAH1p, although notably domains five and six of WDp do not. Alteration of either the Met or Thr residue of the HAH1p MTCXXC motif has no observable effect on the copper-dependent interaction, whereas alteration of either of the two Cys residues abolishes the interaction. Mutation of any one of the HAH1p C-terminal Lys residues (Lys(56), Lys(57), or Lys(60)) to Gly does not affect the interaction, although deletion of the 15 C-terminal residues abolishes the interaction. We show that apo-HAH1p can bind in vitro to copper-loaded WDp, suggesting reversibility of copper transfer from HAH1p to WD/MNKp. The in vitro HAH1/WDp interaction is metalospecific; HAH1 preincubated with Cu2+ or Hg+ but not with Zn2+, Cd2+, Co2+, Ni3+, Fe3+, or Cr3+ interacted with WDp, Finally, we model the protein-protein interaction and present a theoretical representation of the HAH1p Cu WD/MNKp complex.	Columbia Univ Coll Phys & Surg, Columbia Genome Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Gilliam, TC (corresponding author), Columbia Univ Coll Phys & Surg, Columbia Genome Ctr, Russ Berrie Med Sci Pavil,1150 St Nicholas Ave,Bo, New York, NY 10032 USA.			Yang, An-Suei/0000-0002-4699-873X				Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; BEERS J, 1998, BIOCHEMISTRY-US, V37, P7572; Bremner I, 1998, AM J CLIN NUTR, V67, p1069S, DOI 10.1093/ajcn/67.5.1069S; BROWN NL, 1985, TRENDS BIOCHEM SCI, V10, P400, DOI 10.1016/0968-0004(85)90069-6; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Dierick HA, 1997, HUM MOL GENET, V6, P409, DOI 10.1093/hmg/6.3.409; Francis MS, 1997, MOL GEN GENET, V253, P484, DOI 10.1007/s004380050347; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; La Fontaine S, 1998, HUM MOL GENET, V7, P1293, DOI 10.1093/hmg/7.8.1293; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Linder M, 1991, BIOCH COPPER; Linder MC, 1998, AM J CLIN NUTR, V67, p965S, DOI 10.1093/ajcn/67.5.965S; Lontie R., 1984, COPPER PROTEINS COPP, V1st; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Nagano K, 1998, HEPATOLOGY, V27, P799, DOI 10.1002/hep.510270323; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Percival SS, 1998, AM J CLIN NUTR, V67, p1064S, DOI 10.1093/ajcn/67.5.1064S; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Rucker RB, 1998, AM J CLIN NUTR, V67, p996S, DOI 10.1093/ajcn/67.5.996S; SRINIVASAN C, 1997, P NATL ACAD SCI USA, V94, P7481; Steele RA, 1997, BIOCHEMISTRY-US, V36, P6885, DOI 10.1021/bi9631632; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Turnlund JR, 1998, AM J CLIN NUTR, V67, p960S, DOI 10.1093/ajcn/67.5.960S; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YANG A, 1999, IN PRESS PROTEINS; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	39	137	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28497	28504		10.1074/jbc.274.40.28497	http://dx.doi.org/10.1074/jbc.274.40.28497			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497213	hybrid			2022-12-25	WOS:000082912700062
J	Odermatt, A; Arnold, P; Stauffer, A; Frey, BM; Frey, FJ				Odermatt, A; Arnold, P; Stauffer, A; Frey, BM; Frey, FJ			The N-terminal anchor sequences of 11 beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APPARENT MINERALOCORTICOID EXCESS; POSITIVELY CHARGED RESIDUES; ALDOSTERONE TARGET-CELLS; TRANSMEMBRANE ORIENTATION; LUMENAL ORIENTATION; TISSUE DISTRIBUTION; TYPE-2 ENZYME; PROTEINS; LOCALIZATION; CLONING	11 beta-Hydroxysteroid dehydrogenase enzymes (11 beta-HSD) regulate the ratio of active endogenous glucocorticoids to their inactive beto-metabolites, thereby controlling the access of glucocorticoids to their cognate receptors, In this study, the topology and intracellular localization of 11 beta-HSD1 and 11 beta-HSD2 have been analyzed by immunohistochemistry and protease protection assays of in vitro transcription/translation products. 11 beta-HSD constructs, tagged with the FLAG epitope, were transiently expressed in HEK-293 cells. The enzymatic characteristics of tagged and native enzymes were indistinguishable. Fluorescence microscopy demonstrated the localization of both 11 beta-HSD1 and 11 beta-HSD2 exclusively to the endoplasmic reticulum (ER) membrane. To examine the orientation of tagged 11 beta-HSD enzymes within the ER membrane, we stained selectively permeabilized HEK-293 cells with anti-FLAG antibody. Immunohistochemistry revealed that the N terminus of 11 beta-HSD1 is cytoplasmic, and the catalytic domain containing the C terminus is protruding into the ER lumen. In contrast, the N terminus of 11 beta-HSD2 is lumenal, and the catalytic domain is facing the cytoplasm, Chimeric proteins where the N-terminal anchor sequences of 11 beta-HSD1 and 11 beta-HSD2 were exchanged adopted inverted orientation in the ER membrane. However, both chimeric proteins were not catalytically active. Furthermore, mutation of a tyrosine motif to alanine in the transmembrane segment of 11 beta-HSD1 significantly reduced V-max. The subcellular localization of 11 beta-HSD1 was not affected by mutations of the tyrosine motif or of a di-lysine motif in the N terminus. However, residue Lys(5), but not Lys(6), turned out to be critical for the topology of 11 beta-HSD1. Mutation of Lys(5) to Ser inverted the orientation of 11 beta-HSD1 in the ER membrane without loss of catalytic activity. Our results emphasize the importance of the N-terminal transmembrane segments of 11 beta-HSD enzymes for their proper function and demonstrate that they are sufficient to determine their orientation in the ER membrane.	Univ Bern, Dept Med, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland	University of Bern	Odermatt, A (corresponding author), Univ Bern, Dept Med, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland.	alex.odermatt@dkf2.unibe.ch		Odermatt, Alex/0000-0002-6820-2712				AGARWAL AK, 1995, BBA-PROTEIN STRUCT M, V1248, P70, DOI 10.1016/0167-4838(95)00005-F; AGARWAL AK, 1994, J BIOL CHEM, V269, P25959; AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BEAUMONT K, 1983, ENDOCRINOLOGY, V113, P2043, DOI 10.1210/endo-113-6-2043; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BROWN RW, 1993, ENDOCRINOLOGY, V132, P2614, DOI 10.1210/en.132.6.2614; Bujalska O, 1997, STEROIDS, V62, P77, DOI 10.1016/S0039-128X(96)00163-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; Escher G, 1997, J EXP MED, V186, P189, DOI 10.1084/jem.186.2.189; Escher G, 1998, ENDOCRINOLOGY, V139, P1533, DOI 10.1210/en.139.4.1533; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Gao HB, 1997, ENDOCRINOLOGY, V138, P156, DOI 10.1210/en.138.1.156; GomezSanchez EP, 1996, STEROIDS, V61, P110, DOI 10.1016/0039-128X(95)00201-Z; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hult M, 1998, FEBS LETT, V441, P25, DOI 10.1016/S0014-5793(98)01515-4; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KINGSTON RE, 1992, CURRENT PROTOCOLS MO; KOLELEVTSEV Y, 1999, J CLIN INVEST, V103, P683; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KROZOWSKI ZS, 1983, P NATL ACAD SCI-BIOL, V80, P6056, DOI 10.1073/pnas.80.19.6056; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; Maser E, 1997, EUR J BIOCHEM, V249, P365, DOI 10.1111/j.1432-1033.1997.00365.x; MERCER WR, 1992, ENDOCRINOLOGY, V130, P540, DOI 10.1210/en.130.1.540; MONDER C, 1991, FASEB J, V5, P3047, DOI 10.1096/fasebj.5.15.1743437; Morita H, 1996, ENDOCRINOLOGY, V137, P2308, DOI 10.1210/en.137.6.2308; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; Mune T, 1996, HYPERTENSION, V27, P1193, DOI 10.1161/01.HYP.27.6.1193; Naray-Fejes-Toth A, 1998, J STEROID BIOCHEM, V65, P311, DOI 10.1016/S0960-0760(98)00009-0; Naray-Fejes-Toth A, 1998, ENDOCRINOLOGY, V139, P2955, DOI 10.1210/en.139.6.2955; NarayFejesToth A, 1996, J BIOL CHEM, V271, P15436, DOI 10.1074/jbc.271.26.15436; NARAYFEJESTOTH A, 1991, ENDOCRINOLOGY, V129, P17, DOI 10.1210/endo-129-1-17; Nunez BS, 1999, BIOCHEM BIOPH RES CO, V255, P652, DOI 10.1006/bbrc.1999.0259; OBEID J, 1993, MOL ENDOCRINOL, V7, P154, DOI 10.1210/me.7.2.154; Obeyesekere VR, 1997, MOL CELL ENDOCRINOL, V131, P173, DOI 10.1016/S0303-7207(97)00106-8; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; OPPERMANN UCT, 1995, EUR J BIOCHEM, V227, P202, DOI 10.1111/j.1432-1033.1995.tb20377.x; Ozols J, 1998, BIOCHEMISTRY-US, V37, P10336, DOI 10.1021/bi9807916; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Petrelli MD, 1997, ENDOCRINOLOGY, V138, P3077, DOI 10.1210/en.138.7.3077; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Shimojo M, 1997, ENDOCRINOLOGY, V138, P1305, DOI 10.1210/en.138.3.1305; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Tsigelny I, 1995, J STEROID BIOCHEM, V55, P589, DOI 10.1016/0960-0760(95)00210-3; Voice MW, 1996, BIOCHEM J, V317, P621, DOI 10.1042/bj3170621; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P2263, DOI 10.1210/jc.80.7.2263; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P3145, DOI 10.1210/jc.80.11.3145	67	161	164	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28762	28770		10.1074/jbc.274.40.28762	http://dx.doi.org/10.1074/jbc.274.40.28762			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497248	hybrid			2022-12-25	WOS:000082912700097
J	Salazar, EP; Rozengurt, E				Salazar, EP; Rozengurt, E			Bombesin and platelet-derived growth factor induce association of endogenous focal adhesion kinase with Src in intact Swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PAXILLIN TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAYS; STRESS FIBER FORMATION; LYSOPHOSPHATIDIC ACID; PHOSPHOINOSITIDE 3-KINASE; RAPIDLY STIMULATE; PHORBOL ESTERS; PHOSPHATIDYLINOSITOL 3'-KINASE; EXTRACELLULAR-MATRIX	Stimulation of quiescent Swiss 3T3 cells with bombesin induces a rapid increase in the formation of complexes between focal adhesion kinase (FAK) and Src family members, which can be extracted with a buffer containing Triton, deoxycholate, and SDS but not with a buffer containing Triton alone. An increase in complex formation between FAK and Src in response to bombesin could be detected within 1 min, reached a maximum after 10 min, and declined toward base-line levels after 60 min of bombesin treatment. Bradykinin, endothelin, and lysophosphatidic acid also stimulated FAK-Src complex formation. Bombesin stimulated FAW/Src association through a Ca2+ and phosphatidylinositol 3'-kinase-independent pathway that requires the integrity of the actin filament network and is partly dependent on functional protein kinase C. Treatment with the selective Src kinase inhibitor PP-2 inhibited both FAK activation and phosphorylation of FAK at Tyr(577) induced by bombesin in intact cells. Platelet-derived growth factor at low concentrations (1-10 ng/ml) also induced FAK-Src complex formation via a pathway that depended on the integrity of the actin cytoskeleton and phosphatidylinositol 3'-kinase. Thus, G protein-coupled receptor agonists and platelet-derived growth factor promote complex formation between endogenous FAK and Src in attached cells through different signal transduction pathways.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.							ALBERT DA, 1992, P NATL ACAD SCI USA, V89, P1597, DOI 10.1073/pnas.89.5.1597; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Charlesworth A, 1996, ONCOGENE, V12, P1337; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1997, J CELL SCI, V110, P401; ILLC D, 1995, NATURE, V377, P539; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; OKADA T, 1994, J BIOL CHEM, V269, P3563; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Rozengurt E, 1998, AM J PHYSIOL-GASTR L, V275, pG177, DOI 10.1152/ajpgi.1998.275.2.G177; ROZENGURT E, 1995, CANCER SURV, V24, P81; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Seckl MJ, 1996, J BIOL CHEM, V271, P29453, DOI 10.1074/jbc.271.46.29453; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; Withers DJ, 1997, J BIOL CHEM, V272, P2509; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; YANO H, 1993, J BIOL CHEM, V268, P25846; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	82	102	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28371	28378		10.1074/jbc.274.40.28371	http://dx.doi.org/10.1074/jbc.274.40.28371			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497197	hybrid			2022-12-25	WOS:000082912700046
J	Schulenberg, B; Capaldi, RA				Schulenberg, B; Capaldi, RA			The epsilon subunit of the F1F0 complex of Escherichia coli - Cross-linking studies show the same structure in situ as when isolated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-SYNTHASE; ADENOSINE-TRIPHOSPHATASE; F0F1-ATP SYNTHASE; ALPHA-SUBUNIT; BETA-SUBUNITS; H+-ATPASE; F-0 PARTS; NUCLEOTIDE; F1-ATPASE; ROTATION	Four double mutants in the epsilon subunit were generated, each containing two cysteines, which, based on the NMR structure of this subunit, should form internal disulfide bonds. Two of these were designed to generate interdomain cross-links that lock the C-terminal cu-helical domain against the beta-sandwich (epsilon M49C/A126C and epsilon F61C/V130C). The second set should give cross-linking between the two C-terminal alpha-helices (epsilon A94C/L128C and epsilon A101C/L121C), All four mutants cross-linked with 90-100% efficiency upon CuCl2 treatment in isolated Escherichia coli ATP synthase, This shows that the structure obtained for isolated epsilon is essentially the same as in the assembled complex. Functional studies revealed increased ATP hydrolysis after cross-linking between the two domains of the subunit but not after cross-linking between the C-terminal alpha-helices, None of the cross links had any effect on proton pumping coupled ATP hydrolysis, on DCCD sensitivity of this activity, or on ATP synthesis rates. Therefore, big conformational changes within epsilon can be ruled out as a part of the enzyme function. Protease digestion studies, however, showed that subtle changes do occur, since the epsilon subunit could be locked in an ADP or 5'-adenylyl-beta,gamma-imidodiphosphate conformation by the cross-linking with resulting differences in cleavage rates.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 24526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; Battey, 1986, BASIC METHODS MOL BI; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; CRUZ JA, 1995, PLANT PHYSIOL, V109, P1379, DOI 10.1104/pp.109.4.1379; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; FOSTER DL, 1979, J BIOL CHEM, V254, P8230; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Ketchum CJ, 1998, J BIOL CHEM, V273, P22292, DOI 10.1074/jbc.273.35.22292; KUKI M, 1988, J BIOL CHEM, V263, P17437; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; Maniatis T., 1982, MOL CLONING LAB MANU; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; Xiong H, 1998, BIOCHEMISTRY-US, V37, P16423, DOI 10.1021/bi981522i; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	43	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28351	28355		10.1074/jbc.274.40.28351	http://dx.doi.org/10.1074/jbc.274.40.28351			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497194	hybrid			2022-12-25	WOS:000082912700043
J	Zolkiewski, M				Zolkiewski, M			ClpB cooperates with DnaK, DnaJ, and GrpE in suppressing protein aggregation - A novel multi-chaperone system from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MOLECULAR CHAPERONE; HSP104; ATPASE; ASSAY	ClpB is a heat-shock protein from Escherichia coli with an unknown function. We studied a possible molecular chaperone activity of ClpB in vitro. Firefly luciferase was denatured in urea and then diluted into the refolding buffer (in the presence of 5 mM ATP and 0.1 mg/ml bovine serum albumin). Spontaneous reactivation of luciferase was very weak (less than 0.02% of the native activity) because of extensive aggregation. Conventional chaperone systems (GroEL/GroES and DnaK/ DnaJ/GrpE) or ClpB alone did not reactivate luciferase under those conditions. However, ClpB together with DnaK/DnaJ/GrpE greatly enhanced the luciferase activity regain (up to 57% of native activity) by suppressing luciferase aggregation. This coordinated function of ClpB and DnaK/DnaJ/GrpE required ATP hydrolysis, although the ClpB ATPase was not activated by native or denatured luciferase. When the chaperones were added to the luciferase refolding solutions after 5-25 min of refolding, ClpB and Dnak/DnaJ/GrpE recovered the luciferase activity from preformed aggregates. Thus, we have identified a novel multi-chaperone system from E. coli, which is analogous to the Hsp104/Ssal/Ydjl system from yeast. ClpB is the only known bacterial Hsp100 protein capable of cooperating with other heat-shock proteins in suppressing and reversing protein aggregation.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Zolkiewski, M (corresponding author), Kansas State Univ, Dept Biochem, 104 Willard Hall, Manhattan, KS 66506 USA.	michalz@ksu.edu						Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Farrell HM, 1998, J DAIRY SCI, V81, P2974, DOI 10.3168/jds.S0022-0302(98)75861-8; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Thomas JG, 1998, J BACTERIOL, V180, P5165, DOI 10.1128/JB.180.19.5165-5172.1998; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOO KM, 1992, J BIOL CHEM, V267, P20429; ZOLKIEWSKI M, 1999, IN PRESS PROTEIN SCI; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	23	284	290	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28083	28086		10.1074/jbc.274.40.28083	http://dx.doi.org/10.1074/jbc.274.40.28083			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497158	hybrid			2022-12-25	WOS:000082912700007
J	Oakley, RH; Jewell, CM; Yudt, MR; Bofetiado, DM; Cidlowski, JA				Oakley, RH; Jewell, CM; Yudt, MR; Bofetiado, DM; Cidlowski, JA			The dominant negative activity of the human glucocorticoid receptor beta isoform - Specificity and mechanisms of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY DNA-BINDING; NF-KAPPA-B; STEROID-RECEPTORS; FUNCTIONAL ANTAGONISM; MUTUAL INHIBITION; ESTROGEN-RECEPTOR; GENE-EXPRESSION; C-JUN; HORMONE; NUCLEAR	Alternative splicing of the human glucocorticoid receptor gene generates a nonhormone binding splice variant (hGR beta) that differs from the wild-type receptor (hGR alpha) only at the carboxyl terminus. Previously we have shown that hGR beta inhibits the transcriptional activity of hGR alpha, which is consistent with reports of ele vated hGR beta expression in patients with generalized and tissue-specific glucocorticoid resistance. The potential role of hGR beta in the regulation of target cell sensitivity to glucocorticoids prompted us to further evaluate its dominant negative activity in other model systems and to investigate its mode of action. We demonstrate in multiple cell types that hGR beta inhibits hGR alpha-mediated activation of the mouse mammary tumor virus promoter. In contrast, the ability of the progesterone and androgen receptors to activate this promoter is only weakly affected by hGR beta. hGR beta also inhibits hGR alpha-mediated repression of an NF-kappa B-responsive promoter but does not interfere with homologous down-regulation of hGR alpha. We show that hGR beta can associate with the heat shock protein hsp90 although with lower affinity than hGR alpha. In addition, hGR beta binds GRE-containing DNA with a greater capacity than hGR alpha in the absence of glucocorticoids. Glucocorticoid treatment enhances hGR alpha, but not hGR beta, binding to DNA. Moreover, we demonstrate that hGR alpha and hGR beta can physically associate with each other in a heterodimer. Finally, we show that the dominant negative activity of hGR beta resides within its unique carboxyl-terminal 15 amino acids. Taken together, our results suggest that formation of transcriptionally impaired hGR alpha-hGR beta heterodimers is an important component of the mechanism responsible for the dominant negative activity of hGR beta.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233,MD E2-02, Res Triangle Pk, NC 27709 USA.		Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516				BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; Bamberger CM, 1997, J STEROID BIOCHEM, V60, P43, DOI 10.1016/S0960-0760(96)00167-7; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; BURNSTEIN KL, 1991, MOL ENDOCRINOL, V5, P1013, DOI 10.1210/mend-5-7-1013; CADEPOND F, 1992, EXP CELL RES, V201, P99, DOI 10.1016/0014-4827(92)90352-9; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Chen SY, 1997, J BIOL CHEM, V272, P14087, DOI 10.1074/jbc.272.22.14087; CIDLOWSKI JA, 1990, MOL ENDOCRINOL, V4, P1427, DOI 10.1210/mend-4-10-1427; Dahia PLM, 1997, J CLIN ENDOCR METAB, V82, P1088, DOI 10.1210/jc.82.4.1088; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1992, BIOCHEMISTRY-US, V31, P9040, DOI 10.1021/bi00152a047; deCastro M, 1996, MOL MED, V2, P597, DOI 10.1007/BF03401643; DEFRANCO D, 1986, MOL CELL BIOL, V6, P993, DOI 10.1128/MCB.6.4.993; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; ERLMANN T, 1990, J BIOL CHEM, V265, P17222; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FARWELL SE, 1990, CELL, V60, P953; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GOROVITS R, 1994, P NATL ACAD SCI USA, V91, P4786, DOI 10.1073/pnas.91.11.4786; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; Hecht K, 1997, J BIOL CHEM, V272, P26659, DOI 10.1074/jbc.272.42.26659; HERRLICH P, 1994, TRENDS ENDOCRIN MET, V5, P341, DOI 10.1016/1043-2760(94)90164-3; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; NANTHAKUMAR NN, 1993, AM J PHYSIOL, V264, pG306, DOI 10.1152/ajpgi.1993.264.2.G306; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; Oakley RH, 1997, ENDOCRINOLOGY, V138, P5028, DOI 10.1210/en.138.11.5028; OAKLEY RH, 1999, IN PRESS STEROIDS; Oakley Robert H., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P63; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; RUNDLETT SE, 1995, MOL CELL ENDOCRINOL, V109, P1, DOI 10.1016/0303-7207(95)03477-O; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Shahidi H, 1999, BIOCHEM BIOPH RES CO, V254, P559, DOI 10.1006/bbrc.1998.9980; SILVA CM, 1994, STEROIDS, V59, P436, DOI 10.1016/0039-128X(94)90013-2; SLUYSER M, 1994, CRIT REV ONCOGENESIS, V5, P539; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WANG YL, 1991, MOL ENDOCRINOL, V5, P1707, DOI 10.1210/mend-5-11-1707; WEBSTER JC, 1994, ENDOCRINE, V2, P967; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	54	343	367	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27857	27866		10.1074/jbc.274.39.27857	http://dx.doi.org/10.1074/jbc.274.39.27857			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488132	hybrid			2022-12-25	WOS:000082739100071
J	Pak, Y; O'Dowd, BF; Wang, JB; George, SR				Pak, Y; O'Dowd, BF; Wang, JB; George, SR			Agonist-induced, G protein-dependent and -independent down-regulation of the mu opioid receptor - The receptor is a direct substrate for protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOH-TERMINAL TAIL; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; COUPLED RECEPTORS; MEDIATED INTERNALIZATION; PHOSPHORYLATION SITES; CHOLINERGIC RECEPTORS; CARBOXYL-TERMINUS; OPIATE RECEPTOR; DESENSITIZATION	The mu opioid receptor (MOR) has been shown to desensitize after 1 h of exposure to the opioid peptide, [D-Ala(2), N-MePhe(4), Gly-ol(5)]enkephalin (DAMGO), largely by the loss of receptors from the cell surface and receptor down-regulation. We have previously shown that the Thr(394) in the carboxyl tail is essential for agonist-induced early desensitization, presumably by serving as a primary phosphorylation site for G protein-coupled receptor kinase. Using a T394A mutant receptor, we determined that Thr(394) was also responsible for mu opioid receptor down-regulation. The T394A mutant receptor displayed 50% reduction of receptor down-regulation (14.8%) compared with wild type receptor (34%) upon 1 h of exposure to DAMGO, Agonist-induced T394A receptor down-regulation was unaffected by pertussis toxin treatment, indicating involvement of a mechanism independent of G protein function. Interestingly, pertussis toxin-insensitive T394A receptor down-regulation was completely inhibited by a tyrosine kinase inhibitor, genistein. Tyrosine kinase inhibition blocked wild type MOR down-regulation by 50%, and the genistein-resistant wild type MOR down-regulation was completely pertussis toxin-sensitive, Following DAMGO stimulation, MOR was shown to be phosphorylated at tyrosine residue(s), indicating that the receptor was a direct substrate for tyrosine kinase action. Mutagenesis of the four intracellular tyrosine residues resulted in complete inhibition of the G protein-insensitive MOR internalization. Therefore, agonist-induced MOR down-regulation appears to be mediated by two distinct cellular signal transduction pathways. One is G protein-dependent and GRK-dependent, which can be abolished by pertussis toxin treatment of wild type MOR or by mutagenesis of Thr(394). The other novel pathway is G protein-independent but tyrosine kinase-dependent, blocked by genistein treatment, and one in which Thr(394) has no regulatory role but phosphorylation of tyrosine residues appears essential.	Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Toronto, ON M5S 1A8, Canada; Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	University of Toronto; University of Toronto; University of Toronto; Centre for Addiction & Mental Health - Canada; University System of Maryland; University of Maryland Baltimore	George, SR (corresponding author), Univ Toronto, Dept Pharmacol, Med Sci Bldg,Rm 4358, Toronto, ON M5S 1A8, Canada.		George, Susan/W-7494-2019; George, Susan R/P-9669-2018					ALF MS, 1997, J BIOL CHEM, V272, P23382; ALLEN JM, 1989, MOL PHARMACOL, V36, P248; Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN Y, 1994, J BIOL CHEM, V269, P7839; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; FUKUSHIMA N, 1994, NEUROSCI LETT, V176, P55, DOI 10.1016/0304-3940(94)90870-2; Gabilondo AM, 1996, EUR J PHARMACOL, V307, P243, DOI 10.1016/0014-2999(96)00247-6; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; KOOB G, 1992, SCIENCE, V242, P715; KOOB GF, 1992, TRENDS NEUROSCI, V15, P186, DOI 10.1016/0166-2236(92)90171-4; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; Mangoura D, 1997, J NEUROSCI RES, V50, P391, DOI 10.1002/(SICI)1097-4547(19971101)50:3<391::AID-JNR5>3.0.CO;2-D; MORO O, 1994, J BIOL CHEM, V269, P6651; MORO O, 1993, J BIOL CHEM, V268, P6862; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Pak Y, 1996, MOL PHARMACOL, V50, P1214; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PEI G, 1995, MOL PHARMACOL, V48, P173; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	42	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27610	27616		10.1074/jbc.274.39.27610	http://dx.doi.org/10.1074/jbc.274.39.27610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488100	hybrid			2022-12-25	WOS:000082739100039
J	Yao, I; Hata, Y; Hirao, K; Deguchi, M; Ide, N; Takeuchi, M; Takai, Y				Yao, I; Hata, Y; Hirao, K; Deguchi, M; Ide, N; Takeuchi, M; Takai, Y			Synamon, a novel neuronal protein interacting with synapse-associated protein 90/postsynaptic density-95-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY; DOMAINS; HOMOLOG; FAMILY	Guanylate kinase associated protein (GKAP)/SAP90/ PSD-95-associated protein (SAPAP)/DLG-associated protein (DAP) is a protein of the postsynaptic density (PSD), and binds to the guanylate kinase domain of PSD-95/synapse-associated protein (SAP) 90 and synaptic scaffolding molecule. GKAP/SAPAP/DAP recruits PSD-95/SAP90 and its interacting protein, brain-enriched guanylate kinase-interacting protein, into the Triton X-100-insoluble fraction in transfected cells, suggesting that GKAP/SAPAP/DAP may link several PSD components to the Triton X-100-insoluble structures in the PSD, We have identified here a novel neuronal GKAP/SAPAP/DAP-binding protein and named it synamon, Synamon has seven ankyrin repeats at the NH2 terminus followed by one src homology 3 domain and one PSD-95/Dlg-A/ZO-1 domain, and several proline-rich regions at the carboxyl terminus. Synamon interacts with the COOH-terminal region of GKAP/SAPAP/DAP via the middle region containing a PSD-95/Dlg-A/ZO-1 domain. Synamon was coimmunoprecipitated with SAPAP from rat crude synaptosomes and colocalized with SAPAP in primary cultured rat hippocampal neurons. Because synamon is composed of various protein-interacting modules, it may also interact with proteins other than GKAP/SAPAP/DAP to organize the architecture of the PSD.	JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, Exploratory Res Adv Technol, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan; Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University	Takai, Y (corresponding author), JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, Exploratory Res Adv Technol, Takai Biotimer Project,Nishi Ku, 2-2-10 Murotani, Kobe, Hyogo 6512241, Japan.							Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; GARNER C, 1996, TRENDS CELL BIOL, V19, P429; GOMPERTS SN, 1996, CELL, V84, P69; Hata Y, 1996, J NEUROSCI, V16, P2488; HATA Y, 1999, IN PRESS CELL MOL LI; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; ZIFF EB, 1997, CELL, V19, P1153	21	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27463	27466		10.1074/jbc.274.39.27463	http://dx.doi.org/10.1074/jbc.274.39.27463			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488079	hybrid			2022-12-25	WOS:000082739100018
J	Benke, D; Honer, M; Michel, C; Bettler, B; Mohler, H				Benke, D; Honer, M; Michel, C; Bettler, B; Mohler, H			gamma-aminobutyric acid type B receptor splice variant proteins GBR1a and GBR1b are both associated with GBR2 in situ and display differential regional and subcellular distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN; GABA(B) RECEPTORS; SUBUNIT; EXPRESSION; BINDING; ALPHA-1-SUBUNIT; PHARMACOLOGY; BACLOFEN; NEURONS	The subunit architecture of gamma-aminobutyric acid, type B (GABA(B)), receptors in situ is largely unknown. The GABA(B) receptor variants, characterized by the constituents GBR1a and GBR1b, were therefore analyzed with regard to their subunit composition as well as their regional and subcellular distribution in situ. The analysis was based on the use of antisera recognizing selectively GBR1a, GBR1b, and GBR2. Following their solubilization, GBR1a and GBR1b were both found by immunoprecipitation to occur as heterodimers associated with GBR2. Furthermore, monomers of GBR1a, GBR1b, or GBR2 were not detectable, suggesting that practically all GABA(B) receptors are heterodimers in situ. Finally, there was no evidence for an association of GBR1a with GBR1b indicating that these two constituents represent two different receptor populations. A size determination of solubilized GABA(B) receptors by sucrose density centrifugation revealed two distinct peaks of which one corresponded to dimeric receptors, and the higher molecular weight peak pointed to the presence of yet unknown receptor-associated proteins. The distribution and relative abundance of GBR2 immunoreactivity corresponded in all brain regions to that of the sum of GBR1a and GrBR1b, supporting the view that most if not all GBR1 proteins are associated with GBR2. However, GBR1a was present preferentially at postsynaptic densities, whereas GBR1b may be mainly attributed to presynaptic or extrasynaptic sites. Thus, GBR1a and GBR1b, are both associated with GBR2 to form heterodimers at mainly different subcellular locations where they are expected to subserve different functions.	ETH Zurich, Inst Pharmacol, CH-8057 Zurich, Switzerland; Univ Zurich, CH-8057 Zurich, Switzerland; Novartis Pharma AG, Nervous Syst Res, CH-4002 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Novartis	Benke, D (corresponding author), ETH Zurich, Inst Pharmacol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		bettler, bernhard/AAO-8018-2020	Bettler, Bernhard/0000-0003-0842-8207				BENKE D, 1991, J RECEPTOR RES, V11, P407, DOI 10.3109/10799899109066418; BENKE D, 1995, J RECEPT SIGNAL TR R, V15, P393, DOI 10.3109/10799899509045229; BENKE D, 1991, J BIOL CHEM, V266, P4478; Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; BOWERY NG, 1987, NEUROSCIENCE, V20, P365, DOI 10.1016/0306-4522(87)90098-4; BOWERY NG, 1993, ANNU REV PHARMACOL, V33, P109, DOI 10.1146/annurev.pa.33.040193.000545; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHU DCM, 1990, NEUROSCIENCE, V34, P341, DOI 10.1016/0306-4522(90)90144-S; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Deisz RA, 1997, SYNAPSE, V25, P62, DOI 10.1002/(SICI)1098-2396(199701)25:1<62::AID-SYN8>3.0.CO;2-D; DUTAR P, 1988, NEURON, V1, P585, DOI 10.1016/0896-6273(88)90108-0; Fritschy JM, 1999, EUR J NEUROSCI, V11, P761, DOI 10.1046/j.1460-9568.1999.00481.x; HARRISON NL, 1990, J PHYSIOL-LONDON, V422, P433, DOI 10.1113/jphysiol.1990.sp017993; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kaupmann K, 1998, P NATL ACAD SCI USA, V95, P14991, DOI 10.1073/pnas.95.25.14991; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MERTENS S, 1993, J BIOL CHEM, V268, P5965; MISGELD U, 1995, PROG NEUROBIOL, V46, P423, DOI 10.1016/0301-0082(95)00012-K; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; STIRLING JM, 1989, NEUROPHARMACOLOGY, V28, P699, DOI 10.1016/0028-3908(89)90153-6; TURGEON SM, 1994, NEUROSCIENCE, V62, P601, DOI 10.1016/0306-4522(94)90392-1; Wenzel A, 1997, J NEUROCHEM, V68, P469; Wenzel A, 1996, J NEUROCHEM, V66, P1240; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	30	119	127	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27323	27330		10.1074/jbc.274.38.27323	http://dx.doi.org/10.1074/jbc.274.38.27323			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480953	hybrid			2022-12-25	WOS:000082570700092
J	Inoue, K; Akaike, T; Miyamoto, Y; Okamoto, T; Sawa, T; Otagiri, M; Suzuki, S; Yoshimura, T; Maeda, H				Inoue, K; Akaike, T; Miyamoto, Y; Okamoto, T; Sawa, T; Otagiri, M; Suzuki, S; Yoshimura, T; Maeda, H			Nitrosothiol formation catalyzed by ceruloplasmin - Implication for cytoprotective mechanism in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS-SYNDROME; HYDROXYL RADICAL PRODUCTION; NITRIC-OXIDE; S-NITROSOTHIOLS; GENE-EXPRESSION; DOPAMINE NEURONS; OXIDATIVE STRESS; MONOCYTIC CELLS; COPPER; PEROXYNITRITE	Ceruloplasmin (CP) is a major multicopper-containing plasma protein that is not only involved in iron metabolism through its ferroxidase activity but also functions as an antioxidant. However, physiological substrates for CP have not been fully identified nor has the role of CP been fully understood. The reaction of nitric oxide (NO) with CP was investigated in view of nitrosothiol (RS-NO) formation. First, formation of heavy metal- or CP-catalyzed RS-NO was examined with physiologically relevant concentrations of NO and various thiol compounds (RSH) such as glutathione (GSH). Among the various heavy metal ions and copper-containing enzymes and proteins examined, only copper ion (Cu2+) and CP showed potent RS-NO (S-nitrosoglutathione)-producing activity. Also, RS-NO-forming catalytic activity was evident for CP added exogenously to RAW264 cells expressing inducible NO synthase in culture, but this was not the case for copper ion. Similarly, CP produced endogenously by HepG2 cells showed potent RS-NO-forming activity in the cell culture. One-electron oxidation of NO appears to be operative for RS-NO production via electron transfer from type 1 copper to a cluster of types 2 and 3 copper in CP. Neurological disorders are associated with aceruloplasminemia; besides RS-NO, S-nitrosoglutathione particularly has been shown to have neuroprotective effect against oxidative stress induced by iron overload. Thus, we suggest that CP plays an important catalytic role in RS-NO formation, which may contribute to its potent antioxidant and cytoprotective activities in vivo in mammalian biological systems.	Kumamoto Univ, Sch Med, Dept Microbiol, Kumamoto 8600811, Japan; Kumamoto Univ, Fac Pharmaceut Sci, Dept Pharmaceut, Kumamoto 8620973, Japan; Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan; Yamagata Technopolis Fdn, Inst Life Support Technol, Yamagata 9902473, Japan	Kumamoto University; Kumamoto University; Osaka University	Akaike, T (corresponding author), Kumamoto Univ, Sch Med, Dept Microbiol, Kumamoto 8600811, Japan.		Maeda, Hiroshi/N-4471-2016					Akaike T, 1997, J BIOCHEM-TOKYO, V122, P459; BANNISTER JV, 1980, FEBS LETT, V118, P127, DOI 10.1016/0014-5793(80)81233-6; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BUNNELL E, 1993, AM REV RESPIR DIS, V148, P1174, DOI 10.1164/ajrccm/148.5.1174; CALABRESE L, 1989, J BIOL CHEM, V264, P6183; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; Cole AP, 1996, SCIENCE, V273, P1848, DOI 10.1126/science.273.5283.1848; CURZON G, 1967, BIOCHEM J, V105, P243, DOI 10.1042/bj1050243; DAWSON JH, 1978, P NATL ACAD SCI USA, V75, P4078, DOI 10.1073/pnas.75.9.4078; DIPATTI MCB, 1990, J BIOL CHEM, V265, P21016; Ehrenwald E, 1996, J CLIN INVEST, V97, P884, DOI 10.1172/JCI118491; FLEMING RE, 1991, AM J PHYSIOL, V260, pL68, DOI 10.1152/ajplung.1991.260.2.L68; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GITLIN JD, 1988, J BIOL CHEM, V263, P6281; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; GORREN ACF, 1987, BIOCHIM BIOPHYS ACTA, V916, P38, DOI 10.1016/0167-4838(87)90208-1; GUTTERIDGE JMC, 1983, FEBS LETT, V157, P37, DOI 10.1016/0014-5793(83)81111-9; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; KOJ A, 1993, BIOL CHEM H-S, V374, P193, DOI 10.1515/bchm3.1993.374.1-6.193; KONOREV EA, 1995, J PHARMACOL EXP THER, V274, P200; KRSEKSTAPLES JA, 1992, AM REV RESPIR DIS, V145, P1009, DOI 10.1164/ajrccm/145.5.1009; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LOGAN JI, 1994, Q J MED, V87, P663; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Maritano S, 1996, PHYTOCHEMISTRY, V41, P349, DOI 10.1016/0031-9422(95)00632-X; MARKLUND S L, 1986, Journal of Free Radicals in Biology and Medicine, V2, P255, DOI 10.1016/S0748-5514(86)80007-1; MAYERS PR, 1990, NATURE, V345, P161; Mazumder B, 1997, J IMMUNOL, V159, P1938; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; Mukhopadhyay CK, 1998, SCIENCE, V279, P714, DOI 10.1126/science.279.5351.714; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; MUSCI G, 1995, J PROTEIN CHEM, V14, P611, DOI 10.1007/BF01886887; Ogura T, 1997, BIOCHEM BIOPH RES CO, V236, P365, DOI 10.1006/bbrc.1997.6948; Okamoto T, 1997, ARCH BIOCHEM BIOPHYS, V342, P261, DOI 10.1006/abbi.1997.0127; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185; RADI R, 1991, J BIOL CHEM, V266, P4244; Rauhala P, 1998, FASEB J, V12, P165, DOI 10.1096/fasebj.12.2.165; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; Rubbo H, 1996, CHEM RES TOXICOL, V9, P809, DOI 10.1021/tx960037q; SATO K, 1992, J BIOL CHEM, V267, P25371; SATO M, 1991, J BIOL CHEM, V266, P5128; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SUZUKI S, 1989, BIOCHEM BIOPH RES CO, V164, P1366, DOI 10.1016/0006-291X(89)91820-2; SWAIN JA, 1994, FEBS LETT, V342, P49, DOI 10.1016/0014-5793(94)80582-2; Tzeng E, 1998, SURGERY, V124, P278, DOI 10.1067/msy.1998.90569; Vanin AF, 1997, NITRIC OXIDE-BIOL CH, V1, P191, DOI 10.1006/niox.1997.0122; Williams DLH, 1996, METHOD ENZYMOL, V268, P299; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; YAMAGUCHI K, 1995, CHEM LETT, P353, DOI 10.1246/cl.1995.353; YANG F, 1986, P NATL ACAD SCI USA, V83, P3257, DOI 10.1073/pnas.83.10.3257; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	56	172	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27069	27075		10.1074/jbc.274.38.27069	http://dx.doi.org/10.1074/jbc.274.38.27069			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480920	hybrid			2022-12-25	WOS:000082570700059
J	Srikakulam, R; Winkelmann, DA				Srikakulam, R; Winkelmann, DA			Myosin II folding is mediated by a molecular chaperonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX POLYPEPTIDE-1 TCP-1; SKELETAL-MUSCLE MYOSIN; ESSENTIAL LIGHT-CHAIN; ESCHERICHIA-COLI; BETA-TUBULIN; MOTOR DOMAIN; CYTOPLASMIC CHAPERONIN; MONOCLONAL-ANTIBODIES; EUKARYOTIC CYTOSOL; PROTEIN DOMAINS	The folding pathway of the heavy meromyosin subfragment (HMM) of a skeletal muscle myosin has been investigated by in vitro synthesis of the myosin heavy and light chains in a coupled transcription and translation assay. Analysis of the nascent translation products for folding intermediates has identified a major intermediate that contains all three myosin subunits in a complex with the eukaryotic cytosolic chaperonin. Partially folded HMM is released from this complex in an ATP-dependent manner. However, biochemical and functional assays reveal incomplete folding of the myosin motor domain. Dimerization of myosin heavy chains and association of heavy and light chains are accomplished early in the folding pathway. To test for other factors necessary for the complete folding of myosin, a cytoplasmic extract was prepared from myotubes produced by a mouse myogenic cell line. This extract dramatically enhanced the folding of HMM, suggesting a role for muscle-specific factors in the folding pathway. We conclude that the molecular assembly of myosin is mediated by the eukaryotic cytosolic chaperonin with folding of the motor domain as the slow step in the pathway.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Winkelmann, DA (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, 675 Hoes Ln, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038454, R29AR038454] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38454] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATKINSON SJ, 1991, J CELL SCI, V99, P823; Baker JP, 1998, CURR OPIN CELL BIOL, V10, P80, DOI 10.1016/S0955-0674(98)80089-6; BURNS RG, 1994, FEBS LETT, V347, P105, DOI 10.1016/0014-5793(94)00522-2; DELOZANNE A, 1987, J CELL BIOL, V105, P2999, DOI 10.1083/jcb.105.6.2999; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Dunn MK, 1996, DEV DYNAM, V205, P387; Ellis RJ, 1996, SCIENCE, V272, P1448; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUXLEY HE, 1973, NATURE, V244, P445, DOI 10.1038/243445a0; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Kinose F, 1996, J CELL BIOL, V134, P895, DOI 10.1083/jcb.134.4.895; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; Liang P, 1997, J CELL SCI, V110, P1431; Liou AKF, 1998, BIOL CHEM, V379, P311, DOI 10.1515/bchm.1998.379.3.311; LOWEY S, 1994, MYOLOGY, P485; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MCNALLY EM, 1988, P NATL ACAD SCI USA, V85, P7270, DOI 10.1073/pnas.85.19.7270; Mehta AD, 1999, SCIENCE, V283, P1689, DOI 10.1126/science.283.5408.1689; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; Melki R, 1996, BIOCHEMISTRY-US, V35, P10422, DOI 10.1021/bi960788r; MOLDAVE K, 1983, METHOD ENZYMOL, V101, P629; MONCMAN CL, 1993, MOL BIOL CELL, V4, P1051, DOI 10.1091/mbc.4.10.1051; MORNET D, 1989, J MUSCLE RES CELL M, V10, P10, DOI 10.1007/BF01739853; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REINACH FC, 1985, J MOL BIOL, V181, P411, DOI 10.1016/0022-2836(85)90229-3; Roobol A, 1999, EUR J CELL BIOL, V78, P21, DOI 10.1016/S0171-9335(99)80004-1; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SPUDICH JA, 1989, CELL REGUL, V1, P1; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WINKELMANN DA, 1995, BIOPHYS J, V68, P2444, DOI 10.1016/S0006-3495(95)80426-1; WINKELMANN DA, 1993, J MUSCLE RES CELL M, V14, P452, DOI 10.1007/BF00121297; WINKELMANN DA, 1986, J MOL BIOL, V188, P595, DOI 10.1016/S0022-2836(86)80009-2; WOLFFLONG VL, 1993, J BIOL CHEM, V268, P23162; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	57	89	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27265	27273		10.1074/jbc.274.38.27265	http://dx.doi.org/10.1074/jbc.274.38.27265			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480946	hybrid			2022-12-25	WOS:000082570700085
J	Wyckoff, TJO; Raetz, CRH				Wyckoff, TJO; Raetz, CRH			The active site of Escherichia coli UDP-N-acetylglucosamine acyltransferase - Chemical modification and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE ENDOTOXIN; LIPID-A BIOSYNTHESIS; ACYL CARRIER PROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; CORYNEBACTERIUM-GLUTAMICUM; DISACCHARIDE SYNTHASE; CRYSTAL-STRUCTURE; BETA-HELIX; LPXA GENE; 1ST STEP	UDP-N-acetylglucosamine (UDP-GlcNAc) acyltransferase (LpxA) catalyzes the reversible transfer of an R-3-hydroxyacyl chain from R-3-hydroxyacyl-acyl carrier protein to the glucosamine 3-OH of UDP-GlcNAc in the first step of lipid A biosynthesis. Lipid A is required for the growth and virulence of most Gram-negative bacteria, making its biosynthetic enzymes intriguing targets for the development of new antibacterial agents. LpxA is a member of a large family of left-handed beta-helical proteins, many of which are acyl- or acetyltransferases. We now demonstrate that histidine-, lysine-, and arginine-specific reagents effectively inhibit LpxA of Escherichia coli, whereas serine- and cysteine-specific reagents do not. Using this information in conjunction with multiple sequence alignments, we constructed site-directed alanine substitution mutations of conserved histidine, lysine, and arginine residues. Many of these mutant LpxA enzymes show severely decreased specific activities under standard assay conditions. The decrease in activity corresponds to decreased k(cat)/K-m,K-UDP-GlcNAc values for all the mutants. With the exception of H125A, in which no activity is seen under any assay condition, the decrease in k(cat)/K-m,K-UDP-GlcNAc mainly reflects an increased K-m,K-UDP-GlcNAc. His(125) of E. coli LpxA may therefore function as a catalytic: residue, possibly as a general base. LpxA does not catalyze measurable UDP-3-O-(R-3-hydroxymyristoyl)-GlcNAc hydrolysis or UDP-GlcNAc/UDP-3-O-(R-3-hydroxymyristoyl)-GlcNAc exchange, arguing against a ping-pong mechanism with an acyl-enzyme intermediate.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	Raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1988, BIOCHEMISTRY-US, V27, P1908, DOI 10.1021/bi00406a017; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Babinski KJ, 1998, FASEB J, V12, pA1288; Beaman TW, 1998, BIOCHEMISTRY-US, V37, P6689, DOI 10.1021/bi980106v; Beaman TW, 1997, BIOCHEMISTRY-US, V36, P489, DOI 10.1021/bi962522q; Beaman TW, 1998, BIOCHEMISTRY-US, V37, P10363, DOI 10.1021/bi980759b; BRABETZ W, 1991, ARCH MICROBIOL, V155, P607, DOI 10.1007/BF00245357; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; BULAWA CE, 1984, J BIOL CHEM, V259, P4846; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KIM YM, 1990, PROTEINS, V8, P377, DOI 10.1002/prot.340080411; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; KLEANTHOUS C, 1985, BIOCHEMISTRY-US, V24, P5307, DOI 10.1021/bi00341a006; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LESLIE AGW, 1990, J MOL BIOL, V213, P167, DOI 10.1016/S0022-2836(05)80129-9; LIEBL W, 1989, FEMS MICROBIOL LETT, V65, P299, DOI 10.1016/0378-1097(89)90234-6; MATSUYAMA T, 1992, J BIOCHEM-TOKYO, V112, P258, DOI 10.1093/oxfordjournals.jbchem.a123887; MATTHEWS KS, 1991, METHOD ENZYMOL, V208, P468; Miles E W, 1977, Methods Enzymol, V47, P431; Milla ME, 1996, BBA-LIPID LIPID MET, V1304, P245, DOI 10.1016/S0005-2760(96)00124-5; Miller J.H., 1972, EXPT MOL GENETICS; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAY BL, 1984, J BIOL CHEM, V259, P4852; RAY BL, 1987, J BIOL CHEM, V262, P1122; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sorensen PG, 1996, J BIOL CHEM, V271, P25898, DOI 10.1074/jbc.271.42.25898; Steeghs L, 1997, GENE, V190, P263, DOI 10.1016/S0378-1119(97)00005-X; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VAARA M, 1992, FEMS MICROBIOL LETT, V97, P249, DOI 10.1016/0378-1097(92)90344-N; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; VAGELOS PR, 1966, FED PROC, V25, P1485; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384	51	68	70	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27047	27055		10.1074/jbc.274.38.27047	http://dx.doi.org/10.1074/jbc.274.38.27047			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480918	Green Submitted, hybrid			2022-12-25	WOS:000082570700057
J	Fukata, M; Kuroda, S; Nakagawa, M; Kawajiri, A; Itoh, N; Shoji, I; Matsuura, Y; Yonehara, S; Fujisawa, H; Kikuchi, A; Kaibuchi, K				Fukata, M; Kuroda, S; Nakagawa, M; Kawajiri, A; Itoh, N; Shoji, I; Matsuura, Y; Yonehara, S; Fujisawa, H; Kikuchi, A; Kaibuchi, K			Cdc42 and Rac1 regulate the interaction of IQGAP1 with beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; ACTIN-DEPOLYMERIZING PROTEIN; WISKOTT-ALDRICH SYNDROME; TYROSINE PHOSPHORYLATION; SMALL GTPASES; NERVOUS-SYSTEM; ALPHA-CATENIN; MDCK CELLS; N-WASP; TARGET	IQGAP1, a target of Cdc42 and Bad small GTPases, directly interacts with beta-catenin and negatively regulates E-cadherin-mediated cell-cell adhesion by dissociating alpha-catenin from the cadherin-catenin complex in vivo (Kuroda, S., Fukata, M., Nakagawa, M., Fujii, R., Nakamura, T., Ookubo, T., Izawa, I., Nagase, T., Nomura, N., Tani, H., Shoji, I,, Matsuura, Y., Yonehara, S,, and Kaibuchi, IT. (1998) Science 281, 832-855). Here we investigated how Cdc42 and Rad regulate the IQGAP1 function. IQGAP1 interacted with the amino-terminal region (amino acids 1-183) of beta-catenin, which contains the alpha-catenin-binding domain. IQGAP1 dissociated alpha-catenin from the beta-catenin-alpha-catenin complex in a dose-dependent manner in vitro. Guanosine 5'-(3-O-thio)triphosphate (GTP gamma S) glutathione S-transferase (GST)Cdc42 and GTP gamma S.GST-Rac1 inhibited the binding of IQGAP1 to beta-catenin in a dose-dependent manner vitro, whereas neither GDP.GST-Cdc42, GDP.GST-Rac1, in nor GTP gamma S GST-RhoA did. The coexpression of dominant active Cdc42 with IQGAP1 suppressed the dissociation of alpha-catenin from the cadherin-catenin complex induced by the overexpression of IQGAP1 in L cells expressing E-cadherin (EL cells). Consistent with this, the overexpression of either dominant negative Cdc42 or Rad resulted in the reduction of E-cadherin-mediated cell adhesive activity in EL cells. These results indicate that Cdc42 and Rad negatively regulate the IQGAP1 function by inhibiting the interaction of IQGAP1 with beta-catenin, leading to stabilization of the cadherin-catenin complex.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Hiroshima 7348551, Japan; Japan Sci & Technol, PRESTO, Inheritance & Variat Grp, Kyoto 6190237, Japan; Natl Inst Infect Dis, Dept Virol 2, Tokyo 1628640, Japan; Kyoto Univ, Inst Virus Res, Kyoto 6068397, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Grp Dev Neurobiol, Nagoya, Aichi 4648602, Japan	Nara Institute of Science & Technology; Hiroshima University; Japan Science & Technology Agency (JST); National Institute of Infectious Diseases (NIID); Kyoto University; Nagoya University	Kaibuchi, K (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, 8916-5 Takayama, Ikoma 6300101, Japan.		Shoji, Ikuo/Y-7079-2019; Fukata, Masaki/AAZ-2476-2021; KURODA, SHINYA/G-4961-2014	Shoji, Ikuo/0000-0002-0730-4379; Fukata, Masaki/0000-0001-5200-9806; 				ABERLE H, 1994, J CELL SCI, V107, P3655; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brill S, 1996, MOL CELL BIOL, V16, P4869; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; YONEHARA S, 1990, INT IMMUNOL, V2, P143, DOI 10.1093/intimm/2.2.143	41	171	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26044	26050		10.1074/jbc.274.37.26044	http://dx.doi.org/10.1074/jbc.274.37.26044			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473551	hybrid			2022-12-25	WOS:000082469700017
J	Steffen, SE; Bryant, FR				Steffen, SE; Bryant, FR			Reevaluation of the nucleotide cofactor specificity of the RecA protein from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; BINDING-PROTEIN; EXCHANGE; ATP; PURIFICATION; SEQUENCE; GENE	The RecA protein from the Gram-positive bacterium, Bacillus subtilis, has been reported to catalyze (dATP hydrolysis and to promote strand exchange in the presence of dATP but to have no ATP hydrolysis or ATP-dependent strand exchange activity (Lovett, C. M., Jr., and Roberts, J. W. (1985) J. Biol. Chem. 260, 3305-3313). The well characterized RecA protein from Escherichia coli, in contrast, catalyzes the hydrolysis of ATP and (dATP at similar rates and can use either ATP or dATP as a cofactor for the strand exchange reaction. To explore this reported difference in nucleotide cofactor specificity in detail, we developed an overexpression system for the B. subtilis RecA protein and purified the protein to greater than 95% homogeneity. Contrary to the previous report, we find that the B. subtilis RecA protein catalyzes the hydrolysis of both dATP and ATP and can perform strand exchange using either dATP or ATP as a cofactor. Our results suggest that the inability of previous investigators to detect the ATP hydrolysis and ATP-dependent strand exchange activities of the B. subtilis RecA protein may have been due to the particular assay conditions that were used in the earlier study.	Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Johns Hopkins University	Bryant, FR (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [T32CA009110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036516] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09110] Funding Source: Medline; NIGMS NIH HHS [R01 GM36516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1998, CURRENT PROTOCOLS MO, V1; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1982, J BIOL CHEM, V257, P8523; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LOVETT CM, 1985, J BIOL CHEM, V260, P3305; MARRERO R, 1988, J BACTERIOL, V170, P335, DOI 10.1128/jb.170.1.335-344.1988; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MENGE KL, 1992, BIOCHEMISTRY-US, V31, P5151, DOI 10.1021/bi00137a009; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; STRANATHAN MC, 1990, NUCLEIC ACIDS RES, V18, P4249, DOI 10.1093/nar/18.14.4249; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126	15	21	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					25990	25994		10.1074/jbc.274.37.25990	http://dx.doi.org/10.1074/jbc.274.37.25990			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473543	hybrid			2022-12-25	WOS:000082469700009
J	Reddy, DE; Sandhu, AK; DeRiel, JK; Athwal, RS; Kaur, GP				Reddy, DE; Sandhu, AK; DeRiel, JK; Athwal, RS; Kaur, GP			Identification of a gene at 16q24.3 that restores cellular senescence in immortal mammary tumor cells	ONCOGENE			English	Article						cell senescence; gene mapping; immortalization; breast cancer; chromosome transfer	MEDIATED CHROMOSOME TRANSFER; SPORADIC BREAST-CANCER; HUMAN-FIBROBLASTS; INDEFINITE DIVISION; MOUSE CELLS; ALLELE LOSS; CARCINOMA; TUMORIGENICITY; MAP; COMPLEMENTATION	We have mapped a cellular senescence gene, SEN16, within a genetic distance of 3-7 cM, at 16q24.3. Microcell mediated transfer of a normal human chromosome 16, 16q22-qter or 16q23-qter restored cellular senescence in four immortal cell lines, derived from human and rat mammary tumors. The resumption of indefinite cell proliferation, concordant with the segregation of the donor chromosome, confirmed the presence of a senescence gene at 16q23-qter. While microcell hybrids were maintained in selection medium to retain the donor chromosome, sporadic immortal revertant clones arose among senescent cells. Reversion to immortal growth could occur due to inactivation of the senescence gene either by a mutation or a deletion. The analysis for chromosome 16 specific DNA markers, in revertant clones of senescent microcell hybrids, revealed a consensus deletion, spanning a genetic interval of approximately 3-7 cM at 16q24.3.	Temple Univ, Sch Med, Fels Inst Canc Res, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Kaur, GP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res, 3307 N Broad St,AHB Room 201, Philadelphia, PA 19140 USA.							Adams S. M., 1992, Human Molecular Genetics, V1, P91, DOI 10.1093/hmg/1.2.91; ATHWAL RS, 1985, SOMAT CELL MOLEC GEN, V11, P177, DOI 10.1007/BF01534706; AUSTRUY E, 1993, GENOMICS, V15, P684, DOI 10.1006/geno.1993.1126; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; Brenner AJ, 1997, PROG CLIN BIOL RES, V396, P63; BUN CL, 1980, EXP CELL RES, V127, P385; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; DANIEL CW, 1983, MECH AGEING DEV, V23, P259, DOI 10.1016/0047-6374(83)90026-X; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOGGETT NA, 1995, NATURE, V377, P335; EHMANN UK, 1991, IN VITRO CELL DEV B, V27, P749, DOI 10.1007/BF02633221; GANTZ I, 1994, GENOMICS, V19, P394, DOI 10.1006/geno.1994.1080; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOOLSBY CL, 1991, CANCER GENET CYTOGEN, V49, P231; GOTOH S, 1979, J GEN VIROL, V42, P409, DOI 10.1099/0022-1317-42-2-409; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KAUR GP, 1993, SOMAT CELL MOLEC GEN, V19, P83, DOI 10.1007/BF01233957; KOZMAN HM, 1995, GENOMICS, V25, P44, DOI 10.1016/0888-7543(95)80108-X; Latil A, 1997, CANCER RES, V57, P1058; LI S, 1995, CANCER RES, V55, P3992; LIDA A, 1997, BRIT J CANCER, V75, P254; LINDBLOM A, 1993, CANCER RES, V53, P3707; MAW MA, 1992, CANCER RES, V52, P3094; MEDINA D, 1993, CANCER RES, V53, P663; MEDINA D, 1996, J MAMMARY GLAND BIOL, V1, P21; NEGRINI M, 1994, CANCER RES, V54, P1331; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PRONK JC, 1995, NAT GENET, V11, P338, DOI 10.1038/ng1195-338; PULLMAN WE, 1992, NATURE, V356, P529, DOI 10.1038/356529a0; RIMESSI P, 1994, ONCOGENE, V9, P3467; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SATO T, 1991, CANCER RES, V51, P5794; Scott IC, 1996, GENE, V174, P135, DOI 10.1016/0378-1119(96)00510-0; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; STANBRIDGE EJ, 1992, TUMOR SUPPRESSOR GEN, P5; Steenbergen RDM, 1998, INT J CANCER, V76, P412, DOI 10.1002/(SICI)1097-0215(19980504)76:3<412::AID-IJC20>3.0.CO;2-B; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; TSUDA H, 1994, CANCER RES, V54, P513; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; WANG E, 1995, CANCER RES, V55, P2284; WANG XW, 1992, CARCINOGENESIS, V13, P555, DOI 10.1093/carcin/13.4.555; WEBER JL, 1989, AM J HUM GENET, V44, P388; WELCH DR, 1994, ONCOGENE, V9, P255; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316; YAMADA H, 1990, ONCOGENE, V5, P1141; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163	64	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5100	5107		10.1038/sj.onc.1202888	http://dx.doi.org/10.1038/sj.onc.1202888			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490846				2022-12-25	WOS:000082497100009
J	Burr, PD; Argyle, DJ; Reid, SWJ; Nasir, L				Burr, PD; Argyle, DJ; Reid, SWJ; Nasir, L			Nucleotide sequence of the porcine p53 cDNA, and the detection of recombinant porcine p53 expressed in vitro with a variety of anti-p53 antibodies	ONCOGENE			English	Article						porcine; pig; p53; protein; gene; sequence	TUMOR-SUPPRESSOR GENE; STRUCTURAL ASPECTS; GROWTH ARREST; CELL-LINES; PROTEIN; MUTATIONS; XENOTRANSPLANTATION; APOPTOSIS; EVOLUTION; CANCER	The cDNA of porcine p53 was cloned and sequenced by a reverse transcriptase polymerase chain reaction (RT-PCR) approach with primers based on regions of homology between all known p53 sequences. The p53 cDNA was found to be 87% conserved to human p53 and 86% conserved to bovine p53 at the nucleotide level. The porcine p53 sequence was inserted into an expression vector and recombinant protein expressed in vitro. An approximately 50 kDa protein was detected by Western blotting using both polyclonal and monoclonal anti-p53 antibodies. The sequence data of porcine p53 and the ability to detect expressed protein with various anti-p53 antibodies will allow the p53 status of the pig population, and the role of p53 in porcine tumours, to be assessed. An understanding of tumour development in the pig may be important if pig cells, tissues or organs are to be used in the treatment of humans.	Univ Glasgow, Dept Vet Clin Studies, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow; University of Glasgow	Burr, PD (corresponding author), Univ Glasgow, Dept Vet Clin Studies, Glasgow G61 1QH, Lanark, Scotland.			Reid, Stuart/0000-0002-6872-9071				Bach FH, 1998, ANNU REV MED, V49, P301; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Holistein M., 1991, SCIENCE, V253, P49; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komori H, 1996, VET IMMUNOL IMMUNOP, V52, P53, DOI 10.1016/0165-2427(95)05538-X; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Nasir L, 1995, DNA Seq, V6, P61, DOI 10.3109/10425179509074702; OKUDA M, 1994, INT J CANCER, V58, P602, DOI 10.1002/ijc.2910580425; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pazzi KA, 1996, CANCER LETT, V107, P125, DOI 10.1016/0304-3835(96)04359-5; RETTENBERGER G, 1993, ANIM GENET, V24, P307, DOI 10.1111/j.1365-2052.1993.tb00318.x; Rogers NJ, 1998, IMMUNOL TODAY, V19, P206, DOI 10.1016/S0167-5699(98)01254-7; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1990, ONCOGENE, V5, P945; Veldhoen N, 1998, ONCOGENE, V16, P1077, DOI 10.1038/sj.onc.1201863; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	24	2	3	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					5005	5009		10.1038/sj.onc.1202870	http://dx.doi.org/10.1038/sj.onc.1202870			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490836				2022-12-25	WOS:000082321700014
J	Yakicier, MC; Irmak, MB; Romano, A; Kew, M; Ozturk, M				Yakicier, MC; Irmak, MB; Romano, A; Kew, M; Ozturk, M			Smad2 and Smad4 gene mutations in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; Smad2; Smad4; TGF beta; tumor suppressor genes; somatic mutation	TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR-BETA; SOMATIC MUTATIONS; DPC4 GENE; IN-VIVO; CANCERS; HEPATOCYTES; APOPTOSIS; 18Q21; LIVER	TGF-beta is a negative regulator of liver growth. Smad family of genes, as mediators of TGF-beta pathway, are candidate tumor suppressor genes in hepatocellular carcinoma (HCC). We studied 35 HCC and non-tumour liver tissues for possible mutations in Smad2 and Smad4 genes. Three tumours displayed somatic mutations; two in Smad4 (Asp332Gly and Cys401Arg) and one in Smad2 (Gln407Arg) genes. All three mutations were A:T --> G:C transitions suspected to result from oxidative stress as observed in mitochondrial DNA. These observation demonstrate that TGF-beta pathway is altered in hepatocellular carcinoma.	Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey; Univ Witwatersrand, Johannesburg, South Africa	Ihsan Dogramaci Bilkent University; University of Witwatersrand	Ozturk, M (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey.		ozturk, mehmet/G-3330-2014; OZTURK, MEHMET/AAS-7241-2021	OZTURK, MEHMET/0000-0002-6092-9706				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Gressner AM, 1997, J HEPATOL, V26, P1079, DOI 10.1016/S0168-8278(97)80117-1; GRISHAM JW, 1996, CARCINOGENESIS, V18, P59; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kawate S, 1999, INT J ONCOL, V14, P127; Kim SK, 1996, CANCER RES, V56, P2519; MIYAMURA T, 1990, P NATL AAD SCI US, V87, P6971; Miyoshi Y, 1998, CANCER RES, V58, P2524; Moskaluk CA, 1997, DIAGN MOL PATHOL, V6, P85, DOI 10.1097/00019606-199704000-00003; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Ozturk Mehmet, 1995, P511; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Riggins GJ, 1997, CANCER RES, V57, P2578; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; Uchida K, 1996, CANCER RES, V56, P5583; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822	33	143	150	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4879	4883		10.1038/sj.onc.1202866	http://dx.doi.org/10.1038/sj.onc.1202866			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490821	Green Published			2022-12-25	WOS:000082184800012
J	Berk, PD; Zhou, SL; Kiang, CL; Stump, DD; Fan, X; Bradbury, MW				Berk, PD; Zhou, SL; Kiang, CL; Stump, DD; Fan, X; Bradbury, MW			Selective up-regulation of fatty acid uptake by adipocytes characterizes both genetic and diet-induced obesity in rodents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-LIPASE ACTIVITY; LIVER PLASMA-MEMBRANES; BODY-WEIGHT GAIN; LEPTIN RECEPTOR; BINDING-PROTEIN; RAT-LIVER; ASPARTATE-AMINOTRANSFERASE; PHOSPHOLIPID-BILAYERS; ISOLATED HEPATOCYTES; UPTAKE KINETICS	Long chain fatty acid transport is selectively up-regulated in adipocytes of Zucker fatty rats, diverting fatty acids from sites of oxidation toward storage in adipose tissue. To determine whether this is a general feature of obesity, we studied [H-3]oleate uptake by adipocytes and hepatocytes from 1) homozygous male obese (ob), diabetic (db), fat (fat), and tubby (tub) mice and from 2) male Harlan Sprague-Dawley rats fed for 7 weeks a diet containing 55% of calories from fat. V-max and K-m were compared with controls of the appropriate background strain (C57BL/6J or C57BLKS) or diet (13% of calories from fat). V-max for adipocyte fatty acid uptake was increased B-B-fold in ob, db, fat, and tub mice versus controls (p < 0.001), whereas no differences were seen in the corresponding hepatocytes. Similar changes occurred in fat-fed rats. Of three membrane fatty acid transporters expressed in adipocytes, plasma membrane fatty acid-binding protein mRNA was increased 9-11-fold in ob and db, which lack a competent leptin/leptin receptor system, but was not increased in fat and tub, i.e. in strains with normal leptin signaling capability; fatty acid translocase mRNA was increased 2.2-6.5-fold in tub, ob, and fat adipocytes, but not in db adipocytes; and only marginal changes in fatty acid transport protein 1 mRNA were found in any of the mutant strains. Adipocyte fatty acid uptake is generally increased in murine obesity models, but up-regulation of individual transporters depends on the specific pathophysiology, Leptin may normally down-regulate expression of plasma membrane fatty acid binding protein.	CUNY Mt Sinai Sch Med, Dept Med, Div Liver Dis, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Berk, PD (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Liver Dis, Box 1633,1 Gustave L Levy Pl, New York, NY 10029 USA.	paul_berk@smtplink.mssm.edu	Bradbury, Michael W/G-5002-2013	Bradbury, Michael W/0000-0002-6384-2681	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026438, R01DK052401] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52401, DK-26438] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Al Odaib A, 1998, NEW ENGL J MED, V339, P1752, DOI 10.1056/NEJM199812103392405; Astrup A, 1997, ANN NY ACAD SCI, V827, P417, DOI 10.1111/j.1749-6632.1997.tb51852.x; Berk PD, 1999, MOL CELL BIOCHEM, V192, P17, DOI 10.1023/A:1006832001033; Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; BERMAN M, 1967, US PUBLIC HLTH SERVI, V1703; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Bjorntorp P, 1998, HDB OBESITY, P573; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Chua SC, 1996, DIABETES, V45, P1141, DOI 10.2337/diabetes.45.8.1141; Civelek VN, 1996, P NATL ACAD SCI USA, V93, P10139, DOI 10.1073/pnas.93.19.10139; DIGIROLAMO M, 1971, AM J PHYSIOL, V221, P850, DOI 10.1152/ajplegacy.1971.221.3.850; Eckel RH, 1996, AM J PHYSIOL-REG I, V271, pR1280, DOI 10.1152/ajpregu.1996.271.5.R1280; FARESE RV, 1991, METABOLISM, V40, P214, DOI 10.1016/0026-0495(91)90178-Y; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Hamilton JA, 1998, J LIPID RES, V39, P467; HAMILTON JA, 1994, J BIOL CHEM, V269, P20852; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Johnson, 1990, ILAR NEWS, V32, P4, DOI [DOI 10.1093/ILAR.32.3.4, 10.1093/ilar.32.3.4]; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; KIENS B, 1989, J CLIN INVEST, V84, P1124, DOI 10.1172/JCI114275; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; Memon RA, 1998, AM J PHYSIOL-ENDOC M, V274, pE210, DOI 10.1152/ajpendo.1998.274.2.E210; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; Noy Noa, 1993, P313; Pagliassotti MJ, 1997, ANN NY ACAD SCI, V827, P431, DOI 10.1111/j.1749-6632.1997.tb51853.x; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; RICHIERI GV, 1995, J LIPID RES, V36, P229; ROSE H, 1994, BBA-LIPID LIPID MET, V1215, P321, DOI 10.1016/0005-2760(94)90060-4; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHEMMEL R, 1970, J NUTR, V100, P1041; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; SORRENTINO D, 1989, J CLIN INVEST, V84, P1325, DOI 10.1172/JCI114301; SORRENTINO D, 1994, AM J PHYSIOL, V266, pG425, DOI 10.1152/ajpgi.1994.266.3.G425; SORRENTINO D, 1994, J HEPATOL, V21, P551, DOI 10.1016/S0168-8278(94)80100-2; Sorrentino Dario, 1993, P197; SPECTOR AA, 1971, BIOCHEMISTRY-US, V10, P3229; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; STUMP DD, 1992, J HEPATOL, V16, P304, DOI 10.1016/S0168-8278(05)80661-0; STUMP DD, 1993, AM J PHYSIOL, V265, pG894, DOI 10.1152/ajpgi.1993.265.5.G894; Tataranni PA, 1998, DIABETES METAB, V24, P108; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Weinstock PH, 1997, P NATL ACAD SCI USA, V94, P10261, DOI 10.1073/pnas.94.19.10261; Weisiger Richard A., 1993, P171; WHITESELL RR, 1985, J BIOL CHEM, V260, P2894; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WOSILAIT WD, 1976, COMPUT PROG BIOMED, V6, P142, DOI 10.1016/0010-468X(76)90020-9; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	62	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28626	28631		10.1074/jbc.274.40.28626	http://dx.doi.org/10.1074/jbc.274.40.28626			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497230	hybrid			2022-12-25	WOS:000082912700079
J	Chen, Z; Hutchison, M; Cobb, MH				Chen, Z; Hutchison, M; Cobb, MH			Isolation of the protein kinase TAO2 and identification of its mitogen-activated protein kinase/extracellular signal-regulated kinase kinase binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-LINEAGE KINASE-2; MAP KINASE; SACCHAROMYCES-CEREVISIAE; CASCADES; YEAST; SEK1; PHOSPHORYLATES; COMPONENTS; SAPK/JNK; PATHWAYS	We previously reported the cloning of the thousand and one amino acid protein kinase 1 (TAO1), a rat homolog of the Saccharomyces cerevisiae protein kinase sterile 20 protein. Here we report the complete sequence and properties of a related rat protein kinase TAO2. Like TAO1, recombinant TAO2 selectively activated mitogen-activated protein/extracellular signal-regulated kinase kinases (MEKs) 3, 4, and 6 of the stress-responsive mitogen-activated protein kinase pathways in vitro and copurified with MEK3 endogenous to Sf9 cells. To examine TAO2 interactions with MEKs, the MEK binding domain of TAO2 was localized to an similar to 135-residue sequence just C-terminal to the TAO2 catalytic domain. In vitro this MEK binding domain associated with MEKs 3 and 6 but not MEKs 1, 2, or 4, Using chimeric MEK proteins, we found that the MEK N terminus was sufficient for binding to TAO2. Catalytic activity of full-length TAO2 enhanced its binding to MEKs. However, neither the autophosphorylation of the MEK binding domain of TAO2 nor the activity of MEK itself was required for MEK binding. These results suggest that TAO proteins lie in stress-sensitive kinase cascades and define a mechanism by which these kinases may organize downstream targets.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	mcobb@mednet.swmed.edu		Cobb, Melanie/0000-0003-0833-5473	NIGMS NIH HHS [GM53032] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KATOH M, 1995, ONCOGENE, V10, P1447; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056	26	71	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28803	28807		10.1074/jbc.274.40.28803	http://dx.doi.org/10.1074/jbc.274.40.28803			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497253	hybrid			2022-12-25	WOS:000082912700102
J	Kobayashi, YM; Jones, LR				Kobayashi, YM; Jones, LR			Identification of triadin 1 as the predominant triadin isoform expressed in mammalian myocardium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; CORE-GLYCOSYLATION EFFICIENCY; CANINE CARDIAC CALSEQUESTRIN; AMINO-ACID SEQUENCE; SKELETAL-MUSCLE; RYANODINE RECEPTOR; BIOCHEMICAL-CHARACTERIZATION; DIHYDROPYRIDINE RECEPTOR; IMPORTANT DETERMINANT; GLYCOPROTEIN TRIADIN	Triadin is an integral membrane protein of sarcoplasmic reticulum shown to interact with the ryanodine receptor/Ca2+ release channel, junctin, and calsequestrin. Several triadin isoforms have been postulated to exist in cardiac muscle, but to date none has been conclusively identified. Here, we show that only triadin 1 is significantly expressed. We cloned and sequenced cDNAs encoding canine cardiac triadin 1 and 3 but found no evidence for triadin 2. From deduced primary structures, antibodies against domains common to all triadins and an antibody against the unique C terminus of triadin 1 were raised. All antibodies detected two prominent proteins of molecular masses 35 and 40 kDa on immunoblots from cardiac microsomes, including the antibody that recognizes only triadin 1. The 40-kDa mobility form was shown to correspond to the glycosylated form of triadin 1, not a distinct triadin 2 isoform as previously hypothesized. Confirming this, overexpression of triadin 1 in transgenic mouse hearts produced both the 35-kDa deglycosylated and the 40-kDa glycosylated mobility forms. The glycosylation site of triadin 1 was localized to asparagine residue 75, and its bitopic arrangement in the membrane was confirmed. Although a 92-kDa immunoreactive protein could be tentatively identified in myocardium as triadin 3, its expression level was insignificant (less than or equal to 5%) compared with that of triadin 1. We conclude that triadin 1 is the triadin isoform most likely to play a role in Ca2+ release in heart.	Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Jones, LR (corresponding author), Indiana Univ, Sch Med, Krannert Inst Cardiol, 1111 W Tenth St, Indianapolis, IN 46202 USA.	lrjones@iupui.edu			NHLBI NIH HHS [R01-HL-28556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028556] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARL SL, 1995, J CELL BIOL, V129, P673, DOI 10.1083/jcb.129.3.673; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; FAN HR, 1995, BIOCHEMISTRY-US, V34, P14902, DOI 10.1021/bi00045a035; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; Groh S, 1999, J BIOL CHEM, V274, P12278, DOI 10.1074/jbc.274.18.12278; GULICK J, 1991, J BIOL CHEM, V266, P9180; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; JONES LR, 1981, J BIOL CHEM, V256, P1809; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; Kuniyasu A, 1999, BIOCHEM J, V339, P343, DOI 10.1042/0264-6021:3390343; MARTY I, 1995, BIOCHEM J, V307, P769, DOI 10.1042/bj3070769; Mellquist JL, 1998, BIOCHEMISTRY-US, V37, P6833, DOI 10.1021/bi972217k; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; Ohkura M, 1998, BIOCHEMISTRY-US, V37, P12987, DOI 10.1021/bi972803d; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Thompson C, 1998, BIOPHYS J, V74, pA352; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	29	84	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28660	28668		10.1074/jbc.274.40.28660	http://dx.doi.org/10.1074/jbc.274.40.28660			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497235	hybrid			2022-12-25	WOS:000082912700084
J	Liu, XD; Clemens, JA; Yin, TG; Stephenson, DT; Johnstone, EM; Du, YS; Panetta, JA; Paul, SM; Little, SP				Liu, XD; Clemens, JA; Yin, TG; Stephenson, DT; Johnstone, EM; Du, YS; Panetta, JA; Paul, SM; Little, SP			Rat B-2 sequences are induced in the hippocampal CA1 region after transient global cerebral ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTION; CEREBELLAR GRANULE CELLS; DELAYED NEURONAL DEATH; EXCITATORY AMINO-ACIDS; B2 REPEATED SEQUENCES; OPEN READING FRAMES; X-GENE PRODUCT; FACTOR-KAPPA-B; GERBIL HIPPOCAMPUS; FOREBRAIN ISCHEMIA	Global brain ischemia causes cell death in the CA1 region of the hippocampus 3-5 days after reperfusion. The biological pathway leading to such delayed neuronal damage has not been established. By using differential display analysis, we examined expression levels of poly(A) RNAs isolated from hippocampal extracts prepared from rats exposed to global ischemia and found an up-regulated transcript, clone 17a, Northern blot analysis of clone 17a showed an approximately 35-fold increase in the ischemic brain at 24 h after four-vessel occlusion. Rapid amplification of cDNA ends of clone 17a revealed a family of genes (160-540 base pairs) that had the characteristics of rodent B-2 sequences. In situ hybridization demonstrated that the elevated expression of this gene was localized predominantly in the CA1 pyramidal neurons. The level of expression in the CAI region decreased dramatically between 24 and 72 h after ischemia, The elevated expression of done 17a was not observed in four-vessel occlusion rats treated with the compound LY231617, an antioxidant known to exert neuroprotection in rats subjected to global ischemia, Since delayed neuronal death has the characteristics of apoptosis, we speculate that clone 17a may be involved in apoptosis, We examined the expression level of clone 17a in in vitro models of apoptosis using cerebellar granule neurons that were subjected to potassium removal, glutamate toxicity, or 6-hydroxydopamine treatment and found that clone 17a transcripts were induced in cerebellar granule neurons by glutamate or B-hydroxydopamine stimulation but not potassium withdrawal.	Eli Lilly & Co, Neurosci Res Div, Indianapolis, IN 46285 USA	Eli Lilly	Little, SP (corresponding author), Eli Lilly & Co, Neurosci Res Div, Drop Code 0434, Indianapolis, IN 46285 USA.		Paul, Steve/ABE-5400-2020; Du, Yansheng/L-2244-2015					ABE K, 1995, STROKE, V26, P1478, DOI 10.1161/01.STR.26.8.1478; Alwine J C, 1979, Methods Enzymol, V68, P220; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BABLANIAN R, 1986, P NATL ACAD SCI USA, V83, P1290, DOI 10.1073/pnas.83.5.1290; BACHVAROVA R, 1988, DEV BIOL, V130, P513, DOI 10.1016/0012-1606(88)90346-6; Basrai MA, 1997, GENOME RES, V7, P768, DOI 10.1101/gr.7.8.768; BENNETT KL, 1984, MOL CELL BIOL, V4, P1561, DOI 10.1128/MCB.4.8.1561; BLADON TS, 1990, MOL CELL BIOL, V10, P4058, DOI 10.1128/MCB.10.8.4058; BLADON TS, 1991, GENE, V98, P259, DOI 10.1016/0378-1119(91)90183-C; Blum D, 1997, BRAIN RES, V751, P139, DOI 10.1016/S0006-8993(96)01358-3; CAREY MF, 1988, P NATL ACAD SCI USA, V85, P7059, DOI 10.1073/pnas.85.19.7059; Chen J, 1996, J NEUROCHEM, V67, P64; Chen J, 1998, J NEUROSCI, V18, P4914; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Chen SL, 1998, VIROLOGY, V244, P521, DOI 10.1006/viro.1998.9109; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLEMENS JA, 1993, STROKE, V24, P716, DOI 10.1161/01.STR.24.5.716; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; CLEMENS MJ, 1987, CELL, V49, P157, DOI 10.1016/0092-8674(87)90553-8; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; EDWARDS DR, 1985, MOL CELL BIOL, V5, P3280, DOI 10.1128/MCB.5.11.3280; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Feuerstein GZ, 1997, CAN J PHYSIOL PHARM, V75, P731, DOI 10.1139/cjpp-75-6-731; FORNACE AJ, 1986, NUCLEIC ACIDS RES, V14, P5793, DOI 10.1093/nar/14.14.5793; FORNACE AJ, 1989, EXP CELL RES, V182, P61, DOI 10.1016/0014-4827(89)90279-6; Fuse T, 1998, NEUROSURGERY, V42, P843, DOI 10.1097/00006123-199804000-00092; GALLO V, 1987, J NEUROSCI, V7, P2203; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; *GEN COMP GROUP, 1997, WISC PACK VERS 9 1; Glinka Y, 1997, J NEURAL TRANSM-SUPP, P55; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; HERON A, 1993, J NEUROCHEM, V61, P1973, DOI 10.1111/j.1471-4159.1993.tb09843.x; Honkaniemi J, 1996, MOL BRAIN RES, V42, P79, DOI 10.1016/S0169-328X(96)00121-0; Jellinger K, 1995, J NEURAL TRANSM-SUPP, P297; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P121, DOI 10.1016/S0149-7634(96)00001-2; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KOISTINAHO J, 1997, NEUROREPORT, V8, P1; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; KRAMEROV DA, 1985, BIOCHIM BIOPHYS ACTA, V824, P85, DOI 10.1016/0167-4781(85)90084-3; KRAYEV AS, 1982, NUCLEIC ACIDS RES, V10, P7461, DOI 10.1093/nar/10.23.7461; KURITA T, 1994, J CELL PHYSIOL, V161, P63, DOI 10.1002/jcp.1041610109; LANIA L, 1987, FEBS LETT, V219, P400, DOI 10.1016/0014-5793(87)80260-0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; NICOLETTI F, 1986, J NEUROSCI, V6, P1905; NITATORI T, 1995, J NEUROSCI, V15, P1001; OBERBAUMER I, 1992, NUCLEIC ACIDS RES, V20, P671; PANNING B, 1993, MOL CELL BIOL, V13, P3231, DOI 10.1128/MCB.13.6.3231; Paterson IA, 1998, J NEUROCHEM, V70, P515; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; RYSKOV AP, 1985, FEBS LETT, V182, P73, DOI 10.1016/0014-5793(85)81156-X; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sambrook J., 2002, MOL CLONING LAB MANU; SINGH K, 1985, NATURE, V314, P553, DOI 10.1038/314553a0; Tsuda M, 1997, J NEUROSCI, V17, P6678; Tsuda M, 1996, MOL BRAIN RES, V35, P314, DOI 10.1016/0169-328X(95)00211-A; Uberti D, 1998, EUR J NEUROSCI, V10, P246, DOI 10.1046/j.1460-9568.1998.00042.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VASSEUR M, 1985, EMBO J, V4, P1749, DOI 10.1002/j.1460-2075.1985.tb03846.x; WANG HD, 1995, MOL CELL BIOL, V15, P6720; Wang SL, 1997, DEV BIOL, V188, P322, DOI 10.1006/dbio.1997.8655; WANG XK, 1995, P NATL ACAD SCI USA, V92, P11480, DOI 10.1073/pnas.92.25.11480; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WHITE RJ, 1990, EMBO J, V9, P3713, DOI 10.1002/j.1460-2075.1990.tb07584.x; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994	77	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28674	28681		10.1074/jbc.274.40.28674	http://dx.doi.org/10.1074/jbc.274.40.28674			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497237	hybrid			2022-12-25	WOS:000082912700086
J	Tobacman, LS; Lin, D; Butters, C; Landis, C; Back, N; Pavlov, D; Homsher, E				Tobacman, LS; Lin, D; Butters, C; Landis, C; Back, N; Pavlov, D; Homsher, E			Functional consequences of troponin T mutations found in hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC THIN FILAMENT; BINDING-PROTEIN-C; MYOSIN SUBFRAGMENT-1; ALPHA-TROPOMYOSIN; MISSENSE MUTATION; STRUCTURAL INTERPRETATION; MUSCLE-CONTRACTION; HEAVY-MEROMYOSIN; TRANSGENIC MICE; ADULT ISOFORMS	Missense mutations in the cardiac thin filament protein troponin T (TnT) are a cause of familial hypertrophic cardiomyopathy (FHC). To understand how these mutations produce dysfunction, five TnTs were produced and purified containing FHC mutations found in several regions of TnT, Functional defects were diverse. Mutations F110I, E244D, and COOH-terminal truncation weakened the affinity of troponin for the thin filament. Mutation Delta E160 resulted in thin filaments with increased calcium affinity at the regulatory site of troponin C. Mutations R92Q and F110I resulted in impaired troponin solubility, suggesting abnormal protein folding. Depending upon the mutation, the in vitro unloaded actin-myosin sliding speed showed small increases, showed small decreases, or was unchanged. COOH-terminal truncation mutation resulted in a decreased thin filament-myosin subfragment 1 MgATPase rate. The results indicate that the mutations cause diverse immediate effects, despite similarities in disease manifestations. Separable but repeatedly observed abnormalities resulting from FHC TnT mutations include increased unloaded sliding speed, increased or decreased Ca2+ affinity, impairment of folding or sarcomeric integrity, and decreased force. Enhancement as well as impairment of contractile protein function is observed, suggesting that TnT, including the troponin tail region, modulates the regulation of cardiac contraction.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA	University of Iowa; University of Iowa; University of California System; University of California Los Angeles	Tobacman, LS (corresponding author), Univ Iowa, Dept Internal Med, 200 Hawkins,SE610-GH, Iowa City, IA 52242 USA.	tobacman@uiowa.edu			NIAMS NIH HHS [AR-30988] Funding Source: Medline; FDA HHS [BI-38834] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030988] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); FDA HHS; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anan R, 1998, CIRCULATION, V98, P391, DOI 10.1161/01.CIR.98.5.391; Bing W, 1997, BIOCHEM BIOPH RES CO, V236, P760, DOI 10.1006/bbrc.1997.7045; Bottinelli R, 1998, CIRC RES, V82, P106; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Butters CA, 1997, J BIOL CHEM, V272, P13196, DOI 10.1074/jbc.272.20.13196; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; Charron P, 1998, CIRCULATION, V97, P2230, DOI 10.1161/01.CIR.97.22.2230; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; Elliott K, 1999, BIOPHYS J, V76, pA281; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Golitsina N, 1997, BIOCHEMISTRY-US, V36, P4637, DOI 10.1021/bi962970y; GREENE LE, 1981, BIOCHEMISTRY-US, V20, P2120, DOI 10.1021/bi00511a008; HILL LE, 1992, J BIOL CHEM, V267, P16106; Hinkle A, 1999, J BIOL CHEM, V274, P7157, DOI 10.1074/jbc.274.11.7157; Homsher E, 1996, BIOPHYS J, V70, P1881, DOI 10.1016/S0006-3495(96)79753-9; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; Huynh Q, 1996, BIOPHYS J, V70, P1447, DOI 10.1016/S0006-3495(96)79704-7; ISHII Y, 1991, J BIOL CHEM, V266, P6894; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; JIN JP, 1989, J BIOL CHEM, V264, P14471; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MEHEGAN JP, 1991, J BIOL CHEM, V266, P966; Morimoto S, 1998, AM J PHYSIOL-CELL PH, V275, pC200, DOI 10.1152/ajpcell.1998.275.1.C200; NakajimaTaniguchi C, 1997, J MOL CELL CARDIOL, V29, P839, DOI 10.1006/jmcc.1996.0322; Niimura H, 1998, NEW ENGL J MED, V338, P1248, DOI 10.1056/NEJM199804303381802; Oberst L, 1998, J CLIN INVEST, V102, P1498, DOI 10.1172/JCI4088; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; Potter JD, 1999, BIOPHYS J, V76, pA280; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; Rust EM, 1999, J CLIN INVEST, V103, P1459, DOI 10.1172/JCI6377; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sweeney HL, 1998, P NATL ACAD SCI USA, V95, P14406, DOI 10.1073/pnas.95.24.14406; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; TOWNSEND PJ, 1995, J MOL CELL CARDIOL, V27, P2223, DOI 10.1016/S0022-2828(95)91587-7; WALSH TP, 1985, J MOL BIOL, V182, P265, DOI 10.1016/0022-2836(85)90344-4; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; Yanaga F, 1999, J BIOL CHEM, V274, P8806, DOI 10.1074/jbc.274.13.8806; Yang QL, 1998, J CLIN INVEST, V102, P1292, DOI 10.1172/JCI3880	59	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28363	28370		10.1074/jbc.274.40.28363	http://dx.doi.org/10.1074/jbc.274.40.28363			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497196	hybrid			2022-12-25	WOS:000082912700045
J	Knudsen, KE; Fribourg, AF; Strobeck, MW; Blanchard, JM; Knudsen, ES				Knudsen, KE; Fribourg, AF; Strobeck, MW; Blanchard, JM; Knudsen, ES			Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE; GROWTH SUPPRESSION; FAMILY PROTEINS; TRANSCRIPTIONAL REPRESSION; ECTOPIC EXPRESSION; DEPENDENT KINASES; GENE-EXPRESSION; CARCINOMA-CELLS; E2F; PHOSPHORYLATION	Although RE inhibits the G(1)-S transition, the mechanism through which RE prevents cell cycle advancement remains unidentified. To delineate the mechanism(s) utilized by RE to exert its anti-proliferative activity, constitutively active RE proteins (which cannot be inactivated by phosphorylation) or p16ink4a (which prevents RE inactivation) were utilized. Both proteins inhibited the G(1)-S transition, whereas wildtype RE did not. We show that active RE acts to attenuate cyclin A promoter activity, and that overexpression of cyclin E reverses RE-mediated repression of the cyclin A promoter. Although cyclin A is an E2F-regulated gene, and it has been long hypothesized that RE mediates cell cycle advancement through binding to E2F and attenuating its transactivation potential, cyclin E does not reverse dominant negative E2F-mediated repression of the cyclin A promoter. Although active RE repressed both cyclin A and two other paradigm E2F-regulated promoters, only cyclin A transcription was restored upon co-expression of cyclin E. Additionally, we show that RE but not dominant negative E2F regulates the cyclin A promoter through the CCRE element. These data identify cyclin A as a downstream target of RB-mediated arrest. Consistent with this idea, ectopic expression of cyclin A reversed RE-mediated G(1) arrest. The findings presented suggest a pathway wherein cyclin A is a downstream target of RE, and cyclin E functions to antagonize this aspect of RE-mediated G(1)-S inhibition.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Inst Genet Mol Montpellier, CNRS, UMR 5535, F-30433 Montpellier 1, France	University System of Ohio; University of Cincinnati; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Knudsen, ES (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA.			Knudsen, Karen/0000-0002-1301-890X	NCI NIH HHS [CA82034, R01-CA8252-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA082034] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eller C, 1998, LINGUA FRANCA, V8, P65; Geng Y, 1996, ONCOGENE, V12, P1173; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1993, GENE CHROMOSOME CANC, V6, P124, DOI 10.1002/gcc.2870060211; Huet X, 1996, MOL CELL BIOL, V16, P3789; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Kaelin WG, 1997, ANN NY ACAD SCI, V833, P29, DOI 10.1111/j.1749-6632.1997.tb48589.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; KNUDSEN KE, 1999, IN PRESS ONCOGENE; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; Zwicker J, 1997, NUCLEIC ACIDS RES, V25, P4926, DOI 10.1093/nar/25.24.4926; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	57	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27632	27641		10.1074/jbc.274.39.27632	http://dx.doi.org/10.1074/jbc.274.39.27632			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488103	hybrid			2022-12-25	WOS:000082739100042
J	Allan, LA; Fried, M				Allan, LA; Fried, M			p53-dependent apoptosis or growth arrest induced by different forms of radiation in U2OS cells: p21(WAF1/CIP1) repression in UV induced apoptosis	ONCOGENE			English	Article						p53; p21(WAF1/CIP1); UV induced apoptosis; X-ray induced growth arrest; U2OS cells; radiation	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; G1 CHECKPOINT CONTROL; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; P53-INDUCED APOPTOSIS; MEDIATED APOPTOSIS; GAMMA-RADIATION	Following exposure to DNA damaging agents the p53 tumour-suppressor gene induces either a growth arrest (primarily in G1) or apoptosis. The factors governing which response a cell undertakes, however, are unclear. We find that the osteosarcoma cell line, U20S, (wild-type for p53) is capable of undergoing either p53 dependent apoptosis or cell cycle arrest in response to distinct forms of radiation. Following exposure to UVC, the majority of U20S cells were apoptotic within 2 days and cells continued to cycle even as viability was being lost. In contrast, after X-ray treatment, U20S cells exhibited a cell cycle arrest. Western analysis showed that p53 protein was stabilized to a greater extent by UVC than X-ray. Treatment with X-rays induced P21(WAF1/CIP1) whereas p21(WAF1/CIP1) expression was specifically repressed at the post-transcriptional level after exposure to UVC, Ectopic expression of high levels of p21(WAF1/CIP1), which arrested U20S cells in G1 and G2, initially conferred considerable protection against UVC-induced apoptosis. Ultimately, however, cells underwent apoptosis indicating that a high level of p21(WAF1/CIP1) delays but does not block apoptosis. Taken together, these results show that cell cycle arrest and apoptosis can occur in the same cell type in response to different forms of radiation and that the repression of p21(WAF1/CIP1) after UVC may contribute to the efficient induction of apoptosis in response to this particular insult.	Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, London WC2A 3PX, England	Cancer Research UK	Fried, M (corresponding author), Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, Lincolns Inn Fields, London WC2A 3PX, England.							Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Canman CE, 1998, ONCOGENE, V16, P957, DOI 10.1038/sj.onc.1201612; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; ISFORT RJ, 1995, MOL CARCINOGEN, V14, P170, DOI 10.1002/mc.2940140306; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Roemer K, 1996, ONCOGENE, V12, P2069; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Vater CA, 1996, ONCOGENE, V13, P739; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1994, ONCOGENE, V9, P3743	63	64	64	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5403	5412		10.1038/sj.onc.1202931	http://dx.doi.org/10.1038/sj.onc.1202931			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498894				2022-12-25	WOS:000082718600005
J	Gordon, VM; Nelson, KL; Buckley, JT; Stevens, VL; Tweten, RK; Elwood, PC; Leppla, SH				Gordon, VM; Nelson, KL; Buckley, JT; Stevens, VL; Tweten, RK; Elwood, PC; Leppla, SH			Clostridium septicum alpha toxin uses glycosylphosphatidylinositol-anchored protein receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL-FORMING TOXIN; ERYTHROCYTE RECEPTOR; AEROLYSIN; BIOSYNTHESIS; EXPRESSION; MUTANT; CELLS; PURIFICATION; ACTIVATION; SYSTEM	The alpha toxin produced by Clostridium septicum is a channel-forming protein that is an important contributor to the virulence of the organism. Chinese hamster ovary (CHO) cells are sensitive to low concentrations of the toxin, indicating that they contain toxin receptors. Using retroviral mutagenesis, a mutant CHO line (BAG15) was generated that is resistant to alpha toxin. FACS analysis showed that the mutant cells have lost the ability to bind the toxin, indicating that they lack an alpha toxin receptor. The mutant cells are also resistant to aerolysin, a channel-forming protein secreted by Aeromonas spp., which is structurally and functionally related to alpha toxin and which is known to bind to glycosylphosphatidylinositol (GPI)-anchored proteins, such as Thy-1. We obtained evidence that the BAG15 cells lack N-acetylglucosaminyl-phosphatidylinositol deacetylase-L, needed for the second step in GPI anchor biosynthesis, Several lymphocyte cell lines lacking GPI-anchored proteins were also shown to be less sensitive to alpha toxin. On the other hand, the sensitivity of CHO cells to alpha toxin was increased when the cells were transfected with the GPI-anchored folate receptor. We conclude that alpha toxin, like aerolysin, binds to GPI-anchored protein receptors. Evidence is also presented that the two toxins bind to different subsets of GPI-anchored proteins.	NIDCR, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Emory Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, Atlanta, GA 30335 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA; NCI, Med Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Victoria; Emory University; University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Leppla, SH (corresponding author), NIDCR, Oral Infect & Immun Branch, NIH, Bldg 30,Rm 316,30 Convent Dr,MSC 4350, Bethesda, MD 20892 USA.				NIAID NIH HHS [R01 AI032097, AI37657] Funding Source: Medline; NIGMS NIH HHS [R01GM51419] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037657, R01AI032097, R37AI037657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051419] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAIR GM, 1986, SOMAT CELL MOLEC GEN, V12, P111, DOI 10.1007/BF01560658; BALLARD J, 1995, INFECT IMMUN, V63, P340, DOI 10.1128/IAI.63.1.340-344.1995; BALLARD J, 1992, INFECT IMMUN, V60, P784, DOI 10.1128/IAI.60.3.784-790.1992; BALLARD J, 1993, MOL MICROBIOL, V10, P627, DOI 10.1111/j.1365-2958.1993.tb00934.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Buckley JT, 1995, BIOCHEMISTRY-US, V34, P16450, DOI 10.1021/bi00050a028; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; CHANDLER CS, 1986, BIOCHEM J, V237, P123, DOI 10.1042/bj2370123; CHUNG KN, 1995, ARCH BIOCHEM BIOPHYS, V322, P228, DOI 10.1006/abbi.1995.1456; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Cowell S, 1997, MOL MICROBIOL, V25, P343, DOI 10.1046/j.1365-2958.1997.4691828.x; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Diep DB, 1999, MOL MICROBIOL, V31, P785, DOI 10.1046/j.1365-2958.1999.01217.x; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; EIDEN MV, 1994, J VIROL, V68, P626, DOI 10.1128/JVI.68.2.626-631.1994; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Gordon VM, 1997, INFECT IMMUN, V65, P4130, DOI 10.1128/IAI.65.10.4130-4134.1997; GRUBER HJ, 1994, MOL MICROBIOL, V14, P1093, DOI 10.1111/j.1365-2958.1994.tb01341.x; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; LARSON CM, 1995, SURGERY, V118, P592, DOI 10.1016/S0039-6060(05)80023-6; LOW MG, 1987, BIOCHEM J, V244, P1; MOEHRING JM, 1979, SOMAT CELL GENET, V5, P453, DOI 10.1007/BF01538880; MOHNEY RP, 1994, J BIOL CHEM, V269, P6536; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Rossjohn J, 1997, EMBO J, V16, P3426, DOI 10.1093/emboj/16.12.3426; Sellman BR, 1997, MOL MICROBIOL, V23, P551, DOI 10.1046/j.1365-2958.1997.d01-1876.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANLEY P, 1983, SOMAT CELL GENET, V9, P593, DOI 10.1007/BF01574260; STEVENS D L, 1990, Reviews of Infectious Diseases, V12, P286; STEVENS VL, 1993, J BIOL CHEM, V268, P9718; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; STEVENS VL, 1994, J BIOL CHEM, V269, P31397; Stevens VL, 1996, BIOCHEM J, V313, P253, DOI 10.1042/bj3130253; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026	40	114	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27274	27280		10.1074/jbc.274.38.27274	http://dx.doi.org/10.1074/jbc.274.38.27274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480947	hybrid			2022-12-25	WOS:000082570700086
J	Dorman, CM; Johnson, SE				Dorman, CM; Johnson, SE			Activated Raf inhibits avian myogenesis through a MAPK-dependent mechanism	ONCOGENE			English	Article						Raf; MAPK; myogenesis	PROTEIN-KINASE-C; MUSCLE DIFFERENTIATION; GROWTH-FACTORS; MAMMALIAN-CELL; EXPRESSION; PATHWAY; PHOSPHORYLATION; TRANSFORMATION; APOPTOSIS; ONCOGENE	Chronic overexpression of the oncogenic form of Ras is a potent inhibitor of skeletal myogenesis. However, the intracellular signaling pathways that mediate the repressive actions of Ras on myogenic differentiation have yet to be identified. We examined the role of Raf-mediated signaling as a modulator of avian myogenesis. Raf overexpression elicited pronounced effects on both myoblasts and mature myocytes. Most notably, the embryonic chick myoblasts overexpressing a constitutively active form of Raf (RCAS-Raf CAAX or RCAS-Raf BXB) fail to form the large multinucleated myofibers characteristic of myogenic cultures. While residual myofibers were apparent in the RCAS-Raf BXB and RCAS-Raf CAAX infected cultures, these fibers had an atrophic phenotype, The altered morphology is not a result of reinitiation of the myonuclei cell cycle nor is it due to apoptosis, Furthermore, the mononucleated myoblasts misexpressing Raf BXB are differentiation-defective due to overt MAPK activity. Supplementation of the culture media with the MAPK kinase (MEK) inhibitor, PD98059, caused a reversal of the phenotype and allowed the formation of multinucleated myofibers at levels comparable to controls. Our results indicate that the Raf/MEK/MAPK axis is intact in chick myoblasts and that persistent activation of this signaling cascade is inhibitory to myogenesis.	Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Johnson, SE (corresponding author), Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA.							ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FUKUDA M, 1995, ONCOGENE, V11, P239; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KONG Y, 1995, MOL CELL BIOL, V15, P5202; KONIECZNY SF, 1989, ONCOGENE, V4, P473; Lassar AB, 1996, CURR OPIN NEUROBIOL, V6, P57, DOI 10.1016/S0959-4388(96)80009-2; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834	35	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5167	5176		10.1038/sj.onc.1202907	http://dx.doi.org/10.1038/sj.onc.1202907			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498866				2022-12-25	WOS:000082555700005
J	Jankowski, A; Grinstein, S				Jankowski, A; Grinstein, S			A noninvasive fluorimetric procedure for measurement of membrane potential - Quantification of the NADPH oxidase-induced depolarization in activated neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; SUBCELLULAR-LOCALIZATION; PLASMA-MEMBRANE; HUMAN-GRANULOCYTES; RESPIRATORY BURST; INTRACELLULAR PH; CELLS; NA+; CYTOCHROME; CURRENTS	The electrogenic activity of the NADPH oxidase is associated with depolarization of the plasma membrane in activated neutrophils, The magnitude and consequences of this depolarization, however, remain unknown. Neutrophils are not amenable to electrophysiological determinations of membrane potential by current clamp. Instead, the occurrence of depolarization has been inferred from the use of potential-sensitive fluorescent dyes. However, such dyes partition into intracellular organelles and may yield erroneous results, particularly because the NADPH oxidase resides largely in secretory granules, where it has been claimed to become activated. We confirmed the intracellular generation of oxidase products using dihydrorhodamine, which is converted to the fluorescent rhodamine 123 when oxidized. Rhodamine 123 accumulated inside endomembrane organelles in both neutrophils and in differentiated HL60 cells, where it co-localized with the primary granule marker CD63; To estimate the surface membrane potential without interference from organelles, we devised a method based on the voltage-driven uptake of Mn2+ across the plasmalemma. The uptake of Mn2+ through calcium release-activated channels was measured as the rate of Indo-1 fluorescence quenching in thapsigargin-treated cells. The rate of Mn2+ influx was found to vary when the membrane potential was manipulated using conductive ionophores and also when the NADPH oxidase was activated. A calibration curve in the positive potential range was constructed using the Na+ ionophore SQI-Pr. Using this calibration, the membrane potential of phorbol ester-activated neutrophils was found to reach +58 +/- 6 mV, a sustained depolarization of over 100 mV compared with the resting potential. The depolarization was greatly diminished when the NADPH oxidase was inhibited with diphenylene iodonium. Together, these results indicate that the NADPH oxidase can generate a large depolarization of the plasmalemma, which should suffice to activate a variety of voltage-gated channels, including the outwardly rectifying H+ conductance.	Hosp Sick Children, Div Cell Biol, Cell Biol Programme, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Grinstein, S (corresponding author), Hosp Sick Children, Div Cell Biol, Cell Biol Programme, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sgn@sickkids.on.ca						ALI H, 1985, BRIT J PHARMACOL, V85, P705, DOI 10.1111/j.1476-5381.1985.tb10567.x; ANDREW PW, 1980, BIOCHIM BIOPHYS ACTA, V611, P61, DOI 10.1016/0005-2744(80)90042-X; BASHFORD CL, 1985, BIOCHIM BIOPHYS ACTA, V817, P174, DOI 10.1016/0005-2736(85)90080-X; Borregaard N, 1997, ANN NY ACAD SCI, V832, P62, DOI 10.1111/j.1749-6632.1997.tb46237.x; BORREGAARD N, 1988, J BIOENERG BIOMEMBR, V20, P637, DOI 10.1007/BF00762546; BORREGAARD N, 1984, J BIOL CHEM, V259, P47; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; COHEN MS, 1994, CLIN INFECT DIS, V18, pS170, DOI 10.1093/clinids/18.Supplement_2.S170; COLETTE J, 1956, AM CHEM SOC, V78, P3819; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; Demaurex N, 1996, J CELL BIOL, V133, P1391, DOI 10.1083/jcb.133.6.1391; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P4574; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; ELSBACH P, 1985, IMMUNOL LETT, V11, P159, DOI 10.1016/0165-2478(85)90163-4; Geiszt M, 1997, J BIOL CHEM, V272, P26471, DOI 10.1074/jbc.272.42.26471; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRINSTEIN S, 1985, AM J PHYSIOL, V248, pC379, DOI 10.1152/ajpcell.1985.248.3.C379; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; JOHANSSON A, 1995, CELL IMMUNOL, V161, P61, DOI 10.1006/cimm.1995.1009; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; JONES GS, 1980, J CELL PHYSIOL, V104, P425, DOI 10.1002/jcp.1041040315; KORCHAK HM, 1980, BIOCHIM BIOPHYS ACTA, V601, P180, DOI 10.1016/0005-2736(80)90523-4; LUKACS GL, 1993, AM J PHYSIOL, V265, pC3, DOI 10.1152/ajpcell.1993.265.1.C3; Lundqvist H, 1996, J LEUKOCYTE BIOL, V59, P270, DOI 10.1002/jlb.59.2.270; Lundqvist H, 1996, FREE RADICAL BIO MED, V20, P785, DOI 10.1016/0891-5849(95)02189-2; MARTIN MA, 1988, J IMMUNOL, V140, P3928; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; NANDA A, 1991, Cellular Physiology and Biochemistry, V1, P65, DOI 10.1159/000154595; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; REDISKE JJ, 1992, J LEUKOCYTE BIOL, V51, P484, DOI 10.1002/jlb.51.5.484; Schrenzel J, 1998, NATURE, V392, P734, DOI 10.1038/33725; SELIGMANN BE, 1980, J CLIN INVEST, V66, P493, DOI 10.1172/JCI109880; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; ZIPPER H, 1972, BIOCHEMISTRY-US, V11, P4686, DOI 10.1021/bi00775a008	38	87	90	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26098	26104		10.1074/jbc.274.37.26098	http://dx.doi.org/10.1074/jbc.274.37.26098			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473559	hybrid			2022-12-25	WOS:000082469700025
J	Northwood, IC; Tong, AHY; Crawford, B; Drobnies, AE; Cornell, BB				Northwood, IC; Tong, AHY; Crawford, B; Drobnies, AE; Cornell, BB			Shuttling of CTP : phosphocholine cytidylyltransferase between the nucleus and endoplasmic reticulum accompanies the wave of phosphatidylcholine synthesis during the G(0) -> G(1) transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; EPIDERMAL-GROWTH-FACTOR; PHOSPHOLIPASE-C TREATMENT; MEMBRANE-ASSOCIATED CTP; PROTEIN-KINASE-C; HELA-CELLS; RAT-LIVER; ALPHA-THROMBIN; FATTY-ACIDS; IN-VITRO	The transition from quiescence (G(0)) into the cell division cycle is marked by accelerated phospholipid turnover. We examined the rates of phosphatidylcholine (PC) synthesis and the activity, membrane affinity, and intracellular localization of the rate-limiting enzyme in the synthesis of PC, CTP:phosphocholine cytidylyltransferase (CT) during this transition, The addition of serum to quiescent IIC9 fibroblasts resulted in a wave of PC synthesis beginning at similar to 10 min, peaking at similar to 3 h with a >10-fold increase in rate, and declining to near basal rates by 10 h, CT activity, monitored in situ, was elevated similar to 3-fold between I and 2 h postserum, Neither CT mass nor its phosphorylation state changed during the surge in PC synthesis and CT activity, On the other hand, the ratio of particulate/soluble CT surged and then receded in concert with the wave of PC synthesis. During quiescence, CT was confined to the nucleus, as assessed by indirect immunofluorescence. Within 10 min after serum stimulation, a portion of the CT fluorescence appeared in the cytoplasm, where it intensified until similar to 4 h postserum, Thereafter, the cytoplasmic CT signal waned, while the nuclear signal increased, and by 8 h CT was once again predominantly nuclear. The dynamics of CT's apparent translocation in and out of the nucleus paralleled the wave of PC synthesis and the solubility changes of CT. Cytoplasmic CT co-localized with BiP, a resident endoplasmic reticulum protein, in a double labeling experiment. These data suggest that the wave of PC synthesis that accompanies the G(0) --> G(1) transition is regulated by the coordinated changes in CT activity, membrane affinity, and intracellular distribution. We describe for the first time a redistribution of GT from the nucleus to the ER that correlates with an activation of the enzyme. We propose that this movement is required for the stimulation of PC synthesis during entry into the cell cycle.	Simon Fraser Univ, Inst Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Simon Fraser Univ, Biochem Program, Burnaby, BC V5A 1S6, Canada	Simon Fraser University; Simon Fraser University	Cornell, BB (corresponding author), Simon Fraser Univ, Inst Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.			Crawford, Bryan/0000-0002-0512-4649				Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BALLAS LM, 1980, BIOCHIM BIOPHYS ACTA, V602, P578, DOI 10.1016/0005-2736(80)90336-3; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Bladergroen BA, 1998, BBA-LIPID LIPID MET, V1391, P233, DOI 10.1016/S0005-2760(98)00006-X; BLIGH EG, 1959, CAN J BIOCH PHYSL, V62, P983; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; CORNELL R, 1989, J BIOL CHEM, V264, P9077; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P37, DOI 10.1016/0005-2760(87)90215-3; CORNELL R, 1977, EXP CELL RES, V109, P299, DOI 10.1016/0014-4827(77)90009-X; Cornell RB, 1998, BIOCHEM SOC T, V26, P539, DOI 10.1042/bst0260539; CSERPAN I, 1995, J CELL SCI, V108, P1849; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; HATCH GM, 1992, J BIOL CHEM, V267, P15751; Hogan M, 1996, BIOCHEM J, V314, P799, DOI 10.1042/bj3140799; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; Houweling M, 1996, EUR J CELL BIOL, V69, P55; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; Johnson JE, 1997, BBA-BIOMEMBRANES, V1324, P273, DOI 10.1016/S0005-2736(96)00233-7; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; LIM P, 1986, BIOCHEM CELL BIOL, V64, P692, DOI 10.1139/o86-095; Love DC, 1998, P NATL ACAD SCI USA, V95, P10608, DOI 10.1073/pnas.95.18.10608; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; MACDONALD JIS, 1995, BIOCHEM J, V312, P425, DOI 10.1042/bj3120425; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; MORAND JN, 1989, J BIOL CHEM, V264, P13785; Morash SC, 1998, BIOCHEM J, V332, P321, DOI 10.1042/bj3320321; PADDON HB, 1980, BIOCHIM BIOPHYS ACTA, V620, P636, DOI 10.1016/0005-2760(80)90156-3; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; TERCE F, 1994, J LIPID RES, V35, P2130; TERCE F, 1991, BIOCHIM BIOPHYS ACTA, V1084, P69, DOI 10.1016/0005-2760(91)90057-O; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Tran K, 1995, BBA-LIPID LIPID MET, V1259, P283, DOI 10.1016/0005-2760(95)00175-1; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; VANCE DE, 1980, J BIOL CHEM, V255, P1064; VANCE DE, 1984, TRENDS BIOCHEM SCI, V9, P17, DOI 10.1016/0968-0004(84)90041-0; VANCE JE, 1988, J BIOL CHEM, V263, P5898; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; Weinhold PA, 1998, BBA-LIPID LIPID MET, V1391, P307, DOI 10.1016/S0005-2760(97)00206-3; WIEPRECHT M, 1994, FEBS LETT, V353, P221, DOI 10.1016/0014-5793(94)01040-4; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; Zetterberg A, 1996, APOPTOSIS CELL CYCLE, P17; [No title captured]	68	85	86	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26240	26248		10.1074/jbc.274.37.26240	http://dx.doi.org/10.1074/jbc.274.37.26240			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473578	hybrid			2022-12-25	WOS:000082469700044
J	Glaser, T; Wagenknecht, B; Groscurth, P; Krammer, PH; Weller, M				Glaser, T; Wagenknecht, B; Groscurth, P; Krammer, PH; Weller, M			Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells	ONCOGENE			English	Article						glioma; apoptosis; CD95; chemotherapy; caspases	APO-1/FAS RECEPTOR/LIGAND SYSTEM; ETOPOSIDE-INDUCED APOPTOSIS; TUMOR-CELLS; CD95 LIGAND; GAMMA-IRRADIATION; LEUKEMIA-CELLS; WILD-TYPE; IN-VITRO; EXPRESSION; INDUCTION	Death ligand/receptor interactions and caspase activation mediate drug-induced apoptosis in certain cancer cells. The molecular mechanisms responsible for the chemoresistance of human malignant gliomas are largely unknown. Here, me report that malignant glioma cells co-express CD95 and CD95L without undergoing suicidal or fratricidal apoptosis. Glioma cells do not commit CD95/CD95L-dependent suicide or fratricide even when RNA and protein synthesis are inhibited. This is because ectopic expression of the viral caspase inhibitor, crm-A, or exposure to a neutralizing CD95L antibody, block apoptosis induced by exogenous CD95L but not cell death induced by cytotoxic concentrations of inhibitors of RNA and protein synthesis. Although some cytotoxic drugs enhance the expression of CD95 or CD95L, crm-A fails to block drug-induced cytotoxic and clonogenic cell death, suggesting that the drug-induced changes in CD95 and CD95L expression are epiphenomenal. There is also no difference in drug-induced apoptosis between crm-A-transfected and control cells as assessed by electron microscopy, ill situ DNA end labeling and DNA fragmentation. Further, glioma cells selected for resistance to CD95L do not acquire cross-resistance to chemotherapy. However, the broad spectrum caspase inhibitor, zVAD-fmk, inhibits drug-induced cytotoxic cell death, suggesting a role of crm-A-insensitive caspases in drug-induced apoptosis of glioma cells. Thus, drug resistance of malignant glioma cells may involve deficiencies in two interrelated pathways that mediate death in order tumor cell types: (i) death ligand/receptor signalling; and (ii) caspase activation.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Tubingen, Germany; Univ Zurich, Inst Anat, Zurich, Switzerland; German Canc Res Ctr, D-6900 Heidelberg, Germany	Eberhard Karls University of Tubingen; University of Zurich; Helmholtz Association; German Cancer Research Center (DKFZ)	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				Antoku K, 1997, LEUKEMIA, V11, P1665, DOI 10.1038/sj.leu.2400805; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 1998, INT J CANCER, V76, P105; Kataoka T, 1998, J IMMUNOL, V161, P3936; KONDO S, 1995, CANCER RES, V55, P6166; Kondo S, 1998, CANCER RES, V58, P962; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Villunger A, 1997, CANCER RES, V57, P3331; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; Weller M, 1997, CELL PHYSIOL BIOCHEM, V7, P282, DOI 10.1159/000154883; Weller M, 1998, BRAIN PATHOL, V8, P285; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1998, INT J CANCER, V79, P640; Winter S, 1998, EUR J PHARMACOL, V341, P323, DOI 10.1016/S0014-2999(97)01478-7; Yu JS, 1996, CANCER RES, V56, P5423; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zipp F, 1997, J IMMUNOL, V159, P2108	30	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	1999	18	36					5044	5053		10.1038/sj.onc.1202882	http://dx.doi.org/10.1038/sj.onc.1202882			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490841				2022-12-25	WOS:000082497100004
J	Ueda, Y; Hijikata, M; Takagi, S; Chiba, T; Shimotohno, K				Ueda, Y; Hijikata, M; Takagi, S; Chiba, T; Shimotohno, K			New p73 variants with altered C-terminal structures have varied transcriptional activities	ONCOGENE			English	Article						p73; splicing variant; p53; transcriptional activity	CELL-LINES; P53 PROTEIN; GENE	p73 has been identified as a protein which shares significant homology with the tumor suppressor p53, We found two new types of splicing variant mRNAs for p73 expressed in MCF-7 cells which we named p73 gamma and epsilon. Sequence analysis revealed that these mRNAs encode variant p73 proteins bearing distinct carboxy-terminal structures, which are also different from the previously reported variants p73 alpha and beta, The mRNAs encoding p73 gamma and epsilon as well as alpha. and beta were confirmed to be expressed in normal human tissues in varied patterns. All of these splicing variants activated promoter with the p53-binding consensus sequence, but to different degrees. Furthermore, suppressive effects of p73 alpha, gamma and epsilon, but not beta, on endogenous p53 activity were observed when transiently expressed in HepG2 and MCF-7 cells. These results suggested that the carboxy-terminal regions of p73 which were altered by alternative splicing affect these transactivation abilities and modulate the functions of p73 molecules.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Hijikata, M (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.		Ueda, Yoshihide/S-7620-2016	Ueda, Yoshihide/0000-0003-3196-3494				BARTEK J, 1990, ONCOGENE, V5, P893; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDIERY WS, 1994, CANCER RES, V54, P1169; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; TOMINAGA O, 1993, ONCOGENE, V8, P2653	16	134	138	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4993	4998		10.1038/sj.onc.1202817	http://dx.doi.org/10.1038/sj.onc.1202817			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490834	Green Submitted			2022-12-25	WOS:000082321700012
J	Zhu, X; Pattenden, S; Bremner, R				Zhu, X; Pattenden, S; Bremner, R			PRB is required for interferon-gamma-induction of the MHC class II A beta gene	ONCOGENE			English	Article						retinoblastoma; MHC class II; interferon-gamma; transcription; CIITA	MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN GENE; BARE LYMPHOCYTE SYNDROME; HUMAN-ENDOTHELIAL CELLS; BREAST-CARCINOMA CELLS; RETINOBLASTOMA PROTEIN; TRANSACTIVATOR CIITA; TRANSCRIPTION FACTOR; HLA-DR; CYCLIN D1	PRE is required for IFN-gamma-induction of MHC class II in human tumor cell lines, providing a potential link between tumor suppressors and the immune system. However, other genes, such as cyclin D1, show pRB-dependency only in tumor cells, so by analogy, pRB may not be necessary for cII-regulation in normal cells. Here, we demonstrate that induction of the mouse MHC class II I-A heterodimer is normal in RB+/+ mouse embryonic fibroblasts (MEFs), but deficient in RB-/- MEFs, Inducibility is restored in RB-/- MEFs stably transfected with wild type RE cDNA or infected with an adenovirus expressing pRB. Thus, involvement of pRB in MHC class II expression is conserved in the mouse and is not an aberrant feature of tumorigenic, aneuploid, human tumor cells. Although cII genes are generally induced in a coordinate fashion, suggesting a common mechanism, we found that pRB was specifically required for induction of the A beta, but not A alpha or other MHC cII genes including E beta, Ii and H2-M alpha. Finally, IFN-gamma-induction of class II transactivator (CIITA), was pRB-independent, suggesting that pRB works downstream of this master-regulator of MHC class II expression.	Eye Res Inst Canada, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A1, Canada	University of Toronto; University of Toronto	Bremner, R (corresponding author), Eye Res Inst Canada, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Bremner, Rod/I-6490-2012	Bremner, Rod/0000-0001-9184-7212				ALBERT SE, 1994, J EXP MED, V180, P233, DOI 10.1084/jem.180.1.233; AMEGLIO F, 1983, INFECT IMMUN, V42, P122, DOI 10.1128/IAI.42.1.122-125.1983; Anderson Donald M., 1992, Molecular Marine Biology and Biotechnology, V1, P89; ANICHINI A, 1988, J IMMUNOL, V140, P183; Armstrong TD, 1997, P NATL ACAD SCI USA, V94, P6886, DOI 10.1073/pnas.94.13.6886; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BARR CL, 1991, J BIOL CHEM, V266, P3475; BARR E, 1994, GENE THER, V1, P51; BASHAM TY, 1983, J IMMUNOL, V130, P1492; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BROWN AM, 1993, J BIOL CHEM, V268, P26328; BROWN AM, 1991, J IMMUNOL, V146, P3183; BURMESTER GR, 1987, J CLIN INVEST, V80, P595, DOI 10.1172/JCI113111; Celada A, 1996, BIOCHEM J, V313, P737, DOI 10.1042/bj3130737; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHEN JZ, 1993, CURR BIOL, V3, P405, DOI 10.1016/0960-9822(93)90347-Q; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1996, J EXP MED, V183, P2517, DOI 10.1084/jem.183.6.2517; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GONWA TA, 1984, J CLIN INVEST, V74, P859, DOI 10.1172/JCI111503; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON SP, 1995, CELL IMMUNOL, V166, P207, DOI 10.1006/cimm.1995.9977; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1993, IMMUNOGENETICS, V37, P227; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KING DP, 1983, J IMMUNOL, V131, P2814; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; KUBY J, 1994, IMMUNOLOGY, P239; LAMB CA, 1992, J IMMUNOL, V148, P3478; LLOBERAS J, 1995, MOL CELL BIOL, V15, P5092; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LU YM, 1994, ONCOGENE, V9, P1015; LU YM, 1994, MOL IMMUNOL, V31, P1365, DOI 10.1016/0161-5890(94)90055-8; Lu YM, 1996, J IMMUNOL, V156, P2495; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1384; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MANYAK CL, 1988, J IMMUNOL, V140, P3817; Marhin WW, 1996, ONCOGENE, V12, P43; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; Min W, 1996, MOL CELL BIOL, V16, P359; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; MULLER C, 1985, IMMUNOBIOLOGY, V169, P228; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUNCASTER MM, 1992, CANCER RES, V52, P654; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; OSTRANDROSENBERG S, 1994, CURR OPIN IMMUNOL, V6, P722, DOI 10.1016/0952-7915(94)90075-2; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; POBER JS, 1983, J EXP MED, V157, P1339, DOI 10.1084/jem.157.4.1339; RADLEY E, 1994, J BIOL CHEM, V269, P18834; Robinson M. A., 1989, Fundamental immunology., P489; Rohde M, 1996, ONCOGENE, V12, P2393; Scholl T, 1996, J IMMUNOL, V156, P1448; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; SYMINGTON FW, 1985, J IMMUNOL, V135, P1026; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; TSCHICKARDT ME, 1995, INT J CANCER, V62, P461, DOI 10.1002/ijc.2910620417; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westerheide SD, 1997, J IMMUNOL, V158, P4812; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; Williams GS, 1998, INT IMMUNOL, V10, P1957, DOI 10.1093/intimm/10.12.1957; WONG GHW, 1984, EUR J IMMUNOL, V14, P52, DOI 10.1002/eji.1830140110; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; Wright KL, 1998, P NATL ACAD SCI USA, V95, P6267, DOI 10.1073/pnas.95.11.6267; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	91	27	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4940	4947		10.1038/sj.onc.1202876	http://dx.doi.org/10.1038/sj.onc.1202876			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490828				2022-12-25	WOS:000082321700006
J	Gire, V; Marshall, CJ; Wynford-Thomas, D				Gire, V; Marshall, CJ; Wynford-Thomas, D			Activation of mitogen-activated protein kinase is necessary but not sufficient for proliferation of human thyroid epithelial cells induced by mutant Ras	ONCOGENE			English	Article						Ras; MAP kinase; epithelial; thyroid; signalling	SIGNAL-REGULATED KINASE; PHORBOL ESTER; DNA-SYNTHESIS; 3T3 CELLS; IN-VITRO; TRANSFORMATION; GROWTH; CASCADE; PHOSPHORYLATION; PATHWAY	Given the high frequency of ras oncogene activation in several common human cancers, its signal pathways are an important target for novel therapy, For practical reasons, however, these have been studied mainly in the context of transformation of established fibroblast cell lines, whereas ras acts at an earlier stage in human tumorigenesis and predominantly on epithelial cells, Here we have developed a more directly relevant model-human primary thyroid epithelial cells-which are a major target of naturally-occurring Pas mutation, and in which expression of mutant Pas in culture induces clonal expansion without morphological transformation, closely reproducing the phenotype of the corresponding tumour in vivo, Transient or stable expression of mutant H-ras (by scrapeloading or retroviral infection) at levels which stimulated proliferation induced sustained activation and translocation of MAP kinase (MAPK) in these cells, inhibition of the MAPK pathway at the level of MAPKK, by expression of a dominant-negative mutant or by the pharmacological inhibitor PD98059, efficiently blocked the proliferative response, Conversely, selective activation of MAPK by a constitutively-active MAPKK1 mutant failed to mimic the action of Pas and, although this was achievable with activated Raf, micro-injection of anti-ras antibodies showed that this still required endogenous wild-type Ras function, In contrast to recent results obtained with a rodent thyroid cell line (WRT), therefore, activation of the MAPK pathway is necessary, but not sufficient, for the proliferogenic action of mutant Pas on primary human thyroid cells, These data emphasize the unreliability of extrapolation from cell lines and establish the feasibility of using a more representative human epithelial model for Pas signalling studies.	Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF4 4XN, S Glam, Wales; Inst Canc Res, Chester Beatty Labs, Canc Res Campaign Ctr Cell & Mol Biol, London SW3 6JB, England	Cardiff University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.		Gire, Véronique/AAC-2218-2020; Gire, Veronique/N-7553-2017	Gire, Veronique/0000-0002-9009-2185				ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P281; BOND JA, 1996, INT J CANCER, V67, P56; BOS JL, 1989, CANCER RES, V49, P4682; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; DAWSON TP, 1995, CANCER RES, V55, P915; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Gallagher AP, 1998, CANCER RES, V58, P2029; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAMY F, 1993, J BIOL CHEM, V268, P8398; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SUAREZ HG, 1990, ONCOGENE, V5, P565; Tombes RM, 1998, BIOCHEM J, V330, P1451; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; WYNFORDTHOMAS D, 1991, J PATHOL, V165, P187, DOI 10.1002/path.1711650302; WYNFORDTHOMAS D, 1993, CANCER SURV, V16, P115; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586	64	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4819	4832		10.1038/sj.onc.1202857	http://dx.doi.org/10.1038/sj.onc.1202857			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490815				2022-12-25	WOS:000082184800006
J	Okajima, T; Fukumoto, S; Furukawa, K; Urano, T; Furukawa, K				Okajima, T; Fukumoto, S; Furukawa, K; Urano, T; Furukawa, K			Molecular basis for the progeroid variant of Ehlers-Danlos syndrome - Identification and characterization of two mutations in galactosyltransferase I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; PROTEOGLYCAN; FIBROBLASTS; PATIENT; CELLS	Progeroid type Ehlers-Danlos (E-D) syndrome was reported to be caused by defects in galactosyltransferase I (EC 2.4.1.133), which is involved in the synthesis of common linkage regions of proteoglycans. Recently, we isolated cDNA of the galactosyltransferase I (XGalT-1) (Okajima, T., Yoshida, K., Rondo, T., and Furukawa, H, (1999) J. Biol. Chem. 274, 22915-22918), Therefore, we analyzed mutations in this gene of a patient with progeroid type E-D syndrome by reverse transcription polymerase chain reaction and direct sequencing. Two changes of G and T to A and C at 186 and 206, respectively, were detected, Then, we determined the genomic DNA sequences encompassing the A186D and L206P mutations, revealing that the unaffected parents and two siblings were heterozygous for either one of the two different mutations and normal, while the patient had both of two different mutant genes. Enzymatic functions of cDNA clones of XGalT-1 containing the individual mutations were examined, elucidating that L206P clone completely lost the activity, while A186D retained similar to 50% or 10% of the activity when analyzed with extracts from cDNA transfectant cells or recombinant soluble enzymes, respectively. Moreover, L206P enzyme showed diffuse staining in the cytoplasm of transfectant cells, while the wild type or A186D clones showed Golgi pattern. These results indicated that the mutations in XGalT-1 were at least one of main molecular basis for progeroid type E-D syndrome.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528102, Japan	Nagoya University; Nagasaki University	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Okajima, Tetsuya/I-7332-2014	Okajima, Tetsuya/0000-0002-3677-648X; Fukumoto, Satoshi/0000-0002-5046-6891; Urano, Takeshi/0000-0003-3383-3554				ESKO JD, 1987, J BIOL CHEM, V262, P12189; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; KRESSE H, 1987, AM J HUM GENET, V41, P436; Lugemwa FN, 1996, J BIOL CHEM, V271, P19159, DOI 10.1074/jbc.271.32.19159; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; QUENTIN E, 1990, P NATL ACAD SCI USA, V87, P1342, DOI 10.1073/pnas.87.4.1342; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; Rostand KS, 1997, INFECT IMMUN, V65, P1; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149	10	122	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28841	28844		10.1074/jbc.274.41.28841	http://dx.doi.org/10.1074/jbc.274.41.28841			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506123	hybrid			2022-12-25	WOS:000083017800002
J	Renoult, C; Ternent, D; Maciver, SK; Fattoum, A; Astier, C; Benyamin, Y; Roustan, C				Renoult, C; Ternent, D; Maciver, SK; Fattoum, A; Astier, C; Benyamin, Y; Roustan, C			The identification of a second cofilin binding site on actin suggests a novel, intercalated arrangement of F-actin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPOLYMERIZING FACTOR; FILAMENT TURNOVER; ACANTHAMOEBA-CASTELLANII; STRUCTURAL RELATIONSHIP; CRYSTAL-STRUCTURE; STARFISH OOCYTES; YEAST COFILIN; ADP-ACTIN; PROTEINS; GELSOLIN	The cofilins are members of a protein family that binds monomeric and filamentous actin, severs actin filaments, and increases monomer off-rate from the pointed end. Here, we characterize the cofilin-actin interface. We confirm earlier work suggesting the importance of the lower region of subdomain 1 encompassing the N and C termini (site 1) in cofilin binding. In addition, we report the discovery of a new cofilin binding site (site 2) from residues 112-125 that form a helix toward the upper, rear surface of subdomain 1 in the standard actin orientation (Kabsch, W., Mannherz, H. G., Suck, D., Pal, E. F., and Holmes, H. C. (1990) Nature 347, 37-44). We propose that cofilin binds "behind" one monomer and "in front" of the other longitudinally associated monomer, accounting for the fact that cofilin alters the twist in the actin (McGough, A. Pope, B., Chin, W., and Weeds, A. (1997) J. Cell Biol. 138, 771-781). The characterization of the cofilin-actin interface will facilitate an understanding of how cofilin severs and depolymerizes filaments and may shed light on the mechanism of the gelsolin family because they share a similar fold with the cofilins (Hatanaka, H., Ogura, K., Moriyama, K., Ichikawa, S., Yahara, I., and Inagiki, F. (1996) Cell 85, 1047-1055).	Univ Montpellier 2, Ecole Prat Hautes Etud, Lab Motil Cellulaire, CNRS,UMR 5539, F-34095 Montpellier 5, France; Dept Biomed Sci, Edinburgh EH8 9XD, Midlothian, Scotland; Ctr Rech Biochim Macromol, CNRS, UPR 1086, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Roustan, C (corresponding author), Univ Montpellier 2, Ecole Prat Hautes Etud, Lab Motil Cellulaire, CNRS,UMR 5539, CC107,Pl E Bataillon, F-34095 Montpellier 5, France.		Maciver, Sutherland Kester/H-6284-2019	Maciver, Sutherland Kester/0000-0001-8234-6061				Aizawa H, 1996, J CELL BIOL, V132, P335, DOI 10.1083/jcb.132.3.335; AIZAWA H, 1995, J BIOL CHEM, V270, P10923, DOI 10.1074/jbc.270.18.10923; ANDERSSON K, 1978, J IMMUNOL METHODS, V23, P17, DOI 10.1016/0022-1759(78)90105-9; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BAYER EA, 1990, J CHROMATOGR, V510, P3, DOI 10.1016/S0021-9673(01)93733-1; BENYAMIN Y, 1983, FEBS LETT, V160, P41, DOI 10.1016/0014-5793(83)80932-6; BERNSTEIN BW, 1982, CELL MOTIL CYTOSKEL, V2, P1, DOI 10.1002/cm.970020102; Blanchoin L, 1998, J BIOL CHEM, V273, P25106, DOI 10.1074/jbc.273.39.25106; BOTTOMLEY RC, 1975, BIOCHEM J, V149, P365, DOI 10.1042/bj1490365; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; BURTNICK LD, 1984, BIOCHIM BIOPHYS ACTA, V791, P57, DOI 10.1016/0167-4838(84)90281-4; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COOPER JA, 1986, J BIOL CHEM, V261, P477; Engvall E, 1980, Methods Enzymol, V70, P419; Fedorov AA, 1997, NAT STRUCT BIOL, V4, P366, DOI 10.1038/nsb0597-366; Feinberg J, 1997, BIOCHEM BIOPH RES CO, V233, P61, DOI 10.1006/bbrc.1997.6402; Feinberg J, 1996, BIOCHEM BIOPH RES CO, V222, P127, DOI 10.1006/bbrc.1996.0709; GIULIANO KA, 1988, BIOCHEMISTRY-US, V27, P8931, DOI 10.1021/bi00425a009; GUNSALUS KC, 1995, J CELL BIOL, V97, P1263; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; IIDA K, 1993, GENE, V124, P115; Jiang CJ, 1997, P NATL ACAD SCI USA, V94, P9973, DOI 10.1073/pnas.94.18.9973; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LABBE JP, 1993, EUR J BIOCHEM, V215, P17, DOI 10.1111/j.1432-1033.1993.tb18002.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; LEBART MC, 1995, J MUSCLE RES CELL M, V16, P543, DOI 10.1007/BF00126438; LEBART MC, 1993, J BIOL CHEM, V268, P5642; Leonard SA, 1997, NAT STRUCT BIOL, V4, P369, DOI 10.1038/nsb0597-369; Lopez I, 1996, P NATL ACAD SCI USA, V93, P7415, DOI 10.1073/pnas.93.14.7415; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MACIVER SK, 1995, NEUROREPORT, V6, P1985, DOI 10.1097/00001756-199510010-00008; MACIVER SK, 1994, FEBS LETT, V347, P251, DOI 10.1016/0014-5793(94)00552-4; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; Maciver SK, 1998, EUR J BIOCHEM, V256, P388, DOI 10.1046/j.1432-1327.1998.2560388.x; Maciver SK, 1998, CURR OPIN CELL BIOL, V10, P140, DOI 10.1016/S0955-0674(98)80097-5; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCKIM KS, 1994, MOL GEN GENET, V242, P346, DOI 10.1007/BF00280425; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MEJEAN C, 1992, EUR J BIOCHEM, V209, P555, DOI 10.1111/j.1432-1033.1992.tb17320.x; MEJEAN C, 1988, BIOCHEM BIOPH RES CO, V152, P368, DOI 10.1016/S0006-291X(88)80723-X; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MUNEYUKI E, 1985, J BIOCHEM-TOKYO, V97, P573; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; OCONNOR DV, 1979, J PHYS CHEM-US, V83, P1333, DOI 10.1021/j100473a019; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POPE B, 1994, FEBS LETT, V338, P58, DOI 10.1016/0014-5793(94)80116-9; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; ROUSTAN C, 1985, FEBS LETT, V181, P119, DOI 10.1016/0014-5793(85)81125-X; SHETERLINE P, 1995, PROTEIN PROFILE, V2, P58; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOKES DL, 1987, J CELL BIOL, V104, P1005, DOI 10.1083/jcb.104.4.1005; SUTOH K, 1984, BIOCHEMISTRY-US, V23, P6757, DOI 10.1021/bi00321a073; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P102, DOI 10.1021/bi00427a015; TAKASHI R, 1979, BIOCHEMISTRY-US, V18, P5164, DOI 10.1021/bi00590a021; Theriot JA, 1997, J CELL BIOL, V136, P1165, DOI 10.1083/jcb.136.6.1165; Theriot Julie A., 1992, Trends in Cell Biology, V2, P219, DOI 10.1016/0962-8924(92)90298-2; Van Troys M, 1997, J BIOL CHEM, V272, P32750, DOI 10.1074/jbc.272.52.32750; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; Wriggers W, 1998, J MOL BIOL, V282, P921, DOI 10.1006/jmbi.1998.2048; YONEZAWA N, 1988, BIOCHEM J, V251, P121, DOI 10.1042/bj2510121; ZECHEL K, 1993, BIOCHEM J, V290, P411, DOI 10.1042/bj2900411	73	24	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28893	28899		10.1074/jbc.274.41.28893	http://dx.doi.org/10.1074/jbc.274.41.28893			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506133	hybrid			2022-12-25	WOS:000083017800012
J	Benson, LQ; Coon, MR; Krueger, LM; Han, GC; Sarnaik, AA; Wechsler, DS				Benson, LQ; Coon, MR; Krueger, LM; Han, GC; Sarnaik, AA; Wechsler, DS			Expression of MXI1, a Myc antagonist, is regulated by Sp1 and AP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; TUMOR-SUPPRESSOR GENE; C-MYC; PROSTATE-CANCER; BINDING-SITES; NEOPLASTIC TRANSFORMATION; GENOMIC ORGANIZATION; HISTONE DEACETYLASE; N-COR; MAX	MXI1, a member of the MAD family of Myc antagonists, encodes a transcription factor whose expression must be tightly regulated to maintain normal cell growth and differentiation. To more closely investigate the transcriptional regulation of the human MXI1 gene, we have cloned and characterized the MXI1 promoter. After clarification of the 5'- and 3'-untranslated regions of the cDNA (indicating that the true length of the MXI1 transcript is 2643 base pairs), we identified two transcription initiation sites. We subsequently isolated the MXI1 promoter, which is GC-rich and lacks a TATA box. Although it contains at least six potential initiator sequences, functional studies indicate the proximal two initiator sequences in combination with nearby Spl and MED-1 sites together account for virtually all promoter activity. We also demonstrate that MXI1 promoter activity is repressed by high levels of AP2. These studies provide further insight into the complex regulatory mechanisms governing MXI1 gene expression and its role in cellular differentiation and tumor suppression.	Univ Michigan, Div Pediat Hematol Oncol, Dept Pediat & Communicable Dis, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Wechsler, DS (corresponding author), Univ Michigan, Div Pediat Hematol Oncol, Dept Pediat & Communicable Dis, Sch Med, CCGC 4312,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	dwechsl@umich.edu	Sarnaik, Amod/W-5536-2019		NCI NIH HHS [1-P50-CA69568S] Funding Source: Medline; NICHD NIH HHS [1-P30-HD28820-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028820] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA069568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAROSA R, 1995, HUM GENET, V95, P709; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BOAM DSW, 1995, J BIOL CHEM, V270, P19487, DOI 10.1074/jbc.270.33.19487; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dang CV, 1995, C MYC FUNCTION NEOPL; DELGADO MD, 1995, ONCOGENE, V10, P1659; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EDELHOFF S, 1994, ONCOGENE, V9, P665; Edwards SM, 1997, BRIT J CANCER, V76, P992, DOI 10.1038/bjc.1997.498; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Kawamata N, 1996, PROSTATE, V29, P191, DOI 10.1002/1097-0045(199609)29:3<191::AID-PROS2990290305>3.0.CO;2-1; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Najjar SM, 1996, J BIOL CHEM, V271, P8809, DOI 10.1074/jbc.271.15.8809; PAGES G, 1995, J BIOL CHEM, V270, P26986, DOI 10.1074/jbc.270.45.26986; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Potter M, 1997, CURR TOP MICROBIOL, V224, P1; Prochownik EV, 1998, GENE CHROMOSOME CANC, V22, P295, DOI 10.1002/(SICI)1098-2264(199808)22:4<295::AID-GCC5>3.0.CO;2-Q; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHAPIRO DN, 1994, GENOMICS, V23, P282, DOI 10.1006/geno.1994.1496; Shim H, 1997, CURR TOP MICROBIOL, V224, P181; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Wechsler DS, 1996, GENOMICS, V32, P466, DOI 10.1006/geno.1996.0144; WECHSLER DS, 1994, GENOMICS, V21, P669, DOI 10.1006/geno.1994.1336; Wechsler DS, 1997, CANCER RES, V57, P4905; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZERVOS, 1994, CELL, V79, P389; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	59	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28794	28802		10.1074/jbc.274.40.28794	http://dx.doi.org/10.1074/jbc.274.40.28794			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497252	hybrid			2022-12-25	WOS:000082912700101
J	Qin, YM; Marttila, MS; Haapalainen, AM; Siivari, KM; Glumoff, T; Hiltunen, JK				Qin, YM; Marttila, MS; Haapalainen, AM; Siivari, KM; Glumoff, T; Hiltunen, JK			Yeast peroxisomal multifunctional enzyme: (3R)-hydroxyacyl-CoA dehydrogenase domains A and B are required for optimal growth on oleic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENOYL-COA HYDRATASE; BIFUNCTIONAL PROTEIN-DEFICIENCY; BETA-OXIDATION; CANDIDA-TROPICALIS; D-3-HYDROXYACYL-COA DEHYDRATASE; CRYSTAL-STRUCTURE; RAT-LIVER; EPIMERASE; BINDING; PURIFICATION	The yeast peroxisomal (3R)-hydroxyacyl-CoA dehydrogenase/2-enoyl-CoA hydratase 2 (multifunctional enzyme type 2; MFE-2) has two N-terminal domains belonging to the short chain alcohol dehydrogenase/reductase superfamily, To investigate the physiological roles of these domains, here called A and B, Saccharomyces cerevisiae fox-2 cells (devoid of Sc MFE-8) were taken as a model system. Gly(16) and Gly(329) Of the S. cerevisiae A and B domains, corresponding to Gly16, which is mutated in the human MFE-2 deficiency, were mutated to serine and cloned into the yeast expression plasmid pYE352, In oleic acid medium, fox 2 cells transformed with pYE352:: ScMFE-2(a Delta) and pYE352::ScMFE-2(b Delta) grew slower than cells transformed with pYE352::ScMFE-2, whereas cells transformed with pYE352::ScMFE-2(a Delta b Delta) failed to grow. Candida tropicalis MFE-2 with a deleted hydratase 2 domain (Ct MFE- 2(h2 Delta)) and mutational variants of the A and B domains (Ct MFE- 2(h2 Delta a Delta), Ct MFE- 2(h2 Delta b Delta), and Ct MFE- 2(h2 Delta a Delta b Delta)) were overexpressed and characterized. All proteins were dimers with similar secondary structure elements. Both wild type domains were enzymatically active, with the B domain showing the highest activity with short chain and the A domain with medium and long chain (3R)-hydroxyacyl-CoA substrates, The data show that the dehydrogenase domains of yeast MFE-2 have different substrate specificities required to allow the yeast to propagate optimally on fatty acids as the carbon source.	Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90570 Oulu, Finland	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu	Hiltunen, JK (corresponding author), Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland.							AITCHISON JD, 1990, CURR GENET, V17, P481, DOI 10.1007/BF00313075; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; DieuaideNoubhani M, 1996, EUR J BIOCHEM, V240, P660, DOI 10.1111/j.1432-1033.1996.0660h.x; DieuaideNoubhani M, 1997, BIOCHEM J, V325, P367, DOI 10.1042/bj3250367; Engel CK, 1998, J MOL BIOL, V275, P847, DOI 10.1006/jmbi.1997.1491; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; FILPPULA SA, 1995, J BIOL CHEM, V270, P27453, DOI 10.1074/jbc.270.46.27453; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; Jiang LL, 1996, J BIOCHEM-TOKYO, V120, P624; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kiema TR, 1999, BIOCHEMISTRY-US, V38, P2991, DOI 10.1021/bi981646v; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; Leenders F, 1996, J BIOL CHEM, V271, P5438, DOI 10.1074/jbc.271.10.5438; NUTTLEY WM, 1988, GENE, V69, P171, DOI 10.1016/0378-1119(88)90428-3; Qin YM, 1997, BIOCHEM J, V321, P21, DOI 10.1042/bj3210021; Qin YM, 1997, BIOCHEM J, V328, P377, DOI 10.1042/bj3280377; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; Suzuki Y, 1997, AM J HUM GENET, V61, P1153, DOI 10.1086/301599; TANAKA K, 1990, ANN NY ACAD SCI, V321, P577; van Grunsven EG, 1998, P NATL ACAD SCI USA, V95, P2128, DOI 10.1073/pnas.95.5.2128; van Grunsven EG, 1999, AM J HUM GENET, V64, P99, DOI 10.1086/302180	23	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28619	28625		10.1074/jbc.274.40.28619	http://dx.doi.org/10.1074/jbc.274.40.28619			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497229	hybrid			2022-12-25	WOS:000082912700078
J	Tanaka, Y; Patestos, NP; Maekawa, T; Ishii, S				Tanaka, Y; Patestos, NP; Maekawa, T; Ishii, S			B-myb is required for inner cell mass formation at an early stage of development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; HUMAN HEMATOPOIETIC-CELLS; C-MYB; A-MYB; TRANSCRIPTIONAL ACTIVATOR; FUNCTIONAL DOMAINS; GENE-PRODUCT; EXPRESSION; ENCODES; PROTEIN	The myb gene family has three members, c-myb, A-myb, and B-myb, which have distinct expression patterns. Analyses of c-myb and A-myb mutant mice have indicated that c-myb and A-myb are important for hematopoiesis and spermatogenesis, respectively. However, there has been no evidence for a role for B-myb in development. To examine the role of B-myb in development, Foe generated B-myb-deficient mice by gene targeting. Although the heterozygous mutants were healthy, the homozygous mutants died at an early stage of development, around E4.5-E6.5, In vitro culture of blastocyst indicated that B-myb is required for inner cell mass formation. Consistent with the important role of B-myb in early embryonic development, only B-myb among myb family members was expressed in embryonic stem cells, These results indicate that each of the three members of the myb gene family plays a distinct role during development.	RIKEN, Genet Mol Lab, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan; Japan Sci & Technol Agcy, CREST, Tsukuba, Ibaraki 3050074, Japan	RIKEN; Japan Science & Technology Agency (JST)	Ishii, S (corresponding author), RIKEN, Genet Mol Lab, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; ARSURA M, 1992, BLOOD, V79, P2708; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6737; FOOS G, 1994, ONCOGENE, V9, P2481; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; GONDA MA, 1980, J EMBRYOL EXP MORPH, V56, P23; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HOGAN B, MANIPULATING MOUSE E, P86; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Minamisawa S, 1999, J BIOL CHEM, V274, P10066, DOI 10.1074/jbc.274.15.10066; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OGATA K, 1995, NAT STRUCT BIOL, V2, P309, DOI 10.1038/nsb0495-309; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; ROWINSKI J, 1975, J EXP ZOOL, V192, P133, DOI 10.1002/jez.1401920202; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Sitzmann J, 1996, ONCOGENE, V12, P1889; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TASHIRO S, 1995, ONCOGENE, V10, P1699; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WU TC, 1981, J EMBRYOL EXP MORPH, V65, P105; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	49	122	123	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28067	28070		10.1074/jbc.274.40.28067	http://dx.doi.org/10.1074/jbc.274.40.28067			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497154	hybrid			2022-12-25	WOS:000082912700003
J	Christopherson, KS; Hillier, BJ; Lim, WA; Bredt, DS				Christopherson, KS; Hillier, BJ; Lim, WA; Bredt, DS			PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; DENSITY PROTEIN PSD-95; NMDA RECEPTOR; POSTSYNAPTIC DENSITY; MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; CHANNEL; BINDING; LOCALIZATION; MEMBRANE	Nitric oxide (NO) biosynthesis in cerebellum is preferentially activated by calcium influx through N-methyl-D-aspartate (NMDA)-type glutamate receptors, suggesting that there is a specific link between these receptors and neuronal NO synthase (nNOS). Here, we find that PSD-95 assembles a postsynaptic protein complex containing nNOS and NMDA receptors. Formation of this complex is mediated by the PDZ domains of PSD-95, which bind to the COOH termini of specific NMDA receptor subunits. In contrast, nNOS is recruited to this complex by a novel PDZ-PDZ interaction in which PSD-95 recognizes an internal motif adjacent to the consensus nNOS PDZ domain. This internal motif is a structured "pseudo-peptide" extension of the nNOS PDZ that interacts with the peptide-binding pocket of PSD-95 PDZ2. This asymmetric interaction leaves the peptide-binding pocket of the nNOS PDZ domain available to interact with additional COOH-terminal PDZ ligands. Accordingly, we find that the nNOS PDZ domain can bind PSD-95 PDZ2 and a COOH-terminal peptide simultaneously. This bivalent nature of the nNOS PDZ domain further expands the scope for assembly of protein networks by PDZ domains.	Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biomed Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bredt, DS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Physiol, 513 Parnassus Ave, San Francisco, CA 94143 USA.				NINDS NIH HHS [R01-NS34822] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034822] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aoki C, 1997, BRAIN RES, V750, P25, DOI 10.1016/S0006-8993(96)01147-X; AOKI C, 1993, BRAIN RES, V620, P97, DOI 10.1016/0006-8993(93)90275-R; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Chao DS, 1996, J EXP MED, V184, P609, DOI 10.1084/jem.184.2.609; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Firestein BL, 1999, J BIOL CHEM, V274, P10545, DOI 10.1074/jbc.274.15.10545; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Hunt CA, 1996, J NEUROSCI, V16, P1380; HUNTLEY GW, 1994, J NEUROSCI, V14, P3603; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; KIEDROWSKI L, 1992, J NEUROCHEM, V58, P335, DOI 10.1111/j.1471-4159.1992.tb09315.x; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LIM WA, 1994, PROTEIN SCI, V3, P1261, DOI 10.1002/pro.5560030812; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; PETRALIA RS, 1994, J NEUROSCI, V14, P667; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Raymond LA, 1996, MOL CELL NEUROSCI, V7, P102, DOI 10.1006/mcne.1996.0008; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P4901, DOI 10.1021/bi00135a022; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545	49	455	470	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27467	27473		10.1074/jbc.274.39.27467	http://dx.doi.org/10.1074/jbc.274.39.27467			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488080	hybrid			2022-12-25	WOS:000082739100019
J	Slice, LM; Walsh, JH; Rozengurt, E				Slice, LM; Walsh, JH; Rozengurt, E			G alpha(13) stimulates Rho-dependent activation of the cyclooxygenase-2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE-2 GENE-EXPRESSION; NUCLEOTIDE EXCHANGE FACTOR; ACTIN STRESS FIBERS; G-PROTEIN G(13); ALPHA-SUBUNIT; PROSTAGLANDIN SYNTHASE-2; GROWTH-FACTORS; 3T3 CELLS; TRANSCRIPTIONAL REGULATION; TYROSINE PHOSPHORYLATION	Cyclooxygenase-2 (COX-2) gene expression is rapidly increased by cytokines, tumor promoters, and growth factors and is markedly enhanced in various cancer cells. Here, we examine the regulation of COX-2 promoter activity by ct subunits of heterotrimeric G proteins in NIH 3T3 cells. Using a transient transfection assay with a reporter vector in which the murine COX-2 promoter drives the production of luciferase and expression vectors encoding for a subunits of G-proteins, we show that overexpression of wild type and constitutively active G alpha(13) and G alpha(q) induced transcription from the COX-2 promoter. The highest level of induced luciferase activity (5.8-fold) occurred in cells expressing the constitutively active G alpha(13)(Q226L). We also show that expression of a constitutively active mutant of Rho (RhoQ63L) also induced transcription from the COX-2 promoter. Co-expression of Clostridium botulinum C3 toxin specifically blocked induction of the COX-2 promoter by either G alpha(13)Q226L or RhoQ63L but did not prevent the activation of this promoter by Ras, Rac, v-src, or forskolin. We conclude that G alpha(13) signals through a Rho-dependent pathway leading to activation of the COX-2 promoter. This pathway is not inhibited by either cytochalasin D, which disrupts actin filament organization, or genistein, a broad spectrum tyrosine kinase inhibitor, indicating a bifurcation of the signaling pathway used by G alpha(13)/Rho to induce COX-2 expression from that used to induce stress fiber formation and tyrosine phosphorylation of focal adhesion proteins.	Univ Calif Los Angeles, Sch Med, Digest Dis Res Ctr, CURE,Dept Med,Div Digest Dis, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Slice, LM (corresponding author), Univ Calif Los Angeles, Sch Med, Digest Dis Res Ctr, CURE,Dept Med,Div Digest Dis, Warren Hall 11-151,900 Vet Ave, Los Angeles, CA 90095 USA.	lslice@med1.medsch.ucla.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035740, R37DK017294, R01DK017294] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55003, DK35740, DK17294] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; Boolbol SK, 1996, CANCER RES, V56, P2556; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Crofford LJ, 1997, J RHEUMATOL, V24, P15; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEWITT DL, 1991, ADV PROSTAG THROMB L, V21, P65; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; Ferris HA, 1997, J CLIN INVEST, V100, P2530, DOI 10.1172/JCI119795; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hecht JR, 1997, PROSTAG OTH LIPID M, V54, P757, DOI 10.1016/S0090-6980(97)00162-7; HERSCHMAN HR, 1994, PROG NUCLEIC ACID RE, V47, P113, DOI 10.1016/S0079-6603(08)60251-2; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; LIGUMSKY M, 1982, AM J PHYSIOL, V242, pG337, DOI 10.1152/ajpgi.1982.242.4.G337; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ristimaki A, 1997, CANCER RES, V57, P1276; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; SINGER WD, 1994, J BIOL CHEM, V269, P19796; SLICE LW, 1994, J BIOL CHEM, V269, P21755; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Tsuji S, 1996, PROSTAG LEUKOTR ESS, V55, P179, DOI 10.1016/S0952-3278(96)90095-2; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; WU DQ, 1992, J BIOL CHEM, V267, P1811; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yamamoto K, 1997, ADV EXP MED BIOL, V407, P185; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	57	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27562	27566		10.1074/jbc.274.39.27562	http://dx.doi.org/10.1074/jbc.274.39.27562			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488092	hybrid			2022-12-25	WOS:000082739100031
J	Faria, TN; Mendelsohn, C; Chambon, P; Gudas, LJ				Faria, TN; Mendelsohn, C; Chambon, P; Gudas, LJ			The targeted disruption of both alleles of RAR beta(2) in F9 cells results in the loss of retinoic acid-associated growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; EMBRYONAL CARCINOMA-CELLS; MAMMARY EPITHELIAL-CELLS; RECEPTOR-BETA EXPRESSION; HUMAN LUNG-CANCER; TERATOCARCINOMA CELLS; RAR-BETA; DIFFERENTIAL PATTERN; MOUSE DEVELOPMENT; BINDING-PROTEINS	F9 teratocarcinoma cell lines, carrying one or two disrupted alleles of the RAR beta(2) gene, were generated by homologous recombination to study the role of RAR beta(2) in mediating the effects of retinoids on cell growth and differentiation. Retinoic acid (RA) does not induce growth arrest of the RAR beta(2)-/- cells, whereas the F9 WT and RAR beta(2)+/- heterozygote lines undergo RA-induced growth arrest. The RAR beta(2)+/- lines also exhibit a faster cell cycle transit time in the absence of RA. The RAR beta(2)-/- stem cells exhibit an altered morphology when compared with the F9 WT parent line, and after RA treatment, the RAR beta(2)-/- cells do not exhibit a fully differentiated cell morphology, As compared with F9 WT cells, the RAR beta-/- cells exhibited a markedly lower induction of several early RA-responsive genes and no induction of laminin B1, a late response gene. The induction of RA metabolism in the F9 RAR beta(2)-/- cells following differentiation was not impaired. The research presented here, and prior research suggest that RAR beta is required for RA-induced growth arrest in a variety of cell types and that RAR beta also functions in mediating late responses to RA. These findings are significant in view of the reduced expression of RAR beta transcripts in a number of different types of human carcinomas.	Cornell Univ, Weil Med Coll, Dept Pharmacol, New York, NY 10021 USA; Columbia Presbyterian Med Ctr, Dept Urol, New York, NY 10032 USA; Coll France, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Cornell University; Columbia University; NewYork-Presbyterian Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gudas, LJ (corresponding author), Cornell Univ, Weil Med Coll, Dept Pharmacol, New York, NY 10021 USA.		Mendelsohn, Cathy/H-4280-2016	Mendelsohn, Cathy/0000-0002-4026-4073	NATIONAL CANCER INSTITUTE [R01CA043796, T32CA062948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK082963, R01DK061459] Funding Source: NIH RePORTER; NCI NIH HHS [CA62948, R01CA43796] Funding Source: Medline; NIDDK NIH HHS [R01 DK061459-09, R01 DK061459-07S1, R01 DK061459-08, R01 DK061459-07, R56 DK082963, R01 DK061459-06, R01 DK061459, R56 DK082963-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Abed SS, 1998, J BIOL CHEM, V273, P2409, DOI 10.1074/jbc.273.4.2409; Achkar CC, 1996, P NATL ACAD SCI USA, V93, P4879, DOI 10.1073/pnas.93.10.4879; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen AC, 1997, CANCER RES, V57, P4642; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Chiba H, 1997, J CELL BIOL, V139, P735, DOI 10.1083/jcb.139.3.735; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DAMJANOV I, 1975, TERATOMAS DIFFERENTI, P209; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; Faria TN, 1998, MOL CELL ENDOCRINOL, V143, P155, DOI 10.1016/S0303-7207(98)00127-0; Faria TN, 1998, CANCER RES, V58, P2007; GEBERT JF, 1991, ONCOGENE, V6, P1859; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Gudas Lorraine J., 1994, P443; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HU L, 1991, CANCER RES, V51, P3972; Kastner P, 1997, DEVELOPMENT, V124, P313; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; LUO JM, 1995, MECH DEVELOP, V53, P61, DOI 10.1016/0925-4773(95)00424-6; Mangelsdorf David J., 1994, P319; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; McGregor F, 1997, CANCER RES, V57, P3886; MENDELSOHN C, 1994, MECH DEVELOP, V45, P227, DOI 10.1016/0925-4773(94)90010-8; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; STRICKLAND S, 1980, CELL, V21, P2936; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Widschwendter M, 1997, CANCER RES, V57, P4158; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; XU XC, 1994, CANCER RES, V54, P3580; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZHANG XK, 1994, CANCER RES, V54, P5663	59	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26783	26788		10.1074/jbc.274.38.26783	http://dx.doi.org/10.1074/jbc.274.38.26783			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480883	hybrid			2022-12-25	WOS:000082570700022
J	Bjergbaek, L; Jensen, S; Westergaard, O; Andersen, AH				Bjergbaek, L; Jensen, S; Westergaard, O; Andersen, AH			Using a biochemical approach to identify the primary dimerization regions in human DNA topoisomerase II alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; 2-GATE MECHANISM; TERMINAL DOMAIN; YEAST; PROTEIN; TRANSPORT; CLEAVAGE; CELLS; RECOMBINATION; CONDENSATION	Eukaryotic topoisomerase II is a nuclear enzyme essential for DNA metabolism and chromosome dynamics. The enzyme has a dimeric structure, and subunit dimerization is vital to the cellular functions and activities of the enzyme. Two biochemical approaches based on metal ion affinity chromatography and immunoprecipitation have been carried out to map the dimerization region(s) in human topoisomerase II alpha. The results demonstrate that two regions spanning amino acids 1053-1069 and 1124-1143 are both essential for dimerization. The regions correspond to the interaction domains revealed in yeast topoisomerase II after crystallization of a central fragment of this enzyme, indicating that the overall C-terminal dimerization structure of eukaryotic topoisomerase II is conserved from yeast to human. Furthermore, linker insertion analysis has demonstrated that the two dimerization regions are located in a highly flexible part of the enzyme. Topoisomerase II alpha mutant enzymes unable to dimerize via the C-terminal primary dimerization regions due to lack of one of the defined dimerization regions can still be forced to dimerize if DNA and an ATP analog are added to the reaction mixture. The result indicates that secondary interactions occur by ATP analog-mediated clamp closing when the subunits are brought together on DNA.	Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, AH (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.		Bjergbæk, Lotte/AAW-6302-2021; Andersen, Anni/O-1162-2017	Andersen, Anni/0000-0001-7194-3258; Bjergbaek, Lotte/0000-0002-8233-3356				ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Biersack H, 1996, P NATL ACAD SCI USA, V93, P8288, DOI 10.1073/pnas.93.16.8288; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; FRERE V, 1995, J BIOL CHEM, V270, P17502, DOI 10.1074/jbc.270.29.17502; GALE KC, 1992, J BIOL CHEM, V267, P12090; Gardiner LP, 1998, BIOCHEMISTRY-US, V37, P16997, DOI 10.1021/bi9818321; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GOTO T, 1984, J BIOL CHEM, V259, P422; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jensen S, 1996, MOL CELL BIOL, V16, P3866; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; Kroll DJ, 1997, ARCH BIOCHEM BIOPHYS, V345, P175, DOI 10.1006/abbi.1997.0267; KROLL DJ, 1993, MOL ENDOCRINOL, V7, P305, DOI 10.1210/me.7.3.305; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LIU LF, 1983, J BIOL CHEM, V258, P5365; NELSON WG, 1986, NATURE, V322, P187, DOI 10.1038/322187a0; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; SCHMIDT VK, 1994, J MOL BIOL, V241, P18, DOI 10.1006/jmbi.1994.1469; Schultz P, 1996, P NATL ACAD SCI USA, V93, P5936, DOI 10.1073/pnas.93.12.5936; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SIKORSKI RS, 1989, GENETICS, V122, P19; SNAPKA RM, 1988, MOL CELL BIOL, V8, P515, DOI 10.1128/MCB.8.2.515; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; Wang XQ, 1996, NUCLEIC ACIDS RES, V24, P4791, DOI 10.1093/nar/24.23.4791; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; ZWELLING LA, 1989, MOL ENDOCRINOL, V3, P603, DOI 10.1210/mend-3-3-603	41	18	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26529	26536		10.1074/jbc.274.37.26529	http://dx.doi.org/10.1074/jbc.274.37.26529			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473615	hybrid			2022-12-25	WOS:000082469700081
J	Fedosov, SN; Berglund, L; Nexo, E; Petersen, TE				Fedosov, SN; Berglund, L; Nexo, E; Petersen, TE			Sequence, S-S bridges, and spectra of bovine transcobalamin expressed in Pichia pastoris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC INTRINSIC-FACTOR; AFFINITY CHROMATOGRAPHY; BINDING; CDNA; PURIFICATION; HAPTOCORRIN; COBALAMIN; RECEPTOR; PROTEIN; RABBIT	Transcobalamin (TC) -encoding cDNA was isolated from a bovine mammary gland cDNA library. Hybridization of the cloned bovine TC-cDNA to RNA samples from bovine tissues showed that the most intensive synthesis of a TC positive 1.9-kilobase mRNA occurred in kidney, lymphatic nodes, and liver. Bovine TC was expressed in yeast Pichia pastoris, and the isolated recombinant protein showed cobalamin (Cbl) and receptor binding properties similar to TCs from other sources. Alignment of the related Cbl carriers (haptocorrins and intrinsic factors from other species) with bovine TC (414 residues) revealed four conservative clusters in the sequence (85-98, 137-147, 178-190, and 268-288), which may be responsible for Cbl binding. Three S-S bonds connected Cys residues 3-252, 98-294, and 147-190. Treatment with an S-S reducing agent caused liberation of Cbl from TC-Cbl. A significant change was observed in the TC-Cbl absorbance spectrum upon substitution of Co2+-coordinated H2O by azide. The reaction developed several orders of magnitude slower, and the spectral distortions were much stronger than those in free Cbl. This may be caused by significant deformation of the Cbl molecule and/or by its shielding when bound to TC.	Aarhus Univ, Dept Biol Mol & Struct, Prot Chem Lab, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, AKH, Dept Clin Biochem, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University	Petersen, TE (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, Prot Chem Lab, Sci Pk,Gustav Wieds Vej 10, DK-8000 Aarhus C, Denmark.		Fedosov, Sergey N./J-2340-2019	Fedosov, Sergey N./0000-0002-7016-2959; Nexo, Ebba/0000-0001-9406-9081				Allen R H, 1975, Prog Hematol, V9, P57; ALLEN RH, 1973, J BIOL CHEM, V248, P3660; Ausubel F., 1999, CURRENT PROTOCOLS MO; BROWN KL, 1991, J BIOL CHEM, V266, P6737; BURGER RL, 1974, J BIOL CHEM, V249, P7220; DIECKGRAEFE BK, 1988, P NATL ACAD SCI USA, V85, P46, DOI 10.1073/pnas.85.1.46; Fedosov SN, 1995, BIOCHEMISTRY-US, V34, P16082, DOI 10.1021/bi00049a023; Fedosov SN, 1996, BBA-PROTEIN STRUCT M, V1292, P113, DOI 10.1016/0167-4838(95)00173-5; FEDOSOV SN, 1993, BIOCHIM BIOPHYS ACTA, V1153, P322, DOI 10.1016/0005-2736(93)90422-V; FIRTH RA, 1967, BIOCHEMISTRY-US, V6, P2178, DOI 10.1021/bi00859a040; FRISBIE SM, 1993, BIOCHEMISTRY-US, V32, P13886, DOI 10.1021/bi00213a018; GORDON M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P276, DOI 10.1016/0167-4781(92)90161-R; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; HALL CA, 1977, AM J HUM GENET, V29, P619; HEWITT JE, 1990, EUR J BIOCHEM, V189, P125, DOI 10.1111/j.1432-1033.1990.tb15468.x; HEWITT JE, 1991, GENOMICS, V10, P432, DOI 10.1016/0888-7543(91)90329-D; JOHNSTON J, 1989, J BIOL CHEM, V264, P15754; KATZ M, 1974, J CLIN INVEST, V53, P1274, DOI 10.1172/JCI107674; KOLHOUSE JF, 1977, J CLIN INVEST, V60, P1381, DOI 10.1172/JCI108899; KRAUTLER B, 1998, VITAMIN B12 B12 PROT, P3; LI N, 1993, BIOCHIM BIOPHYS ACTA, V1172, P21, DOI 10.1016/0167-4781(93)90264-E; LI N, 1994, HUM MOL GENET, V3, P1835, DOI 10.1093/hmg/3.10.1835; LORENZ RG, 1993, J BIOL CHEM, V268, P26559; MARCHAJ A, 1995, J AM CHEM SOC, V117, P11640, DOI 10.1021/ja00152a003; NEXO E, 1976, BIOCHIM BIOPHYS ACTA, V446, P143, DOI 10.1016/0005-2795(76)90106-9; NEXO E, 1977, BIOCHIM BIOPHYS ACTA, V494, P395, DOI 10.1016/0005-2795(77)90168-4; NEXO E, 1980, BIOCHIM BIOPHYS ACTA, V628, P190, DOI 10.1016/0304-4165(80)90366-9; NEXO E, 1981, SCAND J CLIN LAB INV, V41, P465, DOI 10.3109/00365518109090484; NEXO E, 1998, VITAMIN B12 B12 PROT, P461, DOI DOI 10.1002/9783527612192.CH30; NEXO E, 1990, BIOMEDICINE PHYSL VI, P353; NICOLAS JP, 1995, BAILLIERE CLIN HAEM, V8, P515, DOI 10.1016/S0950-3536(05)80219-7; PLATICA O, 1991, J BIOL CHEM, V266, P7860; QUADROS EV, 1986, J BIOL CHEM, V261, P5455; Quadros EV, 1996, BIOCHEM BIOPH RES CO, V222, P149, DOI 10.1006/bbrc.1996.0713; QUADROS EV, 1993, BLOOD, V81, P1239; Rasmussen JT, 1998, EUR J BIOCHEM, V257, P488, DOI 10.1046/j.1432-1327.1998.2570488.x; ROTHENBERG SP, 1995, BAILLIERE CLIN HAEM, V8, P499, DOI 10.1016/S0950-3536(05)80218-5; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; STUPPERICH E, 1991, EUR J BIOCHEM, V199, P299, DOI 10.1111/j.1432-1033.1991.tb16124.x; TANG LH, 1992, J BIOL CHEM, V267, P22982; VANKAPEL J, 1981, BIOCHIM BIOPHYS ACTA, V676, P307, DOI 10.1016/0304-4165(81)90164-1	41	30	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26015	26020		10.1074/jbc.274.37.26015	http://dx.doi.org/10.1074/jbc.274.37.26015			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473547	hybrid, Green Published			2022-12-25	WOS:000082469700013
J	Hagerhall, C; Magnitsky, S; Sled, VD; Schroder, I; Gunsalus, RP; Cecchini, G; Ohnishi, T				Hagerhall, C; Magnitsky, S; Sled, VD; Schroder, I; Gunsalus, RP; Cecchini, G; Ohnishi, T			An Escherichia coli mutant quinol : fumarate reductase contains an EPR-detectable semiquinone stabilized at the proximal quinone-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINATE-UBIQUINONE REDUCTASE; BACILLUS-SUBTILIS SUCCINATE; CYTOCHROME-B; 3FE-4S CLUSTER; PARACOCCUS-DENITRIFICANS; MENAQUINONE REDUCTASE; UBISEMIQUINONE; DEHYDROGENASE; COMPLEX; DOMAIN	The EPR and thermodynamic properties of semiquinone (SQ) species stabilized by mammalian succinate: quinone reductase (SQR) in situ in the mitochondrial membrane and in the isolated enzyme have been well documented. The equivalent semiquinones in bacterial membranes have not yet been characterized, either in SQR or quinol:fumarate reductase (QFR) in situ, In this work, we describe an EPR-detectable QFR semiquinone using Escherichia coli mutant QFR (FrdC E29L) and the wild-type enzyme. The SQ exhibits a g = 2.005 signal with a peak-to-peak line width of similar to 1.1 milliteslas at 150 K, has a midpoint potential (E-m(pH 7.2)) of -56.6 mV, and has a stability constant of similar to 1.2 x 10(-2) at pH 7.2, It shows extremely fast spin relaxation behavior with a P-1/2 value of much greater than 500 milliwatts at 150 K, which closely resembles the previously described SQ species (SQ,) in mitochondrial SQR, This SQ species seems to be present also in wildtype QFR, but its stability constant is much lower, and its signal intensity is near the EPR detection limit around neutral pH. In contrast to mammalian SQR, the membrane anchor of E. coli QFR lacks heme; thus, this prosthetic group can be excluded as a spin relaxation enhancer. The trinuclear iron-sulfur cluster FR3 in the [3Fe-4S](1+) state is suggested as the dominant spin relaxation enhancer of the SQ(FR) spins in this enzyme. E, coli QFR activity and the fast relaxing SQ species observed in the mutant enzyme are sensitive to the inhibitor 2-n-heptyl-4-hydroxyquinoline N-oxide (HQNO). In wildtype E. coli QFR, HQNO causes EPR spectral line shape perturbations of the iron-sulfur cluster FR3, Similar spectral line shape changes of FR3 are caused by the FrdC E29L mutation, without addition of HQNO, This indicates that the SQ and the inhibitor-binding sites are located in close proximity to the trinuclear iron-sulfur cluster FR3, The data further suggest that this site corresponds to the proximal quinone-binding site in E. coli QFR.	Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Calif Berkeley, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of Pennsylvania; University of California System; University of California Berkeley; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Ohnishi, T (corresponding author), Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.	Ohnishi@mail.med.upenn.edu			NHLBI NIH HHS [HL-16251] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; BLAUT M, 1989, J BIOL CHEM, V264, P13599; BROOMFIELD PLE, 1992, CURR GENET, V22, P117, DOI 10.1007/BF00351470; CECCHINI G, 1986, P NATL ACAD SCI USA, V83, P8898, DOI 10.1073/pnas.83.23.8898; CROWE BA, 1983, EUR J BIOCHEM, V137, P191, DOI 10.1111/j.1432-1033.1983.tb07814.x; DEGLIESPOSTI M, 1989, BIOCHIM BIOPHYS ACTA, V977, P249; Dutton P L, 1978, Methods Enzymol, V54, P411; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P723, DOI 10.1021/bi00169a014; HAGERHALL C, 1995, BIOCHEMISTRY-US, V34, P11080; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; HAGERHALL C, 1995, BBA-BIOENERGETICS, V1229, P356, DOI 10.1016/0005-2728(95)00023-C; HAGERHALL C, 1994, THESIS U LUND LUND; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; INGLEDEW WJ, 1977, BIOCHEM J, V164, P617, DOI 10.1042/bj1640617; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Janssen S, 1997, J BACTERIOL, V179, P5560, DOI 10.1128/jb.179.17.5560-5569.1997; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsson M, 1998, ARCH MICROBIOL, V170, P27, DOI 10.1007/s002030050611; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; MOWERY PC, 1977, ARCH BIOCHEM BIOPHYS, V178, P495, DOI 10.1016/0003-9861(77)90220-X; MOWERY PC, 1976, BIOCHEM BIOPH RES CO, V71, P354, DOI 10.1016/0006-291X(76)90290-4; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; PACE CP, 1991, ARCH BIOCHEM BIOPHYS, V287, P97, DOI 10.1016/0003-9861(91)90393-W; PADDOCK ML, 1989, P NATL ACAD SCI USA, V86, P6602, DOI 10.1073/pnas.86.17.6602; PAPAEFTHYMIOU V, 1987, J AM CHEM SOC, V109, P4703, DOI 10.1021/ja00249a037; RICH PR, 1977, BIOCHIM BIOPHYS ACTA, V462, P501, DOI 10.1016/0005-2728(77)90097-4; RICH PR, 1978, BIOCHIM BIOPHYS ACTA, V504, P345, DOI 10.1016/0005-2728(78)90059-2; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; Rothery RA, 1998, EUR J BIOCHEM, V254, P588, DOI 10.1046/j.1432-1327.1998.2540588.x; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; SALERNO JC, 1980, BIOCHEM J, V192, P769, DOI 10.1042/bj1920769; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; SMIRNOVA IA, 1995, FEBS LETT, V359, P23, DOI 10.1016/0014-5793(94)01442-4; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H; Waldeck AR, 1997, J BIOL CHEM, V272, P19373, DOI 10.1074/jbc.272.31.19373; WERTH MT, 1990, P NATL ACAD SCI USA, V87, P8965, DOI 10.1073/pnas.87.22.8965; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; XU Y, 1987, BIOCHEM BIOPH RES CO, V144, P315, DOI 10.1016/S0006-291X(87)80512-0; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; YU CA, 1982, J BIOL CHEM, V257, P6127	49	35	36	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26157	26164		10.1074/jbc.274.37.26157	http://dx.doi.org/10.1074/jbc.274.37.26157			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473567	hybrid			2022-12-25	WOS:000082469700033
J	Homolya, L; Watt, WC; Lazarowski, ER; Koller, BH; Boucher, RC				Homolya, L; Watt, WC; Lazarowski, ER; Koller, BH; Boucher, RC			Nucleotide-regulated calcium signaling in lung fibroblasts and epithelial cells from normal and P2Y(2) receptor (-/-) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; EXTRACELLULAR ATP; CYSTIC-FIBROSIS; PHARMACOLOGICAL SELECTIVITY; ADENOSINE RECEPTORS; MOLECULAR-CLONING; MOUSE FIBROBLASTS; FLUID TRANSPORT; EXOGENOUS ATP; EXPRESSION	To test for the role of the P2Y(2) receptor (P2Y(2)-R) in the regulation of nueleotide-promoted Ca2+ signaling in the lung, we generated P2Y(2)-R-deficient (P2Y(2)-R(-/-)) mice and measured intracellular Ca-i(2+) responses (Delta Ca-i(2+)) to nucleotides in cultured lung fibroblasts and nasal and tracheal epithelial cells from wild type and P2Y(2)-R(-/-) mice. In the wild type fibroblasts, the rank order of potencies for nucleotide-induced Delta Ca-i(2+) was as follows: UTP greater than or equal to ATP much greater than ADP > UDP. The responses induced by these agonists were completely absent in the P2Y(2)-R(-/-) fibroblasts. Inositol phosphate responses paralleled those of Delta Ca-i(2+) in both groups. ATP and UTP also induced Ca-i(2+) responses in wild type airway epithelial cells. In the P2Y(2)-R(-/-) airway epithelial cells, UTP was ineffective, A small fraction (25%) of the ATP response persisted. Adenosine(-) and alpha,beta-methylene ATP were ineffective, and ATP responses were not affected by adenosine deaminase or by removal of extracellular Ca-i(2+) indicating that neither P1 nor P2X receptors mediated this residual ATP response. In contrast, 2-methylthio-ADP promoted a substantial Ca-i(2+) response in P2Y(2)-R(-/-) cells, which was inhibited by the P2Y(1) receptor antagonist adenosine 3'-5'-diphosphate. These studies demonstrate that P2Y(2)-R is the dominant purinoceptor in airway epithelial cells, which also express a P2Y(1) receptor, and that the P2Y(2)-R is the sole purinergic receptor subtype mediating nucleotide-induced inositol lipid hydrolysis and Ca2+ mobilization in mouse lung fibroblasts.	Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Hungarian Acad Sci, Natl Inst Haematol & Immunol, Membrane Res Grp, H-1113 Budapest, Hungary	University of North Carolina; University of North Carolina Chapel Hill; Hungarian Academy of Sciences	Boucher, RC (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, CB 7248,7011 Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.		Homolya, Laszlo/N-1154-2016	Homolya, Laszlo/0000-0003-1639-8140	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058554, P01HL034322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051791] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58554, HL34322] Funding Source: Medline; NIDDK NIH HHS [DK51791] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENALI R, 1994, AM J RESP CELL MOL, V10, P363, DOI 10.1165/ajrcmb.10.4.8136152; Bogdanov YD, 1998, BRIT J PHARMACOL, V124, P428, DOI 10.1038/sj.bjp.0701880; Boyer JL, 1996, MOL PHARMACOL, V50, P1323; BROWN HA, 1991, MOL PHARMACOL, V40, P648; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; DAVIS CW, 1992, AM J PHYSIOL, V262, pC1313, DOI 10.1152/ajpcell.1992.262.5.C1313; ERB L, 1990, J BIOL CHEM, V265, P7424; Evans RJ, 1998, P2 NUCLEOTIDE RECEPT, P43; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; FINE J, 1989, BIOCHEM J, V263, P371, DOI 10.1042/bj2630371; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; GEARY CA, 1995, AM J PHYSIOL-LUNG C, V268, pL1021, DOI 10.1152/ajplung.1995.268.6.L1021; GIOVANNARDI S, 1992, EXP CELL RES, V202, P398, DOI 10.1016/0014-4827(92)90092-M; GONZALEZ FA, 1989, BIOCHEM BIOPH RES CO, V164, P706, DOI 10.1016/0006-291X(89)91517-9; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; GUBITS RM, 1990, MOL BRAIN RES, V8, P275, DOI 10.1016/0169-328X(90)90040-K; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; JIANG CW, 1993, SCIENCE, V262, P424, DOI 10.1126/science.8211164; JOSEPH J, 1988, EXP CELL RES, V176, P1, DOI 10.1016/0014-4827(88)90115-2; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; LAZAROWSKI ER, 1992, BRIT J PHARMACOL, V106, P774, DOI 10.1111/j.1476-5381.1992.tb14412.x; LETHEM MI, 1993, AM J RESP CELL MOL, V9, P315, DOI 10.1165/ajrcmb/9.3.315; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; OKADA Y, 1984, EXP CELL RES, V152, P552, DOI 10.1016/0014-4827(84)90657-8; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; PIZZO P, 1992, J IMMUNOL, V149, P3372; RATHBONE MP, 1992, IN VITRO CELL DEV-AN, V28A, P529; ROZENGURT E, 1982, EXP CELL RES, V139, P71, DOI 10.1016/0014-4827(82)90319-6; Schachter JB, 1997, BRIT J PHARMACOL, V121, P338, DOI 10.1038/sj.bjp.0701136; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; Tepel M, 1996, BBA-MOL CELL RES, V1312, P145, DOI 10.1016/0167-4889(96)00035-3; TOKUYAMA Y, 1995, BIOCHEM BIOPH RES CO, V211, P211, DOI 10.1006/bbrc.1995.1798; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Webb TE, 1998, J NEUROCHEM, V71, P1348; ZEISKE W, 1978, BIOCHIM BIOPHYS ACTA, V509, P218, DOI 10.1016/0005-2736(78)90042-1; [No title captured]	45	120	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26454	26460		10.1074/jbc.274.37.26454	http://dx.doi.org/10.1074/jbc.274.37.26454			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473605	Green Published, hybrid			2022-12-25	WOS:000082469700071
J	Jaburek, M; Varecha, M; Gimeno, RE; Dembski, M; Jezek, P; Zhang, MB; Burn, P; Tartaglia, LA; Garlid, KD				Jaburek, M; Varecha, M; Gimeno, RE; Dembski, M; Jezek, P; Zhang, MB; Burn, P; Tartaglia, LA; Garlid, KD			Transport function and regulation of mitochondrial uncoupling proteins 2 and 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; NUCLEOTIDE-BINDING-SITE; PROTON TRANSPORT; H+ TRANSPORT; CARRIER; ACID; RECONSTITUTION; IDENTIFICATION; THERMOGENESIS; EXPRESSION	Uncoupling protein 1 (UCP1) dissipates energy and generates heat by catalyzing back-flux of protons into the mitochondrial matrix, probably by a fatty acid cycling mechanism. If the newly discovered UCP2 and UCP3 function similarly, they will enhance peripheral energy expenditure and are potential molecular targets for the treatment of obesity. We expressed UCP2 and UCP3 in Escherichia coli and reconstituted the detergent-extracted proteins into liposomes, Ion flux studies show that purified UCP2 and UCP3 behave identically to UCP1, They catalyze electrophoretic flux of protons and alkylsulfonates, and proton flux exhibits an obligatory requirement for fatty acids. Proton flux is inhibited by purine nucleotides but with much lower affinity than observed with UCP1, These findings are consistent with the hypothesis that UCP2 and UCP3 behave as uncoupling proteins in the cell.	Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA; Acad Sci Czech Republ, Inst Physiol, CZ-14220 Prague, Czech Republic; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA; Hoffmann La Roche Inc, Dept Metab Dis, Nutley, NJ 07110 USA	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Roche Holding	Garlid, KD (corresponding author), Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	garlid@bmb.ogi.edu	Jezek, Petr/B-9264-2012; Varecha, Miroslav/H-4190-2014; Varecha, Miroslav/P-4205-2019; Jaburek, Martin/B-9652-2012; Jabůrek, Martin/H-1114-2019	Jezek, Petr/0000-0002-2720-9395; Varecha, Miroslav/0000-0002-0236-4241; Jabůrek, Martin/0000-0002-4357-1116; Garlid, Keith/0000-0002-6777-1235	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56273] Funding Source: Medline; NIGMS NIH HHS [GM31086] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; Bienengraeber M, 1998, BIOCHEMISTRY-US, V37, P3, DOI 10.1021/bi972463w; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; GARLID KD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P151, DOI 10.1016/0005-2728(90)90237-X; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Garlid KD, 1999, BIOPHYS J, V76, pA1; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P6199; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; HAMILTON JA, 1986, P NATL ACAD SCI USA, V83, P82, DOI 10.1073/pnas.83.1.82; HUANG SG, 1995, BIOCHEMISTRY-US, V34, P349, DOI 10.1021/bi00001a043; JEZEK P, 1990, J BIOL CHEM, V265, P19303; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jezek P, 1996, J BIOL CHEM, V271, P32743, DOI 10.1074/jbc.271.51.32743; JEZEK P, 1990, J BIOL CHEM, V265, P10522; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; LANOUE KF, 1986, J BIOL CHEM, V261, P298; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; MAYINGER P, 1992, BIOCHEMISTRY-US, V31, P10536, DOI 10.1021/bi00158a017; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Modriansky M, 1997, J BIOL CHEM, V272, P24759, DOI 10.1074/jbc.272.40.24759; MURDZAINGLIS DL, 1994, J BIOL CHEM, V269, P7435; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OROSZ DE, 1993, ANAL BIOCHEM, V210, P7, DOI 10.1006/abio.1993.1143; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; STRIELEMAN PJ, 1985, J BIOL CHEM, V260, P3402; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WINKLER E, 1992, EUR J BIOCHEM, V203, P295, DOI 10.1111/j.1432-1033.1992.tb19859.x; Winkler E, 1997, BIOCHEMISTRY-US, V36, P148, DOI 10.1021/bi962178x	36	279	286	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26003	26007		10.1074/jbc.274.37.26003	http://dx.doi.org/10.1074/jbc.274.37.26003			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473545	hybrid			2022-12-25	WOS:000082469700011
J	Park, GT; Morasso, MI				Park, GT; Morasso, MI			Regulation of the Dlx3 homeobox gene upon differentiation of mouse keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; ETS TRANSCRIPTION FACTORS; DISTAL-LESS GENE; NF-Y; PROXIMAL PROMOTER; EPITHELIAL-CELLS; EPIDERMAL DIFFERENTIATION; MAMMALIAN EPIDERMIS; HOMEODOMAIN GENE; AP-1 ELEMENT	The Distal-less Dlx3 homeodomain gene is expressed in terminally differentiated murine epidermal cells, and there is evidence to support an essential role as a transcriptional regulator of the terminal differentiation process in these cells. In an attempt to determine the factors that induce Dlx3 gene expression, we have cloned the 19-kilobase pair proximal region of murine gene and analyzed its cis-regulatory elements and potential trans-acting factors. The proximal region of the Dlx3 gene has a canonical TATA box and CCAAT box, and the transcription start site was located 205 base pairs upstream from the initiation of translation site. Serial deletion analysis showed that the region between -84 and -34 confers the maximal promoter activity both in undifferentiated and differentiated primary mouse keratinocytes. Gel retardation assays and mutational analysis demonstrated that the transcriptional regulator NF-Y (also referred to as CBF) binds to a CCAAT box motif within this region and is responsible for the majority of the Dlx3 promoter activity. In addition, an Sp1-binding site was located immediately upstream of transcription start site that acts as a positive regulatory element of the Dlx3 promoter, independent of the CCAAT box motif. Importantly, elements residing between +30 to +60 of the Dlx3 gene are responsible for the Ca2+-dependent induction of Dlx3 during keratinocyte differentiation.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Morasso, MI (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 6,Rm 134, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041124] Funding Source: NIH RePORTER; NIAMS NIH HHS [Z01 AR041124-06] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Blumenberg Miroslav, 1993, P1; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Darne CH, 1997, MOL CELL ENDOCRINOL, V132, P13, DOI 10.1016/S0303-7207(97)00116-0; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Eggers A, 1998, J BIOL CHEM, V273, P18499, DOI 10.1074/jbc.273.29.18499; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; Feledy JA, 1999, NUCLEIC ACIDS RES, V27, P764, DOI 10.1093/nar/27.3.764; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HINKLEY C, 1992, MOL CELL BIOL, V12, P4400, DOI 10.1128/MCB.12.10.4400; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Lamb KA, 1997, MOL REPROD DEV, V48, P301; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; Lee JH, 1996, J BIOL CHEM, V271, P4561; Li N, 1998, J BIOL CHEM, V273, P16104, DOI 10.1074/jbc.273.26.16104; LU B, 1994, J BIOL CHEM, V269, P7443; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; Morasso MI, 1997, MAMM GENOME, V8, P302, DOI 10.1007/s003359900427; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; MORASSO MI, 1995, P NATL ACAD SCI USA, V92, P3968, DOI 10.1073/pnas.92.9.3968; MORASSO MI, 1994, DEV BIOL, V162, P267, DOI 10.1006/dbio.1994.1084; MORIUCHI H, 1995, VIROLOGY, V214, P256, DOI 10.1006/viro.1995.9932; Nakamura S, 1996, GENOMICS, V38, P314, DOI 10.1006/geno.1996.0634; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; Price JA, 1998, HUM MOL GENET, V7, P563, DOI 10.1093/hmg/7.3.563; PUNNONEN K, 1993, J INVEST DERMATOL, V101, P719, DOI 10.1111/1523-1747.ep12371682; Quinn LM, 1997, GENE, V187, P55, DOI 10.1016/S0378-1119(96)00706-8; REITH W, 1994, J BIOL CHEM, V269, P20020; ROBINSON GW, 1991, NEW BIOL, V3, P1183; ROBINSON GW, 1994, MECH DEVELOP, V48, P199, DOI 10.1016/0925-4773(94)90060-4; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SIMEONE A, 1994, P NATL ACAD SCI USA, V91, P2250, DOI 10.1073/pnas.91.6.2250; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Ueda A, 1998, J BIOL CHEM, V273, P19339, DOI 10.1074/jbc.273.30.19339; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	64	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26599	26608		10.1074/jbc.274.37.26599	http://dx.doi.org/10.1074/jbc.274.37.26599			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473625	Green Accepted, hybrid			2022-12-25	WOS:000082469700091
J	Toledano-Katchalski, H; Elson, A				Toledano-Katchalski, H; Elson, A			The transmembranal and cytoplasmic forms of protein tyrosine phosphatase epsilon physically associate with the adaptor molecule Grb2	ONCOGENE			English	Article						breast cancer; phosphatase; SH2 domain; Jurkat; T-cell receptor	T-CELL ACTIVATION; RECEPTOR SIGNAL-TRANSDUCTION; V-HA-RAS; PHOSPHOTYROSINE PHOSPHATASES; HEMATOPOIETIC-CELLS; CATALYTIC DOMAINS; KINETIC-ANALYSIS; TRANSGENIC MICE; EGF RECEPTOR; SH3 DOMAINS	The protein tyrosine phosphatase Epsilon (PTP epsilon) gene gives rise to two physiologically-distinct protein products-a transmembranal, receptor-like form and a cytoplasmic, non-receptor form. Previous studies have suggested a link between expression of transmembranal PTP epsilon and transformation of mouse mammary epithelium specifically by ras or neu, although little is known about the underlying molecular mechanisms; cytoplasmic PTP epsilon is believed to function mainly in hematopoietic tissues. As part of our efforts to understand PTP epsilon function at the molecular level, we demonstrate here that both forms of PTP epsilon associate with the adaptor molecule Grb2 in vivo. Binding is mediated by the SH2 domain of Grb2; this domain binds exclusively to the carboxy-terminal phosphotyrosine of cytoplasmic PTP epsilon(Y638), and probably to additional phosphotyrosine. residues in transmembranal PTP epsilon. Through its SH2 domain, Grb2 can constitutively associate with transmembranal PTP epsilon in mammary tumors initiated by ras or neu, and can be induced to associate with cytoplasmic PTP epsilon in Jurkat T-cells following stimulation of T-cell receptor signaling by pervanadate. These findings indicate that tyrosine phosphorylation of PTP epsilon and subsequent binding to Grb may link this phosphatase to downstream events which transduce signals from the cell membrane to its interior.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		Toledano, Hila/AGY-6574-2022	Elson, Ari/0000-0001-9808-9135				Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; Elson A, 1996, GENOMICS, V31, P373, DOI 10.1006/geno.1996.0061; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; HAO L, 1997, J BIOL CHEM, V272, P29332; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; IMBODEN JB, 1995, CURR BIOL, V5, P727, DOI 10.1016/S0960-9822(95)00145-X; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lee JM, 1996, ONCOGENE, V12, P253; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lim KL, 1997, EUR J BIOCHEM, V245, P693, DOI 10.1111/j.1432-1033.1997.00693.x; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Mukouyama Y, 1997, MOL BRAIN RES, V50, P230, DOI 10.1016/S0169-328X(97)00193-9; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SU J, 1994, J BIOL CHEM, V269, P18731; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Vogel W, 1996, CELL GROWTH DIFFER, V7, P1589; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994	50	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5024	5031		10.1038/sj.onc.1202883	http://dx.doi.org/10.1038/sj.onc.1202883			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490839				2022-12-25	WOS:000082497100002
J	Hiyama, H; Yokoi, M; Masutani, C; Sugasawa, K; Maekawa, T; Tanaka, K; Hoeijmakers, JHJ; Hanaoka, F				Hiyama, H; Yokoi, M; Masutani, C; Sugasawa, K; Maekawa, T; Tanaka, K; Hoeijmakers, JHJ; Hanaoka, F			Interaction of hHR23 with S5a - The ubiquitin-like domain of hHR23 mediates interaction with S5a subunit of 26 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN MCB1; REPAIR GENE RAD23; SACCHAROMYCES-CEREVISIAE; REGULATORY COMPLEX; MOLECULAR-CLONING; ATPASE SUBUNIT; HUMAN HOMOLOGS; DNA-REPAIR; XPC; EXPRESSION	hHR23B is one of two human homologs of the Saccharomyces cerevisiae nucleotide excision repair (NER) gene product RAD23 and a component of a protein complex that specifically complements the NER defect of xeroderma pigmentosum group C (XP-C) cell extracts in vitro. Although a small proportion of hHR23B is tightly complexed with the XP-C responsible gene product, XPC protein, a vast majority exists as an XPC-free form, indicating that hHR23B has additional functions other than NER in vivo. Here we demonstrate that the human NER factor hHR23B as well as another human homolog of RAD23, hHR23A, interact specifically with S5a, a subunit of the human 26 S proteasome using the yeast two-hybrid system. Furthermore, hHR23 proteins were detected with S5a at the position where 26 S proteasome sediments in glycerol gradient centrifugation of HeLa S100 extracts, intriguingly, hHR23B showed the inhibitory effect on the degradation of I-125-lysozyme in the rabbit reticulocyte lysate. hHR23 proteins thus appear to associate with 26 S proteasome in vivo. From co-precipitation experiments using several series of deletion mutants, we defined the domains in hHR23B and S5a that mediate this interaction. From these results, we propose that part of hHR23 proteins are involved in the proteolytic pathway in cells.	Osaka Univ, Inst Mol & Cellular Biol, Osaka 5650871, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Osaka 5650871, Japan; RIKEN, Cellular Physiol Lab, Wako, Saitama 3510198, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan; Erasmus Univ, Ctr Med Genet, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	Osaka University; Osaka University; RIKEN; Tokyo Metropolitan Institute of Medical Science; Erasmus University Rotterdam	Hanaoka, F (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamada Oka, Osaka 5650871, Japan.		Hoeijmakers, Jan/AAX-6972-2021; Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227; Yokoi, Masayuki/0000-0001-9727-0258				AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; Ferrell K, 1996, FEBS LETT, V381, P143, DOI 10.1016/0014-5793(96)00101-9; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P607; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; HARACSKA L, 1995, EUR J BIOCHEM, V231, P720, DOI 10.1111/j.1432-1033.1995.0720d.x; Haracska L, 1997, FEBS LETT, V412, P331, DOI 10.1016/S0014-5793(97)00808-9; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KOMINAMI K, 1995, EMBO J, V14, P3105, DOI 10.1002/j.1460-2075.1995.tb07313.x; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li L, 1997, MUTAT RES-DNA REPAIR, V383, P197, DOI 10.1016/S0921-8777(97)00002-5; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Masutani C, 1997, MOL CELL BIOL, V17, P6915, DOI 10.1128/MCB.17.12.6915; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; Pusch W, 1998, GENE, V207, P19, DOI 10.1016/S0378-1119(97)00599-4; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sugasawa K, 1997, MOL CELL BIOL, V17, P6924, DOI 10.1128/MCB.17.12.6924; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; TANAKA K, 1983, J CELL BIOL, V96, P1580, DOI 10.1083/jcb.96.6.1580; vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551; VanderSpek PJ, 1996, GENOMICS, V31, P20, DOI 10.1006/geno.1996.0004; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	34	218	228	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					28019	28025		10.1074/jbc.274.39.28019	http://dx.doi.org/10.1074/jbc.274.39.28019			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488153	Green Published, hybrid			2022-12-25	WOS:000082739100092
J	Jin, W; Huang, ESC; Bi, WQ; Cote, GJ				Jin, W; Huang, ESC; Bi, WQ; Cote, GJ			Redundant intronic repressors function to inhibit fibroblast growth factor receptor-1 alpha-exon recognition in glioblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT BINDING-PROTEIN; POLYPYRIMIDINE TRACT; SPLICING ENHANCERS; HUMAN ASTROCYTOMAS; ALTERNATIVE EXON; SUBSTANCE-P; IN-VITRO; RNA; SEQUENCE; SELECTION	The human fibroblast growth factor receptor-1 primary transcript is alternatively processed to produce receptor forms that vary in their affinity for fibroblast growth factor, The inclusion of a single exon (alpha) in normal brain glial cells produces a low affinity form of the receptor. Recognition of the alpha-exon is dysregulated during neoplastic transformation of glial cells to produce a high affinity receptor form. In this study, we have identified a second intronic repressor of RNA splicing located approximately 250 nucleotides upstream of the alpha-exon. Deletion or mutation of this sequence resulted in a significant increase in exon recognition in glioblastoma cells. This intronic repressor was found to share significant sequence homology with an intronic repressor element located downstream of the alpha-exon, The two repressor elements are functionally redundant in that they are capable of inhibiting alpha-exon recognition when positioned upstream or downstream of the exon, Finally, the elements were found to mediate enhanced exclusion of an unrelated exon, but only the repressors were placed flanking the exon, However, under these conditions, the cell-specific exon exclusion was no longer maintained. These results suggest that although the alpha-exon inclusion is actively repressed in glioblastomas, the absence of trans-activators appears to be key to the production of the high affinity form of fibroblast growth factor receptor-1 in glioblastomas.	Univ Texas, MD Anderson Canc Ctr, Dept Med Specialties, Sect Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Cote, GJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Endocrinol Sect, Box 15,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [2P30-CA16672, CA-67946] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA067946] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; Ashiya M, 1997, RNA, V3, P996; Bansal R, 1996, MOL CELL NEUROSCI, V7, P263, DOI 10.1006/mcne.1996.0020; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; CHAN RC, 1995, MOL CELL BIOL, V15, P6377; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Cote GJ, 1997, J BIOL CHEM, V272, P1054, DOI 10.1074/jbc.272.2.1054; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; Deshpande G, 1996, MOL CELL BIOL, V16, P5036; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; Gooding C, 1998, RNA, V4, P85; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; Jin W, 1999, CANCER RES, V59, P316; Jin W, 1998, J BIOL CHEM, V273, P16170, DOI 10.1074/jbc.273.26.16170; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAWAGUCHI Y, 1986, BIOCHEM BIOPH RES CO, V139, P1040, DOI 10.1016/S0006-291X(86)80282-0; KRAUSE JE, 1987, P NATL ACAD SCI USA, V84, P881, DOI 10.1073/pnas.84.3.881; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LOU H, 1995, MOL CELL BIOL, V15, P7135; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; Perez I, 1997, RNA, V3, P764; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Roberts GC, 1996, EMBO J, V15, P6301, DOI 10.1002/j.1460-2075.1996.tb01020.x; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; Si ZH, 1997, NUCLEIC ACIDS RES, V25, P861, DOI 10.1093/nar/25.4.861; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Southby J, 1999, MOL CELL BIOL, V19, P2699; Valcarcel J, 1997, CURR BIOL, V7, pR705, DOI 10.1016/S0960-9822(06)00361-7; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; Wentz MP, 1997, J VIROL, V71, P8542, DOI 10.1128/JVI.71.11.8542-8551.1997; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Zheng ZM, 1996, J VIROL, V70, P4691, DOI 10.1128/JVI.70.7.4691-4699.1996	40	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					28035	28041		10.1074/jbc.274.39.28035	http://dx.doi.org/10.1074/jbc.274.39.28035			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488155	hybrid			2022-12-25	WOS:000082739100094
J	Li, JS; Tong, SP; Wands, JR				Li, JS; Tong, SP; Wands, JR			Identification and expression of glycine decarboxylase (p120) as a duck hepatitis B virus pre-S envelope-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVERLAP EXTENSION; CLEAVAGE SYSTEM; MAMMALIAN-CELLS; INITIATION; TRANSLATION; GENE; PARTICLES; VICTORIN; CHICKEN; EPITOPE	A 120-kilodalton protein (p120) was identified in the duck liver that binds to several truncated versions of duck hepatitis B virus (DHBV) pre-S envelope protein, suggesting p120 may serve as a DHBV co-receptor. The amino acid sequences of tryptic peptides from purified p120 were found to be the duck p protein of the glycine decarboxylase complex (DGD). DGD cDNA cloning revealed extensive protein conservation with the chicken homologue except for several insertions in the N-terminal leader sequence. The DGD cDNA contained no in-frame AUG codon at the predicted initiation site of the open reading frame, and site directed mutagenesis experiments established an AUU codon as the translational initiator. The DGD protein expressed in rabbit reticulocyte lysates bound truncated DHBV pre-S protein identical to that of p120 derived from duck liver confirming DGD as p120. Moreover, transfection studies in liver- and kidney derived cells revealed both cell surface and cytoplasmic expression of the protein. Cloning of the glycine decarboxylase cDNA will permit a direct test of whether it functions as a cell surface co-receptor or as a co-factor in the DHBV replication cycles.	Massachusetts Gen Hosp, Ctr Canc, Mol Hepatol Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Wands, JR (corresponding author), Liver Res Ctr, 55 Claverick St,4th Floor, Providence, RI 02903 USA.				NATIONAL CANCER INSTITUTE [R01CA035711, R37CA035711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA002666, R37AA002666] Funding Source: NIH RePORTER; NCI NIH HHS [CA-35711] Funding Source: Medline; NIAAA NIH HHS [AA-02666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		CHALUT C, 1995, GENE, V156, P43, DOI 10.1016/0378-1119(95)00034-4; CHASSOT S, 1993, VIROLOGY, V192, P217, DOI 10.1006/viro.1993.1024; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Ganem D., 1996, FIELDS VIROLOGY, V3rd; GOLDERER G, 1995, J BACTERIOL, V177, P5994, DOI 10.1128/jb.177.20.5994-5996.1995; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KUME A, 1991, J BIOL CHEM, V266, P3323; KURE S, 1991, J BIOL CHEM, V266, P3330; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; KUROKI K, 1994, J VIROL, V68, P2091, DOI 10.1128/JVI.68.4.2091-2096.1994; LAMBERT V, 1990, J VIROL, V64, P1290, DOI 10.1128/JVI.64.3.1290-1297.1990; Li JS, 1996, J VIROL, V70, P6029, DOI 10.1128/JVI.70.9.6029-6035.1996; MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NAVARRE DA, 1995, PLANT CELL, V7, P463, DOI 10.1105/tpc.7.4.463; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Schmitz J, 1996, NUCLEIC ACIDS RES, V24, P257, DOI 10.1093/nar/24.2.257; TONG SP, 1995, J VIROL, V69, P7106, DOI 10.1128/JVI.69.11.7106-7112.1995; TONG SP, 1991, J MED VIROL, V35, P228, DOI 10.1002/jmv.1890350403; WOLPERT TJ, 1994, PLANT CELL, V6, P1145, DOI 10.1105/tpc.6.8.1145; YOSHIDA T, 1973, J BIOCHEM-TOKYO, V73, P1013, DOI 10.1093/oxfordjournals.jbchem.a130155	22	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27658	27665		10.1074/jbc.274.39.27658	http://dx.doi.org/10.1074/jbc.274.39.27658			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488106	hybrid			2022-12-25	WOS:000082739100045
J	Tanabe, M; Sasai, N; Nagata, K; Liu, XD; Liu, PCC; Thiele, DJ; Nakai, A				Tanabe, M; Sasai, N; Nagata, K; Liu, XD; Liu, PCC; Thiele, DJ; Nakai, A			The mammalian HSF4 gene generates both an activator and a repressor of heat shock genes by alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; NUCLEAR-LOCALIZATION; FACTOR-II; IN-VIVO; TRANSACTIVATION DOMAIN; ERYTHROLEUKEMIA-CELLS; LEUCINE-ZIPPER; EXPRESSION; HSP70	The expression of heat shock genes is controlled at the level of transcription by members of the heat shock transcription factor family in vertebrates. HSF4 is a mammalian factor characterized by its lack of a suppression domain that modulates formation of DNA-binding homotrimer. Here, we have determined the exon structure of the human HSF4 gene and identified a major new isoform, HSF4b, derived by alternative RNA splicing events, in addition to a previously reported HSF4a isoform. In mouse tissues HSF4b mRNA was more abundant than HSF4a as examined by reverse transcription-polymerase chain reaction, and its protein was detected in the brain and lung. Although both mouse HSF4a and HSF4b form trimers in the absence of stress, these two isoforms exhibit different transcriptional activity; HSF4a acts as an inhibitor of the constitutive expression of heat shock genes, and hHSF4b acts as a transcriptional activator. Furthermore HSF4b but not HSF4a complements the viability defect of yeast cells lacking HSF. Moreover, heat shock. and other stresses stimulate transcription of target genes by HSF4b in both yeast and mammalian cells. These results suggest that differential splicing of HSF4 mRNA gives rise to both an inhibitor and activator of tissue-specific heat shock gene expression.	Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cell Biol, Sakyo Ku, Kyoto 6068397, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	Kyoto University; Japan Science & Technology Agency (JST); University of Michigan System; University of Michigan	Nakai, A (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cell Biol, Sakyo Ku, Kyoto 6068397, Japan.	nakai@frontier.kyoto-u.ac.jp		Sasai, Noriaki/0000-0003-0360-1138	NIGMS NIH HHS [GM18858] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHIU CP, 1984, CELL, V37, P879, DOI 10.1016/0092-8674(84)90423-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; FIORENZA MT, 1995, NUCLEIC ACIDS RES, V23, P467, DOI 10.1093/nar/23.3.467; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; GOODSON ML, 1995, BIOCHEM BIOPH RES CO, V211, P943, DOI 10.1006/bbrc.1995.1903; GOODSON ML, 1995, MOL CELL BIOL, V15, P5288; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HALLADAY JT, 1995, MOL CELL BIOL, V15, P4890; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Koch KA, 1996, MOL CELL BIOL, V16, P724; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; Leppa S, 1997, J BIOL CHEM, V272, P15293, DOI 10.1074/jbc.272.24.15293; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MORIMORO RI, 1994, BIOL HEAT SHOCK PROT; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; Nakai A, 1999, CELL STRESS CHAPERON, V4, P86, DOI 10.1379/1466-1268(1999)004<0086:NAITVH>2.3.CO;2; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; Never L, 1996, CELL STRESS CHAPERON, V1, P215, DOI 10.1379/1466-1268(1996)001<0215:THWCAP>2.3.CO;2; Newton EM, 1996, MOL CELL BIOL, V16, P839; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; Orosz A, 1996, MOL CELL BIOL, V16, P7018; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; Remacle JE, 1997, EMBO J, V16, P5722, DOI 10.1093/emboj/16.18.5722; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; Tanabe M, 1998, EMBO J, V17, P1750, DOI 10.1093/emboj/17.6.1750; Tanabe M, 1997, J BIOL CHEM, V272, P15389, DOI 10.1074/jbc.272.24.15389; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wisniewski J, 1996, NUCLEIC ACIDS RES, V24, P367, DOI 10.1093/nar/24.2.367; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Xia WL, 1998, J BIOL CHEM, V273, P8749, DOI 10.1074/jbc.273.15.8749; Zandi E, 1997, GENE DEV, V11, P1299, DOI 10.1101/gad.11.10.1299; Zhong M, 1998, MOL CELL, V2, P101, DOI 10.1016/S1097-2765(00)80118-5; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	69	122	131	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27845	27856		10.1074/jbc.274.39.27845	http://dx.doi.org/10.1074/jbc.274.39.27845			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488131	hybrid			2022-12-25	WOS:000082739100070
J	Yu, R; Lei, W; Mandlekar, S; Weber, MJ; Der, CJ; Wu, J; Kong, ANT				Yu, R; Lei, W; Mandlekar, S; Weber, MJ; Der, CJ; Wu, J; Kong, ANT			Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; YA-SUBUNIT GENE; ANTIOXIDANT RESPONSE ELEMENT; NAD(P)H-QUINONE OXIDOREDUCTASE GENE; PHENOLIC ANTIOXIDANTS; TRANSCRIPTIONAL REGULATION; INDUCIBLE EXPRESSION; MAP KINASE; PROTECTIVE ENZYMES; SIGNALING PATHWAY	Mitogen-activated protein kinase (MAPK) cascades are activated by diverse extracellular signals and participate in the regulation of an array of cellular programs. In this study, we investigated the roles of MAPKs in the induction of phase II detoxifying enzymes by chemicals. Treatment of human hepatoma (HepG2) and murine hepatoma (Hepalclc7) cells with tert-butylhydroquinone (tBHQ) or sulforaphane (SUL), two potent phase II enzyme inducers, stimulated the activity of extracellular signal-regulated protein kinase 2 (ERK2) but not c-Jun N-terminal kinase 1. tBHQ and SUL also activated MAPK kinase. Inhibition of MAPK kinase with its inhibitor, PD98059, abolished ERK2 activation and impaired the induction of quinone reductase, a phase II detoxifying enzyme, and antioxidant response element (ARE)-linked reporter gene by tBHQ and SUL. Overexpression of a dominant-negative mutant of ERK2 also attenuated tBHQ and SUL induction of ARE reporter gene activity. Interestingly, although expression of Ras and its mutant forms showed distinct effects on basal ARE reporter gene activity, they did not affect the activation of reporter gene by the inducers. Furthermore, a dominant-negative mutant of Pas had little effect on ERK2 activation by tBHQ and SUL, implicating a Ras-independent mechanism. Indeed, both tBHQ and SUL were able to stimulate Raf-1 kinase activity in vivo as well as in vitro. Thus, our results indicate that the induction of ARE-dependent phase II detoxifying enzymes is mediated by a MAPK pathway, which may involve direct activation of Raf-1 by the inducers.	Univ Illinois, Coll Pharm, Ctr Pharmaceut Biotechnol, Dept Pharmaceut & Phamacodynam, Chicago, IL 60612 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ S Florida, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Kong, ANT (corresponding author), Univ Illinois, Coll Pharm, Ctr Pharmaceut Biotechnol MC870, Dept Pharmaceut & Phamacodynam, 900 S Ashland Ave,MBRB Rm 3102, Chicago, IL 60607 USA.		Kong, Ah-Ng Tony/AAX-2828-2020	Der, Channing/0000-0002-7751-2747	NCI NIH HHS [R01-CA73647] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ainbinder E, 1997, EUR J BIOCHEM, V243, P49, DOI 10.1111/j.1432-1033.1997.0049a.x; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BENSON AM, 1978, CANCER RES, V38, P4486; BERGELSON S, 1994, ONCOGENE, V9, P565; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DICCIANNI MB, 1992, NUCLEIC ACIDS RES, V20, P5153, DOI 10.1093/nar/20.19.5153; DROBNICA C, 1976, PROTEIN STRUCTURE EV, P105; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; Gerhauser C, 1997, CANCER RES, V57, P272; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAYS JD, 1995, CRIT REV BIOCHEM MOL, V30, P445; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, PHARMACOGENETICS, V4, P1, DOI 10.1097/00008571-199402000-00001; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI Y, 1992, J BIOL CHEM, V267, P15097; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; PROCHASKA HJ, 1988, CANCER RES, V48, P4776; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; WANG B, 1994, BBA-GENE STRUCT EXPR, V1219, P645, DOI 10.1016/0167-4781(94)90223-2; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WATTENBERG LW, 1985, CANCER RES, V45, P1; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Yu R, 1997, J BIOL CHEM, V272, P28962, DOI 10.1074/jbc.272.46.28962; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399	48	260	265	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27545	27552		10.1074/jbc.274.39.27545	http://dx.doi.org/10.1074/jbc.274.39.27545			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488090	hybrid, Green Published			2022-12-25	WOS:000082739100029
J	Soufir, N; Moles, JP; Vilmer, C; Moch, C; Verola, O; Rivet, J; Tesniere, A; Dubertret, L; Basset-Seguin, N				Soufir, N; Moles, JP; Vilmer, C; Moch, C; Verola, O; Rivet, J; Tesniere, A; Dubertret, L; Basset-Seguin, N			P16UV mutations in human skin epithelial tumors	ONCOGENE			English	Article						INKA-ARF locus; p16 gene; p53 gene; Cdk4 gene; non melanoma skin cancers; tandem mutation	SQUAMOUS-CELL CARCINOMAS; P53 GENE-MUTATIONS; SUPPRESSOR GENE; INK4A LOCUS; ULTRAVIOLET-IRRADIATION; GERMLINE MUTATIONS; HUMAN CANCERS; CYCLE ARREST; CDKN2 GENE; MELANOMA	The p16 gene expresses two alternative transcripts (p16 alpha and p16 beta) involved in tumor suppression via the retinoblastoma (Rb) or p53 pathways. Disruption of these pathways can occur through inactivation of p16 or p53, or activating mutations of cyclin dependant kinase 4 gene (Cdk4). We searched for p16, Cdk4 and p53 gene mutations in 20 squamous cell carcinomas (SSCs), 1 actinic keratosis (AK), and 28 basal cell carcinomas (BCCs), using PCR-SSCP. A deletion and methylation analysis of p16 was also performed. Six different mutations (12%) were detected in exon 2 of p16 (common to p16 alpha and p16 beta), in five out of 21 squamous lesions (24%) (one AK and four SCCs) and one out of 28 BCCs (3.5%), These included four (66%) ultraviolet (UV)-type mutations (two tandems CC : GC to TT : AA transitions and two C : G to T : A transitions at dipyrimidic site) and two transversions, P53 mutations were present in 18 samples (37%), mostly of UV type. Of these, only two (one BCC and one AK) harboured simultaneously mutations of p16, but with no consequence on p16 beta transcript. Our data demonstrate for the first time the presence of p16 UV induced mutations in non melanoma skin cancer, particularly in the most aggressive SCC type, and support that p16 and p53 are involved in two independent pathways in skin carcinogenesis.	Hop St Louis, Inst Rech Peau, INSERM, U312, F-75010 Paris, France; IURC, Lab Dermatol Mol, Montpellier, France; Hop St Louis, Serv Anatomopathol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Basset-Seguin, N (corresponding author), Hop St Louis, Inst Rech Peau, INSERM, U312, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.		Molès, Jean-Pierre/M-2286-2017	Molès, Jean-Pierre/0000-0002-6863-6350; Moch, Clara/0000-0002-8674-3440				BASSETSEGUIN N, 1994, J INVEST DERMATOL, V103, pS102, DOI 10.1111/1523-1747.ep12399372; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Chang TG, 1997, BIOCHEM BIOPH RES CO, V230, P85, DOI 10.1006/bbrc.1996.5891; Chaubert P, 1996, MOL CELL PROBE, V10, P467, DOI 10.1006/mcpr.1996.0064; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; Enders GH, 1996, ONCOGENE, V12, P1239; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GRUIS NA, 1995, AM J PATHOL, V146, P1199; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Healy E, 1996, J INVEST DERMATOL, V107, P318, DOI 10.1111/1523-1747.ep12363118; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jares P, 1997, ONCOGENE, V15, P1445, DOI 10.1038/sj.onc.1201309; Kubo Y, 1997, BIOCHEM BIOPH RES CO, V232, P38, DOI 10.1006/bbrc.1997.6217; LAMB A, 1994, SCIENCE, V264, P436; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LIU Q, 1995, ONCOGENE, V10, P1061; LO KW, 1995, CANCER RES, V55, P2039; MAESTRO R, 1995, SCIENCE, V267, P15, DOI 10.1126/science.7809600; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOLES JP, 1993, ONCOGENE, V8, P583; Muzeau F, 1997, INT J CANCER, V72, P27, DOI 10.1002/(SICI)1097-0215(19970703)72:1<27::AID-IJC3>3.0.CO;2-6; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; NISHIGORI C, 1994, P NATL ACAD SCI USA, V91, P7189, DOI 10.1073/pnas.91.15.7189; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; POLLOCK PM, 1995, ONCOGENE, V11, P663; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; QUINN AG, 1994, CANCER RES, V54, P4756; Rehman I, 1996, ONCOGENE, V12, P2483; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; Wang XQ, 1996, CANCER RES, V56, P2510; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yang R, 1996, BIOCHEM BIOPH RES CO, V218, P254, DOI 10.1006/bbrc.1996.0045; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	48	85	87	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5477	5481		10.1038/sj.onc.1202915	http://dx.doi.org/10.1038/sj.onc.1202915			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498902				2022-12-25	WOS:000082718600013
J	Kern, P; Hussey, RE; Spoerl, R; Reinherz, EL; Chang, HC				Kern, P; Hussey, RE; Spoerl, R; Reinherz, EL; Chang, HC			Expression, purification, and functional analysis of murine ectodomain fragments of CD8 alpha alpha and CD8 alpha beta dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD8 CORECEPTOR FUNCTION; T-CELL DEVELOPMENT; CLASS-I MOLECULE; CRYSTAL-STRUCTURE; BETA-CHAIN; MONOCLONAL-ANTIBODIES; SURFACE EXPRESSION; H-2K(B) MOLECULE; LYMPHOCYTES-T; ACTIVATION	Soluble mouse CD8 alpha alpha and CD8 alpha beta dimers corresponding to the paired ectodomains (CD8(f)) or their respective component Ig-like domains (CD8) were expressed in Chinese hamster ovary cells or the glycosylation variant Lec3.2.8.1 cells as secreted proteins using a leucine zipper strategy. The affinity of CD8 alpha alpha(f) for H-2K(b) as measured by BIAcore revealed a similar to 65 mu M K-d, similar to that of CD8 alpha beta(f). Consistent with this result, CD8 alpha alpha(f) as well as CD8 alpha beta(f) blocked the effector function of N15 T cell receptor transgenic cytolytic T cells in a comparable, dose-dependent fashion. Furthermore, both Lec3.2.8.1-produced and Chinese hamster ovary-produced CD8 homodimers and heterodimers were active in the inhibition assay. These results suggest that the Ig-like domains of CD8 molecules are themselves sufficient to block the requisite transmembrane CD8-pMHC interaction between cytolytic T lymphocytes and target cells. Moreover, given the similarities in co-receptor affinities for pMHC, the findings suggest that the greater efficiency of CD8 alpha beta versus CD8 alpha alpha co-receptor function on T cells is linked to differences within their membrane-bound stalk regions and/or intracellular segments. As recently shown for sCD8 alpha alpha, the yield, purity and homogeneity of the deglycosylated protein resulting from this expression system is sufficient for crystallization and x-ray diffraction at atomic resolution.	Dana Farber Canc Inst, Immunol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Chang, HC (corresponding author), Dana Farber Canc Inst, Immunol Lab, 44 Binney St, Boston, MA 02115 USA.	hsiu-ching_chang@dfci.harvard.edu			NIAID NIH HHS [AI39098, AI19807] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039098, R01AI019807, R37AI019807, R56AI019807] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALCOVER A, 1993, MOL IMMUNOL, V30, P55, DOI 10.1016/0161-5890(93)90426-C; Arden B, 1998, CURR OPIN IMMUNOL, V10, P74, DOI 10.1016/S0952-7915(98)80035-6; BOURSIER JP, 1993, J BIOL CHEM, V268, P2013; CASABO LG, 1994, J IMMUNOL, V152, P397; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CLASSON BJ, 1992, INT IMMUNOL, V4, P215, DOI 10.1093/intimm/4.2.215; Devine L, 1999, J IMMUNOL, V162, P846; DISANTO JP, 1988, EMBO J, V7, P3465, DOI 10.1002/j.1460-2075.1988.tb03221.x; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Ghendler Y, 1997, EUR J IMMUNOL, V27, P2279, DOI 10.1002/eji.1830270923; GOLSTEIN P, 1982, IMMUNOL REV, V68, P5, DOI 10.1111/j.1600-065X.1982.tb01058.x; GORMAN SD, 1988, J IMMUNOL, V140, P3646; Irie HY, 1998, J IMMUNOL, V161, P183; ITANO A, 1994, IMMUNITY, V1, P287, DOI 10.1016/1074-7613(94)90080-9; JOHNSON ID, 1991, ANAL BIOCHEM, V198, P228, DOI 10.1016/0003-2697(91)90418-S; KARAKI S, 1992, J IMMUNOL, V149, P1613; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEAHY DJ, 1995, FASEB J, V9, P17, DOI 10.1096/fasebj.9.1.7821755; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; Liu J, 1996, J BIOL CHEM, V271, P33639, DOI 10.1074/jbc.271.52.33639; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; Meyerson HJ, 1996, J IMMUNOL, V156, P574; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; MOEBIUS U, 1991, EUR J IMMUNOL, V21, P1793, DOI 10.1002/eji.1830210803; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; PILLER F, 1988, J BIOL CHEM, V263, P15146; POUSSIER P, 1994, ANNU REV IMMUNOL, V12, P521, DOI 10.1146/annurev.immunol.12.1.521; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; Renard V, 1996, EUR J IMMUNOL, V26, P2999, DOI 10.1002/eji.1830261227; Renard V, 1996, J EXP MED, V184, P2439, DOI 10.1084/jem.184.6.2439; SHIBATA K, 1992, P NATL ACAD SCI USA, V89, P3135, DOI 10.1073/pnas.89.7.3135; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; TOMONARI K, 1990, INT IMMUNOL, V2, P1189, DOI 10.1093/intimm/2.12.1189; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Wheeler CJ, 1998, J IMMUNOL, V160, P4199; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0; Witte T, 1999, CELL IMMUNOL, V191, P90, DOI 10.1006/cimm.1998.1412; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	50	70	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27237	27243		10.1074/jbc.274.38.27237	http://dx.doi.org/10.1074/jbc.274.38.27237			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480942	hybrid			2022-12-25	WOS:000082570700081
J	Veugelers, M; De Cat, B; Ceulemans, H; Bruystens, AM; Coomans, C; Durr, J; Vermeesch, J; Marynen, P; David, G				Veugelers, M; De Cat, B; Ceulemans, H; Bruystens, AM; Coomans, C; Durr, J; Vermeesch, J; Marynen, P; David, G			Glypican-6, a new member of the glypican family of cell surface heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLABI-BEHMEL-SYNDROME; DEVELOPING NERVOUS-SYSTEM; FIBROBLAST GROWTH-FACTOR; OVERGROWTH SYNDROME; K-GLYPICAN; GENE; EXPRESSION; BINDING; GPC3; KIDNEY	The glypicans compose a family of glycosylphosphatidylinositol-anchored heparan sulfate proteoglycans, Mutations in dally, a gene encoding a Drosophila glypican, and in GPC3, the gene for human glypican-3, implicate glypicans in the control of cell growth and division. So far, five members of the glypican family have been identified in vertebrates, By sequencing expressed sequence tag clones and products of rapid amplifications of cDNA ends, we identified a sixth member of the glypican family. The glypican-6 mRNA encodes a protein of 555 amino acids that is most homologous to glypican-4 (identity of 63%). Expression of this protein in Namalwa cells shows a core protein of similar to 60 kDa that is substituted with heparan sulfate only. GPC6, the gene encoding human glypican-6, contains nine exons. Like GPC5, the gene encoding glypican-5, GPC6 maps to chromosome 13q32,Clustering of the GPC5/GPC6 genes on chromosome 13q32 is strongly reminiscent of the clustering of the GPC3/GPC4 genes on chromosome Xq26 and suggests GPCs arose from a series of gene and genome duplications. Based on similarities in sequence and gene organization, glypican-1, glypican-2, glypican-1, and glypican-6 appear to define a subfamily of glypicans, differing from the subfamily comprising so far glypican-3 and glypican-5. Northern blottings indicate that glypican-6 mRNA is widespread, with prominent expressions in human fetal kidney and adult, ovary. In situ hybridization studies localize glypican-6 to mesenchymal tissues in the developing mouse embryo. High expressions occur in smooth muscle cells lining the aorta and other major blood vessels and in mesenchymal cells of the intestine, kidney, lung, tooth, and gonad. Growth factor signaling in these tissues might in part be regulated by the presence of glypican-6 on the cell surface.	Katholieke Univ Leuven, Ctr Human Genet, Lab Human Genome Anal, B-3000 Leuven, Belgium; Katholieke Univ Leuven, Ctr Human Genet, Lab Glycobiol & Dev Genet, B-3000 Leuven, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	David, G (corresponding author), Katholieke Univ Leuven, Ctr Human Genet, Lab Human Genome Anal, Herestr 49,Campus Gasthuisberg,O & N6, B-3000 Leuven, Belgium.	guido.david@med.kuleuven.ac.be		Vermeesch, Joris/0000-0002-3071-1191				BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; DAVID G, 1993, DEVELOPMENT, V119, P841; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; Godin RE, 1998, DEVELOPMENT, V125, P3473; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Huber R, 1997, GENOMICS, V45, P48, DOI 10.1006/geno.1997.4916; HUGHESBENZIE RM, 1992, AM J MED GENET, V43, P428, DOI 10.1002/ajmg.1320430165; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Lander AD, 1996, PERSPECT DEV NEUROBI, V3, P347; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Litwack ED, 1998, DEV DYNAM, V211, P72, DOI 10.1002/(SICI)1097-0177(199801)211:1<72::AID-AJA7>3.3.CO;2-8; Mast AE, 1997, BIOCHEM J, V327, P577; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Pellegrini M, 1998, DEV DYNAM, V213, P431, DOI 10.1002/(SICI)1097-0177(199812)213:4<431::AID-AJA8>3.0.CO;2-7; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; Saunders S, 1997, DEV BIOL, V190, P78, DOI 10.1006/dbio.1997.8690; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; Veugelers M, 1997, GENOMICS, V40, P24, DOI 10.1006/geno.1996.4518; Veugelers M, 1998, GENOMICS, V53, P1, DOI 10.1006/geno.1998.5465; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; Weksberg R, 1996, NAT GENET, V12, P225, DOI 10.1038/ng0396-225; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	33	95	104	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26968	26977		10.1074/jbc.274.38.26968	http://dx.doi.org/10.1074/jbc.274.38.26968			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480909	hybrid			2022-12-25	WOS:000082570700048
J	Yasuhira, S; Morimyo, M; Yasui, A				Yasuhira, S; Morimyo, M; Yasui, A			Transcription dependence and the roles of two excision repair pathways for UV damage in fission yeast Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CYCLOBUTANE PYRIMIDINE DIMERS; SACCHAROMYCES-CEREVISIAE; COCKAYNE-SYNDROME; DNA-DAMAGE; PREFERENTIAL REPAIR; COUPLED REPAIR; GLOBAL GENOME; ACTIVE GENES; RPB2 GENE	Fission yeasts Schizosaccharomyces pombe possess two types of excision repair systems for UV-induced DNA damage, nucleotide excision repair (NER) and UV-damaged DNA endonuclease (UVDE)-dependent excision repair (UVER). Despite its high efficiency in damage removal, UVER defects have less effect on UV survival than NER defects. To understand the differential roles of two pathways, we examined strand-specific damage removal at the myo2 and rpb2 loci. Although NER removes cyclobutane pyrimidine dimers from the transcribed strand more rapidly than from the nontranscribed strand, UVER repairs cyclobutane pyrimidine dimers equally on both strands and at a much higher rate than NER. The low rate of damage removal from the nontranscribed strand in the absence of UVER indicates inefficient global genome repair (GGR) in this organism and a possible function of UVER as an alternative to GGR. Disruption of rhp26, the S. pombe homolog of CSB/RAD26, eliminated the strand bias of NER almost completely and resulted in a significant increase of UV sensitivity of cells in a uvde Delta background. We suggest that the combination of transcription-coupled repair of NER and rapid UVER contributes to UV survival in growing S. pombe cells, which is accomplished by transcription-coupled repair and GGR in other organisms.	Tohoku Univ, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan; Natl Inst Radiol Sci, Genome Res Grp, Inage Ku, Chiba 2638555, Japan	Tohoku University; National Institutes for Quantum Science & Technology	Yasuhira, S (corresponding author), Kyoto Univ, Inst Res Reactor, Div Radiat Life Sci, 1010 Ooaxa Noda, Kumatori, Osaka 5900494, Japan.	shinji@rri.kyoto-u.ac.jp						Bang DD, 1996, MUTAT RES-DNA REPAIR, V364, P57, DOI 10.1016/0921-8777(96)00010-9; Bhatia PK, 1996, J BACTERIOL, V178, P5977, DOI 10.1128/jb.178.20.5977-5988.1996; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; BOWMAN KK, 1994, NUCLEIC ACIDS RES, V22, P3026, DOI 10.1093/nar/22.15.3026; Chen T, 1998, YEAST, V14, P701, DOI 10.1002/(SICI)1097-0061(19980615)14:8<701::AID-YEA247>3.0.CO;2-#; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FREYER GA, 1995, MOL CELL BIOL, V15, P4572; Guzder SN, 1996, J BIOL CHEM, V271, P18314, DOI 10.1074/jbc.271.31.18314; Hasegawa, 1992, COMPUTER SCI MONOGRA, V27; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; KAWAGISHI M, 1993, NUCLEIC ACIDS RES, V21, P469, DOI 10.1093/nar/21.3.469; Kitayama C, 1997, J CELL BIOL, V137, P1309, DOI 10.1083/jcb.137.6.1309; Konat Gregory W., 1994, P37; Lehmann AR, 1996, MUTAT RES-DNA REPAIR, V363, P147, DOI 10.1016/0921-8777(96)00017-1; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SIEDE W, 1994, GENETICS, V138, P271; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Takao M, 1996, NUCLEIC ACIDS RES, V24, P1267, DOI 10.1093/nar/24.7.1267; Tijsterman M, 1997, P NATL ACAD SCI USA, V94, P8027, DOI 10.1073/pnas.94.15.8027; Tijsterman M, 1996, NUCLEIC ACIDS RES, V24, P3499, DOI 10.1093/nar/24.18.3499; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Verhage RA, 1996, MOL CELL BIOL, V16, P496; Verhage RA, 1996, NUCLEIC ACIDS RES, V24, P1020, DOI 10.1093/nar/24.6.1020; YASUHIRA S, 1991, PHOTOCHEM PHOTOBIOL, V53, P211, DOI 10.1111/j.1751-1097.1991.tb03925.x; Yonemasu R, 1997, NUCLEIC ACIDS RES, V25, P1553, DOI 10.1093/nar/25.8.1553	35	19	20	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26822	26827		10.1074/jbc.274.38.26822	http://dx.doi.org/10.1074/jbc.274.38.26822			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480889	hybrid			2022-12-25	WOS:000082570700028
J	Brown, EL; Guo, BP; O'Neal, P; Hook, M				Brown, EL; Guo, BP; O'Neal, P; Hook, M			Adherence of Borrelia burgdorferi - Identification of critical lysine residues in DbpA required for decorin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYME BORRELIOSIS; PROTEIN-A; PROTEOGLYCANS; SEQUENCE; MATRIX; MUTAGENESIS; INFECTION; IMMUNITY; DISEASE	Borrelia burgdorferi, the causative agent of Lyme disease, expresses on its surface two decorin binding adhesins, DbpA and DbpB, Previous studies have demonstrated that vaccination of mice with DbpA provided protection against challenge with heterologous Borrelia strains despite considerable sequence variability among DbpA in these strains. We have now examined the importance of individual amino acid residues in DbpA for decorin binding. We demonstrated that chemical modification of lysine residues resulted in loss of ligand binding activity, Of the 27 lysine residues in native DbpA from strain 297, 6 are present in most and 5 are conserved in all 30 DbpA sequences examined so far. Analysis of recombinant DbpA in which individual lysine residues have been mutated to alanine suggested that three of the conserved residues distributed throughout the DbpA sequence are required for decorin binding These mutants lost their ability to bind decorin in Western ligand blot assay and bound reduced amounts of decorin in an ELISA, Furthermore, these mutant DbpA proteins did not inhibit the adherence of B, burgdorferi to a decorin substrata, and they did not recognize decorin in an extracellular matrix established by human fibroblast cultures. We conclude that the three lysine residues Lys-82, Lys-163, and Lys-170 are crucial for the binding of DbpA to decorin.	Texas A&M Univ, Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Albert B Alkek Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Hook, M (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Albert B Alkek Inst Biosci & Technol, 2121 W Holcombe Blvd,Suite 603, Houston, TX 77030 USA.				PHS HHS [CCU614695] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACHARYA AS, 1984, J CHROMATOGR, V297, P37, DOI 10.1016/S0021-9673(01)89027-0; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BARTHOLD SW, 1993, AM J PATHOL, V143, P959; Cassatt DR, 1998, INFECT IMMUN, V66, P5379, DOI 10.1128/IAI.66.11.5379-5387.1998; CHOI HU, 1989, J BIOL CHEM, V264, P2876; DURAY PH, 1992, LYME DIS MOL IMMUNOL, P11; Feng SL, 1998, INFECT IMMUN, V66, P2827, DOI 10.1128/IAI.66.6.2827-2835.1998; Guo BP, 1998, MOL MICROBIOL, V30, P711, DOI 10.1046/j.1365-2958.1998.01103.x; GUO BP, 1995, INFECT IMMUN, V63, P3467, DOI 10.1128/IAI.63.9.3467-3472.1995; Hagman KE, 1998, INFECT IMMUN, V66, P2674, DOI 10.1128/IAI.66.6.2674-2683.1998; Hanson MS, 1998, INFECT IMMUN, V66, P2143, DOI 10.1128/IAI.66.5.2143-2153.1998; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; MANIATIS T, 1989, MOL CLONING LABORATO, pA3; MCFARLAND RJ, 1995, ANN NY ACAD SCI, V760, P327, DOI 10.1111/j.1749-6632.1995.tb44649.x; PATTHY L, 1975, J BIOL CHEM, V250, P557; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Roberts WC, 1998, INFECT IMMUN, V66, P5275, DOI 10.1128/IAI.66.11.5275-5285.1998; Sambri V, 1996, INFECT IMMUN, V64, P1858, DOI 10.1128/IAI.64.5.1858-1861.1996; STEERE AC, 1985, NEW ENGL J MED, V312, P869, DOI 10.1056/NEJM198504043121401; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; SZCZEPANSKI A, 1991, MICROBIOL REV, V55, P21, DOI 10.1128/MMBR.55.1.21-34.1991; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; VANMIERLO P, 1993, DERMATOLOGY, V186, P306, DOI 10.1159/000247384	27	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26272	26278		10.1074/jbc.274.37.26272	http://dx.doi.org/10.1074/jbc.274.37.26272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473582	hybrid			2022-12-25	WOS:000082469700048
J	Goldberg, M; Pribyl, T; Juhnke, S; Nies, DH				Goldberg, M; Pribyl, T; Juhnke, S; Nies, DH			Energetics and topology of CzcA, a cation/proton antiporter of the resistance-nodulation-cell division protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCALIGENES-EUTROPHUS CH34; GRAM-NEGATIVE BACTERIA; MULTIDRUG EFFLUX SYSTEMS; CATION-PROTON ANTIPORTER; ESCHERICHIA-COLI; HEAVY-METALS; ENCODING RESISTANCE; NUCLEOTIDE-SEQUENCE; MEMBRANE-PROTEINS; EXPRESSION	The membrane-bound CzcA protein, a member of the resistance-nodulation-cell division (RND) permease superfamily, is part of the CzcCB(2)A complex that mediates heavy metal resistance in Ralstonia sp, CH34 by an active cation efflux mechanism driven by cation/proton antiport. CzcA was purified to homogeneity after expression in Escherichia coli, reconstituted into proteoliposomes, and the kinetics of heavy metal transport by CzcA was determined. CzcA is composed of 12 transmembrane cy-helices and two large periplasmic domains. Two conserved aspartate and a glutamate residue in one of these transmembrane spans are essential for heavy metal resistance and proton/cation antiport but not for facilitated diffusion of cations. Generalization of the resulting model for the function of CzcA as a two-channel pump might help to explain the functions of other RND proteins in bacteria and eukaryotes.	Inst Microbiol, D-06099 Halle, Germany		Nies, DH (corresponding author), Inst Microbiol, Kurt Mothes Str 3, D-06099 Halle, Germany.	d.nies@mikrobiologie.uni-halle.de	Nies, Dietrich H/H-4143-2011					Alcedo J, 1997, BIOL CHEM, V378, P583; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brim H, 1999, SYST APPL MICROBIOL, V22, P258, DOI 10.1016/S0723-2020(99)80073-3; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; DERETIC V, 1987, GENE, V57, P61, DOI 10.1016/0378-1119(87)90177-6; DRESSLER C, 1991, APPL ENVIRON MICROB, V57, P3079, DOI 10.1128/AEM.57.11.3079-3085.1991; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Gupta A, 1999, NAT MED, V5, P183, DOI 10.1038/5545; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; Kaback HR, 1997, CURR OPIN STRUC BIOL, V7, P537, DOI 10.1016/S0959-440X(97)80119-4; Kieboom J, 1998, J BACTERIOL, V180, P6769, DOI 10.1128/JB.180.24.6769-6772.1998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lange Y, 1998, CURR OPIN STRUC BIOL, V8, P435, DOI 10.1016/S0959-440X(98)80119-X; Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915; Li XZ, 1998, J BACTERIOL, V180, P2987, DOI 10.1128/JB.180.11.2987-2991.1998; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MERGEAY M, 1985, J BACTERIOL, V162, P328, DOI 10.1128/JB.162.1.328-334.1985; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; NIES A, 1989, J BACTERIOL, V171, P5065, DOI 10.1128/jb.171.9.5065-5070.1989; NIES A, 1990, J BIOL CHEM, V265, P5648; NIES D, 1987, J BACTERIOL, V169, P4865, DOI 10.1128/jb.169.10.4865-4868.1987; NIES DH, 1995, J BACTERIOL, V177, P2707, DOI 10.1128/jb.177.10.2707-2712.1995; NIES DH, 1989, P NATL ACAD SCI USA, V86, P7351, DOI 10.1073/pnas.86.19.7351; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Nikaido H, 1998, J BACTERIOL, V180, P4686, DOI 10.1128/JB.180.17.4686-4692.1998; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1997, FEMS MICROBIOL LETT, V156, P1, DOI 10.1111/j.1574-6968.1997.tb12697.x; Pennisi E, 1996, SCIENCE, V272, P1583, DOI 10.1126/science.272.5268.1583; Ramos JL, 1998, J BACTERIOL, V180, P3323, DOI 10.1128/JB.180.13.3323-3329.1998; Rensing C, 1997, J BACTERIOL, V179, P6871, DOI 10.1128/jb.179.22.6871-6879.1997; RIGAUD JL, 1995, LIPOSOMES TOOLS BASI, P71; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; SAIER MH, 1994, MICROBIOL REV, V58, P71, DOI 10.1128/MMBR.58.1.71-93.1994; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SMALL D, 1996, ENCY MOL BIOL MOL ME, V3, P442; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Taghavi S, 1997, PLASMID, V37, P22, DOI 10.1006/plas.1996.1274; TSENG TT, 1999, J MOL MICROB BIOTECH, V1, P258; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	50	141	144	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26065	26070		10.1074/jbc.274.37.26065	http://dx.doi.org/10.1074/jbc.274.37.26065			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473554	hybrid			2022-12-25	WOS:000082469700020
J	Fianagan, CA; Zhou, W; Chi, L; Yuen, T; Rodic, V; Robertson, D; Johnson, M; Holland, P; Millar, RP; Weinstein, H; Mitchell, R; Sealfon, SC				Fianagan, CA; Zhou, W; Chi, L; Yuen, T; Rodic, V; Robertson, D; Johnson, M; Holland, P; Millar, RP; Weinstein, H; Mitchell, R; Sealfon, SC			The functional microdomain in transmembrane helices 2 and 7 regulates expression, activation, and coupling pathways of the gonadotropin-releasing hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SIGNAL-TRANSDUCTION; PROJECTION STRUCTURE; ANTAGONIST BINDING; PHOSPHOLIPASE-D; LIGAND-BINDING; POINT MUTATION; INCREASES; RHODOPSIN; RESIDUES	Structural microdomains of G protein-coupled receptors (GPCRs) consist of spatially related side chains that mediate discrete functions. The conserved helix 2/helix 7 microdomain was identified because the gonadotropin-releasing hormone (GnRH) receptor appears to have interchanged the Asp(2.50) and Asn(7.49) residues which are conserved in transmembrane helices 2 and 7 of rhodopsin-like GPCRs. me now demonstrate that different side chains of this microdomain contribute specifically to receptor expression, heterotrimeric G protein-, and small G protein-mediated signaling. An Asn residue is required in position 2.50(87) for expression of the GnRH receptor at the cell surface, most likely through an interaction with the conserved Asn(1.50(53)) residue, which we also find is required for receptor expression. Most GPCRs require an Asp side chain at either the helix 2 or helix 7 locus of the microdomain for coupling to heterotrimeric G proteins, but the GnRH. receptor has transferred the requirement for an acidic residue from helix 2 to 7. However, the presence of Asp at the helix 7 locus precludes small G protein-dependent coupling to phospholipase D. These results implicate specific components of the helix 2/helix 7 microdomain in receptor expression and in determining the ability of the receptor to adopt distinct activated conformations that are optimal for interaction with heterotrimeric and small G proteins.	CUNY Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; MRC, Brain Metab Unit, Edinburgh EH8 9JZ, Midlothian, Scotland; Univ Cape Town, Sch Med, MRC, Mol Reprod Endocrinol Res Unit, ZA-7925 Cape Town, South Africa	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Cape Town	Sealfon, SC (corresponding author), CUNY Mt Sinai Sch Med, Dept Neurol, Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.		WEINSTEIN, HAREL/O-8245-2019	WEINSTEIN, HAREL/0000-0003-3473-9818; SEALFON, Stuart/0000-0001-5791-1217; Flanagan, Colleen A./0000-0003-2803-8986; Millar, Robert P/0000-0003-3606-2708	NIDA NIH HHS [K05 DA00060] Funding Source: Medline; NIDDK NIH HHS [R01 DK 46943] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000060] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BERG KA, 1994, MOL PHARMACOL, V46, P477; Blomenrohr M, 1997, BIOCHEM BIOPH RES CO, V238, P517, DOI 10.1006/bbrc.1997.7331; COOK JV, 1993, J ENDOCRINOL, V139, pR1, DOI 10.1677/joe.0.139R001; Davidson JS, 1997, BIOCHEMISTRY-US, V36, P12881, DOI 10.1021/bi971377t; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; Donnelly D, 1999, BIOCHEM J, V339, P55, DOI 10.1042/0264-6021:3390055; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; HARRISON RW, 1994, PROTEIN ENG, V7, P1353, DOI 10.1093/protein/7.11.1353; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Illing N, 1999, P NATL ACAD SCI USA, V96, P2526, DOI 10.1073/pnas.96.5.2526; JAGERSCHMIDT A, 1995, MOL PHARMACOL, V48, P783; Konvicka K, 1998, BIOPHYS J, V75, P601, DOI 10.1016/S0006-3495(98)77551-4; LAWS SC, 1990, ENDOCRINOLOGY, V127, P373, DOI 10.1210/endo-127-1-373; Millar R, 1999, J ENDOCRINOL, V162, P117, DOI 10.1677/joe.0.1620117; MILLAR RP, 1995, METHODS NEUROSCIENCE, P145; MITCHELL R, 1995, BIOCHEM SOC T, V23, pS208, DOI 10.1042/bst023208s; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Parent JL, 1996, J BIOL CHEM, V271, P23298, DOI 10.1074/jbc.271.38.23298; Perlman JH, 1997, J BIOL CHEM, V272, P11937, DOI 10.1074/jbc.272.18.11937; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; SEALFON SC, 1996, METH NEUROSCI, V29, P143; SURPRENANT A, 1992, SCIENCE, V257, P977, DOI 10.1126/science.1354394; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; Xu W, 1999, FEBS LETT, V447, P318, DOI 10.1016/S0014-5793(99)00316-6; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZHOU W, 1995, J BIOL CHEM, V270, P18853, DOI 10.1074/jbc.270.32.18853	37	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28880	28886		10.1074/jbc.274.41.28880	http://dx.doi.org/10.1074/jbc.274.41.28880			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506131	hybrid, Green Published			2022-12-25	WOS:000083017800010
J	Kurokawa, H; Dewan, JC; Mikami, B; Sacchettini, JC; Hirose, M				Kurokawa, H; Dewan, JC; Mikami, B; Sacchettini, JC; Hirose, M			Crystal structure of hen apo-ovotransferrin - Both lopes adopt an open conformation upon loss of iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL HALF-MOLECULE; HUMAN TRANSFERRIN; ANGSTROM RESOLUTION; DUCK OVOTRANSFERRIN; SERUM TRANSFERRIN; N-LOBE; X-RAY; RECEPTOR RECOGNITION; HUMAN APOLACTOFERRIN; CHICK RETICULOCYTES	The three-dimensional crystal structure of hen apo-ovotransferrin has been solved by molecular replacement and refined by simulated annealing and restrained least squares to a 3.0-Angstrom resolution. The final model, which comprises 5312 protein atoms (residues 1 to 686) and 28 carbohydrate atoms (from two monosaccharides attached to Asn(473)), gives an R-factor of 0.231 for the 11,989 observed reflections between 20.0- and 3.0-Angstrom resolution. In the structure, both empty iron binding clefts are in the open conformation, lending weight to the theory that Fe3+ binding or release in transferrin proceeds via a mechanism that involves domain opening and closure. Upon opening, the domains rotate essentially as rigid bodies. The two domains of the N-lobe rotate away from one another by 53 degrees, whereas the C-lobe domains rotate away each another by 35 degrees. These rotations take place about an axis that passes through the two P-strands, linking the domains. The domains of each lobe make different contacts with one another in the open and closed forms. These contacts form two interdomain interfaces on either side of the rotation axis, and domain opening or closing produces a see-saw motion between these two alternative close-packed interfaces. The interdomain disulfide bridge (Cys(478-)Cys(671)), found only in the C-lobe, may restrict domain opening but does not completely prevent it.	Kyoto Univ, Food Sci Res Inst, Uji, Kyoto 611, Japan; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Kyoto University; Yeshiva University; Albert Einstein College of Medicine	Mikami, B (corresponding author), Kyoto Univ, Food Sci Res Inst, Uji, Kyoto 611, Japan.		Kurokawa, Hirofumi/A-7231-2010	Hirose, Masaaki/0000-0003-2672-4384	NIGMS NIH HHS [GM45859] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; AISEN P, 1978, J BIOL CHEM, V253, P1930; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BALI PK, 1991, BIOCHEMISTRY-US, V30, P9947, DOI 10.1021/bi00105a019; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BALI PK, 1992, BIOCHEMISTRY-US, V31, P3963, DOI 10.1021/bi00131a011; BROWNMASON A, 1984, J BIOL CHEM, V259, P1866; BRUNGER AT, 1996, XPLOR VERSION 3 85; Bruns CM, 1997, NAT STRUCT BIOL, V4, P919, DOI 10.1038/nsb1197-919; CHASTEEN ND, 1981, BIOCHEM J, V193, P717, DOI 10.1042/bj1930717; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; DAY CL, 1993, J MOL BIOL, V232, P1084, DOI 10.1006/jmbi.1993.1462; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; DEWAN JC, 1987, J APPL CRYSTALLOGR, V20, P130, DOI 10.1107/S0021889887087004; GERSTEIN M, 1993, J MOL BIOL, V234, P357, DOI 10.1006/jmbi.1993.1592; GROSSMANN JG, 1993, J MOL BIOL, V231, P554, DOI 10.1006/jmbi.1993.1308; GROSSMANN JG, 1992, J MOL BIOL, V225, P811, DOI 10.1016/0022-2836(92)90402-6; HE JL, 1995, NATURE, V373, P721, DOI 10.1038/373721a0; HIROSE M, 1986, AGR BIOL CHEM TOKYO, V50, P59, DOI 10.1080/00021369.1986.10867339; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Jameson GB, 1998, ACTA CRYSTALLOGR D, V54, P1319, DOI 10.1107/S0907444998004417; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUROKAWA H, 1995, J MOL BIOL, V254, P196, DOI 10.1006/jmbi.1995.0611; KUROKAWA H, 1994, J BIOL CHEM, V269, P6671; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN LN, 1991, BIOCHEMISTRY-US, V30, P11660, DOI 10.1021/bi00114a008; LINDLEY PF, 1993, ACTA CRYSTALLOGR D, V49, P292, DOI 10.1107/S0907444992012101; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; MAKEY DG, 1976, BIOCHIM BIOPHYS ACTA, V453, P250, DOI 10.1016/0005-2795(76)90270-1; Mason AB, 1996, BIOCHEM J, V319, P361, DOI 10.1042/bj3190361; MASON AB, 1987, J BIOL CHEM, V262, P9011; Mason AB, 1997, BIOCHEM J, V326, P77, DOI 10.1042/bj3260077; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moore SA, 1997, J MOL BIOL, V274, P222, DOI 10.1006/jmbi.1997.1386; NORRIS GE, 1989, J MOL BIOL, V209, P329, DOI 10.1016/0022-2836(89)90283-0; Rawas A, 1996, ACTA CRYSTALLOGR D, V52, P631, DOI 10.1107/S0907444996000212; Rawas A, 1997, ACTA CRYSTALLOGR D, V53, P464, DOI 10.1107/S0907444997000838; SARRA R, 1990, ACTA CRYSTALLOGR B, V46, P763, DOI 10.1107/S0108768190006450; THIBODEAU SN, 1978, J BIOL CHEM, V253, P3771; Ward PP, 1996, J BIOL CHEM, V271, P12790, DOI 10.1074/jbc.271.22.12790; WILLIAMS J, 1978, BIOCHEM J, V173, P535, DOI 10.1042/bj1730533; WILLIAMS J, 1985, BIOCHEM J, V228, P661, DOI 10.1042/bj2280661; WILLIAMS J, 1982, TRENDS BIOCHEM SCI, V7, P394, DOI 10.1016/0968-0004(82)90183-9; WILLIAMS J, 1982, EUR J BIOCHEM, V122, P297, DOI 10.1111/j.1432-1033.1982.tb05880.x; YOUNG SP, 1984, BIOCHEM J, V219, P505, DOI 10.1042/bj2190505	49	63	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28445	28452		10.1074/jbc.274.40.28445	http://dx.doi.org/10.1074/jbc.274.40.28445			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497206	hybrid			2022-12-25	WOS:000082912700055
J	Marathe, GK; Davies, SS; Harrison, KA; Silva, AR; Murphy, RC; Castro-Faria-Neto, H; Prescott, SM; Zimmerman, GA; McIntyre, TM				Marathe, GK; Davies, SS; Harrison, KA; Silva, AR; Murphy, RC; Castro-Faria-Neto, H; Prescott, SM; Zimmerman, GA; McIntyre, TM			Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; FACTOR RECEPTOR; FACTOR ACETYLHYDROLASE; NEUTROPHIL ADHERENCE; LIPID-PEROXIDATION; MASS-SPECTROMETRY; CIGARETTE-SMOKING; GUINEA-PIG; IN-VIVO; CELLS	Oxidation of human low density lipoprotein (LDL) generates proinflammatory mediators and underlies early events in atherogenesis. We identified mediators in oxidized LDL that induced an inflammatory reaction in vivo, and activated polymorphonuclear leukocytes and cells ectopically expressing human platelet-activating factor (PAF) receptors, Oxidation of a synthetic phosphatidylcholine showed that an sn-l ether bond confers an 800-fold increase in potency. This suggests that rare ether-linked phospholipids in LDL are the likely source of PAF-like activity in oxidized LDL, Accordingly, treatment of oxidized LDL with phospholipase A, greatly reduced phospholipid mass, but did not decrease its PAF-like activity. Tandem mass spectrometry identified traces of PAF, and more abundant levels of 1-O-hexadecyl-2-(butanoyl or butenoyl)-sn-glycero-3-phosphocholines (C-4-PAF analogs) in oxidized LDL that comigrated with PAF-like activity. Synthesis showed that either C-4-PAF was just 10-fold less potent than PAF as a PAF receptor ligand and agonist. Quantitation by gas chromatography-mass spectrometry of pentafluorobenzoyl derivatives shows the C-4-PAF analogs were 100-fold more abundant in oxidized LDL than PAF, Oxidation of synthetic alkyl arachidonoyl phosphatidylcholine generated these C-4-PAFs in abundance. These results show that quite minor constituents of the LDL phosphatidylcholine pool are the exclusive precursors for PAF-like bioactivity in oxidized LDL.	Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Fiocruz MS, Dept Fisiol & Farmacodinam, IOC, BR-21045900 Rio De Janeiro, Brazil	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; National Jewish Health; Fundacao Oswaldo Cruz	McIntyre, TM (corresponding author), Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA.	tom.mcintyre@hmbg.utah.edu	Silva, Adriana R/C-5931-2014; Silva, Adriana/U-7811-2019	Silva, Adriana R/0000-0002-5137-4251; Silva, Adriana/0000-0002-5137-4251; Marathe, Gopal/0000-0002-0025-6677; Davies, Sean/0000-0001-9879-8062	NHLBI NIH HHS [HL 50153, HL 44525, HL 44513] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153, R37HL044525, R01HL044513, R01HL044525] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES BN, 1960, J BIOL CHEM, V235, P769; AOKI Y, 1995, J IMMUNOL METHODS, V186, P225, DOI 10.1016/0022-1759(95)00147-3; BENVENISTE J, 1977, NATURE, V269, P170, DOI 10.1038/269170a0; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHUNG BH, 1980, J LIPID RES, V21, P284; CLAY KL, 1990, METHOD ENZYMOL, V187, P134; Dentan C, 1996, BBA-LIPID LIPID MET, V1299, P353, DOI 10.1016/0005-2760(95)00226-X; DIAGNE A, 1984, BIOCHIM BIOPHYS ACTA, V793, P221, DOI 10.1016/0005-2760(84)90324-2; DUMELIN EE, 1977, LIPIDS, V12, P894, DOI 10.1007/BF02533308; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; GYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall LM, 1998, ANAL BIOCHEM, V258, P184, DOI 10.1006/abio.1998.2602; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; IMAIZUMI TA, 1991, ATHEROSCLEROSIS, V87, P47, DOI 10.1016/0021-9150(91)90231-Q; Kern H, 1998, BBA-LIPID LIPID MET, V1394, P33, DOI 10.1016/S0167-4889(98)00093-7; KIM FJ, 1995, J SURG RES, V58, P636, DOI 10.1006/jsre.1995.1100; KUMAR R, 1984, J LIPID RES, V25, P198; LEHR HA, 1993, ARTERIOSCLER THROMB, V13, P1013, DOI 10.1161/01.ATV.13.7.1013; Lehr HA, 1997, J CLIN INVEST, V99, P2358, DOI 10.1172/JCI119417; LEHR HA, 1991, RES EXP MED, V191, P85, DOI 10.1007/BF02576662; Leitinger N, 1997, ADV EXP MED BIOL, V433, P379; Liu LX, 1998, J IMMUNOL, V161, P3064; MORAND OH, 1988, J BIOL CHEM, V263, P11597; OFLAHERTY JT, 1983, RES COMMUN CHEM PATH, V39, P291; OFLAHERTY JT, 1994, BBA-LIPID LIPID MET, V1210, P209, DOI 10.1016/0005-2760(94)90123-6; PATEL KD, 1992, J BIOL CHEM, V267, P15168; Prescott S. M., 1999, INFLAMMATION BASIC P, P387; Schlame M, 1996, J LIPID RES, V37, P2608; SHEN TY, 1987, PLATELET ACTIVATING, P153; Shen YM, 1998, AM J PHYSIOL-ENDOC M, V275, pE479, DOI 10.1152/ajpendo.1998.275.3.E479; SHIMIZU T, 1992, BIOCHEM PHARMACOL, V44, P1001; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TANAKA T, 1995, BIOSCI BIOTECH BIOCH, V59, P1389, DOI 10.1271/bbb.59.1389; TANAKA T, 1994, BBA-LIPID LIPID MET, V1210, P202, DOI 10.1016/0005-2760(94)90122-8; TANAKA T, 1993, BIOCHIM BIOPHYS ACTA, V1166, P264, DOI 10.1016/0005-2760(93)90107-K; TOKUMURA A, 1987, BIOCHEM BIOPH RES CO, V145, P415, DOI 10.1016/0006-291X(87)91338-6; Tokumura A, 1996, LIPIDS, V31, P1251, DOI 10.1007/BF02587909; Tsoukatos DC, 1997, ARTERIOSCL THROM VAS, V17, P3505, DOI 10.1161/01.ATV.17.12.3505; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; ZIMMERMAN GA, 1986, ANN NY ACAD SCI, V485, P349, DOI 10.1111/j.1749-6632.1986.tb34596.x; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; [No title captured]	48	158	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28395	28404		10.1074/jbc.274.40.28395	http://dx.doi.org/10.1074/jbc.274.40.28395			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497200	hybrid			2022-12-25	WOS:000082912700049
J	Ndisang, D; Budhram-Mahadeo, V; Latchman, DS				Ndisang, D; Budhram-Mahadeo, V; Latchman, DS			The Brn-3a transcription factor plays a critical role in regulating human papilloma virus gene expression and determining the growth characteristics of cervical cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU-DOMAIN; BINDING-SITES; CARCINOMA; ENHANCER; FAMILY; DNA; NEOPLASIA; OUTGROWTH; PROMOTER; DISTINCT	The Brn-3a POU family transcription factor has previously been shown to activate the human papilloma virus type 16 (HPV-16) promoter driving the expression of the E6- and E7-transforming proteins, Moreover, Brn-3a is overexpressed approximately 300-fold in cervical biopsies from women with cervical intra-epithelial neoplasia type 3 (CIN3) compared with normal cervical material. To test the role of Brn-3a in cervical neoplasia we have manipulated its expression in cervical carcinoma-derived cell lines with or without endogenous HPV genes, In HPV-expressing cells, reduction in Brn-3a expression specifically reduces HPV gene expression, growth rate, saturation density and anchorage-independent growth, whereas these effects are not observed when Brn-3a expression is reduced in cervical cells lacking HPV genomes, Together with our previous observations, these findings indicate a critical role for Brn-3a in regulating HPV gene expression and thereby in controlling the growth/transformation of cervical cells.	UCL, Windeyer Inst Med Sci, Dept Mol Pathol, London W1P 6DB, England	University of London; University College London	Latchman, DS (corresponding author), UCL, Windeyer Inst Med Sci, Dept Mol Pathol, Windeyer Bldg,Cleveland St, London W1P 6DB, England.	d.latchman@ucl.ac.uk						AUERSPERG N, 1964, J NATL CANCER I, V32, P135; BURGHARDT E, 1984, CLIN OBSTET GYNAECOL, V11, P239; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; COX MF, 1986, LANCET, V2, P157; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DENT CL, 1991, NUCLEIC ACIDS RES, V19, P4531, DOI 10.1093/nar/19.16.4531; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GLOSS B, 1989, NUCLEIC ACIDS RES, V17, P3519, DOI 10.1093/nar/17.9.3519; GLOSS B, 1987, EMBO J, V6, P3735, DOI 10.1002/j.1460-2075.1987.tb02708.x; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAUSEN HZ, 1986, LANCET, V2, P489; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MEANWELL CA, 1987, LANCET, V1, P703; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; MORRIS PJ, 1993, NUCLEIC ACIDS RES, V21, P1019, DOI 10.1093/nar/21.4.1019; NAKSHATRI H, 1990, VIROLOGY, V178, P92, DOI 10.1016/0042-6822(90)90382-2; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; YEE C, 1985, AM J PATHOL, V119, P361	30	24	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28521	28527		10.1074/jbc.274.40.28521	http://dx.doi.org/10.1074/jbc.274.40.28521			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497216	hybrid			2022-12-25	WOS:000082912700065
J	Shirane, M; Hatakeyama, S; Hattori, K; Nakayama, K; Nakayama, K				Shirane, M; Hatakeyama, S; Hattori, K; Nakayama, K; Nakayama, K			Common pathway for the ubiquitination of I kappa B alpha, I kappa B beta, and I kappa B epsilon mediated by the F-box protein FWD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REL-ASSOCIATED PP40; KINASE COMPLEX; PROTEASOME PATHWAY; ACTIVATION; FAMILY; INHIBITOR; PHOSPHORYLATION; DEGRADATION; GENE; IDENTIFICATION	FWD1 (the mouse homolog of Drosophila Slimb and Xenopus beta TrCP, a member of the F-box- and WD40 repeat-containing family of proteins, and a component of the SCF ubiquitin ligase complex) was recently shown to interact with I kappa B alpha and thereby to promote its ubiquitination and degradation. This protein has now been shown also to bind to I kappa B beta and I kappa B epsilon as well as to induce their ubiquitination and proteolysis, FWD1 was shown to recognize the conserved DSG Psi XS motif (where Psi represents the hydrophobic residue) present in the NH2,terminal regions of these three I kappa B proteins only when the component serine residues are phosphorylated, However, in contrast to I kappa B alpha and I kappa B alpha, the recognition site in I kappa B epsilon for FWD1 is not restricted to the DSG Psi XS motif; FWD1 also interacts with other sites in the NH2 terminal region of I kappa B epsilon, Substitution of the critical serine residues in the NH2-terminal regions of I kappa B alpha, I kappa B beta, and IKBE with alanines also markedly reduced the extent of FWD1-mediated ubiquitination of these proteins and increased their stability. These data indicate that the three I kappa B proteins, despite their substantial structural and functional differences, all undergo ubiquitination mediated by the SCFFWD1 complex. FWD1 may thus play an important role in NF-kappa B signal transduction through regulation of the stability of multiple I kappa B proteins.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Lab Embryon & Genet Engn, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	Kyushu University; Kyushu University; Japan Science & Technology Agency (JST)	Nakayama, K (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp	Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ELLEDGE SJ, 1998, BIOCHIM BIOPHYS ACTA, V1377, P61; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Han YQ, 1999, J BIOL CHEM, V274, P939, DOI 10.1074/jbc.274.2.939; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; PETERS JM, 1998, UBIQUITIN BIOL CELL; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	50	70	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28169	28174		10.1074/jbc.274.40.28169	http://dx.doi.org/10.1074/jbc.274.40.28169			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497169	hybrid			2022-12-25	WOS:000082912700018
J	Sjin, RMTT; Lord, KA; Abdollahi, A; Hoffman, B; Liebermann, DA				Sjin, RMTT; Lord, KA; Abdollahi, A; Hoffman, B; Liebermann, DA			Interleukin-6 and leukemia inhibitory factor induction of JunB is regulated by distinct cell type-specific cis-acting elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE EARLY RESPONSE; STIMULATING FACTOR-III; CRE-LIKE SITE; TERMINAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; GROWTH-FACTORS; CDNA; EXPRESSION; SEQUENCE; PROMOTER	Interleukin (IL)-6 plays an important role in a wide range of biological activities, including differentiation of murine M1 myeloid leukemic cells into mature macrophages, At the onset of M1 differentiation, a set of myeloid differentiation primary response (MyD) genes are induced, including the proto-oncogene for JunB, In order to examine the molecular nature of the mechanisms by which IL-6 activates the immediate early expression of MyD genes, JunB was used as a paradigm. A novel IL-6 response element, -65/-52 IL-6RE, to which a 100-kDa protein complex is bound, has been identified on the JunB promoter. Leukemia inhibitory factor (LIF)induced activation of JunB in M1 cells was also mediated via the -65/-52 IL-6RE. The STAT3 and CRE-like binding sites of the JunB promoter, identified as IL-6-responsive elements in HepG2 liver cells were found, however, to play no role in JunB inducibility by IL-6 in M1 myeloid cells. Conversely, the -65/-52 IL-6RE is shown not to be necessary for JunB inducibility by IL-6 or LIF in liver cells. It appears, therefore, that immediate early activation of JunB is regulated differently in M1 myeloid cells than in HepG2 liver cells. This indicates that distinct cis-acting control elements participate in cell type-specific induction of JunB by members of the IL-6 cytokine superfamily.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Univ Penn, Sch Med, Dept Biochem & Mol Biophys, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Hoffman, B (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	hoffmann@unix.temple.edu; liebma@unix.temple.edu						ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAUMANN H, 1989, J BIOL CHEM, V264, P8046; BAUMANN H, 1989, J IMMUNOL, V143, P1163; CHIU CP, 1988, P NATL ACAD SCI USA, V85, P7099, DOI 10.1073/pnas.85.19.7099; COFFER P, 1995, ONCOGENE, V10, P985; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; Guillouf C, 1998, INT J ONCOL, V13, P107; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; HIRANO T, 1992, CHEM IMMUNOL, V51, P153; Kojima H, 1996, ONCOGENE, V12, P547; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; METCALF D, 1990, BLOOD, V76, P50; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; ROSSELLI F, 1992, HUM GENET, V89, P42, DOI 10.1007/BF00207040; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAITO T, 1991, J IMMUNOL, V147, P168; Sehgal PB, 1995, ANN NY ACAD SCI, V762, P1; SEHGAL PB, 1990, P SOC EXP BIOL MED, V195, P183; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	31	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28697	28707		10.1074/jbc.274.40.28697	http://dx.doi.org/10.1074/jbc.274.40.28697			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497240	hybrid			2022-12-25	WOS:000082912700089
J	Steiner, H; Duff, K; Capell, A; Romig, H; Grim, MG; Lincoln, S; Hardy, J; Yu, X; Picciano, M; Fechteler, K; Citron, M; Kopan, R; Pesold, B; Keck, S; Baader, M; Tomita, T; Iwatsubo, T; Baumeister, R; Haass, C				Steiner, H; Duff, K; Capell, A; Romig, H; Grim, MG; Lincoln, S; Hardy, J; Yu, X; Picciano, M; Fechteler, K; Citron, M; Kopan, R; Pesold, B; Keck, S; Baader, M; Tomita, T; Iwatsubo, T; Baumeister, R; Haass, C			A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; FAMILIAL ALZHEIMERS-DISEASE; IN-VIVO; CAENORHABDITIS-ELEGANS; PRECURSOR PROTEIN; TRANSFECTED CELLS; EXPRESSION; GENE; PS1; ACCUMULATION	Presenilin-1 (PS1) facilitates gamma-secretase cleavage of the beta-amyloid precursor protein and the intramembraneous cleavage of Notch1. Although Alzheimer's disease-associated mutations in the homologous presenilin (PS2) gene elevate amyloid beta-peptide (A beta 42) production like PS1 mutations, here we demonstrate that a gene ablation of PS2 (unlike that of PS1) in mice does not result in a severe phenotype resembling that of Notch-ablated animals. To investigate the amyloidogenic function of PS2 more directly, Foe mutagenized a conserved aspartate at position 366 to alanine, because the corresponding residue of PS1 is known to be required for its amyloidogenic function. Cells expressing the PS2 D366A mutation exhibit significant deficits in proteolytic processing of beta-amyloid precursor protein indicating a defect in gamma-secretase activity. The reduced gamma-secretase activity results in the almost complete inhibition of A beta and p3 production in cells stably expressing PS2 D366A, whereas cells overexpressing the wild-type PS2 cDNA produce robust levels of A beta and p3, Using highly sensitive in vivo assays, we demonstrate that the PS2 D366A mutation not only blocks gamma-secretase activity but also inactivates PS2 activity in Notch signaling by inhibiting the proteolytic release of the cytoplasmic Notch1 domain. These data suggest that PS2 is functionally involved in A beta production and Notch signaling by facilitating similar proteolytic cleavages.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, D-80336 Munich, Germany; Univ Tokyo, Fac Pharmaceut Sci, Dept Neurobiol & Neurosci, Tokyo 113, Japan; Washington Univ, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Amgen Inc, Thousand Oaks, CA 91320 USA; Mayo Clin, Jacksonville, FL 32224 USA; Genzentrum, D-81377 Munich, Germany; Boehringer Ingelheim KG, CNS Res, D-55216 Ingelheim, Germany; Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA; Cent Inst Mental Hlth, Dept Mol Biol, D-68159 Mannheim, Germany	University of Munich; University of Tokyo; Washington University (WUSTL); Washington University (WUSTL); Amgen; Mayo Clinic; University of Munich; Boehringer Ingelheim; Nathan Kline Institute for Psychiatric Research; Central Institute of Mental Health	Haass, C (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Schillerstr 44, D-80336 Munich, Germany.		Hardy, John/C-2451-2009; Kopan, Raphael/AAF-1357-2022; Duff, Karen EK/C-2510-2009; Kopan, Raphael/AFG-3275-2022; Tomita, Taisuke/L-5427-2015	Hardy, John/0000-0002-3122-0423; Tomita, Taisuke/0000-0002-0075-5943; Duff, Karen/0000-0002-6177-868X; Kopan, Raphael/0000-0002-0350-2730				Baumeister R, 1997, Genes Funct, V1, P149; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Grunberg J, 1998, NEUROREPORT, V9, P3293; HERREMAN A, 1999, IN PRESS P NATL ACAD; Hutton M, 1997, HUM MOL GENET, V6, P1639, DOI 10.1093/hmg/6.10.1639; Kim TW, 1997, J BIOL CHEM, V272, P11006; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Westlund B, 1999, P NATL ACAD SCI USA, V96, P2497, DOI 10.1073/pnas.96.5.2497; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096	36	272	281	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28669	28673		10.1074/jbc.274.40.28669	http://dx.doi.org/10.1074/jbc.274.40.28669			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497236	hybrid			2022-12-25	WOS:000082912700085
J	Takada, Y; Hachiya, M; Osawa, Y; Hasegawa, Y; Ando, K; Kobayashi, Y; Akashi, M				Takada, Y; Hachiya, M; Osawa, Y; Hasegawa, Y; Ando, K; Kobayashi, Y; Akashi, M			12-O-tetradecanoylphorbol-13-acetate-induced apoptosis is mediated by tumor necrosis factor alpha in human monocytic U937 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PROMYELOCYTIC LEUKEMIA-CELLS; PHORBOL ESTER; SIGNAL-TRANSDUCTION; TNF RECEPTOR; P53 GENE; DNA FRAGMENTATION; CARCINOMA-CELLS; DOWN-REGULATION; MAP KINASES	12-O-tetradecanoylphorbo-13-acetate (TPA), a phorbol ester that is known as a tumor promoter, induces differentiation of myeloid cells and suppresses their proliferation. We studied the regulation of apoptosis by TPA in human monocytic cell line U937 cells that lack p53. Untreated U937 cells constitutively underwent apoptosis, and TPA enhanced apoptosis in these cells. Further studies showed that TPA increased production of tumor necrosis factor-alpha (TNF alpha) in U937 cells, and exogenously added TNF alpha induced apoptosis, Moreover, the induction of apoptosis by TPA was blocked by anti-TNF alpha antibody. Similar results were obtained in the myeloblastic cell line KY821 cells, We also found that the induction of apoptosis by TPA was increased in cells overexpressed with TNF receptor 1 but not in control cells. Furthermore, TPA failed to induce the production of TNF alpha and apoptosis in cells with either their protein kinase C or mitogen-activated protein kinase pathway blocked. Our results indicate that TPA induces apoptosis, at least in part, through a pathway that requires endogenous production of TNF alpha in U937 cells. Our data also suggest that the induction of apoptosis by TPA occurs through activation of protein kinase C and mitogen-activated protein kinase and TNF alpha is an autocrine-stimulating factor for the induction of apoptosis in these cells.	Natl Inst Radiol Sci, Div Radiat Hlth, Inage Ku, Chiba 2638555, Japan; Natl Inst Radiol Sci, Space & Particle Radiat Sci Res Grp, Inage Ku, Chiba 2638555, Japan; Nagoya Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4668550, Japan; Toho Univ, Fac Sci, Lab Mol Immunol, Dept Biomol Sci, Funabashi, Chiba 2748510, Japan	National Institutes for Quantum Science & Technology; National Institutes for Quantum Science & Technology; Nagoya University; Toho University	Akashi, M (corresponding author), Natl Inst Radiol Sci, Div Radiat Hlth, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.		Hasegawa, Yoshinori/I-1277-2012					AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; Baker SJ, 1996, ONCOGENE, V12, P1; BALOCH Z, 1990, J IMMUNOL, V145, P2908; Battey, 1986, BASIC METHODS MOL BI; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHEN CY, 1995, ONCOGENE, V11, P1487; CLEMENTS MJ, 1984, TRANSCRIPTION TRANSL; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DEVENTE J, 1995, CELL GROWTH DIFFER, V6, P371; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EASTMAN A, 1990, Current Opinion in Oncology, V2, P1109, DOI 10.1097/00001622-199012000-00014; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Ferraris C, 1997, EXP CELL RES, V234, P37, DOI 10.1006/excr.1997.3601; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FLETCHER JR, 1993, ARCH SURG-CHICAGO, V128, P1192; FOTI A, 1990, BRIT J HAEMATOL, V76, P143, DOI 10.1111/j.1365-2141.1990.tb07849.x; FRANSEN L, 1986, CELL IMMUNOL, V100, P260, DOI 10.1016/0008-8749(86)90025-0; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GULUCKMANN A, 1951, BIOL REV, V26, P59; Hall-Jackson CA, 1998, BRIT J CANCER, V78, P641, DOI 10.1038/bjc.1998.554; HEIKKILA J, 1993, BIOCHEM BIOPH RES CO, V197, P1185, DOI 10.1006/bbrc.1993.2602; HELSON L, 1979, EXP CELL BIOL, V47, P53; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; ITOH N, 1993, J BIOL CHEM, V268, P10932; JARVIS WD, 1994, BIOCHEM PHARMACOL, V47, P839; JARVIS WD, 1994, CANCER RES, V54, P1707; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; KEMPER O, 1993, GENE, V134, P209, DOI 10.1016/0378-1119(93)90095-K; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LE JM, 1987, LAB INVEST, V56, P234; LOTEM J, 1991, BLOOD, V78, P953; LUCAS M, 1994, BIOCHEM PHARMACOL, V47, P667, DOI 10.1016/0006-2952(94)90129-5; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; Masuda Y, 1997, INT J CANCER, V71, P691, DOI 10.1002/(SICI)1097-0215(19970516)71:4<691::AID-IJC29>3.0.CO;2-D; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; Messmer UK, 1997, BRIT J PHARMACOL, V121, P625, DOI 10.1038/sj.bjp.0701156; MIYASHITA T, 1993, BLOOD, V81, P151; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; Ohara H, 1998, JPN J CANCER RES, V89, P589, DOI 10.1111/j.1349-7006.1998.tb03302.x; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rusnak JM, 1996, EXP CELL RES, V224, P189, DOI 10.1006/excr.1996.0127; SAITO H, 1992, LEUKEMIA RES, V16, P217, DOI 10.1016/0145-2126(92)90059-G; Sasaguri T, 1996, J BIOL CHEM, V271, P8345, DOI 10.1074/jbc.271.14.8345; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WAYS DK, 1987, CANCER RES, V47, P3344; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANAGA F, 1992, FEBS LETT, V314, P297, DOI 10.1016/0014-5793(92)81493-6; YonishRouach E, 1996, EXPERIENTIA, V52, P1001, DOI 10.1007/BF01920109	82	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28286	28292		10.1074/jbc.274.40.28286	http://dx.doi.org/10.1074/jbc.274.40.28286			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497185	hybrid			2022-12-25	WOS:000082912700034
J	Sugata, N; Munekata, E; Todokoro, K				Sugata, N; Munekata, E; Todokoro, K			Characterization of a novel kinetochore protein, CENP-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSOME/ANAPHASE-PROMOTING COMPLEX; KINESIN-RELATED PROTEIN; SPINDLE CHECKPOINT; CHROMOSOME ALIGNMENT; ANAPHASE; MITOSIS; MAD2; CELLS; MICROINJECTION; LOCALIZATION	Macromolecular centromere-kinetochore complex plays a critical role in sister chromatid separation, but its complete protein composition as well as its precise dynamic function during mitosis has not yet been clearly determined. Here we report the isolation of a novel mouse kinetochore protein, CENP-H. The CENP-H, with an apparent molecular mass of 33 kDa, was found to contain a coiled-coil structure and a nuclear localization signal. The CENP-H transcripts were relatively scarce but were detectable in most tissues and embryos at various stages of development. Immunofluorescence stainings of mouse fibroblast cells with anti-CENP-H-specific antibody demonstrated that the CENP-H is specifically and constitutively localized in kinetochores throughout the cell cycle; this was also confirmed by stainings with anti-centromere-specific antibody. Thus the newly isolated CENP-H may play a role in kinetochore organization and function throughout the cell cycle.	RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	RIKEN; University of Tsukuba	Todokoro, K (corresponding author), RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, 3-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.			Yoshizawa-Sugata, Naoko/0000-0001-8792-8669				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Biggins S, 1999, CURR OPIN GENET DEV, V9, P230, DOI 10.1016/S0959-437X(99)80034-3; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; Cooke CA, 1997, CHROMOSOMA, V106, P446, DOI 10.1007/s004120050266; Dobie KW, 1999, CURR OPIN GENET DEV, V9, P206, DOI 10.1016/S0959-437X(99)80031-8; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; He DC, 1998, CHROMOSOMA, V107, P189, DOI 10.1007/s004120050296; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kalitsis P, 1998, P NATL ACAD SCI USA, V95, P1136, DOI 10.1073/pnas.95.3.1136; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Mackay AM, 1998, J CELL BIOL, V140, P991, DOI 10.1083/jcb.140.5.991; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; TODOKORO K, 1987, P NATL ACAD SCI USA, V84, P4126, DOI 10.1073/pnas.84.12.4126; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Williams BC, 1996, J CELL BIOL, V134, P1127, DOI 10.1083/jcb.134.5.1127; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95	31	64	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27343	27346		10.1074/jbc.274.39.27343	http://dx.doi.org/10.1074/jbc.274.39.27343			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488063	hybrid			2022-12-25	WOS:000082739100002
J	Vance, KW; Campo, MS; Morgan, IM				Vance, KW; Campo, MS; Morgan, IM			An enhanced epithelial response of a papillomavirus promoter to transcriptional activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2 TRANSACTIVATION DOMAIN; LONG CONTROL REGION; DNA-REPLICATION; TYPE-1 E2; IN-VITRO; FUNCTIONAL INTERACTION; MUTATIONAL ANALYSIS; REGULATORY REGION; HPV-16 PROMOTER; E6/E7 PROMOTER	Mucosal epitheliotropic papillomaviruses have a similar long control region (LCR) organization: a promoter region, an enhancer region, and a highly conserved distribution of E2 DNA binding sites. The enhancer of these viruses is epithelial-specific, as it fails to activate transcription from heterologous promoters in nonepithelial cell types (Gloss, B., Bernard, H. U., Seedorf, H., and Klock, G. (1987) EMBO J. 6, 3735-3743; Morgan, I. M., Grindlay, G. J., and Campo, M. S. (1999) J. Gen. Virol. 80, 23-27). Studies on E2 transcriptional regulation of the human mucosal epitheliotropic papillomaviruses have been hindered by poor access to the natural target cell type and by the observation that some of the human papillomavirus promoters, including human papilloma-virus-16, are repressed in immortalized epithelial cells. Here we present results using the bovine papillomavirus-4 (BPV-4) LCR and a bovine primary cell system as a model to study the mechanism of E2 transcriptional regulation of mucosal epitheliotropic papillomaviruses and the cell type specificity of this regulation. E2 up-regulates transcription from the BPV-I LCR preferentially in epithelial cells (Morgan, I, M., Grindlay, G. J., and Campo, M. S. (1998) J. Gen. Virol. 79, 501-508). We demonstrate that the epithelial-specific enhancer element of the BPV-4 LCR is not required for the enhanced activity of E2 in epithelial cells and that the BPV-4 promoter is more responsive, not only to E2, but to other transcriptional activators in epithelial cells, This is the first time a level of epithelial specificity has been shown to reside in a papillomavirus promoter region.	Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Morgan, IM (corresponding author), Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.	i.morgan@beatson.gla.ac.uk	Vance, Keith/AAK-5410-2021	Vance, Keith/0000-0002-3411-8213				APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; CAMPO MS, 1994, CARCINOGENESIS, V15, P1597, DOI 10.1093/carcin/15.8.1597; Connolly JA, 1998, ONCOGENE, V16, P2739, DOI 10.1038/sj.onc.1201796; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; CUTHILL S, 1993, MOL CARCINOGEN, V8, P96, DOI 10.1002/mc.2940080206; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; Demeret C, 1995, NUCLEIC ACIDS RES, V23, P4777, DOI 10.1093/nar/23.23.4777; Desaintes C, 1996, SEMIN CANCER BIOL, V7, P339, DOI 10.1006/scbi.1996.0043; DOLLARD SC, 1993, J VIROL, V67, P1721, DOI 10.1128/JVI.67.3.1721-1726.1993; Ferguson MK, 1996, J VIROL, V70, P4193, DOI 10.1128/JVI.70.7.4193-4199.1996; GAUTHIER JM, 1991, NEW BIOL, V3, P498; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; GLOSS B, 1987, EMBO J, V6, P3735, DOI 10.1002/j.1460-2075.1987.tb02708.x; Grossel MJ, 1996, J VIROL, V70, P7264, DOI 10.1128/JVI.70.10.7264-7269.1996; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAM J, 1994, EMBO J, V13, P147, DOI 10.1002/j.1460-2075.1994.tb06244.x; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HAM J, 1991, EMBO J, V10, P2931, DOI 10.1002/j.1460-2075.1991.tb07843.x; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HIBMA MH, 1995, EUR J BIOCHEM, V229, P517, DOI 10.1111/j.1432-1033.1995.tb20493.x; HOPPESEYLER F, 1992, NUCLEIC ACIDS RES, V20, P6701, DOI 10.1093/nar/20.24.6701; JACKSON ME, 1995, J VIROL, V69, P6038, DOI 10.1128/JVI.69.10.6038-6046.1995; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JAGGAR RT, 1990, J GEN VIROL, V71, P3041, DOI 10.1099/0022-1317-71-12-3041; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; Kasukawa H, 1998, J VIROL, V72, P8166, DOI 10.1128/JVI.72.10.8166-8173.1998; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MAY M, 1994, EMBO J, V13, P1460, DOI 10.1002/j.1460-2075.1994.tb06400.x; Morgan IM, 1998, J GEN VIROL, V79, P501, DOI 10.1099/0022-1317-79-3-501; Morgan IM, 1999, J GEN VIROL, V80, P23, DOI 10.1099/0022-1317-80-1-23; O'Connor MJ, 1998, J VIROL, V72, P10083; OConnor MJ, 1996, J VIROL, V70, P6529, DOI 10.1128/JVI.70.10.6529-6539.1996; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; SMITS PHM, 1993, J GEN VIROL, V74, P121, DOI 10.1099/0022-1317-74-1-121; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; Yao JM, 1998, J VIROL, V72, P1013, DOI 10.1128/JVI.72.2.1013-1019.1998	50	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27839	27844		10.1074/jbc.274.39.27839	http://dx.doi.org/10.1074/jbc.274.39.27839			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488130	hybrid			2022-12-25	WOS:000082739100069
J	Del Villar, K; Urano, J; Guo, L; Tamanoi, F				Del Villar, K; Urano, J; Guo, L; Tamanoi, F			A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYLTRANSFERASE TYPE-I; SITE-DIRECTED MUTAGENESIS; RAS-TRANSFORMED CELLS; BETA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; CONSERVED RESIDUES; TRANSFERASE INHIBITORS; SELECTIVE-INHIBITION; CRYSTAL-STRUCTURE; TRANSGENIC MICE	Protein farnesyltransferase (FTase) is a key enzyme responsible for the lipid modification of a large and important number of proteins including Ras. Recent demonstrations that inhibitors of this enzyme block, the growth of a variety of human tumors point to the importance of this enzyme in human tumor formation. In this paper, we report that a mutant form of human FTase, Y361L, exhibits increased resistance to farnesyltransferase inhibitors, particularly a tricyclic: compound, SCH56582, which is a competitive inhibitor of FTase with respect to the CAAX (where C is cysteine, A is an aliphatic amino acid, and X is the C-terminal residue that is preferentially serine, cysteine, methionine, glutamine or alanine) substrates. The Y361L mutant maintains FTase activity toward substrates ending with CIIS. However, the mutant also exhibits an increased affinity for peptides terminating with CIIL, a motif that is recognized by geranylgeranyltransferase I (GGTase I). The Y361L mutant also demonstrates activity with Ha-Ras and Cdc42Hs proteins, substrates of FTase and GGTase I, respectively. In addition, the Y361L mutant shows a marked sensitivity to a zinc chelator HPH-5 suggesting that the mutant has altered zinc coordination. These results demonstrate that a single amino acid change at a residue at the active site can lead to the generation of a mutant resistant to FTase inhibitors. Such a mutant may be valuable for the study of the effects of FTase inhibitors on tumor cells.	Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Inst Mol Biol, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Tamanoi, F (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Inst Mol Biol, Dept Microbiol & Mol Genet, 1602 Mol Sci Bldg, Los Angeles, CA 90095 USA.	fuyut@microbio.ucla.edu			NATIONAL CANCER INSTITUTE [R01CA041996] Funding Source: NIH RePORTER; NCI NIH HHS [CA41996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barinaga M, 1997, SCIENCE, V278, P1036, DOI 10.1126/science.278.5340.1036; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; Caplin BE, 1998, J BIOL CHEM, V273, P9472, DOI 10.1074/jbc.273.16.9472; COX AD, 1994, J BIOL CHEM, V269, P19203; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; DelVillar K, 1997, J BIOL CHEM, V272, P680; Dolence JM, 1997, BIOCHEMISTRY-US, V36, P9246, DOI 10.1021/bi970039p; Dunten P, 1998, BIOCHEMISTRY-US, V37, P7907, DOI 10.1021/bi980531o; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; Fujita M, 1996, J MED CHEM, V39, P503, DOI 10.1021/jm950831t; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang CC, 1997, J BIOL CHEM, V272, P20; Hunt JT, 1996, J MED CHEM, V39, P353, DOI 10.1021/jm9507284; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Kral AM, 1997, J BIOL CHEM, V272, P27319, DOI 10.1074/jbc.272.43.27319; Kurth DD, 1997, BIOCHEMISTRY-US, V36, P15932, DOI 10.1021/bi971614s; Lebowitz PF, 1997, CANCER RES, V57, P708; Long SB, 1998, BIOCHEMISTRY-US, V37, P9612, DOI 10.1021/bi980708e; MITSUZAWA H, 1995, P NATL ACAD SCI USA, V92, P1704, DOI 10.1073/pnas.92.5.1704; NAGASU T, 1995, CANCER RES, V55, P5310; Otsuka M, 1997, BIOORGAN MED CHEM, V5, P205, DOI 10.1016/S0968-0896(96)00203-9; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; SATTLER I, 1996, REGULATION RAS SIGNA, P95; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Strickland CL, 1998, BIOCHEMISTRY-US, V37, P16601, DOI 10.1021/bi981197z; SUN JZ, 1995, CANCER RES, V55, P4243; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P10499, DOI 10.1073/pnas.95.18.10499; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	41	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27010	27017		10.1074/jbc.274.38.27010	http://dx.doi.org/10.1074/jbc.274.38.27010			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480914	hybrid			2022-12-25	WOS:000082570700053
J	Sloper-Mould, KE; Eyre, HJ; Wang, XW; Sutherland, GR; Baker, RT				Sloper-Mould, KE; Eyre, HJ; Wang, XW; Sutherland, GR; Baker, RT			Characterization and chromosomal localization of USP3, a novel human ubiquitin-specific protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; FAT-FACETS GENE; DEUBIQUITINATING ENZYME; DEGRADATION SIGNAL; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; SHUTTLE VECTORS; MESSENGER-RNAS; EXPRESSION; ENCODES	Conjugation to the small eukaryotic protein ubiquitin can functionally modify or target proteins for degradation by the proteasome. Removal of the ubiquitin modification, or deubiquitination, is performed by ubiquitin-specific proteases and is an important mechanism regulating this pathway. Here we describe a novel human ubiquitin-specific protease, USP3, initially identified as a partial cDNA clone similar to one of two highly conserved sequence regions common to all ubiquitin-specific proteases. We have isolated a complete USP3 cDNA clone containing both of these conserved sequence regions. The USP3 gone appears to be single copy and maps to human chromosome 15q22.3. A USP3 probe detects two mRNA transcripts, one of which corresponds in length to the cDNA. Both are expressed at low levels in all tissues examined, with highest expression in pancreas, The USP3 protein is a functional ubiquitin-specific protease in vitro, and is able to inhibit ubiquitin-dependent degradation of both an N-end Rule substrate and abnormal endogenous proteins in yeast. USP3 is also only the second known ubiquitin-specific protease capable of efficiently cleaving a ubiquitin-proline bond.	Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia; Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Ctr Med Genet, N Adelaide, SA 5006, Australia	Australian National University; John Curtin School of Medical Research	Baker, RT (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, GPO Box 334, Canberra, ACT 2601, Australia.		Sutherland, Grant Robert/D-2606-2012					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amerik AY, 1997, EMBO J, V16, P4826; AnsariLari MA, 1996, GENOME RES, V6, P314, DOI 10.1101/gr.6.4.314; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1994, J BIOL CHEM, V269, P25381; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BAKER RT, 1999, IN PRESS GENOMICS; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; Brown GM, 1998, HUM MOL GENET, V7, P97, DOI 10.1093/hmg/7.1.97; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; FALQUET L, 1995, FEBS LETT, V376, P233, DOI 10.1016/0014-5793(95)01287-7; FALQUET L, 1995, FEBS LETT, V359, P73, DOI 10.1016/0014-5793(94)01451-6; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; Fujiwara T, 1998, GENOMICS, V54, P155, DOI 10.1006/geno.1998.5554; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gilchrist CA, 1997, J BIOL CHEM, V272, P32280, DOI 10.1074/jbc.272.51.32280; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GRAY DA, 1995, ONCOGENE, V10, P2179; GRUNEBAUM L, 1984, J CLIN INVEST, V73, P1491, DOI 10.1172/JCI111354; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; Haas AL, 1997, FASEB J, V11, P1257; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Janssen JWG, 1998, ONCOGENE, V16, P1767, DOI 10.1038/sj.onc.1201695; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Jones MH, 1996, HUM MOL GENET, V5, P1695, DOI 10.1093/hmg/5.11.1695; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINNEN JM, 1993, GENE, V128, P181, DOI 10.1016/0378-1119(93)90561-G; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; Sambrook J., 2002, MOL CLONING LAB MANU; SAUFERT W, 1995, NATURE, V373, P81; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Timms KM, 1998, GENE, V217, P101, DOI 10.1016/S0378-1119(98)00341-2; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu YA, 1997, J BIOL CHEM, V272, P51	52	19	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26878	26884		10.1074/jbc.274.38.26878	http://dx.doi.org/10.1074/jbc.274.38.26878			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480896	hybrid			2022-12-25	WOS:000082570700035
J	Alam, J; Stewart, D; Touchard, C; Boinapally, S; Choi, AMK; Cook, JL				Alam, J; Stewart, D; Touchard, C; Boinapally, S; Choi, AMK; Cook, JL			Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT-RESPONSE-ELEMENT; NAD(P)H-QUINONE OXIDOREDUCTASE GENE; SMALL MAF PROTEINS; BINDING-SITE; MEDIATED EXPRESSION; HEPATOMA-CELLS; HEAVY-METALS; FACTOR NF-E2; BASAL LEVEL; V-MAF	Stress response elements, which mediate induction of the mouse heme oxygenase-l (HO-1) gene by several agents, resemble the binding site for the activator protein-1 (Jun/Fos), Maf, and Cap'n'Collar/basic leucine zipper (CNC-bZIP) families of proteins. In L929 fibroblasts, significant activation of an HO-1 enhancer-reporter fusion gene was observed only with the CNC-bZIP class of proteins with Nrf2 exhibiting the highest level of transactivation, between 25- and 30-fold. To further examine the role of this factor in HO-1 gene regulation, a dominant-negative mutant, Nrf2M, was generated and conditionally expressed in L929 cells. The mutant protein was detected in cytoplasmic and nuclear fractions but did not affect cell growth. Under conditions of Nrf2M overexpression, HO-1 mRNA accumulation in response to heme, cadmium, zinc, arsenite, and tert-butylhydroquinone was inhibited by 85-95%. In contrast, overexpression of a dominant-negative mutant of c-Jun decreased L929 cell growth but did not inhibit HO-1 gene activation. Nrf2 does not homodimerize, but CNC-bZIP small Maf protein heterodimers and Nrf2 Jun protein complexes are proposed to function as trans-activators. Coexpression of Jun proteins or p18, however, had no significant affect or inhibited Nrf2-mediated trans-activation. Taken together, these results implicate Nrf2 in the induction of the HO-1 gene but suggest that the Nrf2 partner in this function is a factor other than p18 or Jun proteins.	Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, New Orleans, LA 70121 USA; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70121 USA; Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06250 USA	Ochsner Health System; Louisiana State University System; Yale University	Alam, J (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, 1516 Jefferson Highway, New Orleans, LA 70121 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NHLBI NIH HHS [HL60234] Funding Source: Medline; NIDDK NIH HHS [DK-43135] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM J, 1992, J BIOL CHEM, V267, P16379; ALAM J, 1994, J BIOL CHEM, V269, P1001; ALAM J, 1994, J BIOL CHEM, V269, P25049; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; ALAM J, 1992, J BIOL CHEM, V267, P21894; ALAM J, 1989, J BIOL CHEM, V264, P6371; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BROWN PH, 1994, ONCOGENE, V9, P791; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUI DHK, 1995, BIOCHEM BIOPH RES CO, V209, P40, DOI 10.1006/bbrc.1995.1467; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; ITOH K, 1998, GENE DEV, V13, P67; Johnsen O, 1998, NUCLEIC ACIDS RES, V26, P512, DOI 10.1093/nar/26.2.512; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; Terry CM, 1998, AM J PHYSIOL-HEART C, V274, pH883, DOI 10.1152/ajpheart.1998.274.3.H883; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wei P, 1998, J STEROID BIOCHEM, V64, P1, DOI 10.1016/S0022-1759(97)89907-3	41	1038	1058	2	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26071	26078		10.1074/jbc.274.37.26071	http://dx.doi.org/10.1074/jbc.274.37.26071			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473555	hybrid			2022-12-25	WOS:000082469700021
J	Bengtsson, J; Rivolta, C; Hederstedt, L; Karamata, D				Bengtsson, J; Rivolta, C; Hederstedt, L; Karamata, D			Bacillus subtilis contains two small c-type cytochromes with homologous heme domains but different types of membrane anchors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOPHILIC BACTERIUM PS3; AIR-LIMITED CONDITIONS; ESCHERICHIA-COLI; OVER-EXPRESSION; BC COMPLEX; OXIDASE; STEAROTHERMOPHILUS; SEQUENCE; CLONING; MUTANTS	We demonstrate that the cccB gene, identified in the Bacillus subtilis genome sequence project, is the structural gene for a 10-kDa membrane-bound cytochrome c(551) lipoprotein described for the first time in B, subtilis, Apparently, CccB corresponds to cytochrome c(551) of the thermophilic bacterium Bacillus PS3, The heme domain of B, subtilis cytochrome c(551) is very similar to that of cytochrome c(550) a protein encoded by the cccA gene and anchored to the membrane by a single transmembrane polypeptide segment. Thus, B, subtilis contains two small, very similar, c-type cytochromes with different types of membrane anchors. The cccB gene is cotranscribed with the yvjA gene, and transcription is repressed by glucose. Mutants deleted for cccB or yujA-cccB show no apparent growth, sporulation, or germination defect. YvjA is not required for the synthesis of cytochrome c(551), and its function remains unknown.	Lund Univ, Dept Microbiol, S-22362 Lund, Sweden; Univ Lausanne, Inst Genet & Biol Microbiennes, CH-1005 Lausanne, Switzerland	Lund University; University of Lausanne	Bengtsson, J (corresponding author), Lund Univ, Dept Microbiol, Solvegatan 12, S-22362 Lund, Sweden.	Jenny.Bengtsson@mikrbiol.lu.se		Rivolta, Carlo/0000-0002-0733-9950; Hederstedt, Lars/0000-0002-6650-6296				Albert I, 1998, BIOCHEMISTRY-US, V37, P9001, DOI 10.1021/bi9731347; ARWERT F, 1973, MOL GEN GENET, V123, P185, DOI 10.1007/BF00267334; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; FERRARI E, 1986, J BACTERIOL, V166, P173, DOI 10.1128/JB.166.1.173-179.1986; FORTNAGEL P, 1968, J BACTERIOL, V95, P1431, DOI 10.1128/JB.95.4.1431-1438.1968; FUJIWARA Y, 1993, BIOCHIM BIOPHYS ACTA, V1144, P213, DOI 10.1016/0005-2728(93)90175-F; HAIMA P, 1987, MOL GEN GENET, V209, P335, DOI 10.1007/BF00329663; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; Hansson M, 1997, BBA-PROTEIN STRUCT M, V1340, P97, DOI 10.1016/S0167-4838(97)00030-7; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HEDERSTEDT L, 1986, METHOD ENZYMOL, V126, P399; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; ITAYA M, 1991, J MOL BIOL, V220, P631, DOI 10.1016/0022-2836(91)90106-G; Kai K, 1997, J FERMENT BIOENG, V84, P190, DOI 10.1016/S0922-338X(97)82053-3; KARAMATA D, 1970, MOL GEN GENET, V108, P277, DOI 10.1007/BF00283358; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Nikaido K, 1998, BBA-GENE STRUCT EXPR, V1397, P262, DOI 10.1016/S0167-4781(98)00043-8; NOGUCHI S, 1994, BBA-BIOENERGETICS, V1188, P302, DOI 10.1016/0005-2728(94)90049-3; Perego Marta, 1993, P615; RIVOLTA C, 1999, THESIS U LAUSANNE LA; Sakamoto J, 1997, J BIOCHEM-TOKYO, V122, P764; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schiott T, 1997, J BACTERIOL, V179, P4523, DOI 10.1128/jb.179.14.4523-4529.1997; Schiott T, 1997, J BACTERIOL, V179, P1962, DOI 10.1128/jb.179.6.1962-1973.1997; SONE N, 1990, J BIOCHEM-TOKYO, V107, P597, DOI 10.1093/oxfordjournals.jbchem.a123092; SONE N, 1989, BIOCHIM BIOPHYS ACTA, V977, P329, DOI 10.1016/S0005-2728(89)80088-X; SONE N, 1994, FEMS MICROBIOL LETT, V122, P203, DOI 10.1111/j.1574-6968.1994.tb07168.x; VANDEROOST J, 1991, MOL MICROBIOL, V5, P2063; VONWACHENFELDT C, 1990, FEBS LETT, V270, P147, DOI 10.1016/0014-5793(90)81255-M; VONWACHENFELDT C, 1992, FEMS MICROBIOL LETT, V100, P91, DOI 10.1016/0378-1097(92)90194-S; VONWACHENFELDT C, 1990, J BIOL CHEM, V265, P13939; VONWACHENFELDT C, 1993, EUR J BIOCHEM, V212, P499; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yu J, 1998, J BIOL CHEM, V273, P8860, DOI 10.1074/jbc.273.15.8860; YU J, 1995, J BACTERIOL, V177, P6751, DOI 10.1128/jb.177.23.6751-6760.1995	37	32	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26179	26184		10.1074/jbc.274.37.26179	http://dx.doi.org/10.1074/jbc.274.37.26179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473570	Green Accepted, hybrid			2022-12-25	WOS:000082469700036
J	DeAngelis, PL				DeAngelis, PL			Molecular directionality of polysaccharide polymerization by the Pasteurella multocida hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED TERATOCARCINOMA CELLS; D-GLUCOSAMINYLTRANSFERASE REACTIONS; GLUCURONOSYL-TRANSFERASE; CHITIN OLIGOSACCHARIDES; IDENTIFICATION; BIOSYNTHESIS; PROTEIN; ACID; XENOPUS; ENZYME	Hyaluronan (HA), a long linear polymer composed of alternating glucuronic acid and N-acetylglucosamine residues, is an essential polysaccharide in vertebrates and a putative virulence factor in certain microbes. All known HA synthases utilize UDP-sugar precursors. Previous reports describing the HA synthase enzymes from Streptococcus bacteria and mammals, however, did not agree on the molecular directionality of polymer elongation. We show here that a HA synthase, PmHAS, from Gram-negative P. multocida bacteria polymerizes the HA chain by the addition of sugar units to the nonreducing terminus. Recombinant PmHAS will elongate exogenous HA oligosaccharide accepters to form long polymers in vitro; thus far no other HA synthase has displayed this capability. The directionality of synthesis was established definitively by testing the ability of PmHAS to elongate defined oligosaccharide derivatives. Analysis of the initial stages of synthesis demonstrated that PmHAS added single monosaccharide units sequentially. Apparently the fidelity of the individual sugar transfer reactions is sufficient to generate the authentic repeating structure of HA. Therefore, simultaneous addition of disaccharide block units is not required as hypothesized in some recent models of polysaccharide biosynthesis. PmHAS appears distinct from other known HA synthases based on differences in sequence, topology in the membrane, and putative reaction mechanism.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asplund T, 1998, BBA-GEN SUBJECTS, V1380, P377, DOI 10.1016/S0304-4165(98)00010-5; CARTER GR, 1953, AM J VET RES, V14, P475; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 1997, SCIENCE, V278, P1800, DOI 10.1126/science.278.5344.1800; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DeAngelis PL, 1996, BIOCHEMISTRY-US, V35, P9768, DOI 10.1021/bi960154k; Griffiths G, 1998, J BIOL CHEM, V273, P11752, DOI 10.1074/jbc.273.19.11752; HALL NA, 1989, ANAL BIOCHEM, V178, P378, DOI 10.1016/0003-2697(89)90656-8; HARMON BG, 1991, AM J VET RES, V52, P1507; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Koyama M, 1997, P NATL ACAD SCI USA, V94, P9091, DOI 10.1073/pnas.94.17.9091; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lidholt K, 1997, BIOCHEM SOC T, V25, P866, DOI 10.1042/bst0250866; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIND T, 1993, J BIOL CHEM, V268, P20705; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; STOOLMILLER AC, 1969, J BIOL CHEM, V244, P236; Sugumaran G, 1997, J BIOL CHEM, V272, P14399, DOI 10.1074/jbc.272.22.14399; TAYLOR KA, 1992, ANAL BIOCHEM, V201, P190, DOI 10.1016/0003-2697(92)90194-C; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317	32	79	85	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26557	26562		10.1074/jbc.274.37.26557	http://dx.doi.org/10.1074/jbc.274.37.26557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473619	hybrid			2022-12-25	WOS:000082469700085
J	Landolt-Marticorena, C; Kahr, WH; Zawarinski, P; Correa, J; Manolson, MF				Landolt-Marticorena, C; Kahr, WH; Zawarinski, P; Correa, J; Manolson, MF			Substrate- and inhibitor-induced conformational changes in the yeast V-ATPase provide evidence for communication between the catalytic and proton-translocating sectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTEIN SECONDARY STRUCTURE; SITE-DIRECTED MUTAGENESIS; ADENOSINE-TRIPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; SUBUNIT VPH1P; GENE ENCODES; (H+)-ATPASE; SYNTHASE	The vacuolar-type H+-ATPases (V-ATPases) are composed of two distinct sectors, a catalytic complex (V,) involved in ATP hydrolysis and a membrane-associated complex (V,) mediating proton translocation across a lipid bilayer, To date, little is known about the mechanism by which these two functions are coupled. We sought to examine the impact of nucleotide and cation binding on the structure of the core components of the catalytic complex and to determine whether conformational changes within the catalytic complex impact subunits of the membrane-associated complex. Nucleotide-and cation- induced changes in the catalytic core of the V-ATPase were investigated by monitoring changes in the rate and pattern of tryptic digests. ATP Mg-induced changes were detected in both the catalytic (Vma1p or 69 kDa) and the regulatory subunits (Vma2p or 60 kDa) of the V, sector. ATP alone increased the rate of trypsinization of the regulatory subunit, but did not have any effect on Vma1p. Surprisingly, ATP also had an impact on the 95-kDa subunit, a component of the V-1 sector of the V-ATPase. Although the presence of divalent cations had no impact on the V-1 sector, the rate of trypsinization of the 95-kDa subunit was greatly enhanced. The effect of divalent cations on the structure of the 95-kDa subunit was abrogated when trypsinization was performed in the absence of the catalytic sector. Addition of bafilomycin A,, a V-ATPase inhibitor that putatively binds to the 95-kDa subunit, increased the rate of trypsinization of the catalytic subunit. These data suggest that structural alterations within the V-0 sector result in alterations within the V-1 sector and vice versa, Clearly, a structural link must exist to couple the two sectors. The 95-kDa subunit is ideally suited to fulfill this role. Hydropathy analysis suggests a bipartite structure, with the NH2-terminal portion predicted to lie in an aqueous environment and the C-terminal portion predicted to contain 6 transmembrane segments. Tryptic digests of sealed vacuolar vesicles and immunofluorescence studies revealed that the large hydrophilic NH2-terminal domain of the 95-kDa subunit is localized toward the cytosol, This region therefore is ideally positioned to interact with components of the V-1 complex, potentially functioning as the elusive link between the two sectors of the V-ATPase.	Univ Toronto, Fac Dent, Res Inst, Dept Dent, Toronto, ON M5G 1G6, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Manolson, MF (corresponding author), Univ Toronto, Fac Dent, Res Inst, Dept Dent, 124 Edward St,Rm 429, Toronto, ON M5G 1G6, Canada.		Kahr, Walter/K-9040-2019	Manolson, Morris/0000-0001-8755-5460				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; BOWMAN J, 1996, MYCOTA, V3, P57; Brisseau GF, 1996, J BIOL CHEM, V271, P2005, DOI 10.1074/jbc.271.4.2005; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1994, J BIOL CHEM, V269, P13224; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HIRATA R, 1990, J BIOL CHEM, V265, P6726; KANE PM, 1992, J EXP BIOL, V172, P93; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1989, BIOCHEM CELL BIOL, V67, P306, DOI 10.1139/o89-047; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Parra KJ, 1996, J BIOL CHEM, V271, P19592, DOI 10.1074/jbc.271.32.19592; PENG SB, 1995, J BIOL CHEM, V270, P16926; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; TAIZ L, 1994, BBA-BIOMEMBRANES, V1194, P329, DOI 10.1016/0005-2736(94)90315-8; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	50	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26057	26064		10.1074/jbc.274.37.26057	http://dx.doi.org/10.1074/jbc.274.37.26057			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473553	hybrid			2022-12-25	WOS:000082469700019
J	Lubke, T; Marquardt, T; von Figura, K; Korner, C				Lubke, T; Marquardt, T; von Figura, K; Korner, C			A new type of carbohydrate-deficient glycoprotein syndrome due to a decreased import of GDP-fucose into the golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE TRANSPORTER; LEUKOCYTE ADHESION DEFICIENCY; SYNDROME TYPE-I; MOLECULAR-CLONING; PHOSPHOMANNOMUTASE DEFICIENCY; GUANOSINE DIPHOSPHATASE; ENDOPLASMIC-RETICULUM; RAT-LIVER; APPARATUS; MANNOSE	The fucosylation of glycoproteins was found to be deficient in a patient with a clinical phenotype resembling that of leukocyte adhesion deficiency type II (LAD II). While in LAD II hypofucosylation of glycoconjugates is secondary to an impaired synthesis of GDP-fucose due to a deficiency of the GDP-D-mannose-4,6-dehydratase, synthesis of GDP-fucose was normal in our patient (korner, C., Linnebank, NI, Koch, H., Harms, E., von Figura, K., and Marquardt, T., (1999) J. Leukoc, Biol., in press). Import of GDP-fucose into Golgi-enriched vesicles was composed of a saturable, high affinity and a nonsaturable component, In our patient the saturable high affinity import of GDP-fucose was deficient, while import of UDP-galactose and the activity of GDPase, which generates the nucleoside phosphate required for antiport of GDP-fucose, were normal, Addition of L-fucose to the medium of fibroblasts restored the fucosylation of glycoproteins. We propose that this new form of carbohydrate-deficient glycoprotein syndrome is caused by impaired import of GDP-fucose into the Golgi.	Univ Gottingen, Biochem Abt 2, D-37073 Gottingen, Germany; Klin & Poliklin Kinderheilkunde, D-48149 Munster, Germany	University of Gottingen; University of Munster	Korner, C (corresponding author), Univ Gottingen, Biochem Abt 2, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	koerner@ukb2-00.uni-bc2.gwdw.de	Lübke, Torben/B-6019-2012	Lubke, Torben/0000-0002-3342-0090				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; CUMMING DA, 1994, METHOD ENZYMOL, V230, P67; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; JAEKEN J, 1994, ARCH DIS CHILD, V71, P123, DOI 10.1136/adc.71.2.123; Korner C, 1999, J LEUKOCYTE BIOL, V66, P95; Korner C, 1998, GLYCOBIOLOGY, V8, P165, DOI 10.1093/glycob/8.2.165; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marquardt T, 1999, J PEDIATR-US, V134, P681, DOI 10.1016/S0022-3476(99)70281-7; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; Puglielli L, 1999, J BIOL CHEM, V274, P4474, DOI 10.1074/jbc.274.7.4474; STIBLER H, 1993, NEUROPEDIATRICS, V24, P51, DOI 10.1055/s-2008-1071513; STIBLER H, 1995, NEUROPEDIATRICS, V26, P235, DOI 10.1055/s-2007-979762; Sturla L, 1998, FEBS LETT, V429, P274, DOI 10.1016/S0014-5793(98)00615-2; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392	28	101	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					25986	25989		10.1074/jbc.274.37.25986	http://dx.doi.org/10.1074/jbc.274.37.25986			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473542	hybrid			2022-12-25	WOS:000082469700008
J	Wahl, RC; Hsu, RY; Huff, JL; Jelinek, MA; Chen, K; Courchesne, P; Patterson, SD; Parsons, JT; Welcher, AA				Wahl, RC; Hsu, RY; Huff, JL; Jelinek, MA; Chen, K; Courchesne, P; Patterson, SD; Parsons, JT; Welcher, AA			Chicken macrophage stimulating protein is a ligand of the receptor protein-tyrosine kinase Sea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; RON; FAMILY; EXPRESSION; GENE; MSP; IDENTIFICATION; PURIFICATION; ACTIVATION; PRODUCT	Affinity chromatography, employing the extracellular domain of the Sea receptor, was used to enrich Sea-binding proteins from chicken serum. One isolated protein bound both a Sea-immunoglobulin fusion protein and an antisera raised against murine macrophage stimulating protein. Amino-terminal sequencing of the dual-reactive protein yielded sequences which were identical to the predicted alpha and beta subunits of chicken macrophage stimulating protein. The partially purified chicken macrophage stimulating protein caused autophosphorylation of the Sea receptor. Previous work showed that recombinant expression of fully activatible human or mouse macrophage stimulating protein required a specific Cys to Ala substitution (Wahl, R. C., Costigan, V. J., Batac, J. P., Chen, K., Cam, L., Courchesne, P. L., Patterson, S. D. Zhang, K., and Pacifici, R. E. (1997) J. Biol. Chem. 272, 1-4). Therefore, we expressed both the wild type and the specific Cys to Ala form of chicken macrophage stimulating protein as recombinant proteins. After proteolytic activation, only conditioned media from COS cells transfected with the C665A chicken macrophage stimulating protein, but not from wild type chicken macrophage-stimulating protein, or control vector, was detected by the Sea-immunoglobulin fusion protein in Western blotting experiments. Conditioned media containing the C665A chicken macrophage-stimulating protein readily caused Sea phosphorylation, while conditioned media containing the wild type chicken macrophage-stimulating protein was only effective at inducing receptor phosphorylation at high concentrations. In addition to receptor phosphorylation, the C665A chicken macrophage-stimulating protein induced phosphorylation of Shc, Erk1, and Erk 2. We conclude that macrophage-stimulating protein is a ligand of the Sea receptor protein-tyrosine kinase.	Amgen Inc, Dept Mol Genom, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept High Throughput Screening, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Mammalian Genom, Thousand Oaks, CA 91320 USA; Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA	Amgen; Amgen; Amgen; University of Virginia	Welcher, AA (corresponding author), Amgen Inc, Dept Mol Genom, MS 14-1-B,1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	awelcher@amgen.com	Patterson, Scott/A-7404-2009	Huff, Janice/0000-0003-4236-7698				Banu N, 1996, J IMMUNOL, V156, P2933; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1988, ONCOGENE, V2, P593; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HEIMARK RL, 1981, METHOD ENZYMOL, V80, P157; Huff JL, 1996, ONCOGENE, V12, P299; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; NALDINI L, 1991, ONCOGENE, V6, P501; OHASHI K, 1994, ONCOGENE, V9, P699; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RONSIN C, 1993, ONCOGENE, V8, P1195; SHIMAMOTO A, 1993, FEBS LETT, V333, P61, DOI 10.1016/0014-5793(93)80375-5; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; SILVERBERG M, 1988, METHOD ENZYMOL, V163, P85; Stubbs EL, 1935, J EXP MED, V61, P593, DOI 10.1084/jem.61.5.593; THERY C, 1995, DEV GENET, V17, P90, DOI 10.1002/dvg.1020170110; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wahl RC, 1997, J BIOL CHEM, V272, P15053, DOI 10.1074/jbc.272.24.15053; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; WANG MH, 1994, J BIOL CHEM, V269, P3436; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZARNEGAR R, 1989, CANCER RES, V49, P3314	35	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26361	26368		10.1074/jbc.274.37.26361	http://dx.doi.org/10.1074/jbc.274.37.26361			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473593	hybrid			2022-12-25	WOS:000082469700059
J	Yount, NY; Yuan, J; Tarver, A; Castro, T; Diamond, G; Tran, PA; Levy, JN; McCullough, C; Cullor, JS; Bevins, CL; Selsted, ME				Yount, NY; Yuan, J; Tarver, A; Castro, T; Diamond, G; Tran, PA; Levy, JN; McCullough, C; Cullor, JS; Bevins, CL; Selsted, ME			Cloning and expression of bovine neutrophil beta-defensins - Biosynthetic profile during neutrophilic maturation and localization of mature peptide to novel cytoplasmic dense granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH ANTIMICROBIAL PEPTIDES; TRACHEAL EPITHELIAL-CELLS; HUMAN BETA-DEFENSIN-1; MOUSE BETA-DEFENSIN-1; MOLECULAR-CLONING; SMALL-INTESTINE; MYELOID CELLS; HOST-DEFENSE; C/EBP FAMILY; GENE	beta-Defensins are microbicidal peptides implicated in host defense functions of phagocytic leukocytes and certain surface epithelial cells. Here we investigated the genetic structures and cellular expression of BNBD-4, -12, and -13, three prototypic bovine neutrophil beta-defensins. Characterization of the corresponding cDNAs indicated that BNBD-4 (41 residues) derives from a 63-amino acid prepropeptide and that BNBD-12 (38 residues) and BNBD-13 (42 residues) derive from a common 60-amino acid precursor (BNBD-12/13). The peptides were found to be encoded by two-exon genes that are closely related to bovine epithelial beta-defensin genes. BNBD-4 and BNBD-12/13 mRNAs were most abundant in bone marrow, but were expressed differentially in certain non-myeloid tissues. In situ hybridization and immunohistochemical studies demonstrated that BNBD-4 synthesis is completed early in myelopoiesis. BNBD-12 was localized exclusively to the novel dense granules, organelles that also contain precursors of cathelicidins, antimicrobial peptides that undergo proteolytic processing during phagocytosis. In contrast to cathelicidins, Western blot analyses revealed that mature beta-defensins are the predominant organellar form in myeloid cells. Stimulation of neutrophils with phorbol myristate acetate induced secretion of BNBD-12, indicating that it is co-secreted with pro-cathelicidins. The exocytosis of BNBD-12 by activated neutrophils reveals different mobilization pathways for myeloid alpha- and beta-defensins.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Childrens Hosp Philadelphia, Div Genet & Mol Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Med & Dent New Jersey, Dept Anat Cell Biol & Injury sci, Newark, NJ 07103 USA; Univ Calif Davis, Dept Vet Pathol, Sch Vet Med, Davis, CA 95616 USA; Cleveland Clin Fdn, Res Inst, Dept Immunol, Cleveland, OH 44195 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California Davis; Cleveland Clinic Foundation	Selsted, ME (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.	meselste@uci.edu	Bevins, Charles L/P-4438-2015	Bevins, Charles L/0000-0003-2725-2622; Yount, Nannette/0000-0002-7079-5211; Castro, Tammy/0000-0002-1631-9281	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032234, R01AI032738, R37AI032738, R01AI032234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008851] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREU D, 1983, P NATL ACAD SCI-BIOL, V80, P6475, DOI 10.1073/pnas.80.21.6475; BAGGIOLINI M, 1985, LAB INVEST, V52, P151; Bals R, 1998, INFECT IMMUN, V66, P1225, DOI 10.1128/IAI.66.3.1225-1232.1998; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; Diamond G, 1998, CLIN IMMUNOL IMMUNOP, V88, P221, DOI 10.1006/clin.1998.4587; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3556, DOI 10.1128/IAI.60.9.3556-3565.1992; EVANS EW, 1994, J LEUKOCYTE BIOL, V56, P661, DOI 10.1002/jlb.56.5.661; FRANK RW, 1990, J BIOL CHEM, V265, P18871; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GANZ T, 1987, INFECT IMMUN, V55, P568, DOI 10.1128/IAI.55.3.568-571.1987; GENNARO R, 1983, J CELL BIOL, V96, P1651, DOI 10.1083/jcb.96.6.1651; GENNARO R, 1983, INFECT IMMUN, V40, P684, DOI 10.1128/IAI.40.2.684-690.1983; GENNARO R, 1989, INFECT IMMUN, V57, P3142, DOI 10.1128/IAI.57.10.3142-3146.1989; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1994, FEBS LETT, V342, P281, DOI 10.1016/0014-5793(94)80517-2; Hiratsuka T, 1998, BIOCHEM BIOPH RES CO, V249, P943, DOI 10.1006/bbrc.1998.9239; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; Huttner KM, 1997, FEBS LETT, V413, P45, DOI 10.1016/S0014-5793(97)00875-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lehrer RI, 1996, ANN NY ACAD SCI, V797, P228, DOI 10.1111/j.1749-6632.1996.tb52963.x; Liu L, 1998, GENE, V222, P237, DOI 10.1016/S0378-1119(98)00480-6; Liu L, 1996, J INVEST MED, V44, pA294; Mahoney MM, 1995, FEBS LETT, V377, P519, DOI 10.1016/0014-5793(95)01390-3; MARTIN R, 1990, BIOTECHNIQUES, V9, P762; McCray PB, 1997, AM J RESP CELL MOL, V16, P343, DOI 10.1165/ajrcmb.16.3.9070620; MICHAELSON D, 1992, J LEUKOCYTE BIOL, V51, P634, DOI 10.1002/jlb.51.6.634; Morrison GM, 1998, MAMM GENOME, V9, P453, DOI 10.1007/s003359900795; NAGAOKA I, 1992, FEBS LETT, V302, P279, DOI 10.1016/0014-5793(92)80459-T; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROMEO D, 1988, J BIOL CHEM, V263, P9573; Russell JP, 1996, INFECT IMMUN, V64, P1565, DOI 10.1128/IAI.64.5.1565-1568.1996; Ryan LK, 1998, INFECT IMMUN, V66, P878, DOI 10.1128/IAI.66.2.878-881.1998; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVOINI A, 1984, ANTIMICROB AGENTS CH, V26, P405, DOI 10.1128/AAC.26.3.405; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SELSTED ME, 1983, J BIOL CHEM, V258, P4485; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Tarver AP, 1998, INFECT IMMUN, V66, P1045, DOI 10.1128/IAI.66.3.1045-1056.1998; VALORE EV, 1992, BLOOD, V79, P1538; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Wang MSC, 1997, ANAL BIOCHEM, V253, P225, DOI 10.1006/abio.1997.2347; WILDE JKH, 1964, RES VET SCI, V5, P213; YOUNT NY, 1995, J IMMUNOL, V155, P4476; ZANETTI M, 1991, J IMMUNOL, V146, P4295; ZANETTI M, 1990, J CELL BIOL, V111, P1363, DOI 10.1083/jcb.111.4.1363; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; Zhang GL, 1998, FEBS LETT, V424, P37, DOI 10.1016/S0014-5793(98)00134-3; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	69	58	64	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26249	26258		10.1074/jbc.274.37.26249	http://dx.doi.org/10.1074/jbc.274.37.26249			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473579	hybrid			2022-12-25	WOS:000082469700045
J	Kramer, PR; Fragoso, G; Pennie, W; Htun, H; Hager, GL; Sinden, RR				Kramer, PR; Fragoso, G; Pennie, W; Htun, H; Hager, GL; Sinden, RR			Transcriptional state of line mouse mammary tumor virus promoter can affect topological domain size in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-CELLS; LONG TERMINAL REPEAT; DNA TOPOISOMERASE-I; SHOCK GENE LOCUS; TORSIONAL TENSION; CHROMATIN STRUCTURE; MMTV PROMOTER; INVIVO; ACTIVATION; NUCLEOSOME	Unrestrained DNA supercoiling and the number of topological domains were measured within a 1.8 megabase pair chromosomal region consisting of about 200 tandem repeats of a mouse mammary tumor virus promoter-driven ha-v-ras gene. When uninduced, unrestrained negative supercoiling was organized into 32-kilobase pair (kb) topological domains. Upon induction, DNA supercoiling throughout the region was completely relaxed. Supercoiling was detected, however, when elongation was blocked before or following induction. The formation of transcription initiation complexes upon addition of dexamethasone decreased the domain size to 16 kb. During transcription the domain size was 9 kb, the length of one repeat. These results suggest that topological domain boundaries can be "functional" in nature, being established by the formation of activated and elongating transcription complexes.	Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Genome Res, Houston, TX 77030 USA; NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20896 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sinden, RR (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Genome Res, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Sinden, Richard/AAE-3086-2019	Kramer, Phillip/0000-0003-0117-542X	NIEHS NIH HHS [P01 ES05652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES005652] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; BOWATER RP, 1994, BIOCHEMISTRY-US, V33, P9266, DOI 10.1021/bi00197a030; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; CHEN DR, 1992, P NATL ACAD SCI USA, V89, P8784, DOI 10.1073/pnas.89.18.8784; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DRLICA K, 1990, TRENDS GENET, V6, P433, DOI 10.1016/0168-9525(90)90306-Q; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; Fragoso G, 1998, MOL CELL BIOL, V18, P3633, DOI 10.1128/MCB.18.6.3633; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GILMOUR DS, 1986, CELL, V44, P401, DOI 10.1016/0092-8674(86)90461-7; HAGER GL, 1993, COLD SPRING HARB SYM, V58, P63, DOI 10.1101/SQB.1993.058.01.010; JACKSON DA, 1992, CELL BIOL INT REP, V16, P687, DOI 10.1016/S0309-1651(05)80013-X; JACKSON DA, 1990, EMBO J, V9, P567, DOI 10.1002/j.1460-2075.1990.tb08144.x; JUPE ER, 1995, BIOCHEMISTRY-US, V34, P2628, DOI 10.1021/bi00008a029; JUPE ER, 1993, EMBO J, V12, P1067, DOI 10.1002/j.1460-2075.1993.tb05748.x; KAUFMAN ER, 1978, P NATL ACAD SCI USA, V75, P4982, DOI 10.1073/pnas.75.10.4982; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; Kramer PR, 1999, METHOD ENZYMOL, V304, P639; Kramer PR, 1997, BIOCHEMISTRY-US, V36, P3151, DOI 10.1021/bi962396q; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; LJUNGMAN M, 1995, NUCLEIC ACIDS RES, V23, P1782, DOI 10.1093/nar/23.10.1782; MCCLELLAN JA, 1990, P NATL ACAD SCI USA, V87, P8373, DOI 10.1073/pnas.87.21.8373; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Mirabella A, 1997, EMBO J, V16, P523, DOI 10.1093/emboj/16.3.523; OSTROWSKI MC, 1983, MOL CELL BIOL, V3, P2045, DOI 10.1128/MCB.3.11.2045; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PETTIJOHN DE, 1980, P NATL ACAD SCI-BIOL, V77, P1331, DOI 10.1073/pnas.77.3.1331; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; RICHARDFOY H, 1987, MOL ENDOCRINOL, V1, P659, DOI 10.1210/mend-1-9-659; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RUPP WD, 1968, J MOL BIOL, V31, P291, DOI 10.1016/0022-2836(68)90445-2; Shykind BM, 1997, GENE DEV, V11, P397, DOI 10.1101/gad.11.3.397; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SINDEN RR, 1980, CELL, V21, P773, DOI 10.1016/0092-8674(80)90440-7; SINDEN RR, 1981, P NATL ACAD SCI-BIOL, V78, P224, DOI 10.1073/pnas.78.1.224; Sinden RR, 1999, METHODS, V17, P112, DOI 10.1006/meth.1998.0723; SINDEN RR, 1982, J MOL BIOL, V162, P659, DOI 10.1016/0022-2836(82)90394-1; SINDEN RR, 1992, METHOD ENZYMOL, V212, P319; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; van Drunen CM, 1999, NUCLEIC ACIDS RES, V27, P2924, DOI 10.1093/nar/27.14.2924; WEISBROD ST, 1982, NUCLEIC ACIDS RES, V10, P2017, DOI 10.1093/nar/10.6.2017; WORKMAN JL, 1985, BIOCHEMISTRY-US, V24, P4731, DOI 10.1021/bi00339a004; ZHENG GX, 1991, J MOL BIOL, V221, P107, DOI 10.1016/0022-2836(91)80208-C	52	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28590	28597		10.1074/jbc.274.40.28590	http://dx.doi.org/10.1074/jbc.274.40.28590			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497225	hybrid			2022-12-25	WOS:000082912700074
J	Shah, SMA; Kumar, A; Geiduschek, EP; Kassavetis, GA				Shah, SMA; Kumar, A; Geiduschek, EP; Kassavetis, GA			Alignment of the B '' subunit of RNA polymerase III transcription factor IIIB in its promoter complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; TFIIIB; INITIATION; GENE; COMPONENT; TBP; BRF; RECRUITMENT; ELEMENT; DOMAINS	TFIIIB, the central transcription initiation factor of the eukaryotic nuclear RNA polymerase (pol) LII is composed of three subunits: the TATA-binding protein; Brf, the TFIIB-related subunit; and B", the Saccharomyces cerevisiae, TFC5 gene product. The orientation of the B" subunit within the TFIIIB-DNA complex has been analyzed at two promoters by two approaches that involve site-specific photochemical protein-DNA cross-linking: a collection of B" internal and external deletion proteins has been surveyed for those deletions that alter the interaction of B" with DNA or change the orientation of B" relative to DNA; a method for regionally mapping crosslinks between specific DNA sites and P-32-end-labeled protein has also been applied. The results map an N-proximal segment of B" to the upstream end of the TFIIIB-DNA complex and amino acids 299-315 to the principal DNA contact site, approximately 8 base pairs upstream of the TATA box, The analysis also indicates that a segment comprising amino acids 316-434 loops away from DNA, and locates the C-proximal 170 amino acids of B" downstream of the TATA box. Examination of two-cross-link products formed by DNA with adjacent and nearby photoactive nucleotides supports the conclusion that Brf and B" share an extended interface along the length of the TFIIIB-DNA complex.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Shah, SMA (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.							BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; Bartholomew B, 1995, METHOD ENZYMOL, V262, P476; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; Colbert T, 1998, MOL CELL BIOL, V18, P1682, DOI 10.1128/MCB.18.3.1682; Grove A, 1999, J MOL BIOL, V285, P1429, DOI 10.1006/jmbi.1998.2347; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Kumar A, 1997, MOL CELL BIOL, V17, P1868, DOI 10.1128/MCB.17.4.1868; LOPEZDELEON A, 1992, CELL, V71, P221; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Persinger J, 1999, MOL CELL BIOL, V19, P5218; White R. J., 1998, RNA POLYMERASE 3 TRA; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974	24	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28736	28744		10.1074/jbc.274.40.28736	http://dx.doi.org/10.1074/jbc.274.40.28736			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497245	hybrid			2022-12-25	WOS:000082912700094
J	Wang, ZX; Lee, BH; Murray, JL; Bonneau, F; Sun, Y; Schweickert, V; Zhang, TY; Peiper, SC				Wang, ZX; Lee, BH; Murray, JL; Bonneau, F; Sun, Y; Schweickert, V; Zhang, TY; Peiper, SC			CCR5 HIV-1 coreceptor activity - Role of cooperativity between residues in N-terminal extracellular and intracellular domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR GENE; DISTINCT CCR5; T-CELLS; ENTRY; INFECTION; FUSION; GP120; GLYCOPROTEINS; MACROPHAGE	Human (H-) CCR5 is the primary coreceptor for ENV-mediated fusion by R5 strains of human immunodeficiency virus type 1, whereas mouse (M-) CCR5 lacks this function. An array of 23 H/M-CCR5 hybrids containing increasing amounts of H-CCR5 extending from the N terminus generated by random chimeragenesis had a biphasic pattern of coreceptor activity with JRFL and 89.6, revealing active regions in the N-terminal extracellular domain (N-ED) and at the junction of cytoplasmic loop 3. The M-CCR5 mutant in which divergent residues were replaced with the corresponding H-CCR5 N-ED sequence (NyYTsE) gained coreceptor function in fusion but not infection experiments. A M-CCR5 double mutant with substitution of human sequences for divergent residues from the N-ED and cytoplasmic loop 3 had augmented coreceptor activity in fusion assays and gain of function in infection experiments. The SIV-251 ENV utilized H- and M-CCR5 and variants, Flow cytometric analysis of M-CCR5 mutants and bifunctional receptors composed of CD4 domains fused to M-CCR5 mutants excluded the possibility that differences in coreceptor activity resulted from variations in cell surface expression. These results demonstrate that the coreceptor activity of the H-CCR5 N-ED is modulated by intracellular residues, illustrating the complexity of CCR5 requirements for interaction with ENV.	Univ Louisville, Henry Vogt Canc Res Inst, Louisville, KY 40202 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; ICOS Corp, Bothell, WA 98021 USA	University of Louisville; University of Pennsylvania; Icos Corporation	Peiper, SC (corresponding author), James Graham Brown Canc Ctr, 529 S Jackson St, Louisville, KY 40202 USA.	scp@bcc.louisville.edu	Lee, Benhur/A-8554-2016	Lee, Benhur/0000-0003-0760-1709; Bonneau, Fabien/0000-0001-8787-7662	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041346] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO8 HL03923] Funding Source: Medline; NIAID NIH HHS [AI 41346] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; Chen ZW, 1998, J EXP MED, V188, P2057, DOI 10.1084/jem.188.11.2057; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Hill CM, 1998, VIROLOGY, V248, P357, DOI 10.1006/viro.1998.9283; KIM JY, 1994, J BIOL CHEM, V269, P28724; Kuhmann SE, 1997, J VIROL, V71, P8642, DOI 10.1128/JVI.71.11.8642-8656.1997; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Martin KA, 1997, SCIENCE, V278, P1470, DOI 10.1126/science.278.5342.1470; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; Olson WC, 1999, J VIROL, V73, P4145, DOI 10.1128/JVI.73.5.4145-4155.1999; Palacios E, 1998, CURR BIOL, V8, P943, DOI 10.1016/S0960-9822(07)00378-8; Peiper SC, 1997, METHOD ENZYMOL, V288, P56; Picard L, 1997, J VIROL, V71, P5003, DOI 10.1128/JVI.71.7.5003-5011.1997; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Ross TM, 1998, J VIROL, V72, P1918, DOI 10.1128/JVI.72.3.1918-1924.1998; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; Siciliano SJ, 1999, J BIOL CHEM, V274, P1905, DOI 10.1074/jbc.274.4.1905; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wang ZX, 1998, J BIOL CHEM, V273, P15007, DOI 10.1074/jbc.273.24.15007; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zhou YH, 1998, J IMMUNOL, V160, P4018	47	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28413	28419		10.1074/jbc.274.40.28413	http://dx.doi.org/10.1074/jbc.274.40.28413			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497202	hybrid			2022-12-25	WOS:000082912700051
J	Yano, T; Magnitsky, S; Sled', VD; Ohnishi, T; Yagi, T				Yano, T; Magnitsky, S; Sled', VD; Ohnishi, T; Yagi, T			Characterization of the putative 2x[4Fe-4S]-binding NQO9 subunit of the proton-translocating NADH-quinone oxidoreductase (NDH-1) of Paracoccus denitrificans - Expression, reconstitution, and EPR characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR SUBUNIT; UBIQUINONE OXIDOREDUCTASE; COMPLEX-I; ESCHERICHIA-COLI; MITOCHONDRIAL NADH; GENE-CLUSTER; 25-KILODALTON SUBUNIT; BINDING SUBUNIT; PROTEINS; SEQUENCE	Molecular properties of the NQO9 subunit of Paracoccus denitrificans NDH-1, which is predicted to contain 2x[4Fe-4S] clusters, were investigated using recombinant expression techniques and EPR spectroscopy. The full-length form of NQO9 subunit co-expressed with thioredoxin in Escherichia coli at ambient temperature was found dominantly in the cytoplasmic membrane with low amplification. Genetic deletion of relatively hydrophobic and less conserved N-terminal stretches (30 or 40 amino acid residues long) of the NQO9 subunit resulted in the overexpression of the truncated soluble form of the subunit in a high yield in the cytoplasm, The purified soluble form of the NQO9 subunit contained only a small quantity of Fe and S2- (2.0-2.2 mol each per mol of subunit), However, the iron-sulfur content was considerably increased by in vitro reconstitution. The reconstituted NQO9 subunit contained 7.6-7.7 mol each of Fe and S2- per molecule and exhibited optical absorption spectra similar to those of 2x[4Fe-4S] ferredoxins, Two sets of relatively broad axial-type EPR signals with different temperature dependence and power saturation profile were detected in the dithionite-reduced preparations at a low temperature range (8-18 K), Due to a negative shift (<600 mV) of the apparent redox midpoint potential of the iron-sulfur clusters in the soluble form of the truncated NQO9 subunit, the following two possible cases could not be discriminated: (i) two sets of EPR signals arise from two distinct species of tetranuclear iron-sulfur clusters with two intrinsically different spectral parameters g(parallel to,perpendicular to) = 2.05, similar to 1.93, and g(parallel to,perpendicular to) = 2.08, similar to 1.90, and respective slow (P-1/2 = 8 milliwatts) and fast (P-1/2 = 342 milliwatts) spin relaxation; (ii) two clusters exhibit similar intrinsic EPR spectra (g(parallel to,perpendicular to) = 2.05, similar to 1.93) with slow spin relaxation, When both clusters in the same subunit are concomitantly paramagnetic, their spin-spin interactions cause a shift of spectra to g(parallel to,perpendicular to) = 2.08, similar to 1.90, with enhanced spin relaxation, in either case, our EPR data provide the first experimental evidence for the presence of two [4Fe-4S] iron-sulfur clusters in the NQO9 subunit.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Scripps Research Institute; University of Pennsylvania	Yagi, T (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA.	yagi@scripps.edu			NCRR NIH HHS [MO1RR00833] Funding Source: Medline; NIGMS NIH HHS [R01GM33712, R01GM30736] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033712, R01GM030736] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRACHT SPJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P221, DOI 10.1016/0005-2728(93)90176-G; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; CROUSE BR, 1994, J BIOL CHEM, V269, P21030; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOEG KA, 1962, ARCH BIOCHEM BIOPHYS, V97, P37, DOI 10.1016/0003-9861(62)90041-3; Dupuis A, 1995, GENE, V167, P99, DOI 10.1016/0378-1119(95)00693-1; Dutton PL, 1998, BBA-BIOENERGETICS, V1364, P245, DOI 10.1016/S0005-2728(98)00031-0; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; HAN AL, 1988, ARCH BIOCHEM BIOPHYS, V267, P490, DOI 10.1016/0003-9861(88)90055-0; HAN AL, 1989, ARCH BIOCHEM BIOPHYS, V275, P166, DOI 10.1016/0003-9861(89)90360-3; HEKMAN C, 1991, ARCH BIOCHEM BIOPHYS, V284, P90, DOI 10.1016/0003-9861(91)90268-N; INGLEDEW WJ, 1980, BIOCHEM J, V186, P111, DOI 10.1042/bj1860111; JOHNSON MK, 1994, ENCY INORGANIC CHEM, P1896; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALKIN R, 1973, IRON SULFUR PROTEINS, P1; MASUI R, 1991, J BIOCHEM-TOKYO, V110, P575, DOI 10.1093/oxfordjournals.jbchem.a123622; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Miyoshi H, 1998, BBA-BIOENERGETICS, V1364, P236, DOI 10.1016/S0005-2728(98)00030-9; OHNISHI T, 1993, J BIOENERG BIOMEMBR, V25, P325, DOI 10.1007/BF00762457; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Ohnishi T, 1982, IRON SULFUR PROTEINS, V4, P285; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; XU XM, 1992, BIOCHEMISTRY-US, V31, P6925, DOI 10.1021/bi00145a009; XU XM, 1992, ARCH BIOCHEM BIOPHYS, V296, P40, DOI 10.1016/0003-9861(92)90542-5; XU XM, 1993, BIOCHEMISTRY-US, V32, P968, DOI 10.1021/bi00054a030; XU XM, 1991, BIOCHEMISTRY-US, V30, P8678, DOI 10.1021/bi00099a027; XU XM, 1991, BIOCHEMISTRY-US, V30, P6422, DOI 10.1021/bi00240a012; YAGI T, 1990, BIOCHEMISTRY-US, V29, P5515, DOI 10.1021/bi00475a015; YAGI T, 1993, J BIOENERG BIOMEMBR, V25, P339, DOI 10.1007/BF00762459; YAGI T, 1986, ARCH BIOCHEM BIOPHYS, V250, P302, DOI 10.1016/0003-9861(86)90731-9; YAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P1, DOI 10.1016/0005-2728(93)90182-F; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; YANO T, 1995, J BIOL CHEM, V270, P18264, DOI 10.1074/jbc.270.31.18264; YANO T, 1994, FEBS LETT, V354, P160, DOI 10.1016/0014-5793(94)01107-9; Yano T, 1997, J BIOL CHEM, V272, P4201, DOI 10.1074/jbc.272.7.4201; YANO T, 1994, BIOCHEMISTRY-US, V33, P494, DOI 10.1021/bi00168a014; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	53	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28598	28605		10.1074/jbc.274.40.28598	http://dx.doi.org/10.1074/jbc.274.40.28598			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497226	hybrid			2022-12-25	WOS:000082912700075
J	Braas, KM; May, V				Braas, KM; May, V			Pituitary adenylate cyclase-activating polypeptides directly stimulate sympathetic neuron neuropeptide Y release through PAC(1) receptor isoform activation of specific intracellular signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; SUPERIOR CERVICAL-GANGLION; MEDULLARY CHROMAFFIN CELLS; PROTEIN-KINASE-C; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; TERMINAL EXTRACELLULAR DOMAIN; CEREBELLAR GRANULE NEURONS; CYTOSOLIC-FREE CALCIUM; RAT ADRENAL-MEDULLA; MOLECULAR-CLONING	Pituitary adenylate cyclase-activating polypeptides (PACAP) have potent regulatory and neurotrophic activities on superior cervical ganglion (SCG) sympathetic neurons with pharmacological profiles consistent for the PACAP-selective PAC(1) receptor. Multiple PAC(1) receptor isoforms are suggested to determine differential peptide potency and receptor coupling to multiple intracellular signaling pathways. The current studies examined rat SCG PAC(1) receptor splice variant expression and coupling to intracellular signaling pathways mediating PACAP-stimulated peptide release. PAC(1) receptor mRNA was localized in over 90% of SCG neurons, which correlated with the cells expressing receptor protein. The neurons expressed the PAC(1)(short)HOP1 receptor but not VIP/PACAP-nonselective VPAC(1) receptors; low VPAC(2) receptor mRNA levels were restricted to ganglionic nonneuronal cells. PACAP27 and PACAP38 potently and efficaciously stimulated both cAMP and inositol phosphate production; inhibition of phospholipase C augmented PACAP-stimulated cAMP production, but inhibition of adenylyl cyclase did not alter stimulated inositol phosphate production. Phospholipase C inhibition blunted neuron peptide release, suggesting that the phosphatidylinositol pathway was a prominent component of the secretory response. These studies demonstrate preferential sympathetic neuron expression of PACAP-selective receptor variants contributing to regulation of autonomic function.	Univ Vermont, Coll Med, Dept Anat & Neurobiol, Burlington, VT 05405 USA	University of Vermont	May, V (corresponding author), Univ Vermont, Coll Med, Dept Anat & Neurobiol, Given Hlth Sci Bldg, Burlington, VT 05405 USA.				NICHD NIH HHS [HD-27468] Funding Source: Medline; NINDS NIH HHS [NS-01638] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027468] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Antoni F A, 1998, Adv Second Messenger Phosphoprotein Res, V32, P153; ARIMURA A, 1991, ENDOCRINOLOGY, V129, P2787, DOI 10.1210/endo-129-5-2787; ARIMURA A, 1994, ANN NY ACAD SCI, V739, P228, DOI 10.1111/j.1749-6632.1994.tb19825.x; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; Banks WA, 1996, ANN NY ACAD SCI, V805, P270; Beaudet MM, 1998, J NEUROBIOL, V36, P325, DOI 10.1002/(SICI)1097-4695(19980905)36:3<325::AID-NEU2>3.0.CO;2-Y; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BRAAS KM, 1988, BRIT J PHARMACOL, V94, P3, DOI 10.1111/j.1476-5381.1988.tb11492.x; BRAAS KM, 1994, ENDOCRINOLOGY, V134, P196, DOI 10.1210/en.134.1.196; BRAAS KM, 1992, ENDOCRINOLOGY, V130, P2778, DOI 10.1210/en.130.5.2778; Braas KM, 1996, ANN NY ACAD SCI, V805, P204; Braas KM, 1998, J NEUROSCI, V18, P9766; BRAAS KM, 1994, ENDOCRINOLOGY, V134, P186, DOI 10.1210/en.134.1.186; Brandenburg CA, 1997, J NEUROSCI, V17, P4045; Brenneman DE, 1996, ANN NY ACAD SCI, V805, P280; Brenneman DE, 1997, ANN NY ACAD SCI, V814, P167, DOI 10.1111/j.1749-6632.1997.tb46155.x; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Cavallaro S, 1996, MOL PHARMACOL, V50, P60; Chatterjee TK, 1997, J BIOL CHEM, V272, P12122, DOI 10.1074/jbc.272.18.12122; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DiCiccoBloom E, 1996, ANN NY ACAD SCI, V805, P244; Festoff BW, 1996, J NEUROBIOL, V30, P255, DOI 10.1002/(SICI)1097-4695(199606)30:2<255::AID-NEU7>3.0.CO;2-4; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; GOTTSCHALL PE, 1994, BRAIN RES, V637, P197, DOI 10.1016/0006-8993(94)91233-5; Gozes I, 1996, J MOL NEUROSCI, V7, P235, DOI 10.1007/BF02737061; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; Hahm SH, 1998, J MOL NEUROSCI, V11, P43, DOI 10.1385/JMN:11:1:43; HARMAR T, 1994, TRENDS PHARMACOL SCI, V15, P97, DOI 10.1016/0165-6147(94)90042-6; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HENION PD, 1990, J NEUROSCI, V10, P2886; HOSOYA M, 1993, BIOCHEM BIOPH RES CO, V194, P133, DOI 10.1006/bbrc.1993.1795; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; Isobe K, 1996, NEUROPEPTIDES, V30, P167, DOI 10.1016/S0143-4179(96)90084-0; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; ISOBE K, 1994, NEUROPEPTIDES, V27, P269, DOI 10.1016/0143-4179(94)90107-4; KLEITMAN N, 1991, CULTURING NERVE CELL, P335; Klimaschewski L, 1996, NEUROREPORT, V7, P2797, DOI 10.1097/00001756-199611040-00078; KODJO MK, 1995, ENDOCRINOLOGY, V136, P4535, DOI 10.1210/en.136.10.4535; Lai CC, 1997, BRAIN RES, V748, P189, DOI 10.1016/S0006-8993(96)01297-8; Lu NR, 1997, P NATL ACAD SCI USA, V94, P3357, DOI 10.1073/pnas.94.7.3357; Lu NR, 1998, J NEUROSCI RES, V53, P651, DOI 10.1002/(SICI)1097-4547(19980915)53:6<651::AID-JNR3>3.0.CO;2-4; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; May V, 1998, ANN NY ACAD SCI, V865, P164, DOI 10.1111/j.1749-6632.1998.tb11175.x; MAY V, 1995, J NEUROCHEM, V65, P978; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P239, DOI 10.1016/0165-6147(93)90019-G; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; Moller K, 1997, BRAIN RES, V775, P166, DOI 10.1016/S0006-8993(97)00923-2; Moller K, 1997, BRAIN RES, V775, P156, DOI 10.1016/S0006-8993(97)00937-2; MORROW JA, 1993, FEBS LETT, V329, P99, DOI 10.1016/0014-5793(93)80202-6; Nogi H, 1997, NEUROSCI LETT, V227, P37, DOI 10.1016/S0304-3940(97)00295-4; OFarrell M, 1997, N-S ARCH PHARMACOL, V356, P536, DOI 10.1007/PL00005088; OGI K, 1990, BIOCHEM BIOPH RES CO, V173, P1271, DOI 10.1016/S0006-291X(05)80924-6; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; RAWLINGS SR, 1995, ENDOCRINOLOGY, V136, P2088, DOI 10.1210/en.136.5.2088; RAWLINGS SR, 1994, MOL CELL ENDOCRINOL, V101, pC5, DOI 10.1016/0303-7207(94)90212-7; Seebeck J, 1996, N-S ARCH PHARMACOL, V354, P424, DOI 10.1007/BF00168432; SHI WX, 1992, J NEUROSCI, V12, P2433; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Sugita S, 1997, J NEUROSCI, V17, P7237; Sundler F, 1996, ANN NY ACAD SCI, V805, P410; SVOBODA M, 1993, BIOCHEM BIOPH RES CO, V195, P881, DOI 10.1006/bbrc.1993.2127; Tanaka K, 1996, ENDOCRINOLOGY, V137, P956, DOI 10.1210/en.137.3.956; TATSUNO I, 1992, ENDOCRINOLOGY, V131, P73, DOI 10.1210/en.131.1.73; Tatsuno I, 1996, ANN NY ACAD SCI, V805, P482; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Wakade A R, 1998, Adv Pharmacol, V42, P595; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V182, P403, DOI 10.1016/S0006-291X(05)80159-7; Zhang JH, 1997, AM J PHYSIOL-HEART C, V273, pH971, DOI 10.1152/ajpheart.1997.273.2.H971; ZHENG LX, 1995, ENDOCRINOLOGY, V136, P1079, DOI 10.1210/en.136.3.1079	75	103	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27702	27710		10.1074/jbc.274.39.27702	http://dx.doi.org/10.1074/jbc.274.39.27702			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488112	hybrid			2022-12-25	WOS:000082739100051
J	Bruno, MD; Whitsett, JA; Ross, GF; Korfhagen, TR				Bruno, MD; Whitsett, JA; Ross, GF; Korfhagen, TR			Transcriptional regulation of the murine surfactant protein-A gene by B-myb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL LUNG INVITRO; CELL-CYCLE; FACTOR-I; FAMILY MEMBERS; DEFICIENT MICE; MESSENGER-RNA; C-MYB; EXPRESSION; BINDING; PHOSPHORYLATION	Surfactant protein A (SP-A) is selectively synthesized in subsets of cells lining the respiratory epithelium, where its expression is regulated by various transcription factors including thyroid transcription factor-1 (TTF-1), Cell-specific transcription of the mouse SP-A promoter is mediated by binding of TTF-1 at four distinct cis-active sites located in the 5'-flanking region of the gene, Mutation of TTF-1-binding sites (TBE) 1, 3, and 4 in combination markedly decreased transcriptional activity of SP-A promoter-chloramphenicol acetyltransferase constructs containing SP-A gene sequences from -256 to +45, In contrast, the same mutations enhanced transcriptional activity in constructs containing additional 5' SP-A sequences from -399 to +45 suggesting that cis-acting elements within the region -399 to -256 influence effects of TTF-1 on SP-A promoter activity. A consensus Myb-binding site was identified within the region, located at positions -380 to -371 in the mouse gene. Mutation of the Myb-binding site decreased activity of SP-A promoter constructs in MLE-15 cells. MLE-15 cells, a cell line expressing SP-A mRNA, also expressed B-Myb. B-Myb bound to the MBS in the SP-A gene as assessed by electrophoretic mobility shift assay. While co-transfection of HeLa cells with a E-Myb expression plasmid activated the transfected SP-A promoter about 3-fold, co-transfection of B-myb with cyclin A and cdk-2, to enhance phosphorylation of B-Myb, increased transcriptional activity of SP-A constructs approximately 20-fold. Taken together, the data support activation of SP-A gene promoter activity by E-Myb which acts at a cis-acting element in the SP-A gene.	Childrens Hosp Res Fdn, Div Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Korfhagen, TR (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	korft0@chmcc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058795, R01HL028623] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58795, HL28623] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acarregui MJ, 1998, AM J PHYSIOL-LUNG C, V274, pL343; Bachurski CJ, 1997, J BIOL CHEM, V272, P32759, DOI 10.1074/jbc.272.52.32759; BOGGARAM V, 1989, J BIOL CHEM, V264, P11421; BOGGARAM V, 1991, MOL ENDOCRINOL, V5, P414, DOI 10.1210/mend-5-3-414; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; BUI KC, 1995, AM J PHYSIOL-LUNG C, V268, pL625, DOI 10.1152/ajplung.1995.268.4.L625; Corti M, 1996, AM J RESP CELL MOL, V14, P309, DOI 10.1165/ajrcmb.14.4.8600933; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; ESS KC, 1995, MOL CELL BIOL, V15, P5707; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; Kabha K, 1997, AM J PHYSIOL-LUNG C, V272, pL344, DOI 10.1152/ajplung.1997.272.2.L344; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; LACAZEMASMONTEIL T, 1992, EUR J BIOCHEM, V206, P613, DOI 10.1111/j.1432-1033.1992.tb16966.x; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; Li JX, 1998, J BIOL CHEM, V273, P4592, DOI 10.1074/jbc.273.8.4592; Mason RJ, 1998, AM J PHYSIOL-LUNG C, V275, pL1, DOI 10.1152/ajplung.1998.275.1.L1; MENDELSON CR, 1991, J DEV PHYSIOL, V15, P61; Michael LF, 1996, MOL ENDOCRINOL, V10, P159, DOI 10.1210/me.10.2.159; NOGEE LM, 1991, AM J RESP CELL MOL, V4, P102, DOI 10.1165/ajrcmb/4.2.102; Robinson C, 1996, ONCOGENE, V12, P1855; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Saville MK, 1998, ADV CANCER RES, V72, P109; Sitzmann J, 1996, ONCOGENE, V12, P1889; Sitzmann J, 1995, ONCOGENE, V11, P2273; TASHIRO S, 1995, ONCOGENE, V10, P1699; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WEISSBACH S, 1994, AM J PHYSIOL-LUNG C, V267, pL660, DOI 10.1152/ajplung.1994.267.6.L660; WRIGHT JR, 1993, AM J PHYSIOL, V264, pL338, DOI 10.1152/ajplung.1993.264.4.L338; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Young PP, 1997, MOL ENDOCRINOL, V11, P1082, DOI 10.1210/me.11.8.1082; Zhou L, 1996, DEV BIOL, V175, P227, DOI 10.1006/dbio.1996.0110; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	43	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27523	27528		10.1074/jbc.274.39.27523	http://dx.doi.org/10.1074/jbc.274.39.27523			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488087	hybrid			2022-12-25	WOS:000082739100026
J	Duncan, RR; Betz, A; Shipston, MJ; Brose, N; Chow, RH				Duncan, RR; Betz, A; Shipston, MJ; Brose, N; Chow, RH			Transient, phorbol ester-induced DOC2-Munc13 interactions in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NEUROTRANSMITTER RELEASE; DOC2; DOC2-BETA; DOMAINS; BRAIN	Munc13-1 and DOC2 have been implicated in the regulation of exocytosis, Here we demonstrate in vivo that these two proteins undergo a transient phorbol ester-mediated and protein kinase C-independent interaction, resulting in the translocation of DOC2 from a vesicular localization to the plasma membrane. The translocation of DOC2 is dependent upon the DOC2 Munc interacting domain that binds specifically to Munc13-1, whereas the association of DOC2 with intracellular membranes is dependent on its C2 domains. This is the first direct in vivo demonstration of a protein-protein interaction between two presynaptic proteins and may represent a molecular basis for phorbol ester-dependent enhancement of exocytosis.	Univ Edinburgh, Sch Med, Dept Biomed Sci, Div Membrane Grp, Edinburgh EH8 9AG, Midlothian, Scotland; Max Planck Inst Expt Med, AG Mol Neurobiol, D-37075 Gottingen, Germany	University of Edinburgh; Max Planck Society	Chow, RH (corresponding author), Univ Edinburgh, Sch Med, Dept Biomed Sci, Div Membrane Grp, Edinburgh EH8 9AG, Midlothian, Scotland.		Chow, Robert/B-8155-2013; Shipston, Mike/C-7309-2013	Shipston, Mike/0000-0001-7544-582X; Duncan, Rory/0000-0003-0693-910X				Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; Hilfiker S, 1999, J PHYSIOL-LONDON, V515, P1, DOI 10.1111/j.1469-7793.1999.001ad.x; Kojima T, 1996, J BIOCHEM-TOKYO, V120, P671; Mochida S, 1998, P NATL ACAD SCI USA, V95, P11418, DOI 10.1073/pnas.95.19.11418; Orita S, 1997, J BIOL CHEM, V272, P16081, DOI 10.1074/jbc.272.26.16081; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Orita S, 1996, MOL BIOL CELL, V7, P2603; Stevens CF, 1998, NEURON, V21, P885, DOI 10.1016/S0896-6273(00)80603-0; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Yawo H, 1999, J PHYSIOL-LONDON, V515, P169, DOI 10.1111/j.1469-7793.1999.169ad.x	13	52	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27347	27350		10.1074/jbc.274.39.27347	http://dx.doi.org/10.1074/jbc.274.39.27347			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488064	hybrid			2022-12-25	WOS:000082739100003
J	Tommasi, S; Pfeifer, GP				Tommasi, S; Pfeifer, GP			In vivo structure of two divergent promoters at the human PCNA locus - Synthesis of antisense RNA and S phase-dependent binding of E2F complexes in intron 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; ADENOVIRUS E1A ONCOPROTEIN; DNA POLYMERASE-DELTA; MESSENGER-RNA; IN-VIVO; TRANSCRIPTION INITIATION; AUXILIARY PROTEIN; GROWTH-REGULATION; CYCLE REGULATION; FAMILY MEMBERS	Proliferating cell nuclear antigen (PCNA) synthesis is strictly regulated during the cell cycle. To investigate PCNA transcriptional regulation, we have analyzed protein-DNA interactions at the promoter region and in the first intron in quiescent fibroblasts and following serum stimulation. Twenty putative protein-binding sites, distributed in two divergent promoters at the PCNA locus, were identified in vivo by genomic footprinting, These elements bind transcription factors continuously throughout the cell cycle with the exception of one E2F consensus site, located in the first intron at position +583. This E2F site becomes strongly occupied 18 h after serum stimulation, implying that an E2F activator complex plays a role in activation of the PCNA gene at the onset of S phase. We detected a 500-600-base pair-long antisense transcript by Northern blot analysis. This RNA has no apparent coding capacity and is constitutively transcribed from a promoter located within the first intron. We suggest that silencing of the PCNA gene is accomplished through base pairing between sense pre-mRNA and antisense RNA. The binding of S phase-specific E2F complexes at the +583 element may help to overcome the negative effect of the antisense transcript, which results in up-regulation of PCNA expression in proliferating cells.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Tommasi, S (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA.			Tommasi, Stella/0000-0001-6897-4985	NIEHS NIH HHS [ES06070] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES006070, R01ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALDER H, 1992, NUCLEIC ACIDS RES, V20, P1769, DOI 10.1093/nar/20.7.1769; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V3; BASERGA R, 1991, J CELL SCI, V98, P433; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; Charollais Renee-Helene, 1992, Gene Expression, V2, P285; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; DOLFINI S, 1993, MOL GEN GENET, V241, P161, DOI 10.1007/BF00280213; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; Kumar M, 1997, P NATL ACAD SCI USA, V94, P3542, DOI 10.1073/pnas.94.8.3542; LABRIE C, 1993, MOL CELL BIOL, V13, P1697, DOI 10.1128/MCB.13.3.1697; LABRIE C, 1995, NUCLEIC ACIDS RES, V23, P3732, DOI 10.1093/nar/23.18.3732; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lee Hu-Hui, 1995, Gene Expression, V4, P95; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Maniatis T., 1982, MOL CLONING LAB MANU; Maxam A M, 1980, Methods Enzymol, V65, P499; MOORE KS, 1987, J BIOL CHEM, V262, P8447; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Muller H, 1997, MOL CELL BIOL, V17, P5508; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; NOGUCHI M, 1994, J BIOL CHEM, V269, P29161; OTTAVIO L, 1990, MOL CELL BIOL, V10, P303, DOI 10.1128/MCB.10.1.303; OTTAVIO L, 1990, BIOCHEM BIOPH RES CO, V169, P509, DOI 10.1016/0006-291X(90)90360-Y; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P567; Pierce AM, 1998, MOL CARCINOGEN, V22, P190, DOI 10.1002/(SICI)1098-2744(199807)22:3<190::AID-MC7>3.0.CO;2-P; PIETRZKOWSKI Z, 1991, EXP CELL RES, V193, P283, DOI 10.1016/0014-4827(91)90098-F; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; RIZZO MG, 1990, EXP CELL RES, V188, P286, DOI 10.1016/0014-4827(90)90172-7; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SELL C, 1992, J CELL PHYSIOL, V152, P177, DOI 10.1002/jcp.1041520122; SHIPMAN PM, 1988, J CELL BIOCHEM, V38, P189, DOI 10.1002/jcb.240380306; Sutterluety H, 1998, NUCLEIC ACIDS RES, V26, P4989, DOI 10.1093/nar/26.21.4989; TOMMASI S, 1993, SOMAT CELL MOLEC GEN, V19, P529, DOI 10.1007/BF01233380; Tommasi S, 1997, J BIOL CHEM, V272, P30483, DOI 10.1074/jbc.272.48.30483; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; WILLIAMS T, 1986, NATURE, V322, P275, DOI 10.1038/322275a0; Xu J, 1999, MOL CELL BIOL, V19, P12; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	66	43	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27829	27838		10.1074/jbc.274.39.27829	http://dx.doi.org/10.1074/jbc.274.39.27829			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488129	hybrid			2022-12-25	WOS:000082739100068
J	Johnson, KA; Mierzwa, ML; Fink, SP; Marnett, LJ				Johnson, KA; Mierzwa, ML; Fink, SP; Marnett, LJ			MutS recognition of exocyclic DNA adducts that are endogenous products of lipid oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; HUMAN MISMATCH REPAIR; ESCHERICHIA-COLI; FRAMESHIFT MUTAGENESIS; MALONDIALDEHYDE; DAMAGE; BASE; PROPANODEOXYGUANOSINE; MALONALDEHYDE; MUTAGENICITY	The ability of the methyl-directed mismatch repair system to recognize and repair the exocyclic adducts propanodeoxyguanosine (PdG) and pyrimido[1,2-alpha] purin-10(3H)-one (M(1)G), the major adduct derived from the endogenous mutagen malondialdehyde, has been assessed both in vivo and in vitro. Both adducts were site-specifically incorporated into M13MB102 DNA, and the adducted genomes were electroporated into wild-type or mutS-deficient Escherichia coli strains. A decrease in mutations caused by both adducts was observed in mutS-deficient strains, suggesting that MutS was binding to the adducts and blocking repair by nucleotide excision repair, This hypothesis was supported by the differences in mutation frequency observed when hemimethylated genomes containing PdG on the (-)-strand were electroporated into a uvrA(-) strain. The ability of purified MutS to bind to PdG- or M(1)G-containing 31-mer duplexes in vitro was assessed using both surface plasmon resonance and gel shift assays. MutS bound to M(1)G: T-containing duplexes with similar affinity to a G:T mismatch but less strongly to M(1)G:C- and PdG-containing duplexes, Dissociation from each of the adduct containing duplexes occurred at a faster rate than from a G:T mismatch. The present results indicate that MutS can bind to exocyclic adducts resulting from endogenous DNA damage and trigger their removal by mismatch repair or protect them from removal by nucleotide excision repair.	Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr,Ctr Mol Toxicol, Dept Biochem,AB Hancock Jr Mem Lab Canc Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr,Ctr Mol Toxicol, Dept Chem,AB Hancock Jr Mem Lab Canc Res, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr,Ctr Mol Toxicol, Dept Biochem,AB Hancock Jr Mem Lab Canc Res, 221 Kirkland Hall, Nashville, TN 37232 USA.			Fink, Stephen/0000-0003-4107-7912	NCI NIH HHS [CA47479, CA68485] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Babic I, 1996, MUTAT RES-FUND MOL M, V372, P87, DOI 10.1016/S0027-5107(96)00170-4; BASU AK, 1988, CHEM RES TOXICOL, V1, P53, DOI 10.1021/tx00001a010; BASU AK, 1983, CARCINOGENESIS, V4, P331, DOI 10.1093/carcin/4.3.331; BENAMIRA M, 1995, CARCINOGENESIS, V16, P93, DOI 10.1093/carcin/16.1.93; BENAMIRA M, 1993, CHEM RES TOXICOL, V6, P317, DOI 10.1021/tx00033a011; BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; BERNHEIM F, 1948, J BIOL CHEM, V174, P257; BURCHAM PC, 1994, J BIOL CHEM, V269, P28844; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Dedon PC, 1998, P NATL ACAD SCI USA, V95, P11113, DOI 10.1073/pnas.95.19.11113; Fang JL, 1996, CARCINOGENESIS, V17, P1035, DOI 10.1093/carcin/17.5.1035; Ferry KV, 1999, BIOCHEM PHARMACOL, V57, P861, DOI 10.1016/S0006-2952(98)00366-9; Fink D, 1996, CANCER RES, V56, P4881; Fink SP, 1997, P NATL ACAD SCI USA, V94, P8652, DOI 10.1073/pnas.94.16.8652; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; FRAM RJ, 1985, MOL PHARMACOL, V28, P51; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; Ji C, 1998, CARCINOGENESIS, V19, P1275, DOI 10.1093/carcin/19.7.1275; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Johnson KA, 1997, J BIOL CHEM, V272, P11434; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; Leuratti C, 1998, CARCINOGENESIS, V19, P1919, DOI 10.1093/carcin/19.11.1919; Levati L, 1998, GENE CHROMOSOME CANC, V23, P159, DOI 10.1002/(SICI)1098-2264(199810)23:2<159::AID-GCC9>3.0.CO;2-1; Liu LL, 1996, CANCER RES, V56, P5375; Mao H, 1999, P NATL ACAD SCI USA, V96, P6615, DOI 10.1073/pnas.96.12.6615; Marnett LJ, 1999, MUTAT RES-FUND MOL M, V424, P83, DOI 10.1016/S0027-5107(99)00010-X; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; MUKAI FH, 1976, SCIENCE, V191, P868, DOI 10.1126/science.766187; Nair J, 1997, CANCER EPIDEM BIOMAR, V6, P597; NAIR V, 1984, J AM CHEM SOC, V106, P3370, DOI 10.1021/ja00323a061; NEIDERNHOFER LJ, 1997, CHEM RES TOXICOL, V10, P556; SETO H, 1981, CHEM LETT, P707, DOI 10.1246/cl.1981.707; Spalding J. W., 1988, NATL TOXICOL PROGRAM, V331, P5; STONE K, 1990, CHEM RES TOXICOL, V3, P33, DOI 10.1021/tx00013a006; Vaisman A, 1998, CANCER RES, V58, P3579; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; YAU TM, 1979, MECH AGEING DEV, V11, P137, DOI 10.1016/0047-6374(79)90031-9	41	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27112	27118		10.1074/jbc.274.38.27112	http://dx.doi.org/10.1074/jbc.274.38.27112			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480926	hybrid			2022-12-25	WOS:000082570700065
J	van Kooyk, Y; van Vliet, SJ; Figdor, CG				van Kooyk, Y; van Vliet, SJ; Figdor, CG			The actin cytoskeleton regulates LFA-1 ligand binding through avidity rather than affinity changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; INTERCELLULAR-ADHESION MOLECULE-1; SUBUNIT CYTOPLASMIC DOMAIN; LEUKOCYTE INTEGRIN LFA-1; CELL-ADHESION; PHORBOL ESTER; BETA-SUBUNIT; MONOCLONAL-ANTIBODY; LYMPHOCYTE ADHESION; GPIIB-IIIA	To elucidate the role of the cytoskeleton regulating avidity or affinity changes in the leukocyte adhesion receptor lymphocyte function-associated antigen-1 (LFA-1) (alpha(L)beta(2)), we generated mutant cytoplasmic LFA-1 receptors and expressed these into the erythroleukemic cell line K562. We determined whether intercellular adhesion molecule-1 (ICAM-1)-mediated adhesion of LFA-1, lacking parts of its cytoplasmic tails, is regulated through receptor diffusion/clustering and/or by altered ligand binding affinity. All cytoplasmic deletion mutants that lack the complete beta(2) cytoplasmic tail and/or the conserved KVGFFKR sequence in the alpha(L) cytoplasmic tail were constitutively active and expressed high levels of the activation epitopes NKI-L16 and M24. Surprisingly, whereas these mutants showed a clustered cell surface distribution of LFA-1, the ligand-binding affinity as measured by titration of soluble ligand ICAM-1 remained unaltered. The notion that redistribution of LFA-1 does not alter ligand-binding affinity is further supported by the finding that disruption of the cytoskeleton by cytochalasin D did not alter the binding affinity nor adhesion to ICAM-1 of these mutants. Most cytoplasmic deletion mutants that spontaneously bound ICAM-1 were not capable to spread on ICAM-1, demonstrating that on these mutants LFA-1 is not coupled to the actin cytoskeleton. From these data we conclude that LFA-1-mediated cell adhesion to ICAM-1 is predominantly regulated by receptor clustering and that affinity alterations do not necessarily coincide with strong ICAM-1 binding.	Univ Nijmegen St Radboud Hosp, Dept Tumor Immunol, NL-6525 EX Nijmegen, Netherlands	Radboud University Nijmegen	van Kooyk, Y (corresponding author), Univ Nijmegen St Radboud Hosp, Dept Tumor Immunol, Philips van Leydenlaan 25, NL-6525 EX Nijmegen, Netherlands.	Y.vanKooyk@dent.kun.nl	Figdor, Carl G/A-4232-2010	Figdor, Carl G/0000-0002-2366-9212; Van Kooyk, Yvette/0000-0001-5997-3665; van Vliet, Sandra/0000-0003-1811-2687				ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; BEATTY PG, 1983, J IMMUNOL, V131, P2913; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; CROWE DT, 1994, J BIOL CHEM, V269, P14411; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DUSTIN ML, 1990, BIOESSAYS, V12, P421, DOI 10.1002/bies.950120905; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; ELEMER GS, 1994, J BIOL CHEM, V269, P3159; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FIGDOR CG, 1990, IMMUNOL TODAY, V11, P277, DOI 10.1016/0167-5699(90)90112-M; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HILDRETH JEK, 1985, J IMMUNOL, V134, P3272; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; KEIZER GD, 1985, EUR J IMMUNOL, V15, P1142, DOI 10.1002/eji.1830151114; KEIZER GD, 1988, J IMMUNOL, V140, P1393; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; KURZINGER K, 1981, J IMMUNOL, V127, P596; Labadia ME, 1998, J IMMUNOL, V161, P836; Lobb RR, 1995, CELL ADHES COMMUN, V3, P385, DOI 10.3109/15419069509081293; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; Lu CF, 1997, J IMMUNOL, V159, P268; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Lub M, 1997, MOL BIOL CELL, V8, P719, DOI 10.1091/mbc.8.4.719; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARTZ E, 1987, HUM IMMUNOL, V18, P3, DOI 10.1016/0198-8859(87)90110-8; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PARDI R, 1995, J IMMUNOL, V155, P1252; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; REILLY PL, 1995, J IMMUNOL, V155, P529; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stewart MP, 1996, J IMMUNOL, V156, P1810; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; Woska JR, 1996, J IMMUNOL, V156, P4680; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; [No title captured]	60	125	125	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26869	26877		10.1074/jbc.274.38.26869	http://dx.doi.org/10.1074/jbc.274.38.26869			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480895	Green Published, hybrid			2022-12-25	WOS:000082570700034
J	Wilharm, E; Parry, MAA; Friebel, R; Tschesche, H; Matschiner, G; Sommerhoff, CP; Jenne, DE				Wilharm, E; Parry, MAA; Friebel, R; Tschesche, H; Matschiner, G; Sommerhoff, CP; Jenne, DE			Generation of catalytically active granzyme K from Escherichia coli inclusion bodies and identification of efficient granzyme K inhibitors in human plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE-MEDIATED APOPTOSIS; URINARY TRYPSIN-INHIBITOR; DIPEPTIDYL PEPTIDASE-I; SERINE-PROTEASE; EXTRACELLULAR ACTIVITIES; THROMBIN RECEPTOR; KILLER-CELLS; MET-ASE; EXPRESSION; CLONING	Granzymes are granule-stored lymphocyte serine proteases that are implicated in T- and natural killer cell-mediated cytotoxic defense reactions after target cell recognition. A fifth human granzyme (granzyme 3, lymphocyte tryptase-2), renamed as granzyme K (gene name GZMK), has recently been cloned from lymphocyte tissue. For its further characterization we successfully generated catalytically active enzyme in milligram quantities per liter of Escherichia coli culture. The natural preform of granzyme K with the amino-terminal propeptide Met-Glu was expressed as inclusion bodies and converted to its active enzyme by cathepsin C after refolding of precursor molecules. Recombinant granzyme K cleaves synthetic thiobenzyl ester substrates after Lys and Arg with k(cat)/K-m values of 3.7 x 10(4) and 4.4 x 10(4) M-1 s(-1), respectively. Granzyme K activity was shown to be inhibited by the synthetic compounds Phe-Pro-Arg-chloromethyl ketone, phenylmethylsulfonyl fluoride, PefablocSC, and benzamidine, by the Kunitz-type inhibitor aprotinin and by human blood plasma. The plasma-derived inter-alpha-trypsin inhibitor complex, its bikunin subunit, and the second carboxyl-terminal Kunitz-type domain of bikunin were identified as genuine physiologic inhibitors with K-i values of 64, 50, and 22 nM, respectively. Inter-alpha-trypsin inhibitor and free bikunin have the potential to neutralize extracellular granzyme K activity after T cell degranulation and may thus control unspecific damage of bystander cells at sites of inflammatory reactions.	Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Biol Struct, D-82152 Martinsried, Germany; Univ Bielefeld, Inst Biochem, D-33615 Bielefeld, Germany; Univ Munich, Dept Clin Chem & Clin Biochem, D-80336 Munich, Germany	Max Planck Society; Max Planck Society; University of Bielefeld; University of Munich	Jenne, DE (corresponding author), Max Planck Inst Neurobiol, Dept Neuroimmunol, Klopferspitz 18A, D-82152 Martinsried, Germany.	djenne@biochem.mpg.de	Jenne, Dieter Erich/AAP-1414-2020					Anel A, 1997, J IMMUNOL, V158, P1999; Babe LM, 1998, BIOTECHNOL APPL BIOC, V27, P117; Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; HADDAD P, 1991, INT IMMUNOL, V3, P57, DOI 10.1093/intimm/3.1.57; HAMEED A, 1988, J IMMUNOL, V141, P3142; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Kummer JA, 1996, J BIOL CHEM, V271, P9281, DOI 10.1074/jbc.271.16.9281; Lowin B, 1995, Curr Top Microbiol Immunol, V198, P1; MASSON D, 1988, MOL IMMUNOL, V25, P1283, DOI 10.1016/0161-5890(88)90043-0; MCDONALD JK, 1969, J BIOL CHEM, V244, P2693; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MEIER M, 1990, BIOCHEMISTRY-US, V29, P4042, DOI 10.1021/bi00469a003; MORISHITA H, 1994, THROMB RES, V73, P193, DOI 10.1016/0049-3848(94)90098-1; NISHINO N, 1989, HAEMOSTASIS, V19, P112; Parry MAA, 1996, BIOCHEM J, V320, P335, DOI 10.1042/bj3200335; Pham CTN, 1998, J BIOL CHEM, V273, P1629, DOI 10.1074/jbc.273.3.1629; PILAT D, 1994, GENOMICS, V24, P445, DOI 10.1006/geno.1994.1651; POTEMPA J, 1989, J BIOL CHEM, V264, P15109; PRZETAK MM, 1995, FEBS LETT, V364, P268, DOI 10.1016/0014-5793(95)00407-Z; SALIER JP, 1983, ANAL BIOCHEM, V133, P336, DOI 10.1016/0003-2697(83)90093-3; Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; Sayers TJ, 1996, J LEUKOCYTE BIOL, V59, P763, DOI 10.1002/jlb.59.5.763; SAYERS TJ, 1994, J IMMUNOL, V152, P2289; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; Simon MM, 1997, J EXP MED, V186, P1781, DOI 10.1084/jem.186.10.1781; SLOTA A, 1994, BIOL CHEM H-S, V375, P127; Smyth MJ, 1996, J LEUKOCYTE BIOL, V60, P555, DOI 10.1002/jlb.60.5.555; Smyth MJ, 1996, J IMMUNOL, V156, P4174; SMYTH MJ, 1993, J IMMUNOL, V151, P6195; SMYTH MJ, 1995, J IMMUNOL, V154, P6299; Sower LE, 1996, CELL IMMUNOL, V171, P159, DOI 10.1006/cimm.1996.0187; Sower LE, 1996, J IMMUNOL, V156, P2585; Spaeny-Dekking EHA, 1998, J IMMUNOL, V160, P3610; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; SUMI H, 1980, EXPERIENTIA, V36, P1103, DOI 10.1007/BF01965994; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Xia ZN, 1998, BIOCHEM BIOPH RES CO, V243, P384, DOI 10.1006/bbrc.1998.8102; Xu YB, 1998, J MOL BIOL, V276, P955, DOI 10.1006/jmbi.1997.1582	42	60	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27331	27337		10.1074/jbc.274.38.27331	http://dx.doi.org/10.1074/jbc.274.38.27331			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480954	hybrid			2022-12-25	WOS:000082570700093
J	Gueguen, V; Macherel, D; Neuburger, M; Saint Pierre, C; Jaquinod, M; Gans, P; Douce, R; Bourguignon, J				Gueguen, V; Macherel, D; Neuburger, M; Saint Pierre, C; Jaquinod, M; Gans, P; Douce, R; Bourguignon, J			Structural and functional characterization of H protein mutants of the glycine decarboxylase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE MULTIENZYME COMPLEX; PEA LEAF MITOCHONDRIA; ESCHERICHIA-COLI; LIPOYL DOMAIN; POSTTRANSLATIONAL MODIFICATION; AZOTOBACTER-VINELANDII; CLEAVAGE SYSTEM; COA CARBOXYLASE; RESOLUTION	The mitochondrial glycine decarboxylase complex (GDC) consists of four component enzymes (P, H, T, and L proteins) involved in the breakdown of glycine. in order to investigate structural interactions involved in the stabilization of the methylamine-loaded H protein (a transient species in the GDC reaction), we designed several mutants of H apoprotein. Structural analysis of the wild-type and mutants of H apoprotein emphasized the necessity to carefully assess, by biophysical techniques, the correct folding of mutated proteins prior to investigate their biochemical properties. The correctly folded wild-type and mutants of H apoprotein were in vitro lipoylated and then characterized in the context of GDC reaction by studying the reconstituted complex and partial reactions. We showed that Val(62) and Ala(64), surrounding the lipoyl-lysine, play an important role in the molecular events that govern the reaction between P and H protein but do not intervene in the recognition of the binding site of Lipoic acid by lipoyl ligase, The biochemical results obtained with the HE14A mutant of H protein pointed out the major role of the Glu(14) amino acid residue in the GDC catalysis and highlighted the importance of the ionic and hydrogen bounds in the hydrophobic cleft of H protein for the stabilization of the methylamine-loaded lipoyl arm.	Univ Grenoble 1, CNRS, Commissairiat Energie Atom,Dept Biol Mol & Struct, Lab Physiol Cellulaire Vegetale,URA 576, F-38054 Grenoble 9, France; CNRS, Inst Biol Struct, Commissariat Energie Atom, Lab Spect Masse Proteines, F-38027 Grenoble, France; CNRS, Inst Biol Struct, Commissariat Energie Atom, Lab Resonance Magnet Nucl, F-38027 Grenoble 1, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Bourguignon, J (corresponding author), Univ Grenoble 1, CNRS, Commissairiat Energie Atom,Dept Biol Mol & Struct, Lab Physiol Cellulaire Vegetale,URA 576, 17 Rue Martyrs, F-38054 Grenoble 9, France.		Macherel, David/B-2084-2012	Macherel, David/0000-0002-3352-2185; Bourguignon, jacques/0000-0001-7517-0600				Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; Berg A, 1998, EUR J BIOCHEM, V252, P45, DOI 10.1046/j.1432-1327.1998.2520045.x; Berg A, 1996, J MOL BIOL, V261, P432, DOI 10.1006/jmbi.1996.0474; BOURGUIGNON J, 1993, EUR J BIOCHEM, V217, P377, DOI 10.1111/j.1432-1033.1993.tb18256.x; BOURGUIGNON J, 1988, BIOCHEM J, V255, P169, DOI 10.1042/bj2550169; BROCKLEHURST SM, 1993, PROTEIN SCI, V2, P626; Cohen-Addad C, 1997, BIOCHIMIE, V79, P637, DOI 10.1016/S0300-9084(97)83496-7; COHENADDAD C, 1995, NAT STRUCT BIOL, V2, P63, DOI 10.1038/nsb0195-63; DOUCE R, 1994, BIOCHEM SOC T, V22, P184, DOI 10.1042/bst0220184; GREEN DE, 1995, BIOCHEM J, V309, P853, DOI 10.1042/bj3090853; GUINIER A, 1955, SMALL ANGELS SCATTER; KIKUCHI G, 1982, MOL CELL BIOCHEM, V45, P137; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macherel D, 1996, EUR J BIOCHEM, V236, P27, DOI 10.1111/j.1432-1033.1996.00027.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; PARES S, 1995, ACTA CRYSTALLOGR D, V51, P1041, DOI 10.1107/S0907444995006421; PARES S, 1994, P NATL ACAD SCI USA, V91, P4850, DOI 10.1073/pnas.91.11.4850; Reche P, 1998, BIOCHEM J, V329, P589, DOI 10.1042/bj3290589; Sambrook J., 2002, MOL CLONING LAB MANU; SAROJINI G, 1985, PLANT PHYSIOL, V77, P786, DOI 10.1104/pp.77.3.786; SHENOY BC, 1988, FASEB J, V2, P2505, DOI 10.1096/fasebj.2.9.3131174; SIEKER L, 1991, J MOL BIOL, V220, P223, DOI 10.1016/0022-2836(91)90007-S; Wallis NG, 1996, J MOL BIOL, V263, P463, DOI 10.1006/jmbi.1996.0589; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130	25	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26344	26352		10.1074/jbc.274.37.26344	http://dx.doi.org/10.1074/jbc.274.37.26344			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473591	hybrid			2022-12-25	WOS:000082469700057
J	Kim, I; Moon, SO; Koh, KN; Kim, H; Uhm, CS; Kwak, HJ; Kim, NG; Koh, GY				Kim, I; Moon, SO; Koh, KN; Kim, H; Uhm, CS; Kwak, HJ; Kim, NG; Koh, GY			Molecular cloning, expression, and characterization of angiopoietin-related protein - Angiopoietin-related protein induces endothelial cell sprouting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; TIE2 RECEPTOR; ANGIOGENESIS; SEQUENCE; DOMAINS; LIGAND; FIBRIN; LECTIN	Using degenerate polymerase chain reaction, we isolated a cDNA encoding a novel 493-amino acid protein from human and mouse adult heart cDNAs and have designated it angiopoietin-related protein-2 (ARP2), The NH2-terminal and COOH-terminal portions of ARP2 contain the characteristic coiled-coil domain and fibrinogen-like domain that are conserved in angiopoietins, ARP2 has two consensus glycosylation sites and a highly hydrophobic region at the NH, terminus that is typical of a secretory signal sequence. Recombinant ARP2 expressed in COS cells is secreted and glycosylated, In human adult tissues, ARP2 mRNA is most abundant in heart, small intestine, spleen, and stomach. In rat embryos, ARP2 mRNA is most abundant in the blood vessels and skeletal muscles. Endothelial and vascular smooth muscle cells also contain ARP2 mRNA, Recombinant ARP2 protein induces sprouting in vascular endothelial cells but does not bind to the Tiel or TieB receptor. These results suggest that ARP2 may exert a function on endothelial cells through autocrine or paracrine action.	Chonbuk Natl Univ, Sch Med, Natl Creat Res Initiat Ctr Cardiac Regenerat, Chonju 560180, South Korea; Chonbuk Natl Univ, Sch Med, Cardiovasc Res Inst, Chonju 560180, South Korea; Korea Univ, Brad Sch Biotechnol, Seoul 136705, South Korea; Korea Univ, Dept Anat, Inst Human Genet, Seoul 136705, South Korea	Jeonbuk National University; Jeonbuk National University; Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine)	Koh, GY (corresponding author), Chonbuk Natl Univ, Sch Med, Natl Creat Res Initiat Ctr Cardiac Regenerat, San 2-20, Chonju 560180, South Korea.	gykoh@moak.chonbuk.ac.kr	Kim, Injune/C-1710-2011; Koh, Gou Young/C-1615-2011; Koh, Kyung-Nam/AAA-2747-2022	Kim, Injune/0000-0001-9244-815X; Koh, Kyung-Nam/0000-0002-6376-672X; Kim, Hyun/0000-0002-7210-5798				BAUMANN RE, 1993, BLOOD, V82, P2117; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; HENSCHEN A, 1977, H-S Z PHYSIOL CHEM, V358, P1643; Kang MJ, 1997, J MOL CELL CARDIOL, V29, P1767, DOI 10.1006/jmcc.1997.0450; KIM H, 1994, J NEUROCHEM, V63, P1991; Kim I, 1999, FEBS LETT, V443, P353, DOI 10.1016/S0014-5793(99)00008-3; KOPBLIZEK TL, 1988, CURR BIOL, V8, P529; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NEHLS V, 1995, HISTOCHEM CELL BIOL, V104, P459, DOI 10.1007/BF01464336; Ohashi T, 1998, ARCH BIOCHEM BIOPHYS, V360, P223, DOI 10.1006/abbi.1998.0957; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Peek R, 1998, INVEST OPHTH VIS SCI, V39, P1782; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sugimoto R, 1998, J BIOL CHEM, V273, P20721, DOI 10.1074/jbc.273.33.20721; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P681, DOI 10.1006/bbrc.1993.1678; ZIEGLER SF, 1993, ONCOGENE, V8, P663	25	173	213	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26523	26528		10.1074/jbc.274.37.26523	http://dx.doi.org/10.1074/jbc.274.37.26523			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473614	hybrid			2022-12-25	WOS:000082469700080
J	Morty, RE; Lonsdale-Eccles, JD; Morehead, J; Caler, EV; Mentele, R; Auerswald, EA; Coetzer, THT; Andrews, NW; Burleigh, BA				Morty, RE; Lonsdale-Eccles, JD; Morehead, J; Caler, EV; Mentele, R; Auerswald, EA; Coetzer, THT; Andrews, NW; Burleigh, BA			Oligopeptidase B from Trypanosoma brucei, a new member of an emerging subgroup of serine oligopeptidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN PROLYL ENDOPEPTIDASE; ENZYME GENE; AFRICAN TRYPANOSOMES; EXPRESSED ENZYME; DIPEPTIDYL AMINOPEPTIDASE; CYSTEINE PROTEINASES; ALKALINE PEPTIDASE; ESCHERICHIA-COLI; MAMMALIAN-CELLS; CDNA CLONING	Trypanosoma brucei contains a soluble serine oligopeptidase (OP-Tb) that is released into the host bloodstream during infection, where it has been postulated to participate in the pathogenesis of African trypanosomiasis. Here, we report the identification of a single copy gene encoding the T. brucei oligopeptidase and a homologue from the related trypanosomatid pathogen Leishmania major. The enzymes encoded by these genes belong to an emerging subgroup of the prolyl oligopeptidase family of serine hydrolases, referred to as oligopeptidase B. The trypanosomatid oligopeptidases share 70% amino acid sequence identity with oligopeptidase B from the intracellular pathogen Trypanosoma cruzi, which has a demonstrated role in mammalian host cell signaling and invasion. OP-Tb exhibited no activity toward the prolyl oligopeptidase substrate H-Gly-Pro-7-amido-4-methylcoumarin. Instead, it had activity toward substrates of trypsin-like enzymes, particularly those that have basic amino acids in both P-1, and P-2, (e.g. benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin k(cat)/K-m = 529 s(-1) mu M-1). The activity of OP-Tb was enhanced by reducing agents and by polyamines, suggesting that these agents may act as in vivo regulators of OP-Tb activity. This study provides the basis of the characterization of a novel subgroup of serine oligopeptidases from kinetoplastid protozoa with potential roles in pathogenesis.	Univ KwaZulu Natal, Dept Biochem, ZA-3209 Scottsville, South Africa; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA; Univ Munich, Klinikum Innenstadt, Klin Chem & Klin Biochem Abt, Chirurg Klin & Poliklin, D-80336 Munich, Germany	University of Kwazulu Natal; University of Alabama System; University of Alabama Birmingham; Yale University; University of Munich	Burleigh, BA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.	bburleig@hsph.harvard.edu	Coetzer, Theresa/AAM-9193-2021; Coetzer, Theresa/AAE-6207-2019	Coetzer, Theresa/0000-0003-0706-3808; Andrews, Norma/0000-0002-0611-2412				ASHALL F, 1990, MOL BIOCHEM PARASIT, V38, P77, DOI 10.1016/0166-6851(90)90207-3; AUERSWALD EA, 1991, EUR J BIOCHEM, V200, P131, DOI 10.1111/j.1432-1033.1991.tb21059.x; BARRETT AJ, 1992, BIOL CHEM H-S, V373, P353, DOI 10.1515/bchm3.1992.373.2.353; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P247, DOI 10.1006/abbi.1995.1227; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandenberger G, 1996, J BIOL RHYTHM, V11, P258, DOI 10.1177/074873049601100307; Burleigh BA, 1997, J CELL BIOL, V136, P609, DOI 10.1083/jcb.136.3.609; BURLEIGH BA, 1995, J BIOL CHEM, V270, P5172, DOI 10.1074/jbc.270.10.5172; Caler EV, 1998, EMBO J, V17, P4975, DOI 10.1093/emboj/17.17.4975; CAUGHEY GH, 1993, J PHARMACOL EXP THER, V264, P676; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; de Andrade ASR, 1998, EXP PARASITOL, V89, P153, DOI 10.1006/expr.1997.4269; Dunn BM., 1989, PROTEOLYTIC ENZYMES, P57; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; GRAB DJ, 1982, ACTA TROP, V39, P363; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; Ishino T, 1998, J BIOCHEM-TOKYO, V123, P540; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; KALWANT S, 1991, BIOCHEM J, V276, P237, DOI 10.1042/bj2760237; KANATANI A, 1991, J BIOCHEM-TOKYO, V110, P315, DOI 10.1093/oxfordjournals.jbchem.a123577; KANATANI A, 1993, J BIOCHEM, V113, P790, DOI 10.1093/oxfordjournals.jbchem.a124120; KORNBLATT MJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P25, DOI 10.1016/0003-9861(92)90360-9; KREIL G, 1990, TRENDS BIOCHEM SCI, V15, P23, DOI 10.1016/0968-0004(90)90126-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Leite MF, 1998, MOL BIOCHEM PARASIT, V92, P1, DOI 10.1016/S0166-6851(97)00211-9; LONSDALEECCLES JD, 1987, EUR J BIOCHEM, V169, P467, DOI 10.1111/j.1432-1033.1987.tb13634.x; MARKWARDT F, 1974, BIOCHEM PHARMACOL, V23, P2247, DOI 10.1016/0006-2952(74)90554-1; MCCANN PP, 1981, MED BIOL, V59, P434; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MHAWA Z, 1991, EUR J BIOCHEM, V195, P183; Morty RE, 1998, FEBS LETT, V433, P251, DOI 10.1016/S0014-5793(98)00914-4; NDUNGU JM, 1992, PARASITOL RES, V78, P553, DOI 10.1007/BF00936451; OGATA S, 1989, J BIOL CHEM, V264, P3596; Polgar L, 1997, PROTEINS, V28, P375; Potempa J, 1997, BIOL CHEM, V378, P223, DOI 10.1515/bchm.1997.378.3-4.223; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; RODRIGUEZ A, 1995, J CELL BIOL, V129, P1263, DOI 10.1083/jcb.129.5.1263; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; Shinoda M, 1997, BIOCHEM BIOPH RES CO, V235, P641, DOI 10.1006/bbrc.1997.6730; SHIRASAWA Y, 1994, J BIOCHEM-TOKYO, V115, P724, DOI 10.1093/oxfordjournals.jbchem.a124402; Shrimpton CN, 1997, J BIOL CHEM, V272, P17395, DOI 10.1074/jbc.272.28.17395; Sreedharan SK, 1996, BIOCHEM J, V316, P777, DOI 10.1042/bj3160777; TETAERT D, 1993, INT J PEPT PROT RES, V41, P147; TIZARD I, 1978, MICROBIOL REV, V42, P661, DOI 10.1128/MMBR.42.4.664-681.1978; Toide K, 1997, PHARMACOL BIOCHEM BE, V56, P427, DOI 10.1016/S0091-3057(96)00238-9; Troeberg L, 1996, EUR J BIOCHEM, V238, P728, DOI 10.1111/j.1432-1033.1996.0728w.x; VANHOOF G, 1994, GENE, V149, P363, DOI 10.1016/0378-1119(94)90177-5; WELCHES WR, 1993, LIFE SCI, V33, P2149; YOSHIMOTO T, 1995, J BIOCHEM-TOKYO, V117, P654, DOI 10.1093/oxfordjournals.jbchem.a124759; YOSHIMOTO T, 1991, J BIOCHEM-TOKYO, V110, P873, DOI 10.1093/oxfordjournals.jbchem.a123682	62	62	69	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26149	26156		10.1074/jbc.274.37.26149	http://dx.doi.org/10.1074/jbc.274.37.26149			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473566	hybrid			2022-12-25	WOS:000082469700032
J	Guo, C; White, PS; Weiss, MJ; Hogarty, MD; Thompson, PM; Stram, DO; Gerbing, R; Matthay, KK; Seeger, RC; Brodeur, GM; Maris, JM				Guo, C; White, PS; Weiss, MJ; Hogarty, MD; Thompson, PM; Stram, DO; Gerbing, R; Matthay, KK; Seeger, RC; Brodeur, GM; Maris, JM			Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas	ONCOGENE			English	Article						neuroblastoma; chromosome, human, pair 11; loss of heterozygosity; genes, suppressor, tumor; deletion mapping	COMPARATIVE GENOMIC HYBRIDIZATION; TANDEM-REPEAT POLYMORPHISMS; FAMILIAL NEUROBLASTOMA; CHROMOSOME 1P; TUMORS; MAP; HETEROZYGOSITY; REGION	Deletions of the long arm of chromosome 11 (11q) have been noted in primary neuroblastomas, but a comprehensive analysis has not been performed. Therefore, we analysed 331 neuroblastomas (295 sporadic, 15 familial and 21 tumor-derived cell Lines) to determine the prevalence of 11q allelic deletions, to map the location of a putative tumor suppressor gene and to perform clinical correlative studies. Assays for loss of heterozygosity (LOH) were performed at 24 microsatellite loci spanning 11q, LOH was observed at multiple 11q loci in 129/295 (44%) sporadic neuroblastomas, 5/15 (33%) familial neuroblastomas, and 5/21 (24%) neuroblastoma cell lines. A single region of 2.1 cM within 11q23,3, flanked by markers D11S1340 and D11S1299, was deleted in all specimens with 11q LOH, Allelic loss at 11q23 was inversely related to MYCN amplification (P < 0,001), Within the subset of cases with a single copy of MYCN 11q LOH was associated with advanced stage disease (P = 0,008), unfavorable histopathology (P = 0,042), and decreased overall survival probability (P = 0,008), However, 11q LOH was not independently prognostic in multivariate analyses, These data support the hypothesis that a tumor suppressor gene mapping within 11q23,3 is commonly inactivated during the malignant evolution of a large subset of neuroblastomas, especially those with unamplified MYCN.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Canc Grp, Arcadia, CA 91066 USA; Univ So Calif, Sch Med, Dept Pediat, Los Angeles, CA 90027 USA; Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Southern California; University of California System; University of California San Francisco	Maris, JM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, ARC 902A,324 S 34th St, Philadelphia, PA 19104 USA.		Thompson, Paul M/C-4194-2018	Thompson, Paul M/0000-0002-4720-8867	NATIONAL CANCER INSTITUTE [U10CA013539, U10CA078966, R01CA078545] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13539, CA-78545, CA-78966] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altura RA, 1997, GENE CHROMOSOME CANC, V19, P176, DOI 10.1002/(SICI)1098-2264(199707)19:3<176::AID-GCC7>3.0.CO;2-V; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Baysal BE, 1997, GENOMICS, V44, P214, DOI 10.1006/geno.1997.4880; BIEDLER JL, 1980, ADV NEUROBLASTOMA RE, P81; BOWN NP, 1993, CANCER GENET CYTOGEN, V69, P166, DOI 10.1016/0165-4608(93)90100-Z; Brinkschmidt C, 1997, J PATHOL, V181, P394; Brodeur Garrett M., 1997, P761; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 1997, J PEDIAT HEMATOL ONC, V19, P93, DOI 10.1097/00043426-199703000-00001; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Caron H, 1996, HUM GENET, V97, P834; COX DR, 1972, J R STAT SOC B, V34, P187; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1992, CANCER RES, V52, P1780; GEHRING M, 1995, CANCER RES, V55, P5366; Hallstensson K, 1997, EUR J CANCER, V33, P1966, DOI 10.1016/S0959-8049(97)00228-1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOIFFMANN CP, 1995, AM J MED GENET, V58, P46, DOI 10.1002/ajmg.1320580110; Lastowska M, 1997, GENE CHROMOSOME CANC, V18, P162; Maris JM, 1997, EUR J CANCER, V33, P1923, DOI 10.1016/S0959-8049(97)00265-7; MARIS JM, 1995, CANCER RES, V55, P4664; Maris JM, 1996, GENOMICS, V35, P289, DOI 10.1006/geno.1996.0359; MARTINSSON T, 1995, CANCER RES, V55, P5681; Mertens F, 1997, CANCER RES, V57, P2765; MOORHEAD PS, 1980, PROGR CANCER RES THE, V12, P109; MOSS TJ, 1991, NEW ENGL J MED, V324, P219, DOI 10.1056/NEJM199101243240403; NOWAK NJ, 1995, CANC INVEST, V13, P649; PEGELOW CH, 1975, J PEDIATR-US, V87, P763, DOI 10.1016/S0022-3476(75)80304-0; Plantaz D, 1997, AM J PATHOL, V150, P81; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; Takeda O, 1996, BRIT J CANCER, V74, P1620, DOI 10.1038/bjc.1996.598; TAKITA J, 1995, ONCOGENE, V11, P1829; Takita J, 1997, CANCER RES, V57, P907; Van Gele M, 1997, EUR J CANCER, V33, P1979, DOI 10.1016/S0959-8049(97)00289-X; Vandesompele J, 1998, GENE CHROMOSOME CANC, V23, P141, DOI 10.1002/(SICI)1098-2264(199810)23:2<141::AID-GCC7>3.0.CO;2-2; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Yuan B, 1997, AM J HUM GENET, V60, P459	42	187	190	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4948	4957		10.1038/sj.onc.1202887	http://dx.doi.org/10.1038/sj.onc.1202887			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490829				2022-12-25	WOS:000082321700007
J	Yamashita, A; Hakura, A; Inoue, H				Yamashita, A; Hakura, A; Inoue, H			Suppression of anchorage-independent growth of human cancer cell lines by the drs gene	ONCOGENE			English	Article						drs; tumor suppressor; anchorage-independent growth; human cancer cell line; cyclin A	LINKED RETINITIS-PIGMENTOSA; RAT EMBRYO FIBROBLASTS; HUMAN-COLON CARCINOMA; V-SRC TRANSFORMATION; CYCLE PROGRESSION; BETA-CATENIN; L-SELECTIN; RETINOBLASTOMA PROTEIN; LEUKOCYTE ADHESION; DNA METHYLATION	We have previously reported that the drs gene, whose mRNA expression is downregulated by retroviral oncogenes such as v-src and v-K-ras, has the ability to suppress transformation by v-src in a rat cell line F2408, We have now isolated a human homolog of this gene (h-drs) and found that the expression of h-dfs mRNA is markedly downregulated in a variety of human cancer cell lines including those of the colon, bladder, and ovary. To investigate the function of the h-drs gene as a tumor suppressor in human cancer cells, we constructed recombinant amphotropic retrovirus containing the drs gene, introduced this virus into human cancer cell lines whose nps expression was downregulated and found that drs has the ability to suppress anchorage-independent growth of these cells without disturbing cell proliferation. Analyses with deletion mutants of the drs gene revealed that both the C-terminal region inside the transmembrane domain and three consensus repeats in the N-terminal region are essential for the suppression of anchorage-independent growth of the cells. We also found that the GI-S progression of the cell cycle and expression of cyclin A mRNA were significantly suppressed in T24 cells expressing the drs gene under non-adhesion culture conditions. In contrast, the expression of cyclin D and E and the phosphorylation of Rb protein were not affected by ectopic expression of the drs gene, suggesting that an Rb-independent downregulation of cyclin A is involved in the suppression of anchorage-independent growth by means of the drs gene.	Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, Osaka 5650871, Japan	Osaka University	Inoue, H (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, 3-1 Yamadaoka, Osaka 5650871, Japan.							Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1989, CANCER RES, V49, P4682; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DRY KL, 1995, HUM MOL GENET, V4, P2347, DOI 10.1093/hmg/4.12.2347; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GUANDAGNO TM, 1993, SCIENCE, V262, P1572; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; INOUE H, 1995, ONCOGENE, V11, P231; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; JUTILA MA, 1992, J EXP MED, V175, P1565, DOI 10.1084/jem.175.6.1565; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LI SH, 1994, J BIOL CHEM, V269, P4431; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEINDL A, 1995, HUM MOL GENET, V4, P2339, DOI 10.1093/hmg/4.12.2339; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MIYASAKA M, 1991, J VIROL, V65, P479, DOI 10.1128/JVI.65.1.479-482.1991; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagase T, 1997, BRIT J CANCER, V76, P1001, DOI 10.1038/bjc.1997.499; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; NEVINS JR, 1992, SCIENCE, V258, P424; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Pan J, 1996, FEBS LETT, V383, P21; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	73	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4777	4787		10.1038/sj.onc.1202852	http://dx.doi.org/10.1038/sj.onc.1202852			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490811				2022-12-25	WOS:000082184800002
J	Ko, YH; Hong, SJ; Pedersen, PL				Ko, YH; Hong, SJ; Pedersen, PL			Chemical mechanism of ATP synthase - Magnesium plays a pivotal role in formation of the transition state where ATP is synthesized from ADP and inorganic phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; ADENOSINE-TRIPHOSPHATASE; MOLECULAR MACHINE; MYOSIN; VANADATE; F1-ATPASE; ROTATION; MITOCHONDRIA; RESOLUTION; CLEAVAGE	The chemical mechanism by which ATP synthases catalyze the synthesis of ATP remains unknown despite the recent elucidation of the three-dimensional structures of two forms of the F-1 catalytic sector (subunit stoichiometry, alpha(3)beta(3)gamma delta epsilon). Lacking is critical information about the chemical events taking place at the catalytic site of each P-subunit in the transition state. In an earlier report (Ko, Y. H., Planchet, M. A., Amzel, L. M., and Pedersen, P. L, (1997) J. Biol. Chem. 272, 18875-18881), we provided evidence for transition state formation in the presence of Mg2+, ADP, and orthovanadate (V-i), a photoreactive phosphate analog with a trigonal bipyramidal geometry resembling that of the gamma-P of ATP in the transition state of enzymes like myosin, In the presence of ultraviolet light and O-2, the MgADP.V-i-F-1 complex was cleaved within the P-loop (GG (A) under bar GVGKT) of a single P-subunit at alanine 158, implicating this residue as within contact distance of the gamma-P of ATP in the transition state. Here, we report that ADP, although facilitating transition state formation, is not essential. In the presence of Mg2+ and V-i alone the catalytic activity of the resultant MgVi-F-1 complex is inhibited to nearly the same extent as that observed for the MgADP.V-i-F-1 complex. Inhibition is not observed with ADP, Mg2+, or V-i alone. Significantly, in the presence of ultraviolet light and O-2, the MgVi-F-1 complex is cleaved also within the P-loop of a single beta-subunit at alanine 158 as confirmed by Western blot analyses with two different antibodies, by N-terminal sequence analyses, and by quantification of the amount of unreacted beta-subunits. These novel findings indicate that Mg2+ plays a pivotal role in transition state formation during ATP synthesis catalyzed by ATP synthases, a role that involves both its preferential coordination with P-i and the repositioning of the P-loop to bring the nonpolar alanine 158 into the catalytic pocket. A reaction scheme for ATP synthases depicting a role for Mg2+ in transition state formation is proposed here for the first time.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				NCI NIH HHS [CA 10951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA010951, R37CA010951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V12, P186; CATTERAL.WA, 1973, J BIOL CHEM, V248, P7427; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; CREMO CR, 1989, J BIOL CHEM, V264, P6608; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P7982, DOI 10.1021/bi00486a029; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Fillingame RH, 1997, J EXP BIOL, V200, P217; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Grammer JC, 1996, BIOCHEMISTRY-US, V35, P15582, DOI 10.1021/bi961901g; HOCHMAN Y, 1993, J BIOL CHEM, V268, P12373; HUNKAPILLER MW, 1983, SCIENCE, V219, P650, DOI 10.1126/science.6687410; Ko YH, 1997, J BIOL CHEM, V272, P18875, DOI 10.1074/jbc.272.30.18875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PEDERSEN PL, 1981, J BIOL CHEM, V256, P1362; RICHTER ML, 1996, ADV PHOTOSYNTH, V4, P453; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1	26	60	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28853	28856		10.1074/jbc.274.41.28853	http://dx.doi.org/10.1074/jbc.274.41.28853			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506126	hybrid			2022-12-25	WOS:000083017800005
J	Abcouwer, SF; Schwarz, C; Meguid, RA				Abcouwer, SF; Schwarz, C; Meguid, RA			Glutamine deprivation induces the expression of GADD45 and GADD153 primarily by mRNA stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; MESSENGER-RNA DEGRADATION; AMINO-ACID LIMITATION; ENDOPLASMIC-RETICULUM; DNA-DAMAGE; P53-REGULATED PROTEIN; MALFOLDED PROTEINS; EPITHELIAL-CELLS; RICH ELEMENTS; CHOP GADD153	The expression of the growth arrest- and DNA damage-inducible genes, GADD45 and GADD153/CHOP (C/EBP-homologous protein), as well as GRP78 (glucose-regulated protein of 78 kDa) was examined in several human breast cell lines subjected to acute glutamine (GLN) deprivation. GLN deprivation caused rapid elevation of GADD45 and GADD153/CHOP mRNA levels in cells that were highly dependent upon GLN for growth and viability. Both GADD mRNAs were rapidly elevated up to several hundred-fold. In contrast, GRP78 expression was elevated by no more than 4-fold by GLN deprivation. The magnitude of GADD up-regulation roughly correlated with the extent of GLN dependence of each cell line. The levels of all three mRNAs were responsive to alterations of ambient GLN content in a physiologically relevant concentration range that corresponded to the affinities of cellular GLN transporters. Provision of GLN-derived metabolites partially inhibited the induction of GADD expression in GLN-deprived cells. Nuclear run-on assays and mRNA decay studies suggested that the primary mechanism leading to increased GADD mRNA levels was not transcriptional, but rather that GADD45 and GADD153/CHOP expression mere up-regulated in response to GLN deprivation via marked stabilization of these mRNAs. These results suggest that the expression of GADD genes contributes to growth arrest and/or protection from metabolic damage during GLN-poor conditions.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Surg Oncol Res Labs, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Abcouwer, SF (corresponding author), Univ New Mexico, Sch Med, Hlth Sci Ctr, Dept Biochem & Mol Biol, Basic Sci Bldg 249, Albuquerque, NM 87131 USA.			Meguid, Robert/0000-0003-2646-4252; Abcouwer, Steven F/0000-0003-2580-1288	NIDDK NIH HHS [P30-DK40561] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abcouwer SF, 1996, AM J PHYSIOL-LUNG C, V270, pL141, DOI 10.1152/ajplung.1996.270.1.L141; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CARRIER F, 1994, J BIOL CHEM, V269, P32672; Chen CH, 1996, ONCOGENE, V13, P1659; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Collins CL, 1998, J CELL PHYSIOL, V176, P166, DOI 10.1002/(SICI)1097-4652(199807)176:1<166::AID-JCP18>3.0.CO;2-5; Delmastro DA, 1997, CANCER CHEMOTH PHARM, V39, P245; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DHALIWAL MK, 1990, ANTICANCER RES, V10, P113; Eymin B, 1997, CANCER RES, V57, P686; GAFFNEY EV, 1976, CELL TISSUE RES, V172, P269, DOI 10.1007/BF00226031; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; GREENBERG ME, 1996, CURRENT PROTOCOLS MO, V1; Halleck MM, 1997, CELL STRESS CHAPERON, V2, P31, DOI 10.1379/1466-1268(1997)002<0031:TMRTRS>2.3.CO;2; JACKMAN J, 1994, CANCER RES, V54, P5656; Jeong JMK, 1996, MOL PHARMACOL, V50, P592; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Landesman Y, 1997, CELL SIGNAL, V9, P291, DOI 10.1016/S0898-6568(97)89890-7; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; LUETHY JD, 1992, CANCER RES, V52, P5; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; PRICE BD, 1992, CANCER RES, V52, P3814; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	38	64	66	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28645	28651		10.1074/jbc.274.40.28645	http://dx.doi.org/10.1074/jbc.274.40.28645			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497233	hybrid			2022-12-25	WOS:000082912700082
J	Simon, S; Le Goff, A; Frobert, Y; Grassi, J; Massoulie, J				Simon, S; Le Goff, A; Frobert, Y; Grassi, J; Massoulie, J			The binding sites of inhibitory monoclonal antibodies on acetylcholinesterase - Identification of a novel regulatory site at the putative "back door"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN ACETYLCHOLINESTERASE; ALLOSTERIC MODULATION; CATALYTIC EFFICIENCY; CRYSTAL-STRUCTURE; ANIONIC SUBSITE; PERIPHERAL SITE; ELECTROPHORUS; TRANSITION; FASCICULIN; EXPRESSION	We investigated the target sites of three inhibitory monoclonal antibodies on Electrophorus acetylcholinesterase (AChE). Previous studies showed that Elec-403 and Elec-410 are directed to overlapping but distinct epitopes in the peripheral site, at the entrance of the catalytic gorge, whereas Elec-408 binds to a different region. Using Electrophorus/rat AChE chimeras, we identified surface residues that differed between sensitive and insensitive AChEs: the replacement of a single Electrophorus residue by its rat homolog was able to abolish binding and inhibition, for each antibody. Reciprocally, binding and inhibition by Elec-403 and by Elec-410 could be conferred to rat AChE by the reverse mutation. Elec-410 appears to bind to one side of the active gorge, whereas Elec-403 covers its opening, explaining why the AChE-Elec-410 complex reacts faster than the AChE-Elec-403 or AChE-fasciculin complexes with two active site inhibitors, m-(N,N,N-trimethyltammonio)trifluoro-acetophenone and echothiophate. Elec-408 binds to the region of the putative "back door," distant from the peripheral site, and does not interfere with the access of inhibitors to the active site. The binding of an antibody to this novel regulatory site may inhibit the enzyme by blocking the back door or by inducing a conformational distortion within the active site.	Ecole Normale Super, Neurobiol Cellulaire & Mol Lab, CNRS, URA 1857, F-75005 Paris, France; CEA Saclay, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay	Massoulie, J (corresponding author), Ecole Normale Super, Neurobiol Cellulaire & Mol Lab, CNRS, URA 1857, 46 Rue Ulm, F-75005 Paris, France.		Simon, Stephanie/E-4289-2012	Simon, Stephanie/0000-0002-6071-8255				ASHANI Y, 1990, BIOCHEMISTRY-US, V29, P2456, DOI 10.1021/bi00462a004; BARAK D, 1995, BIOCHEMISTRY-US, V34, P15444, DOI 10.1021/bi00047a008; BLONDEL A, 1991, NUCLEIC ACIDS RES, V19, P181, DOI 10.1093/nar/19.1.181; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BRIMIJOIN S, 1985, MOL PHARMACOL, V28, P539; Cousin X, 1996, J BIOL CHEM, V271, P15099, DOI 10.1074/jbc.271.25.15099; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Faerman C, 1996, FEBS LETT, V386, P65, DOI 10.1016/0014-5793(96)00374-2; GENTRY MK, 1995, J NEUROCHEM, V64, P842; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; GRASSI J, 1988, ANAL BIOCHEM, V168, P436, DOI 10.1016/0003-2697(88)90341-7; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KRONMAN C, 1994, J BIOL CHEM, V269, P27819; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; Morel N, 1997, BIOCHEM J, V328, P121, DOI 10.1042/bj3280121; NAIR HK, 1994, BIOCHEMISTRY-US, V33, P8566, DOI 10.1021/bi00194a023; NAIR HK, 1993, J AM CHEM SOC, V115, P9939, DOI 10.1021/ja00075a009; ORDENTLICH A, 1995, J BIOL CHEM, V270, P2082, DOI 10.1074/jbc.270.5.2082; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1991, MOL PHARMACOL, V39, P98; Reiner E., 1991, CHOLINESTERASES STRU, P227; REMY MH, 1995, EUR J BIOCHEM, V231, P651, DOI 10.1111/j.1432-1033.1995.tb20744.x; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; Saxena A, 1998, BIOCHEMISTRY-US, V37, P145, DOI 10.1021/bi972061o; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; Simon S, 1997, J BIOL CHEM, V272, P33045, DOI 10.1074/jbc.272.52.33045; Simon S, 1998, EMBO J, V17, P6178, DOI 10.1093/emboj/17.21.6178; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1998, BIOCHEMISTRY-US, V37, P4206, DOI 10.1021/bi972158a; VIGNY M, 1978, EUR J BIOCHEM, V85, P317, DOI 10.1111/j.1432-1033.1978.tb12241.x; [No title captured]	35	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27740	27746		10.1074/jbc.274.39.27740	http://dx.doi.org/10.1074/jbc.274.39.27740			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488117	hybrid			2022-12-25	WOS:000082739100056
J	Zhang, YP; Lemasters, J; Herman, B				Zhang, YP; Lemasters, J; Herman, B			Secretory group IIA phospholipase A(2) generates anti-apoptotic survival signals in kidney fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; GREEN FLUORESCENT PROTEIN; RAT PLATELET PHOSPHOLIPASE-A2; CYCLOSPORINE-A; LYSOPHOSPHATIDIC ACID; CELL-DEATH; KAPPA-B; LIVER; HEPATOCYTES; INHIBITORS	Mammalian group IIA phospholipase A(2) (PLA(2)) is believed to play important roles in inflammation, cell injury, and tumor resistance. However, the cellular site of action has not been clearly defined as it has long been recognized that group IIA PLA(2) is both a secretory and mitochondrial protein. The purpose of this study was to determine the subcellular target of the group IIA PLA(2) and its role in apoptosis stimulated by growth factor withdrawal. Cloning of the rat liver group IIA PLA(2) demonstrated a typical secretory signal and no alternative splicing of the primary transcript. When a sequence including the signal peptide and first 8 residues in the mature enzyme or the entire PLA(2) (including the signal peptide) was fused to enhanced green fluorescent protein, the fusion protein was directed to the secretory pathway rather than mitochondria in baby hamster kidney (BHK) cells. To examine the role of group IIA PLA(2) in cell injury, wild type (wt) rat group IIA PLA(2) and a mutant group IIA PLA(2) containing a His-47 --> Gln mutation (at the catalytic center) were transfected into BHK cells and cells stably expressing these constructs were isolated. After deprivation of growth factors, both normal BHK cells and BHK cells expressing mutant PLA(2) underwent massive apoptosis, while BHK cells expressing wt PLA(2) showed considerable resistance to growth factor withdrawal-induced apoptosis, The secretory PLA(2) inhibitors 12-epi-scalaradial and aristolochic acid abrogated resistance to apoptosis in the wt PLA(2) expressing cells. These two inhibitors did not induce cell death in the presence of fetal bovine serum, suggesting that they induce cell death by blocking PLA(2) generated survival signals. This study demonstrates that group IIA PLA(2) generates anti-apoptotic survival signals in BHK cells targeting the secretory pathway, and suggests that high levels of group HA PLA(2) accumulated at inflammatory sites may not only regulate inflammation, but also may protect cells from unnecessary death induced by pro-inflammatory agents.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA; Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA	University of Texas System; University of Texas Health San Antonio; University of North Carolina; University of North Carolina Chapel Hill	Herman, B (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.	hermanb@uthscsa.edu						AARSMAN AJ, 1984, BIOCHIM BIOPHYS ACTA, V792, P363, DOI 10.1016/0005-2760(84)90205-4; AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; ARITA H, 1991, J BIOL CHEM, V266, P19139; BARNETTE MS, 1994, BIOCHEM PHARMACOL, V47, P1661, DOI 10.1016/0006-2952(94)90545-2; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DEWINTER JM, 1982, BIOCHIM BIOPHYS ACTA, V712, P332, DOI 10.1016/0005-2760(82)90351-4; FAYARD JM, 1994, EUR J PHARMACOL, V251, P281, DOI 10.1016/0014-2999(94)90410-3; Fimia GM, 1996, J BIOL CHEM, V271, P15575, DOI 10.1074/jbc.271.26.15575; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Glaser KB, 1995, SKIN PHARMACOL, V8, P300, DOI 10.1159/000211361; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; Guidet B, 1996, INFECTION, V24, P103, DOI 10.1007/BF01713312; HARRISON DC, 1991, BIOCHEM BIOPH RES CO, V174, P654, DOI 10.1016/0006-291X(91)91467-Q; HATCH GM, 1993, BIOCHEM J, V293, P143, DOI 10.1042/bj2930143; HAYAKAWA M, 1988, J BIOCHEM-TOKYO, V104, P767, DOI 10.1093/oxfordjournals.jbchem.a122547; Healy E, 1998, KIDNEY INT, V54, P1955, DOI 10.1046/j.1523-1755.1998.00202.x; ISHIZAKI J, 1989, BIOCHEM BIOPH RES CO, V162, P1030, DOI 10.1016/0006-291X(89)90777-8; KAETHER C, 1995, FEBS LETT, V369, P267, DOI 10.1016/0014-5793(95)00765-2; Kaether C, 1997, EUR J CELL BIOL, V74, P133; Koh JS, 1998, J CLIN INVEST, V102, P716, DOI 10.1172/JCI1002; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; KUSUNOKI C, 1990, BIOCHIM BIOPHYS ACTA, V1087, P95, DOI 10.1016/0167-4781(90)90127-N; LEVART C, 1992, BIOCHEM BIOPH RES CO, V183, P719; LEVINE JS, 1997, AM J PHYSIOL, V273, pF675; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MartinezSalgado C, 1997, AM J PHYSIOL-RENAL, V273, pF60, DOI 10.1152/ajprenal.1997.273.1.F60; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Nyman KM, 1996, J SURG RES, V60, P7, DOI 10.1006/jsre.1996.0003; OHARA O, 1990, NUCLEIC ACIDS RES, V18, P6997, DOI 10.1093/nar/18.23.6997; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; Paya M, 1996, BRIT J PHARMACOL, V117, P1773, DOI 10.1111/j.1476-5381.1996.tb15353.x; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Thommesen L, 1998, J IMMUNOL, V161, P3421; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tong LJ, 1998, J SURG RES, V75, P165, DOI 10.1006/jsre.1998.5273; VANDENBOSCH H, 1991, METHOD ENZYMOL, V197, P365; VANDENBOSCH H, 1990, BIOCHEM SOC T, V18, P781, DOI 10.1042/bst0180781; VANSCHAIK RHN, 1993, BIOCHIM BIOPHYS ACTA, V1169, P1, DOI 10.1016/0005-2760(93)90075-K; Violon C, 1997, J Pharm Belg, V52, P7; Walker G, 1997, BRIT J PHARMACOL, V121, P787, DOI 10.1038/sj.bjp.0701170; Wang HC, 1996, FASEB J, V10, P1318, DOI 10.1096/fasebj.10.11.8836046; Wang TC, 1998, GASTROENTEROLOGY, V114, P675, DOI 10.1016/S0016-5085(98)70581-5; Yano M, 1997, J BIOL CHEM, V272, P8459, DOI 10.1074/jbc.272.13.8459; YU L, 1991, P NATL ACAD SCI USA, V88, P9325, DOI 10.1073/pnas.88.20.9325	51	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27726	27733		10.1074/jbc.274.39.27726	http://dx.doi.org/10.1074/jbc.274.39.27726			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488115	hybrid			2022-12-25	WOS:000082739100054
J	Adak, S; Crooks, C; Wang, Q; Crane, BR; Tainer, JA; Getzoff, ED; Stuehr, DJ				Adak, S; Crooks, C; Wang, Q; Crane, BR; Tainer, JA; Getzoff, ED; Stuehr, DJ			Tryptophan 409 controls the activity of neuronal nitric-oxide synthase by regulating nitric oxide feedback inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; HEME; TETRAHYDROBIOPTERIN; CALMODULIN; OXYGEN; COORDINATION; PEROXIDASE; COMPLEXES; SUBSTRATE; PROTEINS	The heme of neuronal nitric-oxide synthase participates in oxygen activation but also binds self-generated NO during catalysis resulting in reversible feedback inhibition. We utilized point mutagenesis to investigate if a conserved tryptophan residue (Trp-409), which engages in rr-stacking with the heme and hydrogen bonds to its axial cysteine ligand, helps control catalysis and regulation by NO. Surprisingly, mutants W409F and W409Y were hyperactive compared with the wild type regarding NO synthesis without affecting cytochrome c reduction, reductase-independent N-hydroxyarginine oxidation, or Arg and tetrahydrobiopterin binding In the absence of Arg, NADPH oxidation measurements showed that electron flux through the heme was actually slower in the Trp-409 mutants than in wild-type nNOS. However, little or no NO complex accumulated during NO synthesis by the mutants, as opposed to the wild type. This difference was potentially related to mutants forming unstable 6-coordinate ferrous-NO complexes under anaerobic conditions even in the presence of Arg and tetrahydrobiopterin, Thus, Trp-409 mutations minimize NO feedback inhibition by preventing buildup of an inactive ferrous-NO complex during the steady state. This overcomes the negative effect of the mutation on electron flux and results in hyperactivity. Conservation of Trp-409 among different NOS suggests that the ability of this residue to regulate heme reduction and NO complex formation is important for enzyme physiologic function.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Cleveland Clinic Foundation; Scripps Research Institute; Scripps Research Institute	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org	Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Wang, Qian/0000-0002-2149-384X	NHLBI NIH HHS [HL58883] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; HEMMENS B, 1997, METHOD MOL BIOL, V100, P1; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; ROE JA, 1993, J BIOL CHEM, V268, P20037; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sambrook J., 2002, MOL CLONING LAB MANU; Scheele JS, 1999, J BIOL CHEM, V274, P13105, DOI 10.1074/jbc.274.19.13105; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; TSUBAKI M, 1988, BIOCHEMISTRY-US, V27, P4856, DOI 10.1021/bi00413a041; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; WU C, 1996, BIOCHEM BIOPH RES CO, V22, P439; Yoshimura T, 1995, MCBU, P217	36	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26907	26911		10.1074/jbc.274.38.26907	http://dx.doi.org/10.1074/jbc.274.38.26907			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480900	hybrid			2022-12-25	WOS:000082570700039
J	Constantinescu, A; Diamond, I; Gordon, AS				Constantinescu, A; Diamond, I; Gordon, AS			Ethanol-induced translocation of cAMP-dependent protein kinase to the nucleus - Mechanism and functional consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APLYSIA SENSORY NEURONS; ELEMENT-BINDING PROTEIN; LONG-TERM FACILITATION; CYCLIC-AMP PRODUCTION; CATALYTIC SUBUNIT; MEMORY STORAGE; HETEROLOGOUS DESENSITIZATION; CREB PHOSPHORYLATION; SOLUBLE-PROTEINS; NG108-15 CELLS	Ethanol induces translocation of the catalytic subunit (C alpha) of cAMP-dependent protein kinase (PKA) from the Golgi area to the nucleus in NG108-15 cells. Ethanol also induces translocation of the RII beta regulatory subunit of PKA to the nucleus; RI and C beta are not translocated. Nuclear PKA activity in ethanol-treated cells is no longer regulated by cAMP. Gel filtration and immunoprecipitation analysis confirm that ethanol blocks the dissociation of C alpha with RII but does not induce dissociation of these subunits. Ethanol also reduces inhibition of C alpha by the PKA inhibitor PKI. Pre-incubation of C alpha with ethanol decreases phosphorylation of Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide) and casein but has no effect on the phosphorylation of highly charged molecules such as histone H1 or protamine. cAMP-response element-binding protein (CREB) phosphorylation by C alpha is also increased in ethanol-treated cells. This increase in CREB phosphorylation is inhibited by the PKA antagonist (R-p)-cAMPS and by an adenosine receptor antagonist. These results suggest that ethanol affects a cascade of events allowing for sustained nuclear localization of C alpha and prolonged CREB phosphorylation. These events may account for ethanol-induced changes in cAMP-dependent gene expression.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Cellular & Mol Pharmacol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Neurosci Grad Program, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Ctr Neurobiol Addict, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Gordon, AS (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, Bldg 1,Rm 101,1001 Potrero Ave, San Francisco, CA 94110 USA.	adrienn@itsa.ucsf.edu			NIAAA NIH HHS [R01 AA10039, R01 AA10030] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010030, R01AA010039] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAILEY CH, 1994, ADV SEC MESS PHOSPH, V29, P529; Bailey CH, 1997, NEURON, V18, P913, DOI 10.1016/S0896-6273(00)80331-1; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CHARNESS ME, 1988, BIOCHEM BIOPH RES CO, V155, P138, DOI 10.1016/S0006-291X(88)81060-X; Coe IR, 1996, J PHARMACOL EXP THER, V276, P365; deJongh HHJ, 1997, BIOCHEMISTRY-US, V36, P13603, DOI 10.1021/bi971337p; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DIAMOND I, 1987, P NATL ACAD SCI USA, V84, P1413, DOI 10.1073/pnas.84.5.1413; DIAMOND I, 1994, WESTERN J MED, V161, P279; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; GREENBERG ME, 1992, J PHYSIOLOGY-PARIS, V86, P99, DOI 10.1016/S0928-4257(05)80013-0; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KEMP BE, 1994, PROTEIN KINASES, P30; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKS MS, 1981, J BIOL CHEM, V256, P8775; LI CY, 1994, P NATL ACAD SCI USA, V91, P8200, DOI 10.1073/pnas.91.17.8200; Liu FC, 1996, NEURON, V17, P1133, DOI 10.1016/S0896-6273(00)80245-7; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MOCHLYROSEN D, 1988, NATURE, V333, P848, DOI 10.1038/333848a0; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; NAGY LE, 1989, MOL PHARMACOL, V36, P744; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; RABE CS, 1990, BIOCHEM PHARMACOL, V40, P565, DOI 10.1016/0006-2952(90)90557-2; RABIN RA, 1993, J NEUROCHEM, V60, P1012, DOI 10.1111/j.1471-4159.1993.tb03249.x; RABIN RA, 1992, J PHARMACOL EXP THER, V262, P257; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; RIUS RA, 1986, BRAIN RES, V365, P355, DOI 10.1016/0006-8993(86)91649-5; ROSEVEAR PR, 1984, BIOCHEMISTRY-US, V23, P3161, DOI 10.1021/bi00309a009; SAITO T, 1985, J NEUROCHEM, V44, P1037, DOI 10.1111/j.1471-4159.1985.tb08722.x; SAPRU MK, 1994, J PHARMACOL EXP THER, V271, P542; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; TABAKOFF B, 1988, NEW ENGL J MED, V318, P134, DOI 10.1056/NEJM198801213180302; Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAND GS, 1993, J BIOL CHEM, V268, P2595; WILLIAMS RJ, 1993, J NEUROCHEM, V61, P1163, DOI 10.1111/j.1471-4159.1993.tb03637.x; XIE HJ, 1995, J IMMUNOL, V154, P1717; Yang XJ, 1998, J NEUROCHEM, V70, P224; Yang XJ, 1996, J PHARMACOL EXP THER, V278, P338	50	58	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26985	26991		10.1074/jbc.274.38.26985	http://dx.doi.org/10.1074/jbc.274.38.26985			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480911	hybrid			2022-12-25	WOS:000082570700050
J	Dubois, S; Magrangeas, F; Lehours, P; Raher, S; Bernard, J; Boisteau, O; Leroy, S; Minvielle, S; Godard, A; Jacques, Y				Dubois, S; Magrangeas, F; Lehours, P; Raher, S; Bernard, J; Boisteau, O; Leroy, S; Minvielle, S; Godard, A; Jacques, Y			Natural splicing of exon 2 of human interleukin-15 receptor alpha-chain mRNA results in a shortened form with a distinct pattern of expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH-FACTOR; IL-2 RECEPTOR; MOLECULAR-CLONING; KILLER-CELLS; BETA-CHAIN; CYTOKINE; LEUKEMIA; PROTEINS; BINDING; GENES	We report the existence of eight different interleukin-15 receptor alpha-chain (IL-15R alpha) transcripts resulting from exon-splicing mechanisms within the IL-15R alpha gene. Two main classes of transcripts can be distinguished that do or do not (Delta 2 isoforms) contain the exon 2-coding sequence. Both classes were expressed in numerous cell lines and tissues (including peripheral blood lymphocytes) art comparable levels and could be transcribed in COS-7 cells, and the proteins were expressed at the cell surface. Both receptor forms displayed numerous glycosylation stales, reflecting differential usage of a single N-glycosylation site as well as extensive O-glycosylations. Whereas IL-15R alpha bound IL-15 with high affinity, Delta 2IL-15R alpha was unable to bind IL-15, thus revealing the indispensable role of the exon 2-encoded domain in cytokine binding. A large proportion of IL-15R alpha was expressed at the nuclear membrane with some intranuclear localization, supporting a potential direct action of the IL-15 IL-15R alpha complex at the nuclear level. In sharp contrast, Delta 2IL-15R alpha was found only in the non-nuclear membrane compartments, indicating that the exon alpha-encoded domain (which is shown to contain a potential nuclear localization signal) plays an important role in receptor post-translational routing. Together, our data indicate that exon 2 splicing of human IL-15R alpha is a natural process that might play regulatory roles at different levels.	Inst Biol, INSERM, U463, Grp Rech Cytokines & Recepteurs, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Jacques, Y (corresponding author), Inst Biol, INSERM, U463, Grp Rech Cytokines & Recepteurs, 9 Quai Moncousu, F-44035 Nantes 01, France.	yjacques@nantes.inserm.fr	Minvielle, Stéphane/K-8251-2015; Magrangeas, Florence/L-3080-2015	Dubois, Sigrid/0000-0002-4543-5222; Magrangeas, Florencce/0000-0002-5031-3748; Minvielle, Stephane/0000-0003-1389-312X				ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULLEN BR, 1988, J BIOL CHEM, V263, P4900; FRANCOIS C, 1995, INT IMMUNOL, V7, P1173, DOI 10.1093/intimm/7.8.1173; GIRI JG, 1995, J LEUKOCYTE BIOL, V57, P763, DOI 10.1002/jlb.57.5.763; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GREENE WC, 1985, J EXP MED, V162, P363, DOI 10.1084/jem.162.1.363; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HORI T, 1987, BLOOD, V70, P1069; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; Magrangeas F, 1998, J BIOL CHEM, V273, P16005, DOI 10.1074/jbc.273.26.16005; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; QUINN LS, 1995, ENDOCRINOLOGY, V136, P3669, DOI 10.1210/en.136.8.3669; Reinecker HC, 1996, GASTROENTEROLOGY, V111, P1706, DOI 10.1016/S0016-5085(96)70036-7; Satoh J, 1998, J NEUROL SCI, V155, P170, DOI 10.1016/S0022-510X(97)00310-9; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sorel M, 1996, EUR J DERMATOL, V6, P209; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; TEJEDOR F, 1982, ANAL BIOCHEM, V127, P143, DOI 10.1016/0003-2697(82)90156-7; WILKINSON PC, 1995, J EXP MED, V181, P1255, DOI 10.1084/jem.181.3.1255	32	79	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26978	26984		10.1074/jbc.274.38.26978	http://dx.doi.org/10.1074/jbc.274.38.26978			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480910	hybrid			2022-12-25	WOS:000082570700049
J	Jing, DH; Dong, F; Latham, GJ; von Hippel, PH				Jing, DH; Dong, F; Latham, GJ; von Hippel, PH			Interactions of bacteriophage T4-coded primase (gp61) with the T4 replication helicase (gp41) and DNA in primosome formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLIDING CLAMP INTERACTIONS; POLYMERASE HOLOENZYME; STRUCTURAL-ANALYSES; EXPRESSED PROTEIN; GENE-41 PROTEIN; STRANDED-DNA; ZINC MOTIF; FORK; SEQUENCE; CLONING	One primase (gp61) and six helicase (gp41) subunits interact to form the bacteriophage T4-coded primosome at the DNA replication fork. In order to map some of the detailed interactions of the primase within the primosome, we have constructed and characterized variants of the gp61 primase that carry kinase tags at either the N or the C terminus of the polypeptide chain. These tagged gp61 constructs have been probed using several analytical methods, Proteolytic digestion and protein kinase protection experiments show that specific interactions with single-stranded DNA and the T4 helicase hexamer significantly protect both the N- and the C-terminal regions of the T4 primase polypeptide chain against modification by these procedures and that this protection becomes more pronounced when the primase is assembled within the complete ternary primosome complex. Additional discrete sites of both protection and apparent hypersensitivity along the gp61 polypeptide chain have also been mapped by proteolytic foot-printing reactions for the binary helicase-primase complex and in the three component primosome, These studies provide a detailed map of a number of gp61 contact positions within the primosome and reveal interactions that may be important in the structure and function of this central component of the T4 DNA replication complex.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA	University of Oregon; University of Oregon	von Hippel, PH (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.			von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015792, R01GM029158, R01GM015792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; HIBNER U, 1980, NATURE, V285, P300, DOI 10.1038/285300a0; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HINTON DM, 1985, J BIOL CHEM, V260, P2858; HOYER D, 1990, J AM CHEM SOC, V112, P3249, DOI 10.1021/ja00164a076; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1989, J BIOL CHEM, V264, P12079; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KUROSAWA Y, 1979, J MOL BIOL, V135, P841, DOI 10.1016/0022-2836(79)90515-1; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; Latham GJ, 1997, J BIOL CHEM, V272, P31677, DOI 10.1074/jbc.272.50.31677; Latham GJ, 1997, J BIOL CHEM, V272, P31685, DOI 10.1074/jbc.272.50.31685; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE MS, 1989, J BIOL CHEM, V264, P14531; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V256, P2821; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; NAKAI H, 1988, J BIOL CHEM, V263, P9818; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; Pietroni P, 1997, J BIOL CHEM, V272, P31666, DOI 10.1074/jbc.272.50.31666; PLATIS IE, 1993, BIOCHEMISTRY-US, V32, P12761, DOI 10.1021/bi00210a027; RANA TM, 1991, P NATL ACAD SCI USA, V88, P10578, DOI 10.1073/pnas.88.23.10578; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sexton DJ, 1996, J BIOL CHEM, V271, P28045, DOI 10.1074/jbc.271.45.28045; SINHA NK, 1980, J BIOL CHEM, V255, P4290; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; TOUGU K, 1994, J BIOL CHEM, V269, P4675; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	37	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27287	27298		10.1074/jbc.274.38.27287	http://dx.doi.org/10.1074/jbc.274.38.27287			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480949	hybrid			2022-12-25	WOS:000082570700088
J	Morimoto, S; Tateishi, N; Inuyama, M; Taura, F; Tanaka, H; Shoyama, Y				Morimoto, S; Tateishi, N; Inuyama, M; Taura, F; Tanaka, H; Shoyama, Y			Identification and molecular characterization of novel peroxidase with structural protein-like properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYPROLINE-RICH GLYCOPROTEIN; SCUTELLARIA-BAICALENSIS-GEORGI; CELL-WALL PROTEIN; CROSS-LINKING; ZEA-MAYS; PURIFICATION; EXTENSIN; EXPRESSION; TISSUE; LIGNIN	Elicitor treatment or mechanical damage to Scutellaria baicalensis Georgi (skullcap plants) callus causes an immediate insolubilization of a 36-kDa protein into cell walls. The 36-kDa protein was identified as peroxidase 1 by analysis of its internal amino acid sequence and by immunoblotting using affinity-purified anti-peroxidase 1. Insolubilized peroxidase 1 is cross-linked to lignin through covalent bonds, and the cross-linking is catalyzed in the presence of H2O2 by peroxidase 1 itself. The properties of insolubilized peroxidase 1 resemble those of defense-related structural proteins (extensins and proline-rich proteins) cross-linked to cell wall. Although the isozymes peroxidases 2 and 3 have enzyme activities similar to peroxidase 1, they are not insolubilized by stress treatment. Molecular characterization established that peroxidase 1 contains regions characteristic of structural proteins, but peroxidases 2 and 3 do not have such regions. These results suggest that among the three isozymes, only peroxidase 1 has a structural protein-like function as well as an enzymatic function.	Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan	Kyushu University	Morimoto, S (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 8128582, Japan.							ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; BROWNLEADER MD, 1995, PLANT PHYSIOL, V109, P1115, DOI 10.1104/pp.109.3.1115; Christensen JH, 1998, PLANT PHYSIOL, V118, P125, DOI 10.1104/pp.118.1.125; COOPER JB, 1984, PLANT PHYSIOL, V76, P414, DOI 10.1104/pp.76.2.414; DATTA K, 1989, PLANT CELL, V1, P945, DOI 10.1105/tpc.1.9.945; Dixon R A, 1990, Adv Genet, V28, P165; ESPELIE KE, 1986, PLANT PHYSIOL, V81, P487, DOI 10.1104/pp.81.2.487; EVANS JJ, 1991, J AGR FOOD CHEM, V39, P830, DOI 10.1021/jf00005a002; EVERDEEN DS, 1988, PLANT PHYSIOL, V87, P616, DOI 10.1104/pp.87.3.616; FRY SC, 1982, BIOCHEM J, V204, P449, DOI 10.1042/bj2040449; GOLDBERG T, 1986, MOL PHYSL ASPECTS PL, P208; Grisebach H., 1981, BIOCH PLANTS, V7, P475; HINNMAN RL, 1965, BIOCHEMISTRY-US, V4, P144; HONG JC, 1990, J BIOL CHEM, V265, P2470; Jensen UG, 1997, INSECT BIOCHEM MOLEC, V27, P109, DOI 10.1016/S0965-1748(96)00074-4; KELLER B, 1989, GENE DEV, V3, P1639, DOI 10.1101/gad.3.10.1639; KIELISZEWSKI M, 1987, PLANT PHYSIOL, V85, P823, DOI 10.1104/pp.85.3.823; KIELISZEWSKI MJ, 1990, PLANT PHYSIOL, V92, P316, DOI 10.1104/pp.92.2.316; LAGRIMINI LM, 1987, P NATL ACAD SCI USA, V84, P7542, DOI 10.1073/pnas.84.21.7542; MCDOUGALL GJ, 1993, PHYTOCHEMISTRY, V33, P765, DOI 10.1016/0031-9422(93)85271-R; MOBASSALEH M, 1993, ANAL BIOCHEM, V214, P295, DOI 10.1006/abio.1993.1491; Morimoto S, 1998, J BIOL CHEM, V273, P12606, DOI 10.1074/jbc.273.20.12606; MORIMOTO S, 1995, PLANTA, V195, P535, DOI 10.1007/BF00195712; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; ONEILL MA, 1980, BIOCHEM J, V187, P53, DOI 10.1042/bj1870053; RIDGE I, 1971, NATURE-NEW BIOL, V229, P205, DOI 10.1038/newbio229205a0; SRISUMA N, 1991, J AGR FOOD CHEM, V39, P855, DOI 10.1021/jf00005a007; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9	29	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26192	26198		10.1074/jbc.274.37.26192	http://dx.doi.org/10.1074/jbc.274.37.26192			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473572	hybrid			2022-12-25	WOS:000082469700038
J	van der Werf, MJ; van der Ven, C; Barbirato, F; Eppink, MHM; de Bont, JAM; van Berkel, WJH				van der Werf, MJ; van der Ven, C; Barbirato, F; Eppink, MHM; de Bont, JAM; van Berkel, WJH			Stereoselective carveol dehydrogenase from Rhodococcus erythropolis DCL14 - A novel nicotinoprotein belonging to the short chain dehydrogenase/reductase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY ALCOHOL-DEHYDROGENASE; CRYSTAL-STRUCTURE; LIMONENE-1,2-EPOXIDE HYDROLASE; AMYCOLATOPSIS-METHANOLICA; EPOXIDE HYDROLASES; ESCHERICHIA-COLI; TERNARY COMPLEX; PROTEIN MODELS; BINDING; REDUCTASE	A novel nicotinoprotein, catalyzing the dichlorophenolindophenol-dependent oxidation of carveol to carvone, was purified to homogeneity from Rhodococcus erythropolis DCL14. The enzyme is specifically induced after growth on limonene and carveol Dichlorophenolindophenol-dependent carveol dehydrogenase (CDH) is a homotetramer of 120 kDa with each subunit containing a tightly bound NAD(H) molecule. The enzyme is optimally active at pH 5.5 and 50 degrees C and displays a broad substrate specificity with a preference for substituted cyclohexanols. When incubated with a diastereomeric mixture of (4R)- or (4S)-carveol, CDH stereoselectively catalyzes the conversion of the (6S)-carveol stereoisomers only, Kinetic studies with pure stereoisomers showed that this is due to large differences in V(max)/K(m) values and simultaneous product inhibition by CR)- or (S)-carvone. The R. erythropolis CDH gene (limC) was identified in an operon encoding the enzymes involved in Iimonene degradation. The CDH nucleotide sequence revealed an open reading frame of 831 base pairs encoding a 277-amino acid protein with a deduced mass of 29,531 Da. The CDH primary structure shares 10-30% sequence identity with members of the short chain dehydrogenase/reductase superfamily. Structure homology modeling with trihydroxynaphthalene reductase fi om Magnaporthe grisea suggests-that CDH from R. erythropolis DCL14 is an alpha/beta one-domain protein with an extra loop insertion involved in NAD binding and a flexible C-terminal part involved in monoterpene binding.	Wageningen Univ Agr, Dept Food Technol & Nutrit Sci, Div Ind Microbiol, NL-6703 HD Wageningen, Netherlands; Wageningen Univ Agr, Biochem Lab, Dept Biomol Sci, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research	van der Werf, MJ (corresponding author), Wageningen Univ Agr, Dept Food Technol & Nutrit Sci, Div Ind Microbiol, POB 8129, NL-6700 EV Wageningen, Netherlands.	mariet.vanderwerf@imb.ftns.wau.nl	Eppink, Michel/AAB-6866-2022; van Berkel, Willem J.H./O-2431-2014	Eppink, Michel/0000-0001-8297-9985; van Berkel, Willem J.H./0000-0002-6551-2782				ALLEN SHG, 1966, J BIOL CHEM, V241, P5266; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson A, 1996, STRUCTURE, V4, P1161, DOI 10.1016/S0969-2126(96)00124-4; Arfman N, 1997, EUR J BIOCHEM, V244, P426, DOI 10.1111/j.1432-1033.1997.00426.x; ARMSTRONG JM, 1964, BIOCHIM BIOPHYS ACTA, V86, P194; ASHRAF W, 1990, ARCH MICROBIOL, V153, P163, DOI 10.1007/BF00247815; Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; BALLAL NR, 1967, BIOCHEM BIOPH RES CO, V29, P275, DOI 10.1016/0006-291X(67)90448-2; BALLAL NR, 1968, INDIAN J BIOCHEM, V5, P1; BANTHORPE DV, 1995, NATURAL PRODUCTS THE, P289; Barbirato F, 1998, FEBS LETT, V438, P293, DOI 10.1016/S0014-5793(98)01322-2; BAUER AJ, 1992, PROTEINS, V12, P372, DOI 10.1002/prot.340120409; Bouwmeester HJ, 1998, PLANT PHYSIOL, V117, P901, DOI 10.1104/pp.117.3.901; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, X PLOR VERSION 3 1; Burdock G. A., 1995, FENAROLIS HDB FLAVOU, P107; BYSTRYKH LV, 1993, J BACTERIOL, V175, P1814, DOI 10.1128/JB.175.6.1814-1822.1993; CADWALLADER KR, 1992, J FOOD SCI, V57, P241, DOI 10.1111/j.1365-2621.1992.tb05464.x; Daussmann T, 1997, EUR J BIOCHEM, V248, P889, DOI 10.1111/j.1432-1033.1997.00889.x; DEVON TK, 1972, HDB NATURALLY OCCURR, V2, P3; DHAVALIKAR RS, 1966, INDIAN J BIOCHEM, V3, P158; DUINE JA, 1995, BIOSENS BIOELECTRON, V10, P17, DOI 10.1016/0956-5663(95)96791-V; FREY PA, 1987, PYRIDINE NUCLEOTID B, P461; Gabrielyan K. A., 1992, Applied Biochemistry and Microbiology, V28, P241; GERSHENZON J, 1989, PLANT PHYSIOL, V89, P1351, DOI 10.1104/pp.89.4.1351; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; GUENTHER A, 1995, J GEOPHYS RES-ATMOS, V100, P8873, DOI 10.1029/94JD02950; HARBORNE JB, 1991, ECOLOGICAL CHEM BIOC, P399; HARTMANS S, 1989, APPL ENVIRON MICROB, V55, P2850, DOI 10.1128/AEM.55.11.2850-2855.1989; Hulsmeyer M, 1998, PROTEIN SCI, V7, P1286; HUMMEL W, 1989, EUR J BIOCHEM, V184, P1, DOI 10.1111/j.1432-1033.1989.tb14983.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KATO N, 1986, EUR J BIOCHEM, V156, P59, DOI 10.1111/j.1432-1033.1986.tb09548.x; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KLEPP J, 1989, J AM CHEM SOC, V111, P4440, DOI 10.1021/ja00194a045; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; LUDWIG B, 1995, APPL ENVIRON MICROB, V61, P3729, DOI 10.1128/AEM.61.10.3729-3733.1995; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Nonino E. A., 1997, Perfumer & Flavorist, V22, P53; RAFFERTY JB, 1995, STRUCTURE, V3, P927, DOI 10.1016/S0969-2126(01)00227-1; RAMSEY AJ, 1989, COMP BIOCHEM PHYS B, V93, P77, DOI 10.1016/0305-0491(89)90219-8; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Secundo F, 1996, ENZYME MICROB TECH, V19, P487, DOI 10.1016/S0141-0229(95)00257-X; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; STIRLING LA, 1980, CURR MICROBIOL, V4, P37, DOI 10.1007/BF02602889; STONE CL, 1989, J BIOL CHEM, V264, P11112; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Teunissen MJ, 1995, COLLOQ INRA, P329; Trudgill Peter W., 1994, P33; TRUDGILL PW, 1986, BACTERIA, V10, P483; van der Werf MJ, 1999, APPL ENVIRON MICROB, V65, P2092; van der Werf MJ, 1998, J BACTERIOL, V180, P5052, DOI 10.1128/JB.180.19.5052-5057.1998; van der Werf MJ., 1997, BIOTECHNOLOGY AROMA, P147; van Dyk MS, 1998, BIOTECHNOL LETT, V20, P431, DOI 10.1023/A:1005399918647; VANDERWERF MJ, 1993, APPL ENVIRON MICROB, V59, P2823, DOI 10.1128/AEM.59.9.2823-2829.1993; VANOPHEM PW, 1993, EUR J BIOCHEM, V212, P819; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	68	41	43	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26296	26304		10.1074/jbc.274.37.26296	http://dx.doi.org/10.1074/jbc.274.37.26296			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473585	hybrid			2022-12-25	WOS:000082469700051
J	Huang, SM; Qiu, Y; Stein, RW; Brandt, SJ				Huang, SM; Qiu, Y; Stein, RW; Brandt, SJ			P300 functions as a transcriptional coactivator for the TAL1/SCL oncoprotein	ONCOGENE			English	Article						TAL1/SCL; p300; transcriptional coactivator	T-CELL LEUKEMIA; LOOP-HELIX PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; SCL GENE-PRODUCT; PEDIATRIC-ONCOLOGY-GROUP; CBP-INDUCED STIMULATION; RNA-POLYMERASE-II; ADENOVIRUS E1A; IN-VIVO; ERYTHROID-DIFFERENTIATION	Activation of the TALI (or SCL) gene, originally identified through its involvement by a recurrent chromosomal translocation, is the most frequent gain-of-function mutation recognized in T-cell acute lymphoblastic leukemia (T-ALL). The TAL1 proteins contain a basic helix-loop-helix (bHLH) motif characteristic of a large family of transcription factors that control transcription from an E box target element as heterodimers with the E2A- and HEB-encoded gene products. Gene knockout studies in mice indicate that this transcription factor is required for embryonic and adult hematopoiesis, and considerable evidence suggests it has specific functions in terminal erythroid differentiation. We investigated whether the broadly expressed nuclear protein p300, known to function as a coactivator for other bHLH proteins involved in cellular differentiation, also interacts with TAL1, p300 was found to coimmunoprecipitate with Tal1 in extracts from murine erythroleukemia (MEL) cells induced to differentiate with dimethylsulfoxide (DMSO), and p300 and Tal1 were observed in a common E box DNA-binding complex in extracts from differentiating MEL cells. p300 also interacted with Tal1 in protein pulldown assays, suggesting this was a direct interaction. Finally, p300 augmented transcription by Tal1 from an E box-containing promoter and by a GAL4-Tal1 fusion from a promoter containing the GAL4 DNA-binding element. Deletion analysis identified the bHLH domain of Tall and amino-terminal sequences of p300 as necessary for p300-stimulated transactivation and Tal1-p300 interaction in vitro. These results indicate that recruitment of the transcriptional coactivator p300 can positively regulate TAL1-directed gene expression. The dependence of their interaction in MEL cells on addition of a differentiation inducer suggests, further, that this TAL1-p300 complete may have an important role in terminal erythroid differentiation.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Brandt, SJ (corresponding author), Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Room 547,MRB 2, Nashville, TN 37232 USA.			, Yi/0000-0002-3282-6072	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055091] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL49118] Funding Source: Medline; NIDDK NIH HHS [R01 DK55091] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bain G, 1998, SEMIN IMMUNOL, V10, P143, DOI 10.1006/smim.1998.0116; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BASH RO, 1993, BLOOD, V81, P2110; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARUSO M, 1993, ONCOGENE, V8, P267; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, ONCOGENE, V8, P677; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; Condorelli GL, 1996, CANCER RES, V56, P5113; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Dambly-Chaudiere C, 1998, INT J DEV BIOL, V42, P269; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Elwood NJ, 1998, BLOOD, V91, P3756; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hoang T, 1996, BLOOD, V87, P102; Hofmann TJ, 1996, ONCOGENE, V13, P617; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HWANG LY, 1993, ONCOGENE, V8, P3043; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KALLIANPUR AR, 1994, BLOOD, V83, P1200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MILLER BA, 1994, BLOOD, V84, P2971; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MOUTHON MA, 1993, BLOOD, V81, P647; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; Park ST, 1998, J BIOL CHEM, V273, P7030, DOI 10.1074/jbc.273.12.7030; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PRASAD KSS, 1995, J BIOL CHEM, V270, P11603, DOI 10.1074/jbc.270.19.11603; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7339; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SANDER M, 1997, J MOL MED, V75, P321; Sandmoller A, 1996, MOL CELL BIOL, V16, P5846; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P187; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WADMAN IA, 1994, ONCOGENE, V9, P3713; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	92	63	64	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4958	4967		10.1038/sj.onc.1202889	http://dx.doi.org/10.1038/sj.onc.1202889			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490830				2022-12-25	WOS:000082321700008
J	Belletti, B; Ferraro, P; Arra, C; Baldassarre, G; Bruni, P; Staibano, S; De Rosa, G; Salvatore, G; Fusco, AE; Persico, MG; Viglietto, G				Belletti, B; Ferraro, P; Arra, C; Baldassarre, G; Bruni, P; Staibano, S; De Rosa, G; Salvatore, G; Fusco, AE; Persico, MG; Viglietto, G			Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene	ONCOGENE			English	Article						thyroid tumor; VEGF; angiogenesis; antisense	PERMEABILITY FACTOR; UP-REGULATION; ANGIOGENIC FACTORS; IN-VIVO; EXPRESSION; RECEPTORS; ANGIOPOIETIN-1; METASTASIS; INHIBITION; SEQUENCE	Vascular endothelial growth factor A (VEGF) is a potent mitogen for endothelial cells in vitro and promotes neo-angiogenesis in vivo, VEGF overexpression occurs in most human malignancies including thyroid carcinomas in which elevated VEGF expression is associated with a high tumorigenic potential. To investigate the role of VEGF in angiogenesis associated with development of thyroid carcinomas, we constitutively expressed VEGF(121) into a poorly tumorigenic cell line (NPA) expressing minimal levels of endogenous VEGF. Here we report that VEGF overexpressing NPA cells showed the same growth potential as untransfected NPA in vitro but formed well-vascularized tumors when injected subcutaneously into nude mice with markedly reduced latency compared to parental cells. A complementary approach was to suppress VEGF expression in a highly tumorigenic anaplastic cell line (ARO) by the transfection of an antisense construct. Antisense-transfected ARO cells expressed reduced constitutive levels of VEGF, shelved the same growth potential as untransfected ARO cells in vitro and formed small tumors characterized by minimal vascularization, extensive necrosis and longer latency compared to parental or vector-transfected ARO cells in vivo. Finally, we investigated the expression of both VEGF tyrosine kinase receptors (Flt-1 and Flk-1/KDR) in tumor specimens by RT-PCR, Expression of (Flt-1 and Flk-1/KDR) was low in tissue specimens derived from NPA tumors, but was found enhanced in NPA VEGF tumors; conversely, the expression of VEGF receptors was high in tissue specimens derived from ARO tumors but was decreased in tumors derived from VEGF depleted ARO cells. These results clearly demonstrate that VEGF indirectly promotes the growth of thyroid tumors by stimulating angiogenesis.	Fdn Pascale, Ist Nazl Tumori, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Inst Pathol, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento & Oncol Sperimentale & Clin, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy	IRCCS Fondazione Pascale; University of Naples Federico II; University of Naples Federico II; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Viglietto, G (corresponding author), Fdn Pascale, Ist Nazl Tumori, Via M Semmola, I-80131 Naples, Italy.		Belletti, Barbara/J-2028-2018; Viglietto, Giuseppe/AAC-2852-2019; Baldassarre, Gustavo/K-1350-2016	Belletti, Barbara/0000-0003-2249-0285; Viglietto, Giuseppe/0000-0003-2327-7515; Baldassarre, Gustavo/0000-0002-9750-8825; Arra, Claudio/0000-0003-3162-2091; Fusco, Alfredo/0000-0003-3332-5197; DE ROSA, Gaetano/0000-0002-3635-5853				BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BROWN LF, 1993, CANCER RES, V53, P4727; Claffey KP, 1996, CANCER RES, V56, P172; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEVITA VT, 1997, CANC PRINCIPLES PRAC, P1349; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FINNERTY H, 1993, ONCOGENE, V8, P2293; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HEDINGER C, 1988, HISTOLGYCAL TYPING T; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; OELRICHS RB, 1993, ONCOGENE, V8, P11; OLSON TA, 1994, CANCER RES, V54, P276; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Saleh M, 1996, CANCER RES, V56, P393; Sambrook J., 2002, MOL CLONING LAB MANU; SHIBUYA M, 1990, ONCOGENE, V5, P519; STAUFFER JK, 1990, J BIOL CHEM, V265, P11773; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; TISHER E, 1991, J BIOL CHEM, V266, P11974; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; Viglietto G, 1997, ONCOGENE, V15, P2687, DOI 10.1038/sj.onc.1201456; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857	32	44	52	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4860	4869		10.1038/sj.onc.1202869	http://dx.doi.org/10.1038/sj.onc.1202869			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490819				2022-12-25	WOS:000082184800010
J	Downey, GP; Botelho, RJ; Butler, JR; Moltyaner, Y; Chien, P; Schreiber, AD; Grinstein, S				Downey, GP; Botelho, RJ; Butler, JR; Moltyaner, Y; Chien, P; Schreiber, AD; Grinstein, S			Phagosomal maturation, acidification, and inhibition of bacterial growth in nonphagocytic cells transfected with Fc gamma RIIA receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ACTIVATION MOTIF ITAM; MEDIATED PHAGOCYTOSIS; HUMAN NEUTROPHILS; LYSOSOME FUSION; PHOSPHOINOSITIDE 3-KINASE; MOUSE MACROPHAGES; INTRACELLULAR PH; PHOSPHORYLATION; ANTIGEN	Phagocytosis and killing of microbial pathogens by professional phagocytes is an essential component of the innate immune response. Recently, heterologous transfection of individual receptors into nonmyeloid cells has been used successfully to elucidate the early steps that signal phagosome formation. It is unclear, however, whether the vacuoles formed by such transfected cells are bona fide phagosomes, capable of fusion with endomembranes, of luminal acidification, and of controlling the growth of microorganisms, The aim of the current study was to determine whether COS-1 and Chinese hamster ovary cells, rendered phagocytic by expression of human Fc gamma RIIA receptors, express the cellular machinery required to support phagosomal maturation. Immunolocalization studies demonstrated that early endosomes, as well as late endosomes and/or lysosomes, fuse sequentially with phagosomes in the transfectants, Microfluorescence ratio imaging of particles labeled with pH-sensitive dyes revealed that maturation of the phagosome was accompanied by luminal acidification, The drop in pH, which attained levels comparable to those reported in professional phagocytes, was prevented by inhibitors of vacuolar type HC-ATPases. Optimal phagosomal acidification required elevation of cytosolic [Ca2+], suggesting that it results from fusion of endomembranes bearing proton pumps. Moreover, the transfected cells effectively internalized live bacteria. Opsonization was essential for bacterial internalization, implying that it occurred by Fc gamma RIIA-mediated phagocytosis, as opposed to invasion. Uptake into phagolysosomes was associated with inhibition of bacterial growth, due at least in part to the low intraphagosomal pH. These studies indicate that the biochemical events that follow receptor-mediated particle internalization in cells transfected with Fc gamma RIIA receptors closely resemble the process of phagosomal maturation in neutrophils and macrophages, Fc gamma RIIA-transfected cells can, therefore, be used as a model for the study of additional aspects of phagocyte biology.	Hosp Sick Children, Div Cell Biol, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med, Div Respirol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Toronto Hosp, Toronto, ON M5G 2C4, Canada; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Pennsylvania	Grinstein, S (corresponding author), Hosp Sick Children, Div Cell Biol, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Botelho, Roberto J/B-9145-2013	Botelho, Roberto J/0000-0002-7820-0999; Downey, Gregory P/0000-0003-3253-5862	NIAID NIH HHS [AI-22193] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022193, R21AI022193] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen LAH, 1996, CURR OPIN IMMUNOL, V8, P36, DOI 10.1016/S0952-7915(96)80102-6; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; BERON W, 1995, TRENDS CELL BIOL, V5, P100, DOI 10.1016/S0962-8924(00)88958-8; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; Demaurex N, 1996, J CELL BIOL, V133, P1391, DOI 10.1083/jcb.133.6.1391; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FURUKAWA R, 1994, CELL MOTIL CYTOSKEL, V29, P46, DOI 10.1002/cm.970290105; GABAY JE, 1986, BIOCHEM SOC T, V14, P256, DOI 10.1042/bst0140256; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6; GRINSTEIN S, 1994, AM J PHYSIOL-CELL PH, V267, pC1152, DOI 10.1152/ajpcell.1994.267.4.C1152; Hackam DJ, 1998, J EXP MED, V188, P351, DOI 10.1084/jem.188.2.351; Hackam DJ, 1997, J EXP MED, V186, P955, DOI 10.1084/jem.186.6.955; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; HART PD, 1983, J EXP MED, V158, P477, DOI 10.1084/jem.158.2.477; INDIK Z, 1991, J CLIN INVEST, V88, P1766, DOI 10.1172/JCI115496; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; Isakov N, 1997, J LEUKOCYTE BIOL, V61, P6, DOI 10.1002/jlb.61.1.6; Isakov N, 1997, IMMUNOL RES, V16, P85, DOI 10.1007/BF02786325; JACONI MEE, 1990, J CELL BIOL, V110, P1555, DOI 10.1083/jcb.110.5.1555; JOINER KA, 1984, ANNU REV IMMUNOL, V2, P461, DOI 10.1146/annurev.immunol.2.1.461; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; Lee MA, 1998, CELL CALCIUM, V23, P91, DOI 10.1016/S0143-4160(98)90107-5; Lowry MB, 1998, J EXP MED, V187, P161, DOI 10.1084/jem.187.2.161; Lowry MB, 1998, J BIOL CHEM, V273, P24513, DOI 10.1074/jbc.273.38.24513; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; MITCHELL MA, 1994, BLOOD, V84, P1753; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; MUROI M, 1993, BIOCHEM BIOPH RES CO, V193, P999, DOI 10.1006/bbrc.1993.1724; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; POO H, 1995, J MOL BIOL, V247, P597; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; RUSSELL DG, 1995, TRENDS CELL BIOL, V5, P125, DOI 10.1016/S0962-8924(00)88963-1; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; Suchard SJ, 1997, J IMMUNOL, V158, P4961; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P89, DOI 10.1016/S0962-8924(00)88956-4; THELER JM, 1995, BLOOD, V85, P2194, DOI 10.1182/blood.V85.8.2194.bloodjournal8582194; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	51	93	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28436	28444		10.1074/jbc.274.40.28436	http://dx.doi.org/10.1074/jbc.274.40.28436			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497205	hybrid			2022-12-25	WOS:000082912700054
J	Germain, M; Affar, EB; D'Amours, D; Dixit, VM; Salvesen, GS; Poirier, GG				Germain, M; Affar, EB; D'Amours, D; Dixit, VM; Salvesen, GS; Poirier, GG			Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis - Evidence for involvement of caspase-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; DNA FRAGMENTATION; NUCLEAR PROTEINS; PROTEASES; SUBSTRATE; DEATH; CELLS; VIVO; PROTEOLYSIS; ACTIVATION	The abundant nuclear enzyme poly(ADP-ribose) polymerase (PARP) synthesizes poly(ADP-ribose) in response to DNA strand breaks. During almost all forms of apoptosis, PARP is cleaved by caspases, suggesting the crucial role of its inactivation. A few studies have also reported a stimulation of PARP during apoptosis, However, the role of PARP stimulation and cleavage during this cell death process remains poorly understood. Here, we measured the stimulation of endogenous poly(ADP-ribose) synthesis during VP-16-induced apoptosis in HL60 cells and found that PARP was cleaved by caspases at the time of its poly(ADP-ribosyl)ation. In vitro experiments showed that PARP cleavage by caspase-7, but not by caspase-3, was stimulated by its automodification by long and branched poly(ADP-ribose). Consistently, caspase-7 exhibited an affinity for poly(ADP-ribose), whereas caspase-3 did not. In addition, caspase-7 was activated and accumulated in the nucleus of HL60 cells in response to the VP-16 treatment. Furthermore, caspase-7 activation was concommitant with PARP cleavage in the caspase-3-deficient cell line MCF-7 in response to staurosporine treatment. These results strongly suggest that, in vivo, it is caspase-7 that is responsible for PARP cleavage and that poly(ADP-ribosyl)ation of PARP accelerates its proteolysis. Cleavage of the active form of caspase substrates could be a general feature of the apoptotic process, ensuring the rapid inactivation of stress signaling proteins.	Univ Laval, Hlth & Environm Unit, Med Res Ctr, CHU Quebec,Fac Med, St Foy, PQ G1V 4G2, Canada; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Burnham Inst, La Jolla, CA 92037 USA	Laval University; Roche Holding; Genentech; Sanford Burnham Prebys Medical Discovery Institute	Poirier, GG (corresponding author), Univ Laval, Hlth & Environm Unit, Med Res Ctr, CHU Quebec,Fac Med, 2705 Blvd Laurier, St Foy, PQ G1V 4G2, Canada.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Poirier, Guy/0000-0002-4869-1424				Affar EB, 1998, ANAL BIOCHEM, V259, P280, DOI 10.1006/abio.1998.2664; Affar EB, 1999, BBA-GEN SUBJECTS, V1428, P137, DOI 10.1016/S0304-4165(99)00054-9; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ALTHAUS FR, 1995, BIOCHIMIE, V77, P423, DOI 10.1016/0300-9084(96)88155-7; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; COPPOLA S, 1995, EXP CELL RES, V221, P462, DOI 10.1006/excr.1995.1397; D'Amours D, 1998, RADIAT RES, V150, P3, DOI 10.2307/3579638; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; HULETSKY A, 1989, J BIOL CHEM, V264, P8878; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Legault J, 1997, MOL CELL BIOL, V17, P5437, DOI 10.1128/MCB.17.9.5437; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; Shah GM, 1996, BBA-MOL CELL RES, V1312, P1, DOI 10.1016/0167-4889(96)00004-3; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Smulson ME, 1998, CANCER RES, V58, P3495; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TANIZAWA A, 1989, EXP CELL RES, V185, P237, DOI 10.1016/0014-4827(89)90052-9; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMASSIN H, 1990, NUCLEIC ACIDS RES, V18, P4691, DOI 10.1093/nar/18.16.4691; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yoon YS, 1996, J BIOL CHEM, V271, P9129, DOI 10.1074/jbc.271.15.9129; YOSHIDA S, 1994, MOL CELL BIOCHEM, V138, P39, DOI 10.1007/BF00928441; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x	42	377	389	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28379	28384		10.1074/jbc.274.40.28379	http://dx.doi.org/10.1074/jbc.274.40.28379			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497198	hybrid			2022-12-25	WOS:000082912700047
J	Rawson, RB; DeBose-Boyd, R; Goldstein, JL; Brown, MS				Rawson, RB; DeBose-Boyd, R; Goldstein, JL; Brown, MS			Failure to cleave sterol regulatory element-binding proteins (SREBPs) causes cholesterol auxotrophy in Chinese hamster ovary cells with genetic absence of SREBP cleavage-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND TRANSCRIPTION FACTOR; LOW-DENSITY LIPOPROTEIN; BIOCHEMICAL-CHARACTERIZATION; RESISTANT; LINES; IDENTIFICATION; PROTEOLYSIS; EXPRESSION; MUTATION; CLONING	We describe a line of mutant Chinese hamster ovary cells, designated SRD-13A, that cannot cleave sterol regulatory element-binding proteins (SREBPs) at site 1, due to mutations in the gene encoding SREBP cleavage-activating protein (SCAP), The SRD-13A cells were obtained by two rounds of gamma-irradiation followed first by selection for a deficiency of low density lipoprotein receptors and second for cholesterol auxotrophy. In the SRD-13A cells, the only detectable SCAP allele encodes a truncated nonfunctional protein, In the absence of SCAP, the site 1 protease fails to cleave SREBPs, and their transcriptionally active NH2-terminal fragments cannot enter the nucleus. As a result, the cells manifest a marked reduction in the synthesis of cholesterol and its uptake from low density lipoproteins. The SRD-13A cells grow only when cholesterol is added to the culture medium. SREBP cleavage is restored and the cholesterol requirement is abolished when SRD-13A cells are transfected with expression vectors encoding SCAP. These results provide formal proof that SCAP is essential for the cleavage of SREBPs at site 1.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75235 USA.				NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1978, J BIOL CHEM, V253, P1121; CHANG TY, 1982, BIOCHEMISTRY-US, V21, P5316, DOI 10.1021/bi00264a030; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KRIEGER M, 1979, J SUPRAMOL STR CELL, V10, P467, DOI 10.1002/jss.400100409; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Nohturfft A, 1996, P NATL ACAD SCI USA, V93, P13709, DOI 10.1073/pnas.93.24.13709; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Sambrook J., 2002, MOL CLONING LAB MANU; SATO R, 1994, J BIOL CHEM, V269, P17267; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152	34	143	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28549	28556		10.1074/jbc.274.40.28549	http://dx.doi.org/10.1074/jbc.274.40.28549			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497220	hybrid			2022-12-25	WOS:000082912700069
J	Strumberg, D; Nitiss, JL; Dong, JW; Kohn, KW; Pommier, Y				Strumberg, D; Nitiss, JL; Dong, JW; Kohn, KW; Pommier, Y			Molecular analysis of yeast and human type II topoisomerases - Enzyme-DNA and drug interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TOPOISOMERASE; SEQUENCE SPECIFICITY; CLEAVAGE; COMPLEX; BINDING; MECHANISM; POISONS; GYRASE; DETERMINANTS; CYTOTOXICITY	The DNA sequence selectivity of topoisomerase LI (top2)-DNA cleavage complexes was examined for the human (top2 alpha), yeast, and Escherichia coli (i.e, gyrase) enzymes in the absence or presence of anticancer or antibacterial drugs. Species-specific differences were observed for calcium-promoted DNA cleavage. Similarities and differences in DNA cleavage patterns and nucleic acid sequence preferences were also observed between the human, yeast, and E. coli top2 enzymes in the presence of the non-intercalators fluoroquinolone CP-115,953, etoposide, and azatoxin and the intercalators amsacrine and mitoxantrone. Additional base preferences were generally observed for the yeast when compared with the human top2 alpha enzyme. Preferences in the immediate flanks of the top2-mediated DNA cleavage sites are, however, consistent with the drug stacking model for both enzymes. We also analyzed and compared homologous mutations in yeast and human top2, i.e. Ser(740) --> Trp and Ser(763) --> Trp, respectively. Both mutations decreased the reversibility of the etoposide-stabilized cleavage sites and produced consistent base sequence preference changes. These data demonstrate similarities and differences between human and yeast top2 enzymes. They also indicate that the structure of the enzyme/DNA interface plays a key role in determining the specificity of top2 poisons and cleavage sites for both the intercalating and non-intercalating drugs.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's Research Hospital	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 5D02, Bethesda, MD 20892 USA.	pommier@nih.gov	Nitiss, John/E-9974-2010	Nitiss, John/0000-0002-1013-4972; Strumberg, Dirk/0000-0001-7053-8365	NCI NIH HHS [CA21765, CA52814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052814, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECK WT, 1993, ADV ENZYME REGUL, V33, P113; Berger JM, 1998, CURR OPIN STRUC BIOL, V8, P26, DOI 10.1016/S0959-440X(98)80006-7; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Binaschi M, 1997, CANCER RES, V57, P1710; Burden DA, 1996, J BIOL CHEM, V271, P29238, DOI 10.1074/jbc.271.46.29238; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Capranico G, 1998, BBA-GENE STRUCT EXPR, V1400, P185, DOI 10.1016/S0167-4781(98)00135-3; Capranico G, 1998, J BIOL CHEM, V273, P12732, DOI 10.1074/jbc.273.21.12732; Capranico G, 1997, TRENDS PHARMACOL SCI, V18, P323; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; CAPRANICO G, 1994, J MOL BIOL, V235, P1218, DOI 10.1006/jmbi.1994.1075; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cornarotti M, 1996, MOL PHARMACOL, V50, P1463; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; Critchlow SE, 1996, BIOCHEMISTRY-US, V35, P7387, DOI 10.1021/bi9603175; DEISABELLA P, 1993, MOL PHARMACOL, V43, P715; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; Fass D, 1999, NAT STRUCT BIOL, V6, P322; FISHER LM, 1981, P NATL ACAD SCI-BIOL, V78, P4165, DOI 10.1073/pnas.78.7.4165; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Hasinoff BB, 1998, CURR MED CHEM, V5, P1; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; Kampranis SC, 1998, J BIOL CHEM, V273, P22606, DOI 10.1074/jbc.273.35.22606; KAWADA SZ, 1991, CANCER RES, V51, P2922; Kingma PS, 1999, BIOCHEMISTRY-US, V38, P3457, DOI 10.1021/bi982855i; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; LETEURTRE F, 1994, BIOCHEM BIOPH RES CO, V203, P1259, DOI 10.1006/bbrc.1994.2318; LETEURTRE F, 1995, BIOCHEM PHARMACOL, V49, P1283, DOI 10.1016/0006-2952(95)00047-4; LETEURTRE F, 1994, J NATL CANCER I, V86, P1239, DOI 10.1093/jnci/86.16.1239; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU L, 1994, DNA TOPOISOMERASES T; Liu QY, 1998, J BIOL CHEM, V273, P20252, DOI 10.1074/jbc.273.32.20252; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; NITISS JL, 1994, CANCER CHEMOTH PHARM, V34, pS6, DOI 10.1007/BF00684857; Nitiss JL, 1996, ANN NY ACAD SCI, V803, P32, DOI 10.1111/j.1749-6632.1996.tb26374.x; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Nitiss JL, 1998, BIOCHEMISTRY-US, V37, P3078, DOI 10.1021/bi9723257; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; PANOUSIS C, 1994, NUCLEIC ACIDS RES, V22, P1342, DOI 10.1093/nar/22.8.1342; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Pommier Yves, 1997, P153; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; ROBINSON MJ, 1992, ANTIMICROB AGENTS CH, V36, P751, DOI 10.1128/AAC.36.4.751; Sissi C, 1998, MOL PHARMACOL, V54, P1036, DOI 10.1124/mol.54.6.1036; SPITZNER JR, 1995, MOL PHARMACOL, V48, P238; Strumberg D, 1999, J BIOL CHEM, V274, P7292, DOI 10.1074/jbc.274.11.7292; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5157, DOI 10.1093/nar/21.22.5157; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	53	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28246	28255		10.1074/jbc.274.40.28246	http://dx.doi.org/10.1074/jbc.274.40.28246			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497180	hybrid			2022-12-25	WOS:000082912700029
J	Eichhorn, E; van der Ploeg, JR; Leisinger, T				Eichhorn, E; van der Ploeg, JR; Leisinger, T			Characterization of a two-component alkanesulfonate monooxygenase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENES; EXPRESSION; PROTEIN; SULFUR; IDENTIFICATION; REASSESSMENT; PURIFICATION; METABOLISM; SULFONATES; OXIDATION	The Escherichia coli ssuEADCB gene cluster is required for the utilization of alkanesulfonates as sulfur sources, and is expressed under conditions of sulfate or cysteine starvation. The SsuD and SsuE proteins were overexpressed and characterized. SsuE was purified to homogeneity as an N-terminal histidine-tagged fusion protein. Native SsuE was a homodimeric enzyme of ill, 58,400, which catalyzed an NAD(P)H-dependent reduction of FMN, but it was also able to reduce FAD or riboflavin, The SsuD protein was purified to >98% purity using cation exchange, anion exchange, and hydrophobic interaction chromatography. The pure enzyme catalyzed the conversion of pentanesulfonic acid to sulfite and pentaldehyde and was able to desulfonate a wide range of sulfonated substrates including C-2 to C-10 unsubstituted linear alkanesulfonates, substituted ethanesulfonic acids and sulfonated buffers. SsuD catalysis was absolutely dependent on FMNH2 and oxygen, and was maximal for SsuE/SsuD molar ratios of 2.1 to 4.2 in 10 mM Tris-HCl, pH 9.1. Native SsuD was a homotetrameric enzyme of M-r 181,000. These results demonstrate that SsuD is a broad range FMNH2-dependent monooxygenase catalyzing the oxygenolytic conversion of alkanesulfonates to sulfite and the corresponding aldehydes, SsuE is the FMN reducing enzyme providing SsuD with FMNH2.	ETH Zentrum, Swiss Fed Inst Technol, Inst Mikrobiol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Leisinger, T (corresponding author), ETH Zentrum, Swiss Fed Inst Technol, Inst Mikrobiol, CH-8092 Zurich, Switzerland.	leisinger@micro.biol.ethz.ch		Eichhorn, Eric/0000-0003-2113-6305				Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Becker DF, 1998, J BIOL CHEM, V273, P26462, DOI 10.1074/jbc.273.41.26462; BOOS W, 1996, ESCHERICHIA COLI SAL, p117N5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DENOME SA, 1994, J BACTERIOL, V176, P6707, DOI 10.1128/JB.176.21.6707-6716.1994; Eichhorn E, 1997, J BIOL CHEM, V272, P23031, DOI 10.1074/jbc.272.37.23031; Fieschi F, 1995, J BIOL CHEM, V270, P30392, DOI 10.1074/jbc.270.51.30392; Fisher AJ, 1996, J BIOL CHEM, V271, P21956, DOI 10.1074/jbc.271.36.21956; Higgins TP, 1996, MICROBIOL-SGM, V142, P251, DOI 10.1099/13500872-142-2-251; JAGURA-BURDZY G, 1981, J BACTERIOL, V147, P744, DOI 10.1128/JB.147.3.744-751.1981; JOHNSTON JB, 1975, A VAN LEEUW J MICROB, V41, P493, DOI 10.1007/BF02565092; Kertesz MA, 1999, J BACTERIOL, V181, P1464, DOI 10.1128/JB.181.5.1464-1473.1999; Quadroni M, 1996, EUR J BIOCHEM, V239, P773, DOI 10.1111/j.1432-1033.1996.0773u.x; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STOLL VS, 1990, METHOD ENZYMOL, V182, P24; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THIBAUT D, 1995, J BACTERIOL, V177, P5199, DOI 10.1128/jb.177.18.5199-5205.1995; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THYSSE GJE, 1974, A VAN LEEUW J MICROB, V40, P25, DOI 10.1007/BF00394550; UETZ T, 1992, J BACTERIOL, V174, P1179, DOI 10.1128/jb.174.4.1179-1188.1992; URIANICKELSEN MR, 1994, FEMS MICROBIOL LETT, V123, P43, DOI 10.1111/j.1574-6968.1994.tb07199.x; URIANICKELSEN MR, 1993, J GEN MICROBIOL, V139, P203, DOI 10.1099/00221287-139-2-203; van der Ploeg JR, 1998, MICROBIOL-SGM, V144, P2555, DOI 10.1099/00221287-144-9-2555; vanderPloeg JR, 1996, J BACTERIOL, V178, P5438, DOI 10.1128/jb.178.18.5438-5446.1996; VANDERPLOEG JR, 1999, IN PRESS J BIOL CHEM, V274; VAUPEL M, 1995, EUR J BIOCHEM, V231, P773, DOI 10.1111/j.1432-1033.1995.tb20760.x; Witschel M, 1997, J BACTERIOL, V179, P6937, DOI 10.1128/jb.179.22.6937-6943.1997; Xi L, 1997, BIOCHEM BIOPH RES CO, V230, P73, DOI 10.1006/bbrc.1996.5878; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	162	168	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26639	26646		10.1074/jbc.274.38.26639	http://dx.doi.org/10.1074/jbc.274.38.26639			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480865	hybrid			2022-12-25	WOS:000082570700004
J	Yandell, CA; Dunbar, AJ; Wheldrake, JF; Upton, Z				Yandell, CA; Dunbar, AJ; Wheldrake, JF; Upton, Z			The kangaroo cation-independent mannose 6-phosphate receptor binds insulin-like growth factor II with low affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-II; MANNOSE-6-PHOSPHATE RECEPTOR; HUMAN PLACENTA; CELL-SURFACE; PURIFICATION; EXPRESSION; PROTEINS; LIVER; SEQUENCE; CHICKEN	The mammalian cation-independent mannose 6-phosphate receptor (CI-MPR) binds mannose 6-phosphate-bearing glycoproteins and insulin-like growth factor (IGF)-II. However, the CI-MPR from the opossum has been reported to bind bovine IGF-II with low affinity (Dahms, N. M., Brzycki-Wessell, M. A., Ramanujam, K. S., and Seetharam, B. (1993) Endocrinology 133, 440-446). This may reflect the use of a heterologous ligand, or it may represent the intrinsic binding affinity of this receptor. To examine the binding of IGF-II to a marsupial CI-MPR in a homologous system, we have previously purified kangaroo IGF-II (Yandell, C. A., Francis, G. L., Wheldrake, J. F., and Upton, Z. (1998) J. Endocrinol. 156, 195-204), and we now report the purification and characterization of the CI-MPR from kangaroo liver. The interaction of the kangaroo CI-MPR with IGF-II has been examined by ligand blotting, radioreceptor assay, and real-time biomolecular interaction analysis. Using both a heterologous and homologous approach, we have demonstrated that the kangaroo CI-MPR has a lower binding affinity for IGF-II than its eutherian (placental mammal) counterparts. Furthermore, real-time biomolecular interaction analysis revealed that the kangaroo CI-MPR has a higher affinity for kangaroo IGF-II than for human IGF-II, The cDNA sequence of the kangaroo CI-MPR indicates that there is considerable divergence in the area corresponding to the IGF-II binding site of the eutherian receptor. Thus, the acquisition of a high-affinity binding site for regulating IGF-II appears to be a recent event specific to the eutherian lineage.	Cooperat Res Ctr Tissue Growth & Repair, Adelaide, SA 5000, Australia; CSIRO, Adelaide, SA 5000, Australia; Flinders Univ S Australia, Sch Biol Sci, Adelaide, SA 5001, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Flinders University South Australia	Yandell, CA (corresponding author), Hanson Ctr Canc Res, POB 14,Rundle Mall, Adelaide, SA 5000, Australia.	catherine.yandell@imvs.sa.gov.au	Upton, Zee/I-9777-2012; Upton, Zee/ABC-4642-2021	Yandell, Catherine/0000-0003-1036-1187; Upton, Zee/0000-0002-9928-5864				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAULKE T, 1994, INT CONGR SER, V1056, P117; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; BRETTHAU.RK, 1973, BIOCHEMISTRY-US, V12, P1251, DOI 10.1021/bi00731a002; CANFIELD WM, 1989, J BIOL CHEM, V264, P7100; CLAIRMONT KB, 1989, J BIOL CHEM, V264, P16390; Crawley AC, 1996, J CLIN INVEST, V97, P1864, DOI 10.1172/JCI118617; DAHMS NM, 1993, ENDOCRINOLOGY, V133, P440, DOI 10.1210/en.133.2.440; DECEUNINCK F, 1995, J CHROMATOGR B, V666, P203, DOI 10.1016/0378-4347(94)00576-Q; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; DUGUAY SJ, 1995, FEBS LETT, V371, P69, DOI 10.1016/0014-5793(95)00879-E; FRANCIS GL, 1989, J ENDOCRINOL, V122, P681, DOI 10.1677/joe.0.1220681; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; GUSE AH, 1992, ENDOCRINOLOGY, V130, P145, DOI 10.1210/en.130.1.145; HAMMERMAN MR, 1984, J BIOL CHEM, V259, P3511; HAMPTON B, 1989, J BIOL CHEM, V264, P19155; Han VKM, 1996, J CLIN ENDOCR METAB, V81, P2680, DOI 10.1210/jc.81.7.2680; Hermanson G.T., 1992, IMMOBILIZED AFFINITY; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; KIESS W, 1988, J BIOL CHEM, V263, P9339; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MunierLehmann H, 1996, BIOCHEM SOC T, V24, P133, DOI 10.1042/bst0240133; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; O'Dell SD, 1998, INT J BIOCHEM CELL B, V30, P767, DOI 10.1016/S1357-2725(98)00048-X; OKA Y, 1985, J BIOL CHEM, V260, P9435; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1991, BIOCHEM BIOPH RES CO, V179, P10, DOI 10.1016/0006-291X(91)91326-8; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; POLYCHRONAKOS C, 1988, ENDOCRINOLOGY, V123, P2146, DOI 10.1210/endo-123-4-2146; POLYCHRONAKOS C, 1990, ENDOCRINOLOGY, V127, P1861, DOI 10.1210/endo-127-4-1861; Reynolds TS, 1997, ENDOCRINOLOGY, V138, P886, DOI 10.1210/en.138.3.886; ROTH RA, 1987, BIOCHEM BIOPH RES CO, V149, P600, DOI 10.1016/0006-291X(87)90410-4; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; SCOTT CD, 1987, ENDOCRINOLOGY, V120, P1; SZEBENYI G, 1994, GENOMICS, V19, P120, DOI 10.1006/geno.1994.1021; TAIT JF, 1981, J BIOL CHEM, V256, P1086; THAKKER JK, 1989, J BIOL CHEM, V264, P7169; TONG PY, 1988, J BIOL CHEM, V263, P2585; UPTON Z, 1995, J MOL ENDOCRINOL, V14, P79, DOI 10.1677/jme.0.0140079; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Yandell CA, 1998, J ENDOCRINOL, V156, P195, DOI 10.1677/joe.0.1560195; Yandell CA, 1999, J ENDOCRINOL, V161, P445, DOI 10.1677/joe.0.1610445; YANG YWH, 1991, ENDOCRINOLOGY, V128, P1177, DOI 10.1210/endo-128-2-1177; ZHOU M, 1995, P NATL ACAD SCI USA, V92, P9762, DOI 10.1073/pnas.92.21.9762; ZICK Y, 1984, BIOCHEM BIOPH RES CO, V119, P6, DOI 10.1016/0006-291X(84)91610-3	52	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27076	27082		10.1074/jbc.274.38.27076	http://dx.doi.org/10.1074/jbc.274.38.27076			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480921	hybrid			2022-12-25	WOS:000082570700060
J	Yamane, K; Tsuruo, T				Yamane, K; Tsuruo, T			Conserved BRCT regions of TopBP1 and of the tumor suppressor BRCA1 bind strand breaks and termini of DNA	ONCOGENE			English	Article						checkpoint; Cut5; DNA damage sensor; DNA repair; Nijmegen breakage syndrome	REPLICATION CHECKPOINT CONTROL; FISSION YEAST; PROTEIN; REPAIR; DAMAGE; REGULATOR; RESIDUES; CHK1; CUT5; P53	The BRCT region, the carboxyl-terminus of BRCA1 (the breast cancer susceptibility gene 1 product), is ubiquitous region homologous to regions in DNA repair enzymes and cell cycle regulators. We showed that the BRCT regions bound DNA fragments, using the TopBP1 protein (topoisomerase II binding protein 1), with eight BRCTs as a model protein. The bindings mere independent of DNA sequences, forms of DNA termini and energy. The BRCT-DNA complex showed resistance to an exonuclease, indicating that BRCT bound BNA breaks. The BRCTs also bound DNA nicks, suggesting that BRCTs play an important role in detection of both single- and double-strand DNA breaks or ends. On the other hand, BRCTs did not bind circular intact DNA, BRCTs of BRCA1 also bound DNA termini, Since some BRCTs are unique general elements in some tumor suppressions, these findings will reveal novel aspects of the tumor suppression mechanism.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen NR, 1998, NUCLEIC ACIDS RES, V26, P1032, DOI 10.1093/nar/26.4.1032; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YAMANE K, 1988, J BIOL CHEM, V263, P19690; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x	26	74	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5194	5203		10.1038/sj.onc.1202922	http://dx.doi.org/10.1038/sj.onc.1202922			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498869				2022-12-25	WOS:000082555700008
J	Bhargava, P; Kassavetis, GA				Bhargava, P; Kassavetis, GA			Abortive initiation by Saccharomyces cerevisiae RNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-INITIATION; TERNARY COMPLEXES; IN-VITRO; ELONGATION COMPLEXES; PROMOTER COMPLEXES; CHAIN ELONGATION; GENE-EXPRESSION; LARGEST SUBUNIT; NASCENT RNA; CLEAVAGE	Promoter escape can be rate-limiting for transcription by bacterial RNA polymerases and RNA polymerase II: of higher eukaryotes. Formation of a productive elongation complex requires disengagement of RNA polymerase from promoter-bound eukaryotic transcription factors or bacterial sigma factors. RNA polymerase III (pol III) stably associates with the TFIIIB-DNA complex even in the absence of localized DNA unwinding associated with the open promoter complex. To explore the role that release of pol III from the TFIIIB-DNA complex plays in limiting the overall rate of transcription, we have examined the early steps of RNA synthesis. We find that, on average, only three rounds of abortive initiation precede the formation of each elongation complex and that nearly all pol III molecules escape-the abortive initiation phase of transcription without significant pausing or arrest. However, when elongation is limited to 5 nucleotides, the intrinsic exoribonuclease activity of pol III cleaves Ei-mer RNA at a rate considerably faster than product release or reinitiation. This cleavage also occurs in the normal process of forming a productive elongation complex. The possible role of nucleolytic retraction in disengaging pol III from TFIIIB is discussed.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kassavetis, GA (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM 18386] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018386, R01GM018386] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDELEBEN C, 1994, J MOL BIOL, V235, P1193, DOI 10.1006/jmbi.1994.1073; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; Bobkova EV, 1997, J BIOL CHEM, V272, P22832, DOI 10.1074/jbc.272.36.22832; BROWNLEE GC, 1972, LAB TECHNIQUES BIOCH, V3, P199; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; Chen YF, 1997, J MOL BIOL, V267, P47, DOI 10.1006/jmbi.1996.0853; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; ELLINGER T, 1994, J MOL BIOL, V239, P455, DOI 10.1006/jmbi.1994.1388; GEIDUSCHEK EP, 1995, CURR OPIN CELL BIOL, V7, P344, DOI 10.1016/0955-0674(95)80089-1; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; Hernandez VJ, 1996, J BIOL CHEM, V271, P18775, DOI 10.1074/jbc.271.31.18775; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; HSU LM, 1995, P NATL ACAD SCI USA, V92, P11588, DOI 10.1073/pnas.92.25.11588; JACOB GA, 1994, J BIOL CHEM, V269, P3655; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; JIN DJ, 1994, J MOL BIOL, V236, P72, DOI 10.1006/jmbi.1994.1119; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; KUMAR A, 1998, MECH TRANSCRIPTION, V63, P121; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; LEVEILLARD T, 1993, J BIOL CHEM, V268, P3594; Li BY, 1996, MOL CELL BIOL, V16, P5433; Li XY, 1998, J BIOL CHEM, V273, P23549, DOI 10.1074/jbc.273.36.23549; LUSE DS, 1987, J BIOL CHEM, V262, P14990; Mason PB, 1997, J BIOL CHEM, V272, P33227, DOI 10.1074/jbc.272.52.33227; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; METZGER W, 1993, J MOL BIOL, V232, P35, DOI 10.1006/jmbi.1993.1368; Moreland RJ, 1998, J BIOL CHEM, V273, P26610, DOI 10.1074/jbc.273.41.26610; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; RASMUSSEN EB, 1995, J MOL BIOL, V252, P522, DOI 10.1006/jmbi.1995.0517; REINES D, 1992, J BIOL CHEM, V267, P3795; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; Sastry SS, 1997, J BIOL CHEM, V272, P8644, DOI 10.1074/jbc.272.13.8644; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; SHAABAN SA, 1995, MOL CELL BIOL, V15, P1467; Shaaban SA, 1996, MOL CELL BIOL, V16, P6468; SPENCER CA, 1990, ONCOGENE, V5, P777; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; Thuillier V, 1996, EMBO J, V15, P618, DOI 10.1002/j.1460-2075.1996.tb00394.x; TINTUT Y, 1995, J BIOL CHEM, V270, P24392, DOI 10.1074/jbc.270.41.24392; Tschochner H, 1996, P NATL ACAD SCI USA, V93, P12914, DOI 10.1073/pnas.93.23.12914; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WHITE RJ, 1998, RNA POLYM 3 TRANSCRI; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; Zecherle GN, 1996, MOL CELL BIOL, V16, P5801	64	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26550	26556		10.1074/jbc.274.37.26550	http://dx.doi.org/10.1074/jbc.274.37.26550			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473618	hybrid			2022-12-25	WOS:000082469700084
J	Iwasaki, S; Iguchi, M; Watanabe, K; Hoshino, R; Tsujimoto, M; Kohno, M				Iwasaki, S; Iguchi, M; Watanabe, K; Hoshino, R; Tsujimoto, M; Kohno, M			Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; NEURONAL DIFFERENTIATION; BETA-SUPERFAMILY; MAMMALIAN-CELLS; MESSENGER-RNA; EXPRESSION; CASCADE; TRANSFORMATION; APOPTOSIS; STRESS	Bone morphogenetic protein (BMP)-2 has the capacity to induce the neuronal differentiation of PC12 cells. Unlike nerve growth factor, however, BMP-2 failed to induce the activation of the 41-/43-kDa mitogen-activated protein (MAP) kinase pathway in these cells. In contrast, BMP-2 characteristically induced the sustained activation of the p38 MAP kinase pathway. Pretreatment of PC12 cells with SB203580 inhibited the BMP-2-induced neurite outgrowth formation in a dose-dependent manner; this inhibition coincided well with the ability of SB203580 to inihibit the BMP-2-induced activation of the p38 MAP kinase pathway. Overexpression in PC12 cells of wild-type MAP kinase kinase (MKK)-6 enhanced the BMP-alpha-induced ctivation of p38 MAP kinase, whose activation correlated well with the ability of these cells to induce neurite outgrowth in response to BMP-2. Transient expression of kinase-negative forms of MKK3/6 inhibited the formation of neurite outgrowth in response to BMP-2. Furthermore, expression of constitutively active forms of MKK3/6 induced neurite outgrowth without BMP-2 stimulation, and SB203580 inhibited this induction. These results clearly indicate that activation of the p38 MAP kinase pathway is necessary for BMP-alpha-induced neuronal differentiation of PC12 cells. Our results also suggest that activation of the p38 MAP kinase pathway alone can induce the neuronal differentiation of PC12 cells.	Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, Nagasaki 8528131, Japan; RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan	Nagasaki University; RIKEN	Kohno, M (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Lab Cell Regulat, 1-14 Bunkyo Machi, Nagasaki 8528131, Japan.		Kohno, Michiaki/R-6532-2019	Kohno, Michiaki/0000-0002-7644-0059				Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; CHATANI Y, 1995, J BIOL CHEM, V270, P30868; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FUKUDA M, 1995, ONCOGENE, V11, P239; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hattori A, 1999, J NEUROCHEM, V72, P2264, DOI 10.1046/j.1471-4159.1999.0722264.x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; ISHIDA N, 1994, J BIOCHEM-TOKYO, V115, P279, DOI 10.1093/oxfordjournals.jbchem.a124329; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/jbc.270.10.5476; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; JONES CM, 1991, DEVELOPMENT, V111, P531; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LYONS KM, 1990, DEVELOPMENT, V109, P833; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; OZKAYNAK E, 1991, BIOCHEM BIOPH RES CO, V179, P116, DOI 10.1016/0006-291X(91)91342-A; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHLUESENER HJ, 1994, GLIA, V12, P161, DOI 10.1002/glia.440120210; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TOMIZAWA K, 1995, MOL BRAIN RES, V28, P122, DOI 10.1016/0169-328X(94)00199-O; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; WALL NA, 1993, J CELL BIOL, V120, P493, DOI 10.1083/jcb.120.2.493; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	53	191	204	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26503	26510		10.1074/jbc.274.37.26503	http://dx.doi.org/10.1074/jbc.274.37.26503			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473611	hybrid			2022-12-25	WOS:000082469700077
J	Kamakura, S; Moriguchi, T; Nishida, E				Kamakura, S; Moriguchi, T; Nishida, E			Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases - Identification and characterization of a signaling pathway to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; TERNARY COMPLEX FACTORS; MAP KINASE; TRANSDUCTION PATHWAY; PROTEIN-KINASE-1 BMK1; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; GENE-EXPRESSION; GROWTH-FACTOR; IN-VIVO	ERK5 (also known as BMK1), a member of the mitogen-activated protein kinase (MAPK) superfamily, was known to be activated strongly by oxidant and osmotic stresses. Here we have found that ERK5 is strongly activated by epidermal growth factor and nerve growth factor, whose receptors are tyrosine kinases. The activation of ERK5 was inhibited by expression of dominant-negative Has and induced by expression of active Has in PC12 cells, indicating a requirement for Has in ERK5 activation. The epidermal growth factor-induced activation of ERK5 was found to be inhibited by PD98059 and U0126 inhibitors, which were previously thought to act specifically on classical MAPK kinase (also known as MEK1) and readily reversed by CL100 and MKP-3 dual-specificity phosphatases for which classical MAPKs were previously shown to serve as preferred substrates. The reporter assays demonstrated that the serum-induced enhancement of transcription from serum response element was significantly inhibited by expression of a dominant-negative form of MEK5, which was a direct and specific activator for ERK5 and that transcription from serum response element mediated by the Ets-domain transcription factor Sap1a, but not by Elk1, was stimulated by coexpression of ERK5 and active MEK5. In addition, Sap1a was shown to be phosphorylated by ERK5 in vitro and by the activation of the ERK5 pathway in cells. Moreover, the serum-induced c-Fos expression was markedly inhibited by expression of dominant-negative MEK5. These results reveal a novel signaling pathway to the nucleus mediated by ERK5 that functions downstream of receptor tyrosine kinases to induce immediate early genes, in parallel with the classical MAPK cascade.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.		Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991				Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Li HZ, 1996, J NEUROCHEM, V66, P2287; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	36	448	458	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26563	26571		10.1074/jbc.274.37.26563	http://dx.doi.org/10.1074/jbc.274.37.26563			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473620	hybrid			2022-12-25	WOS:000082469700086
J	Zoog, SJ; Bertin, J; Friesen, PD				Zoog, SJ; Bertin, J; Friesen, PD			Caspase inhibition by Baculovirus P35 requires interaction between the reactive site loop and the beta-sheet core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIAPOPTOTIC PROTEIN P35; CELL-DEATH; CAENORHABDITIS-ELEGANS; INSECT CELLS; APOPTOSIS; REPLICATION; DROSOPHILA; EXPRESSION; PROTEASES; YEAST	Baculovirus P35 is a universal substrate-inhibitor of the death caspases. Stoichiometric inhibition by P35 is correlated with cleavage of its reactive site loop (RSL) and formation of a stable P35.caspase complex through a novel but undefined mechanism. The P35 crystal structure predicts that the RSL associates with the beta-sheet core of P35 positioning the caspase cleavage site at the loop's apex. Here we demonstrate that proper interaction between the RSL and the beta-sheet core is critical for caspase inhibition, but not cleavage. Disruption of RSL interaction with the beta-sheet by substituting hydrophobic residues of the RSL's transverse helix alpha l with destabilizing charged residues caused loss of caspase inhibition, without affecting P35 cleavage. Restabilization of the helix/sheet interaction by charge compensation from within the beta-sheet partially restored anti-caspase potency. Mutational effects on P35 helix/sheet interactions were confirmed by measuring intermolecular helix/sheet association with the yeast two-hybrid system. Moreover, the identification of P35 oligomers in baculovirus-infected cells suggested that similar P35 interactions occur in vivo. These findings indicate that P35's anti-caspase potency depends on a distinct conformation of the RSL which is required for events that promote stable, post-cleavage interactions and inhibition of the target caspase.	Univ Wisconsin, Inst Mol Virol, RM Bock Labs, Madison, WI 53706 USA; Univ Wisconsin, Grad Sch, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Coll Agr & Life Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Friesen, PD (corresponding author), Univ Wisconsin, Inst Mol Virol, RM Bock Labs, 1525 Linden Dr, Madison, WI 53706 USA.	PFriesen@facstaff.wisc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040482, R56AI040482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40482] Funding Source: Medline; NIGMS NIH HHS [T32-GM07215] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1997, J BIOL CHEM, V272, P1421, DOI 10.1074/jbc.272.3.1421; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CARTIER JL, 1994, J VIROL, V68, P7728, DOI 10.1128/JVI.68.12.7728-7737.1994; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Davidson FF, 1998, NATURE, V391, P587, DOI 10.1038/35385; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fisher AJ, 1999, EMBO J, V18, P2031, DOI 10.1093/emboj/18.8.2031; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAY BA, 1994, DEVELOPMENT, V120, P2121; HERSHBERGER PA, 1992, J VIROL, V66, P5525, DOI 10.1128/JVI.66.9.5525-5533.1992; HERSHBERGER PA, 1994, J VIROL, V68, P3467, DOI 10.1128/JVI.68.6.3467-3477.1994; Huang LQ, 1998, BIOCHEM BIOPH RES CO, V248, P548, DOI 10.1006/bbrc.1998.9009; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; Izquierdo M, 1999, EMBO J, V18, P156, DOI 10.1093/emboj/18.1.156; Jacobson MD, 1998, CURR BIOL, V8, pR418, DOI 10.1016/S0960-9822(98)70267-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LaCount DJ, 1997, J VIROL, V71, P1530, DOI 10.1128/JVI.71.2.1530-1537.1997; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER JH, 1972, CSH LAB PRESS; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Robertson NM, 1997, CANCER RES, V57, P43; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w	43	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					25995	26002		10.1074/jbc.274.37.25995	http://dx.doi.org/10.1074/jbc.274.37.25995			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473544	hybrid			2022-12-25	WOS:000082469700010
J	Albagli, O; Lantoine, D; Quief, S; Quignon, F; Englert, C; Kerckaert, JP; Montarras, D; Pinset, C; Lindon, C				Albagli, O; Lantoine, D; Quief, S; Quignon, F; Englert, C; Kerckaert, JP; Montarras, D; Pinset, C; Lindon, C			Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci	ONCOGENE			English	Article						BCL6(LAZ3) protooncogene; tetracycline regulated expression; cell cycle; DNA replication; growth suppression; apoptosis	ACUTE PROMYELOCYTIC LEUKEMIA; GERMINAL-CENTER FORMATION; ZINC-FINGER PROTEIN; B-CELL LYMPHOMA; PLZF-RAR-ALPHA; NON-HODGKINS-LYMPHOMA; AFFECTING BAND 3Q27; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; SOMATIC HYPERMUTATION	One of the most frequent genetic abnormalities associated with non Hodgkin lymphoma is the structural alteration of the 5' non coding/regulatory region of the BCL6 (LAZ3) protooncogene. BCL6 encodes a POZ/Zn finger protein, a structure similar to that of many Drosophila developmental regulators and to another protein involved in a human hematopoietic malignancy, PLZF, BCL6 is a sequence specific transcriptional repressor controlling germinal center formation and T cell dependent immune response. Although the expression of BCL6 negatively correlates with cellular proliferation in different cell types, the influence of BCL6 on cell growth and survival is currently unknown so that the way its deregulation may contribute to cancer remains elusive. To directly address this issue, we used a tetracycline-regulated system in human U2OS osteosarcoma cells and thus found that BCL6 mediates growth suppression associated with impaired S phase progression and apoptosis, Interestingly, overexpressed BCL6 can colocalize with sites of ongoing DNA synthesis, suggesting that it may directly interfere with S phase initiation and/or progression, In contrast, the isolated Zn finger region of BCL6, which binds BCL6 target sequence but lacks transcriptional repression activity, slows, but does not suppress, U2OS cell growth, is less efficient at delaying S phase progression, and does not trigger apoptosis, Thus, for a large part, the effects of BCL6 overexpression on cell growth and survival depend on its ability to engage protein/protein interactions with itself and/or its transcriptional corepressors. That BCL6 restricts cell growth suggests that its deregulation upon structural alterations may alleviate negative controls on the cell cycle and cell survival.	IRCL, INSERM, U524, F-59045 Lille, France; Inst Pasteur, Dept Biol Mol, CNRS, URA 1947, F-72015 Paris, France; Hop St Louis, Ctr Georges Hayem, CNRS, UPR 9051, F-75475 Paris 10, France; Res Ctr Karlsruhe, Inst Genet, D-76344 Eggenstein Leopoldshafen, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); Helmholtz Association; Karlsruhe Institute of Technology	Albagli, O (corresponding author), IRCL, INSERM, U524, Pl Verdun, F-59045 Lille, France.		Quignon, Frédérique/P-4249-2017	Lindon, Catherine/0000-0003-3554-2574; Englert, Christoph/0000-0002-5931-3189				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Albagli-Curiel O, 1998, DIFFERENTIATION, V64, P33, DOI 10.1046/j.1432-0436.1998.6410033.x; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P323, DOI 10.1002/(SICI)1098-2264(199812)23:4<323::AID-GCC7>3.3.CO;2-V; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, ONCOGENE, V17, P1717, DOI 10.1038/sj.onc.1202098; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; FUKUDA T, 1995, ONCOGENE, V11, P1657; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LIMADEFARIA A, 1968, NATURE, V217, P138, DOI 10.1038/217138a0; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAKOSWALES M, 1995, NAT MED, V1, P570; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; NUMOTO M, 1995, JPN J CANCER RES, V86, P277, DOI 10.1111/j.1349-7006.1995.tb03051.x; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yamochi T, 1997, LEUKEMIA, V11, P694, DOI 10.1038/sj.leu.2400631; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642	66	55	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	1999	18	36					5063	5075		10.1038/sj.onc.1202892	http://dx.doi.org/10.1038/sj.onc.1202892			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490843				2022-12-25	WOS:000082497100006
J	Foran, PGP; Fletcher, LM; Oatey, PB; Mohammed, N; Dolly, JO; Tavare, JM				Foran, PGP; Fletcher, LM; Oatey, PB; Mohammed, N; Dolly, JO; Tavare, JM			Protein kinase B stimulates the translocation of GLUT4 but not GLUT1 or transferrin receptors in 3T3-L1 adipocytes by a pathway involving SNAP-23, synaptobrevin-2, and/or cellubrevin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED CHROMAFFIN CELLS; SYNAPTOSOMAL-ASSOCIATED PROTEIN; BOTULINUM NEUROTOXIN-B; RAT SKELETAL-MUSCLE; GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; CLOSTRIDIAL NEUROTOXINS; INSULIN STIMULATION; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; GLUT4-CONTAINING VESICLES	An interaction of SNAP-23 and syntaxin 4 on the plasma membrane with vesicle-associated synaptobrevin-2 and/or cellubrevin, known as SNAP (soluble N-ethyl-maleimide-sensitive factor attachment protein) receptors or SNAREs, has been proposed to provide the targeting and/or fusion apparatus for insulin-stimulated translocation of the GLUT4 isoform of glucose transporter to the plasma membrane. By microinjecting 3T3-L1 adipocytes with the Clostridium botulinum toxin B or E, which proteolyzed synaptobrevin-2/cellubrevin and SNAP-23, respectively, we investigated the role of these SNAREs in GLUT4, GLUT1, and transferrin receptor trafficking. As expected, insulin stimulated the translocation of GLUT4, GLUT1, and transferrin receptors to the plasma membrane, By contrast, a constitutively active protein kinase B (PKB-DD) only stimulated a translocation of GLUT4 and not GLUT1 or the transferrin receptor. The GLUT4 response to PKB-DD was abolished by toxins B or E, whereas the insulin-evoked translocation of GLUT4 was inhibited by approximately 65%. These toxins had no significant effect on insulin-stimulated transferrin receptor appearance at the cell surface. Thus, insulin appears to induce GLUT4 translocation via two distinct routes, only one of which involves SNAP-23 and synaptobrevin-2/cellubrevin, and can be mobilized by PKB-DD, The PKB-, SNAP-23-, and synaptobrevin-2/cellubrevin-independent GLUT4 translocation pathway may involve movement through recycling endosomes, together with GLUT1 and transferrin receptors.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	Imperial College London; University of Bristol	Tavare, JM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England.		Dolly, Oliver/G-1532-2012; Dolly, Oliver/ABH-6677-2020	Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Brozinick JT, 1998, J BIOL CHEM, V273, P14679, DOI 10.1074/jbc.273.24.14679; CAIN CC, 1992, J BIOL CHEM, V267, P11681; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; Chen FS, 1997, BIOCHEMISTRY-US, V36, P5719, DOI 10.1021/bi962331n; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; FORAN P, 1995, BIOCHEMISTRY-US, V34, P5494, DOI 10.1021/bi00016a021; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Jagadish MN, 1996, BIOCHEM J, V317, P945, DOI 10.1042/bj3170945; Jagadish MN, 1997, BIOCHEM J, V321, P151, DOI 10.1042/bj3210151; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LAWRENCE GW, 1994, EUR J BIOCHEM, V222, P325, DOI 10.1111/j.1432-1033.1994.tb18871.x; Lawrence GW, 1997, BIOCHEMISTRY-US, V36, P3061, DOI 10.1021/bi9622478; Lawrence GW, 1996, EUR J BIOCHEM, V236, P877, DOI 10.1111/j.1432-1033.1996.00877.x; Lund S, 1998, FEBS LETT, V425, P472, DOI 10.1016/S0014-5793(98)00293-2; Macaulay SL, 1997, BIOCHEM J, V324, P217, DOI 10.1042/bj3240217; Macaulay SL, 1997, BIOCHEM BIOPH RES CO, V237, P388, DOI 10.1006/bbrc.1997.7143; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MONTECUCCO C, 1993, TRENDS BIOCHEM SCI, V18, P324, DOI 10.1016/0968-0004(93)90065-U; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; Oatey PB, 1997, BIOCHEM J, V327, P637; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, AM J PHYSIOL, V263, P383; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; SHONE CC, 1994, EUR J BIOCHEM, V225, P263, DOI 10.1111/j.1432-1033.1994.00263.x; SIMPSON LL, 1986, INFECT IMMUN, V52, P858, DOI 10.1128/IAI.52.3.858-862.1986; SOLLNER T, 1995, FEBS LETT, V369, P80, DOI 10.1016/0014-5793(95)00594-Y; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Timmers KI, 1996, BIOCHEM J, V320, P429, DOI 10.1042/bj3200429; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; Wang GY, 1997, J CELL SCI, V110, P505; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; ZORZANO A, 1989, J BIOL CHEM, V264, P12358; [No title captured]	68	96	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28087	28095		10.1074/jbc.274.40.28087	http://dx.doi.org/10.1074/jbc.274.40.28087			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497159	hybrid			2022-12-25	WOS:000082912700008
J	Sala, A; Zarini, S; Folco, G; Murphy, RC; Henson, PM				Sala, A; Zarini, S; Folco, G; Murphy, RC; Henson, PM			Differential metabolism of exogenous and endogenous arachidonic acid in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); TRANSCELLULAR BIOSYNTHESIS; POLYMORPHONUCLEAR LEUKOCYTES; SULFIDOPEPTIDE-LEUKOTRIENES; PERFUSED HEART; RABBIT; 5-LIPOXYGENASE; PROTEIN; RELEASE	Leukotrienes can be produced by cooperative interactions between cells in which, for example, arachidonate derived from one cell is oxidized to leukotriene A(4) (LTA(4)) by another and this can then be exported for conversion to LTB4 or cysteinyl leukotrienes (cys-LTs) by yet another. Neutrophils do not contain LTC4 synthase but are known to cooperate with endothelial cells or platelets (which do have this enzyme) to generate cys-LTs, Stimulation of human neutrophils perfusing isolated rabbit hearts resulted in production of cys-LTs, whereas these were not seen with perfused hearts alone or isolated neutrophils. In addition, the stimulated, neutrophil-perfused hearts generated much greater amounts of total LTA(4) products, suggesting that the hearts were supplying arachidonate to the neutrophils and, in addition, that this externally derived arachidonate was preferentially used for exported LTA(4) that could be metabolized to cys-LTs by the coronary endothelium. Stable isotope-labeled arachidonate and electrospray tandem mass spectrometry were used to differentially follow metabolism of exogenous and endogenous arachidonate, Isolated, adherent neutrophils at low concentrations (to minimize transcellular metabolism between them) were shown to generate higher proportions of nonenzymatic LTA(4) products from exogenous arachidonate (deuterium-labeled) than from endogenous (unlabeled) sources. The endogenous arachidonate, on the other hand, was preferentially used for conversion to LTB4 by the LTA(4) hydrolase, This result was not because of saturation of the LTA(4) hydrolase, because it occurred at widely differing concentrations of exogenous arachidonate, Finally, in the presence of platelets (which contain LTC4 synthase), the LTA(4) synthesized from exogenous deuterium-labeled arachidonate was converted to cys-LTs to a greater degree than that from endogenous sources. These experiments suggest that exogenous arachidonate is preferentially converted to LTA(4) for export (not intracellular conversion) and raises the likelihood that there are different intracellular pathways for arachidonate metabolism.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Univ Milan, Ctr Cardiopulm Pharmacol, I-20133 Milan, Italy	National Jewish Health; University of Milan	Henson, PM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.	hensonp@njc.org	Sala, Angelo/H-5478-2019	Sala, Angelo/0000-0001-9290-0257; Zarini, Simona/0000-0002-7460-3299	NHLBI NIH HHS [HL34303] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTOINE C, 1992, BIOCHIM BIOPHYS ACTA, V1128, P139, DOI 10.1016/0005-2760(92)90299-B; BERTI F, 1988, J CARDIOVASC PHARM, V12, P438, DOI 10.1097/00005344-198810000-00009; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BRADY HR, 1992, BIOCHEM BIOPH RES CO, V186, P1307, DOI 10.1016/S0006-291X(05)81548-7; Buccellati C, 1997, BRIT J PHARMACOL, V120, P1128, DOI 10.1038/sj.bjp.0700994; BUSSE WW, 1999, AM J RESP CRIT CAN S, V157, P210; CARLOS TM, 1994, BLOOD, V84, P2068; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; CLUZEL M, 1989, J IMMUNOL, V143, P3659; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MACLOUF J, 1989, BLOOD, V74, P703; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MINAMI M, 1987, J BIOL CHEM, V262, P13873; PATSCHEKE H, 1981, HAEMOSTASIS, V10, P14; Rossoni G, 1996, J PHARMACOL EXP THER, V276, P335; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; SALA A, 1993, BRIT J PHARMACOL, V110, P1206, DOI 10.1111/j.1476-5381.1993.tb13943.x; Sala A, 1996, BLOOD, V87, P1824; SALA A, 1999, INHIBITORS LEUKOTRIE, P113; Samuelsson B, 1997, ADV EXP MED BIOL, V433, P1; Smith WL, 1997, THROMB HAEMOSTASIS, V78, P627; Vane JR, 1998, INFLAMM RES, V47, pS78	26	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28264	28269		10.1074/jbc.274.40.28264	http://dx.doi.org/10.1074/jbc.274.40.28264			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497182	hybrid			2022-12-25	WOS:000082912700031
J	Wisniewski, M; Palaniappan, C; Fu, ZP; Le Grice, SFJ; Fay, P; Bambara, RA				Wisniewski, M; Palaniappan, C; Fu, ZP; Le Grice, SFJ; Fay, P; Bambara, RA			Mutations in the primer grip region of HIV reverse transcriptase can increase replication fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; POLYMERASE INSERTION FIDELITY; ALANINE-SCANNING MUTAGENESIS; MISPAIR EXTENSION KINETICS; DOUBLE-STRANDED DNA; RESISTANCE MUTATIONS; IN-VITRO; NONNUCLEOSIDE INHIBITORS; RETROVIRAL REPLICATION	Mutations in the primer grip region of human immunodeficiency virus reverse transcriptase (HIV-RT) affect its replication fidelity. The primer grip region (residues 227-235) correctly positions the 3'-ends of primers. Point mutations were created by alanine substitution at positions 224-235, Error frequencies were measured by extension of a dG:dA primer-template mismatch. Mutants E224A, P225A, P226A, L228A, and E233A were approximately equal to the wild type in their ability to extend the mismatch. Mutants F227A, W229A, M230A, G231A, and Y232A extended 40, 66, 54, 72, and 76% less efficiently past a dG:dA mismatch compared with the wild type. We also examined the misinsertion rates of dG, dC, or dA across from a DNA template dA using RT mutants F227A and W229A Mutant W229A exhibited high fidelity and did not produce a dC:dA or dC:dA mismatch. Interestingly, mutant F227A displayed high fidelity for dG:dA and dC:dA mismatches but low fidelity for dA:dA misinsertions, This indicates that F227A discriminates against particular base substitutions. However, a primer extension assay with three dNTPs showed that F227A generally displays higher fidelity than the wild type RT. Clearly, primer grip mutations can improve or worsen either the overall or base-specific fidelity of HIV-RT, We hypothesize that wild type RT has evolved to a fidelity that allows genetic variation without compromising yield of viable viruses.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Dept Med, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Case Western Reserve Univ, Sch Med, Ctr AIDS Res, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Div Infect Dis, Cleveland, OH 44106 USA	University of Rochester; University of Rochester; University of Rochester; Case Western Reserve University; Case Western Reserve University	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.				NCI NIH HHS [CA 11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573, GM 52263] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573, R01GM052263] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; Arts EJ, 1998, J VIROL, V72, P4858, DOI 10.1128/JVI.72.6.4858-4865.1998; BAKHANASHVILI M, 1993, FEBS LETT, V319, P201, DOI 10.1016/0014-5793(93)80067-5; BAKHANASHVILI M, 1993, BIOCHEMISTRY-US, V32, P7559, DOI 10.1021/bi00080a030; Balzarini J, 1997, SCIENCE, V275, P229; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BURNS DPW, 1994, J VIROL, V68, P4196, DOI 10.1128/JVI.68.7.4196-4203.1994; COFFIN J, 1996, AIDS S, V10, P75; COFFIN JM, 1995, NATURE, V375, P534, DOI 10.1038/375534a0; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Drosopoulos WC, 1998, J VIROL, V72, P4224, DOI 10.1128/JVI.72.5.4224-4230.1998; Drosopoulos WC, 1996, J VIROL, V70, P4834, DOI 10.1128/JVI.70.7.4834-4838.1996; ECKERT KA, 1993, NUCLEIC ACIDS RES, V21, P5212, DOI 10.1093/nar/21.22.5212; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Hsu ML, 1997, NUCLEIC ACIDS RES, V25, P4532, DOI 10.1093/nar/25.22.4532; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; JACOBOMOLINA A, 1991, P NATL ACAD SCI USA, V88, P10895, DOI 10.1073/pnas.88.23.10895; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P26472; JI JP, 1994, VIROLOGY, V199, P323, DOI 10.1006/viro.1994.1130; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; Keulen W, 1997, SCIENCE, V275, P229; Kew Y, 1996, ANTIMICROB AGENTS CH, V40, P1711, DOI 10.1128/AAC.40.7.1711; Kim B, 1998, BIOCHEMISTRY-US, V37, P5831, DOI 10.1021/bi972672g; Kim B, 1996, J BIOL CHEM, V271, P4872, DOI 10.1074/jbc.271.9.4872; KOHISTAEDT LA, 1992, SCIENCE, V256, P1783; KUNKEL TA, 1987, P NATL ACAD SCI USA, V84, P4865, DOI 10.1073/pnas.84.14.4865; KUNKEL TA, 1980, J BIOL CHEM, V255, P9961; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; LOEB LA, 1979, COLD SPRING HARB SYM, V43, P921, DOI 10.1101/SQB.1979.043.01.101; Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; NAJERA I, 1994, AIDS RES HUM RETROV, V10, P1479, DOI 10.1089/aid.1994.10.1479; Palaniappan C, 1997, J BIOL CHEM, V272, P11157, DOI 10.1074/jbc.272.17.11157; Palaniappan C, 1996, J BIOL CHEM, V271, P22331, DOI 10.1074/jbc.271.37.22331; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; Preston BD, 1997, SCIENCE, V275, P228, DOI 10.1126/science.275.5297.228; PULSINELLI GA, 1994, P NATL ACAD SCI USA, V91, P9490, DOI 10.1073/pnas.91.20.9490; Rezende LF, 1998, NUCLEIC ACIDS RES, V26, P3066, DOI 10.1093/nar/26.12.3066; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; ROBERTS JD, 1986, ENVIRON MUTAGEN, V8, P769, DOI 10.1002/em.2860080511; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; THOMAS DC, 1990, BASIC LIFE SCI, V52, P289; VARELAECHAVARRIA A, 1992, J BIOL CHEM, V267, P24681; VERMA IM, 1975, J VIROL, V15, P843, DOI 10.1128/JVI.15.4.843-854.1975; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242; WILLIAMS KJ, 1992, CURR TOP MICROBIOL, V176, P165; Wohrl BM, 1997, J BIOL CHEM, V272, P17581, DOI 10.1074/jbc.272.28.17581; Wu WM, 1996, NUCLEIC ACIDS RES, V24, P1710, DOI 10.1093/nar/24.9.1710; Yin PD, 1997, J VIROL, V71, P2487, DOI 10.1128/JVI.71.3.2487-2494.1997; Yin PD, 1997, J VIROL, V71, P6237, DOI 10.1128/JVI.71.8.6237-6242.1997; YU H, 1992, J BIOL CHEM, V267, P10888; ZHANG JY, 1994, J VIROL, V68, P2409, DOI 10.1128/JVI.68.4.2409-2414.1994; ZHANG JY, 1993, SCIENCE, V259, P234, DOI 10.1126/science.8421784; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	83	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28175	28184		10.1074/jbc.274.40.28175	http://dx.doi.org/10.1074/jbc.274.40.28175			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497170	hybrid			2022-12-25	WOS:000082912700019
J	Barth, H; Olenik, C; Sehr, P; Schmidt, G; Aktories, K; Meyer, DK				Barth, H; Olenik, C; Sehr, P; Schmidt, G; Aktories, K; Meyer, DK			Neosynthesis and activation of Rho by Escherichia coli cytotoxic necrotizing factor (CNF1) reverse cytopathic effects of ADP-ribosylated Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; BOTULINUM C2 TOXIN; ACTIN STRESS FIBERS; GENE-PRODUCT; ASTROGLIAL CELLS; CDC42 GTPASES; RIBOSYLTRANSFERASE; RAC; SUBSTRATE; IDENTIFICATION	Clostridium botulinum exoenzyme C3 inactivates the small GTPase Rho by ADP-ribosylation. We used a C3 fusion toxin (C2IN-C3) with high cell accessibility to study the kinetics of Rho inactivation by ADP-ribosylation. In primary cultures of rat astroglial cells and Chinese hamster ovary cells, C2IN-C3 induced the complete ADP-ribosylation of RhoA and concomitantly the disassembly of stress fibers within 3 h. Removal of C2IN-C3 from the medium caused the recovery of stress fibers and normal cell morphology within 4 h, The regeneration was preceded by the appearance of non-ADP-ribosylated RhoA. Recovery of cell morphology was blocked by the proteasome inhibitor lactacystin and by the translation inhibitors cycloheximide and puromycin, indicating that intracellular degradation of the C3 fusion toxin and the neosynthesis of Rho were required for reversal of cell morphology, Escherichia coli cytotoxic necrotizing factor CNF1, which activates Rho by deamidation of Gln(63), caused reconstitution of stress fibers and cell morphology in C2IN-C3-treated cells within 30-60 min. The effect of CNF1 was independent of RhoA neosynthesis and occurred in the presence of completely ADP-ribosylated RhoA. The data show three novel findings; 1) the cytopathic effects of ADP-ribosylation of Rho are rapidly reversed by neosynthesis of Rho, 2) CNF1-induced deamidation activates ADP-ribosylated Rho, and 3) inhibition of Rho activation but not inhibition of Rho-effector interaction is a major mechanism underlying inhibition of cellular functions of Rho by ADP-ribosylation.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.		Barth, Holger/E-7920-2013; Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Sehr, Peter/0000-0002-4348-5066				AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHELEY S, 1984, ANAL BIOCHEM, V137, P15, DOI 10.1016/0003-2697(84)90339-7; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Goletz TJ, 1997, P NATL ACAD SCI USA, V94, P12059, DOI 10.1073/pnas.94.22.12059; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hildebrand B, 1997, BRAIN RES, V759, P285, DOI 10.1016/S0006-8993(97)00268-0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOLTKE HJ, 1990, NUCLEIC ACIDS RES, V18, P5843, DOI 10.1093/nar/18.19.5843; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KELLER M, 1985, NEUROCHEM INT, V7, P655, DOI 10.1016/0197-0186(85)90063-4; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; OHISHI I, 1980, INFECT IMMUN, V30, P668; Olenik C, 1997, MOL BRAIN RES, V52, P263, DOI 10.1016/S0169-328X(97)00270-2; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Prepens U, 1996, J BIOL CHEM, V271, P7324, DOI 10.1074/jbc.271.13.7324; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; REUNER KH, 1995, EUR J BIOCHEM, V230, P32, DOI 10.1111/j.1432-1033.1995.0032i.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TAKADA T, 1993, J BIOL CHEM, V268, P17837; WIEGERS W, 1991, EUR J CELL BIOL, V54, P237; Zeeuwen PLJM, 1997, J BIOL CHEM, V272, P20471, DOI 10.1074/jbc.272.33.20471; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	45	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27407	27414		10.1074/jbc.274.39.27407	http://dx.doi.org/10.1074/jbc.274.39.27407			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488072	hybrid			2022-12-25	WOS:000082739100011
J	Tchernitsa, OI; Zuber, J; Sers, C; Brinckmann, R; Britsch, SK; Adams, V; Schafer, R				Tchernitsa, OI; Zuber, J; Sers, C; Brinckmann, R; Britsch, SK; Adams, V; Schafer, R			Gene expression profiling of fibroblasts resistant toward oncogene-mediated transformation reveals preferential transcription of negative growth regulators	ONCOGENE			English	Article						suppression subtractive hybridization; RAS; preneoplastic phenotype; tumour suppressor genes	CARCINOMA-CELLS; RAS ONCOGENES; C-JUN; REPLICATIVE SENESCENCE; EMBRYO FIBROBLASTS; KINASE ACTIVATION; BINDING-PROTEIN; CANCER-CELLS; DIFFERENTIATION; SUPPRESSION	The signal-transducing Res proteins are important driving forces of diverse cellular processes such as proliferation, neoplastic transformation, differentiation and growth inhibition. As a step toward understanding the complex mechanisms underlying cellular responses, gene expression patterns were examined in two phenotypically normal fibroblast lines which differ in their sensitivity toward oncogene-mediated transformation. Suppression subtractive hybridization (SSH) was used to establish a subtracted cDNA library specific for the REF52 cell line which, like normal diploid fibroblasts, is refractory toward neoplastic transformation induced by mutated HRAS oncogenes, In contrast, rat 208F control cells can be efficiently transformed by HRAS. The nucleotide sequence of 549 subtracted cDNA clones ('REF52 minus 208F') was determined. We identified 93 preferentially expressed gene fragments in resistant REF52 cells as compared to 208F cells, Seventeen of the 52 known genes (32.6%) are capable of inhibiting cell proliferation or of adversely affecting oncogenic signal transduction pathways. These results suggest that the anti-oncogenic properties of resistant REF52 cells are determined by multiple negative growth regulators. The preneoplastic state expressed in 208F cells is characterized by impairment of unexpectedly redundant control mechanisms. Our results also demonstrate that SSH is a powerful method for identifying specific transcriptional patterns in closely related cell types.	Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumour Pathol, D-10117 Berlin, Germany; Univ Zurich, Inst Pathol, CH-8091 Zurich, Switzerland; Univ Leipzig, Ctr Cardiol, D-04289 Leipzig, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Zurich; Leipzig University	Schafer, R (corresponding author), Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumour Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.		Sers, Christine/B-5438-2010; Zuber, Johannes/E-7517-2011; Schäfer, Reinhold/AAB-5110-2021	Zuber, Johannes/0000-0001-8810-6835; Schafer, Reinhold/0000-0001-7952-2124				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Castle VP, 1997, LAB INVEST, V77, P51; CELANO P, 1993, CELL GROWTH DIFFER, V4, P341; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; ESINDUY CB, 1995, CARCINOGENESIS, V16, P915, DOI 10.1093/carcin/16.4.915; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FOWLIS DJ, 1993, EUR J CANCER, V29A, P638, DOI 10.1016/S0959-8049(05)80170-4; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gonos ES, 1998, EXP CELL RES, V240, P66, DOI 10.1006/excr.1998.3948; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Kato MV, 1996, ONCOGENE, V12, P1361; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lin XY, 1997, CANCER RES, V57, P2304; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masuelli L, 1996, MOL CELL BIOL, V16, P5466; MISSALE C, 1993, P NATL ACAD SCI USA, V90, P7961, DOI 10.1073/pnas.90.17.7961; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Strachan T, 1997, NAT GENET, V16, P126, DOI 10.1038/ng0697-126; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	55	20	23	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5448	5454		10.1038/sj.onc.1202987	http://dx.doi.org/10.1038/sj.onc.1202987			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498898				2022-12-25	WOS:000082718600009
J	Anderson, DG; Churchill, JJ; Kowalczykowski, SC				Anderson, DG; Churchill, JJ; Kowalczykowski, SC			A single mutation, RecB(D1080A) eliminates RecA protein loading but not chi recognition by RecBCD enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINATION HOTSPOT-CHI; HOT SPOT ACTIVITY; COLI SSB PROTEIN; ESCHERICHIA-COLI; NUCLEASE ACTIVITY; STRAND-EXCHANGE; BACTERIOPHAGE-LAMBDA; HELICASE ACTIVITY; DNA; BINDING	Homologous recombination and double-stranded DNA break repair in Escherichia coli are initiated by the multifunctional RecBCD enzyme. After binding to a double-stranded DNA end, the RecBCD enzyme unwinds and degrades the DNA processively. This processing is regulated by the recombination hot spot, Chi (chi: 5'-GCT-GGTGG-3'), which induces a switch in the polarity of DNA degradation and activates RecBCD enzyme to coordinate the Loading of the DNA strand exchange protein, RecA, onto the single-stranded DNA products of unwinding. Recently, a single mutation in RecB, Asp-1080 --> Ala, was shown to create an enzyme (RecB(D1080A)CD) that is a processive helicase but not a nuclease, Here we show that the RecB(D1080A)CD enzyme is also unable tell coordinate the loading of the RecA protein, regardless of whether chi sites are present in the DNA. However, the RecB(D1080A)CD enzyme does respond to chi sites by inactivating in a chi-dependent manner, These data define a locus of the RecBCD enzyme that is essential not only for nuclease function hut also for the coordination of RecA protein loading.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Hutchison Hall, Davis, CA 95616 USA.				NIGMS NIH HHS [GM-41347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; Bianco PR, 1997, P NATL ACAD SCI USA, V94, P6706, DOI 10.1073/pnas.94.13.6706; CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; Churchill JJ, 1999, GENE DEV, V13, P901, DOI 10.1101/gad.13.7.901; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; EGGLESTON AK, 1993, J MOL BIOL, V231, P605, DOI 10.1006/jmbi.1993.1313; EGGLESTON AK, 1997, CURR BIOL, V7, P745; EMMERSON PT, 1968, GENETICS, V60, P19; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; KONFORTI BB, 1990, J BIOL CHEM, V265, P6916; KORANGY F, 1993, BIOCHEMISTRY-US, V32, P4873, DOI 10.1021/bi00069a024; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LAM ST, 1974, GENETICS, V77, P425; LEBOWITZ JH, 1985, THESIS J HOPKINS U; MASTERSON C, 1992, J BIOL CHEM, V267, P13564; MENETSKI JP, 1988, BIOCHEMISTRY-US, V27, P1205, DOI 10.1021/bi00404a021; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; Yu M, 1998, J MOL BIOL, V283, P797, DOI 10.1006/jmbi.1998.2127; Yu M, 1998, P NATL ACAD SCI USA, V95, P981, DOI 10.1073/pnas.95.3.981	33	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27139	27144		10.1074/jbc.274.38.27139	http://dx.doi.org/10.1074/jbc.274.38.27139			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480929	hybrid, Green Published			2022-12-25	WOS:000082570700068
J	Hiasa, H; Marians, KJ				Hiasa, H; Marians, KJ			Initiation of bidirectional replication at the chromosomal origin is directed by the interaction between helicase and primase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; ESCHERICHIA-COLI CHROMOSOME; OKAZAKI FRAGMENT SIZE; DNA-REPLICATION; PBR322 DNA; FORK; POLYMERASE; COMPLEX; PROTEIN; CYCLE	Several protein-protein interactions have been shown to Be critical for proper replication fork function in Escherichia coli. These include interactions between the polymerase and the helicase, the helicase and the primase, and the primase and the polymerase. We have studied the influence of these interactions on proper initiation at oriC by using mutant primases defective in their interaction with the helicase and DNA polymerase III holoenzyme lacking the tau subunit so that it will not interact with the helicase. We show here that accurate initiation of bidirectional DNA replication from oriC is dependent on proper placement of the primers for leading strand synthesis and is thus governed primarily by the interaction between the helicase and primase.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Hiasa, H (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA.				NIGMS NIH HHS [GM34557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRD RE, 1972, J MOL BIOL, V70, P549, DOI 10.1016/0022-2836(72)90559-1; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Datta HJ, 1999, P NATL ACAD SCI USA, V96, P73, DOI 10.1073/pnas.96.1.73; EKI T, 1992, J BIOL CHEM, V267, P7284; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P2093; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; PRESCOTT DM, 1972, P NATL ACAD SCI USA, V69, P2842, DOI 10.1073/pnas.69.10.2842; Sambrook J., 2002, MOL CLONING LAB MANU; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4074; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHEL K, 1975, J BIOL CHEM, V250, P4684; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	29	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27244	27248		10.1074/jbc.274.38.27244	http://dx.doi.org/10.1074/jbc.274.38.27244			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480943	hybrid			2022-12-25	WOS:000082570700082
J	Moeslein, FM; Myers, MP; Landreth, GE				Moeslein, FM; Myers, MP; Landreth, GE			The CLK family kinases, CLK1 and CLK2, phosphorylate and activate the tyrosine phosphatase, PTP-1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHOTYROSINE PHOSPHATASE; INTRANUCLEAR DISTRIBUTION; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; SPLICING FACTORS; MAMMALIAN-CELLS; SPECIFICITY; 1B; MITOSIS	The protein-tyrosine phosphatase PTP-1B is an important regulator of intracellular protein tyrosine phosphorylation, and is itself regulated by phosphorylation. We report that PTP-1B and its yeast analog, YPTP, are phosphorylated and activated by members of the CLK family of dual specificity kinases. CLK1 and CLK2 phosphorylation of PTP-1B in vitro activated the phosphatase activity approximately 3-5-fold using either p-nitrophenol phosphate, or tyrosine-phosphorylated myelin basic protein as substrates, Co-expression of CLK1 or CLK2 with PTP-1B in HEK 293 cells led to a 2-fold stimulation of phosphatase activity in vivo. Phosphorylation of PTP-1B at Ser(50) by CLK1 or CLK2 is responsible for its enzymatic activation. These findings suggest that phosphorylation at Ser(50) by serine threonine kinases may regulate the activation of PTP-1B in vivo. We also show that CLK1 and CLK2 phosphorylate and activate the S. cerevisiae PTP-1B family member, YPTP1, CLK1 phosphorylation of YPTP1 led to a 3-fold stimulation of phosphatase activity in vitro. We demonstrate that CLK; phosphorylation of Ser(83) on YPTP1 is responsible four the activation of this enzyme. These findings demonstrate that the CLK kinases activate PTP-1B family members, and this phosphatase may be an important cellular target for CLK action.	Case Western Reserve Univ, Sch Med, Alzheimers Res Lab, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Neurol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Landreth, GE (corresponding author), Case Western Reserve Univ, Sch Med, Alzheimers Res Lab, E504,10900 Euclid Ave, Cleveland, OH 44106 USA.	gela@po.cwru.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031987] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31987] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER J, 1994, P NATL ACAD SCI USA, V91, P12105, DOI 10.1073/pnas.91.25.12105; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAUTIGAN DL, 1993, MOL CELL BIOCHEM, V128, P121; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Duncan PI, 1997, MOL CELL BIOL, V17, P5996, DOI 10.1128/MCB.17.10.5996; Duncan PI, 1998, EXP CELL RES, V241, P300, DOI 10.1006/excr.1998.4083; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; GUAN K, 1991, J BIOL CHEM, V266, P12964; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MYERS MP, 1994, MOL CELL BIOL, V14, P6954, DOI 10.1128/MCB.14.10.6954; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; Perez M, 1999, ONCOGENE, V18, P967, DOI 10.1038/sj.onc.1202368; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Sessa G, 1996, PLANT CELL, V8, P2223, DOI 10.1105/tpc.8.12.2223; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALENTINE MA, 1991, EUR J IMMUNOL, V21, P913, DOI 10.1002/eji.1830210409; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160	39	62	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26697	26704		10.1074/jbc.274.38.26697	http://dx.doi.org/10.1074/jbc.274.38.26697			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480872	hybrid			2022-12-25	WOS:000082570700011
J	Prefontaine, GG; Walther, R; Giffin, W; Lemieux, ME; Pope, L; Hache, RJG				Prefontaine, GG; Walther, R; Giffin, W; Lemieux, ME; Pope, L; Hache, RJG			Selective binding of steroid hormone receptors to octamer transcription factors determines transcriptional synergism at the mouse mammary tumor virus promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLUCOCORTICOID RECEPTOR; MMTV PROMOTER; DNA-BINDING; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; GENE ACTIVATION; THYROID-HORMONE; IN-VIVO; NONRECEPTOR FACTORS	Transcriptional synergism between glucocorticoid receptor (GR) and octamer transcription factors 1 and 2 (Oct-1 and Oct-2) in the induction of mouse mammary tumor virus (MMTV) transcription has been proposed to be mediated through directed recruitment of the octamer factors to their binding sites in the viral long terminal repeat. This recruitment correlates with direct binding between the GR DNA binding domain and the POU domain of the octamer factors. In present study, in vitro experiments identified several nuclear hormone receptors to have the potential to bind to the POU domains of Oct-1 and Oct-2 through their DNA binding domains, suggesting that POU domain binding may be a property shared by many nuclear hormone receptors, However, physiologically relevant binding to the POU domain appeared to be a property restricted to only a few nuclear receptors as only GR, progesterone receptor (PR), and androgen receptor (AR), were found to imteract physically and functionally with Oct-1 and Oct-2 in transfected cells. Thus GR, PR, and AR efficiently promoted the recruitment of Oct-2 to adjacent octamer motifs in the cell, whereas mineralocorticoid receptor (MR), estrogen receptor alpha, and retinoid X receptor failed to facilitate octamer factor DNA binding. For MMTV, although GR and MR both induced transcription efficiently, mutation of the promoter proximal octamer motifs strongly decreased OR-induced transcription without affecting the total level of reporter gene activity in response to MR, These results suggest that the configuration of the hormone response element within the MMTV long terminal repeat may promote a dependence for the glucocorticoid response upon the recruitment of octamer transcription factors to their response elements within the viral promoter.	Univ Ottawa, Ottawa Civ Hosp, Loeb Inst Med Res, Grad Program Biochem, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Ottawa Civ Hosp, Loeb Inst Med Res, Dept Med, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Ottawa Civ Hosp, Loeb Inst Med Res, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Hache, RJG (corresponding author), Univ Ottawa, Ottawa Civ Hosp, Loeb Inst Med Res, Grad Program Biochem, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.			Lemieux, Madeleine/0000-0001-6355-8691				ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUETTI E, 1994, MOL CELL BIOL, V14, P1191, DOI 10.1128/MCB.14.2.1191; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1988, J CELL BIOL, V106, P2119, DOI 10.1083/jcb.106.6.2119; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DEGROOT RP, 1994, ONCOGENE, V9, P463; FINKEL T, 1993, J BIOL CHEM, V268, P5; Funder JW, 1997, ANNU REV MED, V48, P231, DOI 10.1146/annurev.med.48.1.231; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; LOOSFELT H, 1986, P NATL ACAD SCI USA, V83, P9045, DOI 10.1073/pnas.83.23.9045; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MYMRYK JS, 1994, NUCLEIC ACIDS RES, V22, P4344, DOI 10.1093/nar/22.20.4344; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; RUNDLETT SE, 1995, MOL CELL ENDOCRINOL, V109, P1, DOI 10.1016/0303-7207(95)03477-O; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	56	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26713	26719		10.1074/jbc.274.38.26713	http://dx.doi.org/10.1074/jbc.274.38.26713			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480874	hybrid			2022-12-25	WOS:000082570700013
J	Kelley, TW; Graham, MM; Doseff, AI; Pomerantz, RW; Lau, SM; Ostrowski, MC; Franke, TF; Marsh, CB				Kelley, TW; Graham, MM; Doseff, AI; Pomerantz, RW; Lau, SM; Ostrowski, MC; Franke, TF; Marsh, CB			Macrophage colony-stimulating factor promotes cell survival through Akt/protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR C-FMS; GROWTH-FACTOR; FACTOR-I; HUMAN CSF-1; PHOSPHATIDYLINOSITOL 3-KINASE; AKT PROTOONCOGENE; DEATH APOPTOSIS; POINT MUTATION; OP/OP MOUSE; ACTIVATION	The signaling pathways activated by the macrophage colony-stimulating factor (M-CSF) to promote survival of monocyte and macrophage lineage cells are not well established. In an effort to elucidate these pathways, we have used two cell types responsive to M-CSF: NIH 3T3 fibroblasts genetically engineered to express human M-CSF receptors (3T3-FMS cells) and human monocytes, M-CSF treatment induced M-CSF receptor tyrosine phosphorylation and recruitment of the p85 subunit of phosphatidylinositol 3-kinase (PI3K) to these receptors, These M-CSF receptor events correlated with activation of the serine/threonine kinase Akt. To clarify that PI3K products activate Akt in response to M-CSF, NIH 3T3 fibroblasts expressing mutant human M-CSF receptors (3T3-FMS(Y809F)) that fail to activate Ras in response to M-CSF also exhibit increased Akt kinase activity in response to M-CSF challenge. Furthermore, Akt appears to be the primary regulator of survival in 3T3-FMS cells, as transfection of genes encoding dominant-negative Akt isoforms into these fibroblasts blocked M-CSF-induced survival. In normal human monocytes, M-CSF increased the levels of tyrosine-phosphorylated proteins and induced Akt activation in a PI3K-dependent manner. The PI3K inhibitor LY294002 blocked M-CSF-mediated monocyte survival, an effect that was partially restored by caspase-9 inhibitors. These data suggest that M-CSF may induce cell survival through Akt-induced suppression of caspase-9 activation.	Ohio State Univ, Med Ctr, Div Pulm & Crit Care Med, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Heart & Lung Inst, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Columbia University	Marsh, CB (corresponding author), Ohio State Univ, Med Ctr, Div Pulm & Crit Care Med, Dept Internal Med, N-325 Means Hall,1654 Upham Dr, Columbus, OH 43210 USA.	marsh.2@osu.edu	Doseff, Andrea/E-2991-2011; Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI040150] Funding Source: NIH RePORTER; NCRR NIH HHS [3MO1RR-00034] Funding Source: Medline; NIAID NIH HHS [P01AI-40150] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CLINE MJ, 1978, ANN INTERN MED, V88, P78, DOI 10.7326/0003-4819-88-1-78; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; FAHY RJ, 1999, IN PRESS J IMMUNOL; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; HEIDIN CH, 1995, CELL, V80, P213; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; MANGAN DF, 1991, J IMMUNOL, V147, P3408; MANGAN DF, 1991, J IMMUNOL, V146, P1541; Marsh CB, 1999, J IMMUNOL, V162, P6217; Nowicki A, 1996, INT J CANCER, V65, P112, DOI 10.1002/(SICI)1097-0215(19960103)65:1<112::AID-IJC19>3.3.CO;2-R; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; PRALORAN V, 1991, NOUV REV FR HEMATOL, V33, P323; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1994, J CELL SCI, P105; Shi CW, 1996, P NATL ACAD SCI USA, V93, P4051, DOI 10.1073/pnas.93.9.4051; SIMM A, 1994, J CELL PHYSIOL, V160, P295, DOI 10.1002/jcp.1041600211; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Testa JR, 1997, LEUKEMIA RES, V21, P1027, DOI 10.1016/S0145-2126(97)00093-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; WIKTORJEDRZEJCZAK W, 1991, EXP HEMATOL, V19, P1049; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	48	135	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26393	26398		10.1074/jbc.274.37.26393	http://dx.doi.org/10.1074/jbc.274.37.26393			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473597	hybrid			2022-12-25	WOS:000082469700063
J	Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Smulson, ME				Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Smulson, ME			Poly(ADP-ribose) polymerase upregulates E2F-1 promoter activity and DNA pol alpha expression during early S phase	ONCOGENE			English	Article						PARP; E2F-1; DNA polymerase alpha; DNA replication; promoter activity; gene expression	ANTISENSE RNA EXPRESSION; TRANSCRIPTION FACTOR; CELL-CYCLE; GROWTH-REGULATION; PRIMASE COMPLEX; IN-VITRO; GENE; PROTEIN; REPLICATION; DIFFERENTIATION	E2F-1, a transcription factor implicated in the activation of genes required for S phase such as DNA pol alpha, is regulated by interactions with Rb and by cell-cycle dependent alterations in E2F-1 abundance. We have shown that depletion of poly(ADP-ribose) polymerase (PARP) by antisense RNA expression downregulates pol alpha and E2F-1 expression during early S phase. To examine the role of PARP in the regulation of pol alpha and E2F-1 gene expression, we utilized immortalized mouse fibroblasts derived from wild-type and PARP knockout (PARP-/-) mice as well as PARP-/- cells stably transfected with PARR cDNA [PARP-/-(+PARP)]. After release from serum deprivation, mild-type and PARP-/-(+PARP) cells, but not PARP-/- cells, exhibited a peak of cells in S phase by 16 h and had progressed through the cell cycle by 22 h, Whereas [H-3]thymidine incorporation remained negligible in PARP-/- cells, in vivo DNA replication maximized after 18 h in mild-type and PARP-/-(+PARP) cells, To investigate the effect of PARP on E2F-1 promoter activity, a construct containing the E2F-1 gene promoter fused to a luciferase reporter gene was transiently transfected into these cells, E2F-1 promoter activity in control and PARP-/-(+PARP) cells increased eightfold after 9 h, but not in PARP-/- cells. PARP-/- cells did not show the marked induction of E2F-1 expression during early S phase apparent in control and PARP-/-(+PARP) cells. RT-PCR analysis and pol alpha activity assays revealed the presence of pol alpha transcripts and a sixfold increase in activity in both wildtype and PARP-/- (+PARP) cells after 20 h, but not in PARP-/- cells. These results suggest that PARP plays a role in the induction of E2F-1 promoter activity, which then positively regulates both E2F-1 and pol alpha expression, when quiescent cells reenter the cell cycle upon recovery from aphidicolin exposure or removal of serum.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Smulson, ME (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Basic Sci Bldg,Room 351,3900 Reservoir Rd NW, Washington, DC 20007 USA.		Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014	Rosenthal, Dean/0000-0002-7624-0209	NCI NIH HHS [P01 CA74175, CA25344] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BASERGA R, 1991, J CELL SCI, V98, P433; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Butler AJ, 1999, MOL CELL BIOL, V19, P296; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; ROSENTHAL DS, 1995, J INVEST DERMATOL, V105, P38, DOI 10.1111/1523-1747.ep12312525; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; SIMBULAN CMG, 1993, J BIOL CHEM, V268, P93; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMULSON ME, 1995, J BIOL CHEM, V270, P119, DOI 10.1074/jbc.270.1.119; SUKHORUKOV VL, 1994, J MEMBRANE BIOL, V142, P77; Tom TD, 1996, J CELL BIOCHEM, V63, P259, DOI 10.1002/(SICI)1097-4644(19961201)63:3<259::AID-JCB1>3.0.CO;2-W; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WONG SW, 1986, J BIOL CHEM, V261, P7958	35	35	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5015	5023		10.1038/sj.onc.1202900	http://dx.doi.org/10.1038/sj.onc.1202900			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490838				2022-12-25	WOS:000082497100001
J	Ariza, ME; Broome-Powell, M; Lahti, JM; Kidd, VJ; Nelson, MA				Ariza, ME; Broome-Powell, M; Lahti, JM; Kidd, VJ; Nelson, MA			Fas-induced apoptosis in human malignant melanoma cell lines is associated with the activation of the p34(cdc2)-related PITSLRE protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CD95 APO-1/FAS SYSTEM; MEDIATED APOPTOSIS; MOLECULAR-CLONING; EXPRESSION; DEATH; INDUCTION; NEUROBLASTOMA; PROTEASES; CARCINOMA	The Cdc2L locus encoding the PITSLRE protein kinases maps to chromosome band 1p36 and consists of two duplicated and tandemly linked genes, The purpose of the present study was to determine whether diminution of PITSLRE kinases leads to deregulation of apoptosis. The human melanoma cell lines A375 (Cdc2L wild-type alleles) and UACC 1227 (mutant Cdc2L alleles) were tested with agonist anti-Fas monoclonal antibody. We found that exposure of these cells to anti-Fas for 24, 48, or 72 h resulted in differential sensitivity to Fas-induced apoptosis, In A375, cell death started at 24-48 h post-treatment, and it was maximal by 72 h. Conversely, UACC 1227 cells were resistant to Fas-mediated apoptosis. Induction of PITSLRE histone H1 kinase activity was observed in A375 anti-Fas treated but not in UACC 1227 cells. Also, the PITSLRE protein kinase activity in A375 anti-Fas-treated cells preceded maximal levels of apoptosis. Finally, fluorescence confocal microscopy revealed a nuclear localization of PITSLRE proteins in normal melanocytes and A375 cells but a cytoplasmic localization in UACC 1227 cells. The differences in PITSLRE protein and cellular localization between A375 and UACC 1227 cells appear to account for the differences in sensitivity of the two cells lines to anti-Fas and staurosporine. These observations suggest that alterations in PITSLRE gene expression and protein localization may result in the loss of apoptotic signaling.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Dept Pathol, Tucson, AZ 85724 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; St Jude Children's Research Hospital	Nelson, MA (corresponding author), Univ Arizona, Arizona Canc Ctr, Rm 3963 B,1515 N Campbell Ave, Tucson, AZ 85724 USA.	mnelson@azcc.arizona.edu			NCI NIH HHS [R29-CA 70145-01] Funding Source: Medline; NIEHS NIH HHS [P30ES06694] Funding Source: Medline; NIGMS NIH HHS [GM44088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA070145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Debatin KM, 1996, CELL DEATH DIFFER, V3, P185; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; Fiers W, 1996, J INFLAMM, V47, P67; Fulda S, 1997, CANCER RES, V57, P3823; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Keane MM, 1996, CANCER RES, V56, P4791; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KIDD VJ, 1991, CELL GROWTH DIFFER, V2, P85; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Loyer P, 1998, J CELL SCI, V111, P1495; MACIEJEWSKI J, 1995, BLOOD, V85, P3183, DOI 10.1182/blood.V85.11.3183.bloodjournal85113183; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nelson MA, 1999, CANCER GENET CYTOGEN, V108, P91, DOI 10.1016/S0165-4608(98)00122-8; OEHM A, 1992, J BIOL CHEM, V267, P10709; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; POWELL MB, 1995, MOL CARCINOGEN, V12, P82, DOI 10.1002/mc.2940120205; Rokhlin OW, 1997, CANCER RES, V57, P1758; SchulzeOsthoff K, 1996, CELL DEATH DIFFER, V3, P177; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SOZZI G, 1988, CANCER GENET CYTOGEN, V30, P151, DOI 10.1016/0165-4608(88)90104-5; Tang H, 1999, J BIOL CHEM, V274, P12401, DOI 10.1074/jbc.274.18.12401; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; XIANG JL, 1994, J BIOL CHEM, V269, P15786	38	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28505	28513		10.1074/jbc.274.40.28505	http://dx.doi.org/10.1074/jbc.274.40.28505			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497214	hybrid			2022-12-25	WOS:000082912700063
J	Bertoni, C; Li, YT; Li, SC				Bertoni, C; Li, YT; Li, SC			Catabolism of asialo-GM2 in man and mouse - Specificity of human/mouse chimeric GM2 activator proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HEXOSAMINIDASE-A; TAY-SACHS-DISEASE; SANDHOFF DISEASES; VARIANT FORM; GANGLIOSIDE; GENE; G(M2); SUBSTITUTION; EXPRESSION; DISRUPTION	Tay-Sachs disease is an inborn lysosomal disease characterized by excessive cerebral accumulation of GM2. The catabolism of GM2 to GM3 in man requires beta-hexosaminidase A (HexA) and a protein cofactor, the GM2 activator. Thus, Tay-Sachs disease can be caused by the deficiency of either HexA or the GM2 activator. The same cofactor found in mouse shares 74.1% amino acid identity (67% nucleotide identity) with the human counterpart. Between the two activators, the mouse GM2 activator can effectively stimulate the hydrolysis of both GM2 and asialo-GM2 (GA2) by HexA and, to a lesser extent, also stimulate HexB to hydrolyze GA2, whereas the human activator is ineffective in stimulating the hydrolysis of GA2 (Yuziuk, J. A., Bertoni, C., Beccari, T., Orlacchio, A., Wu, Y.-Y., Li, S.-C., and Li, Y.-T. (1998) J, Biol, Chem. 273, 66-72), To understand the role of these two activators in stimulating the hydrolyses of GM2 and GA2, we have constructed human/mouse chimeric GM2 activators and studied their specificities. We have identified a narrow region (Asn(106)-Tyr(114)) in the mouse cDNA sequence that might be responsible for stimulating the hydrolysis of GA2, Replacement of the corresponding site in the human sequence with the specific mouse sequence converted the ineffective human activator into an effective chimeric protein for stimulating the hydrolysis of GA2, This chimeric activator protein, like the mouse protein, is also able to stimulate the hydrolysis of GA2 by HexB, The mouse model of human type B Tay-Sachs disease recently engineered by the targeted disruption of the Hexa gene showed less severe clinical manifestation than found in human patients. This has been considered to be the result of the catabolism of GM2 via converting it to GA2 and further hydrolysis of GA2 to lactosylceramide by HexB with the assistance of mouse GM2 activator protein. The chimeric activator protein that bears the characteristics of the mouse GM2 activator may therefore be able to induce an alternative catabolic pathway for GM2 in human type B Tay-Sachs patients.	Tulane Univ, Sch Med, Dept Biochem SL 43, New Orleans, LA 70112 USA	Tulane University	Li, YT (corresponding author), Tulane Univ, Sch Med, Dept Biochem SL 43, 1430 Tulane Ave, New Orleans, LA 70112 USA.		Bertoni, Carmen/N-8901-2015		NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bertoni C, 1997, MAMM GENOME, V8, P90, DOI 10.1007/s003359900364; BURG J, 1983, H-S Z PHYSIOL CHEM, V364, P821, DOI 10.1515/bchm2.1983.364.2.821; COHENTANNOUDJI M, 1995, MAMM GENOME, V6, P844, DOI 10.1007/BF00292433; FURST W, 1990, EUR J BIOCHEM, V192, P709, DOI 10.1111/j.1432-1033.1990.tb19280.x; GRAVEL RA, 1995, METABOLIC MOL BASES, P2839; HARRIS G, 1954, CHEM IND-LONDON, P249; KLIMA H, 1991, FEBS LETT, V289, P260, DOI 10.1016/0014-5793(91)81084-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SC, 1981, J BIOL CHEM, V256, P6234; LI YT, 1973, J BIOL CHEM, V248, P7512; LI YT, 1984, LYSOSOM BIOL PATHOL, V7, P99; Phaneuf D, 1996, HUM MOL GENET, V5, P1, DOI 10.1093/hmg/5.1.1; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Sango K, 1996, NAT GENET, V14, P348, DOI 10.1038/ng1196-348; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; SCHRODER M, 1991, FEBS LETT, V290, P1, DOI 10.1016/0014-5793(91)81211-P; Schutte CG, 1998, PROTEIN SCI, V7, P1039; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; SVENNERHOLM L, 1972, METHODS CARBOHYD CHE, V6, P464; WU YY, 1994, J BIOL CHEM, V269, P16276; Xie B, 1998, BIOCHEMISTRY-US, V37, P814, DOI 10.1021/bi971211s; XIE B, 1992, AM J HUM GENET, V50, P1046; YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975; Yuziuk JA, 1998, J BIOL CHEM, V273, P66, DOI 10.1074/jbc.273.1.66	24	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28612	28618		10.1074/jbc.274.40.28612	http://dx.doi.org/10.1074/jbc.274.40.28612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497228	hybrid			2022-12-25	WOS:000082912700077
J	Razzaq, A; Schmitz, S; Veigel, C; Molloy, JE; Geeves, MA; Sparrow, JC				Razzaq, A; Schmitz, S; Veigel, C; Molloy, JE; Geeves, MA; Sparrow, JC			Actin residue Glu(93) is identified as an amino acid affecting myosin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIRECT FLIGHT-MUSCLE; DROSOPHILA-MELANOGASTER; MUTATIONAL ANALYSIS; ACTOMYOSIN INTERACTIONS; MYOFIBRILLAR PROTEINS; ACT88F GENE; WILD-TYPE; SUBFRAGMENT-1; FILAMENTS; TERMINUS	Many mutants have been described that affect the function of the actin encoded by the Drosophila melanogaster indirect flight muscle-specific actin gene, Act88F. We describe the development of procedures for purification of this actin from the other isoforms expressed in the fly as well as in vitro motility, single molecule force/displacement measurements, and stop-flow solution kinetic studies of the wild-type actin and that of the E93K mutation of the Act88F gene. We show that this mutation affects in vitro motility of F-actin, in both the presence and absence of methylcellulose, and the ability of the ACT88F actin to bind the S1 fragment of rabbit skeletal myosin, However, optical tweezer measurements of the actomyosin working stroke and the force transmitted from the rabbit heavy meromyosin to and through F-actin are unchanged by the mutation. These results support the proposal (Holmes, K. C, (1995) Biophys J. 68, (suppl,) 2-7) that actin residue Glu(93) is part of the secondary myosin binding site and suggest that myosin binding occurs first at the primary myosin binding site and then at the secondary site.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Max Planck Inst Mol Physiol, D-44139 Dortmund, Germany	University of York - UK; Max Planck Society	Sparrow, JC (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5YW, N Yorkshire, England.		Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898; Molloy, Justin/0000-0002-8307-2450				An HS, 1996, J MOL BIOL, V260, P492, DOI 10.1006/jmbi.1996.0417; ANSON M, 1995, BIOPHYS J, V68, P1991, DOI 10.1016/S0006-3495(95)80376-0; Ashman K, 1997, LETT PEPT SCI, V4, P57, DOI 10.1007/BF02443516; BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; Bing W, 1998, J BIOL CHEM, V273, P15016, DOI 10.1074/jbc.273.24.15016; BULLARD B, 1973, BIOCHEM J, V135, P277, DOI 10.1042/bj1350277; BULLARD B, 1985, J MOL BIOL, V182, P443, DOI 10.1016/0022-2836(85)90203-7; Clayton JD, 1998, J MUSCLE RES CELL M, V19, P117, DOI 10.1023/A:1005304527563; COOK RK, 1993, J BIOL CHEM, V268, P2410; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; CRIPPS RM, 1994, GENETICS, V137, P151; CRIPPS RM, 1992, BIOCH GENET, V30, P156; DRUMMOND DR, 1991, MOL GEN GENET, V226, P70, DOI 10.1007/BF00273589; DRUMMOND DR, 1990, NATURE, V348, P440, DOI 10.1038/348440a0; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FYRBERG EA, 1983, CELL, V33, P115, DOI 10.1016/0092-8674(83)90340-9; FYRBERG EA, 1980, CELL, V19, P365, DOI 10.1016/0092-8674(80)90511-5; Geeves M. A., 1995, Biophysical Journal, V68, P194; HENNESSEY ES, 1991, EUR J BIOCHEM, V197, P345, DOI 10.1111/j.1432-1033.1991.tb15917.x; HIROMI Y, 1985, EMBO J, V4, P1681, DOI 10.1002/j.1460-2075.1985.tb03837.x; HOLMES KC, 1995, BIOPHYS J S, V68, P2; HOMSHER E, 1992, AM J PHYSIOL, V262, P714; JOHARA M, 1993, P NATL ACAD SCI USA, V90, P2127, DOI 10.1073/pnas.90.6.2127; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; LANG AB, 1981, NATURE, V291, P506, DOI 10.1038/291506a0; MAHAFFEY JW, 1985, CELL, V40, P101, DOI 10.1016/0092-8674(85)90313-7; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P3670, DOI 10.1021/bi952645v; MILLER CJ, 1995, BIOCHEMISTRY-US, V34, P2694, DOI 10.1021/bi00008a037; Miller CJ, 1996, BIOCHEMISTRY-US, V35, P16557, DOI 10.1021/bi962388+; MOGAMI K, 1981, MOL GEN GENET, V183, P409, DOI 10.1007/BF00268758; MOLLET TS, 1994, MACH DES, V66, P74; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; PECKHAM M, 1990, J MUSCLE RES CELL M, V11, P203, DOI 10.1007/BF01843574; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RUBENSTEIN PA, 1990, BIOESSAYS, V12, P309, DOI 10.1002/bies.950120702; SAIDE JD, 1989, J CELL BIOL, V109, P2157, DOI 10.1083/jcb.109.5.2157; SAKAI Y, 1990, J BIOCHEM-TOKYO, V107, P499, DOI 10.1093/oxfordjournals.jbchem.a123074; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; Sheterline P, 1996, ACTINS; SPARROW J, 1991, J MOL BIOL, V222, P963, DOI 10.1016/0022-2836(91)90588-W; TOBIN SL, 1980, CELL, V19, P121, DOI 10.1016/0092-8674(80)90393-1; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Veigel C, 1998, BIOPHYS J, V75, P1424, DOI 10.1016/S0006-3495(98)74061-5; WERTMAN KF, 1992, GENETICS, V132, P337	53	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28321	28328		10.1074/jbc.274.40.28321	http://dx.doi.org/10.1074/jbc.274.40.28321			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497190	hybrid			2022-12-25	WOS:000082912700039
J	Brady, MJ; Kartha, PM; Aysola, AA; Saltiel, AR				Brady, MJ; Kartha, PM; Aysola, AA; Saltiel, AR			The role of glucose metabolites in the activation and translocation of glycogen synthase by insulin in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; RABBIT SKELETAL-MUSCLE; EPIDIDYMAL FAT-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; RAT HEPATOCYTES; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAYS; POTENTIAL ROLE; GROWTH-FACTOR	The role of increased glucose transport in the hormonal regulation of glycogen synthase by insulin was investigated in 3T3-L1 adipocytes. Insulin treatment stimulated glycogen synthase activity 4-5-fold in these cells. Cytosolic glycogen synthase levels decreased by 75% in response to insulin, whereas, conversely, the glycogenolytic agent isoproterenol increased cytosolic enzyme levels by 200%. Removal of extracellular glucose reduced glycogen synthase activation by 40% and completely blocked enzymatic translocation, Addition of 5 mM 2-deoxyglucose did not restore glycogen synthase translocation but did augment dephosphorylation of the protein by insulin. The translocation event could be reconstituted in vitro only by the addition of UDP-glucose to basal cell lysates. Amylase pretreatment of the extracts suppressed glycogen synthase translocation, indicating that the enzyme was binding to glycogen. Incubation of 3T3-L1 adipocytes with 10 mM glucosamine induced a state of insulin resistance, blocked the translocation of glycogen synthase, and inhibited insulin-stimulated glycogen synthesis by 50%. Surprisingly, glycogen synthase activation by insulin was enhanced 4-fold, in part due to allosteric activation by a glucosamine metabolite. In vitro, glucosamine 6-phosphate and glucose 6-phosphate stimulated glycogen synthase activity with similar concentration curves. These results indicate that glucose metabolites have an impact on the regulation of glycogen synthase activation and localization by insulin.	Warner Lambert Co, Parke Davis Pharmaceut Res Div, Dept Cell Biol, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan	Saltiel, AR (corresponding author), Warner Lambert Co, Parke Davis Pharmaceut Res Div, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; Cadefau J, 1997, BIOCHEM J, V322, P745, DOI 10.1042/bj3220745; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROOK ED, 1995, DIABETES, V44, P314, DOI 10.2337/diabetes.44.3.314; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V281, P443, DOI 10.1042/bj2810443; FernandezNovell JM, 1997, BIOCHEM J, V321, P227, DOI 10.1042/bj3210227; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; FERNANDEZNOVELL JM, 1994, EUR J BIOCHEM, V226, P665, DOI 10.1111/j.1432-1033.1994.tb20094.x; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Halse R, 1999, J BIOL CHEM, V274, P776, DOI 10.1074/jbc.274.2.776; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; KATO K, 1972, J BIOL CHEM, V247, P7420; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAWRENCE JC, 1984, J BIOL CHEM, V259, P7975; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Mastick CC, 1998, MOL CELL BIOCHEM, V182, P65; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OKADA T, 1994, J BIOL CHEM, V269, P3568; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Shulman RG, 1996, P NATL ACAD SCI USA, V93, P7491, DOI 10.1073/pnas.93.15.7491; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; VILLARPALASI C, 1995, BBA-GEN SUBJECTS, V1244, P203, DOI 10.1016/0304-4165(95)00006-W; Virkamaki A, 1999, DIABETES, V48, P1101, DOI 10.2337/diabetes.48.5.1101; Yki-Jarvinen H, 1998, METABOLISM, V47, P449, DOI 10.1016/S0026-0495(98)90058-0	48	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27497	27504		10.1074/jbc.274.39.27497	http://dx.doi.org/10.1074/jbc.274.39.27497			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488084	hybrid			2022-12-25	WOS:000082739100023
J	Kodama, S; Ikeda, S; Asahara, T; Kishida, M; Kikuchi, A				Kodama, S; Ikeda, S; Asahara, T; Kishida, M; Kikuchi, A			Axin directly interacts with plakoglobin and regulates its stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ADENOMATOUS POLYPOSIS-COLI; TRANSCRIPTION FACTOR LEF-1; WNT SIGNALING PATHWAY; BETA-CATENIN; XENOPUS EMBRYOS; CELL-ADHESION; E-CADHERIN; DESMOSOMAL CADHERINS; N-CADHERIN	Plakoglobin is homologous to beta-catenin. Axin, a Wnt signal negative regulator, enhances glycogen synthase kinase (GSK)-3 beta-dependent phosphorylation of beta-catenin and stimulates the degradation of beta-catenin. Therefore, we examined the effect of Axin on plakoglobin stability. Axin formed a complex with plakoglobin in COS cells and SW480 cells. Axin directly bound to plakoglobin, and this binding was inhibited by beta-catenin. Axin promoted GSK-3 beta-dependent phosphorylation of plakoglobin. Furthermore, overexpression of Axin down-regulated the level of plakoglobin in SW480 cells. These results suggest that Axin regulates the stability of plakoglobin by enhancing its phosphorylation by GSK-3 beta and that Axin may act on beta-catenin and plakoglobin in similar manners.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Sch Med, Dept Surg 2, Minami Ku, Hiroshima 7348551, Japan	Hiroshima University; Hiroshima University	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ABERLE H, 1994, J CELL SCI, V107, P3655; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bierkamp C, 1996, DEV BIOL, V180, P780, DOI 10.1006/dbio.1996.0346; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; Dale TC, 1998, BIOCHEM J, V329, P209; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Larue L, 1996, DEVELOPMENT, V122, P3185; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Merriam JM, 1997, DEV BIOL, V185, P67, DOI 10.1006/dbio.1997.8550; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PASDAR M, 1995, CELL MOTIL CYTOSKEL, V32, P258, DOI 10.1002/cm.970320403; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1991, DEVELOPMENT, V111, P1029; Rubenstein A, 1997, DEV GENET, V20, P91, DOI 10.1002/(SICI)1520-6408(1997)20:2<91::AID-DVG2>3.0.CO;2-3; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TANIHARA H, 1994, J CELL SCI, V107, P1697; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TROYANOVSKY SM, 1994, J CELL BIOL, V127, P151, DOI 10.1083/jcb.127.1.151; TROYANOVSKY SM, 1994, P NATL ACAD SCI USA, V91, P10790, DOI 10.1073/pnas.91.23.10790; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wahl JK, 1996, J CELL SCI, V109, P1143; White P, 1998, J CELL BIOL, V140, P183, DOI 10.1083/jcb.140.1.183; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	67	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27682	27688		10.1074/jbc.274.39.27682	http://dx.doi.org/10.1074/jbc.274.39.27682			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488109	hybrid			2022-12-25	WOS:000082739100048
J	Nisole, S; Krust, B; Callebaut, C; Guichard, G; Muller, S; Briand, JP; Hovanessian, AG				Nisole, S; Krust, B; Callebaut, C; Guichard, G; Muller, S; Briand, JP; Hovanessian, AG			The anti-HIV pseudopeptide HE-19 forms a complex with the cell-surface-expressed nucleolin independent of heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST GROWTH-FACTOR; ENVELOPE GLYCOPROTEINS; MONOCLONAL-ANTIBODIES; CHEMOKINE RECEPTORS; TYPE-1 INFECTION; AMINO-ACIDS; V3 LOOP; BINDING; ENTRY	The HB-19 pseudopeptide 5[K psi(CH2N)PR]-TASP, psi(CH2N) for reduced peptide bond, is a specific inhibitor of human immunodeficiency virus (HIV) infection in different CD4(+) cell lines and in primary T-lymphocytes and macrophages. Here, by using an experimental CD4(+) cell model to monitor HIV entry and infection, we demonstrate that HB-19 binds the cell surface and inhibits attachment of HIV particles to permissive cells. At concentrations that inhibit HIV attachment, HB-19 binds cells irreversibly, becomes complexed with the cell-surface-expressed nucleolin, and eventually results in its degradation, Accordingly, by confocal immunofluorescence microscopy, we demonstrate the drastic reduction of the cell-surface-expressed nucleolin following treatment of cells with HB-19, HIV particles can prevent the binding of HB-19 to cells and inhibit complex formation with nucleolin, Such a competition between viral particles and HB-19 is consistent with the implication of nucleolin in the process of HIV attachment to target cells. We show that another inhibitor of HIV infection, the fibroblast growth factor-2 (FGF-2) that uses cell-surface-expressed heparan sulfate proteoglycans as low affinity receptors, binds cells and blocks attachment of HN to permissive cells, FG;F-S does not prevent the binding of HB-19 to cells and to nucleolin, and similarly HB-19 has no apparent effect on the binding of FGF-2 to the cell surface. The lack of competition between these two anti-HIV agents rules out the potential involvement of heparan sulfate proteoglycans in the mechanism of anti-HIV effect of HB-19, thus pointing out that nucleolin is its main target.	Inst Pasteur, Unite Virol & Immunol Cellulaire, CNRS, URA 1930, F-75724 Paris 15, France; Inst Biol Mol & Cellulaire, CNRS, UPR 9021, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hovanessian, AG (corresponding author), Inst Pasteur, Unite Virol & Immunol Cellulaire, CNRS, URA 1930, 28 Rue Dr Roux, F-75724 Paris 15, France.	arahovan@pasteur.fr	Nisole, Sébastien/ABA-2367-2021; Muller, Sylviane/J-5319-2014; GUICHARD, Gilles/I-3858-2016	Nisole, Sébastien/0000-0001-9793-419X; GUICHARD, Gilles/0000-0002-2584-7502				BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUR S, 1995, MICROBIOL REV, V59, P63, DOI 10.1128/MMBR.59.1.63-93.1995; Brynes AP, 1998, J VIROL, V72, P7349, DOI 10.1128/JVI.72.9.7349-7356.1998; Callebaut C, 1996, VIROLOGY, V218, P181, DOI 10.1006/viro.1996.0178; Callebaut C, 1998, J BIOL CHEM, V273, P21988, DOI 10.1074/jbc.273.34.21988; Callebaut C, 1997, J BIOL CHEM, V272, P7159, DOI 10.1074/jbc.272.11.7159; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Chung CS, 1998, J VIROL, V72, P1577, DOI 10.1128/JVI.72.2.1577-1585.1998; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Coutts JC, 1995, IMMUNOL CELL BIOL, V73, P584, DOI 10.1038/icb.1995.92; Deng JS, 1996, MOL BIOL REP, V23, P191, DOI 10.1007/BF00351168; DEVERDUGO UR, 1995, J VIROL, V69, P6751, DOI 10.1128/JVI.69.11.6751-6757.1995; DeVreese K, 1996, ANTIVIR RES, V29, P209, DOI 10.1016/0166-3542(95)00837-3; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; Gallagher JT, 1997, BIOCHEM SOC T, V25, P1206, DOI 10.1042/bst0251206; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001; Ghorpade A, 1998, J VIROL, V72, P3351, DOI 10.1128/JVI.72.4.3351-3361.1998; Husman AMD, 1998, TRENDS MICROBIOL, V6, P244, DOI 10.1016/S0966-842X(98)01249-9; JAVAHERIAN K, 1995, AIDS RES HUM RETROV, V11, P1163, DOI 10.1089/aid.1995.11.1163; KANER RJ, 1990, SCIENCE, V248, P1410, DOI 10.1126/science.2162560; KRUST B, 1993, AIDS RES HUM RETROV, V9, P1087, DOI 10.1089/aid.1993.9.1087; Laquerre S, 1998, J VIROL, V72, P6119, DOI 10.1128/JVI.72.7.6119-6130.1998; Larrucea S, 1998, J BIOL CHEM, V273, P31718, DOI 10.1074/jbc.273.48.31718; Leydet A, 1996, J MED CHEM, V39, P1626, DOI 10.1021/jm950358j; Limal D, 1998, J PEPT RES, V52, P121; MIRDA DP, 1992, J VIROL, V66, P448, DOI 10.1128/JVI.66.1.448-457.1992; Mondor I, 1998, J VIROL, V72, P3623, DOI 10.1128/JVI.72.5.3623-3634.1998; MONESTIER M, 1993, MOL IMMUNOL, V30, P1069, DOI 10.1016/0161-5890(93)90153-3; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; Myers G, 1994, HUMAN RETROVIRUSES A; Nyambi PN, 1998, J VIROL, V72, P9384, DOI 10.1128/JVI.72.11.9384-9391.1998; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Oravecz T, 1996, J IMMUNOL, V157, P1329; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; Seddiki N, 1999, AIDS RES HUM RETROV, V15, P381, DOI 10.1089/088922299311358; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Tamamura H, 1998, BIOORGAN MED CHEM, V6, P473, DOI 10.1016/S0968-0896(97)10055-4; Ugolini S, 1997, J IMMUNOL, V159, P3000; Valenzuela A, 1997, J VIROL, V71, P8289, DOI 10.1128/JVI.71.11.8289-8298.1997; WALICKE PA, 1989, J BIOL CHEM, V264, P4120; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884	60	69	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27875	27884		10.1074/jbc.274.39.27875	http://dx.doi.org/10.1074/jbc.274.39.27875			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488134	hybrid			2022-12-25	WOS:000082739100073
J	Rexach, J; Montero, B; Fernandez, E; Galvan, A				Rexach, J; Montero, B; Fernandez, E; Galvan, A			Differential regulation of the high affinity nitrite transport systems III and IV in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRATE REDUCTASE; ASPERGILLUS-NIDULANS; GENE; EXPRESSION; IDENTIFICATION; ASSIMILATION; ARABIDOPSIS; ENCODES; PLANTS; AMMONIUM	Two high affinity nitrite transporters have been identified in Chlamydomonas reinhardtii. They have been named system III and system IV and shown to be differentially regulated by nitrogen and carbon supply. System III was induced under high CO, and required a micromolar nitrate signal for optimal expression, was inhibited by ammonium, and was not affected by either chloride or the chloride channel inhibitor 5-nitro-2-(3-phenylpropylamino)benzoic acid. System IV was induced optimally under limiting CO2 and did not require nitrate signal, was inhibited by chloride and 5-nitro-2-(3-phenylpropylamino)benzoic acid, but was not affected by ammonium. Two transcripts that shared the expression pattern of systems III and IV activities were detected with an Nrt2;3 gene probe. In addition, a mutant defective in both the activity of system III and the expression of Nrt2;3 gene has been isolated. Genetic crosses and in vivo complementation studies indicate that this mutant is defective in a locus that is closely linked to the regulatory gene Nit2.	Univ Cordoba, Fac Ciencias, Dept Bioquim, E-14071 Cordoba, Spain; Inst Andaluz Biotecnol, Cordoba 14071, Spain; Univ Cordoba, Fac Ciencias, Dept Biol Mol, E-14071 Cordoba, Spain	Universidad de Cordoba; Universidad de Cordoba	Galvan, A (corresponding author), Univ Cordoba, Fac Ciencias, Dept Bioquim, Ave San Alberto Magno S-N, E-14071 Cordoba, Spain.		Fernandez, Emilio/H-2892-2015; Rexach, Jesus/H-9769-2015; Rexach, Jesus/H-9769-2015; Galvan Cejudo, Aurora/A-9483-2010	Rexach, Jesus/0000-0002-0392-8061; Fernandez Reyes, Emilio/0000-0001-5957-5392; Rexach, Jesus/0000-0001-6162-769X; Galvan Cejudo, Aurora/0000-0002-7564-2281				Amarasinghe BHRR, 1998, PLANTA, V206, P44, DOI 10.1007/s004250050372; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Cho MH, 1996, P NATL ACAD SCI USA, V93, P8134, DOI 10.1073/pnas.93.15.8134; CORDOBA F, 1986, PLANT PHYSIOL, V82, P904, DOI 10.1104/pp.82.4.904; Crawford NM, 1998, TRENDS PLANT SCI, V3, P389, DOI 10.1016/S1360-1385(98)01311-9; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; EBERSOLD WT, 1967, SCIENCE, V157, P447, DOI 10.1126/science.157.3787.447; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERNANDEZ E, 1986, CURR GENET, V10, P397, DOI 10.1007/BF00418413; FERNANDEZ E, 1989, P NATL ACAD SCI USA, V86, P6449, DOI 10.1073/pnas.86.17.6449; FERNANDEZ E, 1998, MOL BIOL CHLAMYDOMON, P637; FLORENCIO FJ, 1983, PLANTA, V158, P288, DOI 10.1007/BF00397329; GALVAN A, 1991, BIOCHIM BIOPHYS ACTA, V1074, P6, DOI 10.1016/0304-4165(91)90030-K; GALVAN A, 1992, PLANT PHYSIOL, V98, P422, DOI 10.1104/pp.98.2.422; Galvan A, 1996, J BIOL CHEM, V271, P2088, DOI 10.1074/jbc.271.4.2088; GUERRERO MG, 1981, ANNU REV PLANT PHYS, V32, P169, DOI 10.1146/annurev.pp.32.060181.001125; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HOFF T, 1994, PLANT CELL ENVIRON, V17, P489, DOI 10.1111/j.1365-3040.1994.tb00145.x; Huang NC, 1996, PLANT CELL, V8, P2183, DOI 10.1105/tpc.8.12.2183; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; Lauter FR, 1996, P NATL ACAD SCI USA, V93, P8139, DOI 10.1073/pnas.93.15.8139; Perez MD, 1997, BIOCHEM J, V321, P397, DOI 10.1042/bj3210397; PRIETO R, 1993, MOL GEN GENET, V237, P429, DOI 10.1007/BF00279448; Quesada A, 1998, MOL GEN GENET, V258, P373, DOI 10.1007/s004380050743; Quesada A, 1997, PLANT MOL BIOL, V34, P265, DOI 10.1023/A:1005872816881; QUESADA A, 1994, PLANT J, V5, P407, DOI 10.1111/j.1365-313X.1994.00407.x; QUESADA A, 1993, MOL GEN GENET, V240, P387, DOI 10.1007/BF00280390; RANUM LPW, 1988, GENETICS, V120, P109; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLOSS JA, 1984, MOL CELL BIOL, V4, P424, DOI 10.1128/MCB.4.3.424; SCHNELL RA, 1993, GENETICS, V134, P737; Snell F.D., 1949, COLORIMETRIC METHODS, VVolume 2, P802; Trueman LJ, 1996, GENE, V175, P223, DOI 10.1016/0378-1119(96)00154-0; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; VANWINKLESWIFT KP, 1977, J PHYCOL, V13, P225; Wang RC, 1996, P NATL ACAD SCI USA, V93, P9297, DOI 10.1073/pnas.93.17.9297; Zhou JJ, 1998, J BIOL CHEM, V273, P12017, DOI 10.1074/jbc.273.20.12017; Zhou JZ, 1996, J MOL EVOL, V42, P432, DOI 10.1007/BF02498637	39	38	41	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27801	27806		10.1074/jbc.274.39.27801	http://dx.doi.org/10.1074/jbc.274.39.27801			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488125	hybrid			2022-12-25	WOS:000082739100064
J	Sorokina, EA; Kleinman, JG				Sorokina, EA; Kleinman, JG			Cloning and preliminary characterization of a calcium-binding protein closely related to nucleolin on the apical surface of inner medullary collecting duct cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; STONE DISEASE; NUCLEAR; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; SEQUENCE; KINASE; ACTIN	Calcium stone crystal attachment to the urinary epithelium plays an essential role in the development of kidney stones by allowing small crystals to be retained in the kidney until they become macroscopic. We among others have described attachment of stone crystals to cultured renal epithelia (Wiessner, J. H., Kleinman, J. G., Blumenthal, S. S., Garancis, J. C., and Mandel, G. S. (1987) J. Urol. 138, 640-643). To isolate protein(s) that may participate in crystal attachment, apical membranes of cultured renal inner medullary collecting duct were biotinylated, the cells were lysed with detergent, the lysate was subjected to hydroxyapatite chromatography, and fractions were incubated with calcium oxalate monohydrate. Electrophoresis of material solubilized from the crystals showed several selectively adsorbed protein bands. A 110-kDa band stained positively for biotin and for glycosides and bound Ca-45. The amino acid sequence of this band was determined to be that of a protein closely related to rat nucleolin (nucleolin-related protein; NRP), NRP was cloned and sequenced and was 83% homologous with the previously sequenced nucleolar protein nucleolin. Using temperature-induced phase partitioning with Triton X-114, NRP was associated with both the insoluble membrane skeleton pellet and the soluble aqueous phase but not the soluble detergent phase. This association with the membrane skeleton was increased in the presence of calcium. Thus, NRP is associated with the apical membranes of cultured renal tubular cells and is bound to membrane skeletal elements in a calcium-dependent fashion. The physiological role of NRP remains to be determined; however, a pathophysiological role may be that of mediating the attachment to the renal tubular epithelium of calcium stone crystals.	Dept Vet Affairs Med Ctr, Nephrol Sect, Milwaukee, WI 53295 USA		Kleinman, JG (corresponding author), VA Med Ctr, Nephrol Sect 111K, 5000 W Natl Ave, Milwaukee, WI 53295 USA.	kIeinman@post.its.mcw.edu						ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; Barwise JL, 1996, J CELL SCI, V109, P247; BERRIDGE MJ, 1998, SIGNAL TRANSDUCTION, P205; Bigelow MW, 1997, AM J PHYSIOL-RENAL, V272, pF55, DOI 10.1152/ajprenal.1997.272.1.F55; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOURBON HM, 1990, GENE, V88, P187, DOI 10.1016/0378-1119(90)90031-L; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; BURNS JR, 1980, INVEST UROL, V18, P167; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; DEVERDUGO UR, 1995, J VIROL, V69, P6751, DOI 10.1128/JVI.69.11.6751-6757.1995; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; FINLAYSON B, 1978, INVEST UROL, V15, P442; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; HABEGER CF, 1995, SCI TECHNOLOGY APPL, P111; JORDAN P, 1994, BIOCHEMISTRY-US, V33, P14696, DOI 10.1021/bi00253a007; KIBBEY MC, 1995, J NEUROSCI RES, V42, P314, DOI 10.1002/jnr.490420305; KRANTZ S, 1995, BBA-MOL CELL RES, V1266, P109, DOI 10.1016/0167-4889(95)00028-Q; LEGENDRE N, 1993, PRACTICAL GUIDE PROT, P71; Lenz SE, 1996, BIOCHEM BIOPH RES CO, V225, P1078, DOI 10.1006/bbrc.1996.1298; Lieske JC, 1996, AM J PHYSIOL-RENAL, V270, pF192, DOI 10.1152/ajprenal.1996.270.1.F192; LIESKE JC, 1995, AM J PHYSIOL-RENAL, V268, pF604, DOI 10.1152/ajprenal.1995.268.4.F604; LIESKE JC, 1993, AM J PHYSIOL, V264, pF800, DOI 10.1152/ajprenal.1993.264.5.F800; MANDEL NS, 1989, J UROLOGY, V142, P1516, DOI 10.1016/S0022-5347(17)39145-0; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; NISHIMUNE Y, 1996, GUIDEBOOK CALCIUM BI, P215; RIESE RJ, 1988, AM J PHYSIOL, V255, pF1025, DOI 10.1152/ajprenal.1988.255.5.F1025; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROTH J, 1993, BLOOD, V82, P1875; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SELVAGGIO AM, 1988, AM J PHYSIOL, V254, pF391, DOI 10.1152/ajprenal.1988.254.3.F391; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; SOHNEL O, 1994, SCANNING MICROSCOPY, V8, P513; TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628; THOMAS TC, 1990, METHOD ENZYMOL, V182, P499; WADA I, 1996, GUIDEBOOK CALCIUM BI, P216; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6; WIESSNER JH, 1987, J UROLOGY, V138, P640, DOI 10.1016/S0022-5347(17)43289-7	39	38	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27491	27496		10.1074/jbc.274.39.27491	http://dx.doi.org/10.1074/jbc.274.39.27491			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488083	hybrid			2022-12-25	WOS:000082739100022
J	Stiefel, V; Becerra, EL; Roca, R; Bastida, M; Jahrmann, T; Graziano, E; Puigdomenech, P				Stiefel, V; Becerra, EL; Roca, R; Bastida, M; Jahrmann, T; Graziano, E; Puigdomenech, P			TM20, a gene coding for a new class of transmembrane proteins expressed in the meristematic tissues of maize	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; AUXIN TRANSPORT; ENCODES; EMBRYO; MORPHOGENESIS; MEMBER	In the course of the analysis of lachrima, a recessive, defective kernel, embryo-lethal mutation in Zea mays that alters embryo and endosperm development, a gene coding for a new class of transmembrane proteins was isolated. The mutant was produced by Ac transposon tagging, and a gene located in the insertion region of the transposon was isolated as well as the corresponding cDNA. The predicted protein contains twenty hydrophobic segments that can be grouped in five repeats formed by four segments that fulfill the criteria for membrane spanning domains, and for this reason the gene has been named TM20. The sequences of the domains in each position of each group can be aligned, indicating that TM20 is formed by a four-domain structure duplicated five times. During embryogenesis in wild-type embryos and in the growing plant, TM20 gene expression is associated with meristems.	CSIC, Ctr Invest Desenvolupament, Inst Mol Biol, Dept Mol Genet, Barcelona 08034, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Puigdomenech, P (corresponding author), CSIC, Ctr Invest Desenvolupament, Inst Mol Biol, Dept Mol Genet, Jordi Girona 18, Barcelona 08034, Spain.							ABBE EC, 1954, AM J BOT, V41, P285, DOI 10.2307/2438600; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; Chen J., 1994, MAIZE HDB, P526, DOI [10.1007/978-1-4612-2694-9_85, DOI 10.1007/978-1-4612-2694-9_85]; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK JK, 1991, PLANT CELL, V3, P935, DOI 10.1105/tpc.3.9.935; CLARK JK, 1996, PLANT EMBRYOGENESIS, P89; Dellaporta Stephen L., 1994, P219; Fedoroff N, 1989, MOBILE DNA, P377; Fischer C, 1996, PLANT J, V9, P659, DOI 10.1046/j.1365-313X.1996.9050659.x; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; JURGENS G, 1995, CELL, V81, P467, DOI 10.1016/0092-8674(95)90065-9; KIESELBACH TA, 1949, U NEBR AGR EXP STN B, V161; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Langdale Jane A., 1994, P165; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; MEINERS S, 1991, P NATL ACAD SCI USA, V88, P4119, DOI 10.1073/pnas.88.10.4119; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; Randolph LF, 1936, J AGRIC RES, V53, P0881; Sambrook J., 2002, MOL CLONING LAB MANU; SHERIDAN WF, 1988, ANNU REV GENET, V22, P353, DOI 10.1146/annurev.ge.22.120188.002033; SHERIDAN WF, 1987, TRENDS GENET, V3, P3, DOI 10.1016/0168-9525(87)90153-3; SHERIDAN WF, 1982, J HERED, V73, P318, DOI 10.1093/oxfordjournals.jhered.a109662; SHERIDAN WF, 1995, DEV GENET, V16, P291, DOI 10.1002/dvg.1020160402; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; Utsuno K, 1998, PLANT CELL PHYSIOL, V39, P1111, DOI 10.1093/oxfordjournals.pcp.a029310	34	16	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27734	27739		10.1074/jbc.274.39.27734	http://dx.doi.org/10.1074/jbc.274.39.27734			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488116	hybrid, Green Published			2022-12-25	WOS:000082739100055
J	Hawkins, LM; Chazot, PL; Stephenson, FA				Hawkins, LM; Chazot, PL; Stephenson, FA			Biochemical evidence for the co-association of three N-methyl-D-aspartate (NMDA) R2 subunits in recombinant NMDA receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-BINDING-SITE; NR2B SUBUNITS; RAT-BRAIN; IN-VITRO; C2 EXON; GLUTAMATE; NR1; DETERMINANTS; ANTAGONIST; CHANNELS	Functional characterization of wild-type and mutant cloned N-methyl-D-aspartate (MMDA) receptors has been used to deduce their subunit stoichiometry and quaternary structure. However, the results reported from different groups have been at variance and are thus inconclusive. This sturdy has employed a biochemical approach to determine the number of NMDA R2 (NR2) subunits/receptor together with the NMDA R1 (NR1)/NR2 subunit ratio of both cloned and native NMDA receptors. Thus, human embryonic kidney 293 cells were transfected with the NR1-1a and NR2A NMDA receptor subunits in combination with both FLAG- and c-Myc epitope-tagged NR2B subunits, The expressed receptors were detergent-extracted and subjected to double immunoaffinity purification using anti-NR2A and anti-FLAG antibody immunoaffinity columns in series. Immunoblotting of the double immunopurified NR2A/NR2B(FLAG)-containing material demonstrated the presence of anti-NR1, anti-NR2A, anti-FLAG, and, more important, anti-c-Myc antibody immunoreactivities, The presence of anti-c-Myc antibody immunoreactivity in the double immunoaffinity-purified material showed the co-assembly of three NR2 subunits, i.e. NR2A/NR2B(FLAG)/NRSBc-Myc, within the same NMDA receptor complex. Control experiments excluded the possibility that the co-immunopurification of the three NR2 subunits was an artifact of the solubilization procedure. These results, taken together with those previously described that showed two NR1 subunits/oligomer, suggest that the NMDA receptor is at least pentameric.	Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England	University of London; University College London; University of London School of Pharmacy	Stephenson, FA (corresponding author), Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, 29-39 Brunswick Sq, London WC1N 1AX, England.							BEHE P, 1995, P ROY SOC B-BIOL SCI, V262, P205, DOI 10.1098/rspb.1995.0197; BENVENISTE M, 1991, BIOPHYS J, V59, P560, DOI 10.1016/S0006-3495(91)82272-X; Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; Brimecombe JC, 1997, P NATL ACAD SCI USA, V94, P11019, DOI 10.1073/pnas.94.20.11019; BROSE N, 1993, J BIOL CHEM, V268, P22663; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; Chazot PL, 1997, J NEUROCHEM, V68, P507; Chazot PL, 1997, J NEUROCHEM, V69, P2138; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; HAWKINS LM, 1999, BRIT J PHARMACOL, V127, pP1; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Laube B, 1998, J NEUROSCI, V18, P2954; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Mutel V, 1998, J NEUROCHEM, V70, P2147; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; POLLARD S, 1995, J BIOL CHEM, V270, P21285, DOI 10.1074/jbc.270.36.21285; Premkumar LS, 1997, J GEN PHYSIOL, V110, P485, DOI 10.1085/jgp.110.5.485; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8	24	106	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27211	27218		10.1074/jbc.274.38.27211	http://dx.doi.org/10.1074/jbc.274.38.27211			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480938	hybrid			2022-12-25	WOS:000082570700077
J	Iemura, S; Yamamoto, TS; Takagi, C; Kobayashi, H; Ueno, N				Iemura, S; Yamamoto, TS; Takagi, C; Kobayashi, H; Ueno, N			Isolation and characterization of bone morphogenetic protein-binding proteins from the early Xenopus embryo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPEMANN ORGANIZER; MESODERM INDUCTION; MESSENGER-RNA; IV COLLAGEN; FOLLISTATIN; EXPRESSION; BMP-4; RECEPTOR; VITELLOGENIN; ACTIVIN	Using a surface plasmon resonance biosensor as a sensitive and specific monitor, we have isolated two distinct bone morphogenetic protein (BMP)-binding proteins, and identified them as lipovitellin 1 and Ep45, respectively. Lipovitellin 1 is an egg yolk protein that is processed from vitellogenin. Both vitellogenin and Ep45 are synthesized under estrogen control in the liver, secreted, and taken up by developing oocytes. In this paper, we have shown that of the TGF-beta family members tested, Ep45 can bind only to BMP-4, whereas lipovitellin 1 can bind to both BMP-4 and activin A. Because of this difference in specificity, we have focused on and further studied Ep45. Kinetic parameters were determined by surface plasmon resonance studies and showed that Ep45 associated rapidly with BMP-4 (k(a) = 1.06 x 10(4) M(-1)s(-1)) and dissociated slowly (k(d) = 1.6 x 10(-4) s(-1)). In Xenopus embryos microinjected with Ep45 mRNA Ep45 blocked the ability of follistatin to inhibit BMP activity and to induce a secondary body axis in a dose-dependent manner, whereas it had no effect on other BMP antagonists, chordin and noggin. These results support the possibility that Ep45 interacts with BMP to modulate its activities in vivo.	Natl Inst Basic Biol, Dept Dev Biol, Okazaki, Aichi 4448585, Japan; Minist Agr Forestry & Fisheries, Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Ministry of Agriculture Forestry & Fisheries - Japan; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan; Graduate University for Advanced Studies - Japan	Ueno, N (corresponding author), Natl Inst Basic Biol, Dept Dev Biol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.			Ueno, Naoto/0000-0002-8375-2317				ALBANO RM, 1994, DEVELOPMENT, V120, P803; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bauer H, 1998, DEV BIOL, V204, P488, DOI 10.1006/dbio.1998.9003; BECK BL, 1992, RES COMMUN CHEM PATH, V77, P3; BERRIDGE MV, 1976, CELL, V8, P283, DOI 10.1016/0092-8674(76)90012-X; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Clemens M J, 1974, Prog Biophys Mol Biol, V28, P69, DOI 10.1016/0079-6107(74)90017-0; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; GERBERHUBER S, 1987, NUCLEIC ACIDS RES, V15, P4737, DOI 10.1093/nar/15.12.4737; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HOLLAND LJ, 1992, J BIOL CHEM, V267, P7053; HOLLAND LJ, 1987, MOL CELL ENDOCRINOL, V49, P63, DOI 10.1016/0303-7207(87)90064-5; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONES CM, 1992, DEVELOPMENT, V115, P639; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Lackmann M, 1996, P NATL ACAD SCI USA, V93, P2523, DOI 10.1073/pnas.93.6.2523; MAENO M, 1994, DEV BIOL, V161, P522, DOI 10.1006/dbio.1994.1050; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; Natsume T, 1997, J BIOL CHEM, V272, P11535; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; NISHIMATSU SI, 1993, GROWTH FACTORS, V8, P173, DOI 10.3109/08977199309011020; PARALKAR VM, 1990, J BIOL CHEM, V265, P17281; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432-1033.1996.0295n.x; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SUNDERMAN F, 1993, SCAND J WORK ENV HEA, V1, P75; Suzuki A, 1997, BIOCHEM BIOPH RES CO, V232, P153, DOI 10.1006/bbrc.1997.6219; Thomsen GH, 1997, TRENDS GENET, V13, P209, DOI 10.1016/S0168-9525(97)01117-7; Ueno N, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046927; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	45	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26843	26849		10.1074/jbc.274.38.26843	http://dx.doi.org/10.1074/jbc.274.38.26843			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480892	hybrid			2022-12-25	WOS:000082570700031
J	Arnott, CH; Sale, EM; Miller, J; Sale, GJ				Arnott, CH; Sale, EM; Miller, J; Sale, GJ			Use of an antisense strategy to dissect the signaling role of protein-tyrosine phosphatase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; INTACT-CELLS; IN-VIVO; DEPHOSPHORYLATION; PHOSPHORYLATION; KINASE; LAR; ACTIVATION; OVEREXPRESSION; TRANSDUCTION	The protein-tyrosine phosphatase PTP alpha has been proposed to play an important role in controlling the dephosphorylation of a number of key signaling proteins and in regulating insulin signaling, To examine the potential cellular functions and physiological substrates of PTP alpha a potent phosphorothioate oligonucleotide-based antisense strategy was developed that specifically depleted endogenous PTP alpha from 3T3-L1 adipocytes. The antisense probe, alpha AS1, achieved PTP alpha depletion levels normally of greater than or equal to 85% and which varied up to levels where PTP alpha was not detected at all. Elimination of PTP alpha by 85% inhibited c-Src activity by 80%. Abolishing PTP alpha to levels undetected did not alter the tyrosine dephosphorylation of the insulin receptor or insulin receptor substrate proteins. Moreover, the ability of insulin to activate ERK2 or to stimulate DNA synthesis was not altered by alpha AS1, It is concluded that endogenous PTP alpha is a key regulator of c-Src activity in 3T3-L1 adipocytes and that PTPa! is not required for the dephosphorylation of the insulin receptor or the insulin receptor substrate proteins or for the regulation of several downstream insulin signaling events in 3T3-L1 adipocytes, Finally, the development of the antisense probe, alpha AS1, provides an important molecular tool of general applicability for further dissecting the roles and precise targets of endogenous PTP alpha.	Sch Biol Sci, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England		Sale, GJ (corresponding author), Sch Biol Sci, Div Biochem & Mol Biol, Biomed Sci Bldg,Bassett Crescent E, Southampton SO16 7PX, Hants, England.							Ahmad F, 1997, J BIOL CHEM, V272, P448; AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Arnott CH, 1997, FEBS LETT, V406, P179, DOI 10.1016/S0014-5793(97)00266-4; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; BLOOMFIELD M, 1992, Biochemical Society Transactions, V20, p293S; CHAIKOF EL, 1995, J BIOL CHEM, V270, P7431, DOI 10.1074/jbc.270.13.7431; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; GOLDSTEIN BJ, 1993, RECEPTOR, V3, P1; Harlow E., 1988, ANTIBODIES LAB MANUA; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; KING MJ, 1990, BIOCHEM J, V266, P251, DOI 10.1042/bj2660251; KING MJ, 1991, BIOCHEM J, V275, P413, DOI 10.1042/bj2750413; Kulas DT, 1996, J BIOL CHEM, V271, P755, DOI 10.1074/jbc.271.2.755; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; Lammers R, 1997, FEBS LETT, V404, P37, DOI 10.1016/S0014-5793(97)00080-X; Li PM, 1996, CELL SIGNAL, V8, P467, DOI 10.1016/S0898-6568(96)00101-5; LIU MY, 1995, AM J PHYSIOL-LUNG C, V269, pL178, DOI 10.1152/ajplung.1995.269.2.L178; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SALE GJ, 1988, INT J BIOCHEM, V20, P897, DOI 10.1016/0020-711X(88)90173-5; SALE GJ, 1992, BIOCHEM SOC T, V20, P664, DOI 10.1042/bst0200664; SALE GJ, 1991, ADV PROTEIN PHOSPHAT, V6, P159; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAPPIA PS, 1993, BIOCHEM J, V292, P1; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Zhang WR, 1996, MOL ENDOCRINOL, V10, P575, DOI 10.1210/me.10.5.575; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	44	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26105	26112		10.1074/jbc.274.37.26105	http://dx.doi.org/10.1074/jbc.274.37.26105			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473560	hybrid			2022-12-25	WOS:000082469700026
J	Christenson, LK; Johnson, PF; McAllister, JM; Strauss, JF				Christenson, LK; Johnson, PF; McAllister, JM; Strauss, JF			CCAAT/enhancer-binding proteins regulate expression of the human steroidogenic acute regulatory protein (StAR) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-BETA; TRANSCRIPTIONAL REGULATION; FOLLICULAR DEVELOPMENT; PROMOTER ACTIVITY; GRANULOSA-CELLS; DNA-BINDING; RAT OVARY; ALPHA; FACTOR-1; REGION	Two putative CCAAT/enhancer-binding protein (C/EBP) response elements were identified in the proximal promoter of the human steroidogenic acute regulatory protein (StAR) gene, which encodes a key protein-regulating steroid hormone synthesis. Expression of C/EBP alpha and -beta increased StAR promoter activity in COS-l and HepG2 cells. Cotransfection of C/EBP alpha or -beta and steroidogenic factor 1, a transcription factor required for cAMP regulation of StAR expression, into COS-1 augmented 8-bromoadenosine 3':5'-cyclic monophosphate (8-Br-cAMP)-stimulated promoter activity. When the putative C/EBP response elements were mutated, individually or together, a pronounced decline in basal StAR promoter activity in human granulosa-lutein cells resulted, but the fold stimulation of promoter activity by 8-Br-cAMP was unaffected. Recombinant C/EBP alpha and -beta bound to the two identified sequences but not the mutated elements. Human granulosa-lutein cell nuclear extracts also bound these elements but not the mutated sequences. An antibody to C/EBP beta, but not C/EBP alpha, supershifted the nuclear protein complex associated with the more distal element. The complex formed by nuclear extracts with the proximal element was not supershifted by either antibody. Western blot analysis revealed the presence of C/EBPa and C/EBP beta in human granulosalutein cell nuclear extracts. C/EBP beta levels were up-regulated 3-fold by 8-Br-cAMP treatment. Our studies demonstrate a role for C/EBP beta as well as yet to be identified proteins, which can bind to C/EBP response elements, in the regulation of StAR gene expression and suggest a mechanism by which C/EBP beta participates in the cAMP regulation of StAR gene transcription.	Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; NCI, Frederick Canc Res & Dev Ctr, Adv BioSci Labs, Basic Res Program, Frederick, MD 21702 USA; Penn State Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	University of Pennsylvania; Pennsylvania Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Christenson, LK (corresponding author), 1354 BRBII-III,421 Curie Blvd, Philadelphia, PA 19104 USA.		Christenson, Lane K/G-6435-2013; Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725	NICHD NIH HHS [HD06274, HD34449] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD034449] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Christenson LK, 1998, J BIOL CHEM, V273, P30729, DOI 10.1074/jbc.273.46.30729; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; Gronning LM, 1999, ENDOCRINOLOGY, V140, P835, DOI 10.1210/en.140.2.835; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; Kiriakidou M, 1996, J CLIN ENDOCR METAB, V81, P4122, DOI 10.1210/jc.81.11.4122; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MCALLISTER JM, 1994, J CLIN ENDOCR METAB, V79, P106, DOI 10.1210/jc.79.1.106; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PIONTKEWITZ Y, 1993, ENDOCRINOLOGY, V133, P2327, DOI 10.1210/en.133.5.2327; Piontkewitz Y, 1996, DEV BIOL, V179, P288, DOI 10.1006/dbio.1996.0258; POLL V, 1990, CELL, V63, P643; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; Reinhart AJ, 1999, MOL ENDOCRINOL, V13, P729, DOI 10.1210/me.13.5.729; Ronen-Fuhrmann T, 1998, ENDOCRINOLOGY, V139, P303, DOI 10.1210/en.139.1.303; Rust W, 1998, J MOL ENDOCRINOL, V21, P189, DOI 10.1677/jme.0.0210189; Sandhoff TW, 1998, ENDOCRINOLOGY, V139, P4820, DOI 10.1210/en.139.12.4820; SIROIS J, 1993, J BIOL CHEM, V268, P21931; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; STRAUSS JF, 1999, RECENT PROG HORM RES, V54, P1; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; SUGAWARA T, 1998, ENDOCR SOC P, V98, P118; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yukawa K, 1998, J BIOL CHEM, V273, P31345, DOI 10.1074/jbc.273.47.31345; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899	33	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26591	26598		10.1074/jbc.274.37.26591	http://dx.doi.org/10.1074/jbc.274.37.26591			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473624	hybrid			2022-12-25	WOS:000082469700090
J	Lyons-Darden, T; Topal, MD				Lyons-Darden, T; Topal, MD			Abasic sites induce triplet-repeat expansion during DNA replication in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY-DISEASE GENES; SIMPLE SEQUENCE DNA; SYNTHESIS IN-VITRO; TRINUCLEOTIDE REPEATS; ESCHERICHIA-COLI; MYOTONIC-DYSTROPHY; POLYMERASE-I; INSTABILITY; STRAND; FORM	The occurrence of triplet-repeat expansion (TRE) during transmission of genetic information is involved in many neurological and neuromuscular diseases including Fragile X syndrome and myotonic dystrophy. DNA slippage during replicative synthesis appears to cause TRE. The causes of DNA slippage, however, remain mostly unknown. We investigated the effects of abasic sites on the occurrence of TRE during DNA replication in vitro using Escherichia coli Klenow polymerase I as the model polymerase. Here we show that a single abasic site analog, synthesized in the triplet-repeat tract at the 5' end of the template strand, induced dramatic TRE during DNA synthesis. The amount of TRE induced decreased when the abasic site was moved to the middle of the repeat tract, consistent with effectively decreasing the length of the repeat tract. Placing the abasic site in the primer did not induce TRE. TRE was sequence-dependent. The damage-induced increase in growing strand TRE depended on the sequence of the growing strand repeat as AAT similar to ATT > CAG > CTG. The expansions required replication from a primer complementary to the repeat tract. The expanded tracts were sequenced and contained multiple additions of the original repeat. The results imply that DNA damage can play a significant role in generating TRE in vivo.	Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pathol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Topal, MD (corresponding author), Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA.	mdtopal@med.unc.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007017] Funding Source: NIH RePORTER; NIEHS NIH HHS [5-T-32-ES07017] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; DARLOW JM, 1995, GENETICS, V141, P825; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FRESCO JR, 1960, P NATL ACAD SCI USA, V46, P311, DOI 10.1073/pnas.46.3.311; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GACY AM, 1995, CELL, V81, P533; Harvey SC, 1997, BIOCHEMISTRY-US, V36, P3047, DOI 10.1021/bi962771e; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; Ji JP, 1996, NUCLEIC ACIDS RES, V24, P2835, DOI 10.1093/nar/24.14.2835; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Lyons-Darden T, 1999, NUCLEIC ACIDS RES, V27, P2235, DOI 10.1093/nar/27.11.2235; Miller H, 1997, BIOCHEMISTRY-US, V36, P15336, DOI 10.1021/bi971927n; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Nakamura J, 1998, CANCER RES, V58, P222; Nakayabu M, 1998, NUCLEIC ACIDS RES, V26, P1980, DOI 10.1093/nar/26.8.1980; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; PazElizur T, 1997, BIOCHEMISTRY-US, V36, P1766, DOI 10.1021/bi9621324; Pearson CE, 1998, NUCLEIC ACIDS RES, V26, P816, DOI 10.1093/nar/26.3.816; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; Shimizu H, 1997, NUCLEIC ACIDS RES, V25, P597, DOI 10.1093/nar/25.3.597; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; Wang G, 1997, BIOCHEMISTRY-US, V36, P9486, DOI 10.1021/bi970650o; Weitzmann MN, 1997, J BIOL CHEM, V272, P9517	39	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					25975	25978		10.1074/jbc.274.37.25975	http://dx.doi.org/10.1074/jbc.274.37.25975			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473539	hybrid			2022-12-25	WOS:000082469700005
J	Boehm, JE; Chaika, OV; Lewis, RE				Boehm, JE; Chaika, OV; Lewis, RE			Rac-dependent anti-apoptotic signaling by the insulin receptor cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MYC-INDUCED APOPTOSIS; PROTEIN-KINASE AKT; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; MAP KINASE; FACTOR-I; ACTIVATION; BINDING; PHOSPHORYLATION	Mutations in the cytoplasmic domain of the insulin receptor that block the ability of the receptor to stimulate glucose uptake do not block the receptor's ability to inhibit apoptosis (Boehm, J. E., Chaika, O. V., and Lewis, R. E. (1998) J. Biol. Chem. 273, 7169-7176). To characterize this survival pathway we used a chimeric receptor (CSF1R/IR) consisting of the ligand-binding domain of the colony-stimulating factor-1 receptor spliced to the cytoplasmic domain of the insulin receptor and a mutated version of the chimeric receptor containing a 12-amino acid deletion of the juxtamembrane domain (CSF1R/IR Delta 960). in addition to the inhibition of apoptosis, activation of either the CSF1R/IR or the CSF1R/IR Delta 960 rapidly induced membrane ruffling in Rat1 fibroblasts, The small GTPase Rac mediates membrane ruffling. Activated and dominant-inhibitory mutants of Rac and other small GTPases were expressed in Rat1 fibroblasts to examine a potential link between the intracellular pathways that induce membrane ruffling and promote cell survival. The anti-apoptotic action of the CSF1R/IR Delta 960 was reversed by dominant-inhibitory Rac(N17), but not by Ras(N17) or Cdc42(N17). Activated Rac(V12), but not Ras(D12) or Cdc2(V12), promoted cell survival in the absence of insulin. These data implicate Rac as a mediator of an unique anti-apoptotic signaling pathway activated by the insulin receptor cytoplasmic domain.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Nebraska Med Ctr 986805, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lewis, RE (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Nebraska Med Ctr 986805, Omaha, NE 68198 USA.		Lewis, Robert E./H-3404-2019		NCI NIH HHS [P30 CA36727] Funding Source: Medline; NIDDK NIH HHS [DK52809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Baserga R, 1997, BBA-REV CANCER, V1332, pF105, DOI 10.1016/S0304-419X(97)00007-3; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; Boehm JE, 1998, J BIOL CHEM, V273, P7169, DOI 10.1074/jbc.273.12.7169; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chaika OV, 1999, J BIOL CHEM, V274, P12075, DOI 10.1074/jbc.274.17.12075; Chaika OV, 1997, J BIOL CHEM, V272, P11968, DOI 10.1074/jbc.272.18.11968; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SULEINER DJ, 1997, MOL CELL BIOL, V16, P7115; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; THEIS RS, 1989, J BIOL CHEM, V264, P12820; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	42	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28632	28636		10.1074/jbc.274.40.28632	http://dx.doi.org/10.1074/jbc.274.40.28632			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497231	hybrid			2022-12-25	WOS:000082912700080
J	Effertz, K; Hinderlich, S; Reutter, W				Effertz, K; Hinderlich, S; Reutter, W			Selective loss of either the epimerase or kinase activity of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase due to site-directed mutagenesis based on sequence alignments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLNEURAMINIC ACID BIOSYNTHESIS; BIFUNCTIONAL ENZYME CATALYZES; HUMAN BRAIN HEXOKINASE; FIRST 2 STEPS; RAT-LIVER; MOLECULAR-CLONING; POLYSIALIC ACID; BINDING; PURIFICATION; 2-EPIMERASE	N-Acetylneuraminic acid is the most common naturally occurring sialic acid, as well as being the biosynthetic precursor of this group of compounds. UDP-Glc-NAc 2-epimerase/N-acetylmannosamine kinase has been shown to be the key enzyme of N-acetylneuraminic acid biosynthesis in rat liver, and it is a regulator of cell surface sialylation. The N-terminal region of this bifunctional enzyme displays sequence similarities with prokaryotic UDP-Glc-NAc 2-epimerases, whereas the sequence of its C-terminal region is similar to sequences of members of the sugar kinase superfamily, High level overexpression of active enzyme was established by using the baculovirus/Sf9 system. For functional characterization, site-directed mutagenesis was performed on different conserved amino acid residues. The histidine mutants H45A, H110A, H132A, H155A, and H157A showed a drastic loss of epimerase activity with almost unchanged kinase activity. Conversely, the mutants D413N, D413K, and R420M in the putative kinase active site lost their kinase activity but retained their epimerase activity. To estimate the structural perturbation effect due to site-directed mutagenesis, the oligomeric state of all mutants was determined by gel filtration analysis. The mutants D413N, D413K, and R420M as well as H45A were shown to form a hexamer like the wildtype enzyme, indicating little influence of mutation on protein folding. Histidine mutants H155A and H157A formed mainly trimeric enzyme with small amounts of hexamer, Oligomerization of mutants H110A and H132A was also significantly different from that of the wildtype enzyme. Therefore the loss of epimerase activity in mutants H110A, H132A, H155A, and H157A can largely be attributed to incorrect protein folding. In contrast, the mutation site of mutant H45A seems to be involved directly in the epimerization process, and the amino acids Asp-413 and Arg-420 of UDP-GlcNAc 2-epimerase/N-acetylmannosamine kinase are essential for the phosphorylation process. The fact that either epimerase or kinase activity are lost selectively provides evidence for the existence of two active sites working quite independently.	Free Univ Berlin, Inst Mol & Biochim, D-14195 Berlin, Germany	Free University of Berlin	Effertz, K (corresponding author), Free Univ Berlin, Inst Mol & Biochim, Arnimallee 22, D-14195 Berlin, Germany.	effertzk@zedat.fu-berlin.de						Babbitt PC, 1997, J BIOL CHEM, V272, P30591, DOI 10.1074/jbc.272.49.30591; BAIJAL M, 1995, ARCH BIOCHEM BIOPHYS, V321, P413, DOI 10.1006/abbi.1995.1412; Berninsone P, 1998, J BIOL CHEM, V273, P25556, DOI 10.1074/jbc.273.40.25556; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DENNIS JW, 1986, EUR J BIOCHEM, V161, P359, DOI 10.1111/j.1432-1033.1986.tb10455.x; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EFFERTZ K, 1998, GLYCOBIOLOGY, V88, P1096; Fernandes AI, 1996, BBA-PROTEIN STRUCT M, V1293, P90, DOI 10.1016/0167-4838(95)00227-8; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Hinderlich S, 1998, EUR J BIOCHEM, V252, P133, DOI 10.1046/j.1432-1327.1998.2520133.x; Horstkorte R, 1999, EUR J BIOCHEM, V260, P923, DOI 10.1046/j.1432-1327.1999.00253.x; KAMERLING JP, 1979, BIOCHIM BIOPHYS ACTA, V583, P403, DOI 10.1016/0304-4165(79)90465-3; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; Lucka L, 1999, FEBS LETT, V454, P341, DOI 10.1016/S0014-5793(99)00837-6; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Morgan PM, 1997, J AM CHEM SOC, V119, P10269, DOI 10.1021/ja971718q; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADA R, 1994, J BIOL CHEM, V269, P1425; Seppala R, 1999, AM J HUM GENET, V64, P1563, DOI 10.1086/302411; SOMMAR KM, 1972, BIOCHIM BIOPHYS ACTA, V268, P581, DOI 10.1016/0005-2744(72)90355-5; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; SWARTLEY JS, 1994, J BACTERIOL, V176, P1530, DOI 10.1128/jb.176.5.1530-1534.1994; TRAUT TW, 1994, CRIT REV BIOCHEM MOL, V29, P125, DOI 10.3109/10409239409086799; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Venkatachalam KV, 1998, J BIOL CHEM, V273, P19311, DOI 10.1074/jbc.273.30.19311; YANG PF, 1994, J BIOL CHEM, V269, P23039; ZEITLER R, 1992, BIOMETALS, V5, P103, DOI 10.1007/BF01062221; Zeng CB, 1996, BIOCHEMISTRY-US, V35, P13157, DOI 10.1021/bi960750e; ZENG CB, 1995, J BIOL CHEM, V270, P10509, DOI 10.1074/jbc.270.18.10509	34	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28771	28778		10.1074/jbc.274.40.28771	http://dx.doi.org/10.1074/jbc.274.40.28771			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497249	hybrid			2022-12-25	WOS:000082912700098
J	Kitazawa, S; Kitazawa, R; Maeda, S				Kitazawa, S; Kitazawa, R; Maeda, S			Transcriptional regulation of rat cyclin D1 gene by CpG methylation status in promoter region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN MECP2; RETINOBLASTOMA PROTEIN; EMBRYONIC-DEVELOPMENT; KINASE-ACTIVITY; IN-VITRO; EXPRESSION; DNA; CELLS; MOUSE; SP1	Cyclin D1, a G(1)/S cell cycle-regulating oncogene, is known to be transcriptionally regulated by numerous growth factors. We cloned and characterized the rat cyclin D1 gene 5'-flanking region and, by species- and subspecies-matched transient transfection studies, found that a basic promoter structure with a cAMP response element and two continuous Spl-binding sites was crucial for the steady-state expression of the cyclin D1 gene. Furthermore, the methylation status especially around two continuous Spl-binding sites was found to be an important epigenetical mechanism determining the steady-state expression level in rat leukemic cell lines K4D, K4DT, and K4D16. Whether or not epigenetic control of the cyclin D1 gene existed among normal rat tissues was further examined by high sensitivity mapping of the methylated cytosine, In normal rat tissues, the methylated cytosines at non-CpG loci within two continuous Spl-binding sites were observed in uterine stromal cells of the basal layer and found to be demethylated in the functioning layer, possibly by a passive demethylation mechanism through cell division. Since in the passive demethylation process Spl-binding sites remain methylated in a part of the cell population, methylated cytosines at Spl-binding sites may be essential for keeping a number of the stromal cells in the basal layer live against estrogen-induced proliferation that leads to either apoptosis or compaction.	Kobe Univ, Sch Med, Dept Pathol 2, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Kitazawa, S (corresponding author), Kobe Univ, Sch Med, Dept Pathol 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.		Kitazawa, Sohei/E-5602-2010	Kitazawa, Sohei/0000-0002-7466-7356				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chomet PS, 1991, CURR OPIN CELL BIOL, V3, P438, DOI 10.1016/0955-0674(91)90071-6; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fujita M, 1997, CANCER LETT, V112, P47, DOI 10.1016/S0304-3835(96)04544-2; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERBER B, 1994, ONCOGENE, V9, P1295; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HWANG A, 1995, J BIOL CHEM, V270, P24819; JIANG W, 1992, CANCER RES, V52, P2980; KITAZAWA S, 1998, BIOCHIM BIOPHYS ACTA, V1443, P353; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MAEDA S, 1980, J NATL CANCER I, V64, P539; MAO L, 1995, CANCER RES, V55, P2995; Matsuo K, 1998, EMBO J, V17, P1446, DOI 10.1093/emboj/17.5.1446; MATUSHIME H, 1991, CELL, V65, P701; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOULTON BC, 1994, ENDOCRINOLOGY, V134, P1055, DOI 10.1210/en.134.3.1055; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Perry JE, 1998, PROSTATE, V35, P117; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SHEMER R, 1990, J BIOL CHEM, V265, P1010; SHEMER R, 1991, P NATL ACAD SCI USA, V88, P11300, DOI 10.1073/pnas.88.24.11300; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Simmen MW, 1999, SCIENCE, V283, P1164, DOI 10.1126/science.283.5405.1164; SINCLAIR AJ, 1995, J VIROL, V69, P1292, DOI 10.1128/JVI.69.2.1292-1295.1995; TAMURA K, 1993, ONCOGENE, V8, P2113; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; Villuendas R, 1998, AM J PATHOL, V153, P887, DOI 10.1016/S0002-9440(10)65630-1; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; Yan GZ, 1997, J NEUROSCI, V17, P6122; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181	46	70	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28787	28793		10.1074/jbc.274.40.28787	http://dx.doi.org/10.1074/jbc.274.40.28787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497251	hybrid			2022-12-25	WOS:000082912700100
J	Krieger-Brauer, HI; Medda, PK; Hebling, U; Kather, H				Krieger-Brauer, HI; Medda, PK; Hebling, U; Kather, H			An antibody directed against residues 100-119 within the alpha-helical domain of G alpha(s) defines a novel contact site for beta-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; BINDING REGULATORY PROTEINS; ADENYLYL-CYCLASE; GAMMA-SUBUNIT; GTP-BINDING; SIGNAL-TRANSDUCTION; ACTIVATION; MEMBRANES; STIMULATION; IDENTIFICATION	A polyclonal antiserum that recognizes residues 100-119 within the alpha-helical domain of G alpha(s) (K-20) caused a dissociation of G(s) into its component subunits and activated a cholera toxin-sensitive high affinity GTPase, Consistently, the antibody mimicked the stimulatory effects of the beta-adrenergic agonist, isoproterenol, on adenylyl cyclase, which is mediated by G alpha(s), and its inhibitory action on NADPH-dependent H2O2 generation, a G beta gamma-mediated response. A peptide corresponding to the target sequence of K-20 not only neutralized the receptor-mimetic effects of the antibody but inhibited the whole spectrum of isoproterenol action as well, including its antagonistic effects on adenylyl cyclase and NADPH-dependent H2O2 generation. By contrast, COOH-terminal anti-G alpha(s) selectively inhibited the stimulatory effect of isoproterenol on cAMP formation without affecting its inhibitory effect on NADPH-dependent H2O2 generation. The data are consistent with the concept that beta-adrenergic receptors interact with multiple sites on G alpha(s) each playing a distinct role, and strongly suggest that antibody K-20 defines a novel contact site for beta-adrenergic receptors that localizes to the alpha-helical domain and is essential for eliciting the complete spectrum of beta-adrenergic responses.	Univ Heidelberg, Klin Inst Herzinfarktforsch, Med Klin, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Krieger-Brauer, HI (corresponding author), Univ Heidelberg, Klin Inst Herzinfarktforsch, Med Klin, Bergheimer Str 58, D-69115 Heidelberg, Germany.							Bohm A, 1997, CURR OPIN BIOTECH, V8, P480, DOI 10.1016/S0958-1669(97)80072-9; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; JAKOBS KH, 1988, BIOCHEM J, V249, P639, DOI 10.1042/bj2490639; Klinker JF, 1997, BIOCHEM PHARMACOL, V53, P1621, DOI 10.1016/S0006-2952(97)00065-8; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LIN W, 1998, P NATL ACAD SCI USA, V95, P12878; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; NAIM M, 1994, BIOCHEM J, V297, P451, DOI 10.1042/bj2970451; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NICULESCU F, 1994, J BIOL CHEM, V269, P4417; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; Rodbell M, 1997, ADV ENZYME REGUL, V37, P427, DOI 10.1016/S0065-2571(96)00020-9; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Smine A, 1998, J BIOL CHEM, V273, P16281, DOI 10.1074/jbc.273.26.16281; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TAYLOR JM, 1994, CELL SIGNAL, V6, P841, DOI 10.1016/0898-6568(94)90017-5; TOGOSHIGE M, 1994, BIOCHEMISTRY-US, V33, P4865; TOGOSHIGE M, 1996, J BIOL CHEM, V271, P8791; VITALE N, 1994, J BIOL CHEM, V269, P30293; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; Yilla M, 1996, FEBS LETT, V387, P16, DOI 10.1016/0014-5793(96)00441-3	40	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28308	28313		10.1074/jbc.274.40.28308	http://dx.doi.org/10.1074/jbc.274.40.28308			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497188	hybrid			2022-12-25	WOS:000082912700037
J	Maenaka, K; Juji, T; Nakayama, T; Wyer, JR; Gao, GF; Maenaka, T; Zaccai, NR; Kikuchi, A; Yabe, T; Tokunaga, K; Tadokoro, K; Stuart, DI; Jones, EY; van der Merwe, PA				Maenaka, K; Juji, T; Nakayama, T; Wyer, JR; Gao, GF; Maenaka, T; Zaccai, NR; Kikuchi, A; Yabe, T; Tokunaga, K; Tadokoro, K; Stuart, DI; Jones, EY; van der Merwe, PA			Killer cell immunoglobulin receptors and T cell receptors bind peptide-major histocompatibility complex class I with distinct thermodynamic and kinetic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; PROTEIN-PROTEIN INTERACTIONS; ADHESION MOLECULE CD2; HLA-C MOLECULES; NATURAL-KILLER; INHIBITORY RECEPTOR; LOW-AFFINITY; NK CELLS; RECOGNITION; LIGAND	Human natural killer cells and a subset of T cells express a repertoire of killer cell immunoglobulin receptors (KIRs) that recognize major histocompatibility complex (MHC) class I molecules. KIRs and T cell receptors (TCRs) bind in a peptide-dependent manner to overlapping regions of peptide-MHC class I complexes. KIRs with two immunoglobulin domains (KIR2Ds) recognize distinct subsets of HLA-C alleles. Here we use surface plasmon resonance to study the binding of soluble forms of KIR2DL1 and KIR2DL3 to several peptide-HLA-Cw7 complexes. KIR2DL3 bound to the HLA-Cw7 allele presenting the peptide RYRPGTVAL with a 1:1 stoichiometry and an affinity (K-d similar to 7 mu M at 25 degrees C) within the range of values measured for other cell-cell recognition molecules, including the TCR. Although KIR2DL1 is reported not to recognize the HLA-Cw7 allele in functional assays, it bound RYRPGTVAL/HLA-Cw7, albeit with a 10-20-fold lower affinity. TCR/peptide-MHC interactions are characterized by comparatively slow kinetics and unfavorable entropic changes (Willcox, B. E., Gao, G. F., WS er, J. R., Ladbury, J. E., Bell, J. I., Jakobsen, B. K,, and van der Merwe, P. A. (1999) Immunity 10, 357-365), suggesting that binding is accompanied by conformational adjustments. In contrast, we show that KIR2DL3 binds RYRPGTVAL/HLA-Cw7 with fast kinetics and a favorable binding entropy, consistent with rigid body association. These results indicate that KIR/peptide-MHC class I interactions have properties typical of other cell-cell recognition molecules, and they highlight the unusual nature of TCR/peptide-MHC recognition.	Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Japanese Red Cross Cent Blood Ctr, Shibuya Ku, Tokyo, Japan; Univ Oxford, MRC, Human Immunol Unit, Inst Mol Med,John Radcliffe Hosp, Oxford OX3 9DS, England; Oxford Ctr Mol Sci, Oxford OX1 3QT, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford; Wellcome Centre for Human Genetics; Japanese Red Cross Medical Center; University of Oxford; University of Oxford; University of Oxford	Maenaka, K (corresponding author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.		Gao, George Fu/ABD-5229-2021; Jones, Yvonne/N-8111-2019; van der Merwe, P. Anton/F-8539-2011; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Zaccai, Nathan/0000-0002-1476-2044; Stuart, David/0000-0002-3426-4210				BAKER E, 1995, CHROMOSOME RES, V3, P511; BIASSONI R, 1995, J EXP MED, V182, P605, DOI 10.1084/jem.182.2.605; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Colonna M, 1996, CURR OPIN IMMUNOL, V8, P101, DOI 10.1016/S0952-7915(96)80112-9; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kim J, 1997, J IMMUNOL, V159, P3875; Lanier LL, 1996, IMMUNOL TODAY, V17, P86, DOI 10.1016/0167-5699(96)80585-8; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Maenaka K, 1999, STRUCTURE, V7, P391, DOI 10.1016/S0969-2126(99)80052-5; MALNATI MS, 1995, SCIENCE, V267, P1016, DOI 10.1126/science.7863326; Mandelboim O, 1997, P NATL ACAD SCI USA, V94, P4604, DOI 10.1073/pnas.94.9.4604; Mandelboim O, 1997, IMMUNITY, V6, P341, DOI 10.1016/S1074-7613(00)80336-2; Rajagopalan S, 1997, J EXP MED, V185, P1523, DOI 10.1084/jem.185.8.1523; Reid SW, 1996, FEBS LETT, V383, P119, DOI 10.1016/0014-5793(96)00226-8; Selvakumar A, 1997, TISSUE ANTIGENS, V49, P564, DOI 10.1111/j.1399-0039.1997.tb02803.x; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; Suto Y, 1996, GENOMICS, V35, P270, DOI 10.1006/geno.1996.0355; Suto Y, 1998, IMMUNOGENETICS, V48, P235, DOI 10.1007/s002510050427; Vales-Gomez M, 1998, P NATL ACAD SCI USA, V95, P14326, DOI 10.1073/pnas.95.24.14326; Vales-Gomez M, 1998, IMMUNITY, V9, P337, DOI 10.1016/S1074-7613(00)80616-0; VALESGOMEZ M, 1998, IMMUNITY, V9, P892; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; vanderMerwe PA, 1997, J EXP MED, V185, P393, DOI 10.1084/jem.185.3.393; Vessey SJR, 1997, EUR J IMMUNOL, V27, P879; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Winter CC, 1998, J IMMUNOL, V161, P571; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030; Zappacosta F, 1997, P NATL ACAD SCI USA, V94, P6313, DOI 10.1073/pnas.94.12.6313	41	103	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28329	28334		10.1074/jbc.274.40.28329	http://dx.doi.org/10.1074/jbc.274.40.28329			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497191	hybrid			2022-12-25	WOS:000082912700040
J	Mirzabekov, T; Bannert, N; Farzan, M; Hofmann, W; Kolchinsky, P; Wu, LJ; Wyatt, R; Sodroski, J				Mirzabekov, T; Bannert, N; Farzan, M; Hofmann, W; Kolchinsky, P; Wu, LJ; Wyatt, R; Sodroski, J			Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GP120 ENVELOPE GLYCOPROTEIN; ATOMIC-STRUCTURE; HUMAN CD4; HETEROLOGOUS EXPRESSION; CHEMOKINE RECEPTORS; FUSION; ENTRY; GP41; GENE	Seven-transmembrane segment, G protein-coupled receptors (GPCRs) play important roles in many biological processes in which pharmaceutical intervention may be useful. High level expression and native purification of GPCRs are important steps in the biochemical and structural characterization of these molecules. Here, we describe enhanced mammalian cell expression and purification of a codon-optimized variant of the chemokine receptor CCR5, a GPCR that plays a central role in the entry of the human immunodeficiency virus-1 (HIV-1) into immune cells. CCR5 could be solubilized in its native state as determined by its ability to be precipitated by 2D7, a conformation-dependent anti-CCR5 antibody, and by the HIV-1 gp120 envelope glycoprotein. The 2D7 antibody recognized immature and mature forms of CCR5 equally, whereas gp120 preferentially recognized the mature form, a result that underscores a role for posttranslational modification of CCR5 in its HIV-1 coreceptor function. The methods described herein contribute to the analysis of CCR5 and are likely to be applicable to many other GPCRs.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Leukosite Inc, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Sodroski, J (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.	joseph_sodroski@dfci.harvard.edu		Farzan, Michael/0000-0002-2990-5319	NIAID NIH HHS [AI41851] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041851] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Andre S, 1998, J VIROL, V72, P1497; Bikker JA, 1998, J MED CHEM, V41, P2911, DOI 10.1021/jm970767a; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1994, SCIENCE, V266, P234, DOI 10.1126/science.7939658; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Hamaguchi K, 1992, PROTEIN MOL CONFORMA; HELMREICH EJM, 1996, BIOCHIM BIOPHYS ACTA, V1283, P285; Hoffman TL, 1999, P NATL ACAD SCI USA, V96, P6359, DOI 10.1073/pnas.96.11.6359; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Jones MN, 1999, INT J PHARM, V177, P137, DOI 10.1016/S0378-5173(98)00345-7; KHORANA HG, 1992, J BIOL CHEM, V267, P1; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lanyi JK, 1999, INT REV CYTOL, V187, P161, DOI 10.1016/S0074-7696(08)62418-3; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; REEVES P, 1996, P NATL ACAD SCI USA, V94, P7784; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; Stanasila L, 1998, BIOCHIMIE, V80, P563, DOI 10.1016/S0300-9084(00)80021-8; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Tate CG, 1996, TRENDS BIOTECHNOL, V14, P426, DOI 10.1016/0167-7799(96)10059-7; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884	39	121	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28745	28750		10.1074/jbc.274.40.28745	http://dx.doi.org/10.1074/jbc.274.40.28745			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497246	hybrid			2022-12-25	WOS:000082912700095
J	Snyder, PM; Olson, DR; Bucher, DB				Snyder, PM; Olson, DR; Bucher, DB			A pore segment in DEG/ENaC Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; CAENORHABDITIS-ELEGANS; MEMBRANE TOPOLOGY; CATION CHANNELS; ALPHA-SUBUNIT; ION CHANNELS; AMILORIDE; MUTATIONS; NEURODEGENERATION; MECHANOTRANSDUCTION	DEG/ENaC Na+ channels have diverse functions, including Na+ absorption, neurotransmission, and sensory transduction. The ability of these channels to discriminate between different ions is critical for their normal function. Several findings suggest that DEG/ENaC channels have a pore structure similar to K+ channels. To test this hypothesis, we examined the accessibility of native and introduced cysteines in the putative P loop of ENaC. We identified residues that span a barrier that excludes amiloride as well as anionic and large methanethiosulfonate reagents from the pore. This segment contains a structural element ((S/G)CS) involved in selectivity of ENaC. The results are not consistent with predictions from the K+ channel pore, suggesting that DEG/ENaC Na+ channels have a novel pore structure.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA	University of Iowa	Snyder, PM (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 200K EMRB, Iowa City, IA 52242 USA.	psnyder@blue.weeg.uiowa.edu						Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Adams CM, 1999, J BIOL CHEM, V274, P15500, DOI 10.1074/jbc.274.22.15500; Adams CM, 1998, J CELL BIOL, V140, P143, DOI 10.1083/jcb.140.1.143; Adams CM, 1999, BIOPHYS J, V76, P1377, DOI 10.1016/S0006-3495(99)77299-1; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Cheng C, 1998, J BIOL CHEM, V273, P22693, DOI 10.1074/jbc.273.35.22693; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Garcia-Anoveros J, 1998, NEURON, V20, P1231, DOI 10.1016/S0896-6273(00)80503-6; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Guy H. Robert, 1995, Biophysical Journal, V68, pA243; HILLE B, 1992, IONIC CHANNELS EXCIT, P344; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; RENARD S, 1994, J BIOL CHEM, V269, P12981; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	39	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28484	28490		10.1074/jbc.274.40.28484	http://dx.doi.org/10.1074/jbc.274.40.28484			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497211	hybrid			2022-12-25	WOS:000082912700060
J	Banno, Y; Fujita, H; Ono, Y; Nakashima, S; Ito, Y; Kuzumaki, N; Nozawa, Y				Banno, Y; Fujita, H; Ono, Y; Nakashima, S; Ito, Y; Kuzumaki, N; Nozawa, Y			Differential phospholipase D activation by bradykinin and sphingosine 1-phosphate in NIH 3T3 fibroblasts overexpressing gelsolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; COUPLED RECEPTOR EDG-1; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SIGNALING PATHWAYS; PHOSPHATIDIC-ACID; GROWTH-FACTOR; PLD ACTIVITY; BINDING; HYDROLYSIS	Gelsolin, an actin-binding protein, shows a strong ability to bind to phosphatidylinositol 4,5-bisphosphate (PIP2). Here we showed in in vitro experiments that gelsolin inhibited recombinant phospholipase D1 (PLD1) and PLD2 activities but not the oleate-dependent PLD and that this inhibition was not reversed by increasing PIP2 concentration. To investigate the role of gelsolin in agonist-mediated PLD activation, we used NIH 3T3 fibroblasts stably transfected with the cDNA for human cytosolic gelsolin. Gelsolin overexpression suppressed bradykinin-induced activation of phospholipase C (PLC) and PLD. On the other hand, sphingosine 1-phosphate (S1P)-induced PLD activation could not be modified by gelsolin overexpression, whereas PLC activation was suppressed. PLD activation by phorbol myristate acetate or Ca2+ ionophore A23187 was not affected by gelsolin overexpression. Stimulation of control cells with either bradykinin or S1P caused translocation of protein kinase C (PKC) to the membranes. Translocation of PKC-alpha and PKC-beta 1 but not PKC-epsilon was reduced in gelsolin-overexpressed cells, whereas phosphorylation of mitogen-activated protein kinase was not changed. S1P-induced PLC activation and mitogen-activated protein kinase phosphorylation were sensitive to pertussis toxin, but PLD response was insensitive to such treatment, suggesting that S1P induced PLD activation via certain G protein distinct from G(i) for PLC and mitogen-activated protein kinase pathway. Our results suggest that gelsolin modulates bradykinin-mediated PLD activation via suppression of PLC and PKC activities but did not affect S1P-mediated PLD activation.	Gifu Univ, Sch Med, Dept Biochem, Gifu 500, Japan; Hokkaido Univ, Sch Med, Inst Canc, Mol Genet Lab, Sapporo, Hokkaido 0608638, Japan; Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 657, Japan	Gifu University; Hokkaido University; Kobe University	Banno, Y (corresponding author), Gifu Univ, Sch Med, Dept Biochem, Tsukasamachi 40, Gifu 500, Japan.							Abousalham A, 1997, J BIOL CHEM, V272, P1069, DOI 10.1074/jbc.272.2.1069; An SZ, 1998, J CELL BIOCHEM, P147; Banno Y, 1997, J BIOL CHEM, V272, P5208, DOI 10.1074/jbc.272.8.5208; BANNO Y, 1992, J BIOL CHEM, V267, P6488; Barkalow K, 1996, J CELL BIOL, V134, P389, DOI 10.1083/jcb.134.2.389; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DESAI NN, 1992, J BIOL CHEM, V267, P23122; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hess JA, 1998, J BIOL CHEM, V273, P20517, DOI 10.1074/jbc.273.32.20517; Iwasaki-Bessho Y, 1998, J INVEST DERMATOL, V110, P376; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JONES GA, 1993, J BIOL CHEM, V268, P20845; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; Kiss Z, 1996, CHEM PHYS LIPIDS, V80, P81, DOI 10.1016/0009-3084(96)02547-9; Kiss Z, 1997, BIOCHEM J, V328, P383, DOI 10.1042/bj3280383; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEE YH, 1994, J BIOL CHEM, V269, P26842; Lukowski S, 1998, BIOCHEM BIOPH RES CO, V248, P278, DOI 10.1006/bbrc.1998.8942; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Nakamura Y, 1996, J IMMUNOL, V156, P256; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Singer WD, 1996, J BIOL CHEM, V271, P4504; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; Sun HQ, 1997, J CELL BIOL, V138, P811, DOI 10.1083/jcb.138.4.811; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	47	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27385	27391		10.1074/jbc.274.39.27385	http://dx.doi.org/10.1074/jbc.274.39.27385			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488069	hybrid			2022-12-25	WOS:000082739100008
J	Hildebrand, EL; Grossman, L				Hildebrand, EL; Grossman, L			Oligomerization of the UvrB nucleotide excision repair protein of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CISPLATIN-DAMAGED DNA; UVRABC ENDONUCLEASE; (A)BC EXCINUCLEASE; ENZYMATIC-PROPERTIES; PREINCISION COMPLEX; INCISION REACTION; CROSS-LINKING; HELICASE; BINDING; PURIFICATION	A combination of hydrodynamic and cross-linking studies were used to investigate self-assembly of the Escherichia coli DNA repair protein UvrB. Though the procession of steps leading to incision of DNA at sites flanking damage requires that UvrB engage in an ordered series of complexes, successively with UvrA, DNA and UvrC, the potential for self-association had not yet been reported. Gel permeation chromatography, nondenaturing polyacrylamide gel electrophoresis, and chemical cross linking results combine to show that UvrB stably assembles as a dimer in solution at concentrations in the low micromolar range. Smaller populations of higher order oligomeric species are also observed. Unlike the dimerization of UvrA, an initial step promoted by ATP binding, the monomer-dimer equilibrium for UvrB is unaffected by the presence of ATP. The insensitivity of cross-linking efficiency to a 10-fold variation in salt concentration further suggests that UvrB self-assembly is driven largely by hydrophobic interactions. Self-assembly is significantly weakened by proteolytic removal of the carboxyl terminus of the protein (generating UvrB*), a domain also known to be required for the interaction with UvrC leading to the initial incision of damaged DNA. This suggests that the C terminus may be a multifunctional binding domain, with specificity regulated by protein conformation.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Johns Hopkins University	Grossman, L (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, 615 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022846, R01GM022846] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-22846] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackers G. K., 1975, PROTEINS, V1, P1; ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P9641, DOI 10.1093/nar/16.20.9641; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; Delagoutte E, 1997, J MOL BIOL, V266, P703, DOI 10.1006/jmbi.1996.0830; DYKSTRA CC, 1984, COLD SPRING HARB SYM, V49, P463, DOI 10.1101/SQB.1984.049.01.052; FELGENHA.K, 1974, H-S Z PHYSIOL CHEM, V355, P1281, DOI 10.1515/bchm2.1974.355.2.1281; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; Hildebrand EL, 1998, J BIOL CHEM, V273, P7818, DOI 10.1074/jbc.273.14.7818; HSU DS, 1995, J BIOL CHEM, V270, P8319, DOI 10.1074/jbc.270.14.8319; JI TH, 1983, METHOD ENZYMOL, V91, P580; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MARGOLIS J, 1975, J CHROMATOGR, V106, P204, DOI 10.1016/S0021-9673(01)81066-9; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; POTSCHKA M, 1987, ANAL BIOCHEM, V162, P47, DOI 10.1016/0003-2697(87)90009-1; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; SPRADLIN J, 1970, J BIOL CHEM, V245, P117; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1992, J BIOL CHEM, V267, P6736; VISSE R, 1991, J BIOL CHEM, V266, P7609; VISSE R, 1994, BIOCHEMISTRY-US, V33, P1804, DOI 10.1021/bi00173a025; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157; Zou Y, 1998, J MOL BIOL, V281, P107, DOI 10.1006/jmbi.1998.1903; ZOU Y, 1995, BIOCHEMISTRY-US, V34, P13582, DOI 10.1021/bi00041a038; Zou Y, 1997, J BIOL CHEM, V272, P4820, DOI 10.1074/jbc.272.8.4820	46	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27885	27890		10.1074/jbc.274.39.27885	http://dx.doi.org/10.1074/jbc.274.39.27885			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488135	hybrid			2022-12-25	WOS:000082739100074
J	Huang, SS; Zhou, M; Johnson, FE; Shieh, HS; Huang, JS				Huang, SS; Zhou, M; Johnson, FE; Shieh, HS; Huang, JS			An active site of transforming growth factor-beta(1) for growth inhibition and stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA-RECEPTOR; LUNG EPITHELIAL-CELLS; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; GROWTH-FACTOR-BETA-2; BINDING	Transforming growth factor-beta (TGF-beta) is a bifunctional growth regulator. It inhibits growth of many cell types, including epithelial cells, but stimulates growth of others (e.g. fibroblasts). The active site on the TGF-beta molecule, which mediates its growth regulatory activity, has not been defined. Here, we show that antibody to a TGF-beta(1) peptide containing the motif WSLD (52nd to 55th amino acid residues) completely blocked both I-125-TGF-beta(1) binding to TGF-beta receptors and TGF-beta(1)-induced growth inhibition in mink lung epithelial cells. Site-directed mutagenesis analysis revealed that the replacement of Trp(52) and Asp(55) by alanine residues diminished the growth inhibitory activity of TGF-beta(1) by similar to 90%, Finally, while wild-type TGF-beta(1) was able to stimulate growth of transfected NIH 3T3 cells, the double mutant TGF-beta(1) W52A/D55A was much less active. These results support the hypothesis that the WSLD motif is an active site of TGF-beta(1), which is important for growth inhibition of epithelial cells and growth stimulation of fibroblasts.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Surg, St Louis, MO 63104 USA; Monsanto Co, Searle Discovery Res, St Louis, MO 63198 USA	Saint Louis University; Saint Louis University; Monsanto	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@slu.edu			NCI NIH HHS [CA38808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATAYAKULCHANTLER S, 1994, J BIOL CHEM, V269, P27687; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1152, DOI 10.1021/bi00055a021; BURMESTER JK, 1993, P NATL ACAD SCI USA, V90, P8628, DOI 10.1073/pnas.90.18.8628; Burmester JK, 1998, GROWTH FACTORS, V15, P231, DOI 10.3109/08977199809002119; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; FLANDERS KC, 1988, BIOCHEMISTRY-US, V27, P739, DOI 10.1021/bi00402a037; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; Huang SS, 1998, J BIOL CHEM, V273, P26036, DOI 10.1074/jbc.273.40.26036; HUANG SS, 1988, J BIOL CHEM, V263, P12608; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MERWIN JR, 1991, AM J PATHOL, V138, P37; Qian SW, 1996, J BIOL CHEM, V271, P30656, DOI 10.1074/jbc.271.48.30656; QIAN SW, 1992, P NATL ACAD SCI USA, V89, P6290, DOI 10.1073/pnas.89.14.6290; QIAN SW, 1994, BIOCHEMISTRY-US, V33, P12298, DOI 10.1021/bi00206a037; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SHAH M, 1995, J CELL SCI, V108, P985; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473	28	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27754	27758		10.1074/jbc.274.39.27754	http://dx.doi.org/10.1074/jbc.274.39.27754			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488119	hybrid			2022-12-25	WOS:000082739100058
J	Noe, V; Ciudad, CJ; Chasin, LA				Noe, V; Ciudad, CJ; Chasin, LA			Effect of differential polyadenylation and cell growth phase on dihydrofolate reductase mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; AU-RICH ELEMENTS; MAMMALIAN-CELLS; NONSENSE MUTATIONS; MOUSE FIBROBLASTS; GENE-EXPRESSION; POLYMERASE-II; C-FOS; TRANSCRIPTION; DEADENYLATION	We have constructed tetracycline-responsive dhfr minigenes and transferred them to a Chinese hamster ovary cell. DHFR-deficient deletion mutant to obtained cells in which dhfr transcription can be repressed by tetracycline (tet-off). DHFR mRNA half-life measured after the repression of transcription by tetracycline in these transfectants is about 1.5 h, which is significantly shorter than previously reported. In addition, we observed that DHFR mRNA is less stable in serum-starved cells than in exponentially growing cells. Given that the dhfr gene contains multiple polyadenylation sites, we analyzed the role of polyadenylation site usage on the stability of the resultant mRNA molecules. We found that DHFR mRNA is more stable when a strong polyadenylation site is used. Finally, we have observed that the relative lengths of the poly(A) tails for the different DHFR mRNA species correlated with their relative stability in growing versus resting cells.	Columbia Univ, Fairchild Life Sci Ctr, Dept Biol Sci, New York, NY 10027 USA; Univ Barcelona, Sch Pharm, Dept Biochem, Barcelona 08028, Spain	Columbia University; University of Barcelona	Chasin, LA (corresponding author), Columbia Univ, Fairchild Life Sci Ctr, Dept Biol Sci, New York, NY 10027 USA.		Noe, Veronique/K-3615-2014; Ciudad, Carlos J./D-7917-2014	Noe, Veronique/0000-0001-7937-8038; Ciudad, Carlos J./0000-0002-7855-392X	NIGMS NIH HHS [GM-22529] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAROTHERS AM, 1983, NUCLEIC ACIDS RES, V11, P1997, DOI 10.1093/nar/11.7.1997; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CIUDAD CJ, 1988, J BIOL CHEM, V263, P16274; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P365, DOI 10.1128/MCB.6.2.365; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HENDRICKSON SL, 1980, P NATL ACAD SCI-BIOL, V77, P5140, DOI 10.1073/pnas.77.9.5140; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; KAUFMAN RJ, 1983, MOL CELL BIOL, V3, P1598, DOI 10.1128/MCB.3.9.1598; Kessler O, 1996, MOL CELL BIOL, V16, P4426; LEYS EJ, 1984, J CELL BIOL, V99, P180, DOI 10.1083/jcb.99.1.180; LEYS EJ, 1981, MOL CELL BIOL, V1, P961, DOI 10.1128/MCB.1.11.961; LUSKY M, 1984, CELL, V36, P391, DOI 10.1016/0092-8674(84)90232-0; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; NESIC D, 1995, MOL CELL BIOL, V15, P488, DOI 10.1128/MCB.15.1.488; Noe V, 1997, EUR J BIOCHEM, V249, P13, DOI 10.1111/j.1432-1033.1997.00013.x; NOE V, 1995, ANAL BIOCHEM, V224, P600, DOI 10.1006/abio.1995.1093; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SALLES FJ, 1995, PCR METH APPL, V4, P317; SANTIAGO C, 1984, J CELL PHYSIOL, V118, P79, DOI 10.1002/jcp.1041180114; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; VENOLIA L, 1987, SOMAT CELL MOLEC GEN, V13, P491, DOI 10.1007/BF01534491; Voeltz GK, 1998, MOL CELL BIOL, V18, P7537, DOI 10.1128/MCB.18.12.7537; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; YANG HH, 1995, GENE, V163, P185, DOI 10.1016/0378-1119(95)00381-F	33	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27807	27814		10.1074/jbc.274.39.27807	http://dx.doi.org/10.1074/jbc.274.39.27807			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488126	hybrid			2022-12-25	WOS:000082739100065
J	Reed, KE; Rice, CM				Reed, KE; Rice, CM			Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTIRE NUCLEOTIDE-SEQUENCE; COMPLETE CODING SEQUENCE; PREDOMINANT GENOTYPE; KINASE; RNA; EXPRESSION; INTERFERON; CLONING; REGION; GENOME	The hepatitis C virus (HCV) NS5A protein is phosphorylated by a cellular, serine/threonine kinase. To identify the major site(s) of NS5A phosphorylation, radiolabeled HCV-H NS5A phosphopeptides were purified and subjected to phosphoamino acid analysis and Edman degradation. These data identified the major intracellular phosphorylation site in the HCV-H NS5A protein as Ser(2321), a result verified by two additional, independent methods: (i) substitution of Ala for Ser(2321) and the concomitant disappearance of the major in vivo phosphorylated peptides and corresponding in vitro phosphorylated peptides; and (ii) comigration of the digestion products of a synthetic peptide phosphorylated on Ser(2321) with the major in vivo phosphorylated NS5A peptides. Site directed mutagenesis of Ser(2321) suggested that phosphorylation of NS5A is dispensable for previously described interactions with NS4A and PKR, a cellular, antiviral kinase that does not appear to catalyze NS5A phosphorylation. The proline-rich nature of the amino acid sequence flanking Ser(2321) (PLPPPRS2321 PPVPPPR) suggests that a proline-directed kinase is responsible for the majority of HCV NS5A phosphorylation, consistent with previous kinase inhibitor studies.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Rice, CM (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [R01CA057973] Funding Source: NIH RePORTER; NCI NIH HHS [CA57973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams NJ, 1997, BIOCHEM BIOPH RES CO, V234, P393, DOI 10.1006/bbrc.1997.6627; Asabe SI, 1997, J VIROL, V71, P790, DOI 10.1128/JVI.71.1.790-796.1997; BLACK TL, 1993, J VIROL, V67, P791, DOI 10.1128/JVI.67.2.791-800.1993; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chamberlain RW, 1997, BIOCHEM BIOPH RES CO, V236, P44, DOI 10.1006/bbrc.1997.6902; Chamberlain RW, 1997, J GEN VIROL, V78, P1341, DOI 10.1099/0022-1317-78-6-1341; COBB MH, 1995, PROTEIN KINASE FACTS; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KANEKO T, 1994, BIOCHEM BIOPH RES CO, V205, P320, DOI 10.1006/bbrc.1994.2667; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; OKAMOTO H, 1994, J GEN VIROL, V75, P629, DOI 10.1099/0022-1317-75-3-629; OKAMOTO H, 1991, J GEN VIROL, V72, P2697, DOI 10.1099/0022-1317-72-11-2697; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Reed KE, 1997, J VIROL, V71, P7187, DOI 10.1128/JVI.71.10.7187-7197.1997; REED KE, 1998, THESIS WASHINGTON U; SAKAMOTO M, 1994, J GEN VIROL, V75, P1761, DOI 10.1099/0022-1317-75-7-1761; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	27	52	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					28011	28018		10.1074/jbc.274.39.28011	http://dx.doi.org/10.1074/jbc.274.39.28011			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488152	hybrid			2022-12-25	WOS:000082739100091
J	Windh, RT; Lee, MJ; Hla, T; An, SZ; Barr, AJ; Manning, DR				Windh, RT; Lee, MJ; Hla, T; An, SZ; Barr, AJ; Manning, DR			Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT NEURITE RETRACTION; CELL-SURFACE RECEPTOR; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAYS; PHOSPHOLIPASE-D; 5-HYDROXYTRYPTAMINE(1A) RECEPTOR; ENDOTHELIAL-CELLS; 5-HT1A RECEPTOR; KINASE PATHWAY; P115 RHOGEF	Sphingosine 1-phosphate (S1P) is one of several bioactive phospholipids that exert profound mitogenic and morphogenic actions. Originally characterized as a second messenger, S1P is now recognized to achieve many of its effects through cell surface, G protein-coupled receptors. We used a subunit-selective [S-35]GTP gamma S binding assay to investigate whether the variety of actions exerted through Edg-1, a recently identified receptor for S1P, might be achieved through multiple G proteins. We found, employing both Sf9 and HEK293 cells, that Edg-1 activates only members of the G(i) family, and not G(s), G(q), G(12), or G(13). We additionally established that Edg-1 activates Gi in response not only to S1P but also sphingosylphosphorylcholine; no effects of lysophosphatidic acid through Edg-1 were evident. Our assays further revealed a receptor(s) for S1P endogenous to HEK293 cells that mediates activation of G(13) as well as G(i). Because several of the biological actions of S1P are assumed to proceed through the G(12/13) family, we tested whether Edg-3 and H218/Edg-5, two other receptors for S1P, might have a broader coupling profile than Edg-1. Indeed, Edg-3 and H218/Edg-5 communicate not only with G(i) but also with G(q) and G(13). These studies represent the first characterization of S1P receptor activity through G proteins directly and establish fundamental differences in coupling.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Connecticut, Sch Med, Dept Physiol, Farmington, CT 06030 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of Pennsylvania; University of Connecticut; University of California System; University of California San Francisco	Manning, DR (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	manning@pharm.med.upenn.edu	Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065; Barr, Alastair/0000-0001-7738-8419	NIGMS NIH HHS [GM51196] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051196] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; An SZ, 1998, J CELL BIOCHEM, P147; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; An SZ, 1999, MOL PHARMACOL, V55, P787; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Barr AJ, 1997, J BIOL CHEM, V272, P32979, DOI 10.1074/jbc.272.52.32979; Berger A, 1996, MOL PHARMACOL, V50, P451; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Bunemann M, 1995, J PHYSIOL-LONDON, V489, P701; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CHAO CP, 1994, J BIOL CHEM, V269, P5849; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DESAI NN, 1992, J BIOL CHEM, V267, P23122; Edsall LC, 1997, J NEUROSCI, V17, P6952; FARGIN A, 1989, J BIOL CHEM, V264, P14848; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Heringdorf DMZ, 1996, N-S ARCH PHARMACOL, V354, P397; HLA T, 1990, J BIOL CHEM, V265, P9308; Im DS, 1997, AM J PHYSIOL-GASTR L, V272, pG1091, DOI 10.1152/ajpgi.1997.272.5.G1091; INNIS RB, 1987, EUR J PHARMACOL, V143, P195, DOI 10.1016/0014-2999(87)90533-4; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kiss Z, 1997, BIOCHEM J, V328, P383, DOI 10.1042/bj3280383; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Liliom K, 1998, J BIOL CHEM, V273, P13461, DOI 10.1074/jbc.273.22.13461; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; Noh SJ, 1998, J CELL PHYSIOL, V176, P412, DOI 10.1002/(SICI)1097-4652(199808)176:2<412::AID-JCP20>3.0.CO;2-3; Okajima F, 1996, FEBS LETT, V379, P260, DOI 10.1016/0014-5793(95)01526-4; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; SADAHIRA Y, 1994, FEBS LETT, V340, P99, DOI 10.1016/0014-5793(94)80180-0; Sato K, 1997, BIOCHEM BIOPH RES CO, V240, P329, DOI 10.1006/bbrc.1997.7666; Tornquist K, 1997, ENDOCRINOLOGY, V138, P4049, DOI 10.1210/en.138.10.4049; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; WINDH RT, 1999, IN PRESS HDB EXPT PH; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	62	278	286	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27351	27358		10.1074/jbc.274.39.27351	http://dx.doi.org/10.1074/jbc.274.39.27351			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488065	hybrid			2022-12-25	WOS:000082739100004
J	Ameyar, M; Shatrov, V; Bouquet, C; Capoulade, C; Cai, ZZ; Stancou, R; Badie, C; Haddada, H; Chouaib, S				Ameyar, M; Shatrov, V; Bouquet, C; Capoulade, C; Cai, ZZ; Stancou, R; Badie, C; Haddada, H; Chouaib, S			Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb	ONCOGENE			English	Article						TNF; p53; c-myc; Rb	TUMOR-NECROSIS-FACTOR; CYCLE CHECKPOINT PATHWAY; BREAST-CARCINOMA CELLS; RETINOBLASTOMA PROTEIN; IN-VIVO; TRANSCRIPTION FACTOR; SUPPRESSOR P53; GROWTH ARREST; FACTOR-ALPHA; BAX GENE	Tumor suppressor p53 is a nuclear transcription factor that blocks cell cycle progression and induces apoptosis, We have previously shown that the MCF7 resistance to the cytotoxic action of TNF correlates with p53 mutations. In the present study, we used a recombinant adenovirus carrying a wild-type p53 gene (Adwtp53) in order to investigate the effect of wt p53 transfer on modulation of cell resistance to the cytotoxic action of TNF. Our data indicate that infection of TNF resistant MCF7 cells (1001 and MCF7/Adr) with Adwtp53 resulted in the restoration of wt p53 expression and function as respectively revealed by the yeast assay and the induction of p53 inducible genes MDM2 and p21, Furthermore, the restoration of p53 function significantly sensitized TNF resistant cells to TNF cytotoxic action. This correlated with a significant don n-regulation of c-myc in both TNF-resistant cell lines and a decrease of Retinoblastoma protein (Rb) in 1001 clone. In contrast, the effect of p53 seems to be independent from Bcl-2 and Bax protein level regulation. The present study suggests that the combination of TNF and Adwtp53 may be a potential strategy to sensitize mutant p53 TNF-resistant tumors to the cytotoxic action of this cytokine.	Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Inst Gustave Roussy, UMR 1598, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, UMR 1772, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Chouaib, S (corresponding author), Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France.		Badie, Christophe/L-5890-2019; Chouaib, Salem/F-7939-2016	Badie, Christophe/0000-0003-4572-5008				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Caignard A, 1997, ONCOL REP, V4, P227; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chiarugi V, 1996, TUMORI, V82, P205; CHOUAIB S, 1991, IMMUNOL TODAY, V12, P141, DOI 10.1016/0167-5699(91)90076-6; Chouaib S, 1997, IMMUNOL TODAY, V18, P493, DOI 10.1016/S0167-5699(97)01115-8; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Gorospe M, 1996, CELL GROWTH DIFFER, V7, P1609; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JAATTELA M, 1995, ONCOGENE, V10, P2297; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; LEJEUNE F, 1994, CIRC SHOCK, V43, P191; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LopezMarure R, 1997, BIOCHEM BIOPH RES CO, V236, P819, DOI 10.1006/bbrc.1997.7056; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Tan XQ, 1997, J BIOL CHEM, V272, P9613; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZYAD A, 1994, CANCER RES, V54, P825	56	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5464	5472		10.1038/sj.onc.1202919	http://dx.doi.org/10.1038/sj.onc.1202919			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498900				2022-12-25	WOS:000082718600011
J	Delavaine, L; La Thangue, NB				Delavaine, L; La Thangue, NB			Control of E2F activity by p21(Waf1/Cip1)	ONCOGENE			English	Article						E2F; p21; repression; cell cycle	DEPENDENT DNA-REPLICATION; CELL-CYCLE REGULATION; RNA POLYMERASE-II; C-TERMINAL REGION; TRANSCRIPTIONAL REPRESSION; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; E7 ONCOPROTEIN; P21; INHIBITOR	Cyclin-dependent kinase inhibitors (cdkis), such as p21, are believed to control proliferation through an ability to function as stoichiometric antagonists of cyclin-dependent kinases (cdks). The p21 gene is a direct transcriptional target for the p53 protein, and its activation is likely to be important in effecting the p53 response, It is widely accepted that p21 can influence cell cycle progression by controlling the activity of cdks that act on the retinoblastoma tumour suppressor protein (pRb) which, in a hypophosphorylated state, associates with E2F transcription factors to prevent the activation of genes required for progression into S phase, Phosphorylation of pRb by G1 cdk complexes releases E2F and thereby enables progress through the cell cycle, Here, we describe results which suggest a p21-dependent mechanism that facilitates the regulation of E2F through a pathway that is independent of the cdk control of pRb activity. As p21 can associate with E2F subunits, it is possible that these effects are exerted through a complex with E2F. Furthermore, we find that p21 can regulate transcription in vitro. The results suggest that p21 may control E2F activity through a pathway that acts independently of pRb.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALI SA, 1995, BIOTECHNIQUES, V18, P746; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHEN J, 1994, NATURE, V374, P386; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1996, CURR TOP MICROBIOL I, V208, P1; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SLANSKY JE, 1993, MOL CELL BIOL, V13, P7201; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V378, P312; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	54	127	134	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5381	5392		10.1038/sj.onc.1202923	http://dx.doi.org/10.1038/sj.onc.1202923			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498892				2022-12-25	WOS:000082718600003
J	Hanafusa, H; Ninomiya-Tsuji, J; Masuyama, N; Nishita, M; Fujisawa, J; Shibuya, H; Matsumoto, K; Nishida, E				Hanafusa, H; Ninomiya-Tsuji, J; Masuyama, N; Nishita, M; Fujisawa, J; Shibuya, H; Matsumoto, K; Nishida, E			Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; MAD-RELATED PROTEIN; TGF-BETA; SIGNAL-TRANSDUCTION; SMAD PROTEINS; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; BINDING-PROTEIN; RECEPTOR; PHOSPHORYLATION	Transforming growth factor-beta (TGF-beta)-activated kinase 1 (TAK1), a member of the mitogen-activated protein kinase kinase kinase family, is suggested to be involved in TGF-beta induced gene expression, but the signaling mechanism from TAK1 to the nucleus remains largely undefined. We have found that p38 mitogen-activated protein kinase, and its direct activator MKK6 are rapidly activated in response to TGF-beta. Expression of dominant negative MKK6 or dominant negative TAK1 inhibited the TGF-beta-induced transcriptional activation as well as the p38 activation. Constitutive activation of the p38 pathway :in the absence of TGF-beta induced the transcriptional activation, which was enhanced synergistically by coexpression of Smad2 and Smad4 and was inhibited by expression of the C-terminal truncated, dominant negative Smad4. Furthermore, we have found that activating transcription factor-2 (ATF-2), which is known as a nuclear target of p38, becomes phosphorylated in the N-terminal activation domain in response to TGF-beta, that ATF-2 forms a complex with Smad4, and that the complex formation is enhanced by TGF-beta. In addition, expression of a nonphosphorylatable form of ATF-2 inhibited the TGF-beta-induced transcriptional activation. These results show that the p38 pathway is activated by TGF-beta and is involved in the TGF-beta-induced transcriptional activation by regulating the Smad-mediated pathway.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 46401, Japan; Natl Inst Basic Biol, Dept Dev Biol, Div Morphogenesis, Okazaki, Aichi 4448585, Japan; Kansai Med Univ, Dept Microbiol, Moriguchi, Osaka 570, Japan	Kyoto University; Nagoya University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kansai Medical University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.			Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	49	375	392	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27161	27167		10.1074/jbc.274.38.27161	http://dx.doi.org/10.1074/jbc.274.38.27161			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480932	hybrid			2022-12-25	WOS:000082570700071
J	Inoue, Y; Matsuda, T; Sugiyama, K; Izawa, S; Kimura, A				Inoue, Y; Matsuda, T; Sugiyama, K; Izawa, S; Kimura, A			Genetic analysis of glutathione peroxidase in oxidative stress response of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; YAP-1 TRANSCRIPTIONAL REGULATION; ACTIVE ORGANOSELENIUM COMPOUND; HANSENULA-MRAKII; HYDROGEN-PEROXIDE; FINGER PROTEINS; BZIP PROTEINS; MESSENGER-RNA; TARGET GENE; YEAST	Three glutathione peroxidase homologs (YKL026C, YBR244W, and YIR037W/HYR1) were found in the Saccharomyces Genome Database. We named them GPX1, GPX2, and GPX3, respectively, and we investigated the function of each gene product. The gpx3 Delta mutant was hypersensitive to peroxides, whereas null mutants of the GPX1 and GPX2 did not show any obvious phenotypes, Glutathione peroxidase activity decreased approximately 57 and 93% in the gpx3 Delta and gpx1 Delta/gpx2 Delta/gpx3 Delta mutants, respectively, compared with that of wild type. Expression of the GPX3 gene was not induced by any stresses tested, whereas that of the GPX1 gene was induced by glucose starvation. The GPX2 gene expression was induced by oxidative stress, which was dependent upon the Yap1p. The TSA1 (thiol-specific antioxidant) gene encodes thioredoxin peroxidase that can reduce peroxides by using thioredoxin as a reducing power. Disruption of the TSA1 gene enhanced the basal expression level of the Yap1p target genes such as GSH1, GLR1, and GPX2 and that resulted in increases of total glutathione level and activities of glutathione reductase and glutathione peroxidase. However, expression of the TSA1 gene did not increase in the gpx1 Delta/gpx2 Delta/gpx3 Delta mutant. Therefore, de novo synthesis and recycling of glutathione were increased in the tsa1 Delta mutant to maintain the catalytic cycle of glutathione peroxidase reaction efficiently as a backup system for thioredoxin peroxidase.	Kyoto Univ, Food Sci Res Inst, Kyoto 6110011, Japan	Kyoto University	Inoue, Y (corresponding author), Kyoto Univ, Food Sci Res Inst, Kyoto 6110011, Japan.		kimura, akira/D-1215-2010	Izawa, Shingo/0000-0002-4920-2450				AIKENS J, 1991, J BIOL CHEM, V266, P15091; Asada K., 1997, OXIDATIVE STRESS MOL, V34, P715; AWASTHI YC, 1979, BIOCHEM J, V177, P471, DOI 10.1042/bj1770471; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, BIOFACTORS, V4, P177; CHEN GT, 1992, MOL MICROBIOL, V6, P781, DOI 10.1111/j.1365-2958.1992.tb01528.x; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; GALIAZZO F, 1987, BIOCHEM BIOPH RES CO, V147, P1200, DOI 10.1016/S0006-291X(87)80197-3; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; IIZUKA M, 1988, AGR BIOL CHEM TOKYO, V52, P613; Inoue Y, 1998, BBA-GENE STRUCT EXPR, V1395, P315, DOI 10.1016/S0167-4781(97)00199-1; INOUE Y, 1990, AGR BIOL CHEM TOKYO, V54, P3289, DOI 10.1080/00021369.1990.10870496; Inoue Y, 1995, BBA-GEN SUBJECTS, V1245, P325, DOI 10.1016/0304-4165(95)00117-4; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; INOUE Y, 1993, J FERMENT BIOENG, V75, P229, DOI 10.1016/0922-338X(93)90123-P; INOUE Y, 1998, RRD AGR BIOL CHEM 1, V2, P29; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; Izawa S, 1996, BIOCHEM J, V320, P61, DOI 10.1042/bj3200061; IZAWA S, 1999, IN PRESS J BIOL CHEM, V274; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Miki T, 1996, BIOSCI BIOTECH BIOCH, V60, P1207; Miller J.H., 1972, EXPT MOL GENETICS; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; MULLER A, 1984, BIOCHEM PHARMACOL, V33, P3235, DOI 10.1016/0006-2952(84)90083-2; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULTE F, 1994, T 2 INT HIGH TEMP EL, V1, P3; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SIKORSKI RS, 1989, GENETICS, V122, P19; STADTMAN TC, 1991, J BIOL CHEM, V266, P16257; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Takeuchi T, 1997, FEBS LETT, V416, P339, DOI 10.1016/S0014-5793(97)01233-7; TRAN LT, 1993, BIOCHIM BIOPHYS ACTA, V1164, P166, DOI 10.1016/0167-4838(93)90244-L; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; Wemmie JA, 1997, J BIOL CHEM, V272, P7908, DOI 10.1074/jbc.272.12.7908; WENDEL A, 1984, BIOCHEM PHARMACOL, V33, P3241, DOI 10.1016/0006-2952(84)90084-4; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660	62	207	216	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27002	27009		10.1074/jbc.274.38.27002	http://dx.doi.org/10.1074/jbc.274.38.27002			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480913	hybrid			2022-12-25	WOS:000082570700052
J	Liu, XD; Morano, KA; Thiele, DJ				Liu, XD; Morano, KA; Thiele, DJ			The yeast Hsp110 family member, SSE1, is an Hsp90 cochaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; MOLECULAR CHAPERONE; SIGNAL-TRANSDUCTION; IN-VIVO; FACTOR CONTAINS; GENE; COMPLEX; BINDING	In eukaryotes, production of the diverse repertoire of molecular chaperones during normal growth and in response to stress is governed by the heat shock transcription factor HSF. The HSC82 and HSP82 genes,encoding isoforms of the, yeast Hsp90 molecular chaperone, were recently identified as targets of the HSF carboxyl-terminal activation domain (CTA), whose expression is required for cell cycle progression during prolonged heat stress conditions. In the present study, we have identified additional target genes of the HSF CTA, which include nearly all of the heat shock-inducible members of the Hsp90 chaperone complex, demonstrating coordinate regulation of these components by HSF. Heat shock induction of SSE1, encoding a member of the Hsp110 family of heat shock proteins, was also dependent on the HSF CTA. Disruption of SSE1 along with STI1, encoding an established subunit of the Hsp90 chaperone complex, resulted in a severe synthetic growth phenotype. Sse1 associated with partially purified Hsp90 complexes and deletion of the SSE1 gene rendered cells susceptible to the Hsp90 inhibitors macbecin and geldanamycin, suggesting functional interaction between Sse1 and Hsp90. Sse1 is required for function of the glucocorticoid receptor, a model substrate of the Hsp90 chaperone machinery, and Hsp90-based repression of HSF under nonstress conditions. Taken together, these data establish Sse1 as an integral new component of the Hsp90 chaperone complex in yeast.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	dthiele@umich.edu		Morano, Kevin/0000-0002-5992-0253	NCI NIH HHS [5T32CA09676-06] Funding Source: Medline; NIGMS NIH HHS [1F32 GM19195-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Chung KS, 1998, GENE, V210, P143, DOI 10.1016/S0378-1119(98)00061-4; Craven RA, 1997, TRENDS CELL BIOL, V7, P277, DOI 10.1016/S0962-8924(97)01079-9; Cyr D M, 1996, EXS, V77, P25; Dey B, 1996, MOL BIOL CELL, V7, P1405, DOI 10.1091/mbc.7.9.1405; Dolinski KJ, 1998, MOL CELL BIOL, V18, P7344, DOI 10.1128/MCB.18.12.7344; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; FEIGE U, 1996, STRESS INDUCIBLE CEL, V77; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; KIMURA Y, 1994, MOL GEN GENET, V242, P517, DOI 10.1007/BF00285275; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; Liu HD, 1996, GENE DEV, V10, P592; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; Morano KA, 1999, MOL CELL BIOL, V19, P402; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MUKAI H, 1993, GENE, V132, P57; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; NICOLET CM, 1991, METHOD ENZYMOL, V194, P710; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Plesofsky-Vig N, 1998, J BIOL CHEM, V273, P11335, DOI 10.1074/jbc.273.18.11335; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Santoro N, 1998, MOL CELL BIOL, V18, P6340, DOI 10.1128/MCB.18.11.6340; Santos BC, 1998, AM J PHYSIOL-RENAL, V274, pF1054, DOI 10.1152/ajprenal.1998.274.6.F1054; SHIRAYAMA M, 1993, MOL GEN GENET, V240, P323, DOI 10.1007/BF00280382; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Storozhenko S, 1996, FEBS LETT, V390, P113, DOI 10.1016/0014-5793(96)00640-0; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YASUDA K, 1995, J BIOL CHEM, V270, P29718, DOI 10.1074/jbc.270.50.29718; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Zarzov P, 1997, J CELL SCI, V110, P1879; Zhang L, 1998, MOL CELL BIOL, V18, P3819, DOI 10.1128/MCB.18.7.3819; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	59	96	101	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26654	26660		10.1074/jbc.274.38.26654	http://dx.doi.org/10.1074/jbc.274.38.26654			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480867	hybrid			2022-12-25	WOS:000082570700006
J	Sambamurti, K; Sevlever, D; Koothan, T; Refolo, LM; Pinnix, I; Gandhi, S; Onstead, L; Younkin, L; Prada, CM; Yager, D; Ohyagi, Y; Eckman, CB; Rosenberry, TL; Younkin, SG				Sambamurti, K; Sevlever, D; Koothan, T; Refolo, LM; Pinnix, I; Gandhi, S; Onstead, L; Younkin, L; Prada, CM; Yager, D; Ohyagi, Y; Eckman, CB; Rosenberry, TL; Younkin, SG			Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid beta-protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PRECURSOR PROTEIN; IN-VIVO; DISEASE; PEPTIDE; MUTATION; GENE; YEAST; EXPRESSION; CLEAVAGE	The Alzheimer's amyloid protein (A beta) is released hom the larger amyloid beta-protein precursor (APP) by unidentified enzymes referred to as beta- and gamma-secretase. beta-Secretase cleaves APP on the amino side of A beta producing a large secreted derivative (sAPP beta) and an A beta-bearing C-terminal derivative that is subsequently cleaved by gamma-secretase to release A beta. Alternative cleavage of the APP by alpha-secretase at A beta 16/17 releases the secreted derivative sAPP alpha. In yeast, alpha-secretase activity has been attributed to glycosylphosphatidylinositol (GPI)-anchored aspartyl proteases. To examine the role of GPI-anchored proteins, we specifically removed these proteins from the surface of mammalian cells using phosphatidylinositol-specific phospholipase C (PI-PLC). PI-PLC treatment of fetal guinea pig brain cultures substantially reduced the amount of A beta 40 and A beta 42 in the medium but had no effect on sAPP alpha, A mutant CHO cell line (gpi85), which lacks GPI-anchored proteins, secreted lower levels of A beta 40, A beta 42,and sAPP beta than its parental line (GPI+), When this parental line was treated with PI-PLC, A beta 40, A beta 42, and sAPP beta decreased to levels similar to those observed in the mutant line, and the mutant line was resistant to these effects of PI-PLC. These findings provide strong evidence that one or more GPI-anchored proteins play an important role in beta-secretase activity and A beta secretion in mammalian cells, The cell-surface GPI-anchored protein(s) involved in A beta biogenesis may be excellent therapeutic target(s) in Alzheimer's disease.	Mayo Clin, Jacksonville, FL 32224 USA	Mayo Clinic	Sambamurti, K (corresponding author), Mayo Clin, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	samba@mayo.edu	Sambamurti, Kumar/A-1620-2012	Sambamurti, Kumar/0000-0001-9507-9214	NIA NIH HHS [1RO3AG14883] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R03AG014883] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHECLER F, 1995, J NEUROCHEM, V65, P1431; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Clarke NJ, 1998, FEBS LETT, V430, P419, DOI 10.1016/S0014-5793(98)00706-6; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; FIELD MC, 1994, J BIOL CHEM, V269, P10830; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; HINES V, 1994, CELL MOL BIOL RES, V40, P273; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; KENNEDY AM, 1993, BRAIN, V116, P309, DOI 10.1093/brain/116.2.309; Komano H, 1998, J BIOL CHEM, V273, P31648, DOI 10.1074/jbc.273.48.31648; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Petryniak MA, 1996, BIOCHEM J, V320, P957, DOI 10.1042/bj3200957; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Stevens VL, 1996, BIOCHEM J, V313, P253, DOI 10.1042/bj3130253; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; ZHANG HY, 1994, J BIOL CHEM, V269, P27799; Zhang W, 1997, BBA-MOL CELL RES, V1359, P110, DOI 10.1016/S0167-4889(97)00082-7	43	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26810	26814		10.1074/jbc.274.38.26810	http://dx.doi.org/10.1074/jbc.274.38.26810			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480887	hybrid			2022-12-25	WOS:000082570700026
J	Slack, JK; Catling, AD; Eblen, ST; Weber, MJ; Parsons, JT				Slack, JK; Catling, AD; Eblen, ST; Weber, MJ; Parsons, JT			C-raf-mediated inhibition of epidermal growth factor-stimulated cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR; FEEDBACK-REGULATION; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAY; SOS-GRB2 COMPLEX; MOTILITY; INSULIN; DESENSITIZATION; GRB2	Epidermal growth factor stimulates migration of a number of cell types, yet the signaling pathways that regulate epiderm:al growth factor-stimulated migration are poorly defined. In this report, we employ a transient transfection migration assay to assess the role of components of the Ras-mitogen-activated protein (MAP) kinase signaling pathway in epidermal growth factor-stimulated chemotaxis of rat embryo fibroblasts, Expression of dominant negative Ras blocks epidermal growth factor-mediated chemotaxis, while constitutively active Ras has no effect on chemokinesis or chemotaxis, PD98059 and U0126, inhibitors of MAP kinase kinase (MEK) activity, decreased epidermal growth factor-stimulated migration, while kinase-defective MEK1, an inhibitor of MAP kinase activation, enhanced migration. To understand the paradoxical effects of these molecules on epidermal growth factor-induced migration, we examined the role of c-Raf on migration. Expression of either wild type c-Raf or the catalytic domain of c-Raf effectively inhibited epidermal growth factor-stimulated cell migration. We suggest that, whereas Ras activity is necessary to promote epidermal growth factor-stimulated migration, sustained activation of c-Raf may be important in down-regulating migratory signaling pathways triggered by epidermal growth factor receptor activation, Further, activation of c-Raf upon inhibition of the MEK-MAP kinase pathway may contribute to the inhibition of cell migration observed with pharmacological MEK inhibitors.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia	Parsons, JT (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 441, Charlottesville, VA 22908 USA.	jtp@virginia.edu			NCI NIH HHS [CA0042, CA39076, CA29243] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039076, R01CA029243, R37CA029243, R37CA039076] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; BARSAGI D, 1987, J CELL PHYSIOL, P69; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CHOW YH, 1995, J BIOL CHEM, V270, P14100, DOI 10.1074/jbc.270.23.14100; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FOX PL, 1994, ONCOGENE, V9, P3519; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; KARLUND JK, 1995, J BIOL CHEM, V270, P23421; KARLUND JK, 1996, J BIOL CHEM, V271, P16674; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; MANSKE M, 1994, INT REV CYTOL, V155, P49, DOI 10.1016/S0074-7696(08)62096-3; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; UEKI K, 1994, J BIOL CHEM, V269, P15756; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; Xie H, 1998, J CELL SCI, V111, P615	40	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27177	27184		10.1074/jbc.274.38.27177	http://dx.doi.org/10.1074/jbc.274.38.27177			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480934	hybrid			2022-12-25	WOS:000082570700073
J	Franch, T; Thisted, T; Gerdes, K				Franch, T; Thisted, T; Gerdes, K			Ribonuclease III processing of coaxially stacked RNA helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; ACTIVATED PROTEIN-KINASE; DSRNA BINDING DOMAIN; HOK MESSENGER-RNA; PROGRAMMED CELL-DEATH; ANTISENSE RNA; PLASMID R1; GENE-EXPRESSION; CLEAVAGE; MECHANISM	The RNase III family of endoribonucleases participates in maturation and decay of cellular and viral transcripts by processing of double-stranded RNA. RNase III degradation is inherent to most, antisense RNA-regulated gene systems in Escherichia coli, In the hok/sok system from plasmid RI, Sok antisense RNA targets the holt mRNA for RNase III-mediated degradation. An intermediate in the pairing reaction between Sok RNA and hoh mRNA forms a three-way junction. A complex between a chimeric antisense RNA and hok mRNA that mimics the three-way junction was cleaved by RNase III both in vivo and in vitro. Footprinting using E117A RNase III binding to partially complementary RNAs showed protection of the 13 base pairs of interstrand duplex and of the bottom part of the transcriptional terminator hairpin of the antisense RNA. This suggests that the 13 base pairs of RNA duplex are coaxially stacked on the antisense RNA terminator stem-loop and that each stem forms a monomer half-site, allowing symmetrical binding of the RNase III dimer. This processing scheme shows an unanticipated diversity in RNase III substrates and may have a more general implication for RNA metabolism.	Odense Univ, Dept Biol Mol, DK-5230 Odense M, Denmark; Univ Penn, Sch Med, Dept Genet, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Southern Denmark; Howard Hughes Medical Institute; University of Pennsylvania	Gerdes, K (corresponding author), Odense Univ, Dept Biol Mol, Campusvej 55, DK-5230 Odense M, Denmark.	kgerdes@molbiol.ou.dk	Gerdes, Kenn/M-2420-2014; Gerdes, Kenn/AAS-5548-2021	Gerdes, Kenn/0000-0002-7462-4612; Gerdes, Kenn/0000-0002-7462-4612				ABONELELA S, 1996, CELL, V85, P115; Bevilacqua PC, 1998, BIOCHEMISTRY-US, V37, P6303, DOI 10.1021/bi980113j; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; BLOMBERG P, 1990, EMBO J, V9, P2331, DOI 10.1002/j.1460-2075.1990.tb07405.x; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CASE CC, 1990, EMBO J, V9, P1259, DOI 10.1002/j.1460-2075.1990.tb08234.x; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; Court D. L., 1993, CONTROL MESSENGER RN, P71; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Elela SA, 1998, EMBO J, V17, P3738, DOI 10.1093/emboj/17.13.3738; Franch T, 1997, J MOL BIOL, V273, P38, DOI 10.1006/jmbi.1997.1294; GERDES K, 1992, J MOL BIOL, V226, P637, DOI 10.1016/0022-2836(92)90621-P; Gerdes K, 1997, ANNU REV GENET, V31, P1, DOI 10.1146/annurev.genet.31.1.1; GRANA D, 1988, GENETICS, V120, P319; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HJALT TAH, 1995, NUCLEIC ACIDS RES, V23, P571, DOI 10.1093/nar/23.4.571; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KRINKE L, 1987, GENE DEV, V1, P1005, DOI 10.1101/gad.1.9.1005; KRINKE L, 1990, NUCLEIC ACIDS RES, V18, P4809, DOI 10.1093/nar/18.16.4809; LI HL, 1993, NUCLEIC ACIDS RES, V21, P1919, DOI 10.1093/nar/21.8.1919; Li HL, 1996, EMBO J, V15, P1421, DOI 10.1002/j.1460-2075.1996.tb00484.x; Malmgren C, 1997, J BIOL CHEM, V272, P12508, DOI 10.1074/jbc.272.19.12508; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; Nicholson AW, 1996, PROG NUCLEIC ACID RE, V52, P1, DOI 10.1016/S0079-6603(08)60963-0; ROBERTSON HD, 1982, CELL, V30, P669, DOI 10.1016/0092-8674(82)90270-7; ROBERTSON HD, 1968, J BIOL CHEM, V243, P82; Rotondo G, 1997, RNA, V3, P1182; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scadden ADJ, 1997, EMBO J, V16, P2140, DOI 10.1093/emboj/16.8.2140; THISTED T, 1995, J MOL BIOL, V247, P859, DOI 10.1006/jmbi.1995.0186; THISTED T, 1992, J MOL BIOL, V223, P41, DOI 10.1016/0022-2836(92)90714-U; THISTED T, 1994, EMBO J, V13, P1960, DOI 10.1002/j.1460-2075.1994.tb06465.x; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; YOUNG RA, 1978, P NATL ACAD SCI USA, V75, P3593, DOI 10.1073/pnas.75.8.3593; Zhang KJ, 1997, P NATL ACAD SCI USA, V94, P13437, DOI 10.1073/pnas.94.25.13437	39	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26572	26578		10.1074/jbc.274.37.26572	http://dx.doi.org/10.1074/jbc.274.37.26572			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473621	hybrid			2022-12-25	WOS:000082469700087
J	Jeffers, M; Vande Woude, GF				Jeffers, M; Vande Woude, GF			Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling	ONCOGENE			English	Article						mutant Met; signaling; autophosphorylation	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; KINASE RECEPTOR; PROTOONCOGENE PRODUCT; CELL-TRANSFORMATION; EPITHELIAL-CELLS; ONCOPROTEIN; MOTILITY; GRB2; SITE	Mutations in Met have been identified in human cancer, and we have previously shown that these mutations deregulate the enzymatic activity of this tyrosine kinase receptor, thereby unleashing its oncogenic potential. Signal transduction via mild type Met has been shown to require the autophosphorylation of two tyrosine doublets; Y8,9 which functions to enhance enzymatic activity, and Y14,15 which provides docking sites for signaling molecules, and in the present investigation we examine the importance of these residues for signaling via mutationally activated Met. We find that activating mutations introduced into a membrane-spanning Met receptor circumvent the normally stringent requirement for Y8,9 phosphorylation, and do so in a largely ligand-dependent fashion. Similarly, activating mutations introduced into a constitutively dimerized cytoplasmic form of Met (i.e. Tpr-Met) facilitate its autophosphorylation and oncogenic activity in the absence of Y8,9 phosphorylation. We also find that activating mutations allow a membrane-spanning Met receptor to overcome the requirement for the Y14,15 phosphorylation in a manner which is largely ligand-independent, These findings support a model whereby activating mutations stabilize an active conformation of the Met kinase via a mechanism which can function independently of Y8,9 autophosphorylation and suggest that signaling via wild type Met and mutationally activated Met may proceed through distinct pathways.	NCI, Div Basic Sci, Natl Canc Inst, FCRDC, Ft Detrick, MD 21702 USA; NCI, ABL Basic Res Program, FCRDC, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Vande Woude, GF (corresponding author), NCI, Div Basic Sci, Natl Canc Inst, FCRDC, Bldg 469,POB B, Ft Detrick, MD 21702 USA.							BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5	37	20	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5120	5125		10.1038/sj.onc.1202902	http://dx.doi.org/10.1038/sj.onc.1202902			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490849				2022-12-25	WOS:000082497100012
J	Bratton, DL; Fadok, VA; Richter, DA; Kailey, JM; Frasch, SC; Nakamura, T; Henson, PM				Bratton, DL; Fadok, VA; Richter, DA; Kailey, JM; Frasch, SC; Nakamura, T; Henson, PM			Polyamine regulation of plasma membrane phospholipid flip-flop during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; PLATELET-ACTIVATING-FACTOR; HUMAN-ERYTHROCYTE-MEMBRANE; ELECTRON-SPIN-RESONANCE; LEUKEMIA HL-60 CELLS; TRANSBILAYER MOVEMENT; TISSUE TRANSGLUTAMINASE; PHOSPHATIDYLSERINE EXPOSURE; AMINOPHOSPHOLIPID TRANSLOCASE; POTASSIUM CHANNELS	During apoptosis, phosphatidylserine (PS) is moved from the plasma membrane inner leaflet to the outer leaflet where it triggers recognition and phagocytosis of the apoptotic cell. Although the mechanisms of PS appearance during apoptosis are not well understood, it is thought that declining activity of the aminophospholipid translocase and calcium-mediated, nonspecific flip-flop of phospholipids play a role, As previous studies in the erythrocyte ghost have shown that polyamines can alter flip flop of phospholipids, we asked whether alterations in cellular polyamines in intact cells undergoing apoptosis would affect PS appearance, either by altering aminophospholipid translocase activity or phospholipid flip-flop. Cells of the human leukemic cell line, HL-60, were incubated with or without the orni thine decarboxylase inhibitor, difluoromethylornithine (DFMO), and induced to undergo apoptosis by ultraviolet irradiation. Whereas DFMO treatment resulted in profound depletion of putrescine and spermidine (but not spermine), it had no effect on caspase activity, DNA fragmentation, or plasma membrane vesiculation, typical characteristics of apoptosis, Notably, DFMO treatment prior to ultraviolet irradiation did not alter the decline in PS inward movement by the aminophospholipid translocase as measured by the uptake of 6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl) aminocaproyl] (NBD)-labeled PS detected in the flow cytometer, Conversely, the appearance of endogenous PS in the plasma membrane outer leaflet detected with fluorescein isothiocyanate-labeled annexin V and enhanced phospholipid flip-flop detected by the uptake of 1-palmitoyl-1-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)aminocaproyl]-sn-glycero-3-phosphocholine (NBD-PC) seen during apoptosis were significantly inhibited by prior DFMO treatment, Importantly, replenishment of spermidine, by treatment with exogenous putrescine to bypass the metabolic blockade by DFMO, restored both enhanced phospholipid flip-flop and appearance of PS during apoptosis, Such restoration was seen even in the presence of cycloheximide but was not seen when polyamines were added externally just prior to assay, Taken together, these data show that intracellular polyamines can modulate PS appearance resulting from nonspecific flip-flop of phospholipids across the plasma membrane during apoptosis.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Bratton, DL (corresponding author), Natl Jewish Med & Res Ctr, Denver, CO 80206 USA.							Amendola A, 1996, P NATL ACAD SCI USA, V93, P11057, DOI 10.1073/pnas.93.20.11057; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; BRATTON DL, 1994, J BIOL CHEM, V269, P22517; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; BRATTON DL, 1994, J LIPID MEDIAT CELL, V10, P43; BRATTON DL, 1993, J BIOL CHEM, V268, P3364; BRATTON DL, 1992, J IMMUNOL, V148, P514; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CHANG CP, 1993, J BIOL CHEM, V268, P7171; CHAP HJ, 1977, BIOCHIM BIOPHYS ACTA, V467, P146, DOI 10.1016/0005-2736(77)90192-4; CHUNG L, 1985, BIOCHEMISTRY-US, V24, P442, DOI 10.1021/bi00323a030; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FARMER BT, 1985, BIOCHIM BIOPHYS ACTA, V821, P420, DOI 10.1016/0005-2736(85)90046-X; GERLACH E, 1963, BIOCHEM Z, V337, P477; GRASSILLI E, 1995, BIOCHEM BIOPH RES CO, V216, P708, DOI 10.1006/bbrc.1995.2679; Hampton MB, 1996, FEBS LETT, V399, P277, DOI 10.1016/S0014-5793(96)01341-5; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; HUGHES G, 1994, BIOCHEMISTRY-US, V33, P4745, DOI 10.1021/bi00182a001; Igarashi K, 1997, J BIOL CHEM, V272, P4058, DOI 10.1074/jbc.272.7.4058; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; KOK JW, 1995, BIOCHEM J, V309, P905, DOI 10.1042/bj3090905; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; Leroy D, 1997, BIOCHEMISTRY-US, V36, P1242, DOI 10.1021/bi961949u; Lopatin AN, 1996, J GEN PHYSIOL, V108, P105, DOI 10.1085/jgp.108.2.105; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MEERS P, 1986, BIOCHEMISTRY-US, V25, P3109, DOI 10.1021/bi00359a007; MIN A, 1995, J CELL PHYSIOL, V165, P615, DOI 10.1002/jcp.1041650320; MORUZZI M, 1987, BIOCHEM J, V247, P175, DOI 10.1042/bj2470175; Nagy L, 1996, LEUKEMIA RES, V20, P499, DOI 10.1016/0145-2126(95)00118-2; NORRIS TM, 1996, MOL PHARMACOL, V50, P393; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; PALADE P, 1987, J BIOL CHEM, V262, P6149; PEGG AE, 1988, CANCER RES, V48, P759; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1016, P77, DOI 10.1016/0005-2728(90)90009-S; Rustenbeck I, 1996, BIOCHEM MOL BIOL INT, V38, P1003; SCHUBER F, 1989, BIOCHEM J, V260, P1; Shore LJ, 1997, J BIOL CHEM, V272, P12536, DOI 10.1074/jbc.272.19.12536; Shyng SL, 1996, P NATL ACAD SCI USA, V93, P12014, DOI 10.1073/pnas.93.21.12014; Squier MKT, 1997, J IMMUNOL, V158, P3690; Stout JG, 1997, J CLIN INVEST, V99, P2232, DOI 10.1172/JCI119397; Sulpice JC, 1996, BIOCHEMISTRY-US, V35, P13345, DOI 10.1021/bi960624a; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; SUNE A, 1987, BIOCHEMISTRY-US, V26, P2972, DOI 10.1021/bi00385a003; TILLY RHJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P188, DOI 10.1016/0005-2736(90)90453-U; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Williams K, 1997, CELL SIGNAL, V9, P1, DOI 10.1016/S0898-6568(96)00089-7; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; WYSE JW, 1988, BIOCHIM BIOPHYS ACTA, V941, P141, DOI 10.1016/0005-2736(88)90174-5; Yaroslavov A A, 1997, Membr Cell Biol, V10, P683; ZACHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P2585, DOI 10.1021/bi00357a046; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhou QS, 1998, BIOCHEMISTRY-US, V37, P2356, DOI 10.1021/bi972625o; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	67	39	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28113	28120		10.1074/jbc.274.40.28113	http://dx.doi.org/10.1074/jbc.274.40.28113			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497162	hybrid			2022-12-25	WOS:000082912700011
J	Eladari, D; Chambrey, R; Irinopoulou, T; Leviel, F; Pezy, F; Bruneval, P; Paillard, M; Podevin, RA				Eladari, D; Chambrey, R; Irinopoulou, T; Leviel, F; Pezy, F; Bruneval, P; Paillard, M; Podevin, RA			Polarized expression of different monocarboxylate transporters in rat medullary thick limbs of henle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCENDING LIMB; APICAL MEMBRANE; PROXIMAL TUBULE; PYRUVATE; LACTATE; CLONING; MCT2; MECHANISMS; SUBSTRATE; NEPHRON	Extracellular lactic acid is a major fuel for the mammalian medullary thick ascending Limb (MTAL), whereas under anoxic conditions, this nephron segment generates a large amount of lactic acid, which needs to be excreted. We therefore evaluated, at both the functional and molecular levels, the possible presence of monocarboxylate transporters in basolateral (BLMVs) and luminal (LMVs) membrane vesicles isolated from rat MTALs. Imposing an inward H+ gradient induced the transient uphill accumulation of L-[C-14]lactate in both types of vesicles. However, whereas the pH gradient-stimulated uptake of L-[C-14]lactate in BLMVs was inhibited by anion transport blockers such as alpha-cyano-4-hydroxycinnamate, 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS), and furosemide, it was unaffected by these agents in LMVs, indicating the presence of a L-lactate/H+ cotransporter in BLMVs, but not in LMVs. Under non-pH gradient conditions, however, the uptake of L-[C-14]lactate in LMVs was transstimulated 100% by L-lactate, but by only 30% by D-lactate. Furthermore, this L-lactate self-exchange was markedly inhibited by alpha-cyano-4-hydroxycinnamate and DIDS and almost completely by 1 mM furosemide, findings consistent with the existence of a stereospecific carrier-mediated lactate transport system in LMVs. Using immunofluorescence confocal microscopy and immunoblotting, the monocarboxylate transporter (MCT)-2 isoform was shown to be specifically expressed on the basolateral domain of the rat MTAL, whereas the MCT1 isoform could not be detected in this nephron segment. This study thus demonstrates the presence of different monacarboxylate transporters in rat MTALs; the basolateral H+/L-lactate cotransporter (MCT2) and the luminal H+- independent organic anion exchanger are adapted to play distinct roles in the transport of monocarboxylates in MTALs.	Univ Paris 06, INSERM, U356, F-75270 Paris, France; Univ Paris 06, INSERM, U430, F-75270 Paris, France; Hop Broussais, Assistance Publ Hop Paris, F-75270 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	Podevin, RA (corresponding author), Inst Biomed Cordeliers, 15 Rue Ecole Med, F-75270 Paris 06, France.			Eladari, Dominique/0000-0003-1067-0844				AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; AttmaneElakeb A, 1996, KIDNEY INT, V50, P1051, DOI 10.1038/ki.1996.408; BAGNASCO S, 1985, AM J PHYSIOL, V248, pF522, DOI 10.1152/ajprenal.1985.248.4.F522; Blanchard A, 1998, J PHYSIOL-LONDON, V506, P689, DOI 10.1111/j.1469-7793.1998.689bv.x; BOUMENDILPODEVIN EF, 1983, BIOCHIM BIOPHYS ACTA, V735, P86, DOI 10.1016/0005-2736(83)90263-8; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; CHAMBREY R, 1994, J BIOL CHEM, V269, P3243; DUBASE TDJ, 1983, AM J PHYSIOL, V244, pF497; Eladari D, 1998, AM J PHYSIOL-RENAL, V275, pF334, DOI 10.1152/ajprenal.1998.275.3.F334; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; GULLANS SR, 1996, THE KIDNEY, P211; HALESTRAP AP, 1974, BIOCHEM J, V138, P313, DOI 10.1042/bj1380313; Jackson VN, 1997, BIOCHEM J, V324, P447, DOI 10.1042/bj3240447; Leviel F, 1999, AM J PHYSIOL-RENAL, V276, pF847, DOI 10.1152/ajprenal.1999.276.6.F847; Lin RY, 1998, J BIOL CHEM, V273, P28959, DOI 10.1074/jbc.273.44.28959; Philp NJ, 1998, AM J PHYSIOL, V274, P1824; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; Price NT, 1998, BIOCHEM J, V329, P321; SCAGLIONE PR, 1965, AM J PHYSIOL, V209, P1193, DOI 10.1152/ajplegacy.1965.209.6.1193; Wang X, 1996, AM J PHYSIOL-HEART C, V270, pH476, DOI 10.1152/ajpheart.1996.270.2.H476; WATTS BA, 1994, J GEN PHYSIOL, V103, P917, DOI 10.1085/jgp.103.5.917; Wilson MC, 1998, J BIOL CHEM, V273, P15920, DOI 10.1074/jbc.273.26.15920; WITTNER M, 1984, PFLUG ARCH EUR J PHY, V402, P52, DOI 10.1007/BF00584832	24	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28420	28426		10.1074/jbc.274.40.28420	http://dx.doi.org/10.1074/jbc.274.40.28420			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497203	hybrid			2022-12-25	WOS:000082912700052
J	Goss, SPA; Singh, RJ; Kalyanaraman, B				Goss, SPA; Singh, RJ; Kalyanaraman, B			Bicarbonate enhances the peroxidase activity of Cu,Zn-superoxide dismutase - Role of carbonate anion radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SUPEROXIDE-DISMUTASE; LOW-DENSITY-LIPOPROTEIN; ALPHA-TOCOPHEROL; NITRIC-OXIDE; GAMMA-TOCOPHEROL; TYROSINE NITRATION; HYDROGEN-PEROXIDE; NITROGEN-DIOXIDE; PEROXYNITRITE; OXIDATION	We examined the effect of bicarbonate on the peroxidase activity of copper-zinc superoxide dismutase (SOD1), using the nitrite anion as a peroxidase probe. Oxidation of nitrite by the enzyme-bound oxidant results in the formation of the nitrogen dioxide radical, which was measured by monitoring 5-nitro-gamma-tocopherol formation. Results indicate that the presence of bicarbonate is not required for the peroxidase activity of SOD1, as monitored by the SOD1/H2O2-mediated nitration of gamma-tocopherol in the presence of nitrite, However, bicarbonate enhanced SOD1/H2O2-dependent oxidation of tocopherols in the presence and absence of nitrite and dramatically enhanced SOD1/H2O2-mediated oxidation of unsaturated lipid in the presence of nitrite, These results, coupled with the finding that bicarbonate protects against inactivation of SOD1 by H2O2, suggest that SOD1/H2O2 oxidizes the bicarbonate anion to the carbonate radical anion. Thus, the amplification of peroxidase activity of SOD1/H2O2 by bicarbonate is attributed to the intermediary role of the diffusible oxidant, the carbonate radical anion. We conclude that, contrary to a previous report (Sankarapandi, S., and Zweier, J. L. (1999) J, Biol, Chem. 274, 1226-1282), bicarbonate is not required for peroxidase activity mediated by SOD1 and H2O2. However, bicarbonate enhanced the peroxidase activity of SOD1 via formation of a putative carbonate radical anion, Biological implications of the carbonate radical anion in free radical biology are discussed.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.	balarama@mcw.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063119, R01HL047250] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [HL47250, HL63119] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS GE, 1969, T FARADAY SOC, V65, P2981, DOI 10.1039/tf9696502981; ADAMS GE, 1972, RADIAT RES, V49, P278, DOI 10.2307/3573266; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bisby RH, 1998, J CHEM SOC FARADAY T, V94, P2069, DOI 10.1039/a801239c; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; BRUNTON G, 1979, TETRAHEDRON LETT, P1093; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Caulfield JL, 1996, J BIOL CHEM, V271, P25859, DOI 10.1074/jbc.271.42.25859; CHEN SN, 1973, RADIAT RES, V56, P40, DOI 10.2307/3573789; COONEY RV, 1993, P NATL ACAD SCI USA, V90, P1771, DOI 10.1073/pnas.90.5.1771; Crow JP, 1997, J NEUROCHEM, V69, P1936; CZAPSKI G, 1994, J AM CHEM SOC, V116, P11465, DOI 10.1021/ja00104a028; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Fukai T, 1998, J CLIN INVEST, V101, P2101, DOI 10.1172/JCI2105; GOSS SPA, 1995, CHEM RES TOXICOL, V8, P800, DOI 10.1021/tx00047a021; Goss SPA, 1999, ARCH BIOCHEM BIOPHYS, V363, P333, DOI 10.1006/abbi.1998.1094; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1976, ARCH BIOCHEM BIOPHYS, V172, P202, DOI 10.1016/0003-9861(76)90067-9; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; HOGG N, 1994, ARCH BIOCHEM BIOPHYS, V314, P153, DOI 10.1006/abbi.1994.1423; Hoglen NC, 1997, CHEM RES TOXICOL, V10, P401, DOI 10.1021/tx960200h; HUIE RE, 1991, RADIAT PHYS CHEM, V38, P477; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IWATSUKI M, 1994, BBA-GEN SUBJECTS, V1200, P19, DOI 10.1016/0304-4165(94)90022-1; Jewett SL, 1999, FREE RADICAL BIO MED, V26, P905, DOI 10.1016/S0891-5849(98)00274-3; Jung O., 1998, BIOCHIM BIOPHYS ACTA, V1387, P249; KALYANARAMAN B, 1992, J BIOL CHEM, V267, P6789; KOPPENOL WH, 1987, J PHYS CHEM-US, V91, P4429, DOI 10.1021/j100300a045; LAMBELET P, 1984, CHEM PHYS LIPIDS, V35, P185, DOI 10.1016/0009-3084(84)90045-8; Lemercier JN, 1997, ARCH BIOCHEM BIOPHYS, V345, P160, DOI 10.1006/abbi.1997.0240; LEVINSKI AM, 1983, HARRISONS PRINCIPLES; LIEBLER DC, 1991, CHEM RES TOXICOL, V4, P89, DOI 10.1021/tx00019a012; LILIE J, 1978, RADIAT PHYS CHEM, V11, P225, DOI 10.1016/0146-5724(78)90101-2; Liochev SI, 1998, ARCH BIOCHEM BIOPHYS, V352, P237, DOI 10.1006/abbi.1998.0616; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Meli R, 1999, HELV CHIM ACTA, V82, P722, DOI 10.1002/(SICI)1522-2675(19990505)82:5<722::AID-HLCA722>3.3.CO;2-R; Merenyi G, 1997, CHEM RES TOXICOL, V10, P1216, DOI 10.1021/tx970101j; MICHELSON AM, 1983, BIOCHIMIE, V65, P95, DOI 10.1016/S0300-9084(83)80179-5; POPP JL, 1990, BIOCHEMISTRY-US, V29, P10475, DOI 10.1021/bi00498a008; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; SATO K, 1992, J BIOL CHEM, V267, P25371; Siddique T, 1996, COLD SPRING HARB SYM, V61, P699; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P12912, DOI 10.1073/pnas.95.22.12912; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; SINGH RJ, 1991, PHOTOCHEM PHOTOBIOL, V53, P493, DOI 10.1111/j.1751-1097.1991.tb03661.x; UCHIDA K, 1994, J BIOL CHEM, V269, P2405; Uppu RM, 1998, ARCH BIOCHEM BIOPHYS, V358, P1, DOI 10.1006/abbi.1998.0825; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WOLCOTT RG, 1994, J BIOL CHEM, V269, P9721; YIM MB, 1993, J BIOL CHEM, V268, P4099	56	84	87	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28233	28239		10.1074/jbc.274.40.28233	http://dx.doi.org/10.1074/jbc.274.40.28233			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497178	hybrid			2022-12-25	WOS:000082912700027
J	Miettinen, HM; Gripentrog, JM; Mason, MM; Jesaitis, AJ				Miettinen, HM; Gripentrog, JM; Mason, MM; Jesaitis, AJ			Identification of putative sites of interaction between the human formyl peptide receptor and G protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; BETA-ADRENERGIC-RECEPTOR; CARBOXYL-TERMINAL TAIL; 3RD INTRACELLULAR LOOP; II TYPE-1 RECEPTOR; SIGNAL-TRANSDUCTION; DIRECTED MUTAGENESIS; COUPLED RECEPTORS; HUMAN NEUTROPHILS; BETA(2)-ADRENERGIC RECEPTOR	Wild-type and 35 mutant formyl peptide receptors (FPRs) were stably expressed in Chinese hamster ovary cells. All cell surface-expressed mutant receptors bound N-formyl peptide with similar affinities as wild-type FPR, suggesting that the mutations did not affect the ligand-binding site. G protein coupling was examined by quantitative analysis of N-formyl-methionyl-leucyl-phenylalanine-induced increase in binding of S-35-labeled guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) to membranes. The most prominent uncoupled FPR mutants were located in the N-terminal part of the second transmembrane domain (S63W and D71A) and the C-terminal interface of the third transmembrane domain (R123A and C124S/C126S), In addition, less pronounced uncoupling was detected with deletion mutations in the third cytoplasmic loop and in the cytoplasmic tail. Further analysis of some of the mutants that were judged to be uncoupled based on the [S-35]GTP gamma S membrane-binding assay were found to transduce a signal, as evidenced by intracellular calcium mobilization and activation of p42/44 MAPK. Thus, these single point mutations in FPR did not completely abolish the interaction with G protein, emphasizing that the coupling site is coordinated by several different regions of the receptor. Mutations located in the putative fifth and sixth transmembrane domains near the N- and C-terminal parts of the third cytoplasmic loop did not result in uncoupling. These regions have previously been shown to be critical for G protein coupling to many other G protein-coupled receptors, Thus, FPR appears to have a G protein-interacting site distinct from the adrenergic receptors, the muscarinic receptors, and the angiotensin receptors.	Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA	Montana State University System; Montana State University Bozeman	Miettinen, HM (corresponding author), Montana State Univ, Dept Microbiol, 109 Lewis Hall, Bozeman, MT 59717 USA.	heini@montana.edu		Jesaitis, Algirdas/0000-0001-9001-5617	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040108, R01AI022735, R56AI022735] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22735, AI40108] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMATRUDA TT, 1995, J BIOL CHEM, V270, P28010; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BOMMAKANTI RK, 1993, J LEUKOCYTE BIOL, V54, P572, DOI 10.1002/jlb.54.6.572; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P6720, DOI 10.1021/bi00020a017; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Carlson SA, 1996, J BIOL CHEM, V271, P23146, DOI 10.1074/jbc.271.38.23146; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; Conchon S, 1997, J BIOL CHEM, V272, P25566, DOI 10.1074/jbc.272.41.25566; COOK JV, 1993, J ENDOCRINOL, V139, pR1, DOI 10.1677/joe.0.139R001; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; Damaj BB, 1996, FASEB J, V10, P1426, DOI 10.1096/fasebj.10.12.8903513; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Gao JL, 1998, GENOMICS, V51, P270, DOI 10.1006/geno.1998.5376; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Laporte SA, 1996, MOL PHARMACOL, V49, P89; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Liu J, 1996, J BIOL CHEM, V271, P6172, DOI 10.1074/jbc.271.11.6172; Miettinen HM, 1997, J IMMUNOL, V159, P4045; Mills JS, 1999, CURR INFLAMMAT RES, P215; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; Olah ME, 1997, J BIOL CHEM, V272, P337; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V161, P276, DOI 10.1016/0006-291X(89)91592-1; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; Rane MJ, 1997, J IMMUNOL, V159, P5070; Rane MJ, 1998, J BIOL CHEM, V273, P20916, DOI 10.1074/jbc.273.33.20916; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sano T, 1997, J BIOL CHEM, V272, P23631, DOI 10.1074/jbc.272.38.23631; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; STRADER CD, 1987, J BIOL CHEM, V262, P16439; SueAQuan AK, 1997, J CELL PHYSIOL, V172, P94, DOI 10.1002/(SICI)1097-4652(199707)172:1<94::AID-JCP11>3.0.CO;2-O; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Uthayakumar S, 1995, CELL MOL BIOL RES, V41, P405; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; Wenzel-Seifert K, 1998, J BIOL CHEM, V273, P24181, DOI 10.1074/jbc.273.37.24181; Xie W, 1997, J BIOL CHEM, V272, P24948, DOI 10.1074/jbc.272.40.24948; Ye R D, 1997, Adv Pharmacol, V39, P221, DOI 10.1016/S1054-3589(08)60073-3; YE RD, 1993, J IMMUNOL, V150, P1383; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	59	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27934	27942		10.1074/jbc.274.39.27934	http://dx.doi.org/10.1074/jbc.274.39.27934			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488141	hybrid			2022-12-25	WOS:000082739100080
J	Okada, T; Inoue, R; Yamazaki, K; Maeda, A; Kurosaki, T; Yamakuni, T; Tanaka, I; Shimizu, S; Ikenaka, K; Imoto, K; Mori, Y				Okada, T; Inoue, R; Yamazaki, K; Maeda, A; Kurosaki, T; Yamakuni, T; Tanaka, I; Shimizu, S; Ikenaka, K; Imoto, K; Mori, Y			Molecular and functional characterization of a novel mouse transient receptor potential protein homologue TRP7 - Ca2+-permeable cation channel that is constitutively activated and enhanced by stimulation of G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; RABBIT PORTAL-VEIN; SMOOTH-MUSCLE CELLS; SINOATRIAL NODE CELLS; DROSOPHILA TRP; STORE DEPLETION; CA2+ CHANNEL; HUMAN-LYMPHOCYTES; KINASE-C; GENE	Characterization of mammalian homologues of Drosophila transient receptor potential protein (TRP) is an important clue to understand molecular mechanisms underlying Ca2+ influx activated in response to stimulation of G(q) protein-coupled receptors in vertebrate cells. Here we have isolated cDNA encoding a novel seventh mammalian TRP homologue, TRP7, from mouse brain. TRP7 showed abundant RNA expression in the heart, lung, and eye and moderate expression in the brain, spleen, and testis. TRP7 recombinantly expressed in human embryonic kidney cells exhibited distinctive functional features, compared with other TRP homologues. Basal influx activity accompanied by reduction in Ca2+ release from internal stores was characteristic of TRP7-expressing cells but was by far less significant in cells expressing TRP3, which is structurally the closest to TRP7 in the TRP family. TRP7 induced Ca2+ influx in response to ATP receptor stimulation at ATP concentrations lower than those necessary for activation of TRP3 and for Ca2+ release from the intracellular store, which suggests that the TRP7 channel is activated independently of Ca2+ release. In fact, TRP7 expression did not affect capacitative Ca2+ entry induced by thapsigargin, whereas TRP7 greatly potentiated Mn2+ influx induced by diacylglycerols without involvement of protein kinase C. Nystatin-perforated and conventional whole-cell patch clamp recordings from TRP7-expressing cells demonstrated the constitutively activated and ATP-enhanced inward cation currents, both of which were initially blocked and then subsequently facilitated by extracellular Ca2+ at a physiological concentration. Impairment of TRP7 currents by internal perfusion of the Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid revealed an essential role of intracellular Ca2+ in activation of TRP7, and their potent activation by the diacylglycerol analogue suggests that the TRP7 channel is a new member of diacylglycerol-activated cation channels. Relative permeabilities indicate that TRP7 is slightly selective to divalent cations. Thus, our findings reveal an interesting correspondence of TRP7 to the background and receptor stimulation-induced cation currents in various native systems.	Natl Inst Physiol Sci, Dept Informat Physiol, Lab Humoral Informat, Okazaki, Aichi 4448585, Japan; Natl Inst Physiol Sci, Dept Informat Physiol, Lab Neural Informat, Okazaki, Aichi 4448585, Japan; Kyushu Univ, Fac Med, Dept Pharmacol, Fukuoka 8128582, Japan; Eisai & Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 3002635, Japan; Kanasai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 5708506, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan; Showa Univ, Sch Pharmaceut Sci, Dept Pathophysiol, Tokyo 1428555, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Kyushu University; Eisai Co Ltd; Kansai Medical University; Showa University	Mori, Y (corresponding author), Natl Inst Physiol Sci, Dept Informat Physiol, Lab Humoral Informat, Okazaki, Aichi 4448585, Japan.	moriy@nips.ac.jp	Maeda, Akito/AAX-6252-2020; Okada, Takaharu/N-7931-2015; Yamakuni, Tohru/AAE-3541-2019	Yamakuni, Tohru/0000-0003-3968-7949; Imoto, Keiji/0000-0002-2861-5985				Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; Bae YM, 1999, J PHYSIOL-LONDON, V514, P747, DOI 10.1111/j.1469-7793.1999.747ad.x; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHEN S, 1993, BRIT J PHARMACOL, V109, P793, DOI 10.1111/j.1476-5381.1993.tb13644.x; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DENYER JC, 1990, J PHYSIOL-LONDON, V429, P401, DOI 10.1113/jphysiol.1990.sp018264; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; HAGIWARA N, 1992, J PHYSIOL-LONDON, V448, P53, DOI 10.1113/jphysiol.1992.sp019029; Hardie RC, 1997, CELL CALCIUM, V21, P431, DOI 10.1016/S0143-4160(97)90054-3; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Helliwell RM, 1998, J PHYSIOL-LONDON, V512, P731, DOI 10.1111/j.1469-7793.1998.731bd.x; Helliwell RM, 1996, J PHYSIOL-LONDON, V492, P75, DOI 10.1113/jphysiol.1996.sp021290; Helliwell RM, 1997, J PHYSIOL-LONDON, V499, P417, DOI 10.1113/jphysiol.1997.sp021938; HIDAKA H, 1983, METHOD ENZYMOL, V102, P185; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Hunter JJ, 1998, GENOMICS, V54, P116, DOI 10.1006/geno.1998.5549; INESI G, 1994, J MEMBRANE BIOL, V141, P1; INOUE R, 1993, J PHYSIOL-LONDON, V465, P427, DOI 10.1113/jphysiol.1993.sp019685; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; Mizuno N, 1999, MOL BRAIN RES, V64, P41, DOI 10.1016/S0169-328X(98)00296-4; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Mori Y, 1998, NEUROREPORT, V9, P507; MOZHAYEVA GN, 1991, J MEMBRANE BIOL, V124, P113, DOI 10.1007/BF01870456; Mubagwa K, 1997, J PHYSIOL-LONDON, V502, P235, DOI 10.1111/j.1469-7793.1997.235bk.x; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sakura H, 1997, DIABETOLOGIA, V40, P528, DOI 10.1007/s001250050711; Sankaranarayanan S, 1996, AM J PHYSIOL-CELL PH, V271, pC1927, DOI 10.1152/ajpcell.1996.271.6.C1927; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; Sinkins WG, 1996, J BIOL CHEM, V271, P2955, DOI 10.1074/jbc.271.6.2955; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Taylor CW, 1998, TRENDS PHARMACOL SCI, V19, P370, DOI 10.1016/S0165-6147(98)01243-7; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UEDA S, 1989, BIOCHIM BIOPHYS ACTA, V1012, P254, DOI 10.1016/0167-4889(89)90105-5; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; WANG Q, 1993, PFLUG ARCH EUR J PHY, V423, P28, DOI 10.1007/BF00374957; WANG Q, 1991, J PHYSIOL-LONDON, V435, P21, DOI 10.1113/jphysiol.1991.sp018496; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	73	382	395	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27359	27370		10.1074/jbc.274.39.27359	http://dx.doi.org/10.1074/jbc.274.39.27359			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488066	hybrid			2022-12-25	WOS:000082739100005
J	Wang, YW; Tran, K; Yao, ZM				Wang, YW; Tran, K; Yao, ZM			The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells - A unified model for the assembly of very low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; APO-B; LIPID RECRUITMENT; HEPG2 CELLS; RAT-LIVER; SECRETION; BINDING; ABETALIPOPROTEINEMIA	Previously, based on distinct requirement of microsomal triglyceride transfer protein (MTP) and kinetics of triglyceride (TG) utilization, we concluded that assembly of very low density lipoproteins (VLDL) containing B48 or B100 was achieved through different paths (Wang, Y., McLeod, R. S., and Yao, Z. (1997) J. Biol. Chem. 272, 12272-12278). To test if the apparent dual mechanisms were accounted for by apolipoprotein B (apoE) length, we studied VLDL assembly using transfected cells expressing various apoB forms (e.g. B64, B72, B80, and B100). For each apoB, enlargement of lipoprotein to form VLDL via bulk TG incorporation was induced by exogenous oleate, which could be blocked by MTP inhibitor BMS-197636 treatment, While particle enlargement was readily demonstrable by density ultracentrifugation for B64- and B72-VLDL, it was not obvious for B80- and B100-VLDL unless the VLDL was further resolved by cumulative rate flotation into VLDL1 (S-f > 100) and VLDL2 (S-f 20-100), BMS-197636 diminished B100 secretion in a dose-dependent manner (0.05-0.5 mu M) and also blocked the particle enlargement from small to large B100-lipoproteins. These results yield a unified model that can accommodate VLDL assembly with all apoB forms, which invalidates our previous conclusion. To gain a better understanding of the MTP action, we examined the effect of BMS-197636 on lipid and apoB synthesis during VLDL assembly. While BMS-197636 (0.2 mu M) entirely abolished B100-VLDL, assembly/secretion, it did not affect B100 translation or translocation across the microsomal membrane, nor did it affect TG synthesis and cell TG mass. However, BMS-197636 drastically decreased accumulation of [H-3]glycerol-labeled TG and TG mass within microsomal lumen. The decreased TG accumulation was not a result of impaired B100-VLDL assembly, because in cells treated with brefeldin A (0.2 mu g/ml), the assembly of B100-VLDL was blocked yet lumenal TG accumulation was normal, Thus, MTP plays a role in facilitating accumulation of TG within microsomes, a prerequisite for the post-translational assembly of TG-enriched VLDL.	Univ Ottawa, Inst Heart, Lipoprot & Atheriosclerosis Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Biochem, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute	Yao, ZM (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atheriosclerosis Grp, Ottawa, ON K1Y 4W7, Canada.							ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Bakillah A, 1998, BIOCHEMISTRY-US, V37, P3727, DOI 10.1021/bi972629t; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BOREN J, 1994, J BIOL CHEM, V269, P25879; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; CARTWRIGHT IJ, 1995, BIOCHEM J, V310, P897, DOI 10.1042/bj3100897; CHAN L, 1992, J BIOL CHEM, V267, P25621; ELOVSON J, 1988, J LIPID RES, V29, P1461; ELOVSON J, 1994, CIRCULATION, V90, P185; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Hamilton RL, 1998, J LIPID RES, V39, P1543; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; HIGGINS JA, 1984, J LIPID RES, V25, P1295; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macri J, 1997, J BIOL CHEM, V272, P7328, DOI 10.1074/jbc.272.11.7328; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; NERI BP, 1973, CLIN CHEM, V19, P1201; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Rusinol AE, 1997, J BIOL CHEM, V272, P8019, DOI 10.1074/jbc.272.12.8019; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SWIFT LL, 1995, J LIPID RES, V36, P395; van Greevenbroek MMJ, 1998, J LIPID RES, V39, P173; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YAO ZM, 1992, J BIOL CHEM, V267, P1175	42	115	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27793	27800		10.1074/jbc.274.39.27793	http://dx.doi.org/10.1074/jbc.274.39.27793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488124	hybrid			2022-12-25	WOS:000082739100063
J	Galibert, MD; Yavuzer, U; Dexter, TJ; Goding, CR				Galibert, MD; Yavuzer, U; Dexter, TJ; Goding, CR			Pax3 and regulation of the melanocyte-specific tyrosinase-related protein-1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIN-B RECEPTOR; MICROPHTHALMIA GENE-PRODUCT; WAARDENBURG SYNDROME; PAIRED DOMAIN; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; IN-VITRO; BOX GENE; MUTATIONS; EXPRESSION	Previous work has established that the melanocyte-specific tyrosinase-related protein-1 (TRP-1) promoter is regulated positively by the microphthalmia-associated transcription factor Mitf, acting through the conserved M box and negatively by the T-box factor Tbx2, which can bind two "melanocyte-specific elements" termed the MSEu and MSEi. Both the MSEu and MSEi, which share a 6-base pair GTGTGA consensus, are also recognized by a previously unidentified melanocyte-specific factor, MSF. Here we show using a combination of DNA binding assays, proteolytic clipping, and anti-Pax3 antibodies that MSF is indistinguishable from Pax3, a paired homeodomain transcription factor implicated genetically in melanocyte development and the regulation of the Mitf promoter. Consistent with Pax3 being able to bind the TRP-1 promoter, Pax3 is expressed in melanocytes and melanomas, and TRP-I promoter activity is up-regulated by Pax3. The results identify a novel role for Pax3 in the expression of TRP-1, and the potential role of Pax3 in the melanocyte lineage is discussed.	Marie Curie Res Inst, Eukaryot Transcript Lab, Surrey RH8 0TL, England; Bilkent Univ, Dept Mol Biol, TR-06533 Bilkent, Turkey	Ihsan Dogramaci Bilkent University	Goding, CR (corresponding author), Marie Curie Res Inst, Eukaryot Transcript Lab, Surrey RH8 0TL, England.		Yavuzer, Ugur/C-1599-2016	Goding, Colin/0000-0002-1614-3909				Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; BALDWIN CT, 1994, HUM MUTAT, V3, P205, DOI 10.1002/humu.1380030306; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Carreira S, 1998, MOL CELL BIOL, V18, P5099, DOI 10.1128/MCB.18.9.5099; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; EISEN T, 1995, ONCOGENE, V11, P2157; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Jun S, 1996, DEVELOPMENT, V122, P2639; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lam PYP, 1999, MOL CELL BIOL, V19, P594; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; Magnaghi P, 1998, NAT GENET, V20, P74, DOI 10.1038/1739; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494; YAVUZER U, 1995, ONCOGENE, V10, P123	37	103	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26894	26900		10.1074/jbc.274.38.26894	http://dx.doi.org/10.1074/jbc.274.38.26894			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480898	hybrid, Green Published			2022-12-25	WOS:000082570700037
J	Okuda, M; Takahashi, M; Suero, J; Murry, CE; Traub, O; Kawakatsu, H; Berk, BC				Okuda, M; Takahashi, M; Suero, J; Murry, CE; Traub, O; Kawakatsu, H; Berk, BC			Shear stress stimulation of p130(cas) tyrosine phosphorylation requires calcium-dependent c-Src activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; VASCULAR ENDOTHELIAL-CELLS; PROTEIN-1 GENE-EXPRESSION; GROWTH-FACTOR; ADAPTER PROTEIN; V-CRK; SIGNALING PATHWAYS; COMPLEX-FORMATION; TRANSFORMATION; FLOW	Fluid shear stress (flow) modulates endothelial cell function via specific intracellular signaling events. Previously we showed that flow activated ERK1/2 in an integrin-dependent manner (Takahashi, M., and Berk, B. C. (1996) J. Clin. Invest. 98, 2623-2631). p130 Crk-associated substrate (Cas), a putative c-Src substrate, was originally identified as a highly phosphorylated protein that is localized to focal adhesions and acts as an adapter protein. Recent reports have shown that Cas is important in cardiovascular development and actin filament assembly. Flow (shear stress = 12 dynes/cm(2)) stimulated Cas tyrosine phosphorylation within 1 min in human umbilical vein endothelial cells. Phosphorylation peaked at 5 min (3.5 +/- 0.7-fold) and was sustained to 20 min. Tyrosine phosphorylation of Cas was functionally important because flow stimulated association of Cas with Crk in a time- and force-dependent manner. Flow-mediated activation of c-Src, phosphorylation of Gas, and association of Cas with Crk were all inhibited by calcium chelation and pretreatment with the Src family-specific tyrosine kinase inhibitor PP1. To determine the role of c-Src in flow-stimulated phosphorylation of Gas, we transduced cells with adenovirus encoding kinase-inactive Src. Expression of kinase-inactive Src prevented flow-induced Cas tyrosine phosphorylation but not ERK1/2 activation. Calcium dependent activation of c-Src and tyrosine phosphorylation of Cas defines a new flow-stimulated signal pathway, different from ERK1/2 activation. This pathway may be involved in focal adhesion remodeling and actin filament assembly.	Univ Rochester, Sch Med & Dent, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Washington, Dept Med, Div Cardiol, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94110 USA	University of Rochester; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco	Berk, BC (corresponding author), Univ Rochester, Sch Med & Dent, Cardiovasc Res Ctr, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.	bradford_berk@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; ANDO J, 1988, IN VITRO CELL DEV B, V24, P871; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Burnham MR, 1996, ONCOGENE, V12, P2467; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Chiu JJ, 1997, ARTERIOSCL THROM VAS, V17, P3570, DOI 10.1161/01.ATV.17.12.3570; DAVIES PF, 1993, J CLIN INVEST, V91, P2640, DOI 10.1172/JCI116503; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HELMLINGER G, 1995, AM J PHYSIOL-CELL PH, V269, pC367, DOI 10.1152/ajpcell.1995.269.2.C367; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; HSIEH HJ, 1992, J CELL PHYSIOL, V150, P552, DOI 10.1002/jcp.1041500316; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Korenaga R, 1997, AM J PHYSIOL-CELL PH, V273, pC1506; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li YS, 1996, MOL CELL BIOL, V16, P5947; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; LOZIER JN, 1994, HUM GENE THER, V5, P313, DOI 10.1089/hum.1994.5.3-313; MALEK A, 1992, AM J PHYSIOL, V263, pC389, DOI 10.1152/ajpcell.1992.263.2.C389; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Murase T, 1998, CIRC RES, V83, P328, DOI 10.1161/01.RES.83.3.328; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Rieder MJ, 1997, CIRC RES, V80, P312, DOI 10.1161/01.RES.80.3.312; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Takahashi T, 1998, AM J PHYSIOL-HEART C, V274, pH1059, DOI 10.1152/ajpheart.1998.274.4.H1059; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; TRAUB O, 1998, MECH FORCES ENDOTHEL, P89; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143	55	103	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26803	26809		10.1074/jbc.274.38.26803	http://dx.doi.org/10.1074/jbc.274.38.26803			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480886	hybrid			2022-12-25	WOS:000082570700025
J	Yao, Y; Slosberg, ED; Wang, L; Hibshoosh, H; Zhang, YJ; Xing, WQ; Santella, RM; Weinstein, IB				Yao, Y; Slosberg, ED; Wang, L; Hibshoosh, H; Zhang, YJ; Xing, WQ; Santella, RM; Weinstein, IB			Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice	ONCOGENE			English	Article						Cdc25B; transgenic mice; DMBA; synergy; mammary tumor; MMTV-LTR	PHOSPHORYLATES HUMAN CDC25C; XENOPUS EGG EXTRACTS; GROWTH-FACTOR-ALPHA; MOUSE MAMMARY; CELL-CYCLE; FISSION YEAST; MITOTIC INDUCER; SYNERGISTIC INTERACTION; TRANSCRIPTIONAL CONTROL; TYROSINE PHOSPHATASE	Cdc25 phosphatases activate cyclin-dependent kinases (Cdks) by dephosphorylating critical phospho-tyrosine and phospho-threonine residues on these proteins. Several types of studies indicate that Cdc25s can enhance cell proliferation and oncogenesis, Furthermore, overexpression of Cdc25A and/or B have been detected in several types of primary human cancers, including breast cancers. To further assess the oncogenic capacity of Cdc25B in vivo, we have generated transgenic mice that overexpress Cdc25B in the mammary epithelium, driven by the MMTV-LTR promoter. Although these mice are grossly normal for up to 18 months, the ectopic expression of Cdc25B in their mammary glands increases the susceptibility of these mice to induction of mammary tumors by the carcinogen 9,10-dimethyl-1,2-benzanthracene (DMBA).	Columbia Univ Coll Phys & Surg, Dept Med, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program CMBS, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Sch Publ Hlth, Div Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Weinstein, IB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Herbert Irving Comprehens Canc Ctr, 701 W 168th St, New York, NY 10032 USA.				NCI NIH HHS [R01 CA/ES63467, T32CA09503] Funding Source: Medline; NIGMS NIH HHS [T32GM07088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063467, T32CA009503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; ARCHULETA MM, 1992, TOXICOL APPL PHARM, V113, P133, DOI 10.1016/0041-008X(92)90017-M; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CARDIFF RD, 1993, CANCER SURV, V16, P97; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HALTER SA, 1992, AM J PATHOL, V140, P1131; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOFFMANN I, 1994, J CELL SCI, P75; HOGAN B, 1994, ANIPULATING MOUSE EM; Iavarone A, 1997, NATURE, V387, P417; JIANG W, 1993, ONCOGENE, V8, P3447; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LI BL, 1995, MOL CARCINOGEN, V14, P75, DOI 10.1002/mc.2940140203; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MEDINA D, 1980, CANCER RES, V40, P368; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NAGATA A, 1991, NEW BIOL, V3, P959; NIELSEN LL, 1991, CANCER RES, V51, P3762; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Quezado MM, 1998, HUM PATHOL, V29, P604, DOI 10.1016/S0046-8177(98)80010-5; ROLLINI P, 1992, J VIROL, V66, P4580, DOI 10.1128/JVI.66.7.4580-4586.1992; ROSS SR, 1990, MOL CELL BIOL, V10, P5822, DOI 10.1128/MCB.10.11.5822; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santarelli R, 1996, ONCOGENE, V12, P495; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Spitkovsky D, 1996, ONCOGENE, V12, P2549; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Stutman O, 1975, Adv Cancer Res, V22, P261; TRUSS M, 1992, J STEROID BIOCHEM, V41, P241, DOI 10.1016/0960-0760(92)90350-R; TURUSOV VS, 1994, TUMORS MOUSE PATHOLO, V2, P776; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WITTY JP, 1995, CANCER RES, V55, P1401; Wu W., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P544	65	69	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	1999	18	37					5159	5166		10.1038/sj.onc.1202908	http://dx.doi.org/10.1038/sj.onc.1202908			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498865				2022-12-25	WOS:000082555700004
J	Cressman, VL; Lazarowski, E; Homolya, L; Boucher, RC; Koller, BH; Grubb, BR				Cressman, VL; Lazarowski, E; Homolya, L; Boucher, RC; Koller, BH; Grubb, BR			Effect of loss of P2Y(2) receptor gene expression on nucleotide regulation of murine epithelial Cl- transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; CYSTIC-FIBROSIS; MOLECULAR-CLONING; PHOSPHOLIPASE-C; ION-TRANSPORT; INTRACELLULAR CALCIUM; SENSORY NEURONS; NASAL EPITHELIA; P2X RECEPTORS; CELLS	Extracellular nucleotides are believed to be important regulators of ion transport in epithelial tissues as a result of their ability to activate cell surface receptors. Although numerous receptors that bind nucleotides have been identified, the complexity of this receptor family, combined with the lack of pharmacological agents specific for these receptors, has made the assignment of particular receptors and ligands to physiological responses difficult. Because ATP and UTP appear equipotent and equieffective in regulating ion transport in many epithelia, we tested the hypothesis that the P2Y(2) receptor (P2Y(2)-R) subtype mediates these responses in mouse epithelia, with gene targeting techniques. Mice with the P2Y(2)-R locus targeted and inactivated (P2Y(2)-R(-/-)) were generated, airways (trachea), gallbladder, and intestines (jejunum) excised, and Cl- secretory responses to luminal nucleotide additions measured in Ussing chambers. Comparison of P2Y(2)-R(+/+) with P2Y(2)-R(-/-) mice revealed that P2Y(2)-R mediated most (>85-95%) nucleotide-stimulated Cl- secretion in trachea, about 50% of nucleotide responses in the gallbladder, and none of the responses in the jejunum, Dose-effect relationships for nucleotides in tissues from P2Y(2)-R(-/-) mice suggest that the PSY2-R regulates ion transport in gallbladder and to a lesser extent trachea, whereas P2Y(4) and/or unidentified receptor(s) regulate ion transport in jejunum, We conclude that the P2Y(2) receptor is the dominant P2Y purinoceptor that regulates airway epithelial ion transport, whereas other P2Y receptor subtypes are relatively more important in other nonrespiratory epithelia.	Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Grubb, BR (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA.		Homolya, Laszlo/N-1154-2016	Homolya, Laszlo/0000-0003-1639-8140	NHLBI NIH HHS [HL34322] Funding Source: Medline; NIDDK NIH HHS [DK51791] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051791] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bogdanov YD, 1998, BRIT J PHARMACOL, V124, P428, DOI 10.1038/sj.bjp.0701880; Boyer JL, 1996, MOL PHARMACOL, V50, P1323; Boyer JL, 1998, BRIT J PHARMACOL, V124, P1, DOI 10.1038/sj.bjp.0701837; BROWN HA, 1991, MOL PHARMACOL, V40, P648; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; CALRKE LL, 1997, AM J PHYSIOL, V272, pL1084; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; Communi D, 1996, EUR J PHARMACOL, V317, P383, DOI 10.1016/S0014-2999(96)00740-6; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; COTTON CU, 1991, J GEN PHYSIOL, V97, P949, DOI 10.1085/jgp.97.5.949; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; Devor DC, 1999, AM J PHYSIOL-CELL PH, V276, pC827, DOI 10.1152/ajpcell.1999.276.4.C827; DONALDSON SH, 1998, P2 NUCLEOTIDE RECEPT, P413; Evans RJ, 1998, P2 NUCLEOTIDE RECEPT, P43; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; GLOVER GG, 1996, PEDIATR PULM, V13, P285; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; GRUBB BR, 1995, AM J PHYSIOL-GASTR L, V268, pG505, DOI 10.1152/ajpgi.1995.268.3.G505; GRUBB BR, 1994, AM J PHYSIOL, V267, pC293, DOI 10.1152/ajpcell.1994.267.1.C293; HARLINE MC, 1996, PEDIATR PULM, V13, P284; Homolya L, 1999, J BIOL CHEM, V274, P26454, DOI 10.1074/jbc.274.37.26454; HOMOLYA L, 1997, PEDIATR PULM, V14, P234; HUMPHREY PPA, 1995, N-S ARCH PHARMACOL, V352, P585; Inoue CN, 1997, AM J PHYSIOL-CELL PH, V272, pC1862, DOI 10.1152/ajpcell.1997.272.6.C1862; Janssens R, 1996, BIOCHEM BIOPH RES CO, V221, P588, DOI 10.1006/bbrc.1996.0640; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; KOHN PG, 1970, J PHYSIOL-LONDON, V208, P203, DOI 10.1113/jphysiol.1970.sp009114; KOLLER BH, 1992, ANNU REV IMMUNOL, V10, P705, DOI 10.1146/annurev.iy.10.040192.003421; KORMAN LY, 1982, BIOCHIM BIOPHYS ACTA, V721, P47, DOI 10.1016/0167-4889(82)90022-2; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; Palmer RK, 1998, MOL PHARMACOL, V54, P1118, DOI 10.1124/mol.54.6.1118; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; Soto F, 1997, J MEMBRANE BIOL, V160, P91, DOI 10.1007/s002329900298; Surprenant A, 1996, CIBA F SYMP, V198, P208; TOKUYAMA Y, 1995, BIOCHEM BIOPH RES CO, V211, P211, DOI 10.1006/bbrc.1995.1798; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Webb TE, 1998, J NEUROCHEM, V71, P1348	46	155	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26461	26468		10.1074/jbc.274.37.26461	http://dx.doi.org/10.1074/jbc.274.37.26461			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473606	Green Published, hybrid			2022-12-25	WOS:000082469700072
J	Tvrdik, P; Asadi, A; Kozak, LP; Nuglozeh, E; Parente, F; Nedergaard, J; Jacobsson, A				Tvrdik, P; Asadi, A; Kozak, LP; Nuglozeh, E; Parente, F; Nedergaard, J; Jacobsson, A			Cig30 and Pitx3 genes are arranged in a partially overlapping tail-to-tail array resulting in complementary transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ELONGATION; SACCHAROMYCES-CEREVISIAE; CHROMOSOME 10Q23-Q24; EXPRESSION; FAMILY; MEMBER; LOCUS	The mouse Cig30 gene codes for a 30-kDa membrane glycoprotein, which appears to have a role in the recruitment of brown adipose tissue. To elucidate the structure of the Cig30 gene, we have isolated a A phage genomic DNA clone containing the entire mouse gene and found that Cig30 consists of four exons that are spread over 4 kilobase pairs of genomic sequence. Using a fluorescence in situ hybridization assay and interspecific backcross panel mapping, we have localized the Cig30 locus to the distal region of mouse chromosome 19, between the Tlx1 and Ins1 loci. Sequencing of the corresponding lambda clone to completion revealed that the insert contained yet another gene in the opposite orientation. It turned out to be the newly identified homeobox gene Pitx3, Interestingly, the genes are very tightly linked, so that the 3' ends of their transcripts are complementary. Thus, our results provide evidence for bidirectional transcription of a several hundred base pair-long DNA region as a result of the extremely tight linkage between Cig30 and Pitx3.	Arrhenius Lab, Wenner Gren Inst, Stockholm, Sweden; Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Jackson Lab, Bar Harbor, ME 04609 USA; CNRS, UMR 6549, UNSA, F-06107 Nice, France	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Jackson Laboratory; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Jacobsson, A (corresponding author), Arrhenius Lab, Wenner Gren Inst, Stockholm, Sweden.		Tvrdik, Petr/AAK-4398-2021; Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010	Tvrdik, Petr/0000-0002-8750-9672; Nedergaard, Jan/0000-0003-2070-1587				BARON B, 1984, EXP CELL RES, V152, P220, DOI 10.1016/0014-4827(84)90247-7; Batshake B, 1996, BIOCHEM BIOPH RES CO, V227, P70, DOI 10.1006/bbrc.1996.1469; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Campbell HD, 1997, GENOMICS, V42, P46, DOI 10.1006/geno.1997.4709; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COURSEAUX A, 1995, LEUKEMIA, V9, P1313; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Jacoby RF, 1997, AM J MED GENET, V70, P361, DOI 10.1002/(SICI)1096-8628(19970627)70:4<361::AID-AJMG6>3.0.CO;2-W; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LERNER A, 1993, J IMMUNOL, V151, P3152; Nagase S, 1996, BRIT J CANCER, V74, P1979, DOI 10.1038/bjc.1996.663; Nikali K, 1997, GENOMICS, V39, P185, DOI 10.1006/geno.1996.4465; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; OTTMAN R, 1995, NAT GENET, V10, P56, DOI 10.1038/ng0595-56; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Sambrook J., 2002, MOL CLONING LAB MANU; Semina EV, 1997, HUM MOL GENET, V6, P2109, DOI 10.1093/hmg/6.12.2109; Semina EV, 1998, NAT GENET, V19, P167, DOI 10.1038/527; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Tvrdik P, 1997, J BIOL CHEM, V272, P31738, DOI 10.1074/jbc.272.50.31738; Wang CY, 1997, AM J HUM GENET, V60, P1461, DOI 10.1086/515469; Yee RW, 1997, GENOMICS, V46, P152, DOI 10.1006/geno.1997.5028	25	10	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26387	26392		10.1074/jbc.274.37.26387	http://dx.doi.org/10.1074/jbc.274.37.26387			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473596	hybrid			2022-12-25	WOS:000082469700062
J	Zubov, AI; Kaznacheeva, EV; Nikolaev, AV; Alexeenko, VA; Kiselyov, K; Muallem, S; Mozhayeva, GN				Zubov, AI; Kaznacheeva, EV; Nikolaev, AV; Alexeenko, VA; Kiselyov, K; Muallem, S; Mozhayeva, GN			Regulation of the miniature plasma membrane Ca2+ channel I-min by inositol 1,4,5-trisphosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ENTRY; CELLS; STORES; DEPLETION; INFLUX; ACTIVATION; RESOLUTION; MESSENGER; PHOSPHATE	I-min is a plasma membrane-located, Ca2+-selective channel that is activated by store depletion and regulated by inositol 1,4,5-trisphosphate (IP3). In the present work we examined the coupling between I-min and IP3 receptors in excised plasma membrane patches from A431 cells. I-min was recorded in cell-attached mode and the patches were excised into medium containing IP3. In about 50% of experiments excision caused the loss of activation of I-min by IP3. In the remaining patches activation of I-min by IP3, was lost upon extensive washes of the patch surface. The ability of IP3 to activate I-min was restored by treating the patches with rat cerebellar microsomes reach in IP3, receptors but not by control forebrain microsomes. The re-activated I-min had the same kinetic properties as I-min when it is activated by Ca2+-mobilizing agonists in intact cells and by IP3 in excised plasma membrane patches and it was inhibited by the I-crac inhibitor SKF95365. We propose that I-min, is a form of I-crac and is gated by IP3 receptors.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mozhayeva, GN (corresponding author), Russian Acad Sci, Inst Cytol, Tikhoretsky Ave 4, St Petersburg 194064, Russia.		Kaznacheyeva, Elena/I-7260-2017	Kaznacheyeva, Elena/0000-0003-1273-1188; Kiselyov, Kirill/0000-0001-6683-2895				FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Gailly P, 1998, CELL CALCIUM, V24, P293, DOI 10.1016/S0143-4160(98)90053-7; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1992, ION CHANNELS CELL ME; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; Kaznacheyeva E, 1998, J GEN PHYSIOL, V111, P847, DOI 10.1085/jgp.111.6.847; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kiselyov KI, 1999, PFLUG ARCH EUR J PHY, V437, P305, DOI 10.1007/s004240050784; Kiselyov KI, 1997, FEBS LETT, V407, P309, DOI 10.1016/S0014-5793(97)00366-9; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Muallem S, 1997, CELL CALCIUM, V22, P1, DOI 10.1016/S0143-4160(97)90083-X; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SHARP AH, 1993, J NEUROSCI, V13, P3051; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	20	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					25983	25985		10.1074/jbc.274.37.25983	http://dx.doi.org/10.1074/jbc.274.37.25983			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473541	hybrid			2022-12-25	WOS:000082469700007
J	Kido, S; Miyamoto, K; Mizobuchi, H; Taketani, Y; Ohkido, I; Ogawa, N; Kaneko, Y; Harashima, S; Takeda, E				Kido, S; Miyamoto, K; Mizobuchi, H; Taketani, Y; Ohkido, I; Ogawa, N; Kaneko, Y; Harashima, S; Takeda, E			Identification of regulatory sequences and binding proteins in the type II sodium/phosphate cotransporter NPT2 gene responsive to dietary phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORTER NAPI-2; MESSENGER-RNA; RAT-KIDNEY; TRANSCRIPTION; ACTIVATOR; DOMAINS; GROWTH; TFE3; ADAPTATION	Dietary phosphate (P-i) is a most important regulator for renal P-i reabsorption. The type II sodium-dependent phosphate (Na/P-i) cotransporters (NPT2) are located at the apical membranes of renal proximal tubular cells and major functional transporters associated with renal P-i reabsorption. The consumption of a low-P-i diet induces the synthesis of NPT2, whereas a high P-i diet decreases it, The molecular mechanisms of regulation by dietary P-i are not yet known. In this report, in weaning mice fed a low-P-i diet for 4 days, the NPT2 mRNA level was increased 1.8-fold compared with mice fed a normal P-i diet. This increase was due to an elevation of the transcriptional activity. In the NPT2 gene promoter, the DNA footprint analysis showed that six regions were masked by the binding protein, but at the position -1010 to -985 upstream of the transcription start site, the binding clearly responded to the levels of dietary P-i, The phosphate response element (PRE) of the NPT2 gene was found to consist of the motif related to the E box, 5'-CACGTG-3'. A yeast one-hybrid system was used to clone a transcription factor that binds to the PRE sequences in the proximal promoter of the NPT2 gene. Two cDNA clones that encoded protein of the mouse transcription factor mu E3 (TFE3) were isolated. This is a DNA-binding protein that activates transcription through the mu E3 site of the immunoglobulin heavy chain enhancer. TFE3 antibody completely inhibited the binding to the PRE. The coexpression of TFE3 in COS-7 cells transfected with the NPT2 gene promoter markedly stimulated the transcriptional activity. The feeding of a low P-i diet significantly increased the amount of TFE3 mRNA in the kidney. These findings suggest that TFE3 may participate in the transcriptional regulation of the NPT2 gene by dietary P-i.	Univ Tokushima, Sch Med, Dept Clin Nutr, Tokushima 770, Japan; Osaka Univ, Grad Sch Engn, Dept Biotechnol, Genet Mol Lab, Suita, Osaka 565, Japan	Tokushima University; Osaka University	Miyamoto, K (corresponding author), Univ Tokushima, Sch Med, Dept Clin Nutr, Kuramoto Cho 3, Tokushima 770, Japan.							ARAKAWA T, 1995, FEBS LETT, V363, P105, DOI 10.1016/0014-5793(95)00293-I; ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; BERNDT TJ, 1992, KIDNEY PHYSL PATHOPH, V2, P2511; Biber J, 1996, KIDNEY INT, V49, P981, DOI 10.1038/ki.1996.139; BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Collins JF, 1997, NUTR RES, V17, P295, DOI 10.1016/S0271-5317(96)00259-X; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; Hilfiker H, 1998, AM J PHYSIOL-RENAL, V274, pF197, DOI 10.1152/ajprenal.1998.274.1.F197; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Katai K, 1997, J BIOCHEM-TOKYO, V121, P50, DOI 10.1093/oxfordjournals.jbchem.a021569; Kavanaugh MP, 1996, KIDNEY INT, V49, P959, DOI 10.1038/ki.1996.135; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; Lotscher M, 1996, KIDNEY INT, V49, P1012, DOI 10.1038/ki.1996.146; MARKOVICH D, 1995, PFLUG ARCH EUR J PHY, V430, P459, DOI 10.1007/BF00373881; MIURA Y, 1993, BIOSCI BIOTECH BIOCH, V57, P358, DOI 10.1271/bbb.57.358; MOALLEM E, 1991, J BIOL CHEM, V6, P3229; Morita K, 1998, J BONE MINER METAB, V16, P234, DOI 10.1007/s007740050050; Murayama A, 1998, BIOCHEM BIOPH RES CO, V249, P11, DOI 10.1006/bbrc.1998.9098; Murer H, 1996, ANNU REV PHYSIOL, V58, P607, DOI 10.1146/annurev.physiol.58.1.607; Murer H., 1992, KIDNEY PHYSL PATHOPH, V2, P2481; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; OKUDA S, 1991, P NATL ACAD SCI USA, V88, P9765, DOI 10.1073/pnas.88.21.9765; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; ROSE MD, 1990, METHODS YEAST GENETI, P265; Shinki T, 1997, P NATL ACAD SCI USA, V94, P12920, DOI 10.1073/pnas.94.24.12920; Slatopolsky E, 1996, J CLIN INVEST, V97, P2534, DOI 10.1172/JCI118701; Takahashi F, 1998, BIOCHEM J, V333, P175, DOI 10.1042/bj3330175; Taketani Y, 1997, BIOCHEM J, V324, P927, DOI 10.1042/bj3240927; Taketani Y, 1998, J BIOL CHEM, V273, P14575, DOI 10.1074/jbc.273.23.14575; TANAKA Y, 1973, ARCH BIOCHEM BIOPHYS, V154, P566, DOI 10.1016/0003-9861(73)90010-6; Vidal M, 1999, NUCLEIC ACIDS RES, V27, P919, DOI 10.1093/nar/27.4.919; WERNER A, 1994, J BIOL CHEM, V269, P6637; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294	37	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28256	28263		10.1074/jbc.274.40.28256	http://dx.doi.org/10.1074/jbc.274.40.28256			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497181	hybrid			2022-12-25	WOS:000082912700030
J	Quan, TH; Fisher, GJ				Quan, TH; Fisher, GJ			Cloning and characterization of the human protein kinase C-eta promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN KERATINOCYTES; RNA POLYMERASE-II; TRANSCRIPTION FACTORS; HUMAN SKIN; BETA-GENE; EXPRESSION; ISOFORM; FAMILY; CELLS; DIFFERENTIATION	Protein kinase C-eta (PRC-eta) is predominantly expressed in epithelial tissue, including lung, intestine, and skin. In skin, PKC-eta expression is limited to keratinocytes in the upper layers of the epidermis. To investigate regulation of cell, type-specific expression of PKC-eta, we cloned the 5'-segment of the PRC-eta gene from a P1 genomic library. A 9.4-kilobase pair fragment encompassing the 5'-flanking region, first exon, and first intron, was localized on human chromosome 14 (14q22-23). Two major transcription initiation sites identified by reverse transcriptase polymerase chain reaction, primer extension, and S1 nuclease mapping, were located approximately 650 base pairs upstream from the translation start site. The human PKC-eta proximal promoter region lacks canonical TATA and CAAT boxes and GC-rich regions. A 1.6-kilobase pair 5'-flanking region displayed maximal promoter activity. This promoter was active in human keratinocytes but not human skin fibroblasts, in accord with endogenous PRC-p gene expression. Stepwise 5' deletion analysis revealed the presence of adjacent regulatory regions containing silencer and enhancer elements located 1821-1702 base pairs and 1259-1189 base pairs upstream of the transcription initiation site. Deletion of the proximal PKC-eta promoter rendered the enhancer element inactive. Both the silencer and enhancer elements regulated heterologous promoters in keratinocytes but not fibroblasts, Electrophoretic mobility shift analysis demonstrated specific protein binding to Ets/heat shock factor and Ets/activator protein-1 consensus sequences in the enhancer and silencer regions, respectively, Mutations of the Ets/heat shock factor binding sites caused loss of functional enhancer activity, These data elucidate transcriptional regulation and tissue-specific expression of the PBC-eta gene.	Univ Michigan, Med Ctr, Dept Dermatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), Univ Michigan, Med Ctr, Dept Dermatol, 1150 W Med Ctr Dr,Med Sci 1,Rm 6447, Ann Arbor, MI 48109 USA.			Quan, Taihao/0000-0002-0954-5109	NIAMS NIH HHS [R01AR42419] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042419] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; FAISST S, 1991, NUCLEIC ACIDS RES, V20, P3; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Frevert EU, 1996, BIOCHEM J, V316, P865, DOI 10.1042/bj3160865; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; Lee JH, 1996, J BIOL CHEM, V271, P4561; MAHAJNA J, 1995, DNA CELL BIOL, V14, P213, DOI 10.1089/dna.1995.14.213; MARTINI G, 1986, EMBO J, V5, P1849, DOI 10.1002/j.1460-2075.1986.tb04436.x; MILLER JH, 1972, EXPRESSION MOL GENET; Murakami A, 1996, J INVEST DERMATOL, V106, P790, DOI 10.1111/1523-1747.ep12346391; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OBEID LM, 1992, J BIOL CHEM, V267, P20804; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OSADA S, 1990, J BIOL CHEM, V265, P22434; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; Ueda E, 1996, J BIOL CHEM, V271, P9790, DOI 10.1074/jbc.271.16.9790; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WIDEN SG, 1988, J BIOL CHEM, V263, P16992	39	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28566	28574		10.1074/jbc.274.40.28566	http://dx.doi.org/10.1074/jbc.274.40.28566			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497222	hybrid			2022-12-25	WOS:000082912700071
J	Becq, F; Mettey, Y; Gray, MA; Galietta, LJV; Dormer, RL; Merten, M; Metaye, T; Chappe, V; Marvingt-Mounir, C; Zegarra-Moran, O; Tarran, R; Bulteau, L; Derand, R; Pereira, MMC; McPherson, MK; Rogier, C; Joffre, M; Argent, BE; Sarrouilhe, D; Kammouni, W; Figarella, C; Verrier, B; Gola, M; Vierfond, JM				Becq, F; Mettey, Y; Gray, MA; Galietta, LJV; Dormer, RL; Merten, M; Metaye, T; Chappe, V; Marvingt-Mounir, C; Zegarra-Moran, O; Tarran, R; Bulteau, L; Derand, R; Pereira, MMC; McPherson, MK; Rogier, C; Joffre, M; Argent, BE; Sarrouilhe, D; Kammouni, W; Figarella, C; Verrier, B; Gola, M; Vierfond, JM			Development of substituted benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PANCREATIC DUCT CELLS; RABBIT SKELETAL-MUSCLE; RECEPTOR ANTAGONISTS; MUCIN SECRETION; CFTR; PHOSPHORYLATION; GENE; ANTILEUKOPROTEASE; TRANSPORT	Chloride channels play an important role in the physiology and pathophysiology of epithelia, but their pharmacology is still poorly developed. We have chemically synthesized a series of substituted benzo[c]quinolizinium (MPB) compounds. Among them, 6-hydroxy-7-chlorobenzo[c]quinolizinium (MPB-27) and 6-hydroxy-10-chlorobenzo[c]quinolizinium (MPB 07), which we show to be potent and selective activators of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. We examined the effect of MPB compounds on the activity of CFTR channels in a variety of established epithelial and nonepithelial cell systems. Using the iodide efflux technique, we show that MPB compounds activate CFTR chloride channels in Chinese hamster ovary (CHO) cells stably expressing CFTR but not in CHO cells lacking CFTR. Single and whole cell patch clamp recordings from CHO cells confirm that CFTR is the only channel activated by the drugs. Ussing chamber experiments reveal that the apical addition of MPB to human nasal epithelial cells produces a large increase of the short circuit current. This current can be totally inhibited by glibenclamide. Whole cell experiments performed on native respiratory cells isolated from wild type and CF null mice also show that MPB compounds specifically activate CFTR channels. The activation of CFTR by MPB compounds was glibenclamide-sensitive and 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid-insensitive. In the human tracheal gland cell line MM39, RIPE drugs activate CFTR channels and stimulate the secretion of the antibacterial secretory leukoproteinase inhibitor. In submandibular acinar cells, MPB compounds slightly stimulate CFTR-mediated submandibular mucin secretion without changing intracellular cAMP and ATP levels. Similarly, in CHO cells MPB compounds have no effect on the intracellular levels of cAMP and ATP or on the activity of various protein phosphatases (PP1, PP2A, PP2C, or alkaline phosphatase). Our results provide evidence that substituted benzo[c]quinolizinium compounds are a novel family of activators of CFTR and of CFTR-mediated protein secretion and therefore represent a new tool to study CFTR-mediated chloride and secretory functions in epithelial tissues.	Univ Poitiers, UMR 6558, Lab Physiol Regulat Cellulaires, F-86022 Poitiers, France; CNRS, UPR 9024, Neurobiol Lab, F-13402 Marseille 20, France; Fac Med & Pharm Poitiers, Chim Organ Lab, F-86005 Poitiers, France; Newcastle Univ, Sch Med, Dept Physiol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy; Cardiff Univ, Dept Med Biochem, Cardiff CF4 4XN, S Glam, Wales; Fac Med Marseille, GRGE, F-13385 Marseille, France; Fac Med Pharm Poitiers, Biol Cellulaire Lab, F-86005 Poitiers, France	Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Newcastle University - UK; University of Genoa; IRCCS Istituto Giannina Gaslini; Cardiff University; UDICE-French Research Universities; Aix-Marseille Universite; Universite de Poitiers	Becq, F (corresponding author), Univ Poitiers, UMR 6558, Lab Physiol Regulat Cellulaires, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	frederic.becq@campus.univ-poitiers.fr	Becq, Frederic/P-9233-2016; Galietta, Luis JV/HCG-8692-2022	Becq, Frederic/0000-0003-3915-0973; GRAY, MICHAEL/0000-0002-6774-6283; Chappe, Valerie/0000-0002-8339-1363; Galietta, Luis/0000-0001-8686-3461				BECQ F, 1993, FEBS LETT, V327, P337, DOI 10.1016/0014-5793(93)81016-S; Becq F, 1996, J BIOL CHEM, V271, P16171, DOI 10.1074/jbc.271.27.16171; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; BECQ F, 1997, Patent No. 01436; CHANG XB, 1993, J BIOL CHEM, V268, P11304; Chappe V, 1998, BRIT J PHARMACOL, V123, P683, DOI 10.1038/sj.bjp.0701648; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL785, DOI 10.1152/ajplung.1996.271.5.L785; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EIDELMAN O, 1992, P NATL ACAD SCI USA, V89, P5562, DOI 10.1073/pnas.89.12.5562; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; Galietta LJV, 1998, AM J PHYSIOL-LUNG C, V275, pL917, DOI 10.1152/ajplung.1998.275.5.L917; GRAY MA, 1994, AM J PHYSIOL, V266, pC213, DOI 10.1152/ajpcell.1994.266.1.C213; GRAY MA, 1988, J MEMBRANE BIOL, V105, P131, DOI 10.1007/BF02009166; GRIBKOFF VK, 1994, J BIOL CHEM, V269, P10983; HANRAHAN JW, 1995, SOC GEN PHY, V50, P125; Hiemstra PS, 1996, INFECT IMMUN, V64, P4520, DOI 10.1128/IAI.64.11.4520-4524.1996; HWANG TC, 1993, J GEN PHYSIOL, V101, P629, DOI 10.1085/jgp.101.5.629; ILLEK B, 1995, AM J PHYSIOL-CELL PH, V268, pC886, DOI 10.1152/ajpcell.1995.268.4.C886; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; Kammouni W, 1999, AM J RESP CELL MOL, V20, P684, DOI 10.1165/ajrcmb.20.4.3341; Luo JX, 1998, AM J PHYSIOL-CELL PH, V274, pC1397, DOI 10.1152/ajpcell.1998.274.5.C1397; MACKINTOSH C, 1993, PROTEIN PHOSPHORYLAT, P197; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MCPHERSON MA, 1986, LANCET, V2, P1007; Mergey M, 1995, AM J PHYSIOL-LUNG C, V269, pL855, DOI 10.1152/ajplung.1995.269.6.L855; Merten MD, 1996, AM J RESP CELL MOL, V15, P520, DOI 10.1165/ajrcmb.15.4.8879186; MERTEN MD, 1993, AM J PHYSIOL, V264, pL93, DOI 10.1152/ajplung.1993.264.2.L93; MILLS CL, 1992, BIOCHEM BIOPH RES CO, V188, P1146, DOI 10.1016/0006-291X(92)91351-P; MONSERRAT C, 1996, FEBS LETT, V393, P264; Pereira MMC, 1998, BRIT J PHARMACOL, V125, P697, DOI 10.1038/sj.bjp.0702128; PICCIONI PD, 1992, CHEST, V102, P1470, DOI 10.1378/chest.102.5.1470; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RATCLIFF R, 1993, NAT GENET, V4, P35, DOI 10.1038/ng0593-35; Reenstra WW, 1996, AM J PHYSIOL-CELL PH, V271, pC650, DOI 10.1152/ajpcell.1996.271.2.C650; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tarran R, 1998, AM J PHYSIOL-CELL PH, V274, pC904, DOI 10.1152/ajpcell.1998.274.4.C904; TOURNIER JM, 1983, ANAL BIOCHEM, V131, P345, DOI 10.1016/0003-2697(83)90181-1; Travis SM, 1997, P NATL ACAD SCI USA, V94, P11055, DOI 10.1073/pnas.94.20.11055; Tsui L C, 1991, Adv Hum Genet, V20, P153; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; Yang ICH, 1997, AM J PHYSIOL-CELL PH, V272, pC142, DOI 10.1152/ajpcell.1997.272.1.C142	49	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27415	27425		10.1074/jbc.274.39.27415	http://dx.doi.org/10.1074/jbc.274.39.27415			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488073	hybrid			2022-12-25	WOS:000082739100012
J	Canceill, D; Viguera, E; Ehrlich, SD				Canceill, D; Viguera, E; Ehrlich, SD			Replication slippage of different DNA polymerases is inversely related to their strand displacement efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; BINDING-PROTEIN SSB; T4 GENE 32; ESCHERICHIA-COLI; III HOLOENZYME; UNWINDING PROTEIN; LAGGING-STRAND; SECONDARY STRUCTURE; DELETION FORMATION; T7-DNA POLYMERASE	Replication slippage is a particular type of error caused by DNA polymerases believed to occur both in bacterial and eukaryotic cells. Previous studies have shown that deletion events can occur in Escherichia coli by replication slippage between short duplications and that the main E. coli polymerase, DNA polymerase III holoenzyme is prone to such slippage. In this work, we present evidence that the two other DNA polymerases of E. coli, DNA polymerase I and DNA polymerase II, as well as polymerases of two phages, T4 (T4 pol) and T7 (T7 pol), undergo slippage in vitro, whereas DNA polymerase from another phage, Phi 29, does not. Furthermore, we have measured the strand displacement activity of the different polymerases tested for slippage in the absence and in the presence of the E, coli single-stranded DNA-binding protein (SSB), and we show that: (i) polymerases having a strong strand displacement activity cannot slip (DNA polymerase from Phi 29); (ii) polymerases devoid of any strand displacement activity slip very efficiently (DNA polymerase II and T4 pol); and (iii) stimulation of the strand displacement activity by E. coli SSB (DNA polymerase I and T7 pol), by phagic SSB (T4 pol), or by a mutation that affects the 3' --> 5' exonuclease domain (DNA polymerase II exo(-) and T7 pol exo(-)) is correlated with the inhibition of slippage. We propose that these observations can be interpreted in terms of a model, for which we have shown that high strand displacement activity of a polymerase diminishes its propensity to slip.	INRA, Lab Genet Microbienne, F-78352 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Canceill, D (corresponding author), INRA, Lab Genet Microbienne, Domaine Vilvert, F-78352 Jouy En Josas, France.	canceill@biotec.jouy.inra.fr	Ehrlich, S./Y-2423-2019; Mínguez, Enrique Viguera/H-4416-2015	Ehrlich, S./0000-0002-7563-4046; Mínguez, Enrique Viguera/0000-0001-5475-3807				Bierne H, 1997, MOL MICROBIOL, V24, P1225, DOI 10.1046/j.1365-2958.1997.4381795.x; BLANCO L, 1989, J BIOL CHEM, V264, P8935; Blanco L, 1996, J BIOL CHEM, V271, P8509, DOI 10.1074/jbc.271.15.8509; BONNER CA, 1992, J BIOL CHEM, V267, P11431; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; Canceill D, 1996, P NATL ACAD SCI USA, V93, P6647, DOI 10.1073/pnas.93.13.6647; CHA TA, 1989, J BIOL CHEM, V264, P12220; DALENCON E, 1994, EMBO J, V13, P2725, DOI 10.1002/j.1460-2075.1994.tb06563.x; Debrauwere H, 1997, BIOCHIMIE, V79, P577, DOI 10.1016/S0300-9084(97)82006-8; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; Djian P, 1998, CELL, V94, P155, DOI 10.1016/S0092-8674(00)81415-4; ENGLER MJ, 1983, J BIOL CHEM, V258, P1165; ESCARCELLER M, 1994, J BACTERIOL, V176, P6221, DOI 10.1128/jb.176.20.6221-6228.1994; ESTEBAN JA, 1994, J BIOL CHEM, V269, P31946; FAY PJ, 1981, J BIOL CHEM, V256, P976; Feschenko VV, 1998, J MOL BIOL, V276, P559, DOI 10.1006/jmbi.1997.1566; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; GUTIERREZ C, 1991, J BIOL CHEM, V266, P2104; HILLEBRAND GG, 1985, J BIOL CHEM, V260, P3116; HUANG CC, 1981, J BIOL CHEM, V256, P4087; HUBERMAN JA, 1971, J MOL BIOL, V62, P39, DOI 10.1016/0022-2836(71)90129-X; HUGHES AJ, 1991, J BIOL CHEM, V266, P4568; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KORNBERG A, 1992, DNA REPLICATION, P162; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Lovett ST, 1996, P NATL ACAD SCI USA, V93, P7120, DOI 10.1073/pnas.93.14.7120; MADSEN CS, 1993, P NATL ACAD SCI USA, V90, P7671, DOI 10.1073/pnas.90.16.7671; MARTIN G, 1989, NUCLEIC ACIDS RES, V17, P3663, DOI 10.1093/nar/17.10.3663; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; MOLINEUX IJ, 1974, J BIOL CHEM, V249, P6090; MYERS TW, 1988, J BIOL CHEM, V263, P17006; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NOSSAL NG, 1974, J BIOL CHEM, V249, P5668; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; PAPANICOLAOU C, 1989, J MOL BIOL, V207, P335, DOI 10.1016/0022-2836(89)90258-1; PazElizur T, 1996, J BIOL CHEM, V271, P24662, DOI 10.1074/jbc.271.40.24662; Pearson CE, 1998, CURR OPIN STRUC BIOL, V8, P321, DOI 10.1016/S0959-440X(98)80065-1; Rangarajan S, 1997, P NATL ACAD SCI USA, V94, P946, DOI 10.1073/pnas.94.3.946; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; RIGLER MN, 1995, J BIOL CHEM, V270, P8910, DOI 10.1074/jbc.270.15.8910; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROSCHE WA, 1995, J BACTERIOL, V177, P4385, DOI 10.1128/jb.177.15.4385-4391.1995; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SHERMAN LA, 1976, J MOL BIOL, V103, P61, DOI 10.1016/0022-2836(76)90052-8; SIGAL N, 1972, P NATL ACAD SCI USA, V69, P3537, DOI 10.1073/pnas.69.12.3537; SOENGAS MS, 1992, EMBO J, V11, P4227, DOI 10.1002/j.1460-2075.1992.tb05517.x; SOENGAS MS, 1995, J MOL BIOL, V253, P517, DOI 10.1006/jmbi.1995.0570; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1989, J BIOL CHEM, V264, P6447; TRAN HT, 1995, MOL CELL BIOL, V15, P5607; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; TRINH TQ, 1993, GENETICS, V134, P409; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WICKNER RB, 1972, J BIOL CHEM, V247, P498; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	66	63	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27481	27490		10.1074/jbc.274.39.27481	http://dx.doi.org/10.1074/jbc.274.39.27481			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488082	Green Published			2022-12-25	WOS:000082739100021
J	Metjian, A; Roll, RL; Ma, AD; Abrams, CS				Metjian, A; Roll, RL; Ma, AD; Abrams, CS			Agonists cause nuclear translocation of phosphatidylinositol 3-kinase gamma - A G beta gamma-dependent pathway that requires the p110-gamma amino terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; POLYMERASE CHAIN-REACTION; CELL-CYCLE; PHOSPHOINOSITIDE-3 KINASE; GROWTH-FACTOR; ACTIVATION; SUFFICIENT; SUBUNITS; MAPK; RAS	In hematopoietic cells, the signals initiated by activation of the phosphoinositide 3-kinase (PI3K) family have been implicated in cell proliferation and survival, membrane and cytoskeletal reorganization, chemotaxis, and the neutrophil respiratory burst. Of the four isoforms of human PI3K that phosphorylate phosphatidylinositol 4,5-bisphosphate, only p110 gamma (or PI3K gamma) is associated with the regulatory subunit, p101, and is stimulated by G protein beta gamma heterodimers. We performed immunolocalization of transfected p110 gamma in HepG2 cells and found that, under resting conditions, p110 gamma was present in a diffuse cytoplasmic pattern, but translocated to the cell nucleus after serum stimulation. Serum-stimulated p110 gamma translocation was inhibited by pertussis toxin and could also be induced by overexpression of G beta gamma in the absence of serum. In addition, we found that deletion of the amino-terminal 33 residues of p110 gamma had no effect on association with p101 or on its agonist-regulated translocation, but truncation of the amino-terminal 82 residues yielded a p110 gamma variant that did not associate with p101 and was constitutively localized in the nucleus. This finding implies that the intracellular localization of p110 gamma is regulated by p101 as well as G beta gamma. The effect of PI3K gamma in the nucleus is an area of active investigation.	Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania	Abrams, CS (corresponding author), Univ Penn, Dept Med, Div Hematol Oncol, Biomed Res Bldg 2-3,Rm 912,421 Curie Blvd, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [HL40378, HL54500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrams CS, 1996, J BIOL CHEM, V271, P25192, DOI 10.1074/jbc.271.41.25192; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOBOS GJ, 1993, FEBS LETT, V324, P143, DOI 10.1016/0014-5793(93)81381-9; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Manzoli L, 1996, ANTICANCER RES, V16, P3283; NAKANISHI S, 1995, CELL SIGNAL, V7, P545, DOI 10.1016/0898-6568(95)00033-L; NERI LM, 1994, CELL MOL BIOL, V40, P619; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; TERCE F, 1994, J LIPID RES, V35, P2130	25	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27943	27947		10.1074/jbc.274.39.27943	http://dx.doi.org/10.1074/jbc.274.39.27943			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488142	hybrid			2022-12-25	WOS:000082739100081
J	Davidson, HW				Davidson, HW			Direct transport of newly synthesized HLA-DR from the trans-Golgi network to major histocompatibility complex class II containing compartments (MIICS) demonstrated using a novel tyrosine-sulfated chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVARIANT CHAIN COMPLEXES; B-CELL LINE; MONOCLONAL-ANTIBODIES; MHC MOLECULES; ENDOPLASMIC-RETICULUM; ANTIGEN PRESENTATION; SURFACE EXPRESSION; SEMIINTACT CELLS; LYMPHOCYTES-B; ALPHA-CHAIN	Binding of antigenic peptides to major histocompatibility complex (MHC) class II glycoproteins occurs in specialized endocytic compartments of antigen-presenting cells, which in man are termed MIICs. Newly synthesized MHC class II molecules are transported from the trans-Golgi network to MIICs, but previous studies of this important step in antigen processing have failed to conclusively determine whether most immature MHC class II complexes are transported directly to the processing compartments or are first transiently exposed at the cell surface. To attempt to resolve this question, I constructed a chimeric HLA-DR alpha chain containing two optimal tyrosine sulfation motifs. When expressed in a human B lymphoblastoid cell line lacking functional DR alpha chains, the chimera was correctly incorporated into complexes containing endogenous beta and invariant chains, transported to the trans-Golgi network, and efficiently sulfated. Pulse-chase experiments showed that the sulfated complexes were rapidly transported to processing compartments with kinetics consistent with direct transport from the trans-Golgi network. The rate of maturation was not significantly altered in cells expressing a temperature-sensitive mutant of dynamin under conditions where the endocytosis of transferrin was inhibited by 95%, confirming that endocytosis was not required for delivery to MIICs. Maturation of MHC class II-containing complexes was inhibited by aluminum fluoride and brefeldin A, indicating the involvement of heterotrimeric G-proteins and ADP-ribosylation factor in the transport event(s). The procedure described provides a unique mechanism to study critical events in antigen processing and presentation.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2XY, England; Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Davidson, HW (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.							BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; Barr FA, 1996, FEBS LETT, V384, P65, DOI 10.1016/0014-5793(96)00285-2; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BERGEN JV, 1997, P NATL ACAD SCI USA, V94, P7499; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DEALMEIDA JB, 1993, J CELL SCI, V106, P1239; DIAZESPADA F, 1987, MOL IMMUNOL, V24, P595, DOI 10.1016/0161-5890(87)90040-X; EDWARDS PAW, 1982, EUR J IMMUNOL, V12, P641, DOI 10.1002/eji.1830120804; EPSTEIN AL, 1984, J IMMUNOL, V133, P1028; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; Ferrari G, 1997, J CELL BIOL, V139, P1433, DOI 10.1083/jcb.139.6.1433; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GIACOLETTO KS, 1986, J EXP MED, V164, P1422, DOI 10.1084/jem.164.5.1422; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; Harding CV, 1996, CRIT REV IMMUNOL, V16, P13, DOI 10.1615/CritRevImmunol.v16.i1.20; HENNE C, 1995, IMMUNOLOGY, V84, P177; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; JASANOFF A, 1995, P NATL ACAD SCI USA, V92, P9900, DOI 10.1073/pnas.92.21.9900; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; Kleijmeer Monique J., 1996, Methods (Orlando), V10, P191, DOI 10.1006/meth.1996.0095; KOPPELMAN B, 1990, J IMMUNOL, V145, P2730; LAMB CA, 1992, J IMMUNOL, V148, P3478; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LEITINGER B, 1994, J BIOL CHEM, V269, P8115; Liu SH, 1998, J CELL BIOL, V140, P1023, DOI 10.1083/jcb.140.5.1023; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MACHAMER CE, 1982, J IMMUNOL, V129, P2564; MADDOX JF, 1989, IMMUNOBIOLOGY HLA, V2, P373; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MCNEALL J, 1989, GENE, V76, P81, DOI 10.1016/0378-1119(89)90010-3; MILLER SG, 1992, METHOD ENZYMOL, V219, P234; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; NIEHRS C, 1992, J BIOL CHEM, V267, P15938; NIEHRS C, 1990, J BIOL CHEM, V265, P8525; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; SANT AJ, 1988, J IMMUNOL, V140, P155; SHACKELFORD DA, 1981, J IMMUNOL, V127, P1403; SIVAK LE, 1987, J IMMUNOL, V138, P1319; SMYTHE E, 1992, METHOD ENZYMOL, V219, P223; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUBTIL A, 1994, J CELL SCI, V107, P3461; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; Wang K, 1997, J BIOL CHEM, V272, P17055, DOI 10.1074/jbc.272.27.17055; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787; ZHANG Q, 1994, EUR J IMMUNOL, V24, P1467, DOI 10.1002/eji.1830240635	66	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27315	27322		10.1074/jbc.274.38.27315	http://dx.doi.org/10.1074/jbc.274.38.27315			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480952	hybrid			2022-12-25	WOS:000082570700091
J	Malaviya, R; Zhu, DM; Dibirdik, I; Uckun, FM				Malaviya, R; Zhu, DM; Dibirdik, I; Uckun, FM			Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; PROTEIN-TYROSINE KINASES; MICE LACKING JAK3; LYMPHOMA B-CELLS; RBL-2H3 CELLS; CYTOTOXIC ACTIVITY; CROSS-LINKING; TNF-ALPHA; DEGRANULATION; SYK	Janus kinase 3 (JAK3), a member of the Janus family protein-tyrosine kinases, is expressed in mast cells, and its enzymatic activity is enhanced by IgE receptor/Fc epsilon RI cross-linking Selective inhibition of JAK3 in mast cells with 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline) (WHI-P131) blocked the phospholipase C activation, calcium mobilization, and activation of microtubule-associated protein kinase after IgE receptor/Fc epsilon RI cross-linking. Treatment of IgE-sensitized rodent as well as human mast cells with WHI-P131 effectively inhibited the activation-associated morphological changes, degranulation, and proinflammatory mediator release after specific antigen challenge without affecting the functional integrity of the distal secretory machinery. In vivo administration of the JAK3 inhibitor WHI-P131 prevented mast cell degranulation and development of cutaneous as well as systemic fatal anaphylaxis in mice at nontoxic dose levels. Thus, JAK3 plays a pivotal role in IgE receptor/Fc epsilon RI-mediated mast cell responses, and targeting JAK3 with a specific inhibitor, such as WHI-P131, may provide the basis for new and effective treatment as well as prevention programs for mast cell-mediated allergic reactions.	Hughes Inst, Dept Immunol, St Paul, MN 55113 USA; Hughes Inst, Dept Allergy, St Paul, MN 55113 USA; Hughes Inst, Dept Biochem, St Paul, MN 55113 USA; Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA		Uckun, FM (corresponding author), Hughes Inst, Dept Immunol, 2665 Long Lake Rd,Suite 330, St Paul, MN 55113 USA.			Uckun, Fatih M./0000-0001-9334-183X				AMIR S, 1991, EUR J PHARMACOL, V203, P125, DOI 10.1016/0014-2999(91)90800-6; Apgar JR, 1997, J CELL SCI, V110, P771; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; Costello PS, 1996, ONCOGENE, V13, P2595; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dibirdik I, 1998, J BIOL CHEM, V273, P4035, DOI 10.1074/jbc.273.7.4035; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GHOSH S, 1999, CLIN CANCER RES, V47, P121; Goodman PA, 1998, J BIOL CHEM, V273, P17742, DOI 10.1074/jbc.273.28.17742; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; Hogan AD, 1997, METHODS, V13, P43, DOI 10.1006/meth.1997.0494; Ihle JN, 1996, PHILOS T R SOC B, V351, P159, DOI 10.1098/rstb.1996.0012; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; Levy David E., 1997, Cytokine and Growth Factor Reviews, V8, P81, DOI 10.1016/S1359-6101(96)00054-8; LIU FT, 1980, J IMMUNOL, V124, P2728; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; Malaviya R, 1999, BIOCHEM BIOPH RES CO, V257, P807, DOI 10.1006/bbrc.1999.0513; MALAVIYA R, 1995, METHOD ENZYMOL, V253, P27; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; Malaviya R, 1996, J INVEST DERMATOL, V106, P785, DOI 10.1111/1523-1747.ep12346356; MALAVIYA R, 1994, J CLIN INVEST, V93, P1645, DOI 10.1172/JCI117146; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Miyazaki T, 1996, CANCER SURV, V27, P25; Narla RK, 1998, CLIN CANCER RES, V4, P1405; NELSON BH, 1996, MOL CELL BIOL, V16, P369; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; OZAWA K, 1993, J BIOL CHEM, V268, P1749; RISKE F, 1991, J BIOL CHEM, V266, P11245; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SIRAGANIAN RP, 1998, PRINCIPLES PRACTICE, V1, P204; Sudbeck EA, 1999, CLIN CANCER RES, V5, P1569; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; Uckun FM, 1998, CLIN CANCER RES, V4, P901; UCKUN FM, 1988, BLOOD, V71, P13; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Villa A, 1996, BLOOD, V88, P817; WEI YF, 1986, J IMMUNOL, V137, P1993; Witthuhn BA, 1999, LEUKEMIA LYMPHOMA, V32, P289, DOI 10.3109/10428199909167389; WONG A, 1992, BIOCHEMISTRY-US, V31, P4046, DOI 10.1021/bi00131a021; Xia HZ, 1997, J IMMUNOL, V159, P2911; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71; Zhu DM, 1998, CLIN CANCER RES, V4, P2967	53	66	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27028	27038		10.1074/jbc.274.38.27028	http://dx.doi.org/10.1074/jbc.274.38.27028			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480916	hybrid			2022-12-25	WOS:000082570700055
J	Rossi, EA; Li, Z; Feng, H; Rubin, CS				Rossi, EA; Li, Z; Feng, H; Rubin, CS			Characterization of the targeting, binding, and phosphorylation site domains of an A kinase anchor protein and a myristoylated alanine-rich C kinase substrate-like analog that are encoded by a single gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; A-KINASE; MOLECULAR CHARACTERIZATION; II-BETA; CAENORHABDITIS-ELEGANS; MARCKS; CYTOSKELETON; EXPRESSION; FAMILY; BRAIN	A novel Drosophila A kinase anchor protein, Drosophila A kinase anchor protein 200 (DAKAP200), is predicted to be involved in routing, mediating, and integrating signals carried by cAMP, Ca2+, and diacylglycerol (Li, Z., Rossi, E. A., Hoheisel, J. D., Kallderon, D., and Rubin, C. S. (1999) J. Biol. Chem, 274, 27191-27200). Experiments designed to assess this hypothesis now (a) establish the function, boundaries and identity of critical amino acids of the protein kinase ATI (PKAII) tethering site of DAKAP200; (b) demonstrate that residues 119-148 mediate binding with Ca2+-calmodulin and F-actin; (c) show that a polybasic region of DAKAP200 is a substrate for protein kinase C; (d) reveal that phosphorylation of the polybasic domain regulates affinity for F-actin and Ca2+-calmodulin; and (e) indicate that DAKAP200 is myristoylated a;nd that this modification promotes targeting of DAKAP200 to plasma membrane, Delta DAKAP200, a second product of the DAKAP200 gene, cannot tether PKAII. However, Delta DAKAP200 is myristoylated and contains a phosphorylation site domain that binds Ca2+-calmodulin and F-actin An atypical amino acid composition, a high level of negative charge, exceptional thermostability, unusual hydrodynamic properties, properties of the phosphorylation site domain, and a calculated M-r of 38,000 suggest that Delta DAKAP200 is a new member of the myristoylated alanine-rich C kinase substrate protein family. DAKAP200 is a potentially mobile, chimeric A kinase anchor protein-myristoylated alanine-rich C kinase substrate protein that may facilitate localized reception and targeted transmission of signals carried by cAMP, Ca2+, and diacylglycerol.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rubin, CS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol F229, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792, T32GM007260] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07513] Funding Source: Medline; NIGMS NIH HHS [GM07260, GM22792] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; Arbuzova A, 1998, BBA-REV BIOMEMBRANES, V1376, P369, DOI 10.1016/S0304-4157(98)00011-2; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; Dong F, 1998, J BIOL CHEM, V273, P6533, DOI 10.1074/jbc.273.11.6533; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Kennedy MT, 1996, J BIOL CHEM, V271, P26517, DOI 10.1074/jbc.271.43.26517; LAND M, 1994, J BIOL CHEM, V269, P9234; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; Li Z, 1999, J BIOL CHEM, V274, P27191, DOI 10.1074/jbc.274.38.27191; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Myat MM, 1998, CURR BIOL, V8, P677, DOI 10.1016/S0960-9822(98)70273-8; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503	35	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27201	27210		10.1074/jbc.274.38.27201	http://dx.doi.org/10.1074/jbc.274.38.27201			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480937	hybrid			2022-12-25	WOS:000082570700076
J	Banerjee, A; Shih, T; Alexander, EA; Schwartz, JH				Banerjee, A; Shih, T; Alexander, EA; Schwartz, JH			SNARE proteins regulate H+-ATPase redistribution to the apical membrane in rat renal inner medullary collecting duct cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CA2+-ACTIVATED EXOCYTOSIS; INTERCALATED CELLS; TURTLE BLADDER; IN-VITRO; FUSION; SYNAPTOBREVIN; SECRETION; VESICLES; DOCKING	The interaction of soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins provides the necessary steps for vesicle docking fusion, In inner medullary collecting duct (IMCD) cells, acid secretion is regulated in part by exocytotic insertion and endocytotic retrieval of an H+-ATPase to and from the apical membrane. We previously suggested a role for SNARE proteins in exocytotic insertion of proton pumps in IMCD cells. The purpose of the present study was to determine whether SNARE proteins are associated with the 31-kDa subunit of H+-ATPase in IMCD cells during exocytosis and to determine the effects of clostridial toxins on SNARE-mediated trafficking of H+-ATPase. Cell acidification induced a marked increment of H+-ATPase in the apical membrane. However, pretreating cells with clostridial toxins blocked the cellular translocation of the 31-kDa subunit. Immunoprecipitation of IMCD cell homogenate, using antibodies against either the 31-kDa subunit of H+-ATPase or vesicle-associated membrane protein-2, co-immunoprecipitated N-ethylmaleimide-sensitive factor, alpha-soluble NSF attachment protein (alpha-SNAP), synaptosome-associated protein-23, syntaxin, and vesicle-associated membrane protein-2. Pretreatment with clostridial toxin resulted in reduced co-immunoprecipitation of WC-ATPase and syntaxin. These experiments document, for the first time, a putative docking fusion complex in IMCD cells and a physical association of the H+-ATPase with the complex, The sensitivity to the action of clostridial toxin indicates the docking-fusion complex is a part of the exocytotic mechanism of the proton pump.	Boston Univ, Med Ctr, Renal Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Physiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University	Schwartz, JH (corresponding author), Evans 401,1 Boston Med Ctr Pl, Boston, MA 02118 USA.		Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681; Alexander, Edward/0000-0002-6659-8186	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028164] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-28164] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexander EA, 1997, AM J PHYSIOL-RENAL, V273, pF1054, DOI 10.1152/ajprenal.1997.273.6.F1054; ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BRION LP, 1989, AM J PHYSIOL, V257, pF486, DOI 10.1152/ajprenal.1989.257.3.F486; Calakos N, 1996, PHYSIOL REV, V76, P1; DIXON TE, 1988, J MEMBRANE BIOL, V102, P49, DOI 10.1007/BF01875352; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; GLUCK S, 1988, AM J PHYSIOL, V254, pF71, DOI 10.1152/ajprenal.1988.254.1.F71; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HohneZell B, 1997, ENDOCRINOLOGY, V138, P5518, DOI 10.1210/en.138.12.5518; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; JO IH, 1995, P NATL ACAD SCI USA, V92, P1876, DOI 10.1073/pnas.92.6.1876; Kishore BK, 1998, AM J PHYSIOL-RENAL, V275, pF131, DOI 10.1152/ajprenal.1998.275.1.F131; Mandon B, 1996, J CLIN INVEST, V98, P906, DOI 10.1172/JCI118873; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Martin TFJ, 1997, J BIOL CHEM, V272, P14447, DOI 10.1074/jbc.272.22.14447; NIELSEN S, 1995, J CLIN INVEST, V96, P1834, DOI 10.1172/JCI118229; Schiavo G, 1995, CURR TOP MICROBIOL, V195, P257; Schulz JR, 1997, DEV BIOL, V191, P80, DOI 10.1006/dbio.1997.8712; SCHWARTZ GJ, 1985, J CLIN INVEST, V75, P1638, DOI 10.1172/JCI111871; SCHWARTZ JH, 1994, AM J PHYSIOL, V266, pF94, DOI 10.1152/ajprenal.1994.266.1.F94; SCOTT RE, 1979, J CELL SCI, V35, P229; SCOTT RE, 1979, J CELL SCI, V35, P245; SELVAGGIO AM, 1988, AM J PHYSIOL, V254, pF391, DOI 10.1152/ajprenal.1988.254.3.F391; SLOTKI I, 1993, AM J PHYSIOL, V265, pC432, DOI 10.1152/ajpcell.1993.265.2.C432; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STLOKI IN, 1989, AM J PHYSIOL, V257, pF210; VERLANDER JW, 1994, AM J PHYSIOL, V266, pF633, DOI 10.1152/ajprenal.1994.266.4.F633	30	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26518	26522		10.1074/jbc.274.37.26518	http://dx.doi.org/10.1074/jbc.274.37.26518			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473613	hybrid			2022-12-25	WOS:000082469700079
J	Bates, PJ; Kahlon, JB; Thomas, SD; Trent, JO; Miller, DM				Bates, PJ; Kahlon, JB; Thomas, SD; Trent, JO; Miller, DM			Antiproliferative activity of G-rich oligonucleotides correlates with protein binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SELF-CLEAVING ACTIVITY; ANTISENSE OLIGONUCLEOTIDES; GENE-EXPRESSION; NUCLEOLAR PROTEINS; CELL-PROLIFERATION; RIBOSOMAL-RNA; CANCER-CELLS; SEQUENCE; DNA	Oligonucleotides have been extensively studied as antisense or antigene agents that can potentially modulate the expression of specific genes. These strategies rely on sequence-specific hybridization of the oligonucleotide to mRNA or genomic DNA. Recently, it has become clear that oligonucleotides often have biological activities that cannot be attributed to their sequence-specific interactions with nucleic acids. Here we describe a series of guanosine-rich phosphodiester oligodeoxynucleotides that strongly inhibit proliferation in a number of human tumor cell lines. The presence of G-quartets in the active oligonucleotides is demonstrated using an UV melting technique. We show that G-rich oligonucleotides bind to a specific cellular protein and that the biological activity of the oligonucleotides correlates with binding to this protein. The G-rich oligonucleotide-binding protein was detected in both nuclear and cytoplasmic extracts and in proteins derived from the plasma membrane of cells. We present strong evidence that this protein is nucleolin, a multifunctional phosphoprotein whose levels are related to the rate of cell proliferation. Our results indicate that binding of G-rich oligonucleotides to nucleolin may be responsible for their non-sequence-specific effects. Furthermore, these oligonucleotides represent a new class of potentially therapeutic agents with a novel mechanism of action.	Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Miller, DM (corresponding author), 520 Wallace Tumor Inst, 1824 6th Ave S, Birmingham, AL 35294 USA.	donald.miller@ccc.uab.edu		Bates, Paula/0000-0002-4622-4152; trent, John/0000-0002-7346-4231				Agrawal S, 1998, ANTISENSE NUCLEIC A, V8, P135, DOI 10.1089/oli.1.1998.8.135; AUSUBEL M, 1996, CURRENT PROTOCOLS MO; BARTON CM, 1995, BRIT J CANCER, V71, P429, DOI 10.1038/bjc.1995.88; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; Benimetskaya L, 1997, NUCLEIC ACIDS RES, V25, P2648, DOI 10.1093/nar/25.13.2648; Branch AD, 1998, TRENDS BIOCHEM SCI, V23, P45, DOI 10.1016/S0968-0004(97)01155-9; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Callebaut C, 1998, J BIOL CHEM, V273, P21988, DOI 10.1074/jbc.273.34.21988; CAPACCIOLI S, 1993, BIOCHEM BIOPH RES CO, V197, P818, DOI 10.1006/bbrc.1993.2552; CHEN CM, 1991, J BIOL CHEM, V266, P7754; Coulson JM, 1996, MOL PHARMACOL, V50, P314; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; DERENZINI M, 1995, LAB INVEST, V73, P497; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; Dryden S, 1998, J ENDOCRINOL, V157, P169, DOI 10.1677/joe.0.1570169; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; FENNEWALD SM, 1995, J BIOL CHEM, V270, P21718, DOI 10.1074/jbc.270.37.21718; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Gotzmann J, 1997, ELECTROPHORESIS, V18, P2645, DOI 10.1002/elps.1150181421; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; Hartmann G, 1996, MOL MED, V2, P429, DOI 10.1007/BF03401902; Helene C, 1997, CIBA F SYMP, V209, P94; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; JORDAN P, BIOCHEMISTRY, V33, P14696; KIBBEY MC, 1995, J NEUROSCI RES, V42, P314, DOI 10.1002/jnr.490420305; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; Larrucea S, 1998, J BIOL CHEM, V273, P31718, DOI 10.1074/jbc.273.48.31718; Lee CH, 1998, J BIOL CHEM, V273, P7650, DOI 10.1074/jbc.273.13.7650; LegerSilvestre I, 1997, CHROMOSOMA, V105, P542, DOI 10.1007/BF02510491; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; Mergny JL, 1998, FEBS LETT, V435, P74, DOI 10.1016/S0014-5793(98)01043-6; Morgan MM, 1998, J NEUROPHYSIOL, V79, P174, DOI 10.1152/jn.1998.79.1.174; MURCHIE AIH, 1992, NUCLEIC ACIDS RES, V20, P49, DOI 10.1093/nar/20.1.49; NAITO M, 1988, J BIOL CHEM, V263, P11887; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; RAMANATHAN M, 1994, J BIOL CHEM, V269, P24564; Rockwell P, 1997, P NATL ACAD SCI USA, V94, P6523, DOI 10.1073/pnas.94.12.6523; ROUSSEL P, 1994, EXP CELL RES, V214, P465, DOI 10.1006/excr.1994.1283; Saijo Y, 1997, JPN J CANCER RES, V88, P26, DOI 10.1111/j.1349-7006.1997.tb00297.x; Scaggiante B, 1998, EUR J BIOCHEM, V252, P207, DOI 10.1046/j.1432-1327.1998.2520207.x; Schwab MS, 1997, EUR J CELL BIOL, V73, P287; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Sonehara K, 1996, J INTERF CYTOK RES, V16, P799, DOI 10.1089/jir.1996.16.799; Stein CA, 1998, ANTISENSE NUCLEIC A, V8, P129, DOI 10.1089/oli.1.1998.8.129; Stein CA, 1997, CIBA F SYMP, V209, P79; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; VLASSOV VV, 1994, BBA-REV BIOMEMBRANES, V1197, P95, DOI 10.1016/0304-4157(94)90001-9; Waggoner S, 1998, J VIROL, V72, P6699, DOI 10.1128/JVI.72.8.6699-6709.1998; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; White JR, 1996, BIOCHEM BIOPH RES CO, V227, P118, DOI 10.1006/bbrc.1996.1476; Yao GQ, 1996, BIOCHEM PHARMACOL, V51, P431, DOI 10.1016/0006-2952(95)02198-1; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	61	318	352	3	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26369	26377		10.1074/jbc.274.37.26369	http://dx.doi.org/10.1074/jbc.274.37.26369			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473594	hybrid			2022-12-25	WOS:000082469700060
J	Briggs, SD; Smithgall, TE				Briggs, SD; Smithgall, TE			SH2-kinase linker mutations release Hck tyrosine kinase and transforming activities in Rat-2 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC ACTIVITY; SH3 DOMAINS; GENE HCK; REGULATORY INTERACTIONS; FUNCTIONAL ASSOCIATION; HEMATOPOIETIC-CELLS; CRYSTAL-STRUCTURE; BINDING PROTEIN; ACTIVATION; EXPRESSION	Biochemical and structural studies of Src and related kinases demonstrate that two intramolecular interactions suppress kinase activity. These interactions involve binding of the SH2 domain to a phosphotyrosine residue in the C-terminal tail and association of the SH3 domain with a polyproline type II helix formed by amino acids linking the SH2 and kinase domains. Recent studies have shown that high affinity interaction of the SH3 domain of Hck with the human immunodeficiency virus type I Nef protein activates Hck tyrosine kinase and biological activities, suggesting a mechanism that involves disruption of the SH3-linker interaction. To test the role of this interaction in the regulation of Hck kinase activity in living cells, we substituted alanines for prolines 225 and 228 in the linker region and observed that the resulting mutant (Hck-2PA) demonstrated strong transforming activity in a Rat-8 fibroblast focus-forming assay. Hck-2PA also exhibited elevated tyrosine kinase activity in terms of autophosphorylation, endogenous substrate phosphorylation, and in an in vitro kinase assay. The transforming and kinase activities of Hck-2PA were remarkably similar to those observed with a Hck mutant activated by Phe substitution of the conserved tail Tyr residue and with wild-type Hck following co-expression with human immunodeficiency virus Nef. Introduction of the 2PA and tail mutations into a single Hck expression construct did not increase kinase or transforming activity relative to the individual mutations. These data provide new evidence that SH3-linker interaction may represent the dominant mechanism controlling Hck tyrosine kinase activity in vivo.	Univ Pittsburgh, Sch Med, Eppley Inst Res Canc, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol & Microbiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.			Briggs, Scott D/0000-0003-2852-3594	NCI NIH HHS [CA81398, CA58667] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058667, R01CA081398] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1995, J IMMUNOL, V155, P1660; BOULET I, 1992, ONCOGENE, V7, P703; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; LICHTENBERG U, 1992, ONCOGENE, V7, P849; LINNEKIN D, 1994, BLOOD, V84, P94, DOI 10.1182/blood.V84.1.94.bloodjournal84194; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smithgall TE, 1998, PHARMACOL REV, V50, P1; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	32	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26579	26583		10.1074/jbc.274.37.26579	http://dx.doi.org/10.1074/jbc.274.37.26579			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473622	hybrid			2022-12-25	WOS:000082469700088
J	Han, B; Fischbach, GD				Han, B; Fischbach, GD			The release of acetylcholine receptor inducing activity (ARIA) from its transmembrane precursor in transfected fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NEU DIFFERENTIATION FACTOR; GROWTH-FACTOR; CELL-SURFACE; FACTOR-ALPHA; TGF-ALPHA; PROTEOLYTIC RELEASE; MOLECULAR-CLONING; MEMBRANE-PROTEINS; CYTOPLASMIC TAIL	Acetylcholine receptor inducing activity (ARIA) is made by motoneurons and is released at the neuromuscular synapse to stimulate the synthesis of acetylcholine receptors by skeletal muscle. ARIA is derived from a transmembrane precursor (pro-ARIA) via proteolytic cleavage of the ectodomain. We studied requirements in the amino acid sequence at the cleavage site with various substitution and deletion mutations. Wild type (WT) and mutant proteins were transiently expressed in COS cells, and release of ARIA into the conditioned medium was measured by tyrosine phosphorylation of its receptor, p185, in L6 cells. Removal of all potential cleavage sites between the extracellular epidermal growth factor domain and the transmembrane domain by substitution and small deletions (<11 amino acid residues out of 21) did not significantly reduce ARIA release, whereas larger deletions abolished it. We propose that cleavage occurs independently of amino acid sequence at a short distance from the epidermal growth factor domain, unless sterically hindered by the nearby secondary structure. A mutant with shorter cytoplasmic domain ("c" isoform) released significantly less ARIA than the WT ("a" isoform), suggesting that the c isoform may be suitable for signaling through direct cell-cell contact. Alternatively, proteolytic conversion of the a isoform to the c isoform may rapidly down-regulate release of ARIA.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Fischbach, GD (corresponding author), NINDS, NIH, 31 Ctr Dr,Bldg 31,Rm 8A52, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018458] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS18458] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; Ehlers MRW, 1997, IMMUNOPHARMACOLOGY, V36, P271, DOI 10.1016/S0162-3109(97)00032-5; Ehlers MRW, 1996, BIOCHEMISTRY-US, V35, P9549, DOI 10.1021/bi9602425; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Liu XF, 1998, P NATL ACAD SCI USA, V95, P13024, DOI 10.1073/pnas.95.22.13024; Loeb JA, 1998, MOL CELL NEUROSCI, V11, P77, DOI 10.1006/mcne.1998.0676; Loeb JA, 1999, DEVELOPMENT, V126, P781; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; USDIN TB, 1986, J CELL BIOL, V103, P493, DOI 10.1083/jcb.103.2.493; Wang JY, 1998, J BIOL CHEM, V273, P20525, DOI 10.1074/jbc.273.32.20525; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	43	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26407	26415		10.1074/jbc.274.37.26407	http://dx.doi.org/10.1074/jbc.274.37.26407			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473599	hybrid			2022-12-25	WOS:000082469700065
J	Kim, JS; Cha, SS; Kim, HJ; Kim, TJ; Ha, NC; Oh, ST; Cho, HS; Cho, MJ; Kim, MJ; Lee, HS; Kim, JW; Choi, KY; Park, KH; Oh, BH				Kim, JS; Cha, SS; Kim, HJ; Kim, TJ; Ha, NC; Oh, ST; Cho, HS; Cho, MJ; Kim, MJ; Lee, HS; Kim, JW; Choi, KY; Park, KH; Oh, BH			Crystal structure of a maltogenic amylase provides insights into a catalytic versatility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMYLASE; AMINO-ACID; STARCH; GENE; CYCLOMALTODEXTRINASE; NEOPULLULANASE; CYCLODEXTRIN; HYDROLYSIS; MECHANISM	Amylases catalyze the hydrolysis of starch material and play central roles in carbohydrate metabolism. Compared with many different amylases that are able to hydrolyze only alpha-D-(1,4)-glycosidic bonds, maltogenic amylases exhibit catalytic versatility: hydrolysis of alpha-D-(1,4)- and alpha-D-(1,6)-glycosidic bonds and transglycosylation of oligosaccharides to C3-, C4-, or CB-hydroxyl groups of various acceptor mono- or disaccharides. It has been speculated that the catalytic property of the enzymes is linked to the additional similar to 130 residues at the N terminus that are absent in other typical alpha-amylases. The crystal structure of a maltogenic amylase from a Thermus strain was determined at 2.8 Angstrom The structure, an analytical centrifugation, and a size exclusion column chromatography proved that the enzyme is a dimer in solution. The N-terminal segment of the enzyme folds into a distinct domain and comprises the enzyme active site together with the central (alpha/beta)(8) barrel of the adjacent subunit. The active site is a narrow and deep cleft suitable for binding cyclodextrins, which are the preferred substrates to other starch materials. At the bottom of the active site cleft, an extra space, absent in the other typical alpha-amylases, is present whose size is comparable with that of a disaccharide. The space is most likely to host an acceptor molecule for the transglycosylation and to allow binding of a branched oligosaccharide for hydrolysis of alpha-D-(1,4)-glycosidic or alpha-D-(1,6)-glycosidic bond. The (alpha/beta)(8) barrel of the enzyme is the preserved scaffold in all the known amylases. The structure represents a novel example of how an enzyme acquires a different substrate profile and a catalytic versatility from a common active site and represents a framework for explaining the catalytic activities of transglycosylation and hydrolysis of alpha-D-(1,6)-glycosidic bond.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Sch Environm Engn, Pohang 790784, Kyungbuk, South Korea; Seoul Natl Univ, Dept Food Sci, Suwon 441744, South Korea; Seoul Natl Univ, Technol & Res Ctr New Biomat Agr, Suwon 441744, South Korea; Univ Inchon, Dept Biol, Inchon 402749, South Korea; Univ Tsukuba, Ctr TARA, Tsukuba, Ibaraki 305, Japan	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Seoul National University (SNU); Seoul National University (SNU); Incheon National University; University of Tsukuba	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea.	bhoh@postech.ac.kr	Oh, Byung-Ha/C-2061-2011	Cha, Sun-Shin/0000-0002-0913-8706				Adachi M, 1998, J BIOL CHEM, V273, P19859, DOI 10.1074/jbc.273.31.19859; Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, X PLOR VERSION 3 843; Cha HJ, 1998, EUR J BIOCHEM, V253, P251, DOI 10.1046/j.1432-1327.1998.2530251.x; Cho MJ, 1998, ACTA CRYSTALLOGR D, V54, P416, DOI 10.1107/S0907444997011736; delRio G, 1997, FEBS LETT, V416, P221, DOI 10.1016/S0014-5793(97)01192-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fiedler G, 1996, J MOL BIOL, V256, P279, DOI 10.1006/jmbi.1996.0085; Fujimoto Z, 1998, J MOL BIOL, V277, P393, DOI 10.1006/jmbi.1997.1599; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JESPERSEN HM, 1993, J PROTEIN CHEM, V12, P791, DOI 10.1007/BF01024938; Kadziola A, 1998, J MOL BIOL, V278, P205, DOI 10.1006/jmbi.1998.1683; Kamitori S, 1999, J MOL BIOL, V287, P907, DOI 10.1006/jmbi.1999.2647; KIM IC, 1992, J BIOL CHEM, V267, P22108; Kim TJ, 1999, APPL ENVIRON MICROB, V65, P1644; Kim TJ, 1998, ARCH BIOCHEM BIOPHYS, V353, P221, DOI 10.1006/abbi.1998.0639; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; NAKAJIMA R, 1986, APPL MICROBIOL BIOT, V23, P355; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OGUMA T, 1993, APPL MICROBIOL BIOT, V39, P197, DOI 10.1007/BF00228606; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park KH, 1998, CARBOHYD RES, V313, P235; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; SZEJTLI J, 1967, BIOPOLYMERS, V5, P5, DOI 10.1002/bip.1967.360050103; TAKATA H, 1992, J BIOL CHEM, V267, P18447; TAO BY, 1989, BIOCHIM BIOPHYS ACTA, V995, P214, DOI 10.1016/0167-4838(89)90038-1; TONOZUKA T, 1993, BIOSCI BIOTECH BIOCH, V57, P395, DOI 10.1271/bbb.57.395; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	30	148	153	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26279	26286		10.1074/jbc.274.37.26279	http://dx.doi.org/10.1074/jbc.274.37.26279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473583	hybrid			2022-12-25	WOS:000082469700049
J	Xiao, ZC; Ragsdale, DS; Malhotra, JD; Mattei, LN; Braun, PE; Schachner, M; Isom, LL				Xiao, ZC; Ragsdale, DS; Malhotra, JD; Mattei, LN; Braun, PE; Schachner, M; Isom, LL			Tenascin-R is a functional modulator of sodium channel beta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-CONE COLLAPSE; IN-VITRO; ADHESION MOLECULE; ALPHA-SUBUNITS; NEURITE GROWTH; MESSENGER-RNA; CELL-ADHESION; OPTIC-NERVE; ADULT-MOUSE; JANUSIN	Voltage-gated sodium channels isolated from mammalian brain are composed of a, beta 1 and beta 2 subunits, The cu subunit forms the ion conducting pore of the channel, whereas the beta 1 and beta 2 subunits modulate channel function, as well as channel plasma membrane expression levels, beta 1 and beta 2 each contain a single, extracellular Ig-like domain with structural similarity to the neural cell adhesion molecule (CAM), myelin Po. beta 2 contains strong amino acid homology to the third Ig domain and to the juxtamembrane region of F3/contactin. Many CAMs of the Ig superfamily have been shown to interact with extracellular matrix molecules. We hypothesized that beta 2 may interact with tenascin-alpha (TN-R), an extracellular matrix molecule that is secreted by oligodendrocytes during myelination and that binds F3-contactin. We show here that cells expressing sodium channel beta 1 or beta 2 subunits are functionally modulated by TN-R, Transfected cells stably expressing beta 1 or beta 2 subunits initially recognized and then were repelled from TN-R substrates, The cysteine-rich amino-terminal domain of TN-R expressed as a recombinant peptide, termed EGF-L, appears to be responsible for the repellent effect on beta subunit-expressing cells. The epidermal growth factor-like repeats and fibronectin-like repeats 6-8 are most effective in the initial adhesion of id subunit-expressing cells. Application of EGF-L to alpha IIA beta 1 beta 2 channels expressed in Xenopus oocytes potentiated expressed sodium currents without significantly altering current time course or the voltage dependence of current activation or inactivation. Thus, sodium channel beta subunits appear to function as CAMs, and TN-R may be an important regulator of sodium channel localization and function in neurons.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	University of Michigan System; University of Michigan; McGill University; McGill University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Isom, LL (corresponding author), Univ Michigan, Dept Pharmacol, 1301 MSRB III, Ann Arbor, MI 48109 USA.	lisom@umich.edu	xiao, zhicheng/A-1529-2011; xiao, zhicheng/G-5887-2010	Isom, Lori/0000-0002-9479-6729				ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; Bartsch U, 1996, PROG NEUROBIOL, V49, P145; BARTSCH U, 1993, GLIA, V9, P57, DOI 10.1002/glia.440090108; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CHIQUETEHRISMANN R, 1994, PERSPECT DEV NEUROBI, V2, P3; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; FIELDS RD, 1994, J NEUROBIOL, V25, P281, DOI 10.1002/neu.480250308; FUSS B, 1991, J NEUROSCI RES, V29, P299, DOI 10.1002/jnr.490290305; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LOCHTER A, 1993, J NEUROSCI, V13, P3986; LOCHTER A, 1994, EUR J NEUROSCI, V6, P597, DOI 10.1111/j.1460-9568.1994.tb00304.x; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; McCormick KA, 1998, J BIOL CHEM, V273, P3954, DOI 10.1074/jbc.273.7.3954; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; MOORMAN SJ, 1993, J NEUROSCI, V13, P4727; MULLER B, 1990, J EXP BIOL, V153, P29; PATTON DE, 1994, J BIOL CHEM, V269, P17649; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; Schwab ME, 1996, NEUROCHEM RES, V21, P755, DOI 10.1007/BF02532297; SKOFF RP, 1976, J COMP NEUROL, V169, P313, DOI 10.1002/cne.901690304; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; TAYLOR J, 1993, J NEUROSCI RES, V35, P347, DOI 10.1002/jnr.490350402; TESSIERLAVIGNE M, 1994, CURR OPIN GENET DEV, V4, P596, DOI 10.1016/0959-437X(94)90078-H; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Weber P, 1999, J NEUROSCI, V19, P4245, DOI 10.1523/jneurosci.19-11-04245.1999; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WINTERGERST ES, 1993, EUR J NEUROSCI, V5, P299, DOI 10.1111/j.1460-9568.1993.tb00497.x; Xiao ZC, 1997, J NEUROSCI RES, V49, P698, DOI 10.1002/(SICI)1097-4547(19970915)49:6<698::AID-JNR4>3.0.CO;2-2; Xiao ZC, 1996, EUR J NEUROSCI, V8, P766, DOI 10.1111/j.1460-9568.1996.tb01262.x; Xiao ZC, 1998, J NEUROSCI RES, V52, P390, DOI 10.1002/(SICI)1097-4547(19980515)52:4<390::AID-JNR3>3.3.CO;2-6	42	171	176	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26511	26517		10.1074/jbc.274.37.26511	http://dx.doi.org/10.1074/jbc.274.37.26511			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473612	hybrid			2022-12-25	WOS:000082469700078
J	Pantoja, C; Serrano, M				Pantoja, C; Serrano, M			Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras	ONCOGENE			English	Article						p21; cell cycle; senescence; ras; transformation	CELL-CYCLE ARREST; MAMMARY EPITHELIAL-CELLS; ARF TUMOR-SUPPRESSOR; REPLICATIVE SENESCENCE; GROWTH-CHARACTERISTICS; EMBRYO FIBROBLASTS; P53-DEFICIENT MICE; BINDING PROTEIN-3; DEPENDENT KINASES; DNA-SYNTHESIS	The cell-cycle inhibitor p21 is upregulated during senescence and upon induction of senescence-like arrest by oncogenic Pas, We have used primary fibroblasts derived from p21-null mice to evaluate the role of p21 in these processes. We find that primary p21(-/-) cells enter senescence and have a lifespan similar to wild-ta pe cells. Upon immortalization, most wild-type and p21(-/-) cultures acquire alterations in either p53 or p16(INK4a), further indicating that p21-deficiency is not sufficient by itself to allow immortalization. Primary p21(-/-) cells, like wild-type cells, respond to oncogenic Pas by accumulating p53 and p16(INK4a), and by decreasing their proliferation rate. In agreement with this, p21(-/-) cells are refractory to neoplasic transformation by oncogenic Ras when compared to p53(-/-) cells. We conclude that, in murine fibroblasts, p21 is not essential neither for senescence nor for preventing neoplasic transformation by oncogenic Ras.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Serrano, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312; Pantoja, Cristina/0000-0003-0180-5823				AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1995, CANCER RES, V55, P2404; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Carman TA, 1998, EXP CELL RES, V244, P33, DOI 10.1006/excr.1998.4207; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erickson S, 1998, ONCOGENE, V17, P595, DOI 10.1038/sj.onc.1201965; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gallimore PH, 1997, J VIROL, V71, P6629, DOI 10.1128/JVI.71.9.6629-6640.1997; Garkavtsev I, 1998, EXP GERONTOL, V33, P81, DOI 10.1016/S0531-5565(97)00086-7; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2357; HARVEY M, 1993, ONCOGENE, V8, P2457; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; Medcalf ASC, 1996, CANCER RES, V56, P4582; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Reznikoff CA, 1996, CANCER RES, V56, P2886; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; RITTLING SR, 1992, ONCOGENE, V7, P935; Rittling SR, 1996, EXP CELL RES, V229, P7, DOI 10.1006/excr.1996.0337; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAHARA H, 1995, ONCOGENE, V10, P835; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TSUKADA T, 1993, ONCOGENE, V8, P3313; VOTJA PJ, 1995, BIOCHIM BIOPHYS ACTA, V1242, P29; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Yan Y, 1996, MOL BIOL CELL, V7, P975, DOI 10.1091/mbc.7.6.975; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	83	152	157	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4974	4982		10.1038/sj.onc.1202880	http://dx.doi.org/10.1038/sj.onc.1202880			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490832				2022-12-25	WOS:000082321700010
J	Bongarzone, I; Vigano, E; Alberti, L; Mondellini, P; Uggeri, M; Pasini, B; Borrello, MG; Pierotti, MA				Bongarzone, I; Vigano, E; Alberti, L; Mondellini, P; Uggeri, M; Pasini, B; Borrello, MG; Pierotti, MA			The Glu632-Leu633 deletion in cysteine rich domain of Bet induces constitutive dimerization and alters the processing of the receptor protein	ONCOGENE			English	Article						RET; oncogenic activation; dimerization	MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; NEOPLASIA TYPE 2B; RET PROTOONCOGENE; ENDOPLASMIC-RETICULUM; POINT MUTATIONS; ACTIVATION; FMTC; 2A; RESIDUES	Mutations of the RET gene, encoding a receptor tyrosine kinase, have been associated with the inherited cancer syndromes MEN 2A and MEN 2B, They have also further been associated with both familial and sporadic medullary thyroid carcinomas. Missense mutations affecting cysteine residues within the extracellular domain of the receptor causes constitutive tyrosine kinase activation through the formation of disulfide-bonded homodimers. We have recently reported that a somatic 6 bp in-frame deletion, originally coding for Glu632-Leu633, potently activates the RET gene. This activation is increased with respect to the frequent MEN 2A-associated missense mutation Cys634Arg. This finding specifically correlated to the clinic behavior of the corresponding tumor, which was characterized by an unusually aggressive progression with both multiple and recurrent metastases. By examining the possibility that this deletion acts in a manner similar to cysteine substitution, we have analysed the molecular mechanism by which this oncogenic activation occurs. Phosphorylated dimers of the deleted Ret receptor were detected in immunoprecipitates separated under non-reducing conditions. Like other Cys point mutations, this 6 bp deletion affecting two amino acid residues between two adjacent Cys, is capable of activating the transforming ability of Ret by promoting receptor dimerization, These results suggest that alteration to cysteine residue position or pairing is capable of inducing ligand independent dimerization, Furthermore, we present data demonstrating that the processing and sorting of the Bet membrane receptor to the cell surface is affected by mutation type.	Ist Nazl Tumori, Div Expt Oncol A, I-20133 Milan, Italy; Ist Nazl Tumori, Sci Direct, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Bongarzone, I (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Via Venezian 1, I-20133 Milan, Italy.		Bongarzone, Italia/B-9544-2017; Pasini, Barbara/AHI-2004-2022; Borrello, Maria Grazia/C-3161-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Bongarzone, Italia/0000-0003-2530-9170; Pasini, Barbara/0000-0002-4373-1212; Borrello, Maria Grazia/0000-0002-6854-2848; Pierotti, Marco Alessandro/0000-0002-7431-8332				ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BLAUGRUND JE, 1994, HUM MOL GENET, V3, P1895, DOI 10.1093/hmg/3.10.1895; BOLINO A, 1995, ONCOGENE, V10, P2415; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Ceccherini I, 1997, ONCOGENE, V14, P2609, DOI 10.1038/sj.onc.1201079; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Eng C, 1996, CANCER RES, V56, P2167; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; Hofstra RMW, 1996, J CLIN ENDOCR METAB, V81, P2881, DOI 10.1210/jc.81.8.2881; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hoppner W, 1997, HUM MOL GENET, V6, P587, DOI 10.1093/hmg/6.4.587; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; KALININ V, 1998, IN PRESS J MOL MED; KOMMINOTH P, 1995, CANCER, V76, P479; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MURAGAKI Y, 1995, J COMP NEUROL, V356, P387, DOI 10.1002/cne.903560306; Romei C, 1996, J CLIN ENDOCR METAB, V81, P1619, DOI 10.1210/jc.81.4.1619; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878	26	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4833	4838		10.1038/sj.onc.1202848	http://dx.doi.org/10.1038/sj.onc.1202848			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490816				2022-12-25	WOS:000082184800007
J	Chairoungdua, A; Segawa, H; Kim, JY; Miyamoto, K; Haga, H; Fukui, Y; Mizoguchi, K; Ito, H; Takeda, E; Endou, H; Kanai, Y				Chairoungdua, A; Segawa, H; Kim, JY; Miyamoto, K; Haga, H; Fukui, Y; Mizoguchi, K; Ito, H; Takeda, E; Endou, H; Kanai, Y			Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY 4F2; EXPRESSION CLONING; HEAVY-CHAIN; RAT-KIDNEY; ANTIGEN; SYSTEM; PROTEIN; INTESTINE; OOCYTES; TUBULES	We identified an amino acid transporter that is associated with the cystinuria-related type II membrane glycoprotein, rBAT (related to b(0,+) amino acid transporter). The transporter designated BAT1 (b(0,+)'-type amino acid transporter 1) from rat kidney was found to be structurally related to recently identified amino acid transporters for system L, system y(+)L, and system x-C, which are linked, via a disulfide bond, to the other type II membrane glycoprotein, 4F2hc (4F2 heavy chain). In the nonreducing condition, a 125-kDa band, which seems to correspond to the heterodimeric complex of BAT1 and rBAT, was detected in rat kidney with anti-BAT1 antibody. The band was shifted to 41 kDa in the reducing condition, confirming that BAT1 and rBAT are linked via a disulfide bond. The BAT1 and rBAT proteins were shown to be colocalized in the apical membrane of the renal proximal tubules where massive cystine transport had been proposed. When expressed in COS-7 cells with rBAT, but not with 4F2hc, BAT1 exhibited a Na+-independent transport of cystine as well as basic and neutral amino acids with the properties of system b(0,+). The results from the present investigation were used to establish a family of amino acid transporters associated with type II membrane glycoproteins.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Tokyo 1818611, Japan; Univ Tokushima, Sch Med, Dept Clin Nutr, Tokushima 7708503, Japan; Univ Tokushima, Sch Med, Dept Anat, Tokushima 7708503, Japan; Chiba Univ, Sch Med, Dept Urol, Chiba 2608677, Japan; Japan Sci & Technol Corp, PRESTO, Kyoto, Japan	Kyorin University; Tokushima University; Tokushima University; Chiba University; Japan Science & Technology Agency (JST)	Kanai, Y (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa, Tokyo 1818611, Japan.							ALTMAN A, 1984, P NATL ACAD SCI-BIOL, V81, P2176, DOI 10.1073/pnas.81.7.2176; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; DENT CE, 1951, Q J MED, V20, P205; FOREMAN JW, 1980, METABOLISM, V29, P53, DOI 10.1016/0026-0495(80)90098-0; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEMLER ME, 1982, J IMMUNOL, V129, P623; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hisano S, 1996, BRAIN RES, V710, P299, DOI 10.1016/0006-8993(95)01442-X; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; PALACIN M, 1994, J EXP BIOL, V196, P123; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; ROSENBERG LE, 1965, NEW ENGL J MED, V273, P1239, DOI 10.1056/NEJM196512022732303; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Taketani Y, 1998, J BIOL CHEM, V273, P14575, DOI 10.1074/jbc.273.23.14575; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Tojo A, 1999, J AM SOC NEPHROL, V10, P464; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; UtsunomiyaTate N, 1997, FEBS LETT, V416, P312, DOI 10.1016/S0014-5793(97)01232-5; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; VONWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	35	148	152	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28845	28848		10.1074/jbc.274.41.28845	http://dx.doi.org/10.1074/jbc.274.41.28845			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506124	hybrid			2022-12-25	WOS:000083017800003
J	Na, SY; Choi, JE; Kim, HJ; Jhun, BH; Lee, YC; Lee, JW				Na, SY; Choi, JE; Kim, HJ; Jhun, BH; Lee, YC; Lee, JW			Bcl3, an I kappa B protein, stimulates activating protein-1 transactivation and cellular proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; NUCLEAR HORMONE RECEPTORS; C-FOS; HISTONE ACETYLTRANSFERASE; MEDIATED TRANSACTIVATIONS; CBP; EXPRESSION; REPRESSION; INTERACTS; COMPLEX	Bcl3, an I kappa B protein, was originally isolated as a putative proto-oncogene in a subset of B cell chronic lymphocytic leukemias. Bcl3 was subsequently shown to associate tightly with and transactivate the NF kappa B p50 or p52 homodimer. Herein, we show that Bcl3 stimulates the activating protein-1 (AP-1) transactivation, either alone or in conjunction with transcription integrators steroid receptor coactivator-l and CREB-binding protein/p300. The C-terminal 158 residues of Bcl3 exhibited an autonomous transactivation function and interacted with specific subregions of the AP-1 components c-Jun and c-Fos, CREB-binding protein/p300, and steroid receptor coactivator-l, as demonstrated by the yeast and mammalian two-hybrid tests as well as glutathione S-transferase pull-down assays. In addition, anti-HA antibody co-precipitated c-Jun from HeLa cells co-expressing c-Jun and HA-tagged Bcl3, consistent with the idea that Bcl3 directly associates with AP-1 in vivo. Furthermore, microinjection of Bcl3 expression vector into Rat-1 fibroblast cells significantly enhanced DNA synthesis and expression of c-jun, one of the cellular target genes of AP-1. These results suggest that Bcl3 may directly participate in the tumorigenesis processes as a novel transcription coactivator of the mitogenic transcription factor AP-1 in vivo.	Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Pusan National University	Lee, JW (corresponding author), Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea.							Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LEE SK, 1999, IN PRESS MOL ENDOCRI; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKeithan TW, 1997, GENE CHROMOSOME CANC, V20, P64, DOI 10.1002/(SICI)1098-2264(199709)20:1<64::AID-GCC10>3.0.CO;2-F; Moore DD, 1995, GLOB MOB SURV; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1999, J BIOL CHEM, V274, P7674, DOI 10.1074/jbc.274.12.7674; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Ong ST, 1998, ONCOGENE, V16, P2333, DOI 10.1038/sj.onc.1201771; PFAHL M, 1993, SKIN PHARMACOL, V6, P8, DOI 10.1159/000211158; Rogers MB, 1997, CURR TOP DEV BIOL, V35, P1, DOI 10.1016/S0070-2153(08)60255-0; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234	39	60	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28491	28496		10.1074/jbc.274.40.28491	http://dx.doi.org/10.1074/jbc.274.40.28491			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497212	hybrid			2022-12-25	WOS:000082912700061
J	Yano, T; Yagi, T				Yano, T; Yagi, T			H+-translocating NADH-quinone oxidoreductase (NDH-1) of Paracoccus denitrificans - Studies on topology and stoichiometry of the peripheral subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; CYTOCHROME BC(1) COMPLEX; ATP SYNTHASE COMPLEX; IRON-SULFUR CLUSTERS; UBIQUINONE OXIDOREDUCTASE; ESCHERICHIA-COLI; GENE-CLUSTER; RHODOBACTER-CAPSULATUS; 25-KILODALTON SUBUNIT; DEHYDROGENASE COMPLEX	The proton-translocating NADH-quinone oxidoreductase (NDH-1) of Paracoccus denitrificans is composed of at least 14 subunits (NQO1-14) and is located in the cytoplasmic membrane. In the present study, topological properties and stoichiometry of the 7 subunits (NQO1-6 and NQO9) of the P. denitrificans NDH-1 in the membranes were investigated using immunological techniques. Treatments with chaotropic reagents (urea, NaI, or NaBr) or with alkaline buffer (pH 10-12) resulted in partial or complete extraction of all the subunits from the membranes. Of interest is that when NaBr or urea were used, the NQO6 and NQO9 subunits remained in the membranes, whereas tbe other subunits were completely extracted, suggesting their direct association with the membrane part of the enzyme complex. Both deletion study and homologous expression study of the NQO9 subunit provided a clue that its hydrophobic N-terminal stretch plays an important role in such an association. In light of this observation and others, topological properties of the subunits in the NDH-1 enzyme complex are discussed. In addition, determination of stoichiometry of the peripheral subunits of the P. denitrificans NDH-1 was completed by radioimmunological methods. All the peripheral subunits are present as one molecule each in the enzyme complex. These results estimated the total number of cofactors in the P. denitrificans NDH-1; the enzyme complex contains one molecule of FMN and up to eight iron-sulfur clusters, 2x[2Fe-2S] and 6x[4Fe-4S], provided that the NQO6 subunit bears one [4Fe-4S] cluster.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA	Scripps Research Institute	Yagi, T (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033712] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1RR00833] Funding Source: Medline; NIGMS NIH HHS [R01GM33712] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZEVEDO JE, 1992, BIOCHEM J, V288, P29, DOI 10.1042/bj2880029; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; CROUSE BR, 1994, J BIOL CHEM, V269, P21030; Dupuis A, 1998, BBA-BIOENERGETICS, V1364, P147, DOI 10.1016/S0005-2728(98)00025-5; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; GERHUS E, 1993, FEMS MICROBIOL LETT, V113, P29; HAN AL, 1988, ARCH BIOCHEM BIOPHYS, V267, P490, DOI 10.1016/0003-9861(88)90055-0; HAN AL, 1989, ARCH BIOCHEM BIOPHYS, V275, P166, DOI 10.1016/0003-9861(89)90360-3; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HATEFI Y, 1985, ENZYMES BIOL MEMBR, P1; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; HEKMAN C, 1991, ARCH BIOCHEM BIOPHYS, V284, P90, DOI 10.1016/0003-9861(91)90268-N; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUNOYAGI A, 1984, BIOCHEMISTRY-US, V23, P3508, DOI 10.1021/bi00310a019; MEINHARDT SW, 1987, J BIOL CHEM, V262, P9147; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; RAGAN CI, 1982, BIOCHEMISTRY-US, V21, P2518, DOI 10.1021/bi00539a035; Saribas AS, 1998, BIOCHEMISTRY-US, V37, P8105, DOI 10.1021/bi973146s; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; STEINRUCKE P, 1993, FEMS MICROBIOL LETT, V104, P83, DOI 10.1111/j.1574-6968.1993.tb05865.x; Stoll R, 1996, MICROBIOL-UK, V142, P2577, DOI 10.1099/00221287-142-9-2577; STOUTHAMER AH, 1992, ANTON LEEUW INT J G, V61, P1, DOI 10.1007/BF00572119; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; VANSPANNING RJM, 1990, J BACTERIOL, V172, P986, DOI 10.1128/jb.172.2.986-996.1990; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; XU XM, 1992, BIOCHEMISTRY-US, V31, P6925, DOI 10.1021/bi00145a009; XU XM, 1992, ARCH BIOCHEM BIOPHYS, V296, P40, DOI 10.1016/0003-9861(92)90542-5; XU XM, 1993, BIOCHEMISTRY-US, V32, P968, DOI 10.1021/bi00054a030; XU XM, 1991, BIOCHEMISTRY-US, V30, P8678, DOI 10.1021/bi00099a027; XU XM, 1991, BIOCHEMISTRY-US, V30, P6422, DOI 10.1021/bi00240a012; YAGI T, 1990, BIOCHEMISTRY-US, V29, P5515, DOI 10.1021/bi00475a015; YAGI T, 1993, J BIOENERG BIOMEMBR, V25, P339, DOI 10.1007/BF00762459; YAGI T, 1986, ARCH BIOCHEM BIOPHYS, V250, P302, DOI 10.1016/0003-9861(86)90731-9; YAGI T, 1992, BIOCHIM BIOPHYS ACTA, V1101, P181, DOI 10.1016/S0005-2728(05)80014-3; YAGI T, 1991, J BIOENERG BIOMEMBR, V23, P211, DOI 10.1007/BF00762218; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; YANO T, 1995, J BIOL CHEM, V270, P18264, DOI 10.1074/jbc.270.31.18264; YANO T, 1994, FEBS LETT, V354, P160, DOI 10.1016/0014-5793(94)01107-9; Yano T, 1997, J BIOL CHEM, V272, P4201, DOI 10.1074/jbc.272.7.4201; YANO T, 1994, BIOCHEMISTRY-US, V33, P494, DOI 10.1021/bi00168a014	49	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28606	28611		10.1074/jbc.274.40.28606	http://dx.doi.org/10.1074/jbc.274.40.28606			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497227	hybrid			2022-12-25	WOS:000082912700076
J	Trybus, KM; Krementsova, E; Freyzon, Y				Trybus, KM; Krementsova, E; Freyzon, Y			Kinetic characterization of a monomeric unconventional myosin V construct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; KINESIN HEAD DOMAINS; SACCHAROMYCES-CEREVISIAE; MECHANISM; ATPASE; ACTIN; MICROTUBULE; SUBFRAGMENT-1; CONTRACTION; MOLECULES	An expressed, monomeric murine myosin V construct composed of the motor domain and two calmodulin-binding IQ motifs (MD(2IQ)) was used to assess the regulatory and kinetic properties of this unconventional myosin, In EGTA, the actin-activated ATPase activity of MD(SIQ) was 7.4 +/- 1.6 s(-1) with a K-app of similar to 1 mu M (37 degrees C), and the velocity of actin movement was similar to 0.3 mu m/s (30 degrees C), Calcium inhibited both of these activities, but the addition of calmodulin restored the values to similar to 70% of control, indicating that calmodulin dissociation caused inhibition. In contrast to myosin II, MD(2IQ) is highly associated with actin at physiological ionic strength in the presence of ATP, but the motor is in a weakly bound conformation based on the pyrene-actin signal. The rate of dissociation of acto-MD(wIQ) by ATP is fast (>850 s(-1)), and ATP hydrolysis occurs at similar to 200 s(-1). The affinity of acto-MD(2IQ) for ADP is somewhat higher than that of smooth S1, and ADP dissociates more slowly. Actin does not cause a large increase in the rate of ADP release, nor does the presence of ADP appreciably alter the affinity of MD(SIQ) for actin, These kinetic data suggest that monomeric myosin V is not processive.	Univ Vermont, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA	University of Vermont	Trybus, KM (corresponding author), Univ Vermont, Dept Physiol & Mol Biophys, Given Bldg E205, Burlington, VT 05405 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038113, R01HL038113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; Evans LL, 1998, J CELL SCI, V111, P2055; Geeves M. A., 1995, Biophysical Journal, V68, P194; GEEVES MA, 1991, BIOCHEM J, V274, P1; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Jiang W, 1997, J BIOL CHEM, V272, P5616, DOI 10.1074/jbc.272.9.5616; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Pechatnikova E, 1997, J BIOL CHEM, V272, P30735, DOI 10.1074/jbc.272.49.30735; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Stevens RC, 1998, J CELL BIOL, V142, P711, DOI 10.1083/jcb.142.3.711; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017	29	97	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27448	27456		10.1074/jbc.274.39.27448	http://dx.doi.org/10.1074/jbc.274.39.27448			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488077	hybrid			2022-12-25	WOS:000082739100016
J	Maroulakou, IG; Shibata, MA; Anver, M; Jorcyk, CL; Liu, ML; Roche, N; Roberts, AB; Tsarfaty, I; Reseau, J; Ward, J; Green, JE				Maroulakou, IG; Shibata, MA; Anver, M; Jorcyk, CL; Liu, ML; Roche, N; Roberts, AB; Tsarfaty, I; Reseau, J; Ward, J; Green, JE			Heterotopic endochondrial ossification with mixed tumor formation in C3(1)/Tag transgenic mice is associated with elevated TGF-beta1 and BMP-2 expression	ONCOGENE			English	Article						heterotopic bone; endochondrial ossification; mixed tumors; transgenic mice; transforming growth factor-beta; bone morphogenetic protein-2	LARGE T-ANTIGEN; BONE-FORMATION; TRANSFORMING GROWTH-FACTOR-BETA-1; SV40-TRANSFORMED CELLS; P53 MUTATIONS; PROGRESSION; GROWTH; GENE; OVEREXPRESSION; TUMORIGENESIS	Transgenic mice which express the simian virus 40 large T-antigen (Tag) under the regulatory control of the hormone responsive rat C3(1) gene develop unusual lesions of heterotopic bone growth associated with mixed tumor formation arising from eccrine sweat glands found only in the foot pads of mice, ischiocavernosus muscle adjacent to bulbourethral glands and occasionally the salivary and mammary glands. These lesions are very similar to mixed tumors arising in several types of human cancers. Based upon electron microscopic examination and immunocytochemical analyses of cellular differentiation markers, the mixed proliferative lesions in this transgenic mouse model begin with the Tag-induced proliferation of epithelial and myoepithelial cells. The proliferation of these two types of cells results in hyperplasia and adenomatous transformation of the epithelial component, whereas the proliferating myoepithelial cells undergo metaplasia to form chondrocytes which deposit extracellular matrix, including collagen fibers. Cartilage develops focally between areas of epithelial proliferation and subsequently ossifies through process of endochondrial bone formation, The metaplasia of myoepithelial cells to chondrocytes appears to require the inductive interaction of factors produced by the closely associated proliferating epithelial cells, including members of the TGF-beta superfamily, We demonstrate that TGF-beta1 protein accumulates in the extracellular matrix of the lesions, whereas RNA in situ hybridization reveals that BMP-2, another strong inducer of heterotopic bone formation, is overexpressed by the proliferating epithelial cells during the development of ectopic bone. The formation of sarcomatous tumors within the mixed tumors appears to be androgen-dependent and more frequent in mice lacking a normal allele of p53. This process of cartilage and bone induction may mimic epithelial-mesenchymal interactions which occur during embryonic bone formation. These transgenic mice may provide new insights into the processes of ectopic endochondrial bone formation associated with mixed tumor formation and serve as a useful model for human heterotopic bone disease.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Pathol Histol Lab, SAIC, Frederick, MD 21702 USA; Sackler Sch Med, Tel Aviv, Israel; NCI, Frederick Canc Res & Dev Ctr, ABL, Frederick, MD 21702 USA; NCI, OLAS, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Green, JE (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.		Shibata, Masa-Aki/L-1624-2019	Shibata, Masa-Aki/0000-0002-3350-7305; Tsarfaty, Ilan/0000-0002-5230-7093	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01CO56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ASHLEY DJB, 1990, EVANS HISTOLOGICAL A, P611; BLECHER SR, 1986, J INVEST DERMATOL, V87, P720, DOI 10.1111/1523-1747.ep12456718; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; CAMPBELL JT, 1992, CALCIFIED TISSUE INT, V50, P283, DOI 10.1007/BF00296294; CAPLAN AI, 1994, CLIN PLAST SURG, V21, P429; CHEN JD, 1992, ONCOGENE, V7, P1167; COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623-199302000-00008; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOBASHI Y, 1993, DIAGN MOL PATHOL, V2, P257; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; Duneas N, 1998, GROWTH FACTORS, V15, P259, DOI 10.3109/08977199809017482; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; GNEPP DR, 1993, PATHOL ANNU, V28, P279; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huggins CB, 1931, ARCH SURG-CHICAGO, V22, P377, DOI 10.1001/archsurg.1931.01160030026002; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JACOBSON ES, 1973, J ORAL SURG, V31, P539; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JUBB KVF, 1993, PATHOLOGY DOMESTIC A, V1, P315; KAPLAN FS, 1994, J BONE JOINT SURG AM, V76A, P425, DOI 10.2106/00004623-199403000-00013; KAPLAN FS, 1993, J BONE JOINT SURG AM, V75A, P220, DOI 10.2106/00004623-199302000-00009; KURKI P, 1986, EXP CELL RES, V166, P209, DOI 10.1016/0014-4827(86)90520-3; Kurosumi K, 1970, Arch Histol Jpn, V31, P455; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Maroulakou IG, 1997, MOL CARCINOGEN, V20, P168, DOI 10.1002/(SICI)1098-2744(199710)20:2<168::AID-MC3>3.0.CO;2-J; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P13510; MERLINO G, 1994, CANCER INVEST, V12, P203, DOI 10.3109/07357909409024875; Michiels L, 1993, Cancer Treat Res, V62, P7; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOULTON JE, 1978, TUMORS DOMESTIC ANIM, P350; Olmsted EA, 1998, CLIN ORTHOP RELAT R, P81; PERZIN KH, 1980, CANCER, V45, P2593, DOI 10.1002/1097-0142(19800515)45:10<2593::AID-CNCR2820451019>3.0.CO;2-S; PRAKASH UBS, 1989, MAYO CLIN PROC, V64, P1091, DOI 10.1016/S0025-6196(12)64978-7; PULLEY LT, 1973, AM J VET RES, V34, P1513; REDONO C, 1982, CANCER, V48, P1690, DOI 10.1002/1097-0142(19820415)49:8<1690::AID-CNCR2820490825>3.0.CO;2-O; Ripamonti U, 1997, J BONE MINER RES, V12, P1584, DOI 10.1359/jbmr.1997.12.10.1584; Rosen V, 1996, ANN NY ACAD SCI, V785, P59, DOI 10.1111/j.1749-6632.1996.tb56244.x; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; RUSSO CL, 1994, MED PEDIATR ONCOL, V23, P354, DOI 10.1002/mpo.2950230407; SCHOLZ RB, 1992, PEDIATR HEMAT ONCOL, V9, P125, DOI 10.3109/08880019209018328; SCHRECK RR, 1992, PEDIATR HEMAT ONCOL, V9, pR9, DOI 10.3109/08880019209018322; Schulick AH, 1998, P NATL ACAD SCI USA, V95, P6983, DOI 10.1073/pnas.95.12.6983; Shafritz AB, 1996, NEW ENGL J MED, V335, P555, DOI 10.1056/NEJM199608223350804; SHAFRITZ AB, 1998, CLIN ORTHOP RELAT R, V346, P46; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Shibata MA, 1996, CANCER RES, V56, P2998; Shibata MA, 1998, CARCINOGENESIS, V19, P195, DOI 10.1093/carcin/19.1.195; Shibata MA, 1996, CANCER RES, V56, P4894; SMITHSORENSEN B, 1993, HUM MUTAT, V2, P274, DOI 10.1002/humu.1380020407; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; WADAYAMA B, 1993, BRIT J CANCER, V68, P1134, DOI 10.1038/bjc.1993.493; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1993, MOL BASIS MORPHOGENE, P221	62	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5435	5447		10.1038/sj.onc.1202926	http://dx.doi.org/10.1038/sj.onc.1202926			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498897				2022-12-25	WOS:000082718600008
J	Perez-Juste, G; Aranda, A				Perez-Juste, G; Aranda, A			Differentiation of neuroblastoma cells by phorbol esters and insulin-like growth factor 1 is associated with induction of retinoic acid receptor beta gene expression	ONCOGENE			English	Article						neuroblastoma; retinoic acid; RAR beta; TPA; IGF-1; Ras	PROTEIN-KINASE-C; HUMAN NEURO-BLASTOMA; TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; RAR-ALPHA; BINDING; PHOSPHORYLATION; RESPONSIVENESS; HETERODIMERS; TARGET	The retinoic acid (RA) receptor beta isoform (RAR beta) plays an important role in RA-induced differentiation of human neuroblastoma, In this study we show that insulin-like growth factor 1 (IGF-1) and tetradecanoyl phorbol acetate (TPA) induce RAR beta gene expression in neuroblastoma SH-SY5Y cells. IGF-1 and TPA caused a marked induction of RAR beta 2 promoter activity and had a synergistic effect with RA that also upregulates transcription. The effect of RA is mediated by two RA responsive elements (RAREs), whereas the IGF-1 and TPA actions are independent of the RAREs and map to sequences that overlap the TATA box. These results suggest that the signaling pathways stimulated by TPA and IGF-1 could modify the components assembled at the core RAR beta 2 promoter and activate transcription. Expression of Ras(Val12) mimics the effect of IGF-1 and TPA on the promoter, and a dominant negative Ras mutant abrogates activation. A dominant negative Raf also blocks activation showing that the Ras-Raf pathway mediates stimulation of the RAR beta 2 promoter. Our results show that neuronal differentiation induced by non-retinoid agents that activate Ras is accompanied by increased transcription of the RAR beta gene.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589				BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Carpentier A, 1997, ONCOGENE, V15, P1805, DOI 10.1038/sj.onc.1201335; Cheung B, 1996, BIOCHEM BIOPH RES CO, V229, P349, DOI 10.1006/bbrc.1996.1804; Desmarais D, 1996, J BIOL CHEM, V271, P24976, DOI 10.1074/jbc.271.40.24976; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gudas Lorraine J., 1994, P443; Hampsey M, 1997, CURR BIOL, V7, pR44, DOI 10.1016/S0960-9822(06)00018-2; HAUSSLER M, 1983, P NATL ACAD SCI-BIOL, V80, P5525, DOI 10.1073/pnas.80.18.5525; Irving H, 1998, EUR J CANCER, V34, P111, DOI 10.1016/S0959-8049(97)10027-2; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRUYT FAE, 1992, NUCLEIC ACIDS RES, V20, P6393, DOI 10.1093/nar/20.23.6393; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; Lovat PE, 1997, EUR J CANCER, V33, P2075, DOI 10.1016/S0959-8049(97)00242-6; LOVAT PE, 1993, NEUROSCI LETT, V162, P109, DOI 10.1016/0304-3940(93)90572-3; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PAHLMAN S, 1991, P NATL ACAD SCI USA, V88, P9994, DOI 10.1073/pnas.88.22.9994; PARROW V, 1992, J CELL PHYSIOL, V152, P536, DOI 10.1002/jcp.1041520313; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; REDFERN CPF, 1994, BIOCHEM J, V304, P147, DOI 10.1042/bj3040147; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; Sanguedolce MV, 1997, EMBO J, V16, P2861, DOI 10.1093/emboj/16.10.2861; SCHONTHAL A, 1992, NEW BIOL, V4, P16; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMANTRAN VN, 1993, ENDOCRINOLOGY, V132, P2017, DOI 10.1210/en.132.5.2017; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1991, CANCER METAST REV, V10, P311, DOI 10.1007/BF00554793; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; VILLABLANCA JG, 1995, J CLIN ONCOL, V13, P894, DOI 10.1200/JCO.1995.13.4.894; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	48	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5393	5402		10.1038/sj.onc.1202906	http://dx.doi.org/10.1038/sj.onc.1202906			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498893				2022-12-25	WOS:000082718600004
J	Eskandari, S; Snyder, PM; Kreman, M; Zampighi, GA; Welsh, MJ; Wright, EM				Eskandari, S; Snyder, PM; Kreman, M; Zampighi, GA; Welsh, MJ; Wright, EM			Number of subunits comprising the epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; LIDDLES-SYNDROME; MEMBRANE TOPOLOGY; EXPRESSION; STOICHIOMETRY; MECHANISM; PROTEINS; CLONING; NEDD4; ENAC	The human epithelial sodium channel (hENaC) is a hetero-oligomeric complex composed of three subunits, alpha, beta, and gamma. Understanding the structure and function of this channel and its abnormal behavior in disease requires knowledge of the number of subunits that comprise the channel complex. We used freeze-fracture electron microscopy and electrophysiological methods to evaluate the number of subunits in the ENaC complex expressed in Xenopus laevis oocytes, In oocytes expressing wild-type hENaC (alpha, beta, and gamma subunits), clusters of particles appeared in the protoplasmic face of the plasma membranes. The total number of particles in the clusters was consistent with the whole-cell amiloride-sensitive current measured in the same cells. The size frequency histogram for the particles in the clusters suggested the presence of an integral membrane protein complex composed of 17 +/- 2 transmembrane alpha-helices. Because each ENaC subunit has two putative transmembrane helices, these data suggest that in the oocyte plasma membrane, the ENaC complex is composed of eight or nine subunits. At high magnification, individual ENaC particles exhibited a near-square geometry. Functional studies using wild-type alpha beta-hENaC coexpressed with gamma-hENaC mutants, which rendered the functional channel differentially sensitive to methanethiosulfonate reagents and. cadmium, suggested that the functional channel complex contains more than one gamma subunit, These data suggest that functional ENaC consists of eight or nine subunits of which a minimum of two are gamma subunits.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa	Eskandari, S (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, 10833 Le Conte Ave,53-317 CHS, Los Angeles, CA 90095 USA.	seskandari@mednet.ucla.edu		Welsh, Michael/0000-0002-1646-6206	NATIONAL EYE INSTITUTE [R01EY004110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS025554] Funding Source: NIH RePORTER; NEI NIH HHS [EY-04110] Funding Source: Medline; NIDDK NIH HHS [DK-19567] Funding Source: Medline; NINDS NIH HHS [NS-25554] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; BRANTON D, 1966, P NATL ACAD SCI USA, V55, P1048, DOI 10.1073/pnas.55.5.1048; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Cheng C, 1998, J BIOL CHEM, V273, P22693, DOI 10.1074/jbc.273.35.22693; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Hummler E, 1999, AM J PHYSIOL-GASTR L, V276, pG567, DOI 10.1152/ajpgi.1999.276.3.G567; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; RENARD S, 1994, J BIOL CHEM, V269, P12981; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Wright EM, 1997, J EXP BIOL, V200, P287; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	30	96	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27281	27286		10.1074/jbc.274.38.27281	http://dx.doi.org/10.1074/jbc.274.38.27281			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480948	hybrid			2022-12-25	WOS:000082570700087
J	Maingret, F; Patel, AJ; Lesage, F; Lazdunski, M; Honore, E				Maingret, F; Patel, AJ; Lesage, F; Lazdunski, M; Honore, E			Mechano- or acid stimulation, two interactive modes of activation of the TREK-1 potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACKGROUND K+ CHANNEL; ARACHIDONIC-ACID; INTRACELLULAR PH; ION CHANNELS; MECHANOSENSITIVE CHANNELS; FUNCTIONAL EXPRESSION; ELEGANS GENOME; FATTY-ACIDS; HEART-CELLS; TRANSDUCTION	TREK-1 is a member of the novel structural class of K+ channels with four transmembrane segments and two pore domains in tandem (1, 2). TREK-1 is opened by membrane stretch and arachidonic acid. It is also an important target for volatile anesthetics (2, 3). Here we show that internal acidification opens TREK-1. Indeed, lowering pH(i) shifts the pressure-activation relationship toward positive values and leads to channel opening at atmospheric pressure. The pH(i)-sensitive region in the carboxyl terminus of TREK-1 is the same that is critically involved in mechano-gating as well as arachidonic acid activation. A convergence, which is dependent on the carboxyl terminus, occurs between mechanical, fatty acids and acidic stimuli. Intracellular acidosis, which occurs during brain and heart ischemia, will induce TREK-1 opening with subsequent K+ efflux and hyperpolarization.	Inst Pharmacol Mol & Cellulaire, CNRS, UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	Lesage, Florian/P-9780-2019; Lesage, Florian/D-5097-2011	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106; HONORE, Eric/0000-0002-8007-0919				Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BELARDETTI F, 1988, TRENDS NEUROSCI, V11, P232, DOI 10.1016/0166-2236(88)90132-4; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; EDWARDS KL, 1987, CELL SURFACE SIGNAL, P41; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; FOSSET M, 1988, J BIOL CHEM, V263, P7933; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GUSTIN MC, 1992, ADV COMP ENV PHYSL, V10, P19; Hamill OP, 1996, PHARMACOL REV, V48, P231; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; HEURTEAUX C, 1993, P NATL ACAD SCI USA, V90, P9431, DOI 10.1073/pnas.90.20.9431; HOWARD J, 1988, ANNU REV BIOPHYS BIO, V17, P99; KIM D, 1992, J GEN PHYSIOL, V100, P1021, DOI 10.1085/jgp.100.6.1021; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; KIM DH, 1990, CIRC RES, V67, P1040, DOI 10.1161/01.RES.67.4.1040; KIM DH, 1995, J PHYSIOL-LONDON, V484, P643, DOI 10.1113/jphysiol.1995.sp020693; Lauritzen I, 1997, J NEUROCHEM, V69, P1570; LAZDUNSKI M, 1994, J CARDIOVASC PHARM, V24, pS1; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1999, CURR TOP MEMBR, V46, P199; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; LWEISS JN, 1993, CARDIOVASC DRUG THER, V3, P499; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; MARTINAC B, 1992, THERMODYNAMICS CELL, P327; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Patel AJ, 1998, J NEUROSCI, V18, P3117; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; SACHS F, 1988, CRIT REV BIOMED ENG, V16, P141; Sachs F, 1997, SOC GEN PHY, V52, P209; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; SCHAEFFER P, 1991, BRAIN RES, V539, P155, DOI 10.1016/0006-8993(91)90699-V; Shivkumar K, 1997, J CLIN INVEST, V100, P1782, DOI 10.1172/JCI119705; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Takahashi KI, 1996, NEUROSCI RES, V24, P109, DOI 10.1016/0168-0102(95)00989-2; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8	44	332	346	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26691	26696		10.1074/jbc.274.38.26691	http://dx.doi.org/10.1074/jbc.274.38.26691			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480871	hybrid			2022-12-25	WOS:000082570700010
J	Mastrandrea, LD; You, JX; Niles, EG; Pickart, CM				Mastrandrea, LD; You, JX; Niles, EG; Pickart, CM			E2/E3-mediated assembly of lysine 29-linked polyubiquitin chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; MULTIUBIQUITIN CHAIN; CONJUGATING ENZYME; DEGRADATION SIGNAL; PROTEOLYTIC PATHWAY; ACTIVATING ENZYME; CARRIER PROTEIN; IN-VIVO; PROTEASOME; MECHANISM	Polyubiquitin (Ub) chains linked through Lys-48-Gly-76 isopeptide bonds represent the principal signal by which substrates of the Ub-dependent protein degradation pathway are targeted to the 26 S proteasome, but the mechanism(s) whereby these chains are assembled on substrate proteins is poorly understood, Nor have assembly mechanisms or definitive functions been assigned to polyubiquitin chains linked through several other lysine residues of ubiquitin, We show that rabbit reticulocyte lysate harbors enzymatic components that catalyze the assembly of unanchored Lys-29-linked polyubiquitin chains. This reaction can be reconstituted using the ubiquitin-conjugating enzyme (E2) known as UbcH5A, a 120-kDa protein(s) that behaves as a ubiquitin-protein ligase (E3), and ubiquitin-activating enzyme (E1). The same partially purified E3 preparation also catalyzes the assembly of unanchored chains linked through Lys-48. Kinetic studies revealed a K(m) of similar to 9 mu M for the acceptor ubiquitin in the synthesis of diubiquitin; this value is similar to the concentration of free ubiquitin in most cells. Similar kinetic behavior was observed for conjugation to Lys-48 versus Lys-29 and for conjugation to tetraubiquitin versus monoubiquitin. The properties of these enzymes suggest that there may be distinct pathways for ubiquitin-ubiquitin ligation versus substrate-ubiquitin ligation in vivo.	Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA	Johns Hopkins University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Pickart, CM (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, 615 N Wolfe St, Baltimore, MD 21205 USA.	cpickart@welchlink.welch.jhu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46984] Funding Source: Medline; NIGMS NIH HHS [GM54816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 1997, EMBO J, V16, P4826; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; BAMEZAI S, 1991, ARCH BIOCHEM BIOPHYS, V289, P343, DOI 10.1016/0003-9861(91)90421-E; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; BERLETH ES, 1992, J BIOL CHEM, V267, P16403; Berleth ES, 1996, BIOCHEMISTRY-US, V35, P1664, DOI 10.1021/bi952105y; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1988, J BIOL CHEM, V263, P13268; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HALDEMAN MT, 1995, J BIOL CHEM, V270, P9507, DOI 10.1074/jbc.270.16.9507; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hodgins R, 1996, J BIOL CHEM, V271, P28766, DOI 10.1074/jbc.271.46.28766; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI J, 1995, BIOCHEMISTRY-US, V28, P6035; Liu Z, 1996, J BIOL CHEM, V271, P2817, DOI 10.1074/jbc.271.5.2817; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PICKART CM, 1994, J BIOL CHEM, V269, P7115; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; PICKART CM, 1988, J BIOL CHEM, V263, P12028; PICKART CM, 1998, UBIQUITIN BIOL CELL, P19; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SIEPMANN TJ, 1996, FASEB J, V10, P1402; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032	52	56	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27299	27306		10.1074/jbc.274.38.27299	http://dx.doi.org/10.1074/jbc.274.38.27299			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480950	hybrid			2022-12-25	WOS:000082570700089
J	Wosten, MMSM; Groisman, EA				Wosten, MMSM; Groisman, EA			Molecular characterization of the PmrA regulon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT REGULATORY SYSTEM; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; RNA-POLYMERASE; DNA-BINDING; LIPID-A; TRANSCRIPTION ACTIVATION; PROTEIN-PHOSPHORYLATION; POLYMYXIN RESISTANCE; SIGNAL-TRANSDUCTION	The two-component system PmrA/PmrB of Salmonella enterica controls expression of several loci including those mediating modifications in the lipopolysaccharide that result in polymyxin resistance. To gain insight in the regulation of polymyxin resistance, we mapped the transcription start sites of the PmrA-regulated genes pmrC, pmrG, pbgPE, and ugd and identified a conserved sequence in the promoter region of the first three genes. His-tagged PmrA protein could gel shift DNA fragments containing the promoters of the pmrC, pmrG, and pbgPE genes but not the udg promoter. DNase I footprinting analysis of the pmrC,,pmrG, and pbgPE promoters indicate that phosphorylated as well as unphosphorylated PmrA bind to a 16-base pair imperfect inverted repeat sequence (5'-TTAAKTTCTTAAKGTT-3'), which is found 40, 80, and 38 nucleotides upstream from the transcription start sites of the pmrC, pmrG, and pbgPE genes, respectively. Our data suggest that a PmrA dimer activates transcription of the divergent pmrG and pbgPE promoters by binding to a single site in the pmrG-pbgPE intergenic region and that the ugd gene is regulated by the PmrA/PmrB system only indirectly.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL)	Groisman, EA (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, 660 S Euclid Ave,Campus Box 8230, St Louis, MO 63110 USA.	groisman@borcim.wustl.edu		Wosten, Marc/0000-0002-7464-7232	NIAID NIH HHS [AI42236] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042236, R56AI042236] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; Baker SJ, 1999, MICROBIOL-SGM, V145, P367, DOI 10.1099/13500872-145-2-367; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Boucher PE, 1997, J BACTERIOL, V179, P1755, DOI 10.1128/jb.179.5.1755-1763.1997; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; Chien YT, 1998, J BIOL CHEM, V273, P2645, DOI 10.1074/jbc.273.5.2645; Dahl JL, 1997, J BIOL CHEM, V272, P1910, DOI 10.1074/jbc.272.3.1910; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; GRALLA JD, 1996, ESCHERICHIA COLI SAL, V1, P1232; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Hakenbeck R, 1996, METHOD ENZYMOL, V273, P281; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; Hoch JA, 1995, 2 COMPONENT SIGNAL T; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; Liu W, 1997, J BACTERIOL, V179, P6302, DOI 10.1128/jb.179.20.6302-6310.1997; MAKELA PH, 1978, FEMS MICROBIOL LETT, V3, P323; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; MARKOVITZ A, 1977, SURFACE CARBOHYDRATE, V1, P415; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RAIBAUD O, 1984, ANNU REV GENET, V18, P173, DOI 10.1146/annurev.ge.18.120184.001133; ROGGIANI M, 1993, J BACTERIOL, V175, P3182, DOI 10.1128/JB.175.10.3182-3187.1993; ROLAND KL, 1993, J BACTERIOL, V175, P4154, DOI 10.1128/JB.175.13.4154-4164.1993; ROLAND KL, 1994, J BACTERIOL, V176, P3589, DOI 10.1128/JB.176.12.3589-3597.1994; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SCHLEIF R, 1996, ESCHERICHIA COLI SAL, V1, P1300; SHAFER WM, 1984, INFECT IMMUN, V43, P834, DOI 10.1128/IAI.43.3.834-838.1984; SHAFER WM, 1986, INFECT IMMUN, V53, P651, DOI 10.1128/IAI.53.3.651-655.1986; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; Soncini FC, 1996, J BACTERIOL, V178, P6796, DOI 10.1128/jb.178.23.6796-6801.1996; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; WALKER MS, 1994, MOL MICROBIOL, V14, P633, DOI 10.1111/j.1365-2958.1994.tb01302.x; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4	36	82	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27185	27190		10.1074/jbc.274.38.27185	http://dx.doi.org/10.1074/jbc.274.38.27185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480935	hybrid			2022-12-25	WOS:000082570700074
J	Xu, ASL; Labotka, RJ; London, RE				Xu, ASL; Labotka, RJ; London, RE			Acetylation of human hemoglobin by methyl acetylphosphate - Evidence of broad regio-selectivity revealed by NMR studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL HEMOGLOBIN; PHOSPHATE; BINDING; ASPIRIN; CHAINS; AGENT; SITES	The development of chemical modification agents that reduce the tendency of sickle hemoglobin (HbS) to aggregate represents an important chemotherapeutic goal. Methyl acetylphosphate (MAP) has been reported to bind to the 2,3-diphosphoglycerate (2,3-DPG) binding site of hemoglobin, where it selectively acetylates residues, resulting in increased solubility of HbS. We have prepared [1-C-13]MAP and evaluated the adduct formation with hemoglobin using H-1-C-13 HMQC and HSQC NMR studies. These spectra of the acetylated hemoglobin adducts showed 10-11 well resolved adduct peaks, indicating that the acetylation was not highly residue specific. The chemical shift pattern observed is in general similar to that obtained recently using [1'-C-13]aspirin as the acetylating agent (Xu, A. S. L., Macdonald, J. M,, Labotka, R, J., and London, R. E. (1999) Biochim, Biophys. Acta 1432, 333-349). Blocking the 2,3-DPG binding site with inositol hexaphosphate (IHP) resulted in, a selective reduction in intensity of adduct resonances, presumably corresponding to residues located in the 2,3-DPG binding cleft. The pattern of residue protection appeared to be identical to that observed in our previous study using IHP and labeled aspirin, Pre-acetylation of hemoglobin using unlabeled MAP, followed by acetylation with [1'-C-13]aspirin indicated a general protective effect, with the greatest reduction of intensity for resonances corresponding to acetylated residues in the 2,3-DPG binding site. These studies indicated that both MAP and aspirin exhibit similar, although not identical, acetylation profiles and target primarily the beta Lys-82 residue in the 2,3-DPG binding site, as well as sites such as beta Lys-59 and alpha Lys-90, which are not located in the beta-cleft of hemoglobin.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Illinois, Dept Pediat, Chicago, IL 60612 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	London, RE (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	London@NIEHS.NIH.GOV	London, Robert E/F-7990-2019	London, Robert E/0000-0001-9108-8463	NHLBI NIH HHS [5RO1 HL57604] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057604] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRYGIER J, 1975, EUR J BIOCHEM, V60, P379, DOI 10.1111/j.1432-1033.1975.tb21013.x; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CERAMI A, 1971, P NATL ACAD SCI USA, V68, P1180, DOI 10.1073/pnas.68.6.1180; CHATTERJEE R, 1986, J BIOL CHEM, V261, P9929; JONES RT, 1993, BIOCHEMISTRY-US, V32, P215, DOI 10.1021/bi00052a028; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KLOTZ IM, 1973, P NATL ACAD SCI USA, V70, P1313, DOI 10.1073/pnas.70.5.1313; KLUGER R, 1980, J ORG CHEM, V45, P2723, DOI 10.1021/jo01301a039; KLUGER R, 1986, BIOCHEM CELL BIOL, V64, P434, DOI 10.1139/o86-061; LABOTKA RJ, 1990, ANAL BIOCHEM, V191, P376, DOI 10.1016/0003-2697(90)90235-2; Macdonald JM, 1999, BIOCHEM PHARMACOL, V57, P1233, DOI 10.1016/S0006-2952(99)00039-8; MANNING JM, 1994, METH ENZYM MOL, V76, P159; SHAMSUDDIN M, 1974, P NATL ACAD SCI USA, V71, P4693, DOI 10.1073/pnas.71.12.4693; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; UENO H, 1989, J BIOL CHEM, V264, P12344; UENO H, 1986, ARCH BIOCHEM BIOPHYS, V244, P795, DOI 10.1016/0003-9861(86)90648-X; UENO H, 1987, BIOCHEMISTRY-US, V26, P3125, DOI 10.1021/bi00385a027; UENO H, 1989, ANN NY ACAD SCI, V565, P239, DOI 10.1111/j.1749-6632.1989.tb24172.x; UENO H, 1988, AM J PEDIAT HEMATOL, V10, P348; UENO H, 1987, PATHOPHYSIOLOGICAL A, P105; WALDER JA, 1979, BIOCHEMISTRY-US, V18, P4265, DOI 10.1021/bi00587a001; Xu ASL, 1999, BBA-PROTEIN STRUCT M, V1432, P333, DOI 10.1016/S0167-4838(99)00094-1	22	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26629	26632		10.1074/jbc.274.38.26629	http://dx.doi.org/10.1074/jbc.274.38.26629			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480863	hybrid			2022-12-25	WOS:000082570700002
J	Allerson, CR; Cazzola, M; Rouault, TA				Allerson, CR; Cazzola, M; Rouault, TA			Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; L-SUBUNIT GENE; HUMAN-SERUM FERRITIN; BINDING PROTEIN; REGULATORY PROTEIN-2; METABOLISM; DEGRADATION; MISMATCHES; ACONITASE; DYNAMICS	Hereditary hyperferritinemia-cataract syndrome (HHCS) is a novel genetic disorder characterized by elevated serum ferritin and early onset cataract formation. The excessive ferritin production in HHCS patients arises from aberrant regulation of L-ferritin translation caused by mutations within the iron-responsive element (IRE) of the L-ferritin transcript. IREs serve as binding sites for iron regulatory proteins (IRPs), iron-sensing proteins that regulate ferritin translation. Previous observations suggested that each unique HHCS mutation conferred a characteristic degree of hyperferritinemia and cataract severity in affected individuals. Here we have measured the in vitro affinity of the IRPs for the mutant IREs and correlated decreases in binding affinity with clinical severity. Thermodynamic analysis of these IREs has also revealed that although some HHCS mutations lead to changes in the stability and secondary structure of the IRE, others appear to disrupt IRP-IRE recognition with minimal effect on IRE stability. HHCS is a noteworthy example of a human genetic disorder that arises from mutations within a protein-binding site of an mRNA cis-acting element. Analysis of the effects of these mutations on the energetics of the RNA-protein interaction explains the phenotypic variabilities of the disease state.	NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Univ Pavia, Sch Med, Dept Internal Med & Med Therapy, I-27100 Pavia, Italy; Univ Pavia, Sch Med, Dept Internal Med & Med Oncol, I-27100 Pavia, Italy; Policlin San Matteo, IRCCS, I-27100 Pavia, Italy	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Pavia; University of Pavia; IRCCS Fondazione San Matteo; University of Pavia	Rouault, TA (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Rm 101,9000 Rockville Pike, Bethesda, MD 20892 USA.	trou@helix.nih.gov	Cazzola, Mario/AAQ-8854-2021	Cazzola, Mario/0000-0001-6984-8817	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001602] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001602] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Addess KJ, 1997, J MOL BIOL, V274, P72, DOI 10.1006/jmbi.1997.1377; AguilarMartinez P, 1996, BLOOD, V88, P1895; Arnold JD, 1997, GUT, V41, P408, DOI 10.1136/gut.41.3.408; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BONNEAU D, 1995, J MED GENET, V32, P778, DOI 10.1136/jmg.32.10.778; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; Cazzola M, 1997, BLOOD, V90, P814, DOI 10.1182/blood.V90.2.814.814_814_821; Cicilano M, 1999, HAEMATOLOGICA, V84, P489; Ciftan SA, 1998, CHEM BIOL, V5, P679, DOI 10.1016/S1074-5521(98)90661-5; CRAGG SJ, 1981, BIOCHEM J, V199, P565, DOI 10.1042/bj1990565; Drake SK, 1996, BIOCHEMISTRY-US, V35, P6697, DOI 10.1021/bi952430l; Draper DE, 1995, METHOD ENZYMOL, V259, P281; GAUTHERET D, 1994, J MOL BIOL, V242, P1, DOI 10.1006/jmbi.1994.1552; GIRELLI D, 1995, BRIT J HAEMATOL, V90, P931, DOI 10.1111/j.1365-2141.1995.tb05218.x; Girelli D, 1997, BLOOD, V90, P2084, DOI 10.1182/blood.V90.5.2084; GIRELLI D, 1995, BLOOD, V86, P4050, DOI 10.1182/blood.V86.11.4050.bloodjournal86114050; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Hall KB, 1998, BIOCHEMISTRY-US, V37, P9323, DOI 10.1021/bi9805285; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Henderson ER, 1996, J BIOL CHEM, V271, P4900; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; Kim HY, 1996, J BIOL CHEM, V271, P24226, DOI 10.1074/jbc.271.39.24226; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kohler SA, 1999, J BIOL CHEM, V274, P2401, DOI 10.1074/jbc.274.4.2401; Laing LG, 1996, BIOCHEMISTRY-US, V35, P13586, DOI 10.1021/bi961310q; LEE MH, 1995, AM J MED, V98, P566, DOI 10.1016/S0002-9343(99)80015-1; Levi S, 1998, BLOOD, V91, P4180, DOI 10.1182/blood.V91.11.4180.411k38_4180_4187; Martin ME, 1998, BLOOD, V91, P319, DOI 10.1182/blood.V91.1.319; Merkt J, 1997, DEUT MED WOCHENSCHR, V122, P504, DOI 10.1055/s-2008-1047644; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORSE SE, 1995, NUCLEIC ACIDS RES, V23, P302, DOI 10.1093/nar/23.2.302; Muckenthaler M, 1998, MOL CELL, V2, P383, DOI 10.1016/S1097-2765(00)80282-8; Mumford AD, 1998, BLOOD, V91, P367, DOI 10.1182/blood.V91.1.367.367_367_368; Rouault TA, 1996, J BIOL INORG CHEM, V1, P494, DOI 10.1007/s007750050083; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SANTAMBROGIO P, 1987, BRIT J HAEMATOL, V65, P235, DOI 10.1111/j.1365-2141.1987.tb02271.x; Serra MJ, 1995, METHOD ENZYMOL, V259, P242; Thorp HH, 1996, INORG CHEM, V35, P2773, DOI 10.1021/ic951094u; Trudo EW, 1998, POSTGRAD MED, V103, P114, DOI 10.3810/pgm.1998.05.478	44	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26439	26447		10.1074/jbc.274.37.26439	http://dx.doi.org/10.1074/jbc.274.37.26439			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473603	hybrid			2022-12-25	WOS:000082469700069
J	Osaki, T; Omotezako, M; Nagayama, R; Hirata, M; Iwanaga, S; Kasahara, J; Hattori, J; Ito, I; Sugiyama, H; Kawabata, S				Osaki, T; Omotezako, M; Nagayama, R; Hirata, M; Iwanaga, S; Kasahara, J; Hattori, J; Ito, I; Sugiyama, H; Kawabata, S			Horseshoe crab hemocyte-derived antimicrobial polypeptides, tachystatins, with sequence similarity to spider neurotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNNEL-WEB SPIDER; INTRACELLULAR COAGULATION INHIBITOR; TACHYPLEUS-TRIDENTATUS HEMOCYTES; AMINO-ACID-SEQUENCE; CDNA CLONING; CELL-WALL; ANTIBACTERIAL ACTIVITY; CALCOFLUOR WHITE; CLOTTING FACTORS; INNATE IMMUNITY	Antimicrobial peptides, named tachystatins A, B, and C, were identified from hemocytes of the horseshoe crab Tachypleus tridentatus. Tachystatins exhibited a broad spectrum of antimicrobial activity against Gram-negative and Gram-positive bacteria and fungi. Of these tachystatins, tachystatin C was most effective. Tachystatin A is homologous to tachystatin B, but tachystatin C has no significant sequence similarity to tachystatins A and B. Tachystatins A and B showed sequence similarity to omega-agatoxin-IVA of funnel web spider venom, a potent blocker of voltage-dependent calcium channels. However, they exhibited no blocking activity of the P-type calcium channel in rat Purkinje cells. Tachystatin C also showed sequence similarity to several insecticidal neurotoxins of spider venoms. Tachystatins A, B, and C bound significantly to chitin, A causal relationship was observed between chitin binding activity and antifungal activity. Tachystatins caused morphological changes against a budding yeast, and tachystatin C had a strong cell lysis activity. The septum between mother cell and bud, a chitin-rich region, was stained by fluorescence-labeled tachystatin C, suggesting that the primary recognizing substance on the cell wall is chitin. As horseshoe crab is a close relative of the spider, tachystatins and spider neurotoxins may have evolved from a common ancestral peptide, with adaptive functions.	Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan; Iwate Med Univ, Dept Bacteriol, Morioka, Iwate 0208505, Japan	Kyushu University; Iwate Medical University	Kawabata, S (corresponding author), Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan.			Osaki, Tsukasa/0000-0002-9487-3253				ADAMS ME, 1989, J COMP PHYSIOL A, V164, P333, DOI 10.1007/BF00612993; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CHARBONNEAU H, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P15; EhretSabatier L, 1996, J BIOL CHEM, V271, P29537, DOI 10.1074/jbc.271.47.29537; ELORZA MV, 1983, J GEN MICROBIOL, V129, P1577; FISCHER G, 1982, NEUROSCI LETT, V28, P325, DOI 10.1016/0304-3940(82)90079-9; HOFFMANN JA, 1993, FEBS LETT, V325, P63, DOI 10.1016/0014-5793(93)81414-U; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; Inamori K, 1999, J BIOL CHEM, V274, P3272, DOI 10.1074/jbc.274.6.3272; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; IWANAGA S, 1992, THROMB RES, V68, P1, DOI 10.1016/0049-3848(92)90124-S; Iwanaga S, 1998, J BIOCHEM, V123, P1; Kasahara J, 1998, NEUROSCI LETT, V247, P139, DOI 10.1016/S0304-3940(98)00299-7; Kawabata S, 1997, BIOL CHEM, V378, P289, DOI 10.1515/bchm.1997.378.3-4.289; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Kawabata Shun-ichiro, 1996, P255; KIM JI, 1995, J MOL BIOL, V250, P659, DOI 10.1006/jmbi.1995.0406; KINI RM, 1989, INT J PEPT PROT RES, V34, P277; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALAGARWARA K, 1996, J BIOCH, V119, P85; LOTAN R, 1973, BIOCHEM BIOPH RES CO, V55, P1340, DOI 10.1016/S0006-291X(73)80041-5; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MIURA Y, 1995, J BIOL CHEM, V270, P558, DOI 10.1074/jbc.270.2.558; MIURA Y, 1994, J BIOL CHEM, V269, P542; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; NAKAMURA T, 1987, J BIOCHEM, V101, P1297, DOI 10.1093/oxfordjournals.jbchem.a121994; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; Omecinsky DO, 1996, BIOCHEMISTRY-US, V35, P2836, DOI 10.1021/bi952605r; PRIVAT JP, 1974, EUR J BIOCHEM, V47, P5, DOI 10.1111/j.1432-1033.1974.tb03661.x; RONCERO C, 1985, J BACTERIOL, V163, P1180, DOI 10.1128/JB.163.3.1180-1185.1985; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERRER R, 1971, J BACTERIOL, V107, P718, DOI 10.1128/JB.107.3.718-735.1971; SHIGENAGA T, 1990, J BIOL CHEM, V265, P21350; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; Shimizu T, 1997, BIOCHEMISTRY-US, V36, P12071, DOI 10.1021/bi970922n; SKINNER WS, 1989, J BIOL CHEM, V264, P2150; SKINNER WS, 1992, TOXICON, V30, P1043, DOI 10.1016/0041-0101(92)90049-B; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; STAPLETON A, 1990, J BIOL CHEM, V265, P2054; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720	46	89	106	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26172	26178		10.1074/jbc.274.37.26172	http://dx.doi.org/10.1074/jbc.274.37.26172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473569	hybrid			2022-12-25	WOS:000082469700035
J	Zhu, C; Lang, DW; Coffino, P				Zhu, C; Lang, DW; Coffino, P			Antizyme2 is a negative regulator of ornithine decarboxylase and polyamine transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; RETICULOCYTE LYSATE; MAMMALIAN ANTIZYME; DROSOPHILA GENE; MOUSE-BRAIN; DEGRADATION; CELLS; SEQUENCE; ACCUMULATION; EXPRESSION	The antizyme family consists of closely homologous proteins believed to regulate cellular polyamine pools. Antizyme1, the first described, negatively regulates ornithine decarboxylase, the initial enzyme in the biosynthetic pathway for polyamines, Antizyme1 targets ornithine decarboxylase for degradation and inhibits polyamine transport into cells, thereby diminishing polyamine pools. A polyamine-stimulated ribosomal frameshift is required for decoding antizyme1 mRNA. Recently, additional novel conserved members of the antizyme family have been described. We report here the properties of one of these, antizyme2. Antizyme2, like antizyme1, binds to ornithine decarboxylase and inhibits polyamine transport. Using a baculovirus expression system in cultured Sf21 insect cells, both antizymes were found to accelerate ornithine decarboxylase degradation. Expression of either antizyme1 or 2 in Sf21 cells also diminished their uptake of the polyamine spermidine. Both forms of antizyme can therefore function as negative regulators of polyamine production and transport. However, in contrast to antizyme1, antizyme2 has negligible ability to stimulate degradation of ornithine decarboxylase in a rabbit reticulocyte lysate.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Coffino, P (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.			Coffino, Philip/0000-0003-0344-5083	NIGMS NIH HHS [GM45335] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; GUPTA M, 1985, J BIOL CHEM, V260, P2941; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ICHIBA T, 1994, BIOCHEM BIOPH RES CO, V200, P1721, DOI 10.1006/bbrc.1994.1651; Ivanov IP, 1998, GENOMICS, V52, P119, DOI 10.1006/geno.1998.5434; Ivanov IP, 1998, MOL CELL BIOL, V18, P1553, DOI 10.1128/MCB.18.3.1553; Kajiwara K, 1996, BIOCHEM BIOPH RES CO, V219, P795, DOI 10.1006/bbrc.1996.0313; LAITINEN PH, 1986, BIOCHEM J, V236, P613, DOI 10.1042/bj2360613; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; Li XQ, 1996, J BIOL CHEM, V271, P4441; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Matsufuji S, 1996, EMBO J, V15, P1360, DOI 10.1002/j.1460-2075.1996.tb00478.x; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MURAKAMI Y, 1994, BIOCHEM J, V304, P183, DOI 10.1042/bj3040183; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1993, BIOCHEM J, V295, P305, DOI 10.1042/bj2950305; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; ONOUE H, 1988, BIOCHEM J, V250, P797, DOI 10.1042/bj2500797; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Sakata K, 1997, BIOCHEM BIOPH RES CO, V238, P415, DOI 10.1006/bbrc.1997.7266; Salzberg A, 1996, GENETICS, V144, P183; STEGLICH C, 1982, J BIOL CHEM, V257, P4603; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	36	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26425	26430		10.1074/jbc.274.37.26425	http://dx.doi.org/10.1074/jbc.274.37.26425			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473601	hybrid			2022-12-25	WOS:000082469700067
J	Alper, O; Hacker, NF; Cho-Chung, YS				Alper, O; Hacker, NF; Cho-Chung, YS			Protein kinase A-I alpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway	ONCOGENE			English	Article						protein kinase A; antisense; ovarian cancer; tyrosine kinase; EGF receptor	REGULATORY SUBUNIT; CAMP; EXPRESSION; DIFFERENTIATION; OLIGODEOXYNUCLEOTIDE; TRANSFORMATION; ACTIVATION; RECEPTOR; SITE; FIBROBLASTS	Expression of the RI alpha subunit of cAMP-dependent protein kinase type I is increased in human cancers in which an autocrine pathway for epidermal growth factor-related growth factors is activated. We have investigated the effect of sequence-specific inhibition of RI alpha gene expression on ovarian cancer cell growth. We report that RI alpha antisense treatment results in a reduction in RI alpha expression and protein kinase A type I, and inhibition of cell growth. The growth inhibition was accompanied by changes in cell morphology and appearance of apoptotic nuclei. In addition, EGF receptor, c-erbB-2 and c-erbB-3 levels were reduced, and the basal and EGF-stimulated mitogen-activated protein kinase activities were reduced. Protein kinase A type I and EGF receptor levels were also reduced in cells overexpressing EGF receptor antisense cDNA. These results suggest that the antisense depletion of RI alpha leads to blockade of both the serine-threonine kinase and the tyrosine kinase signaling pathways resulting in arrest of ovarian cancer cell growth.	NCI, Cellular Biochem Sect, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA; Royal Hosp Women, Gynaecol Canc Ctr, Randwick, NSW 2031, Australia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cho-Chung, YS (corresponding author), NCI, Cellular Biochem Sect, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA.			ALPER, OZGE/0000-0002-9067-3270; Hacker, Neville/0000-0002-1445-2302				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Alper O., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P646; BEEBE SJ, 1986, ENZYMES, V17, P43; BUDILLON A, 1995, P NATL ACAD SCI USA, V92, P10634, DOI 10.1073/pnas.92.23.10634; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; ChoChung YS, 1997, ANTISENSE NUCLEIC A, V7, P217, DOI 10.1089/oli.1.1997.7.217; CHOCHUNG YS, 1989, CANCER INVEST, V7, P161, DOI 10.3109/07357908909038282; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; ChoChung YS, 1996, ANTISENSE NUCLEIC A, V6, P237, DOI 10.1089/oli.1.1996.6.237; CIARDIELLO F, 1990, J BIOL CHEM, V265, P1016; Ciardiello F, 1998, BREAST CANCER RES TR, V47, P57, DOI 10.1023/A:1005909419828; COBB CE, 1987, J BIOL CHEM, V262, P16566; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dean N, 1996, CANCER RES, V56, P3499; Guyton KZ, 1996, CANCER RES, V56, P3480; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; METELEV V, 1994, BIOORG MED CHEM LETT, V4, P2929, DOI 10.1016/S0960-894X(01)80842-8; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; Nesterova M, 1996, EUR J BIOCHEM, V235, P486, DOI 10.1111/j.1432-1033.1996.00486.x; NESTEROVA M, 1995, NAT MED, V1, P528, DOI 10.1038/nm0695-528; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; Pegues JC, 1997, CANCER LETT, V117, P73, DOI 10.1016/S0304-3835(97)00209-7; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; Srivastava RK, 1998, BREAST CANCER RES TR, V49, P97, DOI 10.1023/A:1005905723550; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; Tortora G, 1997, ONCOGENE, V14, P923, DOI 10.1038/sj.onc.1200906; TORTORA G, 1989, FEBS LETT, V242, P363, DOI 10.1016/0014-5793(89)80502-2; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YOKOZAKI H, 1993, CANCER RES, V53, P868	35	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4999	5004		10.1038/sj.onc.1202830	http://dx.doi.org/10.1038/sj.onc.1202830			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490835				2022-12-25	WOS:000082321700013
J	Novikova, EG; Eng, FJ; Yan, L; Qian, YM; Fricker, LD				Novikova, EG; Eng, FJ; Yan, L; Qian, YM; Fricker, LD			Characterization of the enzymatic properties of the first and second domains of metallocarboxypeptidase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE SECRETORY PATHWAY; MESSENGER-RNA DISTRIBUTION; OBESE FAT/FAT MICE; B VIRUS-PARTICLES; CARBOXYPEPTIDASE-E; PROPROTEIN CONVERTASES; INTRACELLULAR TRAFFICKING; CHROMOSOMAL LOCALIZATION; TISSUE DISTRIBUTION; PRECURSOR CLEAVAGE	Carboxypeptidase D (CPD) contains three domains with homology to other metallocarboxypeptidases. To further characterize the various domains, we constructed a series of point mutants with a critical active site Glu of duck CPD converted to Gln. The proteins were expressed in the baculovirus system, purified to homogeneity, and characterized. Point mutations within both the first and second domains eliminated enzyme activity, indicating that the third domain is inactive toward dansyl-Phe-Ala-Arg. CPD removed only the C-terminal Lys or Arg from peptides, with the first domain more efficient toward Arg and the second domain more efficient toward Lys, Peptides containing Pro in the penultimate position were poorly cleaved by either domain. Cleavage of a peptide with Ala in the penultimate position was most efficient, with the relative order Ala greater than or equal to Met > Ser, Phe > Tyr > Trp > Thr greater than or equal to Gln, Asp, Leu, Gly >> Pro for CPD with both domains active. There were only minor differences between the first and the second domains regarding the influence of the penultimate amino acid. The first domain was optimally active at pH 6.3-7.5, whereas the second domain was optimally active at pH 5.0-6.5. Thus, the first and second carboxypeptidase domains have complementary enzyme activities. Furthermore, the finding that CPD with both domains active shows a broad activity to a wide range of substrates is consistent with a role for this enzyme in the processing of many proteins that transit the secretory pathway.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Fricker, LD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	fricker@aecom.yu.edu			NCI NIH HHS [CA13330] Funding Source: Medline; NIDA NIH HHS [DA-00194] Funding Source: Medline; NIDDK NIH HHS [R01 DK-51271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; Dong W, 1999, NEUROSCIENCE, V89, P1301, DOI 10.1016/S0306-4522(98)00381-9; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Eng FJ, 1998, J BIOL CHEM, V273, P8382, DOI 10.1074/jbc.273.14.8382; Eng FJ, 1999, MOL BIOL CELL, V10, P35, DOI 10.1091/mbc.10.1.35; Fan XM, 1999, DNA CELL BIOL, V18, P121, DOI 10.1089/104454999315501; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1998, HDB PROTEOLYTIC ENZY, P1341; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GUEST PC, 1992, J BIOL CHEM, V267, P22401; GUEST PC, 1991, ENDOCRINOLOGY, V129, P734, DOI 10.1210/endo-129-2-734; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HORNBY PJ, 1993, NEUROENDOCRINOLOGY, V58, P555, DOI 10.1159/000126590; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; Lei YH, 1999, DNA CELL BIOL, V18, P175, DOI 10.1089/104454999315565; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NALAMACHU SR, 1994, J BIOL CHEM, V269, P11192; Qian YM, 1999, J BIOL CHEM, V274, P11582, DOI 10.1074/jbc.274.17.11582; Reznik SE, 1998, J HISTOCHEM CYTOCHEM, V46, P1359, DOI 10.1177/002215549804601204; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; RUSSELL JT, 1984, J BIOL CHEM, V259, P9496; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SETTLE SH, 1995, P NATL ACAD SCI USA, V92, P9470, DOI 10.1073/pnas.92.21.9470; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; Song LX, 1997, J BIOL CHEM, V272, P10543; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; SONG LX, 1995, J NEUROCHEM, V65, P444; Song LX, 1996, J BIOL CHEM, V271, P28884, DOI 10.1074/jbc.271.46.28884; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; Varlamov O, 1999, J BIOL CHEM, V274, P14759, DOI 10.1074/jbc.274.21.14759; Varlamov O, 1998, J CELL SCI, V111, P877; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WEI L, 1991, J BIOL CHEM, V266, P9002; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; Xin XN, 1998, DNA CELL BIOL, V17, P311, DOI 10.1089/dna.1998.17.311; Xin XN, 1998, DNA CELL BIOL, V17, P897, DOI 10.1089/dna.1998.17.897; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHENG M, 1994, J NEUROSCI, V14, P4656	56	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28887	28892		10.1074/jbc.274.41.28887	http://dx.doi.org/10.1074/jbc.274.41.28887			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506132	hybrid			2022-12-25	WOS:000083017800011
J	Calderwood, DA; Zent, R; Grant, R; Rees, DJG; Hynes, RO; Ginsberg, MH				Calderwood, DA; Zent, R; Grant, R; Rees, DJG; Hynes, RO; Ginsberg, MH			The talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESIONS; PROTEIN; SEQUENCE; RECEPTOR; CELLS; ALPHA; IIIA	The beta subunit cytoplasmic domains of integrin adhesion receptors are necessary for the connection of these receptors to the actin cytoskeleton. The cytoplasmic protein, talin, binds to beta integrin cytoplasmic tails and actin filaments, hence forming an integrin-cytoskeletal linkage. We used recombinant structural mimics of beta(1)A, beta(1)D and beta(3) integrin cytoplasmic tails to characterize integrin-binding sites within talin, Here we report that an integrin-binding site is localized minics the N-terminal talin head domain. The binding of the talin head domain to integrin beta tails is specific in that it is abrogated by a single point mutation that disrupts integrin localization to talin-rich focal adhesions. Integrin-cytoskeletal interactions regulate integrin affinity for ligands (activation), Overexpression of a fragment of talin containing the head domain led to activation of integrin alpha(IIb)beta(3); activation was dependent on the presence of both the talin head domain and the integrin beta(3) cytoplasmic tail. The head domain of talin thus binds to integrins to form a link to the actin cytoskeleton and can thus regulate integrin function.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Cambridge Mol, Cambridge CB5 8PB, England; Univ Western Cape, Dept Biochem, ZA-7535 Bellville, South Africa; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Scripps Research Institute; University of the Western Cape; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA.		Grant, Richard/E-3276-2010; Rees, David Jasper Gilbert/AAZ-8073-2020; Calderwood, David A/AAC-6954-2019; Rees, Jasper/D-9672-2011	Rees, David Jasper Gilbert/0000-0003-3321-1325; Calderwood, David A/0000-0002-0791-4142; Rees, Jasper/0000-0003-3321-1325; Grant, Richard/0000-0003-2386-8876	NATIONAL CANCER INSTITUTE [R01CA017007] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NCI NIH HHS [CA17007] Funding Source: Medline; NHLBI NIH HHS [HL59007, HL48728] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKERLE MC, 1989, J CELL BIOL, V109, P3333, DOI 10.1083/jcb.109.6.3333; BOITON SJ, 1997, CELL MOTIL CYTOSKEL, V36, P363; Borowsky ML, 1998, J CELL BIOL, V143, P429, DOI 10.1083/jcb.143.2.429; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; ELEMER GS, 1994, J BIOL CHEM, V269, P3159; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; Hemmings L, 1996, J CELL SCI, V109, P2715; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; MUGURUMA M, 1995, J BIOCHEM-TOKYO, V117, P1036, DOI 10.1093/oxfordjournals.jbchem.a124803; NUCKOLLS GH, 1990, J CELL BIOL, V110, P1635, DOI 10.1083/jcb.110.5.1635; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	23	541	549	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28071	28074		10.1074/jbc.274.40.28071	http://dx.doi.org/10.1074/jbc.274.40.28071			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497155	hybrid			2022-12-25	WOS:000082912700004
J	Hewagama, A; Guy, HI; Vickrey, JF; Evans, DR				Hewagama, A; Guy, HI; Vickrey, JF; Evans, DR			Functional linkage between the glutaminase and synthetase domains of carbamoyl-phosphate synthetase - Role of serine 44 in carbamoyl-phosphate synthetase-aspartate carbamoyltransferase-dihydroorotase (CAD)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; INITIATES PYRIMIDINE BIOSYNTHESIS; ATP-BINDING-SITES; ESCHERICHIA-COLI; AMIDOTRANSFERASE DOMAIN; REVERSIBLE DISSOCIATION; HAMSTER-CELLS; CARBOXY PHOSPHATE; MAMMALIAN-CELLS; CATALYTIC TRIAD	Mammalian carbamoyl-phosphate synthetase is part of carbamoyl-phosphate synthetase-aspartate carbamoyltransferase-dihydroorotase (CAD), a multifunctional protein that also catalyzes the second and third steps of pyrimidine biosynthesis. Carbamoyl phosphate synthesis requires the concerted action of the glutaminase (GLN) and carbamoyl-phosphate synthetase domains of CAD. There is a functional linkage between these domains such that glutamine hydrolysis on the GLN domain does not occur at a significant rate unless ATP and HCO3-, the other substrates needed for carbamoyl phosphate synthesis, bind to the synthetase domain. The GLN domain consists of catalytic and attenuation subdomains, In the separately cloned GLN domain, the catalytic subdomain is down-regulated by interactions with the attenuation domain, a process thought to be part of the functional linkage. Replacement of Ser(44) in the GLN attenuation domain with alanine increases the k(cat)/K-m for glutamine hydrolysis 680-fold. The formation of a functional hybrid between the mammalian Ser(44) GLN domain and the Escherichia coli carbamoyl-phosphate synthetase large subunit had little effect on glutamine hydrolysis, In contrast, ATP and HCO3- did not stimulate the glutaminase activity, indicating that the interdomain linkage had been disrupted. In accord with this interpretation, the rate of glutamine hydrolysis and carbamoyl phosphate synthesis were no longer coordinated. Approximately 3 times more glutamine was hydrolyzed by the Ser(44) --> Ala mutant than that needed for carbamoyl phosphate synthesis. Ser(44), the only attenuation subdomain residue that extends into the GLN active site, appears to be an integral component of the regulatory circuit that phases glutamine hydrolysis and carbamoyl phosphate synthesis.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Evans, DR (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.	devans@cmb.biosci.wayne.edu			NIGMS NIH HHS [GM47399] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1973, BIOCHEM BIOPH RES CO, V55, P246, DOI 10.1016/S0006-291X(73)80086-5; ANDERSON PM, 1975, BIOCHEMISTRY-US, V14, P3688, DOI 10.1021/bi00687a027; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1995, NITROGEN METABOLISM, P38; BEIN K, 1991, J BIOL CHEM, V266, P3791; BOETTCHER BR, 1980, J BIOL CHEM, V255, P7129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P1381; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUY HI, 1995, J BIOL CHEM, V270, P2190, DOI 10.1074/jbc.270.5.2190; GUY HI, 1994, J BIOL CHEM, V269, P7702; Hanahan D., 1985, DNA CLONING PRACTICA, VI, P109; Hewagama A, 1998, BBA-PROTEIN STRUCT M, V1388, P489, DOI 10.1016/S0167-4838(98)00212-X; JavidMajd F, 1996, BIOCHEMISTRY-US, V35, P14362, DOI 10.1021/bi961184q; KHEDOURI E, 1966, BIOCHEMISTRY-US, V5, P3552, DOI 10.1021/bi00875a024; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KIM HS, 1992, J BIOL CHEM, V267, P7177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING LAB MANU; Massiere F, 1998, CELL MOL LIFE SCI, V54, P205, DOI 10.1007/s000180050145; MEI B, 1989, J BIOL CHEM, V264, P16613; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; Miles BW, 1998, BIOCHEMISTRY-US, V37, P16773, DOI 10.1021/bi982018g; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POWERSLEE SG, 1987, J BIOL CHEM, V262, P15683; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1999, ACTA CRYSTALLOGR D, V55, P8, DOI 10.1107/S0907444998006234; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P2347, DOI 10.1021/bi982517h; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P482; TROTTA PP, 1974, J BIOL CHEM, V249, P492; WELLNER VP, 1973, BIOCHEMISTRY-US, V12, P2061, DOI 10.1021/bi00735a006; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; ZALKIN H, 1985, METHOD ENZYMOL, V113, P263	50	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28240	28245		10.1074/jbc.274.40.28240	http://dx.doi.org/10.1074/jbc.274.40.28240			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497179	hybrid			2022-12-25	WOS:000082912700028
J	Lavoie, L; Band, CJ; Kong, M; Bergeron, JJM; Posner, BI				Lavoie, L; Band, CJ; Kong, M; Bergeron, JJM; Posner, BI			Regulation of glycogen synthase in rat hepatocytes - Evidence for multiple signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; EPIDIDYMAL FAT-CELLS; PHOSPHOINOSITIDE 3-KINASE; PEROXOVANADIUM COMPOUNDS; INSULIN STIMULATION; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; TUMOR-SUPPRESSOR; SKELETAL-MUSCLE	We examined the signaling pathways regulating glycogen synthase (GS) in primary cultures of rat hepatocytes. The activation of GS by insulin and glucose was completely reversed by the phosphatidylinositol 3-kinase inhibitor wortmannin. Wortmannin also inhibited insulin-induced phosphorylation and activation of protein kinase B/Akt (PKB/Akt) as well as insulin-induced inactivation of GS kinase-3 (GSK-3), consistent with a role for the phosphatidylinositol 3-kinase/PKB-Akt/GSK-3 axis in insulin-induced GS activation. Although wortmannin completely inhibited the significantly greater level of GS activation produced by the insulin-mimetic bisperoxovanadium 1,10-phenanthroline (bpV-(phen)), there was only minimal accompanying inhibition of bpV(phen)-induced phosphorylation and activation of PKB/Akt, and inactivation of GSK-3. Thus, PKB/Akt activation and GSK-3 inactivation may be necessary but are not sufficient to induce GS activation in rat hepatocytes, Rapamycin partially inhibited the GS activation induced by bpV(phen) but not that effected by insulin. Both insulin- and bpV(phen)-induced activation of the atypical protein kinase C (zeta/lambda) (PKC (zeta/lambda)) was reversed by wortmannin, Inhibition of PKC (zeta/lambda) with a pseudosubstrate peptide had no effect on GS activation by insulin, but substantially reversed GS activation by bpV(phen). The combination of this inhibitor with rapamycin produced an additive inhibitory effect on bpV(phen)-mediated GS activation. Taken together, our results indicate that the signaling components mammalian target of rapamycin and PKC (zeta/lambda) as well as other yet to be defined effector(s) contribute to the modulation of GS in rat hepatocytes.	McGill Univ, Polypeptide Hormone Lab, Fac Med, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	McGill University; McGill University	Posner, BI (corresponding author), McGill Univ, Polypeptide Hormone Lab, Fac Med, Strathcona Anat Bldg,3640 Univ St, Montreal, PQ H3A 2B2, Canada.		Posner, Barry/B-6733-2008; Bergeron, John/AAW-1893-2021					Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Band CJ, 1997, MOL ENDOCRINOL, V11, P1899, DOI 10.1210/me.11.13.1899; Band CJ, 1997, J BIOL CHEM, V272, P138; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Bevan AP, 1995, MOL CELL BIOCHEM, V153, P49, DOI 10.1007/BF01075918; BEVAN PA, 1995, AM J PHYSIOL, V268, P60; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cadefau J, 1997, BIOCHEM J, V322, P745, DOI 10.1042/bj3220745; Carlsen J, 1997, CELL SIGNAL, V9, P447, DOI 10.1016/S0898-6568(97)00035-1; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Coffer PJ, 1998, BIOCHEM J, V335, P1; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CURNOW RT, 1975, AM J PHYSIOL, V228, P80, DOI 10.1152/ajplegacy.1975.228.1.80; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; HADJUCH E, 1998, DIABETES, V47, P1006; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MILLER TB, 1986, J BIOL CHEM, V261, P785; Mithieux G, 1998, J BIOL CHEM, V273, P17, DOI 10.1074/jbc.273.1.17; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Peak M, 1998, DIABETOLOGIA, V41, P16, DOI 10.1007/s001250050861; PEAK M, 1994, EUR J BIOCHEM, V221, P529, DOI 10.1111/j.1432-1033.1994.tb18765.x; POSNER BI, 1994, J BIOL CHEM, V269, P4596; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PUGAZHENTHI S, 1995, MOL CELL BIOCHEM, V149, P95, DOI 10.1007/BF01076568; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SAPRU MK, 1987, INDIAN J BIOCHEM BIO, V24, P340; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; STALMANS W, 1975, EUR J BIOCHEM, V54, P341, DOI 10.1111/j.1432-1033.1975.tb04144.x; STALMANS W, 1987, Diabetes Metabolism Reviews, V3, P127; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Standaert ML, 1999, J BIOL CHEM, V274, P14074, DOI 10.1074/jbc.274.20.14074; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Sung CK, 1998, J RECEPT SIGNAL TR R, V18, P243, DOI 10.3109/10799899809047746; THOMAS AP, 1985, J BIOL CHEM, V260, P5963; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TOTH B, 1988, J BIOL CHEM, V263, P14061; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; VANDEWERVE G, 1977, BIOCHEM J, V162, P143, DOI 10.1042/bj1620143; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Yale JF, 1995, MOL CELL BIOCHEM, V153, P181, DOI 10.1007/BF01075936; YALE JF, 1995, DIABETES, V44, P1274, DOI 10.2337/diabetes.44.11.1274; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729	71	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28279	28285		10.1074/jbc.274.40.28279	http://dx.doi.org/10.1074/jbc.274.40.28279			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497184	hybrid			2022-12-25	WOS:000082912700033
J	Wu, HJ; Lima, WF; Crooke, ST				Wu, HJ; Lima, WF; Crooke, ST			Properties of cloned and expressed human RNase H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ANTISENSE OLIGONUCLEOTIDE; RIBONUCLEASE-H; DNA-REPLICATION; GENE-EXPRESSION; PURIFICATION; BINDING; IDENTIFICATION; CELLS; SPECIFICITY	We have characterized cloned His-tag human RNase H1. The activity of the enzyme exhibited a bell-shaped response to divalent cations and pH. The optimum conditions for catalysis consisted of 1 mM Mg2+ and pH 7-8. In the presence of Mg2+, Mn2+ was inhibitory. Human RNase H1 shares many enzymatic properties with Escherichia coli RNase H1. The human enzyme cleaves RNA in a DNA-RNA duplex resulting in products with 5'-phosphate and 3'-hydroxy termini, can cleave overhanging single strand RNA adjacent to a DNA-RNA duplex, and is unable to cleave substrates in which either the RNA or DNA strand has 2' modifications at the cleavage site. Human RNase H1 binds selectively to "A-form"-type duplexes with approximately 10-20-fold greater affinity than that observed for E. coli RNase H1. The human enzyme displays a greater initial rate of cleavage of a heteroduplex-containing RNA-phosphorothioate DNA than an RNA-DNA duplex. Unlike the E. coli enzyme, human RNase H1 displays a strong positional preference for cleavage, i.e. it cleaves between 8 and 12 nucleotides from the 5'-RNA-3'-DNA terminus of the duplex. Within the preferred cleavage site, the enzyme displays modest sequence preference with GU being a preferred dinucleotide. The enzyme is inhibited by single-strand phosphorothioate oligonucleotides and displays no evidence of processivity. The minimum RNA-DNA duplex length that supports cleavage is 6 base pairs, and the minimum RNA-DNA "gap size" that supports cleavage is 5 base pairs.	ISIS Pharmaceut Inc, Carlsbad, CA 92082 USA	Isis Pharmaceuticals Inc	Crooke, ST (corresponding author), ISIS Pharmaceut Inc, 2292 Faraday Ave, Carlsbad, CA 92082 USA.	scrooke@isisph.com						Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; Blyn LB, 1996, P NATL ACAD SCI USA, V93, P11115, DOI 10.1073/pnas.93.20.11115; BUSEN W, 1980, J BIOL CHEM, V255, P9434; Cerritelli SM, 1998, GENOMICS, V53, P300, DOI 10.1006/geno.1998.5497; Cerritelli SM, 1998, NUCLEIC ACIDS RES, V26, P1834, DOI 10.1093/nar/26.7.1834; Copeland RA, 1996, ENZYMES PRACTICAL IN; CROOKE ST, 1995, BIOCHEM J, V312, P599, DOI 10.1042/bj3120599; Crooke ST, 1998, ANTISENSE NUCLEIC A, V8, P115, DOI 10.1089/oli.1.1998.8.115; CROUCH RJ, 1982, COLD SPRING HARBOR M, V14, P211; EDER PS, 1991, J BIOL CHEM, V266, P6472; Flachmann R, 1996, P NATL ACAD SCI USA, V93, P14966, DOI 10.1073/pnas.93.25.14966; FRANK P, 1994, NUCLEIC ACIDS RES, V22, P5247, DOI 10.1093/nar/22.24.5247; Frank P, 1998, P NATL ACAD SCI USA, V95, P12872, DOI 10.1073/pnas.95.22.12872; GUINOSSO CJ, 1991, NUCLEOS NUCLEOT, V10, P259, DOI 10.1080/07328319108046455; Hanecak R, 1996, J VIROL, V70, P5203, DOI 10.1128/JVI.70.8.5203-5212.1996; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; Hughes SH, 1998, RESEARCH IN, P195; INOUE H, 1987, FEBS LETT, V215, P327, DOI 10.1016/0014-5793(87)80171-0; ITAYA M, 1990, P NATL ACAD SCI USA, V87, P8587, DOI 10.1073/pnas.87.21.8587; ITOH H, 1992, BIOCHEM BIOPH RES CO, V188, P1205, DOI 10.1016/0006-291X(92)91359-X; Kanaya S, 1998, RESEARCH IN, P1; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KANE CM, 1988, BIOCHEMISTRY-US, V27, P3187, DOI 10.1021/bi00409a010; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; Keck JL, 1998, J BIOL CHEM, V273, P34128, DOI 10.1074/jbc.273.51.34128; Kogoma T, 1998, RESEARCH IN, P39; KOGOMA T, 1985, MOL GEN GENET, V200, P103, DOI 10.1007/BF00383320; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Lima WF, 1997, J BIOL CHEM, V272, P18191, DOI 10.1074/jbc.272.29.18191; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; Lima WF, 1997, J BIOL CHEM, V272, P27513, DOI 10.1074/jbc.272.44.27513; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; Lindner Peter, 1992, Methods (Orlando), V4, P41, DOI 10.1016/1046-2023(92)90055-D; MASUTANI C, 1990, J BIOL CHEM, V265, P10210; Monia BP, 1996, J BIOL CHEM, V271, P14533, DOI 10.1074/jbc.271.24.14533; Moore DD, 1995, GLOB MOB SURV; Morvan F, 1996, J AM CHEM SOC, V118, P255, DOI 10.1021/ja9533959; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; Ohtani N, 1999, BIOCHEMISTRY-US, V38, P605, DOI 10.1021/bi982207z; PISZKIEWICZ D, 1977, KINETICS CHEM ENZYME, P80; RUSEN W, 1977, EUR J BIOCHEM, V74, P203; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; Sonnenburg WK, 1995, J BIOL CHEM, V270, P30989, DOI 10.1074/jbc.270.52.30989; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; TOMIZAWA J, 1990, J MOL BIOL, V212, P683, DOI 10.1016/0022-2836(90)90230-J; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; Wu HJ, 1998, ANTISENSE NUCLEIC A, V8, P53, DOI 10.1089/oli.1.1998.8.53; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3	51	134	151	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28270	28278		10.1074/jbc.274.40.28270	http://dx.doi.org/10.1074/jbc.274.40.28270			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497183	hybrid			2022-12-25	WOS:000082912700032
J	Patturajan, M; Conrad, NK; Bregman, DB; Corden, JL				Patturajan, M; Conrad, NK; Bregman, DB; Corden, JL			Yeast carboxyl-terminal domain kinase I positively and negatively regulates RNA polymerase II carboxyl-terminal domain phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; TRANSCRIPTION FACTOR TFIIH; CYCLIN-DEPENDENT KINASES; SACCHAROMYCES-CEREVISIAE; P-TEFB; REPEAT DOMAIN; LARGEST SUBUNIT; STATIONARY-PHASE; PROTEIN-KINASE; CTDK-I	Monoclonal antibodies that recognize specific carboxyl-terminal domain (CTD) phosphoepitopes were used to examine CTD phosphorylation in yeast cells lacking carboxyl-terminal domain kinase I (CTDK-I). We show that deletion of the kinase subunit CTK1 results in an increase in phosphorylation of serine in position 5 (Ser(5)) of the CTD repeat (Tyr(1)-Ser(2)-Pro(3)-Thr(4)-Ser(5)-Pro(6)-Ser(7)) during logarithmic growth. This result indicates that CTDK-I negatively regulates CTD Ser5 phosphorylation. We also show that CTK1 deletion (cth1 Delta) eliminates the transient increase in CTD serine 2 (Ser(2)) phosphorylation observed during the diauxic shift. This result suggests that CTDK-I may play a direct role in phosphorylating CTD Ser(2) in response to nutrient depletion. Northern blot analysis was used to show that genes normally induced during the diauxic shift are not properly induced in a ctk1 Delta strain. Glycogen synthase (GSY2) and cytosolic catalase (CTT1) mRNA levels increase about 10-fold in wild-type cells, but this increase is not observed in ctk1 Delta cells suggesting that increased message levels may require Ser(2) phosphorylation. Heat shock also induces Ser(2) phosphorylation, but we show here that this change in CTD modification and an accompanying induction of heat shock gene expression is independent of CTDK-I. The observation that SSA3/SSA4 expression is increased in ctk1 Delta cells grown at normal temperature suggests a possible role for CTDK-I in transcription repression. We discuss several possible positive and negative roles for CTDK-I in regulating CTD phosphorylation and gene expression.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine	Corden, JL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.							Akoulitchev S, 1998, GENE DEV, V12, P3541, DOI 10.1101/gad.12.22.3541; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Baxter BK, 1998, J BACTERIOL, V180, P6484, DOI 10.1128/JB.180.24.6484-6492.1998; BISSINGER PH, 1989, MOL CELL BIOL, V9, P1309, DOI 10.1128/MCB.9.3.1309; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Bush GL, 1996, J CELL BIOL, V135, P1229, DOI 10.1083/jcb.135.5.1229; CADENA DL, 1987, J BIOL CHEM, V262, P12468; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; CORDEN JL, 1992, TRANSCRIPTIONAL REGU, V1, P81; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Lee JM, 1997, J BIOL CHEM, V272, P10990; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Meisels E, 1995, J BIOL CHEM, V270, P31255, DOI 10.1074/jbc.270.52.31255; Moore DD, 1995, GLOB MOB SURV; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Rickert P, 1999, ONCOGENE, V18, P1093, DOI 10.1038/sj.onc.1202399; Rickert P, 1996, ONCOGENE, V12, P2631; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WEST ML, 1995, GENETICS, V140, P1223; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; ZHANG J, 1991, J BIOL CHEM, V266, P2290; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	64	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27823	27828		10.1074/jbc.274.39.27823	http://dx.doi.org/10.1074/jbc.274.39.27823			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488128	hybrid			2022-12-25	WOS:000082739100067
J	Pugazhenthi, S; Millers, E; Sable, C; Young, P; Heidenreich, KA; Boxer, LM; Reusch, JEB				Pugazhenthi, S; Millers, E; Sable, C; Young, P; Heidenreich, KA; Boxer, LM; Reusch, JEB			Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADENOVIRUS TYPE-5; HUMAN-MELANOMA CELLS; P38 MAP KINASE; PHOSPHORYLATED CREB; APOPTOSIS; EXPRESSION; GENE; ACTIVATION; SURVIVAL; REGION	Insulin-like growth factor-I (IGF-I) is known to prevent apoptosis induced by diverse stimuli. The present study examined the effect of IGF-I on the promoter activity of bcl-2, a gene with antiapoptotic function, A luciferase reporter driven by the promoter region of bcl-2 from -1640 to -1287 base pairs upstream of the translation start site containing a cAMP-response element was used in transient transfection assays, Treatment of PC12 cells with IGF-I enhanced the bcl-2 promoter activity by 2.3-fold, which was inhibited significantly (p < 0.01) by SB203580, an inhibitor of p38 mitogen-activated protein kinase (MAPK), Cotransfection of the bcl-2 promoter with MAPK kinase 6 and the beta isozyme of p38 MAPK resulted in 2-3-fold increase in the reporter activity. The dominant negative form of MAP-KAP-K3, a downstream kinase activated by p38 MAPK, and the dominant negative form of cAMP-response element-binding protein, inhibited the reporter gene activation by IGF-I and p38 beta MAPK significantly (p < 0.01). IGF-I increased the activity of p38 beta MAPK introduced into the cells by adenoviral infection. Thus, we have characterized a novel signaling pathway (MAPK kinase 6/p38 beta MAPK/MAPKAP-K3) that defines a transcriptional mechanism for the induction of the antiapoptotic protein Bcl-2 by IGF-I through the nuclear transcription factor cAMP-response element-binding protein in PC12 cells.	Vet Affairs Med Ctr, Sect Endocrinol 111H, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Endocrinol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; SmithKline Beecham Pharmaceut, Mol Immunol, King Of Prussia, PA 19406 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; GlaxoSmithKline; Stanford University	Reusch, JEB (corresponding author), Vet Affairs Med Ctr, Sect Endocrinol 111H, 1055 Clermont St, Denver, CO 80220 USA.			Reusch, Jane/0000-0001-8620-1003	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002351] Funding Source: NIH RePORTER; NIDDK NIH HHS [KO8 DK02351] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; JONES N, 1978, CELL, V13, P181, DOI 10.1016/0092-8674(78)90148-4; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Minshall C, 1997, J IMMUNOL, V159, P1225; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; NOVACK DV, 1994, AM J PATHOL, V145, P61; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang YM, 1996, ONCOGENE, V12, P2223; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232	45	182	189	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27529	27535		10.1074/jbc.274.39.27529	http://dx.doi.org/10.1074/jbc.274.39.27529			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488088	hybrid			2022-12-25	WOS:000082739100027
J	Saher, G; Hildt, E				Saher, G; Hildt, E			Activation of c-Raf-1 kinase signal transduction pathway in alpha(7) integrin-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; HEPATITIS-B VIRUS; SPLICE VARIANTS; PROTEINS; BETA-1D; MODULATION; DOMAINS; MUSCLE; CELLS; GENE	Integrin alpha(7)-deficient mice develop a novel form of muscular dystrophy, Here we report that deficiency of alpha(7) integrin causes an activation of the c-Raf-1/mitogen-activated protein (MAP) 2 kinase signal transduction pathway in muscle cells. The observed activation of c-Raf-1/MAP2 kinases is a specific effect, because the alpha(7) integrin deficiency does not cause unspecific stress as determined by measurement of the Hsp72/73 level and activity of the JNK2 kinase, Because an increased level of activated FAK was found in muscle of alpha(7)-integrin-deficient mice, the activation of c-Raf-1 kinase is triggered most likely by an integrin-dependent pathway. In accordance with this, in the integrin cu, deficient mice, part of the integrin beta(1D) variant in muscle is replaced by the beta(1A) variant, which permits the FAK activation. A recent report describes that integrin activity can be down-modulated by the c-Raf-1/MAP2 kinase pathway. Specific activation of the c-Raf-1/MAP2 kinases by cell-permeable peptides in skeletal muscle of rabbits causes degeneration of muscle fibers, Therefore, we conclude that in alpha(7) integrin deficient mice, the continuous activation of c-Raf-1 kinase causes a permanent reduction of integrin activity diminishing integrin-dependent cell-matrix interactions and thereby contributing to the development of the dystrophic phenotype.	Tech Univ Munich, Klinikum Rechts Isar, Inst Expt Onkol & Therapieforsch, D-81675 Munich, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Technical University of Munich; Max Planck Society	Hildt, E (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Inst Expt Onkol & Therapieforsch, Ismaninger Str 22, D-81675 Munich, Germany.		Hildt, Eberhard/A-1040-2015					BAO ZZ, 1993, J CELL SCI, V106, P579; Baudoin C, 1996, CELL ADHES COMMUN, V4, P1, DOI 10.3109/15419069609010759; Baudoin C, 1998, GENE DEV, V12, P1202, DOI 10.1101/gad.12.8.1202; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; HILDT E, 1995, ONCOGENE, V11, P2055; Hildt E, 1998, RECENT RES CANCER, V154, P315; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; STEVENSON MA, 1994, CANCER RES, V54, P12; Tomatis D, 1999, EXP CELL RES, V246, P421, DOI 10.1006/excr.1998.4315; Yamada KM, 1997, MATRIX BIOL, V16, P137, DOI 10.1016/S0945-053X(97)90001-9; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	23	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27651	27657		10.1074/jbc.274.39.27651	http://dx.doi.org/10.1074/jbc.274.39.27651			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488105	hybrid			2022-12-25	WOS:000082739100044
J	Geerlof, A; Lewendon, A; Shaw, WV				Geerlof, A; Lewendon, A; Shaw, WV			Purification and characterization of phosphopantetheine adenylyltransferase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; TRANSFER-RNA-SYNTHETASE; COENZYME-A BIOSYNTHESIS; PANTETHEINE PHOSPHATE ADENYLYLTRANSFERASE; PANTOTHENATE KINASE; MYCOBACTERIUM-TUBERCULOSIS; CYTIDYLYLTRANSFERASE; IDENTIFICATION; PROTEINS; BINDING	Phosphopantetheine adenylyltransferase (PPAT) catalyzes the penultimate step in coenzyme A (CoA) biosynthesis: the reversible adenylation of 4'-phosphopantetheine yielding 3'-dephospho-CoA and pyrophosphate. Wild-type PPAT from Escherichia coli was purified to homogeneity. N-terminal sequence analysis revealed that the enzyme is encoded by a gene designated kdtB, purported to encode a protein involved in lipopolysaccharide core biosynthesis. The gene,here renamed coaD, is found in a wide range of microorganisms, indicating that it plays a key role in the synthesis of 3'-dephospho-CoA. Overexpression of coaD yielded highly purified recombinant PPAT, which is a homohexamer of 108 kDa, Not less than 50% of the purified enzyme was found to be associated with CoA, and a method was developed for its removal. A steady state kinetic analysis of the reverse reaction revealed that the mechanism of PPAT involves a ternary complex of enzyme and substrates. Since purified PPAT lacks dephospho-CoA kinase activity, the two final steps of CoA biosynthesis in E. coli must be catalyzed by separate enzymes.	Univ Leicester, Dept Microbiol & Immunol, Leicester LE1 9HN, Leics, England	University of Leicester	Geerlof, A (corresponding author), Univ Leicester, Dept Microbiol & Immunol, Univ Rd, Leicester LE1 9HN, Leics, England.	ag35@le.ac.uk						Abiko Y., 1975, METABOLIC PATHWAYS, V7, P1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barnard E A, 1975, Methods Enzymol, V42, P6; BARNES SJ, 1986, FEBS LETT, V201, P267, DOI 10.1016/0014-5793(86)80621-4; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BORK P, 1995, PROTEINS, V22, P259, DOI 10.1002/prot.340220306; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; Bucovaz ET, 1997, BIOCHIMIE, V79, P787, DOI 10.1016/S0300-9084(97)86938-6; CHAN KW, 1994, BBA-PROTEIN STRUCT M, V1205, P223, DOI 10.1016/0167-4838(94)90237-2; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DOLGANOV N, 1993, J BACTERIOL, V175, P7644, DOI 10.1128/JB.175.23.7644-7651.1993; EIGLMEIER K, 1993, MOL MICROBIOL, V7, P197, DOI 10.1111/j.1365-2958.1993.tb01111.x; FALK KL, 1993, ARCH BIOCHEM BIOPHYS, V301, P424, DOI 10.1006/abbi.1993.1166; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FISHER MN, 1985, FEBS LETT, V190, P293, DOI 10.1016/0014-5793(85)81303-X; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; HALVORSEN O, 1982, EUR J BIOCHEM, V124, P211, DOI 10.1111/j.1432-1033.1982.tb05927.x; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; JACKOWSKI S, 1984, J BACTERIOL, V158, P115, DOI 10.1128/JB.158.1.115-120.1984; Jaworek D, 1974, METHODS ENZYMATIC AN, P2127, DOI 10.1016/B978-0-12-091304-6.50066-5; Kaneko T, 1996, DNA Res, V3, P109; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPRECHT W, 1974, METHOD ENZYMAT AN, V4, P2101; LAUE TM, 1990, METHOD ENZYMOL, V182, P566; LOWE CR, 1984, METHOD ENZYMOL, V104, P97; MARTIN DP, 1993, BIOCHEM BIOPH RES CO, V192, P1155, DOI 10.1006/bbrc.1993.1537; Martsen EO, 1997, BIOTECHNIQUES, V22, P420, DOI 10.2144/97223bm09; Moulis JM, 1996, BBA-GENE STRUCT EXPR, V1308, P12, DOI 10.1016/0167-4781(96)00082-6; OBRIEN WE, 1976, ANAL BIOCHEM, V76, P423, DOI 10.1016/0003-2697(76)90337-7; Park YS, 1997, J BIOL CHEM, V272, P15161, DOI 10.1074/jbc.272.24.15161; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; ROBISHAW JD, 1985, AM J PHYSIOL, V248, pE1, DOI 10.1152/ajpendo.1985.248.1.E1; RONCERO C, 1992, J BACTERIOL, V174, P3250, DOI 10.1128/jb.174.10.3250-3260.1992; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmitt E, 1995, NUCLEIC ACIDS RES, V23, P4793, DOI 10.1093/nar/23.23.4793; SIEZEN RJ, 1980, EUR J BIOCHEM, V107, P243, DOI 10.1111/j.1432-1033.1980.tb04644.x; STEWART CJ, 1966, BIOCHEMISTRY-US, V5, P3883, DOI 10.1021/bi00876a021; SUZUKI T, 1967, J BIOCHEM-TOKYO, V62, P642, DOI 10.1093/oxfordjournals.jbchem.a128719; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vaara M, 1996, SCIENCE, V274, P939, DOI 10.1126/science.274.5289.939; Vagelos P. R., 1973, ENZYMES, V8, P155; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; VANIERSEL J, 1985, ANAL BIOCHEM, V151, P196, DOI 10.1016/0003-2697(85)90072-7; Veitch DP, 1998, EUR J BIOCHEM, V255, P227, DOI 10.1046/j.1432-1327.1998.2550227.x; WORRALL DM, 1985, FEBS LETT, V187, P277, DOI 10.1016/0014-5793(85)81258-8; WORRALL DM, 1983, BIOCHEM J, V215, P153, DOI 10.1042/bj2150153; WORRALL DM, 1985, THESIS U CAMBRIDGE C; ZHU PP, 1994, PROTEIN SCI, V3, P2115, DOI 10.1002/pro.5560031125	59	102	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27105	27111		10.1074/jbc.274.38.27105	http://dx.doi.org/10.1074/jbc.274.38.27105			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480925	hybrid			2022-12-25	WOS:000082570700064
J	Mruk, DD; Cheng, CY				Mruk, DD; Cheng, CY			Sertolin is a novel gene marker of cell-cell interactions in the rat testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACHADO-JOSEPH-DISEASE; ANDROGEN-BINDING-PROTEIN; ACUTE-PHASE PROTEINS; GERM-CELLS; SPINOCEREBELLAR ATAXIA; INFLAMMATORY DISORDERS; PLASMINOGEN-ACTIVATOR; SPERMATID BINDING; 14-KDA PROTEIN; CULTURE-MEDIUM	A novel testicular protein designated sertolin was cloned, The full-length sertolin cDNA consists of 853 base pairs with an open reading frame of 381 base pairs coding for a 127-amino acid polypeptide that shares limited identities with antaxin/josephin and thrombospondin proteins. Sertolin (calculated molecular mass, 13,759 daltons) has two mRNA transcripts of 2.3 and 1 kilobase, A 22-amino acid peptide based on the deduced amino acid sequence of sertolin (NH2-KKEHFNLFKAASVSHLVQVVPQ) was synthesized and used for polyclonal antibody production, Immunoblot analysis detected a 17-kDa immunoreactive band in the Sertoli cell cytosol. Using Sertoli-germ cell cocultures, sertolin expression was found to be reduced by as much as 5-fold at the time when germ cells attach onto Sertoli cells but preceding the establishment of specialized inter-Sertoli-germ cell junctions, Neither FSH nor 17 beta-hydroxy-5 alpha-androstan-3-one was able to affect sertolin expression, whereas estradiol-17 beta and progesterone induced a significant increase in Sertoli cell sertolin expression in vitro, In addition, interleukin-1 alpha, a germ cell-derived cytokine, was also able to elicit a transient but significant increase in Sertoli cell sertolin expression. Sertolin expression was also shown to increase with testicular development and is likely to be associated with the onset of spermatogenesis. In addition, sertolin expression increased in the testis when generalized inflammation was induced in adult rats by injection of fermented yeast. These results show that sertolin will be useful in characterizing cell-cell interactions in the testis.	Populat Council, Ctr Biomed Res, New York, NY 10021 USA; Univ Hong Kong, Dept Zool, Hong Kong, Peoples R China	Population Council; University of Hong Kong	Cheng, CY (corresponding author), Populat Council, Ctr Biomed Res, 1230 York Ave, New York, NY 10021 USA.			Cheng, C Yan/0000-0003-3117-3791	NICHD NIH HHS [U54-HD 13541] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD013541] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AILENBERG M, 1988, ENDOCRINOLOGY, V122, P2613, DOI 10.1210/endo-122-6-2613; ANDUS T, 1988, EUR J BIOCHEM, V173, P287, DOI 10.1111/j.1432-1033.1988.tb13997.x; Aravindan GR, 1996, J CELL PHYSIOL, V168, P123; Aravindan GR, 1997, ENDOCRINOLOGY, V138, P3259, DOI 10.1210/en.138.8.3259; BARDIN CW, 1988, PHYSL REPRODUCTION, V1, P933; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BEER J, 1995, NEURODEGENERATION, V4, P51, DOI 10.1006/neur.1995.0006; BOOCKFOR FR, 1991, ENDOCRINOLOGY, V129, P256, DOI 10.1210/endo-129-1-256; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braghiroli L, 1998, BIOL REPROD, V59, P111, DOI 10.1095/biolreprod59.1.111; BYERS S, 1998, SERTOLI CELL, P431; CAMERON DF, 1991, J CELL SCI, V100, P623; CHAN YL, 1990, FEBS LETT, V263, P85, DOI 10.1016/0014-5793(90)80711-Q; CHENG CY, 1988, BIOCHEM BIOPH RES CO, V155, P398; CHENG CY, 1989, J BIOL CHEM, V264, P21386; CHENG CY, 1990, BIOCHEMISTRY-US, V29, P1063, DOI 10.1021/bi00456a031; CHENG CY, 1985, J BIOL CHEM, V260, P5631; CHENG CY, 1986, ENDOCRINOLOGY, V118, P480, DOI 10.1210/endo-118-2-480; CHENG CY, 1987, J BIOL CHEM, V262, P12768; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; Chung SSW, 1998, ENDOCRINOLOGY, V139, P1853, DOI 10.1210/en.139.4.1853; Chung SSW, 1998, J ANDROL, V19, P686; CHUNG SSW, 1999, IN PRESS J CELL PHYS; CLERMONT Y, 1957, AM J ANAT, V100, P241, DOI 10.1002/aja.1001000205; COLLINS PM, 1975, J ENDOCRINOL, V65, pP21; Cudicini C, 1997, J CLIN ENDOCR METAB, V82, P1426, DOI 10.1210/jc.82.5.1426; DEKRETSER DM, 1988, PHYSL REPRODUCTION, V1, P837; Durr A, 1996, ANN NEUROL, V39, P490, DOI 10.1002/ana.410390411; ENDERS GC, 1988, J CELL SCI, V90, P105; FONG R, 1972, TISSUE ANTIGENS, V2, P57; FRITZ IB, 1993, SERTOLI CELL, P217; Galdieri M, 1981, J ANDROL, V5, P249; Grima J, 1998, J BIOL CHEM, V273, P21040, DOI 10.1074/jbc.273.33.21040; Grima J, 1997, J BIOL CHEM, V272, P6499, DOI 10.1074/jbc.272.10.6499; GRIMA J, 1992, MOL CELL ENDOCRINOL, V89, P127, DOI 10.1016/0303-7207(92)90219-V; GUSELLA JF, 1995, SEMIN CELL BIOL, V6, P21, DOI 10.1016/1043-4682(95)90011-X; HABERHAUSEN G, 1995, J NEUROL SCI, V132, P71, DOI 10.1016/0022-510X(95)90927-I; HEINDEL JJ, 1989, TOXICOL PATHOL, V17, P411, DOI 10.1177/019262338901700219; JANECKI A, 1987, ENDOCRINOLOGY, V120, P291, DOI 10.1210/endo-120-1-291; KARZAI AW, 1992, BIOL REPROD, V47, P823, DOI 10.1095/biolreprod47.5.823; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Koeppen AH, 1998, J NEUROPATH EXP NEUR, V57, P531, DOI 10.1097/00005072-199806000-00001; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LaSpada AR, 1997, BRAIN PATHOL, V7, P943; LAWLER J, 1986, BLOOD, V67, P1197; LI AHY, 1994, BIOL REPROD, V50, P1287, DOI 10.1095/biolreprod50.6.1287; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LILES WC, 1995, J INFECT DIS, V172, P1573, DOI 10.1093/infdis/172.6.1573; MACIEL P, 1995, AM J HUM GENET, V57, P54; MACKIEWICZ A, 1989, CLIN EXP IMMUNOL, V75, P70; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MCGINLEY DM, 1979, TISSUE CELL, V11, P741, DOI 10.1016/0040-8166(79)90028-4; Mruk D, 1997, J ANDROL, V18, P612; Mruk D, 1998, BIOL REPROD, V59, P298, DOI 10.1095/biolreprod59.2.298; MULLANEY BP, 1991, BAILLIERE CLIN ENDOC, V5, P771, DOI 10.1016/S0950-351X(10)80014-X; NAKAJO S, 1990, J NEUROCHEM, V55, P2031, DOI 10.1111/j.1471-4159.1990.tb05792.x; NIEDERBERGER CS, 1993, WORLD J UROL, V11, P120; Nishiyama K, 1996, ANN NEUROL, V40, P776, DOI 10.1002/ana.410400514; PAS O, 1990, CLIN EXP IMMUNOL, V82, P579; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; PHILLIPS HJ, 1957, EXP CELL RES, V13, P341, DOI 10.1016/0014-4827(57)90013-7; Rivier C, 1993, Rev Neurosci, V4, P223; Rooprai HK, 1997, ANTICANCER RES, V17, P4151; RUSSELL L, 1977, TISSUE CELL, V9, P475, DOI 10.1016/0040-8166(77)90007-6; SASO L, 1993, ANAL BIOCHEM, V212, P315, DOI 10.1006/abio.1993.1336; Schlatt S, 1997, EUR J ENDOCRINOL, V137, P107, DOI 10.1530/eje.0.1370107; Setchell BP, 1989, HDB PHYSIOLOGY, V5, P143; Shibayama-Imazu T, 1998, MOL REPROD DEV, V50, P163, DOI 10.1002/(SICI)1098-2795(199806)50:2<163::AID-MRD6>3.0.CO;2-I; SILVERSTEIN RL, 1986, J BIOL CHEM, V261, P9959; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SILVESTRINI B, 1989, CLIN CHEM, V35, P2207; SILVESTRINI B, 1990, CLIN CHEM, V36, P277; STAHLER MS, 1991, ENDOCRINOLOGY, V128, P2805, DOI 10.1210/endo-128-6-2805; SUAREZQUIAN CA, 1983, J ANDROL, V4, P203; SUDARSKY L, 1995, CLIN NEUROSCI, V3, P17; TCHOLAKIAN RK, 1978, ENDOCRINOLOGY, V103, P1335, DOI 10.1210/endo-103-4-1335; TILBE KS, 1981, ENDOCRINOLOGY, V108, P597, DOI 10.1210/endo-108-2-597; TOBE T, 1992, J NEUROCHEM, V59, P1624, DOI 10.1111/j.1471-4159.1992.tb10991.x; TWIST EC, 1995, J MED GENET, V32, P25, DOI 10.1136/jmg.32.1.25; VAITUKAITIS J, 1971, J CLIN ENDOCR METAB, V33, P988, DOI 10.1210/jcem-33-6-988; Wang GH, 1997, BIOCHEM BIOPH RES CO, V233, P476, DOI 10.1006/bbrc.1997.6484; Watanabe M, 1996, J NEUROL SCI, V136, P101, DOI 10.1016/0022-510X(95)00307-N; WELSH MJ, 1978, ENDOCRINOLOGY, V103, P838, DOI 10.1210/endo-103-3-838; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	87	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27056	27068		10.1074/jbc.274.38.27056	http://dx.doi.org/10.1074/jbc.274.38.27056			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480919	hybrid			2022-12-25	WOS:000082570700058
J	Toyama, T; Iwase, H; Watson, P; Muzik, H; Saettler, E; Magliocco, A; DiFrancesco, L; Forsyth, P; Garkavtsev, I; Kobayashi, S; Riabowol, K				Toyama, T; Iwase, H; Watson, P; Muzik, H; Saettler, E; Magliocco, A; DiFrancesco, L; Forsyth, P; Garkavtsev, I; Kobayashi, S; Riabowol, K			Suppression of ING1 expression in sporadic breast cancer	ONCOGENE			English	Article						ING1; tumour suppressor gene; breast cancer; SSCP; mutation; expression	CANDIDATE TUMOR-SUPPRESSOR; PREFERENTIAL LOSS; DNA METHYLATION; MESSENGER-RNA; BRCA1; GROWTH; GENE; IDENTIFICATION; HYBRIDIZATION; INHIBITOR	Down regulation of the ING1 candidate tumour suppressor promotes growth in soft agar and focus formation in vitro and tumour formation in vivo. ING1 encodes a nuclear, cell cycle-regulated protein, overexpression of which efficiently blocks cell growth and is capable of inducing apoptosis in different experimental systems. Here we present the first report of ING1 mutation and expression analysis in a total of 452 cancer samples. One germline missense alteration and three germline silent alterations were detected in 377 primary breast cancers while marked (2-10-fold) decreases in ING1 mRNA expression were seen in 44% of primary breast cancers and in ten of ten breast cancer cell lines examined. Furthermore, the majority of breast cancers (58%) showing decreased ING1 expression had metastasized to regional lymph nodes whereas only 9% of cancers with elevated ING1 expression, compared to adjacent normal tissues, were metastatic. Thus, ING1 mutation is very rare in breast or ovarian cancers, however, repression of ING1 expression frequently accompanies tumour development of breast cancer.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, So Alberta Canc Res Ctr, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Univ Manitoba, Fac Med, Dept Pathol, Winnipeg, MB R3E 0W3, Canada; Univ Saskatchewan, Royal Hosp, Coll Med, Dept Pathol, Saskatoon, SK S7N 0W8, Canada; Foothills Prov Gen Hosp, Dept Pathol, Calgary, AB T2N 2T9, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary; Nagoya City University; University of Manitoba; University of Saskatchewan; University of Calgary	Riabowol, K (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Magliocco, Anthony M/E-5723-2010	Watson, Peter/0000-0002-1642-0638; Toyama, Tatsuya/0000-0003-4713-7795				Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dobrovic A, 1997, CANCER RES, V57, P3347; Garkavtsev I, 1997, HYBRIDOMA, V16, P537, DOI 10.1089/hyb.1997.16.537; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; HARVEY MB, 1995, DEVELOPMENT, V121, P1005; Helbing CC, 1997, CANCER RES, V57, P1255; HERMAN JG, 1995, CANCER RES, V55, P4525; Iwase H, 1996, CANCER LETT, V108, P179, DOI 10.1016/S0304-3835(96)04406-0; *JAP BREAST CANC S, 1992, GEN RUL CLIN PATH RE, P1; Leco KJ, 1997, FEBS LETT, V401, P213, DOI 10.1016/S0014-5793(96)01474-3; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Maestro R, 1996, CANCER RES, V56, P1146; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; MOTOMURA K, 1988, Genomics, V2, P180, DOI 10.1016/0888-7543(88)90101-2; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; VIDALPUIG A, 1994, BIOTECHNIQUES, V17, P490; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; YAMASHITA H, 1993, JPN J CANCER RES, V84, P871, DOI 10.1111/j.1349-7006.1993.tb02060.x; YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414	28	124	141	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5187	5193		10.1038/sj.onc.1202905	http://dx.doi.org/10.1038/sj.onc.1202905			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498868				2022-12-25	WOS:000082555700007
J	Rabus, R; Reizer, J; Paulsen, I; Saier, MH				Rabus, R; Reizer, J; Paulsen, I; Saier, MH			Enzyme I-Ntr from Escherichia coli - A novel enzyme of the phosphoenolpyruvate-dependent phosphotransferase system exhibiting strict specificity for its phosphoryl acceptor, NPr	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGMA-FACTOR SIGMA(54); SUGAR-TRANSPORT; SALMONELLA-TYPHIMURIUM; RPON GENE; PROTEINS; NITROGEN; BACTERIA; IIA(NTR); MUTANTS; OPERON	The phosphoenolpyruvate (PEP)-dependent phosphotransferase system (PTS) phosphorylates sugars and regulates cellular metabolic processes using a phosphoryl transfer chain including the general energy coupling proteins, Enzyme I (EI) and HPr as well as the sugar-specific Enzyme II complexes. Analysis of the Escherichia coli genome has revealed the presence of 5 paralogues of EI and 5 paralogues of HPr, most of unknown function. The ptsP gene encodes an EI paralogue designated Enzyme I-nitrogen (EINtr), and two genes located in the rpoN operon encode PTS protein paralogues, NPr and IIANtr both implicated in the regulation of sigma(54) activity. The ptsP gene was polymerase chain reaction amplified from the E. coli chromosome and cloned into an overexpression vector allowing the overproduction and purification of EINtr. EINtr was shown to phosphorylate NPr in vitro using either a [P-32]PEP-dependent protein phosphorylation assay or a quantitative sugar phosphorylation assay. EINtr phosphorylated NPr but not HPr, whereas Enzyme I exhibited a strong preference for HPr, These two pairs of proteins (EINtr/NPr and EI/HPr) thus exhibit little cross-reactivity. Phosphoryl transfer from PEP to NPr catalyzed by EINtr has a pH optimum of 8.0 is dependent on Mg2+ is stimulated by high ionic strength, and exhibits two K-m values for NPr (2 and 10 mu M) possibly because of negative cooperativity. The results suggest that E. coli possesses at least two distinct PTS phosphoryl transfer chains, EINtr --> NPr --> IIA(Ntr) and EI --> HPr --> IIA(sugar). Sequence comparisons allow prediction of residues likely to be important for specificity. This is the first report demonstrating specificity at the level of the energy coupling proteins of the PTS.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Saier, MH (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	msaier@ucsd.edu	Paulsen, Ian T/K-3832-2012	Paulsen, Ian T/0000-0001-9015-9418	NIAID NIH HHS [2RO1 AI14176] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014176] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; AUSTIN S, 1994, J BACTERIOL, V176, P3460, DOI 10.1128/JB.176.12.3460-3465.1994; Bordo D, 1998, J MOL BIOL, V279, P245, DOI 10.1006/jmbi.1998.1753; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Britton RA, 1998, MOL MICROBIOL, V27, P739, DOI 10.1046/j.1365-2958.1998.00719.x; CHAUVIN F, 1994, J BIOL CHEM, V269, P20263; CHIN AM, 1987, J BACTERIOL, V169, P894, DOI 10.1128/jb.169.2.894-896.1987; CORDARO JC, 1972, J BACTERIOL, V112, P17, DOI 10.1128/JB.112.1.17-29.1972; Du Y, 1996, RES MICROBIOL, V147, P129, DOI 10.1016/0923-2508(96)80212-9; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; HAN MK, 1990, J BIOL CHEM, V265, P1996; HOVING H, 1982, BIOCHEMISTRY-US, V21, P3128, DOI 10.1021/bi00256a015; JIN SG, 1994, J BACTERIOL, V176, P1316, DOI 10.1128/jb.176.5.1316-1322.1994; JONES DHA, 1994, MICROBIOL-SGM, V140, P1035, DOI 10.1099/13500872-140-5-1035; KUKURUZINSKA MA, 1982, J BIOL CHEM, V257, P4470; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; KUNDIG W, 1971, J BIOL CHEM, V246, P1407; Magasanik B., 1996, ESCHERICHIA COLI SAL, P1344; MATTOO RL, 1983, ANAL BIOCHEM, V128, P245, DOI 10.1016/0003-2697(83)90372-X; MATTOO RL, 1982, CAN J BIOCHEM, V61, P29; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Merrick M. J., 1995, Nitrogen fixation: fundamentals and applications. Proceedings of the 10th International Congress on Nitrogen Fixation, St. Petersburg, Russia, May 28-June 3 1995., P189; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MERRICK MJ, 1989, MOL MICROBIOL, V3, P1765, DOI 10.1111/j.1365-2958.1989.tb00162.x; Michiels J, 1998, J BACTERIOL, V180, P1729, DOI 10.1128/JB.180.7.1729-1740.1998; MISSET O, 1980, BIOCHEMISTRY-US, V19, P883, DOI 10.1021/bi00546a009; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; REIZER J, 1992, J BIOL CHEM, V267, P9158; Reizer J, 1997, CURR OPIN STRUC BIOL, V7, P407, DOI 10.1016/S0959-440X(97)80059-0; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1992, PROTEIN SCI, V1, P722, DOI 10.1002/pro.5560010604; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; Reizer J, 1996, GENE, V181, P103, DOI 10.1016/S0378-1119(96)00481-7; REPHAELI AW, 1980, J BACTERIOL, V141, P658, DOI 10.1128/JB.141.2.658-663.1980; SAIER MH, 1980, J BIOL CHEM, V255, P8579; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1994, MOL MICROBIOL, V13, P755; Saier MH, 1996, MICROBIOL-UK, V142, P217, DOI 10.1099/13500872-142-2-217; SAIER MH, 1989, MICROBIOL REV, V53, P108; Segel IH, 1975, ENZYME KINETICS BEHA; Segura D, 1998, J BACTERIOL, V180, P4790, DOI 10.1128/JB.180.18.4790-4798.1998; Van Montfort RLM, 1998, PROTEIN SCI, V7, P2210, DOI 10.1002/pro.5560071019; WAYGOOD EB, 1980, CAN J BIOCHEM CELL B, V58, P40, DOI 10.1139/o80-006; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WEIGEL N, 1982, J BIOL CHEM, V257, P4477	47	92	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26185	26191		10.1074/jbc.274.37.26185	http://dx.doi.org/10.1074/jbc.274.37.26185			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473571	hybrid			2022-12-25	WOS:000082469700037
J	da Costa, LT; He, TC; Yu, J; Sparks, AB; Morin, PJ; Polyak, K; Laken, S; Vogelstein, B; Kinzler, KW				da Costa, LT; He, TC; Yu, J; Sparks, AB; Morin, PJ; Polyak, K; Laken, S; Vogelstein, B; Kinzler, KW			CDX2 is mutated in a colorectal cancer with normal APC/beta-catenin signaling	ONCOGENE			English	Article						CDX2; APC; colorectal cancer; mutation; regulation	TUMOR-SUPPRESSOR PROTEIN; APC GENE-PRODUCT; BETA-CATENIN; COLON-CARCINOMA; TUMORIGENESIS; ASSOCIATION; EXPRESSION; ACTIVATION; POLYPOSIS; MUTATIONS	The majority of human colorectal cancers have elevated beta-catenin/TCF regulated transcription due to either inactivating mutations of the APC tumor suppressor gene or activating mutations of beta-catenin, Surprisingly, one commonly used colorectal cancer cell line was found to have intact APC and beta-catenin and no demonstrable beta-catenin/TCF regulated transcription. However, this line did possess a truncating mutation in one allele of CDX2, a gene whose inactivation has recently been shown to cause colon tumorigenesis in mice. Expression of CDX2 was found to be induced by restoring expression of wild type APC in a colorectal cancer cell line. These findings raise the intriguing possibility that CDX2 contributes to APC's tumor suppressive effects.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Program Human Genet & Mol Biol, Baltimore, MD 21231 USA; NIA, Biol Chem Lab, NIH, Baltimore, MD 21224 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Baltimore, MD 20815 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Johns Hopkins University	Kinzler, KW (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.		Yu, Jian/A-8301-2009	Yu, Jian/0000-0002-4021-1000	NCI NIH HHS [CA57345] Funding Source: Medline; NIGMS NIH HHS [GM07814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA057345, R01CA057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; EE HC, 1995, AM J PATHOL, V147, P586; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; He TC, 1997, BIOESSAYS, V19, P551, DOI 10.1002/bies.950190705; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RIGGINS GJ, 1995, CANCER RES, V55, P5184; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971	27	113	120	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					5010	5014		10.1038/sj.onc.1202872	http://dx.doi.org/10.1038/sj.onc.1202872			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490837				2022-12-25	WOS:000082321700015
J	Yageta, M; Tsunoda, H; Yamanaka, T; Nakajima, T; Tomooka, Y; Tsuchida, N; Oda, K				Yageta, M; Tsunoda, H; Yamanaka, T; Nakajima, T; Tomooka, Y; Tsuchida, N; Oda, K			The adenovirus E1A domains required for induction of DNA rereplication in G(2)/M arrested cells coincide with those required for apoptosis	ONCOGENE			English	Article						adenovirus E1A; Id; apoptosis; cyclin D1 promoter; DNA rereplication	CYCLIN D1; RETINOBLASTOMA PROTEIN; E1A-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; NUCLEAR ANTIGEN; ID PROTEINS; P53; EXPRESSION; GADD45; PCNA	Induction of apoptosis by adenovirus E1A in rodent cells is stimulated by wild type (wt) p53 but completely suppressed by mutated p53, The suppression is overcome by coexpression with Id proteins (Ids), The cells expressing E1A and Ids undergo apoptosis after accumulation in S phase, suggesting that S phase events are perturbed by E1A and Ids. The E1A domains required for induction of apoptosis, analysed by transfection with expression vectors for E1A, Ids and their mutants, followed by flow cytometry, reside in N-terminal (positions 17-38), CR1 and CR2 regions. Interaction of E1A with Ids requires the N-terminal and CR1 regions. The cyclin D1 promoter activity in S phase was reduced severely by E1A and this reduction is caused through CR1 and CR2 regions required for interaction with pRB. Analysis of DNA synthesis in G(2)/M arrested cells indicated that E1A is capable of inducing >4N cells and this E1A-mediated DNA rereplication is enhanced by coexpression with Id-1H, The E1A domains required for induction of DNA rereplication coincide with those required for apoptosis.	Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan; Tokyo Med & Dent Univ, Fac Dent, Dept Mol Cellular Oncol & Microbiol, Bunkyo Ku, Tokyo 113, Japan	Tokyo University of Science; Tokyo Medical & Dental University (TMDU)	Oda, K (corresponding author), Sci Univ Tokyo, Dept Biol Sci & Technol, 2641 Yamazaki, Noda, Chiba 278, Japan.		Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cox LS, 1997, TRENDS CELL BIOL, V7, P493, DOI 10.1016/S0962-8924(97)01170-7; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Di Leonardo A, 1997, CANCER RES, V57, P1013; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HALL PA, 1995, ONCOGENE, V10, P2427; ISHII T, 1993, EXP CELL RES, V208, P407, DOI 10.1006/excr.1993.1262; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Lahti JM, 1997, J BIOL CHEM, V272, P10859; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; NAKAJIMA T, 1995, ONCOGENE, V10, P651; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; Tsunoda H, 1999, BIOCHEM BIOPH RES CO, V255, P722, DOI 10.1006/bbrc.1999.0143; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Xu J, 1999, MOL CELL BIOL, V19, P12; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	38	12	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4767	4776		10.1038/sj.onc.1203063	http://dx.doi.org/10.1038/sj.onc.1203063			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490810				2022-12-25	WOS:000082184800001
J	Nakao, K; Nakata, K; Yamashita, M; Tamada, Y; Hamasaki, K; Ishikawa, H; Kato, Y; Eguchi, K; Ishii, N				Nakao, K; Nakata, K; Yamashita, M; Tamada, Y; Hamasaki, K; Ishikawa, H; Kato, Y; Eguchi, K; Ishii, N			p48 (ISGF-3 gamma) is involved in interferon-alpha-induced suppression of hepatitis B virus enhancer-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE REGULATORY ELEMENTS; CYTOTOXIC T-LYMPHOCYTES; IFN-INDUCIBLE GENES; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; GAMMA-INTERFERONS; VIRAL-HEPATITIS; PROTEIN-KINASE; SUBTYPE ADR; EXPRESSION	Interferon-alpha (IFN-alpha) suppresses hepatitis B virus (HBV) gene expression by reducing its enhancer-1 activity. IFN-alpha induces transcription factors, interferon-stimulated gene factor 3 (ISGF3), and interferon regulatory factor-1 (IRF-1), which activate interferon-inducible gene expression through binding to the interferon-stimulated regulatory element (ISRE) "AGTTTCNNTTTCNC" in the gene promoters. We found the ISRE-like sequence "AGGCTTTCACTTTCTC'' in the HBV enhancer-1 region and elucidated the role of this sequence. Gel mobility shift assay showed binding of in vitro translated IRF-1 and in vitro translated p48 (ISGF3-gamma), which is a component of ISGF3 to this sequence. However, nuclear extracts binding to this sequence from human hepatoma cells (HuH-7) treated with IFN-alpha contained only the protein consisted of p48, In transfection experiments, IFN-alpha suppressed the HBV enhancer-1 activity, and overexpression of p48 enhanced this inhibitory effect. Both mutation and deletion of the ISRE-like sequence in the HBV enhancer-1 region reduced the suppressive effect of IFN-alpha, Our results suggest that the ISRE-like sequence in the HBV enhancer-1 can interact with the protein containing p48 and mediate the IFN-alpha-induced suppression of the enhancer activity.	Nagasaki Univ, Hlth Res Ctr, Nagasaki 8528501, Japan; Nagasaki Univ, Dept Clin Pharmacol, Nagasaki 8528501, Japan; Nagasaki Univ, Sch Med, Dept Internal Med 1, Nagasaki 8528501, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Nakao, K (corresponding author), Nagasaki Univ, Hlth Res Ctr, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.	kazuhiko@net.nagasaki-u.ac.jp						Chisari FV, 1997, J CLIN INVEST, V99, P1472, DOI 10.1172/JCI119308; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GUIDOTTI LG, 1994, P NATL ACAD SCI USA, V91, P3764, DOI 10.1073/pnas.91.9.3764; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; HAMASAKI K, 1992, BIOCHEM BIOPH RES CO, V183, P904, DOI 10.1016/0006-291X(92)90569-7; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; Kiermer V, 1998, J VIROL, V72, P5526, DOI 10.1128/JVI.72.7.5526-5534.1998; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; Lehtonen A, 1997, J IMMUNOL, V159, P794; Leonard GT, 1997, J VIROL, V71, P5095, DOI 10.1128/JVI.71.7.5095-5101.1997; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; NAKAO K, 1989, NUCLEIC ACIDS RES, V17, P9833, DOI 10.1093/nar/17.23.9833; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Nonkwelo C, 1997, J VIROL, V71, P6887, DOI 10.1128/JVI.71.9.6887-6897.1997; OKAMOTO H, 1986, J GEN VIROL, V67, P2305, DOI 10.1099/0022-1317-67-11-2305; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; POPPER H, 1987, HEPATOLOGY, V7, P764, DOI 10.1002/hep.1840070425; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Schaefer BC, 1997, MOL CELL BIOL, V17, P873, DOI 10.1128/MCB.17.2.873; SHIOJIRI S, 1986, J BIOCHEM, V99, P1455, DOI 10.1093/oxfordjournals.jbchem.a135615; SU H, 1992, P NATL ACAD SCI USA, V89, P2708, DOI 10.1073/pnas.89.7.2708; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; TSUTSUMI T, 1994, GASTROENTEROLOGY, V107, P499, DOI 10.1016/0016-5085(94)90177-5; TURKASPA R, 1990, J VIROL, V64, P1821, DOI 10.1128/JVI.64.4.1821-1824.1990; VanLint C, 1997, J VIROL, V71, P6113, DOI 10.1128/JVI.71.8.6113-6127.1997; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Xiao WH, 1999, ANTIVIR RES, V40, P145, DOI 10.1016/S0166-3542(98)00056-4	42	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28075	28078		10.1074/jbc.274.40.28075	http://dx.doi.org/10.1074/jbc.274.40.28075			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497156	hybrid			2022-12-25	WOS:000082912700005
J	Rubin, DA; Juppner, H				Rubin, DA; Juppner, H			Zebrafish express the common parathyroid hormone/parathyroid hormone-related peptide receptor (PTH1R) and a novel receptor (PTH3R) that is preferentially activated by mammalian and fugufish parathyroid hormone-related peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; PTH/PTHRP RECEPTOR; SUPRAOPTIC NUCLEUS; PROTEIN; RAT; GENE; BINDING; CELLS; PTHRP; IDENTIFICATION	To further explore the evolution of receptors for parathyroid hormone (PTH) and PTH-related peptide (PTHrP), we searched for zebrafish (z) homologs of the PTH/PTHrP receptor (PTH1R). In mammalian genes encoding this receptor, exons M6/7 and M7 are highly conserved and separated by 81-84 intronic nucleotides. Genomic polymerase chain reaction using degenerate primers based on these exons led to two distinct DNA fragments comprising portions of genes encoding the zPTH1R and the novel zPTH3R. Sequence comparison of both full-length teleost receptors revealed 69% similarity (61% identity), but less homology with zPTH2R, When compared with hPTH1R, zPTH1R showed 76% and zPTH3R 67% amino acid sequence similarity; similarity with hPTH2R was only 59% for both teleost receptors. When expressed in COS-7 cells, zPTH1R bound [TyrS4]hPTH-(1-34)-amide (hPTH), [Tyr(36)]hPTHrP(1-36)-amide (hPTHrP), and [Ala(29),Glu(30),Ala(34),Glu(35), Tyr(36)]fugufish PTHrP-(1-36)-amide (fuguPTHrP) with a high apparent affinity (IC50: 1.2-3.5 nM), and was efficiently activated by all three peptides (EC50: 1.1-1.7 nM). In contrast, zPTH3R showed higher affinity for fuguPTHrP and hPTHrP (IC50: 2.1-11.1 nM) than for hPTH (IC50: 118.2-127.0 nM); cAMP accumulation was more efficiently stimulated by fugufish and human PTHrP (EC50: 0.47 +/- 0.27 and 0.45 +/- 0.16, respectively) than by hPTH (EC50: 9.95 +/- 1.5 nM). Agonist-stimulated total inositol phosphate accumulation was observed with zPTH1R, but not zPTH3R.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Serv Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Juppner, H (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794, F32DK009500] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09500, DK-11794, F32 DK09500] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergwitz C, 1998, ENDOCRINOLOGY, V139, P723, DOI 10.1210/en.139.2.723; Bettoun JD, 1998, J CLIN INVEST, V102, P958, DOI 10.1172/JCI3678; Broadus Arthur E., 1994, P259; FUKAYAMA S, 1995, P NATL ACAD SCI USA, V92, P10182, DOI 10.1073/pnas.92.22.10182; GAICH G, 1993, ENDOCRINOLOGY, V132, P1402, DOI 10.1210/en.132.3.1402; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; HEDGES SB, 1992, MOL BIOL EVOL, V9, P366; IIDAKLEIN A, 1995, MINER ELECTROL METAB, V21, P177; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; Jobert AS, 1996, MOL ENDOCRINOL, V10, P1066, DOI 10.1210/me.10.9.1066; Joun H, 1997, ENDOCRINOLOGY, V138, P1742, DOI 10.1210/en.138.4.1742; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; MADDSISON WP, 1992, MACCLADE; ORLOFF JJ, 1992, AM J PHYSIOL, V262, pE599, DOI 10.1152/ajpendo.1992.262.5.E599; Philbrick WM, 1998, P NATL ACAD SCI USA, V95, P11846, DOI 10.1073/pnas.95.20.11846; POTTS JT, 1997, METABOLIC BONE DIS, P51; Pough FH, 1989, VERTEBRATE LIFE; Rubin DA, 1999, J BIOL CHEM, V274, P23035, DOI 10.1074/jbc.274.33.23035; SCHIPANI E, 1995, J CLIN ENDOCR METAB, V80, P1611, DOI 10.1210/jc.80.5.1611; Swofford David L., 1990, P411; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; Usdin TB, 1996, ENDOCRINOLOGY, V137, P4285, DOI 10.1210/en.137.10.4285; Wysolmerski JJ, 1998, DEVELOPMENT, V125, P1285; Yamamoto S, 1998, ENDOCRINOLOGY, V139, P383, DOI 10.1210/en.139.1.383; Yamamoto S, 1997, ENDOCRINOLOGY, V138, P2066, DOI 10.1210/en.138.5.2066	29	85	94	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28185	28190		10.1074/jbc.274.40.28185	http://dx.doi.org/10.1074/jbc.274.40.28185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497171	hybrid			2022-12-25	WOS:000082912700020
J	Appay, V; Brown, A; Cribbes, S; Randle, E; Czaplewski, LG				Appay, V; Brown, A; Cribbes, S; Randle, E; Czaplewski, LG			Aggregation of RANTES is responsible for its inflammatory properties - Characterization of nonaggregating, noninflammatory RANTES mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; CHEMOKINE EXPRESSION; CYTOKINE FAMILY; ACTIVATION; IDENTIFICATION; SUBPOPULATIONS; MIP-1-ALPHA; STIMULATION; MIP-1-BETA; RECEPTORS	The biology of RANTES (regulated on activation normal T cell expressed) aggregation has been investigated using RANTES and disaggregated variants, enabling comparison of aggregated, tetrameric, and dimeric RANTES forms. Disaggregated variants retain their G(i)-type G protein-coupled receptor-mediated biological activities. A correlation between RANTES aggregation and cellular activation has been demonstrated. Aggregated RANTES, but not disaggregated RANTES, activates human T cells, monocytes, and neutrophils. Dimeric RANTES has lost its cellular activating activity, rendering it noninflammatory. Macrophage inflammatory protein 1 alpha, macrophage inflammatory protein-1 beta, and erythrocytes are potent natural antagonists of aggregated RANTES-induced cellular activation. There is a clear difference in the signaling properties of aggregated and disaggregated RANTES forms, separating the dual signaling pathways of RANTES and the enhancing and suppressive effects of RANTES on human immunodeficiency virus infection. Disaggregated RANTES will be a valuable tool to explore the biology of RANTES action in human immunodeficiency virus infection and in inflammatory disease.	British Biotechnol Pharmaceut Ltd, Oxford OX4 5LY, England		Czaplewski, LG (corresponding author), British Biotechnol Pharmaceut Ltd, Watlington Rd, Oxford OX4 5LY, England.		Appay, Victor/M-4830-2017; Appay, Victor/AAM-7701-2021	Appay, Victor/0000-0001-5434-3963				Al-Aoukaty A, 1998, IMMUNOLOGY, V95, P618; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Conklyn MJ, 1996, CYTOKINE, V8, P762, DOI 10.1006/cyto.1996.0101; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; Dackiw APB, 1996, J SURG RES, V64, P210, DOI 10.1006/jsre.1996.0330; Dairaghi DJ, 1998, J IMMUNOL, V160, P426; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; Gordon CJ, 1999, J VIROL, V73, P684, DOI 10.1128/JVI.73.1.684-694.1999; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; KHORRAM O, 1993, AM J OBSTET GYNECOL, V169, P1545, DOI 10.1016/0002-9378(93)90433-J; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Kurashima K, 1996, J LEUKOCYTE BIOL, V59, P313, DOI 10.1002/jlb.59.3.313; LIU Z, 1994, BIOCHEM BIOPH RES CO, V210, P829; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; NEOTE K, 1994, BLOOD, V84, P44; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PATTISON JM, 1995, CLIN IMMUNOTHER, V4, P1; ROBINSON E, 1995, CLIN EXP IMMUNOL, V101, P398; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SIMON SI, 1995, J IMMUNOL, V155, P1502; Szabo MC, 1997, EUR J IMMUNOL, V27, P1061, DOI 10.1002/eji.1830270504; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309	29	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27505	27512		10.1074/jbc.274.39.27505	http://dx.doi.org/10.1074/jbc.274.39.27505			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488085	hybrid			2022-12-25	WOS:000082739100024
J	Maechler, P; Jornot, L; Wollheim, CB				Maechler, P; Jornot, L; Wollheim, CB			Hydrogen peroxide alters mitochondrial activation and insulin secretion in pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; OXIDATIVE STRESS; INS-1 CELLS; CA2+; DNA; DAMAGE; METABOLISM; APOPTOSIS; NUCLEAR; RESPONSES	The effects of a transient exposure to hydrogen peroxide (10 min at 200 mu M H2O2) On pancreatic beta cell signal transduction and insulin secretion have been evaluated, In rat islets, insulin secretion evoked by glucose (16.7 mM) or by the mitochondrial substrate methyl succinate (5 mM) was markedly blunted following exposure to H2O2. In contrast, the secretory response induced by plasma membrane depolarization (20 mM KCl) was not significantly affected. Similar results were obtained in insulinoma INS-1 cells using glucose (12.8 mM) as secretagogue. After H2O2 treatment, glucose no longer depolarized the membrane potential (Delta Psi) of INS-1 cells or increased cytosolic Ca2+. Both Delta Psi and Ca2+ responses were still observed with 30 mM KCl despite an elevated baseline of cytosolic Ca2+ appearing similar to 10 min after exposure to H2O2. The mitochondrial Delta Psi of INS-1 cells was depolarized by H2O2 abolishing the hyperpolarizing action of glucose. These Delta Psi changes correlated with altered mitochondrial morphology; the latter was not preserved by the overexpression of the antiapoptotic protein Bcl-2, Mitochondrial Ca2+ was increased following exposure to H2O2 up to the micromolar range. No further augmentation occurred after glucose addition, which normally raises this parameter. Nevertheless, KCl was still efficient in enhancing mitochondrial Ca2+. Cytosolic ATP was markedly reduced by H2O2 treatment, probably explaining the decreased endoplasmic reticulum Ca2+. Taken together, these data point to the mitochondria as primary targets for H2O2 damage, which will eventually interrupt the transduction of signals normally coupling glucose metabolism to insulin secretion.	Ctr Med Univ Geneva, Div Clin Biochem, CH-1211 Geneva 4, Switzerland; Ctr Med Univ Geneva, Dept Internal Med, Div Resp, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Wollheim, CB (corresponding author), Ctr Med Univ Geneva, Div Clin Biochem, 1 Rue Michel-Servet, CH-1211 Geneva 4, Switzerland.			Maechler, Pierre/0000-0002-2005-1433				ANDERSON R, 1992, J IMMUNOL METHODS, V155, P49, DOI 10.1016/0022-1759(92)90270-4; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Benhamou PY, 1998, DIABETOLOGIA, V41, P1093, DOI 10.1007/s001250051035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; COORDT MC, 1995, P SOC EXP BIOL MED, V209, P213; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; FEHSEL K, 1993, DIABETES, V42, P496, DOI 10.2337/diabetes.42.3.496; Garofano A, 1999, DIABETOLOGIA, V42, P711, DOI 10.1007/s001250051219; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; Herson PS, 1999, J BIOL CHEM, V274, P833, DOI 10.1074/jbc.274.2.833; Herson PS, 1997, J PHYSIOL-LONDON, V501, P59, DOI 10.1111/j.1469-7793.1997.059bo.x; Isobe K, 1998, J BIOL CHEM, V273, P4601, DOI 10.1074/jbc.273.8.4601; Janjic D, 1999, BIOCHEM PHARMACOL, V57, P639, DOI 10.1016/S0006-2952(98)00346-3; Jornot L, 1999, J CELL SCI, V112, P1013; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Krippeit-Drews P, 1999, J PHYSIOL-LONDON, V514, P471, DOI 10.1111/j.1469-7793.1999.471ae.x; KRIPPEITDREWS P, 1994, PFLUG ARCH EUR J PHY, V426, P552, DOI 10.1007/BF00378534; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; MACDONALD MJ, 1988, DIABETES, V37, P997, DOI 10.2337/diabetes.37.7.997; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; Maechler P, 1998, BIOFACTORS, V8, P255, DOI 10.1002/biof.5520080313; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Maechler P, 1999, J BIOL CHEM, V274, P12583, DOI 10.1074/jbc.274.18.12583; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Rabinovitch A, 1996, J CLIN ENDOCR METAB, V81, P3197, DOI 10.1210/jc.81.9.3197; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Satoh T, 1997, J NEUROSCI RES, V50, P413, DOI 10.1002/(SICI)1097-4547(19971101)50:3<413::AID-JNR7>3.0.CO;2-L; Shimizu M, 1996, DIABETES CARE, V19, P8, DOI 10.2337/diacare.19.1.8; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; STARNES JW, 1991, AM J PHYSIOL, V260, pE59, DOI 10.1152/ajpendo.1991.260.1.E59; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; Wilson GL, 1997, DIABETES, V46, P1291, DOI 10.2337/diabetes.46.8.1291; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245; [No title captured]	45	265	268	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27905	27913		10.1074/jbc.274.39.27905	http://dx.doi.org/10.1074/jbc.274.39.27905			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488138	hybrid, Green Published			2022-12-25	WOS:000082739100077
J	Uchiumi, T; Hori, K; Nomura, T; Hachimori, A				Uchiumi, T; Hori, K; Nomura, T; Hachimori, A			Replacement of L7/L12.L10 protein complex in Escherichia coli ribosomes with the eukaryotic counterpart changes the specificity of elongation factor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EF-G; ACIDIC PHOSPHOPROTEINS; CRYSTAL-STRUCTURE; RNA AUTOANTIBODY; GTPASE DOMAIN; SITES; L11; TU; P0; P1	The L8 protein complex consisting of L7/L12 and L10 in Escherichia coli ribosomes is assembled on the conserved region of 23 S rRNA termed the GTPase associated domain. We replaced the L8 complex in E, coli 50 S subunits with the rat counterpart P protein complex consisting of P1, P2, and P0. The L8 complex was removed from the ribosome with 50% ethanol, 10 mM MgCI2, 0.5 M NH4Cl, at 30 degrees C, and the rat P complex bound to the core particle. Binding of the P complex to the core was prevented by addition of RNA fragment covering the GTPase-associated domain of E, coli 23 S rRNA to which rat P complex bound strongly, suggesting a direct role of the RNA domain in this incorporation. The resultant hybrid ribosomes showed eukaryotic translocase elongation factor (EF)-2-dependent, but not prokaryotic EF-G-dependent, GTPase activity comparable with rat 80 S ribosomes. The EF-2-dependent activity was dependent upon the P complex binding and was inhibited by the antibiotic thiostrepton, a ligand for a portion of the GTPase-associated domain of prokaryotic ribosomes, This hybrid system clearly shows significance of binding of the P complex to the GTPase-associated RNA domain for interaction of EF-2 with the ribosome. The results also suggest that E, coli 23 S rRNA participates in the eukaryotic translocase-dependent GTPase activity in the hybrid system.	Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868567, Japan	Shinshu University	Uchiumi, T (corresponding author), Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868567, Japan.	uchiumi@giptc.shinshu-u.ac.jp						AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; BRIGOTTI M, 1989, BIOCHEM J, V257, P723, DOI 10.1042/bj2570723; CUNDLIFFE E, 1990, RIBOSOME, P479; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; GRASMUK H, 1977, FEBS LETT, V82, P237, DOI 10.1016/0014-5793(77)80592-9; HAMEL E, 1972, J BIOL CHEM, V247, P805; HOLMBERG L, 1994, BIOCHEMISTRY-US, V33, P15159, DOI 10.1021/bi00254a027; Iwasaki K, 1979, Methods Enzymol, V60, P657; KAZIRO Y, 1972, J BIOCHEM, V72, P853, DOI 10.1093/oxfordjournals.jbchem.a129980; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACCONNELL WP, 1982, J BIOL CHEM, V257, P5359; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOLLER W, 1983, J MOL BIOL, V163, P553, DOI 10.1016/0022-2836(83)90112-2; Moller W., 1986, STRUCTURE FUNCTION G, P309; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; PETTERSSON I, 1979, NUCLEIC ACIDS RES, V6, P2637, DOI 10.1093/nar/6.7.2637; PETTERSSON I, 1976, FEBS LETT, V64, P135, DOI 10.1016/0014-5793(76)80267-0; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOS C, 1995, J BIOL CHEM, V270, P20608, DOI 10.1074/jbc.270.35.20608; SANTOS C, 1994, J BIOL CHEM, V269, P15689; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; TAIRA H, 1972, J BIOCHEM-TOKYO, V72, P1527, DOI 10.1093/oxfordjournals.jbchem.a130044; THOMPSON J, 1993, EMBO J, V12, P1499, DOI 10.1002/j.1460-2075.1993.tb05793.x; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; UCHIUMI T, 1990, J BIOL CHEM, V265, P89; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; UCHIUMI T, 1994, EMBO J, V13, P3389, DOI 10.1002/j.1460-2075.1994.tb06641.x; UCHIUMI T, 1992, J BIOL CHEM, V267, P19179; Uchiumi T, 1999, J BIOL CHEM, V274, P681, DOI 10.1074/jbc.274.2.681; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; WADA A, 1986, J BIOCHEM, V100, P1583, DOI 10.1093/oxfordjournals.jbchem.a121866; WEISSBACH H, 1976, ANNU REV BIOCHEM, V45, P191, DOI 10.1146/annurev.bi.45.070176.001203; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o	44	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27578	27582		10.1074/jbc.274.39.27578	http://dx.doi.org/10.1074/jbc.274.39.27578			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488095	hybrid			2022-12-25	WOS:000082739100034
J	Yang, ML; May, WS; Ito, T				Yang, ML; May, WS; Ito, T			JAZ requires the double-stranded RNA-binding zinc finger motifs for nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; XENOPUS; RECOGNITION; KNOWLEDGE; TRANSPORT; DOMAIN; UPDATE; DSRNA; CELLS	We have cloned and characterized a novel zinc finger protein, termed JAZ, JAZ contains four C2H2-type zinc finger motifs that are connected by long (28-38) amino acid linker sequences, JAZ is expressed in all tissues tested and localizes in the nucleus, primarily the nucleolus. JAZ preferentially binds to double-stranded (ds) RNA or RNA/DNA hybrids rather than DNA. Mutation of individual zinc finger motifs reveals that the zinc finger domains are not only essential for dsRNA binding but are also required for its nucleolar localization, which demonstrates a complex trafficking mechanism dependent on the nucleic acid-binding capability of the protein. Furthermore, forced expression of JAZ potently induces apoptosis in murine fibroblast cells. Thus, JAZ may belong to a class of zinc finger proteins that features dsRNA binding and may regulate cell growth via the unique dsRNA binding properties.	Univ Texas, Med Branch, Dept Internal Med, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Ito, T (corresponding author), Univ Texas, Med Branch, Dept Internal Med, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA.			Yang, Mingli/0000-0002-4781-690X	NATIONAL CANCER INSTITUTE [R01CA044649] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054083] Funding Source: NIH RePORTER; NCI NIH HHS [CA44649] Funding Source: Medline; NHLBI NIH HHS [HL54083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BECKER KG, 1995, HUM MOL GENET, V4, P685, DOI 10.1093/hmg/4.4.685; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Eckmann CR, 1997, J CELL BIOL, V138, P239, DOI 10.1083/jcb.138.2.239; Endo S, 1989, Virus Genes, V3, P99; Finerty PJ, 1999, BIOCHEMISTRY-US, V38, P4001, DOI 10.1021/bi9825293; Finerty PJ, 1997, J MOL BIOL, V271, P195, DOI 10.1006/jmbi.1997.1177; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Harlow E., 1988, ANTIBODIES LABORATOR, P310; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HERNANDEZVERDUN D, 1994, BIOESSAYS, V16, P179, DOI 10.1002/bies.950160308; ICELY PL, 1991, J BIOL CHEM, V266, P16073; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Izaurralde E, 1998, RNA, V4, P351; KOSTER M, 1991, EMBO J, V10, P3087, DOI 10.1002/j.1460-2075.1991.tb07861.x; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nicholson AW, 1996, PROG NUCLEIC ACID RE, V52, P1, DOI 10.1016/S0079-6603(08)60963-0; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; PIELER T, 1994, MOL BIOL REP, V20, P1, DOI 10.1007/BF00999848; RHODES D, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0293-56; SHASTRY BS, 1993, EXPERIENTIA, V49, P831, DOI 10.1007/BF01952592; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; SHI YG, 1995, SCIENCE, V268, P282, DOI 10.1126/science.7536342; SMETANA K, 1974, CELL NUCLEUS, P75, DOI DOI 10.1016/B978-0-12-147601-4.50010-5; STEITZ TA, 1993, RNA WORLD, P219; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; WICKNER RB, 1992, ANNU REV MICROBIOL, V46, P347, DOI 10.1146/annurev.micro.46.1.347; WYATT R, 1993, RNA WORLD, P465; [No title captured]	35	49	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27399	27406		10.1074/jbc.274.39.27399	http://dx.doi.org/10.1074/jbc.274.39.27399			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488071	hybrid			2022-12-25	WOS:000082739100010
J	Lee, C; Piazza, F; Brutsaert, S; Valens, J; Strehlow, I; Jarosinski, M; Saris, C; Schindler, C				Lee, C; Piazza, F; Brutsaert, S; Valens, J; Strehlow, I; Jarosinski, M; Saris, C; Schindler, C			Characterization of the Stat5 protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MAMMARY-GLAND FACTOR; RECEPTOR-BETA CHAIN; SERINE-PROTEASE; INTERFERON-GAMMA; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; IFN-ALPHA; CELL-LINE	Immature myeloid cells have been shown to transduce signals through a carboxyl-terminally truncated isoform of Stat5. This functionally distinct signal transducer and activator of transcription isoform is generated through a unique protein-processing event. Evaluation of numerous cell lines has determined that there is a direct correlation between the expression of truncated Stat5 and protease activity. Moreover, protease activity is found only in the myeloid and not in lymphoid progenitors. To further characterize the protease small quantities have been purified to near homogeneity. Studies on this purified material indicate that the protease has an apparent molecular mass of similar to 25 kDa and is active over a wide range of pH values. The protease will also cleave both activated (i.e. tyrosine-phosphorylated) and inactivate Stat5. Although this activity is sensitive to phenylmethylsulfonyl fluoride, it is notably not sensitive to several other serine protease inhibitors. Additional studies have led to the identification of the unique site where the protease cleaves Stat5. Mutagenesis of this site renders Stat5 resistant to cleavage. Consistent with the model that Stat5 cleavage is important for early myeloid development, introduction of a "non-cleavable" isoform of Stat5 into FDC-P1 cells (a myeloid progenitor line) leads to significant phenotypic changes.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Amgen, Boulder, CO 80301 USA	Columbia University; Columbia University	Schindler, C (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, HHSC 1208,701 W 168th St, New York, NY 10032 USA.							Azam JP, 1997, J AFR ECON, V6, P1; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bovolenta C, 1998, J BIOL CHEM, V273, P20779, DOI 10.1074/jbc.273.33.20779; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; Esmon CT, 1998, NAT STRUCT BIOL, V5, P933, DOI 10.1038/2906; FONTENOT G, 1992, VIROLOGY, V190, P1, DOI 10.1016/0042-6822(92)91186-X; FOXWELL BMJ, 1995, EUR J IMMUNOL, V25, P3041, DOI 10.1002/eji.1830251109; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GILMOUR KC, 1995, P NATL ACAD SCI USA, V92, P10772, DOI 10.1073/pnas.92.23.10772; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HAWLEY RG, 1995, ONCOGENE, V11, P1113; HORIBATA K, 1970, EXP CELL RES, V60, P61, DOI 10.1016/0014-4827(70)90489-1; HYMAN R, 1980, IMMUNOGENETICS, V10, P261, DOI 10.1007/BF01561574; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; Kwong AD, 1998, ANTIVIR RES, V40, P1, DOI 10.1016/S0166-3542(98)00043-6; Lecine P, 1996, MOL CELL BIOL, V16, P6829; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Lokuta MA, 1998, J IMMUNOL, V161, P1594; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MIYAJIMA A, 1993, BLOOD, V82, P1960; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; PERNIS A, 1995, J BIOL CHEM, V270, P14517, DOI 10.1074/jbc.270.24.14517; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SACHS L, 1993, BLOOD CELLS, V19, P709; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SLIVA D, 1994, J BIOL CHEM, V269, P26208; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tong L, 1996, NATURE, V383, P272, DOI 10.1038/383272a0; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wood TJJ, 1997, MOL CELL ENDOCRINOL, V130, P69, DOI 10.1016/S0303-7207(97)00075-0; YIPSCHNEIDER MT, 1995, BLOOD, V85, P3494, DOI 10.1182/blood.V85.12.3494.bloodjournal85123494; Yoshida S, 1998, BBA-GENE STRUCT EXPR, V1399, P225, DOI 10.1016/S0167-4781(98)00116-X; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	60	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26767	26775		10.1074/jbc.274.38.26767	http://dx.doi.org/10.1074/jbc.274.38.26767			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480881	hybrid			2022-12-25	WOS:000082570700020
J	Ollendorff, V; Guasch, G; Isnardon, D; Galindo, R; Birnbaum, D; Pebusque, MJ				Ollendorff, V; Guasch, G; Isnardon, D; Galindo, R; Birnbaum, D; Pebusque, MJ			Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-1; DNA BIFUNCTIONAL INTERCALATORS; ACRIDINE ETHIDIUM HETERODIMER; TYROSINE KINASE; TRANSCRIPTION FACTOR; APOPTOSIS; PROTEIN; GENE; LEUKEMIA; ZNF198	The t(8;13) translocation found in a rare type of stem cell myeloproliferative disorder generates a constitutively activated tyrosine kinase containing N-terminal sequence encoded by the FIM gene linked to the FGFR1 kinase domain. Here we have further characterized FIM and FIM-FGFR1 proteins. Firstly, we have studied their respective subcellular localization,We show that FIM has nuclear and nucleolar localization, whereas FIM-FGFR1 is mainly cytoplasmic. Within the nucleolus, FIM colocalizes with the upstream binding factor in interphasic cells, indicating that FIM may be involved in the regulation of rRNA transcription. We demonstrate that the targetting of FIM to the nucleus depends upon its C-terminal region, which is absent in the cytoplasmic FIM-FGFR1 protein, Secondly, we demonstrate that FIM-FGFR1 has constitutive dimerization capability mediated by the FIM N-terminal sequences. Finally, we show that FIM-FGFR1 promotes survival of pro-B Ba/F3 cells after interleukin-3 withdrawal, whereas Ligand-activated FGFR1 induced not only cell survival but also interleukin-3 independence. Taken together, these results indicate that FIM-FGFR1 is activated by dimerization as a cytoplasmic kinase and suggest that FIM-FGFR1 partially signals through the FGFR1 pathways.	Inst Cancerol & Immunol, Oncol Mol Lab, INSERM, U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, Lab Biol Tumeurs, F-13009 Marseille, France; Inst J Paoli I Calmettes, Biol Cellulaire Lab, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), Inst Cancerol & Immunol, Oncol Mol Lab, INSERM, U119, 27 Blvd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr; pebusque@marseille.inserm.fr		Guasch, Geraldine/0000-0001-7362-9318; Ollendorff, Vincent/0000-0001-9751-2202				Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Chaffanet M, 1998, ONCOGENE, V16, P945, DOI 10.1038/sj.onc.1201601; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GAUGAIN B, 1978, BIOCHEMISTRY-US, V17, P5078, DOI 10.1021/bi00617a002; GAUGAIN B, 1978, BIOCHEMISTRY-US, V17, P5071, DOI 10.1021/bi00617a001; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KOUHARA H, 1995, ONCOGENE, V10, P2315; Kudla AJ, 1998, J CELL BIOL, V142, P241, DOI 10.1083/jcb.142.1.241; LOOK AT, 1998, GENETIC BASIS HUMAN, P109; MACDONALD D, 1995, LEUKEMIA, V9, P1628; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; POPOVICI C, 1998, HEMATOLOGIE, V4, P361; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; ROUSSEL P, 1993, J CELL SCI, V104, P327; Roussel P, 1996, J CELL BIOL, V133, P235, DOI 10.1083/jcb.133.2.235; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; Smedley D, 1998, HUM MOL GENET, V7, P637, DOI 10.1093/hmg/7.4.637; SONGYANG Z, 1977, P NATL ACAD SCI USA, V94, P11345; Still IH, 1998, BLOOD, V92, P1456, DOI 10.1182/blood.V92.4.1456.splL3_1456_1458; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; vanderMaarel SM, 1996, HUM MOL GENET, V5, P887, DOI 10.1093/hmg/5.7.887; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang JK, 1996, ONCOGENE, V13, P721; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; ZATSEPINA OV, 1993, CHROMOSOMA, V102, P599, DOI 10.1007/BF00352307	45	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26922	26930		10.1074/jbc.274.38.26922	http://dx.doi.org/10.1074/jbc.274.38.26922			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480903	hybrid, Green Published			2022-12-25	WOS:000082570700042
J	Adam, L; Bouvier, M; Jones, TLZ				Adam, L; Bouvier, M; Jones, TLZ			Nitric oxide modulates beta(2)-adrenergic receptor palmitoylation and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; PROTEIN-ALPHA-SUBUNIT; MAMMALIAN HEART-RATE; SYNTHASE INHIBITION; MEMBRANE ATTACHMENT; BINDING; PHOSPHORYLATION; STIMULATION; ACTIVATION	To determine whether nitric oxide (NO) modulates the beta-adrenergic signaling pathway, we treated cells expressing beta(2)-adrenergic receptors (beta(2)AR) with the NO donors, 3-morpholinosydnonimine (SIN-1) and 1,2,3,4-oxatriazolium,5-amino-3-(3-chloro-2-meth chloride and determined the intracellular production of cAMP after exposure to beta-adrenergic receptor agonists, cholera toxin and forskolin. NO significantly decreased the potency of the beta-adrenergic agonist, isoproterenol, to stimulate cAMP production without affecting the stimulatory action of forskolin and cholera toxin, which directly activate adenylyl cyclase and G(s), respectively. Treatment with the NO donor increased the guanyl nucleotide-sensitive high affinity constant for the agonist, isoproterenol, thus suggesting that it reduced functional coupling between the receptor and G(s). Stimulation of endogenous NO production by lipopolysaccharide in RAW 264.7 macrophages also caused a significant increase in the EC50 for isoproterenol-stimulated cAMP production. SIN-1 treatment also led to a reduction in both basal and isoproterenol-stimulated incorporation of [H-3]palmitate into the beta(2)AR. Signaling through the nonpalmitoylated, Gly(341)beta(2)AR mutant was unchanged by SIN-1 treatment. Given the link between beta(2)AR palmitoylation and its responsiveness to agonist, these results suggest that the primary action of NO was depalmitoylation of the beta(2)AR resulting in decreased signaling through the beta(2)AR.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Montreal, Dept Biochim, Montreal, PQ H3T 1J4, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3T 1J4, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Universite de Montreal; Universite de Montreal	Jones, TLZ (corresponding author), NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA.		Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043010] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASSENDER JW, 1992, BIOCHEM J, V288, P527, DOI 10.1042/bj2880527; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BOHME E, 1984, ADV CYCLIC NUCL PROT, V17, P259; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JF, 1993, BIOCHEM BIOPH RES CO, V195, P1354, DOI 10.1006/bbrc.1993.2192; BRUNE B, 1989, J BIOL CHEM, V264, P8455; CHAKDER S, 1993, AM J PHYSIOL, V264, pG702, DOI 10.1152/ajpgi.1993.264.4.G702; Cook JA, 1996, NEUROCHEM INT, V28, P609, DOI 10.1016/0197-0186(95)00125-5; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DISCHIA M, 1995, BIOORGAN MED CHEM, V3, P923, DOI 10.1016/0968-0896(95)00083-S; Fukuto J M, 1995, Adv Pharmacol, V34, P1; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAN X, 1995, J GEN PHYSIOL, V106, P45, DOI 10.1085/jgp.106.1.45; HAN X, 1994, J PHYSIOL-LONDON, V476, P309, DOI 10.1113/jphysiol.1994.sp020132; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; HARE JM, 1995, J CLIN INVEST, V95, P360, DOI 10.1172/JCI117664; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; HESS DT, 1994, NEUROPHARMACOLOGY, V33, P1283, DOI 10.1016/0028-3908(94)90028-0; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; HEUZEJOUBERT I, 1992, EUR J PHARMACOL, V220, P161, DOI 10.1016/0014-2999(92)90744-O; HOLLENBERG SM, 1993, AM J PHYSIOL, V264, pH660, DOI 10.1152/ajpheart.1993.264.2.H660; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Joe EL, 1998, J MOL CELL CARDIOL, V30, P303, DOI 10.1006/jmcc.1997.0593; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KENT RS, 1980, MOL PHARMACOL, V17, P14; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDER HM, 1993, J IMMUNOL, V151, P7182; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; MALORANTA U, 1994, FEBS LETT, V337, P179, DOI 10.1016/0014-5793(94)80269-6; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Miyamoto A, 1997, J BIOL CHEM, V272, P19601, DOI 10.1074/jbc.272.31.19601; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MURAD F, 1994, RECENT PROG HORM RES, V49, P239; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; RESEK JF, 1988, J BIOL CHEM, V263, P14410; ROZANSKI GJ, 1994, AM J PHYSIOL-HEART C, V267, pH1753, DOI 10.1152/ajpheart.1994.267.5.H1753; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHORR RGL, 1981, J BIOL CHEM, V256, P5820; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Sterin-Borda L, 1998, CELL SIGNAL, V10, P253, DOI 10.1016/S0898-6568(97)00125-3; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILLEMSEN JJ, 1995, CLIN CHEM, V41, P1455; Wink DA, 1996, CURR TOP CELL REGUL, V34, P159, DOI 10.1016/S0070-2137(96)80006-9; Yasuda S, 1997, CIRC RES, V81, P1011	55	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26337	26343		10.1074/jbc.274.37.26337	http://dx.doi.org/10.1074/jbc.274.37.26337			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473590	hybrid			2022-12-25	WOS:000082469700056
J	Goldwaser, I; Li, JP; Gershonov, E; Armoni, M; Karnieli, E; Fridkin, M; Shechter, Y				Goldwaser, I; Li, JP; Gershonov, E; Armoni, M; Karnieli, E; Fridkin, M; Shechter, Y			L-glutamic acid gamma-monohydroxamate - A potentiator of vanadium-evoked glucose metabolism in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; PROTEIN-TYROSINE KINASES; LONG-TERM IMPROVEMENT; INSULIN-LIKE ACTIONS; RAT ADIPOCYTES; VANADATE TREATMENT; FA/FA RATS; OBESE RAT; RECEPTOR; HOMEOSTASIS	We report that the vanadium ligand L-Glu(gamma)HXM potentiates the capacity of free vanadium ions to activate glucose uptake and glucose metabolism in rat adipocytes in vitro (by 4-5-fold) and to lower blood glucose levels in hyperglycemic rats in vivo (by 5-7-fold). A molar ratio of two L-Glu(gamma)HXM molecules to one vanadium ion was most effective. Unlike other vanadium ligands that potentiate the insulinomimetic actions of vanadium, L-Glu(gamma)HXM partially activated lipogenesis in rat adipocytes in the absence of exogenous vanadium, This effect was not manifested by D-Glu(gamma)HMM, At 10-20 mu M L-Glu(gamma)HXM, lipogenesis was activated 9-21%, This effect was approximately g-fold higher (140 +/- 15% of maximal insulin response) in adipocytes derived from rats that had been treated with vanadium for several days. Titration of vanadium(lV) with L-Glu(gamma)HXM led to a rapid decrease in the absorbance of vanadium(IV) at 765 nm, and V-51 NMR spectroscopy revealed that the chemical shift of vanadium(IV) at -490 ppm disappeared with the appearance of a signal characteristic to vanadium(V) (-530 ppm) upon adding one equivalent of L-Glu(gamma)HXM. In summary, L-Glu(gamma)HXM is highly active in potentiating vanadium-activated glucose metabolism in vitro and in vivo and facilitating glucose metabolism in rat adipocytes in the absence of exogenous vanadium probably through conversion of trace intracellular vanadium into an active insulinomimetic compound. We propose that the active species is either a 1:1 or 2:1 L-Glu(gamma)HXM vanadium complex in which the endogenous vanadium(IV) has been altered to vanadium(V), Finally we demonstrate that L-Glu(gamma)HXM- and L-Glu(gamma)HXM vanadium-evoked lipogenesis is arrested by wortmannin and that activation of glucose uptake in rat adipocytes is because of enhanced translocation of GLUT4 from low density microsomes to the plasma membrane.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Inst Endocrinol, Rambam Med Ctr, IL-31096 Haifa, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; Technion Israel Institute of Technology	Shechter, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.			Gershonov, Eytan/0000-0002-0235-4027				ARMONI M, 1995, ENDOCRINOLOGY, V136, P3292, DOI 10.1210/en.136.8.3292; Boehlein SK, 1996, BIOCHEMISTRY-US, V35, P3031, DOI 10.1021/bi952505l; BRICHARD SM, 1989, ENDOCRINOLOGY, V125, P2510, DOI 10.1210/endo-125-5-2510; BRICHARD SM, 1992, ENDOCRINOLOGY, V131, P311, DOI 10.1210/en.131.1.311; BRICHARD SM, 1988, ENDOCRINOLOGY, V123, P2048, DOI 10.1210/endo-123-4-2048; BRICHARD SM, 1995, TRENDS PHARMACOL SCI, V16, P265, DOI 10.1016/S0165-6147(00)89043-4; BRICHARD SM, 1990, DIABETES, V39, P1326, DOI 10.2337/diabetes.39.11.1326; CASTEEN ND, 1981, BIOL MAGN RESON, V2, P53; COHEN N, 1995, J CLIN INVEST, V95, P2501, DOI 10.1172/JCI117951; CRANS DC, 1989, J AM CHEM SOC, V111, P7597, DOI 10.1021/ja00201a049; Crans DC, 1995, MOL CELL BIOCHEM, V153, P17, DOI 10.1007/BF01075914; CRANS DC, 1994, COMMENT INORG CHEM, V16, P1; DADNEY SK, 1995, MOL CELL BIOCHEM, V153, P69; DEKOCH RJ, 1974, BIOCHEMISTRY-US, V13, P4347, DOI 10.1021/bi00718a017; DONOFRIO F, 1994, FEBS LETT, V340, P269, DOI 10.1016/0014-5793(94)80152-5; ELBERG E, 1997, VANADIUM ENV, P277; ELBERG G, 1994, J BIOL CHEM, V269, P9521; Elberg G, 1997, DIABETES, V46, P1684, DOI 10.2337/diabetes.46.11.1684; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FISHBEIN WN, 1973, J PHARMACOL EXP THER, V186, P173; GOLDFINE AB, 1995, J CLIN ENDOCR METAB, V80, P3311, DOI 10.1210/jc.80.11.3311; GREEN A, 1986, BIOCHEM J, V238, P663, DOI 10.1042/bj2380663; Halberstam M, 1996, DIABETES, V45, P659, DOI 10.2337/diabetes.45.5.659; HISSIN PJ, 1982, J CLIN INVEST, V70, P780, DOI 10.1172/JCI110674; Li JP, 1996, BIOCHEMISTRY-US, V35, P8314, DOI 10.1021/bi960209i; Li JP, 1997, ENDOCRINOLOGY, V138, P2274, DOI 10.1210/en.138.6.2274; LOPEZ V, 1976, ARCH BIOCHEM BIOPHYS, V175, P31, DOI 10.1016/0003-9861(76)90482-3; MACARA IG, 1980, TRENDS BIOCHEM SCI, V5, P92, DOI 10.1016/0968-0004(80)90256-X; MCLEAN P, 1968, HDB BIOCH; McNeill JH, 1995, MOL CELL BIOCHEM, V153, P175, DOI 10.1007/BF01075935; MCNEILL JH, 1992, J MED CHEM, V35, P1489, DOI 10.1021/jm00086a020; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; MEYEROVITCH J, 1991, J CLIN INVEST, V87, P1286, DOI 10.1172/JCI115131; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; RODBELL M, 1964, J BIOL CHEM, V239, P375; SAKURAI H, 1995, BIOCHEM BIOPH RES CO, V214, P1095, DOI 10.1006/bbrc.1995.2398; SAKURAI H, 1994, ENV HLTH PERSPECT, V3, P35; Sekar N, 1996, CRIT REV BIOCHEM MOL, V31, P339, DOI 10.3109/10409239609108721; SHECHTER Y, 1980, NATURE, V284, P556, DOI 10.1038/284556a0; Shechter Y, 1995, MOL CELL BIOCHEM, V153, P39, DOI 10.1007/BF01075917; SHECHTER Y, 1992, BIOCHEMISTRY-US, V31, P2063, DOI 10.1021/bi00122a024; SHISHEVA A, 1992, FEBS LETT, V300, P93, DOI 10.1016/0014-5793(92)80171-C; SHISHEVA A, 1993, J BIOL CHEM, V268, P6463; SHISHEVA A, 1992, BIOCHEMISTRY-US, V31, P8059, DOI 10.1021/bi00149a041; STROUT HV, 1989, ENDOCRINOLOGY, V124, P1918, DOI 10.1210/endo-124-4-1918; VENKATESAN N, 1991, DIABETES, V40, P492, DOI 10.2337/diabetes.40.4.492; VILA J, 1990, INT J CANCER, V45, P737, DOI 10.1002/ijc.2910450428; WATANABE H, 1994, J MED CHEM, V37, P876, DOI 10.1021/jm00033a002; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276	51	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26617	26624		10.1074/jbc.274.37.26617	http://dx.doi.org/10.1074/jbc.274.37.26617			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473627	hybrid			2022-12-25	WOS:000082469700093
J	Gupta, IR; Piscione, TD; Grisaru, S; Phan, T; Macias-Silva, M; Zhou, XP; Whiteside, C; Wrana, JL; Rosenblum, ND				Gupta, IR; Piscione, TD; Grisaru, S; Phan, T; Macias-Silva, M; Zhou, XP; Whiteside, C; Wrana, JL; Rosenblum, ND			Protein kinase a is a negative regulator of renal branching morphogenesis and modulates inhibitory and stimulatory bone morphogenetic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; SIGNALING PATHWAYS; GROWTH-FACTOR; ACTIVATION; CAMP; CELLS; PHOSPHORYLATION; TUBULOGENESIS; COACTIVATORS; MECHANISM	Protein kinase A (PKA) regulates morphogenetic responses to bone morphogenetic proteins (BMPs) during embryogenesis. However, the mechanisms by which PKA regulates BMP function are unknown. During kidney development, BMP-2 and high doses of BMP-7 inhibit branching morphogenesis, whereas low doses of BMP-7 are stimulatory (Piscione, T. D., Yager, T. D., Gupta, I. R., Grinfeld, B., Pei, Y., Attisano, L., Wrana, J. L., and Rosenblum, N. D. (1997) Am. J. Physiol. 273, F961-F975). We examined the interactions between PI(A and these BMPs in embryonic kidney explants and in the mouse inner medullary collecting duct-3 model of collecting duct morphogenesis. H-89, an inhibitor of PKA, stimulated branching morphogenesis and enhanced the stimulatory effect of low doses of BMP-7 on tubule formation. Furthermore, H-89 rescued the inhibition of tubulogenesis by BMP-S (or high doses of BMP-7) by attenuating BMP-a-induced collecting duct apoptosis. In contrast, 8-bromo-cAMP, an activator of PKA, inhibited tubule formation and attenuated the stimulatory effects of low doses of BMP-7. To determine mechanisms underlying the interdependence of BMP signaling and PKA activity, we examined the effect of PKA on the known signaling events in the BMP-2-dependent Smad1 signaling pathway and the effect of BMP-2 on PKA activity. PKA did not induce endogenous Smad1 phosphorylation, Smad1-Smad4 complex formation, or Smad1 nuclear translocation. In contrast, BMP-2 increased endogenous PKA activity and induced phosphorylation of the PKA effector, cAMP-response element-binding protein, in a PKA-dependent manner. We conclude that BMP-2 induces activation of PKA and that PKA regulates the effects of BMPs on collecting duct morphogenesis without activating the known signaling events in the BMP-2-dependent Smad1 signaling pathway.	Univ Toronto, Hosp Sick Children, Div Nephrol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto Hosp, Div Nephrol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Rosenblum, ND (corresponding author), Univ Toronto, Hosp Sick Children, Div Nephrol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Wrana, Jeffrey/F-8857-2013; Rosenblum, Norman D/H-4737-2015	Rosenblum, Norman D/0000-0003-1767-6464; Macias-Silva, Marina/0000-0002-3972-0983				ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; CANTLEY LG, 1994, AM J PHYSIOL, V267, pF271, DOI 10.1152/ajprenal.1994.267.2.F271; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Dudley AT, 1997, DEV DYNAM, V208, P349; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; LARSEN E, 1987, BIOESSAYS, V7, P130, DOI 10.1002/bies.950070309; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Lee YS, 1997, J CELL PHYSIOL, V170, P153, DOI 10.1002/(SICI)1097-4652(199702)170:2<153::AID-JCP7>3.0.CO;2-N; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; Piscione TD, 1997, AM J PHYSIOL-RENAL, V273, pF961, DOI 10.1152/ajprenal.1997.273.6.F961; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SANTOS OFP, 1993, DEV BIOL, V159, P535, DOI 10.1006/dbio.1993.1262; SAXEN L, 1987, ORGANOGENESIS KIDNEY, P51; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wang LW, 1998, J BIOL CHEM, V273, P8522, DOI 10.1074/jbc.273.14.8522; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	32	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26305	26314		10.1074/jbc.274.37.26305	http://dx.doi.org/10.1074/jbc.274.37.26305			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473586	hybrid			2022-12-25	WOS:000082469700052
J	Yeo, CY; Chen, X; Whitman, M				Yeo, CY; Chen, X; Whitman, M			The role of FAST-1 and Smads in transcriptional regulation by activin during early Xenopus embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; GROWTH-FACTOR-BETA; TGF-BETA; TUMOR-SUPPRESSOR; SMAD4/DPC4; RECEPTOR; GENE; ACTIVATOR; MOUSE; GASTRULATION	Smads are signal transducers for the transforming growth factor-p superfamily of factors. In early Xenopns embryos, the transforming growth factor-beta member activin induces the gene Mix,a by stimulating the formation of a multiprotein complex, activin-responsive factor (ARF). This complex contains Smad2 or Smad3, Smad4, and a novel forkhead transcription factor, FAST-1, and binds to an enhancer (activin-responsive element; ARE)that confers activin regulation of Mix.2 transcription. Both FAST-1 and Smads can bind directly to the ARE; we have investigated 1) the role of FAST-1 and Smad DNA binding sites in ARF recognition of the ARE, 2) the contributions of FAST-1 and Smad binding to ARF binding in vitro and to ARE regulation in early Xenopus embryos, 3) the extent to which different Smads can replace Smad4 in regulation of the ARE. We find that ARF binds to ARE through both FAST-1 and Smad binding sites. FAST-1 recognition of the ARE is essential both for ARF binding in vitro and activin regulation in vivo. In contrast, Smad binding of ARE is unnecessary for ARF binding or activin regulation but does enhance the binding and regulatory activity of ARF. Also, Smad3 can partially substitute for Smad4 in the regulation of the ARE. These observations elucidate how broadly expressed signal transducers (Smads) regulate a developmentally specific transcriptional response in conjunction with a temporally restricted transcription factor, FAST-I.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Grad Program Biol & Biomed Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Whitman, M (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	mwhitman@hms.harvard.edu		Yeo, Chang-Yeol/0000-0002-4440-1215				Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; AUSUBEL FM, 1988, CURRENT PROTOCOLS MO, V2; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CONLON FL, 1994, DEVELOPMENT, V120, P1919; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; Weisberg E, 1998, MECH DEVELOP, V79, P17, DOI 10.1016/S0925-4773(98)00160-9; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	38	90	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26584	26590		10.1074/jbc.274.37.26584	http://dx.doi.org/10.1074/jbc.274.37.26584			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473623	hybrid			2022-12-25	WOS:000082469700089
J	Ayoubi, TAY; Jansen, E; Meulemans, SMP; Van de Ven, WJM				Ayoubi, TAY; Jansen, E; Meulemans, SMP; Van de Ven, WJM			Regulation of HMGIC expression: an architectural transcription factor involved in growth control and development	ONCOGENE			English	Article						HMGIC; gene expression; promoter activity; growth factors; solid tumor formation	BENIGN MESENCHYMAL TUMORS; GENE-EXPRESSION; DNA-BINDING; ADIPOCYTE DIFFERENTIATION; FUNCTIONAL INTERACTION; CHROMOSOMAL-PROTEINS; C GENE; DISTINCT; INHIBITION; DOMAIN	The HMGIC gene has been implicated in the control of cell proliferation and development. We show here that HMGIC has multiple mRNA isoforms that arise by transcription initiation from alternative tandem promoters. These transcripts are not only differentially expressed between cell lines, but they can also differ within an individual cell line, in response to particular stimuli. Whereas quiescent 3T3-L1 preadipocytes express low levels of HMGIC mRNA, stimulation by serum results in a dramatic upregulation with the characteristics of a delayed-early response gene. Characterization of involved signal transduction pathways showed that both FGF-1 and PDGF-BB are strong inducers of HMGIC expression mediated via both the PI-3 kinase and MAP kinase pathways. In order to characterize the regulatory elements, sequences upstream of the translation initiation site of HMGIC were assayed for promoter activity. The HMGIC 5' flanking sequences had constitutive promoter activity in all cell lines tested, suggesting that HMGIC is regulated by negative regulatory elements that were not present in the 5'-flanking regions analysed here.	Univ Leuven VIB, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven	Jansen, E (corresponding author), Univ Leuven VIB, Ctr Human Genet, Mol Oncol Lab, Herestr 49, B-3000 Louvain, Belgium.							ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; ASHAR HR, 1995, CELL, V82, P57; Ashar HR, 1996, GENOMICS, V31, P207, DOI 10.1006/geno.1996.0033; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; CHAU KY, 1995, NUCLEIC ACIDS RES, V23, P4262, DOI 10.1093/nar/23.21.4262; Chiappetta G, 1998, CANCER RES, V58, P4193; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Elferink CJ, 1996, BIOTECHNIQUES, V20, P470; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; Geurts JMW, 1997, CANCER GENET CYTOGEN, V95, P198, DOI 10.1016/S0165-4608(96)00411-6; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; HYUN SW, 1994, J BIOL CHEM, V269, P364; Ishwad CS, 1997, HUM GENET, V99, P103; Jansen E, 1997, J BIOL CHEM, V272, P2500; JANSEN E, 1999, GENE THER MOL BIOL, V3, P387; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kazmierczak B, 1998, GENE CHROMOSOME CANC, V23, P279, DOI 10.1002/(SICI)1098-2264(199812)23:4<279::AID-GCC1>3.0.CO;2-1; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEGER H, 1995, MOL CELL BIOL, V15, P3738; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; Manfioletti G, 1995, GENE, V167, P249, DOI 10.1016/0378-1119(95)00666-4; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; Moore DD, 1995, GLOB MOB SURV; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; PARK K, 1992, J BIOL CHEM, V267, P10810; REEVES R, 1990, J BIOL CHEM, V265, P8573; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Zhou XJ, 1996, NUCLEIC ACIDS RES, V24, P4071, DOI 10.1093/nar/24.20.4071	41	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5076	5087		10.1038/sj.onc.1202881	http://dx.doi.org/10.1038/sj.onc.1202881			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490844				2022-12-25	WOS:000082497100007
J	Koh, H; Jee, K; Lee, B; Kim, J; Kim, D; Yun, YH; Kim, JW; Choi, HS; Chung, J				Koh, H; Jee, K; Lee, B; Kim, J; Kim, D; Yun, YH; Kim, JW; Choi, HS; Chung, J			Cloning and characterization of a nuclear S6 kinase, S6 kinase-related kinase (SRK); A novel nuclear target of Akt	ONCOGENE			English	Article						human; S6 kinase; Akt; nucleus	ACTIVATION; PHOSPHORYLATION; GENE; TRANSLOCATION; EXPRESSION; P70(S6K); PDK1	Akt is stimulated by several growth factors, and mediates their cell survival signals. Recent studies have shown that Akt may play an intermediate role between phosphatidylinositol 3-kinase (PI3K) and p70 S6 kinase (p70S6K), Here we show that a novel nuclear p70S6K-related kinase (SRK) exists and that its in vivo function is also augmented by over-expression of Akt, Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K, However, the Nand C-terminal domains of SRK were quite different from those of p70S6K. In immunolocalization analyses, we demonstrated a constitutive nuclear localization of SRK and the presence of a nuclear localization signal in its C-terminus, In vitro S6 phosphotransferase activities of SRK were stimulated with a slower kinetics by a variety of agonists to p70S6K, Interestingly, overexpression of the proto-oncogene Akt resulted in EGF-independent activation of SRK, while over-expression of kinase-dead Akt actually had an inhibitory effect, This relationship between Akt and SRK suggests that SRK may be a novel target of Akt and perhaps an important downstream component in the nuclear function of Akt.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Pai Chai Univ, Dept Biochem, Taejon 302735, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Chonnam National University; Pai Chai University	Chung, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Koh, Hyoungjong/C-1615-2012	Koh, Hyongjong/0000-0003-2594-4799				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649	18	59	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5115	5119		10.1038/sj.onc.1202895	http://dx.doi.org/10.1038/sj.onc.1202895			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490848				2022-12-25	WOS:000082497100011
J	Hoare, S; Copland, JA; Strakova, Z; Ives, K; Jeng, YJ; Hellmich, MR; Soloff, MS				Hoare, S; Copland, JA; Strakova, Z; Ives, K; Jeng, YJ; Hellmich, MR; Soloff, MS			The proximal portion of the COOH terminus of the oxytocin receptor is required for coupling to G(q), but not G(i) - Independent mechanisms for elevating intracellular calcium concentrations from intracellular stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SITE-DIRECTED MUTAGENESIS; HUMAN BETA-2-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; PUTATIVE PALMITOYLATION SITE; VASOPRESSIN V2 RECEPTOR; G-BETA-GAMMA; CYTOPLASMIC TAIL; SPHINGOSINE KINASE; TYROSINE-KINASE	As the oxytocin receptor plays a key role in parturition and lactation, there is considerable interest in defining its structure/functional relationships, We previously showed that the rat oxytocin receptor transfected into Chinese hamster ovary cells was coupled to both G(q/11) and G(i/o), and that oxytocin stimulated ERK-2 phosphorylation and prostaglandin E-2 synthesis via protein kinase C activity. In this study, we show that deletion of 51 amino acid residues from the carboxyl terminus resulted in reduced affinity for oxytocin and a corresponding rightward shift in the dose-response curve for oxytocin-stimulated [Ca2+](i). However, oxytocin-stimulated ERK-2 phosphorylation and prostaglandin E-2 synthesis did not occur in cells expressing the truncated receptor. Oxytocin also failed to increase phospholipase A activity or activate protein kinase C, indicating that the mutant receptor is uncoupled from G(q)-mediated pathways. The Delta 51 receptor is coupled to G(i), as oxytocin-stimulated Ca2+ transients were inhibited by pertussis toxin, and a G beta gamma sequestrant. Preincubation of Delta 51 cells with the tyrosine kinase inhibitor, genistein, also blocked the oxytocin effect. A Delta 39 mutant had all the activities of the wild type oxytocin receptor, These results show that the portion between 39 and 51 residues from the COOH terminus of the rat oxytocin receptor is required for interaction with G(q/11), but not G(i/o). Furthermore, an increase in intracellular calcium was generated via a G(i)beta gamma-tyrosine kinase pathway from intracellular stores that are distinct from G(q)-mediated inositol trisphosphate-regulated stores.	Univ Texas, Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Soloff, MS (corresponding author), Univ Texas, Med Branch, Dept Obstet & Gynecol, 301 Univ Blvd, Galveston, TX 77555 USA.	msoloff@utmb.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026168] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26168] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; Aquilla E, 1996, J BIOL CHEM, V271, P31572, DOI 10.1074/jbc.271.49.31572; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Choi OH, 1996, NATURE, V380, P634; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; HAWES BE, 1994, J BIOL CHEM, V269, P15776; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HINKO A, 1993, ENDOCRINOLOGY, V133, P1511, DOI 10.1210/en.133.4.1511; HIPKIN RW, 1995, J BIOL CHEM, V270, P26683, DOI 10.1074/jbc.270.44.26683; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; Jeng YJ, 1996, NEUROPEPTIDES, V30, P557, DOI 10.1016/S0143-4179(96)90039-6; Jin H, 1997, EUR J PHARMACOL, V324, P109, DOI 10.1016/S0014-2999(97)00059-9; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KENNEDY ME, 1994, J BIOL CHEM, V269, P31915; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KOSHIMIZU T, 1995, BIOCHEM BIOPH RES CO, V217, P354, DOI 10.1006/bbrc.1995.2784; Kosugi S, 1996, BIOCHEM BIOPH RES CO, V221, P636, DOI 10.1006/bbrc.1996.0648; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MacrezLepretre N, 1997, J BIOL CHEM, V272, P5261, DOI 10.1074/jbc.272.8.5261; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; Ogiwara T, 1997, BIOCHEM PHARMACOL, V53, P95, DOI 10.1016/S0006-2952(96)00694-6; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; PINNOCK RD, 1994, EUR J PHARM-MOLEC PH, V269, P73, DOI 10.1016/0922-4106(94)90028-0; Postina R, 1996, J BIOL CHEM, V271, P31593, DOI 10.1074/jbc.271.49.31593; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; Qian A, 1998, CELL SIGNAL, V10, P101, DOI 10.1016/S0898-6568(97)00097-1; RADDATZ R, 1995, J NEUROCHEM, V64, P1183; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SANCHEZYAGUE J, 1992, J BIOL CHEM, V267, P7217; SCHNEIDER H, 1994, FEBS LETT, V351, P281, DOI 10.1016/0014-5793(94)00878-7; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Shibata T, 1996, BIOCHEM BIOPH RES CO, V218, P383, DOI 10.1006/bbrc.1996.0067; SOLOFF MS, 1982, J BIOL CHEM, V257, P687; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; Strakova Z, 1997, AM J PHYSIOL-ENDOC M, V272, pE870, DOI 10.1152/ajpendo.1997.272.5.E870; Strakova Z, 1998, AM J PHYSIOL-ENDOC M, V274, pE634, DOI 10.1152/ajpendo.1998.274.4.E634; Strakova Z, 1997, MOL PHARMACOL, V51, P217, DOI 10.1124/mol.51.2.217; Suda N, 1997, J GEN PHYSIOL, V109, P619, DOI 10.1085/jgp.109.5.619; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TAKANO T, 1994, J BIOL CHEM, V269, P22453; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771	66	63	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28682	28689		10.1074/jbc.274.40.28682	http://dx.doi.org/10.1074/jbc.274.40.28682			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497238	hybrid			2022-12-25	WOS:000082912700087
J	Cengel, KA; Freund, GG				Cengel, KA; Freund, GG			JAK1-dependent phosphorylation of insulin receptor substrate-1 (IRS-1) is inhibited by IRS-1 serine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; I INTERFERON RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; SERINE/THREONINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; GROWTH-FACTOR; JANUS KINASE; ALPHA; ACTIVATION	Serine phosphorylation of insulin receptor substrate-1 (IRS-1) reduces its ability to act as an insulin receptor substrate and inhibits insulin receptor signal transduction. Here, we report that serine phosphorylation of IRS-1 induced by either okadaic acid (OA) or chronic insulin stimulation prevents interferon-alpha (IFN-alpha)-dependent IRS-1 tyrosine phosphorylation and IFN-alpha-dependent IRS-1/phosphatidylinositol 3'-kinase (PI3K) association. In addition, we demonstrate that serine phosphorylation of IRS-1 renders it a poorer substrate for JAK1 ((J) under bar anus (k) under bar inase-1). We found that treatment of U266 cells with OA induced serine phosphorylation of IRS-1 and completely blocked IFN-alpha-dependent tyrosine phosphorylation of IRS-1 and IFN-alpha-dependent IRS-1/PI3K association. Additionally, IRS-1 hom OA-treated cells could not be phosphorylated in vitro by IFN-cu activated JAK1. Chronic treatment of U266 cells with insulin led to a 50% reduction in IFN-alpha-dependent tyrosine phosphorylation of IRS-1 and IRS-1/PI3K association. More importantly, serine-phosphorylated IRS-1-(511-722) could not be phosphorylated in vitro by IFN-alpha-activated JAK1. Taken together, these data indicate that serine phosphorylation of IRS-1 prevents its subsequent tyrosine phosphorylation by JAK1 and suggest that IRS-1 serine phosphorylation may play a counter regulatory role in pathways outside the insulin signaling system.	Univ Illinois, Coll Med, Dept Pathol, Urbana, IL 61801 USA; Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Freund, GG (corresponding author), Univ Illinois, Coll Med, Dept Pathol, 506 S Mathews Ave, Urbana, IL 61801 USA.	freun@ux1.cso.uiuc.edu			NCI NIH HHS [CA-61931] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA061931] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cengel KA, 1998, BIOCHEM BIOPH RES CO, V242, P513, DOI 10.1006/bbrc.1997.7996; Cengel KA, 1998, BIOCHEM J, V335, P397, DOI 10.1042/bj3350397; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; DULCOS B, 1991, METHOD ENZYMOL, V201, P10; Folli F, 1997, J CLIN INVEST, V100, P2158, DOI 10.1172/JCI119752; FREUND GG, 1994, CANCER RES, V54, P3179; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HORTON ES, 1995, DIABETES RES CLIN PR, V28, pS3, DOI 10.1016/0168-8227(95)01087-T; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; MAYOR P, 1992, DIABETES, V41, P274, DOI 10.2337/diabetes.41.3.274; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; SAAD MJA, 1995, ENDOCRINOLOGY, V136, P1579, DOI 10.1210/en.136.4.1579; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Sun XJ, 1998, DIABETES, V47, pA35; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Uddin S, 1997, J IMMUNOL, V158, P2390; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Wang HY, 1998, J BIOL CHEM, V273, P9898, DOI 10.1074/jbc.273.16.9898; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zamorano J, 1996, J IMMUNOL, V157, P4926	47	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27969	27974		10.1074/jbc.274.39.27969	http://dx.doi.org/10.1074/jbc.274.39.27969			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488146	hybrid			2022-12-25	WOS:000082739100085
J	Nakashima, K; Hagiwara, T; Ishigami, A; Nagata, S; Asaga, H; Kuramoto, M; Senshu, T; Yamada, M				Nakashima, K; Hagiwara, T; Ishigami, A; Nagata, S; Asaga, H; Kuramoto, M; Senshu, T; Yamada, M			Molecular characterization of peptidylarginine deiminase in HL-60 cells induced by retinoic acid and 1 alpha,25-dihydroxyvitamin D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; HAIR FOLLICLE; CITRULLINE RESIDUES; RAT; CLONING; CDNA; EXPRESSION; DIFFERENTIATION; BRAIN; LINE	Three types of peptidylarginine deiminase (PAD), which converts a protein arginine residue to a citrulline residue, are widely distributed in animal tissues. Little is known about PAD of hemopoietic cells. We found that PAD activity in human myeloid leukemia HL-60 cells was induced with the granulocyte-inducing agents retinoic acid and dimethyl sulfoxide and with the monocyte-inducing agent 1 alpha,25-dihydroxyvitamin D-3. We cloned and characterized a PAD cDNA from retinoic acid-induced cells. The cDNA was 2,238 base pairs long and encoded a 663-amino acid polypeptide. The HL-60 PAD had 50-55% amino acid sequence identities with the three known enzymes and 73% identity with the recently cloned keratinocyte PAD. The recombinant enzyme differs in kinetic properties from the known enzymes. Immunoblotting and Northern blotting with an antiserum against the enzyme and the cDNA, respectively, showed that a protein of approximately 67 kDa increased concomitantly with increase of mRNA of approximately 2.6 kilobases during granulocyte differentiation. During monocyte differentiation the same mRNA and protein increased as in granulocyte differentiation. Neither the enzyme activity nor the protein was found in macrophage-induced cells. These results suggested that expression of the PAD gene is tightly linked to myeloid differentiation.	Yokohama City Univ, Grad Sch Integrated Sci, Kanazawa Ku, Yokohama, Kanagawa 2360027, Japan; Tokyo Metropolitan Inst Gerontol, Dept Bioactiv Regulat, Itabashi Ku, Tokyo 1730015, Japan	Yokohama City University; Tokyo Metropolitan Institute of Gerontology	Yamada, M (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Kanazawa Ku, 22-2 Seto, Yokohama, Kanagawa 2360027, Japan.	myamada@yokohama-cu.ac.jp						Abu Rus'd A, 1999, EUR J BIOCHEM, V259, P660; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Asaga H, 1998, BIOCHEM BIOPH RES CO, V243, P641, DOI 10.1006/bbrc.1998.8148; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1987, BLOOD, V70, P1233; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Girbal-Neuhauser E, 1999, J IMMUNOL, V162, P585; GOLDMAN DW, 1985, J IMMUNOL, V135, P525; IMPARL JM, 1995, ARCH BIOCHEM BIOPHYS, V318, P370, DOI 10.1006/abbi.1995.1242; Ishigami A, 1998, FEBS LETT, V433, P113, DOI 10.1016/S0014-5793(98)00893-X; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; KUBILUS J, 1983, BIOCHIM BIOPHYS ACTA, V745, P285, DOI 10.1016/0167-4838(83)90060-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMENSA JWE, 1993, J NEUROCHEM, V61, P987, DOI 10.1111/j.1471-4159.1993.tb03612.x; MCLAURIN J, 1992, J NEUROCHEM, V59, P1414, DOI 10.1111/j.1471-4159.1992.tb08455.x; Mizoguchi M, 1998, J HISTOCHEM CYTOCHEM, V46, P1303, DOI 10.1177/002215549804601110; NAGATA S, 1990, EXPERIENTIA, V46, P72, DOI 10.1007/BF01955420; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; Nishijyo T, 1997, J BIOCHEM, V121, P868; Nusse O, 1997, J BIOL CHEM, V272, P28360, DOI 10.1074/jbc.272.45.28360; PITTET D, 1990, J BIOL CHEM, V265, P14256; Rogers G, 1997, J INVEST DERMATOL, V108, P700, DOI 10.1111/1523-1747.ep12292083; ROGERS GE, 1977, BIOCHIM BIOPHYS ACTA, V495, P159, DOI 10.1016/0005-2795(77)90250-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schellekens GA, 1998, J CLIN INVEST, V101, P273, DOI 10.1172/JCI1316; SENSHU T, 1992, ANAL BIOCHEM, V203, P94, DOI 10.1016/0003-2697(92)90047-B; SENSHU T, 1995, J INVEST DERMATOL, V105, P163, DOI 10.1111/1523-1747.ep12317070; Senshu T, 1996, BIOCHEM BIOPH RES CO, V225, P712, DOI 10.1006/bbrc.1996.1240; STEINERT PM, 1969, BIOCHIM BIOPHYS ACTA, V175, P1, DOI 10.1016/0005-2795(69)90138-X; TAKAHARA H, 1985, J BIOL CHEM, V260, P8378; Tarcsa E, 1996, J BIOL CHEM, V271, P30709, DOI 10.1074/jbc.271.48.30709; TERAKAWA H, 1991, J BIOCHEM, V110, P661, DOI 10.1093/oxfordjournals.jbchem.a123636; Tsuchiya N, 1998, J BIOCHEM-TOKYO, V123, P499; WATANABE K, 1988, BIOCHIM BIOPHYS ACTA, V966, P375, DOI 10.1016/0304-4165(88)90088-8; WATANABE K, 1989, J BIOL CHEM, V264, P15255; Wood DD, 1996, ANN NEUROL, V40, P18, DOI 10.1002/ana.410400106; YAMADA M, 1984, J BIOL CHEM, V259, P3021; Yamakoshi A, 1998, BBA-PROTEIN STRUCT M, V1386, P227, DOI 10.1016/S0167-4838(98)00084-3	41	150	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27786	27792		10.1074/jbc.274.39.27786	http://dx.doi.org/10.1074/jbc.274.39.27786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488123	hybrid			2022-12-25	WOS:000082739100062
J	Ten Hagen, KG; Tetaert, D; Hagen, FK; Richet, C; Beres, TM; Gagnon, J; Balys, MM; VanWuyckhuyse, B; Bedi, GS; Degand, P; Tabak, LA				Ten Hagen, KG; Tetaert, D; Hagen, FK; Richet, C; Beres, TM; Gagnon, J; Balys, MM; VanWuyckhuyse, B; Bedi, GS; Degand, P; Tabak, LA			Characterization of a UDP-GalNAc : polypeptide N-acetylgalactosaminyltransferase that displays glycopeptide N-acetylgalactosaminyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; VITRO O-GLYCOSYLATION; MOLECULAR-CLONING; CDNA CLONING; CHROMOSOMAL LOCALIZATION; TANDEM REPEAT; MUCIN; EXPRESSION; SEPARATION; IDENTIFICATION	We report the cloning, expression, and characterization of a novel member of the mammalian UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase (ppGaNTase) family that transfers GalNAc to a GalNAc-containing glycopeptide. Northern blot analysis revealed that the gene encoding this enzyme, termed ppGaNTase-T6, is expressed in a highly tissue-specific manner. Significant levels of transcript were found in rat and mouse sublingual gland, stomach, small intestine, and colon; trace amounts were seen in the ovary, cervix, and uterus. Recombinant constructs were expressed transiently in COS7 cells but demonstrated no transferase activity in vitro against a panel of unmodified peptides, including GTTPSPVPTTSTTSAP (MUC5AC). However, when incubated with the total glycosylated products obtained by action of ppGaNTase-T1 on MUC5AC (mainly GTT(GalNAc)PSPVPTTST(GalNAc)SAP), additional incorporation of GalNAc was achieved, resulting in new hydroxyamino acids being modified. The MUC5AC glycopeptide failed to serve as a substrate for ppGaNTase-T6 after modification of the GalNAc residues by periodate oxidation and sodium borohydride reduction, indicating a requirement for the presence of intact GalNAc. This suggests that O-glycosylation of multisite substrates may proceed in a specific hierarchical manner and underscores the potential complexity of the processes that regulate O-glycosylation.	Univ Rochester, Rochester Inst Biomed Sci, Ctr Oral Biol, Rochester, NY 14642 USA; INSERM, U377, F-59045 Lille, France; CEA, CNRS, Inst Biol Struct, F-38027 Grenoble 1, France	University of Rochester; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Tabak, LA (corresponding author), Univ Rochester, Rochester Inst Biomed Sci, Ctr Oral Biol, 601 Elmwood Ave,Box 611, Rochester, NY 14642 USA.	Lawrence_Tabak@urmc.rochester.edu	Gagnon, Jean/C-3136-2008	Gagnon, Jean/0000-0002-0177-824X	NIDCR NIH HHS [DE-08108] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008108, R37DE008108] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBONE EF, 1994, J BIOL CHEM, V269, P16845; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; BIELHER R, 1995, TECHNICAL B TIBC, V105, P1; Boulis Y, 1998, J CHROMATOGR A, V805, P285, DOI 10.1016/S0021-9673(97)01303-4; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; DOWBENKO D, 1993, J BIOL CHEM, V268, P4525; DUPERAT VG, 1995, BIOCHEM J, V305, P211, DOI 10.1042/bj3050211; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GOLDSTEIN I. J., 1965, METHOD CARBOHYD CHEM, V5, P361; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; Hennebicq S, 1998, GLYCOCONJUGATE J, V15, P275, DOI 10.1023/A:1006949129456; HennebicqReig S, 1996, CARBOHYD RES, V280, P121, DOI 10.1016/0008-6215(95)00297-9; HOMA FL, 1993, J BIOL CHEM, V268, P12609; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KINLOCH RA, 1995, P NATL ACAD SCI USA, V92, P263, DOI 10.1073/pnas.92.1.263; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Moore DD, 1995, GLOB MOB SURV; Nielsen PA, 1997, GLYCOBIOLOGY, V7, P413, DOI 10.1093/glycob/7.3.413; OHMORI H, 1994, J BIOL CHEM, V269, P17833; PILLER V, 1990, J BIOL CHEM, V265, P9264; Rottger S, 1998, J CELL SCI, V111, P45; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEKELS LL, 1995, BIOCHEM J, V311, P775, DOI 10.1042/bj3110775; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; Soudan B, 1998, J PEPT RES, V51, P346; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Troxler RF, 1997, GLYCOBIOLOGY, V7, P965, DOI 10.1093/glycob/7.7.965; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	35	97	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27867	27874						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488133				2022-12-25	WOS:000082739100072
J	Valasek, L; Hasek, J; Trachsel, H; Imre, EM; Ruis, H				Valasek, L; Hasek, J; Trachsel, H; Imre, EM; Ruis, H			The Saccharomyces cerevisiae HCR1 gene encoding a homologue of the p35 subunit of human translation initiation factor 3 (eIF3) is a high copy suppressor of a temperature-sensitive mutation in the Rpg1p subunit of yeast eIF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; RNA-BINDING; PRT1 PROTEIN; COMPLEX; IDENTIFICATION; GCN4; INTERACTS; PHASE	The complex eukaryotic initiation factor 3 (eIF3) was shown to promote the formation of the 43 S preinitiation complex by dissociating 40 S and 60 S ribosomal subunits, stabilizing the ternary complex, and aiding mRNA binding to 40 S ribosomal subunits. Recently, we described the identification of RPG1 (TIF32), the p110 subunit of the eIF3 core complex in yeast. In a screen for Saccharomyces cerevisiae multicopy suppressors of the rpg1-1 temperature-sensitive mutant, an unknown gene corresponding to the open reading frame YLR192C was identified. When overexpressed, the 30-kDa gene product, named Hcr1p, was able to support, under restrictive conditions, growth of the rpg1-1 temperature-sensitive mutant, but not of a Rpg1p-depleted mutant. An hcr1 null mutant was viable, but showed slight reduction of growth when compared with the wild-type strain. Physical interaction between the Hcr1 and Rpg1 proteins was shown by co-immunoprecipitation analysis. The combination of Delta hcr1 and rpg1-1 mutations resulted in a synthetic enhancement of the slow growth phenotype at a semipermissive temperature. In a computer search, a significant homology to the human p35 subunit of the eIF3 complex was found. We assume that the yeast Hcr1 protein participates in translation initiation likely as a protein associated with the eIF3 complex.	Univ Vienna, Inst Biochem & Mol Cell Biol, Vienna Bioctr, A-1030 Vienna, Austria; Ludwig Boltzmann Forschungsstelle Biochem, A-1030 Vienna, Austria; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic; Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland	University of Vienna; Vienna Biocenter (VBC); Ludwig Boltzmann Institute; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Bern	Valasek, L (corresponding author), NICHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA.	lvalasek@aghmac1.nichd.nih.gov	Valášek, Leoš Shivaya/I-5743-2014; Hasek, Jiri/H-2427-2014	Valášek, Leoš Shivaya/0000-0001-8123-8667; Hasek, Jiri/0000-0001-6634-2386				Altmann M, 1997, METHODS, V11, P343, DOI 10.1006/meth.1996.0432; Anderson J, 1998, GENE DEV, V12, P3650, DOI 10.1101/gad.12.23.3650; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; Bandyopadhyay A, 1999, NUCLEIC ACIDS RES, V27, P1331, DOI 10.1093/nar/27.5.1331; BENNE R, 1978, J BIOL CHEM, V253, P3078; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; delaCruz J, 1997, P NATL ACAD SCI USA, V94, P5201, DOI 10.1073/pnas.94.10.5201; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOURMANS H, 1980, BIOCHIM BIOPHYS ACTA, V608, P39; Greenberg JR, 1998, J BIOL CHEM, V273, P23485, DOI 10.1074/jbc.273.36.23485; GUPTA NK, 1990, POSTTRANSCRIPTIONAL, P521; Hanachi P, 1999, J BIOL CHEM, V274, P8546, DOI 10.1074/jbc.274.13.8546; HANNIG EM, 1988, MOL CELL BIOL, V8, P4808, DOI 10.1128/MCB.8.11.4808; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kovarik P, 1998, CURR GENET, V33, P100, DOI 10.1007/s002940050314; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; PAWITT GD, 1998, GENE DEV, V12, P514; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F, 1986, LAB COURSE MANUAL ME; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; Valasek L, 1998, J BIOL CHEM, V273, P21253, DOI 10.1074/jbc.273.33.21253; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	44	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27567	27572		10.1074/jbc.274.39.27567	http://dx.doi.org/10.1074/jbc.274.39.27567			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488093	hybrid			2022-12-25	WOS:000082739100032
J	Zaika, A; Marchenko, N; Moll, UM				Zaika, A; Marchenko, N; Moll, UM			Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; TUMOR-SUPPRESSOR; ONCOPROTEIN MDM2; COLORECTAL ADENOCARCINOMA; NUCLEAR EXCLUSION; BREAST-CANCER; CELL-LINES; IN-VIVO; BINDING; PHOSPHORYLATION	The Mdm2 oncoprotein mediates p53 degradation at cytoplasmic proteasomes and is the principal regulator for maintaining low, often undetectable levels of p53 in unstressed cells. However, a subset of human tumors including neuroblastoma constitutively harbor high levels of wild type p53 protein localized to the cytoplasm. Here we show that the abnormal p53 accumulation in such cells is due to a profound resistance to Mdm2-mediated degradation. Overexpression of Mdma in neuroblastoma (NB)(1) cell lines failed to decrease the high steady state levels of endogenous p53. Moreover, exogenous p53, when introduced into these cells, was also resistant to Mdm2-directed degradation. This resistance is not due to a lack of Mdm2 expression in NE cells or a lack of p53-Mdm2 interaction, nor is it due to a deficiency in the ubiquitination state of p53 or proteasome dysfunction. Instead, Mdma-resistant p53 from NE cells is associated with covalent modification of p53 and masking of the modification sensitive PAb 421 epitope. This system provides evidence for an important level of regulation of Mdma-directed p53 destruction in vivo that is linked to p53 modification.	SUNY Stony Brook, Hlth Sci Ctr, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Moll, UM (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Pathol, Stony Brook, NY 11794 USA.				NCI NIH HHS [R01 CA60664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060664] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOSARI S, 1995, AM J PATHOL, V147, P790; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Isaacs JS, 1998, CELL GROWTH DIFFER, V9, P545; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lou MA, 1997, BRIT J CANCER, V75, P746, DOI 10.1038/bjc.1997.132; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Patterson RM, 1996, ARCH BIOCHEM BIOPHYS, V330, P71, DOI 10.1006/abbi.1996.0227; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Shaw P, 1996, ONCOGENE, V12, P921; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STENMARKASKMALM M, 1994, EUR J CANCER, V30A, P175, DOI 10.1016/0959-8049(94)90082-5; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; SUN XF, 1996, EUR J CANCER, V32, P963; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	51	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27474	27480		10.1074/jbc.274.39.27474	http://dx.doi.org/10.1074/jbc.274.39.27474			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488081	hybrid			2022-12-25	WOS:000082739100020
J	Daftari, P; Gavva, NR; Shen, CKJ				Daftari, P; Gavva, NR; Shen, CKJ			Distinction between AP1 and NF-E2 factor-binding at specific chromatin regions in mammalian cells	ONCOGENE			English	Article						chromatin immunoprecipitation; AP1; NF-E2; in vivo binding	PROTEIN-DNA INTERACTIONS; LOCUS-CONTROL REGION; GLOBIN GENE-EXPRESSION; TRANSCRIPTION FACTOR NF-E2; C-JUN PROMOTER; IN-VIVO; ALPHA-GLOBIN; INTERACTIONS INVIVO; INDUCIBLE ENHANCER; REGULATORY ELEMENT	Specific nuclear factor-DNA complexes formed within the promoters and enhancers are essential for transcriptional regulation, For eukaryotic systems, however, some DNA motif(s) are capable of binding to a family of related factors, thus making it difficult to identify the factor actually binding on the chromatic DNA in vivo and modulating the local transcription processes, To resolve this matter, we have refined a chromatin immunoprecipitation assay. Using the assay, we could directly link the regulatory functions of tao members of the AP1/NF-E2 transcription factor family and their stable binding in vivo within distinct chromatin regions, The study demonstrated the feasibility of a general scheme in the determination of the identity of specific factor(s), among a group of family members, bound at unique sequence(s) in living mammalian cells.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Acad Sinica, Inst Mol Biol, Taipei, Taiwan	University of California System; University of California Davis; Academia Sinica - Taiwan	Shen, CKJ (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK29800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Amrolia PJ, 1997, P NATL ACAD SCI USA, V94, P10051, DOI 10.1073/pnas.94.19.10051; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; FLEENOR DE, 1993, BLOOD, V81, P2781; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Gong QH, 1996, MOL CELL BIOL, V16, P6055; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; Huang BL, 1998, P NATL ACAD SCI USA, V95, P14669, DOI 10.1073/pnas.95.25.14669; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Walter J, 1996, P NATL ACAD SCI USA, V93, P2680, DOI 10.1073/pnas.93.7.2680; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; ZHANG QY, 1993, MOL CELL BIOL, V13, P2298, DOI 10.1128/MCB.13.4.2298	42	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5482	5486		10.1038/sj.onc.1202916	http://dx.doi.org/10.1038/sj.onc.1202916			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498903				2022-12-25	WOS:000082718600014
J	Togawa, A; Miyoshi, J; Ishizaki, H; Tanaka, M; Takakura, A; Nishioka, H; Yoshida, H; Doi, T; Mizoguchi, A; Matsuura, N; Niho, Y; Nishimune, Y; Nishikawa, S; Takai, Y				Togawa, A; Miyoshi, J; Ishizaki, H; Tanaka, M; Takakura, A; Nishioka, H; Yoshida, H; Doi, T; Mizoguchi, A; Matsuura, N; Niho, Y; Nishimune, Y; Nishikawa, S; Takai, Y			Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDI alpha	ONCOGENE			English	Article						gene targeting; small G protein; Rho; Rho GDI alpha; nephrotic syndrome; infertility	GTP-BINDING PROTEINS; DISSOCIATION INHIBITOR GDI; CELL-CYCLE PROGRESSION; SMALL GTPASES RAC; REGULATORY PROTEIN; MDCK CELLS; CA2+-DEPENDENT EXOCYTOSIS; STRESS FIBERS; CDC42 GTPASES; MAST-CELLS	The Rho small G protein family members regulate various actin cytoskeleton-dependent cell functions. The Rho GDI (GDP dissociation inhibitor) family, consisting of Rho GDI alpha, -beta, and -gamma, is a regulator that keeps the Rho family members in the cytosol as the GDP-bound inactive form and translocates the GDP-bound form from the membranes to the cytosol after the GTP-bound form accomplishes their functions. Rho GDI alpha is ubiquitously expressed in mouse tissues and shows GDI activity on all the Rho family members in vitro. We have generated mice lacking Rho GDI alpha by homologous recombination to clarify its in vivo function. Rho GDI alpha -/- mice showed several abnormal phenotypes, Firstly, Rho GDI alpha -/- mice were initially viable but developed massive proteinuria mimicking nephrotic syndrome, leading to death due to renal failure within a year. Histologically, degeneration of tubular epithelial cells and dilatation of distal and collecting tubules were readily detected in the kidneys. Secondly, Rho GDI alpha -/- male mice were infertile and showed impaired spermatogenesis with vacuolar degeneration of seminiferous tubules in their testes. Thirdly, Rho GDI alpha -/- embryos derived from Rho GDI alpha -/- female mice were defective in the postimplantation development, In addition, these morphological and functional abnormalities showed age-dependent progression. These results suggest that the signaling pathways of the Rho family members regulated by Rho GDI alpha play important roles in maintaining the structure and physiological function of at least kidneys and reproductive systems in adult mice.	JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan; Kyoto Univ, Fac Med, Dept Mol Genet, Kyoto 6068507, Japan; Kyoto Univ Hosp, Div Artificial Kidneys, Kyoto 6068507, Japan; Kyoto Univ, Fac Med, Dept Anat, Kyoto 6068507, Japan; Osaka Univ, Sch Allied Hlth Sci, Dept Pathol, Osaka 5650871, Japan; Kyushu Univ, Fac Med, Dept Internal Med 4, Fukuoka 81282, Japan; Osaka Univ, Microbial Dis Res Inst, Div Mol Embryol, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Mol Biol & Biochem, ERATO,Takai Biotimer Project, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Kyoto University; Kyoto University; Kyoto University; Osaka University; Kyushu University; Osaka University; Japan Science & Technology Agency (JST); Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, ERATO,Takai Biotimer Project, Osaka 5650871, Japan.			Tanaka-Okamoto, Miki/0000-0002-6429-7662				Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; Hogan B., 1994, MANIPULATING MOUSE E, P296; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; ISOMURA M, 1991, ONCOGENE, V6, P119; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; Kotani H, 1997, ONCOGENE, V14, P1705, DOI 10.1038/sj.onc.1200998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Mariot P, 1996, EMBO J, V15, P6476, DOI 10.1002/j.1460-2075.1996.tb01038.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA Y, 1993, J BIOL CHEM, V268, P510; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PLATKO JV, 1995, P NATL ACAD SCI USA, V92, P2974, DOI 10.1073/pnas.92.7.2974; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; Roberts R G, 1987, Biomed Chromatogr, V2, P71, DOI 10.1002/bmc.1130020207; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; UEDA T, 1990, J BIOL CHEM, V265, P9373; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366	42	163	166	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5373	5380		10.1038/sj.onc.1202921	http://dx.doi.org/10.1038/sj.onc.1202921			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498891				2022-12-25	WOS:000082718600002
J	Li, XF; Thinakaran, G; Sisodia, SS; Yu, FSX				Li, XF; Thinakaran, G; Sisodia, SS; Yu, FSX			Amyloid precursor-like protein 2 promotes cell migration toward fibronectin and collagen IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE GLYCOSAMINOGLYCAN; EXTRACELLULAR-MATRIX COMPONENTS; BASEMENT-MEMBRANE; VI COLLAGEN; ALZHEIMERS-DISEASE; EPITHELIAL-CELLS; ALPHA-2-BETA-1 INTEGRIN; SYNTHETIC PEPTIDES; NG2 PROTEOGLYCAN; BINDING-SITES	Previous studies have established that in response to wounding, the expression of amyloid precursor-like protein 2 (APLP2) in the basal cells of migrating corneal epithelium is greatly up-regulated. To further our understanding of the functional significance of APLP2 in wound healing, we have measured the migratory response of transfected Chinese hamster ovary (CHO) cells expressing APLP2 isoforms to a variety of extracellular matrix components including laminin, collagen types I, IV, and VII, fibronectin, and heparan sulfate proteoglycans (HSPGs). CHO cells overexpressing either of two APLP2 variants, differing in chondroitin sulfate (CS) attachment, exhibit a marked increase in chemotaxis toward type IV collagen and fibronectin but not to laminin, collagen types I and VII, and HSPGs. Cells overexpressing APLP2-751 (CS-modified) exhibited a greater migratory response to fibronectin and type TV collagen than their non-CS-attached counterparts (APLP2-763), suggesting that CS modification enhanced APLP2 effects on cell migration. Moreover, in the presence of chlondroitin sulfate, transfectants overexpressing APLP2-751 failed to exhibit this enhanced migration toward fibronectin, The APLP2-ECM interactions were also explored by solid phase adhesion assays. While overexpression of APLP2 isoforms moderately enhanced CHO adhesion to laminin, collagen types I and VII, and HSPGs lines, especially those overexpressing APLP2-751, exhibited greatly increased adhesion to type TV collagen and fibronectin. These observations suggest that APLP2 contributes to re-epithelialization during wound healing by supporting epithelial cell adhesion to fibronectin and collagen IV, thus influencing their capacity to migrate over the wound bed. Furthermore, APLP2 interactions with fibronectin and collagen IV appear to be potentiated by the addition of a CS chain to the core proteins.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; University of Chicago	Yu, FSX (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.				NATIONAL EYE INSTITUTE [R01EY010869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS020471, P01NS020471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER; NEI NIH HHS [EY10869] Funding Source: Medline; NIA NIH HHS [AG05146] Funding Source: Medline; NINDS NIH HHS [NS 20471] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; Burg MA, 1997, EXP CELL RES, V235, P254, DOI 10.1006/excr.1997.3674; CAMERON JD, 1991, INVEST OPHTH VIS SCI, V32, P2766; Carey DJ, 1997, BIOCHEM J, V327, P1; CHEN M, 1991, NEUROSCI LETT, V125, P223, DOI 10.1016/0304-3940(91)90034-Q; Clark RA, 1996, J CELL BIOL, V134, P1075, DOI 10.1083/jcb.134.4.1075; CORLESS CL, 1992, DEV DYNAM, V193, P346, DOI 10.1002/aja.1001930408; Daniels KJ, 1996, LAB INVEST, V75, P55; DONALDSON DJ, 1994, J CELL PHYSIOL, V158, P79, DOI 10.1002/jcp.1041580111; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FUJIKAWA LS, 1981, LAB INVEST, V45, P120; GHISO J, 1992, BIOCHEM J, V288, P1053, DOI 10.1042/bj2881053; Guo J, 1998, INVEST OPHTH VIS SCI, V39, P292; HAN J, 1995, CANCER LETT, V88, P127, DOI 10.1016/0304-3835(94)03627-U; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IIDA J, 1995, CANCER RES, V55, P2177; ISHIZAKI M, 1993, INVEST OPHTH VIS SCI, V34, P2680; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM JP, 1994, LAB INVEST, V71, P401; Knutson JR, 1996, MOL BIOL CELL, V7, P383, DOI 10.1091/mbc.7.3.383; KUHN K, 1995, MATRIX BIOL, V14, P439, DOI 10.1016/0945-053X(95)90001-2; Lin XH, 1996, J CELL BIOCHEM, V63, P463, DOI 10.1002/(SICI)1097-4644(19961215)63:4<463::AID-JCB8>3.0.CO;2-R; LJUBIMOV AV, 1995, LAB INVEST, V72, P461; Maguen E, 1997, CORNEA, V16, P675; MALDONADO BA, 1995, INVEST OPHTH VIS SCI, V36, P364; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; NARINDRASORASAK S, 1995, LAB INVEST, V72, P272; NARINDRASORASAK S, 1992, NEUROSCI LETT, V144, P46; NARINDRASORASAK S, 1991, BRAIN RES MOL BRAIN, V10, P173; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PERRIS R, 1993, EXP CELL RES, V209, P103, DOI 10.1006/excr.1993.1290; PERRIS R, 1993, DEV DYNAM, V198, P135, DOI 10.1002/aja.1001980207; RICKARD KA, 1993, AM J RESP CELL MOL, V8, P63, DOI 10.1165/ajrcmb/8.1.63; Romberger DJ, 1997, INT J BIOCHEM CELL B, V29, P939, DOI 10.1016/S1357-2725(96)00172-0; Sado Y, 1998, J BIOCHEM-TOKYO, V123, P767; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; STREIT A, 1993, J CELL BIOL, V120, P799, DOI 10.1083/jcb.120.3.799; THESLEFF I, 1990, CELL DIFFER DEV, V32, P383, DOI 10.1016/0922-3371(90)90054-Z; THINAKARAN G, 1995, J NEUROSCI, V15, P6314; THINAKARAN G, 1994, J BIOL CHEM, V269, P22099; THINAKARAN G, 1995, J BIOL CHEM, V270, P16522, DOI 10.1074/jbc.270.28.16522; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; VANNOSTRAND WE, 1994, BBA-PROTEIN STRUCT M, V1209, P165, DOI 10.1016/0167-4838(94)90180-5; VERFAILLIE CM, 1994, BLOOD, V84, P1802; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10857; Yamada K.M., 1996, MOL CELLULAR BIOL WO, P51; Yamazaki T, 1997, J NEUROSCI, V17, P1004	56	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27249	27256		10.1074/jbc.274.38.27249	http://dx.doi.org/10.1074/jbc.274.38.27249			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480944	hybrid			2022-12-25	WOS:000082570700083
J	McDaniels, CPJ; Jensen, LT; Srinivasan, C; Winge, DR; Tullius, TD				McDaniels, CPJ; Jensen, LT; Srinivasan, C; Winge, DR; Tullius, TD			The yeast transcription factor Mac1 binds to DNA in a modular fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINOR-GROOVE INTERACTIONS; SACCHAROMYCES-CEREVISIAE; COPPER UPTAKE; HIN RECOMBINASE; METALLOTHIONEIN GENE; CANDIDA-GLABRATA; PROTEIN; DOMAIN; RECOGNITION; EXPRESSION	Mad is a metalloregulatory protein that regulates expression of the high affinity copper transport system in the yeast Saccharomyces cerevisiae, Under conditions of high copper concentration, Mad represses transcription of genes coding for copper transport proteins. Mad binds to DNA sequences called copper response elements (CuREs), which have the consensus sequence 5'-TTTGC(T/G)C(A/G)-3'. Mad contains two zinc binding sites, a copper binding site, and the sequence motif RGRP, which has been found in other proteins to mediate binding to the minor groove of AT-rich sequences in DNA. We have used hydroxyl radical footprinting, missing nucleoside, and methylation interference experiments to investigate the structure of the complex of the DNA binding domain of Mac1 (called here Mac1(t)) with the two CuRE sites found in the yeast CTR1 promoter. We conclude from these experiments that Mac1(t) binds in a modular fashion to DNA, with its RGRP AT-hook motif interacting with the TTT sequence at the 5' end of the CTR1 CuRE site, and with another DNA-binding module(s) binding in the adjacent major groove in the GCTCA sequence.	Boston Univ, Dept Chem, Boston, MA 02215 USA; Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	Boston University; Johns Hopkins University; Utah System of Higher Education; University of Utah	Tullius, TD (corresponding author), Boston Univ, Dept Chem, Boston, MA 02215 USA.		Tullius, Thomas D./A-9685-2008; Winge, Dennis/G-3611-2010	Tullius, Thomas D./0000-0003-4425-796X; Jensen, Laran/0000-0003-3199-1743	NATIONAL CANCER INSTITUTE [R01CA061286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM015503, R01GM041930] Funding Source: NIH RePORTER; NCI NIH HHS [CA61286] Funding Source: Medline; NIGMS NIH HHS [GM41930, GM15503, R01 GM041930, R01 GM041930-10] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; Farrell RA, 1996, BIOCHEMISTRY-US, V35, P1571, DOI 10.1021/bi9517087; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Jensen LT, 1998, J BIOL CHEM, V273, P23805, DOI 10.1074/jbc.273.37.23805; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; Joshi A, 1999, J BIOL CHEM, V274, P218, DOI 10.1074/jbc.274.1.218; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1996, MOL CELL BIOL, V16, P724; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; LEVIN S, 1991, BIOMED CHROMATOGR, V5, P133, DOI 10.1002/bmc.1130050308; MACK DP, 1990, BIOCHEMISTRY-US, V29, P6561, DOI 10.1021/bi00480a003; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; Maxam A M, 1980, Methods Enzymol, V65, P499; Shadle SE, 1997, NUCLEIC ACIDS RES, V25, P850, DOI 10.1093/nar/25.4.850; SLUKA JP, 1990, BIOCHEMISTRY-US, V29, P6551, DOI 10.1021/bi00480a002; SLUKA JP, 1987, SCIENCE, V238, P1129, DOI 10.1126/science.3120311; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112	30	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26962	26967		10.1074/jbc.274.38.26962	http://dx.doi.org/10.1074/jbc.274.38.26962			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480908	hybrid			2022-12-25	WOS:000082570700047
J	Pengue, G; Srivastava, AK; Kere, J; Schlessinger, D; Durmowicz, MC				Pengue, G; Srivastava, AK; Kere, J; Schlessinger, D; Durmowicz, MC			Functional characterization of the promoter of the X-linked ectodermal dysplasia gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; CPG ISLAND; EDA GENE; SYNERGISTIC ACTIVATION; ECTODYSPLASIN-A; BETA-CATENIN; PROTEINS SP1; BINDING; EXPRESSION; ELEMENTS	Anhidrotic ectodermal dysplasia (EDA) is a disorder characterized by poor development of hair, teeth, and sweat glands, and results from lesions in the X-linked EDA gene. We have cloned a 1,6-kilobase 5'-flanking region of the human EDA gene and used it to analyze features of transcriptional regulation. Primer extension analysis located a single transcription initiation site 264 base pairs (bp) upstream of the translation start site. When the intact cloned fragment or truncated derivatives were placed upstream of a reporter luciferase gene and transfected into a series of cultured cells, expression comparable with that conferred by an SV40 promoter-enhancer was observed. The region lacks a TATA box sequence, and basal transcription from the unique start site is dependent on two binding sites for the Spl transcription factor. One site lies 38 bp 5' to the transcription start site, in a 71-bp sequence that is sufficient to support up to 35% of maximal transcription. The functional importance of the Sp1 sites was demonstrated when cotransfection of an Sp1expression vector transactivated the EDA promoter in the SL2 Drosophila cell line that otherwise lacks endogenous Sp1. Also, both Sp1 binding sites were active in footprinting and gel shift assays in the presence of either crude HeLa cell nuclear extract or purified Sp1 and lost activity when the binding sites were mutated. A second region involved in positive control was localized to a 40-bp sequence between -673 and -633 bp, This region activated an SV40 minimal promoter 4- to 5-fold in an orientation-independent manner and is thus inferred to contain an enhancer region.	NIA, Triad Technol Ctr, Genet Lab, Baltimore, MD 21224 USA; Univ Helsinki, Dept Med Genet, Haarman Inst, Helsinki 00014, Finland; Greenwood Genet Ctr, JC Self Res Inst Human Genet, Greenwood, SC 29646 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Helsinki; Greenwood Genetic Center; Washington University (WUSTL)	Durmowicz, MC (corresponding author), NIA, Triad Technol Ctr, Genet Lab, Suite 4000,333 Cassell Dr, Baltimore, MD 21224 USA.		Kere, Juha/AAX-9117-2021; Kere, Juha/A-9179-2008	Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271	NATIONAL INSTITUTE ON AGING [ZIAAG000643, Z01AG000643] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; CHEN XR, 1992, ONCOGENE, V7, P1805; CLARKE A, 1987, J MED GENET, V24, P653; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Ezer S, 1997, HUM MOL GENET, V6, P1581, DOI 10.1093/hmg/6.9.1581; Ferguson BM, 1997, HUM MOL GENET, V6, P1589, DOI 10.1093/hmg/6.9.1589; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Monreal AW, 1998, AM J HUM GENET, V63, P380, DOI 10.1086/301984; Montonen O, 1998, J HISTOCHEM CYTOCHEM, V46, P281, DOI 10.1177/002215549804600301; ORDAHL CP, 1984, J BIOL CHEM, V259, P5224; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; Srivastava AK, 1996, AM J HUM GENET, V58, P126; TIJAN R, 1994, CELL, V77, P5; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; ZHOU P, 1995, GENE DEV, V9, P570; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	49	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26477	26484		10.1074/jbc.274.37.26477	http://dx.doi.org/10.1074/jbc.274.37.26477			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473608	hybrid			2022-12-25	WOS:000082469700074
J	Van Orden, K; Giebler, HA; Lemasson, I; Gonzales, M; Nyborg, JK				Van Orden, K; Giebler, HA; Lemasson, I; Gonzales, M; Nyborg, JK			Binding of p53 to the KIX domain of CREB binding protein - A potential link to human T-cell leukemia virus, type I-associated leukemogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; TRANSCRIPTIONAL COACTIVATOR CBP; PRIMARY HUMAN-LYMPHOCYTES; HTLV-I; TAX PROTEIN; TRANSACTIVATOR TAX; DNA-BINDING; ABERRANT EXPRESSION; MOLECULAR MECHANISM	The pleiotropic cellular coactivator CREB binding protein (CBP) plays a critical role in supporting p53-dependent tumor suppressor functions. p53 has been shown to directly interact with a carboxyl-terminal region of CBP for recruitment of the coactivator to p53-responsive genes. In this report, we identify the KM domain as a new p53 contact point on CBP. We show that both recombinant and endogenous forms of p53 specifically interact with KM. We demonstrate that the activation domain of p53 participates in KM binding and provide evidence showing that this interaction is critical for p53 transactivation function. The human T-cell leukemia virus, type-I-encoded oncoprotein Tax is a well established repressor of p53 transcription function. Like p53, Tax also binds to KIX. The finding that both transcription factors bind to a common region of CBP suggests that coactivator competition may account for the observed repression. We demonstrate reciprocal repression between Tax and p53 in transient transfection assays, supporting the idea of intracellular coactivator competition. We biochemically confirm coactivator competition by directly showing that both transcription factors bind to KM in a mutually exclusive fashion. These data provide molecular evidence for the observed intracellular competition and suggest that Tax inhibits p53 function by abrogating a novel p53-KIX interaction. Thus, Tax competition for the p53-KIX complex may be a pivotal event in the human T-cell leukemia virus, type I transformation pathway.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Nyborg, JK (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	jnyborg@lamar.colostate.edu	Lemasson, Isabelle/N-1355-2013		NATIONAL CANCER INSTITUTE [R01CA055035, R55CA055035] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55035, R01 CA055035, R01 CA055035-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; DYNAN WS, 1987, GENETIC ENG PRINCIPL, V9, P75; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mori N, 1997, BLOOD, V90, P4924, DOI 10.1182/blood.V90.12.4924.4924_4924_4932; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Parker D, 1996, MOL CELL BIOL, V16, P694; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; REID RL, 1993, ONCOGENE, V8, P3029; SANTUCCI M, 1993, RADIAT ONCOL INVEST, V1, P131; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SLAMON DJ, 1985, SCIENCE, V228, P1427, DOI 10.1126/science.2990027; Smits PHM, 1996, ONCOGENE, V12, P1529; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Van Orden K, 1999, ONCOGENE, V18, P3766, DOI 10.1038/sj.onc.1202703; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YEARGIN J, 1992, LEUKEMIA, V6, pS85; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	62	101	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26321	26328		10.1074/jbc.274.37.26321	http://dx.doi.org/10.1074/jbc.274.37.26321			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473588	hybrid			2022-12-25	WOS:000082469700054
J	Steegenga, WT; Riteco, N; Bos, JL				Steegenga, WT; Riteco, N; Bos, JL			Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and Delta E1B adenovirus replication in human cells	ONCOGENE			English	Article						p53; adenovirus; E1B; tumor therapy; replication; CPE	P53 MUTATIONS; 55-KILODALTON PROTEIN; TUMOR-SUPPRESSOR; INFECTED CELLS; HUMAN CANCERS; GENE-TRANSFER; ACTIVATION; CYCLE; LINES; RETINOBLASTOMA	An adenovirus mutant lacking the expression of the large E1B protein (Delta E1B) has been reported to replicate selectively in cells lacking the expression of functionally wild-type (wt) p53. Based on these results the Delta E1B or ONYX-015 virus has been proposed to be an oncolytic virus which might be useful to treat p53-deficient tumors. Recently however, contradictory results have been published indicating that p53-dependent cell death is required for productive adenovirus infection. Since there is an urgent need for new methods to treat aggressive, mutant p53-expressing primary tumors and their metastases we carefully examined adenovirus replication in human cells to determine whether or not the Delta E1B virus can be used for tumor therapy. The results we present here show that not all human tumor cell lines take up adenovirus efficiently. In addition, we observed inhibition of the expression of adenovirus early proteins in tumor cells. We present evidence that these two factors rather than the p53 status of the cell determine whether adenovirus infection results in lytic cell death. Furthermore, the results we obtained by infecting a panel of different tumor cell lines show that viral spread of the Delta E1B is strongly inhibited in almost all p53-proficient and -deficient cell lines compared to the,vt virus. We conclude that the efficiency of the Delta E1B virus to replicate efficiently in tumor cells is determined by the ability to infect cells and to express the early adenovirus proteins rather than the status of p53.	Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3508 TA Utrecht, Netherlands	Utrecht University; Utrecht University	Steegenga, WT (corresponding author), Univ Utrecht, Physiol Chem Lab, POB 80042, NL-3508 TA Utrecht, Netherlands.							BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Furuwatari C, 1998, AM J CLIN PATHOL, V110, P368, DOI 10.1093/ajcp/110.3.368; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PELTENBURG LTC, 1994, IMMUNOGENETICS, V40, P54, DOI 10.1007/BF00163964; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; STEEGENGA WT, 1995, VIROLOGY, V212, P543, DOI 10.1006/viro.1995.1512; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; van der Eb A J, 1980, Methods Enzymol, V65, P826; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	34	22	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5032	5043		10.1038/sj.onc.1202886	http://dx.doi.org/10.1038/sj.onc.1202886			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490840				2022-12-25	WOS:000082497100003
J	Fu, XY; McGrath, S; Pasillas, M; Nakazawa, S; Kamps, MP				Fu, XY; McGrath, S; Pasillas, M; Nakazawa, S; Kamps, MP			EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1	ONCOGENE			English	Article						E2a-Pbx1; pre-B ALL; RDA; target genes	HUMAN PROTOONCOGENE PBX1; DNA-BINDING; MESSENGER-RNA; TRANSLOCATION PROTEIN; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; CELL LEUKEMIA; FUSION; RECEPTOR; DOMAIN	The t(1;19) translocation of pre-B cell acute lymphocytic leukemia (ALL) produces E2a-Pbx1, a chimeric oncoprotein containing the transactivation domains of E2a joined to the homeodomain protein, Pbx1, E2a-Pbx1 causes T cell and myeloid leukemia in mice, blocks differentiation of cultured myeloid progenitors, and transforms fibroblasts through a mechanism accompanied by aberrant expression of tissue-specific and developmentally-regulated genes. Here we investigate whether aberrant gene expression also occurs specifically in the t(1;19)-containing subset of pre-B cell ALL in man. Two new genes, EB-1 and EB-2, as well as Caldesmon were transcriptionally activated in each of seven t(1;19) cell Lines. EB-1 expression was extremely low in marrow from patients having pre-B ALL not associated with the t(1;19), and elevated more than 100-fold in marrow from patients with pre-B ALL associated with the t(1;19), Normal EB-1 expression,vas strong in brain and testis, the same tissues exhibiting the highest levels of PBX1 expression. EB-1 encodes a signaling protein containing a phosphotyrosine binding domain homologous to that of dNumb developmental regulators and two SAM domains homologous to those in the C-terminal tail of Eph receptor tyrosine kinases. We conclude that aberrant expression of tissue-specific genes is a characteristic of t(1;19) pre-B ALL, as was previously found in fibroblasts transformed by E2a-Pbx1, Potentially, EB-1 overexpression could interfere with normal signaling controlling proliferation or differentiation.	Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Yamanashi Med Univ, Dept Pediat, Yamanashi 40938, Japan	University of California System; University of California San Diego; University of Yamanashi	Kamps, MP (corresponding author), Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA.				NATIONAL CANCER INSTITUTE [P01CA050528, R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [2P01 CA50528, CA56876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barr MM, 1996, MOL CELL BIOL, V16, P5597; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; CARROLL AJ, 1984, BLOOD, V63, P721; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES BR, 1993, ONCOGENE, V8, P999; de Lau WBM, 1998, ONCOGENE, V17, P503, DOI 10.1038/sj.onc.1201967; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DESILVA R, 1994, CELL MOL BIOL RES, V40, P323; Feldman BJ, 1997, ONCOGENE, V15, P2735, DOI 10.1038/sj.onc.1201670; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; GREEN JA, 1990, CARCINOGENESIS, V11, P1175, DOI 10.1093/carcin/11.7.1175; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Hisano T, 1996, FEBS LETT, V397, P101, DOI 10.1016/S0014-5793(96)01150-7; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Inada T, 1997, BLOOD, V89, P2757, DOI 10.1182/blood.V89.8.2757; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; KIYOKAWA E, 1994, CANCER RES, V54, P3645; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; Magni M, 1996, BLOOD, V87, P1097, DOI 10.1182/blood.V87.3.1097.bloodjournal8731097; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; ROBERTS VJ, 1995, MECH DEVELOP, V51, P193, DOI 10.1016/0925-4773(95)00364-9; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Schultz J, 1997, PROTEIN SCI, V6, P249; Sefton M, 1997, CELL TISSUE RES, V290, P243, DOI 10.1007/s004410050928; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; SURGUCHEVA I, 1995, CELL MOTIL CYTOSKEL, V32, P233, DOI 10.1002/cm.970320307; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Thompson AD, 1996, ONCOGENE, V13, P2649; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VOGLER LB, 1978, NEW ENGL J MED, V298, P872, DOI 10.1056/NEJM197804202981603; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611	54	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4920	4929		10.1038/sj.onc.1202874	http://dx.doi.org/10.1038/sj.onc.1202874			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490826				2022-12-25	WOS:000082321700004
J	Faro, C; Ramalho-Santos, M; Vieira, M; Mendes, A; Simoes, I; Andrade, R; Verissimo, P; Lin, XL; Tang, J; Pires, E				Faro, C; Ramalho-Santos, M; Vieira, M; Mendes, A; Simoes, I; Andrade, R; Verissimo, P; Lin, XL; Tang, J; Pires, E			Cloning and characterization of cDNA encoding cardosin A, all RGD-containing plant aspartic proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYNARA-CARDUNCULUS L; EXTRACELLULAR-MATRIX; ARABIDOPSIS-THALIANA; VITRONECTIN-LIKE; PLASMA-MEMBRANE; CELL-WALL; NK-LYSIN; BARLEY; ADHESION; INTEGRIN	Cardosin A is an abundant aspartic proteinase from pistils of Cynara cardunculus L. whose milk-clotting activity has been exploited for the manufacture of cheese. Here we report the cloning and characterization of cardosin A cDNA. The deduced amino acid sequence contains the conserved features of plant aspartic proteinases, including the plant-specific insertion (PSI), and revealed the presence of an Arg-Gly-Asp (RGD) motif, which is known to function in cell surface receptor binding by extracellular proteins. Cardosin A mRNA was detected predominantly in young flower buds but not in mature or senescent pistils, suggesting that its expression is likely to be developmentally regulated. Procardosin A, the single chain precursor, was found associated with microsomal membranes of flower buds, whereas the active two-chain enzyme generated upon removal of PSI is soluble. This result implies a role for PSI in promoting the association of plant aspartic proteinase precursors to cell membranes. To get further insights about cardosin A, the functional relevance of the RGD motif was also investigated. A 100-kDa protein that interacts specifically with the RGD sequence was isolated from octyl glucoside pollen extracts by affinity chromatography on cardosin A-Sepharose. This result suggests that the 100-kDa protein is a cardosin A receptor and indicates that the interaction between these two proteins is apparently mediated through RGD recognition. It is possible therefore that cardosin A may have a role in adhesion-mediated proteolytic mechanisms involved in pollen recognition and growth.	Univ Coimbra, Dept Bioquim, Fac Ciencias & Tecnol, P-3000 Coimbra, Portugal; Univ Coimbra, Dept Biol Mol & Biotecnol, Ctr Neurociencias & Biol Celular, P-3000 Coimbra, Portugal; Oklahoma Med Res Fdn, Prot Studies Program, Oklahoma City, OK 73104 USA	Universidade de Coimbra; Universidade de Coimbra; Oklahoma Medical Research Foundation	Faro, C (corresponding author), Univ Coimbra, Dept Bioquim, Fac Ciencias & Tecnol, Apt 3126, P-3000 Coimbra, Portugal.		Simões, Isaura I G/F-3239-2010; Simões, Isaura/N-4210-2019; Verissimo, Paula/AAB-2281-2021; Ramalho-Santos, Miguel/L-9092-2018	Simões, Isaura I G/0000-0002-9331-6340; Simões, Isaura/0000-0002-9331-6340; Verissimo, Paula/0000-0003-0532-4242; Ramalho-Santos, Miguel/0000-0003-0177-5556; Pires, Euclides/0000-0002-5853-0165; Faro, Carlos/0000-0002-0480-8379				ANDERSSON M, 1995, FEBS LETT, V362, P328, DOI 10.1016/0014-5793(95)00268-E; ASAKURA T, 1995, EUR J BIOCHEM, V232, P77, DOI 10.1111/j.1432-1033.1995.tb20783.x; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Canut H, 1998, PLANT J, V16, P63, DOI 10.1046/j.1365-313x.1998.00276.x; CORDEIRO MC, 1994, PLANT MOL BIOL, V24, P733, DOI 10.1007/BF00029855; Costa J, 1997, EUR J BIOCHEM, V243, P695, DOI 10.1111/j.1432-1033.1997.t01-1-00695.x; DHondt K, 1997, PLANT MOL BIOL, V33, P187, DOI 10.1023/A:1005794917200; ELPIDINA EN, 1990, J EXP BOT, V41, P969, DOI 10.1093/jxb/41.8.969; Faik A, 1998, EUR J BIOCHEM, V253, P552, DOI 10.1046/j.1432-1327.1998.2530552.x; Gens JS, 1996, PROTOPLASMA, V194, P215, DOI 10.1007/BF01882029; Glathe S, 1998, J BIOL CHEM, V273, P31230, DOI 10.1074/jbc.273.47.31230; GURUPRASAD K, 1994, FEBS LETT, V352, P131, DOI 10.1016/0014-5793(94)00935-X; James MNG, 1998, ASPARTIC PROTEINASES; Katembe WJ, 1997, PHYSIOL PLANTARUM, V99, P7, DOI 10.1034/j.1399-3054.1997.990102.x; KERVINEN J, 1995, ADV EXP MED BIOL, V362, P241; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P793, DOI 10.1038/nsb1097-793; LIN XL, 1993, J BIOL CHEM, V268, P20143; LORD EM, 1992, DEV BIOL, V153, P16, DOI 10.1016/0012-1606(92)90088-X; Mutlu A, 1998, PHYTOCHEMISTRY, V47, P1453, DOI 10.1016/S0031-9422(97)00834-0; QUATRANO RS, 1991, DEVELOPMENT, P11; Ramalho-Santos M, 1998, EUR J BIOCHEM, V255, P133, DOI 10.1046/j.1432-1327.1998.2550133.x; RamalhoSantos M, 1996, BBA-PROTEIN STRUCT M, V1297, P83, DOI 10.1016/0167-4838(96)00103-3; RamalhoSantos M, 1997, PLANTA, V203, P204, DOI 10.1007/s004250050183; RODRIGO I, 1991, PLANT PHYSIOL, V95, P616, DOI 10.1104/pp.95.2.616; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; RUNEBERGROOS P, 1994, PLANT PHYSIOL, V105, P321, DOI 10.1104/pp.105.1.321; RUNEBERGROOS P, 1991, EUR J BIOCHEM, V202, P1021, DOI 10.1111/j.1432-1033.1991.tb16465.x; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SANDERS LC, 1991, PLANT CELL, V3, P629, DOI 10.1105/tpc.3.6.629; Schaller A, 1996, PLANT MOL BIOL, V31, P1073, DOI 10.1007/BF00040725; SCHINDLER M, 1989, J CELL BIOL, V108, P1955, DOI 10.1083/jcb.108.5.1955; Shilperoort, 1994, PLANT MOL BIOL MAN D, P1, DOI 10.1007/978-94-011-0511-8_16; TOKES ZA, 1974, PLANTA, V119, P39, DOI 10.1007/BF00390820; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; Verissimo P, 1996, EUR J BIOCHEM, V235, P762, DOI 10.1111/j.1432-1033.1996.00762.x; WAGNER VT, 1992, P NATL ACAD SCI USA, V89, P3644, DOI 10.1073/pnas.89.8.3644; WANG CS, 1994, PLANT PHYSIOL, V104, P711, DOI 10.1104/pp.104.2.711; WAYNE R, 1992, J CELL SCI, V101, P611; ZHU JK, 1994, PLANT CELL, V6, P393, DOI 10.1105/tpc.6.3.393; ZHU JK, 1993, PLANT J, V3, P637, DOI 10.1111/j.1365-313X.1993.00637.x	42	70	74	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28724	28729		10.1074/jbc.274.40.28724	http://dx.doi.org/10.1074/jbc.274.40.28724			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497243	hybrid			2022-12-25	WOS:000082912700092
J	Nishihara, A; Hanai, J; Imamura, T; Miyazono, K; Kawabata, M				Nishihara, A; Hanai, J; Imamura, T; Miyazono, K; Kawabata, M			E1A inhibits transforming growth factor-beta signaling through binding to Smad proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; INDUCED TRANSCRIPTION; COACTIVATOR; INDUCTION; RESPONSES; PROMOTER; CBP/P300; P21/WAF1/CIP1; COOPERATION; ACTIVATORS	Smads form a recently identified family of proteins that mediate intracellular signaling of the transforming growth factor (TGF)-beta superfamily. Smads bind to DNA and act as transcriptional regulators. Smads interact with a variety of transcription factors, and the interaction is likely to determine the target specificity of gene induction. Smads also associate with transcriptional coactivators such as p300 and CBP, E1A, an adenoviral oncoprotein, inhibits TGF-beta-induced transactivation, and the ability of E1A to bind p300/CBP is required for the inhibition. Here we determined the Smad interaction domain (SID) in p300 and found that two adjacent regions are required for the interaction. One of the regions is the C/H3 domain conserved between p300 and CBP, and the other is a nonconserved region. p300 mutants containing SID inhibit transactivation by TGF-beta in a dose-dependent manner, E1A inhibits the interaction of Smad3 with a p300 mutant that contains SLD but lacks the E1A binding domain. We found that E1A interacts specifically with receptor-regulated Smads, suggesting a novel mechanism whereby ELA antagonizes TGF-beta signaling.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Japan Soc Promot Sci, Res Future Program, Toshima Ku, Tokyo 1708455, Japan	Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science	Kawabata, M (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.							ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; Brummel T, 1999, GENE DEV, V13, P98, DOI 10.1101/gad.13.1.98; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; COUSSENS LM, 1994, J CELL PHYSIOL, V160, P435, DOI 10.1002/jcp.1041600306; Das P, 1999, GENES CELLS, V4, P123, DOI 10.1046/j.1365-2443.1999.00244.x; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; DEGROOT RP, 1995, CELL GROWTH DIFFER, V6, P531; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Inoue H, 1998, MOL BIOL CELL, V9, P2145, DOI 10.1091/mbc.9.8.2145; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kricka L. J., 1992, NONISOTOPIC DNA PROB; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Waltzer L, 1999, EMBO J, V18, P1630, DOI 10.1093/emboj/18.6.1630; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	39	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28716	28723		10.1074/jbc.274.40.28716	http://dx.doi.org/10.1074/jbc.274.40.28716			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497242	hybrid			2022-12-25	WOS:000082912700091
J	Reddy, RK; Lu, J; Lee, AS				Reddy, RK; Lu, J; Lee, AS			The endoplasmic reticulum chaperone glycoprotein GRP94 with Ca2+-binding and antiapoptotic properties is a novel proteolytic target of calpain during etoposide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; HEAT-SHOCK; CELL-DEATH; STRESS PROTEINS; CYTOCHROME-C; PROTEASE; CALCIUM; GENES; INDUCTION; GRP78	GRP94 is a 94-kDa chaperone glycoprotein with Ca2+-binding properties. We report here that during apoptosis induced by the topoisomerase II inhibitor etoposide, a fraction of GRP94 associated with the endoplasmic reticulum membrane undergoes specific proteolytic cleavage, coinciding with the activation of the caspase CPP32 and initiation of DNA fragmentation. In vivo, inhibitors of caspases able to block etoposide-induced apoptosis can only partially protect GRP94 from proteolytic cleavage, whereas complete inhibition is observed with calpain inhibitor I but not with the proteasome inhibitor. In vitro, GRP94 is not a substrate for CPP32; rather, it can be completely cleaved by calpain, a Ca2+-regulated protease, The cleavage of GRP94 by calpain is Ca2+-dependent and generates a discrete polypeptide of 80 kDa, In contrast, calpain has no effect on other stress proteins such as GRP78 or HSP70. Further, immunohistochemical staining reveals specific co-localization of GRP94 with calpain in the perinuclear region following etoposide treatment. We further showed that reduction of GRP94 by antisense decreased cell viability in etoposide-treated Jurkat cells, Our studies provide new evidence that the cytoprotective GRP94, as in the case of the antiapoptotic protein Bcl-2, can be targets of proteolytic cleavage themselves during the apoptotic process.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Sch Med, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Sch Med, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Lee, AS (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Sch Med, MS 73,Rm 5307, Los Angeles, CA 90089 USA.	amylee@hsc.usc.edu		Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [CA27607] Funding Source: Medline; NEI NIH HHS [EY03040] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027607, R37CA027607] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hoshino T, 1998, BLOOD, V91, P4379, DOI 10.1182/blood.V91.11.4379.411k14_4379_4386; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; KANG HS, 1991, J BIOL CHEM, V266, P5643; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; KOCH G, 1986, J CELL SCI, V86, P217; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1981, J CELL PHYSIOL, V106, P119, DOI 10.1002/jcp.1041060113; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEMON SA, 1995, J IMMUNOL METHODS, V180, P15, DOI 10.1016/0022-1759(94)00294-7; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Ramakrishnan M, 1997, J CELL PHYSIOL, V170, P115, DOI 10.1002/(SICI)1097-4652(199702)170:2<115::AID-JCP3>3.3.CO;2-J; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Squier MKT, 1997, J IMMUNOL, V158, P3690; SUGAWARA S, 1993, CANCER RES, V53, P6001; Ubeda M, 1997, J BIOL CHEM, V272, P19562, DOI 10.1074/jbc.272.31.19562; VAN PN, 1989, J BIOL CHEM, V264, P17494; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381	51	127	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28476	28483		10.1074/jbc.274.40.28476	http://dx.doi.org/10.1074/jbc.274.40.28476			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497210	hybrid			2022-12-25	WOS:000082912700059
J	Hallden, G; Hadi, M; Hong, HT; Aponte, GW				Hallden, G; Hadi, M; Hong, HT; Aponte, GW			Y receptor-mediated induction of CD63 transcripts, a tetraspanin determined to be necessary for differentiation of the intestinal epithelial cell line, hBRIE 380i cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-PROTEIN; NEUROPEPTIDE-Y; PEPTIDE-YY; PANCREATIC-POLYPEPTIDE; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; MESSENGER-RNA; GROWTH-FACTOR; TRANSMEMBRANE-4 SUPERFAMILY	Peptide YY (PYY) and neuropeptide Y (NPY) are peptides that coordinate intestinal activities in response to luminal and neuronal signals. In this study, using the rat hybrid small intestinal epithelial cell line, hBRIE 380i cells, we demonstrated that PYY- and NPY-induced rearrangement of actin filaments may be in part through a Y1 alpha and/or a nonneuronal Y2 receptor, which were cloned from both the intestinal mucosa and the hBRIE 380i cells. A number of PYY/NPY-responsive genes were also identified by subtractive hybridization of the hBRIE 380i cells in the presence or absence of a 6-h treatment with PYY. Several of these genes coded for proteins associated with the cell cytoskeleton or extracellular matrix. One of these proteins was the transmembrane-4 superfamily protein CD63, previously shown to associate with beta(1)-integrin and implicated in cell adhesion. CD63 immunoreactivity, using antibody to the extracellular domain, was highest in the differentiated cell clusters of the hBRIE 380i cells. The hBRIE 380i cells transfected with antisense CD63 cDNA lost these differentiated clusters. These studies suggest a new role for NPY and PYY in modulating differentiation through cytoskeletal associated proteins.	Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Aponte, GW (corresponding author), Univ Calif Berkeley, Dept Nutr Sci, 119 Morgan Hall, Berkeley, CA 94720 USA.	gwa@nature.berkeley.edu						APONTE GW, 1991, P NATL ACAD SCI USA, V88, P5282, DOI 10.1073/pnas.88.12.5282; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BenPorath I, 1996, GENE, V183, P69, DOI 10.1016/S0378-1119(96)00475-1; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; CASTAN I, 1992, ENDOCRINOLOGY, V131, P1970, DOI 10.1210/en.131.4.1970; Chen XL, 1997, AM J PHYSIOL-HEART C, V273, pH1737, DOI 10.1152/ajpheart.1997.273.4.H1737; ChoiMiura NH, 1996, NEUROBIOL AGING, V17, P717; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLASSON BJ, 1990, J EXP MED, V172, P1007, DOI 10.1084/jem.172.3.1007; CORR LA, 1990, CIRC RES, V66, P1602, DOI 10.1161/01.RES.66.6.1602; Cox HM, 1998, REGUL PEPTIDES, V75-6, P3, DOI 10.1016/S0167-0115(98)00047-0; DAUCA M, 1990, International Journal of Developmental Biology, V34, P205; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; Feletou M, 1998, REGUL PEPTIDES, V75-6, P221, DOI 10.1016/S0167-0115(98)00072-X; FIELD CM, 1995, J CELL BIOL, V131, P165, DOI 10.1083/jcb.131.1.165; FRENCH LE, 1993, J CELL BIOL, V122, P1119, DOI 10.1083/jcb.122.5.1119; Goumain M, 1998, BIOCHEM BIOPH RES CO, V247, P52, DOI 10.1006/bbrc.1998.8647; Gregor P, 1996, FEBS LETT, V381, P58, DOI 10.1016/0014-5793(96)00067-1; HALLDEN G, 1994, AM J PHYSIOL-GASTR L, V267, pG730, DOI 10.1152/ajpgi.1994.267.4.G730; Hallden G, 1997, J BIOL CHEM, V272, P12591, DOI 10.1074/jbc.272.19.12591; Hermiston Michelle L., 1994, P521; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; Holehouse EL, 1998, BBA-LIPID LIPID MET, V1390, P52, DOI 10.1016/S0005-2760(97)00176-8; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; Hu YH, 1996, J BIOL CHEM, V271, P26315, DOI 10.1074/jbc.271.42.26315; Iwase K, 1997, GASTROENTEROLOGY, V113, P782, DOI 10.1016/S0016-5085(97)70172-0; Jackerott M, 1997, J HISTOCHEM CYTOCHEM, V45, P1643, DOI 10.1177/002215549704501207; Jacques D, 1997, NEUROSCIENCE, V79, P129, DOI 10.1016/S0306-4522(96)00639-2; KELLER HU, 1985, INT J CANCER, V36, P495, DOI 10.1002/ijc.2910360414; Kiss Z, 1997, FEBS LETT, V415, P71, DOI 10.1016/S0014-5793(97)01095-8; KITANI S, 1991, J BIOL CHEM, V266, P1903; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; KUIJPERS TW, 1991, BLOOD, V78, P1105; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; LABURTHE M, 1986, ENDOCRINOLOGY, V118, P1910, DOI 10.1210/endo-118-5-1910; LABURTHE M, 1990, TRENDS ENDOCRIN MET, V1, P168, DOI 10.1016/1043-2760(90)90031-W; Larhammar D, 1996, REGUL PEPTIDES, V65, P165, DOI 10.1016/0167-0115(96)00110-3; Lee CC, 1998, REGUL PEPTIDES, V75-6, P71, DOI 10.1016/S0167-0115(98)00054-8; LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V116, P393, DOI 10.1111/j.1748-1716.1982.tb07157.x; MACKERELL AD, 1988, J COMPUT AID MOL DES, V2, P55, DOI 10.1007/BF01532053; MALEKHEDAYAT S, 1995, GENE, V158, P287, DOI 10.1016/0378-1119(94)00911-B; MCDONALD JK, 1988, CRIT REV NEUROBIOL, V4, P97; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MIYAMOTO H, 1994, BBA-GENE STRUCT EXPR, V1217, P312, DOI 10.1016/0167-4781(94)90291-7; Nakamura M, 1996, BBA-BIOMEMBRANES, V1284, P134, DOI 10.1016/S0005-2736(96)00166-6; NAKAMURA M, 1995, J BIOL CHEM, V270, P30102, DOI 10.1074/jbc.270.50.30102; NISHIBORI M, 1993, J CLIN INVEST, V91, P1775, DOI 10.1172/JCI116388; NISHIKATA H, 1992, J IMMUNOL, V149, P862; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; ODONOHUE TL, 1985, PEPTIDES, V6, P755, DOI 10.1016/0196-9781(85)90180-9; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; PAPPAS TN, 1986, J CLIN INVEST, V77, P49, DOI 10.1172/JCI112300; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; Pheng LH, 1998, REGUL PEPTIDES, V75-6, P79, DOI 10.1016/S0167-0115(98)00055-X; Radford KJ, 1997, J IMMUNOL, V158, P3353; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSE PM, 1995, J BIOL CHEM, V270, P29038; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; RUBIN DC, 1989, P NATL ACAD SCI USA, V86, P1278, DOI 10.1073/pnas.86.4.1278; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SERVIN AL, 1989, ENDOCRINOLOGY, V124, P692, DOI 10.1210/endo-124-2-692; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SHIGERI Y, 1994, J BIOL CHEM, V269, P8842; SOHMA Y, 1994, CELL STRUCT FUNCT, V19, P219, DOI 10.1247/csf.19.219; St-Pierre JA, 1998, BRIT J PHARMACOL, V123, P183, DOI 10.1038/sj.bjp.0701589; Stoker AW, 1990, CURR OPIN CELL BIOL, V2, P864, DOI 10.1016/0955-0674(90)90085-S; Todisco A, 1997, AM J PHYSIOL-GASTR L, V273, pG891, DOI 10.1152/ajpgi.1997.273.4.G891; VISCHER UM, 1993, BLOOD, V82, P1184, DOI 10.1182/blood.V82.4.1184.1184; VOISIN T, 1993, J BIOL CHEM, V268, P20547; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7; WALSH DA, 1993, BRIT J PHARMACOL, V108, P304, DOI 10.1111/j.1476-5381.1993.tb12800.x; Weinberg DH, 1996, J BIOL CHEM, V271, P16435, DOI 10.1074/jbc.271.28.16435; WHARTON J, 1993, P NATL ACAD SCI USA, V90, P687, DOI 10.1073/pnas.90.2.687; WONG P, 1993, J BIOL CHEM, V268, P5021; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; Yan H, 1996, P NATL ACAD SCI USA, V93, P4661, DOI 10.1073/pnas.93.10.4661; Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187; ZUKOWSKAGROJEC Z, 1993, BIOL NEUROPEPTIDE Y	87	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27914	27924		10.1074/jbc.274.39.27914	http://dx.doi.org/10.1074/jbc.274.39.27914			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488139	hybrid			2022-12-25	WOS:000082739100078
J	Miki, H; Fukuda, M; Nishida, E; Takenawa, T				Miki, H; Fukuda, M; Nishida, E; Takenawa, T			Phosphorylation of WAVE downstream of mitogen-activated protein kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; TYROSINE KINASES; CYTOSKELETAL REORGANIZATION; N-WASP; ACTIN; BINDING; RAC; VERPROLIN; CDC42HS; GROWTH	WAVE is a Wiskott-Aldrich syndrome protein (WASP)family protein that functions in membrane-ruffling formation induced by Pac, a Rho family small GTPase. Here we report that WAVE is a phosphoprotein whose phosphorylation increases in response to various external stimuli that activate mitogen-activated protein (MAP) kinase signaling. When Swiss 3T3 cells are stimulated with platelet-derived growth factor, electrophoretic mobility shift occurs to WAVE, which reflects hyperphosphorylation. This is perfectly inhibited by the addition of PD98059, a specific inhibitor of MAP kinase kinase. Indeed, the ectopic expression of an activated mutant of MAP kinase kinase induces WAVE mobility shift. When MAP kinase activation is suppressed by PD98059, the intensity of platelet derived growth factor-induced membrane ruffling is greatly reduced. In various cancer cell lines, the amount of WAVE mobility shift was found to increase significantly, suggesting the importance of WAVE hyperphosphorylation in the formation of membrane ruffles and oncogenic transformation.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 108, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 60601, Japan	University of Tokyo; Kyoto University	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.		Fukuda, Makoto/C-9745-2009; Fukuda, Makoto/I-7915-2014; Fukuda, Makoto/S-9748-2019	Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925				Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DONNELLY SFH, 1993, MOL MICROBIOL, V10, P585, DOI 10.1111/j.1365-2958.1993.tb00930.x; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fusaki N, 1996, J IMMUNOL, V156, P1369; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; MIKI H, 1994, J BIOL CHEM, V269, P5489; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shirouzu M, 1998, J BIOL CHEM, V273, P7737, DOI 10.1074/jbc.273.13.7737; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Vaduva G, 1997, J CELL BIOL, V139, P1821, DOI 10.1083/jcb.139.7.1821; WATANABE K, 1995, J BIOL CHEM, V270, P13733, DOI 10.1074/jbc.270.23.13733	30	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27605	27609		10.1074/jbc.274.39.27605	http://dx.doi.org/10.1074/jbc.274.39.27605			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488099	hybrid			2022-12-25	WOS:000082739100038
J	Thomas, D; Zhang, W; Karle, CA; Kathofer, S; Schols, W; Kubler, W; Kiehn, J				Thomas, D; Zhang, W; Karle, CA; Kathofer, S; Schols, W; Kubler, W; Kiehn, J			Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; PHOSPHODIESTERASE INHIBITORS; PHORBOL ESTERS; CYCLIC-AMP; K+-CHANNEL; RECTIFIER; BLOCK; HEART; ARRHYTHMIAS; MECHANISMS	We investigated the role of protein kinase A (PKA) in regulation of the human ether-a-go-go-related gene (HERG) potassium channel activation. HERG clones with single mutations destroying one of four consensus PKA phosphorylation sites (S283A, S890A, T895A, S1137A), as well as one clone carrying all mutations with no PKA phosphorylation sites (HERG 4M) were constructed. These clones were expressed heterologously in Xenopus oocytes, and HERG potassium currents were measured with the two microelectrode voltage clamp technique. Application of the cAMP-specific phosphodiesterase (PDE TV) inhibitor Ro-20-1724 (100 mu M), which results in an increased cAMP level and PKA stimulation, induced a reduction of HERG wild type outward currents by 19.1% due to a shift in the activation curve of 12.4 mV. When 100 mu M Ro-20-1724 was applied to the HERG; 4m channel, missing all PKA sites, there was no significant shift in the activation curve, and the current amplitude was not reduced. Furthermore, the adenylate cyclase activator forskolin that leads to PKA activation (400 mu M, 60 min), shifted HERG wild type channel activation by 14.1 mV and reduced currents by 39.9%, whereas HERG 4M channels showed only a small shift of 4.3 mV and a weaker current reduction of 22.3%. We conclude that PKA regulates HERG channel activation, and direct phosphorylation of the HERG channel protein has a functional role that may be important in regulation of cardiac repolarization.	Med Univ Hosp Heidelberg, Dept Cardiol, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Kiehn, J (corresponding author), Med Univ Hosp Heidelberg, Dept Cardiol, Bergheimerstr 58, D-69115 Heidelberg, Germany.		Thomas, Dierk/V-3940-2017; Thomas, Dierk/ABA-4706-2021	Thomas, Dierk/0000-0002-5687-7843				Beavo JA, 1998, ADV 2 MESSENGER PHOS, V22, P1; Bender JS, 1996, AM SURGEON, V62, P73; CARMELIET E, 1993, EUR HEART J, V14, P3, DOI 10.1093/eurheartj/14.suppl_H.3; DARBON JM, 1986, BIOCHEM PHARMACOL, V35, P2683, DOI 10.1016/0006-2952(86)90175-9; Hsu C, 1997, J SURG RES, V71, P161, DOI 10.1006/jsre.1997.5143; KANG JX, 1995, BIOCHEM BIOPH RES CO, V208, P629, DOI 10.1006/bbrc.1995.1385; Kiehn J, 1999, N-S ARCH PHARMACOL, V359, P212, DOI 10.1007/PL00005344; Kiehn J, 1998, J BIOL CHEM, V273, P25285, DOI 10.1074/jbc.273.39.25285; Kiehn J, 1996, CIRCULATION, V94, P2572, DOI 10.1161/01.CIR.94.10.2572; LERMAN BB, 1986, CIRCULATION, V74, P270, DOI 10.1161/01.CIR.74.2.270; NACCARELLI GV, 1989, AM J CARDIOL, V63, pA35, DOI 10.1016/0002-9149(89)90391-3; PACKER M, 1989, AM J CARDIOL, V63, pA41, DOI 10.1016/0002-9149(89)90392-5; Palma E, 1998, CIRCULATION, V98, P57; Priori SG, 1997, PACE, V20, P2052, DOI 10.1111/j.1540-8159.1997.tb03626.x; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; SAMAN S, 1988, J MOL CELL CARDIOL, V20, P91, DOI 10.1016/S0022-2828(88)80022-1; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; SANGUINETTI MC, 1995, CELL, V81, P1; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Sun ZH, 1998, J AM COLL CARDIOL, V31, P1400, DOI 10.1016/S0735-1097(98)00104-1; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; VARRIALE P, 1995, J ELECTROCARDIOL, V28, P327, DOI 10.1016/S0022-0736(05)80051-2; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Yang SL, 1997, SHOCK, V8, P68, DOI 10.1097/00024382-199707000-00011; ZHOU JT, 1992, PACE, V15, P2164, DOI 10.1111/j.1540-8159.1992.tb03041.x	28	109	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27457	27462		10.1074/jbc.274.39.27457	http://dx.doi.org/10.1074/jbc.274.39.27457			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488078	hybrid			2022-12-25	WOS:000082739100017
J	Tiganis, T; Kemp, BE; Tonks, NK				Tiganis, T; Kemp, BE; Tonks, NK			The protein-tyrosine phosphatase TCPTP regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3-kinase-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-RECEPTOR; SH2 DOMAINS; KINASE-B; GENE AMPLIFICATION; ACTIVATION; CELLS; EXPRESSION; 3'-KINASE; 3-KINASE; TRANSDUCTION	In this study we have investigated the down-regulation of epidermal growth factor (EGF) receptor signaling by protein-tyrosine phosphatases (PTPs) in COS1 cells. The 45-kDa variant of the PTP TCPTP (TC45) exits the nucleus upon EGF receptor activation and recognizes the EGF receptor as a cellular substrate. We report that TC45 inhibits the EGF-dependent activation of the c-Jun N-terminal kinase, but does not alter the activation of extracellular signal-regulated kinase 2. These data demonstrate that TC45 can regulate selectively mitogen-activated protein kinase signaling pathways emanating from the EGF receptor. In EGF receptor-mediated signaling, the protein kinase PKB/Akt and the mitogen-activated protein kinase c-Jun N-terminal kinase, but not extracellular signal-regulated kinase 2, function downstream of phosphatidylinositol 3-kinase (PI 3-kinase). We have found that TC45 and the TC45-D182A mutant, which is capable of forming stable complexes with TC45 substrates, inhibit almost completely the EGF-dependent activation of PI 3-kinase and PKB/Akt. TC45 and TC45-D182A act upstream of PI 3-kinase, most likely by inhibiting the recruitment of the p85 regulatory subunit of PI 3-kinase by the EGF receptor. Recent studies have indicated that the EGF receptor can be activated in the absence of EGF following integrin ligation. We find that the integrin-mediated activation of PKB/Akt in COS1 cells is abrogated by the specific EGF receptor protein-tyrosine kinase inhibitor tyrphostin AG1478, and that TC45 and TC45-D182A can inhibit activation of PKB/Akt following the attachment of COS1 cells to fibronectin. Thus, TC45 may serve as a negative regulator of growth factor or integrin-induced, EGF receptor-mediated PI 3-kinase signaling.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	St. Vincent's Institute of Medical Research; Cold Spring Harbor Laboratory	Tiganis, T (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.	tiganis@ariel.ucs.unimelb.edu.au	Kemp, Bruce/G-9602-2019; Tiganis, Tony/AAV-3495-2020; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Tiganis, Tony/0000-0002-8065-9942; Kemp, Bruce E/0000-0001-6735-5082	NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Boudewijn MT, 1995, NATURE, V376, P599; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P1203; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Harris A L, 1992, J Natl Cancer Inst Monogr, P181; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUNTS J, 1985, JPN J CANCER RES, V76, P663; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; SCHLEGEL J, 1994, INT J CANCER, V56, P72; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	88	91	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27768	27775		10.1074/jbc.274.39.27768	http://dx.doi.org/10.1074/jbc.274.39.27768			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488121	hybrid			2022-12-25	WOS:000082739100060
J	Awad, TA; Bigler, J; Ulmer, JE; Hu, YJ; Moore, JM; Lutz, M; Neiman, PE; Collins, SJ; Renkawitz, R; Lobanenkov, VV; Filippova, GN				Awad, TA; Bigler, J; Ulmer, JE; Hu, YJ; Moore, JM; Lutz, M; Neiman, PE; Collins, SJ; Renkawitz, R; Lobanenkov, VV; Filippova, GN			Negative transcriptional regulation mediated by thyroid hormone response element 144 requires binding of the multivalent factor CTCF to a novel target DNA sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PRECURSOR PROMOTER; C-MYC GENE; TUMOR-SUPPRESSOR P53; NUCLEAR FACTOR; 5'-FLANKING SEQUENCE; RECEPTORS; REPRESSOR; INTERACTS; ACTIVATION; EXPRESSION	DNA target sites for a "multivalent" 11-zinc-finger CCTC-binding factor (CTCF) are unusually long (similar to 50 base pairs) and remarkably different, In conjunction with the thyroid receptor (TR), CTCF binding to the lysozyme gene transcriptional silencer mediates the thyroid hormone response element (TRE)-dependent transcriptional repression. We tested whether other TREs, which in addition to the presence of a TR binding site require neighboring sequences for transcriptional function, might also contain a previously unrecognized binding site(s) for CTCF, One such candidate DNA region, previously isolated by Bigler and Eisenman (Bigler, J., and Eisenman, R. N. (1995) EMBO J, 14, 5710-5723), is the TRE-containing genomic element 144. We have identified a new CTCF target sequence that is adjacent to the TR binding site within the 144 fragment. Comparison of CTCF recognition nucleotides in the lysozyme silencer and in the 144 sequences revealed both similarities and differences. Several C-terminal CTCF zinc fingers contribute differently to binding each of these sequences. Mutations that eliminate CTCF binding impair 144-mediated negative transcriptional regulation, Thus, the 144 element provides an additional example of a functionally significant composite "TRE plus CTCF binding site" regulatory element suggesting an important role for CTCF in cooperation with the steroid/thyroid superfamily of nuclear receptors to mediate TRE-dependent transcriptional repression.	Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Giessen, Genet Inst, D-35392 Giessen, Germany	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Justus Liebig University Giessen	Filippova, GN (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, Suite C2-023,1100 Fairview Ave N, Seattle, WA 98109 USA.	gfilippo@fred.fhcrc.org	Lobanenkov, Victor V./AGQ-8903-2022; Powers, Donald/A-1704-2009; Lobanenkov, Victor/ABD-5710-2021	Powers, Donald/0000-0003-1126-7141; Lobanenkov, Victor/0000-0001-6665-3635	NCI NIH HHS [R01 CA68360, CA71732] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071732, R01CA068360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Belandia B, 1998, J BIOL CHEM, V273, P30366, DOI 10.1074/jbc.273.46.30366; Bhat MK, 1997, J BIOL CHEM, V272, P28989, DOI 10.1074/jbc.272.46.28989; BIGLER J, 1995, EMBO J, V14, P5710, DOI 10.1002/j.1460-2075.1995.tb00258.x; BIGLER J, 1994, MOL CELL BIOL, V14, P7621, DOI 10.1128/MCB.14.11.7621; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; CARNAC G, 1992, MOL ENDOCRINOL, V6, P1185, DOI 10.1210/me.6.8.1185; CARR FE, 1994, J BIOL CHEM, V269, P4175; CHANG TC, 1990, J BIOL CHEM, V265, P8176; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Klenova EM, 1998, J BIOL CHEM, V273, P26571, DOI 10.1074/jbc.273.41.26571; KOHNE AC, 1993, J MOL BIOL, V232, P747, DOI 10.1006/jmbi.1993.1428; LOBANENKOV VV, 1989, DOKL AKAD NAUK SSSR+, V309, P741; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; LOBANENKOV VV, 1989, GENE REGULATION AIDS, P45; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADISON LD, 1993, MOL CELL ENDOCRINOL, V94, P129, DOI 10.1016/0303-7207(93)90060-W; MCCORMICK M, 1994, INNOVATIONS, V1, P4; MUSCAT GEO, 1994, NUCLEIC ACIDS RES, V22, P583, DOI 10.1093/nar/22.4.583; Neiman PE, 1997, CURR TOP MICROBIOL, V224, P231; QUITSCHKE WW, 1994, J BIOL CHEM, V269, P21229; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; Radoja N, 1997, J INVEST DERMATOL, V109, P566, DOI 10.1111/1523-1747.ep12337483; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZPACHECO A, 1995, MOL CELL BIOL, V15, P6322; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; TEVOSYAN S G, 1991, Molekulyarnaya Biologiya (Moscow), V25, P1013; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; WADGAONKAR R, 1996, P ANN M AM ASS CANC, V37, pA4092; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273	38	61	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27092	27098		10.1074/jbc.274.38.27092	http://dx.doi.org/10.1074/jbc.274.38.27092			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480923	hybrid			2022-12-25	WOS:000082570700062
J	Cohen, A; Perzov, N; Nelson, H; Nelson, N				Cohen, A; Perzov, N; Nelson, H; Nelson, N			A novel family of yeast chaperons involved in the distribution of V-ATPase and other membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; ENDOPLASMIC-RETICULUM; MUTATIONAL ANALYSIS; SUPPRESSOR MUTANTS; 14-KDA SUBUNIT; ENZYME COMPLEX; TRANSFORMATION	Null mutations in genes encoding V-ATPase subunits in Saccharomyces cerevisiae result in a phenotype that is unable to grow at high pH and is sensitive to high and low metal-ion concentrations. Treatment of these null mutants with ethylmethanesulfonate causes mutations that suppress the V-ATPase null phenotype, and the mutant cells are able to grow at pH 7.5. The suppressor mutants were denoted as svf (suppressor of V-ATPase function). The frequency of svf is relatively high, suggesting a large target containing several genes for the ethylmethanesulfonate mutagenesis. The suppressors' frequency is dependent on the individual genes that were inactivated to manifest the V-ATPase null mutation. The svf mutations are recessive, because crossing the svf mutants with their corresponding V-ATPase null mutants resulted in diploid strains that are unable to grow at pH 7.5. A novel gene family in which null mutations cause pleiotropic effects on metal-ion resistance or sensitivity and distribution of membrane proteins in different targets was discovered. The family was defined as VTC (Vacuolar Transporter Chaperon) and it contains four genes in the S. cerevisiae genome. Inactivation of one of them, VTC1, in the background of V-ATPase null mutations resulted in svf phenotype manifested by growth at pH 7.5. Deletion of the VTC1 gene (Delta VTC1) results in a reduced amount of V-ATPase in the vacuolar membrane. These mutant cells fail to accumulate quinacrine into their vacuoles, but they are able to grow at pH 7.5. The VTC1 null mutant also results in a reduced amount of the plasma membrane H+-ATPase (Pma1p) in membrane preparations and possibly mistargeting. This observation may provide an explanation for the svf phenotype in the double disruptant mutants of Delta VTC1 and Delta VMA subunits.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University	Nelson, N (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.							BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; Bowman EJ, 1997, J BIOL CHEM, V272, P14776, DOI 10.1074/jbc.272.23.14776; BRADA D, 1988, J BACTERIOL, V170, P2775, DOI 10.1128/jb.170.6.2775-2783.1988; BunYa M, 1996, CURR GENET, V29, P344, DOI 10.1007/s002940050055; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; Dow JAT, 1997, J EXP BIOL, V200, P237; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; HOLCOMB CL, 1988, J CELL BIOL, V106, P641, DOI 10.1083/jcb.106.3.641; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; Lupashin VV, 1997, MOL BIOL CELL, V8, P2659, DOI 10.1091/mbc.8.12.2659; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1983, METHOD ENZYMOL, V97, P510; Nelson N, 1996, EXPERIENTIA, V52, P1101, DOI 10.1007/BF01952108; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OGAWA N, 1995, MOL CELL BIOL, V15, P997; Perzov N, 1998, ACTA PHYSIOL SCAND, V163, P185; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; SUPEK F, 1994, J BIOL CHEM, V269, P26479; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; Tailor CS, 1999, P NATL ACAD SCI USA, V96, P927, DOI 10.1073/pnas.96.3.927; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7	48	73	78	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26885	26893		10.1074/jbc.274.38.26885	http://dx.doi.org/10.1074/jbc.274.38.26885			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480897	hybrid			2022-12-25	WOS:000082570700036
J	Kato, M; Miki, H; Imai, K; Nonoyama, S; Suzuki, T; Sasakawa, C; Takenawa, T				Kato, M; Miki, H; Imai, K; Nonoyama, S; Suzuki, T; Sasakawa, C; Takenawa, T			Wiskott-Aldrich syndrome protein induces actin clustering without direct binding to Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; BRUTON TYROSINE KINASE; BETA-GAMMA-SUBUNITS; N-WASP; DEPOLYMERIZING PROTEIN; RECEPTOR KINASE; POLYMERIZATION; FILOPODIA; GTPASES; RAC	WASP (Wiskott-Aldrich syndrome protein) was identified as the gene product whose mutation causes the human hereditary disease Wiskott-Aldrich syndrome. WASP contains many functional domains and has been shown to induce the formation of clusters of actin filaments in a manner dependent on Cdc42. However, there has been no report investigating what domain(s) is(are) important for the function. Here we present for the first time the results of detailed analyses on the domain-function relationship of WASP. First, the C-terminal ver-prolin-cofilin-acidic domain was shown to be essential for the regulation of actin cytoskeleton. In addition, we found that the clustering of WASP itself is distinct from actin clustering, The partial protein containing the region from the N-terminal pleckstrin homology domain to the basic residue-rich region also clustered especially around the nucleus as wild type WASP without inducing actin clustering. Finally, we obtained the quite unexpected result that; a WASP mutant deficient in binding to Cdc42 still induced actin cluster formation, indicating that direct interaction between Cdc42 and WASP is not required for the regulation of actin cytoskeleton. This result may explain why no Wiskott-Aldrich syndrome patients have been identified with a missense mutation in the Cdc42-binding site.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Bacteriol, Minato Ku, Tokyo 1088639, Japan; Tokyo Med & Dent Univ, Dept Pediat, Bunkyo Ku, Tokyo 1138519, Japan; Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan	University of Tokyo; University of Tokyo; Tokyo Medical & Dental University (TMDU); Chiba University	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Imai, Kohsuke/Q-2602-2015	Imai, Kohsuke/0000-0003-2132-8403				Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Cory GOC, 1996, J IMMUNOL, V157, P3791; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; MIKI H, 1994, J BIOL CHEM, V269, P5489; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Miki H, 1997, CELL GROWTH DIFFER, V8, P195; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	31	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27225	27230		10.1074/jbc.274.38.27225	http://dx.doi.org/10.1074/jbc.274.38.27225			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480940	hybrid			2022-12-25	WOS:000082570700079
J	Marsischky, GT; Kolodner, RD				Marsischky, GT; Kolodner, RD			Biochemical characterization of the interaction between the Saccharomyces cerevisiae MSH2-MSH6 complex and mispaired bases in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH-REPAIR PROTEINS; NONPOLYPOSIS COLORECTAL-CANCER; MUTS-ENCODED PROTEIN; ESCHERICHIA-COLI; MICROSATELLITE INSTABILITY; HETERODUPLEX DNA; CELL-LINES; DUPLEX OLIGONUCLEOTIDES; TRANSLOCATION MECHANISM; SPECIFICALLY BINDS	The interaction of the Saccharomyces cerevisiae MSH2-MSH6 complex with mispaired bases was analyzed using gel mobility shift assays and surface plasmon resonance methods. Under equilibrium binding conditions, MSH2-MSH6 bound to homoduplex DNA with a K-d of 3.9 nM and bound oligonucleotide duplexes containing T:G, +1, +2, +4, and +10 insertion/deletion loop (IDL) mispairs with K-d values of 0.20, 0,25, 11, 3.2, and 0.55 nM, respectively. Competition binding experiments using 65 different substrates repealed a 10-fold range in mispair discrimination. In general, base-base mispairs and a +1 insertion/deletion mispair were recognized better than intermediate sized insertion/deletion mispairs of 2-8 bases. Larger IDL mispairs (>8 bases) were recognized almost as well as the +1 IDL mispair. Recognition of mispairs by MSH2-MSH6 was influenced by sequence context, with the 6-nucleotide region surrounding the mispair being primarily responsible for influencing mispair recognition. Effects of sequences as far away as 15 nucleotides were also observed, Differential effects of ATP on the stability of MSH2-MSH6-mispair complexes suggested that base-base mispairs and the smaller IDL mispairs were recognized by a different binding mode than larger IDL mispairs, consistent with genetic experiments indicating that MSH2-MSH6 functions primarily in the repair of base-base and small IDL mispairs.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Canc, La Jolla, CA 92093 USA; Dana Farber Canc Inst, Charles A Dana Div Human Canc Genet, Boston, MA 02115 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Dana-Farber Cancer Institute	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, CMME3080,9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Alani E, 1996, MOL CELL BIOL, V16, P5604; Alani E, 1997, J MOL BIOL, V265, P289, DOI 10.1006/jmbi.1996.0743; Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; Allawi HT, 1998, BIOCHEMISTRY-US, V37, P9435, DOI 10.1021/bi9803729; Allawi HT, 1998, BIOCHEMISTRY-US, V37, P2170, DOI 10.1021/bi9724873; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; Biswas I, 1997, J BIOL CHEM, V272, P13355, DOI 10.1074/jbc.272.20.13355; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; BOYER JC, 1995, CANCER RES, V55, P6063; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHENG JW, 1992, J MOL BIOL, V228, P1037, DOI 10.1016/0022-2836(92)90312-8; CHI NW, 1994, J BIOL CHEM, V269, P29984; Corradi A, 1996, GENOMICS, V36, P288, DOI 10.1006/geno.1996.0464; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DOHET C, 1985, P NATL ACAD SCI USA, V82, P503, DOI 10.1073/pnas.82.2.503; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P367; FUJII H, 1989, J BIOL CHEM, V264, P10057; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Glaab WE, 1998, J BIOL CHEM, V273, P26662, DOI 10.1074/jbc.273.41.26662; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Greene CN, 1997, MOL CELL BIOL, V17, P2844, DOI 10.1128/MCB.17.5.2844; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Her C, 1998, GENOMICS, V52, P50, DOI 10.1006/geno.1998.5374; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; JONES M, 1987, GENETICS, V115, P605; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KRAMER B, 1989, MOL CELL BIOL, V9, P4432, DOI 10.1128/MCB.9.10.4432; LAENGLEROUAULT F, 1986, EMBO J, V5, P2009, DOI 10.1002/j.1460-2075.1986.tb04457.x; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU K, 1994, GENE, V147, P169, DOI 10.1016/0378-1119(94)90062-0; Luhr B, 1998, MOL GEN GENET, V257, P362, DOI 10.1007/s004380050658; Macpherson P, 1998, MUTAT RES-DNA REPAIR, V408, P55, DOI 10.1016/S0921-8777(98)00017-2; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; Nicolaides NC, 1996, GENOMICS, V31, P395, DOI 10.1006/geno.1996.0067; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PaquisFlucklinger V, 1997, GENOMICS, V44, P188, DOI 10.1006/geno.1997.4857; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Pochart P, 1997, J BIOL CHEM, V272, P30345, DOI 10.1074/jbc.272.48.30345; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SANSING GA, 1975, APPL MICROBIOL, V29, P300, DOI 10.1128/AEM.29.2.300-302.1975; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; UMAR A, 1994, J BIOL CHEM, V269, P14367; Umar A, 1998, GENETICS, V148, P1637; Umar A, 1997, CANCER RES, V57, P3949; Viswanathan M, 1998, GENETICS, V149, P7; Wierdl M, 1997, GENETICS, V146, P769; Winand NJ, 1998, GENOMICS, V53, P69, DOI 10.1006/geno.1998.5447; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	91	109	113	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26668	26682		10.1074/jbc.274.38.26668	http://dx.doi.org/10.1074/jbc.274.38.26668			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480869	hybrid			2022-12-25	WOS:000082570700008
J	Shimanuki, T; Sato, H; Daff, S; Sagami, I; Shimizu, T				Shimanuki, T; Sato, H; Daff, S; Sagami, I; Shimizu, T			Crucial role of Lys(423) in the electron transfer of neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HYDROXY-L-ARGININE; COMPLEX; REDUCTASE; TETRAHYDROBIOPTERIN; CYTOCHROME-P-450; CONVERSION; CITRULLINE; ACTIVATION; SUBSTRATE	Nitric-oxide synthase (NOS) is composed of an oxygenase domain having cytochrome P450-type heme active site and a reductase domain having FAD- and FMN-binding sites, To investigate the route of electron transfer from the reductase domain to the heme, we generated mutants at Lys(423) in the heme proximal site of neuronal NOS and examined the catalytic activities, electron transfer rates, and NADPH oxidation rates. A K423E mutant showed no NO formation activity (<0.1 nmol/min/nmol heme), in contrast with that (72 nmol/min/nmol heme) of the wild type enzyme. The electron transfer rate (0.01 min(-1)) of the K423E on addition of excess NADPH was much slower than that (>10 min(-1)) of the wild type enzyme. From the crystal structure of the oxygenase domain of endothelial NOS, Lys(423) of neuronal NOS is likely to interact with Trp(409) which lies in contact with the heme plane and with Cys(415), the axial ligand. It is also exposed to solvent and lies in the region where the heme is closest to the protein surface. Thus, it seems likely that ionic interactions between Lys(423) and the reductase domain may help to form a flavin to heme electron transfer pathway.	Tohoku Univ, Inst Chem React Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Shimizu, T (corresponding author), Tohoku Univ, Inst Chem React Sci, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	shimizu@icrs.tohoku.ac.jp		Shimizu, Toru/0000-0002-3950-5554				AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Clague MJ, 1997, BIOCHEMISTRY-US, V36, P14465, DOI 10.1021/bi971024u; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DEMONTELLANO PRO, 1995, CYTOCHROME P459 STRU; Feelisch M., 1996, METHODS NITRIC OXIDE; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Groves John T., 1995, P3; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; IGNARRO L, 1996, NITRIC OXIDE BIOCH M; JOHNSON EF, 1996, METHOD ENZYMOL, V272, P1; KORTH HG, 1994, J BIOL CHEM, V269, P17776; Lancaster J, 1996, NITRIC OXIDE PRINCIP; Maines MD., 1996, NITRIC OXIDE SYNTHAS; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYUZUMI H, 1993, BIOCHEMISTRY-US, V32, P5622, DOI 10.1021/bi00072a018; MONCADA S, 1996, BIOL NITRIC OXIDE 5; Nakano R, 1996, J BIOL CHEM, V271, P8570, DOI 10.1074/jbc.271.15.8570; Nishimura JS, 1999, J BIOL CHEM, V274, P5399, DOI 10.1074/jbc.274.9.5399; Perry JM, 1998, P NATL ACAD SCI USA, V95, P11101, DOI 10.1073/pnas.95.19.11101; PORTER TD, 1991, J BIOL CHEM, V266, P13469; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; RAAG R, 1989, BIOCHEMISTRY-US, V28, P917, DOI 10.1021/bi00428a077; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SHEN AL, 1991, J BIOL CHEM, V266, P19976; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411	37	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26956	26961		10.1074/jbc.274.38.26956	http://dx.doi.org/10.1074/jbc.274.38.26956			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480907	hybrid			2022-12-25	WOS:000082570700046
J	Srinivasan, S; Nichols, CJ; Lawless, GN; Olsen, RW; Tobin, AJ				Srinivasan, S; Nichols, CJ; Lawless, GN; Olsen, RW; Tobin, AJ			Two invariant tryptophans on the alpha 1 subunit define domains necessary for GABA(A) receptor assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; CELL-SURFACE; H-3 MUSCIMOL; EXPRESSION; STOICHIOMETRY; PHARMACOLOGY; PROTEINS; SUBTYPES; SYSTEM; SITE	Two invariant tryptophan residues on the N-terminal extracellular region of the rat alpha 1 subunit, Trp-69 and Trp-94, are critical for the assembly of the GABA(A) (gamma-aminobutyric acid, type A) receptor into a pentamer. These tryptophans are common not only to sill GABA(A) receptor subunits, but also to all ligand-gated ion channel subunits, Converting each Trp residue to, Pine and Gly by site-directed mutagenesis allowed us to study the role of these invariant tryptophan residues. Mutant alpha 1 subunits, coexpressed with beta 2 subunits in baculcuvirus-infected Sf9 cells, displayed high affinity binding to [H-3]muscimol, a GABA site ligand, but no binding to [S-35]t-butyl bicyclophosphorothionate, a ligand for the receptor-associated ion channel. Neither [H-3]muscimol binding to intact cells nor immunostaining of nonpermeabilized cells gave evidence of surface expression of the receptor. When expressed with beta 2 and gamma 2 polypeptides, the mutant alpha 1 polypeptides did not farm [H-3]flunitrazepam binding sites though wild-type alpha 1 polypeptides did. The distribution of the mutant receptors on sucrose gradients suggests that the effects on ligand binding result from the inability of the mutant alpha 1 subunits to form pentamers, We conclude that Trp-69 and Trp-94 participate in the formation of the interface between alpha and beta subunits, but not of the GABA binding site.	Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Mental Retardat Res Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Tobin, AJ (corresponding author), Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028772, R01NS022256] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM08375] Funding Source: Medline; NINDS NIH HHS [NS28772, NS22256] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Chang YC, 1996, J NEUROSCI, V16, P5415; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Duncalfe LL, 1996, J BIOL CHEM, V271, P9209, DOI 10.1074/jbc.271.16.9209; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; Hackam AS, 1998, J NEUROCHEM, V70, P40; Hales T. G., 1994, Society for Neuroscience Abstracts, V20, P511; Hartnett C, 1996, RECEPTOR CHANNEL, V4, P179; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kellenberger S, 1996, NEUROPHARMACOLOGY, V35, P1403, DOI 10.1016/S0028-3908(96)00034-2; Knight AR, 1998, RECEPTOR CHANNEL, V6, P1; KUSAMA T, 1993, BRIT J PHARMACOL, V109, P200, DOI 10.1111/j.1476-5381.1993.tb13554.x; LUDDENS H, 1995, NEUROPHARMACOLOGY, V34, P245, DOI 10.1016/0028-3908(94)00158-O; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; PREGENZER JF, 1993, MOL PHARMACOL, V43, P801; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Tretter V, 1997, J NEUROSCI, V17, P2728; TYNDALE RF, 1995, LIGAND VOLTAGE GATED, P265; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Whiting PJ, 1997, J NEUROSCI, V17, P5027	29	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26633	26638		10.1074/jbc.274.38.26633	http://dx.doi.org/10.1074/jbc.274.38.26633			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480864	hybrid			2022-12-25	WOS:000082570700003
J	Vasquez-Vivar, J; Hogg, N; Martasek, P; Karoui, H; Pritchard, KA; Kalyanaraman, B				Vasquez-Vivar, J; Hogg, N; Martasek, P; Karoui, H; Pritchard, KA; Kalyanaraman, B			Tetrahydrobiopterin-dependent inhibition of superoxide generation from neuronal nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; ELECTRON-TRANSFER; SUBUNIT DIMERIZATION; BINDING; OXYGEN; HEME; COFACTOR; DOMAIN; MACROPHAGES; ACTIVATION	The binding of calcium/calmodulin stimulates electron transfer between the reductase and oxygenase domains of neuronal nitric oxide synthase (nNOS). Here, we demonstrate using electron spin resonance spin-trapping with 5-diethoxyphosphoryl-5-methyl-1-pyrroline N-oxide that pterin-free nNOS generates superoxide from the reductase and the oxygenase domain by a calcium/calmodulin-dependent mechanism. Tetrahydrobiopterin (BH4) diminishes the formation of superoxide by a mechanism that does not cause inhibition of NADPH consumption. In contrast, BH4 analogs 7,8-dihydrobiopterin and sepiapterin do not affect superoxide yields. L-Arginine alone inhibits the generation of superoxide by nNOS but not by C331A-nNOS mutant that has a low affinity for L-arginine. A greater decrease in superoxide peroxide yields is observed when nNOS is preincubated with L-arginine. This effect is in accordance with the slow binding rates of L-arginine to NOS in the absence of BH4. L-Arginine alone or in combination with BH, decreases the rates of NADPH consumption. The effect of L-arginine on superoxide yields, however, was less dramatic than that caused by BH4 as much higher concentrations of L-arginine are necessary to attain the same inhibition. In combination, L-arginine and BH4 inhibit the formation of superoxide generation and stimulate the formation of L-citrulline. We conclude that, in contrast to L-arginine, BH4 does not inhibit the generation of superoxide by controlling electron transfer through the enzyme but by stimulating the formation of the heme-peroxo species.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Cardiovasc Res Ctr, Dept Pathol, Milwaukee, WI 53226 USA; Univ Aix Marseille 1, Lab Struct & React Especes Paramagnet, CNRS, URA 1412, F-13397 Marseille, France; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	Medical College of Wisconsin; Medical College of Wisconsin; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Texas System; University of Texas Health San Antonio	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA.		KAROUI, HAKIM/ABE-3416-2020; Martásek, Pavel/G-6622-2017	Martásek, Pavel/0000-0001-6165-4444	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027665] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [HL45058] Funding Source: Medline; NIGMS NIH HHS [GM27665] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; de Montellano PRO, 1998, DRUG METAB DISPOS, V26, P1185; FELDMAN PL, 1993, CHEM ENG NEWS, V20, P26; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; FRONCISZ W, J MAGN RES, V43, P515; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HUBER C, 1984, J EXP MED, V160, P310, DOI 10.1084/jem.160.1.310; KAUFMAN S, 1983, ADV HUM GENET, V13, P217; KAUFMAN S, 1963, P NATL ACAD SCI USA, V50, P1085, DOI 10.1073/pnas.50.6.1085; KAUFMAN S, 1986, P185; Kaufman S., 1974, MOL MECH OXYGEN ACTI, P285; KLATT P, 1994, J BIOL CHEM, V269, P13861; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; LEONE AM, 1991, J BIOL CHEM, V266, P23790; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; MILSTIEN S, 1990, CHEM BIOL PTERIDINES, P506; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; OHUE T, 1991, NEUROSCI LETT, V128, P93, DOI 10.1016/0304-3940(91)90767-N; POU S, 1992, J BIOL CHEM, V267, P24173; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SCHAFFNER A, 1994, BIOCHEM BIOPH RES CO, V205, P516, DOI 10.1006/bbrc.1994.2695; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Tiefenbacher CP, 1996, CIRCULATION, V94, P1423, DOI 10.1161/01.CIR.94.6.1423; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 1999, METHOD ENZYMOL, V301, P169; VASQUEZVIVAR J, 1999, IN PRESS FREE RAD; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705	44	160	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26736	26742		10.1074/jbc.274.38.26736	http://dx.doi.org/10.1074/jbc.274.38.26736			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480877	hybrid			2022-12-25	WOS:000082570700016
J	AbdAlla, S; Zaki, E; Lother, H; Quitterer, U				AbdAlla, S; Zaki, E; Lother, H; Quitterer, U			Involvement of the amino terminus of the B-2 receptor in agonist-induced receptor dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRADYKININ RECEPTOR; HUMAN-FIBROBLASTS; HIGH-AFFINITY; ACTIVATION; PROTEIN; BINDING	The mechanisms and the functional importance of G-protein-coupled receptor dimerization are poorly understood. We therefore analyzed dimerization of the bradykinin B-2, receptor. The binding of the agonist bradykinin to the B-2, receptor endogenously expressed on PC-12 cells led to the formation of receptor dimers, whereas the B-2, antagonist HOE140 did not induce dimerization, suggesting that B-2 receptor dimerization was linked to receptor activation. Addition of a peptide corresponding to the amino terminus of the receptor reduced the amount of detected B-2 receptor dimers, whereas peptides derived from the extracellular loops had no effect. To further analyze the role of the amino terminus of the receptor in receptor dimerization, we created two different rat B-2 receptor variants with truncated amino termini, B-2(53) and B-2(65) Starting at amino acids 53 and 65, In contrast to the wild-type B-2 receptor and to B-2(53) bradykinin did not induce dimerization of the B-2(65) receptor. Both receptor variants were similar to the wild-type B-2 receptor with respect to agonist binding and signal generation. However, B-2(65) Was not phosphorylated, did not desensitize, and was not downregulated upon bradykinin stimulation. Likewise, antibodies directed to the amino terminus of the receptor partially reduced internalization of [H-3]bradykinin on PC-12 cells. These findings suggest that the amino terminus of the B-2 receptor is necessary for triggering agonist-induced B-2 receptor dimerization, and receptor dimers are involved in receptor-mediated signal attenuation.	Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany; Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Genet Engn & Biotechnol Res Inst, Alexandria, Egypt	University of Wurzburg; Heinrich Pette Institute	Quitterer, U (corresponding author), Univ Wurzburg, Inst Pharmakol & Toxikol, Versbacher Str 9, D-97078 Wurzburg, Germany.		Zaki, Essam/K-8456-2015	Zaki, Essam/0000-0002-3906-623X				Abd Alla S., 1996, J BIOL CHEM, V271, P1748; AbdAlla S, 1996, BIOCHEMISTRY-US, V35, P7514, DOI 10.1021/bi9601060; AbdAlla S, 1996, J BIOL CHEM, V271, P27382, DOI 10.1074/jbc.271.44.27382; ABDALLA S, 1993, J BIOL CHEM, V268, P17277; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; INGLESE J, 1993, J BIOL CHEM, V268, P23735; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; PITCHER JA, 1992, SCIENCE, V257, P235; QUITTERER U, 1995, J BIOL CHEM, V270, P1992, DOI 10.1074/jbc.270.5.1992; Quitterer U, 1999, J BIOL CHEM, V274, P14773, DOI 10.1074/jbc.274.21.14773; Quitterer U, 1996, BIOCHEMISTRY-US, V35, P13368, DOI 10.1021/bi961163w; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; ROSCHER AA, 1984, J CLIN INVEST, V74, P552, DOI 10.1172/JCI111452; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806	22	96	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26079	26084		10.1074/jbc.274.37.26079	http://dx.doi.org/10.1074/jbc.274.37.26079			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473556	hybrid			2022-12-25	WOS:000082469700022
J	Chattopadhyay, A; Vecchi, M; Ji, QS; Mernaugh, R; Carpenter, G				Chattopadhyay, A; Vecchi, M; Ji, QS; Mernaugh, R; Carpenter, G			The role of individual SH2 domains in mediating association of phospholipase C-gamma 1 with the activated EGF receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; AUTOPHOSPHORYLATION SITES; C-GAMMA; TYROSINE KINASE; POINT MUTATION; BINDING-SITE; PLC-GAMMA; PHOSPHORYLATION SITES; SELF-PHOSPHORYLATION	The two SH2 (Src homology domain 2) domains present in phospholipase C-gamma 1 (PLC-gamma 1) were assayed for their capacities to recognize the five autophosphorylation sites in the epidermal growth factor receptor. Plasmon resonance and immunological techniques were employed to measure interactions between SH2 fusion proteins and phosphotyrosine-containing peptides. The N-SH2 domain recognized peptides in the order of pY1173 > pY992 > pY1068 > pY1148 much greater than pY1086, while the C-SH2 domain recognized peptides in the order of pY992 > pY1068 > pY1148 much greater than pY1086 and pY1173. The major autophosphorylation site, pY1173, was recognized only by the N-SH2 domain. Contributions of the N-SH2 and C-SH2 domains to the association of the intact PLC-gamma 1 molecule with the activated epidermal growth factor (EGF) receptor were assessed in vivo. Loss of function mutants of each SH2 domain were produced in a full-length epitope-tagged PLC-gamma 1. After expression of the mutants, cells were treated with EGF and association of exogenous PLC-gamma 1 with EGF receptors was measured. In this context the N-SH2 is the primary contributor to PLC-gamma 1 association with the EGF receptor. The combined results suggest an association mechanism involving the N-SH2 domain and the pY1173 autophosphorylation site as a primary event and the C-SH2 domain and the pY992 autophosphorylation site as a secondary event.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 606 Light Hall, Nashville, TN 37232 USA.	Graham.Carpenter@mcmail.vanderbilt.edu	Vecchi, Manuela/L-3502-2017	Vecchi, Manuela/0000-0002-2750-9160; Chattopadhyay, Ansuman/0000-0002-5412-3749	NATIONAL CANCER INSTITUTE [R01CA075195, R01CA024071, P30CA068485] Funding Source: NIH RePORTER; NCI NIH HHS [CA24071, CA68485, CA75195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alimandi M, 1997, ONCOGENE, V15, P585, DOI 10.1038/sj.onc.1201221; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; EMORI Y, 1989, J BIOL CHEM, V264, P21885; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Hall H, 1996, CURR BIOL, V6, P580, DOI 10.1016/S0960-9822(02)00544-4; HARLOW E, 1988, ANTIBODIES LAB MANUA, P348; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; Homma MK, 1997, J BIOCHEM, V122, P738; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kamat Asha, 1997, Cytokine and Growth Factor Reviews, V8, P109, DOI 10.1016/S1359-6101(97)00003-8; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; KOBAYASHI S, 1994, J BIOL CHEM, V269, P9011; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAROSE L, 1993, ONCOGENE, V8, P2493; MAGNI M, 1991, BIOCHEM J, V277, P305, DOI 10.1042/bj2770305; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Nebigil CG, 1997, BIOCHEMISTRY-US, V36, P15949, DOI 10.1021/bi971721m; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; Panayotou G, 1998, METH MOL B, V88, P1; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SOLER C, 1994, J BIOL CHEM, V269, P12320; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Thackeray JR, 1998, DEVELOPMENT, V125, P5033; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; WEBER W, 1984, J BIOL CHEM, V259, P4631; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	55	104	106	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26091	26097		10.1074/jbc.274.37.26091	http://dx.doi.org/10.1074/jbc.274.37.26091			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473558	hybrid			2022-12-25	WOS:000082469700024
J	Farver, O; Bendahl, L; Skov, LK; Pecht, I				Farver, O; Bendahl, L; Skov, LK; Pecht, I			Human ceruloplasmin - Intramolecular electron transfer kinetics and equilibration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBATE OXIDASE; REDUCTION POTENTIALS; CRYSTAL-STRUCTURE; COPPER; ACTIVATION; LACCASE; OXYGEN; AZURIN; FORMS; SITE	Pulse radiolytic reduction of disulfide bridges in ceruloplasmin yielding RSSR- radicals induces a cascade of intramolecular electron transfer (ET) processes. Based on the three-dimensional structure of ceruloplasmin identification of individual kinetically active disulfide groups and type 1 (T1) copper centers, the following is proposed. The first T1 copper(II) ion to be reduced in ceruloplasmin is the blue copper center of domain 6 (T1A) by ET from RSSR- of domain 5. The rate constant is 28 +/- 2 s(-1) at 279 K and pH 7.0, T1A is in close covalent contact with the type 3 copper pair and indeed electron equilibration between T1A and the trinuclear copper center in the domain 1-6 interface takes place with a rate constant of 2.9 +/- 0.6 s(-1). The equilibrium constant is 0.17. Following reduction of T1A Cu(II), another ET process takes place between RSSR- and T1B copper(II) of domain 4 with a rate constant of 3.9 +/- 0.8. No reoxidation of T1B Cu(I) could be resolved. It appears that the third T1 center (T1C of domain 2) is not participating in intramolecular ET, as it seems to be in a reduced state in the resting enzyme.	Royal Danish Sch Pharm, Inst Analyt & Pharmaceut Chem, DK-2100 Copenhagen 0, Denmark; Univ Copenhagen, Dept Chem, Prot Struct Grp, DK-2100 Copenhagen, Denmark; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Royal Danish School of Pharmacy; University of Copenhagen; Weizmann Institute of Science	Farver, O (corresponding author), Royal Danish Sch Pharm, Inst Analyt & Pharmaceut Chem, 2 Univ Pk, DK-2100 Copenhagen 0, Denmark.			Pecht, Israel/0000-0002-1883-9547				AVIGLIANO L, 1997, ELECT TRANSFER REACT, P251; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BOAS JF, 1984, COPPER PROTEINS COPP, V1, P5; CALABRESE L, 1989, J BIOL CHEM, V264, P6183; DEINUM J, 1973, BIOCHIM BIOPHYS ACTA, V310, P321, DOI 10.1016/0005-2795(73)90112-8; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; FARAGGI M, 1973, J BIOL CHEM, V248, P3146; FARVER O, 1991, MOL CRYST LIQ CRYST, V194, P215, DOI 10.1080/00268949108041167; Farver O, 1997, J BIOL INORG CHEM, V2, P387, DOI 10.1007/s007750050148; FARVER O, 1994, J BIOL CHEM, V269, P22933; Farver O, 1997, J AM CHEM SOC, V119, P5453, DOI 10.1021/ja964386i; FARVER O, 1992, P NATL ACAD SCI USA, V89, P8283, DOI 10.1073/pnas.89.17.8283; FARVER O, 1993, J INORG BIOCHEM, V51, P14; FARVER O, 1997, ELECT TRANSFER REACT, P355; FEE JA, 1975, STRUCT BOND, V22, P1; HARRIS ED, 1996, NUTR REV, V53, P170; Hazzard JT, 1997, ARCH BIOCHEM BIOPHYS, V339, P24, DOI 10.1006/abbi.1996.9860; HUBER CT, 1970, J BIOL CHEM, V245, P3973; Machonkin TE, 1998, BIOCHEMISTRY-US, V37, P9570, DOI 10.1021/bi980434v; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; MEYER TE, 1991, BIOCHEMISTRY-US, V30, P4619, DOI 10.1021/bi00232a037; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; PASCHER T, 1993, EUR J BIOCHEM, V212, P289, DOI 10.1111/j.1432-1033.1993.tb17661.x; Pecht I, 1998, PHOTOCHEMISTRY RAD C, P65; SAITZEV V, 1995, J INORG BIOCHEM, V59, P719; SAITZEVA I, 1996, J BIOL INORG CHEM, V1, P15; TOLLIN G, 1993, BIOCHIM BIOPHYS ACTA, V1183, P3096	29	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26135	26140		10.1074/jbc.274.37.26135	http://dx.doi.org/10.1074/jbc.274.37.26135			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473564	hybrid			2022-12-25	WOS:000082469700030
J	Fialka, I; Steinlein, P; Ahorn, H; Bock, G; Burbelo, PD; Haberfellner, M; Lottspeich, F; Paiha, K; Pasquali, C; Huber, LA				Fialka, I; Steinlein, P; Ahorn, H; Bock, G; Burbelo, PD; Haberfellner, M; Lottspeich, F; Paiha, K; Pasquali, C; Huber, LA			Identification of syntenin as a protein of the apical early endocytic compartment in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROBE TRIMETHYLAMINO-DIPHENYLHEXATRIENE; 2-DIMENSIONAL GEL-ELECTROPHORESIS; POLARIZED EPITHELIAL-CELLS; PLASMA-MEMBRANE; EARLY ENDOSOMES; MDCK CELLS; L929 CELLS; SUBCELLULAR FRACTIONATION; PHASE ENDOCYTOSIS; CARRIER VESICLES	We used flow cytometry to sort and analyze apical and basolateral endocytic vesicles from filter-grown Madin-Darby canine kidney (MDCK) cells after membrane internalization of the lipophilic fluorescent probe trimethylamino-diphenylhexatriene. Western blot analysis of sorted fractions showed enrichment of the early endosomal markers transferrin receptor and the small GTPase Rab5, Two-dimensional gel analysis indicated that the apical and basolateral early endosomes differed significantly in their protein composition. We found nine polypeptides to be specifically enriched in apical or basolateral endocytic vesicles. An apical protein identified by microsequencing was the adaptor molecule syntenin, This protein contains two PDZ domains (PSD-95, Dig, and ZO-1 homology) that bind syndecan and ephrin-B2 cytoplasmic domains. In MDCK cells, transiently overexpressed Myc-tagged syntenin localized to both plasma membrane domains and to an intracellular vesicular compartment, Syntenin positive vesicles colocalized with internalized transferrin in the perinuclear region. In addition, syntenin colocalized in the apical supranuclear region with Rab5 and Rab11; the latter is a marker for the apical recycling endosomes in MDCK cells.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Boehringer Ingelheim GmbH & Co KG, A-1121 Vienna, Austria; Univ Innsbruck, Dept Gen & Expt Pathol, A-6020 Innsbruck, Austria; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Boehringer Ingelheim; University of Innsbruck; Georgetown University; Max Planck Society	Huber, LA (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	huber@nt.imp.univie.ac.at	Burbelo, Peter D./B-1027-2009; Huber, Lukas Alfons/AAM-3499-2021	Huber, Lukas Alfons/0000-0003-1116-2120				Aniento F, 1995, COLD SPRING HARB SYM, V60, P205, DOI 10.1101/SQB.1995.060.01.023; Appel RD, 1997, ELECTROPHORESIS, V18, P2724, DOI 10.1002/elps.1150181506; Bischof J, 1999, BIOL CHEM, V380, P269, DOI 10.1515/BC.1999.036; BOCK G, 1998, CELL BIOL LAB HDB, V2, P63; Bock I, 1997, TRENDS CELL BIOL, V7, P499, DOI 10.1016/S0962-8924(97)01160-4; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CUPERS P, 1994, J CELL BIOL, V127, P725, DOI 10.1083/jcb.127.3.725; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Fialka I, 1997, ELECTROPHORESIS, V18, P2582, DOI 10.1002/elps.1150181414; Fiedler K, 1997, ELECTROPHORESIS, V18, P2613, DOI 10.1002/elps.1150181417; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GHOSH RN, 1994, J CELL SCI, V107, P2177; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1992, PROTEIN TARGETING PR, P187; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; HOWELL KE, 1989, TRENDS BIOCHEM SCI, V14, P44, DOI 10.1016/0968-0004(89)90040-6; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; ILLINGER D, 1994, J CELL BIOL, V125, P783, DOI 10.1083/jcb.125.4.783; ILLINGER D, 1991, BIOL CELL, V71, P293, DOI 10.1016/0248-4900(91)90273-P; ILLINGER D, 1995, BBA-BIOMEMBRANES, V1239, P58, DOI 10.1016/0005-2736(95)00135-P; ILLINGER D, 1991, BIOL CELL, V73, P131, DOI 10.1016/0248-4900(91)90095-5; ILLINGER D, 1990, BIOCHIM BIOPHYS ACTA, V1030, P73, DOI 10.1016/0005-2736(90)90240-O; LEGRIMELLEC C, 1988, AM J PHYSIOL, V255, pF22, DOI 10.1152/ajprenal.1988.255.1.F22; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; MASUMOTO N, 1993, BIOCHEM BIOPH RES CO, V197, P207, DOI 10.1006/bbrc.1993.2462; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; Nunez MT, 1996, J NUTR, V126, P2151, DOI 10.1093/jn/126.9.2151; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; Pasquali C, 1997, ELECTROPHORESIS, V18, P2573, DOI 10.1002/elps.1150181413; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Simons K, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P101; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	50	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26233	26239		10.1074/jbc.274.37.26233	http://dx.doi.org/10.1074/jbc.274.37.26233			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473577	hybrid			2022-12-25	WOS:000082469700043
J	Razani, B; Rubin, CS; Lisanti, MP				Razani, B; Rubin, CS; Lisanti, MP			Regulation of cAMP-mediated signal transduction via interaction of caveolins with the catalytic subunit of protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RICH MEMBRANE DOMAINS; IN-VIVO; SCAFFOLDING DOMAIN; TYROSINE KINASE; PLASMA-MEMBRANE; A-KINASE; MUTATIONAL ANALYSIS; ANCHORING PROTEINS; CELL CAVEOLAE	cAMP-dependent processes are essential for cell growth, differentiation, and homeostasis. The classic components of this system include the serpentine receptors, heterotrimeric G-proteins, adenylyl cyclase, protein kinase A (PKA), and numerous downstream target substrates. Evidence is accumulating that some members of this cascade are concentrated within membrane microdomains, termed caveolae and caveolae-related domains. In addition, the caveolin-1 protein has been shown to interact with some of these components, and this interaction inhibits their enzymatic activity, However, the functional effects of caveolins on cAMP-mediated signaling at the most pivotal step, PEA activation, remain unknown. Here, we show that caveolin-1 can dramatically inhibit cAMP-dependent signaling in vivo. We provide evidence for a direct interaction between caveolin-1 and the catalytic subunit of PKA both in vitro and in vivo. Caveolin-1 binding appears to be mediated both by the caveolin scaffolding domain (residues 82-101) and a portion of the C-terminal domain (residues 135-156), Further functional analysis indicates that caveolin-based peptides derived from these binding regions can inhibit the catalytic activity of purified PKA in vitro. Mutational analysis of the caveolin scaffolding domain reveals that a series of aromatic residues within the caveolin scaffolding domain are critical for mediating inhibition of PKA, In addition, co-expression of caveolin-1 and PKA in cultured cells results in their co-localization as seen by immunofluorescence microscopy. In cells co-expressing caveolin-1 and PKA, PKA assumed a punctate distribution that coincided with the distribution of caveolin-1. In contrast, in cells expressing PKA alone, PKA was localized throughout the cytoplasm and yielded a diffuse staining pattern. Taken together, our results suggest that the direct inhibition of PKA by caveolin-1 is an important and previously unrecognized mechanism for modulating cAMP-mediated signaling.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Razani, Babak/0000-0002-7172-9240	NCI NIH HHS [R01-CA-80250] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; FAN JY, 1983, J CELL SCI, V61, P219; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, CELL MOL BIOL, V43, P293; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	58	160	164	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26353	26360		10.1074/jbc.274.37.26353	http://dx.doi.org/10.1074/jbc.274.37.26353			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473592	hybrid			2022-12-25	WOS:000082469700058
J	Tsai, CW; Chang, SC; Chang, MF				Tsai, CW; Chang, SC; Chang, MF			A 12-amino acid stretch in the hypervariable region of the spike protein S1 subunit is critical for cell fusion activity of mouse hepatitis virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONAVIRUS SURFACE GLYCOPROTEIN; RECEPTOR-BINDING SITE; MURINE CORONAVIRUS; PROTEOLYTIC CLEAVAGE; DELTA-ANTIGEN; MONOCLONAL-ANTIBODIES; MEMBRANE-FUSION; ENVELOPE GLYCOPROTEIN; PEPLOMER GLYCOPROTEIN; CONFORMATIONAL CHANGE	The spike (S) glycoprotein of mouse hepatitis virus (MHV) plays a major role in the viral pathogenesis, It is often processed into the N-terminal S1 and the C-terminal 52 subunits that were evidently important for binding to cell receptor and inducing cell-cell fusion, respectively. As a consequence of cell-cell fusion, most of the naturally occurring infections of MHV are associated with syncytia formation. So far, only MW-2 was identified to be fusion-negative. In this study, the S gene of MHV-2 was molecularly cloned, and the nucleotide sequence was determined. The MHV-2 S protein lacks a 12-amino acid stretch in the S1 hypervariable region from amino acid residue 446 to 457 when compared with the fusion-positive strain MHV-JHM, In addition, there are three amino acid substitutions in the 52 subunit, Tyr-1144 to Asp, Glu-1165 to Asp, and Arg-1209 to Lys. The cloned MHV-2 S protein exhibited the fusion-negative property in DBT cells as the intrinsic viral protein. Furthermore, similar to the fusion-positive MHV-JHM strain, proteolytic cleavage activity was detected both in DBT cells infected with the fusion-negative MHV-8 and in the transfected cells that expressed the cloned MHV-S S protein. Domain swapping experiments demonstrated that the 12-amino acid stretch missing in the MHV-2 S1 subunit, but not the proteolytic cleavage site, was critical for the cell-fusion activity of MHV.	Natl Taiwan Univ, Coll Med, Inst Biochem, Sect 1, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Inst Microbiol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Lab Anim Ctr, Taipei 100, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University	Chang, MF (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem, Sect 1, 1 Jen Ai Rd, Taipei 100, Taiwan.			CHANG, MING-FU/0000-0001-7062-3578				BANNER LR, 1990, VIROLOGY, V175, P548, DOI 10.1016/0042-6822(90)90439-X; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Bold S, 1996, J GEN VIROL, V77, P2297, DOI 10.1099/0022-1317-77-9-2297; Bos ECW, 1995, VIROLOGY, V214, P453, DOI 10.1006/viro.1995.0056; CAVANAGH D, 1986, J GEN VIROL, V67, P1435, DOI 10.1099/0022-1317-67-7-1435; CHANG MF, 1988, J VIROL, V62, P2403, DOI 10.1128/JVI.62.7.2403-2410.1988; CHANG MF, 1994, J VIROL, V68, P646, DOI 10.1128/JVI.68.2.646-653.1994; CHANG MF, 1993, J VIROL, V67, P2529, DOI 10.1128/JVI.67.5.2529-2536.1993; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS AR, 1982, VIROLOGY, V119, P358, DOI 10.1016/0042-6822(82)90095-2; DANIEL C, 1993, J VIROL, V67, P1185, DOI 10.1128/JVI.67.3.1185-1194.1993; DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990; FAZAKERLEY JK, 1992, VIROLOGY, V187, P178, DOI 10.1016/0042-6822(92)90306-A; FRANA MF, 1985, J VIROL, V56, P912, DOI 10.1128/JVI.56.3.912-920.1985; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLAGHER TM, 1991, J VIROL, V65, P1916, DOI 10.1128/JVI.65.4.1916-1928.1991; Gallagher TM, 1996, J VIROL, V70, P4683, DOI 10.1128/JVI.70.7.4683-4690.1996; GALLAGHER TM, 1990, J VIROL, V64, P731, DOI 10.1128/JVI.64.2.731-741.1990; GOMBOLD JL, 1993, J VIROL, V67, P4504, DOI 10.1128/JVI.67.8.4504-4512.1993; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HIRANO N, 1981, ARCH VIROL, V70, P69, DOI 10.1007/BF01320795; HIRANO N, 1974, ARCH GES VIRUSFORSCH, V44, P298, DOI 10.1007/BF01240618; KECK JG, 1988, J VIROL, V62, P1989, DOI 10.1128/JVI.62.6.1989-1998.1988; KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994; LAI MMC, 1990, ANNU REV MICROBIOL, V44, P303, DOI 10.1146/annurev.mi.44.100190.001511; Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9; Lee CH, 1998, J BIOL CHEM, V273, P7650, DOI 10.1074/jbc.273.13.7650; Luo ZL, 1998, VIROLOGY, V244, P483, DOI 10.1006/viro.1998.9121; LUYTJES W, 1989, J VIROL, V63, P1408, DOI 10.1128/JVI.63.3.1408-1412.1989; LUYTJES W, 1987, VIROLOGY, V161, P479, DOI 10.1016/0042-6822(87)90142-5; MAKINO S, 1983, MICROBIOL IMMUNOL, V27, P445, DOI 10.1111/j.1348-0421.1983.tb00603.x; MORRISON TG, 1988, VIRUS RES, V10, P113, DOI 10.1016/0168-1702(88)90010-X; PARKER SE, 1989, VIROLOGY, V173, P664, DOI 10.1016/0042-6822(89)90579-5; Perrin C, 1998, VIROLOGY, V242, P338, DOI 10.1006/viro.1997.9016; PFLEIDERER M, 1990, ADV EXP MED BIOL, V276, P21; RICHARDSON CD, 1983, VIROLOGY, V131, P518, DOI 10.1016/0042-6822(83)90517-2; Risco C, 1996, J VIROL, V70, P4773, DOI 10.1128/JVI.70.7.4773-4777.1996; ROUTLEDGE E, 1991, J VIROL, V65, P254, DOI 10.1128/JVI.65.1.254-262.1991; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; SCHMIDT I, 1987, J GEN VIROL, V68, P47, DOI 10.1099/0022-1317-68-1-47; SCHMIDT MFG, 1982, VIROLOGY, V116, P327, DOI 10.1016/0042-6822(82)90424-X; SHIEH CK, 1989, J VIROL, V63, P3729, DOI 10.1128/JVI.63.9.3729-3736.1989; SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761; SPAAN W, 1988, J GEN VIROL, V69, P2939, DOI 10.1099/0022-1317-69-12-2939; STAUBER R, 1993, J GEN VIROL, V74, P183, DOI 10.1099/0022-1317-74-2-183; STOHLMAN SA, 1988, J VIROL, V62, P4288, DOI 10.1128/JVI.62.11.4288-4295.1988; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STURMAN L, 1985, TRENDS BIOCHEM SCI, V10, P17, DOI 10.1016/0968-0004(85)90010-6; STURMAN LS, 1983, ADV VIRUS RES, V28, P35, DOI 10.1016/S0065-3527(08)60721-6; STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985; STURMAN LS, 1980, J VIROL, V33, P449, DOI 10.1128/JVI.33.1.449-462.1980; STURMAN LS, 1990, J VIROL, V64, P3042, DOI 10.1128/JVI.64.6.3042-3050.1990; Suzuki H, 1996, J VIROL, V70, P2632, DOI 10.1128/JVI.70.4.2632-2636.1996; TAGUCHI F, 1993, J VIROL, V67, P1195, DOI 10.1128/JVI.67.3.1195-1202.1993; TAGUCHI F, 1992, J GEN VIROL, V73, P1066; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990; WANG FI, 1992, VIROLOGY, V186, P742, DOI 10.1016/0042-6822(92)90041-M; WEGE H, 1982, CURR TOP MICROBIOL, V99, P165; WEISMILLER DG, 1990, J VIROL, V64, P3051, DOI 10.1128/JVI.64.6.3051-3055.1990; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; Yamada YK, 1997, VIROLOGY, V227, P215, DOI 10.1006/viro.1996.8313; YOKOMORI K, 1991, VIROLOGY, V183, P647, DOI 10.1016/0042-6822(91)90994-M; Young JK, 1998, VIROLOGY, V243, P21, DOI 10.1006/viro.1998.9044; ZHANG L, 1994, J VIROL, V68, P2186, DOI 10.1128/JVI.68.4.2186-2193.1994	67	17	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26085	26090		10.1074/jbc.274.37.26085	http://dx.doi.org/10.1074/jbc.274.37.26085			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473557	hybrid			2022-12-25	WOS:000082469700023
J	Geijsen, N; Spaargaren, M; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; Coffer, PJ				Geijsen, N; Spaargaren, M; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; Coffer, PJ			Association of RACK1 and PKC beta with the common beta-chain of the IL-5/IL3/GM-CSF receptor	ONCOGENE			English	Article						RACK1; PKC; receptor; cytokine; interleukin	COLONY-STIMULATING FACTOR; PROTEIN-KINASE-C; INTERLEUKIN-3 RECEPTOR; SIGNAL TRANSDUCTION; HUMAN EOSINOPHILS; PHORBOL ESTERS; MESSENGER-RNA; GM-CSF; EXPRESSION; SUBUNIT	Granulocyte macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and interleukin-5 (IL-5 belong to a family of cytokines that regulate proliferation, differentiation and function of haematopoietic cells. Their receptor consists of a ligand specific alpha-chain and a signal transducing beta-chain (beta c). While, the role of phosphotyrosine residues in the beta c as mediators of downstream signalling cascades has been established, little is known about non-phosphotyrosine mediated events. To identify proteins interacting with beta c, me screened a yeast two-hybrid library with the intracellular domain of beta c. We found that RACK1, a molecule associating with activated PKC, PLC gamma and Src kinases, associated with the membrane proximal region of beta c in both yeast two-hybrid, immunoprecipitation and GST-pull-down assays. The association of RACK1 was constitutive, demonstrating no alteration upon cellular stimulation. Furthermore, upon stimulation of cells with IL-5 or PMA, a complex of beta c and PKC beta was found. Together, these findings suggest a novel role for RACK1 as a possible adapter molecule associating with the intracellular domain of cytokine receptors.	Univ Utrecht Hosp, Dept Pulm Dis, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University	Coffer, PJ (corresponding author), Univ Utrecht Hosp, Dept Pulm Dis, Heidelberglaan 100,POB 85500, NL-3508 GA Utrecht, Netherlands.		Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009; Koenderman, Leo/AAE-7870-2020; Spaargaren, Marcel/AAU-1298-2021	Koenderman, Leo/0000-0002-5636-6453; Spaargaren, Marcel/0000-0002-3135-5109				AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; CloudHeflin BA, 1996, EUR J BIOCHEM, V239, P796, DOI 10.1111/j.1432-1033.1996.0796u.x; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; deGroot RP, 1997, J BIOL CHEM, V272, P2319; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; FUJISAWA T, 1990, J IMMUNOL, V144, P642; Gale RE, 1998, BLOOD, V91, P54, DOI 10.1182/blood.V91.1.54.54_54_63; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI Y, 1995, J IMMUNOL, V155, P2165; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Padanilam BJ, 1997, AM J PHYSIOL-RENAL, V272, pF160, DOI 10.1152/ajprenal.1997.272.2.F160; Pascale A, 1996, J NEUROCHEM, V67, P2471; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460-2075.1996.tb00540.x; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VANDERBRUGGEN T, 1993, J LEUKOCYTE BIOL, V53, P347, DOI 10.1002/jlb.53.4.347	34	79	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5126	5130		10.1038/sj.onc.1202896	http://dx.doi.org/10.1038/sj.onc.1202896			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490850				2022-12-25	WOS:000082497100013
J	Lin, J; Weiss, A; Finco, TS				Lin, J; Weiss, A; Finco, TS			Localization of LAT in glycolipid-enriched microdomains is required for T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; PROTOONCOGENE PRODUCT; ADAPTER PROTEIN; MEMBRANE; GRB2; EXCHANGE; CBL; VAV	LAT, a transmembrane adapter protein found in glycolipid-enriched microdomains (GEMs), is essential for T cell activation. In this study, we have utilized a LAT-deficient mutant of the Jurkat T cell line, J.CaM2, to explore various requirements for LAT function. First, we demonstrate that LAT must be present in GEMs for coupling T cell receptor (TCR) engagement to activation of the Ras signaling pathway, increases in intracellular Ca2+, and induction of the transcription factor nuclear factor of activated T cells (NF-AT). Second, we show that the extracellular and transmembrane domains of LAT are dispensable for these TCR-mediated events once LAT has localized to GEMs. These results provide important insights into both the structural domains of LAT and its subcellular localization that are required for effective TCR signaling.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weiss, A (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA.							Brdicka T, 1998, BIOCHEM BIOPH RES CO, V248, P356, DOI 10.1006/bbrc.1998.8857; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GOLDSMITH MA, 1988, P NATL ACAD SCI USA, V85, P5613; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zlatkine P, 1997, J CELL SCI, V110, P673	31	130	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	1999	274	41					28861	28864		10.1074/jbc.274.41.28861	http://dx.doi.org/10.1074/jbc.274.41.28861			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	243VH	10506128	hybrid			2022-12-25	WOS:000083017800007
J	Caruso, R; Miele, C; Oriente, F; Maitan, A; Bifulco, G; Andreozzi, F; Condorelli, G; Formisano, P; Beguinot, F				Caruso, R; Miele, C; Oriente, F; Maitan, A; Bifulco, G; Andreozzi, F; Condorelli, G; Formisano, P; Beguinot, F			In L6 skeletal muscle cells, glucose induces cytosolic translocation of protein kinase C-alpha and trans-activates the insulin receptor kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; RAT-1 FIBROBLASTS; HYPERGLYCEMIA; PHOSPHORYLATION; METABOLISM; ISOFORMS; AUTOPHOSPHORYLATION; TRANSPORTERS; INHIBITION; ISOENZYMES	In L6 skeletal muscle cells expressing human insulin receptors (L6(hIR)), exposure to 25 mM glucose for 3 min induced a rapid 3-fold increase in GLUT1 and GLUT4 membrane translocation and glucose uptake. The high glucose concentration also activated the insulin receptor kinase toward the endogenous insulin receptor substrates (IRS)-1 and IRS-2. At variance, in L6 cells expressing kinase-deficient insulin receptors, the exposure to 25 mM glucose elicited no effect on glucose disposal. In the L6(hIR) cells, the acute effect of glucose on insulin receptor kinase was paralleled by a a-fold decrease in both the membrane and the insulin receptor co-precipitated protein kinase C (PKC) activities and a 3-fold decrease in receptor Ser/Thr phosphorylation, Western blotting of the receptor precipitates with isoform-specific PKC antibodies revealed that the glucose-induced decrease in membrane- and receptor-associated PKC activities was accounted for by dissociation of PRC alpha but not of PKC beta or -delta. This decrease in PKC alpha was paralleled by a similarly sized increase in cytosolic PKC alpha, In intact L6(hIR) cells, inhibition of PKC alpha expression by using a specific antisense oligonucleotide caused a 3-fold increase in IRS phosphorylation by the insulin receptor. This effect was independent of insulin and accompanied by a 2.5-fold increase in glucose disposal by the cells. Thus, in the L6 skeletal muscle cells, glucose acutely regulates its own utilization through the insulin signaling system, independent of insulin. Glucose autoregulation appears to involve PKC alpha dissociation from the insulin receptor and its cytosolic translocation.	Univ Naples Federico II, Dept Biol & Patol Cellulare & Mol, CNR, I-80131 Naples, Italy; Univ Naples Federico II, Ctr Endocrinol & Oncol Sperimentale, CNR, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Beguinot, F (corresponding author), Univ Naples Federico II, Dept Biol & Patol Cellulare & Mol, CNR, Via S Pansini 5, I-80131 Naples, Italy.	beguino@unina.it	Formisano, Pietro/J-4237-2018; Condorelli, Gerolama/AAC-3472-2022; ORIENTE, Francesco/J-6652-2018; Andreozzi, Francesco/J-4073-2018	Condorelli, Gerolama/0000-0003-0177-8829; ORIENTE, Francesco/0000-0003-4375-4526; Formisano, Pietro/0000-0001-7020-6870; Andreozzi, Francesco/0000-0001-9375-1513; BIFULCO, Giuseppe/0000-0001-7772-8591	Fondazione Telethon Funding Source: Custom; Telethon [E.0896] Funding Source: Medline	Fondazione Telethon(Fondazione Telethon); Telethon(Fondazione Telethon)		AVRUCH J, 1989, MOL CELLULAR BIOL DI, V2, P65; AZEVEDO JL, 1995, DIABETES, V44, P695, DOI 10.2337/diabetes.44.6.695; BARASH V, 1977, BIOCHIM BIOPHYS ACTA, V481, P86, DOI 10.1016/0005-2744(77)90140-1; BERGER M, 1975, BIOCHEM J, V146, P231, DOI 10.1042/bj1460231; BERTI L, 1994, J BIOL CHEM, V269, P3381; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; Bossenmaier B, 1997, DIABETOLOGIA, V40, P863, DOI 10.1007/s001250050761; Caruso M, 1997, J BIOL CHEM, V272, P7290, DOI 10.1074/jbc.272.11.7290; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; CHIN JE, 1993, J BIOL CHEM, V268, P6338; CONTOR L, 1987, ANAL BIOCHEM, V160, P414, DOI 10.1016/0003-2697(87)90069-8; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; DOUEN AG, 1989, ENDOCRINOLOGY, V124, P449, DOI 10.1210/endo-124-1-449; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; Formisano P, 1998, J BIOL CHEM, V273, P13197, DOI 10.1074/jbc.273.21.13197; GALANTE P, 1995, DIABETES, V44, P646, DOI 10.2337/diabetes.44.6.646; HELIN K, 1991, ONCOGENE, V6, P825; HOCKADAY TDR, 1982, LANCET, V1, P1304; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; IDE R, 1994, BIOCHEM BIOPH RES CO, V201, P71, DOI 10.1006/bbrc.1994.1670; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KAZANIETZ MG, 1996, CELLULAR MOL PATHOGE, P389; Keppler D, 1974, METHODS ENZYMATIC AN; Koopmans SJ, 1998, AM J PHYSIOL-ENDOC M, V274, pE642, DOI 10.1152/ajpendo.1998.274.4.E642; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; MANDARINO LJ, 1993, AM J PHYSIOL, V265, pE898, DOI 10.1152/ajpendo.1993.265.6.E898; Miele C, 1999, J BIOL CHEM, V274, P3094, DOI 10.1074/jbc.274.5.3094; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; MULLER HK, 1991, DIABETES, V40, P1440, DOI 10.2337/diabetes.40.11.1440; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NOLTE LA, 1995, DIABETES, V44, P1345, DOI 10.2337/diabetes.44.11.1345; Pillay TS, 1996, J CLIN INVEST, V97, P613, DOI 10.1172/JCI118457; REVERS RR, 1984, J CLIN INVEST, V73, P664, DOI 10.1172/JCI111258; SACCA L, 1981, METABOLISM, V30, P457, DOI 10.1016/0026-0495(81)90180-3; Sawai H, 1997, J BIOL CHEM, V272, P2452; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WALKER PS, 1989, J BIOL CHEM, V264, P6587; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; YKIJARVINEN H, 1990, DIABETOLOGIA, V33, P579, DOI 10.1007/BF00400200; YKIJARVINEN H, 1987, J CLIN INVEST, V79, P1713, DOI 10.1172/JCI113011	49	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28637	28644		10.1074/jbc.274.40.28637	http://dx.doi.org/10.1074/jbc.274.40.28637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497232				2022-12-25	WOS:000082912700081
J	Gechtman, Z; Alonso, JL; Raab, G; Ingber, DE; Klagsbrun, M				Gechtman, Z; Alonso, JL; Raab, G; Ingber, DE; Klagsbrun, M			The shedding of membrane-anchored heparin-binding epidermal-like growth factor is regulated by the Raf/mitogen-activated protein kinase cascade and by cell adhesion and spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; NECROSIS-FACTOR-ALPHA; DIPHTHERIA-TOXIN RECEPTOR; PHORBOL-ESTER; TYROSINE PHOSPHORYLATION; TGF-ALPHA; SIGNAL-TRANSDUCTION; T-LYMPHOCYTES; TNF RECEPTOR; EGF	Heparin-binding epidermal-like growth factor (HB-EGF) is synthesized as a transmembrane precursor (HB-EGF(TM)). The addition of phorbol ester (PMA, phorbol 12-myristate 13-acetate) to cells expressing HB-EGF(TM) results in the metalloproteinase-dependent release (shedding) of soluble HB-EGF. To analyze mechanisms that regulate HB-EGF shedding, a stable cell line was established expressing HB-EGF(TM) in which the ectodomain and the cytoplasmic tail were tagged with hemagglutinin (HA) and Myc epitopes, respectively (HB-EGF(TM)HA/Myc). HB-EGF(TM)HA/Myc cleavage was followed by the appearance of soluble HB-EGFHA in conditioned medium, the loss of biotinylated cell surface HB-EGF(TM)HA/Myc, and the appearance of a Myc-tagged cytoplasmic tail fragment in cell lysates, By using this approach, several novel metalloproteinase-dependent regulators of HB-EGF(TM) shedding were identified as follows. (i) HB-EGF(TM)HA/Myc shedding induced by PMA was blocked by the mitogen-activated protein (MAP) kinase kinase inhibitor, PD98059. PMA activated MAP kinase within 5 min, but HB-EGF(TM)HA/Myc shedding did not occur until 20 min, suggesting that MAP kinase activation was a necessary step in the pathway of PMA-induced HB-EGF, cleavage. (ii) Activation of an inducible Raf-l kinase, Delta Raf-1:estrogen receptor, resulted in a rapid MAP kinase activation within 10 min and shedding of HB-EGF(TM)HA/Myc within 20-40 min. (iii) Serum induced MAP kinase activation and HB-EGF(TM)HA/Myc shedding that were inhibited by PD98059, (iv) Whereas PMA induced HB-EGF(TM)HA/Myc shedding in attached cells, no shedding occurred when the cells were placed in suspension. Shedding was fully restored shortly after cells mere allowed to spread on fibronectin, and the extent of PMA-induced shedding increased with the extent of cell spreading. PMA induced the same level of MAP kinase activation whether the cells were attached or in suspension suggesting that although MAP kinase activation might be necessary for shedding, it was not sufficient. Taken together, these results suggest that there are two components of cell regulation that contribute to the shedding process, not previously recognized, the Raf-1/MAP kinase signal transduction pathway and cell adhesion and spreading.	Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Klagsbrun, M (corresponding author), Childrens Hosp, Dept Surg Res, 300 Longwood Ave, Boston, MA 02115 USA.		Alonso, Jose Luis/G-7961-2012; Ingber, Donald E/AAC-5894-2019; Alonso, José Luis/ABF-5483-2021		NCI NIH HHS [CA 45548] Funding Source: Medline; NHLBI NIH HHS [HL 56398] Funding Source: Medline; NIGMS NIH HHS [GM RO1.47397] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CROWE PD, 1993, J IMMUNOL, V151, P6882; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Frey M, 1997, J IMMUNOL, V158, P5424; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HIGUCHI M, 1993, J BIOL CHEM, V268, P5624; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Igura T, 1996, ARTERIOSCL THROM VAS, V16, P1524, DOI 10.1161/01.ATV.16.12.1524; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LANZREIN M, 1995, BIOCHEM J, V310, P285, DOI 10.1042/bj3100285; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; MULLBERG J, 1995, J IMMUNOL, V155, P5198; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; POWELL PP, 1993, AM J PATHOL, V143, P784; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; Raab G, 1996, DEVELOPMENT, V122, P637; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SLACK BE, 1995, J BIOL CHEM, V270, P8337, DOI 10.1074/jbc.270.14.8337; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZHANG L, 1994, J BIOL CHEM, V269, P10270	62	156	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28828	28835		10.1074/jbc.274.40.28828	http://dx.doi.org/10.1074/jbc.274.40.28828			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497257	hybrid, Green Published			2022-12-25	WOS:000082912700106
J	Kester, HA; Blanchetot, C; den Hertog, J; van der Saag, PT; van der Burg, B				Kester, HA; Blanchetot, C; den Hertog, J; van der Saag, PT; van der Burg, B			Transforming growth factor-beta-stimulated clone-22 is a member of a family of leucine zipper proteins that can homo- and heterodimerize and has transcriptional repressor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN HISTONE DEACETYLASE; SLEEP-INDUCING PEPTIDE; GLAND CANCER CELL; GENE-TRANSCRIPTION; DNA-BINDING; RECEPTOR; TSC-22; ACID; EXPRESSION; REGULATOR	TGF-beta-stimulated clone-22 (TSC-22) encodes a leucine zipper-containing protein that is highly conserved during evolution. Two homologues are known that share a similar leucine zipper domain and another conserved domain (designated the TSC box). Only limited data are available on the function of TSC-22 and its homologues. TSC-22 is transcriptionally up-regulated by many different stimuli, including anti-cancer drugs and growth inhibitors, and recent data suggest that TSC-22 may play a suppressive role in tumorigenesis. In this paper we show that TSC-22 forms homodimers via its conserved leucine zipper domain. Using a yeast two-hybrid screen, we identified a TSC-22 homologue (THG-1) as heterodimeric partner. Furthermore, we report the presence of two more mammalian family members with highly conserved leucine zippers and TSC boxes. Interestingly, both TSC-22 and THG-1 have transcriptional repressor activity when fused to a heterologous DNA-binding domain. The repressor activity of TSC-22 appears sensitive for promoter architecture, but not for the histone deacetylase inhibitor trichostatin A. Mutational analysis showed that this repressor activity resides in the non-conserved regions of the protein and is enhanced by the conserved dimerization domain. Our results suggest that TSC-22 belongs to a family of leucine zipper-containing transcription factors that can homodimerize and heterodimerize with other family members and that at least two TSC-22 family members may be repressors of transcription.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	van der Burg, B (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.			Blanchetot, christophe/0000-0001-9152-9978				ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Dobens LL, 1997, MECH DEVELOP, V65, P197, DOI 10.1016/S0925-4773(97)00080-4; FOLKERS GE, 1993, MOL ENDOCRINOL, V7, P616, DOI 10.1210/me.7.4.616; FOLKERS GE, 1995, J BIOL CHEM, V270, P23552, DOI 10.1074/jbc.270.40.23552; FOLKERS GE, 1995, MOL CELL BIOL, V15, P5868; HAMIL KG, 1994, ENDOCRINOLOGY, V134, P1205, DOI 10.1210/en.134.3.1205; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Jay P, 1996, BIOCHEM BIOPH RES CO, V222, P821, DOI 10.1006/bbrc.1996.0825; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kawamata H, 1998, BRIT J CANCER, V77, P71, DOI 10.1038/bjc.1998.11; KAWAUCHI T, 1995, ENDOCRINE, V3, P833, DOI 10.1007/BF02935689; Kester HA, 1997, J BIOL CHEM, V272, P16637, DOI 10.1074/jbc.272.26.16637; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakashiro K, 1998, CANCER RES, V58, P549; Ohta S, 1996, EUR J BIOCHEM, V242, P460, DOI 10.1111/j.1432-1033.1996.460rr.x; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Seidel G, 1997, J BIOL CHEM, V272, P30918, DOI 10.1074/jbc.272.49.30918; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; SILLARD R, 1993, EUR J BIOCHEM, V216, P429, DOI 10.1111/j.1432-1033.1993.tb18160.x; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; Trenkle T, 1998, NUCLEIC ACIDS RES, V26, P3883, DOI 10.1093/nar/26.17.3883; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Vogel P, 1996, BBA-GENE STRUCT EXPR, V1309, P200, DOI 10.1016/S0167-4781(96)00177-7; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	38	105	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27439	27447		10.1074/jbc.274.39.27439	http://dx.doi.org/10.1074/jbc.274.39.27439			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488076	hybrid			2022-12-25	WOS:000082739100015
J	Mate, MJ; Sevinc, MS; Hu, B; Bujons, J; Bravo, J; Switala, J; Ens, W; Loewen, PC; Fita, I				Mate, MJ; Sevinc, MS; Hu, B; Bujons, J; Bravo, J; Switala, J; Ens, W; Loewen, PC; Fita, I			Mutants that alter the covalent structure of catalase hydroperoxidase II from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEEF-LIVER CATALASE; PENICILLIUM-VITALE; CRYSTAL-STRUCTURE; MACROMOLECULAR STRUCTURES; 3-DIMENSIONAL STRUCTURE; PROTEUS-MIRABILIS; HPII; RESOLUTION; PEROXIDASE; MUTAGENESIS	The three-dimensional structures of two HPII variants, V169C and H392Q, have been determined at resolutions of 1.8 and 2.1 Angstrom respectively. The V169C variant contains a new type of covalent bond between the sulfur atom of Cys(169) and, carbon atom on the imidazole ring of the essential His(128). This variant enzyme has only residual catalytic activity and contains heme b, The chain of water molecules visible in the main channel may reflect the organization of the hydrogen peroxide substrates in the active enzyme. Two alternative mechanisms, involving either compound I or free radical intermediates, are presented to explain the formation of the Cys-His covalent bond. The H392Q and H392E variants exhibit 75 and 25% of native catalytic activity, respectively, The Gln(392) variant contains only heme b, whereas the Glu(392) variant contains a mixture of heme b and cis and trans isomers of heme d, suggesting of a role for this residue in heme conversion. Replacement of either Gln(419) and Ser(414), both of which interact with the heme, affected the cis:trans ratio of spirolactone heme d, Implications for the heme oxidation mechanism and the His-Tyr bond formation in HPII are considered.	Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada; CSIC, Cid, ES-08034 Barcelona, Spain; Univ Manitoba, Dept Phys, Winnipeg, MB R3T 2N2, Canada	University of Manitoba; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); University of Manitoba	Loewen, PC (corresponding author), Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada.	peter_loewen@umanitoba.ca	Bujons, Jordi/AAA-9283-2020; Bujons, Jordi/K-8486-2012; Bravo, Jeronimo/K-9103-2014; Fita, Ignasi/R-4515-2019	Bujons, Jordi/0000-0003-2944-2905; Bujons, Jordi/0000-0003-2944-2905; Bravo, Jeronimo/0000-0001-6695-2846; Fita, Ignasi/0000-0002-7521-2679				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blodig W, 1998, BIOCHEMISTRY-US, V37, P8832, DOI 10.1021/bi9727186; BRAVO J, 1995, STRUCTURE, V3, P491, DOI 10.1016/S0969-2126(01)00182-4; Bravo J, 1999, PROTEINS, V34, P155, DOI 10.1002/(SICI)1097-0134(19990201)34:2<155::AID-PROT1>3.0.CO;2-P; Bravo J., 1997, OXIDATIVE STRESS MOL, P407; BRUNGER AT, 1992, XPLOR MANUAL VERSION; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; ENS W, 1993, ORG MASS SPECTROM, V28, P1430, DOI 10.1002/oms.1210281212; Evans W, 1997, CHEM BRIT, V33, P22; FITA I, 1986, ACTA CRYSTALLOGR B, V42, P497, DOI 10.1107/S0108768186097835; GOUET P, 1995, J MOL BIOL, V249, P933, DOI 10.1006/jmbi.1995.0350; GRIESBAUM K, 1970, ANGEW CHEM INT EDIT, V9, P273, DOI 10.1002/anie.197002731; Guarne A, 1996, PROTEIN SCI, V5, P167; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kozlov EA, 1998, BIOORG KHIM+, V24, P163; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; LOEWEN PC, 1993, BIOCHEMISTRY-US, V32, P10159, DOI 10.1021/bi00089a035; Mate MJ, 1999, J MOL BIOL, V286, P135, DOI 10.1006/jmbi.1998.2453; MEAD DA, 1985, NUCLEIC ACIDS RES, V13, P1103, DOI 10.1093/nar/13.4.1103; MELIKADAMYAN WR, 1986, J MOL BIOL, V188, P63, DOI 10.1016/0022-2836(86)90480-8; MULVEY MR, 1988, GENE, V73, P337, DOI 10.1016/0378-1119(88)90498-2; MURSHUDOV GN, 1992, FEBS LETT, V312, P127, DOI 10.1016/0014-5793(92)80919-8; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURTHY MRN, 1981, J MOL BIOL, V152, P465, DOI 10.1016/0022-2836(81)90254-0; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peach M. E., 1974, CHEM THIOL GROUP 2, P721; RORTH M, 1967, BIOCHIM BIOPHYS ACTA, V139, P171, DOI 10.1016/0005-2744(67)90124-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEVINC MS, 1995, EUR J BIOCHEM, V230, P127, DOI 10.1111/j.1432-1033.1995.tb20542.x; STEHLE T, 1991, J MOL BIOL, V221, P1325, DOI 10.1016/0022-2836(91)90936-Z; VAINSHTEIN BK, 1986, J MOL BIOL, V188, P49, DOI 10.1016/0022-2836(86)90479-1; VONOSSOWSKI I, 1991, J BACTERIOL, V173, P514, DOI 10.1128/jb.173.2.514-520.1991; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAMOCKY M, 1995, FEBS LETT, V367, P241, DOI 10.1016/0014-5793(95)00568-T	40	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27717	27725		10.1074/jbc.274.39.27717	http://dx.doi.org/10.1074/jbc.274.39.27717			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488114	hybrid			2022-12-25	WOS:000082739100053
J	Nakajima, Y; Yamamoto, T; Nakayama, T; Nakanishi, S				Nakajima, Y; Yamamoto, T; Nakayama, T; Nakanishi, S			A relationship between protein kinase C phosphorylation and calmodulin binding to the metabotropic glutamate receptor subtype 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; MESSENGER-RNA; ADULT-RAT; LOCALIZATION; DOMAINS; CLONING; HOMER; BRAIN; INACTIVATION; HIPPOCAMPUS	Metabotropic glutamate receptor subtype 7 (mGluR7) is coupled to the inhibitory cyclic AMP cascade and is selectively activated by a glutamate analogue, L-2-amino-4-phosphonobutyrate. Among L-2-amino-4-phosphonobutyrate-sensitive mGluR subtypes, mGluR7 is highly concentrated at the presynaptic terminals and is thought to play an important role in modulation of glutamatergic synaptic transmission by presynaptic inhibition of glutamate release. To gain further insight into the intracellular signaling mechanisms of mGluR7, with the aid of glutathione S-transferase fusion affinity chromatography, we attempted to identify proteins that interact with the intracellular carboxyl terminus of mGluR7. Here, we report that calmodulin (CaM) directly binds to the carboxyl terminus of mGluR7 in a Ca2+-dependent manner. The CaM-binding domain is located immediately following the 7th transmembrane segment. We also show that the CaM-binding domain of mGluR7 is phosphorylated by protein kinase C (PKC). This phosphorylation is inhibited by the binding of Ca2+/CaM to the receptor. Conversely, the Ca2+/CaM binding is prevented by PKC phosphorylation. Collectively, these results suggest that mGluR7 serves to cross-link the cyclic AMP, Ca2+, and PKC phosphorylation signal transduction cascades.	Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Kyoto 6068501, Japan; Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448585, Japan; Miyazaki Med Coll, Dept Biochem, Miyazaki 8891692, Japan	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); University of Miyazaki	Nakanishi, S (corresponding author), Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Kyoto 6068501, Japan.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALALUF S, 1995, J NEUROCHEM, V64, P1548; Bradley SR, 1996, J NEUROSCI, V16, P2044; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Bushell T. J., 1996, Neuropharmacology, V35, pA6, DOI 10.1016/0028-3908(96)84669-7; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kinoshita A, 1998, J COMP NEUROL, V393, P332; KINZIE JM, 1995, NEUROSCIENCE, V69, P167, DOI 10.1016/0306-4522(95)00244-D; Macek TA, 1998, J NEUROSCI, V18, P6138; Macek TA, 1996, J NEUROPHYSIOL, V76, P3798, DOI 10.1152/jn.1996.76.6.3798; Makoff A, 1996, MOL BRAIN RES, V40, P165, DOI 10.1016/0169-328X(96)00110-6; Masugi M, 1999, J NEUROSCI, V19, P955; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; OHISHI H, 1995, J COMP NEUROL, V360, P555, DOI 10.1002/cne.903600402; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; Saugstad JA, 1997, MOL PHARMACOL, V51, P119, DOI 10.1124/mol.51.1.119; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	34	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27573	27577		10.1074/jbc.274.39.27573	http://dx.doi.org/10.1074/jbc.274.39.27573			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488094	hybrid			2022-12-25	WOS:000082739100033
J	Rai, R; Daugherty, JR; Cunningham, TS; Cooper, TG				Rai, R; Daugherty, JR; Cunningham, TS; Cooper, TG			Overlapping positive and negative GATA factor binding sites mediate inducible DAL7 gene expression in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN-CATABOLITE REPRESSION; UPSTREAM ACTIVATION SEQUENCES; ALLANTOIN DEGRADATIVE ENZYMES; TRANSCRIPTIONAL ACTIVATION; REGULATORY GENE; INDUCTION SEQUENCE; ZINC FINGER; UGA4 GENE; ELEMENTS; PROTEIN	Allantoin pathway gene expression in Saccharomyces cerevisiae responds to two different environmental stimuli. The expression of these genes is induced in the presence of allantoin or its degradative metabolites and repressed when a good nitrogen source (e.g. asparagine or glutamine) is provided. Three types of cis-acting sites and trans acting factors are required for allantoin pathway gene transcription as follows: (i) UAS(NTR) element associated with the transcriptional activators Gln3p and Gat1p, (ii) URSGATA element associated with the repressor Dal80p, and (iii) UISALL element associated with the Dal82 and Dal81 proteins required for inducer-dependent transcription. Most of the work leading to the above conclusions has employed inducer-independent allantoin pathway genes (e.g, DAL5 and DAL3), The purpose of this work is to extend our understanding of these elements and their roles to inducible allantoin pathway genes using the DAL7 (encoding malate synthase) as a model. We show that eight distinct cis-acting sites participate in the process as follows: a newly identified GC-rich element, two UAS(NTR), two UISALL, and three URSGATA elements. The two GATA-containing UAS(GATA) elements are coincident with two of the three GATA sequences that make up the URSGATA elements. The remaining URSGATA GATA sequence, however, is not a UAS(NTR) element but appears to function only in repression. The data provide insights into how these cis- and trans-acting factors function together to accomplish the regulated expression of the DAL7 gene that is observed in vivo.	Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA.			Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM035642, GM-35642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRE B, 1995, NUCLEIC ACIDS RES, V23, P558, DOI 10.1093/nar/23.4.558; BLINDER D, 1995, J BACTERIOL, V177, P4190, DOI 10.1128/jb.177.14.4190-4193.1995; BYSANI N, 1991, J BACTERIOL, V173, P4977, DOI 10.1128/jb.173.16.4977-4982.1991; CHISHOLM G, 1982, MOL CELL BIOL, V2, P1088, DOI 10.1128/MCB.2.9.1088; Coffman JA, 1996, MOL CELL BIOL, V16, P847; Coffman JA, 1997, J BACTERIOL, V179, P3416, DOI 10.1128/jb.179.11.3416-3429.1997; COFFMAN JA, 1995, J BACTERIOL, V177, P6910, DOI 10.1128/jb.177.23.6910-6918.1995; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; COOPER TG, 1973, P NATL ACAD SCI USA, V70, P2340, DOI 10.1073/pnas.70.8.2340; COOPER TG, 1989, MOL CELL BIOL, V9, P5440, DOI 10.1128/MCB.9.12.5440; Cooper TG, 1996, MYCOTA, V3, P139; COORNAERT D, 1992, CURR GENET, V21, P301, DOI 10.1007/BF00351687; COORNAERT D, 1991, GENE, V97, P163, DOI 10.1016/0378-1119(91)90048-G; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; CUNNINGHAM TS, 1993, J BACTERIOL, V175, P5851, DOI 10.1128/JB.175.18.5851-5861.1993; CUNNINGHAM TS, 1994, J BACTERIOL, V176, P4718, DOI 10.1128/JB.176.15.4718-4725.1994; Cunningham TS, 1996, J BACTERIOL, V178, P3470, DOI 10.1128/jb.178.12.3470-3479.1996; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; DORRINGTON RA, 1993, NUCLEIC ACIDS RES, V21, P3777, DOI 10.1093/nar/21.16.3777; Iraqui I, 1999, MOL CELL BIOL, V19, P989; JACOBS E, 1981, CURR GENET, V4, P13, DOI 10.1007/BF00376780; JACOBS E, 1985, CURR GENET, V9, P333, DOI 10.1007/BF00421602; MILLER SM, 1991, MOL CELL BIOL, V11, P6229, DOI 10.1128/MCB.11.12.6229; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; MITCHELL AP, 1984, MOL CELL BIOL, V4, P2758, DOI 10.1128/MCB.4.12.2758; OLIVE MG, 1991, J BACTERIOL, V173, P255, DOI 10.1128/jb.173.1.255-261.1991; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PARK HD, 1992, NUCLEIC ACIDS RES, V20, P1909, DOI 10.1093/nar/20.8.1909; RAI R, 1987, J BACTERIOL, V169, P3521, DOI 10.1128/jb.169.8.3521-3524.1987; RAI R, 1995, YEAST, V11, P247, DOI 10.1002/yea.320110307; RAI R, 1989, MOL CELL BIOL, V9, P602, DOI 10.1128/MCB.9.2.602; Smart WC, 1996, MOL CELL BIOL, V16, P5876; STANBROUGH M, 1995, P NATL ACAD SCI USA, V92, P9450, DOI 10.1073/pnas.92.21.9450; SUMRADA R, 1974, J BACTERIOL, V117, P1240, DOI 10.1128/JB.117.3.1240-1247.1974; SUMRADA RA, 1985, P NATL ACAD SCI USA, V82, P643, DOI 10.1073/pnas.82.3.643; Svetlov V, 1997, J BACTERIOL, V179, P7644, DOI 10.1128/jb.179.24.7644-7652.1997; Svetlov VV, 1998, J BACTERIOL, V180, P5682, DOI 10.1128/JB.180.21.5682-5688.1998; TUROSCY V, 1982, J BACTERIOL, V151, P1237, DOI 10.1128/JB.151.3.1237-1246.1982; VANVUUREN HJJ, 1991, J BACTERIOL, V173, P7186, DOI 10.1128/jb.173.22.7186-7195.1991; VISSERS S, 1990, EUR J BIOCHEM, V187, P611, DOI 10.1111/j.1432-1033.1990.tb15344.x; VISSERS S, 1989, EUR J BIOCHEM, V181, P357, DOI 10.1111/j.1432-1033.1989.tb14732.x; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X; YOO HS, 1991, GENE, V104, P55, DOI 10.1016/0378-1119(91)90464-M; YOO HS, 1989, MOL CELL BIOL, V9, P3231, DOI 10.1128/MCB.9.8.3231	44	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					28026	28034		10.1074/jbc.274.39.28026	http://dx.doi.org/10.1074/jbc.274.39.28026			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488154	hybrid			2022-12-25	WOS:000082739100093
J	Kleeff, J; Ishiwata, T; Maruyama, H; Friess, H; Truong, P; Buchler, MW; Falb, D; Korc, M				Kleeff, J; Ishiwata, T; Maruyama, H; Friess, H; Truong, P; Buchler, MW; Falb, D; Korc, M			The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer	ONCOGENE			English	Article						Smad7; TGF-beta; pancreas; cancer	GROWTH-FACTOR-BETA; DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR GENE; MAD-RELATED PROTEIN; II RECEPTOR GENE; CYCLIN D1; CELL-LINE; PLASMINOGEN-ACTIVATOR; CARCINOMA CELLS; EXPRESSION	Transforming growth factor-beta (TGF-beta) signaling is dependent on the heterodimerization of the type II TGF-beta receptor (T beta RII) with the type I TGF-beta receptor (T beta RI), Activated T beta RI then mediates TGF-beta signals by inducing the phosphorylation of Smad2 and/or Smad3, which separately hetetorodimerize with Smad4 and translocate to the nucleus. Phosphorylation of Smad2/Smad3 by activated T beta RI is inhibited by two newly discovered members of the Smad family, Smad6 and Smad7. We now report that Smad7 mRNA levels are increased in human pancreatic cancer by comparison with the normal pancreas, and that by in situ hybridization, Smad7 is over-expressed in the cancer cells within the tumor mass, Stable transfection of COLO-357 human pancreatic cancer cells with a full-length Smad7 construct leads to complete loss of the growth inhibitory response to TGF-beta 1, without altering TGF-beta 1-mediated induction of PAI-I. Furthermore, Smad7 transfected COLO-357 cells display enhanced anchorage-independent growth and accelerated growth in nude mice. These findings point to a previously unrecognized mechanism for selective suppression of TGF-beta-mediated growth inhibition in cancer cells that allows for continued activation of the PAI-I promoter by TGF-beta 1, which may act to enhance the tumorigenicity of certain cancer cells.	Univ Calif Irvine, Dept Med, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Bern, Dept Visceral & Transplantat Surg, CH-3010 Bern, Switzerland; Millennium Pharmaceut, Cambridge, MA 02139 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Bern; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Korc, M (corresponding author), Univ Calif Irvine, Dept Med, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA.		Kleeff, Jorg/B-2124-2009; Ishiwata, Toshiyuki/H-1151-2014	Kleeff, Jorg/0000-0003-3432-6669; Ishiwata, Toshiyuki/0000-0002-4180-0069	NCI NIH HHS [CA75059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; BALDWIN RL, 1993, GROWTH FACTORS, V8, P23, DOI 10.3109/08977199309029131; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; BERGMANN U, 1995, CANCER RES, V55, P2007; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DeCoteau JF, 1997, P NATL ACAD SCI USA, V94, P5877, DOI 10.1073/pnas.94.11.5877; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FRIESS H, 1993, CANCER RES, V53, P2704; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Gansauge S, 1997, CANCER RES, V57, P1634; Goggins M, 1998, CANCER RES, V58, P5329; Grau AM, 1997, CANCER RES, V57, P3929; GrondahlHansen J, 1997, BREAST CANCER RES TR, V43, P153, DOI 10.1023/A:1005744914124; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hofmann R, 1996, CANCER, V78, P487; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishiwata T, 1998, AM J PATHOL, V153, P213, DOI 10.1016/S0002-9440(10)65562-9; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; Kim IY, 1996, CANCER RES, V56, P44; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Kore M, 1992, J CLIN INVEST, V90, P1352; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Kornmann M, 1998, ONCOLOGY-BASEL, V55, P363, DOI 10.1159/000011879; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Maesawa C, 1997, JPN J CANCER RES, V88, P340, DOI 10.1111/j.1349-7006.1997.tb00386.x; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAITANO AB, 1990, J BIOL CHEM, V265, P10466; Reiss M, 1997, ONCOL RES, V9, P447; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Riggins GJ, 1997, CANCER RES, V57, P2578; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; Schutte M, 1996, CANCER RES, V56, P2527; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Venkatasubbarao K, 1998, GENE CHROMOSOME CANC, V22, P138, DOI 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; White RL, 1998, CELL, V92, P591, DOI 10.1016/S0092-8674(00)81124-1; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yamamoto H, 1996, J BIOL CHEM, V271, P16253, DOI 10.1074/jbc.271.27.16253	55	218	242	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5363	5372		10.1038/sj.onc.1202909	http://dx.doi.org/10.1038/sj.onc.1202909			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498890				2022-12-25	WOS:000082718600001
J	Langille, SE; Patki, V; Klarlund, JK; Buxton, JM; Holik, JJ; Chawla, A; Corvera, S; Czech, MP				Langille, SE; Patki, V; Klarlund, JK; Buxton, JM; Holik, JJ; Chawla, A; Corvera, S; Czech, MP			ADP-ribosylation factor 6 as a target of guanine nucleotide exchange factor GRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; BINDING PROTEIN RAC; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3-KINASE; HOMOLOGY DOMAINS; TYROSINE KINASES; ARF6; PLECKSTRIN; CELLS; TRANSLOCATION	The GRP1 protein contains a Sec7 homology domain that catalyzes guanine nucleotide exchange on ADP-ribosylation factors (ARF) 1 and 5 as well as a pleckstrin homology domain that binds phosphatidylinositol(3,4,5)P-3, an intermediate in cell signaling by insulin and other extracellular stimuli (Klarlund, J. K., Guilherme, A., Holik, J. J., Virbasius, J. V., Chawla, A., and Czech, M. P. (1997) Science 275, 1927-1930). Here we show that both endogenous GRP1 and ARF6 rapidly co-localize in plasma membrane ruffles in Chinese hamster ovary (CHO-T) cells expressing human insulin receptors and COS-1 cells in response to insulin and epidermal growth factor, respectively. The pleckstrin homology domain of GRP1 appears to be sufficient for regulated membrane localization. Using a novel method to estimate GTP loading of expressed HA epitope-tagged ARF proteins in intact cells, levels of biologically active, GTP-bound ARF6 as well as GTP-bound ARF1 were elevated when these ARF proteins were co-expressed with GRP1 or the related protein cytohesin-1. GTP loading of ARF6 in both control cells and in response to GRP1 or cytohesin-1 was insensitive to brefeldin A, consistent with previous data on endogenous ARF6 exchange activity. The ability of GRP1 to catalyze GTP/GDP exchange on ARF6 was confirmed using recombinant proteins in a cell-free system. Taken together, these results suggest that phosphatidylinositol(3,4,5)P-3 may be generated in cell membrane ruffles where receptor tyrosine kinases are concentrated in response to growth factors, causing recruitment of endogenous GRP1. Further, co-localization of GRP1 with ARF6, combined with its demonstrated ability to activate ARF6, suggests a physiological role for GRP1 in regulating ARF6 functions.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	Michael.Czech@umassmed.edu			NIDDK NIH HHS [DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashery U, 1999, P NATL ACAD SCI USA, V96, P1094, DOI 10.1073/pnas.96.3.1094; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clodi M, 1998, ENDOCRINOLOGY, V139, P4984, DOI 10.1210/en.139.12.4984; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; Klarlund JK, 1996, J BIOL CHEM, V271, P16674, DOI 10.1074/jbc.271.28.16674; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; Song J, 1998, J CELL SCI, V111, P2257; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WHITE MF, 1994, J BIOL CHEM, V269, P1; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977	33	98	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27099	27104		10.1074/jbc.274.38.27099	http://dx.doi.org/10.1074/jbc.274.38.27099			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480924	hybrid			2022-12-25	WOS:000082570700063
J	Menon, S; Stahl, M; Kumar, R; Xu, GY; Sullivan, F				Menon, S; Stahl, M; Kumar, R; Xu, GY; Sullivan, F			Stereochemical course and steady state mechanism of the reaction catalyzed by the GDP-fucose synthetase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE 4-EPIMERASE; LEUKOCYTE ADHESION DEFICIENCY; X-RAY STRUCTURE; CRYSTAL-STRUCTURE; TERNARY COMPLEX; REDUCTASE; DEHYDROGENASE; PROTEIN; BIOSYNTHESIS; RESOLUTION	Recently the genes encoding the human and Escherichia coli GDP-mannose dehydratase and GDP-fucose synthetase (GFS) protein have been cloned and it has been shown that these two proteins alone are sufficient to convert GDP mannose to GDP fucose in vitro. GDP-fucose synthetase from E. coli is a novel dual function enzyme in that it catalyzes epimerizations and a reduction reaction at the same active site. This aspect separates fucose biosynthesis from that of other deoxy and dideoxy sugars in which the epimerase and reductase activities are present on separate enzymes encoded by separate genes. By NMR spectroscopy we have shown that GFS catalyzes the stereospecific hydride transfer of the ProS hydrogen from NADPH to carbon 4 of the mannose sugar. This is consistent with the stereospecificity observed for other members of the short chain dehydrogenase reductase family of enzymes of which GFS is a member. Additionally the enzyme is able to catalyze the epimerization reaction in the absence of NADP or NADPH. The kinetic mechanism of GFS as determined by product inhibition and fluorescence binding studies is consistent with a random mechanism. The dissociation constants determined from fluorescence studies indicate that the enzyme displays a 40-fold stronger affinity for the substrate NADPH as compared with the product NADP and utilizes NADPH preferentially as compared with NADH. This study on GFS, a unique member of the short chain dehydrogenase reductase family, coupled with that of its recently published crystal structure should aid in the development of antimicrobial or anti-inflammatory compounds that act by blocking selectin-mediated cell adhesion.	Wyeth Ayerst Res, Cambridge, MA 02140 USA	Pfizer	Menon, S (corresponding author), Wyeth Ayerst Res, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.	smenon@genetics.com						Andersson A, 1996, STRUCTURE, V4, P1161, DOI 10.1016/S0969-2126(96)00124-4; ARNOLD LJ, 1976, BIOCHEMISTRY-US, V15, P4844, DOI 10.1021/bi00667a014; BENSON TE, 1993, BIOCHEMISTRY-US, V32, P2024, DOI 10.1021/bi00059a019; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; CHANG S, 1988, J BIOL CHEM, V263, P1693; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FEIZI T, 1991, TRENDS BIOCHEM SCI, V16, P84, DOI 10.1016/0968-0004(91)90038-W; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GINSBURG V, 1960, J BIOL CHEM, V235, P2196; GINSBURG V, 1961, J BIOL CHEM, V236, P2389; Hallis TM, 1998, BIOCHEMISTRY-US, V37, P4935, DOI 10.1021/bi9725529; He XM, 1996, BIOCHEMISTRY-US, V35, P4721, DOI 10.1021/bi952706p; Hulsmeyer M, 1998, PROTEIN SCI, V7, P1286; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; McGowan CC, 1998, MOL MICROBIOL, V30, P19, DOI 10.1046/j.1365-2958.1998.t01-1-01079.x; Mergaert P, 1997, FEBS LETT, V409, P312, DOI 10.1016/S0014-5793(97)00461-4; MORELLI A, 1977, ARCH BIOCHEM BIOPHYS, V179, P698, DOI 10.1016/0003-9861(77)90159-X; NAKAJMA K, 1996, P NATL ACAD SCI USA, V95, P4876; ORR GA, 1984, ANAL BIOCHEM, V142, P232, DOI 10.1016/0003-2697(84)90544-X; PERSSON B, 1995, ADV EXP MED BIOL, V372, P383; RAFFERTY JB, 1995, STRUCTURE, V3, P927, DOI 10.1016/S0969-2126(01)00227-1; Rizzi M, 1998, STRUCTURE, V6, P1453, DOI 10.1016/S0969-2126(98)00144-0; Somers WS, 1998, STRUCTURE, V6, P1601, DOI 10.1016/S0969-2126(98)00157-9; Sturla L, 1998, FEBS LETT, V429, P274, DOI 10.1016/S0014-5793(98)00615-2; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6294, DOI 10.1021/bi970025j; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Tonetti M, 1996, J BIOL CHEM, V271, P27274, DOI 10.1074/jbc.271.44.27274; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080	35	32	34	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26743	26750		10.1074/jbc.274.38.26743	http://dx.doi.org/10.1074/jbc.274.38.26743			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480878	hybrid			2022-12-25	WOS:000082570700017
J	Du, GG; MacLennan, DH				Du, GG; MacLennan, DH			Ca2+ inactivation sites are located in the COOH-terminal quarter of recombinant rabbit skeletal muscle Ca2+ release channels (ryanodine receptors)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CARDIAC-MUSCLE; CA-2+ RELEASE; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; AMINO-ACIDS; BINDING; IDENTIFICATION; CDNA; ACTIVATION	showed that chimeras RF10, RF9/10, and RF9/10/11 were Ca2+ activation of skeletal (RyR1) and cardiac (RyR2) muscle Ca2+ release channels (ryanodine receptors) occurs with IC50 values of about 1 mu M. Ca2+ inactivation occurs with an IC50 value of about 3.7 mM for RyR1, but RyR2 shows little inactivation, even at >100 mM Ca2+ in an attempt to localize the low affinity Ca2+ binding sites responsible for Ca2+ inactivation in RyR1, chimeric RyR1/RyR2 molecules were constructed. Because [H-3]ryanodine binds only to open channels, and because channel opening and closing ant Ca2+-dependent, the Ca2+ dependence of [H-3]ryanodine binding was used as an indirect measurement of Ca2+ release channel opening and closing. IC50 values for [H-3]ryanodine binding suggested that Ca2+ affinity for the low affinity Ca2+ inactivation sites was unchanged in a chimera in which a glutamate-rich sequence (amino acids 1743-1964) in RyR1 was replaced with the corresponding, less acidic sequence from RyR2. Ca2+ affinity (IC50) for low affinity Ca2+ inactivation sites was intermediate in RyR1/RyR2 chimeras containing RyR2 amino acids 3726-4186 (RF9), 4187-4628 (RF10), or 4629-5037 (RF11), was closer to RyR2 values in RyR1 chimeras with longer RyR2 replacements (RF9/10 or RF10/11), and was indistinguishable from RyR2 in RyR1 containing all three RyR2 replacements (RF9/10/11). These data suggest that multiple low affinity Ca2+ binding sites or multiple components of a low affinity Ca2+ binding site are located between amino acids 3726 and 503'9 and that their effects on Ca2+ inactivation of the release channel are cooperative. Measurement of Ca2+ activation of [H-3]ryanodine binding more sensitive to Ca2+ than was either RyR1 or RyR2. Measurement of caffeine activation of Ca2+ release in vivo showed that chimeras RF9, RF10, RF9/10, RF10/11, and RF9/10/11 were more sensitive to caffeine than wild-type RyR1. These results suggest that Ca2+ and caffeine activation sites also involve COOH-terminal sequences in RyR1 and RyR2.	Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada	University of Toronto	MacLennan, DH (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.	david.maclennan@utoronto.ca						AIREY JA, 1990, J BIOL CHEM, V265, P14187; Bhat MB, 1997, BIOPHYS J, V73, P1320, DOI 10.1016/S0006-3495(97)78165-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1993, J BIOL CHEM, V268, P13414; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; Chen SRW, 1997, BIOPHYS J, V73, P1904, DOI 10.1016/S0006-3495(97)78221-3; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; CHU A, 1993, J MEMBRANE BIOL, V135, P49; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Du GG, 1998, J BIOL CHEM, V273, P31867, DOI 10.1074/jbc.273.48.31867; Du GG, 1998, J BIOL CHEM, V273, P33259, DOI 10.1074/jbc.273.50.33259; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Feng W, 1996, MOL MEMBR BIOL, V13, P85, DOI 10.3109/09687689609160581; HADAD N, 1994, J BIOL CHEM, V269, P24864; INUI M, 1987, J BIOL CHEM, V262, P1740; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVER DR, 1995, J MEMBRANE BIOL, V147, P7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tripathy A, 1996, BIOPHYS J, V70, P2600, DOI 10.1016/S0006-3495(96)79831-4; Xiong H, 1998, BIOCHEMISTRY-US, V37, P4804, DOI 10.1021/bi971198b; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; Zucchi R, 1997, PHARMACOL REV, V49, P1	35	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26120	26126		10.1074/jbc.274.37.26120	http://dx.doi.org/10.1074/jbc.274.37.26120			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473562	hybrid			2022-12-25	WOS:000082469700028
J	Lai, MM; Hong, JJ; Ruggiero, AM; Burnett, PE; Slepnev, VI; De Camilli, P; Snyder, SH				Lai, MM; Hong, JJ; Ruggiero, AM; Burnett, PE; Slepnev, VI; De Camilli, P; Snyder, SH			The calcineurin-dynamin 1 complex as a calcium sensor for synaptic vesicle endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ENDOCYTOSIS; PROTEIN; SYNAPTOTAGMIN; INHIBITION; TERMINALS; RELEASE; DOMAIN	Exocytosis of synaptic vesicles is calcium-dependent, with synaptotagmin serving as the calcium sensor. Endocytosis of synaptic vesicles has also been postulated as a calcium-dependent process; however, an endocytic calcium sensor has not been found. We now report a physical association between the calcium-dependent phosphatase calcineurin and dynamin 1, a component of the synaptic endocytic machinery. The calcineurin-dynamin 1 interaction is calcium-dependent, with an EC50 for calcium in the range of 0.1-0.4 mu M. Disruption of the calcineurin-dynamin 1 interaction inhibits clathrin-mediated endocytosis. Thus, the calcium-dependent formation of the calcineurin-dynamin 1 complex, delivered to the other endocytic coat proteins, provides a calcium-sensing mechanism that facilitates endocytosis.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Yale University; Yale University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.				NIDA NIH HHS [DA-00074] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Engisch KL, 1998, J PHYSIOL-LONDON, V506, P591, DOI 10.1111/j.1469-7793.1998.591bv.x; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Gad H, 1998, NEURON, V21, P607, DOI 10.1016/S0896-6273(00)80570-X; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GRAHS D, 1997, J BIOL CHEM, V272, P13419; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Marks B, 1998, CURR BIOL, V8, P740, DOI 10.1016/S0960-9822(98)70297-0; NEBER E, 1993, NEURON, V10, P21; Palfrey HC, 1998, NEUROSCIENCE, V83, P969, DOI 10.1016/S0306-4522(97)00453-3; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5	25	124	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					25963	25966		10.1074/jbc.274.37.25963	http://dx.doi.org/10.1074/jbc.274.37.25963			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473536	hybrid			2022-12-25	WOS:000082469700002
J	Yaseen, NR; Blobel, G				Yaseen, NR; Blobel, G			GTP hydrolysis links initiation and termination of nuclear import on the nucleoporin Nup358	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; PORE COMPLEX; ACTIVATING PROTEIN; RAN-GTP; NUCLEOCYTOPLASMIC TRANSPORT; BINDING-PROTEIN; RAN/TC4 GTPASE; SUMO-1 MODIFICATION; KARYOPHERIN-BETA; EXPORT SIGNAL	Binding of GTP-bound Ran (RanGTP) to karyopherin pi (Kap beta 1) releases import cargo into the nucleus. Using an ultrastructural, biochemical, and functional approach, we have studied the mechanism by which Kap beta 1 RanGTP is recycled at the nuclear pore complex for repeated rounds of import. In vitro, Kap beta 1 bound to the RanBP1-homologous (RBH) domains of Nup358 in the presence of either RanGTP or RanGDP, forming trimeric complexes. The Kap beta 1 RanGTP RBH complex resisted dissociation by RanBP1 and GTP hydrolysis by Ran GTPase activating protein 1. Ran-dependent binding of gold-conjugated Kap beta 1 to the cytoplasmic fibers of the nuclear pore complex in digitonin-permeabilized cells and RanBP1 competition confirmed the in vitro binding data. Interaction of karyopherin cu and a classical nuclear localization sequence peptide with the Kap beta 1 RanGTP RBH complex stimulated GTP hydrolysis by Ran GTPase activating protein 1 both in vitro and in permeabilized cells. This GTP hydrolysis was required for reinitiation of import of a nuclear localization sequence-bearing substrate in permeabilized cells. These data suggest that GTP hydrolysis on the RBH domains of Nup358 couples the termination of one cycle of nuclear import with the initiation of the next.	Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Cornell University	Blobel, G (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.	blobel@rockvax.rockefeller.edu		Yaseen, Nabeel/0000-0001-6902-5116	NCI NIH HHS [K08 CA72959] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA072959] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; Avis JM, 1996, J CELL SCI, V109, P2423; Bastos R, 1995, INT REV CYTOL, V162B, P257; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FELDHERR CM, 1991, J CELL BIOL, V115, P933, DOI 10.1083/jcb.115.4.933; Feldherr CM, 1997, J CELL SCI, V110, P3065; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; KUSSEL P, 1995, MOL GEN GENET, V248, P351, DOI 10.1007/BF02191602; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; Moore MS, 1995, COLD SPRING HARB SYM, V60, P701, DOI 10.1101/SQB.1995.060.01.076; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Murphy GA, 1997, MOL BIOL CELL, V8, P2591, DOI 10.1091/mbc.8.12.2591; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; Percipalle P, 1997, J MOL BIOL, V266, P722, DOI 10.1006/jmbi.1996.0801; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Rutherford SA, 1997, EXP CELL RES, V232, P146, DOI 10.1006/excr.1997.3487; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; Seki T, 1996, J BIOCHEM, V120, P207; Shah S, 1998, J CELL BIOL, V141, P31, DOI 10.1083/jcb.141.1.31; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; Yaseen NR, 1999, P NATL ACAD SCI USA, V96, P5516, DOI 10.1073/pnas.96.10.5516; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	66	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26493	26502		10.1074/jbc.274.37.26493	http://dx.doi.org/10.1074/jbc.274.37.26493			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473610	hybrid			2022-12-25	WOS:000082469700076
J	Lee-Fruman, KK; Kuo, CJ; Lippincott, J; Terada, N; Blenis, J				Lee-Fruman, KK; Kuo, CJ; Lippincott, J; Terada, N; Blenis, J			Characterization of S6K2, a novel kinase homologous to S6K1	ONCOGENE			English	Article						p70(S6k); S6K1; S6K2; rapamycin; wortmannin; PDK1	PROTEIN-SYNTHESIS; RAPAMYCIN; ACTIVATION; PHOSPHORYLATION; TRANSLATION; P70(S6K); CELLS; LOCALIZATION; REQUIREMENT; EXPRESSION	Rapamycin is an immunosuppressant which antagonizes cellular proliferation by inhibiting the function of mTOR. The mTOR:FKBP12:rapamycin complex blocks G1/S transition by inhibiting downstream targets essential for cell cycle progression. One such target is p70(S6k1) (S6K1), a serine/threonine kinase which is inactivated by the mTOR:FKBP12: rapamycin complex, and which has been linked to translational control by virtue of its ability to phosphorylate the ribosomal protein S6. In the current work, me describe cloning and characterization of a novel S6K1 homolog, p54 S6 kinase 2 (p54(S6k2)/S6K2). Similar to S6K1, S6K2 is activated by mitogens and by constitutively active PI3K, and is inhibited by rapamycin as well as wortmannin. Differences between activation of S6K1 and S6K2 by PDK1 were observed, suggesting potential differences in the regulation of these homologs. Strikingly, S6K2 activity and S6 phosphorylation were both intact in S6K1(-/-)ES cell, indicating a possible role for S6K2 in in vivo S6 phosphorylation. Interestingly, we found two isoforms of S6K2 which are localized to distinct cellular compartments; the smaller form resides in the detergent-soluble fraction, whereas the larger form is found in the particulate fraction. Our findings demonstrate the existence of a family of rapamycin-sensitive protein kinases potentially involved in S6 phosphorylation, translational control, and transduction of mTOR signals.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; National Jewish Health	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.				NIGMS NIH HHS [GM51405] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CALVO V, 1992, P NATL ACAD SCI USA, V89, P426; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1994, BIOCHEM BIOPH RES CO, V198, P780, DOI 10.1006/bbrc.1994.1112; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; GRAMMER TC, 1996, CANC SURVEYS; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kleijn M, 1998, J BIOL CHEM, V273, P5536, DOI 10.1074/jbc.273.10.5536; KOH H, 1999, BRIT J PHARMACOL, V36, P5115; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saitoh M, 1998, BIOCHEM BIOPH RES CO, V253, P470, DOI 10.1006/bbrc.1998.9784; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744	33	112	118	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5108	5114		10.1038/sj.onc.1202894	http://dx.doi.org/10.1038/sj.onc.1202894			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490847				2022-12-25	WOS:000082497100010
J	Almenar-Queralt, A; Lee, A; Conley, CA; de Pouplana, LR; Fowler, VM				Almenar-Queralt, A; Lee, A; Conley, CA; de Pouplana, LR; Fowler, VM			Identification of a novel tropomodulin isoform, skeletal tropomodulin, that caps actin filament pointed ends in fast skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPOMYOSIN-BINDING PROTEIN; CHICK CARDIAC MYOCYTES; MYOSIN LIGHT-CHAINS; THIN FILAMENT; BETA-TROPOMYOSIN; ALPHA-TROPOMYOSIN; STRIATED-MUSCLE; MYOFIBRILLAR PROTEINS; SMOOTH-MUSCLE; BREAST MUSCLE	Tropomodulin (E-Tmod) is an actin filament pointed end capping protein that maintains the length of the sarcomeric actin filaments in striated muscle. Here, we describe the identification and characterization of a novel tropomodulin isoform, skeletal tropomodulin (Sk-Tmod) from chickens. Sk-Tmod is 62% identical in amino acid sequence to the previously described chicken E-Tmod and is the product of a different gene. Sk-Tmod isoform sequences are highly conserved across vertebrates and constitute an independent group in the tropomodulin family, In vitro, chicken Sk-Tmod caps actin and tropomyosin-actin filament pointed ends to the same extent as does chicken E-Tmod, However, E- and Sk-Tmods differ in their tissue distribution; Sk-Tmod predominates in fast skeletal muscle fibers, lens, and erythrocytes, while E-Tmod is found in heart and slow skeletal muscle fibers. Additionally, their expression is developmentally regulated during chicken breast muscle differentiation with Sk-Tmod replacing E-Tmod after hatching. Finally, in skeletal muscle fibers that coexpress both Sk- and E-Tmod, they are recruited to different actin filament-containing cytoskeletal structures within the cell: myofibrils and costameres, respectively. All together, these observations support the hypothesis that vertebrates have acquired different tropomodulin isoforms that play distinct roles in vivo.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Fowler, VM (corresponding author), Scripps Res Inst, Dept Cell Biol, MB24,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	velia@scripps.edu	de Pouplana, Lluis Ribas/AAA-4738-2019	de Pouplana, Lluis Ribas/0000-0002-2087-0359	NATIONAL EYE INSTITUTE [R01EY010814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034225] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10814] Funding Source: Medline; NIGMS NIH HHS [GM-34225] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN ER, 1965, AM J ANAT, V116, P115, DOI 10.1002/aja.1001160107; Almenar-Queralt A, 1999, J CELL SCI, V112, P1111; Anastasi Giuseppe, 1998, Italian Journal of Anatomy and Embryology, V103, P1; AUBER J, 1969, J MICROSC-PARIS, V8, P367; BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; Berthier C, 1997, BIOL CELL, V89, P413, DOI 10.1016/S0248-4900(97)89313-6; BRONSON DD, 1982, J BIOL CHEM, V257, P3937; CONLEY CA, 1999, IN PRESS CURR EYE RE; CRAIG SW, 1983, CELL MOTIL CYTOSKEL, V3, P449, DOI 10.1002/cm.970030513; CUMMINS P, 1974, BIOCHEM J, V141, P43, DOI 10.1042/bj1410043; CUMMINS P, 1973, BIOCHEM J, V133, P765, DOI 10.1042/bj1330765; DONG Q, 1991, J CLIN ENDOCR METAB, V72, P1375, DOI 10.1210/jcem-72-6-1375; Dye CA, 1998, DEVELOPMENT, V125, P1845; Ehmer S, 1997, ACTA NEUROPATHOL, V94, P240, DOI 10.1007/s004010050699; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FELSENSTEIN J, 1992, GENET RES, V59, P139, DOI 10.1017/S0016672300030354; FISCHMAN DA, 1967, J CELL BIOL, V32, P557, DOI 10.1083/jcb.32.3.557; Fowler VM, 1996, CURR OPIN CELL BIOL, V8, P86, DOI 10.1016/S0955-0674(96)80052-4; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; Fowler VM, 1997, SOC GEN PHY, V52, P79; FOWLER VM, 1992, J CELL BIOL, V119, P1559, DOI 10.1083/jcb.119.6.1559; GRANGER BL, 1982, J CELL BIOL, V92, P299, DOI 10.1083/jcb.92.2.299; GRANZIER HLM, 1991, AM J PHYSIOL, V260, pC1060, DOI 10.1152/ajpcell.1991.260.5.C1060; GREGORIO CC, 1995, J CELL BIOL, V129, P683, DOI 10.1083/jcb.129.3.683; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; HATTORI A, 1995, BBA-GEN SUBJECTS, V1244, P179, DOI 10.1016/0304-4165(94)00224-L; Huxley H. E., 1960, CELL, V4, P365; ITO M, 1995, DEV BIOL, V167, P317, DOI 10.1006/dbio.1995.1026; KELLER CS, 1995, CURR OPIN CELL BIOL, V7, P32, DOI 10.1016/0955-0674(95)80042-5; KRUGER M, 1991, J CELL BIOL, V115, P97, DOI 10.1083/jcb.115.1.97; LABEIT S, 1991, FEBS LETT, V282, P313, DOI 10.1016/0014-5793(91)80503-U; LABEIT S, 1995, J MOL BIOL, V248, P308, DOI 10.1016/S0022-2836(95)80052-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Littlefield R, 1998, ANNU REV CELL DEV BI, V14, P487, DOI 10.1146/annurev.cellbio.14.1.487; MATSUDA R, 1983, DEV BIOL, V95, P484, DOI 10.1016/0012-1606(83)90050-7; MEINNEL T, 1989, DEV BIOL, V131, P430, DOI 10.1016/S0012-1606(89)80015-6; MONTARRAS D, 1982, J BIOL CHEM, V257, P545; Muthuchamy M, 1998, J MOL CELL CARDIOL, V30, P1545, DOI 10.1006/jmcc.1998.0720; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; NELSON WJ, 1983, P NATL ACAD SCI-BIOL, V80, P363, DOI 10.1073/pnas.80.2.363; OBINATA T, 1985, ZOOL SCI, V2, P833; OHTSUKI I, 1979, J BIOCHEM-TOKYO, V85, P1377; Palmiter KA, 1996, J BIOL CHEM, V271, P11611, DOI 10.1074/jbc.271.20.11611; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; Porter GA, 1997, CELL MOTIL CYTOSKEL, V37, P7, DOI 10.1002/(SICI)1097-0169(1997)37:1<7::AID-CM2>3.0.CO;2-7; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; REPASKY EA, 1982, CELL, V29, P821, DOI 10.1016/0092-8674(82)90444-5; ROBINSON TF, 1979, J PHYSIOL-LONDON, V286, P607, DOI 10.1113/jphysiol.1979.sp012640; ROY RK, 1979, DEV BIOL, V69, P15, DOI 10.1016/0012-1606(79)90271-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SCHULTHEISS T, 1990, J CELL BIOL, V110, P1159, DOI 10.1083/jcb.110.4.1159; SMALL JV, 1992, EUR J BIOCHEM, V208, P559, DOI 10.1111/j.1432-1033.1992.tb17220.x; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SOSA H, 1994, BIOPHYS J, V67, P283, DOI 10.1016/S0006-3495(94)80479-5; Stromer MH, 1998, HISTOL HISTOPATHOL, V13, P283, DOI 10.14670/HH-13.283; SUNG LA, 1992, J BIOL CHEM, V267, P2616; Sussman MA, 1998, CIRC RES, V82, P94; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOKUYASU KT, 1989, J CELL BIOL, V108, P43, DOI 10.1083/jcb.108.1.43; TRINICK J, 1994, TRENDS BIOCHEM SCI, V19, P405, DOI 10.1016/0968-0004(94)90088-4; Watakabe A, 1996, J CELL SCI, V109, P2299; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; WOO MK, 1994, J CELL SCI, V107, P1359; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005; [No title captured]	70	94	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28466	28475		10.1074/jbc.274.40.28466	http://dx.doi.org/10.1074/jbc.274.40.28466			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497209	hybrid			2022-12-25	WOS:000082912700058
J	Rusnati, M; Tulipano, G; Spillmann, D; Tanghetti, E; Oreste, P; Zoppetti, G; Giacca, M; Presta, M				Rusnati, M; Tulipano, G; Spillmann, D; Tanghetti, E; Oreste, P; Zoppetti, G; Giacca, M; Presta, M			Multiple interactions of HIV-I tat protein with size-defined heparin oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST GROWTH-FACTOR; METAL-LINKED DIMER; TRANSGENIC MICE; KAPOSIS-SARCOMA; ENDOTHELIAL-CELLS; SULFATE; BINDING; TYPE-1; APOPTOSIS	Tat protein, a transactivating factor of the human immunodeficiency virus type I, acts also as an extracellular molecule. Heparin affects the bioavailability and biological activity of extracellular Tat (Rusnati, Prl., Coltrini, D., Oreste, P., Zoppetti, G., Albini, k, Noonan, D., D'Adda di Fagagna, F., Giacca, M., and Presta, M. (1997) J. Biol. Chem. 272, 11313-11320). Here, a series of homogeneously sized, H-3-labeled heparin fragments were evaluated for their capacity to hind to free glutathione S-transferase (GST)-Tat protein and to immobilized GST-Tat. Hexasaccharides represent the minimum sized heparin fragments able to interact with GST-Tat at physiological ionic strength. Also, the affinity of binding increases with increasing the molecular size of the oligosaccharides, with large fragments (greater than or equal to 18 saccharides) approaching the affinity of full-size heparin. 6-Mer heparin binds GST-Tat with a dissociation constant (K-d) equal to 0.7 +/- 0.4 mu M and a molar oligosaccharide:GST-Tat ratio of about 1:1. Interaction of GST-Tat with 22-mer or full-size heparin is consistent instead with two-component binding. At subsaturating concentrations, a single molecule of heparin interacts with 4-6 molecules of GST-Tat with high affinity K-d values in the nanomolar range of concentration at saturating concentrations, heparin binds GST-Tat with lower affinity (K-d, values in the micromolar range of concentration) and a molar oligosaccharide:GST-Tat ratio of about 1:1. In agreement with the binding data, a positive correlation exists between the size of heparin oligosaccharides and their capacity to inhibit cell internalization, long terminal repeat-transactivating activity of extracellular Tat in HL3T1 cells, and its mitogenic activity in murine adenocarcinoma T53 Tat-less cells. The data demonstrate that the modality of heparin-Tat interaction is strongly affected by the size of the saccharide chain. The possibility of establishing multiple interactions increases the affinity of large heparin fragments for Tat protein and the capacity of the glycosaminoglycan to modulate the biological activity of extracellular Tat.	Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Glycores 2000, I-20100 Milan, Italy; Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, Biochem Unit, S-75123 Uppsala, Sweden; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	University of Brescia; Uppsala University; International Center for Genetic Engineering & Biotechnology (ICGEB)	Presta, M (corresponding author), Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, Via Valsabbina 19, I-25123 Brescia, Italy.	presta@med.unibs.it	Giacca, Mauro/J-9287-2016; Presta, Marco/B-4345-2010; Rusnati, Marco/F-1168-2010	Giacca, Mauro/0000-0003-2927-7225; Rusnati, Marco/0000-0001-9968-5908; PRESTA, Marco/0000-0002-4398-8376				ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; ARAKAWA T, 1994, ARCH BIOCHEM BIOPHYS, V308, P267, DOI 10.1006/abbi.1994.1037; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; COLTRINI D, 1993, EUR J BIOCHEM, V214, P51, DOI 10.1111/j.1432-1033.1993.tb17895.x; CORALLINI A, 1993, CANCER RES, V53, P5569; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; Dewhurst S, 1996, MOL MED TODAY, V2, P16, DOI 10.1016/1357-4310(96)88754-5; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Figueroa JE, 1999, BIOCHEM BIOPH RES CO, V254, P642, DOI 10.1006/bbrc.1998.9985; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297; Gibellini D, 1998, J IMMUNOL, V160, P3891; Goldstein G, 1996, NAT MED, V2, P960, DOI 10.1038/nm0996-960; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Howell AL, 1996, INT J CLIN LAB RES, V26, P124, DOI 10.1007/BF02592355; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Menegon A, 1997, BIOCHEM BIOPH RES CO, V238, P800, DOI 10.1006/bbrc.1997.7393; Milani D, 1996, J BIOL CHEM, V271, P22961, DOI 10.1074/jbc.271.38.22961; Milani D, 1998, AIDS, V12, P1275, DOI 10.1097/00002030-199811000-00008; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; NERLICH A, 1991, PATHOL RES PRACT, V187, P444, DOI 10.1016/S0344-0338(11)80005-1; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; Rusnati M, 1996, NONANTICOAGULANT ACTIONS OF GLYCOSAMINOGLYCANS, P171; Sakata H, 1997, J BIOL CHEM, V272, P9457; Sastry KJ, 1996, ONCOGENE, V13, P487; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WALKER A, 1994, J BIOL CHEM, V269, P931; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	55	110	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28198	28205		10.1074/jbc.274.40.28198	http://dx.doi.org/10.1074/jbc.274.40.28198			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497173	hybrid			2022-12-25	WOS:000082912700022
J	Stubauer, G; Giuffre, A; Sarti, P				Stubauer, G; Giuffre, A; Sarti, P			Mechanism of S-nitrosothiol formation and degradation mediated by copper ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE RELEASE; SERUM-ALBUMIN; GLUTATHIONE; NITROSATION; KINETICS; THIOLS; NITROSOGLUTATHIONE; NITROSOHEMOGLOBIN; DECOMPOSITION; PEROXYNITRITE	Experimental evidence is presented supporting a mechanism of S-nitrosothiol formation and degradation mediated by copper ions using bovine serum albumin, human hemoglobin and glutathione as models. We found that Cu2+, but not Fe3+, induces in the presence of NO a fast S-nitrosation of bovine serum albumin and human hemoglobin, and the reaction is prevented by thiol blocking reagents. During the reaction, Cu is accumulated and accounts for destabilization of the S-nitrosothiol formed. In contrast, glutathione rapidly dimerizes in the presence of Cu2+, the reaction competing with S-nitrosation and therefore preventing the formation of S-nitrosoglutathione. We have combined the presented role of Cu2+ in S-nitrosothiol formation with the known destabilizing effect of Cu+, providing a unique simple picture where the redox state of copper determines either the NO release from S-nitrosothiols or the NO scavenging by thiol groups. The reactions described are fast, efficient, and may occur at micromolar concentration of all reactants, We propose that the mechanism presented may provide a general method for in vitro S-nitrosation.	Univ Rome La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Rome La Sapienza, CNR, Ctr Mol Biol, I-00185 Rome, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Sarti, P (corresponding author), Univ Rome La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Giuffrè, Alessandro/K-4341-2015; Sarti, Paolo/D-2946-2009	Giuffrè, Alessandro/0000-0001-5301-0681; Sarti, Paolo/0000-0002-8219-4827				ASKEW SC, 1995, J CHEM SOC PERK T, V2, P741; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; CAVALLINI D, 1969, ARCH BIOCHEM BIOPHYS, V130, P351; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; Gorren ACF, 1996, ARCH BIOCHEM BIOPHYS, V330, P219, DOI 10.1006/abbi.1996.0247; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; HALLIWELL B, 1994, BIOCHEM J, V219, P1; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KashibaIwatsuki M, 1997, ARCH BIOCHEM BIOPHYS, V345, P237, DOI 10.1006/abbi.1997.0258; KashibaIwatsuki M, 1997, J BIOCHEM-TOKYO, V122, P1208; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; Koppenol WH, 1998, FREE RADICAL BIO MED, V25, P385, DOI 10.1016/S0891-5849(98)00093-8; KRONECK P, 1975, J AM CHEM SOC, V97, P3839, DOI 10.1021/ja00846a059; Malinski T, 1996, METHOD ENZYMOL, V268, P58; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MIN X, 1992, NATURE, V358, P209; MIYOSHI K, 1980, J AM CHEM SOC, V102, P6130, DOI 10.1021/ja00539a027; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pfeiffer S, 1998, ANAL BIOCHEM, V258, P68, DOI 10.1006/abio.1998.2562; PIETRAFORTE D, 1995, BIOCHEMISTRY-US, V34, P7177, DOI 10.1021/bi00021a032; RADI R, 1991, J BIOL CHEM, V266, P4244; ROSSIFANELLI A, 1961, J BIOL CHEM, V236, P165; Scorza G, 1997, FREE RADICAL BIO MED, V22, P633, DOI 10.1016/S0891-5849(96)00378-4; SCUDDER PR, 1978, ANN RHEUM DIS, V37, P67, DOI 10.1136/ard.37.1.67; SCUDDER PR, 1978, ANN RHEUM DIS, V37, P71, DOI 10.1136/ard.37.1.71; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; SMITH GF, 1952, ANAL CHEM, V24, P371, DOI 10.1021/ac60062a029; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Stubauer G, 1998, BIOCHEM BIOPH RES CO, V245, P459, DOI 10.1006/bbrc.1998.8457; Vanin AF, 1997, NITRIC OXIDE-BIOL CH, V1, P191, DOI 10.1006/niox.1997.0122; VANYSEK P, 1996, CRC HDB CHEM PHYSICS, V8, P20; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zhang YY, 1996, J BIOL CHEM, V271, P14271, DOI 10.1074/jbc.271.24.14271	44	114	121	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28128	28133		10.1074/jbc.274.40.28128	http://dx.doi.org/10.1074/jbc.274.40.28128			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497164	hybrid			2022-12-25	WOS:000082912700013
J	Yamaga, M; Fujii, M; Kamata, H; Hirata, H; Yagisawa, H				Yamaga, M; Fujii, M; Kamata, H; Hirata, H; Yagisawa, H			Phospholipase C delta 1 contains a functional nuclear export signal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; YEAST SACCHAROMYCES-CEREVISIAE; PLECKSTRIN HOMOLOGY DOMAIN; SWISS 3T3 CELLS; PLASMA-MEMBRANE; LEPTOMYCIN-B; NUCLEOCYTOPLASMIC TRANSPORT; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; DELTA(1) REQUIRES	We have previously observed, using a green fluorescent protein (GFP) fusion system, that PLC-delta 1 is localized mainly at the plasma membrane and in the cytosol, whereas little is present in the nucleus in Madin-Darby canine kidney cells (Fujii, M., Ohtsubo, M., Ogawa, T., Kamata, H., Hirata, H., and Yagisawa, H. (1999) Biochem. Biophys. Res. Commun. 254, 284-291). Herein, we demonstrate that PLC-delta 1 has a functional nuclear export signal (NES) sequence in amino acid residues 164-177 of the EF-hand domain. The fluorescence of NES-disrupted GFP/PLC-delta 1 expressed in Madin-Darby canine kidney cells was present not only at the plasma membrane and in the cytosol but also in the nucleus. Moreover, treatment with leptomycin B, a specific inhibitor of NES-dependent nuclear export, resulted in the accumulation of GFP/PLC-delta 1 in the nucleus. A site directed mutant containing a pleckstrin homology domain, which does not bind inositol 1,4,5-trisphosphate and cannot hydrolyze phosphatidylinositol 4,5-bisphosphate in vitro, accumulated in the nucleus to a much greater extent than wildtype GFP/PLC-delta 1 after treatment with leptomycin B. These results suggest that PLC-delta 1 is shuttled between the cytoplasm and the nucleus; its nuclear export is dependent on the leucine-rich NES sequence and its active nuclear import is regulated by an unidentified signal(s).	Himeji Inst Technol, Fac Sci, Dept Life Sci, Harima Sci Garden City, Hyogo 6781297, Japan	University of Hyogo	Yagisawa, H (corresponding author), Himeji Inst Technol, Fac Sci, Dept Life Sci, Harima Sci Garden City, Hyogo 6781297, Japan.		Kamata, Hideaki/N-3907-2017					BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bertagnolo V, 1997, BIOCHEM BIOPH RES CO, V235, P831, DOI 10.1006/bbrc.1997.6893; BERTAGNOLO V, 1995, CELL SIGNAL, V7, P669, DOI 10.1016/0898-6568(95)00036-O; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; COCCO L, 1989, BIOCHEM BIOPH RES CO, V159, P1720; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DRAYER AL, 1992, J BIOL CHEM, V267, P18387; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Fujii M, 1999, BIOCHEM BIOPH RES CO, V254, P284, DOI 10.1006/bbrc.1998.9936; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Ghosh S, 1997, PROTEIN EXPRES PURIF, V9, P262, DOI 10.1006/prep.1996.0682; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Grobler JA, 1998, BIOCHEMISTRY-US, V37, P5020, DOI 10.1021/bi972952w; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; KRITZ R, 1990, CIBA F S, V150, P112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lee SB, 1996, J BIOL CHEM, V271, P25, DOI 10.1074/jbc.271.1.25; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELDRUM E, 1989, EUR J BIOCHEM, V182, P673, DOI 10.1111/j.1432-1033.1989.tb14878.x; MELDRUM E, 1991, EUR J BIOCHEM, V196, P159, DOI 10.1111/j.1432-1033.1991.tb15799.x; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; Neri LM, 1998, J BIOL CHEM, V273, P29738, DOI 10.1074/jbc.273.45.29738; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DG, 1993, J BIOL CHEM, V268, P3710; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SHI JR, 1995, PLANT J, V8, P381, DOI 10.1046/j.1365-313X.1995.08030381.x; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; WU DQ, 1993, J BIOL CHEM, V268, P3704; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; YAGISAWA H, 1991, J HYPERTENS, V9, P997, DOI 10.1097/00004872-199111000-00004; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; YOKOO T, 1995, MOL GEN GENET, V247, P148, DOI 10.1007/BF00705644; YORK JD, 1994, J BIOL CHEM, V269, P7847; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	60	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 1	1999	274	40					28537	28541		10.1074/jbc.274.40.28537	http://dx.doi.org/10.1074/jbc.274.40.28537			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	241ZA	10497218	hybrid			2022-12-25	WOS:000082912700067
J	Frazao, C; Bento, I; Costa, J; Soares, CM; Verissimo, P; Faro, C; Pires, E; Cooper, J; Carrondo, MA				Frazao, C; Bento, I; Costa, J; Soares, CM; Verissimo, P; Faro, C; Pires, E; Cooper, J; Carrondo, MA			Crystal structure of cardosin A, a glycosylated and Arg-Gly-Asp-containing aspartic proteinase from the flowers of Cynara cardunculus L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY ANALYSES; ANGSTROM RESOLUTION; 3-DIMENSIONAL STRUCTURE; PEPTIDE-INHIBITOR; BARLEY; REFINEMENT; CRYSTALLIZATION; SPECIFICITY; ENZYME	Aspartic proteinases (AP) have been widely studied within the living world, but so far no plant AP have been structurally characterized. The refined cardosin A crystallographic structure includes two molecules, built up by two glycosylated peptide chains (31 and 15 kDa each). The fold of cardosin A is typical within the AP family, The glycosyl content is described by 19 sugar rings attached to Asn-67 and Asn-257. They are localized on the molecular surface away from the conserved active site and show a new glycan of the plant complex type. A hydrogen bond between Gin-126 and Man beta 4 renders the monosaccharide oxygen O-2 sterically inaccessible to accept a xylosyl residue, therefore explaining the new type of the identified plant glycan. The Arg-Gly-Asp sequence, which has been shown to be involved in recognition of a putative cardosin A receptor, was found in a loop between two beta-strands on the molecular surface opposite the active site cleft. Based on the crystal structure, a possible mechanism whereby cardosin A might be orientated at the cell surface of the style to interact with its putative receptor from pollen is proposed. The biological implications of these findings are also discussed.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780 Oeiras, Portugal; Univ Coimbra, Dept Bioquim, P-3000 Coimbra, Portugal; Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England	Universidade Nova de Lisboa; Universidade de Coimbra; University of Southampton	Carrondo, MA (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Apartado 127, P-2780 Oeiras, Portugal.	carrondo@itqb.unl.pt	Soares, Claudio M/E-2675-2012; Verissimo, Paula/AAB-2281-2021; Costa, Júlia C/B-7131-2008; Bento, Isabel/A-5436-2011; Frazao, Carlos/C-1965-2008	Soares, Claudio M/0000-0003-1154-556X; Verissimo, Paula/0000-0003-0532-4242; Costa, Júlia C/0000-0001-7782-6319; Frazao, Carlos/0000-0002-7725-1671; Faro, Carlos/0000-0002-0480-8379; Pires, Euclides/0000-0002-5853-0165; Bento, Isabel/0000-0003-3801-4929; Carrondo, Maria Armenia/0000-0002-1261-1162				Abola EE, 1997, METHOD ENZYMOL, V277, P556, DOI 10.1016/S0076-6879(97)77031-9; Aguilar CF, 1997, J MOL BIOL, V267, P899, DOI 10.1006/jmbi.1996.0880; AIKAWA J, 1990, J BIOL CHEM, V265, P13955; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Bento I, 1998, ACTA CRYSTALLOGR D, V54, P991, DOI 10.1107/S0907444998001048; Bento I, 1998, ADV EXP MED BIOL, V436, P445; BLUNDELL TL, 1990, J MOL BIOL, V211, P919, DOI 10.1016/0022-2836(90)90084-Y; BLUNDELL TL, 1985, ASPARTIC PROTEINASES, P151; BRUNGER A, 1993, XPLOR VERSION 3 1; CORDEIRO MC, 1994, PLANT MOL BIOL, V24, P733, DOI 10.1007/BF00029855; Costa J, 1997, EUR J BIOCHEM, V243, P695, DOI 10.1111/j.1432-1033.1997.t01-1-00695.x; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DEALWIS CG, 1994, J MOL BIOL, V236, P342, DOI 10.1006/jmbi.1994.1139; DHANARAJ V, 1992, NATURE, V357, P466, DOI 10.1038/357466a0; DOMBROWSKI JE, 1993, PLANT CELL, V5, P587, DOI 10.1105/tpc.5.5.587; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; Faro C, 1998, ADV EXP MED BIOL, V436, P423; Glathe S, 1998, J BIOL CHEM, V273, P31230, DOI 10.1074/jbc.273.47.31230; GURUPRASAD K, 1994, FEBS LETT, V352, P131, DOI 10.1016/0014-5793(94)00935-X; HORI H, 1988, FEBS LETT, V232, P391, DOI 10.1016/0014-5793(88)80777-4; James MNG, 1998, ASPARTIC PROTEINASES; KERVINEN J, 1995, ADV EXP MED BIOL, V362, P241; KOSTKA V, 1985, ASPARTIC PROTEINASES; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P793, DOI 10.1038/nsb1097-793; MEHLER EL, 1991, PROTEIN ENG, V4, P903, DOI 10.1093/protein/4.8.903; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEWMAN M, 1991, J MOL BIOL, V221, P1295, DOI 10.1016/0022-2836(91)80127-G; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P179, DOI 10.1016/S0968-0004(00)89003-9; Ramalho-Santos M, 1998, EUR J BIOCHEM, V255, P133, DOI 10.1046/j.1432-1327.1998.2550133.x; RamalhoSantos M, 1996, BBA-PROTEIN STRUCT M, V1297, P83, DOI 10.1016/0167-4838(96)00103-3; RamalhoSantos M, 1997, PLANTA, V203, P204, DOI 10.1007/s004250050183; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROUSSEL A, 1990, 15 IUCR C BORD FRANC, P66; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; SMITH LJ, 1995, BIOCHEMISTRY-US, V34, P10918, DOI 10.1021/bi00034a026; STAEHELIN LA, 1995, ANNU REV PLANT PHYS, V46, P261, DOI 10.1146/annurev.pp.46.060195.001401; SUGUNA K, 1987, P NATL ACAD SCI USA, V84, P7009, DOI 10.1073/pnas.84.20.7009; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOKES ZA, 1974, PLANTA, V119, P39, DOI 10.1007/BF00390820; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; VERISSIMO P, 1995, BIOTECHNOL LETT, V17, P621, DOI 10.1007/BF00129389; Verissimo P, 1996, EUR J BIOCHEM, V235, P762, DOI 10.1111/j.1432-1033.1996.00762.x; Yang J, 1997, J MOL BIOL, V268, P449, DOI 10.1006/jmbi.1997.0968	53	73	75	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27694	27701		10.1074/jbc.274.39.27694	http://dx.doi.org/10.1074/jbc.274.39.27694			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488111	hybrid			2022-12-25	WOS:000082739100050
J	Kim, B; Ayran, JC; Sagar, SG; Adman, ET; Fuller, SM; Tran, NH; Horrigan, J				Kim, B; Ayran, JC; Sagar, SG; Adman, ET; Fuller, SM; Tran, NH; Horrigan, J			New human immunodeficiency virus, type 1 reverse transcriptase (HIV-1 RT) mutants with increased fidelity of DNA synthesis - Accuracy, template binding, and processivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMICS IN-VIVO; POLYMERASE FIDELITY; GENETIC SELECTION; ESCHERICHIA-COLI; MUTAGENESIS; MISINCORPORATION; POLYMERIZATION; RESOLUTION; RESISTANCE; MECHANISMS	Infidelity of DNA synthesis by human immunodeficiency virus, type 1 reverse transcriptase (HTV-1 RT) is a presumptive determinant of HIV-1 hypervariability and is incompletely understood at the mechanistic and structural levels. Amino acid substitution at only three residues, including Asp-76 (Kim, B., Hathaway, T. R., and Loeb, L. A (1996) Biochemistry 37, 5831-5839), is known to increase fidelity, We report here that substitution at Arg-78 can also increase accuracy. Mutant R78A RT showed reduced primer extension in misincorporation assays lacking a complementary dNTP and exhibited a 9-fold decrease in mutation frequency in the M13mp2 lacZ forward mutation assay. Previous structural studies indicate that Arg-78 and Asp-76 lie in a region that interacts with template nucleotides. Interestingly, R78A RT exhibited 6- to 8-fold decreases in binding affinity (K-d) for RNA and DNA templates relative to wild type RT. In contrast, D76V RT, which also increases fidelity (Kim ct al., 1996), showed a 6- to 7-fold increased affinity. The processivity of R78A RT on both RNA and DNA templates was substantially reduced relative to wild type RT, whereas the processivity of D76V RT was increased. We discuss relationships of fidelity, template binding, and processivity in these and other HIV RT mutants.	Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA	University of Rochester; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kim, B (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Box 672,601 Elmwood Ave, Rochester, NY 14642 USA.	baek_kim@urmc.rochester.edu			NIEHS NIH HHS [P30-ES07033] Funding Source: Medline; NIGMS NIH HHS [R29-GM55500] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055500] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Back NKT, 1997, ANTIMICROB AGENTS CH, V41, P2484, DOI 10.1128/AAC.41.11.2484; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; Coffin J. M., 1990, Applied Virology Research, V2, P11; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COFFIN JM, 1990, RETROVIRIDAE THEIR R, P1437; DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X; Drosopoulos WC, 1996, J VIROL, V70, P4834, DOI 10.1128/JVI.70.7.4834-4838.1996; Essink BBO, 1997, NUCLEIC ACIDS RES, V25, P3212, DOI 10.1093/nar/25.16.3212; FITZGIBBON JE, 1993, AIDS RES HUM RETROV, V9, P833, DOI 10.1089/aid.1993.9.833; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Jonckheere H, 1998, AIDS RES HUM RETROV, V14, P249, DOI 10.1089/aid.1998.14.249; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kim B, 1997, METHODS, V12, P318, DOI 10.1006/meth.1997.0485; Kim B, 1998, BIOCHEMISTRY-US, V37, P5831, DOI 10.1021/bi972672g; Kim B, 1996, J BIOL CHEM, V271, P4872, DOI 10.1074/jbc.271.9.4872; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; Palaniappan C, 1996, J BIOL CHEM, V271, P22331, DOI 10.1074/jbc.271.37.22331; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; Quan YD, 1998, J BIOL CHEM, V273, P21918, DOI 10.1074/jbc.273.34.21918; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; Vartanian JP, 1997, J MOL BIOL, V270, P139, DOI 10.1006/jmbi.1997.1104; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; WILLIAMS KJ, 1992, CURR TOP MICROBIOL, V176, P165; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263	39	64	65	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27666	27673		10.1074/jbc.274.39.27666	http://dx.doi.org/10.1074/jbc.274.39.27666			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488107	hybrid			2022-12-25	WOS:000082739100046
J	Kondo, H; Shiroishi, M; Matsushima, M; Tsumoto, K; Kumagai, I				Kondo, H; Shiroishi, M; Matsushima, M; Tsumoto, K; Kumagai, I			Crystal structure of anti-hen egg white lysozyme antibody (HyHEL-10) Fv-antigen complex - Local structural changes in the protein antigen and water-mediated interactions of Fv-antigen and light chain-heavy chain interfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTILYSOZYME MONOCLONAL-ANTIBODY; SITE-DIRECTED MUTAGENESIS; FAB COMPLEX; 3-DIMENSIONAL STRUCTURES; CHICKEN LYSOZYME; ESCHERICHIA-COLI; BOUND WATER; BINDING; ASSOCIATION; FRAGMENTS	In order to address the recognition mechanism of the fragments of antibody variable regions, termed Fv, toward their target antigen, an x-ray crystal structure of an anti-hen egg white lysozyme antibody (HyHEL-10) Ft fragment complexed with its cognate antigen, hen egg white lysozyme (HEL), was solved at 2.3 Angstrom. The overall structure of the complex is similar to that reported in a previous article dealing with the Fab fragment-MEL complex (PDB ID code, 3HFM), However, the areas of Fv covered by HEL upon complex formation increased by about 100 Angstrom(2) in comparison with the Fab-HEL complex, and two local structural differences were observed in the heavy chain of the variable region (VH), In addition, small but significant local structural changes were observed in the antigen, HEL. The x-ray data permitted the identification of two water molecules between the VH and HEL and six water molecules retained in the interface between the antigen and the light chain complementarity determining regions (CDRs) 2 and 3 (CDR-L2 and CDR-L3), These water molecules bridge the antigen-antibody interface through hydrogen bond formation in the VL-HEL interface. Eleven water molecules were found to complete the imperfect VH-VL interface, suggesting that solvent molecules mediate the stabilization of interaction between variable regions. These results suggest that the unfavorable effect of deletion of constant regions on the antigen-antibody interaction is compensated by an increase in favorable interactions, including structural changes in the antigen-antibody interface and solvent-mediated hydrogen bond formation upon complex formation, which may lead to a minimum decreased affinity of the antibody Fv fragment toward its antigen.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan; Rat Drug Design Labs, Fukushima 9601242, Japan	Tohoku University	Kumagai, I (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Yama 07, Sendai, Miyagi 9808579, Japan.	kmiz@mail.cc.tohoku.ac.jp	Kondo, Hidemasa/M-7465-2018	Kondo, Hidemasa/0000-0003-2799-1775; Shiroishi, Mitsunori/0000-0002-3133-157X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; BRADEN BC, 1994, J MOL BIOL, V243, P767, DOI 10.1016/0022-2836(94)90046-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR MANUAL; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; Cohen GH, 1996, ACTA CRYSTALLOGR D, V52, P315, DOI 10.1107/S0907444995014855; Colman PM, 1991, CURR OPIN STRUC BIOL, V1, P232, DOI 10.1016/0959-440X(91)90067-4; DAVIES DR, 1993, ACCOUNTS CHEM RES, V26, P421, DOI 10.1021/ar00032a005; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; Goldbaum FA, 1996, J MOL RECOGNIT, V9, P6, DOI 10.1002/(SICI)1099-1352(199601)9:1<6::AID-JMR240>3.3.CO;2-M; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; Holdgate GA, 1997, BIOCHEMISTRY-US, V36, P9663, DOI 10.1021/bi970294+; Huston JS, 1996, ADV PROTEIN CHEM, V49, P329, DOI 10.1016/S0065-3233(08)60493-3; JANCARIK J, 1991, J APPL CRYSTALLOGR, V26, P795; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat E. A., 1991, SEQUENCES PROTEINS I; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Maenaka K, 1998, BBA-PROTEIN STRUCT M, V1384, P23, DOI 10.1016/S0167-4838(97)00199-4; MALBY RL, 1994, STRUCTURE, V2, P733, DOI 10.1016/S0969-2126(00)00074-5; Mallender WD, 1996, J BIOL CHEM, V271, P5338, DOI 10.1074/jbc.271.10.5338; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILNERWHITE EJ, 1988, J MOL BIOL, V204, P777, DOI 10.1016/0022-2836(88)90368-3; Murshudov GN, 1996, P CCP4 STUDY WEEKEND, P93; NAVAZA J, 1994, ACTA CRYSTALLOGR D, V50, P805; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; PLUCKTHUN A, 1991, BIO-TECHNOL, V9, P545, DOI 10.1038/nbt0691-545; PLUCKTHUN A, 1992, IMMUNOL REV, V130, P151, DOI 10.1111/j.1600-065X.1992.tb01525.x; Pons J, 1999, PROTEIN SCI, V8, P958, DOI 10.1110/ps.8.5.958; Rajpal A, 1998, PROTEIN SCI, V7, P1868, DOI 10.1002/pro.5560070903; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SKERRA A, 1993, CURR OPIN IMMUNOL, V5, P256, DOI 10.1016/0952-7915(93)90014-J; SMITHGILL SJ, 1984, J IMMUNOL, V133, P384; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; TAKAHASHI H, 1994, J MOL BIOL, V243, P494, DOI 10.1006/jmbi.1994.1675; TELLO D, 1993, BIOCHEM SOC T, V21, P943, DOI 10.1042/bst0210943; Tsumoto K, 1997, PROTEIN ENG, V10, P1311, DOI 10.1093/protein/10.11.1311; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; Tsumoto K, 1996, J BIOL CHEM, V271, P32612, DOI 10.1074/jbc.271.51.32612; TULIP WR, 1992, J MOL BIOL, V227, P122, DOI 10.1016/0022-2836(92)90687-F; Ueda H, 1996, NAT BIOTECHNOL, V14, P1714, DOI 10.1038/nbt1296-1714; UEDA Y, 1993, GENE, V129, P129; WALLS PH, 1992, J MOL BIOL, V228, P277, DOI 10.1016/0022-2836(92)90506-F; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; WILSON AJC, 1950, ACTA CRYSTALLOGR, V3, P397, DOI 10.1107/S0365110X50001129; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Xavier KA, 1998, BIOPHYS J, V74, P2036; Ysern X, 1998, NAT STRUCT BIOL, V5, P412, DOI 10.1038/nsb0698-412	70	61	62	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	1999	274	39					27623	27631		10.1074/jbc.274.39.27623	http://dx.doi.org/10.1074/jbc.274.39.27623			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	238XB	10488102	hybrid			2022-12-25	WOS:000082739100041
J	Saez, C; Japon, MA; Ramos-Morales, F; Romero, F; Segura, DI; Tortolero, M; Pintor-Toro, JA				Saez, C; Japon, MA; Ramos-Morales, F; Romero, F; Segura, DI; Tortolero, M; Pintor-Toro, JA			hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias	ONCOGENE			English	Article						hpttg; pituitary adenomas; oncogene; tumorigenesis; mammary adenocarcinoma; pulmonary adenocarcinoma	RAS MUTATIONS; TUMORS; GENE; PROTEIN; ORIGIN; PTTG	The role of oncogenes in pituitary tumorigenesis remains elusive since few genetic changes have been identified so far in pituitary tumors. Pituitary tumor-transforming gene (pttg) has been recently cloned from rat GH4 pituitary tumor cells. We have previously isolated and characterized hpttg from human thymus, In the present study, we analyse the expression of hpttg mRNA in a series of human pituitary adenomas. We show that hpttg is highly expressed in the majority of pituitary adenomas while only very low levels of mRNA can be detected in normal pituitary gland by Northern blot analysis. hPTTG protein was immunolocalized mainly in the cytoplasm of adenoma cells. Other common extra-cranial malignant tumors were also analysed by immunohistochemistry. Interestingly, strong hPTTG immunoreactivity was detected in most adenocarcinomas of mammary and pulmonary origins.	CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain; Hosp Univ Virgen del Rocio, Dept Anat Patol, Seville 41013, Spain; Univ Sevilla, Fac Biol, Dept Microbiol, E-41080 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); Virgen del Rocio University Hospital; University of Sevilla	Pintor-Toro, JA (corresponding author), CSIC, Inst Recursos Nat & Agrobiol, Apdo 1052, E-41080 Seville, Spain.		Tortolero, Maria/K-5744-2014; Romero, Francisco/K-2101-2014; Sáez, Carmen/B-9468-2015; Japón, Miguel A/L-2555-2017; IBIS, TUMORIGENESIS/P-3506-2015; Ramos-Morales, Francisco/C-5734-2008; Pintor-Toro, Jose/L-4737-2014	Tortolero, Maria/0000-0003-1797-9940; Romero, Francisco/0000-0002-9588-6881; Sáez, Carmen/0000-0002-8600-0508; Japón, Miguel A/0000-0002-5980-5044; Ramos-Morales, Francisco/0000-0002-1151-4547; Pintor-Toro, Jose/0000-0002-9060-5243				ALEXANDER JM, 1990, J CLIN INVEST, V86, P336, DOI 10.1172/JCI114705; ALVARO V, 1993, J CLIN ENDOCR METAB, V77, P1125, DOI 10.1210/jc.77.5.1125; ASA SL, 1992, ENDOCRINOLOGY, V131, P2083, DOI 10.1210/en.131.5.2083; BERTHERAT J, 1995, MOL ENDOCRINOL, V9, P777, DOI 10.1210/me.9.7.777; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; HERMAN V, 1993, J CLIN ENDOCR METAB, V77, P50, DOI 10.1210/jc.77.1.50; HERMAN V, 1990, J CLIN ENDOCR METAB, V71, P1427, DOI 10.1210/jcem-71-6-1427; KARGA HJ, 1992, J CLIN ENDOCR METAB, V74, P914, DOI 10.1210/jc.74.4.914; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LYONS J, 1990, SCIENCE, V249, P255; MCANDREW J, 1995, ENDOCRINOLOGY, V136, P4479, DOI 10.1210/en.136.10.4479; PEI L, 1994, J CLIN ENDOCR METAB, V78, P842, DOI 10.1210/jc.78.4.842; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; SPADA A, 1994, EUR J ENDOCRINOL, V130, P43, DOI 10.1530/eje.0.1300043; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; SUMI T, 1993, ENDOCR PATHOL, V4, P95, DOI 10.1007/BF02914458; THAPAR K, 1995, BAILLIERE CLIN ENDOC, V9, P243, DOI 10.1016/S0950-351X(95)80322-X; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhuang ZP, 1997, CANCER RES, V57, P5446	22	125	139	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5473	5476		10.1038/sj.onc.1202914	http://dx.doi.org/10.1038/sj.onc.1202914			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498901				2022-12-25	WOS:000082718600012
J	Chen, LT; Gilman, AG; Kozasa, T				Chen, LT; Gilman, AG; Kozasa, T			A candidate target for G protein action in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; GROWTH CONE; ADENYLYL-CYCLASE; PLASMA-MEMBRANE; BINDING PROTEIN; CELLS; MYRISTOYLATION; NUCLEOBINDIN; INHIBITION; ANTIBODIES	An effector candidate for G protein action, GRIN1, was identified by screening a cDNA expression library with phosphorylatled GTP gamma S-G(z)alpha as a probe. GRIN1 is a novel protein without substantial homology to known protein domains. It is expressed largely in brain and binds specifically to activated G(z)alpha, G(o)alpha, and G(i)alpha through its carboxyl-terminal region. The protein KIAA0514 (GRIN2) is homologous to GRIN1 at its carboxyl terminus and also binds to activated G(o)alpha. Both GRIN1 and G(o)alpha are membrane-bound proteins that are enriched in the growth cones of neurites. Coexpression of GRIN1, or GRIN2 with activated G(o)alpha causes formation of a network of fine processes in Neuro2a cells, suggesting that these pathways may function downstream of G(o)alpha to control growth of neurites.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	alfred.gilman@email.swmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUDE EJ, 1994, J BIOL CHEM, V269, P2316; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; LEE E, 1994, METHOD ENZYMOL, V237, P146; LI XH, 1995, J NEUROCHEM, V64, P1107; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; MIURA K, 1992, BIOCHEM BIOPH RES CO, V187, P375, DOI 10.1016/S0006-291X(05)81503-7; MOCHIZUKI N, 1995, FEBS LETT, V373, P155, DOI 10.1016/0014-5793(95)01031-9; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; MUNTZ KH, 1992, CIRCULATION, V86, P764; NAGESE T, 1998, DNA RES, V5, P31; PFENNINGER KH, 1983, CELL, V35, P573, DOI 10.1016/0092-8674(83)90191-5; SCHMIDT CJ, 1994, J NEUROSCI RES, V38, P182, DOI 10.1002/jnr.490380208; SIMKOWITZ P, 1989, J NEUROSCI, V9, P1004; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; Suman T, 1980, Basic Appl Histochem, V24, P145; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3	27	58	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26931	26938		10.1074/jbc.274.38.26931	http://dx.doi.org/10.1074/jbc.274.38.26931			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480904	hybrid			2022-12-25	WOS:000082570700043
J	Hishiya, A; Ohnishi, M; Tamura, S; Nakamura, F				Hishiya, A; Ohnishi, M; Tamura, S; Nakamura, F			Protein phosphatase 2C inactivates F-actin binding of human platelet moesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EZRIN/RADIXIN/MOESIN ERM PROTEINS; RABBIT SKELETAL-MUSCLE; CELL-CELL CONTACTS; AFFINITY CHROMATOGRAPHY; MYOSIN PHOSPHATASE; MOLECULAR-CLONING; ACID-PHOSPHATASE; FISSION YEAST; T-LYMPHOCYTES; EZRIN	During activation of platelets by thrombin phosphorylation of Thr(558) in the C-terminal domain of the membrane-F-actin linking protein moesin increases transiently, and this correlates with protrusion of filopodial structures. Calyculin A enhances phosphorylation of moesin by inhibition of phosphatases. To measure this moesin-specific activity, a nonradioactive enzyme-linked immunosorbent assay method was developed with the synthetic peptide Cys-Lys(555)-Tyr-Lys-Thr(P)-Leu-Arg(560) coupled to bovine serum albumin as the substrate and moesin phosphorylation state-specific polyclonal antibodies for the detection and quantitation of dephosphorylation, Calyculin A-sensitive and -insensitive protein-threonine phosphatase activities were detected in platelet lysates and separated by DEAE-cellulose chromatography, The calyculin A-sensitive enzyme was identified as a type 1 protein phosphatase, The calyculin A-insensitive enzyme activity was purified to homogeneity by phenyl- Sepharose, protamine-, and phosphonic acid peptide-agarose chromatography and characterized biochemically and immunologically as a 53-kDa protein(s) and a type 2C protein phosphatase (PP2C), Phosphorylation of Thr(558) is necessary for F-actin binding of moesin in vitro. The purified enzyme, as well as bacterially made PPBC alpha and PP2C beta, efficiently dephosphorylate(s) highly purified platelet phosphomoesin. This reverses the activating effect of phosphorylation, and moesin no longer co-sediments with actin filaments. In vivo, regulation of these phosphatase activities are likely to influence dynamic interactions between the actin cytoskeleton and membrane constituents linked to moesin.	Tohoku Univ, Grad Sch Agr Sci, Dept Environm Biol, Lab Environm Biochem, Sendai, Miyagi 9818555, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Biochem, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University	Nakamura, F (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Dept Environm Biol, Lab Environm Biochem, Sendai, Miyagi 9818555, Japan.		Nakamura, Fumihiko/N-5476-2016	Nakamura, Fumihiko/0000-0002-6872-4246				AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; BERRYMAN M, 1993, J CELL SCI, V105, P1025; DISSING J, 1979, BIOCHIM BIOPHYS ACTA, V569, P159, DOI 10.1016/0005-2744(79)90051-2; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; ERDODI F, 1992, ARCH BIOCHEM BIOPHYS, V298, P682, DOI 10.1016/0003-9861(92)90466-A; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; Guthridge MA, 1997, MOL CELL BIOL, V17, P5485, DOI 10.1128/MCB.17.9.5485; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; KATO S, 1995, ARCH BIOCHEM BIOPHYS, V318, P387, DOI 10.1006/abbi.1995.1244; Kato S, 1996, FEBS LETT, V396, P293, DOI 10.1016/0014-5793(96)01119-2; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P296, DOI 10.1006/bbrc.1998.9467; Kobayashi T, 1996, MUTAT RES-DNA REPAIR, V362, P213, DOI 10.1016/0921-8777(95)00036-4; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; LANDT M, 1978, BIOCHEMISTRY-US, V17, P915, DOI 10.1021/bi00598a027; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nakai K, 1997, BLOOD, V90, P3936, DOI 10.1182/blood.V90.10.3936; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; Nakamura F, 1996, BIOCHEM BIOPH RES CO, V226, P650, DOI 10.1006/bbrc.1996.1410; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; Packer NH, 1997, ELECTROPHORESIS, V18, P452, DOI 10.1002/elps.1150180320; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Takuma T, 1996, J BIOCHEM, V120, P35; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; TERASAWA T, 1993, ARCH BIOCHEM BIOPHYS, V307, P242; Travis SM, 1997, FEBS LETT, V412, P415, DOI 10.1016/S0014-5793(97)00837-5; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; WAYMACK PP, 1991, ARCH BIOCHEM BIOPHYS, V288, P621, DOI 10.1016/0003-9861(91)90245-E; WOODGETT JR, 1989, ANAL BIOCHEM, V180, P237, DOI 10.1016/0003-2697(89)90423-5; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; Yan JX, 1998, J CHROMATOGR A, V808, P23, DOI 10.1016/S0021-9673(98)00115-0; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885	47	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26705	26712		10.1074/jbc.274.38.26705	http://dx.doi.org/10.1074/jbc.274.38.26705			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480873	hybrid			2022-12-25	WOS:000082570700012
J	Pommer, AJ; Kuhlmann, UC; Cooper, A; Hemmings, AM; Moore, GR; James, R; Kleanthous, C				Pommer, AJ; Kuhlmann, UC; Cooper, A; Hemmings, AM; Moore, GR; James, R; Kleanthous, C			Homing in on the role of transition metals in the HNH motif of colicin endonucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; GROUP-II INTRONS; IMMUNITY PROTEIN; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; FEMTOMOLAR AFFINITY; NUCLEASE DOMAIN; FORMING DOMAIN; ZINC-BINDING; E9	The cytotoxic domain of the bacteriocin colicin E9 (the E9 DNase) is a nonspecific endonuclease that must traverse two membranes to reach its cellular target, bacterial DNA. Recent structural studies revealed that the active site of colicin DNases encompasses the HNH motif found in homing endonucleases, and bound within this motif a single transition metal ion (either Zn2+ or Ni2+) the role of which is unknown. In the present work we find that neither Zn2+ nor Ni2+ is required for DNase activity, which instead requires Mg2+ ions, but binding transition metals to the E9 DNase causes subtle changes to both secondary and tertiary structure. Spectroscopic, proteolytic, and calorimetric data show that, accompanying the binding of 1 eq of Zn2+, Ni2+, or Co2+, the thermodynamic st;ability of the domain increased substantially, and that the equilibrium dissociation constant for Zn2+ was less than or equal to nanomolar, while that for Co2+ and Ni2+ was micromolar, Our data demonstrate that the transition metal is not essential for colicin DNase activity but rather serves a structural role. We speculate that the HNH motif has been adapted for use by endonuclease colicins because of its involvement in DNA recognition and because removal of the bound metal ion destabilizes the DNase domain, a likely prerequisite for its translocation across bacterial membranes.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; Univ E Anglia, Sch Chem Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia; University of Glasgow; University of East Anglia	Kleanthous, C (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	c.kleanthous@uea.ac.uk	Cooper, Alan/F-7813-2011; HEMMINGS, ANDREW MICHAEL/E-5517-2011; James, Richard/B-2252-2009	Cooper, Alan/0000-0001-6709-7343; HEMMINGS, ANDREW MICHAEL/0000-0003-3053-3134; James, Richard/0000-0002-5086-788X				ALEXANDER RS, 1991, BIOCHEMISTRY-US, V30, P11064, DOI 10.1021/bi00110a008; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BOON T, 1971, P NATL ACAD SCI USA, V68, P2421, DOI 10.1073/pnas.68.10.2421; Bouveret E, 1997, MOL MICROBIOL, V23, P909, DOI 10.1046/j.1365-2958.1997.2751640.x; BRANDAONETO J, 1994, AM J HEMATOL, V45, P1, DOI 10.1002/ajh.2830450102; Chak KF, 1996, P NATL ACAD SCI USA, V93, P6437, DOI 10.1073/pnas.93.13.6437; CHAK KF, 1991, J GEN MICROBIOL, V137, P91, DOI 10.1099/00221287-137-1-91; Cooper A, 1994, Methods Mol Biol, V22, P137; Cooper A., 1999, PROTEIN C T, P217; Cramer WA, 1999, NAT STRUCT BIOL, V6, P295, DOI 10.1038/7520; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; Derbyshire V, 1997, J MOL BIOL, V265, P494, DOI 10.1006/jmbi.1996.0754; DUCHE D, 1994, J BIOL CHEM, V269, P24820; Dunbar J, 1997, PROTEIN SCI, V6, P1727, DOI 10.1002/pro.5560060813; EDDY SR, 1991, GENE DEV, V5, P1032, DOI 10.1101/gad.5.6.1032; Elkins P, 1997, STRUCTURE, V5, P443, DOI 10.1016/S0969-2126(97)00200-1; Flick KE, 1998, NATURE, V394, P96, DOI 10.1038/27952; FREDERICQ P, 1957, ANNU REV MICROBIOL, V11, P7, DOI 10.1146/annurev.mi.11.100157.000255; GarinotSchneider C, 1996, J MOL BIOL, V260, P731, DOI 10.1006/jmbi.1996.0433; GarinotSchneider C, 1997, MICROBIOL-SGM, V143, P2931, DOI 10.1099/00221287-143-9-2931; GELI V, 1988, P NATL ACAD SCI USA, V85, P689, DOI 10.1073/pnas.85.3.689; GORBALENYA AE, 1994, PROTEIN SCI, V3, P1117, DOI 10.1002/pro.5560030716; Hannan JP, 1999, PROTEIN SCI, V8, P1711, DOI 10.1110/ps.8.8.1711; IPPOLITO JA, 1995, P NATL ACAD SCI USA, V92, P5017, DOI 10.1073/pnas.92.11.5017; JAKES KS, 1974, P NATL ACAD SCI USA, V71, P3380, DOI 10.1073/pnas.71.9.3380; James R, 1996, MICROBIOL-SGM, V142, P1569, DOI 10.1099/13500872-142-7-1569; Kleanthous C, 1999, NAT STRUCT BIOL, V6, P243, DOI 10.1038/6683; Kleanthous C, 1998, MOL MICROBIOL, V28, P227, DOI 10.1046/j.1365-2958.1998.00811.x; Ko TP, 1999, STRUCT FOLD DES, V7, P91, DOI 10.1016/S0969-2126(99)80012-4; KRONE WJA, 1986, J BACTERIOL, V166, P260, DOI 10.1128/jb.166.1.260-268.1986; Kuhlmann UC, 1999, ACTA CRYSTALLOGR D, V55, P256, DOI 10.1107/S0108444998002590; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; Lippard S. J., 1994, PRINCIPLES BIOINORGA; Luria S. E., 1987, ESCHERICHIA COLI SAL, P1615; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MUELLER JE, 1993, NUCLEASES, P111; Ogawa T, 1999, SCIENCE, V283, P2097, DOI 10.1126/science.283.5410.2097; Plotnikov VV, 1997, ANAL BIOCHEM, V250, P237, DOI 10.1006/abio.1997.2236; Pommer AJ, 1998, BIOCHEM J, V334, P387, DOI 10.1042/bj3340387; SCHALLER K, 1976, P NATL ACAD SCI USA, V73, P3989, DOI 10.1073/pnas.73.11.3989; SENIOR BW, 1971, P NATL ACAD SCI USA, V68, P959, DOI 10.1073/pnas.68.5.959; SHUB DA, 1994, TRENDS BIOCHEM SCI, V19, P402, DOI 10.1016/0968-0004(94)90086-8; TOBA M, 1988, J BACTERIOL, V170, P3237, DOI 10.1128/jb.170.7.3237-3242.1988; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; WALLIS R, 1995, BIOCHEMISTRY-US, V34, P13751, DOI 10.1021/bi00042a005; WALLIS R, 1992, EUR J BIOCHEM, V207, P687, DOI 10.1111/j.1432-1033.1992.tb17096.x; WALLIS R, 1994, EUR J BIOCHEM, V220, P447, DOI 10.1111/j.1432-1033.1994.tb18642.x; WALLIS R, 1995, BIOCHEMISTRY-US, V34, P13743, DOI 10.1021/bi00042a004; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	54	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27153	27160		10.1074/jbc.274.38.27153	http://dx.doi.org/10.1074/jbc.274.38.27153			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480931	hybrid			2022-12-25	WOS:000082570700070
J	Stacey, MG; von Arnim, AG				Stacey, MG; von Arnim, AG			A novel motif mediates the targeting of the Arabidopsis COP1 protein to subnuclear foci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CONTROL; SEEDLING DEVELOPMENT; INTERPHASE NUCLEI; GENE-EXPRESSION; FUSION PROTEINS; LOCALIZATION; ORGANIZATION; PLANTS; TRANSLOCATION; REGULATORS	The constitutive photomorphogenesis 1 (COP1) protein of Arabidopsis thaliana accumulates in discrete subnuclear foci. To better understand the role of subnuclear architecture in COP1-mediated gene expression, we investigated the structural motifs of COP1 that mediate its localization to subnuclear foci using mutational analysis with green fluorescent protein as a reporter. In a transient expression assay, a subnuclear localization signal consisting of 58 residues between amino acids 120 and 177 of COP1 was able to confer speckled localization onto the heterologous nuclear NIa protein from tobacco etch virus. The subnuclear localization signal overlaps two previously characterized motifs, a cytoplasmic localization signal and a putative alpha-helical coiled-coil domain that has been implicated in COP1 dimerization. Moreover, phenotypically lethal mutations in the carboxyl-terminal WD-40 repeats inhibited localization to subnuclear foci, consistent with a functional role for the accumulation of COP1 at sub-nuclear sites.	Univ Tennessee, Dept Bot, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville	von Arnim, AG (corresponding author), Univ Tennessee, Dept Bot, Knoxville, TN 37996 USA.	vonarmin@utk.edu		von Arnim, Albrecht/0000-0003-3472-3357				Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; BAUNOCH D, 1988, J ULTRA MOL STRUCT R, V99, P203, DOI 10.1016/0889-1605(88)90064-X; BEVEN AF, 1995, J CELL SCI, V108, P509; Beven AF, 1996, J CELL SCI, V109, P1241; Boudonck K, 1998, J CELL SCI, V111, P3687; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; Chattopadhyay S, 1998, PLANT J, V15, P69, DOI 10.1046/j.1365-313X.1998.00180.x; Chattopadhyay S, 1998, PLANT CELL, V10, P673, DOI 10.1105/tpc.10.5.673; Daros JA, 1997, VIROLOGY, V237, P327, DOI 10.1006/viro.1997.8802; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; GLYN MCP, 1995, PLANT J, V8, P531, DOI 10.1046/j.1365-313X.1995.8040531.x; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lamond Angus I., 1993, Trends in Cell Biology, V3, P198, DOI 10.1016/0962-8924(93)90214-L; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MATSUI M, 1995, P NATL ACAD SCI USA, V92, P4239, DOI 10.1073/pnas.92.10.4239; McNellis TW, 1996, PLANT CELL, V8, P1491, DOI 10.1105/tpc.8.9.1491; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; Osterlund MT, 1998, PLANT J, V16, P201, DOI 10.1046/j.1365-313x.1998.00290.x; RAWLINS DJ, 1991, CHROMOSOMA, V100, P424, DOI 10.1007/BF00364552; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shaw P J, 1996, Essays Biochem, V31, P77; Shaw PJ, 1996, J MICROSC-OXFORD, V181, P178, DOI 10.1046/j.1365-2818.1996.101381.x; Stacey MG, 1999, PLANT CELL, V11, P349, DOI 10.1105/tpc.11.3.349; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Strouboulis J, 1996, J CELL SCI, V109, P1991; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torii KU, 1998, EMBO J, V17, P5577, DOI 10.1093/emboj/17.19.5577; von Arnim AG, 1998, GENE, V221, P35, DOI 10.1016/S0378-1119(98)00433-8; vonArnim A, 1996, ANNU REV PLANT PHYS, V47, P215, DOI 10.1146/annurev.arplant.47.1.215; vonArnim AG, 1997, PLANT PHYSIOL, V114, P779, DOI 10.1104/pp.114.3.779; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Yamaguchi R, 1999, J CELL BIOL, V145, P437, DOI 10.1083/jcb.145.3.437; Yamamoto YY, 1998, PLANT CELL, V10, P1083, DOI 10.1105/tpc.10.7.1083; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Zhao L, 1998, BBA-GENE STRUCT EXPR, V1395, P326, DOI 10.1016/S0167-4781(97)00200-5	44	39	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					27231	27236		10.1074/jbc.274.38.27231	http://dx.doi.org/10.1074/jbc.274.38.27231			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480941	hybrid			2022-12-25	WOS:000082570700080
J	Stockand, JD; Edinger, RS; Al-Baldawi, N; Sariban-Sohraby, S; Al-Khalili, O; Eaton, DC; Johnson, JP				Stockand, JD; Edinger, RS; Al-Baldawi, N; Sariban-Sohraby, S; Al-Khalili, O; Eaton, DC; Johnson, JP			Isoprenylcysteine-O-carboxyl methyltransferase regulates aldosterone-sensitive Na+ reabsorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; SODIUM-TRANSPORT; METHYLATION; PROTEIN; CHANNELS; EPITHELIA; ANALOGS	The Xenopus laevis distal tubule epithelial cell line A6 was used as a model epithelia to study the role of isoprenylcysteine-O-carboxyl methyltransferase (pcMTase) in aldosterone-mediated stimulation of Na+ transport. Polyclonal antibodies raised against X. laevis pcMTase were immunoreactive with a 33-kDa protein in whole cell lysate. These antibodies were also reactive with a 33-kDa product from in vitro translation of the pcMTase cDNA. Aldosterone application increased pcMTase activity resulting in elevation of total protein methyl esterification in vivo, but pcMTase protein levels were not affected by steroid, suggesting that aldosterone increased activity independent of enzyme number. Inhibition of pcMTase resulted in a reduction of aldosterone-induced Na+ transport demonstrating the necessity of pcMTase-mediated transmethylation for steroid induced Na+ reabsorption. Transfection with an eukaryotic expression construct containing pcMTase cDNA increased pcMTase protein level and activity. This resulted in potentiation of the natriferic actions of aldosterone. However, overexpression did not change Na+ reabsorption in the absence of steroid, suggesting that pcMTase activity is not limiting Na+ transport in the absence of steroid, but that subsequent to aldosterone addition pcMTase activity becomes limiting. These results suggest that a critical transmethylation is necessary for aldosterone-induction of Na+ transport. It is likely that the protein catalyzing this methylation is isoprenylcysteine-O-carboxyl methyltransferase and that aldosterone activates pcMTase without affecting transferase expression.	Emory Univ, Sch Med, Dept Physiol, Ctr Cell & Mol Signalling, Atlanta, GA 30322 USA; Univ Pittsburgh, Dept Med, Lab Epithelial Cell Biol, Pittsburgh, PA 15213 USA; Free Univ Brussels, Lab Physiol & Physiopatol, B-1070 Brussels, Belgium	Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Stockand, JD (corresponding author), Emory Univ, Sch Med, Dept Physiol, Ctr Cell & Mol Signalling, 1648 Pierce Dr, Atlanta, GA 30322 USA.			Stockand, James/0000-0002-3817-4319; Eaton, Douglas/0000-0002-2686-6692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037963, R37DK037963, F32DK009729, R01DK047874] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47874, DK37963, DK09729] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBALDAWI NF, 1998, FASEB J, V21, P2447; BlazerYost BL, 1997, AM J PHYSIOL-CELL PH, V272, pC1928, DOI 10.1152/ajpcell.1997.272.6.C1928; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Desrosiers RR, 1998, ARCH BIOCHEM BIOPHYS, V351, P149, DOI 10.1006/abbi.1997.0538; Dudler T, 1997, BIOCHEMISTRY-US, V36, P12434, DOI 10.1021/bi971054x; EATON DC, 1995, KIDNEY INT, V48, P941, DOI 10.1038/ki.1995.375; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Imai Y, 1997, MOL CELL BIOL, V17, P1543, DOI 10.1128/MCB.17.3.1543; ISMAILOV II, 1994, J BIOL CHEM, V269, P22193; MARCIANO D, 1995, J MED CHEM, V38, P1267, DOI 10.1021/jm00008a004; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; Rokaw MD, 1996, J BIOL CHEM, V271, P4491; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SARIBANSOHRABY S, 1995, KIDNEY INT, V48, P965, DOI 10.1038/ki.1995.378; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; Stockand JD, 1999, J BIOL CHEM, V274, P3842, DOI 10.1074/jbc.274.6.3842; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43; WONG DL, 1992, FASEB J, V6, P3310, DOI 10.1096/fasebj.6.14.1426768	26	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26912	26916		10.1074/jbc.274.38.26912	http://dx.doi.org/10.1074/jbc.274.38.26912			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480901	hybrid			2022-12-25	WOS:000082570700040
J	Wibbenmeyer, JA; Schuck, P; Smith-Gill, SJ; Willson, RC				Wibbenmeyer, JA; Schuck, P; Smith-Gill, SJ; Willson, RC			Salt links dominate affinity of antibody HyHEL-5 for lysozyme through enthalpic contributions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEN EGG LYSOZYME; BINDING-ENERGY; WHITE LYSOZYME; AVIAN LYSOZYME; ANTIGEN; ASSOCIATION; COMPLEX; STABILITY; THERMODYNAMICS; MUTAGENESIS	The binding of murine monoclonal antibody HyHEL-5 to lysozyme has been the subject of extensive crystallographic, computational, and experimental investigations. The complex of HyHEL-5 with hen egg lysozyme (HEL) features salt bridges between Fab heavy chain residue Glu(50), and Arg(45) Arg(68) of HEL. This interaction has been predicted to play a dominant role in the association on the basis of molecular electrostatics calculations. The association of aspartic acid and glutamine mutants at position 50(H) of the cloned HyHEL-5 Fab with HEL and bobwhite quail lysozyme (BQL), an avian variant bearing an Arg(68) --> Lys substitution in the epitope, was characterized by isothermal titration calorimetry and sedimentation equilibrium. Affinities for HEL were reduced by 400-fold (E50(H)D) and 40,000-fold (E50(H)Q) (Delta Delta G degrees estimated at 4.0 and 6.4 kcal mol(-1), respectively). The same mutations reduce affinity for BQL by only 7- and 55-fold, respectively, indicating a reduced specificity for HEL. The loss of affinity upon mutation is in each case primarily due to an unfavorable change in the enthalpy of the interaction; the entropic contribution is virtually unchanged. An enthalpy-entropy compensation exists for each interaction; Delta H degrees decreases, while Delta S degrees increases with temperature. The Delta Cp for each mutant interaction is less negative than the wild-type. Mutant-cycle analysis suggests the mutations present in the HyHEL-5 Fab mutants are linked to those present in the BQL with coupling energies between 3 and 4 kcal mol(-1).	Univ Houston, Dept Biol & Biochem, Houston, TX 77024 USA; NIH, Mol Interact Resource Bioengn & Phys Sci Program, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA; Univ Houston, Dept Chem Engn, Houston, TX 77024 USA	University of Houston System; University of Houston; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Houston System; University of Houston	Willson, RC (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77024 USA.	willson@uh.edu	Schuck, Peter/AAA-6888-2020; Willson, richard/AAD-4832-2019	Schuck, Peter/0000-0002-8859-6966; 	DIVISION OF BASIC SCIENCES - NCI [Z01BC008950] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AUNE KC, 1969, BIOCHEMISTRY-US, V8, P4579, DOI 10.1021/bi00839a052; BENJAMIN DC, 1992, BIOCHEMISTRY-US, V31, P9539, DOI 10.1021/bi00155a005; BEVINGTON BR, 1992, DATA REDUCTION ERROR; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; CHACKO S, 1995, J MOL BIOL, V245, P261, DOI 10.1006/jmbi.1994.0022; CHACKO S, 1995, PROTEIN-STRUCT FUNCT, V26, P55; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cohen GH, 1996, ACTA CRYSTALLOGR D, V52, P315, DOI 10.1107/S0907444995014855; Faiman GA, 1996, J BIOL CHEM, V271, P13829, DOI 10.1074/jbc.271.23.13829; Goldbaum FA, 1996, J MOL RECOGNIT, V9, P6, DOI 10.1002/(SICI)1099-1352(199601)9:1<6::AID-JMR240>3.3.CO;2-M; Goldman ER, 1997, BIOCHEMISTRY-US, V36, P49, DOI 10.1021/bi961769k; GRIVEL JC, 1996, STRUCTURES ANTIGENS, V3, P92; HIBBITS KA, 1994, BIOCHEMISTRY-US, V33, P3584, DOI 10.1021/bi00178a015; KOZACK RE, 1993, PROTEIN SCI, V2, P915, DOI 10.1002/pro.5560020605; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LEWIS MS, 1994, MODERN ANAL ULTRACEN; McDonald SM, 1995, PROTEIN ENG, V8, P915, DOI 10.1093/protein/8.9.915; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PRESS WH, 1992, NUMERICAL RECIPES C, P693; RAMAN CS, 1995, BIOCHEMISTRY-US, V34, P5831, DOI 10.1021/bi00017a015; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; Shick KA, 1997, BBA-PROTEIN STRUCT M, V1340, P205, DOI 10.1016/S0167-4838(97)00035-6; SLAGLE SP, 1994, J BIOMOL STRUCT DYN, V12, P439, DOI 10.1080/07391102.1994.10508750; SMITHGILL SJ, 1984, J IMMUNOL, V132, P963; SMITHGILL SJ, 1984, J IMMUNOL, V133, P384; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Tissot AC, 1996, BIOCHEMISTRY-US, V35, P6786, DOI 10.1021/bi952930e; Tsumoto K, 1996, J BIOL CHEM, V271, P32612, DOI 10.1074/jbc.271.51.32612; TULIP WR, 1994, BIOCHEMISTRY-US, V33, P7986, DOI 10.1021/bi00192a002; Wibbenmeyer JA, 1999, BBA-PROTEIN STRUCT M, V1430, P191, DOI 10.1016/S0167-4838(98)00285-4; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xavier KA, 1998, BIOPHYS J, V74, P2036; Xavier KA, 1997, BIOPHYS J, V73, P2116, DOI 10.1016/S0006-3495(97)78242-0	37	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	1999	274	38					26838	26842		10.1074/jbc.274.38.26838	http://dx.doi.org/10.1074/jbc.274.38.26838			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	235YD	10480891	hybrid			2022-12-25	WOS:000082570700030
J	Karata, K; Inagawa, T; Wilkinson, AJ; Tatsuta, T; Ogura, T				Karata, K; Inagawa, T; Wilkinson, AJ; Tatsuta, T; Ogura, T			Dissecting the role of a conserved motif (the second region of homology) in the AAA family of ATPases - Site-directed mutagenesis of the ATP-dependent protease FtsH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; ESCHERICHIA-COLI FTSH; GENE-EXPRESSION; IN-VIVO; MEMBRANE; HFLB; COMPLEX; DOMAIN; DEGRADATION; YEAST	Escherichia coli FtsH is an ATP-dependent protease that belongs to the AAA protein family. The second region of homology (SRH) is a highly conserved motif among AAA family members and distinguishes these proteins in part from the wider family of Walker-type ATPases. Despite its conservation across the AAA family of proteins, very little is known concerning the function of the SRH. To address this question, we introduced point mutations systematically into the SRH of FtsH and studied the activities of the mutant proteins. Highly conserved amino acid residues within the SRH were found to be critical for the function of FtsH, with mutations at these positions leading to decreased or abolished ATPase activity. The effects of the mutations on the protease activity of FtsH correlated strikingly with their effects on the ATPase activity. The ATPase-deficient SRH mutants underwent an ATP-induced conformational change similar to wild type FtsH, suggesting an important role for the SRH in ATP hydrolysis but not ATP binding. Analysis of the data in the light of the crystal structure of the hexamerization domain of N-ethylmaleimide-sensitive fusion protein suggests a plausible mechanism of ATP hydrolysis by the AAA ATPases, which invokes an intermolecular catalytic role for the SRH.	Kumamoto Univ, Sch Med, Dept Mol Cell Biol, Inst Mol Embryol & Genet, Kumamoto 8620986, Japan; Univ York, Dept Chem, York YO1 5DD, N Yorkshire, England	Kumamoto University; University of York - UK	Ogura, T (corresponding author), Kumamoto Univ, Sch Med, Dept Mol Cell Biol, Inst Mol Embryol & Genet, Kumamoto 8620986, Japan.	ogura@gpo.kumamoto-u.ac.jp		Wilkinson, Anthony/0000-0003-4577-9479; Ogura, Teru/0000-0003-3784-0970				Akiyama Y, 1998, J BIOL CHEM, V273, P22326, DOI 10.1074/jbc.273.35.22326; Akiyama Y, 1998, MOL MICROBIOL, V28, P803, DOI 10.1046/j.1365-2958.1998.00843.x; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; Akiyama Y, 1996, FEBS LETT, V399, P26, DOI 10.1016/S0014-5793(96)01283-5; Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; BEGG KJ, 1992, J BACTERIOL, V174, P2416, DOI 10.1128/JB.174.7.2416-2417.1992; Beyer A, 1997, PROTEIN SCI, V6, P2043; Bussey H, 1997, NATURE, V387, P103, DOI 10.1038/387s103; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; FROHLICH KU, 1995, BBA-PROTEIN STRUCT M, V1253, P25, DOI 10.1016/0167-4838(95)00136-I; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Herman C, 1997, J BACTERIOL, V179, P358, DOI 10.1128/jb.179.2.358-363.1997; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Kihara A, 1998, J MOL BIOL, V279, P175, DOI 10.1006/jmbi.1998.1781; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leffers GG, 1998, J BACTERIOL, V180, P1573, DOI 10.1128/JB.180.6.1573-1577.1998; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Makino Y, 1997, J BIOL CHEM, V272, P23201, DOI 10.1074/jbc.272.37.23201; Matveeva EA, 1997, J BIOL CHEM, V272, P26413, DOI 10.1074/jbc.272.42.26413; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Neuwald AF, 1999, GENOME RES, V9, P27; Neuwald AF, 1999, STRUCTURE, V7, pR19, DOI 10.1016/S0969-2126(99)80015-X; OGURA T, 1991, RES MICROBIOL, V142, P279, DOI 10.1016/0923-2508(91)90041-8; Ogura T, 1999, MOL MICROBIOL, V31, P833, DOI 10.1046/j.1365-2958.1999.01221.x; Pamnani V, 1997, FEBS LETT, V404, P263, DOI 10.1016/S0014-5793(97)00138-5; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; Qu JN, 1996, J BACTERIOL, V178, P3457, DOI 10.1128/jb.178.12.3457-3461.1996; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Shirahama K, 1997, CELL STRUCT FUNCT, V22, P501, DOI 10.1247/csf.22.501; Shotland Y, 1997, MOL MICROBIOL, V24, P1303, DOI 10.1046/j.1365-2958.1997.4231796.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; Tatsuta T, 1998, MOL MICROBIOL, V30, P583, DOI 10.1046/j.1365-2958.1998.01091.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Wang RF, 1998, J BACTERIOL, V180, P1929, DOI 10.1128/JB.180.7.1929-1938.1998; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Wolf S, 1998, J MOL BIOL, V277, P13, DOI 10.1006/jmbi.1997.1589; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871	59	168	173	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26225	26232		10.1074/jbc.274.37.26225	http://dx.doi.org/10.1074/jbc.274.37.26225			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473576	hybrid			2022-12-25	WOS:000082469700042
J	Kinet, S; Bernichtein, S; Kelly, PA; Martial, JA; Goffin, V				Kinet, S; Bernichtein, S; Kelly, PA; Martial, JA; Goffin, V			Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; ALANINE-SCANNING MUTAGENESIS; RECOMBINANT HUMAN PROLACTIN; GENE FAMILY; PLACENTAL-LACTOGEN; TYROSINE KINASE; RATIONAL DESIGN; NB2 CELLS; ZINC; ANTAGONISTS	Zinc increases the affinity of human growth hormone (hGH) for the human prolactin receptor (hPRLR) due to the coordination of one zinc ion involving GlU-174(hGH) and His-18(hGH),,. In contrast, binding of h:PRL to the hPRLR is zinc-independent. We engineered in binding site 1 of hPRL a hGH-like zinc coordination site, by mutating Asp-183(hPRL) (homologous to Glu-174(hGH)) into Glu (D183E mutation). This mutation was also introduced into G129R hPRL, a binding site 2 mutant (Goffin, V., Kinet, S., Ferrag, F., Binart, N., Martial, J. A., and Kelly, P, A. (1996) J. Biol. Chem. 271, 16573-16579), These analogs were characterized using a stable clone expressing both the hPRLR and a PRLR-responsive reporter gene. The D183E mutation per se decreases the binding affinity and transcriptional activity of hPRL. However, this loss is partially rescued by the addition of zinc and the effect is much more marked on bioactivity than on binding affinity. These data indicate that the D183E mutation confers zinc sensitivity to hPRL biological properties. Due to an impaired site 2, the agonistic activity of G129R analog is almost nil. Although the double mutant D183E/G129R displays lower affinity (similar to 1 log) compared with G129R hPRL, it unexpectedly recovers partial agonistic activity in the absence of zinc. Moreover, whereas zinc increases the affinity of D183E/G129R, it paradoxically abolishes its agonistic activity. Our results demonstrate that the biological properties of hPRL analogs do not necessarily parallel their overall affinity. Rather, the relative affinities of the individual binding sites 1 and 2 may play an even more important role.	INSERM, U344, F-75730 Paris 15, France; Univ Liege, Lab Mol Biol & Genet Engn, B-4000 Sart Tilman, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Liege	Goffin, V (corresponding author), INSERM, U344, 156 Rue Vaugirard, F-75730 Paris 15, France.		GOFFIN, Vincent/G-3322-2013; Kelly, Paul/A-7951-2008	GOFFIN, Vincent/0000-0002-8021-3086; kinet, sandrina/0000-0003-0699-108X				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ALI S, 1991, J BIOL CHEM, V266, P20110; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; Chen TJ, 1998, ENDOCRINOLOGY, V139, P609, DOI 10.1210/en.139.2.609; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DATTANI MT, 1993, ENDOCRINOLOGY, V133, P2803, DOI 10.1210/en.133.6.2803; DATTANI MT, 1995, J BIOL CHEM, V270, P9222, DOI 10.1074/jbc.270.16.9222; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOFFIN V, 1994, J BIOL CHEM, V269, P32598; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; Goffin V, 1996, CLIN ENDOCRINOL, V45, P247, DOI 10.1046/j.1365-2265.1996.00799.x; Goffin V, 1999, ENDOCRINOLOGY, V140, P3853, DOI 10.1210/en.140.8.3853; Goffin V, 1996, ENDOCR REV, V17, P385, DOI 10.1210/er.17.4.385; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Goffin V, 1995, PROTEIN ENG, V8, P1215, DOI 10.1093/protein/8.12.1215; Goffin V, 1997, J MAMMARY GLAND BIOL, V2, P7, DOI 10.1023/A:1026313211704; GOUT PW, 1980, CANCER RES, V40, P2433; Halaby D, 1997, PROTEINS, V27, P459, DOI 10.1002/(SICI)1097-0134(199703)27:3<459::AID-PROT13>3.0.CO;2-K; Helman D, 1998, J BIOL CHEM, V273, P16067, DOI 10.1074/jbc.273.26.16067; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Kinet S, 1996, J BIOL CHEM, V271, P14353, DOI 10.1074/jbc.271.24.14353; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LOCHNAN HA, 1995, MOL CELL ENDOCRINOL, V114, P91, DOI 10.1016/0303-7207(95)03645-N; Lorenson MY, 1996, ENDOCRINOLOGY, V137, P809, DOI 10.1210/en.137.3.809; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; Moutoussamy S, 1998, EUR J BIOCHEM, V255, P1, DOI 10.1046/j.1432-1327.1998.2550001.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PARIS N, 1990, BIOTECHNOL APPL BIOC, V12, P436; POSTELVINAY MC, 1991, P NATL ACAD SCI USA, V88, P6687, DOI 10.1073/pnas.88.15.6687; SINHA YN, 1995, ENDOCR REV, V16, P354, DOI 10.1210/er.16.3.354; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Sun ZY, 1996, MOL ENDOCRINOL, V10, P265, DOI 10.1210/me.10.3.265; Sun ZY, 1997, MOL ENDOCRINOL, V11, P1544, DOI 10.1210/me.11.10.1544; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1	50	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26033	26043		10.1074/jbc.274.37.26033	http://dx.doi.org/10.1074/jbc.274.37.26033			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473550	hybrid			2022-12-25	WOS:000082469700016
J	Rui, LY; Herrington, J; Carter-Su, C				Rui, LY; Herrington, J; Carter-Su, C			SH2-B, a membrane-associated adapter, is phosphorylated on multiple serines/threonines in response to nerve growth factor by kinases within the MEK/ERK cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAIN; FACTOR-INDUCED DIFFERENTIATION; ACTIVATED PROTEIN-KINASE; PROLINE-RICH REGION; FACTOR-I RECEPTOR; PC12 CELLS; TRK PROTOONCOGENE; SIGNAL-TRANSDUCTION; MAP KINASE; NEURONAL DIFFERENTIATION	SH2-B has been shown to be required for nerve growth factor (NGF)-mediated neuronal differentiation and survival, associate with NGF receptor TrkA, and be tyrosylphosphorylated in response to NGF. In this work, we examined whether NGF stimulates phosphorylation of SH2-B on serines/threonines. NGF promotes a dramatic upward shift in mobility of SH2-B, resulting in multiple forms that cannot be attributed to tyrosyl phosphorylation. Treatment of SH2-B with protein phosphatase 2A, a serine/threonine phosphatase, reduces the many forms to two. PD98059, a MEK inhibitor, dramatically inhibits NGF-promoted phosphorylation of SH2-B on serines/threonines, whereas depletion of 4 beta-phorbol 12-myristate 13-acetate-sensitive protein kinase Cs does not. ERKs 1 and 2 phosphorylate SH2-B beta primarily on Ser-96 in vitro. However, NGF still stimulates serine/threonine phosphorylation of SH2-B beta(S96A). SH2-B beta(S96A), like wildtype SH2-B beta, enhances NGF-induced neurite outgrowth. In contrast, SH2-B beta(R555E) containing a defective SH2 domain blocks NGF-induced neurite outgrowth and displays greatly reduced phosphorylation on serines/threonines in response to NGF. SH2-B beta(R555E), like wild-type SH2-B beta, associates with the plasma membrane, suggesting that the dominant negative effect of SH2-B beta(R555E) cannot be explained by an abnormal subcellular distribution. In summary, NGF stimulates phosphorylation of SH2-B on serines/threonines by kinases downstream of MEK, which may be important for NGF-mediated neuronal differentiation and survival.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.				NCI NIH HHS [P30 CA 46592] Funding Source: Medline; NIDDK NIH HHS [R01 DK034171, DK 34171, P60-DK-20572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034171, P60DK020572, R01DK034171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; COLEMAN ES, 1994, J MOL NEUROSCI, V5, P39, DOI 10.1007/BF02736693; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Craparo A, 1997, J BIOL CHEM, V272, P11663; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Holt KH, 1996, MOL CELL BIOL, V16, P577; Horita DA, 1998, J MOL BIOL, V278, P253, DOI 10.1006/jmbi.1998.1690; Hoshino M, 1998, J BIOL CHEM, V273, P4878, DOI 10.1074/jbc.273.9.4878; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LEWIN GR, 1993, J NEUROSCI, V13, P2136; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Ohba T, 1998, BIOCHEM J, V330, P1249, DOI 10.1042/bj3301249; OHMICHI M, 1993, BIOCHEM J, V295, P767, DOI 10.1042/bj2950767; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Okkenhaug K, 1998, J BIOL CHEM, V273, P21194, DOI 10.1074/jbc.273.33.21194; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEARSON J, 1983, DEV BIOL, V96, P32, DOI 10.1016/0012-1606(83)90308-1; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rui LY, 1999, J BIOL CHEM, V274, P10590, DOI 10.1074/jbc.274.15.10590; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yoon SO, 1997, J BIOL CHEM, V272, P23231, DOI 10.1074/jbc.272.37.23231; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	65	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 10	1999	274	37					26485	26492		10.1074/jbc.274.37.26485	http://dx.doi.org/10.1074/jbc.274.37.26485			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	234DR	10473609	hybrid			2022-12-25	WOS:000082469700075
J	Reardon, DB; Contessa, JN; Mikkelsen, RB; Valerie, K; Amir, C; Dent, P; Schmidt-Ullrich, RK				Reardon, DB; Contessa, JN; Mikkelsen, RB; Valerie, K; Amir, C; Dent, P; Schmidt-Ullrich, RK			Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells	ONCOGENE			English	Article						EGFR; EGFR-CD533, dominant-negative; MAPK; JNK1; ionizing radiation; mammary carcinoma cells	EPIDERMAL GROWTH-FACTOR; N-TERMINAL KINASE; RAS-DEPENDENT ACTIVATION; FACTOR RECEPTOR MUTANTS; BREAST-CANCER CELLS; PROTEIN-KINASE; C-JUN; INDUCED APOPTOSIS; IONIZING-RADIATION; SOS PHOSPHORYLATION	Exposure of MDA-MB-231 human mammary carcinoma cells to an ionizing radiation dose of 2 Gy results in immediate activation and Tyr phosphorylation of the epidermal growth factor receptor (EGFR), Doxycycline induced expression of a dominant negative EGFR-CD533 mutant, lacking the COOH-terminal 533 amino acids, in MDA-TR15-EGFR-CD533 cells was used to characterize intracellular signaling responses following irradiation. Within 10 min, radiation exposure caused an immediate, transient activation of mitogen activated protein kinase (MAPK) which was completely blocked by expression of EGFR-CD533, The same radiation treatment also induced an immediate activation of the c-Jun-NH2-terminal kinase 1 (JNK1) pathway that was followed by an extended rise in kinase activity after 30 min. Expression of EGFR-CD533 did not block the immediate JNK1 response but completely inhibited the later activation. Treatment of MDA-TR15-ECFR-CD533 cells with the MEK1/2 inhibitor, PD98059, resulted in similar to 70% inhibition of radiation-induced MAPK activity, and potentiated the radiation-induced increase of immediate JNK1 activation twofold. Inhibition of Ras farnesylation with a concomitant inhibition of Res function completely blocked radiation-induced MAPK( and JNK1 activation, Modulation of EGFR and MAPK functions also altered overall cellular responses of growth and apoptosis, Induction of EGFR-CD533 or treatment with PD98059 caused a 3-5-fold increase in radiation toxicity in a novel repeated radiation exposure growth assay by interfering with cell proliferation and potentiating apoptosis, In summary, this data demonstrates that both MAPK and JNK1 activation in response to radiation occur through EGFR-dependent and -independent mechanisms, and are mediated by signaling through Ras, Furthermore, we have demonstrated that radiation-induced activation of EGFR results in downstream activation of MAPK which may affect the radiosensitivity of carcinoma cells.	Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Dept Radiat Oncol, Med Coll Virginia Campus, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [CA65896, CA72955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065896, P01CA072955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; BENTZEN SM, 1991, RADIOTHER ONCOL, V22, P161, DOI 10.1016/0167-8140(91)90019-D; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1993, ONCOGENE, V8, P877; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARMICHAEL J, 1987, CANCER RES, V47, P943; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chelliah J, 1997, BIOCHEM PHARMACOL, V54, P563, DOI 10.1016/S0006-2952(97)00212-8; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chmura SJ, 1997, CANCER RES, V57, P1270; Contessa JN, 1999, CLIN CANCER RES, V5, P405; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; GORCZYCA W, 1993, CANCER RES, V53, P1945; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Gupta AK, 1997, MOL CELL BIOCHEM, V170, P23, DOI 10.1023/A:1006890316102; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HEERDT BG, 1994, CANCER RES, V54, P3288; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; JARVIS M, 1997, MOL PHARMACOL, V2, P935; Jarvis WD, 1997, FEBS LETT, V412, P9, DOI 10.1016/S0014-5793(97)00705-9; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Kavanagh BD, 1995, CLIN CANCER RES, V1, P1557; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; KWOK TT, 1991, BRIT J CANCER, V64, P251, DOI 10.1038/bjc.1991.286; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LADEROUTE KR, 1994, CANCER RES, V54, P1407; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lee HS, 1997, INT J RADIAT ONCOL, V38, P1079, DOI 10.1016/S0360-3016(97)00073-4; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MANNE V, 1995, ONCOGENE, V10, P1763; Michael JM, 1997, CANCER RES, V57, P3600; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TODD DG, 1999, IN PRESS J RECEPT SI; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; WOLLMAN R, 1994, INT J RADIAT ONCOL, V30, P91, DOI 10.1016/0360-3016(94)90523-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	66	111	113	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4756	4766		10.1038/sj.onc.1202849	http://dx.doi.org/10.1038/sj.onc.1202849			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467423				2022-12-25	WOS:000082154400013
